Tricuspid	B-Disease	D014262
valve	I-Disease	D014262
regurgitation	I-Disease	D014262
and	O	O
lithium	B-Chemical	D016651
carbonate	I-Chemical	D016651
toxicity	B-Disease	D064420
in	O	O
a	O	O
newborn	O	O
infant	O	O
.	O	O

A	O	O
newborn	O	O
with	O	O
massive	O	O
tricuspid	B-Disease	D014262
regurgitation	I-Disease	D014262
,	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
,	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
,	O	O
and	O	O
a	O	O
high	O	O
serum	O	O
lithium	B-Chemical	D008094
level	O	O
is	O	O
described	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
patient	O	O
to	O	O
initially	O	O
manifest	O	O
tricuspid	B-Disease	D014262
regurgitation	I-Disease	D014262
and	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
,	O	O
and	O	O
the	O	O
11th	O	O
described	O	O
patient	O	O
with	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
among	O	O
infants	O	O
exposed	O	O
to	O	O
lithium	B-Chemical	D008094
compounds	O	O
in	O	O
the	O	O
first	O	O
trimester	O	O
of	O	O
pregnancy	O	O
.	O	O

Sixty	O	O
-	O	O
three	O	O
percent	O	O
of	O	O
these	O	O
infants	O	O
had	O	O
tricuspid	O	O
valve	O	O
involvement	O	O
.	O	O

Lithium	B-Chemical	D016651
carbonate	I-Chemical	D016651
may	O	O
be	O	O
a	O	O
factor	O	O
in	O	O
the	O	O
increasing	O	O
incidence	O	O
of	O	O
congenital	B-Disease	D006331
heart	I-Disease	D006331
disease	I-Disease	D006331
when	O	O
taken	O	O
during	O	O
early	O	O
pregnancy	O	O
.	O	O

It	O	O
also	O	O
causes	O	O
neurologic	B-Disease	D003866
depression	I-Disease	D003866
,	O	O
cyanosis	B-Disease	D003490
,	O	O
and	O	O
cardiac	B-Disease	D001145
arrhythmia	I-Disease	D001145
when	O	O
consumed	O	O
prior	O	O
to	O	O
delivery	O	O
.	O	O

Phenobarbital	B-Chemical	D010634
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
in	O	O
a	O	O
neurologically	B-Disease	D009422
-	I-Disease	D009422
impaired	I-Disease	D009422
child	O	O
.	O	O

A	O	O
2	O	O
-	O	O
year	O	O
-	O	O
old	O	O
child	O	O
with	O	O
known	O	O
neurologic	B-Disease	D009422
impairment	I-Disease	D009422
developed	O	O
a	O	O
dyskinesia	B-Disease	D004409
soon	O	O
after	O	O
starting	O	O
phenobarbital	B-Chemical	D010634
therapy	O	O
for	O	O
seizures	B-Disease	D012640
.	O	O

Known	O	O
causes	O	O
of	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
were	O	O
eliminated	O	O
after	O	O
evaluation	O	O
.	O	O

On	O	O
repeat	O	O
challenge	O	O
with	O	O
phenobarbital	B-Chemical	D010634
,	O	O
the	O	O
dyskinesia	B-Disease	D004409
recurred	O	O
.	O	O

Phenobarbital	B-Chemical	D010634
should	O	O
be	O	O
added	O	O
to	O	O
the	O	O
list	O	O
of	O	O
anticonvulsant	O	O
drugs	O	O
that	O	O
can	O	O
cause	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
.	O	O

Acute	O	O
changes	O	O
of	O	O
blood	O	O
ammonia	B-Chemical	D000641
may	O	O
predict	O	O
short	O	O
-	O	O
term	O	O
adverse	O	O
effects	O	O
of	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
.	O	O

Valproic	B-Chemical	D014635
acid	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
was	O	O
given	O	O
to	O	O
24	O	O
epileptic	B-Disease	D004827
patients	O	O
who	O	O
were	O	O
already	O	O
being	O	O
treated	O	O
with	O	O
other	O	O
antiepileptic	O	O
drugs	O	O
.	O	O

A	O	O
standardized	O	O
loading	O	O
dose	O	O
of	O	O
VPA	B-Chemical	D014635
was	O	O
administered	O	O
,	O	O
and	O	O
venous	O	O
blood	O	O
was	O	O
sampled	O	O
at	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
4	O	O
hours	O	O
.	O	O

Ammonia	B-Chemical	D000641
(	O	O
NH3	B-Chemical	D000641
)	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
who	O	O
,	O	O
during	O	O
continuous	O	O
therapy	O	O
,	O	O
complained	O	O
of	O	O
drowsiness	B-Disease	D006970
(	O	O
7	O	O
patients	O	O
)	O	O
than	O	O
in	O	O
those	O	O
who	O	O
were	O	O
symptom	O	O
-	O	O
free	O	O
(	O	O
17	O	O
patients	O	O
)	O	O
,	O	O
although	O	O
VPA	B-Chemical	D014635
plasma	O	O
levels	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

By	O	O
measuring	O	O
VPA	B-Chemical	D014635
-	O	O
induced	O	O
changes	O	O
of	O	O
blood	O	O
NH3	B-Chemical	D000641
content	O	O
,	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
identify	O	O
patients	O	O
at	O	O
higher	O	O
risk	O	O
of	O	O
obtundation	O	O
when	O	O
VPA	B-Chemical	D014635
is	O	O
given	O	O
chronically	O	O
.	O	O

Effects	O	O
of	O	O
calcitonin	O	O
on	O	O
rat	O	O
extrapyramidal	O	O
motor	O	O
system	O	O
:	O	O
behavioral	O	O
and	O	O
biochemical	O	O
data	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

c	O	O
.	O	O

injection	O	O
of	O	O
human	O	O
and	O	O
salmon	O	O
calcitonin	O	O
on	O	O
biochemical	O	O
and	O	O
behavioral	O	O
parameters	O	O
related	O	O
to	O	O
the	O	O
extrapyramidal	O	O
motor	O	O
system	O	O
,	O	O
were	O	O
investigated	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

Calcitonin	O	O
injection	O	O
resulted	O	O
in	O	O
a	O	O
potentiation	O	O
of	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
and	O	O
a	O	O
partial	O	O
prevention	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

Moreover	O	O
calcitonin	O	O
induced	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
nigral	O	O
GAD	O	O
activity	O	O
but	O	O
no	O	O
change	O	O
in	O	O
striatal	O	O
DA	B-Chemical	D004298
and	O	O
DOPAC	B-Chemical	D015102
concentration	O	O
or	O	O
GAD	O	O
activity	O	O
.	O	O

The	O	O
results	O	O
are	O	O
discussed	O	O
in	O	O
view	O	O
of	O	O
a	O	O
primary	O	O
action	O	O
of	O	O
calcitonin	O	O
on	O	O
the	O	O
striatonigral	O	O
GABAergic	O	O
pathway	O	O
mediating	O	O
the	O	O
DA	B-Chemical	D004298
-	O	O
related	O	O
behavioral	O	O
messages	O	O
of	O	O
striatal	O	O
origin	O	O
.	O	O

Development	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
.	O	O

The	O	O
development	O	O
of	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
was	O	O
studied	O	O
in	O	O
adult	O	O
female	O	O
Wistar	O	O
rats	O	O
following	O	O
daily	O	O
subcutaneous	O	O
injections	O	O
of	O	O
isoproterenol	B-Chemical	D007545
(	O	O
ISO	B-Chemical	D007545
)	O	O
(	O	O
0	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
.	O	O

A	O	O
time	O	O
course	O	O
was	O	O
established	O	O
for	O	O
the	O	O
change	O	O
in	O	O
tissue	O	O
mass	O	O
,	O	O
RNA	O	O
and	O	O
DNA	O	O
content	O	O
,	O	O
as	O	O
well	O	O
as	O	O
hydroxyproline	B-Chemical	D006909
content	O	O
.	O	O

Heart	O	O
weight	O	O
increased	O	O
44%	O	O
after	O	O
8	O	O
days	O	O
of	O	O
treatment	O	O
with	O	O
a	O	O
half	O	O
time	O	O
of	O	O
3	O	O
.	O	O

4	O	O
days	O	O
.	O	O

Ventricular	O	O
RNA	O	O
content	O	O
was	O	O
elevated	O	O
26%	O	O
after	O	O
24	O	O
h	O	O
of	O	O
a	O	O
single	O	O
injection	O	O
and	O	O
reached	O	O
a	O	O
maximal	O	O
level	O	O
following	O	O
8	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

The	O	O
half	O	O
time	O	O
for	O	O
RNA	O	O
accumulation	O	O
was	O	O
2	O	O
.	O	O

0	O	O
days	O	O
.	O	O

The	O	O
total	O	O
content	O	O
of	O	O
hydroxyproline	B-Chemical	D006909
remained	O	O
stable	O	O
during	O	O
the	O	O
first	O	O
2	O	O
days	O	O
of	O	O
treatment	O	O
but	O	O
increased	O	O
46%	O	O
after	O	O
4	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

Ventricular	O	O
DNA	O	O
content	O	O
was	O	O
unchanged	O	O
during	O	O
the	O	O
early	O	O
stage	O	O
(	O	O
1	O	O
-	O	O
4	O	O
days	O	O
)	O	O
of	O	O
hypertrophic	B-Disease	D006984
growth	O	O
but	O	O
increased	O	O
to	O	O
a	O	O
new	O	O
steady	O	O
-	O	O
state	O	O
level	O	O
19%	O	O
above	O	O
the	O	O
controls	O	O
after	O	O
8	O	O
days	O	O
of	O	O
treatment	O	O
.	O	O

Intraventricular	O	O
pressures	O	O
and	O	O
coronary	O	O
flow	O	O
measures	O	O
were	O	O
similar	O	O
for	O	O
control	O	O
and	O	O
experimental	O	O
animals	O	O
following	O	O
4	O	O
days	O	O
of	O	O
developed	O	O
hypertrophy	B-Disease	D006984
.	O	O

However	O	O
,	O	O
dP	O	O
/	O	O
dt	O	O
in	O	O
the	O	O
ISO	B-Chemical	D007545
-	O	O
treated	O	O
hearts	O	O
was	O	O
slightly	O	O
but	O	O
significantly	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
elevated	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
adaptive	O	O
response	O	O
to	O	O
ISO	B-Chemical	D007545
shows	O	O
an	O	O
early	O	O
hypertrophic	B-Disease	D006984
phase	O	O
(	O	O
1	O	O
-	O	O
4	O	O
days	O	O
)	O	O
characterized	O	O
by	O	O
a	O	O
substantial	O	O
increase	O	O
in	O	O
RNA	O	O
content	O	O
and	O	O
cardiac	O	O
mass	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
changes	O	O
in	O	O
DNA	O	O
.	O	O

However	O	O
,	O	O
prolonged	O	O
stimulation	O	O
(	O	O
8	O	O
-	O	O
12	O	O
days	O	O
)	O	O
appears	O	O
to	O	O
represent	O	O
a	O	O
complex	O	O
integration	O	O
of	O	O
both	O	O
cellular	O	O
hypertrophy	B-Disease	D006984
and	O	O
hyperplasia	B-Disease	D006965
within	O	O
the	O	O
heart	O	O
.	O	O

Co	O	O
-	O	O
carcinogenic	B-Disease	D063646
effect	O	O
of	O	O
retinyl	B-Chemical	C009166
acetate	I-Chemical	C009166
on	O	O
forestomach	B-Disease	D013274
carcinogenesis	I-Disease	D013274
of	O	O
male	O	O
F344	O	O
rats	O	O
induced	O	O
with	O	O
butylated	B-Chemical	D002083
hydroxyanisole	I-Chemical	D002083
.	O	O

The	O	O
potential	O	O
modifying	O	O
effect	O	O
of	O	O
retinyl	B-Chemical	C009166
acetate	I-Chemical	C009166
(	O	O
RA	B-Chemical	C009166
)	O	O
on	O	O
butylated	B-Chemical	D002083
hydroxyanisole	I-Chemical	D002083
(	O	O
BHA	B-Chemical	D002083
)	O	O
-	O	O
induced	O	O
rat	O	O
forestomach	B-Disease	D013274
tumorigenesis	I-Disease	D013274
was	O	O
examined	O	O
.	O	O

Male	O	O
F344	O	O
rats	O	O
,	O	O
5	O	O
weeks	O	O
of	O	O
age	O	O
,	O	O
were	O	O
maintained	O	O
on	O	O
diet	O	O
containing	O	O
1%	O	O
or	O	O
2%	O	O
BHA	B-Chemical	D002083
by	O	O
weight	O	O
and	O	O
simultaneously	O	O
on	O	O
drinking	O	O
water	O	O
supplemented	O	O
with	O	O
RA	B-Chemical	C009166
at	O	O
various	O	O
concentrations	O	O
(	O	O
w	O	O
/	O	O
v	O	O
)	O	O
for	O	O
52	O	O
weeks	O	O
.	O	O

In	O	O
groups	O	O
given	O	O
2%	O	O
BHA	B-Chemical	D002083
,	O	O
although	O	O
marked	O	O
hyperplastic	O	O
changes	O	O
of	O	O
the	O	O
forestomach	O	O
epithelium	O	O
were	O	O
observed	O	O
in	O	O
all	O	O
animals	O	O
,	O	O
co	O	O
-	O	O
administration	O	O
of	O	O
0	O	O
.	O	O

25%	O	O
RA	B-Chemical	C009166
significantly	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
increased	O	O
the	O	O
incidence	O	O
of	O	O
forestomach	B-Disease	D013274
tumors	I-Disease	D013274
(	O	O
squamous	B-Disease	D010212
cell	I-Disease	D010212
papilloma	I-Disease	D010212
and	O	O
carcinoma	B-Disease	D002277
)	O	O
to	O	O
60%	O	O
(	O	O
9	O	O
/	O	O
15	O	O
,	O	O
2	O	O
rats	O	O
with	O	O
carcinoma	B-Disease	D002277
)	O	O
from	O	O
15%	O	O
(	O	O
3	O	O
/	O	O
20	O	O
,	O	O
one	O	O
rat	O	O
with	O	O
carcinoma	B-Disease	D002277
)	O	O
in	O	O
the	O	O
group	O	O
given	O	O
RA	B-Chemical	C009166
-	O	O
free	O	O
water	O	O
.	O	O

In	O	O
rats	O	O
given	O	O
1%	O	O
BHA	B-Chemical	D002083
,	O	O
RA	B-Chemical	C009166
co	O	O
-	O	O
administered	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

05	O	O
,	O	O
0	O	O
.	O	O

1	O	O
,	O	O
0	O	O
.	O	O

2	O	O
or	O	O
0	O	O
.	O	O

25%	O	O
showed	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
enhancing	O	O
effect	O	O
on	O	O
the	O	O
development	O	O
of	O	O
the	O	O
BHA	B-Chemical	D002083
-	O	O
induced	O	O
epithelial	B-Disease	D017573
hyperplasia	I-Disease	D017573
.	O	O

Tumors	B-Disease	D009369
,	O	O
all	O	O
papillomas	B-Disease	D010212
,	O	O
were	O	O
induced	O	O
in	O	O
3	O	O
rats	O	O
(	O	O
17%	O	O
)	O	O
with	O	O
0	O	O
.	O	O

25%	O	O
RA	B-Chemical	C009166
and	O	O
in	O	O
one	O	O
rat	O	O
(	O	O
10%	O	O
)	O	O
with	O	O
0	O	O
.	O	O

05%	O	O
RA	B-Chemical	C009166
co	O	O
-	O	O
administration	O	O
.	O	O

RA	B-Chemical	C009166
alone	O	O
did	O	O
not	O	O
induce	O	O
hyperplastic	O	O
changes	O	O
in	O	O
the	O	O
forestomach	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
RA	B-Chemical	C009166
acted	O	O
as	O	O
a	O	O
co	O	O
-	O	O
carcinogen	O	O
in	O	O
the	O	O
BHA	B-Chemical	D002083
forestomach	B-Disease	D013274
carcinogenesis	I-Disease	D013274
of	O	O
the	O	O
rat	O	O
.	O	O

Ketanserin	B-Chemical	D007650
pretreatment	O	O
reverses	O	O
alfentanil	B-Chemical	D015760
-	O	O
induced	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
.	O	O

Systemic	O	O
pretreatment	O	O
with	O	O
ketanserin	B-Chemical	D007650
,	O	O
a	O	O
relatively	O	O
specific	O	O
type	O	O
-	O	O
2	O	O
serotonin	B-Chemical	D012701
receptor	O	O
antagonist	O	O
,	O	O
significantly	O	O
attenuated	O	O
the	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
produced	O	O
in	O	O
rats	O	O
by	O	O
the	O	O
potent	O	O
short	O	O
-	O	O
acting	O	O
opiate	O	O
agonist	O	O
alfentanil	B-Chemical	D015760
.	O	O

Following	O	O
placement	O	O
of	O	O
subcutaneous	O	O
electrodes	O	O
in	O	O
each	O	O
animal's	O	O
left	O	O
gastrocnemius	O	O
muscle	O	O
,	O	O
rigidity	B-Disease	D009127
was	O	O
assessed	O	O
by	O	O
analyzing	O	O
root	O	O
-	O	O
mean	O	O
-	O	O
square	O	O
electromyographic	O	O
activity	O	O
.	O	O

Intraperitoneal	O	O
ketanserin	B-Chemical	D007650
administration	O	O
at	O	O
doses	O	O
of	O	O
0	O	O
.	O	O

63	O	O
and	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
prevented	O	O
the	O	O
alfentanil	B-Chemical	D015760
-	O	O
induced	O	O
increase	O	O
in	O	O
electromyographic	O	O
activity	O	O
compared	O	O
with	O	O
animals	O	O
pretreated	O	O
with	O	O
saline	O	O
.	O	O

Chlordiazepoxide	B-Chemical	D002707
at	O	O
doses	O	O
up	O	O
to	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
failed	O	O
to	O	O
significantly	O	O
influence	O	O
the	O	O
rigidity	B-Disease	D009127
produced	O	O
by	O	O
alfentanil	B-Chemical	D015760
.	O	O

Despite	O	O
the	O	O
absence	O	O
of	O	O
rigidity	B-Disease	D009127
,	O	O
animals	O	O
that	O	O
received	O	O
ketanserin	B-Chemical	D007650
(	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

31	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
followed	O	O
by	O	O
alfentanil	B-Chemical	D015760
were	O	O
motionless	O	O
,	O	O
flaccid	O	O
,	O	O
and	O	O
less	O	O
responsive	O	O
to	O	O
external	O	O
stimuli	O	O
than	O	O
were	O	O
animals	O	O
receiving	O	O
alfentanil	B-Chemical	D015760
alone	O	O
.	O	O

Rats	O	O
that	O	O
received	O	O
ketanserin	B-Chemical	D007650
and	O	O
alfentanil	B-Chemical	D015760
exhibited	O	O
less	O	O
rearing	O	O
and	O	O
exploratory	O	O
behavior	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
60	O	O
-	O	O
min	O	O
recording	O	O
period	O	O
than	O	O
did	O	O
animals	O	O
that	O	O
received	O	O
ketanserin	B-Chemical	D007650
alone	O	O
.	O	O

These	O	O
results	O	O
,	O	O
in	O	O
combination	O	O
with	O	O
previous	O	O
work	O	O
,	O	O
suggest	O	O
that	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
,	O	O
a	O	O
clinically	O	O
relevant	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
parenteral	O	O
narcotic	O	O
administration	O	O
,	O	O
may	O	O
be	O	O
partly	O	O
mediated	O	O
via	O	O
serotonergic	O	O
pathways	O	O
.	O	O

Pretreatment	O	O
with	O	O
type	O	O
-	O	O
2	O	O
serotonin	B-Chemical	D012701
antagonists	O	O
may	O	O
be	O	O
clinically	O	O
useful	O	O
in	O	O
attenuating	O	O
opiate	O	O
-	O	O
induced	O	O
rigidity	B-Disease	D009127
,	O	O
although	O	O
further	O	O
studies	O	O
will	O	O
be	O	O
necessary	O	O
to	O	O
assess	O	O
the	O	O
interaction	O	O
of	O	O
possibly	O	O
enhanced	O	O
CNS	O	O
,	O	O
cardiovascular	O	O
,	O	O
and	O	O
respiratory	O	O
depression	O	O
.	O	O

Glycopyrronium	B-Chemical	D006024
requirements	O	O
for	O	O
antagonism	O	O
of	O	O
the	O	O
muscarinic	O	O
side	O	O
effects	O	O
of	O	O
edrophonium	B-Chemical	D004491
.	O	O

We	O	O
have	O	O
compared	O	O
,	O	O
in	O	O
60	O	O
adult	O	O
patients	O	O
,	O	O
the	O	O
cardiovascular	O	O
effects	O	O
of	O	O
glycopyrronium	B-Chemical	D006024
5	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
and	O	O
10	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
given	O	O
either	O	O
simultaneously	O	O
or	O	O
1	O	O
min	O	O
before	O	O
edrophonium	B-Chemical	D004491
1	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
.	O	O

Significant	O	O
differences	O	O
between	O	O
the	O	O
four	O	O
groups	O	O
were	O	O
detected	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Both	O	O
groups	O	O
receiving	O	O
10	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
showed	O	O
increases	O	O
in	O	O
heart	O	O
rate	O	O
of	O	O
up	O	O
to	O	O
30	O	O
beat	O	O
min	O	O
-	O	O
1	O	O
(	O	O
95%	O	O
confidence	O	O
limits	O	O
28	O	O
-	O	O
32	O	O
beat	O	O
min	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Use	O	O
of	O	O
glycopyrronium	B-Chemical	D006024
5	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
provided	O	O
greater	O	O
cardiovascular	O	O
stability	O	O
and	O	O
,	O	O
given	O	O
1	O	O
min	O	O
before	O	O
the	O	O
edrophonium	B-Chemical	D004491
,	O	O
was	O	O
sufficient	O	O
to	O	O
minimize	O	O
early	O	O
,	O	O
edrophonium	B-Chemical	D004491
-	O	O
induced	O	O
bradycardias	B-Disease	D001919
.	O	O

This	O	O
low	O	O
dose	O	O
of	O	O
glycopyrronium	B-Chemical	D006024
provided	O	O
good	O	O
control	O	O
of	O	O
oropharyngeal	O	O
secretions	O	O
.	O	O

Involvement	O	O
of	O	O
locus	O	O
coeruleus	O	O
and	O	O
noradrenergic	O	O
neurotransmission	O	O
in	O	O
fentanyl	B-Chemical	D005283
-	O	O
induced	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
in	O	O
the	O	O
rat	O	O
.	O	O

Whereas	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
side	O	O
effect	O	O
that	O	O
is	O	O
associated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
fentanyl	B-Chemical	D005283
anesthesia	O	O
,	O	O
a	O	O
paucity	O	O
of	O	O
information	O	O
exists	O	O
with	O	O
regard	O	O
to	O	O
its	O	O
underlying	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
.	O	O

We	O	O
investigated	O	O
in	O	O
this	O	O
study	O	O
the	O	O
possible	O	O
engagement	O	O
of	O	O
locus	O	O
coeruleus	O	O
of	O	O
the	O	O
pons	O	O
in	O	O
this	O	O
phenomenon	O	O
,	O	O
using	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
anesthetized	O	O
with	O	O
ketamine	B-Chemical	D007649
.	O	O

Under	O	O
proper	O	O
control	O	O
of	O	O
respiration	O	O
,	O	O
body	O	O
temperature	O	O
and	O	O
end	O	O
-	O	O
tidal	O	O
CO2	B-Chemical	D002245
,	O	O
intravenous	O	O
administration	O	O
of	O	O
fentanyl	B-Chemical	D005283
(	O	O
50	O	O
or	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
consistently	O	O
promoted	O	O
an	O	O
increase	O	O
in	O	O
electromyographic	O	O
activity	O	O
recorded	O	O
from	O	O
the	O	O
gastrocnemius	O	O
and	O	O
abdominal	O	O
rectus	O	O
muscles	O	O
.	O	O

Such	O	O
an	O	O
induced	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
by	O	O
the	O	O
narcotic	O	O
agent	O	O
was	O	O
significantly	O	O
antagonized	O	O
or	O	O
even	O	O
reduced	O	O
by	O	O
prior	O	O
electrolytic	O	O
lesions	O	O
of	O	O
the	O	O
locus	O	O
coeruleus	O	O
or	O	O
pretreatment	O	O
with	O	O
the	O	O
alpha	O	O
-	O	O
adrenoceptor	O	O
blocker	O	O
,	O	O
prazosin	B-Chemical	D011224
.	O	O

Microinjection	O	O
of	O	O
fentanyl	B-Chemical	D005283
(	O	O
2	O	O
.	O	O

5	O	O
micrograms	O	O
/	O	O
50	O	O
nl	O	O
)	O	O
directly	O	O
into	O	O
this	O	O
pontine	O	O
nucleus	O	O
,	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
elicited	O	O
discernible	O	O
electromyographic	O	O
excitation	O	O
.	O	O

It	O	O
is	O	O
speculated	O	O
that	O	O
the	O	O
induction	O	O
of	O	O
muscular	B-Disease	D009127
rigidity	I-Disease	D009127
by	O	O
fentanyl	B-Chemical	D005283
may	O	O
involve	O	O
the	O	O
coerulospinal	O	O
noradrenergic	O	O
fibers	O	O
to	O	O
the	O	O
spinal	O	O
motoneurons	O	O
.	O	O

Cerebral	B-Disease	D012851
sinus	I-Disease	D012851
thrombosis	I-Disease	D012851
as	O	O
a	O	O
potential	O	O
hazard	O	O
of	O	O
antifibrinolytic	O	O
treatment	O	O
in	O	O
menorrhagia	B-Disease	D008595
.	O	O

We	O	O
describe	O	O
a	O	O
42	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
superior	O	O
sagittal	O	O
and	O	O
left	O	O
transverse	O	O
sinus	O	O
thrombosis	O	O
associated	O	O
with	O	O
prolonged	O	O
epsilon	B-Chemical	D015119
-	I-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
therapy	O	O
for	O	O
menorrhagia	B-Disease	D008595
.	O	O

This	O	O
antifibrinolytic	O	O
agent	O	O
has	O	O
been	O	O
used	O	O
in	O	O
women	O	O
with	O	O
menorrhagia	B-Disease	D008595
to	O	O
promote	O	O
clotting	O	O
and	O	O
reduce	O	O
blood	B-Disease	D006473
loss	I-Disease	D006473
.	O	O

Although	O	O
increased	O	O
risk	O	O
of	O	O
thromboembolic	B-Disease	D013923
disease	I-Disease	D013923
has	O	O
been	O	O
reported	O	O
during	O	O
treatment	O	O
with	O	O
epsilon	B-Chemical	D015119
-	I-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
,	O	O
cerebral	B-Disease	D012851
sinus	I-Disease	D012851
thrombosis	I-Disease	D012851
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

Careful	O	O
use	O	O
of	O	O
epsilon	B-Chemical	D015119
-	I-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
therapy	O	O
is	O	O
recommended	O	O
.	O	O

Hemorrhagic	O	O
cystitis	O	O
complicating	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O

Hemorrhagic	O	O
cystitis	O	O
is	O	O
a	O	O
potentially	O	O
serious	O	O
complication	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
cyclophosphamide	B-Chemical	D003520
therapy	O	O
administered	O	O
before	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O

As	O	O
standard	O	O
practice	O	O
at	O	O
our	O	O
institution	O	O
,	O	O
patients	O	O
who	O	O
are	O	O
scheduled	O	O
to	O	O
receive	O	O
a	O	O
bone	O	O
marrow	O	O
transplant	O	O
are	O	O
treated	O	O
prophylactically	O	O
with	O	O
forced	O	O
hydration	O	O
and	O	O
bladder	O	O
irrigation	O	O
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
obviate	O	O
the	O	O
inconvenience	O	O
of	O	O
bladder	O	O
irrigation	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
feasibility	O	O
trial	O	O
of	O	O
uroprophylaxis	O	O
with	O	O
mesna	B-Chemical	D015080
,	O	O
which	O	O
neutralizes	O	O
the	O	O
hepatic	O	O
metabolite	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
that	O	O
causes	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

Of	O	O
97	O	O
patients	O	O
who	O	O
received	O	O
standard	O	O
prophylaxis	O	O
,	O	O
4	O	O
had	O	O
symptomatic	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
two	O	O
of	O	O
four	O	O
consecutive	O	O
patients	O	O
who	O	O
received	O	O
mesna	B-Chemical	D015080
uroprophylaxis	O	O
before	O	O
allogeneic	O	O
bone	O	O
marrow	O	O
transplantation	O	O
had	O	O
severe	O	O
hemorrhagic	O	O
cystitis	O	O
for	O	O
at	O	O
least	O	O
2	O	O
weeks	O	O
.	O	O

Because	O	O
of	O	O
this	O	O
suboptimal	O	O
result	O	O
,	O	O
we	O	O
resumed	O	O
the	O	O
use	O	O
of	O	O
bladder	O	O
irrigation	O	O
and	O	O
forced	O	O
hydration	O	O
to	O	O
minimize	O	O
the	O	O
risk	O	O
of	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

Reversal	O	O
of	O	O
central	O	O
benzodiazepine	B-Chemical	D001569
effects	O	O
by	O	O
flumazenil	B-Chemical	D005442
after	O	O
intravenous	O	O
conscious	O	O
sedation	O	O
with	O	O
diazepam	B-Chemical	D003975
and	O	O
opioids	O	O
:	O	O
report	O	O
of	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
multicenter	O	O
study	O	O
.	O	O

The	O	O
Flumazenil	B-Chemical	D005442
in	O	O
Intravenous	O	O
Conscious	O	O
Sedation	O	O
with	O	O
Diazepam	B-Chemical	D003975
Multicenter	O	O
Study	O	O
Group	O	O
II	O	O
.	O	O

The	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
a	O	O
new	O	O
benzodiazepine	B-Chemical	D001569
antagonist	O	O
,	O	O
flumazenil	B-Chemical	D005442
,	O	O
were	O	O
assessed	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
multicenter	O	O
study	O	O
.	O	O

Flumazenil	B-Chemical	D005442
(	O	O
mean	O	O
dose	O	O
,	O	O
0	O	O
.	O	O

76	O	O
mg	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
mean	O	O
dose	O	O
,	O	O
8	O	O
.	O	O

9	O	O
ml	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
to	O	O
130	O	O
and	O	O
67	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
who	O	O
had	O	O
been	O	O
given	O	O
diazepam	B-Chemical	D003975
in	O	O
conjunction	O	O
with	O	O
an	O	O
opioid	O	O
(	O	O
fentanyl	B-Chemical	D005283
,	O	O
meperidine	B-Chemical	D008614
,	O	O
or	O	O
morphine	B-Chemical	D009020
)	O	O
for	O	O
the	O	O
induction	O	O
and	O	O
maintenance	O	O
of	O	O
intravenous	O	O
conscious	O	O
sedation	O	O
for	O	O
diagnostic	O	O
or	O	O
therapeutic	O	O
surgical	O	O
procedures	O	O
.	O	O

The	O	O
group	O	O
assessable	O	O
for	O	O
efficacy	O	O
comprised	O	O
122	O	O
patients	O	O
treated	O	O
with	O	O
flumazenil	B-Chemical	D005442
and	O	O
64	O	O
patients	O	O
given	O	O
placebo	O	O
.	O	O

After	O	O
5	O	O
minutes	O	O
,	O	O
80	O	O
/	O	O
115	O	O
(	O	O
70%	O	O
)	O	O
flumazenil	B-Chemical	D005442
-	O	O
treated	O	O
patients	O	O
,	O	O
compared	O	O
with	O	O
21	O	O
/	O	O
63	O	O
(	O	O
33%	O	O
)	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
,	O	O
were	O	O
completely	O	O
awake	O	O
and	O	O
alert	O	O
,	O	O
as	O	O
indicated	O	O
by	O	O
a	O	O
score	O	O
of	O	O
5	O	O
on	O	O
the	O	O
Observer's	O	O
Assessment	O	O
of	O	O
Alertness	O	O
/	O	O
Sedation	O	O
Scale	O	O
.	O	O

Ninety	O	O
-	O	O
five	O	O
percent	O	O
of	O	O
patients	O	O
in	O	O
each	O	O
group	O	O
who	O	O
attained	O	O
a	O	O
score	O	O
of	O	O
5	O	O
at	O	O
the	O	O
5	O	O
-	O	O
minute	O	O
assessment	O	O
showed	O	O
no	O	O
loss	O	O
of	O	O
alertness	O	O
throughout	O	O
the	O	O
180	O	O
-	O	O
minute	O	O
assessment	O	O
period	O	O
.	O	O

Flumazenil	B-Chemical	D005442
-	O	O
treated	O	O
patients	O	O
also	O	O
performed	O	O
significantly	O	O
better	O	O
on	O	O
the	O	O
Finger	O	O
-	O	O
to	O	O
-	O	O
Nose	O	O
Test	O	O
and	O	O
the	O	O
recall	O	O
of	O	O
pictures	O	O
shown	O	O
at	O	O
the	O	O
5	O	O
-	O	O
minute	O	O
assessment	O	O
.	O	O

Flumazenil	B-Chemical	D005442
was	O	O
well	O	O
tolerated	O	O
,	O	O
with	O	O
no	O	O
serious	O	O
adverse	O	O
effects	O	O
reported	O	O
.	O	O

Thirty	O	O
-	O	O
nine	O	O
(	O	O
30%	O	O
)	O	O
of	O	O
flumazenil	B-Chemical	D005442
-	O	O
treated	O	O
patients	O	O
,	O	O
compared	O	O
with	O	O
17	O	O
(	O	O
25%	O	O
)	O	O
of	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
had	O	O
one	O	O
or	O	O
more	O	O
drug	O	O
-	O	O
related	O	O
adverse	O	O
experiences	O	O
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
effects	O	O
were	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
in	O	O
the	O	O
flumazenil	B-Chemical	D005442
group	O	O
and	O	O
nausea	B-Disease	D009325
and	O	O
injection	O	O
-	O	O
site	O	O
pain	B-Disease	D010146
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

Flumazenil	B-Chemical	D005442
was	O	O
found	O	O
to	O	O
promptly	O	O
reverse	O	O
sedation	O	O
induced	O	O
by	O	O
diazepam	B-Chemical	D003975
in	O	O
the	O	O
presence	O	O
of	O	O
opioids	O	O
.	O	O

Hepatic	O	O
adenomas	B-Disease	D000236
and	O	O
focal	B-Disease	D020518
nodular	I-Disease	D020518
hyperplasia	I-Disease	D020518
of	O	O
the	O	O
liver	O	O
in	O	O
young	O	O
women	O	O
on	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
:	O	O
case	O	O
reports	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
hepatic	O	O
adenoma	B-Disease	D000236
and	O	O
one	O	O
of	O	O
focal	B-Disease	D020518
nodular	I-Disease	D020518
hyperplasia	I-Disease	D020518
presumably	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
,	O	O
are	O	O
reported	O	O
.	O	O

Special	O	O
reference	O	O
is	O	O
made	O	O
to	O	O
their	O	O
clinical	O	O
presentation	O	O
,	O	O
which	O	O
may	O	O
be	O	O
totally	O	O
asymptomatic	O	O
.	O	O

Liver	O	O
-	O	O
function	O	O
tests	O	O
are	O	O
of	O	O
little	O	O
diagnostic	O	O
value	O	O
,	O	O
but	O	O
valuable	O	O
information	O	O
may	O	O
be	O	O
obtained	O	O
from	O	O
both	O	O
liver	O	O
scanning	O	O
and	O	O
hepatic	O	O
angiography	O	O
.	O	O

Histologic	O	O
differences	O	O
and	O	O
clinical	O	O
similarities	O	O
between	O	O
hepatic	O	O
adenoma	B-Disease	D000236
and	O	O
focal	B-Disease	D020518
nodular	I-Disease	D020518
hyperplasia	I-Disease	D020518
of	O	O
the	O	O
liver	O	O
are	O	O
discussed	O	O
.	O	O

Arterial	O	O
thromboembolism	B-Disease	D013923
in	O	O
patients	O	O
receiving	O	O
systemic	O	O
heparin	B-Chemical	D006493
therapy	O	O
:	O	O
a	O	O
complication	O	O
associated	O	O
with	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

Arterial	O	O
thromboembolism	B-Disease	D013923
is	O	O
a	O	O
recognized	O	O
complication	O	O
of	O	O
systemic	O	O
heparin	B-Chemical	D006493
therapy	O	O
.	O	O

Characteristic	O	O
of	O	O
the	O	O
entity	O	O
is	O	O
arterial	B-Disease	D001157
occlusion	I-Disease	D001157
by	O	O
platelet	O	O
-	O	O
fibrin	O	O
thrombi	B-Disease	D013927
with	O	O
distal	O	O
ischemia	B-Disease	D007511
occurring	O	O
four	O	O
to	O	O
twenty	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
,	O	O
preceded	O	O
by	O	O
profound	O	O
thrombocytopenia	B-Disease	D013921
with	O	O
platelet	O	O
counts	O	O
in	O	O
the	O	O
range	O	O
of	O	O
30	O	O
,	O	O
000	O	O
to	O	O
40	O	O
,	O	O
000	O	O
per	O	O
cubic	O	O
millimeter	O	O
.	O	O

The	O	O
clinically	O	O
apparent	O	O
occlusion	O	O
may	O	O
be	O	O
preceded	O	O
by	O	O
gastrointestinal	O	O
and	O	O
musculoskeletal	O	O
symptoms	O	O
that	O	O
appear	O	O
to	O	O
be	O	O
ischemic	B-Disease	D007511
in	O	O
origin	O	O
,	O	O
and	O	O
might	O	O
serve	O	O
to	O	O
warn	O	O
the	O	O
clinician	O	O
of	O	O
these	O	O
complications	O	O
.	O	O

Previous	O	O
reports	O	O
of	O	O
these	O	O
phenomena	O	O
as	O	O
well	O	O
as	O	O
recent	O	O
studies	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
heparin	B-Chemical	D006493
are	O	O
reviewed	O	O
.	O	O

The	O	O
common	O	O
factor	O	O
relating	O	O
thromboembolism	B-Disease	D013923
and	O	O
thrombocytopenia	B-Disease	D013921
is	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
.	O	O

Appropriate	O	O
treatment	O	O
consists	O	O
of	O	O
discontinuation	O	O
of	O	O
heparin	B-Chemical	D006493
,	O	O
and	O	O
anticoagulation	O	O
with	O	O
sodium	B-Chemical	D014859
warfarin	I-Chemical	D014859
if	O	O
necessary	O	O
.	O	O

Vascular	O	O
procedures	O	O
are	O	O
performed	O	O
as	O	O
indicated	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
prognosis	O	O
for	O	O
transplant	O	O
-	O	O
free	O	O
survivors	O	O
of	O	O
paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
prognosis	O	O
for	O	O
transplant	O	O
-	O	O
free	O	O
survivors	O	O
of	O	O
paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
remains	O	O
unknown	O	O
.	O	O

AIM	O	O
:	O	O
To	O	O
examine	O	O
whether	O	O
paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
increases	O	O
long	O	O
-	O	O
term	O	O
mortality	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
followed	O	O
up	O	O
all	O	O
transplant	O	O
-	O	O
free	O	O
survivors	O	O
of	O	O
paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D056486
liver	I-Disease	D056486
injury	I-Disease	D056486
,	O	O
hospitalized	O	O
in	O	O
a	O	O
Danish	O	O
national	O	O
referral	O	O
centre	O	O
during	O	O
1984	O	O
-	O	O
2004	O	O
.	O	O

We	O	O
compared	O	O
age	O	O
-	O	O
specific	O	O
mortality	O	O
rates	O	O
from	O	O
1	O	O
year	O	O
post	O	O
-	O	O
discharge	O	O
through	O	O
2008	O	O
between	O	O
those	O	O
in	O	O
whom	O	O
the	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
led	O	O
to	O	O
an	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
and	O	O
those	O	O
in	O	O
whom	O	O
it	O	O
did	O	O
not	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
included	O	O
641	O	O
patients	O	O
.	O	O

On	O	O
average	O	O
,	O	O
age	O	O
-	O	O
specific	O	O
mortality	O	O
rates	O	O
were	O	O
slightly	O	O
higher	O	O
for	O	O
the	O	O
101	O	O
patients	O	O
whose	O	O
paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
had	O	O
caused	O	O
an	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
adjusted	O	O
mortality	O	O
rate	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O

70	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

02	O	O
-	O	O
2	O	O
.	O	O

85	O	O
)	O	O
,	O	O
but	O	O
the	O	O
association	O	O
was	O	O
age	O	O
-	O	O
dependent	O	O
,	O	O
and	O	O
no	O	O
survivors	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
died	O	O
of	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
,	O	O
whereas	O	O
suicides	O	O
were	O	O
frequent	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

These	O	O
observations	O	O
speak	O	O
against	O	O
long	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

More	O	O
likely	O	O
,	O	O
the	O	O
elevated	O	O
mortality	O	O
rate	O	O
ratio	O	O
resulted	O	O
from	O	O
incomplete	O	O
adjustment	O	O
for	O	O
the	O	O
greater	O	O
prevalence	O	O
of	O	O
substance	B-Disease	D019966
abuse	I-Disease	D019966
among	O	O
survivors	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

CONCLUSIONS	O	O
:	O	O
Paracetamol	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
did	O	O
not	O	O
affect	O	O
long	O	O
-	O	O
term	O	O
mortality	O	O
.	O	O

Clinical	O	O
follow	O	O
-	O	O
up	O	O
may	O	O
be	O	O
justified	O	O
by	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
,	O	O
but	O	O
not	O	O
by	O	O
the	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
itself	O	O
.	O	O

Serotonin	B-Chemical	D012701
6	O	O
receptor	O	O
gene	O	O
is	O	O
associated	O	O
with	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
in	O	O
a	O	O
Japanese	O	O
population	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Altered	O	O
serotonergic	O	O
neural	O	O
transmission	O	O
is	O	O
hypothesized	O	O
to	O	O
be	O	O
a	O	O
susceptibility	O	O
factor	O	O
for	O	O
psychotic	B-Disease	D011605
disorders	I-Disease	D011605
such	O	O
as	O	O
schizophrenia	B-Disease	D012559
.	O	O

The	O	O
serotonin	B-Chemical	D012701
6	O	O
(	O	O
5	O	O
-	O	O
HT6	O	O
)	O	O
receptor	O	O
is	O	O
therapeutically	O	O
targeted	O	O
by	O	O
several	O	O
second	O	O
generation	O	O
antipsychotics	O	O
,	O	O
such	O	O
as	O	O
clozapine	B-Chemical	D003024
and	O	O
olanzapine	B-Chemical	C076029
,	O	O
and	O	O
d	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
in	O	O
rats	O	O
is	O	O
corrected	O	O
with	O	O
the	O	O
use	O	O
of	O	O
a	O	O
selective	O	O
5	O	O
-	O	O
HT6	O	O
receptor	O	O
antagonist	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
disrupted	O	O
prepulse	O	O
inhibition	O	O
induced	O	O
by	O	O
d	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
or	O	O
phencyclidine	B-Chemical	D010622
was	O	O
restored	O	O
by	O	O
5	O	O
-	O	O
HT6	O	O
receptor	O	O
antagonist	O	O
in	O	O
an	O	O
animal	O	O
study	O	O
using	O	O
rats	O	O
.	O	O

These	O	O
animal	O	O
models	O	O
were	O	O
considered	O	O
to	O	O
reflect	O	O
the	O	O
positive	O	O
symptoms	O	O
of	O	O
schizophrenia	B-Disease	D012559
,	O	O
and	O	O
the	O	O
above	O	O
evidence	O	O
suggests	O	O
that	O	O
altered	O	O
5	O	O
-	O	O
HT6	O	O
receptors	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
psychotic	B-Disease	D011605
disorders	I-Disease	D011605
.	O	O

The	O	O
symptoms	O	O
of	O	O
methamphetamine	B-Chemical	D008694
(	O	O
METH	B-Chemical	D008694
)	O	O
-	O	O
induced	O	O
psychosis	B-Disease	D011605
are	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
paranoid	B-Disease	D012563
type	I-Disease	D012563
schizophrenia	I-Disease	D012563
.	O	O

Therefore	O	O
,	O	O
we	O	O
conducted	O	O
an	O	O
analysis	O	O
of	O	O
the	O	O
association	O	O
of	O	O
the	O	O
5	O	O
-	O	O
HT6	O	O
gene	O	O
(	O	O
HTR6	O	O
)	O	O
with	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
.	O	O

METHOD	O	O
:	O	O
Using	O	O
five	O	O
tagging	O	O
SNPs	O	O
(	O	O
rs6693503	O	O
,	O	O
rs1805054	O	O
,	O	O
rs4912138	O	O
,	O	O
rs3790757	O	O
and	O	O
rs9659997	O	O
)	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
genetic	O	O
association	O	O
analysis	O	O
of	O	O
case	O	O
-	O	O
control	O	O
samples	O	O
(	O	O
197	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
patients	O	O
and	O	O
337	O	O
controls	O	O
)	O	O
in	O	O
the	O	O
Japanese	O	O
population	O	O
.	O	O

The	O	O
age	O	O
and	O	O
sex	O	O
of	O	O
the	O	O
control	O	O
subjects	O	O
did	O	O
not	O	O
differ	O	O
from	O	O
those	O	O
of	O	O
the	O	O
methamphetamine	B-Chemical	D008694
dependence	O	O
patients	O	O
.	O	O

RESULTS	O	O
:	O	O
rs6693503	O	O
was	O	O
associated	O	O
with	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
patients	O	O
in	O	O
the	O	O
allele	O	O
/	O	O
genotype	O	O
-	O	O
wise	O	O
analysis	O	O
.	O	O

Moreover	O	O
,	O	O
this	O	O
association	O	O
remained	O	O
significant	O	O
after	O	O
Bonferroni	O	O
correction	O	O
.	O	O

In	O	O
the	O	O
haplotype	O	O
-	O	O
wise	O	O
analysis	O	O
,	O	O
we	O	O
detected	O	O
an	O	O
association	O	O
between	O	O
two	O	O
markers	O	O
(	O	O
rs6693503	O	O
and	O	O
rs1805054	O	O
)	O	O
and	O	O
three	O	O
markers	O	O
(	O	O
rs6693503	O	O
,	O	O
rs1805054	O	O
and	O	O
rs4912138	O	O
)	O	O
in	O	O
HTR6	O	O
and	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
patients	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
:	O	O
HTR6	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
in	O	O
the	O	O
Japanese	O	O
population	O	O
.	O	O

Effect	O	O
of	O	O
increasing	O	O
intraperitoneal	O	O
infusion	O	O
rates	O	O
on	O	O
bupropion	B-Chemical	D016642
hydrochloride	I-Chemical	D016642
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
mice	O	O
.	O	O

BACKGROUND	O	O
:	O	O
It	O	O
is	O	O
not	O	O
known	O	O
if	O	O
there	O	O
is	O	O
a	O	O
relationship	O	O
between	O	O
input	O	O
rate	O	O
and	O	O
incidence	O	O
of	O	O
bupropion	B-Chemical	D016642
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

This	O	O
is	O	O
important	O	O
,	O	O
since	O	O
different	O	O
controlled	O	O
release	O	O
formulations	O	O
of	O	O
bupropion	B-Chemical	D016642
release	O	O
the	O	O
active	O	O
drug	O	O
at	O	O
different	O	O
rates	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
varying	O	O
the	O	O
intraperitoneal	O	O
infusion	O	O
rates	O	O
of	O	O
bupropion	B-Chemical	D016642
HCl	O	O
120	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
a	O	O
known	O	O
convulsive	B-Disease	D012640
dose	O	O
50	O	O
(	O	O
CD50	O	O
)	O	O
,	O	O
on	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
bupropion	B-Chemical	D016642
-	O	O
induced	O	O
convulsions	B-Disease	D012640
in	O	O
the	O	O
Swiss	O	O
albino	O	O
mice	O	O
.	O	O

A	O	O
total	O	O
of	O	O
69	O	O
mice	O	O
,	O	O
approximately	O	O
7	O	O
weeks	O	O
of	O	O
age	O	O
,	O	O
and	O	O
weighing	O	O
21	O	O
.	O	O

0	O	O
to	O	O
29	O	O
.	O	O

1	O	O
g	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
bupropion	B-Chemical	D016642
HCl	O	O
120	O	O
mg	O	O
/	O	O
kg	O	O
treatment	O	O
by	O	O
intraperitoneal	O	O
(	O	O
IP	O	O
)	O	O
administration	O	O
in	O	O
7	O	O
groups	O	O
(	O	O
9	O	O
to	O	O
10	O	O
animals	O	O
per	O	O
group	O	O
)	O	O
.	O	O

Bupropion	B-Chemical	D016642
HCl	I-Chemical	D016642
was	O	O
infused	O	O
through	O	O
a	O	O
surgically	O	O
implanted	O	O
IP	O	O
dosing	O	O
catheter	O	O
with	O	O
infusions	O	O
in	O	O
each	O	O
group	O	O
of	O	O
0	O	O
min	O	O
,	O	O
15	O	O
min	O	O
,	O	O
30	O	O
min	O	O
,	O	O
60	O	O
min	O	O
,	O	O
90	O	O
min	O	O
,	O	O
120	O	O
min	O	O
,	O	O
and	O	O
240	O	O
min	O	O
.	O	O

The	O	O
number	O	O
,	O	O
time	O	O
of	O	O
onset	O	O
,	O	O
duration	O	O
and	O	O
the	O	O
intensity	O	O
of	O	O
the	O	O
convulsions	B-Disease	D012640
or	O	O
absence	O	O
of	O	O
convulsions	B-Disease	D012640
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
results	O	O
showed	O	O
that	O	O
IP	O	O
administration	O	O
of	O	O
bupropion	B-Chemical	D016642
HCl	O	O
120	O	O
mg	O	O
/	O	O
kg	O	O
by	O	O
bolus	O	O
injection	O	O
induced	O	O
convulsions	B-Disease	D012640
in	O	O
6	O	O
out	O	O
of	O	O
10	O	O
mice	O	O
(	O	O
60%	O	O
of	O	O
convulsing	O	O
mice	O	O
)	O	O
in	O	O
group	O	O
1	O	O
.	O	O

Logistic	O	O
regression	O	O
analysis	O	O
revealed	O	O
that	O	O
infusion	O	O
time	O	O
was	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0004	O	O
;	O	O
odds	O	O
ratio	O	O
=	O	O
0	O	O
.	O	O

974	O	O
)	O	O
and	O	O
increasing	O	O
the	O	O
IP	O	O
infusion	O	O
time	O	O
of	O	O
bupropion	B-Chemical	D016642
HCl	O	O
120	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
91%	O	O
reduced	O	O
odds	O	O
of	O	O
convulsions	B-Disease	D012640
at	O	O
infusion	O	O
times	O	O
of	O	O
15	O	O
to	O	O
90	O	O
min	O	O
compared	O	O
to	O	O
bolus	O	O
injection	O	O
.	O	O

Further	O	O
increase	O	O
in	O	O
infusion	O	O
time	O	O
resulted	O	O
in	O	O
further	O	O
reduction	O	O
in	O	O
the	O	O
odds	O	O
of	O	O
convulsions	B-Disease	D012640
to	O	O
99	O	O
.	O	O

8%	O	O
reduction	O	O
at	O	O
240	O	O
min	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
conclusion	O	O
,	O	O
the	O	O
demonstration	O	O
of	O	O
an	O	O
inverse	O	O
relationship	O	O
between	O	O
infusion	O	O
time	O	O
of	O	O
a	O	O
fixed	O	O
and	O	O
convulsive	B-Disease	D012640
dose	O	O
of	O	O
bupropion	B-Chemical	D016642
and	O	O
the	O	O
risk	O	O
of	O	O
convulsions	B-Disease	D012640
in	O	O
a	O	O
prospective	O	O
study	O	O
is	O	O
novel	O	O
.	O	O

Detailed	O	O
spectral	O	O
profile	O	O
analysis	O	O
of	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
epileptiform	B-Disease	D004827
activity	I-Disease	D004827
in	O	O
anesthetized	O	O
rats	O	O
.	O	O

Penicillin	B-Chemical	D010406
model	O	O
is	O	O
a	O	O
widely	O	O
used	O	O
experimental	O	O
model	O	O
for	O	O
epilepsy	B-Disease	D004827
research	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
portray	O	O
a	O	O
detailed	O	O
spectral	O	O
analysis	O	O
of	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
epileptiform	B-Disease	D004827
activity	I-Disease	D004827
in	O	O
comparison	O	O
with	O	O
basal	O	O
brain	O	O
activity	O	O
in	O	O
anesthetized	O	O
Wistar	O	O
rats	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
anesthetized	O	O
with	O	O
i	O	O
.	O	O

p	O	O
.	O	O

urethane	B-Chemical	D014520
and	O	O
connected	O	O
to	O	O
an	O	O
electrocorticogram	O	O
setup	O	O
.	O	O

After	O	O
a	O	O
short	O	O
period	O	O
of	O	O
basal	O	O
activity	O	O
recording	O	O
,	O	O
epileptic	B-Disease	D004827
focus	O	O
was	O	O
induced	O	O
by	O	O
injecting	O	O
400IU	O	O
/	O	O
2	O	O
microl	O	O
penicillin	B-Chemical	D010406
-	O	O
G	O	O
potassium	O	O
into	O	O
the	O	O
left	O	O
lateral	O	O
ventricle	O	O
while	O	O
the	O	O
cortical	O	O
activity	O	O
was	O	O
continuously	O	O
recorded	O	O
.	O	O

Basal	O	O
activity	O	O
,	O	O
latent	O	O
period	O	O
and	O	O
the	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
epileptiform	B-Disease	D004827
activity	I-Disease	D004827
periods	O	O
were	O	O
then	O	O
analyzed	O	O
using	O	O
both	O	O
conventional	O	O
methods	O	O
and	O	O
spectral	O	O
analysis	O	O
.	O	O

Spectral	O	O
analyses	O	O
were	O	O
conducted	O	O
by	O	O
dividing	O	O
the	O	O
whole	O	O
spectrum	O	O
into	O	O
different	O	O
frequency	O	O
bands	O	O
including	O	O
delta	O	O
,	O	O
theta	O	O
(	O	O
slow	O	O
and	O	O
fast	O	O
)	O	O
,	O	O
alpha	O	O
-	O	O
sigma	O	O
,	O	O
beta	O	O
(	O	O
1	O	O
and	O	O
2	O	O
)	O	O
and	O	O
gamma	O	O
(	O	O
1	O	O
and	O	O
2	O	O
)	O	O
bands	O	O
.	O	O

Our	O	O
results	O	O
show	O	O
that	O	O
the	O	O
most	O	O
affected	O	O
frequency	O	O
bands	O	O
were	O	O
delta	O	O
,	O	O
theta	O	O
,	O	O
beta	O	O
-	O	O
2	O	O
and	O	O
gamma	O	O
-	O	O
2	O	O
bands	O	O
during	O	O
the	O	O
epileptiform	B-Disease	D004827
activity	I-Disease	D004827
and	O	O
there	O	O
were	O	O
marked	O	O
differences	O	O
in	O	O
terms	O	O
of	O	O
spectral	O	O
densities	O	O
between	O	O
three	O	O
investigated	O	O
episodes	O	O
(	O	O
basal	O	O
activity	O	O
,	O	O
latent	O	O
period	O	O
and	O	O
epileptiform	B-Disease	D004827
activity	I-Disease	D004827
)	O	O
.	O	O

Our	O	O
results	O	O
may	O	O
help	O	O
to	O	O
analyze	O	O
novel	O	O
data	O	O
obtained	O	O
using	O	O
similar	O	O
experimental	O	O
models	O	O
and	O	O
the	O	O
simple	O	O
analysis	O	O
method	O	O
described	O	O
here	O	O
can	O	O
be	O	O
used	O	O
in	O	O
similar	O	O
studies	O	O
to	O	O
investigate	O	O
the	O	O
basic	O	O
neuronal	O	O
mechanism	O	O
of	O	O
this	O	O
or	O	O
other	O	O
types	O	O
of	O	O
experimental	O	O
epilepsies	B-Disease	D004827
.	O	O

High	O	O
dose	O	O
dexmedetomidine	B-Chemical	D020927
as	O	O
the	O	O
sole	O	O
sedative	O	O
for	O	O
pediatric	O	O
MRI	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
large	O	O
-	O	O
scale	O	O
retrospective	O	O
review	O	O
evaluates	O	O
the	O	O
sedation	O	O
profile	O	O
of	O	O
dexmedetomidine	B-Chemical	D020927
.	O	O

AIM	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
hemodynamic	O	O
responses	O	O
,	O	O
efficacy	O	O
and	O	O
adverse	O	O
events	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
high	O	O
dose	O	O
dexmedetomidine	B-Chemical	D020927
as	O	O
the	O	O
sole	O	O
sedative	O	O
for	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
studies	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Dexmedetomidine	B-Chemical	D020927
has	O	O
been	O	O
used	O	O
at	O	O
our	O	O
institution	O	O
since	O	O
2005	O	O
to	O	O
provide	O	O
sedation	O	O
for	O	O
pediatric	O	O
radiological	O	O
imaging	O	O
studies	O	O
.	O	O

Over	O	O
time	O	O
,	O	O
an	O	O
effective	O	O
protocol	O	O
utilizing	O	O
high	O	O
dose	O	O
dexmedetomidine	B-Chemical	D020927
as	O	O
the	O	O
sole	O	O
sedative	O	O
agent	O	O
has	O	O
evolved	O	O
.	O	O

METHODS	O	O
/	O	O
MATERIALS	O	O
:	O	O
As	O	O
part	O	O
of	O	O
the	O	O
ongoing	O	O
Quality	O	O
Assurance	O	O
process	O	O
,	O	O
data	O	O
on	O	O
all	O	O
sedations	O	O
are	O	O
reviewed	O	O
monthly	O	O
and	O	O
protocols	O	O
modified	O	O
as	O	O
needed	O	O
.	O	O

Data	O	O
were	O	O
analyzed	O	O
from	O	O
all	O	O
747	O	O
consecutive	O	O
patients	O	O
who	O	O
received	O	O
dexmedetomidine	B-Chemical	D020927
for	O	O
MRI	O	O
sedation	O	O
from	O	O
April	O	O
2005	O	O
to	O	O
April	O	O
2007	O	O
.	O	O

RESULTS	O	O
:	O	O
Since	O	O
2005	O	O
,	O	O
the	O	O
10	O	O
-	O	O
min	O	O
loading	O	O
dose	O	O
of	O	O
our	O	O
dexmedetomidine	B-Chemical	D020927
protocol	O	O
increased	O	O
from	O	O
2	O	O
to	O	O
3	O	O
microg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
and	O	O
the	O	O
infusion	O	O
rate	O	O
increased	O	O
from	O	O
1	O	O
to	O	O
1	O	O
.	O	O

5	O	O
to	O	O
2	O	O
microg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

h	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

The	O	O
current	O	O
sedation	O	O
protocol	O	O
progressively	O	O
increased	O	O
the	O	O
rate	O	O
of	O	O
successful	O	O
sedation	O	O
(	O	O
able	O	O
to	O	O
complete	O	O
the	O	O
imaging	O	O
study	O	O
)	O	O
when	O	O
using	O	O
dexmedetomidine	B-Chemical	D020927
alone	O	O
from	O	O
91	O	O
.	O	O

8%	O	O
to	O	O
97	O	O
.	O	O

6%	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

009	O	O
)	O	O
,	O	O
reducing	O	O
the	O	O
requirement	O	O
for	O	O
adjuvant	O	O
pentobarbital	B-Chemical	D010424
in	O	O
the	O	O
event	O	O
of	O	O
sedation	O	O
failure	O	O
with	O	O
dexmedetomidine	B-Chemical	D020927
alone	O	O
and	O	O
decreased	O	O
the	O	O
mean	O	O
recovery	O	O
time	O	O
by	O	O
10	O	O
min	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Although	O	O
dexmedetomidine	B-Chemical	D020927
sedation	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
16%	O	O
incidence	O	O
of	O	O
bradycardia	B-Disease	D001919
,	O	O
all	O	O
concomitant	O	O
mean	O	O
arterial	O	O
blood	O	O
pressures	O	O
were	O	O
within	O	O
20%	O	O
of	O	O
age	O	O
-	O	O
adjusted	O	O
normal	O	O
range	O	O
and	O	O
oxygen	B-Chemical	D010100
saturations	O	O
were	O	O
95%	O	O
or	O	O
higher	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Dexmedetomidine	B-Chemical	D020927
in	O	O
high	O	O
doses	O	O
provides	O	O
adequate	O	O
sedation	O	O
for	O	O
pediatric	O	O
MRI	O	O
studies	O	O
.	O	O

While	O	O
use	O	O
of	O	O
high	O	O
dose	O	O
dexmedetomidine	B-Chemical	D020927
is	O	O
associated	O	O
with	O	O
decreases	O	O
in	O	O
heart	O	O
rate	O	O
and	O	O
blood	O	O
pressure	O	O
outside	O	O
the	O	O
established	O	O
'awake'	O	O
norms	O	O
,	O	O
this	O	O
deviation	O	O
is	O	O
generally	O	O
within	O	O
20%	O	O
of	O	O
norms	O	O
,	O	O
and	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
adverse	O	O
sequelae	O	O
.	O	O

Dexmedetomidine	B-Chemical	D020927
is	O	O
useful	O	O
as	O	O
the	O	O
sole	O	O
sedative	O	O
for	O	O
pediatric	O	O
MRI	O	O
.	O	O

Methamphetamine	B-Chemical	D008694
causes	O	O
alterations	O	O
in	O	O
the	O	O
MAP	O	O
kinase	O	O
-	O	O
related	O	O
pathways	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
mice	O	O
that	O	O
display	O	O
increased	O	O
aggressiveness	B-Disease	D001523
.	O	O

Aggressive	B-Disease	D001523
behaviors	I-Disease	D001523
have	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
who	O	O
suffer	O	O
from	O	O
some	O	O
psychiatric	B-Disease	D001523
disorders	I-Disease	D001523
,	O	O
and	O	O
are	O	O
common	O	O
in	O	O
methamphetamine	B-Chemical	D008694
(	O	O
METH	B-Chemical	D008694
)	O	O
abusers	O	O
.	O	O

Herein	O	O
,	O	O
we	O	O
report	O	O
that	O	O
multiple	O	O
(	O	O
but	O	O
not	O	O
single	O	O
)	O	O
injections	O	O
of	O	O
METH	B-Chemical	D008694
significantly	O	O
increased	O	O
aggressiveness	B-Disease	D001523
in	O	O
male	O	O
CD	O	O
-	O	O
1	O	O
mice	O	O
.	O	O

This	O	O
increase	O	O
in	O	O
aggressiveness	B-Disease	D001523
was	O	O
not	O	O
secondary	O	O
to	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

Analysis	O	O
of	O	O
protein	O	O
expression	O	O
using	O	O
antibody	O	O
microarrays	O	O
and	O	O
Western	O	O
blotting	O	O
revealed	O	O
differential	O	O
changes	O	O
in	O	O
MAP	O	O
kinase	O	O
-	O	O
related	O	O
pathways	O	O
after	O	O
multiple	O	O
and	O	O
single	O	O
METH	B-Chemical	D008694
injections	O	O
.	O	O

There	O	O
were	O	O
statistically	O	O
significant	O	O
(	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
decreases	O	O
in	O	O
MEK1	O	O
,	O	O
Erk2p	O	O
,	O	O
GSK3alpha	O	O
,	O	O
14	O	O
-	O	O
3	O	O
-	O	O
3e	O	O
,	O	O
and	O	O
MEK7	O	O
in	O	O
the	O	O
striata	O	O
of	O	O
mice	O	O
after	O	O
multiple	O	O
injections	O	O
of	O	O
METH	B-Chemical	D008694
.	O	O

MEK1	O	O
was	O	O
significantly	O	O
decreased	O	O
also	O	O
after	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
METH	B-Chemical	D008694
,	O	O
but	O	O
to	O	O
a	O	O
much	O	O
lesser	O	O
degree	O	O
than	O	O
after	O	O
multiple	O	O
injections	O	O
of	O	O
METH	B-Chemical	D008694
.	O	O

In	O	O
the	O	O
frontal	O	O
cortex	O	O
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
decrease	O	O
in	O	O
GSK3alpha	O	O
after	O	O
multiple	O	O
(	O	O
but	O	O
not	O	O
single	O	O
)	O	O
injections	O	O
of	O	O
METH	B-Chemical	D008694
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
alterations	O	O
in	O	O
MAP	O	O
kinase	O	O
-	O	O
related	O	O
pathways	O	O
in	O	O
the	O	O
prefronto	O	O
-	O	O
striatal	O	O
circuitries	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
manifestation	O	O
of	O	O
aggressive	B-Disease	D001523
behaviors	I-Disease	D001523
in	O	O
mice	O	O
.	O	O

Lamotrigine	B-Chemical	C047781
associated	O	O
with	O	O
exacerbation	O	O
or	O	O
de	O	O
novo	O	O
myoclonus	B-Disease	D009207
in	O	O
idiopathic	B-Disease	C562694
generalized	I-Disease	C562694
epilepsies	I-Disease	C562694
.	O	O

Five	O	O
patients	O	O
with	O	O
idiopathic	B-Disease	C562694
generalized	I-Disease	C562694
epilepsies	I-Disease	C562694
(	O	O
IGE	B-Disease	C562694
)	O	O
treated	O	O
with	O	O
lamotrigine	B-Chemical	C047781
(	O	O
LTG	B-Chemical	C047781
)	O	O
experienced	O	O
exacerbation	O	O
or	O	O
de	O	O
novo	O	O
appearance	O	O
of	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
(	O	O
MJ	B-Disease	D009207
)	O	O
.	O	O

In	O	O
three	O	O
patients	O	O
,	O	O
LTG	B-Chemical	C047781
exacerbated	O	O
MJ	B-Disease	D009207
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
with	O	O
early	O	O
aggravation	O	O
during	O	O
titration	O	O
.	O	O

MJ	B-Disease	D009207
disappeared	O	O
when	O	O
LTG	B-Chemical	C047781
dose	O	O
was	O	O
decreased	O	O
by	O	O
25	O	O
to	O	O
50%	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
LTG	B-Chemical	C047781
exacerbated	O	O
MJ	B-Disease	D009207
in	O	O
a	O	O
delayed	O	O
but	O	O
more	O	O
severe	O	O
manner	O	O
,	O	O
with	O	O
myoclonic	B-Disease	D009207
status	I-Disease	D009207
that	O	O
only	O	O
ceased	O	O
after	O	O
LTG	B-Chemical	C047781
withdrawal	O	O
.	O	O

rTMS	O	O
of	O	O
supplementary	O	O
motor	O	O
area	O	O
modulates	O	O
therapy	O	O
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
Parkinson	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

The	O	O
neural	O	O
mechanisms	O	O
and	O	O
circuitry	O	O
involved	O	O
in	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
are	O	O
unclear	O	O
.	O	O

Using	O	O
repetitive	O	O
transcranial	O	O
magnetic	O	O
stimulation	O	O
(	O	O
rTMS	O	O
)	O	O
over	O	O
the	O	O
supplementary	O	O
motor	O	O
area	O	O
(	O	O
SMA	O	O
)	O	O
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
advanced	O	O
Parkinson	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
the	O	O
authors	O	O
investigated	O	O
whether	O	O
modulation	O	O
of	O	O
SMA	O	O
excitability	O	O
may	O	O
result	O	O
in	O	O
a	O	O
modification	O	O
of	O	O
a	O	O
dyskinetic	B-Disease	D004409
state	O	O
induced	O	O
by	O	O
continuous	O	O
apomorphine	B-Chemical	D001058
infusion	O	O
.	O	O

rTMS	O	O
at	O	O
1	O	O
Hz	O	O
was	O	O
observed	O	O
to	O	O
markedly	O	O
reduce	O	O
drug	B-Disease	D004409
-	I-Disease	D004409
induced	I-Disease	D004409
dyskinesias	I-Disease	D004409
,	O	O
whereas	O	O
5	O	O
-	O	O
Hz	O	O
rTMS	O	O
induced	O	O
a	O	O
slight	O	O
but	O	O
not	O	O
significant	O	O
increase	O	O
.	O	O

Assessment	O	O
of	O	O
the	O	O
onset	O	O
and	O	O
persistence	O	O
of	O	O
amnesia	B-Disease	D000647
during	O	O
procedural	O	O
sedation	O	O
with	O	O
propofol	B-Chemical	D015742
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
patients'	O	O
ability	O	O
to	O	O
repeat	O	O
and	O	O
recall	O	O
words	O	O
presented	O	O
to	O	O
them	O	O
while	O	O
undergoing	O	O
procedural	O	O
sedation	O	O
with	O	O
propofol	B-Chemical	D015742
,	O	O
and	O	O
correlate	O	O
their	O	O
recall	O	O
with	O	O
their	O	O
level	O	O
of	O	O
awareness	O	O
as	O	O
measured	O	O
by	O	O
bispectral	O	O
index	O	O
(	O	O
BIS	O	O
)	O	O
monitoring	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
was	O	O
a	O	O
prospective	O	O
,	O	O
single	O	O
-	O	O
intervention	O	O
study	O	O
of	O	O
consenting	O	O
adult	O	O
patients	O	O
undergoing	O	O
procedural	O	O
sedation	O	O
with	O	O
propofol	B-Chemical	D015742
between	O	O
December	O	O
28	O	O
,	O	O
2002	O	O
,	O	O
and	O	O
October	O	O
31	O	O
,	O	O
2003	O	O
.	O	O

BIS	O	O
monitoring	O	O
was	O	O
initiated	O	O
starting	O	O
3	O	O
minutes	O	O
before	O	O
the	O	O
procedure	O	O
and	O	O
continuing	O	O
until	O	O
the	O	O
patient	O	O
had	O	O
regained	O	O
baseline	O	O
mental	O	O
status	O	O
.	O	O

At	O	O
1	O	O
-	O	O
minute	O	O
intervals	O	O
during	O	O
the	O	O
procedural	O	O
sedation	O	O
,	O	O
until	O	O
the	O	O
patient	O	O
regained	O	O
baseline	O	O
mental	O	O
status	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
procedure	O	O
,	O	O
a	O	O
word	O	O
from	O	O
a	O	O
standardized	O	O
list	O	O
was	O	O
read	O	O
aloud	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
asked	O	O
to	O	O
immediately	O	O
repeat	O	O
the	O	O
word	O	O
to	O	O
the	O	O
investigator	O	O
.	O	O

The	O	O
BIS	O	O
score	O	O
at	O	O
the	O	O
time	O	O
the	O	O
word	O	O
was	O	O
read	O	O
and	O	O
the	O	O
patient's	O	O
ability	O	O
to	O	O
repeat	O	O
the	O	O
word	O	O
were	O	O
recorded	O	O
.	O	O

After	O	O
the	O	O
procedure	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
asked	O	O
to	O	O
state	O	O
all	O	O
of	O	O
the	O	O
words	O	O
from	O	O
the	O	O
list	O	O
that	O	O
he	O	O
or	O	O
she	O	O
could	O	O
recall	O	O
,	O	O
and	O	O
to	O	O
identify	O	O
the	O	O
last	O	O
word	O	O
recalled	O	O
from	O	O
prior	O	O
to	O	O
the	O	O
start	O	O
of	O	O
the	O	O
procedure	O	O
and	O	O
the	O	O
first	O	O
word	O	O
recalled	O	O
from	O	O
after	O	O
the	O	O
procedure	O	O
was	O	O
completed	O	O
.	O	O

RESULTS	O	O
:	O	O
Seventy	O	O
-	O	O
five	O	O
consenting	O	O
patients	O	O
were	O	O
enrolled	O	O
;	O	O
one	O	O
patient	O	O
was	O	O
excluded	O	O
from	O	O
data	O	O
analysis	O	O
for	O	O
a	O	O
protocol	O	O
violation	O	O
.	O	O

No	O	O
serious	O	O
adverse	O	O
events	O	O
were	O	O
noted	O	O
during	O	O
the	O	O
procedural	O	O
sedations	O	O
.	O	O

The	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
standard	O	O
deviation	O	O
)	O	O
time	O	O
of	O	O
data	O	O
collection	O	O
was	O	O
16	O	O
.	O	O

4	O	O
minutes	O	O
(	O	O
+	O	O
/	O	O
-	O	O
7	O	O
.	O	O

1	O	O
;	O	O
range	O	O
5	O	O
to	O	O
34	O	O
minutes	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
initial	O	O
(	O	O
preprocedure	O	O
)	O	O
BIS	O	O
score	O	O
was	O	O
97	O	O
.	O	O

1	O	O
(	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

3	O	O
;	O	O
range	O	O
92	O	O
to	O	O
99	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
lowest	O	O
BIS	O	O
score	O	O
occurring	O	O
during	O	O
these	O	O
procedural	O	O
sedations	O	O
was	O	O
66	O	O
.	O	O

9	O	O
(	O	O
+	O	O
/	O	O
-	O	O
14	O	O
.	O	O

4	O	O
;	O	O
range	O	O
33	O	O
to	O	O
91	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
lowest	O	O
BIS	O	O
score	O	O
corresponding	O	O
to	O	O
the	O	O
ability	O	O
of	O	O
the	O	O
patient	O	O
to	O	O
immediately	O	O
repeat	O	O
words	O	O
read	O	O
from	O	O
the	O	O
list	O	O
was	O	O
77	O	O
.	O	O

1	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
74	O	O
.	O	O

3	O	O
to	O	O
80	O	O
.	O	O

0	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
highest	O	O
BIS	O	O
score	O	O
corresponding	O	O
to	O	O
the	O	O
inability	B-Disease	D000647
to	I-Disease	D000647
repeat	I-Disease	D000647
words	I-Disease	D000647
was	O	O
81	O	O
.	O	O

5	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
78	O	O
.	O	O

1	O	O
to	O	O
84	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
BIS	O	O
score	O	O
corresponding	O	O
to	O	O
the	O	O
last	O	O
word	O	O
recalled	O	O
from	O	O
prior	O	O
to	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
sedation	O	O
was	O	O
96	O	O
.	O	O

7	O	O
(	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

4	O	O
;	O	O
range	O	O
84	O	O
to	O	O
98	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
BIS	O	O
score	O	O
corresponding	O	O
to	O	O
the	O	O
first	O	O
word	O	O
recalled	O	O
after	O	O
the	O	O
procedure	O	O
was	O	O
completed	O	O
was	O	O
91	O	O
.	O	O

2	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
88	O	O
.	O	O

1	O	O
to	O	O
94	O	O
.	O	O

3	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
recalled	O	O
at	O	O
least	O	O
one	O	O
word	O	O
that	O	O
had	O	O
been	O	O
read	O	O
to	O	O
them	O	O
during	O	O
the	O	O
protocol	O	O
.	O	O

The	O	O
mean	O	O
lowest	O	O
BIS	O	O
score	O	O
for	O	O
any	O	O
recalled	O	O
word	O	O
was	O	O
91	O	O
.	O	O

5	O	O
(	O	O
+	O	O
/	O	O
-	O	O
11	O	O
.	O	O

1	O	O
;	O	O
range	O	O
79	O	O
to	O	O
98	O	O
)	O	O
,	O	O
and	O	O
no	O	O
words	O	O
were	O	O
recalled	O	O
when	O	O
the	O	O
corresponding	O	O
BIS	O	O
score	O	O
was	O	O
less	O	O
than	O	O
90	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
There	O	O
is	O	O
a	O	O
range	O	O
of	O	O
BIS	O	O
scores	O	O
during	O	O
which	O	O
sedated	O	O
patients	O	O
are	O	O
able	O	O
to	O	O
repeat	O	O
words	O	O
read	O	O
to	O	O
them	O	O
but	O	O
are	O	O
not	O	O
able	O	O
to	O	O
subsequently	O	O
recall	O	O
these	O	O
words	O	O
.	O	O

Furthermore	O	O
,	O	O
patients	O	O
had	O	O
no	O	O
recall	O	O
of	O	O
words	O	O
repeated	O	O
prior	O	O
to	O	O
procedural	O	O
sedation	O	O
in	O	O
BIS	O	O
ranges	O	O
associated	O	O
with	O	O
recall	O	O
after	O	O
procedural	O	O
sedation	O	O
,	O	O
suggestive	O	O
of	O	O
retrograde	B-Disease	D000648
amnesia	I-Disease	D000648
.	O	O

Assessment	O	O
of	O	O
perinatal	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
and	O	O
rubella	B-Disease	D012409
prevention	O	O
in	O	O
New	O	O
Hampshire	O	O
delivery	O	O
hospitals	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
current	O	O
performance	O	O
on	O	O
recommended	O	O
perinatal	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
and	O	O
rubella	B-Disease	D012409
prevention	O	O
practices	O	O
in	O	O
New	O	O
Hampshire	O	O
.	O	O

METHODS	O	O
:	O	O
Data	O	O
were	O	O
extracted	O	O
from	O	O
2021	O	O
paired	O	O
mother	O	O
-	O	O
infant	O	O
records	O	O
for	O	O
the	O	O
year	O	O
2000	O	O
birth	O	O
cohort	O	O
in	O	O
New	O	O
Hampshire's	O	O
25	O	O
delivery	O	O
hospitals	O	O
.	O	O

Assessment	O	O
was	O	O
done	O	O
on	O	O
the	O	O
following	O	O
:	O	O
prenatal	O	O
screening	O	O
for	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
and	O	O
rubella	B-Disease	D012409
,	O	O
administration	O	O
of	O	O
the	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
vaccine	O	O
birth	O	O
dose	O	O
to	O	O
all	O	O
infants	O	O
,	O	O
administration	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
to	O	O
infants	O	O
who	O	O
were	O	O
born	O	O
to	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
-	O	O
positive	O	O
mothers	O	O
,	O	O
rubella	B-Disease	D012409
immunity	O	O
,	O	O
and	O	O
administration	O	O
of	O	O
in	O	O
-	O	O
hospital	O	O
postpartum	O	O
rubella	B-Disease	D012409
vaccine	O	O
to	O	O
rubella	B-Disease	D012409
nonimmune	O	O
women	O	O
.	O	O

RESULTS	O	O
:	O	O
Prenatal	O	O
screening	O	O
rates	O	O
for	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
(	O	O
98	O	O
.	O	O

8%	O	O
)	O	O
and	O	O
rubella	B-Disease	D012409
(	O	O
99	O	O
.	O	O

4%	O	O
)	O	O
were	O	O
high	O	O
.	O	O

Hepatitis	B-Disease	D006509
B	I-Disease	D006509
vaccine	O	O
birth	O	O
dose	O	O
was	O	O
administered	O	O
to	O	O
76	O	O
.	O	O

2%	O	O
of	O	O
all	O	O
infants	O	O
.	O	O

All	O	O
infants	O	O
who	O	O
were	O	O
born	O	O
to	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
-	O	O
positive	O	O
mothers	O	O
also	O	O
received	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
.	O	O

Multivariate	O	O
logistic	O	O
regression	O	O
showed	O	O
that	O	O
the	O	O
month	O	O
of	O	O
delivery	O	O
and	O	O
infant	O	O
birth	O	O
weight	O	O
were	O	O
independent	O	O
predictors	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
vaccination	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
infants	O	O
who	O	O
were	O	O
vaccinated	O	O
in	O	O
January	O	O
and	O	O
February	O	O
2000	O	O
(	O	O
48	O	O
.	O	O

5%	O	O
and	O	O
67	O	O
.	O	O

5%	O	O
,	O	O
respectively	O	O
)	O	O
was	O	O
less	O	O
than	O	O
any	O	O
other	O	O
months	O	O
,	O	O
whereas	O	O
the	O	O
proportion	O	O
who	O	O
were	O	O
vaccinated	O	O
in	O	O
December	O	O
2000	O	O
(	O	O
88	O	O
.	O	O

2%	O	O
)	O	O
was	O	O
the	O	O
highest	O	O
.	O	O

Women	O	O
who	O	O
were	O	O
born	O	O
between	O	O
1971	O	O
and	O	O
1975	O	O
had	O	O
the	O	O
highest	O	O
rate	O	O
of	O	O
rubella	B-Disease	D012409
nonimmunity	O	O
(	O	O
9	O	O
.	O	O

5%	O	O
)	O	O
.	O	O

In	O	O
-	O	O
hospital	O	O
postpartum	O	O
rubella	B-Disease	D012409
vaccine	O	O
administration	O	O
was	O	O
documented	O	O
for	O	O
75	O	O
.	O	O

6%	O	O
of	O	O
nonimmune	O	O
women	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
documents	O	O
good	O	O
compliance	O	O
in	O	O
New	O	O
Hampshire's	O	O
birthing	O	O
hospitals	O	O
with	O	O
national	O	O
guidelines	O	O
for	O	O
perinatal	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
and	O	O
rubella	B-Disease	D012409
prevention	O	O
and	O	O
highlights	O	O
potential	O	O
areas	O	O
for	O	O
improvement	O	O
.	O	O

Expression	O	O
of	O	O
p300	O	O
protects	O	O
cardiac	O	O
myocytes	O	O
from	O	O
apoptosis	O	O
in	O	O
vivo	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
is	O	O
an	O	O
anti	O	O
-	O	O
tumor	B-Disease	D009369
agent	O	O
that	O	O
represses	O	O
cardiac	O	O
-	O	O
specific	O	O
gene	O	O
expression	O	O
and	O	O
induces	O	O
myocardial	O	O
cell	O	O
apoptosis	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
depletes	O	O
cardiac	O	O
p300	O	O
,	O	O
a	O	O
transcriptional	O	O
coactivator	O	O
that	O	O
is	O	O
required	O	O
for	O	O
the	O	O
maintenance	O	O
of	O	O
the	O	O
differentiated	O	O
phenotype	O	O
of	O	O
cardiac	O	O
myocytes	O	O
.	O	O

However	O	O
,	O	O
the	O	O
role	O	O
of	O	O
p300	O	O
in	O	O
protection	O	O
against	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
apoptosis	O	O
is	O	O
unknown	O	O
.	O	O

Transgenic	O	O
mice	O	O
overexpressing	O	O
p300	O	O
in	O	O
the	O	O
heart	O	O
and	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
were	O	O
subjected	O	O
to	O	O
doxorubicin	B-Chemical	D004317
treatment	O	O
.	O	O

Compared	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
,	O	O
transgenic	O	O
mice	O	O
exhibited	O	O
higher	O	O
survival	O	O
rate	O	O
as	O	O
well	O	O
as	O	O
more	O	O
preserved	O	O
left	O	O
ventricular	O	O
function	O	O
and	O	O
cardiac	O	O
expression	O	O
of	O	O
alpha	O	O
-	O	O
sarcomeric	O	O
actin	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
induced	O	O
myocardial	O	O
cell	O	O
apoptosis	O	O
in	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
but	O	O
not	O	O
in	O	O
transgenic	O	O
mice	O	O
.	O	O

Expression	O	O
of	O	O
p300	O	O
increased	O	O
the	O	O
cardiac	O	O
level	O	O
of	O	O
bcl	O	O
-	O	O
2	O	O
and	O	O
mdm	O	O
-	O	O
2	O	O
,	O	O
but	O	O
not	O	O
that	O	O
of	O	O
p53	O	O
or	O	O
other	O	O
members	O	O
of	O	O
the	O	O
bcl	O	O
-	O	O
2	O	O
family	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
that	O	O
overexpression	O	O
of	O	O
p300	O	O
protects	O	O
cardiac	O	O
myocytes	O	O
from	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
apoptosis	O	O
and	O	O
reduces	O	O
the	O	O
extent	O	O
of	O	O
acute	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
in	O	O
adult	O	O
mice	O	O
in	O	O
vivo	O	O
.	O	O

Mitochondrial	O	O
DNA	O	O
and	O	O
its	O	O
respiratory	O	O
chain	O	O
products	O	O
are	O	O
defective	O	O
in	O	O
doxorubicin	B-Chemical	D004317
nephrosis	B-Disease	D009401
.	O	O

BACKGROUND	O	O
:	O	O
Doxorubicin	B-Chemical	D004317
induces	O	O
a	O	O
self	O	O
-	O	O
perpetuating	O	O
nephropathy	B-Disease	D007674
characterized	O	O
by	O	O
early	O	O
glomerular	B-Disease	D007674
and	I-Disease	D007674
late	I-Disease	D007674
-	I-Disease	D007674
onset	I-Disease	D007674
tubular	I-Disease	D007674
lesions	I-Disease	D007674
in	O	O
rats	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
mitochondrial	B-Disease	D028361
injury	I-Disease	D028361
in	O	O
the	O	O
onset	O	O
of	O	O
these	O	O
lesions	O	O
.	O	O

METHODS	O	O
:	O	O
Rats	O	O
were	O	O
treated	O	O
with	O	O
intravenous	O	O
doxorubicin	B-Chemical	D004317
(	O	O
1	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
week	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
for	O	O
7	O	O
weeks	O	O
and	O	O
were	O	O
sacrificed	O	O
either	O	O
1	O	O
week	O	O
(	O	O
'short	O	O
-	O	O
term'	O	O
)	O	O
or	O	O
30	O	O
weeks	O	O
(	O	O
'long	O	O
-	O	O
term'	O	O
)	O	O
following	O	O
the	O	O
last	O	O
dose	O	O
.	O	O

Additional	O	O
rats	O	O
received	O	O
a	O	O
single	O	O
dose	O	O
either	O	O
6	O	O
days	O	O
or	O	O
2	O	O
h	O	O
prior	O	O
to	O	O
euthanasia	O	O
.	O	O

All	O	O
rats	O	O
were	O	O
killed	O	O
at	O	O
48	O	O
weeks	O	O
of	O	O
age	O	O
.	O	O

Glomerular	B-Disease	D007674
and	I-Disease	D007674
tubular	I-Disease	D007674
injury	I-Disease	D007674
was	O	O
monitored	O	O
and	O	O
correlated	O	O
to	O	O
the	O	O
activity	O	O
or	O	O
expression	O	O
of	O	O
respiratory	O	O
chain	O	O
components	O	O
.	O	O

Finally	O	O
,	O	O
we	O	O
quantified	O	O
both	O	O
nuclear	O	O
and	O	O
mitochondrial	O	O
DNA	O	O
(	O	O
mtDNA	O	O
)	O	O
as	O	O
well	O	O
as	O	O
superoxide	B-Chemical	D013481
production	O	O
and	O	O
the	O	O
4834	O	O
base	O	O
pair	O	O
'common'	O	O
mtDNA	O	O
deletion	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
'long	O	O
-	O	O
term'	O	O
group	O	O
had	O	O
significant	O	O
glomerular	B-Disease	D007674
and	I-Disease	D007674
tubular	I-Disease	D007674
lesions	I-Disease	D007674
,	O	O
depressed	O	O
activities	O	O
of	O	O
mtDNA	O	O
-	O	O
encoded	O	O
NADH	O	O
dehydrogenase	O	O
and	O	O
cytochrome	O	O
-	O	O
c	O	O
oxidase	O	O
(	O	O
COX	O	O
)	O	O
and	O	O
increased	O	O
citrate	B-Chemical	C102006
synthase	O	O
activity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
expression	O	O
of	O	O
the	O	O
mtDNA	O	O
-	O	O
encoded	O	O
COX	O	O
subunit	O	O
I	O	O
was	O	O
reduced	O	O
and	O	O
mtDNA	O	O
levels	O	O
were	O	O
decreased	O	O
.	O	O

In	O	O
'short	O	O
-	O	O
term'	O	O
rats	O	O
,	O	O
there	O	O
were	O	O
fewer	O	O
tubular	B-Disease	D007674
lesions	I-Disease	D007674
,	O	O
but	O	O
similar	O	O
numbers	O	O
of	O	O
glomerular	B-Disease	D007674
lesions	I-Disease	D007674
activity	O	O
.	O	O

Among	O	O
all	O	O
animals	O	O
,	O	O
glomerular	B-Disease	D007674
and	I-Disease	D007674
tubular	I-Disease	D007674
injury	I-Disease	D007674
were	O	O
inversely	O	O
correlated	O	O
with	O	O
mtDNA	O	O
levels	O	O
,	O	O
mtDNA	O	O
-	O	O
encoded	O	O
respiratory	O	O
chain	O	O
activities	O	O
and	O	O
with	O	O
the	O	O
expression	O	O
of	O	O
the	O	O
mtDNA	O	O
-	O	O
encoded	O	O
respiratory	O	O
chain	O	O
subunit	O	O
COX	O	O
-	O	O
I	O	O
.	O	O

Injury	O	O
was	O	O
positively	O	O
correlated	O	O
with	O	O
superoxide	B-Chemical	D013481
production	O	O
and	O	O
the	O	O
activities	O	O
of	O	O
nucleus	O	O
-	O	O
encoded	O	O
mitochondrial	O	O
or	O	O
cytoplasmic	O	O
enzymes	O	O
.	O	O

Kidneys	O	O
from	O	O
the	O	O
'long	O	O
-	O	O
term'	O	O
group	O	O
showed	O	O
more	O	O
mtDNA	O	O
deletions	O	O
than	O	O
in	O	O
'short	O	O
-	O	O
term'	O	O
animals	O	O
and	O	O
these	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
an	O	O
important	O	O
role	O	O
for	O	O
quantitative	O	O
and	O	O
qualitative	O	O
mtDNA	O	O
alterations	O	O
through	O	O
the	O	O
reduction	O	O
of	O	O
mtDNA	O	O
-	O	O
encoded	O	O
respiratory	O	O
chain	O	O
function	O	O
and	O	O
induction	O	O
of	O	O
superoxide	B-Chemical	D013481
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
renal	B-Disease	D007674
lesions	I-Disease	D007674
.	O	O

Amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
a	O	O
patient	O	O
with	O	O
AIDS	B-Disease	D000163
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
multiple	O	O
episodes	O	O
of	O	O
seizure	B-Disease	D012640
activity	O	O
in	O	O
an	O	O
AIDS	B-Disease	D000163
patent	O	O
following	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
infusion	O	O
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
46	O	O
-	O	O
year	O	O
-	O	O
old	O	O
African	O	O
-	O	O
American	O	O
man	O	O
experienced	O	O
recurrent	O	O
grand	B-Disease	D004830
mal	I-Disease	D004830
seizures	I-Disease	D004830
during	O	O
intravenous	O	O
infusion	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
,	O	O
then	O	O
petit	O	O
mal	O	O
seizures	B-Disease	D012640
as	O	O
the	O	O
infusion	O	O
was	O	O
stopped	O	O
and	O	O
the	O	O
drug	O	O
concentrations	O	O
decreased	O	O
with	O	O
time	O	O
.	O	O

The	O	O
patients	O	O
concurrent	O	O
medications	O	O
included	O	O
didanosine	B-Chemical	D016049
,	O	O
hydroxyzine	B-Chemical	D006919
,	O	O
promethazine	B-Chemical	D011398
,	O	O
hydrocortisone	B-Chemical	D006854
,	O	O
and	O	O
prochlorperazine	B-Chemical	D011346
.	O	O

Despite	O	O
administration	O	O
of	O	O
phenytoin	B-Chemical	D010672
and	O	O
lorazepam	B-Chemical	D008140
,	O	O
the	O	O
seizures	B-Disease	D012640
persisted	O	O
and	O	O
occurred	O	O
only	O	O
during	O	O
amphotercin	B-Chemical	D000666
B	I-Chemical	D000666
administration	O	O
.	O	O

DISCUSSION	O	O
:	O	O
AIDS	B-Disease	D000163
and	O	O
cryptococcal	B-Disease	D016919
meningitis	I-Disease	D016919
,	O	O
both	O	O
of	O	O
which	O	O
the	O	O
patient	O	O
had	O	O
,	O	O
can	O	O
potentially	O	O
cause	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
patient	O	O
had	O	O
a	O	O
history	O	O
of	O	O
alcohol	B-Disease	D000437
abuse	I-Disease	D000437
;	O	O
alcohol	B-Chemical	D000431
intake	O	O
as	O	O
well	O	O
as	O	O
withdrawal	O	O
can	O	O
also	O	O
cause	O	O
seizures	B-Disease	D012640
.	O	O

Didanosine	B-Chemical	D016049
also	O	O
has	O	O
a	O	O
potential	O	O
for	O	O
inducing	O	O
seizures	B-Disease	D012640
.	O	O

However	O	O
,	O	O
these	O	O
other	O	O
potential	O	O
causes	O	O
of	O	O
seizure	B-Disease	D012640
were	O	O
ruled	O	O
out	O	O
.	O	O

The	O	O
time	O	O
course	O	O
of	O	O
events	O	O
suggested	O	O
that	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
was	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
seizures	B-Disease	D012640
in	O	O
this	O	O
AIDS	B-Disease	D000163
patient	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
seems	O	O
to	O	O
be	O	O
the	O	O
probable	O	O
cause	O	O
of	O	O
the	O	O
seizures	B-Disease	D012640
.	O	O

To	O	O
date	O	O
,	O	O
only	O	O
three	O	O
cases	O	O
of	O	O
seizures	B-Disease	D012640
associated	O	O
with	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
but	O	O
healthcare	O	O
providers	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
this	O	O
rare	O	O
adverse	O	O
effect	O	O
.	O	O

Therapeutic	O	O
drug	O	O
monitoring	O	O
of	O	O
tobramycin	B-Chemical	D014031
:	O	O
once	O	O
-	O	O
daily	O	O
versus	O	O
twice	O	O
-	O	O
daily	O	O
dosage	O	O
schedules	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
dosage	O	O
regimen	O	O
(	O	O
once	O	O
-	O	O
daily	O	O
vs	O	O
.	O	O

twice	O	O
-	O	O
daily	O	O
)	O	O
of	O	O
tobramicyn	B-Chemical	D014031
on	O	O
steady	O	O
-	O	O
state	O	O
serum	O	O
concentrations	O	O
and	O	O
toxicity	B-Disease	D064420
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Patients	O	O
undergoing	O	O
treatment	O	O
with	O	O
i	O	O
.	O	O

v	O	O
.	O	O

tobramycin	B-Chemical	D014031
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
were	O	O
randomised	O	O
to	O	O
two	O	O
groups	O	O
.	O	O

Group	O	O
OD	O	O
(	O	O
n	O	O
=	O	O
22	O	O
)	O	O
received	O	O
a	O	O
once	O	O
-	O	O
daily	O	O
dose	O	O
of	O	O
tobramycin	B-Chemical	D014031
and	O	O
group	O	O
TD	O	O
(	O	O
n	O	O
=	O	O
21	O	O
)	O	O
received	O	O
the	O	O
same	O	O
dose	O	O
divided	O	O
into	O	O
two	O	O
doses	O	O
daily	O	O
.	O	O

Tobramycin	B-Chemical	D014031
serum	O	O
concentrations	O	O
(	O	O
peak	O	O
and	O	O
trough	O	O
)	O	O
were	O	O
measured	O	O
by	O	O
enzyme	O	O
multiplied	O	O
immunoassay	O	O
.	O	O

The	O	O
renal	O	O
and	O	O
auditory	O	O
functions	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
monitored	O	O
before	O	O
,	O	O
during	O	O
and	O	O
immediately	O	O
after	O	O
treatment	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
two	O	O
groups	O	O
were	O	O
comparable	O	O
with	O	O
respect	O	O
to	O	O
sex	O	O
,	O	O
age	O	O
,	O	O
body	O	O
weight	O	O
and	O	O
renal	O	O
function	O	O
.	O	O

No	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
mean	O	O
daily	O	O
dose	O	O
,	O	O
duration	O	O
of	O	O
treatment	O	O
,	O	O
or	O	O
cumulative	O	O
dose	O	O
.	O	O

Trough	O	O
concentrations	O	O
were	O	O
<	O	O
2	O	O
g	O	O
/	O	O
ml	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
(	O	O
100%	O	O
)	O	O
.	O	O

Peak	O	O
concentrations	O	O
were	O	O
>	O	O
6	O	O
microg	O	O
/	O	O
ml	O	O
in	O	O
100%	O	O
of	O	O
the	O	O
OD	O	O
group	O	O
and	O	O
in	O	O
67%	O	O
of	O	O
the	O	O
TD	O	O
group	O	O
(	O	O
P<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Mean	O	O
peak	O	O
concentrations	O	O
were	O	O
markedly	O	O
different	O	O
:	O	O
11	O	O
.	O	O

00+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

89	O	O
microg	O	O
/	O	O
ml	O	O
in	O	O
OD	O	O
vs	O	O
.	O	O

6	O	O
.	O	O

53+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

45	O	O
microg	O	O
/	O	O
ml	O	O
in	O	O
TD	O	O
(	O	O
P<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

The	O	O
pharmacokinetics	O	O
parameters	O	O
were	O	O
:	O	O
Ke	O	O
,	O	O
(	O	O
0	O	O
.	O	O

15+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

03	O	O
/	O	O
h	O	O
in	O	O
OD	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

24+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

06	O	O
/	O	O
h	O	O
in	O	O
TD	O	O
)	O	O
,	O	O
t1	O	O
/	O	O
2	O	O
,	O	O
(	O	O
4	O	O
.	O	O

95+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

41	O	O
h	O	O
in	O	O
OD	O	O
vs	O	O
.	O	O

3	O	O
.	O	O

07+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

71	O	O
h	O	O
in	O	O
TD	O	O
)	O	O
,	O	O
Vd	O	O
(	O	O
0	O	O
.	O	O

35+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

11	O	O
l	O	O
/	O	O
kg	O	O
in	O	O
OD	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

33+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

09	O	O
l	O	O
/	O	O
kg	O	O
in	O	O
TD	O	O
)	O	O
,	O	O
Cl	O	O
(	O	O
0	O	O
.	O	O

86+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

29	O	O
ml	O	O
/	O	O
min	O	O
/	O	O
kg	O	O
in	O	O
OD	O	O
vs	O	O
.	O	O

1	O	O
.	O	O

28+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

33	O	O
ml	O	O
/	O	O
min	O	O
/	O	O
kg	O	O
in	O	O
TD	O	O
)	O	O
.	O	O

Increased	O	O
serum	O	O
creatinine	B-Chemical	D003404
was	O	O
observed	O	O
in	O	O
73%	O	O
of	O	O
patients	O	O
in	O	O
OD	O	O
versus	O	O
57%	O	O
of	O	O
patients	O	O
in	O	O
TD	O	O
,	O	O
without	O	O
evidence	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

In	O	O
TD	O	O
group	O	O
,	O	O
three	O	O
patients	O	O
developed	O	O
decreased	B-Disease	D034381
auditory	I-Disease	D034381
function	I-Disease	D034381
,	O	O
of	O	O
which	O	O
one	O	O
presented	O	O
with	O	O
an	O	O
auditory	B-Disease	D034381
loss	I-Disease	D034381
of	O	O
-	O	O
30	O	O
dB	O	O
,	O	O
whereas	O	O
in	O	O
the	O	O
OD	O	O
group	O	O
only	O	O
one	O	O
patient	O	O
presented	O	O
decreased	B-Disease	D034381
auditory	I-Disease	D034381
function	I-Disease	D034381
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
small	O	O
study	O	O
suggests	O	O
that	O	O
a	O	O
once	O	O
-	O	O
daily	O	O
dosing	O	O
regimen	O	O
of	O	O
tobramycin	B-Chemical	D014031
is	O	O
at	O	O
least	O	O
as	O	O
effective	O	O
as	O	O
and	O	O
is	O	O
no	O	O
more	O	O
and	O	O
possibly	O	O
less	O	O
toxic	O	O
than	O	O
the	O	O
twice	O	O
-	O	O
daily	O	O
regimen	O	O
.	O	O

Using	O	O
a	O	O
single	O	O
-	O	O
dose	O	O
therapy	O	O
,	O	O
peak	O	O
concentration	O	O
determination	O	O
is	O	O
not	O	O
necessary	O	O
,	O	O
only	O	O
trough	O	O
samples	O	O
should	O	O
be	O	O
monitored	O	O
to	O	O
ensure	O	O
levels	O	O
below	O	O
2	O	O
microg	O	O
/	O	O
ml	O	O
.	O	O

Chronic	O	O
effects	O	O
of	O	O
a	O	O
novel	O	O
synthetic	O	O
anthracycline	B-Chemical	D018943
derivative	O	O
(	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
)	O	O
on	O	O
normal	O	O
heart	O	O
and	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
in	O	O
beagle	O	O
dogs	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
chronic	O	O
cardiotoxic	B-Disease	D066126
potential	O	O
of	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
and	O	O
a	O	O
possible	O	O
deteriorating	O	O
effect	O	O
of	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
on	O	O
low	O	O
-	O	O
grade	O	O
cardiotoxicity	B-Disease	D066126
pre	O	O
-	O	O
induced	O	O
by	O	O
doxorubicin	B-Chemical	D004317
in	O	O
beagle	O	O
dogs	O	O
.	O	O

In	O	O
the	O	O
chronic	O	O
treatment	O	O
,	O	O
beagle	O	O
dogs	O	O
of	O	O
each	O	O
sex	O	O
were	O	O
given	O	O
intravenously	O	O
once	O	O
every	O	O
3	O	O
weeks	O	O
,	O	O
either	O	O
a	O	O
sublethal	O	O
dose	O	O
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
experiment	O	O
was	O	O
terminated	O	O
3	O	O
weeks	O	O
after	O	O
the	O	O
ninth	O	O
dosing	O	O
.	O	O

Animals	O	O
which	O	O
received	O	O
over	O	O
six	O	O
courses	O	O
of	O	O
doxorubicin	B-Chemical	D004317
demonstrated	O	O
the	O	O
electrocardiogram	O	O
(	O	O
ECG	O	O
)	O	O
changes	O	O
,	O	O
decrease	O	O
of	O	O
blood	O	O
pressure	O	O
and	O	O
high	O	O
-	O	O
grade	O	O
histopathological	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
while	O	O
animals	O	O
which	O	O
were	O	O
terminally	O	O
sacrificed	O	O
after	O	O
the	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
administration	O	O
did	O	O
not	O	O
show	O	O
any	O	O
changes	O	O
in	O	O
ECG	O	O
,	O	O
blood	O	O
pressure	O	O
and	O	O
histopathological	O	O
examinations	O	O
.	O	O

To	O	O
examine	O	O
a	O	O
possibly	O	O
deteriorating	O	O
cardiotoxic	B-Disease	D066126
effect	O	O
of	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
,	O	O
low	O	O
-	O	O
grade	O	O
cardiomyopathy	B-Disease	D009202
was	O	O
induced	O	O
in	O	O
dogs	O	O
by	O	O
four	O	O
courses	O	O
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Nine	O	O
weeks	O	O
after	O	O
pre	O	O
-	O	O
treatment	O	O
,	O	O
dogs	O	O
were	O	O
given	O	O
four	O	O
courses	O	O
of	O	O
either	O	O
doxorubicin	B-Chemical	D004317
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
once	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

The	O	O
low	O	O
-	O	O
grade	O	O
cardiotoxic	B-Disease	D066126
changes	O	O
were	O	O
enhanced	O	O
by	O	O
the	O	O
additional	O	O
doxorubicin	B-Chemical	D004317
treatment	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
the	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
treatment	O	O
did	O	O
not	O	O
progress	O	O
the	O	O
grade	O	O
of	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

In	O	O
conclusion	O	O
,	O	O
SM	B-Chemical	C055866
-	I-Chemical	C055866
5887	I-Chemical	C055866
does	O	O
not	O	O
have	O	O
any	O	O
potential	O	O
of	O	O
chronic	O	O
cardiotoxicity	B-Disease	D066126
and	O	O
deteriorating	O	O
effect	O	O
on	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
dogs	O	O
.	O	O

Posteroventral	O	O
medial	O	O
pallidotomy	O	O
in	O	O
advanced	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

BACKGROUND	O	O
:	O	O
Posteroventral	O	O
medial	O	O
pallidotomy	O	O
sometimes	O	O
produces	O	O
striking	O	O
improvement	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
but	O	O
the	O	O
studies	O	O
to	O	O
date	O	O
have	O	O
involved	O	O
small	O	O
numbers	O	O
of	O	O
patients	O	O
and	O	O
short	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

METHODS	O	O
:	O	O
Forty	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
underwent	O	O
serial	O	O
,	O	O
detailed	O	O
assessments	O	O
both	O	O
after	O	O
drug	O	O
withdrawal	O	O
(	O	O
"off"	O	O
period	O	O
)	O	O
and	O	O
while	O	O
taking	O	O
their	O	O
optimal	O	O
medical	O	O
regimens	O	O
(	O	O
"on"	O	O
period	O	O
)	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
examined	O	O
preoperatively	O	O
and	O	O
39	O	O
were	O	O
examined	O	O
at	O	O
six	O	O
months	O	O
;	O	O
27	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
also	O	O
examined	O	O
at	O	O
one	O	O
year	O	O
,	O	O
and	O	O
11	O	O
at	O	O
two	O	O
years	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
percent	O	O
improvements	O	O
at	O	O
six	O	O
months	O	O
were	O	O
as	O	O
follows	O	O
:	O	O
off	O	O
-	O	O
period	O	O
score	O	O
for	O	O
overall	O	O
motor	O	O
function	O	O
,	O	O
28	O	O
percent	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
19	O	O
to	O	O
38	O	O
percent	O	O
)	O	O
,	O	O
with	O	O
most	O	O
of	O	O
the	O	O
improvement	O	O
in	O	O
the	O	O
contralateral	O	O
limbs	O	O
;	O	O
off	O	O
-	O	O
period	O	O
score	O	O
for	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
,	O	O
29	O	O
percent	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
19	O	O
to	O	O
39	O	O
percent	O	O
)	O	O
;	O	O
on	O	O
-	O	O
period	O	O
score	O	O
for	O	O
contralateral	O	O
dyskinesias	B-Disease	D004409
,	O	O
82	O	O
percent	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
72	O	O
to	O	O
91	O	O
percent	O	O
)	O	O
;	O	O
and	O	O
on	O	O
-	O	O
period	O	O
score	O	O
for	O	O
ipsilateral	O	O
dyskinesias	B-Disease	D004409
,	O	O
44	O	O
percent	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
29	O	O
to	O	O
59	O	O
percent	O	O
)	O	O
.	O	O

The	O	O
improvements	O	O
in	O	O
dyskinesias	B-Disease	D004409
and	O	O
the	O	O
total	O	O
scores	O	O
for	O	O
off	O	O
-	O	O
period	O	O
parkinsonism	B-Disease	D010300
,	O	O
contralateral	O	O
bradykinesia	B-Disease	D018476
,	O	O
and	O	O
rigidity	B-Disease	D009127
were	O	O
sustained	O	O
in	O	O
the	O	O
11	O	O
patients	O	O
examined	O	O
at	O	O
two	O	O
years	O	O
.	O	O

The	O	O
improvement	O	O
in	O	O
ipsilateral	O	O
dyskinesias	B-Disease	D004409
was	O	O
lost	O	O
after	O	O
one	O	O
year	O	O
,	O	O
and	O	O
the	O	O
improvements	O	O
in	O	O
postural	O	O
stability	O	O
and	O	O
gait	O	O
lasted	O	O
only	O	O
three	O	O
to	O	O
six	O	O
months	O	O
.	O	O

Approximately	O	O
half	O	O
the	O	O
patients	O	O
who	O	O
had	O	O
been	O	O
dependent	O	O
on	O	O
assistance	O	O
in	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
in	O	O
the	O	O
off	O	O
period	O	O
before	O	O
surgery	O	O
became	O	O
independent	O	O
after	O	O
surgery	O	O
.	O	O

The	O	O
complications	O	O
of	O	O
surgery	O	O
were	O	O
generally	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
changes	O	O
in	O	O
the	O	O
use	O	O
of	O	O
medication	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
late	O	O
-	O	O
stage	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
pallidotomy	O	O
significantly	O	O
reduces	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
and	O	O
off	O	O
-	O	O
period	O	O
disability	O	O
.	O	O

Much	O	O
of	O	O
the	O	O
benefit	O	O
is	O	O
sustained	O	O
at	O	O
two	O	O
years	O	O
,	O	O
although	O	O
some	O	O
improvements	O	O
,	O	O
such	O	O
as	O	O
those	O	O
on	O	O
the	O	O
ipsilateral	O	O
side	O	O
and	O	O
in	O	O
axial	O	O
symptoms	O	O
,	O	O
wane	O	O
within	O	O
the	O	O
first	O	O
year	O	O
.	O	O

The	O	O
on	O	O
-	O	O
period	O	O
symptoms	O	O
that	O	O
are	O	O
resistant	O	O
to	O	O
dopaminergic	O	O
therapy	O	O
do	O	O
not	O	O
respond	O	O
to	O	O
pallidotomy	O	O
.	O	O

Neuropeptide	O	O
-	O	O
Y	O	O
immunoreactivity	O	O
in	O	O
the	O	O
pilocarpine	B-Chemical	D010862
model	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

Neuropeptide	O	O
-	O	O
Y	O	O
(	O	O
NPY	O	O
)	O	O
is	O	O
expressed	O	O
by	O	O
granule	O	O
cells	O	O
and	O	O
mossy	O	O
fibres	O	O
of	O	O
the	O	O
hippocampal	O	O
dentate	O	O
gyrus	O	O
during	O	O
experimental	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
(	O	O
TLE	B-Disease	D004833
)	O	O
.	O	O

This	O	O
expression	O	O
may	O	O
represent	O	O
an	O	O
endogenous	O	O
damping	O	O
mechanism	O	O
since	O	O
NPY	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
block	O	O
seizure	B-Disease	D012640
-	O	O
like	O	O
events	O	O
following	O	O
high	O	O
-	O	O
frequency	O	O
stimulation	O	O
in	O	O
hippocampal	O	O
slices	O	O
.	O	O

The	O	O
pilocarpine	B-Chemical	D010862
(	O	O
PILO	B-Chemical	D010862
)	O	O
model	O	O
of	O	O
epilepsy	B-Disease	D004827
is	O	O
characterized	O	O
by	O	O
an	O	O
acute	O	O
period	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
followed	O	O
by	O	O
spontaneous	O	O
recurrent	O	O
seizures	B-Disease	D012640
and	O	O
related	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
.	O	O

We	O	O
report	O	O
peroxidase	O	O
-	O	O
antiperoxidase	O	O
immunostaining	O	O
for	O	O
NPY	O	O
in	O	O
several	O	O
brain	O	O
regions	O	O
in	O	O
this	O	O
model	O	O
.	O	O

PILO	B-Chemical	D010862
-	O	O
injected	O	O
animals	O	O
exhibited	O	O
NPY	O	O
immunoreactivity	O	O
in	O	O
the	O	O
region	O	O
of	O	O
the	O	O
mossy	O	O
fibre	O	O
terminals	O	O
,	O	O
in	O	O
the	O	O
dentate	O	O
gyrus	O	O
inner	O	O
molecular	O	O
layer	O	O
and	O	O
,	O	O
in	O	O
a	O	O
few	O	O
cases	O	O
,	O	O
within	O	O
presumed	O	O
granule	O	O
cells	O	O
.	O	O

NPY	O	O
immunoreactivity	O	O
was	O	O
also	O	O
dramatically	O	O
changed	O	O
in	O	O
the	O	O
entorhinal	O	O
cortex	O	O
,	O	O
amygdala	O	O
and	O	O
sensorimotor	O	O
areas	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
PILO	B-Chemical	D010862
injected	O	O
animals	O	O
exhibited	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
NPY	O	O
-	O	O
immunoreactive	O	O
interneurons	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

The	O	O
results	O	O
demonstrate	O	O
that	O	O
changes	O	O
in	O	O
NPY	O	O
expression	O	O
,	O	O
including	O	O
expression	O	O
in	O	O
the	O	O
granule	O	O
cells	O	O
and	O	O
mossy	O	O
fibres	O	O
and	O	O
the	O	O
loss	O	O
of	O	O
vulnerable	O	O
NPY	O	O
neurons	O	O
,	O	O
are	O	O
present	O	O
in	O	O
the	O	O
PILO	B-Chemical	D010862
model	O	O
of	O	O
TLE	B-Disease	D004833
.	O	O

However	O	O
,	O	O
the	O	O
significance	O	O
of	O	O
this	O	O
changed	O	O
synthesis	O	O
of	O	O
NPY	O	O
remains	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

Effect	O	O
of	O	O
myopic	O	O
excimer	O	O
laser	O	O
photorefractive	O	O
keratectomy	O	O
on	O	O
the	O	O
electrophysiologic	O	O
function	O	O
of	O	O
the	O	O
retina	O	O
and	O	O
optic	O	O
nerve	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
by	O	O
electrophysiologic	O	O
testing	O	O
the	O	O
effect	O	O
of	O	O
photorefractive	O	O
keratectomy	O	O
(	O	O
PRK	O	O
)	O	O
on	O	O
the	O	O
retina	O	O
and	O	O
optic	O	O
nerve	O	O
.	O	O

SETTING	O	O
:	O	O
Eye	O	O
Clinic	O	O
,	O	O
S	O	O
.	O	O

Salvatore	O	O
Hospital	O	O
,	O	O
L'Aquila	O	O
University	O	O
,	O	O
Italy	O	O
.	O	O

METHODS	O	O
:	O	O
Standard	O	O
pattern	O	O
electroretinograms	O	O
(	O	O
P	O	O
-	O	O
ERGs	O	O
)	O	O
and	O	O
standard	O	O
pattern	O	O
visual	O	O
evoked	O	O
potentials	O	O
(	O	O
P	O	O
-	O	O
VEPs	O	O
)	O	O
were	O	O
done	O	O
in	O	O
25	O	O
eyes	O	O
of	O	O
25	O	O
patients	O	O
who	O	O
had	O	O
myopic	O	O
PRK	O	O
for	O	O
an	O	O
attempted	O	O
correction	O	O
between	O	O
5	O	O
.	O	O

00	O	O
and	O	O
15	O	O
.	O	O

00	O	O
diopters	O	O
(	O	O
D	O	O
)	O	O
(	O	O
mean	O	O
8	O	O
.	O	O

00	O	O
D	O	O
)	O	O
.	O	O

Testing	O	O
was	O	O
done	O	O
preoperatively	O	O
and	O	O
3	O	O
,	O	O
6	O	O
,	O	O
12	O	O
,	O	O
and	O	O
18	O	O
months	O	O
postoperatively	O	O
.	O	O

The	O	O
contralateral	O	O
eyes	O	O
served	O	O
as	O	O
controls	O	O
.	O	O

During	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
3	O	O
patients	O	O
(	O	O
12%	O	O
)	O	O
developed	O	O
steroid	B-Chemical	D013256
-	O	O
induced	O	O
elevated	B-Disease	D009798
intraocular	I-Disease	D009798
pressure	I-Disease	D009798
(	O	O
IOP	O	O
)	O	O
that	O	O
resolved	O	O
after	O	O
corticosteroid	B-Chemical	D000305
therapy	O	O
was	O	O
discontinued	O	O
.	O	O

RESULTS	O	O
:	O	O
No	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
seen	O	O
between	O	O
treated	O	O
and	O	O
control	O	O
eyes	O	O
nor	O	O
between	O	O
treated	O	O
eyes	O	O
preoperatively	O	O
and	O	O
postoperatively	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Myopic	O	O
excimer	O	O
laser	O	O
PRK	O	O
did	O	O
not	O	O
seem	O	O
to	O	O
affect	O	O
the	O	O
posterior	O	O
segment	O	O
.	O	O

The	O	O
transient	O	O
steroid	B-Chemical	D013256
-	O	O
induced	O	O
IOP	B-Disease	D009798
rise	I-Disease	D009798
did	O	O
not	O	O
seem	O	O
to	O	O
cause	O	O
functional	O	O
impairment	O	O
.	O	O

Liposomal	O	O
daunorubicin	B-Chemical	D003630
in	O	O
advanced	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
:	O	O
a	O	O
phase	O	O
II	O	O
study	O	O
.	O	O

We	O	O
report	O	O
a	O	O
non	O	O
-	O	O
randomized	O	O
Phase	O	O
II	O	O
clinical	O	O
trial	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
liposomal	O	O
daunorubicin	B-Chemical	D003630
(	O	O
DaunoXome	O	O
)	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
AIDS	B-Disease	D000163
related	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
.	O	O

Eleven	O	O
homosexual	O	O
men	O	O
with	O	O
advanced	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
were	O	O
entered	O	O
in	O	O
the	O	O
trial	O	O
.	O	O

Changes	O	O
in	O	O
size	O	O
,	O	O
colour	O	O
and	O	O
associated	O	O
oedema	B-Disease	D004487
of	O	O
selected	O	O
'target'	O	O
lesions	O	O
were	O	O
measured	O	O
.	O	O

Clinical	O	O
,	O	O
biochemical	O	O
and	O	O
haematological	O	O
toxicities	B-Disease	D064420
were	O	O
assessed	O	O
.	O	O

Ten	O	O
subjects	O	O
were	O	O
evaluated	O	O
.	O	O

A	O	O
partial	O	O
response	O	O
was	O	O
achieved	O	O
in	O	O
four	O	O
,	O	O
of	O	O
whom	O	O
two	O	O
subsequently	O	O
relapsed	O	O
.	O	O

Stabilization	O	O
of	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
occurred	O	O
in	O	O
the	O	O
remaining	O	O
six	O	O
,	O	O
maintained	O	O
until	O	O
the	O	O
end	O	O
of	O	O
the	O	O
trial	O	O
period	O	O
in	O	O
four	O	O
.	O	O

The	O	O
drug	O	O
was	O	O
generally	O	O
well	O	O
tolerated	O	O
,	O	O
with	O	O
few	O	O
mild	O	O
symptoms	O	O
of	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
main	O	O
problem	O	O
encountered	O	O
was	O	O
haematological	O	O
toxicity	B-Disease	D064420
,	O	O
with	O	O
three	O	O
subjects	O	O
experiencing	O	O
severe	O	O
neutropenia	B-Disease	D009503
(	O	O
neutrophil	O	O
count	O	O
<	O	O
0	O	O
.	O	O

5	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
l	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

In	O	O
this	O	O
small	O	O
patient	O	O
sample	O	O
,	O	O
liposomal	O	O
daunorubicin	B-Chemical	D003630
was	O	O
an	O	O
effective	O	O
and	O	O
well	O	O
tolerated	O	O
agent	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Kaposi's	B-Disease	D012514
sarcoma	I-Disease	D012514
.	O	O

Failure	O	O
of	O	O
ancrod	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
arterial	O	O
thrombosis	B-Disease	D013927
.	O	O

The	O	O
morbidity	O	O
and	O	O
mortality	O	O
associated	O	O
with	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombosis	B-Disease	D013927
remain	O	O
high	O	O
despite	O	O
numerous	O	O
empirical	O	O
therapies	O	O
.	O	O

Ancrod	O	O
has	O	O
been	O	O
used	O	O
successfully	O	O
for	O	O
prophylaxis	O	O
against	O	O
development	O	O
of	O	O
thrombosis	B-Disease	D013927
in	O	O
patients	O	O
with	O	O
heparin	B-Chemical	D006493
induced	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
who	O	O
require	O	O
brief	O	O
reexposure	O	O
to	O	O
heparin	B-Chemical	D006493
,	O	O
but	O	O
its	O	O
success	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
developed	O	O
the	O	O
thrombosis	B-Disease	D013927
syndrome	O	O
is	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

The	O	O
authors	O	O
present	O	O
a	O	O
case	O	O
of	O	O
failure	O	O
of	O	O
ancrod	O	O
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombosis	B-Disease	D013927
.	O	O

Seizure	B-Disease	D012640
after	O	O
flumazenil	B-Chemical	D005442
administration	O	O
in	O	O
a	O	O
pediatric	O	O
patient	O	O
.	O	O

Flumazenil	B-Chemical	D005442
is	O	O
a	O	O
benzodiazepine	B-Chemical	D001569
receptor	O	O
antagonist	O	O
used	O	O
to	O	O
reverse	O	O
sedation	O	O
and	O	O
respiratory	B-Disease	D012131
depression	I-Disease	D012131
induced	O	O
by	O	O
benzodiazepines	B-Chemical	D001569
.	O	O

Seizures	B-Disease	D012640
and	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
have	O	O
complicated	O	O
its	O	O
use	O	O
in	O	O
adult	O	O
patients	O	O
.	O	O

Overdose	B-Disease	D062787
patients	O	O
who	O	O
have	O	O
coingested	O	O
tricyclic	O	O
antidepressants	O	O
have	O	O
a	O	O
higher	O	O
risk	O	O
of	O	O
these	O	O
complications	O	O
.	O	O

Little	O	O
information	O	O
exists	O	O
concerning	O	O
adverse	O	O
effects	O	O
of	O	O
flumazenil	B-Chemical	D005442
in	O	O
children	O	O
.	O	O

We	O	O
report	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
generalized	O	O
tonic	B-Disease	D012640
-	I-Disease	D012640
clonic	I-Disease	D012640
seizure	I-Disease	D012640
in	O	O
a	O	O
pediatric	O	O
patient	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
flumazenil	B-Chemical	D005442
.	O	O

Remodelling	O	O
of	O	O
nerve	O	O
structure	O	O
in	O	O
experimental	O	O
isoniazid	B-Chemical	D007538
neuropathy	B-Disease	D009422
in	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
neuropathy	B-Disease	D009422
caused	O	O
by	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
isoniazid	B-Chemical	D007538
in	O	O
rats	O	O
was	O	O
studied	O	O
with	O	O
a	O	O
computer	O	O
-	O	O
assisted	O	O
morphometric	O	O
method	O	O
.	O	O

Scatter	O	O
diagrams	O	O
of	O	O
the	O	O
g	O	O
ratio	O	O
(	O	O
quotient	O	O
fibre	O	O
diameter	O	O
/	O	O
axon	O	O
diameter	O	O
)	O	O
define	O	O
regenerating	O	O
fibres	O	O
as	O	O
a	O	O
distinct	O	O
population	O	O
,	O	O
distinguishable	O	O
from	O	O
the	O	O
surviving	O	O
fibres	O	O
by	O	O
reduced	O	O
sheath	O	O
thickness	O	O
and	O	O
reduced	O	O
axon	O	O
calibre	O	O
.	O	O

There	O	O
was	O	O
also	O	O
evidence	O	O
of	O	O
a	O	O
subtle	O	O
direct	O	O
toxic	O	O
effect	O	O
on	O	O
the	O	O
entire	O	O
fibre	O	O
population	O	O
,	O	O
causing	O	O
axon	O	O
shrinkage	O	O
masked	O	O
by	O	O
readjustment	O	O
of	O	O
the	O	O
myelin	O	O
sheath	O	O
.	O	O

Selective	O	O
injection	O	O
of	O	O
iopentol	B-Chemical	C053571
,	O	O
iohexol	B-Chemical	D007472
and	O	O
metrizoate	B-Chemical	D008794
into	O	O
the	O	O
left	O	O
coronary	O	O
artery	O	O
of	O	O
the	O	O
dog	O	O
.	O	O

Induction	O	O
of	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
and	O	O
decrease	O	O
of	O	O
aortic	O	O
pressure	O	O
.	O	O

In	O	O
twenty	O	O
beagle	O	O
dogs	O	O
selective	O	O
injections	O	O
were	O	O
made	O	O
into	O	O
the	O	O
left	O	O
coronary	O	O
artery	O	O
with	O	O
iopentol	B-Chemical	C053571
,	O	O
iohexol	B-Chemical	D007472
and	O	O
metrizoate	B-Chemical	D008794
in	O	O
doses	O	O
of	O	O
4	O	O
ml	O	O
,	O	O
8	O	O
ml	O	O
and	O	O
16	O	O
ml	O	O
.	O	O

Thirty	O	O
-	O	O
six	O	O
iopentol	B-Chemical	C053571
injections	O	O
,	O	O
35	O	O
iohexol	B-Chemical	D007472
injections	O	O
and	O	O
37	O	O
metrizoate	B-Chemical	D008794
injections	O	O
were	O	O
made	O	O
.	O	O

Frequencies	O	O
of	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
were	O	O
significantly	O	O
lower	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
after	O	O
iopentol	B-Chemical	C053571
(	O	O
0%	O	O
)	O	O
and	O	O
iohexol	B-Chemical	D007472
(	O	O
3%	O	O
)	O	O
than	O	O
after	O	O
metrizoate	B-Chemical	D008794
(	O	O
22%	O	O
)	O	O
.	O	O

Iopentol	B-Chemical	C053571
and	O	O
iohexol	B-Chemical	D007472
also	O	O
produced	O	O
significantly	O	O
less	O	O
decrease	O	O
in	O	O
aortic	O	O
blood	O	O
pressure	O	O
than	O	O
metrizoate	B-Chemical	D008794
at	O	O
the	O	O
different	O	O
doses	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
of	O	O
cerebral	O	O
venous	B-Disease	D020246
thrombosis	I-Disease	D020246
secondary	O	O
to	O	O
"low	O	O
-	O	O
dose"	O	O
birth	O	O
control	O	O
pills	O	O
.	O	O

The	O	O
clinical	O	O
and	O	O
radiographic	O	O
features	O	O
of	O	O
cerebral	O	O
deep	B-Disease	D020246
venous	I-Disease	D020246
thrombosis	I-Disease	D020246
in	O	O
a	O	O
21	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
woman	O	O
are	O	O
presented	O	O
.	O	O

This	O	O
nulliparous	O	O
patient	O	O
presented	O	O
with	O	O
relatively	O	O
mild	O	O
clinical	O	O
symptoms	O	O
and	O	O
progressing	O	O
mental	O	O
status	O	O
changes	O	O
.	O	O

The	O	O
only	O	O
known	O	O
risk	O	O
factor	O	O
was	O	O
"low	O	O
-	O	O
dose"	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
pills	O	O
.	O	O

The	O	O
magnetic	O	O
resonance	O	O
image	O	O
(	O	O
MRI	O	O
)	O	O
showed	O	O
increased	O	O
signal	O	O
intensity	O	O
from	O	O
the	O	O
internal	O	O
cerebral	O	O
veins	O	O
,	O	O
vein	O	O
of	O	O
Galen	O	O
,	O	O
and	O	O
straight	O	O
sinus	O	O
.	O	O

The	O	O
diagnosis	O	O
was	O	O
confirmed	O	O
by	O	O
arterial	O	O
angiography	O	O
.	O	O

Relation	O	O
of	O	O
perfusion	O	O
defects	O	O
observed	O	O
with	O	O
myocardial	O	O
contrast	O	O
echocardiography	O	O
to	O	O
the	O	O
severity	O	O
of	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
:	O	O
correlation	O	O
with	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
single	O	O
-	O	O
photon	O	O
emission	O	O
tomography	O	O
.	O	O

It	O	O
has	O	O
been	O	O
previously	O	O
shown	O	O
that	O	O
myocardial	O	O
contrast	O	O
echocardiography	O	O
is	O	O
a	O	O
valuable	O	O
technique	O	O
for	O	O
delineating	O	O
regions	O	O
of	O	O
myocardial	O	O
underperfusion	O	O
secondary	O	O
to	O	O
coronary	B-Disease	D054059
occlusion	I-Disease	D054059
and	O	O
to	O	O
critical	O	O
coronary	B-Disease	D023921
stenoses	I-Disease	D023921
in	O	O
the	O	O
presence	O	O
of	O	O
hyperemic	B-Disease	D006940
stimulation	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
myocardial	O	O
contrast	O	O
echocardiography	O	O
performed	O	O
with	O	O
a	O	O
stable	O	O
solution	O	O
of	O	O
sonicated	O	O
albumin	O	O
could	O	O
detect	O	O
regions	O	O
of	O	O
myocardial	O	O
underperfusion	O	O
resulting	O	O
from	O	O
various	O	O
degrees	O	O
of	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
.	O	O

The	O	O
perfusion	O	O
defect	O	O
produced	O	O
in	O	O
16	O	O
open	O	O
chest	O	O
dogs	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
anatomic	O	O
area	O	O
at	O	O
risk	O	O
measured	O	O
by	O	O
the	O	O
postmortem	O	O
dual	O	O
-	O	O
perfusion	O	O
technique	O	O
and	O	O
with	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
single	O	O
-	O	O
photon	O	O
emission	O	O
tomography	O	O
(	O	O
SPECT	O	O
)	O	O
.	O	O

During	O	O
a	O	O
transient	O	O
(	O	O
20	O	O
-	O	O
s	O	O
)	O	O
coronary	B-Disease	D054059
occlusion	I-Disease	D054059
,	O	O
a	O	O
perfusion	O	O
defect	O	O
was	O	O
observed	O	O
with	O	O
contrast	O	O
echocardiography	O	O
in	O	O
14	O	O
of	O	O
the	O	O
15	O	O
dogs	O	O
in	O	O
which	O	O
the	O	O
occlusion	O	O
was	O	O
produced	O	O
.	O	O

The	O	O
perfusion	O	O
defect	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
anatomic	O	O
area	O	O
at	O	O
risk	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

74	O	O
;	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

During	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
hyperemia	B-Disease	D006940
,	O	O
12	O	O
of	O	O
the	O	O
16	O	O
dogs	O	O
with	O	O
a	O	O
partial	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
had	O	O
a	O	O
visible	O	O
area	O	O
of	O	O
hypoperfusion	O	O
by	O	O
contrast	O	O
echocardiography	O	O
.	O	O

The	O	O
four	O	O
dogs	O	O
without	O	O
a	O	O
perfusion	O	O
defect	O	O
had	O	O
a	O	O
stenosis	O	O
that	O	O
resulted	O	O
in	O	O
a	O	O
mild	O	O
(	O	O
0%	O	O
to	O	O
50%	O	O
)	O	O
reduction	O	O
in	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
hyperemia	B-Disease	D006940
.	O	O

The	O	O
size	O	O
of	O	O
the	O	O
perfusion	O	O
defect	O	O
during	O	O
stenosis	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
anatomic	O	O
area	O	O
at	O	O
risk	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

61	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Thallium	B-Chemical	D013793
-	O	O
201	O	O
SPECT	O	O
demonstrated	O	O
a	O	O
perfusion	O	O
defect	O	O
in	O	O
all	O	O
14	O	O
dogs	O	O
analyzed	O	O
during	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
hyperemia	B-Disease	D006940
;	O	O
the	O	O
size	O	O
of	O	O
the	O	O
perfusion	O	O
defect	O	O
correlated	O	O
with	O	O
the	O	O
anatomic	O	O
area	O	O
at	O	O
risk	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

58	O	O
;	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

03	O	O
)	O	O
and	O	O
with	O	O
the	O	O
perfusion	O	O
defect	O	O
by	O	O
contrast	O	O
echocardiography	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

58	O	O
;	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

03	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
myocardial	O	O
contrast	O	O
echocardiography	O	O
can	O	O
be	O	O
used	O	O
to	O	O
visualize	O	O
and	O	O
quantitate	O	O
the	O	O
amount	O	O
of	O	O
jeopardized	O	O
myocardium	O	O
during	O	O
moderate	O	O
to	O	O
severe	O	O
degrees	O	O
of	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
.	O	O

The	O	O
results	O	O
obtained	O	O
show	O	O
a	O	O
correlation	O	O
with	O	O
the	O	O
anatomic	O	O
area	O	O
at	O	O
risk	O	O
similar	O	O
to	O	O
that	O	O
obtained	O	O
with	O	O
thallium	B-Chemical	D013793
-	O	O
201	O	O
SPECT	O	O
.	O	O

Potential	O	O
deleterious	O	O
effect	O	O
of	O	O
furosemide	B-Chemical	D005665
in	O	O
radiocontrast	O	O
nephropathy	B-Disease	D007674
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
furosemide	B-Chemical	D005665
in	O	O
addition	O	O
to	O	O
intravenous	O	O
fluids	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
radiocontrast	O	O
nephropathy	B-Disease	D007674
.	O	O

18	O	O
patients	O	O
,	O	O
referred	O	O
to	O	O
a	O	O
radiocontrast	O	O
study	O	O
,	O	O
considered	O	O
at	O	O
risk	O	O
because	O	O
of	O	O
preexisting	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
,	O	O
were	O	O
enrolled	O	O
in	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
trial	O	O
,	O	O
performed	O	O
at	O	O
the	O	O
secondary	O	O
care	O	O
center	O	O
of	O	O
a	O	O
1	O	O
,	O	O
100	O	O
-	O	O
bed	O	O
private	O	O
university	O	O
hospital	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
fluids	O	O
,	O	O
the	O	O
treatment	O	O
group	O	O
received	O	O
furosemide	B-Chemical	D005665
(	O	O
mean	O	O
dose	O	O
110	O	O
mg	O	O
)	O	O
intravenously	O	O
30	O	O
min	O	O
prior	O	O
to	O	O
the	O	O
injection	O	O
of	O	O
contrast	O	O
material	O	O
.	O	O

The	O	O
control	O	O
group	O	O
received	O	O
fluids	O	O
(	O	O
mean	O	O
3	O	O
liters	O	O
)	O	O
.	O	O

Radiological	O	O
studies	O	O
were	O	O
mostly	O	O
angiographies	O	O
performed	O	O
with	O	O
both	O	O
ionic	O	O
and	O	O
non	O	O
-	O	O
ionic	O	O
contrast	O	O
material	O	O
,	O	O
at	O	O
an	O	O
average	O	O
dose	O	O
of	O	O
245	O	O
ml	O	O
.	O	O

Renal	B-Disease	D058186
function	I-Disease	D058186
significantly	I-Disease	D058186
deteriorated	I-Disease	D058186
in	O	O
the	O	O
group	O	O
pretreated	O	O
with	O	O
furosemide	B-Chemical	D005665
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

005	O	O
by	O	O
ANOVA	O	O
)	O	O
,	O	O
with	O	O
a	O	O
rise	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
from	O	O
145	O	O
+	O	O
/	O	O
-	O	O
13	O	O
to	O	O
182	O	O
+	O	O
/	O	O
-	O	O
16	O	O
mumol	O	O
/	O	O
l	O	O
at	O	O
24	O	O
h	O	O
,	O	O
while	O	O
no	O	O
change	O	O
occurred	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
from	O	O
141	O	O
+	O	O
/	O	O
-	O	O
6	O	O
to	O	O
142	O	O
+	O	O
/	O	O
-	O	O
7	O	O
mumol	O	O
/	O	O
l	O	O
)	O	O
.	O	O

Renal	B-Disease	D051437
failure	I-Disease	D051437
was	O	O
associated	O	O
with	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
in	O	O
the	O	O
furosemide	B-Chemical	D005665
-	O	O
treated	O	O
group	O	O
.	O	O

Furosemide	B-Chemical	D005665
may	O	O
be	O	O
deleterious	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
radiocontrast	O	O
nephropathy	B-Disease	D007674
.	O	O

The	O	O
renal	O	O
pathology	O	O
in	O	O
a	O	O
case	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
.	O	O

A	O	O
case	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
is	O	O
reported	O	O
.	O	O

At	O	O
necropsy	O	O
microscopy	O	O
shoed	O	O
unique	O	O
and	O	O
extensive	O	O
damage	O	O
to	O	O
cells	O	O
lining	O	O
the	O	O
distal	O	O
nephron	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
these	O	O
changes	O	O
represent	O	O
a	O	O
specific	O	O
toxic	O	O
effect	O	O
of	O	O
lithium	B-Chemical	D008094
,	O	O
reported	O	O
here	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
man	O	O
.	O	O

Etiologic	O	O
factors	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
liver	B-Disease	D008113
tumors	I-Disease	D008113
associated	O	O
with	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

Within	O	O
the	O	O
last	O	O
several	O	O
years	O	O
,	O	O
previously	O	O
rare	O	O
liver	B-Disease	D008113
tumors	I-Disease	D008113
have	O	O
been	O	O
seen	O	O
in	O	O
young	O	O
women	O	O
using	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
steroids	B-Chemical	D013256
.	O	O

The	O	O
Registry	O	O
for	O	O
Liver	B-Disease	D008113
Tumors	I-Disease	D008113
Associated	O	O
with	O	O
Oral	B-Chemical	D003276
Contraceptives	I-Chemical	D003276
at	O	O
the	O	O
University	O	O
of	O	O
California	O	O
,	O	O
Irvine	O	O
,	O	O
has	O	O
clearly	O	O
identified	O	O
27	O	O
cases	O	O
.	O	O

The	O	O
recent	O	O
literature	O	O
contains	O	O
44	O	O
case	O	O
reports	O	O
.	O	O

Common	O	O
to	O	O
these	O	O
71	O	O
cases	O	O
has	O	O
been	O	O
a	O	O
histopathologic	O	O
diagnosis	O	O
of	O	O
focal	B-Disease	D020518
nodular	I-Disease	D020518
hyperplasia	I-Disease	D020518
,	O	O
adenoma	B-Disease	D000236
,	O	O
hamartoma	B-Disease	D006222
,	O	O
and	O	O
hepatoma	B-Disease	D006528
.	O	O

Significant	O	O
statistical	O	O
etiologic	O	O
factors	O	O
include	O	O
prolonged	O	O
uninterrupted	O	O
usage	O	O
of	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
steroids	B-Chemical	D013256
.	O	O

Eight	O	O
deaths	O	O
and	O	O
liver	O	O
rupture	B-Disease	D012421
in	O	O
18	O	O
patients	O	O
attest	O	O
to	O	O
the	O	O
seriousness	O	O
of	O	O
this	O	O
new	O	O
potentially	O	O
lethal	O	O
adverse	O	O
phenomenon	O	O
.	O	O

Graft	B-Disease	D006086
-	I-Disease	D006086
versus	I-Disease	D006086
-	I-Disease	D006086
host	I-Disease	D006086
disease	I-Disease	D006086
prophylaxis	O	O
with	O	O
everolimus	B-Chemical	C107135
and	O	O
tacrolimus	B-Chemical	D016559
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
sinusoidal	B-Disease	D006504
obstruction	I-Disease	D006504
syndrome	I-Disease	D006504
and	O	O
microangiopathy	B-Disease	D014652
:	O	O
results	O	O
of	O	O
the	O	O
EVTAC	O	O
trial	O	O
.	O	O

A	O	O
calcineurin	O	O
inhibitor	O	O
combined	O	O
with	O	O
methotrexate	B-Chemical	D008727
is	O	O
the	O	O
standard	O	O
prophylaxis	O	O
for	O	O
graft	B-Disease	D006086
-	I-Disease	D006086
versus	I-Disease	D006086
-	I-Disease	D006086
host	I-Disease	D006086
disease	I-Disease	D006086
(	O	O
GVHD	B-Disease	D006086
)	O	O
after	O	O
allogeneic	O	O
hematopoietic	O	O
stem	O	O
cell	O	O
transplantation	O	O
(	O	O
HSCT	O	O
)	O	O
.	O	O

Everolimus	B-Chemical	C107135
,	O	O
a	O	O
derivative	O	O
of	O	O
sirolimus	B-Chemical	D020123
,	O	O
seems	O	O
to	O	O
mediate	O	O
antileukemia	O	O
effects	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
combination	O	O
of	O	O
everolimus	B-Chemical	C107135
and	O	O
tacrolimus	B-Chemical	D016559
in	O	O
24	O	O
patients	O	O
(	O	O
median	O	O
age	O	O
,	O	O
62	O	O
years	O	O
)	O	O
with	O	O
either	O	O
myelodysplastic	B-Disease	D009190
syndrome	I-Disease	D009190
(	O	O
MDS	B-Disease	D009190
;	O	O
n	O	O
=	O	O
17	O	O
)	O	O
or	O	O
acute	B-Disease	D015470
myeloid	I-Disease	D015470
leukemia	I-Disease	D015470
(	O	O
AML	B-Disease	D015470
;	O	O
n	O	O
=	O	O
7	O	O
)	O	O
undergoing	O	O
intensive	O	O
conditioning	O	O
followed	O	O
by	O	O
HSCT	O	O
from	O	O
related	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
or	O	O
unrelated	O	O
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
donors	O	O
.	O	O

All	O	O
patients	O	O
engrafted	O	O
,	O	O
and	O	O
only	O	O
1	O	O
patient	O	O
experienced	O	O
grade	O	O
IV	O	O
mucositis	B-Disease	D052016
.	O	O

Nine	O	O
patients	O	O
(	O	O
37%	O	O
)	O	O
developed	O	O
acute	O	O
grade	O	O
II	O	O
-	O	O
IV	O	O
GVHD	B-Disease	D006086
,	O	O
and	O	O
11	O	O
of	O	O
17	O	O
evaluable	O	O
patients	O	O
(	O	O
64%	O	O
)	O	O
developed	O	O
chronic	O	O
extensive	O	O
GVHD	B-Disease	D006086
.	O	O

Transplantation	B-Disease	D014652
-	I-Disease	D014652
associated	I-Disease	D014652
microangiopathy	I-Disease	D014652
(	O	O
TMA	B-Disease	D014652
)	O	O
occurred	O	O
in	O	O
7	O	O
patients	O	O
(	O	O
29%	O	O
)	O	O
,	O	O
with	O	O
2	O	O
cases	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

The	O	O
study	O	O
was	O	O
terminated	O	O
prematurely	O	O
because	O	O
an	O	O
additional	O	O
6	O	O
patients	O	O
(	O	O
25%	O	O
)	O	O
developed	O	O
sinusoidal	B-Disease	D006504
obstruction	I-Disease	D006504
syndrome	I-Disease	D006504
(	O	O
SOS	B-Disease	D006504
)	O	O
,	O	O
which	O	O
was	O	O
fatal	O	O
in	O	O
2	O	O
cases	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
26	O	O
months	O	O
,	O	O
the	O	O
2	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
rate	O	O
was	O	O
47%	O	O
.	O	O

Although	O	O
this	O	O
new	O	O
combination	O	O
appears	O	O
to	O	O
be	O	O
effective	O	O
as	O	O
a	O	O
prophylactic	O	O
regimen	O	O
for	O	O
acute	O	O
GVHD	B-Disease	D006086
,	O	O
the	O	O
incidence	O	O
of	O	O
TMA	B-Disease	D014652
and	O	O
SOS	B-Disease	D006504
is	O	O
considerably	O	O
higher	O	O
than	O	O
seen	O	O
with	O	O
other	O	O
regimens	O	O
.	O	O

Effect	O	O
of	O	O
some	O	O
convulsants	O	O
on	O	O
the	O	O
protective	O	O
activity	O	O
of	O	O
loreclezole	B-Chemical	C066440
and	O	O
its	O	O
combinations	O	O
with	O	O
valproate	B-Chemical	D014635
or	O	O
clonazepam	B-Chemical	D002998
in	O	O
amygdala	O	O
-	O	O
kindled	O	O
rats	O	O
.	O	O

Loreclezole	B-Chemical	C066440
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
exerted	O	O
a	O	O
significant	O	O
protective	O	O
action	O	O
in	O	O
amygdala	O	O
-	O	O
kindled	O	O
rats	O	O
,	O	O
reducing	O	O
both	O	O
seizure	B-Disease	D012640
and	O	O
afterdischarge	O	O
durations	O	O
.	O	O

The	O	O
combinations	O	O
of	O	O
loreclezole	B-Chemical	C066440
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
with	O	O
valproate	B-Chemical	D014635
,	O	O
clonazepam	B-Chemical	D002998
,	O	O
or	O	O
carbamazepine	B-Chemical	D002220
(	O	O
applied	O	O
at	O	O
their	O	O
subprotective	O	O
doses	O	O
)	O	O
also	O	O
exhibited	O	O
antiseizure	O	O
effect	O	O
in	O	O
this	O	O
test	O	O
.	O	O

However	O	O
,	O	O
only	O	O
two	O	O
first	O	O
combinations	O	O
occurred	O	O
to	O	O
be	O	O
of	O	O
pharmacodynamic	O	O
nature	O	O
.	O	O

Among	O	O
several	O	O
chemoconvulsants	O	O
,	O	O
bicuculline	B-Chemical	D001640
,	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartic	I-Chemical	D016202
acid	I-Chemical	D016202
and	O	O
BAY	B-Chemical	D001498
k	I-Chemical	D001498
-	I-Chemical	D001498
8644	I-Chemical	D001498
(	O	O
the	O	O
opener	O	O
of	O	O
L	O	O
-	O	O
type	O	O
calcium	B-Chemical	D002118
channels	O	O
)	O	O
reversed	O	O
the	O	O
protective	O	O
activity	O	O
of	O	O
loreclezole	B-Chemical	C066440
alone	O	O
and	O	O
its	O	O
combination	O	O
with	O	O
valproate	B-Chemical	D014635
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
bicuculline	B-Chemical	D001640
,	O	O
aminophylline	B-Chemical	D000628
and	O	O
BAY	B-Chemical	D001498
k	I-Chemical	D001498
-	I-Chemical	D001498
8644	I-Chemical	D001498
inhibited	O	O
the	O	O
anticonvulsive	O	O
action	O	O
of	O	O
loreclezole	B-Chemical	C066440
combined	O	O
with	O	O
clonazepam	B-Chemical	D002998
.	O	O

The	O	O
results	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
protective	O	O
activity	O	O
of	O	O
loreclezole	B-Chemical	C066440
and	O	O
its	O	O
combinations	O	O
with	O	O
other	O	O
antiepileptics	O	O
may	O	O
involve	O	O
potentiation	O	O
of	O	O
GABAergic	O	O
neurotransmission	O	O
and	O	O
blockade	O	O
of	O	O
L	O	O
-	O	O
type	O	O
of	O	O
calcium	B-Chemical	D002118
channels	O	O
.	O	O

Acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
with	O	O
concurrent	O	O
bupropion	B-Chemical	D016642
and	O	O
carbimazole	B-Chemical	D002231
therapy	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
fatal	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
possibly	O	O
associated	O	O
with	O	O
concurrent	O	O
use	O	O
of	O	O
bupropion	B-Chemical	D016642
and	O	O
carbimazole	B-Chemical	D002231
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
41	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Chinese	O	O
man	O	O
with	O	O
a	O	O
history	O	O
of	O	O
hyperthyroidism	B-Disease	D006980
had	O	O
been	O	O
treated	O	O
with	O	O
carbimazole	B-Chemical	D002231
and	O	O
propranolol	B-Chemical	D011433
for	O	O
the	O	O
past	O	O
5	O	O
years	O	O
.	O	O

He	O	O
received	O	O
a	O	O
10	O	O
-	O	O
day	O	O
course	O	O
of	O	O
bupropion	B-Chemical	D016642
as	O	O
an	O	O
aid	O	O
for	O	O
smoking	O	O
cessation	O	O
10	O	O
weeks	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

He	O	O
developed	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
with	O	O
rapid	O	O
deterioration	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

Liver	O	O
biopsy	O	O
showed	O	O
evidence	O	O
of	O	O
nonspecific	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
acute	I-Disease	D056486
liver	I-Disease	D056486
injury	I-Disease	D056486
.	O	O

His	O	O
condition	O	O
was	O	O
further	O	O
complicated	O	O
by	O	O
sepsis	B-Disease	D018805
and	O	O
coagulopathy	B-Disease	D001778
.	O	O

Death	O	O
resulted	O	O
19	O	O
days	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
symptoms	O	O
.	O	O

The	O	O
likelihood	O	O
that	O	O
bupropion	B-Chemical	D016642
induced	O	O
hepatotoxicity	B-Disease	D056486
in	O	O
our	O	O
patient	O	O
was	O	O
possible	O	O
,	O	O
based	O	O
on	O	O
the	O	O
Naranjo	O	O
probability	O	O
scale	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Although	O	O
there	O	O
is	O	O
increasing	O	O
evidence	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
induced	O	O
by	O	O
bupropion	B-Chemical	D016642
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
case	O	O
of	O	O
fatality	O	O
that	O	O
could	O	O
have	O	O
resulted	O	O
from	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
in	O	O
a	O	O
patient	O	O
receiving	O	O
bupropion	B-Chemical	D016642
while	O	O
on	O	O
concomitant	O	O
treatment	O	O
with	O	O
carbimazole	B-Chemical	D002231
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
insult	I-Disease	D017114
induced	O	O
by	O	O
bupropion	B-Chemical	D016642
given	O	O
concurrently	O	O
with	O	O
other	O	O
hepatotoxic	B-Disease	D056486
drugs	O	O
.	O	O

Long	O	O
term	O	O
hormone	O	O
therapy	O	O
for	O	O
perimenopausal	O	O
and	O	O
postmenopausal	O	O
women	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Hormone	O	O
therapy	O	O
(	O	O
HT	O	O
)	O	O
is	O	O
widely	O	O
used	O	O
for	O	O
controlling	O	O
menopausal	O	O
symptoms	O	O
and	O	O
has	O	O
also	O	O
been	O	O
used	O	O
for	O	O
the	O	O
management	O	O
and	O	O
prevention	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
osteoporosis	B-Disease	D010024
and	O	O
dementia	B-Disease	D003704
in	O	O
older	O	O
women	O	O
.	O	O

This	O	O
is	O	O
an	O	O
updated	O	O
version	O	O
of	O	O
the	O	O
original	O	O
Cochrane	O	O
review	O	O
first	O	O
published	O	O
in	O	O
2005	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
HT	O	O
on	O	O
mortality	O	O
,	O	O
cardiovascular	O	O
outcomes	O	O
,	O	O
cancer	B-Disease	D009369
,	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
,	O	O
cognition	O	O
,	O	O
fractures	B-Disease	D050723
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

SEARCH	O	O
STRATEGY	O	O
:	O	O
We	O	O
searched	O	O
the	O	O
following	O	O
databases	O	O
to	O	O
November	O	O
2007	O	O
:	O	O
Trials	O	O
Register	O	O
of	O	O
the	O	O
Cochrane	O	O
Menstrual	B-Disease	D008599
Disorders	I-Disease	D008599
and	O	O
Subfertility	O	O
Group	O	O
,	O	O
Cochrane	O	O
Central	O	O
Register	O	O
of	O	O
Controlled	O	O
Trials	O	O
,	O	O
MEDLINE	O	O
,	O	O
EMBASE	O	O
,	O	O
Biological	O	O
Abstracts	O	O
.	O	O

Also	O	O
relevant	O	O
non	O	O
-	O	O
indexed	O	O
journals	O	O
and	O	O
conference	O	O
abstracts	O	O
.	O	O

SELECTION	O	O
CRITERIA	O	O
:	O	O
Randomised	O	O
double	O	O
-	O	O
blind	O	O
trials	O	O
of	O	O
HT	O	O
versus	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
at	O	O
least	O	O
one	O	O
year	O	O
by	O	O
perimenopausal	O	O
or	O	O
postmenopausal	O	O
women	O	O
.	O	O

HT	O	O
included	O	O
oestrogens	B-Chemical	D004967
,	O	O
with	O	O
or	O	O
without	O	O
progestogens	B-Chemical	D011374
,	O	O
via	O	O
oral	O	O
,	O	O
transdermal	O	O
,	O	O
subcutaneous	O	O
or	O	O
transnasal	O	O
routes	O	O
.	O	O

DATA	O	O
COLLECTION	O	O
AND	O	O
ANALYSIS	O	O
:	O	O
Two	O	O
authors	O	O
independently	O	O
assessed	O	O
trial	O	O
quality	O	O
and	O	O
extracted	O	O
data	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
:	O	O
Nineteen	O	O
trials	O	O
involving	O	O
41	O	O
,	O	O
904	O	O
women	O	O
were	O	O
included	O	O
.	O	O

In	O	O
relatively	O	O
healthy	O	O
women	O	O
,	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thrombo	I-Disease	D054556
-	I-Disease	D054556
embolism	I-Disease	D054556
or	O	O
coronary	O	O
event	O	O
(	O	O
after	O	O
one	O	O
year's	O	O
use	O	O
)	O	O
,	O	O
stroke	B-Disease	D020521
(	O	O
after	O	O
three	O	O
years	O	O
)	O	O
,	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
.	O	O

Long	O	O
-	O	O
term	O	O
oestrogen	B-Chemical	D004967
-	O	O
only	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thrombo	I-Disease	D054556
-	I-Disease	D054556
embolism	I-Disease	D054556
,	O	O
stroke	B-Disease	D020521
and	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
(	O	O
after	O	O
one	O	O
to	O	O
two	O	O
years	O	O
,	O	O
three	O	O
years	O	O
and	O	O
seven	O	O
years'	O	O
use	O	O
respectively	O	O
)	O	O
,	O	O
but	O	O
did	O	O
not	O	O
significantly	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

The	O	O
only	O	O
statistically	O	O
significant	O	O
benefits	O	O
of	O	O
HT	O	O
were	O	O
a	O	O
decreased	O	O
incidence	O	O
of	O	O
fractures	B-Disease	D050723
and	O	O
(	O	O
for	O	O
combined	O	O
HT	O	O
)	O	O
colon	B-Disease	D003110
cancer	I-Disease	D003110
,	O	O
with	O	O
long	O	O
-	O	O
term	O	O
use	O	O
.	O	O

Among	O	O
women	O	O
aged	O	O
over	O	O
65	O	O
who	O	O
were	O	O
relatively	O	O
healthy	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

generally	O	O
fit	O	O
,	O	O
without	O	O
overt	O	O
disease	O	O
)	O	O
and	O	O
taking	O	O
continuous	O	O
combined	O	O
HT	O	O
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
dementia	B-Disease	D003704
.	O	O

Among	O	O
women	O	O
with	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thrombo	I-Disease	D054556
-	I-Disease	D054556
embolism	I-Disease	D054556
.	O	O

One	O	O
trial	O	O
analysed	O	O
subgroups	O	O
of	O	O
2839	O	O
relatively	O	O
healthy	O	O
50	O	O
to	O	O
59	O	O
year	O	O
old	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
and	O	O
1637	O	O
taking	O	O
oestrogen	B-Chemical	D004967
-	O	O
only	O	O
HT	O	O
,	O	O
versus	O	O
similar	O	O
-	O	O
sized	O	O
placebo	O	O
groups	O	O
.	O	O

The	O	O
only	O	O
significantly	O	O
increased	O	O
risk	O	O
reported	O	O
was	O	O
for	O	O
venous	B-Disease	D054556
thrombo	I-Disease	D054556
-	I-Disease	D054556
embolism	I-Disease	D054556
in	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
:	O	O
their	O	O
absolute	O	O
risk	O	O
remained	O	O
low	O	O
,	O	O
at	O	O
less	O	O
than	O	O
1	O	O
/	O	O
500	O	O
.	O	O

However	O	O
,	O	O
this	O	O
study	O	O
was	O	O
not	O	O
powered	O	O
to	O	O
detect	O	O
differences	O	O
between	O	O
groups	O	O
of	O	O
younger	O	O
women	O	O
.	O	O

AUTHORS'	O	O
CONCLUSIONS	O	O
:	O	O
HT	O	O
is	O	O
not	O	O
indicated	O	O
for	O	O
the	O	O
routine	O	O
management	O	O
of	O	O
chronic	O	O
disease	O	O
.	O	O

We	O	O
need	O	O
more	O	O
evidence	O	O
on	O	O
the	O	O
safety	O	O
of	O	O
HT	O	O
for	O	O
menopausal	O	O
symptom	O	O
control	O	O
,	O	O
though	O	O
short	O	O
-	O	O
term	O	O
use	O	O
appears	O	O
to	O	O
be	O	O
relatively	O	O
safe	O	O
for	O	O
healthy	O	O
younger	O	O
women	O	O
.	O	O

Passage	O	O
of	O	O
mannitol	B-Chemical	D008353
into	O	O
the	O	O
brain	O	O
around	O	O
gliomas	B-Disease	D005910
:	O	O
a	O	O
potential	O	O
cause	O	O
of	O	O
rebound	O	O
phenomenon	O	O
.	O	O

A	O	O
study	O	O
on	O	O
21	O	O
patients	O	O
.	O	O

AIM	O	O
:	O	O
Widespread	O	O
use	O	O
of	O	O
mannitol	B-Chemical	D008353
to	O	O
reduce	O	O
brain	B-Disease	D001929
edema	I-Disease	D001929
and	O	O
lower	O	O
elevated	B-Disease	D019586
ICP	I-Disease	D019586
in	O	O
brain	B-Disease	D001932
tumor	I-Disease	D001932
patients	O	O
continues	O	O
to	O	O
be	O	O
afflicted	O	O
by	O	O
the	O	O
so	O	O
-	O	O
called	O	O
rebound	O	O
phenomenon	O	O
.	O	O

Leakage	O	O
of	O	O
mannitol	B-Chemical	D008353
into	O	O
the	O	O
brain	O	O
parenchyma	O	O
through	O	O
an	O	O
altered	O	O
BBB	O	O
and	O	O
secondary	O	O
reversal	O	O
of	O	O
osmotic	O	O
gradient	O	O
is	O	O
considered	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
rebound	O	O
.	O	O

This	O	O
has	O	O
only	O	O
been	O	O
demonstrated	O	O
experimentally	O	O
in	O	O
animals	O	O
.	O	O

As	O	O
a	O	O
contribution	O	O
to	O	O
this	O	O
issue	O	O
we	O	O
decided	O	O
to	O	O
research	O	O
the	O	O
possible	O	O
passage	O	O
of	O	O
mannitol	B-Chemical	D008353
into	O	O
the	O	O
brain	O	O
after	O	O
administration	O	O
to	O	O
21	O	O
brain	B-Disease	D001932
tumor	I-Disease	D001932
patients	O	O
.	O	O

METHODS	O	O
:	O	O
Mannitol	B-Chemical	D008353
(	O	O
18%	O	O
solution	O	O
;	O	O
1	O	O
g	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
administered	O	O
as	O	O
a	O	O
bolus	O	O
to	O	O
patients	O	O
(	O	O
ten	O	O
had	O	O
malignant	B-Disease	D005910
glioma	I-Disease	D005910
,	O	O
seven	O	O
brain	O	O
metastases	B-Disease	D009362
and	O	O
four	O	O
meningioma	B-Disease	D008579
)	O	O
about	O	O
30	O	O
minutes	O	O
before	O	O
craniotomy	O	O
.	O	O

During	O	O
resection	O	O
,	O	O
a	O	O
sample	O	O
of	O	O
the	O	O
surrounding	O	O
edematous	B-Disease	D004487
white	O	O
matter	O	O
was	O	O
taken	O	O
at	O	O
the	O	O
same	O	O
time	O	O
as	O	O
a	O	O
10	O	O
ml	O	O
venous	O	O
blood	O	O
sample	O	O
.	O	O

Mannitol	B-Chemical	D008353
concentrations	O	O
were	O	O
measured	O	O
in	O	O
plasma	O	O
and	O	O
white	O	O
matter	O	O
by	O	O
a	O	O
modified	O	O
version	O	O
of	O	O
the	O	O
enzyme	O	O
assay	O	O
of	O	O
Blonquist	O	O
et	O	O
al	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
most	O	O
glioma	B-Disease	D005910
patients	O	O
,	O	O
mannitol	B-Chemical	D008353
concentrations	O	O
in	O	O
white	O	O
matter	O	O
were	O	O
2	O	O
to	O	O
6	O	O
times	O	O
higher	O	O
than	O	O
in	O	O
plasma	O	O
(	O	O
mean	O	O
3	O	O
.	O	O

5	O	O
times	O	O
)	O	O
.	O	O

In	O	O
meningioma	B-Disease	D008579
and	O	O
metastases	B-Disease	D009362
patients	O	O
plasma	O	O
concentrations	O	O
of	O	O
mannitol	B-Chemical	D008353
were	O	O
higher	O	O
than	O	O
white	O	O
matter	O	O
concentrations	O	O
except	O	O
in	O	O
three	O	O
cases	O	O
with	O	O
infiltration	O	O
by	O	O
neoplastic	O	O
cells	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
of	O	O
our	O	O
study	O	O
show	O	O
that	O	O
even	O	O
after	O	O
a	O	O
single	O	O
bolus	O	O
,	O	O
mannitol	B-Chemical	D008353
may	O	O
leak	O	O
through	O	O
the	O	O
altered	O	O
BBB	O	O
near	O	O
gliomas	B-Disease	D005910
,	O	O
reversing	O	O
the	O	O
initial	O	O
plasma	O	O
-	O	O
to	O	O
-	O	O
blood	O	O
osmotic	O	O
gradient	O	O
,	O	O
aggravating	O	O
peritumoral	O	O
edema	B-Disease	D004487
and	O	O
promoting	O	O
rebound	O	O
of	O	O
ICP	O	O
.	O	O

Can	O	O
lidocaine	B-Chemical	D008012
reduce	O	O
succinylcholine	B-Chemical	D013390
induced	O	O
postoperative	O	O
myalgia?	O	O
This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
lidocaine	B-Chemical	D008012
pretreatment	O	O
on	O	O
reduction	O	O
of	O	O
succinylcholine	B-Chemical	D013390
-	O	O
induced	O	O
myalgia	B-Disease	D063806
in	O	O
patients	O	O
undergoing	O	O
general	O	O
anesthesia	O	O
for	O	O
gynecological	O	O
surgery	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
thirty	O	O
-	O	O
five	O	O
patients	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
three	O	O
groups	O	O
in	O	O
a	O	O
prospective	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
randomized	O	O
manner	O	O
.	O	O

Group	O	O
PS	O	O
,	O	O
the	O	O
control	O	O
group	O	O
,	O	O
received	O	O
normal	O	O
saline	O	O
and	O	O
succinylcholine	B-Chemical	D013390
1	O	O
.	O	O

5	O	O
mg	O	O
x	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
;	O	O
Group	O	O
LS	O	O
,	O	O
lidocaine	B-Chemical	D008012
1	O	O
.	O	O

5	O	O
mg	O	O
x	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
and	O	O
succinylcholine	B-Chemical	D013390
1	O	O
.	O	O

5	O	O
mg	O	O
x	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
;	O	O
Group	O	O
PR	O	O
,	O	O
normal	O	O
saline	O	O
and	O	O
rocuronium	B-Chemical	C061870
0	O	O
.	O	O

6	O	O
mg	O	O
x	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Morphine	B-Chemical	D009020
0	O	O
.	O	O

1	O	O
mg	O	O
x	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
iv	O	O
was	O	O
given	O	O
for	O	O
premedication	O	O
and	O	O
all	O	O
patients	O	O
were	O	O
monitored	O	O
with	O	O
a	O	O
noninvasive	O	O
blood	O	O
pressure	O	O
monitor	O	O
,	O	O
ECG	O	O
and	O	O
pulse	O	O
oximetry	O	O
.	O	O

Anesthesia	O	O
was	O	O
induced	O	O
with	O	O
5	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
thiopental	B-Chemical	D013874
iv	O	O
.	O	O

followed	O	O
by	O	O
succinylcholine	B-Chemical	D013390
(	O	O
Group	O	O
PS	O	O
,	O	O
LS	O	O
)	O	O
or	O	O
rocuronium	B-Chemical	C061870
(	O	O
Group	O	O
PR	O	O
)	O	O
for	O	O
tracheal	O	O
intubation	O	O
.	O	O

Following	O	O
administration	O	O
of	O	O
these	O	O
agents	O	O
,	O	O
the	O	O
presence	O	O
,	O	O
and	O	O
degree	O	O
of	O	O
fasciculation	B-Disease	D005207
were	O	O
assessed	O	O
visually	O	O
on	O	O
a	O	O
four	O	O
point	O	O
scale	O	O
by	O	O
one	O	O
investigator	O	O
who	O	O
was	O	O
blinded	O	O
to	O	O
the	O	O
drug	O	O
administered	O	O
.	O	O

The	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
of	O	O
each	O	O
patient	O	O
were	O	O
monitored	O	O
on	O	O
nine	O	O
occasions	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
hours	O	O
later	O	O
,	O	O
any	O	O
myalgia	B-Disease	D063806
experienced	O	O
was	O	O
assessed	O	O
according	O	O
to	O	O
a	O	O
structured	O	O
questionaire	O	O
and	O	O
graded	O	O
by	O	O
a	O	O
four	O	O
point	O	O
scale	O	O
by	O	O
one	O	O
investigator	O	O
blinded	O	O
to	O	O
the	O	O
intraoperative	O	O
management	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
muscle	B-Disease	D005207
fasciculation	I-Disease	D005207
was	O	O
not	O	O
found	O	O
in	O	O
Group	O	O
PR	O	O
while	O	O
the	O	O
patients	O	O
in	O	O
Group	O	O
LS	O	O
had	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
muscle	B-Disease	D005207
fasciculation	I-Disease	D005207
than	O	O
those	O	O
in	O	O
Group	O	O
PS	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

At	O	O
24	O	O
h	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
myalgia	B-Disease	D063806
was	O	O
higher	O	O
in	O	O
Group	O	O
PS	O	O
than	O	O
in	O	O
Group	O	O
LS	O	O
and	O	O
PR	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

A	O	O
correlation	O	O
was	O	O
not	O	O
found	O	O
between	O	O
the	O	O
incidence	O	O
of	O	O
myalgia	B-Disease	D063806
and	O	O
the	O	O
occurrence	O	O
of	O	O
muscle	B-Disease	D005207
fasciculation	I-Disease	D005207
.	O	O

The	O	O
changes	O	O
in	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
not	O	O
significant	O	O
among	O	O
the	O	O
three	O	O
groups	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
where	O	O
succinylcholine	B-Chemical	D013390
is	O	O
used	O	O
,	O	O
lidocaine	B-Chemical	D008012
is	O	O
proven	O	O
to	O	O
be	O	O
the	O	O
useful	O	O
pretreatment	O	O
agent	O	O
for	O	O
the	O	O
reduction	O	O
of	O	O
postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
.	O	O

Open	O	O
-	O	O
label	O	O
assessment	O	O
of	O	O
levofloxacin	B-Chemical	D064704
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bacterial	O	O
sinusitis	B-Disease	D012852
in	O	O
adults	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
levofloxacin	B-Chemical	D064704
(	O	O
500	O	O
mg	O	O
orally	O	O
once	O	O
daily	O	O
for	O	O
10	O	O
to	O	O
14	O	O
days	O	O
)	O	O
in	O	O
treating	O	O
adult	O	O
outpatients	O	O
with	O	O
acute	O	O
bacterial	O	O
sinusitis	B-Disease	D012852
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
329	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
at	O	O
24	O	O
centers	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
a	O	O
pre	O	O
-	O	O
therapy	O	O
Gram's	O	O
stain	O	O
and	O	O
culture	O	O
of	O	O
sinus	O	O
exudate	O	O
obtained	O	O
by	O	O
antral	O	O
puncture	O	O
or	O	O
nasal	O	O
endoscopy	O	O
.	O	O

Clinical	O	O
response	O	O
was	O	O
assessed	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
signs	O	O
and	O	O
symptoms	O	O
and	O	O
sinus	O	O
radiograph	O	O
or	O	O
computed	O	O
tomography	O	O
results	O	O
.	O	O

Microbiologic	O	O
cure	O	O
rates	O	O
were	O	O
determined	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
presumed	O	O
plus	O	O
documented	O	O
eradication	O	O
of	O	O
the	O	O
pre	O	O
-	O	O
therapy	O	O
pathogen	O	O
(	O	O
s	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
most	O	O
common	O	O
pathogens	O	O
were	O	O
Haemophilus	O	O
influenzae	O	O
,	O	O
Streptococcus	O	O
pneumoniae	O	O
,	O	O
Staphylococcus	O	O
aureus	O	O
,	O	O
and	O	O
Moraxella	O	O
catarrhalis	O	O
.	O	O

Of	O	O
300	O	O
clinically	O	O
evaluable	O	O
patients	O	O
,	O	O
175	O	O
(	O	O
58%	O	O
)	O	O
were	O	O
cured	O	O
and	O	O
90	O	O
(	O	O
30%	O	O
)	O	O
were	O	O
improved	O	O
at	O	O
the	O	O
post	O	O
-	O	O
therapy	O	O
evaluation	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
clinical	O	O
success	O	O
rate	O	O
of	O	O
88%	O	O
.	O	O

Thirty	O	O
-	O	O
five	O	O
patients	O	O
(	O	O
12%	O	O
)	O	O
clinically	O	O
failed	O	O
treatment	O	O
.	O	O

The	O	O
microbiologic	O	O
eradication	O	O
rate	O	O
(	O	O
presumed	O	O
plus	O	O
documented	O	O
)	O	O
among	O	O
138	O	O
microbiologically	O	O
evaluable	O	O
patients	O	O
was	O	O
92%	O	O
.	O	O

Microbiologic	O	O
eradication	O	O
rates	O	O
(	O	O
presumed	O	O
plus	O	O
documented	O	O
)	O	O
of	O	O
the	O	O
most	O	O
common	O	O
pathogens	O	O
ranged	O	O
from	O	O
93%	O	O
(	O	O
M	O	O
.	O	O

catarrhalis	O	O
)	O	O
to	O	O
100%	O	O
(	O	O
S	O	O
.	O	O

pneumoniae	O	O
)	O	O
at	O	O
the	O	O
post	O	O
-	O	O
therapy	O	O
visit	O	O
.	O	O

All	O	O
but	O	O
one	O	O
of	O	O
the	O	O
265	O	O
patients	O	O
who	O	O
were	O	O
cured	O	O
or	O	O
improved	O	O
at	O	O
post	O	O
-	O	O
therapy	O	O
returned	O	O
for	O	O
a	O	O
long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
visit	O	O
;	O	O
243	O	O
(	O	O
92%	O	O
)	O	O
remained	O	O
well	O	O
4	O	O
to	O	O
6	O	O
weeks	O	O
after	O	O
therapy	O	O
;	O	O
and	O	O
21	O	O
(	O	O
8%	O	O
)	O	O
had	O	O
a	O	O
relapse	O	O
of	O	O
symptoms	O	O
.	O	O

Adverse	O	O
events	O	O
considered	O	O
to	O	O
be	O	O
related	O	O
to	O	O
levofloxacin	B-Chemical	D064704
administration	O	O
were	O	O
reported	O	O
by	O	O
29	O	O
patients	O	O
(	O	O
9%	O	O
)	O	O
.	O	O

The	O	O
most	O	O
common	O	O
drug	O	O
-	O	O
related	O	O
adverse	O	O
events	O	O
were	O	O
diarrhea	B-Disease	D003967
,	O	O
flatulence	B-Disease	D005414
,	O	O
and	O	O
nausea	B-Disease	D009325
;	O	O
most	O	O
adverse	O	O
events	O	O
were	O	O
mild	O	O
to	O	O
moderate	O	O
in	O	O
severity	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
levofloxacin	B-Chemical	D064704
500	O	O
mg	O	O
once	O	O
daily	O	O
is	O	O
an	O	O
effective	O	O
and	O	O
safe	O	O
treatment	O	O
for	O	O
acute	O	O
bacterial	O	O
sinusitis	B-Disease	D012852
.	O	O

Clinical	O	O
evaluation	O	O
on	O	O
combined	O	O
administration	O	O
of	O	O
oral	O	O
prostacyclin	B-Chemical	D011464
analogue	O	O
beraprost	B-Chemical	C048081
and	O	O
phosphodiesterase	O	O
inhibitor	O	O
cilostazol	B-Chemical	C045645
.	O	O

Among	O	O
various	O	O
oral	O	O
antiplatelets	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
a	O	O
novel	O	O
prostacyclin	B-Chemical	D011464
analogue	O	O
beraprost	B-Chemical	C048081
(	O	O
BPT	B-Chemical	C048081
)	O	O
and	O	O
a	O	O
potent	O	O
phosphodiesterase	O	O
inhibitor	O	O
cilostazol	B-Chemical	C045645
(	O	O
CLZ	B-Chemical	C045645
)	O	O
may	O	O
result	O	O
in	O	O
untoward	O	O
clinical	O	O
effects	O	O
due	O	O
to	O	O
possible	O	O
synergistic	O	O
elevation	O	O
of	O	O
intracellular	O	O
cAMP	B-Chemical	D000242
(	O	O
cyclic	B-Chemical	D000242
adenosine	I-Chemical	D000242
3'	I-Chemical	D000242
,	I-Chemical	D000242
5'	I-Chemical	D000242
-	I-Chemical	D000242
monophosphate	I-Chemical	D000242
)	O	O
.	O	O

Thereby	O	O
,	O	O
a	O	O
clinical	O	O
study	O	O
of	O	O
the	O	O
combined	O	O
administration	O	O
of	O	O
the	O	O
two	O	O
agents	O	O
was	O	O
attempted	O	O
.	O	O

Twelve	O	O
healthy	O	O
volunteers	O	O
were	O	O
assigned	O	O
to	O	O
take	O	O
BPT	B-Chemical	C048081
/	O	O
CLZ	B-Chemical	C045645
in	O	O
the	O	O
following	O	O
schedule	O	O
;	O	O
BPT	B-Chemical	C048081
:	O	O
40	O	O
micrograms	O	O
at	O	O
day	O	O
1	O	O
and	O	O
120	O	O
micrograms	O	O
t	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

from	O	O
day	O	O
7	O	O
to	O	O
14	O	O
,	O	O
CLZ	B-Chemical	C045645
:	O	O
200	O	O
mg	O	O
t	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

from	O	O
day	O	O
3	O	O
to	O	O
14	O	O
.	O	O

At	O	O
various	O	O
time	O	O
intervals	O	O
,	O	O
physical	O	O
examination	O	O
and	O	O
blood	O	O
collection	O	O
for	O	O
ex	O	O
vivo	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
and	O	O
determination	O	O
of	O	O
intraplatelet	O	O
cAMP	B-Chemical	D000242
were	O	O
performed	O	O
.	O	O

Throughout	O	O
the	O	O
observation	O	O
period	O	O
,	O	O
no	O	O
significant	O	O
alteration	O	O
in	O	O
vital	O	O
signs	O	O
was	O	O
observed	O	O
.	O	O

Seven	O	O
out	O	O
of	O	O
12	O	O
subjects	O	O
experienced	O	O
headache	B-Disease	D006261
of	O	O
a	O	O
short	O	O
duration	O	O
accompanying	O	O
facial	B-Disease	D005483
flush	I-Disease	D005483
in	O	O
one	O	O
and	O	O
nausea	B-Disease	D009325
in	O	O
one	O	O
,	O	O
especially	O	O
after	O	O
ingestion	O	O
of	O	O
CLZ	B-Chemical	C045645
.	O	O

All	O	O
of	O	O
these	O	O
symptoms	O	O
,	O	O
probably	O	O
caused	O	O
by	O	O
the	O	O
vasodilating	O	O
effect	O	O
of	O	O
the	O	O
two	O	O
agents	O	O
,	O	O
were	O	O
of	O	O
mild	O	O
degree	O	O
and	O	O
no	O	O
special	O	O
treatment	O	O
was	O	O
required	O	O
.	O	O

Intraplatelet	O	O
cAMP	B-Chemical	D000242
content	O	O
was	O	O
gradually	O	O
but	O	O
significantly	O	O
increased	O	O
to	O	O
9	O	O
.	O	O

84	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

59	O	O
pmol	O	O
per	O	O
10	O	O
(	O	O
9	O	O
)	O	O
platelets	O	O
at	O	O
day	O	O
14	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
initial	O	O
value	O	O
(	O	O
6	O	O
.	O	O

87	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

25	O	O
pmol	O	O
)	O	O
.	O	O

The	O	O
platelet	O	O
aggregability	O	O
was	O	O
significantly	O	O
suppressed	O	O
at	O	O
various	O	O
time	O	O
intervals	O	O
but	O	O
no	O	O
additive	O	O
or	O	O
synergistic	O	O
inhibitory	O	O
effect	O	O
by	O	O
the	O	O
combined	O	O
administration	O	O
was	O	O
noted	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
combined	O	O
administration	O	O
of	O	O
BPT	B-Chemical	C048081
/	O	O
CLZ	B-Chemical	C045645
is	O	O
safe	O	O
at	O	O
doses	O	O
used	O	O
in	O	O
the	O	O
study	O	O
,	O	O
though	O	O
the	O	O
beneficial	O	O
clinical	O	O
effect	O	O
of	O	O
the	O	O
combined	O	O
administration	O	O
has	O	O
yet	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

Gastrointestinal	O	O
tolerability	O	O
of	O	O
etoricoxib	B-Chemical	C422649
in	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
patients	O	O
:	O	O
results	O	O
of	O	O
the	O	O
etoricoxib	B-Chemical	C422649
vs	O	O
diclofenac	B-Chemical	D004008
sodium	I-Chemical	D004008
gastrointestinal	O	O
tolerability	O	O
and	O	O
effectiveness	O	O
trial	O	O
(	O	O
EDGE	O	O
-	O	O
II	O	O
)	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
A	O	O
randomised	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
to	O	O
compare	O	O
the	O	O
gastrointestinal	O	O
(	O	O
GI	O	O
)	O	O
tolerability	O	O
,	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
etoricoxib	B-Chemical	C422649
and	O	O
diclofenac	B-Chemical	D004008
in	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
(	O	O
RA	B-Disease	D001172
)	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
4086	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
60	O	O
.	O	O

8	O	O
years	O	O
)	O	O
diagnosed	O	O
with	O	O
RA	B-Disease	D001172
were	O	O
enrolled	O	O
and	O	O
received	O	O
etoricoxib	B-Chemical	C422649
90	O	O
mg	O	O
daily	O	O
(	O	O
n	O	O
=	O	O
2032	O	O
)	O	O
or	O	O
diclofenac	B-Chemical	D004008
75	O	O
mg	O	O
twice	O	O
daily	O	O
(	O	O
n	O	O
=	O	O
2054	O	O
)	O	O
.	O	O

Use	O	O
of	O	O
gastroprotective	O	O
agents	O	O
and	O	O
low	O	O
-	O	O
dose	O	O
aspirin	B-Chemical	D001241
was	O	O
allowed	O	O
.	O	O

The	O	O
prespecified	O	O
primary	O	O
end	O	O
point	O	O
consisted	O	O
of	O	O
the	O	O
cumulative	O	O
rate	O	O
of	O	O
patient	O	O
discontinuations	O	O
due	O	O
to	O	O
clinical	O	O
and	O	O
laboratory	O	O
GI	O	O
adverse	O	O
experiences	O	O
(	O	O
AEs	O	O
)	O	O
.	O	O

General	O	O
safety	O	O
was	O	O
also	O	O
assessed	O	O
,	O	O
including	O	O
adjudicated	O	O
thrombotic	B-Disease	D002318
cardiovascular	I-Disease	D002318
event	O	O
data	O	O
.	O	O

Efficacy	O	O
was	O	O
evaluated	O	O
using	O	O
the	O	O
Patient	O	O
Global	O	O
Assessment	O	O
of	O	O
Disease	O	O
Status	O	O
(	O	O
PGADS	O	O
;	O	O
0	O	O
-	O	O
4	O	O
point	O	O
scale	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Mean	O	O
(	O	O
SD	O	O
;	O	O
maximum	O	O
)	O	O
duration	O	O
of	O	O
treatment	O	O
was	O	O
19	O	O
.	O	O

3	O	O
(	O	O
10	O	O
.	O	O

3	O	O
;	O	O
32	O	O
.	O	O

9	O	O
)	O	O
and	O	O
19	O	O
.	O	O

1	O	O
(	O	O
10	O	O
.	O	O

4	O	O
;	O	O
33	O	O
.	O	O

1	O	O
)	O	O
months	O	O
in	O	O
the	O	O
etoricoxib	B-Chemical	C422649
and	O	O
diclofenac	B-Chemical	D004008
groups	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
cumulative	O	O
discontinuation	O	O
rate	O	O
due	O	O
to	O	O
GI	B-Disease	D005767
AEs	I-Disease	D005767
was	O	O
significantly	O	O
lower	O	O
with	O	O
etoricoxib	B-Chemical	C422649
than	O	O
diclofenac	B-Chemical	D004008
(	O	O
5	O	O
.	O	O

2	O	O
vs	O	O
8	O	O
.	O	O

5	O	O
events	O	O
per	O	O
100	O	O
patient	O	O
-	O	O
years	O	O
,	O	O
respectively	O	O
;	O	O
hazard	O	O
ratio	O	O
0	O	O
.	O	O

62	O	O
(	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

47	O	O
,	O	O
0	O	O
.	O	O

81	O	O
;	O	O
p<or=0	O	O
.	O	O

001	O	O
)	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
discontinuations	O	O
for	O	O
hypertension	B-Disease	D006973
-	O	O
related	O	O
and	O	O
oedema	B-Disease	D004487
-	O	O
related	O	O
AEs	O	O
were	O	O
significantly	O	O
higher	O	O
with	O	O
etoricoxib	B-Chemical	C422649
(	O	O
2	O	O
.	O	O

5%	O	O
and	O	O
1	O	O
.	O	O

1%	O	O
respectively	O	O
)	O	O
compared	O	O
with	O	O
diclofenac	B-Chemical	D004008
(	O	O
1	O	O
.	O	O

5%	O	O
and	O	O
0	O	O
.	O	O

4%	O	O
respectively	O	O
;	O	O
p<0	O	O
.	O	O

001	O	O
for	O	O
hypertension	B-Disease	D006973
and	O	O
p<0	O	O
.	O	O

01	O	O
for	O	O
oedema	B-Disease	D004487
)	O	O
.	O	O

Etoricoxib	B-Chemical	C422649
and	O	O
diclofenac	B-Chemical	D004008
treatment	O	O
resulted	O	O
in	O	O
similar	O	O
efficacy	O	O
(	O	O
PGADS	O	O
mean	O	O
changes	O	O
from	O	O
baseline	O	O
-	O	O
0	O	O
.	O	O

62	O	O
vs	O	O
-	O	O
0	O	O
.	O	O

58	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Etoricoxib	B-Chemical	C422649
90	O	O
mg	O	O
demonstrated	O	O
a	O	O
significantly	O	O
lower	O	O
risk	O	O
for	O	O
discontinuing	O	O
treatment	O	O
due	O	O
to	O	O
GI	B-Disease	D005767
AEs	I-Disease	D005767
compared	O	O
with	O	O
diclofenac	B-Chemical	D004008
150	O	O
mg	O	O
.	O	O

Discontinuations	O	O
from	O	O
renovascular	O	O
AEs	O	O
,	O	O
although	O	O
less	O	O
common	O	O
than	O	O
discontinuations	O	O
from	O	O
GI	B-Disease	D005767
AEs	I-Disease	D005767
,	O	O
were	O	O
significantly	O	O
higher	O	O
with	O	O
etoricoxib	B-Chemical	C422649
.	O	O

Placebo	O	O
-	O	O
level	O	O
incidence	O	O
of	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
(	O	O
EPS	B-Disease	D001480
)	O	O
with	O	O
quetiapine	B-Chemical	C069541
in	O	O
controlled	O	O
studies	O	O
of	O	O
patients	O	O
with	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
(	O	O
EPS	B-Disease	D001480
)	O	O
,	O	O
including	O	O
akathisia	B-Disease	D017109
,	O	O
with	O	O
quetiapine	B-Chemical	C069541
in	O	O
patients	O	O
with	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
.	O	O

METHODS	O	O
:	O	O
Data	O	O
were	O	O
analyzed	O	O
from	O	O
four	O	O
similarly	O	O
designed	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
3	O	O
-	O	O
to	O	O
12	O	O
-	O	O
week	O	O
studies	O	O
.	O	O

Two	O	O
studies	O	O
evaluated	O	O
quetiapine	B-Chemical	C069541
monotherapy	O	O
(	O	O
up	O	O
to	O	O
800	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
(	O	O
n	O	O
=	O	O
209	O	O
)	O	O
versus	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
198	O	O
)	O	O
,	O	O
with	O	O
lithium	B-Chemical	D008094
or	O	O
haloperidol	B-Chemical	D006220
monotherapy	O	O
as	O	O
respective	O	O
active	O	O
controls	O	O
.	O	O

Two	O	O
studies	O	O
evaluated	O	O
quetiapine	B-Chemical	C069541
(	O	O
up	O	O
to	O	O
800	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
a	O	O
mood	O	O
stabilizer	O	O
(	O	O
lithium	B-Chemical	D008094
or	O	O
divalproex	B-Chemical	D014635
,	O	O
QTP	B-Chemical	C069541
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
)	O	O
(	O	O
n	O	O
=	O	O
196	O	O
)	O	O
compared	O	O
to	O	O
placebo	O	O
and	O	O
mood	O	O
stabilizer	O	O
(	O	O
PBO	O	O
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
)	O	O
(	O	O
n	O	O
=	O	O
203	O	O
)	O	O
.	O	O

Extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
were	O	O
evaluated	O	O
using	O	O
the	O	O
Simpson	O	O
-	O	O
Angus	O	O
Scale	O	O
(	O	O
SAS	O	O
)	O	O
,	O	O
the	O	O
Barnes	O	O
Akathisia	O	O
Rating	O	O
Scale	O	O
(	O	O
BARS	O	O
)	O	O
,	O	O
adverse	O	O
event	O	O
reports	O	O
and	O	O
anticholinergic	O	O
drug	O	O
usage	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
EPS	B-Disease	D001480
-	O	O
related	O	O
adverse	O	O
events	O	O
,	O	O
including	O	O
akathisia	B-Disease	D017109
,	O	O
was	O	O
no	O	O
different	O	O
with	O	O
quetiapine	B-Chemical	C069541
monotherapy	O	O
(	O	O
12	O	O
.	O	O

9%	O	O
)	O	O
than	O	O
with	O	O
placebo	O	O
(	O	O
13	O	O
.	O	O

1%	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
EPS	B-Disease	D001480
-	O	O
related	O	O
adverse	O	O
events	O	O
with	O	O
QTP	B-Chemical	C069541
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
(	O	O
21	O	O
.	O	O

4%	O	O
)	O	O
were	O	O
no	O	O
different	O	O
than	O	O
with	O	O
PBO	O	O
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
(	O	O
19	O	O
.	O	O

2%	O	O
)	O	O
.	O	O

Adverse	O	O
events	O	O
related	O	O
to	O	O
EPS	B-Disease	D001480
occurred	O	O
in	O	O
59	O	O
.	O	O

6%	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
haloperidol	B-Chemical	D006220
(	O	O
n	O	O
=	O	O
99	O	O
)	O	O
monotherapy	O	O
,	O	O
whereas	O	O
26	O	O
.	O	O

5%	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
lithium	B-Chemical	D008094
(	O	O
n	O	O
=	O	O
98	O	O
)	O	O
monotherapy	O	O
experienced	O	O
adverse	O	O
events	O	O
related	O	O
to	O	O
EPS	B-Disease	D001480
.	O	O

The	O	O
incidence	O	O
of	O	O
akathisia	B-Disease	D017109
was	O	O
low	O	O
and	O	O
similar	O	O
with	O	O
quetiapine	B-Chemical	C069541
monotherapy	O	O
(	O	O
3	O	O
.	O	O

3%	O	O
)	O	O
and	O	O
placebo	O	O
(	O	O
6	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
and	O	O
with	O	O
QTP	B-Chemical	C069541
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
(	O	O
3	O	O
.	O	O

6%	O	O
)	O	O
and	O	O
PBO	O	O
+	O	O
Li	B-Chemical	D008094
/	O	O
DVP	B-Chemical	D014635
(	O	O
4	O	O
.	O	O

9%	O	O
)	O	O
.	O	O

Lithium	B-Chemical	D008094
was	O	O
associated	O	O
with	O	O
a	O	O
significantly	O	O
higher	O	O
incidence	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
of	O	O
tremor	B-Disease	D014202
(	O	O
18	O	O
.	O	O

4%	O	O
)	O	O
than	O	O
quetiapine	B-Chemical	C069541
(	O	O
5	O	O
.	O	O

6%	O	O
)	O	O
;	O	O
cerebellar	O	O
tremor	B-Disease	D014202
,	O	O
which	O	O
is	O	O
a	O	O
known	O	O
adverse	O	O
effect	O	O
of	O	O
lithium	B-Chemical	D008094
,	O	O
may	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
elevated	O	O
rate	O	O
of	O	O
tremor	B-Disease	D014202
in	O	O
patients	O	O
receiving	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

Haloperidol	B-Chemical	D006220
induced	O	O
a	O	O
significantly	O	O
higher	O	O
incidence	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
of	O	O
akathisia	B-Disease	D017109
(	O	O
33	O	O
.	O	O

3%	O	O
versus	O	O
5	O	O
.	O	O

9%	O	O
)	O	O
,	O	O
tremor	B-Disease	D014202
(	O	O
30	O	O
.	O	O

3%	O	O
versus	O	O
7	O	O
.	O	O

8%	O	O
)	O	O
,	O	O
and	O	O
extrapyramidal	B-Disease	D001480
syndrome	I-Disease	D001480
(	O	O
35	O	O
.	O	O

4%	O	O
versus	O	O
5	O	O
.	O	O

9%	O	O
)	O	O
than	O	O
quetiapine	B-Chemical	C069541
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
quetiapine	B-Chemical	C069541
and	O	O
placebo	O	O
on	O	O
SAS	O	O
and	O	O
BARS	O	O
scores	O	O
.	O	O

Anticholinergic	O	O
use	O	O
was	O	O
low	O	O
and	O	O
similar	O	O
with	O	O
quetiapine	B-Chemical	C069541
or	O	O
placebo	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
,	O	O
the	O	O
incidence	O	O
of	O	O
EPS	B-Disease	D001480
,	O	O
including	O	O
akathisia	B-Disease	D017109
,	O	O
with	O	O
quetiapine	B-Chemical	C069541
therapy	O	O
is	O	O
similar	O	O
to	O	O
that	O	O
with	O	O
placebo	O	O
.	O	O

Contribution	O	O
of	O	O
the	O	O
sympathetic	O	O
nervous	O	O
system	O	O
to	O	O
salt	O	O
-	O	O
sensitivity	O	O
in	O	O
lifetime	O	O
captopril	B-Chemical	D002216
-	O	O
treated	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
,	O	O
in	O	O
lifetime	O	O
captopril	B-Chemical	D002216
-	O	O
treated	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
(	O	O
SHR	O	O
)	O	O
,	O	O
the	O	O
sympathetic	O	O
nervous	O	O
system	O	O
contributes	O	O
importantly	O	O
to	O	O
the	O	O
hypertensive	B-Disease	D006973
effect	O	O
of	O	O
dietary	B-Chemical	D017673
sodium	I-Chemical	D017673
chloride	I-Chemical	D017673
supplementation	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
SHR	O	O
(	O	O
aged	O	O
6	O	O
weeks	O	O
)	O	O
that	O	O
had	O	O
been	O	O
treated	O	O
from	O	O
conception	O	O
onward	O	O
with	O	O
either	O	O
captopril	B-Chemical	D002216
or	O	O
vehicle	O	O
remained	O	O
on	O	O
a	O	O
basal	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
diet	O	O
or	O	O
were	O	O
fed	O	O
a	O	O
high	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
diet	O	O
.	O	O

After	O	O
2	O	O
weeks	O	O
,	O	O
the	O	O
rats	O	O
were	O	O
subjected	O	O
to	O	O
ganglionic	O	O
blockade	O	O
and	O	O
2	O	O
days	O	O
later	O	O
,	O	O
an	O	O
infusion	O	O
of	O	O
clonidine	B-Chemical	D003000
.	O	O

RESULTS	O	O
:	O	O
Lifetime	O	O
captopril	B-Chemical	D002216
treatment	O	O
significantly	O	O
lowered	O	O
mean	O	O
arterial	O	O
pressure	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Intravenous	O	O
infusion	O	O
of	O	O
the	O	O
ganglionic	O	O
blocker	O	O
hexamethonium	B-Chemical	D018738
resulted	O	O
in	O	O
a	O	O
rapid	O	O
decline	O	O
in	O	O
MAP	O	O
that	O	O
eliminated	O	O
the	O	O
dietary	B-Chemical	D017673
sodium	I-Chemical	D017673
chloride	I-Chemical	D017673
-	O	O
induced	O	O
increase	B-Disease	D006973
in	I-Disease	D006973
MAP	I-Disease	D006973
in	O	O
both	O	O
groups	O	O
.	O	O

Infusion	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
alpha2	B-Chemical	D058647
-	I-Chemical	D058647
adrenergic	I-Chemical	D058647
receptor	I-Chemical	D058647
agonist	I-Chemical	D058647
clonidine	B-Chemical	D003000
also	O	O
resulted	O	O
in	O	O
a	O	O
greater	O	O
reduction	O	O
in	O	O
MAP	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
SHR	O	O
that	O	O
were	O	O
fed	O	O
the	O	O
high	O	O
(	O	O
compared	O	O
with	O	O
the	O	O
basal	O	O
)	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
diet	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
both	O	O
lifetime	O	O
captopril	B-Chemical	D002216
-	O	O
treated	O	O
and	O	O
control	O	O
SHR	O	O
,	O	O
the	O	O
sympathetic	O	O
nervous	O	O
system	O	O
contributes	O	O
to	O	O
the	O	O
pressor	O	O
effects	O	O
of	O	O
a	O	O
high	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
diet	O	O
.	O	O

Dose	O	O
-	O	O
related	O	O
beneficial	O	O
and	O	O
adverse	O	O
effects	O	O
of	O	O
dietary	O	O
corticosterone	B-Chemical	D003345
on	O	O
organophosphorus	B-Chemical	D010755
-	O	O
induced	O	O
delayed	O	O
neuropathy	B-Disease	D009422
in	O	O
chickens	O	O
.	O	O

Tri	B-Chemical	C025541
-	I-Chemical	C025541
ortho	I-Chemical	C025541
-	I-Chemical	C025541
tolyl	I-Chemical	C025541
phosphate	I-Chemical	C025541
(	O	O
TOTP	B-Chemical	C025541
)	O	O
,	O	O
360	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
po	O	O
,	O	O
and	O	O
0	B-Chemical	D007531
,	I-Chemical	D007531
0'	I-Chemical	D007531
-	I-Chemical	D007531
diisopropyl	I-Chemical	D007531
phosphorofluoridate	I-Chemical	D007531
(	O	O
DFP	B-Chemical	D007531
)	O	O
,	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
,	O	O
were	O	O
administered	O	O
to	O	O
adult	O	O
White	O	O
Leghorn	O	O
chickens	O	O
24	O	O
hr	O	O
after	O	O
they	O	O
were	O	O
placed	O	O
on	O	O
diets	O	O
containing	O	O
0	O	O
to	O	O
300	O	O
ppm	O	O
corticosterone	B-Chemical	D003345
.	O	O

Supplemented	O	O
diets	O	O
were	O	O
continued	O	O
until	O	O
clinical	O	O
signs	O	O
and	O	O
lesions	O	O
of	O	O
delayed	O	O
neuropathy	B-Disease	D009422
appeared	O	O
.	O	O

Although	O	O
low	O	O
concentrations	O	O
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
50	O	O
ppm	O	O
)	O	O
of	O	O
corticosterone	B-Chemical	D003345
had	O	O
beneficial	O	O
effects	O	O
on	O	O
TOTP	B-Chemical	C025541
-	O	O
induced	O	O
neuropathy	B-Disease	D009422
,	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
200	O	O
ppm	O	O
exacerbated	O	O
clinical	O	O
signs	O	O
in	O	O
chickens	O	O
given	O	O
either	O	O
TOTP	B-Chemical	C025541
or	O	O
DFP	B-Chemical	D007531
.	O	O

Neurotoxic	B-Disease	D020258
esterase	O	O
activities	O	O
24	O	O
hr	O	O
after	O	O
TOTP	B-Chemical	C025541
or	O	O
DFP	B-Chemical	D007531
were	O	O
less	O	O
than	O	O
20%	O	O
of	O	O
values	O	O
measured	O	O
in	O	O
chickens	O	O
not	O	O
given	O	O
organophosphorous	B-Chemical	D010755
compounds	O	O
.	O	O

Chickens	O	O
given	O	O
200	O	O
ppm	O	O
corticosterone	B-Chemical	D003345
without	O	O
TOTP	B-Chemical	C025541
or	O	O
DFP	B-Chemical	D007531
had	O	O
significantly	O	O
elevated	O	O
activity	O	O
of	O	O
plasma	O	O
cholinesterase	O	O
and	O	O
significantly	O	O
inhibited	O	O
activity	O	O
of	O	O
liver	O	O
carboxylesterase	O	O
.	O	O

Degenerating	B-Disease	D009410
myelinated	I-Disease	D009410
fibers	I-Disease	D009410
were	O	O
also	O	O
evident	O	O
in	O	O
distal	O	O
levels	O	O
of	O	O
the	O	O
peripheral	O	O
nerves	O	O
of	O	O
chickens	O	O
given	O	O
TOTP	B-Chemical	C025541
or	O	O
DFP	B-Chemical	D007531
.	O	O

In	O	O
vivo	O	O
characterization	O	O
of	O	O
a	O	O
dual	O	O
adenosine	B-Chemical	D058915
A2A	I-Chemical	D058915
/	I-Chemical	D058915
A1	I-Chemical	D058915
receptor	I-Chemical	D058915
antagonist	I-Chemical	D058915
in	O	O
animal	O	O
models	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

The	O	O
in	O	O
vivo	O	O
characterization	O	O
of	O	O
a	O	O
dual	O	O
adenosine	B-Chemical	D058915
A	I-Chemical	D058915
(	I-Chemical	D058915
2A	I-Chemical	D058915
)	I-Chemical	D058915
/	I-Chemical	D058915
A	I-Chemical	D058915
(	I-Chemical	D058915
1	I-Chemical	D058915
)	I-Chemical	D058915
receptor	I-Chemical	D058915
antagonist	I-Chemical	D058915
in	O	O
several	O	O
animal	O	O
models	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
is	O	O
described	O	O
.	O	O

Discovery	O	O
and	O	O
scale	O	O
-	O	O
up	O	O
syntheses	O	O
of	O	O
compound	O	O
1	O	O
are	O	O
described	O	O
in	O	O
detail	O	O
,	O	O
highlighting	O	O
optimization	O	O
steps	O	O
that	O	O
increased	O	O
the	O	O
overall	O	O
yield	O	O
of	O	O
1	O	O
from	O	O
10	O	O
.	O	O

0%	O	O
to	O	O
30	O	O
.	O	O

5%	O	O
.	O	O

Compound	O	O
1	O	O
is	O	O
a	O	O
potent	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
/	O	O
A	O	O
(	O	O
1	O	O
)	O	O
receptor	O	O
antagonist	O	O
in	O	O
vitro	O	O
(	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
4	O	O
.	O	O

1	O	O
nM	O	O
;	O	O
A	O	O
(	O	O
1	O	O
)	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
17	O	O
.	O	O

0	O	O
nM	O	O
)	O	O
that	O	O
has	O	O
excellent	O	O
activity	O	O
,	O	O
after	O	O
oral	O	O
administration	O	O
,	O	O
across	O	O
a	O	O
number	O	O
of	O	O
animal	O	O
models	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
including	O	O
mouse	O	O
and	O	O
rat	O	O
models	O	O
of	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
,	O	O
mouse	O	O
model	O	O
of	O	O
reserpine	B-Chemical	D012110
-	O	O
induced	O	O
akinesia	B-Disease	D004409
,	O	O
rat	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
(	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
)	O	O
lesion	O	O
model	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
rotation	O	O
,	O	O
and	O	O
MPTP	B-Chemical	D015632
-	O	O
treated	O	O
non	O	O
-	O	O
human	O	O
primate	O	O
model	O	O
.	O	O

An	O	O
extremely	O	O
rare	O	O
case	O	O
of	O	O
delusional	B-Disease	D063726
parasitosis	I-Disease	D063726
in	O	O
a	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
patient	O	O
during	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
alpha	I-Chemical	C417083
-	I-Chemical	C417083
2b	I-Chemical	C417083
and	O	O
ribavirin	B-Chemical	D012254
treatment	O	O
.	O	O

During	O	O
treatment	O	O
of	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
patients	O	O
with	O	O
interferon	O	O
and	O	O
ribavirin	B-Chemical	D012254
,	O	O
a	O	O
lot	O	O
of	O	O
side	O	O
effects	O	O
are	O	O
described	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
percent	O	O
to	O	O
44%	O	O
of	O	O
patients	O	O
develop	O	O
depression	B-Disease	D003866
.	O	O

A	O	O
minority	O	O
of	O	O
patients	O	O
evolve	O	O
to	O	O
psychosis	B-Disease	D011605
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
no	O	O
cases	O	O
of	O	O
psychogenic	B-Disease	D063726
parasitosis	I-Disease	D063726
occurring	O	O
during	O	O
interferon	O	O
therapy	O	O
have	O	O
been	O	O
described	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

We	O	O
present	O	O
a	O	O
49	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
a	O	O
delusional	B-Disease	D063726
parasitosis	I-Disease	D063726
during	O	O
treatment	O	O
with	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
alpha	I-Chemical	C417083
-	I-Chemical	C417083
2b	I-Chemical	C417083
weekly	O	O
and	O	O
ribavirin	B-Chemical	D012254
.	O	O

She	O	O
complained	O	O
of	O	O
seeing	O	O
parasites	O	O
and	O	O
the	O	O
larvae	O	O
of	O	O
fleas	O	O
in	O	O
her	O	O
stools	O	O
.	O	O

This	O	O
could	O	O
not	O	O
be	O	O
confirmed	O	O
by	O	O
any	O	O
technical	O	O
examination	O	O
.	O	O

All	O	O
the	O	O
complaints	O	O
disappeared	O	O
after	O	O
stopping	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
alpha	I-Chemical	C417083
-	I-Chemical	C417083
2b	I-Chemical	C417083
and	O	O
reappeared	O	O
after	O	O
restarting	O	O
it	O	O
.	O	O

She	O	O
had	O	O
a	O	O
complete	O	O
sustained	O	O
viral	O	O
response	O	O
.	O	O

Possible	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
related	O	O
to	O	O
concomitant	O	O
treatment	O	O
with	O	O
paroxetine	B-Chemical	D017374
and	O	O
alprazolam	B-Chemical	D000525
.	O	O

A	O	O
74	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
depressive	B-Disease	D003866
symptoms	I-Disease	D003866
was	O	O
admitted	O	O
to	O	O
a	O	O
psychiatric	B-Disease	D001523
hospital	O	O
due	O	O
to	O	O
insomnia	B-Disease	D007319
,	O	O
loss	B-Disease	D001068
of	I-Disease	D001068
appetite	I-Disease	D001068
,	O	O
exhaustion	O	O
,	O	O
and	O	O
agitation	B-Disease	D011595
.	O	O

Medical	O	O
treatment	O	O
was	O	O
initiated	O	O
at	O	O
a	O	O
daily	O	O
dose	O	O
of	O	O
20	O	O
mg	O	O
paroxetine	B-Chemical	D017374
and	O	O
1	O	O
.	O	O

2	O	O
mg	O	O
alprazolam	B-Chemical	D000525
.	O	O

On	O	O
the	O	O
10th	O	O
day	O	O
of	O	O
paroxetine	B-Chemical	D017374
and	O	O
alprazolam	B-Chemical	D000525
treatment	O	O
,	O	O
the	O	O
patient	O	O
exhibited	O	O
marked	O	O
psychomotor	B-Disease	D011596
retardation	I-Disease	D011596
,	O	O
disorientation	O	O
,	O	O
and	O	O
severe	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
with	O	O
tremors	B-Disease	D014202
.	O	O

The	O	O
patient	O	O
had	O	O
a	O	O
fever	B-Disease	D005334
(	O	O
38	O	O
.	O	O

2	O	O
degrees	O	O
C	O	O
)	O	O
,	O	O
fluctuating	O	O
blood	O	O
pressure	O	O
(	O	O
between	O	O
165	O	O
/	O	O
90	O	O
and	O	O
130	O	O
/	O	O
70	O	O
mg	O	O
mm	O	O
Hg	O	O
)	O	O
,	O	O
and	O	O
severe	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
.	O	O

Laboratory	O	O
tests	O	O
showed	O	O
an	O	O
elevation	O	O
of	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
(	O	O
2218	O	O
IU	O	O
/	O	O
L	O	O
)	O	O
,	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
(	O	O
134	O	O
IU	O	O
/	O	O
L	O	O
)	O	O
,	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
(	O	O
78	O	O
IU	O	O
/	O	O
L	O	O
)	O	O
,	O	O
and	O	O
BUN	O	O
(	O	O
27	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
levels	O	O
.	O	O

The	O	O
patient	O	O
received	O	O
bromocriptine	B-Chemical	D001971
and	O	O
diazepam	B-Chemical	D003975
to	O	O
treat	O	O
his	O	O
symptoms	O	O
.	O	O

7	O	O
days	O	O
later	O	O
,	O	O
the	O	O
fever	B-Disease	D005334
disappeared	O	O
and	O	O
the	O	O
patient's	O	O
serum	O	O
CPK	O	O
levels	O	O
were	O	O
normalized	O	O
(	O	O
175	O	O
IU	O	O
/	O	O
L	O	O
)	O	O
.	O	O

This	O	O
patient	O	O
presented	O	O
with	O	O
symptoms	O	O
of	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
(	O	O
NMS	B-Disease	D009459
)	O	O
,	O	O
thus	O	O
demonstrating	O	O
that	O	O
NMS	B-Disease	D009459
-	O	O
like	O	O
symptoms	O	O
can	O	O
occur	O	O
after	O	O
combined	O	O
paroxetine	B-Chemical	D017374
and	O	O
alprazolam	B-Chemical	D000525
treatment	O	O
.	O	O

The	O	O
adverse	O	O
drug	O	O
reaction	O	O
score	O	O
obtained	O	O
by	O	O
the	O	O
Naranjo	O	O
algorithm	O	O
was	O	O
6	O	O
in	O	O
our	O	O
case	O	O
,	O	O
indicating	O	O
a	O	O
probable	O	O
relationship	O	O
between	O	O
the	O	O
patient's	O	O
NMS	B-Disease	D009459
-	O	O
like	O	O
adverse	O	O
symptoms	O	O
and	O	O
the	O	O
combined	O	O
treatment	O	O
used	O	O
in	O	O
this	O	O
case	O	O
.	O	O

The	O	O
involvement	O	O
of	O	O
physiologic	O	O
and	O	O
environmental	O	O
aspects	O	O
specific	O	O
to	O	O
this	O	O
patient	O	O
was	O	O
suspected	O	O
.	O	O

Several	O	O
risk	O	O
factors	O	O
for	O	O
NMS	B-Disease	D009459
should	O	O
be	O	O
noted	O	O
in	O	O
elderly	O	O
depressive	B-Disease	D003866
patients	O	O
whose	O	O
symptoms	O	O
often	O	O
include	O	O
dehydration	B-Disease	D003681
,	O	O
agitation	B-Disease	D011595
,	O	O
malnutrition	B-Disease	D044342
,	O	O
and	O	O
exhaustion	O	O
.	O	O

Careful	O	O
therapeutic	O	O
intervention	O	O
is	O	O
necessary	O	O
in	O	O
cases	O	O
involving	O	O
elderly	O	O
patients	O	O
who	O	O
suffer	O	O
from	O	O
depression	B-Disease	D003866
.	O	O

Pilocarpine	B-Chemical	D010862
seizures	B-Disease	D012640
cause	O	O
age	O	O
-	O	O
dependent	O	O
impairment	B-Disease	D001308
in	I-Disease	D001308
auditory	I-Disease	D001308
location	I-Disease	D001308
discrimination	I-Disease	D001308
.	O	O

Children	O	O
who	O	O
have	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
have	O	O
continuous	O	O
or	O	O
rapidly	O	O
repeating	O	O
seizures	B-Disease	D012640
that	O	O
may	O	O
be	O	O
life	O	O
-	O	O
threatening	O	O
and	O	O
may	O	O
cause	O	O
life	O	O
-	O	O
long	O	O
changes	O	O
in	O	O
brain	O	O
and	O	O
behavior	O	O
.	O	O

The	O	O
extent	O	O
to	O	O
which	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
causes	O	O
deficits	B-Disease	D001308
in	I-Disease	D001308
auditory	I-Disease	D001308
discrimination	I-Disease	D001308
is	O	O
unknown	O	O
.	O	O

A	O	O
naturalistic	O	O
auditory	O	O
location	O	O
discrimination	O	O
method	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
this	O	O
question	O	O
using	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
saline	O	O
on	O	O
postnatal	O	O
day	O	O
(	O	O
P	O	O
)	O	O
20	O	O
,	O	O
or	O	O
a	O	O
convulsant	O	O
dose	O	O
of	O	O
pilocarpine	B-Chemical	D010862
on	O	O
P20	O	O
or	O	O
P45	O	O
.	O	O

Pilocarpine	B-Chemical	D010862
on	O	O
either	O	O
day	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
;	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
at	O	O
P45	O	O
resulted	O	O
in	O	O
CA3	O	O
cell	O	O
loss	O	O
and	O	O
spontaneous	O	O
seizures	B-Disease	D012640
,	O	O
whereas	O	O
P20	O	O
rats	O	O
had	O	O
no	O	O
cell	O	O
loss	O	O
or	O	O
spontaneous	O	O
seizures	B-Disease	D012640
.	O	O

Mature	O	O
rats	O	O
were	O	O
trained	O	O
with	O	O
sound	O	O
-	O	O
source	O	O
location	O	O
and	O	O
sound	O	O
-	O	O
silence	O	O
discriminations	O	O
.	O	O

Control	O	O
(	O	O
saline	O	O
P20	O	O
)	O	O
rats	O	O
acquired	O	O
both	O	O
discriminations	O	O
immediately	O	O
.	O	O

In	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
P20	O	O
)	O	O
rats	O	O
,	O	O
acquisition	O	O
of	O	O
the	O	O
sound	O	O
-	O	O
source	O	O
location	O	O
discrimination	O	O
was	O	O
moderately	O	O
impaired	O	O
.	O	O

Status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
P45	O	O
)	O	O
rats	O	O
failed	O	O
to	O	O
acquire	O	O
either	O	O
sound	O	O
-	O	O
source	O	O
location	O	O
or	O	O
sound	O	O
-	O	O
silence	O	O
discriminations	O	O
.	O	O

Status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
rat	O	O
causes	O	O
an	O	O
age	O	O
-	O	O
dependent	O	O
,	O	O
long	O	O
-	O	O
term	O	O
impairment	B-Disease	D001308
in	I-Disease	D001308
auditory	I-Disease	D001308
discrimination	I-Disease	D001308
.	O	O

This	O	O
impairment	O	O
may	O	O
explain	O	O
one	O	O
cause	O	O
of	O	O
impaired	B-Disease	D001308
auditory	I-Disease	D001308
location	I-Disease	D001308
discrimination	I-Disease	D001308
in	O	O
humans	O	O
.	O	O

Cardiovascular	O	O
risk	O	O
with	O	O
cyclooxygenase	B-Chemical	D016861
inhibitors	I-Chemical	D016861
:	O	O
general	O	O
problem	O	O
with	O	O
substance	O	O
specific	O	O
differences?	O	O
Randomised	O	O
clinical	O	O
trials	O	O
and	O	O
observational	O	O
studies	O	O
have	O	O
shown	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
,	O	O
stroke	B-Disease	D020521
,	O	O
hypertension	B-Disease	D006973
and	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
during	O	O
treatment	O	O
with	O	O
cyclooxygenase	B-Chemical	D016861
inhibitors	I-Chemical	D016861
.	O	O

Adverse	O	O
cardiovascular	O	O
effects	O	O
occurred	O	O
mainly	O	O
,	O	O
but	O	O
not	O	O
exclusively	O	O
,	O	O
in	O	O
patients	O	O
with	O	O
concomitant	O	O
risk	O	O
factors	O	O
.	O	O

Cyclooxygenase	B-Chemical	D016861
inhibitors	I-Chemical	D016861
cause	O	O
complex	O	O
changes	O	O
in	O	O
renal	O	O
,	O	O
vascular	O	O
and	O	O
cardiac	O	O
prostanoid	O	O
profiles	O	O
thereby	O	O
increasing	O	O
vascular	O	O
resistance	O	O
and	O	O
fluid	O	O
retention	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiovascular	O	O
adverse	O	O
events	O	O
tends	O	O
to	O	O
increase	O	O
with	O	O
the	O	O
daily	O	O
dose	O	O
and	O	O
total	O	O
exposure	O	O
time	O	O
.	O	O

A	O	O
comparison	O	O
of	O	O
individual	O	O
selective	O	O
and	O	O
unselective	O	O
cyclooxygenase	B-Chemical	D016861
inhibitors	I-Chemical	D016861
suggests	O	O
substance	O	O
-	O	O
specific	O	O
differences	O	O
,	O	O
which	O	O
may	O	O
depend	O	O
on	O	O
differences	O	O
in	O	O
pharmacokinetic	O	O
parameters	O	O
or	O	O
inhibitory	O	O
potency	O	O
and	O	O
may	O	O
be	O	O
contributed	O	O
by	O	O
prostaglandin	B-Chemical	D011453
-	O	O
independent	O	O
effects	O	O
.	O	O

Diagnostic	O	O
markers	O	O
such	O	O
as	O	O
N	B-Chemical	C109794
-	I-Chemical	C109794
terminal	I-Chemical	C109794
pro	I-Chemical	C109794
brain	I-Chemical	C109794
natriuretic	I-Chemical	C109794
peptide	I-Chemical	C109794
(	O	O
NT	B-Chemical	C109794
-	I-Chemical	C109794
proBNP	I-Chemical	C109794
)	O	O
or	O	O
high	O	O
-	O	O
sensitive	O	O
C	O	O
-	O	O
reactive	O	O
protein	O	O
might	O	O
help	O	O
in	O	O
the	O	O
early	O	O
identification	O	O
of	O	O
patients	O	O
at	O	O
risk	O	O
,	O	O
thus	O	O
avoiding	O	O
the	O	O
occurrence	O	O
of	O	O
serious	O	O
cardiovascular	B-Disease	D002318
toxicity	I-Disease	D002318
.	O	O

Predictors	O	O
of	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
in	O	O
patients	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
during	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
therapy	O	O
:	O	O
results	O	O
from	O	O
the	O	O
studies	O	O
of	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
(	O	O
SOLVD	O	O
)	O	O
BACKGROUND	O	O
:	O	O
Although	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
therapy	O	O
reduces	O	O
mortality	O	O
rates	O	O
in	O	O
patients	O	O
with	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
(	O	O
CHF	B-Disease	D006333
)	O	O
,	O	O
it	O	O
may	O	O
also	O	O
cause	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
.	O	O

Little	O	O
information	O	O
is	O	O
available	O	O
to	O	O
predict	O	O
which	O	O
patients	O	O
are	O	O
at	O	O
highest	O	O
risk	O	O
for	O	O
this	O	O
complication	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
quantify	O	O
specific	O	O
clinical	O	O
predictors	O	O
of	O	O
reduction	B-Disease	D051437
in	I-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
in	O	O
patients	O	O
with	O	O
CHF	B-Disease	D006333
who	O	O
are	O	O
prescribed	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
therapy	O	O
.	O	O

METHOD	O	O
:	O	O
We	O	O
analyzed	O	O
data	O	O
from	O	O
the	O	O
Studies	O	O
of	O	O
Left	B-Disease	D018487
Ventricular	I-Disease	D018487
Dysfunction	I-Disease	D018487
(	O	O
SOLVD	O	O
)	O	O
,	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
of	O	O
enalapril	B-Chemical	D004656
for	O	O
the	O	O
treatment	O	O
of	O	O
CHF	B-Disease	D006333
.	O	O

There	O	O
were	O	O
3379	O	O
patients	O	O
randomly	O	O
assigned	O	O
to	O	O
enalapril	B-Chemical	D004656
with	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
974	O	O
days	O	O
and	O	O
3379	O	O
patients	O	O
randomly	O	O
assigned	O	O
to	O	O
placebo	O	O
with	O	O
a	O	O
mean	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
967	O	O
days	O	O
.	O	O

Decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
was	O	O
defined	O	O
as	O	O
a	O	O
rise	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
>	O	O
/	O	O
=0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
44	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
from	O	O
baseline	O	O
.	O	O

We	O	O
used	O	O
time	O	O
-	O	O
to	O	O
-	O	O
event	O	O
analysis	O	O
to	O	O
identify	O	O
potential	O	O
predictors	O	O
of	O	O
decrease	O	O
in	O	O
renal	O	O
function	O	O
including	O	O
age	O	O
,	O	O
baseline	O	O
ejection	O	O
fraction	O	O
,	O	O
baseline	O	O
creatinine	B-Chemical	D003404
,	O	O
low	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
<100	O	O
mm	O	O
Hg	O	O
)	O	O
,	O	O
history	O	O
of	O	O
hypertension	B-Disease	D006973
,	O	O
diabetes	B-Disease	D003920
,	O	O
and	O	O
use	O	O
of	O	O
antiplatelet	O	O
,	O	O
diuretic	B-Chemical	D004232
,	O	O
and	O	O
beta	O	O
-	O	O
blocker	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
randomly	O	O
assigned	O	O
to	O	O
enalapril	B-Chemical	D004656
had	O	O
a	O	O
33%	O	O
greater	O	O
likelihood	O	O
of	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
than	O	O
controls	O	O
(	O	O
P	O	O
=	O	O
.	O	O

003	O	O
)	O	O
.	O	O

By	O	O
multivariate	O	O
analysis	O	O
,	O	O
in	O	O
both	O	O
the	O	O
placebo	O	O
and	O	O
enalapril	B-Chemical	D004656
groups	O	O
older	O	O
age	O	O
,	O	O
diuretic	B-Chemical	D004232
therapy	O	O
,	O	O
and	O	O
diabetes	B-Disease	D003920
were	O	O
associated	O	O
with	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
,	O	O
whereas	O	O
beta	O	O
-	O	O
blocker	O	O
therapy	O	O
and	O	O
higher	O	O
ejection	O	O
fraction	O	O
were	O	O
renoprotective	O	O
.	O	O

Older	O	O
age	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
of	O	O
developing	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
in	O	O
both	O	O
groups	O	O
,	O	O
but	O	O
significantly	O	O
more	O	O
so	O	O
in	O	O
the	O	O
enalapril	B-Chemical	D004656
group	O	O
(	O	O
enalapril	B-Chemical	D004656
:	O	O
risk	O	O
ratio	O	O
[	O	O
RR	O	O
]	O	O
1	O	O
.	O	O

42	O	O
per	O	O
10	O	O
years	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
1	O	O
.	O	O

32	O	O
-	O	O
1	O	O
.	O	O

52	O	O
with	O	O
enalapril	B-Chemical	D004656
;	O	O
placebo	O	O
:	O	O
RR	O	O
1	O	O
.	O	O

18	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

12	O	O
-	O	O
1	O	O
.	O	O

25	O	O
)	O	O
.	O	O

Diuretic	B-Chemical	D004232
therapy	O	O
was	O	O
likewise	O	O
associated	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
of	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
in	O	O
the	O	O
enalapril	B-Chemical	D004656
group	O	O
(	O	O
RR	O	O
1	O	O
.	O	O

89	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

70	O	O
-	O	O
2	O	O
.	O	O

08	O	O
)	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
RR	O	O
1	O	O
.	O	O

35	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

09	O	O
-	O	O
1	O	O
.	O	O

66	O	O
)	O	O
.	O	O

Conversely	O	O
,	O	O
enalapril	B-Chemical	D004656
had	O	O
a	O	O
relative	O	O
renoprotective	O	O
effect	O	O
(	O	O
RR	O	O
1	O	O
.	O	O

33	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

13	O	O
-	O	O
1	O	O
.	O	O

53	O	O
)	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
RR	O	O
1	O	O
.	O	O

96	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

57	O	O
-	O	O
2	O	O
.	O	O

44	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
.	O	O

A	O	O
lower	O	O
risk	O	O
of	O	O
renal	B-Disease	D051437
impairment	I-Disease	D051437
was	O	O
seen	O	O
in	O	O
both	O	O
groups	O	O
with	O	O
beta	O	O
-	O	O
blocker	O	O
therapy	O	O
(	O	O
RR	O	O
0	O	O
.	O	O

70	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

57	O	O
-	O	O
0	O	O
.	O	O

85	O	O
)	O	O
and	O	O
higher	O	O
baseline	O	O
ejection	O	O
fraction	O	O
(	O	O
RR	O	O
0	O	O
.	O	O

93	O	O
per	O	O
5%	O	O
increment	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

91	O	O
-	O	O
0	O	O
.	O	O

96	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Enalapril	B-Chemical	D004656
use	O	O
caused	O	O
a	O	O
33%	O	O
increase	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
decreased	B-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
in	O	O
patients	O	O
with	O	O
CHF	B-Disease	D006333
.	O	O

Diuretic	B-Chemical	D004232
use	O	O
and	O	O
advanced	O	O
age	O	O
increased	O	O
this	O	O
risk	O	O
.	O	O

Diabetes	B-Disease	D003920
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
renal	B-Disease	D051437
impairment	I-Disease	D051437
in	O	O
all	O	O
patients	O	O
with	O	O
CHF	B-Disease	D006333
,	O	O
but	O	O
this	O	O
risk	O	O
was	O	O
reduced	O	O
in	O	O
the	O	O
enalapril	B-Chemical	D004656
group	O	O
compared	O	O
with	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

beta	O	O
-	O	O
Blocker	O	O
therapy	O	O
and	O	O
higher	O	O
ejection	O	O
fraction	O	O
were	O	O
renoprotective	O	O
in	O	O
all	O	O
patients	O	O
regardless	O	O
of	O	O
therapy	O	O
.	O	O

Pemoline	B-Chemical	D010389
induced	O	O
acute	O	O
choreoathetosis	B-Disease	D002819
:	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Pemoline	B-Chemical	D010389
is	O	O
an	O	O
oxazolidine	B-Chemical	C064210
derivative	O	O
that	O	O
is	O	O
structurally	O	O
different	O	O
from	O	O
amphetamines	B-Chemical	D000662
and	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
attention	B-Disease	D001289
deficit	I-Disease	D001289
disorder	I-Disease	D001289
.	O	O

Pemoline	B-Chemical	D010389
has	O	O
not	O	O
been	O	O
commonly	O	O
associated	O	O
in	O	O
the	O	O
literature	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
.	O	O

The	O	O
following	O	O
case	O	O
describes	O	O
two	O	O
children	O	O
acutely	O	O
poisoned	O	O
with	O	O
pemoline	B-Chemical	D010389
who	O	O
experienced	O	O
profound	O	O
choreoathetosis	B-Disease	D002819
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
Two	O	O
,	O	O
3	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
,	O	O
identical	O	O
twin	O	O
siblings	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
after	O	O
found	O	O
playing	O	O
with	O	O
a	O	O
an	O	O
empty	O	O
bottle	O	O
of	O	O
pemoline	B-Chemical	D010389
originally	O	O
containing	O	O
59	O	O
tablets	O	O
.	O	O

The	O	O
children	O	O
had	O	O
a	O	O
medical	O	O
history	O	O
significant	O	O
for	O	O
attention	B-Disease	D001289
deficit	I-Disease	D001289
disorder	I-Disease	D001289
previously	O	O
treated	O	O
with	O	O
methylphenidate	B-Chemical	D008774
without	O	O
success	O	O
.	O	O

This	O	O
was	O	O
their	O	O
first	O	O
day	O	O
of	O	O
pemoline	B-Chemical	D010389
therapy	O	O
.	O	O

The	O	O
choreoathetoid	B-Disease	D002819
movements	O	O
began	O	O
45	O	O
min	O	O
to	O	O
1	O	O
h	O	O
after	O	O
ingestion	O	O
.	O	O

The	O	O
children	O	O
gave	O	O
no	O	O
history	O	O
of	O	O
prior	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
and	O	O
there	O	O
was	O	O
no	O	O
family	O	O
history	O	O
of	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
.	O	O

The	O	O
children	O	O
received	O	O
gastrointestinal	O	O
decontamination	O	O
and	O	O
high	O	O
doses	O	O
of	O	O
intravenous	O	O
benzodiazepines	B-Chemical	D001569
in	O	O
an	O	O
attempt	O	O
to	O	O
control	O	O
the	O	O
choreoathetoid	B-Disease	D002819
movements	O	O
.	O	O

Despite	O	O
treatment	O	O
,	O	O
the	O	O
children	O	O
continued	O	O
to	O	O
have	O	O
choreoathetosis	B-Disease	D002819
for	O	O
approximately	O	O
24	O	O
hours	O	O
.	O	O

Forty	O	O
-	O	O
eight	O	O
hours	O	O
after	O	O
admission	O	O
,	O	O
the	O	O
children	O	O
appeared	O	O
to	O	O
be	O	O
at	O	O
their	O	O
baseline	O	O
and	O	O
were	O	O
discharged	O	O
home	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Pemoline	B-Chemical	D010389
associated	O	O
movement	B-Disease	D009069
disorder	I-Disease	D009069
has	O	O
been	O	O
rarely	O	O
reported	O	O
in	O	O
the	O	O
acute	O	O
toxicology	O	O
literature	O	O
.	O	O

The	O	O
possibility	O	O
of	O	O
choreoathetoid	B-Disease	D002819
movements	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
presenting	O	O
after	O	O
pemoline	B-Chemical	D010389
overdose	B-Disease	D062787
.	O	O

Continuous	O	O
subcutaneous	O	O
administration	O	O
of	O	O
mesna	B-Chemical	D015080
to	O	O
prevent	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

Hemorrhagic	O	O
cystitis	O	O
is	O	O
a	O	O
major	O	O
potential	O	O
toxicity	B-Disease	D064420
of	O	O
ifosfamide	B-Chemical	D007069
that	O	O
can	O	O
be	O	O
prevented	O	O
by	O	O
administering	O	O
mesna	B-Chemical	D015080
along	O	O
with	O	O
the	O	O
cytotoxic	O	O
agent	O	O
.	O	O

Mesna	B-Chemical	D015080
is	O	O
generally	O	O
administered	O	O
by	O	O
the	O	O
intravenous	O	O
route	O	O
,	O	O
although	O	O
experience	O	O
with	O	O
oral	O	O
delivery	O	O
of	O	O
the	O	O
drug	O	O
has	O	O
increased	O	O
.	O	O

The	O	O
continuous	O	O
subcutaneous	O	O
administration	O	O
of	O	O
mesna	B-Chemical	D015080
has	O	O
the	O	O
advantage	O	O
of	O	O
not	O	O
requiring	O	O
intravenous	O	O
access	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
subcutaneous	O	O
delivery	O	O
of	O	O
the	O	O
neutralizing	O	O
agent	O	O
will	O	O
not	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
risk	O	O
of	O	O
inadequate	O	O
urinary	O	O
mesna	B-Chemical	D015080
concentrations	O	O
,	O	O
such	O	O
as	O	O
in	O	O
a	O	O
patient	O	O
taking	O	O
oral	O	O
mesna	B-Chemical	D015080
who	O	O
experiences	O	O
severe	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
emesis	B-Disease	D014839
and	O	O
is	O	O
unable	O	O
to	O	O
absorb	O	O
the	O	O
drug	O	O
.	O	O

Limited	O	O
clinical	O	O
experience	O	O
with	O	O
continuous	O	O
subcutaneous	O	O
mesna	B-Chemical	D015080
administration	O	O
suggests	O	O
it	O	O
is	O	O
a	O	O
safe	O	O
,	O	O
practical	O	O
,	O	O
and	O	O
economic	O	O
method	O	O
of	O	O
drug	O	O
delivery	O	O
that	O	O
permits	O	O
ifosfamide	B-Chemical	D007069
to	O	O
be	O	O
administered	O	O
successfully	O	O
in	O	O
the	O	O
outpatient	O	O
setting	O	O
.	O	O

Modification	O	O
of	O	O
drug	O	O
action	O	O
by	O	O
hyperammonemia	B-Disease	D022124
.	O	O

Pretreatment	O	O
with	O	O
ammonium	B-Chemical	C018824
acetate	I-Chemical	C018824
(	O	O
NH4Ac	B-Chemical	C018824
)	O	O
(	O	O
6	O	O
mmol	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
approximately	O	O
doubled	O	O
the	O	O
time	O	O
morphine	B-Chemical	D009020
-	O	O
treated	O	O
mice	O	O
remained	O	O
on	O	O
a	O	O
hot	O	O
surface	O	O
and	O	O
similarly	O	O
increased	O	O
muscular	O	O
incoordination	B-Disease	D001259
by	O	O
diazepam	B-Chemical	D003975
,	O	O
but	O	O
NH4Ac	B-Chemical	C018824
treatment	O	O
alone	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

Thus	O	O
,	O	O
hyperammonemia	B-Disease	D022124
is	O	O
capable	O	O
of	O	O
altering	O	O
drug	O	O
action	O	O
and	O	O
must	O	O
be	O	O
considered	O	O
along	O	O
with	O	O
impaired	O	O
drug	O	O
metabolism	O	O
in	O	O
enhanced	O	O
drug	O	O
responses	O	O
associated	O	O
with	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

Experiments	O	O
in	O	O
vitro	O	O
showed	O	O
that	O	O
acetylcholine	B-Chemical	D000109
-	O	O
induced	O	O
catecholamine	B-Chemical	D002395
release	O	O
from	O	O
bovine	O	O
adrenal	O	O
medulla	O	O
is	O	O
depressed	O	O
as	O	O
much	O	O
as	O	O
50%	O	O
by	O	O
0	O	O
.	O	O

3	O	O
mM	O	O
NH4Ac	B-Chemical	C018824
and	O	O
KCl	B-Chemical	D011189
-	O	O
induced	O	O
contractions	O	O
of	O	O
guinea	O	O
-	O	O
pig	O	O
ileum	O	O
were	O	O
inhibited	O	O
20%	O	O
by	O	O
5	O	O
mM	O	O
NH4Ac	B-Chemical	C018824
.	O	O

Addition	O	O
of	O	O
excess	O	O
calcium	B-Chemical	D002118
reversed	O	O
the	O	O
depression	B-Disease	D003866
in	O	O
both	O	O
tissues	O	O
,	O	O
but	O	O
calcium	B-Chemical	D002118
-	O	O
independent	O	O
catecholamine	B-Chemical	D002395
release	O	O
by	O	O
acetaldehyde	B-Chemical	D000079
was	O	O
not	O	O
blocked	O	O
by	O	O
NH4Ac	B-Chemical	C018824
.	O	O

These	O	O
results	O	O
suggested	O	O
that	O	O
ammonia	B-Chemical	D000641
blocks	O	O
calcium	B-Chemical	D002118
channels	O	O
.	O	O

Parallels	O	O
in	O	O
the	O	O
actions	O	O
of	O	O
NH4Ac	B-Chemical	C018824
and	O	O
the	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
verapamil	B-Chemical	D014700
support	O	O
this	O	O
concept	O	O
.	O	O

Both	O	O
verapamil	B-Chemical	D014700
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
NH4Ac	B-Chemical	C018824
pretreatment	O	O
enhanced	O	O
morphine	B-Chemical	D009020
analgesia	B-Disease	D000699
-	O	O
and	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
muscular	O	O
incoordination	B-Disease	D001259
and	O	O
antagonized	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
motor	O	O
activity	O	O
,	O	O
and	O	O
neither	O	O
verapamil	B-Chemical	D014700
nor	O	O
NH4Ac	B-Chemical	C018824
affected	O	O
the	O	O
convulsant	O	O
action	O	O
of	O	O
metrazol	B-Chemical	D010433
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
hyperammonemia	B-Disease	D022124
exerts	O	O
a	O	O
calcium	B-Chemical	D002118
channel	O	O
blocking	O	O
action	O	O
which	O	O
enhances	O	O
the	O	O
effects	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
depressants	O	O
and	O	O
certain	O	O
opioid	O	O
analgesics	O	O
.	O	O

Risk	O	O
of	O	O
nephropathy	B-Disease	D007674
after	O	O
consumption	O	O
of	O	O
nonionic	O	O
contrast	B-Chemical	D003287
media	I-Chemical	D003287
by	O	O
children	O	O
undergoing	O	O
cardiac	O	O
angiography	O	O
:	O	O
a	O	O
prospective	O	O
study	O	O
.	O	O

Despite	O	O
increasing	O	O
reports	O	O
on	O	O
nonionic	O	O
contrast	B-Chemical	D003287
media	I-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
(	O	O
CIN	B-Disease	D007674
)	O	O
in	O	O
hospitalized	O	O
adult	O	O
patients	O	O
during	O	O
cardiac	O	O
procedures	O	O
,	O	O
the	O	O
studies	O	O
in	O	O
pediatrics	O	O
are	O	O
limited	O	O
,	O	O
with	O	O
even	O	O
less	O	O
focus	O	O
on	O	O
possible	O	O
predisposing	O	O
factors	O	O
and	O	O
preventive	O	O
measures	O	O
for	O	O
patients	O	O
undergoing	O	O
cardiac	O	O
angiography	O	O
.	O	O

This	O	O
prospective	O	O
study	O	O
determined	O	O
the	O	O
incidence	O	O
of	O	O
CIN	B-Disease	D007674
for	O	O
two	O	O
nonionic	O	O
contrast	B-Chemical	D003287
media	I-Chemical	D003287
(	O	O
CM	B-Chemical	D003287
)	O	O
,	O	O
iopromide	B-Chemical	C038192
and	O	O
iohexol	B-Chemical	D007472
,	O	O
among	O	O
80	O	O
patients	O	O
younger	O	O
than	O	O
18	O	O
years	O	O
and	O	O
compared	O	O
the	O	O
rates	O	O
for	O	O
this	O	O
complication	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
type	O	O
and	O	O
dosage	O	O
of	O	O
CM	B-Chemical	D003287
and	O	O
the	O	O
presence	O	O
of	O	O
cyanosis	B-Disease	D003490
.	O	O

The	O	O
80	O	O
patients	O	O
in	O	O
the	O	O
study	O	O
consecutively	O	O
received	O	O
either	O	O
iopromide	B-Chemical	C038192
(	O	O
group	O	O
A	O	O
,	O	O
n	O	O
=	O	O
40	O	O
)	O	O
or	O	O
iohexol	B-Chemical	D007472
(	O	O
group	O	O
B	O	O
,	O	O
n	O	O
=	O	O
40	O	O
)	O	O
.	O	O

Serum	O	O
sodium	B-Chemical	D012964
(	O	O
Na	B-Chemical	D012964
)	O	O
,	O	O
potassium	B-Chemical	D011188
(	O	O
K	B-Chemical	D011188
)	O	O
,	O	O
and	O	O
creatinine	B-Chemical	D003404
(	O	O
Cr	B-Chemical	D003404
)	O	O
were	O	O
measured	O	O
24	O	O
h	O	O
before	O	O
angiography	O	O
as	O	O
baseline	O	O
values	O	O
,	O	O
then	O	O
measured	O	O
again	O	O
at	O	O
12	O	O
-	O	O
,	O	O
24	O	O
-	O	O
,	O	O
and	O	O
48	O	O
-	O	O
h	O	O
intervals	O	O
after	O	O
CM	B-Chemical	D003287
use	O	O
.	O	O

Urine	O	O
samples	O	O
for	O	O
Na	B-Chemical	D012964
and	O	O
Cr	B-Chemical	D003404
also	O	O
were	O	O
checked	O	O
at	O	O
the	O	O
same	O	O
intervals	O	O
.	O	O

Risk	O	O
of	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
Injury	B-Disease	D058186
to	I-Disease	D058186
the	I-Disease	D058186
kidney	I-Disease	D058186
,	O	O
Failure	B-Disease	D051437
of	I-Disease	D051437
kidney	I-Disease	D051437
function	I-Disease	D051437
,	O	O
Loss	B-Disease	D051437
of	I-Disease	D051437
kidney	I-Disease	D051437
function	I-Disease	D051437
,	O	O
and	O	O
End	O	O
-	O	O
stage	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
(	O	O
RIFLE	O	O
criteria	O	O
)	O	O
were	O	O
used	O	O
to	O	O
define	O	O
CIN	B-Disease	D007674
and	O	O
its	O	O
incidence	O	O
in	O	O
the	O	O
study	O	O
population	O	O
.	O	O

Accordingly	O	O
,	O	O
among	O	O
the	O	O
15	O	O
CIN	B-Disease	D007674
patients	O	O
(	O	O
18	O	O
.	O	O

75%	O	O
)	O	O
,	O	O
7	O	O
.	O	O

5%	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
group	O	O
A	O	O
had	O	O
increased	O	O
risk	O	O
and	O	O
3	O	O
.	O	O

75%	O	O
had	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
,	O	O
whereas	O	O
5%	O	O
of	O	O
group	O	O
B	O	O
had	O	O
increased	O	O
risk	O	O
and	O	O
2	O	O
.	O	O

5%	O	O
had	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
.	O	O

Whereas	O	O
33	O	O
.	O	O

3%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
CIN	B-Disease	D007674
were	O	O
among	O	O
those	O	O
who	O	O
received	O	O
the	O	O
proper	O	O
dosage	O	O
of	O	O
CM	B-Chemical	D003287
,	O	O
the	O	O
percentage	O	O
increased	O	O
to	O	O
66	O	O
.	O	O

6%	O	O
among	O	O
those	O	O
who	O	O
received	O	O
larger	O	O
doses	O	O
,	O	O
with	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
CIN	B-Disease	D007674
related	O	O
to	O	O
the	O	O
different	O	O
dosages	O	O
of	O	O
CM	B-Chemical	D003287
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

014	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
15	O	O
patients	O	O
with	O	O
CIN	B-Disease	D007674
,	O	O
6	O	O
had	O	O
cyanotic	O	O
congenital	B-Disease	D006331
heart	I-Disease	D006331
diseases	I-Disease	D006331
,	O	O
but	O	O
the	O	O
incidence	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
from	O	O
that	O	O
for	O	O
the	O	O
noncyanotic	O	O
patients	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

243	O	O
)	O	O
.	O	O

Although	O	O
clinically	O	O
silent	O	O
,	O	O
CIN	B-Disease	D007674
is	O	O
not	O	O
rare	O	O
in	O	O
pediatrics	O	O
.	O	O

The	O	O
incidence	O	O
depends	O	O
on	O	O
dosage	O	O
but	O	O
not	O	O
on	O	O
the	O	O
type	O	O
of	O	O
consumed	O	O
nonionic	O	O
CM	B-Chemical	D003287
,	O	O
nor	O	O
on	O	O
the	O	O
presence	O	O
of	O	O
cyanosis	B-Disease	D003490
,	O	O
and	O	O
although	O	O
CIN	B-Disease	D007674
usually	O	O
is	O	O
reversible	O	O
,	O	O
more	O	O
concern	O	O
is	O	O
needed	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
such	O	O
a	O	O
complication	O	O
in	O	O
children	O	O
.	O	O

A	O	O
case	O	O
of	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
related	O	O
to	O	O
caffeine	B-Chemical	D002110
pretreatment	O	O
.	O	O

Suboptimal	O	O
seizure	B-Disease	D012640
duration	O	O
is	O	O
commonly	O	O
encountered	O	O
in	O	O
electroconvulsive	O	O
therapy	O	O
practice	O	O
,	O	O
especially	O	O
in	O	O
older	O	O
patients	O	O
with	O	O
higher	O	O
seizure	B-Disease	D012640
thresholds	O	O
.	O	O

Intravenous	O	O
caffeine	B-Chemical	D002110
is	O	O
commonly	O	O
used	O	O
to	O	O
improve	O	O
seizure	B-Disease	D012640
duration	O	O
and	O	O
quality	O	O
in	O	O
such	O	O
patients	O	O
and	O	O
is	O	O
generally	O	O
well	O	O
tolerated	O	O
aside	O	O
from	O	O
occasional	O	O
reports	O	O
of	O	O
relatively	O	O
benign	O	O
ventricular	B-Disease	D018879
ectopy	I-Disease	D018879
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
no	O	O
previous	O	O
history	O	O
of	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
or	O	O
arrhythmia	B-Disease	D001145
who	O	O
developed	O	O
sustained	O	O
bigeminy	O	O
and	O	O
2	O	O
brief	O	O
runs	O	O
of	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
after	O	O
caffeine	B-Chemical	D002110
administration	O	O
.	O	O

Although	O	O
intravenous	O	O
caffeine	B-Chemical	D002110
is	O	O
generally	O	O
well	O	O
tolerated	O	O
,	O	O
the	O	O
clinician	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
unpredictable	O	O
and	O	O
serious	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

Optical	O	O
coherence	O	O
tomography	O	O
can	O	O
measure	O	O
axonal	O	O
loss	O	O
in	O	O
patients	O	O
with	O	O
ethambutol	B-Chemical	D004977
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
map	O	O
and	O	O
identify	O	O
the	O	O
pattern	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
of	O	O
axonal	B-Disease	D009410
degeneration	I-Disease	D009410
in	O	O
ethambutol	B-Chemical	D004977
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
using	O	O
optical	O	O
coherence	O	O
tomography	O	O
(	O	O
OCT	O	O
)	O	O
.	O	O

Ethambutol	B-Chemical	D004977
is	O	O
an	O	O
antimycobacterial	O	O
agent	O	O
often	O	O
used	O	O
to	O	O
treat	O	O
tuberculosis	B-Disease	D014376
.	O	O

A	O	O
serious	O	O
complication	O	O
of	O	O
ethambutol	B-Chemical	D004977
is	O	O
an	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
that	O	O
impairs	O	O
visual	O	O
acuity	O	O
,	O	O
contrast	O	O
sensitivity	O	O
,	O	O
and	O	O
color	O	O
vision	O	O
.	O	O

However	O	O
,	O	O
early	O	O
on	O	O
,	O	O
when	O	O
the	O	O
toxic	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
is	O	O
mild	O	O
and	O	O
partly	O	O
reversible	O	O
,	O	O
the	O	O
funduscopic	O	O
findings	O	O
are	O	O
often	O	O
subtle	O	O
and	O	O
easy	O	O
to	O	O
miss	O	O
.	O	O

METHODS	O	O
:	O	O
Three	O	O
subjects	O	O
with	O	O
a	O	O
history	O	O
of	O	O
ethambutol	B-Chemical	D004977
(	O	O
EMB	B-Chemical	D004977
)	O	O
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
of	O	O
short	O	O
-	O	O
,	O	O
intermediate	O	O
-	O	O
,	O	O
and	O	O
long	O	O
-	O	O
term	O	O
visual	B-Disease	D014786
deficits	I-Disease	D014786
were	O	O
administered	O	O
a	O	O
full	O	O
neuro	O	O
-	O	O
ophthalmologic	O	O
examination	O	O
including	O	O
visual	O	O
acuity	O	O
,	O	O
color	O	O
vision	O	O
,	O	O
contrast	O	O
sensitivity	O	O
,	O	O
and	O	O
fundus	O	O
examination	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
OCT	O	O
(	O	O
OCT	O	O
3000	O	O
,	O	O
Humphrey	O	O
-	O	O
Zeiss	O	O
,	O	O
Dublin	O	O
,	O	O
CA	O	O
)	O	O
was	O	O
performed	O	O
on	O	O
both	O	O
eyes	O	O
of	O	O
each	O	O
subject	O	O
using	O	O
the	O	O
retinal	O	O
nerve	O	O
fiber	O	O
layer	O	O
(	O	O
RNFL	O	O
)	O	O
analysis	O	O
protocol	O	O
.	O	O

OCT	O	O
interpolates	O	O
data	O	O
from	O	O
100	O	O
points	O	O
around	O	O
the	O	O
optic	O	O
nerve	O	O
to	O	O
effectively	O	O
map	O	O
out	O	O
the	O	O
RNFL	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
results	O	O
were	O	O
compared	O	O
to	O	O
the	O	O
calculated	O	O
average	O	O
RNFL	O	O
of	O	O
normal	O	O
eyes	O	O
accumulated	O	O
from	O	O
four	O	O
prior	O	O
studies	O	O
using	O	O
OCT	O	O
,	O	O
n=661	O	O
.	O	O

In	O	O
all	O	O
subjects	O	O
with	O	O
history	O	O
of	O	O
EMB	B-Chemical	D004977
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
,	O	O
there	O	O
was	O	O
a	O	O
mean	O	O
loss	O	O
of	O	O
72%	O	O
nerve	O	O
fiber	O	O
layer	O	O
thickness	O	O
in	O	O
the	O	O
temporal	O	O
quadrant	O	O
(	O	O
patient	O	O
A	O	O
,	O	O
with	O	O
eventual	O	O
recovery	O	O
of	O	O
visual	O	O
acuity	O	O
and	O	O
fields	O	O
,	O	O
58%	O	O
loss	O	O
;	O	O
patient	O	O
B	O	O
,	O	O
with	O	O
intermediate	O	O
visual	B-Disease	D014786
deficits	I-Disease	D014786
,	O	O
68%	O	O
loss	O	O
;	O	O
patient	O	O
C	O	O
,	O	O
with	O	O
chronic	O	O
visual	B-Disease	D014786
deficits	I-Disease	D014786
,	O	O
90%	O	O
loss	O	O
)	O	O
,	O	O
with	O	O
an	O	O
average	O	O
mean	O	O
optic	O	O
nerve	O	O
thickness	O	O
of	O	O
26+	O	O
/	O	O
-	O	O
16	O	O
microm	O	O
.	O	O

There	O	O
was	O	O
a	O	O
combined	O	O
mean	O	O
loss	O	O
of	O	O
46%	O	O
of	O	O
fibers	O	O
from	O	O
the	O	O
superior	O	O
,	O	O
inferior	O	O
,	O	O
and	O	O
nasal	O	O
quadrants	O	O
in	O	O
the	O	O
(	O	O
six	O	O
)	O	O
eyes	O	O
of	O	O
all	O	O
three	O	O
subjects	O	O
(	O	O
mean	O	O
average	O	O
thickness	O	O
of	O	O
55+	O	O
/	O	O
-	O	O
29	O	O
microm	O	O
)	O	O
.	O	O

In	O	O
both	O	O
sets	O	O
(	O	O
four	O	O
)	O	O
of	O	O
eyes	O	O
of	O	O
the	O	O
subjects	O	O
with	O	O
persistent	O	O
visual	B-Disease	D014786
deficits	I-Disease	D014786
(	O	O
patients	O	O
B	O	O
and	O	O
C	O	O
)	O	O
,	O	O
there	O	O
was	O	O
an	O	O
average	O	O
loss	O	O
of	O	O
79%	O	O
of	O	O
nerve	O	O
fiber	O	O
thickness	O	O
in	O	O
the	O	O
temporal	O	O
quadrant	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
OCT	O	O
results	O	O
in	O	O
these	O	O
patients	O	O
with	O	O
EMB	B-Chemical	D004977
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
show	O	O
considerable	O	O
loss	O	O
especially	O	O
of	O	O
the	O	O
temporal	O	O
fibers	O	O
.	O	O

This	O	O
is	O	O
consistent	O	O
with	O	O
prior	O	O
histopathological	O	O
studies	O	O
that	O	O
show	O	O
predominant	O	O
loss	O	O
of	O	O
parvo	O	O
-	O	O
cellular	O	O
axons	O	O
(	O	O
or	O	O
small	O	O
-	O	O
caliber	O	O
axons	O	O
)	O	O
within	O	O
the	O	O
papillo	O	O
-	O	O
macular	O	O
bundle	O	O
in	O	O
toxic	O	O
or	O	O
hereditary	O	O
optic	B-Disease	D009901
neuropathies	I-Disease	D009901
.	O	O

OCT	O	O
can	O	O
be	O	O
a	O	O
valuable	O	O
tool	O	O
in	O	O
the	O	O
quantitative	O	O
analysis	O	O
of	O	O
optic	B-Disease	D009901
neuropathies	I-Disease	D009901
.	O	O

Additionally	O	O
,	O	O
in	O	O
terms	O	O
of	O	O
management	O	O
of	O	O
EMB	B-Chemical	D004977
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
properly	O	O
manage	O	O
ethambutol	B-Chemical	D004977
dosing	O	O
in	O	O
patients	O	O
with	O	O
renal	B-Disease	D051437
impairment	I-Disease	D051437
and	O	O
to	O	O
achieve	O	O
proper	O	O
transition	O	O
to	O	O
a	O	O
maintenance	O	O
dose	O	O
once	O	O
an	O	O
appropriate	O	O
loading	O	O
dose	O	O
has	O	O
been	O	O
reached	O	O
.	O	O

Effects	O	O
of	O	O
the	O	O
cyclooxygenase	O	O
-	O	O
2	O	O
specific	O	O
inhibitor	O	O
valdecoxib	B-Chemical	C406224
versus	O	O
nonsteroidal	O	O
antiinflammatory	O	O
agents	O	O
and	O	O
placebo	O	O
on	O	O
cardiovascular	O	O
thrombotic	B-Disease	D013927
events	O	O
in	O	O
patients	O	O
with	O	O
arthritis	B-Disease	D001168
.	O	O

There	O	O
have	O	O
been	O	O
concerns	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
cardiovascular	O	O
thrombotic	B-Disease	D013927
events	O	O
may	O	O
be	O	O
higher	O	O
with	O	O
cyclooxygenase	O	O
(	O	O
COX	O	O
)	O	O
-	O	O
2	O	O
-	O	O
specific	O	O
inhibitors	O	O
than	O	O
nonselective	O	O
nonsteroidal	O	O
antiinflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
.	O	O

We	O	O
evaluated	O	O
cardiovascular	O	O
event	O	O
data	O	O
for	O	O
valdecoxib	B-Chemical	C406224
,	O	O
a	O	O
new	O	O
COX	O	O
-	O	O
2	O	O
-	O	O
specific	O	O
inhibitor	O	O
in	O	O
approximately	O	O
8000	O	O
patients	O	O
with	O	O
osteoarthritis	B-Disease	D010003
and	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
treated	O	O
with	O	O
this	O	O
agent	O	O
in	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiovascular	O	O
thrombotic	B-Disease	D013927
events	O	O
(	O	O
cardiac	O	O
,	O	O
cerebrovascular	O	O
and	O	O
peripheral	O	O
vascular	O	O
,	O	O
or	O	O
arterial	O	O
thrombotic	B-Disease	D013927
)	O	O
was	O	O
determined	O	O
by	O	O
analyzing	O	O
pooled	O	O
valdecoxib	B-Chemical	C406224
(	O	O
10	O	O
-	O	O
80	O	O
mg	O	O
daily	O	O
)	O	O
,	O	O
nonselective	O	O
NSAID	O	O
(	O	O
diclofenac	B-Chemical	D004008
75	O	O
mg	O	O
bid	O	O
,	O	O
ibuprofen	B-Chemical	D007052
800	O	O
mg	O	O
tid	O	O
,	O	O
or	O	O
naproxen	B-Chemical	D009288
500	O	O
mg	O	O
bid	O	O
)	O	O
and	O	O
placebo	O	O
data	O	O
from	O	O
10	O	O
randomized	O	O
osteoarthritis	B-Disease	D010003
and	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
trials	O	O
that	O	O
were	O	O
6	O	O
-	O	O
52	O	O
weeks	O	O
in	O	O
duration	O	O
.	O	O

The	O	O
incidence	O	O
rates	O	O
of	O	O
events	O	O
were	O	O
determined	O	O
in	O	O
all	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
7934	O	O
)	O	O
and	O	O
in	O	O
users	O	O
of	O	O
low	O	O
-	O	O
dose	O	O
(	O	O
<	O	O
or	O	O
=325	O	O
mg	O	O
daily	O	O
)	O	O
aspirin	B-Chemical	D001241
(	O	O
n	O	O
=	O	O
1051	O	O
)	O	O
and	O	O
nonusers	O	O
of	O	O
aspirin	B-Chemical	D001241
(	O	O
n	O	O
=	O	O
6883	O	O
)	O	O
.	O	O

Crude	O	O
and	O	O
exposure	O	O
-	O	O
adjusted	O	O
incidences	O	O
of	O	O
thrombotic	B-Disease	D013927
events	O	O
were	O	O
similar	O	O
for	O	O
valdecoxib	B-Chemical	C406224
,	O	O
NSAIDs	O	O
,	O	O
and	O	O
placebo	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
serious	O	O
thrombotic	B-Disease	D013927
events	O	O
was	O	O
also	O	O
similar	O	O
for	O	O
each	O	O
valdecoxib	B-Chemical	C406224
dose	O	O
.	O	O

Thrombotic	B-Disease	D013927
risk	O	O
was	O	O
consistently	O	O
higher	O	O
for	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
users	O	O
than	O	O
nonusers	O	O
of	O	O
aspirin	B-Chemical	D001241
(	O	O
placebo	O	O
,	O	O
1	O	O
.	O	O

4%	O	O
vs	O	O
.	O	O

0%	O	O
;	O	O
valdecoxib	B-Chemical	C406224
,	O	O
1	O	O
.	O	O

7%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

2%	O	O
;	O	O
NSAIDs	O	O
,	O	O
1	O	O
.	O	O

9%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

5%	O	O
)	O	O
.	O	O

The	O	O
rates	O	O
of	O	O
events	O	O
in	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
were	O	O
similar	O	O
for	O	O
all	O	O
3	O	O
treatment	O	O
groups	O	O
and	O	O
across	O	O
valdecoxib	B-Chemical	C406224
doses	O	O
.	O	O

Short	O	O
-	O	O
and	O	O
intermediate	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
therapeutic	O	O
(	O	O
10	O	O
or	O	O
20	O	O
mg	O	O
daily	O	O
)	O	O
and	O	O
supratherapeutic	O	O
(	O	O
40	O	O
or	O	O
80	O	O
mg	O	O
daily	O	O
)	O	O
valdecoxib	B-Chemical	C406224
doses	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
thrombotic	B-Disease	D013927
events	O	O
relative	O	O
to	O	O
nonselective	O	O
NSAIDs	O	O
or	O	O
placebo	O	O
in	O	O
osteoarthritis	B-Disease	D010003
and	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
patients	O	O
in	O	O
controlled	O	O
clinical	O	O
trials	O	O
.	O	O

A	O	O
randomized	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
crossover	O	O
study	O	O
of	O	O
ephedrine	B-Chemical	D004809
for	O	O
SSRI	O	O
-	O	O
induced	O	O
female	O	O
sexual	B-Disease	D020018
dysfunction	I-Disease	D020018
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
ephedrine	B-Chemical	D004809
,	O	O
an	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
agonist	O	O
previously	O	O
shown	O	O
to	O	O
enhance	O	O
genital	O	O
blood	O	O
flow	O	O
in	O	O
women	O	O
,	O	O
has	O	O
beneficial	O	O
effects	O	O
in	O	O
reversing	O	O
antidepressant	O	O
-	O	O
induced	O	O
sexual	B-Disease	D020018
dysfunction	I-Disease	D020018
.	O	O

Nineteen	O	O
sexually	B-Disease	D020018
dysfunctional	I-Disease	D020018
women	O	O
receiving	O	O
either	O	O
fluoxetine	B-Chemical	D005473
,	O	O
sertraline	B-Chemical	D020280
,	O	O
or	O	O
paroxetine	B-Chemical	D017374
participated	O	O
in	O	O
an	O	O
eight	O	O
-	O	O
week	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
ephedrine	B-Chemical	D004809
(	O	O
50	O	O
mg	O	O
)	O	O
on	O	O
self	O	O
-	O	O
report	O	O
measures	O	O
of	O	O
sexual	O	O
desire	O	O
,	O	O
arousal	O	O
,	O	O
orgasm	O	O
,	O	O
and	O	O
sexual	O	O
satisfaction	O	O
.	O	O

Although	O	O
there	O	O
were	O	O
significant	O	O
improvements	O	O
relative	O	O
to	O	O
baseline	O	O
in	O	O
sexual	O	O
desire	O	O
and	O	O
orgasm	O	O
intensity	O	O
/	O	O
pleasure	O	O
on	O	O
50	O	O
mg	O	O
ephedrine	B-Chemical	D004809
1	O	O
-	O	O
hr	O	O
prior	O	O
to	O	O
sexual	O	O
activity	O	O
,	O	O
significant	O	O
improvements	O	O
in	O	O
these	O	O
measures	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
sexual	O	O
arousal	O	O
and	O	O
orgasmic	O	O
ability	O	O
also	O	O
were	O	O
noted	O	O
with	O	O
placebo	O	O
.	O	O

These	O	O
findings	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
conducting	O	O
placebo	O	O
-	O	O
controlled	O	O
trials	O	O
for	O	O
this	O	O
condition	O	O
.	O	O

Erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
occurs	O	O
following	O	O
substantia	O	O
nigra	O	O
lesions	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Erectile	O	O
function	O	O
was	O	O
assessed	O	O
6	O	O
weeks	O	O
following	O	O
uni	O	O
-	O	O
and	O	O
bilateral	O	O
injections	O	O
of	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
in	O	O
the	O	O
substantia	O	O
nigra	O	O
nucleus	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

Behavioral	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
penile	O	O
erections	O	O
were	O	O
reduced	O	O
(	O	O
5	O	O
/	O	O
8	O	O
)	O	O
and	O	O
increased	O	O
(	O	O
3	O	O
/	O	O
8	O	O
)	O	O
in	O	O
uni	O	O
-	O	O
and	O	O
bilateral	O	O
lesioned	O	O
animals	O	O
.	O	O

Intracavernous	O	O
pressures	O	O
,	O	O
following	O	O
electrical	O	O
stimulation	O	O
of	O	O
the	O	O
cavernous	O	O
nerve	O	O
,	O	O
decreased	O	O
in	O	O
lesioned	O	O
animals	O	O
.	O	O

Lesions	O	O
of	O	O
the	O	O
substantia	O	O
nigra	O	O
were	O	O
confirmed	O	O
by	O	O
histology	O	O
.	O	O

Concentration	O	O
of	O	O
dopamine	B-Chemical	D004298
and	O	O
its	O	O
metabolites	O	O
were	O	O
decreased	O	O
in	O	O
the	O	O
striatum	O	O
of	O	O
substantia	O	O
nigra	O	O
lesioned	O	O
rats	O	O
.	O	O

Lesions	O	O
of	O	O
the	O	O
substantia	O	O
nigra	O	O
are	O	O
therefore	O	O
associated	O	O
with	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
in	O	O
rats	O	O
and	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
model	O	O
to	O	O
study	O	O
erectile	B-Disease	D007172
dysfunction	I-Disease	D007172
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Potential	O	O
therapeutic	O	O
use	O	O
of	O	O
the	O	O
selective	O	O
dopamine	B-Chemical	D004298
D1	O	O
receptor	O	O
agonist	O	O
,	O	O
A	B-Chemical	C095427
-	I-Chemical	C095427
86929	I-Chemical	C095427
:	O	O
an	O	O
acute	O	O
study	O	O
in	O	O
parkinsonian	B-Disease	D020734
levodopa	B-Chemical	D007980
-	O	O
primed	O	O
monkeys	O	O
.	O	O

The	O	O
clinical	O	O
utility	O	O
of	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
D1	O	O
receptor	O	O
agonists	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
is	O	O
still	O	O
unclear	O	O
.	O	O

The	O	O
therapeutic	O	O
use	O	O
of	O	O
selective	O	O
DA	B-Chemical	D004298
D1	O	O
receptor	O	O
agonists	O	O
such	O	O
as	O	O
SKF	B-Chemical	C071262
-	I-Chemical	C071262
82958	I-Chemical	C071262
(	O	O
6	B-Chemical	C071262
-	I-Chemical	C071262
chloro	I-Chemical	C071262
-	I-Chemical	C071262
7	I-Chemical	C071262
,	I-Chemical	C071262
8	I-Chemical	C071262
-	I-Chemical	C071262
dihydroxy	I-Chemical	C071262
-	I-Chemical	C071262
3	I-Chemical	C071262
-	I-Chemical	C071262
allyl	I-Chemical	C071262
-	I-Chemical	C071262
1	I-Chemical	C071262
-	I-Chemical	C071262
phenyl	I-Chemical	C071262
-	I-Chemical	C071262
2	I-Chemical	C071262
,	I-Chemical	C071262
3	I-Chemical	C071262
,	I-Chemical	C071262
4	I-Chemical	C071262
,	I-Chemical	C071262
5	I-Chemical	C071262
-	I-Chemical	C071262
tetrahydro	I-Chemical	C071262
-	I-Chemical	C071262
1H	I-Chemical	C071262
-	I-Chemical	C071262
3	I-Chemical	C071262
-	I-Chemical	C071262
benzaze	I-Chemical	C071262
pine	I-Chemical	C071262
hydrobromide	I-Chemical	C071262
)	O	O
and	O	O
A	B-Chemical	C079415
-	I-Chemical	C079415
77636	I-Chemical	C079415
(	O	O
[	B-Chemical	C079415
1R	I-Chemical	C079415
,	I-Chemical	C079415
3S	I-Chemical	C079415
]	I-Chemical	C079415
3	I-Chemical	C079415
-	I-Chemical	C079415
[	I-Chemical	C079415
1'	I-Chemical	C079415
-	I-Chemical	C079415
admantyl	I-Chemical	C079415
]	I-Chemical	C079415
-	I-Chemical	C079415
1	I-Chemical	C079415
-	I-Chemical	C079415
aminomethyl	I-Chemical	C079415
-	I-Chemical	C079415
3	I-Chemical	C079415
,	I-Chemical	C079415
4	I-Chemical	C079415
-	I-Chemical	C079415
dihydro	I-Chemical	C079415
-	I-Chemical	C079415
5	I-Chemical	C079415
,	I-Chemical	C079415
6	I-Chemical	C079415
-	I-Chemical	C079415
dihydroxy	I-Chemical	C079415
-	I-Chemical	C079415
1H	I-Chemical	C079415
-	I-Chemical	C079415
2	I-Chemical	C079415
-	I-Chemical	C079415
benzo	I-Chemical	C079415
pyran	I-Chemical	C079415
hydrochloride	I-Chemical	C079415
)	O	O
seems	O	O
limited	O	O
because	O	O
of	O	O
their	O	O
duration	O	O
of	O	O
action	O	O
,	O	O
which	O	O
is	O	O
too	O	O
short	O	O
for	O	O
SKF	B-Chemical	C071262
-	I-Chemical	C071262
82958	I-Chemical	C071262
(	O	O
<	O	O
1	O	O
hr	O	O
)	O	O
and	O	O
too	O	O
long	O	O
for	O	O
A	B-Chemical	C079415
-	I-Chemical	C079415
77636	I-Chemical	C079415
(	O	O
>	O	O
20	O	O
hr	O	O
,	O	O
leading	O	O
to	O	O
behavioral	O	O
tolerance	O	O
)	O	O
.	O	O

We	O	O
therefore	O	O
conducted	O	O
the	O	O
present	O	O
acute	O	O
dose	O	O
-	O	O
response	O	O
study	O	O
in	O	O
four	O	O
1	B-Chemical	D015632
-	I-Chemical	D015632
methyl	I-Chemical	D015632
-	I-Chemical	D015632
4	I-Chemical	D015632
-	I-Chemical	D015632
phenyl	I-Chemical	D015632
-	I-Chemical	D015632
1	I-Chemical	D015632
,	I-Chemical	D015632
2	I-Chemical	D015632
,	I-Chemical	D015632
3	I-Chemical	D015632
,	I-Chemical	D015632
6	I-Chemical	D015632
-	I-Chemical	D015632
tetrahydropyridine	I-Chemical	D015632
(	O	O
MPTP	B-Chemical	D015632
)	O	O
-	O	O
exposed	O	O
cynomolgus	O	O
monkeys	O	O
primed	O	O
to	O	O
exhibit	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
to	O	O
evaluate	O	O
the	O	O
locomotor	O	O
and	O	O
dyskinetic	B-Disease	D004409
effects	O	O
on	O	O
challenge	O	O
with	O	O
four	O	O
doses	O	O
(	O	O
from	O	O
0	O	O
.	O	O

03	O	O
to	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
A	B-Chemical	C095427
-	I-Chemical	C095427
86929	I-Chemical	C095427
(	O	O
[	B-Chemical	C095427
-	I-Chemical	C095427
]	I-Chemical	C095427
-	I-Chemical	C095427
[	I-Chemical	C095427
5aR	I-Chemical	C095427
,	I-Chemical	C095427
11bS	I-Chemical	C095427
]	I-Chemical	C095427
-	I-Chemical	C095427
4	I-Chemical	C095427
,	I-Chemical	C095427
5	I-Chemical	C095427
,	I-Chemical	C095427
5a	I-Chemical	C095427
,	I-Chemical	C095427
6	I-Chemical	C095427
,	I-Chemical	C095427
7	I-Chemical	C095427
,	I-Chemical	C095427
11b	I-Chemical	C095427
-	I-Chemical	C095427
hexahydro	I-Chemical	C095427
-	I-Chemical	C095427
2	I-Chemical	C095427
-	I-Chemical	C095427
propyl	I-Chemical	C095427
-	I-Chemical	C095427
3	I-Chemical	C095427
-	I-Chemical	C095427
thia	I-Chemical	C095427
-	I-Chemical	C095427
5	I-Chemical	C095427
-	I-Chemical	C095427
+	I-Chemical	C095427
++azacyclopent	I-Chemical	C095427
-	I-Chemical	C095427
1	I-Chemical	C095427
-	I-Chemical	C095427
ena	I-Chemical	C095427
[	I-Chemical	C095427
c	I-Chemical	C095427
]	I-Chemical	C095427
phenathrene	I-Chemical	C095427
-	I-Chemical	C095427
9	I-Chemical	C095427
-	I-Chemical	C095427
10	I-Chemical	C095427
-	I-Chemical	C095427
diol	I-Chemical	C095427
)	O	O
,	O	O
a	O	O
selective	O	O
and	O	O
full	O	O
DA	B-Chemical	D004298
D1	O	O
-	O	O
like	O	O
receptor	O	O
agonist	O	O
with	O	O
an	O	O
intermediate	O	O
duration	O	O
of	O	O
action	O	O
.	O	O

Levodopa	B-Chemical	D007980
and	O	O
the	O	O
DA	B-Chemical	D004298
D2	O	O
-	O	O
like	O	O
receptor	O	O
agonist	O	O
,	O	O
LY	B-Chemical	C416545
-	I-Chemical	C416545
171555	I-Chemical	C416545
(	O	O
[	B-Chemical	C416545
4aR	I-Chemical	C416545
-	I-Chemical	C416545
trans	I-Chemical	C416545
]	I-Chemical	C416545
-	I-Chemical	C416545
4	I-Chemical	C416545
,	I-Chemical	C416545
4a	I-Chemical	C416545
,	I-Chemical	C416545
5	I-Chemical	C416545
,	I-Chemical	C416545
6	I-Chemical	C416545
,	I-Chemical	C416545
7	I-Chemical	C416545
,	I-Chemical	C416545
8	I-Chemical	C416545
,	I-Chemical	C416545
8a	I-Chemical	C416545
,	I-Chemical	C416545
9	I-Chemical	C416545
-	I-Chemical	C416545
o	I-Chemical	C416545
-	I-Chemical	C416545
dihydro	I-Chemical	C416545
-	I-Chemical	C416545
5n	I-Chemical	C416545
-	I-Chemical	C416545
propyl	I-Chemical	C416545
-	I-Chemical	C416545
2H	I-Chemical	C416545
-	I-Chemical	C416545
pyrazo	I-Chemical	C416545
lo	I-Chemical	C416545
-	I-Chemical	C416545
3	I-Chemical	C416545
-	I-Chemical	C416545
4	I-Chemical	C416545
-	I-Chemical	C416545
quinoline	I-Chemical	C416545
hydrochloride	I-Chemical	C416545
)	O	O
were	O	O
also	O	O
used	O	O
for	O	O
comparison	O	O
.	O	O

Acute	O	O
administration	O	O
of	O	O
A	B-Chemical	C095427
-	I-Chemical	C095427
86929	I-Chemical	C095427
was	O	O
as	O	O
efficacious	O	O
in	O	O
alleviating	O	O
MPTP	B-Chemical	D015632
-	O	O
induced	O	O
parkinsonism	B-Disease	D020734
as	O	O
levodopa	B-Chemical	D007980
and	O	O
LY	B-Chemical	C416545
-	I-Chemical	C416545
171555	I-Chemical	C416545
,	O	O
but	O	O
was	O	O
less	O	O
likely	O	O
to	O	O
reproduce	O	O
the	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
these	O	O
animals	O	O
than	O	O
with	O	O
either	O	O
LY	B-Chemical	C416545
-	I-Chemical	C416545
171555	I-Chemical	C416545
or	O	O
subsequent	O	O
challenge	O	O
of	O	O
levodopa	B-Chemical	D007980
.	O	O

Selective	O	O
stimulation	O	O
of	O	O
the	O	O
DA	B-Chemical	D004298
D1	O	O
receptor	O	O
may	O	O
provide	O	O
better	O	O
integration	O	O
of	O	O
neural	O	O
inputs	O	O
transmitted	O	O
to	O	O
the	O	O
internal	O	O
segment	O	O
of	O	O
the	O	O
globus	O	O
pallidus	O	O
(	O	O
referred	O	O
to	O	O
as	O	O
the	O	O
basal	O	O
ganglia	O	O
output	O	O
)	O	O
compared	O	O
with	O	O
levodopa	B-Chemical	D007980
and	O	O
selective	O	O
DA	B-Chemical	D004298
D2	O	O
receptor	O	O
agonist	O	O
.	O	O

Potent	O	O
DA	B-Chemical	D004298
D1	O	O
receptor	O	O
agents	O	O
with	O	O
an	O	O
intermediate	O	O
duration	O	O
of	O	O
efficacy	O	O
such	O	O
as	O	O
A	B-Chemical	C095427
-	I-Chemical	C095427
86929	I-Chemical	C095427
(	O	O
approximately	O	O
4	O	O
hr	O	O
at	O	O
higher	O	O
doses	O	O
tested	O	O
)	O	O
are	O	O
potential	O	O
therapeutic	O	O
tools	O	O
in	O	O
PD	B-Disease	D010300
and	O	O
merit	O	O
further	O	O
attention	O	O
.	O	O

Deaths	O	O
from	O	O
local	O	O
anesthetic	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
in	O	O
mice	O	O
.	O	O

Median	O	O
convulsant	O	O
(	O	O
CD50	O	O
)	O	O
and	O	O
median	O	O
lethal	O	O
(	O	O
LD50	O	O
)	O	O
doses	O	O
of	O	O
three	O	O
representative	O	O
local	O	O
anesthetics	O	O
were	O	O
determined	O	O
in	O	O
adult	O	O
mice	O	O
to	O	O
evaluate	O	O
the	O	O
threat	O	O
to	O	O
life	O	O
of	O	O
local	O	O
anesthetic	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

The	O	O
CD50	O	O
and	O	O
LD50	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
57	O	O
.	O	O

7	O	O
and	O	O
58	O	O
.	O	O

7	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
bupivacaine	B-Chemical	D002045
,	O	O
111	O	O
.	O	O

0	O	O
and	O	O
133	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
lidocaine	B-Chemical	D008012
,	O	O
and	O	O
243	O	O
.	O	O

4	O	O
and	O	O
266	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
chloroprocaine	B-Chemical	C004616
.	O	O

When	O	O
given	O	O
intraperitoneally	O	O
,	O	O
bupivacaine	B-Chemical	D002045
thus	O	O
was	O	O
only	O	O
about	O	O
twice	O	O
as	O	O
toxic	O	O
as	O	O
lidocaine	B-Chemical	D008012
and	O	O
four	O	O
times	O	O
as	O	O
toxic	O	O
as	O	O
chloroprocaine	B-Chemical	C004616
.	O	O

Convulsions	B-Disease	D012640
always	O	O
preceded	O	O
death	O	O
,	O	O
except	O	O
after	O	O
precipitous	O	O
cardiopulmonary	B-Disease	D006323
arrest	I-Disease	D006323
from	O	O
extreme	O	O
doses	O	O
.	O	O

A	O	O
CD50	O	O
dose	O	O
of	O	O
local	O	O
anesthetic	O	O
(	O	O
causing	O	O
convulsions	B-Disease	D012640
in	O	O
50%	O	O
of	O	O
mice	O	O
)	O	O
was	O	O
fatal	O	O
in	O	O
90%	O	O
of	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
seizures	B-Disease	D012640
,	O	O
in	O	O
57%	O	O
of	O	O
the	O	O
chloroprocaine	B-Chemical	C004616
group	O	O
,	O	O
and	O	O
in	O	O
6%	O	O
of	O	O
the	O	O
lidocaine	B-Chemical	D008012
group	O	O
.	O	O

The	O	O
narrow	O	O
gap	O	O
between	O	O
convulsant	O	O
and	O	O
lethal	O	O
doses	O	O
of	O	O
local	O	O
anesthetics	O	O
indicates	O	O
that	O	O
untreated	O	O
convulsions	B-Disease	D012640
present	O	O
much	O	O
more	O	O
of	O	O
a	O	O
threat	O	O
to	O	O
life	O	O
than	O	O
heretofore	O	O
appreciated	O	O
.	O	O

Myoclonic	O	O
,	O	O
atonic	O	O
,	O	O
and	O	O
absence	O	O
seizures	B-Disease	D012640
following	O	O
institution	O	O
of	O	O
carbamazepine	B-Chemical	D002220
therapy	O	O
in	O	O
children	O	O
.	O	O

Five	O	O
children	O	O
,	O	O
aged	O	O
3	O	O
to	O	O
11	O	O
years	O	O
,	O	O
treated	O	O
with	O	O
carbamazepine	B-Chemical	D002220
for	O	O
epilepsy	B-Disease	D004827
,	O	O
had	O	O
an	O	O
acute	O	O
aberrant	O	O
reaction	O	O
characterized	O	O
by	O	O
the	O	O
onset	O	O
of	O	O
myoclonic	O	O
,	O	O
atypical	O	O
absence	O	O
and	O	O
/	O	O
or	O	O
atonic	O	O
(	O	O
minor	O	O
motor	O	O
)	O	O
seizures	B-Disease	D012640
within	O	O
a	O	O
few	O	O
days	O	O
.	O	O

When	O	O
the	O	O
carbamazepine	B-Chemical	D002220
was	O	O
discontinued	O	O
,	O	O
two	O	O
of	O	O
the	O	O
children	O	O
returned	O	O
to	O	O
their	O	O
former	O	O
state	O	O
very	O	O
quickly	O	O
,	O	O
two	O	O
had	O	O
the	O	O
minor	O	O
motor	O	O
seizures	B-Disease	D012640
resolve	O	O
in	O	O
3	O	O
and	O	O
6	O	O
months	O	O
,	O	O
and	O	O
one	O	O
had	O	O
the	O	O
seizures	B-Disease	D012640
persist	O	O
.	O	O

The	O	O
child	O	O
in	O	O
whom	O	O
the	O	O
seizures	B-Disease	D012640
persisted	O	O
was	O	O
later	O	O
found	O	O
to	O	O
have	O	O
ceroid	B-Disease	D009472
lipofuscinosis	I-Disease	D009472
.	O	O

The	O	O
other	O	O
children	O	O
are	O	O
doing	O	O
well	O	O
on	O	O
other	O	O
anticonvulsants	O	O
.	O	O

Naloxone	B-Chemical	D009270
reversal	O	O
of	O	O
hypotension	B-Disease	D007022
due	O	O
to	O	O
captopril	B-Chemical	D002216
overdose	B-Disease	D062787
.	O	O

The	O	O
hemodynamic	O	O
effects	O	O
of	O	O
captopril	B-Chemical	D002216
and	O	O
other	O	O
angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
inhibitors	I-Chemical	D000806
may	O	O
be	O	O
mediated	O	O
by	O	O
the	O	O
endogenous	O	O
opioid	O	O
system	O	O
.	O	O

The	O	O
opioid	O	O
antagonist	O	O
naloxone	B-Chemical	D009270
has	O	O
been	O	O
shown	O	O
to	O	O
block	O	O
or	O	O
reverse	O	O
the	O	O
hypotensive	B-Disease	D007022
actions	O	O
of	O	O
captopril	B-Chemical	D002216
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
an	O	O
intentional	O	O
captopril	B-Chemical	D002216
overdose	B-Disease	D062787
,	O	O
manifested	O	O
by	O	O
marked	O	O
hypotension	B-Disease	D007022
,	O	O
that	O	O
resolved	O	O
promptly	O	O
with	O	O
the	O	O
administration	O	O
of	O	O
naloxone	B-Chemical	D009270
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
captopril	B-Chemical	D002216
-	O	O
induced	O	O
hypotension	B-Disease	D007022
treated	O	O
with	O	O
naloxone	B-Chemical	D009270
.	O	O

Our	O	O
experience	O	O
demonstrates	O	O
a	O	O
possible	O	O
role	O	O
of	O	O
naloxone	B-Chemical	D009270
in	O	O
the	O	O
reversal	O	O
of	O	O
hypotension	B-Disease	D007022
resulting	O	O
from	O	O
captopril	B-Chemical	D002216
.	O	O

Carbamazepine	B-Chemical	D002220
-	O	O
induced	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
.	O	O

Characterization	O	O
of	O	O
two	O	O
distinct	O	O
clinical	O	O
syndromes	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
sinus	O	O
bradycardia	B-Disease	D001919
and	O	O
atrioventricular	B-Disease	D054537
block	I-Disease	D054537
,	O	O
induced	O	O
by	O	O
carbamazepine	B-Chemical	D002220
,	O	O
prompted	O	O
an	O	O
extensive	O	O
literature	O	O
review	O	O
of	O	O
all	O	O
previously	O	O
reported	O	O
cases	O	O
.	O	O

From	O	O
the	O	O
analysis	O	O
of	O	O
these	O	O
cases	O	O
,	O	O
two	O	O
distinct	O	O
forms	O	O
of	O	O
carbamazepine	B-Chemical	D002220
-	O	O
associated	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
emerged	O	O
.	O	O

One	O	O
patient	O	O
group	O	O
developed	O	O
sinus	B-Disease	D013616
tachycardias	I-Disease	D013616
in	O	O
the	O	O
setting	O	O
of	O	O
a	O	O
massive	O	O
carbamazepine	B-Chemical	D002220
overdose	B-Disease	D062787
.	O	O

The	O	O
second	O	O
group	O	O
consisted	O	O
almost	O	O
exclusively	O	O
of	O	O
elderly	O	O
women	O	O
who	O	O
developed	O	O
potentially	O	O
life	O	O
-	O	O
threatening	O	O
bradyarrhythmias	B-Disease	D001919
or	O	O
atrioventricular	B-Disease	D054537
conduction	I-Disease	D054537
delay	I-Disease	D054537
,	O	O
associated	O	O
with	O	O
either	O	O
therapeutic	O	O
or	O	O
modestly	O	O
elevated	O	O
carbamazepine	B-Chemical	D002220
serum	O	O
levels	O	O
.	O	O

Because	O	O
carbamazepine	B-Chemical	D002220
is	O	O
widely	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
neurologic	O	O
and	O	O
psychiatric	B-Disease	D001523
conditions	O	O
,	O	O
the	O	O
recognition	O	O
of	O	O
the	O	O
latter	O	O
syndrome	O	O
has	O	O
important	O	O
implications	O	O
for	O	O
the	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

Glutamatergic	O	O
neurotransmission	O	O
mediated	O	O
by	O	O
NMDA	B-Chemical	D016202
receptors	O	O
in	O	O
the	O	O
inferior	O	O
colliculus	O	O
can	O	O
modulate	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

The	O	O
inferior	O	O
colliculus	O	O
(	O	O
IC	O	O
)	O	O
is	O	O
primarily	O	O
involved	O	O
in	O	O
the	O	O
processing	O	O
of	O	O
auditory	O	O
information	O	O
,	O	O
but	O	O
it	O	O
is	O	O
distinguished	O	O
from	O	O
other	O	O
auditory	O	O
nuclei	O	O
in	O	O
the	O	O
brainstem	O	O
by	O	O
its	O	O
connections	O	O
with	O	O
structures	O	O
of	O	O
the	O	O
motor	O	O
system	O	O
.	O	O

Functional	O	O
evidence	O	O
relating	O	O
the	O	O
IC	O	O
to	O	O
motor	O	O
behavior	O	O
derives	O	O
from	O	O
experiments	O	O
showing	O	O
that	O	O
activation	O	O
of	O	O
the	O	O
IC	O	O
by	O	O
electrical	O	O
stimulation	O	O
or	O	O
excitatory	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
microinjection	O	O
causes	O	O
freezing	O	O
,	O	O
escape	O	O
-	O	O
like	O	O
behavior	O	O
,	O	O
and	O	O
immobility	O	O
.	O	O

However	O	O
,	O	O
the	O	O
nature	O	O
of	O	O
this	O	O
immobility	O	O
is	O	O
still	O	O
unclear	O	O
.	O	O

The	O	O
present	O	O
study	O	O
examined	O	O
the	O	O
influence	O	O
of	O	O
excitatory	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
-	O	O
mediated	O	O
mechanisms	O	O
in	O	O
the	O	O
IC	O	O
on	O	O
the	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
the	O	O
dopamine	B-Chemical	D004298
receptor	O	O
blocker	O	O
haloperidol	B-Chemical	D006220
administered	O	O
systemically	O	O
(	O	O
1	O	O
or	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
rats	O	O
.	O	O

Haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
was	O	O
challenged	O	O
with	O	O
prior	O	O
intracollicular	O	O
microinjections	O	O
of	O	O
glutamate	B-Chemical	D018698
NMDA	B-Chemical	D016202
receptor	O	O
antagonists	O	O
,	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
15	O	O
or	O	O
30	O	O
mmol	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
)	O	O
and	O	O
AP7	B-Chemical	C031231
(	O	O
10	O	O
or	O	O
20	O	O
nmol	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
)	O	O
,	O	O
or	O	O
of	O	O
the	O	O
NMDA	B-Chemical	D016202
receptor	O	O
agonist	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
d	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
,	O	O
20	O	O
or	O	O
30	O	O
nmol	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
)	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
intracollicular	O	O
microinjection	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
and	O	O
AP7	B-Chemical	C031231
previous	O	O
to	O	O
systemic	O	O
injections	O	O
of	O	O
haloperidol	B-Chemical	D006220
significantly	O	O
attenuated	O	O
the	O	O
catalepsy	B-Disease	D002375
,	O	O
as	O	O
indicated	O	O
by	O	O
a	O	O
reduced	O	O
latency	O	O
to	O	O
step	O	O
down	O	O
from	O	O
a	O	O
horizontal	O	O
bar	O	O
.	O	O

Accordingly	O	O
,	O	O
intracollicular	O	O
microinjection	O	O
of	O	O
NMDA	B-Chemical	D016202
increased	O	O
the	O	O
latency	O	O
to	O	O
step	O	O
down	O	O
the	O	O
bar	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
glutamate	B-Chemical	D018698
-	O	O
mediated	O	O
mechanisms	O	O
in	O	O
the	O	O
neural	O	O
circuits	O	O
at	O	O
the	O	O
IC	O	O
level	O	O
influence	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
and	O	O
participate	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
motor	O	O
activity	O	O
.	O	O

Metabotropic	O	O
glutamate	B-Chemical	D018698
7	O	O
receptor	O	O
subtype	O	O
modulates	O	O
motor	O	O
symptoms	O	O
in	O	O
rodent	O	O
models	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Metabotropic	O	O
glutamate	B-Chemical	D018698
(	O	O
mGlu	O	O
)	O	O
receptors	O	O
modulate	O	O
synaptic	O	O
transmission	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
and	O	O
represent	O	O
promising	O	O
therapeutic	O	O
targets	O	O
for	O	O
symptomatic	O	O
treatment	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
.	O	O

Among	O	O
the	O	O
eight	O	O
mGlu	O	O
receptor	O	O
subtypes	O	O
,	O	O
mGlu7	O	O
receptor	O	O
is	O	O
prominently	O	O
expressed	O	O
in	O	O
the	O	O
basal	O	O
ganglia	O	O
,	O	O
but	O	O
its	O	O
role	O	O
in	O	O
restoring	O	O
motor	O	O
function	O	O
in	O	O
animal	O	O
models	O	O
of	O	O
PD	B-Disease	D010300
is	O	O
not	O	O
known	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
N	B-Chemical	C507346
,	I-Chemical	C507346
N'	I-Chemical	C507346
-	I-Chemical	C507346
dibenzhydrylethane	I-Chemical	C507346
-	I-Chemical	C507346
1	I-Chemical	C507346
,	I-Chemical	C507346
2	I-Chemical	C507346
-	I-Chemical	C507346
diamine	I-Chemical	C507346
dihydrochloride	I-Chemical	C507346
(	O	O
AMN082	B-Chemical	C507346
)	O	O
,	O	O
the	O	O
first	O	O
selective	O	O
allosteric	O	O
activator	O	O
of	O	O
mGlu7	O	O
receptors	O	O
,	O	O
were	O	O
thus	O	O
tested	O	O
in	O	O
different	O	O
rodent	O	O
models	O	O
of	O	O
PD	B-Disease	D010300
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
oral	O	O
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
intrastriatal	O	O
administration	O	O
(	O	O
0	O	O
.	O	O

1	O	O
and	O	O
0	O	O
.	O	O

5	O	O
nmol	O	O
)	O	O
of	O	O
AMN082	B-Chemical	C507346
reverses	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
rats	O	O
.	O	O

AMN082	B-Chemical	C507346
(	O	O
2	O	O
.	O	O

5	O	O
and	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
reduces	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
rotations	O	O
in	O	O
unilateral	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
(	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
)	O	O
-	O	O
lesioned	O	O
rats	O	O
.	O	O

In	O	O
a	O	O
more	O	O
complex	O	O
task	O	O
commonly	O	O
used	O	O
to	O	O
evaluate	O	O
major	O	O
akinetic	B-Disease	D018476
symptoms	O	O
of	O	O
PD	B-Disease	D010300
patients	O	O
,	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
AMN082	B-Chemical	C507346
reverses	O	O
the	O	O
increased	O	O
reaction	O	O
time	O	O
to	O	O
respond	O	O
to	O	O
a	O	O
cue	O	O
of	O	O
bilateral	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
-	O	O
lesioned	O	O
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
AMN082	B-Chemical	C507346
reduces	O	O
the	O	O
duration	O	O
of	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
a	O	O
mGlu7	O	O
receptor	O	O
-	O	O
dependent	O	O
manner	O	O
in	O	O
wild	O	O
-	O	O
type	O	O
but	O	O
not	O	O
mGlu7	O	O
receptor	O	O
knockout	O	O
mice	O	O
.	O	O

Higher	O	O
doses	O	O
of	O	O
AMN082	B-Chemical	C507346
(	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
have	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
same	O	O
models	O	O
of	O	O
PD	B-Disease	D010300
.	O	O

Overall	O	O
these	O	O
findings	O	O
suggest	O	O
that	O	O
mGlu7	O	O
receptor	O	O
activation	O	O
can	O	O
reverse	O	O
motor	O	O
dysfunction	O	O
associated	O	O
with	O	O
reduced	O	O
dopamine	B-Chemical	D004298
activity	O	O
.	O	O

Selective	O	O
ligands	O	O
of	O	O
mGlu7	O	O
receptor	O	O
subtypes	O	O
may	O	O
thus	O	O
be	O	O
considered	O	O
as	O	O
promising	O	O
compounds	O	O
for	O	O
the	O	O
development	O	O
of	O	O
antiparkinsonian	O	O
therapeutic	O	O
strategies	O	O
.	O	O

Nimodipine	B-Chemical	D009553
prevents	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
caused	O	O
by	O	O
nitroglycerin	B-Chemical	D005996
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
adult	O	O
mice	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Hypotension	B-Disease	D007022
and	O	O
a	O	O
resultant	O	O
decrease	O	O
in	O	O
cerebral	O	O
blood	O	O
flow	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
development	O	O
of	O	O
cognitive	B-Disease	D003072
dysfunction	I-Disease	D003072
.	O	O

We	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
nimodipine	B-Chemical	D009553
(	O	O
NIMO	B-Chemical	D009553
)	O	O
administered	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
nitroglycerin	B-Chemical	D005996
(	O	O
NTG	B-Chemical	D005996
)	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
would	O	O
preserve	O	O
long	O	O
-	O	O
term	O	O
associative	O	O
memory	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
passive	O	O
avoidance	O	O
(	O	O
PA	O	O
)	O	O
paradigm	O	O
was	O	O
used	O	O
to	O	O
assess	O	O
memory	O	O
retention	O	O
.	O	O

For	O	O
PA	O	O
training	O	O
,	O	O
latencies	O	O
(	O	O
seconds	O	O
)	O	O
were	O	O
recorded	O	O
for	O	O
entry	O	O
from	O	O
a	O	O
suspended	O	O
platform	O	O
into	O	O
a	O	O
Plexiglas	O	O
tube	O	O
where	O	O
a	O	O
shock	O	O
was	O	O
automatically	O	O
delivered	O	O
.	O	O

Latencies	O	O
were	O	O
recorded	O	O
48	O	O
h	O	O
later	O	O
for	O	O
a	O	O
testing	O	O
trial	O	O
.	O	O

Ninety	O	O
-	O	O
six	O	O
Swiss	O	O
-	O	O
Webster	O	O
mice	O	O
(	O	O
30	O	O
-	O	O
35	O	O
g	O	O
,	O	O
6	O	O
-	O	O
8	O	O
wk	O	O
)	O	O
,	O	O
were	O	O
randomized	O	O
into	O	O
6	O	O
groups	O	O
1	O	O
)	O	O
saline	O	O
(	O	O
control	O	O
)	O	O
,	O	O
2	O	O
)	O	O
NTG	B-Chemical	D005996
immediately	O	O
after	O	O
learning	O	O
,	O	O
3	O	O
)	O	O
NTG	B-Chemical	D005996
3	O	O
h	O	O
after	O	O
learning	O	O
,	O	O
4	O	O
)	O	O
NTG	B-Chemical	D005996
and	O	O
NIMO	B-Chemical	D009553
,	O	O
5	O	O
)	O	O
vehicle	O	O
,	O	O
and	O	O
6	O	O
)	O	O
NIMO	B-Chemical	D009553
alone	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
hypotension	B-Disease	D007022
and	O	O
changes	O	O
in	O	O
brain	O	O
tissue	O	O
oxygenation	O	O
(	O	O
PbtO	O	O
(	O	O
2	O	O
)	O	O
)	O	O
and	O	O
in	O	O
cerebral	O	O
blood	O	O
flow	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
animals	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
groups	O	O
exhibited	O	O
similar	O	O
training	O	O
latencies	O	O
(	O	O
17	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

6	O	O
s	O	O
)	O	O
.	O	O

Mice	O	O
subjected	O	O
to	O	O
hypotensive	B-Disease	D007022
episodes	O	O
showed	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
latency	O	O
time	O	O
(	O	O
178	O	O
+	O	O
/	O	O
-	O	O
156	O	O
s	O	O
)	O	O
compared	O	O
with	O	O
those	O	O
injected	O	O
with	O	O
saline	O	O
,	O	O
NTG	B-Chemical	D005996
+	O	O
NIMO	B-Chemical	D009553
,	O	O
or	O	O
delayed	O	O
NTG	B-Chemical	D005996
(	O	O
580	O	O
+	O	O
/	O	O
-	O	O
81	O	O
s	O	O
,	O	O
557	O	O
+	O	O
/	O	O
-	O	O
67	O	O
s	O	O
,	O	O
and	O	O
493	O	O
+	O	O
/	O	O
-	O	O
146	O	O
s	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

A	O	O
Kruskal	O	O
-	O	O
Wallis	O	O
1	O	O
-	O	O
way	O	O
analysis	O	O
of	O	O
variance	O	O
indicated	O	O
a	O	O
significant	O	O
difference	O	O
among	O	O
the	O	O
4	O	O
treatment	O	O
groups	O	O
(	O	O
H	O	O
=	O	O
15	O	O
.	O	O

34	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
mice	O	O
not	O	O
subjected	O	O
to	O	O
behavioral	O	O
studies	O	O
,	O	O
the	O	O
same	O	O
dose	O	O
of	O	O
NTG	B-Chemical	D005996
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
and	O	O
NTG	B-Chemical	D005996
+	O	O
NIMO	B-Chemical	D009553
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
caused	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
to	O	O
decrease	O	O
from	O	O
85	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
sem	O	O
to	O	O
31	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
sem	O	O
and	O	O
from	O	O
86	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

7	O	O
mm	O	O
Hg	O	O
sem	O	O
to	O	O
32	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
mm	O	O
Hg	O	O
sem	O	O
,	O	O
respectively	O	O
.	O	O

Mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
NIMO	B-Chemical	D009553
alone	O	O
decreased	O	O
from	O	O
88	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
to	O	O
80	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

9	O	O
mm	O	O
Hg	O	O
.	O	O

The	O	O
intergroup	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

PbtO	O	O
(	O	O
2	O	O
)	O	O
decreased	O	O
from	O	O
51	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

5	O	O
mm	O	O
Hg	O	O
sem	O	O
to	O	O
33	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

2	O	O
mm	O	O
Hg	O	O
sem	O	O
in	O	O
the	O	O
NTG	B-Chemical	D005996
group	O	O
and	O	O
from	O	O
38	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

1	O	O
mm	O	O
Hg	O	O
sem	O	O
to	O	O
25	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

0	O	O
mm	O	O
Hg	O	O
sem	O	O
in	O	O
the	O	O
NTG	B-Chemical	D005996
+	O	O
NIMO	B-Chemical	D009553
groups	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
among	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
a	O	O
PA	O	O
retention	O	O
paradigm	O	O
,	O	O
the	O	O
injection	O	O
of	O	O
NTG	B-Chemical	D005996
immediately	O	O
after	O	O
learning	O	O
produced	O	O
a	O	O
significant	O	O
impairment	O	O
of	O	O
long	O	O
-	O	O
term	O	O
associative	O	O
memory	O	O
in	O	O
mice	O	O
,	O	O
whereas	O	O
delayed	O	O
induced	O	O
hypotension	B-Disease	D007022
had	O	O
no	O	O
effect	O	O
.	O	O

NIMO	B-Chemical	D009553
attenuated	O	O
the	O	O
disruption	O	O
in	O	O
consolidation	O	O
of	O	O
long	O	O
-	O	O
term	O	O
memory	O	O
caused	O	O
by	O	O
NTG	B-Chemical	D005996
but	O	O
did	O	O
not	O	O
improve	O	O
latency	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
hypotension	B-Disease	D007022
.	O	O

The	O	O
observed	O	O
effect	O	O
of	O	O
NIMO	B-Chemical	D009553
may	O	O
have	O	O
been	O	O
attributable	O	O
to	O	O
the	O	O
preservation	O	O
of	O	O
calcium	B-Chemical	D002118
homeostasis	O	O
during	O	O
hypotension	B-Disease	D007022
,	O	O
because	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
PbtO	O	O
(	O	O
2	O	O
)	O	O
indices	O	O
among	O	O
groups	O	O
.	O	O

Fatal	O	O
haemopericardium	B-Disease	D010490
and	O	O
gastrointestinal	B-Disease	D006471
haemorrhage	I-Disease	D006471
due	O	O
to	O	O
possible	O	O
interaction	O	O
of	O	O
cranberry	O	O
juice	O	O
with	O	O
warfarin	B-Chemical	D014859
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
fatal	O	O
internal	O	O
haemorrhage	B-Disease	D006470
in	O	O
an	O	O
elderly	O	O
man	O	O
who	O	O
consumed	O	O
only	O	O
cranberry	O	O
juice	O	O
for	O	O
two	O	O
weeks	O	O
while	O	O
maintaining	O	O
his	O	O
usual	O	O
dosage	O	O
of	O	O
warfarin	B-Chemical	D014859
.	O	O

We	O	O
propose	O	O
that	O	O
naturally	O	O
occurring	O	O
compounds	O	O
such	O	O
as	O	O
flavonoids	B-Chemical	D005419
,	O	O
which	O	O
are	O	O
present	O	O
in	O	O
fruit	O	O
juices	O	O
,	O	O
may	O	O
increase	O	O
the	O	O
potency	O	O
of	O	O
warfarin	B-Chemical	D014859
by	O	O
competing	O	O
for	O	O
the	O	O
enzymes	O	O
that	O	O
normally	O	O
inactivate	O	O
warfarin	B-Chemical	D014859
.	O	O

While	O	O
traditionally	O	O
regarded	O	O
as	O	O
foodstuffs	O	O
,	O	O
consumption	O	O
of	O	O
fruit	O	O
juices	O	O
should	O	O
be	O	O
considered	O	O
when	O	O
patients	O	O
develop	O	O
adverse	O	O
drug	O	O
reactions	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
induces	O	O
primary	O	O
loss	O	O
of	O	O
dystrophin	O	O
in	O	O
rat	O	O
hearts	O	O
:	O	O
correlation	O	O
with	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
.	O	O

The	O	O
mechanism	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
is	O	O
unknown	O	O
,	O	O
but	O	O
a	O	O
mismatch	O	O
of	O	O
oxygen	B-Chemical	D010100
supply	O	O
vs	O	O
.	O	O

demand	O	O
following	O	O
coronary	O	O
hypotension	B-Disease	D007022
and	O	O
myocardial	B-Disease	D009202
hyperactivity	I-Disease	D009202
is	O	O
the	O	O
best	O	O
explanation	O	O
for	O	O
the	O	O
complex	O	O
morphological	O	O
alterations	O	O
observed	O	O
.	O	O

Severe	O	O
alterations	O	O
in	O	O
the	O	O
structural	O	O
integrity	O	O
of	O	O
the	O	O
sarcolemma	O	O
of	O	O
cardiomyocytes	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
isoproterenol	B-Chemical	D007545
.	O	O

Taking	O	O
into	O	O
account	O	O
that	O	O
the	O	O
sarcolemmal	O	O
integrity	O	O
is	O	O
stabilized	O	O
by	O	O
the	O	O
dystrophin	O	O
-	O	O
glycoprotein	O	O
complex	O	O
(	O	O
DGC	O	O
)	O	O
that	O	O
connects	O	O
actin	O	O
and	O	O
laminin	O	O
in	O	O
contractile	O	O
machinery	O	O
and	O	O
extracellular	O	O
matrix	O	O
and	O	O
by	O	O
integrins	O	O
,	O	O
this	O	O
study	O	O
tests	O	O
the	O	O
hypothesis	O	O
that	O	O
isoproterenol	B-Chemical	D007545
affects	O	O
sarcolemmal	O	O
stability	O	O
through	O	O
changes	O	O
in	O	O
the	O	O
DGC	O	O
and	O	O
integrins	O	O
.	O	O

We	O	O
found	O	O
different	O	O
sensitivity	O	O
of	O	O
the	O	O
DGC	O	O
and	O	O
integrin	O	O
to	O	O
isoproterenol	B-Chemical	D007545
subcutaneous	O	O
administration	O	O
.	O	O

Immunofluorescent	O	O
staining	O	O
revealed	O	O
that	O	O
dystrophin	O	O
is	O	O
the	O	O
most	O	O
sensitive	O	O
among	O	O
the	O	O
structures	O	O
connecting	O	O
the	O	O
actin	O	O
in	O	O
the	O	O
cardiomyocyte	O	O
cytoskeleton	O	O
and	O	O
the	O	O
extracellular	O	O
matrix	O	O
.	O	O

The	O	O
sarcomeric	O	O
actin	O	O
dissolution	O	O
occurred	O	O
after	O	O
the	O	O
reduction	O	O
or	O	O
loss	O	O
of	O	O
dystrophin	O	O
.	O	O

Subsequently	O	O
,	O	O
after	O	O
lysis	O	O
of	O	O
myofilaments	O	O
,	O	O
gamma	O	O
-	O	O
sarcoglycan	O	O
,	O	O
beta	O	O
-	O	O
dystroglycan	O	O
,	O	O
beta1	O	O
-	O	O
integrin	O	O
,	O	O
and	O	O
laminin	O	O
alpha	O	O
-	O	O
2	O	O
expressions	O	O
were	O	O
reduced	O	O
followed	O	O
by	O	O
their	O	O
breakdown	O	O
,	O	O
as	O	O
epiphenomena	O	O
of	O	O
the	O	O
myocytolytic	O	O
process	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
administration	O	O
of	O	O
isoproterenol	B-Chemical	D007545
to	O	O
rats	O	O
results	O	O
in	O	O
primary	O	O
loss	O	O
of	O	O
dystrophin	O	O
,	O	O
the	O	O
most	O	O
sensitive	O	O
among	O	O
the	O	O
structural	O	O
proteins	O	O
that	O	O
form	O	O
the	O	O
DGC	O	O
that	O	O
connects	O	O
the	O	O
extracellular	O	O
matrix	O	O
and	O	O
the	O	O
cytoskeleton	O	O
in	O	O
cardiomyocyte	O	O
.	O	O

These	O	O
changes	O	O
,	O	O
related	O	O
to	O	O
ischaemic	B-Disease	D007511
injury	I-Disease	D007511
,	O	O
explain	O	O
the	O	O
severe	O	O
alterations	O	O
in	O	O
the	O	O
structural	O	O
integrity	O	O
of	O	O
the	O	O
sarcolemma	O	O
of	O	O
cardiomyocytes	O	O
and	O	O
hence	O	O
severe	O	O
and	O	O
irreversible	O	O
injury	O	O
induced	O	O
by	O	O
isoproterenol	B-Chemical	D007545
.	O	O

High	O	O
fat	B-Chemical	D004041
diet	O	O
-	O	O
fed	O	O
obese	B-Disease	D009765
rats	O	O
are	O	O
highly	O	O
sensitive	O	O
to	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Often	O	O
,	O	O
chemotherapy	O	O
by	O	O
doxorubicin	B-Chemical	D004317
(	O	O
Adriamycin	B-Chemical	D004317
)	O	O
is	O	O
limited	O	O
due	O	O
to	O	O
life	O	O
threatening	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
patients	O	O
during	O	O
and	O	O
posttherapy	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
have	O	O
shown	O	O
that	O	O
moderate	O	O
diet	O	O
restriction	O	O
remarkably	O	O
protects	O	O
against	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

This	O	O
cardioprotection	O	O
is	O	O
accompanied	O	O
by	O	O
decreased	O	O
cardiac	O	O
oxidative	O	O
stress	O	O
and	O	O
triglycerides	B-Chemical	D014280
and	O	O
increased	O	O
cardiac	O	O
fatty	O	O
-	O	O
acid	O	O
oxidation	O	O
,	O	O
ATP	B-Chemical	D000255
synthesis	O	O
,	O	O
and	O	O
upregulated	O	O
JAK	O	O
/	O	O
STAT3	O	O
pathway	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
whether	O	O
a	O	O
physiological	O	O
intervention	O	O
by	O	O
feeding	O	O
40%	O	O
high	O	O
fat	B-Chemical	D004041
diet	O	O
(	O	O
HFD	O	O
)	O	O
,	O	O
which	O	O
induces	O	O
obesity	B-Disease	D009765
in	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
(	O	O
250	O	O
-	O	O
275	O	O
g	O	O
)	O	O
,	O	O
sensitizes	O	O
to	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

A	O	O
LD	O	O
(	O	O
10	O	O
)	O	O
dose	O	O
(	O	O
8	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
,	O	O
ip	O	O
)	O	O
administered	O	O
on	O	O
day	O	O
43	O	O
of	O	O
the	O	O
HFD	O	O
feeding	O	O
regimen	O	O
led	O	O
to	O	O
higher	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
,	O	O
lipid	O	O
peroxidation	O	O
,	O	O
and	O	O
80%	O	O
mortality	O	O
in	O	O
the	O	O
obese	B-Disease	D009765
(	O	O
OB	B-Disease	D009765
)	O	O
rats	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
any	O	O
significant	O	O
renal	O	O
or	O	O
hepatic	O	O
toxicity	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
toxicokinetics	O	O
studies	O	O
revealed	O	O
no	O	O
change	O	O
in	O	O
accumulation	O	O
of	O	O
doxorubicin	B-Chemical	D004317
and	O	O
doxorubicinol	B-Chemical	C010013
(	O	O
toxic	O	O
metabolite	O	O
)	O	O
in	O	O
the	O	O
normal	O	O
diet	O	O
-	O	O
fed	O	O
(	O	O
ND	O	O
)	O	O
and	O	O
OB	B-Disease	D009765
hearts	O	O
.	O	O

Mechanistic	O	O
studies	O	O
revealed	O	O
that	O	O
OB	B-Disease	D009765
rats	O	O
are	O	O
sensitized	O	O
due	O	O
to	O	O
:	O	O
(	O	O
1	O	O
)	O	O
higher	O	O
oxyradical	O	O
stress	O	O
leading	O	O
to	O	O
upregulation	O	O
of	O	O
uncoupling	O	O
proteins	O	O
2	O	O
and	O	O
3	O	O
,	O	O
(	O	O
2	O	O
)	O	O
downregulation	O	O
of	O	O
cardiac	O	O
peroxisome	O	O
proliferators	O	O
activated	O	O
receptor	O	O
-	O	O
alpha	O	O
,	O	O
(	O	O
3	O	O
)	O	O
decreased	O	O
plasma	O	O
adiponectin	O	O
levels	O	O
,	O	O
(	O	O
4	O	O
)	O	O
decreased	O	O
cardiac	O	O
fatty	O	O
-	O	O
acid	O	O
oxidation	O	O
(	O	O
666	O	O
.	O	O

9+	O	O
/	O	O
-	O	O
14	O	O
.	O	O

0	O	O
nmol	O	O
/	O	O
min	O	O
/	O	O
g	O	O
heart	O	O
in	O	O
ND	O	O
versus	O	O
400	O	O
.	O	O

2+	O	O
/	O	O
-	O	O
11	O	O
.	O	O

8	O	O
nmol	O	O
/	O	O
min	O	O
/	O	O
g	O	O
heart	O	O
in	O	O
OB	B-Disease	D009765
)	O	O
,	O	O
(	O	O
5	O	O
)	O	O
decreased	O	O
mitochondrial	O	O
AMP	B-Chemical	D000249
-	O	O
alpha2	O	O
protein	O	O
kinase	O	O
,	O	O
and	O	O
(	O	O
6	O	O
)	O	O
86%	O	O
drop	O	O
in	O	O
cardiac	O	O
ATP	B-Chemical	D000255
levels	O	O
accompanied	O	O
by	O	O
decreased	O	O
ATP	B-Chemical	D000255
/	O	O
ADP	B-Chemical	D000244
ratio	O	O
after	O	O
doxorubicin	B-Chemical	D004317
administration	O	O
.	O	O

Decreased	O	O
cardiac	O	O
erythropoietin	O	O
and	O	O
increased	O	O
SOCS3	O	O
further	O	O
downregulated	O	O
the	O	O
cardioprotective	O	O
JAK	O	O
/	O	O
STAT3	O	O
pathway	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
HFD	O	O
-	O	O
induced	O	O
obese	B-Disease	D009765
rats	O	O
are	O	O
highly	O	O
sensitized	O	O
to	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
by	O	O
substantially	O	O
downregulating	O	O
cardiac	O	O
mitochondrial	O	O
ATP	B-Chemical	D000255
generation	O	O
,	O	O
increasing	O	O
oxidative	O	O
stress	O	O
and	O	O
downregulating	O	O
the	O	O
JAK	O	O
/	O	O
STAT3	O	O
pathway	O	O
.	O	O

Complete	O	O
atrioventricular	B-Disease	D054537
block	I-Disease	D054537
secondary	O	O
to	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

Sinus	B-Disease	D012804
node	I-Disease	D012804
dysfunction	I-Disease	D012804
has	O	O
been	O	O
reported	O	O
most	O	O
frequently	O	O
among	O	O
the	O	O
adverse	O	O
cardiovascular	O	O
effects	O	O
of	O	O
lithium	B-Chemical	D008094
.	O	O

In	O	O
the	O	O
present	O	O
case	O	O
,	O	O
complete	O	O
atrioventricular	B-Disease	D054537
(	I-Disease	D054537
AV	I-Disease	D054537
)	I-Disease	D054537
block	I-Disease	D054537
with	O	O
syncopal	B-Disease	D013575
attacks	I-Disease	D013575
developed	O	O
secondary	O	O
to	O	O
lithium	B-Chemical	D008094
therapy	O	O
,	O	O
necessitating	O	O
permanent	O	O
pacemaker	O	O
implantation	O	O
.	O	O

Serum	O	O
lithium	B-Chemical	D008094
levels	O	O
remained	O	O
under	O	O
or	O	O
within	O	O
the	O	O
therapeutic	O	O
range	O	O
during	O	O
the	O	O
syncopal	B-Disease	D013575
attacks	I-Disease	D013575
.	O	O

Lithium	B-Chemical	D008094
should	O	O
be	O	O
used	O	O
with	O	O
extreme	O	O
caution	O	O
,	O	O
especially	O	O
in	O	O
patients	O	O
with	O	O
mild	O	O
disturbance	O	O
of	O	O
AV	O	O
conduction	O	O
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
induced	O	O
by	O	O
ziprasidone	B-Chemical	C092292
on	O	O
the	O	O
second	O	O
day	O	O
of	O	O
treatment	O	O
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
(	O	O
NMS	B-Disease	D009459
)	O	O
is	O	O
the	O	O
rarest	O	O
and	O	O
most	O	O
serious	O	O
of	O	O
the	O	O
neuroleptic	O	O
-	O	O
induced	O	O
movement	B-Disease	D009069
disorders	I-Disease	D009069
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
(	O	O
NMS	B-Disease	D009459
)	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
ziprasidone	B-Chemical	C092292
.	O	O

Although	O	O
conventional	O	O
neuroleptics	O	O
are	O	O
more	O	O
frequently	O	O
associated	O	O
with	O	O
NMS	B-Disease	D009459
,	O	O
atypical	O	O
antipsychotic	O	O
drugs	O	O
like	O	O
ziprasidone	B-Chemical	C092292
may	O	O
also	O	O
be	O	O
a	O	O
cause	O	O
.	O	O

The	O	O
patient	O	O
is	O	O
a	O	O
24	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
with	O	O
a	O	O
history	O	O
of	O	O
schizophrenia	B-Disease	D012559
who	O	O
developed	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
NMS	B-Disease	D009459
after	O	O
2	O	O
days	O	O
of	O	O
treatment	O	O
with	O	O
an	O	O
80	O	O
-	O	O
mg	O	O
/	O	O
day	O	O
dose	O	O
of	O	O
orally	O	O
administrated	O	O
ziprasidone	B-Chemical	C092292
.	O	O

This	O	O
case	O	O
is	O	O
the	O	O
earliest	O	O
(	O	O
second	O	O
day	O	O
of	O	O
treatment	O	O
)	O	O
NMS	B-Disease	D009459
due	O	O
to	O	O
ziprasidone	B-Chemical	C092292
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Role	O	O
of	O	O
mangiferin	B-Chemical	C013592
on	O	O
biochemical	O	O
alterations	O	O
and	O	O
antioxidant	O	O
status	O	O
in	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
.	O	O

The	O	O
current	O	O
study	O	O
dealt	O	O
with	O	O
the	O	O
protective	O	O
role	O	O
of	O	O
mangiferin	B-Chemical	C013592
,	O	O
a	O	O
polyphenol	B-Chemical	D059808
from	O	O
Mangifera	O	O
indica	O	O
Linn	O	O
.	O	O

(	O	O
Anacardiaceae	O	O
)	O	O
,	O	O
on	O	O
isoproterenol	B-Chemical	D007545
(	O	O
ISPH	B-Chemical	D007545
)	O	O
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
in	O	O
rats	O	O
through	O	O
its	O	O
antioxidative	O	O
mechanism	O	O
.	O	O

Subcutaneous	O	O
injection	O	O
of	O	O
ISPH	B-Chemical	D007545
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
in	O	O
1	O	O
ml	O	O
saline	O	O
)	O	O
to	O	O
rats	O	O
for	O	O
2	O	O
consecutive	O	O
days	O	O
caused	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
in	O	O
rat	O	O
heart	O	O
,	O	O
which	O	O
was	O	O
determined	O	O
by	O	O
the	O	O
increased	O	O
activity	O	O
of	O	O
serum	O	O
lactate	B-Chemical	D019344
dehydrogenase	O	O
(	O	O
LDH	O	O
)	O	O
and	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
isoenzymes	O	O
(	O	O
CK	O	O
-	O	O
MB	O	O
)	O	O
,	O	O
increased	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
level	O	O
and	O	O
reduced	O	O
plasma	O	O
iron	B-Chemical	D007501
binding	O	O
capacity	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
mangiferin	B-Chemical	C013592
was	O	O
analyzed	O	O
by	O	O
triphenyl	B-Chemical	C009591
tetrazolium	I-Chemical	C009591
chloride	I-Chemical	C009591
(	O	O
TTC	B-Chemical	C009591
)	O	O
test	O	O
used	O	O
for	O	O
macroscopic	O	O
enzyme	O	O
mapping	O	O
assay	O	O
of	O	O
the	O	O
ischemic	B-Disease	D017202
myocardium	I-Disease	D017202
.	O	O

The	O	O
heart	O	O
tissue	O	O
antioxidant	O	O
enzymes	O	O
such	O	O
as	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
,	O	O
catalase	O	O
,	O	O
glutathione	B-Chemical	D005978
peroxidase	O	O
,	O	O
glutathione	B-Chemical	D005978
transferase	O	O
and	O	O
glutathione	B-Chemical	D005978
reductase	O	O
activities	O	O
,	O	O
non	O	O
-	O	O
enzymic	O	O
antioxidants	O	O
such	O	O
as	O	O
cerruloplasmin	O	O
,	O	O
Vitamin	B-Chemical	D001205
C	I-Chemical	D001205
,	O	O
Vitamin	B-Chemical	D014810
E	I-Chemical	D014810
and	O	O
glutathione	B-Chemical	D005978
levels	O	O
were	O	O
altered	O	O
in	O	O
MI	B-Disease	D009203
rats	O	O
.	O	O

Upon	O	O
pretreatment	O	O
with	O	O
mangiferin	B-Chemical	C013592
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
suspended	O	O
in	O	O
2	O	O
ml	O	O
of	O	O
dimethyl	B-Chemical	D004121
sulphoxide	I-Chemical	D004121
)	O	O
given	O	O
intraperitoneally	O	O
for	O	O
28	O	O
days	O	O
to	O	O
MI	B-Disease	D009203
rats	O	O
protected	O	O
the	O	O
above	O	O
-	O	O
mentioned	O	O
parameters	O	O
to	O	O
fall	O	O
from	O	O
the	O	O
normal	O	O
levels	O	O
.	O	O

Activities	O	O
of	O	O
heart	O	O
tissue	O	O
enzymic	O	O
antioxidants	O	O
and	O	O
serum	O	O
non	O	O
-	O	O
enzymic	O	O
antioxidants	O	O
levels	O	O
rose	O	O
significantly	O	O
upon	O	O
mangiferin	B-Chemical	C013592
administration	O	O
as	O	O
compared	O	O
to	O	O
ISPH	B-Chemical	D007545
-	O	O
induced	O	O
MI	B-Disease	D009203
rats	O	O
.	O	O

From	O	O
the	O	O
present	O	O
study	O	O
it	O	O
is	O	O
concluded	O	O
that	O	O
mangiferin	B-Chemical	C013592
exerts	O	O
a	O	O
beneficial	O	O
effect	O	O
against	O	O
ISPH	B-Chemical	D007545
-	O	O
induced	O	O
MI	B-Disease	D009203
due	O	O
to	O	O
its	O	O
antioxidant	O	O
potential	O	O
,	O	O
which	O	O
regulated	O	O
the	O	O
tissues	O	O
defense	O	O
system	O	O
against	O	O
cardiac	B-Disease	D006331
damage	I-Disease	D006331
.	O	O

Remifentanil	B-Chemical	C071741
pretreatment	O	O
reduces	O	O
myoclonus	B-Disease	D009207
after	O	O
etomidate	B-Chemical	D005045
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
the	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
remifentanil	B-Chemical	C071741
1	O	O
microg	O	O
/	O	O
kg	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
gender	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
myoclonus	B-Disease	D009207
after	O	O
anesthesia	O	O
induction	O	O
with	O	O
etomidate	B-Chemical	D005045
.	O	O

DESIGN	O	O
:	O	O
This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
The	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
a	O	O
university	O	O
hospital	O	O
.	O	O

PATIENTS	O	O
:	O	O
Sixty	O	O
patients	O	O
were	O	O
pretreated	O	O
in	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blinded	O	O
fashion	O	O
with	O	O
remifentanil	B-Chemical	C071741
1	O	O
microg	O	O
/	O	O
kg	O	O
or	O	O
placebo	O	O
.	O	O

Two	O	O
minutes	O	O
after	O	O
remifentanil	B-Chemical	C071741
or	O	O
placebo	O	O
injection	O	O
,	O	O
etomidate	B-Chemical	D005045
0	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
given	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Myoclonus	B-Disease	D009207
was	O	O
recorded	O	O
with	O	O
a	O	O
scale	O	O
of	O	O
0	O	O
to	O	O
3	O	O
.	O	O

The	O	O
grade	O	O
of	O	O
sedation	O	O
(	O	O
none	O	O
,	O	O
mild	O	O
,	O	O
moderate	O	O
,	O	O
severe	O	O
)	O	O
,	O	O
nausea	B-Disease	D009325
,	O	O
pruritus	B-Disease	D011537
,	O	O
and	O	O
apnea	B-Disease	D001049
were	O	O
recorded	O	O
after	O	O
injection	O	O
of	O	O
both	O	O
drugs	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
myoclonus	B-Disease	D009207
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
remifentanil	B-Chemical	C071741
group	O	O
(	O	O
6	O	O
.	O	O

7%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
(	O	O
70%	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
experienced	O	O
sedation	O	O
,	O	O
apnea	B-Disease	D001049
,	O	O
nausea	B-Disease	D009325
,	O	O
or	O	O
pruritus	B-Disease	D011537
after	O	O
injection	O	O
of	O	O
both	O	O
drugs	O	O
.	O	O

In	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
male	O	O
patients	O	O
were	O	O
associated	O	O
with	O	O
significantly	O	O
increased	O	O
incidence	O	O
of	O	O
myoclonus	B-Disease	D009207
after	O	O
etomidate	B-Chemical	D005045
administration	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Pretreatment	O	O
with	O	O
remifentanil	B-Chemical	C071741
1	O	O
microg	O	O
/	O	O
kg	O	O
reduced	O	O
myoclonus	B-Disease	D009207
after	O	O
etomidate	B-Chemical	D005045
induction	O	O
without	O	O
side	O	O
effects	O	O
such	O	O
as	O	O
sedation	O	O
,	O	O
apnea	B-Disease	D001049
,	O	O
nausea	B-Disease	D009325
,	O	O
or	O	O
pruritus	B-Disease	D011537
.	O	O

Men	O	O
experience	O	O
increased	O	O
incidence	O	O
of	O	O
myoclonus	B-Disease	D009207
than	O	O
women	O	O
after	O	O
etomidate	B-Chemical	D005045
administration	O	O
.	O	O

Daidzein	B-Chemical	C004742
activates	O	O
choline	B-Chemical	D002794
acetyltransferase	O	O
from	O	O
MC	O	O
-	O	O
IXC	O	O
cells	O	O
and	O	O
improves	O	O
drug	O	O
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

The	O	O
choline	B-Chemical	D002794
acetyltransferase	O	O
(	O	O
ChAT	O	O
)	O	O
activator	O	O
,	O	O
which	O	O
enhances	O	O
cholinergic	O	O
transmission	O	O
via	O	O
an	O	O
augmentation	O	O
of	O	O
the	O	O
enzymatic	O	O
production	O	O
of	O	O
acetylcholine	B-Chemical	D000109
(	O	O
ACh	B-Chemical	D000109
)	O	O
,	O	O
is	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
(	O	O
AD	B-Disease	D000544
)	O	O
.	O	O

Methanolic	O	O
extracts	O	O
from	O	O
Pueraria	O	O
thunbergiana	O	O
exhibited	O	O
an	O	O
activation	O	O
effect	O	O
(	O	O
46%	O	O
)	O	O
on	O	O
ChAT	O	O
in	O	O
vitro	O	O
.	O	O

Via	O	O
the	O	O
sequential	O	O
isolation	O	O
of	O	O
Pueraria	O	O
thunbergiana	O	O
,	O	O
the	O	O
active	O	O
component	O	O
was	O	O
ultimately	O	O
identified	O	O
as	O	O
daidzein	B-Chemical	C004742
(	O	O
4'	B-Chemical	C004742
,	I-Chemical	C004742
7	I-Chemical	C004742
-	I-Chemical	C004742
dihydroxy	I-Chemical	C004742
-	I-Chemical	C004742
isoflavone	I-Chemical	C004742
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
daidzein	B-Chemical	C004742
from	O	O
Pueraria	O	O
thunbergiana	O	O
on	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
impairments	O	O
of	O	O
learning	O	O
and	O	O
memory	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
series	O	O
of	O	O
in	O	O
vivo	O	O
tests	O	O
.	O	O

Administration	O	O
of	O	O
daidzein	B-Chemical	C004742
(	O	O
4	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
to	O	O
mice	O	O
was	O	O
shown	O	O
significantly	O	O
to	O	O
reverse	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
,	O	O
according	O	O
to	O	O
the	O	O
results	O	O
of	O	O
a	O	O
Y	O	O
-	O	O
maze	O	O
test	O	O
.	O	O

Injections	O	O
of	O	O
scopolamine	B-Chemical	D012601
into	O	O
mice	O	O
resulted	O	O
in	O	O
impaired	O	O
performance	O	O
on	O	O
Y	O	O
-	O	O
maze	O	O
tests	O	O
(	O	O
a	O	O
37%	O	O
decreases	O	O
in	O	O
alternation	O	O
behavior	O	O
)	O	O
.	O	O

By	O	O
way	O	O
of	O	O
contrast	O	O
,	O	O
mice	O	O
treated	O	O
with	O	O
daidzein	B-Chemical	C004742
prior	O	O
to	O	O
the	O	O
scopolamine	B-Chemical	D012601
injections	O	O
were	O	O
noticeably	O	O
protected	O	O
from	O	O
this	O	O
performance	O	O
impairment	O	O
(	O	O
an	O	O
approximately	O	O
12%	O	O
-	O	O
21%	O	O
decrease	O	O
in	O	O
alternation	O	O
behavior	O	O
)	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
daidzein	B-Chemical	C004742
might	O	O
play	O	O
a	O	O
role	O	O
in	O	O
acetylcholine	B-Chemical	D000109
biosynthesis	O	O
as	O	O
a	O	O
ChAT	O	O
activator	O	O
,	O	O
and	O	O
that	O	O
it	O	O
also	O	O
ameliorates	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

Possible	O	O
azithromycin	B-Chemical	D017963
-	O	O
associated	O	O
hiccups	B-Disease	D006606
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
persistent	O	O
hiccups	B-Disease	D006606
associated	O	O
by	O	O
azithromycin	B-Chemical	D017963
therapy	O	O
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
76	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
presented	O	O
with	O	O
persistent	O	O
hiccups	B-Disease	D006606
after	O	O
beginning	O	O
azithromycin	B-Chemical	D017963
for	O	O
the	O	O
treatment	O	O
of	O	O
pharyngitis	B-Disease	D010612
.	O	O

Hiccups	B-Disease	D006606
were	O	O
persistent	O	O
and	O	O
exhausting	O	O
.	O	O

Discontinuation	O	O
of	O	O
azithromycin	B-Chemical	D017963
and	O	O
therapy	O	O
with	O	O
baclofen	B-Chemical	D001418
finally	O	O
resolved	O	O
hiccups	B-Disease	D006606
.	O	O

No	O	O
organic	O	O
cause	O	O
of	O	O
hiccups	B-Disease	D006606
was	O	O
identified	O	O
despite	O	O
extensive	O	O
investigation	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Pharmacotherapeutic	O	O
agents	O	O
have	O	O
been	O	O
uncommonly	O	O
associated	O	O
with	O	O
hiccups	B-Disease	D006606
.	O	O

Corticosteroids	O	O
(	O	O
dexamethasone	B-Chemical	D003907
and	O	O
methylprednisolone	B-Chemical	D008775
)	O	O
,	O	O
benzodiazepines	B-Chemical	D001569
(	O	O
midazolam	B-Chemical	D008874
)	O	O
and	O	O
general	O	O
anaesthesia	O	O
have	O	O
been	O	O
the	O	O
specific	O	O
agents	O	O
mentioned	O	O
most	O	O
frequently	O	O
in	O	O
the	O	O
literature	O	O
as	O	O
being	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
hiccups	B-Disease	D006606
.	O	O

Few	O	O
cases	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hiccups	B-Disease	D006606
have	O	O
been	O	O
reported	O	O
related	O	O
to	O	O
macrolide	B-Chemical	D018942
antimicrobials	O	O
.	O	O

Using	O	O
the	O	O
Naranjo	O	O
adverse	O	O
effect	O	O
reaction	O	O
probability	O	O
scale	O	O
this	O	O
event	O	O
could	O	O
be	O	O
classified	O	O
as	O	O
possible	O	O
(	O	O
score	O	O
5	O	O
points	O	O
)	O	O
,	O	O
mostly	O	O
because	O	O
of	O	O
the	O	O
close	O	O
temporal	O	O
sequence	O	O
,	O	O
previous	O	O
reports	O	O
on	O	O
this	O	O
reaction	O	O
with	O	O
other	O	O
macrolides	B-Chemical	D018942
and	O	O
the	O	O
absence	O	O
of	O	O
any	O	O
alternative	O	O
explanation	O	O
for	O	O
hiccups	B-Disease	D006606
.	O	O

Our	O	O
hypothesis	O	O
is	O	O
that	O	O
a	O	O
vagal	O	O
mechanism	O	O
mediated	O	O
by	O	O
azithromycin	B-Chemical	D017963
could	O	O
be	O	O
the	O	O
pathogenesis	O	O
of	O	O
hiccups	B-Disease	D006606
in	O	O
our	O	O
patient	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Diagnosis	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hiccups	B-Disease	D006606
is	O	O
difficult	O	O
and	O	O
often	O	O
achieved	O	O
only	O	O
by	O	O
a	O	O
process	O	O
of	O	O
elimination	O	O
.	O	O

However	O	O
,	O	O
macrolide	B-Chemical	D018942
antimicrobials	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
hiccups	B-Disease	D006606
and	O	O
vagal	O	O
mechanism	O	O
could	O	O
explain	O	O
the	O	O
development	O	O
of	O	O
this	O	O
side	O	O
-	O	O
effect	O	O
.	O	O

Time	O	O
trends	O	O
in	O	O
warfarin	B-Chemical	D014859
-	O	O
associated	O	O
hemorrhage	B-Disease	D006470
.	O	O

The	O	O
annual	O	O
incidence	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
related	O	O
bleeding	B-Disease	D006470
at	O	O
Brigham	O	O
and	O	O
Women's	O	O
Hospital	O	O
increased	O	O
from	O	O
0	O	O
.	O	O

97	O	O
/	O	O
1	O	O
,	O	O
000	O	O
patient	O	O
admissions	O	O
in	O	O
the	O	O
first	O	O
time	O	O
period	O	O
(	O	O
January	O	O
1995	O	O
to	O	O
October	O	O
1998	O	O
)	O	O
to	O	O
1	O	O
.	O	O

19	O	O
/	O	O
1	O	O
,	O	O
000	O	O
patient	O	O
admissions	O	O
in	O	O
the	O	O
second	O	O
time	O	O
period	O	O
(	O	O
November	O	O
1998	O	O
to	O	O
August	O	O
2002	O	O
)	O	O
of	O	O
this	O	O
study	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
patients	O	O
with	O	O
major	O	O
and	O	O
intracranial	B-Disease	D020300
bleeding	I-Disease	D020300
increased	O	O
from	O	O
20	O	O
.	O	O

2%	O	O
and	O	O
1	O	O
.	O	O

9%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
first	O	O
time	O	O
period	O	O
,	O	O
to	O	O
33	O	O
.	O	O

3%	O	O
and	O	O
7	O	O
.	O	O

8%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
second	O	O
.	O	O

Fatal	O	O
haemorrhagic	O	O
myocarditis	O	O
secondary	O	O
to	O	O
cyclophosphamide	B-Chemical	D003520
therapy	O	O
.	O	O

Haemorrhagic	O	O
myocarditis	O	O
is	O	O
a	O	O
rare	O	O
but	O	O
important	O	O
complication	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
therapy	O	O
.	O	O

Echocardiographic	O	O
identification	O	O
of	O	O
the	O	O
disorder	O	O
can	O	O
be	O	O
made	O	O
.	O	O

We	O	O
believe	O	O
that	O	O
the	O	O
ultrasound	O	O
features	O	O
of	O	O
this	O	O
disorder	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
induces	O	O
attacks	O	O
of	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
in	O	O
sufferers	O	O
of	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
.	O	O

Migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
and	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
have	O	O
the	O	O
same	O	O
pain	B-Disease	D010146
phase	O	O
,	O	O
thus	O	O
indicating	O	O
that	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
and	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
share	O	O
a	O	O
common	O	O
pathway	O	O
of	O	O
nociception	O	O
.	O	O

In	O	O
recent	O	O
years	O	O
,	O	O
increasing	O	O
evidence	O	O
has	O	O
suggested	O	O
that	O	O
the	O	O
messenger	O	O
molecule	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
is	O	O
involved	O	O
in	O	O
pain	B-Disease	D010146
mechanisms	O	O
of	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
.	O	O

In	O	O
order	O	O
to	O	O
clarify	O	O
whether	O	O
the	O	O
same	O	O
is	O	O
true	O	O
for	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
,	O	O
in	O	O
the	O	O
present	O	O
study	O	O
we	O	O
examined	O	O
the	O	O
headache	B-Disease	D006261
response	O	O
to	O	O
intravenous	O	O
infusion	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
(	O	O
GTN	B-Chemical	D005996
)	O	O
(	O	O
0	O	O
.	O	O

5	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
for	O	O
20	O	O
min	O	O
)	O	O
in	O	O
12	O	O
sufferers	O	O
of	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
.	O	O

The	O	O
specific	O	O
aim	O	O
was	O	O
to	O	O
elucidate	O	O
whether	O	O
an	O	O
aura	O	O
and	O	O
/	O	O
or	O	O
an	O	O
attack	O	O
of	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
could	O	O
be	O	O
induced	O	O
.	O	O

Fourteen	O	O
healthy	O	O
subjects	O	O
served	O	O
as	O	O
controls	O	O
.	O	O

Aura	O	O
symptoms	O	O
were	O	O
not	O	O
elicited	O	O
in	O	O
any	O	O
subject	O	O
.	O	O

Headache	B-Disease	D006261
was	O	O
more	O	O
severe	O	O
in	O	O
migraineurs	B-Disease	D008881
than	O	O
in	O	O
the	O	O
controls	O	O
during	O	O
and	O	O
immediately	O	O
after	O	O
GTN	B-Chemical	D005996
infusion	O	O
(	O	O
p=0	O	O
.	O	O

037	O	O
)	O	O
as	O	O
well	O	O
as	O	O
during	O	O
the	O	O
following	O	O
11	O	O
h	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

008	O	O
)	O	O
.	O	O

In	O	O
the	O	O
controls	O	O
,	O	O
the	O	O
GTN	B-Chemical	D005996
-	O	O
induced	O	O
headache	B-Disease	D006261
gradually	O	O
disappeared	O	O
,	O	O
whereas	O	O
in	O	O
migraineurs	B-Disease	D008881
peak	O	O
headache	B-Disease	D006261
intensity	O	O
occurred	O	O
at	O	O
a	O	O
mean	O	O
time	O	O
of	O	O
240	O	O
min	O	O
post	O	O
-	O	O
infusion	O	O
.	O	O

At	O	O
this	O	O
time	O	O
the	O	O
induced	O	O
headache	B-Disease	D006261
in	O	O
6	O	O
of	O	O
12	O	O
migraineurs	B-Disease	D008881
fulfilled	O	O
the	O	O
diagnostic	O	O
criteria	O	O
for	O	O
migraine	B-Disease	D020326
without	I-Disease	D020326
aura	I-Disease	D020326
of	O	O
the	O	O
International	O	O
Headache	B-Disease	D006261
Society	O	O
.	O	O

The	O	O
results	O	O
therefore	O	O
suggest	O	O
that	O	O
NO	B-Chemical	D009569
is	O	O
involved	O	O
in	O	O
the	O	O
pain	B-Disease	D010146
mechanisms	O	O
of	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
.	O	O

Since	O	O
cortical	O	O
spreading	O	O
depression	B-Disease	D003866
has	O	O
been	O	O
shown	O	O
to	O	O
liberate	O	O
NO	B-Chemical	D009569
in	O	O
animals	O	O
,	O	O
this	O	O
finding	O	O
may	O	O
help	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
coupling	O	O
between	O	O
cortical	O	O
spreading	O	O
depression	B-Disease	D003866
and	O	O
headache	B-Disease	D006261
in	O	O
migraine	B-Disease	D020325
with	I-Disease	D020325
aura	I-Disease	D020325
.	O	O

Stroke	B-Disease	D020521
and	O	O
cocaine	B-Chemical	D003042
or	O	O
amphetamine	B-Chemical	D000661
use	O	O
.	O	O

The	O	O
association	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
amphetamine	B-Chemical	D000661
use	O	O
with	O	O
hemorrhagic	O	O
and	O	O
ischemic	B-Disease	D007511
stroke	B-Disease	D020521
is	O	O
based	O	O
almost	O	O
solely	O	O
on	O	O
data	O	O
from	O	O
case	O	O
series	O	O
.	O	O

The	O	O
limited	O	O
number	O	O
of	O	O
epidemiologic	O	O
studies	O	O
of	O	O
stroke	B-Disease	D020521
and	O	O
use	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
/	O	O
or	O	O
amphetamine	B-Chemical	D000661
have	O	O
been	O	O
done	O	O
in	O	O
settings	O	O
that	O	O
serve	O	O
mostly	O	O
the	O	O
poor	O	O
and	O	O
/	O	O
or	O	O
minorities	O	O
.	O	O

This	O	O
case	O	O
-	O	O
control	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
the	O	O
defined	O	O
population	O	O
comprising	O	O
members	O	O
of	O	O
Kaiser	O	O
Permanente	O	O
of	O	O
Northern	O	O
and	O	O
Southern	O	O
California	O	O
.	O	O

We	O	O
attempted	O	O
to	O	O
identify	O	O
all	O	O
incident	O	O
strokes	B-Disease	D020521
in	O	O
women	O	O
ages	O	O
15	O	O
-	O	O
44	O	O
years	O	O
during	O	O
a	O	O
3	O	O
-	O	O
year	O	O
period	O	O
using	O	O
hospital	O	O
admission	O	O
and	O	O
discharge	O	O
records	O	O
,	O	O
emergency	O	O
department	O	O
logs	O	O
,	O	O
and	O	O
payment	O	O
requests	O	O
for	O	O
out	O	O
-	O	O
of	O	O
-	O	O
plan	O	O
hospitalizations	O	O
.	O	O

We	O	O
selected	O	O
controls	O	O
,	O	O
matched	O	O
on	O	O
age	O	O
and	O	O
facility	O	O
of	O	O
usual	O	O
care	O	O
,	O	O
at	O	O
random	O	O
from	O	O
healthy	O	O
members	O	O
of	O	O
the	O	O
health	O	O
plan	O	O
.	O	O

We	O	O
obtained	O	O
information	O	O
in	O	O
face	O	O
-	O	O
to	O	O
-	O	O
face	O	O
interviews	O	O
.	O	O

There	O	O
were	O	O
347	O	O
confirmed	O	O
stroke	B-Disease	D020521
cases	O	O
and	O	O
1	O	O
,	O	O
021	O	O
controls	O	O
.	O	O

The	O	O
univariate	O	O
matched	O	O
odds	O	O
ratio	O	O
for	O	O
stroke	B-Disease	D020521
in	O	O
women	O	O
who	O	O
admitted	O	O
to	O	O
using	O	O
cocaine	B-Chemical	D003042
and	O	O
/	O	O
or	O	O
amphetamine	B-Chemical	D000661
was	O	O
8	O	O
.	O	O

5	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
=	O	O
3	O	O
.	O	O

6	O	O
-	O	O
20	O	O
.	O	O

0	O	O
)	O	O
.	O	O

After	O	O
further	O	O
adjustment	O	O
for	O	O
potential	O	O
confounders	O	O
,	O	O
the	O	O
odds	O	O
ratio	O	O
in	O	O
women	O	O
who	O	O
reported	O	O
using	O	O
cocaine	B-Chemical	D003042
and	O	O
/	O	O
or	O	O
amphetamine	B-Chemical	D000661
was	O	O
7	O	O
.	O	O

0	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
=	O	O
2	O	O
.	O	O

8	O	O
-	O	O
17	O	O
.	O	O

9	O	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
/	O	O
or	O	O
amphetamine	B-Chemical	D000661
is	O	O
a	O	O
strong	O	O
risk	O	O
factor	O	O
for	O	O
stroke	B-Disease	D020521
in	O	O
this	O	O
socioeconomically	O	O
heterogeneous	O	O
,	O	O
insured	O	O
urban	O	O
population	O	O
.	O	O

Prevention	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
with	O	O
tamoxifen	B-Chemical	D013629
:	O	O
preliminary	O	O
findings	O	O
from	O	O
the	O	O
Italian	O	O
randomised	O	O
trial	O	O
among	O	O
hysterectomised	O	O
women	O	O
.	O	O

Italian	O	O
Tamoxifen	B-Chemical	D013629
Prevention	O	O
Study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Tamoxifen	B-Chemical	D013629
is	O	O
a	O	O
candidate	O	O
chemopreventive	O	O
agent	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
although	O	O
the	O	O
drug	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
.	O	O

Therefore	O	O
we	O	O
did	O	O
a	O	O
trial	O	O
in	O	O
hysterectomised	O	O
women	O	O
of	O	O
tamoxifen	B-Chemical	D013629
as	O	O
a	O	O
chemopreventive	O	O
.	O	O

METHODS	O	O
:	O	O
In	O	O
October	O	O
,	O	O
1992	O	O
,	O	O
we	O	O
started	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
randomised	O	O
trial	O	O
of	O	O
tamoxifen	B-Chemical	D013629
in	O	O
women	O	O
(	O	O
mainly	O	O
in	O	O
Italy	O	O
)	O	O
who	O	O
did	O	O
not	O	O
have	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
who	O	O
had	O	O
had	O	O
a	O	O
hysterectomy	O	O
.	O	O

Women	O	O
were	O	O
randomised	O	O
to	O	O
receive	O	O
tamoxifen	B-Chemical	D013629
20	O	O
mg	O	O
per	O	O
day	O	O
or	O	O
placebo	O	O
,	O	O
both	O	O
orally	O	O
for	O	O
5	O	O
years	O	O
.	O	O

The	O	O
original	O	O
plan	O	O
was	O	O
to	O	O
follow	O	O
the	O	O
intervention	O	O
phase	O	O
by	O	O
5	O	O
years'	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

In	O	O
June	O	O
,	O	O
1997	O	O
,	O	O
the	O	O
trialists	O	O
and	O	O
the	O	O
data	O	O
-	O	O
monitoring	O	O
committee	O	O
decided	O	O
to	O	O
end	O	O
recruitment	O	O
primarily	O	O
because	O	O
of	O	O
the	O	O
number	O	O
of	O	O
women	O	O
dropping	O	O
out	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Recruitment	O	O
ended	O	O
on	O	O
July	O	O
11	O	O
,	O	O
1997	O	O
,	O	O
and	O	O
the	O	O
study	O	O
will	O	O
continue	O	O
as	O	O
planned	O	O
.	O	O

The	O	O
primary	O	O
endpoints	O	O
are	O	O
the	O	O
occurrence	O	O
of	O	O
and	O	O
deaths	O	O
from	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

This	O	O
preliminary	O	O
interim	O	O
analysis	O	O
is	O	O
based	O	O
on	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
.	O	O

FINDINGS	O	O
:	O	O
5408	O	O
women	O	O
were	O	O
randomised	O	O
;	O	O
participating	O	O
women	O	O
have	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
46	O	O
months	O	O
for	O	O
major	O	O
endpoints	O	O
.	O	O

41	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
occurred	O	O
so	O	O
far	O	O
;	O	O
there	O	O
have	O	O
been	O	O
no	O	O
deaths	O	O
from	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

There	O	O
is	O	O
no	O	O
difference	O	O
in	O	O
breast	B-Disease	D001943
-	I-Disease	D001943
cancer	I-Disease	D001943
frequency	O	O
between	O	O
the	O	O
placebo	O	O
(	O	O
22	O	O
cases	O	O
)	O	O
and	O	O
tamoxifen	B-Chemical	D013629
(	O	O
19	O	O
)	O	O
arms	O	O
.	O	O

There	O	O
is	O	O
a	O	O
statistically	O	O
significant	O	O
reduction	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
among	O	O
women	O	O
receiving	O	O
tamoxifen	B-Chemical	D013629
who	O	O
also	O	O
used	O	O
hormone	O	O
-	O	O
replacement	O	O
therapy	O	O
during	O	O
the	O	O
trial	O	O
:	O	O
among	O	O
390	O	O
women	O	O
on	O	O
such	O	O
therapy	O	O
and	O	O
allocated	O	O
to	O	O
placebo	O	O
,	O	O
we	O	O
found	O	O
eight	O	O
cases	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
compared	O	O
with	O	O
one	O	O
case	O	O
among	O	O
362	O	O
women	O	O
allocated	O	O
to	O	O
tamoxifen	B-Chemical	D013629
.	O	O

Compared	O	O
with	O	O
the	O	O
placebo	O	O
group	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significantly	O	O
increased	O	O
risk	O	O
of	O	O
vascular	B-Disease	D014652
events	I-Disease	D014652
and	O	O
hypertriglyceridaemia	B-Disease	D015228
among	O	O
women	O	O
on	O	O
tamoxifen	B-Chemical	D013629
.	O	O

INTERPRETATION	O	O
:	O	O
Although	O	O
this	O	O
preliminary	O	O
analysis	O	O
has	O	O
low	O	O
power	O	O
,	O	O
in	O	O
this	O	O
cohort	O	O
of	O	O
women	O	O
at	O	O
low	O	O
-	O	O
to	O	O
-	O	O
normal	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
the	O	O
postulated	O	O
protective	O	O
effects	O	O
of	O	O
tamoxifen	B-Chemical	D013629
are	O	O
not	O	O
yet	O	O
apparent	O	O
.	O	O

Women	O	O
using	O	O
hormone	O	O
-	O	O
replacement	O	O
therapy	O	O
appear	O	O
to	O	O
have	O	O
benefited	O	O
from	O	O
use	O	O
of	O	O
tamoxifen	B-Chemical	D013629
.	O	O

There	O	O
were	O	O
no	O	O
deaths	O	O
from	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
recorded	O	O
in	O	O
women	O	O
in	O	O
the	O	O
study	O	O
.	O	O

It	O	O
is	O	O
essential	O	O
to	O	O
continue	O	O
follow	O	O
-	O	O
up	O	O
to	O	O
quantify	O	O
the	O	O
long	O	O
-	O	O
term	O	O
risks	O	O
and	O	O
benefits	O	O
of	O	O
tamoxifen	B-Chemical	D013629
therapy	O	O
.	O	O

A	O	O
measure	O	O
of	O	O
pupillary	B-Disease	D011681
oscillation	I-Disease	D011681
as	O	O
a	O	O
marker	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
paranoia	B-Disease	D010259
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
paranoia	B-Disease	D010259
(	O	O
CIP	B-Disease	D010259
)	O	O
remains	O	O
an	O	O
important	O	O
drug	O	O
-	O	O
induced	O	O
model	O	O
of	O	O
idiopathic	O	O
paranoia	B-Disease	D010259
for	O	O
which	O	O
no	O	O
psychophysiologic	O	O
marker	O	O
has	O	O
yet	O	O
emerged	O	O
.	O	O

Measures	O	O
of	O	O
pupillary	B-Disease	D011681
oscillation	I-Disease	D011681
were	O	O
able	O	O
to	O	O
significantly	O	O
distinguish	O	O
a	O	O
group	O	O
of	O	O
abstinent	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
abusers	O	O
endorsing	O	O
past	O	O
CIP	B-Disease	D010259
(	O	O
n	O	O
=	O	O
32	O	O
)	O	O
from	O	O
another	O	O
group	O	O
of	O	O
crack	B-Chemical	D016578
addicts	O	O
who	O	O
denied	O	O
past	O	O
CIP	B-Disease	D010259
(	O	O
n	O	O
=	O	O
29	O	O
)	O	O
.	O	O

Seizures	B-Disease	D012640
induced	O	O
by	O	O
combined	O	O
levomepromazine	B-Chemical	D008728
-	O	O
fluvoxamine	B-Chemical	D016666
treatment	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
combined	O	O
levomepromazine	B-Chemical	D008728
-	O	O
fluvoxamine	B-Chemical	D016666
treatment	O	O
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

It	O	O
seems	O	O
that	O	O
combined	O	O
treatment	O	O
of	O	O
fluvoxamine	B-Chemical	D016666
with	O	O
phenothiazines	B-Chemical	D010640
may	O	O
possess	O	O
proconvulsive	O	O
activity	O	O
.	O	O

Why	O	O
may	O	O
epsilon	B-Chemical	D015119
-	I-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
(	O	O
EACA	B-Chemical	D015119
)	O	O
induce	O	O
myopathy	B-Disease	D009135
in	O	O
man?	O	O
Report	O	O
of	O	O
a	O	O
case	O	O
and	O	O
literature	O	O
review	O	O
.	O	O

A	O	O
case	O	O
of	O	O
necrotizing	O	O
myopathy	B-Disease	D009135
due	O	O
to	O	O
a	O	O
short	O	O
epsilon	B-Chemical	D015119
-	I-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
(	O	O
EACA	B-Chemical	D015119
)	O	O
treatment	O	O
in	O	O
a	O	O
72	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
with	O	O
subarachnoid	B-Disease	D013345
haemorrhage	I-Disease	D013345
(	O	O
SAH	B-Disease	D013345
)	O	O
is	O	O
described	O	O
.	O	O

Pathogenetic	O	O
hypotheses	O	O
are	O	O
discussed	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
effectiveness	O	O
of	O	O
ranitidine	B-Chemical	D011899
and	O	O
cimetidine	B-Chemical	D002927
in	O	O
inhibiting	O	O
acid	O	O
secretion	O	O
in	O	O
patients	O	O
with	O	O
gastric	O	O
hypersecretory	O	O
states	O	O
.	O	O

The	O	O
H2	O	O
-	O	O
histamine	B-Chemical	D006632
receptor	O	O
antagonists	O	O
ranitidine	B-Chemical	D011899
and	O	O
cimetidine	B-Chemical	D002927
were	O	O
compared	O	O
for	O	O
their	O	O
abilities	O	O
to	O	O
control	O	O
gastric	O	O
acid	O	O
hypersecretion	O	O
on	O	O
a	O	O
short	O	O
-	O	O
and	O	O
long	O	O
-	O	O
term	O	O
basis	O	O
in	O	O
22	O	O
patients	O	O
with	O	O
gastric	O	O
acid	O	O
hypersecretory	O	O
states	O	O
.	O	O

Nineteen	O	O
patients	O	O
had	O	O
Zollinger	B-Disease	D015043
-	I-Disease	D015043
Ellison	I-Disease	D015043
syndrome	I-Disease	D015043
,	O	O
one	O	O
patient	O	O
had	O	O
systemic	B-Disease	D034721
mastocytosis	I-Disease	D034721
,	O	O
and	O	O
two	O	O
patients	O	O
had	O	O
idiopathic	O	O
hypersecretion	O	O
.	O	O

The	O	O
rates	O	O
of	O	O
onset	O	O
of	O	O
the	O	O
action	O	O
of	O	O
cimetidine	B-Chemical	D002927
and	O	O
ranitidine	B-Chemical	D011899
were	O	O
the	O	O
same	O	O
.	O	O

The	O	O
actions	O	O
of	O	O
both	O	O
drugs	O	O
were	O	O
increased	O	O
by	O	O
anticholinergic	O	O
agents	O	O
,	O	O
and	O	O
there	O	O
was	O	O
a	O	O
close	O	O
correlation	O	O
between	O	O
the	O	O
daily	O	O
maintenance	O	O
dose	O	O
of	O	O
each	O	O
drug	O	O
needed	O	O
to	O	O
control	O	O
acid	O	O
secretion	O	O
.	O	O

However	O	O
,	O	O
ranitidine	B-Chemical	D011899
was	O	O
threefold	O	O
more	O	O
potent	O	O
than	O	O
cimetidine	B-Chemical	D002927
both	O	O
in	O	O
acute	O	O
inhibition	O	O
studies	O	O
and	O	O
in	O	O
the	O	O
median	O	O
maintenance	O	O
dose	O	O
needed	O	O
(	O	O
1	O	O
.	O	O

2	O	O
g	O	O
per	O	O
day	O	O
for	O	O
ranitidine	B-Chemical	D011899
and	O	O
3	O	O
.	O	O

6	O	O
g	O	O
per	O	O
day	O	O
for	O	O
cimetidine	B-Chemical	D002927
)	O	O
.	O	O

Sixty	O	O
percent	O	O
of	O	O
the	O	O
males	O	O
developed	O	O
breast	O	O
changes	O	O
or	O	O
impotence	B-Disease	D007172
while	O	O
taking	O	O
cimetidine	B-Chemical	D002927
and	O	O
in	O	O
all	O	O
cases	O	O
these	O	O
changes	O	O
disappeared	O	O
when	O	O
cimetidine	B-Chemical	D002927
was	O	O
replaced	O	O
by	O	O
ranitidine	B-Chemical	D011899
.	O	O

Treatment	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
cimetidine	B-Chemical	D002927
(	O	O
one	O	O
to	O	O
60	O	O
months	O	O
;	O	O
median	O	O
,	O	O
11	O	O
months	O	O
)	O	O
or	O	O
ranitidine	B-Chemical	D011899
(	O	O
two	O	O
to	O	O
31	O	O
months	O	O
;	O	O
median	O	O
,	O	O
14	O	O
months	O	O
)	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
hepatic	O	O
or	O	O
hematologic	O	O
toxicity	O	O
or	O	O
alterations	O	O
of	O	O
serum	O	O
gastrin	O	O
concentrations	O	O
,	O	O
but	O	O
ranitidine	B-Chemical	D011899
therapy	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
significantly	O	O
lower	O	O
serum	O	O
creatinine	B-Chemical	D003404
level	O	O
than	O	O
seen	O	O
with	O	O
cimetidine	B-Chemical	D002927
therapy	O	O
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
both	O	O
drugs	O	O
can	O	O
adequately	O	O
inhibit	O	O
acid	O	O
secretion	O	O
in	O	O
patients	O	O
with	O	O
gastric	O	O
hypersecretory	O	O
states	O	O
.	O	O

Both	O	O
are	O	O
safe	O	O
at	O	O
high	O	O
doses	O	O
,	O	O
but	O	O
ranitidine	B-Chemical	D011899
is	O	O
threefold	O	O
more	O	O
potent	O	O
and	O	O
does	O	O
not	O	O
cause	O	O
the	O	O
antiandrogen	O	O
side	O	O
effects	O	O
frequently	O	O
seen	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
cimetidine	B-Chemical	D002927
.	O	O

A	O	O
catch	O	O
in	O	O
the	O	O
Reye	B-Disease	D012202
.	O	O

Twenty	O	O
-	O	O
six	O	O
cases	O	O
of	O	O
Reye	B-Disease	D012202
syndrome	O	O
from	O	O
The	O	O
Children's	O	O
Hospital	O	O
,	O	O
Camperdown	O	O
,	O	O
Australia	O	O
,	O	O
occurring	O	O
between	O	O
1973	O	O
and	O	O
1982	O	O
were	O	O
reviewed	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
20	O	O
cases	O	O
met	O	O
the	O	O
US	O	O
Public	O	O
Health	O	O
Service	O	O
Centers	O	O
for	O	O
Disease	O	O
Control	O	O
criteria	O	O
for	O	O
the	O	O
diagnosis	O	O
of	O	O
Reye	B-Disease	D012202
syndrome	O	O
.	O	O

Aspirin	B-Chemical	D001241
or	O	O
salicylate	B-Chemical	D012459
ingestion	O	O
had	O	O
occurred	O	O
in	O	O
only	O	O
one	O	O
of	O	O
the	O	O
20	O	O
cases	O	O
(	O	O
5%	O	O
)	O	O
,	O	O
and	O	O
paracetamol	B-Chemical	D000082
(	O	O
acetaminophen	B-Chemical	D000082
)	O	O
had	O	O
been	O	O
administered	O	O
in	O	O
only	O	O
six	O	O
of	O	O
the	O	O
cases	O	O
(	O	O
30%	O	O
)	O	O
.	O	O

Pathologic	O	O
confirmation	O	O
of	O	O
the	O	O
diagnosis	O	O
of	O	O
Reye	B-Disease	D012202
syndrome	O	O
was	O	O
accomplished	O	O
in	O	O
90%	O	O
of	O	O
the	O	O
cases	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
Reye	B-Disease	D012202
syndrome	O	O
in	O	O
New	O	O
South	O	O
Wales	O	O
,	O	O
Australia	O	O
,	O	O
is	O	O
estimated	O	O
from	O	O
this	O	O
study	O	O
to	O	O
be	O	O
approximately	O	O
nine	O	O
cases	O	O
per	O	O
1	O	O
million	O	O
children	O	O
compared	O	O
with	O	O
recent	O	O
US	O	O
data	O	O
of	O	O
ten	O	O
to	O	O
20	O	O
cases	O	O
per	O	O
1	O	O
million	O	O
children	O	O
and	O	O
three	O	O
to	O	O
seven	O	O
cases	O	O
per	O	O
1	O	O
million	O	O
children	O	O
in	O	O
Great	O	O
Britain	O	O
.	O	O

The	O	O
mortality	O	O
for	O	O
these	O	O
Reye	B-Disease	D012202
syndrome	O	O
cases	O	O
in	O	O
Australia	O	O
was	O	O
45%	O	O
as	O	O
compared	O	O
with	O	O
a	O	O
32%	O	O
case	O	O
-	O	O
fatality	O	O
rate	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

In	O	O
Australia	O	O
,	O	O
the	O	O
pediatric	O	O
usage	O	O
of	O	O
aspirin	B-Chemical	D001241
has	O	O
been	O	O
extremely	O	O
low	O	O
for	O	O
the	O	O
past	O	O
25	O	O
years	O	O
(	O	O
less	O	O
than	O	O
1%	O	O
of	O	O
total	O	O
dosage	O	O
units	O	O
sold	O	O
)	O	O
,	O	O
with	O	O
paracetamol	B-Chemical	D000082
(	O	O
acetaminophen	B-Chemical	D000082
)	O	O
dominating	O	O
the	O	O
pediatric	O	O
analgesic	O	O
and	O	O
antipyretic	O	O
market	O	O
.	O	O

Reye	B-Disease	D012202
syndrome	O	O
may	O	O
be	O	O
disappearing	O	O
from	O	O
Australia	O	O
despite	O	O
a	O	O
total	O	O
lack	O	O
of	O	O
association	O	O
with	O	O
salicylates	B-Chemical	D012459
or	O	O
aspirin	B-Chemical	D001241
ingestion	O	O
,	O	O
since	O	O
there	O	O
were	O	O
no	O	O
cases	O	O
found	O	O
at	O	O
The	O	O
Children's	O	O
Hospital	O	O
in	O	O
1983	O	O
,	O	O
1984	O	O
,	O	O
or	O	O
1985	O	O
.	O	O

St	B-Disease	D004881
.	I-Disease	D004881

Anthony's	I-Disease	D004881
fire	I-Disease	D004881
,	O	O
then	O	O
and	O	O
now	O	O
:	O	O
a	O	O
case	O	O
report	O	O
and	O	O
historical	O	O
review	O	O
.	O	O

A	O	O
rare	O	O
case	O	O
of	O	O
morbid	O	O
vasospasm	B-Disease	D014652
,	O	O
together	O	O
with	O	O
striking	O	O
angiographic	O	O
findings	O	O
,	O	O
is	O	O
described	O	O
secondary	O	O
to	O	O
the	O	O
ingestion	O	O
of	O	O
methysergide	B-Chemical	D008784
by	O	O
a	O	O
48	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
.	O	O

A	O	O
brief	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
on	O	O
similar	O	O
cases	O	O
is	O	O
presented	O	O
.	O	O

A	O	O
discussion	O	O
of	O	O
the	O	O
history	O	O
of	O	O
ergot	B-Chemical	D004876
includes	O	O
its	O	O
original	O	O
discovery	O	O
,	O	O
the	O	O
epidemics	O	O
of	O	O
gangrene	B-Disease	D005734
that	O	O
it	O	O
has	O	O
caused	O	O
through	O	O
the	O	O
ages	O	O
and	O	O
its	O	O
past	O	O
and	O	O
present	O	O
role	O	O
in	O	O
the	O	O
management	O	O
of	O	O
migraine	B-Disease	D008881
headache	I-Disease	D008881
.	O	O

Despite	O	O
the	O	O
advent	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonists	O	O
,	O	O
ergot	B-Chemical	D004876
preparations	O	O
continue	O	O
to	O	O
play	O	O
a	O	O
major	O	O
role	O	O
in	O	O
migraine	B-Disease	D008881
therapy	O	O
,	O	O
so	O	O
that	O	O
the	O	O
danger	O	O
of	O	O
St	B-Disease	D004881
.	I-Disease	D004881

Anthony's	I-Disease	D004881
fire	I-Disease	D004881
persists	O	O
.	O	O

Beta	O	O
-	O	O
2	O	O
-	O	O
adrenoceptor	O	O
-	O	O
mediated	O	O
hypokalemia	B-Disease	D007008
and	O	O
its	O	O
abolishment	O	O
by	O	O
oxprenolol	B-Chemical	D010096
.	O	O

The	O	O
time	O	O
course	O	O
and	O	O
concentration	O	O
-	O	O
effect	O	O
relationship	O	O
of	O	O
terbutaline	B-Chemical	D013726
-	O	O
induced	O	O
hypokalemia	B-Disease	D007008
was	O	O
studied	O	O
,	O	O
using	O	O
computer	O	O
-	O	O
aided	O	O
pharmacokinetic	O	O
-	O	O
dynamic	O	O
modeling	O	O
.	O	O

Subsequently	O	O
we	O	O
investigated	O	O
the	O	O
efficacy	O	O
of	O	O
oxprenolol	B-Chemical	D010096
in	O	O
antagonizing	O	O
such	O	O
hypokalemia	B-Disease	D007008
,	O	O
together	O	O
with	O	O
the	O	O
pharmacokinetic	O	O
interaction	O	O
between	O	O
both	O	O
drugs	O	O
.	O	O

Six	O	O
healthy	O	O
subjects	O	O
were	O	O
given	O	O
a	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
subcutaneous	O	O
dose	O	O
of	O	O
terbutaline	B-Chemical	D013726
on	O	O
two	O	O
occasions	O	O
:	O	O
1	O	O
hour	O	O
after	O	O
oral	O	O
administration	O	O
of	O	O
a	O	O
placebo	O	O
and	O	O
1	O	O
hour	O	O
after	O	O
80	O	O
mg	O	O
oxprenolol	B-Chemical	D010096
orally	O	O
.	O	O

In	O	O
the	O	O
7	O	O
-	O	O
hour	O	O
period	O	O
after	O	O
terbutaline	B-Chemical	D013726
administration	O	O
,	O	O
plasma	O	O
samples	O	O
were	O	O
taken	O	O
for	O	O
determination	O	O
of	O	O
plasma	O	O
potassium	B-Chemical	D011188
levels	O	O
and	O	O
drug	O	O
concentrations	O	O
.	O	O

The	O	O
sigmoid	O	O
Emax	O	O
model	O	O
offered	O	O
a	O	O
good	O	O
description	O	O
of	O	O
the	O	O
relation	O	O
between	O	O
terbutaline	B-Chemical	D013726
concentrations	O	O
and	O	O
potassium	B-Chemical	D011188
effects	O	O
.	O	O

Oxprenolol	B-Chemical	D010096
caused	O	O
decreases	O	O
of	O	O
65%	O	O
and	O	O
56%	O	O
of	O	O
terbutaline	B-Chemical	D013726
volume	O	O
of	O	O
distribution	O	O
and	O	O
clearance	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
130%	O	O
of	O	O
its	O	O
AUC	O	O
.	O	O

In	O	O
spite	O	O
of	O	O
higher	O	O
terbutaline	B-Chemical	D013726
concentrations	O	O
after	O	O
oxprenolol	B-Chemical	D010096
pretreatment	O	O
,	O	O
the	O	O
hypokalemia	B-Disease	D007008
was	O	O
almost	O	O
completely	O	O
antagonized	O	O
by	O	O
the	O	O
beta	O	O
2	O	O
-	O	O
blocking	O	O
action	O	O
.	O	O

Midline	O	O
B3	O	O
serotonin	B-Chemical	D012701
nerves	O	O
in	O	O
rat	O	O
medulla	O	O
are	O	O
involved	O	O
in	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
methyldopa	B-Chemical	D008750
.	O	O

Previous	O	O
experiments	O	O
in	O	O
this	O	O
laboratory	O	O
have	O	O
shown	O	O
that	O	O
microinjection	O	O
of	O	O
methyldopa	B-Chemical	D008750
onto	O	O
the	O	O
ventrolateral	O	O
cells	O	O
of	O	O
the	O	O
B3	O	O
serotonin	B-Chemical	D012701
neurons	O	O
in	O	O
the	O	O
medulla	O	O
elicits	O	O
a	O	O
hypotensive	B-Disease	D007022
response	O	O
mediated	O	O
by	O	O
a	O	O
projection	O	O
descending	O	O
into	O	O
the	O	O
spinal	O	O
cord	O	O
.	O	O

The	O	O
present	O	O
experiments	O	O
were	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
the	O	O
midline	O	O
cells	O	O
of	O	O
the	O	O
B3	O	O
serotonin	B-Chemical	D012701
neurons	O	O
in	O	O
the	O	O
medulla	O	O
,	O	O
coinciding	O	O
with	O	O
the	O	O
raphe	O	O
magnus	O	O
.	O	O

In	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
,	O	O
stroke	B-Disease	D020521
-	O	O
prone	O	O
rats	O	O
,	O	O
microinjection	O	O
of	O	O
methyldopa	B-Chemical	D008750
into	O	O
the	O	O
area	O	O
of	O	O
the	O	O
midline	O	O
B3	O	O
serotonin	B-Chemical	D012701
cell	O	O
group	O	O
in	O	O
the	O	O
ventral	O	O
medulla	O	O
caused	O	O
a	O	O
potent	O	O
hypotension	B-Disease	D007022
of	O	O
30	O	O
-	O	O
40	O	O
mm	O	O
Hg	O	O
,	O	O
which	O	O
was	O	O
maximal	O	O
2	O	O
-	O	O
3	O	O
h	O	O
after	O	O
administration	O	O
and	O	O
was	O	O
abolished	O	O
by	O	O
the	O	O
serotonin	B-Chemical	D012701
neurotoxin	O	O
5	B-Chemical	D015116
,	I-Chemical	D015116
7	I-Chemical	D015116
-	I-Chemical	D015116
dihydroxytryptamine	I-Chemical	D015116
(	O	O
5	B-Chemical	D015116
,	I-Chemical	D015116
7	I-Chemical	D015116
-	I-Chemical	D015116
DHT	I-Chemical	D015116
)	O	O
injected	O	O
intracerebroventricularly	O	O
.	O	O

However	O	O
,	O	O
intraspinal	O	O
injection	O	O
of	O	O
5	B-Chemical	D015116
,	I-Chemical	D015116
7	I-Chemical	D015116
-	I-Chemical	D015116
DHT	I-Chemical	D015116
to	O	O
produce	O	O
a	O	O
more	O	O
selective	O	O
lesion	O	O
of	O	O
only	O	O
descending	O	O
serotonin	B-Chemical	D012701
projections	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
did	O	O
not	O	O
affect	O	O
this	O	O
hypotension	B-Disease	D007022
.	O	O

Further	O	O
,	O	O
5	B-Chemical	D015116
,	I-Chemical	D015116
7	I-Chemical	D015116
-	I-Chemical	D015116
DHT	I-Chemical	D015116
lesion	O	O
of	O	O
serotonin	B-Chemical	D012701
nerves	O	O
travelling	O	O
in	O	O
the	O	O
median	O	O
forebrain	O	O
bundle	O	O
,	O	O
one	O	O
of	O	O
the	O	O
main	O	O
ascending	O	O
pathways	O	O
from	O	O
the	O	O
B3	O	O
serotonin	B-Chemical	D012701
cells	O	O
,	O	O
did	O	O
not	O	O
affect	O	O
the	O	O
fall	O	O
in	O	O
blood	O	O
pressure	O	O
associated	O	O
with	O	O
a	O	O
midline	O	O
B3	O	O
serotonin	B-Chemical	D012701
methyldopa	B-Chemical	D008750
injection	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
therefore	O	O
that	O	O
,	O	O
unlike	O	O
the	O	O
ventrolateral	O	O
B3	O	O
cells	O	O
which	O	O
mediate	O	O
a	O	O
methyldopa	B-Chemical	D008750
-	O	O
induced	O	O
hypotension	B-Disease	D007022
via	O	O
descending	O	O
projections	O	O
,	O	O
the	O	O
midline	O	O
serotonin	B-Chemical	D012701
B3	O	O
cells	O	O
in	O	O
the	O	O
medulla	O	O
contribute	O	O
to	O	O
the	O	O
hypotensive	B-Disease	D007022
action	O	O
of	O	O
methyldopa	B-Chemical	D008750
,	O	O
either	O	O
by	O	O
way	O	O
of	O	O
an	O	O
ascending	O	O
projection	O	O
which	O	O
does	O	O
not	O	O
pass	O	O
through	O	O
the	O	O
median	O	O
forebrain	O	O
bundle	O	O
,	O	O
or	O	O
through	O	O
a	O	O
projection	O	O
restricted	O	O
to	O	O
the	O	O
caudal	O	O
brainstem	O	O
.	O	O

Yohimbine	B-Chemical	D015016
treatment	O	O
of	O	O
sexual	B-Disease	D020018
side	I-Disease	D020018
effects	I-Disease	D020018
induced	O	O
by	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
blockers	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Preclinical	O	O
and	O	O
clinical	O	O
studies	O	O
suggest	O	O
that	O	O
yohimbine	B-Chemical	D015016
facilitates	O	O
sexual	O	O
behavior	O	O
and	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
male	B-Disease	D007172
impotence	I-Disease	D007172
.	O	O

A	O	O
single	O	O
case	O	O
report	O	O
suggests	O	O
that	O	O
yohimbine	B-Chemical	D015016
may	O	O
be	O	O
used	O	O
to	O	O
treat	O	O
the	O	O
sexual	B-Disease	D020018
side	I-Disease	D020018
effects	I-Disease	D020018
of	O	O
clomipramine	B-Chemical	D002997
.	O	O

This	O	O
study	O	O
evaluated	O	O
yohimbine	B-Chemical	D015016
as	O	O
a	O	O
treatment	O	O
for	O	O
the	O	O
sexual	B-Disease	D020018
side	I-Disease	D020018
effects	I-Disease	D020018
caused	O	O
by	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
blockers	O	O
.	O	O

METHOD	O	O
:	O	O
Six	O	O
patients	O	O
with	O	O
either	O	O
obsessive	B-Disease	D009771
compulsive	I-Disease	D009771
disorder	I-Disease	D009771
,	O	O
trichotillomania	B-Disease	D014256
,	O	O
anxiety	B-Disease	D001008
,	O	O
or	O	O
affective	B-Disease	D019964
disorders	I-Disease	D019964
who	O	O
suffered	O	O
sexual	B-Disease	D020018
side	I-Disease	D020018
effects	I-Disease	D020018
after	O	O
treatment	O	O
with	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
blockers	O	O
were	O	O
given	O	O
yohimbine	B-Chemical	D015016
on	O	O
a	O	O
p	O	O
.	O	O

r	O	O
.	O	O

n	O	O
.	O	O

basis	O	O
in	O	O
an	O	O
open	O	O
clinical	O	O
trial	O	O
.	O	O

Various	O	O
doses	O	O
of	O	O
yohimbine	B-Chemical	D015016
were	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
ideal	O	O
dose	O	O
for	O	O
each	O	O
patient	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
of	O	O
the	O	O
six	O	O
patients	O	O
experienced	O	O
improved	O	O
sexual	O	O
functioning	O	O
after	O	O
taking	O	O
yohimbine	B-Chemical	D015016
.	O	O

One	O	O
patient	O	O
who	O	O
failed	O	O
to	O	O
comply	O	O
with	O	O
yohimbine	B-Chemical	D015016
treatment	O	O
had	O	O
no	O	O
therapeutic	O	O
effects	O	O
.	O	O

Side	O	O
effects	O	O
of	O	O
yohimbine	B-Chemical	D015016
included	O	O
excessive	O	O
sweating	O	O
,	O	O
increased	O	O
anxiety	B-Disease	D001008
,	O	O
and	O	O
a	O	O
wound	O	O
-	O	O
up	O	O
feeling	O	O
in	O	O
some	O	O
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
yohimbine	B-Chemical	D015016
may	O	O
be	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
the	O	O
sexual	B-Disease	D020018
side	I-Disease	D020018
effects	I-Disease	D020018
caused	O	O
by	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
blockers	O	O
.	O	O

Future	O	O
controlled	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
further	O	O
investigate	O	O
the	O	O
effectiveness	O	O
and	O	O
safety	O	O
of	O	O
yohimbine	B-Chemical	D015016
for	O	O
this	O	O
indication	O	O
.	O	O

Hypersensitivity	B-Disease	D004342
immune	O	O
reaction	O	O
as	O	O
a	O	O
mechanism	O	O
for	O	O
dilevalol	B-Chemical	D007741
-	O	O
associated	O	O
hepatitis	B-Disease	D056486
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
lymphocyte	O	O
reactivity	O	O
to	O	O
dilevalol	B-Chemical	D007741
and	O	O
to	O	O
serum	O	O
containing	O	O
putative	O	O
ex	O	O
vivo	O	O
dilevalol	B-Chemical	D007741
antigens	O	O
or	O	O
metabolites	O	O
in	O	O
a	O	O
case	O	O
of	O	O
dilevalol	B-Chemical	D007741
-	O	O
induced	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

PATIENT	O	O
:	O	O
A	O	O
58	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
clinical	O	O
diagnosis	O	O
of	O	O
dilevalol	B-Chemical	D007741
-	O	O
induced	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

METHODS	O	O
:	O	O
Peripheral	O	O
blood	O	O
mononuclear	O	O
cells	O	O
collected	O	O
from	O	O
the	O	O
patient	O	O
were	O	O
cultured	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
solution	O	O
of	O	O
dilevalol	B-Chemical	D007741
and	O	O
also	O	O
with	O	O
sera	O	O
collected	O	O
from	O	O
a	O	O
volunteer	O	O
before	O	O
and	O	O
after	O	O
dilevalol	B-Chemical	D007741
intake	O	O
.	O	O

A	O	O
similar	O	O
protocol	O	O
was	O	O
performed	O	O
with	O	O
lymphocytes	O	O
from	O	O
a	O	O
healthy	O	O
subject	O	O
.	O	O

RESULTS	O	O
:	O	O
No	O	O
lymphocyte	O	O
proliferation	O	O
was	O	O
observed	O	O
either	O	O
in	O	O
the	O	O
patient	O	O
or	O	O
in	O	O
the	O	O
healthy	O	O
volunteer	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
dilevalol	B-Chemical	D007741
solutions	O	O
.	O	O

A	O	O
significant	O	O
proliferative	O	O
response	O	O
to	O	O
serum	O	O
collected	O	O
after	O	O
dilevalol	B-Chemical	D007741
intake	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
case	O	O
of	O	O
the	O	O
patient	O	O
compared	O	O
with	O	O
the	O	O
proliferative	O	O
response	O	O
to	O	O
the	O	O
serum	O	O
collected	O	O
before	O	O
the	O	O
drug	O	O
intake	O	O
.	O	O

No	O	O
reactivity	O	O
was	O	O
found	O	O
when	O	O
lymphocytes	O	O
from	O	O
the	O	O
healthy	O	O
subject	O	O
were	O	O
tested	O	O
under	O	O
similar	O	O
conditions	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
methodology	O	O
used	O	O
allowed	O	O
the	O	O
detection	O	O
of	O	O
lymphocyte	O	O
sensitization	O	O
to	O	O
sera	O	O
containing	O	O
ex	O	O
vivo	O	O
-	O	O
prepared	O	O
dilevalol	B-Chemical	D007741
antigens	O	O
,	O	O
suggesting	O	O
the	O	O
involvement	O	O
of	O	O
an	O	O
immunologic	O	O
mechanism	O	O
in	O	O
dilevalol	B-Chemical	D007741
-	O	O
induced	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

Reversible	O	O
myocardial	B-Disease	D006332
hypertrophy	I-Disease	D006332
induced	O	O
by	O	O
tacrolimus	B-Chemical	D016559
in	O	O
a	O	O
pediatric	O	O
heart	O	O
transplant	O	O
recipient	O	O
:	O	O
case	O	O
report	O	O
.	O	O

Tacrolimus	B-Chemical	D016559
is	O	O
a	O	O
potent	O	O
immunosuppressant	O	O
that	O	O
is	O	O
frequently	O	O
used	O	O
in	O	O
organ	O	O
transplantation	O	O
.	O	O

However	O	O
,	O	O
adverse	O	O
effects	O	O
include	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
.	O	O

Herein	O	O
we	O	O
describe	O	O
transient	O	O
myocardial	B-Disease	D006332
hypertrophy	I-Disease	D006332
induced	O	O
by	O	O
tacrolimus	B-Chemical	D016559
after	O	O
heart	O	O
transplantation	O	O
.	O	O

The	O	O
hypertrophy	B-Disease	D006984
caused	O	O
no	O	O
clinical	O	O
symptoms	O	O
but	O	O
was	O	O
noted	O	O
because	O	O
of	O	O
elevation	O	O
of	O	O
plasma	O	O
brain	O	O
natriuretic	O	O
peptide	O	O
concentration	O	O
and	O	O
confirmed	O	O
at	O	O
echocardiography	O	O
.	O	O

Initially	O	O
,	O	O
allograft	O	O
rejection	O	O
was	O	O
feared	O	O
;	O	O
however	O	O
,	O	O
myocardial	O	O
biopsy	O	O
samples	O	O
revealed	O	O
only	O	O
interstitial	O	O
edema	B-Disease	D004487
and	O	O
mild	O	O
myocardial	B-Disease	D006332
hypertrophy	I-Disease	D006332
;	O	O
neither	O	O
cellular	O	O
nor	O	O
humoral	O	O
rejection	O	O
was	O	O
detected	O	O
.	O	O

The	O	O
blood	O	O
tacrolimus	B-Chemical	D016559
concentration	O	O
was	O	O
higher	O	O
than	O	O
usual	O	O
at	O	O
that	O	O
time	O	O
;	O	O
thus	O	O
,	O	O
tacrolimus	B-Chemical	D016559
dosage	O	O
was	O	O
reduced	O	O
.	O	O

Myocardial	B-Disease	D006332
hypertrophy	I-Disease	D006332
completely	O	O
resolved	O	O
upon	O	O
reducing	O	O
the	O	O
target	O	O
concentration	O	O
of	O	O
tacrolimus	B-Chemical	D016559
and	O	O
did	O	O
not	O	O
recur	O	O
,	O	O
as	O	O
confirmed	O	O
at	O	O
echocardiography	O	O
and	O	O
myocardial	O	O
biopsy	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
tacrolimus	B-Chemical	D016559
induces	O	O
reversible	O	O
myocardial	B-Disease	D006332
hypertrophy	I-Disease	D006332
.	O	O

In	O	O
patients	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
therapy	O	O
,	O	O
blood	O	O
concentration	O	O
should	O	O
be	O	O
carefully	O	O
controlled	O	O
and	O	O
extreme	O	O
attention	O	O
paid	O	O
to	O	O
cardiac	O	O
involvement	O	O
.	O	O

Comparison	O	O
of	O	O
unilateral	O	O
pallidotomy	O	O
and	O	O
subthalamotomy	O	O
findings	O	O
in	O	O
advanced	O	O
idiopathic	B-Disease	D010300
Parkinson's	I-Disease	D010300
disease	I-Disease	D010300
.	O	O

A	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
pilot	O	O
study	O	O
to	O	O
compare	O	O
the	O	O
results	O	O
of	O	O
stereotactic	O	O
unilateral	O	O
pallidotomy	O	O
and	O	O
subthalamotomy	O	O
in	O	O
advanced	O	O
idiopathic	B-Disease	D010300
Parkinson's	I-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
refractory	O	O
to	O	O
medical	O	O
treatment	O	O
was	O	O
designed	O	O
.	O	O

Ten	O	O
consecutive	O	O
patients	O	O
(	O	O
mean	O	O
age	O	O
,	O	O
58	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

8	O	O
years	O	O
;	O	O
7	O	O
men	O	O
,	O	O
3	O	O
women	O	O
)	O	O
with	O	O
similar	O	O
characteristics	O	O
at	O	O
the	O	O
duration	O	O
of	O	O
disease	O	O
(	O	O
mean	O	O
disease	O	O
time	O	O
,	O	O
8	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

5	O	O
years	O	O
)	O	O
,	O	O
disabling	O	O
motor	O	O
fluctuations	O	O
(	O	O
Hoehn	O	O
_	O	O
Yahr	O	O
stage	O	O
3	O	O
-	O	O
5	O	O
in	O	O
off	O	O
-	O	O
drug	O	O
phases	O	O
)	O	O
and	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
were	O	O
selected	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
bilateral	O	O
symptoms	O	O
and	O	O
their	O	O
levodopa	B-Chemical	D007980
equivalent	O	O
dosing	O	O
were	O	O
analysed	O	O
.	O	O

Six	O	O
patients	O	O
were	O	O
operated	O	O
on	O	O
in	O	O
the	O	O
globus	O	O
pallidus	O	O
interna	O	O
(	O	O
GPi	O	O
)	O	O
and	O	O
four	O	O
in	O	O
the	O	O
subthalamic	O	O
nucleus	O	O
(	O	O
STN	O	O
)	O	O
.	O	O

Clinical	O	O
evaluation	O	O
included	O	O
the	O	O
use	O	O
of	O	O
the	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
(	O	O
UPDRS	O	O
)	O	O
,	O	O
Hoehn_Yahr	O	O
score	O	O
and	O	O
Schwab	O	O
England	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
(	O	O
ADL	O	O
)	O	O
score	O	O
in	O	O
'on'	O	O
-	O	O
and	O	O
'off'	O	O
-	O	O
drug	O	O
conditions	O	O
before	O	O
surgery	O	O
and	O	O
6	O	O
months	O	O
after	O	O
surgery	O	O
.	O	O

There	O	O
was	O	O
statistically	O	O
significant	O	O
improvement	O	O
in	O	O
all	O	O
contralateral	O	O
major	O	O
parkinsonian	B-Disease	D010300
motor	O	O
signs	O	O
in	O	O
all	O	O
patients	O	O
followed	O	O
for	O	O
6	O	O
months	O	O
.	O	O

Levodopa	B-Chemical	D007980
equivalent	O	O
daily	O	O
intake	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
the	O	O
STN	O	O
group	O	O
.	O	O

Changes	O	O
in	O	O
UPDRS	O	O
,	O	O
Hoehn	O	O
_	O	O
Yahr	O	O
and	O	O
Schwab	O	O
England	O	O
ADL	O	O
scores	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Cognitive	O	O
functions	O	O
were	O	O
unchanged	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Complications	O	O
were	O	O
observed	O	O
in	O	O
two	O	O
patients	O	O
:	O	O
one	O	O
had	O	O
a	O	O
left	O	O
homonymous	B-Disease	D006423
hemianopsia	I-Disease	D006423
after	O	O
pallidotomy	O	O
and	O	O
another	O	O
one	O	O
developed	O	O
left	O	O
hemiballistic	O	O
movements	O	O
3	O	O
days	O	O
after	O	O
subthalamotomy	O	O
which	O	O
partly	O	O
improved	O	O
within	O	O
1	O	O
month	O	O
with	O	O
Valproate	B-Chemical	D014635
1000	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

The	O	O
findings	O	O
of	O	O
this	O	O
study	O	O
suggest	O	O
that	O	O
lesions	O	O
of	O	O
the	O	O
unilateral	O	O
STN	O	O
and	O	O
GPi	O	O
are	O	O
equally	O	O
effective	O	O
treatment	O	O
for	O	O
patients	O	O
with	O	O
advanced	O	O
PD	B-Disease	D010300
refractory	O	O
to	O	O
medical	O	O
treatment	O	O
.	O	O

Protective	O	O
effects	O	O
of	O	O
antithrombin	O	O
on	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephrosis	B-Disease	D009401
in	O	O
rats	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
antithrombin	O	O
,	O	O
a	O	O
plasma	O	O
inhibitor	O	O
of	O	O
coagulation	O	O
factors	O	O
,	O	O
in	O	O
rats	O	O
with	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrosis	B-Disease	D009401
,	O	O
which	O	O
is	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
human	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Antithrombin	O	O
(	O	O
50	O	O
or	O	O
500	O	O
IU	O	O
/	O	O
kg	O	O
/	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
was	O	O
administered	O	O
to	O	O
rats	O	O
once	O	O
a	O	O
day	O	O
for	O	O
10	O	O
days	O	O
immediately	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
.	O	O

Treatment	O	O
with	O	O
antithrombin	O	O
attenuated	O	O
the	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
hematological	B-Disease	D006402
abnormalities	I-Disease	D006402
.	O	O

Puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
and	O	O
hyperlipidemia	B-Disease	D006949
were	O	O
also	O	O
suppressed	O	O
.	O	O

Histopathological	O	O
examination	O	O
revealed	O	O
severe	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
such	O	O
as	O	O
proteinaceous	O	O
casts	O	O
in	O	O
tubuli	O	O
and	O	O
tubular	O	O
expansion	O	O
in	O	O
the	O	O
kidney	O	O
of	O	O
control	O	O
rats	O	O
,	O	O
while	O	O
an	O	O
improvement	O	O
of	O	O
the	O	O
damage	O	O
was	O	O
seen	O	O
in	O	O
antithrombin	O	O
-	O	O
treated	O	O
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
antithrombin	O	O
treatment	O	O
markedly	O	O
suppressed	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
apoptosis	O	O
of	O	O
renal	O	O
tubular	O	O
epithelial	O	O
cells	O	O
.	O	O

Furthermore	O	O
,	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
increases	O	O
in	O	O
renal	O	O
cytokine	O	O
content	O	O
were	O	O
also	O	O
decreased	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
thrombin	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Treatment	O	O
with	O	O
antithrombin	O	O
may	O	O
be	O	O
clinically	O	O
effective	O	O
in	O	O
patients	O	O
with	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Reverse	O	O
or	O	O
inverted	O	O
left	B-Disease	D054549
ventricular	I-Disease	D054549
apical	I-Disease	D054549
ballooning	I-Disease	D054549
syndrome	I-Disease	D054549
(	O	O
reverse	O	O
Takotsubo	B-Disease	D054549
cardiomyopathy	I-Disease	D054549
)	O	O
in	O	O
a	O	O
young	O	O
woman	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
amphetamine	B-Chemical	D000661
use	O	O
.	O	O

Transient	O	O
left	B-Disease	D054549
ventricular	I-Disease	D054549
apical	I-Disease	D054549
ballooning	I-Disease	D054549
syndrome	I-Disease	D054549
was	O	O
first	O	O
described	O	O
in	O	O
Japan	O	O
as	O	O
"Takotsubo	O	O
cardiomyopathy	O	O
.	O	O

"	O	O
This	O	O
syndrome	O	O
has	O	O
been	O	O
identified	O	O
in	O	O
many	O	O
other	O	O
countries	O	O
.	O	O

Many	O	O
variations	O	O
of	O	O
this	O	O
syndrome	O	O
have	O	O
been	O	O
recently	O	O
described	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

One	O	O
of	O	O
the	O	O
rarest	O	O
is	O	O
the	O	O
reverse	O	O
type	O	O
of	O	O
this	O	O
syndrome	O	O
,	O	O
with	O	O
hyperdynamic	O	O
apex	O	O
and	O	O
complete	O	O
akinesia	B-Disease	D004409
of	O	O
the	O	O
base	O	O
(	O	O
as	O	O
opposed	O	O
to	O	O
the	O	O
classic	O	O
apical	B-Disease	D054549
ballooning	I-Disease	D054549
)	O	O
.	O	O

In	O	O
this	O	O
article	O	O
,	O	O
we	O	O
report	O	O
an	O	O
interesting	O	O
case	O	O
of	O	O
a	O	O
young	O	O
woman	O	O
who	O	O
presented	O	O
with	O	O
this	O	O
rare	O	O
type	O	O
of	O	O
reverse	O	O
apical	B-Disease	D054549
ballooning	I-Disease	D054549
syndrome	O	O
occurring	O	O
after	O	O
amphetamine	B-Chemical	D000661
use	O	O
.	O	O

This	O	O
report	O	O
is	O	O
followed	O	O
by	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

Attenuated	O	O
disruption	O	O
of	O	O
prepulse	O	O
inhibition	O	O
by	O	O
dopaminergic	O	O
stimulation	O	O
after	O	O
maternal	O	O
deprivation	O	O
and	O	O
adolescent	O	O
corticosterone	B-Chemical	D003345
treatment	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
development	O	O
of	O	O
schizophrenia	B-Disease	D012559
may	O	O
include	O	O
an	O	O
early	O	O
neurodevelopmental	O	O
stress	O	O
component	O	O
which	O	O
increases	O	O
vulnerability	O	O
to	O	O
later	O	O
stressful	O	O
life	O	O
events	O	O
,	O	O
in	O	O
combination	O	O
leading	O	O
to	O	O
overt	O	O
disease	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
an	O	O
early	O	O
stress	O	O
,	O	O
in	O	O
the	O	O
form	O	O
of	O	O
maternal	O	O
deprivation	O	O
,	O	O
combined	O	O
with	O	O
a	O	O
later	O	O
stress	O	O
,	O	O
simulated	O	O
by	O	O
chronic	O	O
periadolescent	O	O
corticosterone	B-Chemical	D003345
treatment	O	O
,	O	O
on	O	O
behaviour	O	O
in	O	O
rats	O	O
.	O	O

Acute	O	O
treatment	O	O
with	O	O
apomorphine	B-Chemical	D001058
caused	O	O
disruption	O	O
of	O	O
prepulse	O	O
inhibition	O	O
(	O	O
PPI	O	O
)	O	O
in	O	O
controls	O	O
and	O	O
in	O	O
rats	O	O
that	O	O
had	O	O
undergone	O	O
either	O	O
maternal	O	O
deprivation	O	O
or	O	O
corticosterone	B-Chemical	D003345
treatment	O	O
,	O	O
but	O	O
was	O	O
surprisingly	O	O
absent	O	O
in	O	O
rats	O	O
that	O	O
had	O	O
undergone	O	O
the	O	O
combined	O	O
early	O	O
and	O	O
late	O	O
stress	O	O
.	O	O

Amphetamine	B-Chemical	D000661
treatment	O	O
significantly	O	O
disrupted	O	O
PPI	O	O
in	O	O
both	O	O
non	O	O
-	O	O
deprived	O	O
groups	O	O
,	O	O
but	O	O
was	O	O
absent	O	O
in	O	O
both	O	O
maternally	O	O
deprived	O	O
groups	O	O
.	O	O

The	O	O
serotonin	B-Chemical	D012701
-	O	O
1A	O	O
receptor	O	O
agonist	O	O
,	O	O
8	B-Chemical	D017371
-	I-Chemical	D017371
OH	I-Chemical	D017371
-	I-Chemical	D017371
DPAT	I-Chemical	D017371
,	O	O
induced	O	O
a	O	O
significant	O	O
disruption	O	O
of	O	O
PPI	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

Amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotor	B-Disease	D006948
hyperactivity	I-Disease	D006948
was	O	O
similar	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

These	O	O
results	O	O
show	O	O
an	O	O
inhibitory	O	O
interaction	O	O
of	O	O
early	O	O
stress	O	O
,	O	O
caused	O	O
by	O	O
maternal	O	O
deprivation	O	O
,	O	O
combined	O	O
with	O	O
'adolescent'	O	O
stress	O	O
,	O	O
simulated	O	O
by	O	O
corticosterone	B-Chemical	D003345
treatment	O	O
,	O	O
on	O	O
dopaminergic	O	O
regulation	O	O
of	O	O
PPI	O	O
.	O	O

The	O	O
altered	O	O
effects	O	O
of	O	O
apomorphine	B-Chemical	D001058
and	O	O
amphetamine	B-Chemical	D000661
could	O	O
indicate	O	O
differential	O	O
changes	O	O
in	O	O
dopamine	B-Chemical	D004298
receptor	O	O
signalling	O	O
leading	O	O
to	O	O
functional	O	O
desensitisation	O	O
,	O	O
or	O	O
altered	O	O
modulation	O	O
of	O	O
sensory	O	O
gating	O	O
in	O	O
the	O	O
nucleus	O	O
accumbens	O	O
by	O	O
limbic	O	O
structures	O	O
such	O	O
as	O	O
the	O	O
hippocampus	O	O
.	O	O

Peripheral	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
induced	O	O
degeneration	B-Disease	D009410
of	I-Disease	D009410
dopaminergic	I-Disease	D009410
neurons	I-Disease	D009410
in	O	O
rat	O	O
substantia	O	O
nigra	O	O
.	O	O

Iron	B-Chemical	D007501
accumulation	O	O
is	O	O
considered	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

To	O	O
demonstrate	O	O
the	O	O
relationship	O	O
between	O	O
peripheral	O	O
iron	B-Chemical	D007501
overload	O	O
and	O	O
dopaminergic	O	O
neuron	O	O
loss	O	O
in	O	O
rat	O	O
substantia	O	O
nigra	O	O
(	O	O
SN	O	O
)	O	O
,	O	O
in	O	O
the	O	O
present	O	O
study	O	O
we	O	O
used	O	O
fast	O	O
cyclic	O	O
voltammetry	O	O
,	O	O
tyrosine	B-Chemical	D014443
hydroxylase	O	O
(	O	O
TH	O	O
)	O	O
immunohistochemistry	O	O
,	O	O
Perls'	O	O
iron	B-Chemical	D007501
staining	O	O
,	O	O
and	O	O
high	O	O
performance	O	O
liquid	O	O
chromatography	O	O
-	O	O
electrochemical	O	O
detection	O	O
to	O	O
study	O	O
the	O	O
degeneration	B-Disease	D009410
of	I-Disease	D009410
dopaminergic	I-Disease	D009410
neurons	I-Disease	D009410
and	O	O
increased	O	O
iron	B-Chemical	D007501
content	O	O
in	O	O
the	O	O
SN	O	O
of	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
overloaded	O	O
animals	O	O
.	O	O

The	O	O
findings	O	O
showed	O	O
that	O	O
peripheral	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
overload	O	O
increased	O	O
the	O	O
iron	B-Chemical	D007501
staining	O	O
positive	O	O
cells	O	O
and	O	O
reduced	O	O
the	O	O
number	O	O
of	O	O
TH	O	O
-	O	O
immunoreactive	O	O
neurons	O	O
in	O	O
the	O	O
SN	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
dopamine	B-Chemical	D004298
release	O	O
and	O	O
content	O	O
,	O	O
as	O	O
well	O	O
as	O	O
its	O	O
metabolites	O	O
contents	O	O
were	O	O
decreased	O	O
in	O	O
caudate	O	O
putamen	O	O
.	O	O

Even	O	O
more	O	O
dramatic	O	O
changes	O	O
were	O	O
found	O	O
in	O	O
chronic	O	O
overload	O	O
group	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
peripheral	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
can	O	O
increase	O	O
the	O	O
iron	B-Chemical	D007501
level	O	O
in	O	O
the	O	O
SN	O	O
,	O	O
where	O	O
excessive	O	O
iron	B-Chemical	D007501
causes	O	O
the	O	O
degeneration	B-Disease	D009410
of	I-Disease	D009410
dopaminergic	I-Disease	D009410
neurons	I-Disease	D009410
.	O	O

The	O	O
chronic	O	O
iron	B-Chemical	D007501
overload	O	O
may	O	O
be	O	O
more	O	O
destructive	O	O
to	O	O
dopaminergic	O	O
neurons	O	O
than	O	O
the	O	O
acute	O	O
iron	B-Chemical	D007501
overload	O	O
.	O	O

Warfarin	B-Chemical	D014859
-	O	O
induced	O	O
leukocytoclastic	B-Disease	C535509
vasculitis	I-Disease	C535509
.	O	O

Skin	O	O
reactions	O	O
associated	O	O
with	O	O
oral	O	O
coumarin	B-Chemical	C030123
-	O	O
derived	O	O
anticoagulants	O	O
are	O	O
an	O	O
uncommon	O	O
occurrence	O	O
.	O	O

Leukocytoclastic	B-Disease	C535509
vasculitis	I-Disease	C535509
(	O	O
LV	B-Disease	C535509
)	O	O
is	O	O
primarily	O	O
a	O	O
cutaneous	B-Disease	C565222
small	I-Disease	C565222
vessel	I-Disease	C565222
vasculitis	I-Disease	C565222
,	O	O
though	O	O
systemic	O	O
involvement	O	O
may	O	O
be	O	O
encountered	O	O
.	O	O

We	O	O
report	O	O
4	O	O
patients	O	O
with	O	O
late	O	O
-	O	O
onset	O	O
LV	B-Disease	C535509
probably	O	O
due	O	O
to	O	O
warfarin	B-Chemical	D014859
.	O	O

All	O	O
4	O	O
patients	O	O
presented	O	O
with	O	O
skin	B-Disease	D012871
eruptions	I-Disease	D012871
that	O	O
developed	O	O
after	O	O
receiving	O	O
warfarin	B-Chemical	D014859
for	O	O
several	O	O
years	O	O
.	O	O

The	O	O
results	O	O
of	O	O
skin	B-Disease	D012871
lesion	I-Disease	D012871
biopsies	O	O
were	O	O
available	O	O
in	O	O
3	O	O
patients	O	O
,	O	O
confirming	O	O
LV	B-Disease	C535509
Cutaneous	O	O
lesions	O	O
resolved	O	O
in	O	O
all	O	O
patients	O	O
after	O	O
warfarin	B-Chemical	D014859
was	O	O
discontinued	O	O
.	O	O

In	O	O
2	O	O
of	O	O
the	O	O
4	O	O
patients	O	O
,	O	O
rechallenge	O	O
with	O	O
warfarin	B-Chemical	D014859
led	O	O
to	O	O
recurrence	O	O
of	O	O
the	O	O
lesions	O	O
.	O	O

LV	B-Disease	C535509
may	O	O
be	O	O
a	O	O
late	O	O
-	O	O
onset	O	O
adverse	O	O
reaction	O	O
associated	O	O
with	O	O
warfarin	B-Chemical	D014859
therapy	O	O
.	O	O

The	O	O
activation	O	O
of	O	O
spinal	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
receptors	O	O
may	O	O
contribute	O	O
to	O	O
degeneration	O	O
of	O	O
spinal	O	O
motor	O	O
neurons	O	O
induced	O	O
by	O	O
neuraxial	O	O
morphine	B-Chemical	D009020
after	O	O
a	O	O
noninjurious	O	O
interval	O	O
of	O	O
spinal	B-Disease	D020760
cord	I-Disease	D020760
ischemia	I-Disease	D020760
.	O	O

We	O	O
investigated	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
degeneration	O	O
of	O	O
spinal	O	O
motor	O	O
neurons	O	O
and	O	O
activation	O	O
of	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
d	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptors	O	O
after	O	O
neuraxial	O	O
morphine	B-Chemical	D009020
following	O	O
a	O	O
noninjurious	O	O
interval	O	O
of	O	O
aortic	B-Disease	D001157
occlusion	I-Disease	D001157
in	O	O
rats	O	O
.	O	O

Spinal	B-Disease	D020760
cord	I-Disease	D020760
ischemia	I-Disease	D020760
was	O	O
induced	O	O
by	O	O
aortic	B-Disease	D001157
occlusion	I-Disease	D001157
for	O	O
6	O	O
min	O	O
with	O	O
a	O	O
balloon	O	O
catheter	O	O
.	O	O

In	O	O
a	O	O
microdialysis	O	O
study	O	O
,	O	O
10	O	O
muL	O	O
of	O	O
saline	O	O
(	O	O
group	O	O
C	O	O
;	O	O
n	O	O
=	O	O
8	O	O
)	O	O
or	O	O
30	O	O
mug	O	O
of	O	O
morphine	B-Chemical	D009020
(	O	O
group	O	O
M	O	O
;	O	O
n	O	O
=	O	O
8	O	O
)	O	O
was	O	O
injected	O	O
intrathecally	O	O
(	O	O
IT	O	O
)	O	O
0	O	O
.	O	O

5	O	O
h	O	O
after	O	O
reflow	O	O
,	O	O
and	O	O
30	O	O
mug	O	O
of	O	O
morphine	B-Chemical	D009020
(	O	O
group	O	O
SM	O	O
;	O	O
n	O	O
=	O	O
8	O	O
)	O	O
or	O	O
10	O	O
muL	O	O
of	O	O
saline	O	O
(	O	O
group	O	O
SC	O	O
;	O	O
n	O	O
=	O	O
8	O	O
)	O	O
was	O	O
injected	O	O
IT	O	O
0	O	O
.	O	O

5	O	O
h	O	O
after	O	O
sham	O	O
operation	O	O
.	O	O

Microdialysis	O	O
samples	O	O
were	O	O
collected	O	O
preischemia	O	O
,	O	O
before	O	O
IT	O	O
injection	O	O
,	O	O
and	O	O
at	O	O
2	O	O
,	O	O
4	O	O
,	O	O
8	O	O
,	O	O
24	O	O
,	O	O
and	O	O
48	O	O
h	O	O
of	O	O
reperfusion	O	O
(	O	O
after	O	O
IT	O	O
injection	O	O
)	O	O
.	O	O

Second	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
IT	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
30	O	O
mug	O	O
)	O	O
on	O	O
the	O	O
histopathologic	O	O
changes	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
after	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
spastic	B-Disease	D020336
paraparesis	I-Disease	D020336
.	O	O

After	O	O
IT	O	O
morphine	B-Chemical	D009020
,	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
(	O	O
CSF	O	O
)	O	O
glutamate	B-Chemical	D018698
concentration	O	O
was	O	O
increased	O	O
in	O	O
group	O	O
M	O	O
relative	O	O
to	O	O
both	O	O
baseline	O	O
and	O	O
group	O	O
C	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

This	O	O
increase	O	O
persisted	O	O
for	O	O
8	O	O
hrs	O	O
.	O	O

IT	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
significantly	O	O
reduced	O	O
the	O	O
number	O	O
of	O	O
dark	O	O
-	O	O
stained	O	O
alpha	O	O
-	O	O
motoneurons	O	O
after	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
spastic	B-Disease	D020336
paraparesis	I-Disease	D020336
compared	O	O
with	O	O
the	O	O
saline	O	O
group	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
IT	O	O
morphine	B-Chemical	D009020
induces	O	O
spastic	B-Disease	D020336
paraparesis	I-Disease	D020336
with	O	O
a	O	O
concomitant	O	O
increase	O	O
in	O	O
CSF	O	O
glutamate	B-Chemical	D018698
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
NMDA	B-Chemical	D016202
receptor	O	O
activation	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
opioids	O	O
may	O	O
be	O	O
neurotoxic	B-Disease	D020258
in	O	O
the	O	O
setting	O	O
of	O	O
spinal	B-Disease	D020760
cord	I-Disease	D020760
ischemia	I-Disease	D020760
via	O	O
NMDA	B-Chemical	D016202
receptor	O	O
activation	O	O
.	O	O

Reduced	O	O
sodium	B-Chemical	D012964
channel	O	O
density	O	O
,	O	O
altered	O	O
voltage	O	O
dependence	O	O
of	O	O
inactivation	O	O
,	O	O
and	O	O
increased	O	O
susceptibility	O	O
to	O	O
seizures	B-Disease	D012640
in	O	O
mice	O	O
lacking	O	O
sodium	B-Chemical	D012964
channel	O	O
beta	O	O
2	O	O
-	O	O
subunits	O	O
.	O	O

Sodium	B-Chemical	D012964
channel	O	O
beta	O	O
-	O	O
subunits	O	O
modulate	O	O
channel	O	O
gating	O	O
,	O	O
assembly	O	O
,	O	O
and	O	O
cell	O	O
surface	O	O
expression	O	O
in	O	O
heterologous	O	O
cell	O	O
systems	O	O
.	O	O

We	O	O
generated	O	O
beta2	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
beta2	O	O
in	O	O
control	O	O
of	O	O
sodium	B-Chemical	D012964
channel	O	O
density	O	O
,	O	O
localization	O	O
,	O	O
and	O	O
function	O	O
in	O	O
neurons	O	O
in	O	O
vivo	O	O
.	O	O

Measurements	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
saxitoxin	B-Chemical	D012530
(	O	O
STX	B-Chemical	D012530
)	O	O
binding	O	O
showed	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
level	O	O
of	O	O
plasma	O	O
membrane	O	O
sodium	B-Chemical	D012964
channels	O	O
in	O	O
beta2	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
neurons	O	O
.	O	O

The	O	O
loss	O	O
of	O	O
beta2	O	O
resulted	O	O
in	O	O
negative	O	O
shifts	O	O
in	O	O
the	O	O
voltage	O	O
dependence	O	O
of	O	O
inactivation	O	O
as	O	O
well	O	O
as	O	O
significant	O	O
decreases	O	O
in	O	O
sodium	B-Chemical	D012964
current	O	O
density	O	O
in	O	O
acutely	O	O
dissociated	O	O
hippocampal	O	O
neurons	O	O
.	O	O

The	O	O
integral	O	O
of	O	O
the	O	O
compound	O	O
action	O	O
potential	O	O
in	O	O
optic	O	O
nerve	O	O
was	O	O
significantly	O	O
reduced	O	O
,	O	O
and	O	O
the	O	O
threshold	O	O
for	O	O
action	O	O
potential	O	O
generation	O	O
was	O	O
increased	O	O
,	O	O
indicating	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
level	O	O
of	O	O
functional	O	O
plasma	O	O
membrane	O	O
sodium	B-Chemical	D012964
channels	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
conduction	O	O
velocity	O	O
,	O	O
the	O	O
number	O	O
and	O	O
size	O	O
of	O	O
axons	O	O
in	O	O
the	O	O
optic	O	O
nerve	O	O
,	O	O
and	O	O
the	O	O
specific	O	O
localization	O	O
of	O	O
Na	B-Chemical	D012964
(	O	O
v	O	O
)	O	O
1	O	O
.	O	O

6	O	O
channels	O	O
in	O	O
the	O	O
nodes	O	O
of	O	O
Ranvier	O	O
were	O	O
unchanged	O	O
.	O	O

beta2	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
displayed	O	O
increased	O	O
susceptibility	O	O
to	O	O
seizures	B-Disease	D012640
,	O	O
as	O	O
indicated	O	O
by	O	O
reduced	O	O
latency	O	O
and	O	O
threshold	O	O
for	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
,	O	O
but	O	O
seemed	O	O
normal	O	O
in	O	O
other	O	O
neurological	O	O
tests	O	O
.	O	O

Our	O	O
observations	O	O
show	O	O
that	O	O
beta2	O	O
-	O	O
subunits	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
sodium	B-Chemical	D012964
channel	O	O
density	O	O
and	O	O
function	O	O
in	O	O
neurons	O	O
in	O	O
vivo	O	O
and	O	O
are	O	O
required	O	O
for	O	O
normal	O	O
action	O	O
potential	O	O
generation	O	O
and	O	O
control	O	O
of	O	O
excitability	O	O
.	O	O

Screening	O	O
for	O	O
stimulant	O	O
use	O	O
in	O	O
adult	O	O
emergency	O	O
department	O	O
seizure	B-Disease	D012640
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
positive	O	O
plasma	O	O
drug	O	O
screening	O	O
for	O	O
cocaine	B-Chemical	D003042
or	O	O
amphetamine	B-Chemical	D000661
in	O	O
adult	O	O
emergency	O	O
department	O	O
seizure	B-Disease	D012640
patients	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
prospective	O	O
study	O	O
evaluated	O	O
consecutive	O	O
eligible	O	O
seizure	B-Disease	D012640
patients	O	O
who	O	O
had	O	O
a	O	O
plasma	O	O
sample	O	O
collected	O	O
as	O	O
part	O	O
of	O	O
their	O	O
clinical	O	O
evaluation	O	O
.	O	O

Plasma	O	O
was	O	O
tested	O	O
for	O	O
amphetamine	B-Chemical	D000661
and	O	O
the	O	O
cocaine	B-Chemical	D003042
metabolite	O	O
benzoylecgonine	B-Chemical	C005618
using	O	O
enzyme	O	O
-	O	O
mediated	O	O
immunoassay	O	O
methodology	O	O
.	O	O

Plasma	O	O
samples	O	O
with	O	O
benzoylecgonine	B-Chemical	C005618
greater	O	O
than	O	O
150	O	O
ng	O	O
/	O	O
mL	O	O
or	O	O
an	O	O
amphetamine	B-Chemical	D000661
greater	O	O
than	O	O
500	O	O
ng	O	O
/	O	O
mL	O	O
were	O	O
defined	O	O
as	O	O
positive	O	O
.	O	O

Patient	O	O
demographics	O	O
,	O	O
history	O	O
of	O	O
underlying	O	O
drug	O	O
or	O	O
alcohol	B-Chemical	D000431
-	O	O
related	O	O
seizure	B-Disease	D012640
disorder	O	O
,	O	O
estimated	O	O
time	O	O
from	O	O
seizure	B-Disease	D012640
to	O	O
sample	O	O
collection	O	O
,	O	O
history	O	O
or	O	O
suspicion	O	O
of	O	O
cocaine	B-Chemical	D003042
or	O	O
amphetamine	B-Chemical	D000661
abuse	O	O
,	O	O
results	O	O
of	O	O
clinical	O	O
urine	O	O
testing	O	O
for	O	O
drugs	O	O
of	O	O
abuse	O	O
,	O	O
and	O	O
assay	O	O
results	O	O
were	O	O
recorded	O	O
without	O	O
patient	O	O
identifiers	O	O
.	O	O

RESULTS	O	O
:	O	O
Fourteen	O	O
of	O	O
248	O	O
(	O	O
5	O	O
.	O	O

6%	O	O
,	O	O
95%	O	O
CI	O	O
2	O	O
.	O	O

7%	O	O
-	O	O
8	O	O
.	O	O

5%	O	O
)	O	O
plasma	O	O
samples	O	O
were	O	O
positive	O	O
by	O	O
immunoassay	O	O
testing	O	O
for	O	O
benzoylecgonine	B-Chemical	C005618
and	O	O
no	O	O
samples	O	O
(	O	O
0%	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
-	O	O
1	O	O
.	O	O

2%	O	O
)	O	O
were	O	O
positive	O	O
for	O	O
amphetamine	B-Chemical	D000661
.	O	O

Positive	O	O
test	O	O
results	O	O
were	O	O
more	O	O
common	O	O
in	O	O
patient	O	O
visits	O	O
where	O	O
there	O	O
was	O	O
a	O	O
history	O	O
or	O	O
suspicion	O	O
of	O	O
cocaine	B-Chemical	D003042
or	O	O
amphetamine	B-Chemical	D000661
abuse	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

0005	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
During	O	O
this	O	O
study	O	O
period	O	O
,	O	O
routine	O	O
plasma	O	O
screening	O	O
for	O	O
cocaine	B-Chemical	D003042
and	O	O
amphetamines	B-Chemical	D000662
in	O	O
adult	O	O
seizure	B-Disease	D012640
patients	O	O
had	O	O
a	O	O
low	O	O
yield	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
routine	O	O
plasma	O	O
screening	O	O
would	O	O
yield	O	O
few	O	O
cases	O	O
of	O	O
stimulant	O	O
drug	O	O
in	O	O
which	O	O
there	O	O
was	O	O
neither	O	O
a	O	O
history	O	O
nor	O	O
suspicion	O	O
of	O	O
drug	B-Disease	D019966
abuse	I-Disease	D019966
in	O	O
this	O	O
population	O	O
.	O	O

Evidence	O	O
of	O	O
functional	O	O
somatotopy	O	O
in	O	O
GPi	O	O
from	O	O
results	O	O
of	O	O
pallidotomy	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
explore	O	O
the	O	O
functional	O	O
anatomy	O	O
of	O	O
the	O	O
globus	O	O
pallidus	O	O
internus	O	O
(	O	O
GPi	O	O
)	O	O
by	O	O
studying	O	O
the	O	O
effects	O	O
of	O	O
unilateral	O	O
pallidotomy	O	O
on	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
and	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
(	O	O
LID	B-Disease	D004409
)	O	O
.	O	O

We	O	O
found	O	O
significant	O	O
positive	O	O
correlations	O	O
between	O	O
the	O	O
preoperative	O	O
levodopa	B-Chemical	D007980
responsiveness	O	O
of	O	O
motor	O	O
signs	O	O
and	O	O
the	O	O
levodopa	B-Chemical	D007980
responsiveness	O	O
of	O	O
scores	O	O
in	O	O
timed	O	O
tests	O	O
(	O	O
Core	O	O
Assessment	O	O
Program	O	O
for	O	O
Intracerebral	O	O
Transplantations	O	O
)	O	O
in	O	O
the	O	O
contralateral	O	O
limbs	O	O
and	O	O
the	O	O
improvement	O	O
in	O	O
these	O	O
scores	O	O
after	O	O
surgery	O	O
,	O	O
whereas	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
with	O	O
the	O	O
improvement	O	O
in	O	O
LID	B-Disease	D004409
.	O	O

We	O	O
also	O	O
found	O	O
a	O	O
highly	O	O
significant	O	O
correlation	O	O
(	O	O
P	O	O
:	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
,	O	O
r	O	O
=	O	O
0	O	O
.	O	O

8	O	O
)	O	O
between	O	O
the	O	O
volume	O	O
of	O	O
the	O	O
ventral	O	O
lesion	O	O
in	O	O
the	O	O
GPi	O	O
and	O	O
the	O	O
improvement	O	O
in	O	O
LID	B-Disease	D004409
in	O	O
the	O	O
contralateral	O	O
limbs	O	O
,	O	O
whereas	O	O
there	O	O
was	O	O
no	O	O
correlation	O	O
between	O	O
the	O	O
ventral	O	O
volume	O	O
and	O	O
the	O	O
improvement	O	O
in	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
.	O	O

The	O	O
volumes	O	O
of	O	O
the	O	O
total	O	O
lesion	O	O
cylinder	O	O
and	O	O
the	O	O
dorsal	O	O
lesion	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
the	O	O
outcome	O	O
of	O	O
either	O	O
dyskinesias	B-Disease	D004409
or	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
.	O	O

The	O	O
differential	O	O
predictive	O	O
value	O	O
of	O	O
levodopa	B-Chemical	D007980
responsiveness	O	O
for	O	O
the	O	O
outcome	O	O
of	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
and	O	O
LID	B-Disease	D004409
and	O	O
the	O	O
different	O	O
correlations	O	O
of	O	O
ventral	O	O
lesion	O	O
volume	O	O
with	O	O
dyskinesias	B-Disease	D004409
and	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
indicate	O	O
that	O	O
different	O	O
anatomical	O	O
or	O	O
pathophysiological	O	O
substrates	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
generation	O	O
of	O	O
parkinsonian	B-Disease	D010300
'off'	O	O
signs	O	O
and	O	O
dyskinesias	B-Disease	D004409
.	O	O

Whereas	O	O
cells	O	O
in	O	O
a	O	O
wider	O	O
area	O	O
of	O	O
the	O	O
GPi	O	O
may	O	O
be	O	O
implicated	O	O
in	O	O
parkinsonism	B-Disease	D010300
,	O	O
the	O	O
ventral	O	O
GPi	O	O
seems	O	O
to	O	O
be	O	O
crucial	O	O
for	O	O
the	O	O
manifestation	O	O
of	O	O
LID	B-Disease	D004409
.	O	O

We	O	O
suggest	O	O
that	O	O
our	O	O
observations	O	O
are	O	O
additional	O	O
proof	O	O
of	O	O
the	O	O
functional	O	O
somatotopy	O	O
of	O	O
the	O	O
systems	O	O
within	O	O
the	O	O
GPi	O	O
that	O	O
mediate	O	O
parkinsonism	B-Disease	D010300
and	O	O
dyskinesias	B-Disease	D004409
,	O	O
especially	O	O
along	O	O
the	O	O
dorsoventral	O	O
trajectory	O	O
used	O	O
in	O	O
pallidotomy	O	O
.	O	O

The	O	O
outcome	O	O
of	O	O
pallidotomy	O	O
in	O	O
which	O	O
the	O	O
lesion	O	O
involves	O	O
the	O	O
ventral	O	O
and	O	O
dorsal	O	O
GPi	O	O
could	O	O
be	O	O
the	O	O
net	O	O
effect	O	O
of	O	O
alteration	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
pathways	O	O
which	O	O
mediate	O	O
different	O	O
symptoms	O	O
,	O	O
and	O	O
hence	O	O
could	O	O
be	O	O
variable	O	O
.	O	O

Pain	B-Disease	D010146
responses	O	O
in	O	O
methadone	B-Chemical	D008691
-	O	O
maintained	O	O
opioid	O	O
abusers	O	O
.	O	O

Providing	O	O
pain	B-Disease	D010146
management	O	O
for	O	O
known	O	O
opioid	O	O
abusers	O	O
is	O	O
a	O	O
challenging	O	O
clinical	O	O
task	O	O
,	O	O
in	O	O
part	O	O
because	O	O
little	O	O
is	O	O
known	O	O
about	O	O
their	O	O
pain	B-Disease	D010146
experience	O	O
and	O	O
analgesic	O	O
requirements	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
describe	O	O
pain	B-Disease	D010146
tolerance	O	O
and	O	O
analgesic	O	O
response	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
opioid	B-Disease	D009293
addicts	I-Disease	D009293
stabilized	O	O
in	O	O
methadone	B-Chemical	D008691
-	O	O
maintenance	O	O
(	O	O
MM	O	O
)	O	O
treatment	O	O
(	O	O
n	O	O
=	O	O
60	O	O
)	O	O
in	O	O
comparison	O	O
to	O	O
matched	O	O
nondependent	O	O
control	O	O
subjects	O	O
(	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

By	O	O
using	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
two	O	O
-	O	O
way	O	O
factorial	O	O
design	O	O
,	O	O
tolerance	O	O
to	O	O
cold	O	O
-	O	O
pressor	O	O
(	O	O
CP	O	O
)	O	O
pain	B-Disease	D010146
was	O	O
examined	O	O
,	O	O
both	O	O
before	O	O
and	O	O
after	O	O
oral	O	O
administration	O	O
of	O	O
therapeutic	O	O
doses	O	O
of	O	O
common	O	O
opioid	O	O
(	O	O
hydromorphone	B-Chemical	D004091
2	O	O
mg	O	O
)	O	O
and	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
(	O	O
ketorolac	B-Chemical	D020910
10	O	O
mg	O	O
)	O	O
analgesic	O	O
agents	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
MM	O	O
individuals	O	O
were	O	O
significantly	O	O
less	O	O
tolerant	O	O
of	O	O
CP	O	O
pain	B-Disease	D010146
than	O	O
control	O	O
subjects	O	O
,	O	O
replicating	O	O
previous	O	O
work	O	O
.	O	O

Analgesic	O	O
effects	O	O
were	O	O
significant	O	O
neither	O	O
for	O	O
medication	O	O
nor	O	O
group	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
MM	O	O
opioid	O	O
abusers	O	O
represent	O	O
a	O	O
pain	B-Disease	D010146
-	O	O
intolerant	O	O
subset	O	O
of	O	O
clinical	O	O
patients	O	O
.	O	O

Their	O	O
complaints	O	O
of	O	O
pain	B-Disease	D010146
should	O	O
be	O	O
evaluated	O	O
seriously	O	O
and	O	O
managed	O	O
aggressively	O	O
.	O	O

Urine	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
D	O	O
-	O	O
glucosaminidase	O	O
-	O	O
-	O	O
a	O	O
marker	O	O
of	O	O
tubular	O	O
damage?	O	O
BACKGROUND	O	O
:	O	O
Although	O	O
an	O	O
indicator	O	O
of	O	O
renal	B-Disease	D005198
tubular	I-Disease	D005198
dysfunction	I-Disease	D005198
,	O	O
an	O	O
increased	O	O
urinary	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
D	O	O
-	O	O
glucosaminidase	O	O
(	O	O
NAG	O	O
)	O	O
activity	O	O
might	O	O
reflect	O	O
increased	O	O
lysosomal	O	O
activity	O	O
in	O	O
renal	O	O
tubular	O	O
cells	O	O
.	O	O

METHODS	O	O
:	O	O
Puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
was	O	O
administered	O	O
to	O	O
Sprague	O	O
Dawley	O	O
rats	O	O
to	O	O
induce	O	O
proteinuria	B-Disease	D011507
.	O	O

Total	O	O
protein	O	O
,	O	O
albumin	O	O
,	O	O
NAG	O	O
activity	O	O
and	O	O
protein	O	O
electrophoretic	O	O
pattern	O	O
were	O	O
assessed	O	O
in	O	O
daily	O	O
urine	O	O
samples	O	O
for	O	O
33	O	O
days	O	O
.	O	O

The	O	O
morphological	O	O
appearance	O	O
of	O	O
the	O	O
kidneys	O	O
was	O	O
examined	O	O
on	O	O
days	O	O
three	O	O
,	O	O
four	O	O
,	O	O
six	O	O
,	O	O
eight	O	O
and	O	O
thirty	O	O
three	O	O
and	O	O
the	O	O
NAG	O	O
isoenzyme	O	O
patterns	O	O
on	O	O
days	O	O
zero	O	O
,	O	O
four	O	O
,	O	O
eight	O	O
and	O	O
thirty	O	O
three	O	O
.	O	O

RESULTS	O	O
:	O	O
Following	O	O
intravenous	O	O
PAN	B-Chemical	D011692
urine	O	O
volume	O	O
and	O	O
urine	O	O
NAG	O	O
activity	O	O
increased	O	O
significantly	O	O
by	O	O
day	O	O
two	O	O
,	O	O
but	O	O
returned	O	O
to	O	O
normal	O	O
by	O	O
day	O	O
four	O	O
.	O	O

After	O	O
day	O	O
four	O	O
all	O	O
treated	O	O
animals	O	O
exhibited	O	O
a	O	O
marked	O	O
rise	O	O
in	O	O
urine	O	O
albumin	O	O
,	O	O
total	O	O
protein	O	O
excretion	O	O
and	O	O
NAG	O	O
activity	O	O
.	O	O

Electrophoresis	O	O
showed	O	O
a	O	O
generalised	O	O
increase	O	O
in	O	O
middle	O	O
and	O	O
high	O	O
molecular	O	O
weight	O	O
urine	O	O
proteins	O	O
from	O	O
day	O	O
four	O	O
onwards	O	O
.	O	O

Protein	O	O
droplets	O	O
first	O	O
appeared	O	O
prominent	O	O
in	O	O
tubular	O	O
cells	O	O
on	O	O
day	O	O
four	O	O
.	O	O

Peak	O	O
urine	O	O
NAG	O	O
activity	O	O
and	O	O
a	O	O
change	O	O
in	O	O
NAG	O	O
isoenzyme	O	O
pattern	O	O
coincided	O	O
with	O	O
both	O	O
the	O	O
peak	O	O
proteinuria	B-Disease	D011507
and	O	O
the	O	O
reduction	O	O
in	O	O
intracellular	O	O
protein	O	O
and	O	O
NAG	O	O
droplets	O	O
(	O	O
day	O	O
six	O	O
onwards	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
animal	O	O
model	O	O
demonstrates	O	O
that	O	O
an	O	O
increase	O	O
in	O	O
lysosomal	O	O
turnover	O	O
and	O	O
hence	O	O
urine	O	O
NAG	O	O
activity	O	O
,	O	O
occurs	O	O
when	O	O
increased	O	O
protein	O	O
is	O	O
presented	O	O
to	O	O
the	O	O
tubular	O	O
cells	O	O
.	O	O

Urine	O	O
NAG	O	O
activity	O	O
is	O	O
thus	O	O
a	O	O
measure	O	O
of	O	O
altered	O	O
function	O	O
in	O	O
the	O	O
renal	O	O
tubules	O	O
and	O	O
not	O	O
simply	O	O
an	O	O
indicator	O	O
of	O	O
damage	O	O
.	O	O

Over	O	O
expression	O	O
of	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
and	O	O
its	O	O
receptor	O	O
during	O	O
the	O	O
development	O	O
of	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
rat	O	O
pituitary	B-Disease	D010911
tumors	I-Disease	D010911
may	O	O
mediate	O	O
estrogen	B-Chemical	D004967
-	O	O
initiated	O	O
tumor	B-Disease	D009369
angiogenesis	O	O
.	O	O

Estrogens	B-Chemical	D004967
,	O	O
which	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
several	O	O
types	O	O
of	O	O
human	O	O
and	O	O
animal	O	O
cancers	B-Disease	D009369
,	O	O
can	O	O
induce	O	O
tumor	B-Disease	D009369
angiogenesis	O	O
in	O	O
the	O	O
pituitary	O	O
of	O	O
Fischer	O	O
344	O	O
rats	O	O
.	O	O

The	O	O
mechanistic	O	O
details	O	O
of	O	O
tumor	B-Disease	D009369
angiogenesis	O	O
induction	O	O
,	O	O
during	O	O
estrogen	B-Chemical	D004967
carcinogenesis	B-Disease	D063646
,	O	O
are	O	O
still	O	O
unknown	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
role	O	O
of	O	O
estrogen	B-Chemical	D004967
in	O	O
the	O	O
regulation	O	O
of	O	O
tumor	B-Disease	D009369
angiogenesis	O	O
in	O	O
the	O	O
pituitary	O	O
of	O	O
female	O	O
rats	O	O
,	O	O
the	O	O
density	O	O
of	O	O
blood	O	O
vessels	O	O
was	O	O
analysed	O	O
using	O	O
factor	O	O
VIII	O	O
related	O	O
antigen	O	O
(	O	O
FVIIIRAg	O	O
)	O	O
immunohistochemistry	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
/	O	O
vascular	O	O
permeability	O	O
factor	O	O
(	O	O
VEGF	O	O
/	O	O
VPF	O	O
)	O	O
was	O	O
examined	O	O
by	O	O
Western	O	O
blot	O	O
and	O	O
immunohistochemical	O	O
analysis	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
VEGF	O	O
receptor	O	O
(	O	O
VEGFR	O	O
-	O	O
2	O	O
/	O	O
Flk	O	O
-	O	O
1	O	O
/	O	O
KDR	O	O
)	O	O
was	O	O
also	O	O
examined	O	O
by	O	O
immunohistochemistry	O	O
.	O	O

The	O	O
results	O	O
demonstrated	O	O
that	O	O
17beta	B-Chemical	D004958
-	I-Chemical	D004958
estradiol	I-Chemical	D004958
(	O	O
E2	B-Chemical	D004958
)	O	O
induces	O	O
neovascularization	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
growth	O	O
and	O	O
enlargement	O	O
of	O	O
blood	O	O
vessels	O	O
after	O	O
7	O	O
days	O	O
of	O	O
exposure	O	O
.	O	O

The	O	O
high	O	O
tumor	B-Disease	D009369
angiogenic	O	O
potential	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
elevated	O	O
VEGF	O	O
/	O	O
VPF	O	O
protein	O	O
expression	O	O
in	O	O
the	O	O
E2	B-Chemical	D004958
exposed	O	O
pituitary	O	O
of	O	O
ovariectomized	O	O
(	O	O
OVEX	O	O
)	O	O
rats	O	O
.	O	O

VEGF	O	O
/	O	O
VPF	O	O
and	O	O
FVIIIRAg	O	O
immunohistochemistry	O	O
and	O	O
endothelial	O	O
specific	O	O
lectin	O	O
(	O	O
UEA1	O	O
)	O	O
binding	O	O
studies	O	O
,	O	O
indicate	O	O
that	O	O
the	O	O
elevation	O	O
of	O	O
VEGF	O	O
protein	O	O
expression	O	O
initially	O	O
occurred	O	O
in	O	O
both	O	O
blood	O	O
vessels	O	O
and	O	O
non	O	O
-	O	O
endothelial	O	O
cells	O	O
.	O	O

After	O	O
15	O	O
days	O	O
of	O	O
E2	B-Chemical	D004958
exposure	O	O
,	O	O
VEGF	O	O
/	O	O
VPF	O	O
protein	O	O
expression	O	O
,	O	O
in	O	O
the	O	O
non	O	O
-	O	O
endothelial	O	O
cell	O	O
population	O	O
,	O	O
sharply	O	O
declined	O	O
and	O	O
was	O	O
restricted	O	O
to	O	O
the	O	O
blood	O	O
vessels	O	O
.	O	O

The	O	O
function	O	O
of	O	O
non	O	O
-	O	O
endothelial	O	O
-	O	O
derived	O	O
VEGF	O	O
is	O	O
not	O	O
clear	O	O
.	O	O

Furthermore	O	O
,	O	O
immunohistochemical	O	O
studies	O	O
demonstrated	O	O
that	O	O
VEGFR	O	O
-	O	O
2	O	O
(	O	O
flk	O	O
-	O	O
1	O	O
/	O	O
KDR	O	O
)	O	O
,	O	O
expression	O	O
was	O	O
elevated	O	O
significantly	O	O
in	O	O
the	O	O
endothelial	O	O
cells	O	O
of	O	O
microblood	O	O
vessels	O	O
after	O	O
7	O	O
days	O	O
of	O	O
E2	B-Chemical	D004958
exposure	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
over	O	O
expression	O	O
of	O	O
VEGF	O	O
and	O	O
its	O	O
receptor	O	O
(	O	O
VEGFR	O	O
-	O	O
2	O	O
)	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
initial	O	O
step	O	O
of	O	O
the	O	O
regulation	O	O
of	O	O
estrogen	B-Chemical	D004967
induced	O	O
tumor	B-Disease	D009369
angiogenesis	O	O
in	O	O
the	O	O
rat	O	O
pituitary	O	O
.	O	O

Pravastatin	B-Chemical	D017035
-	O	O
associated	O	O
myopathy	B-Disease	D009135
.	O	O

Report	O	O
of	O	O
a	O	O
case	O	O
.	O	O

A	O	O
case	O	O
of	O	O
acute	O	O
inflammatory	B-Disease	D009220
myopathy	I-Disease	D009220
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
pravastatin	B-Chemical	D017035
,	O	O
a	O	O
new	O	O
hydrophilic	O	O
3	O	O
-	O	O
hydroxy	O	O
-	O	O
3	O	O
methylglutaril	O	O
coenzyme	O	O
A	O	O
reductase	O	O
inhibitor	O	O
,	O	O
is	O	O
reported	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
a	O	O
69	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
was	O	O
affected	O	O
by	O	O
non	B-Disease	D003924
-	I-Disease	D003924
insulin	I-Disease	D003924
-	I-Disease	D003924
dependent	I-Disease	D003924
diabetes	I-Disease	D003924
mellitus	I-Disease	D003924
and	O	O
hypertension	B-Disease	D006973
.	O	O

He	O	O
assumed	O	O
pravastatin	B-Chemical	D017035
(	O	O
20	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
because	O	O
of	O	O
hypercholesterolemia	B-Disease	D006937
.	O	O

He	O	O
was	O	O
admitted	O	O
with	O	O
acute	O	O
myopathy	B-Disease	D009135
of	O	O
the	O	O
lower	O	O
limbs	O	O
which	O	O
resolved	O	O
in	O	O
a	O	O
few	O	O
days	O	O
after	O	O
pravastatin	B-Chemical	D017035
discontinuation	O	O
.	O	O

A	O	O
previously	O	O
unknown	O	O
hypothyroidism	B-Disease	D007037
,	O	O
probably	O	O
due	O	O
to	O	O
chronic	O	O
autoimmune	B-Disease	D013967
thyroiditis	I-Disease	D013967
,	O	O
was	O	O
evidenced	O	O
.	O	O

Muscle	O	O
biopsy	O	O
(	O	O
left	O	O
gastrocnemius	O	O
)	O	O
revealed	O	O
a	O	O
perimysial	O	O
and	O	O
endomysial	O	O
inflammatory	O	O
infiltrate	O	O
with	O	O
a	O	O
prevalence	O	O
of	O	O
CD4+	O	O
lymphocytes	O	O
.	O	O

While	O	O
lovastatin	B-Chemical	D008148
and	O	O
simvastatin	B-Chemical	D019821
have	O	O
been	O	O
associated	O	O
with	O	O
toxic	O	O
myopathy	B-Disease	D009135
,	O	O
pravastatin	B-Chemical	D017035
-	O	O
associated	O	O
myopathy	B-Disease	D009135
could	O	O
represent	O	O
a	O	O
distinct	O	O
,	O	O
inflammatory	O	O
entity	O	O
.	O	O

Dose	O	O
-	O	O
effect	O	O
and	O	O
structure	O	O
-	O	O
function	O	O
relationships	O	O
in	O	O
doxorubicin	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
.	O	O

The	O	O
cardiomyopathy	B-Disease	D009202
(	O	O
CM	B-Disease	D009202
)	O	O
produced	O	O
by	O	O
the	O	O
anticancer	O	O
drug	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DXR	B-Chemical	D004317
)	O	O
(	O	O
Adriamycin	B-Chemical	D004317
)	O	O
provides	O	O
a	O	O
unique	O	O
opportunity	O	O
to	O	O
analyze	O	O
dose	O	O
-	O	O
effect	O	O
and	O	O
structure	O	O
-	O	O
function	O	O
relationships	O	O
during	O	O
development	O	O
of	O	O
myocardial	B-Disease	D009202
disease	I-Disease	D009202
.	O	O

We	O	O
measured	O	O
the	O	O
degree	O	O
of	O	O
morphologic	O	O
damage	O	O
by	O	O
ultrastructural	O	O
examination	O	O
of	O	O
endomyocardial	O	O
biopsy	O	O
and	O	O
the	O	O
degree	O	O
of	O	O
performance	O	O
abnormally	O	O
by	O	O
right	O	O
heart	O	O
catheterization	O	O
in	O	O
patients	O	O
receiving	O	O
DXR	B-Chemical	D004317
.	O	O

Morphologic	O	O
damage	O	O
was	O	O
variable	O	O
but	O	O
was	O	O
proportional	O	O
to	O	O
the	O	O
total	O	O
cumulative	O	O
DXR	B-Chemical	D004317
dose	O	O
between	O	O
100	O	O
and	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

Performance	O	O
abnormalities	O	O
correlated	O	O
weakly	O	O
with	O	O
dose	O	O
,	O	O
exhibited	O	O
a	O	O
curvilinear	O	O
relationship	O	O
,	O	O
and	O	O
had	O	O
a	O	O
"threshold"	O	O
for	O	O
expression	O	O
.	O	O

Catheterization	O	O
abnormalities	O	O
correlated	O	O
well	O	O
with	O	O
morphologic	O	O
damage	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

57	O	O
to	O	O
0	O	O
.	O	O

78	O	O
)	O	O
in	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
in	O	O
whom	O	O
exercise	O	O
hemodynamics	O	O
were	O	O
measured	O	O
,	O	O
and	O	O
this	O	O
relationship	O	O
also	O	O
exhibited	O	O
a	O	O
curvilinear	O	O
,	O	O
threshold	O	O
configuration	O	O
.	O	O

In	O	O
DXR	B-Chemical	D004317
-	O	O
CM	B-Disease	D009202
myocardial	B-Disease	D009202
damage	I-Disease	D009202
is	O	O
proportional	O	O
to	O	O
the	O	O
degree	O	O
of	O	O
cytotoxic	O	O
insult	O	O
(	O	O
DXR	B-Chemical	D004317
dose	O	O
)	O	O
while	O	O
myocardial	O	O
function	O	O
is	O	O
preserved	O	O
until	O	O
a	O	O
critical	O	O
dose	O	O
or	O	O
degree	O	O
of	O	O
damage	O	O
is	O	O
reached	O	O
,	O	O
after	O	O
which	O	O
myocardial	O	O
performance	O	O
deteriorates	O	O
rapidly	O	O
.	O	O

Fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
following	O	O
topical	O	O
administration	O	O
of	O	O
ophthalmic	O	O
chloramphenicol	B-Chemical	D002701
.	O	O

A	O	O
73	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
died	O	O
of	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
less	O	O
than	O	O
two	O	O
months	O	O
after	O	O
undergoing	O	O
cataract	B-Disease	D002386
extraction	O	O
and	O	O
beginning	O	O
topical	O	O
therapy	O	O
with	O	O
chloramphenicol	B-Chemical	D002701
.	O	O

The	O	O
first	O	O
signs	O	O
of	O	O
pancytopenia	B-Disease	D010198
began	O	O
within	O	O
one	O	O
month	O	O
of	O	O
the	O	O
surgery	O	O
.	O	O

The	O	O
pattern	O	O
of	O	O
the	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
was	O	O
associated	O	O
with	O	O
an	O	O
idiosyncratic	O	O
response	O	O
to	O	O
chloramphenicol	B-Chemical	D002701
.	O	O

This	O	O
was	O	O
the	O	O
second	O	O
report	O	O
of	O	O
fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
after	O	O
topical	O	O
treatment	O	O
with	O	O
chloramphenicol	B-Chemical	D002701
for	O	O
ocular	O	O
conditions	O	O
,	O	O
although	O	O
two	O	O
cases	O	O
of	O	O
reversible	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
hypoplasia	I-Disease	D001855
have	O	O
also	O	O
been	O	O
reported	O	O
.	O	O

Any	O	O
other	O	O
suspected	O	O
cases	O	O
of	O	O
ocular	B-Disease	D005128
toxicity	I-Disease	D005128
associated	O	O
with	O	O
topically	O	O
applied	O	O
chloramphenicol	B-Chemical	D002701
should	O	O
be	O	O
reported	O	O
to	O	O
the	O	O
National	O	O
Registry	O	O
of	O	O
Drug	O	O
-	O	O
Induced	O	O
Ocular	O	O
Side	O	O
Effects	O	O
,	O	O
Oregon	O	O
Health	O	O
Sciences	O	O
University	O	O
,	O	O
Portland	O	O
,	O	O
OR	O	O
97201	O	O
.	O	O

Bradycardia	B-Disease	D001919
due	O	O
to	O	O
trihexyphenidyl	B-Chemical	D014282
hydrochloride	I-Chemical	D014282
.	O	O

A	O	O
chronic	O	O
schizophrenic	B-Disease	D012559
patient	O	O
was	O	O
treated	O	O
with	O	O
an	O	O
anticholinergic	O	O
drug	O	O
,	O	O
trihexyphenidyl	B-Chemical	D014282
hydrochloride	I-Chemical	D014282
.	O	O

The	O	O
patient	O	O
developed	O	O
,	O	O
paradoxically	O	O
,	O	O
sinus	O	O
bradycardia	B-Disease	D001919
.	O	O

The	O	O
reaction	O	O
was	O	O
specific	O	O
to	O	O
trihexyphenidyl	B-Chemical	D014282
and	O	O
not	O	O
to	O	O
other	O	O
anticholinergic	O	O
drugs	O	O
.	O	O

This	O	O
antidyskinetic	O	O
drug	O	O
is	O	O
widely	O	O
used	O	O
in	O	O
clinical	O	O
psychiatric	B-Disease	D001523
practice	O	O
and	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
side	O	O
effect	O	O
.	O	O

Experimental	O	O
cyclosporine	B-Chemical	D016572
nephrotoxicity	B-Disease	D007674
:	O	O
risk	O	O
of	O	O
concomitant	O	O
chemotherapy	O	O
.	O	O

The	O	O
role	O	O
of	O	O
cyclosporine	B-Chemical	D016572
(	O	O
CSA	B-Chemical	D016572
)	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
various	O	O
chemotherapeutics	O	O
in	O	O
the	O	O
development	O	O
of	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
was	O	O
evaluated	O	O
in	O	O
rats	O	O
.	O	O

Administration	O	O
of	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
CSA	B-Chemical	D016572
for	O	O
4	O	O
weeks	O	O
caused	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
changes	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
in	O	O
man	O	O
.	O	O

The	O	O
combined	O	O
administration	O	O
of	O	O
CSA	B-Chemical	D016572
and	O	O
various	O	O
chemotherapeutic	O	O
drugs	O	O
with	O	O
a	O	O
nephrotoxic	B-Disease	D007674
potential	O	O
,	O	O
such	O	O
as	O	O
gentamicin	B-Chemical	D005839
(	O	O
at	O	O
therapeutic	O	O
doses	O	O
)	O	O
,	O	O
amphothericin	B-Chemical	D000666
B	I-Chemical	D000666
and	O	O
ketoconazole	B-Chemical	D007654
,	O	O
which	O	O
are	O	O
frequently	O	O
used	O	O
in	O	O
immunosuppressed	O	O
patients	O	O
,	O	O
did	O	O
not	O	O
aggravate	O	O
the	O	O
CSA	B-Chemical	D016572
induced	O	O
toxicity	B-Disease	D064420
in	O	O
the	O	O
rat	O	O
model	O	O
.	O	O

Gentamicin	B-Chemical	D005839
at	O	O
toxic	O	O
doses	O	O
,	O	O
however	O	O
,	O	O
increased	O	O
CSA	B-Chemical	D016572
nephrotoxicity	B-Disease	D007674
.	O	O

Thus	O	O
,	O	O
the	O	O
nephrotoxicity	B-Disease	D007674
induced	O	O
by	O	O
CSA	B-Chemical	D016572
has	O	O
a	O	O
different	O	O
pathogenetic	O	O
mechanism	O	O
.	O	O

Receptor	O	O
mechanisms	O	O
of	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
locomotor	B-Disease	D006948
hyperactivity	I-Disease	D006948
in	O	O
chronic	O	O
nicotine	B-Chemical	D009538
-	O	O
treated	O	O
rats	O	O
.	O	O

Rats	O	O
were	O	O
pretreated	O	O
with	O	O
saline	O	O
or	O	O
nicotine	B-Chemical	D009538
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
)	O	O
by	O	O
subcutaneously	O	O
implanting	O	O
each	O	O
animal	O	O
with	O	O
an	O	O
Alzet	O	O
osmotic	O	O
mini	O	O
-	O	O
pump	O	O
which	O	O
continuously	O	O
released	O	O
saline	O	O
or	O	O
nicotine	B-Chemical	D009538
for	O	O
1	O	O
,	O	O
5	O	O
and	O	O
14	O	O
days	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
each	O	O
pretreatment	O	O
period	O	O
,	O	O
animals	O	O
were	O	O
used	O	O
for	O	O
(	O	O
i	O	O
)	O	O
determining	O	O
their	O	O
locomotor	O	O
response	O	O
to	O	O
acutely	O	O
injected	O	O
nicotine	B-Chemical	D009538
(	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
measuring	O	O
the	O	O
density	O	O
of	O	O
L	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
nicotine	B-Chemical	D009538
and	O	O
[	O	O
3H	O	O
]	O	O
spiperone	B-Chemical	D013134
binding	O	O
sites	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

We	O	O
observed	O	O
no	O	O
changes	O	O
in	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
locomotor	O	O
response	O	O
,	O	O
striatal	O	O
L	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
nicotine	B-Chemical	D009538
and	O	O
[	O	O
3H	O	O
]	O	O
spiperone	B-Chemical	D013134
binding	O	O
in	O	O
the	O	O
animals	O	O
pretreated	O	O
with	O	O
nicotine	B-Chemical	D009538
for	O	O
1	O	O
day	O	O
.	O	O

In	O	O
rats	O	O
which	O	O
were	O	O
pretreated	O	O
with	O	O
nicotine	B-Chemical	D009538
for	O	O
5	O	O
days	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
nicotine	B-Chemical	D009538
-	O	O
stimulated	O	O
locomotor	O	O
response	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
L	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
nicotine	B-Chemical	D009538
binding	O	O
sites	O	O
and	O	O
also	O	O
with	O	O
an	O	O
elevated	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
level	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

The	O	O
number	O	O
of	O	O
striatal	O	O
[	O	O
3H	O	O
]	O	O
spiperone	B-Chemical	D013134
binding	O	O
sites	O	O
was	O	O
not	O	O
affected	O	O
.	O	O

In	O	O
animals	O	O
pretreated	O	O
with	O	O
nicotine	B-Chemical	D009538
for	O	O
14	O	O
days	O	O
,	O	O
the	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
locomotor	O	O
response	O	O
remained	O	O
to	O	O
be	O	O
potentiated	O	O
.	O	O

However	O	O
,	O	O
this	O	O
response	O	O
was	O	O
correlated	O	O
with	O	O
an	O	O
elevated	O	O
number	O	O
of	O	O
striatal	O	O
[	O	O
3H	O	O
]	O	O
spiperone	B-Chemical	D013134
binding	O	O
sites	O	O
,	O	O
whereas	O	O
the	O	O
number	O	O
of	O	O
striatal	O	O
L	O	O
-	O	O
[	O	O
3H	O	O
]	O	O
nicotine	B-Chemical	D009538
binding	O	O
sites	O	O
and	O	O
the	O	O
striatal	O	O
DA	B-Chemical	D004298
level	O	O
were	O	O
normal	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
chronic	O	O
nicotine	B-Chemical	D009538
-	O	O
treated	O	O
rats	O	O
develop	O	O
locomotor	B-Disease	D006948
hyperactivity	I-Disease	D006948
in	O	O
response	O	O
to	O	O
nicotine	B-Chemical	D009538
initially	O	O
due	O	O
to	O	O
increases	O	O
of	O	O
both	O	O
the	O	O
density	O	O
of	O	O
nicotinic	O	O
receptors	O	O
and	O	O
DA	B-Chemical	D004298
concentration	O	O
,	O	O
followed	O	O
by	O	O
inducing	O	O
DA	B-Chemical	D004298
receptor	O	O
supersensitivity	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

Hydrocortisone	B-Chemical	D006854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
humans	O	O
:	O	O
pressor	O	O
responsiveness	O	O
and	O	O
sympathetic	O	O
function	O	O
.	O	O

Oral	O	O
hydrocortisone	B-Chemical	D006854
increases	O	O
blood	O	O
pressure	O	O
and	O	O
enhances	O	O
pressor	O	O
responsiveness	O	O
in	O	O
normal	O	O
human	O	O
subjects	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
1	O	O
week	O	O
of	O	O
oral	O	O
hydrocortisone	B-Chemical	D006854
(	O	O
200	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
on	O	O
blood	O	O
pressure	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
,	O	O
forearm	O	O
vascular	O	O
resistance	O	O
,	O	O
and	O	O
norepinephrine	B-Chemical	D009638
spillover	O	O
to	O	O
plasma	O	O
in	O	O
eight	O	O
healthy	O	O
male	O	O
volunteers	O	O
.	O	O

Although	O	O
diastolic	O	O
blood	O	O
pressure	O	O
remained	O	O
unchanged	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
increased	O	O
from	O	O
119	O	O
to	O	O
135	O	O
mm	O	O
Hg	O	O
(	O	O
SED	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

4	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
associated	O	O
with	O	O
an	O	O
increased	B-Disease	D016534
cardiac	I-Disease	D016534
output	I-Disease	D016534
(	O	O
5	O	O
.	O	O

85	O	O
-	O	O
7	O	O
.	O	O

73	O	O
l	O	O
/	O	O
min	O	O
,	O	O
SED	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

46	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Total	O	O
peripheral	O	O
vascular	O	O
resistance	O	O
fell	O	O
from	O	O
15	O	O
.	O	O

1	O	O
to	O	O
12	O	O
.	O	O

2	O	O
mm	O	O
Hg	O	O
/	O	O
l	O	O
/	O	O
min	O	O
(	O	O
SED	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

03	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Resting	O	O
forearm	O	O
vascular	O	O
resistance	O	O
remained	O	O
unchanged	O	O
,	O	O
but	O	O
the	O	O
reflex	O	O
response	O	O
to	O	O
the	O	O
cold	O	O
pressor	O	O
test	O	O
was	O	O
accentuated	O	O
,	O	O
the	O	O
rise	O	O
in	O	O
resistance	O	O
increasing	O	O
from	O	O
10	O	O
.	O	O

5	O	O
mm	O	O
Hg	O	O
/	O	O
ml	O	O
/	O	O
100	O	O
ml	O	O
/	O	O
min	O	O
(	O	O
R	O	O
units	O	O
)	O	O
before	O	O
treatment	O	O
to	O	O
32	O	O
.	O	O

6	O	O
R	O	O
units	O	O
after	O	O
treatment	O	O
(	O	O
SED	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

4	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

025	O	O
)	O	O
.	O	O

The	O	O
rise	O	O
in	O	O
forearm	O	O
vascular	O	O
resistance	O	O
accompanying	O	O
intra	O	O
-	O	O
arterial	O	O
norepinephrine	B-Chemical	D009638
(	O	O
25	O	O
,	O	O
50	O	O
,	O	O
and	O	O
100	O	O
ng	O	O
/	O	O
min	O	O
)	O	O
was	O	O
also	O	O
significantly	O	O
greater	O	O
after	O	O
hydrocortisone	B-Chemical	D006854
,	O	O
increasing	O	O
from	O	O
an	O	O
average	O	O
of	O	O
14	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

4	O	O
R	O	O
units	O	O
before	O	O
treatment	O	O
to	O	O
35	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

5	O	O
R	O	O
units	O	O
after	O	O
hydrocortisone	B-Chemical	D006854
(	O	O
SED	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

0	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

A	O	O
shift	O	O
to	O	O
the	O	O
left	O	O
in	O	O
the	O	O
dose	O	O
-	O	O
response	O	O
relation	O	O
and	O	O
fall	O	O
in	O	O
threshold	O	O
suggested	O	O
increased	O	O
sensitivity	O	O
to	O	O
norepinephrine	B-Chemical	D009638
after	O	O
treatment	O	O
.	O	O

Measurement	O	O
of	O	O
resting	O	O
norepinephrine	B-Chemical	D009638
spillover	O	O
rate	O	O
to	O	O
plasma	O	O
and	O	O
norepinephrine	B-Chemical	D009638
uptake	O	O
indicated	O	O
that	O	O
overall	O	O
resting	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
was	O	O
not	O	O
increased	O	O
.	O	O

The	O	O
rise	B-Disease	D006973
in	I-Disease	D006973
resting	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
with	O	O
hydrocortisone	B-Chemical	D006854
is	O	O
associated	O	O
with	O	O
an	O	O
increased	B-Disease	D016534
cardiac	I-Disease	D016534
output	I-Disease	D016534
(	O	O
presumably	O	O
due	O	O
to	O	O
increased	O	O
blood	O	O
volume	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Effects	O	O
of	O	O
suprofen	B-Chemical	D013496
on	O	O
the	O	O
isolated	O	O
perfused	O	O
rat	O	O
kidney	O	O
.	O	O

Although	O	O
suprofen	B-Chemical	D013496
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
in	O	O
greater	O	O
than	O	O
100	O	O
subjects	O	O
,	O	O
the	O	O
mechanism	O	O
of	O	O
damage	O	O
remains	O	O
unclear	O	O
.	O	O

The	O	O
direct	O	O
nephrotoxic	B-Disease	D007674
effects	O	O
of	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
15	O	O
mg	O	O
of	O	O
suprofen	B-Chemical	D013496
were	O	O
compared	O	O
in	O	O
the	O	O
recirculating	O	O
isolated	O	O
rat	O	O
kidney	O	O
perfused	O	O
with	O	O
cell	O	O
-	O	O
free	O	O
buffer	O	O
with	O	O
or	O	O
without	O	O
the	O	O
addition	O	O
of	O	O
5	O	O
mg	O	O
/	O	O
dL	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
renal	O	O
sodium	B-Chemical	D012964
excretion	O	O
,	O	O
oxygen	B-Chemical	D010100
consumption	O	O
,	O	O
or	O	O
urinary	O	O
flow	O	O
rates	O	O
in	O	O
kidneys	O	O
perfused	O	O
with	O	O
suprofen	B-Chemical	D013496
compared	O	O
with	O	O
the	O	O
drug	O	O
-	O	O
free	O	O
control	O	O
groups	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
significant	O	O
decline	O	O
in	O	O
glomerular	O	O
filtration	O	O
rate	O	O
was	O	O
found	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
suprofen	B-Chemical	D013496
to	O	O
the	O	O
kidney	O	O
perfused	O	O
with	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
;	O	O
no	O	O
changes	O	O
were	O	O
found	O	O
with	O	O
suprofen	B-Chemical	D013496
in	O	O
the	O	O
absence	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
.	O	O

A	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
baseline	O	O
excretion	O	O
rate	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
was	O	O
found	O	O
in	O	O
rats	O	O
given	O	O
suprofen	B-Chemical	D013496
,	O	O
compared	O	O
with	O	O
drug	O	O
-	O	O
free	O	O
controls	O	O
.	O	O

However	O	O
,	O	O
the	O	O
fractional	O	O
excretion	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
was	O	O
unchanged	O	O
between	O	O
the	O	O
groups	O	O
over	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
suprofen	B-Chemical	D013496
causes	O	O
acute	B-Disease	D058186
declines	I-Disease	D058186
in	I-Disease	D058186
renal	I-Disease	D058186
function	I-Disease	D058186
,	O	O
most	O	O
likely	O	O
by	O	O
directly	O	O
altering	O	O
the	O	O
intrarenal	O	O
distribution	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
brainstem	O	O
seizures	B-Disease	D012640
and	O	O
behavior	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
abnormal	O	O
sensory	O	O
/	O	O
motor	O	O
behaviors	O	O
associated	O	O
with	O	O
electrical	O	O
discharges	O	O
recorded	O	O
from	O	O
the	O	O
bilateral	O	O
brainstem	O	O
were	O	O
induced	O	O
in	O	O
adult	O	O
WKY	O	O
rats	O	O
by	O	O
mechanical	O	O
(	O	O
electrode	O	O
implants	O	O
)	O	O
and	O	O
DC	O	O
electrical	O	O
current	O	O
stimulations	O	O
and	O	O
by	O	O
acute	O	O
and	O	O
chronic	O	O
administration	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

The	O	O
electrode	O	O
implant	O	O
implicated	O	O
one	O	O
side	O	O
or	O	O
the	O	O
other	O	O
of	O	O
the	O	O
reticular	O	O
system	O	O
of	O	O
the	O	O
brainstem	O	O
but	O	O
subjects	O	O
were	O	O
not	O	O
incapacitated	O	O
by	O	O
the	O	O
stimulations	O	O
.	O	O

Cocaine	B-Chemical	D003042
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
injected	O	O
subcutaneously	O	O
for	O	O
an	O	O
acute	O	O
experiment	O	O
and	O	O
subsequent	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
doses	O	O
twice	O	O
daily	O	O
for	O	O
3	O	O
days	O	O
in	O	O
a	O	O
chronic	O	O
study	O	O
.	O	O

Cocaine	B-Chemical	D003042
generated	O	O
more	O	O
abnormal	O	O
behaviors	O	O
in	O	O
the	O	O
brainstem	O	O
perturbation	O	O
group	O	O
,	O	O
especially	O	O
the	O	O
electrically	O	O
perturbated	O	O
subjects	O	O
.	O	O

The	O	O
abnormal	O	O
behaviors	O	O
were	O	O
yawning	O	O
,	O	O
retrocollis	O	O
,	O	O
hyperactivity	B-Disease	D006948
,	O	O
hypersensitivity	B-Disease	D004342
,	O	O
"beating	O	O
drum"	O	O
behavior	O	O
,	O	O
squealing	O	O
,	O	O
head	O	O
bobbing	O	O
,	O	O
circling	O	O
,	O	O
sniffing	O	O
,	O	O
abnormal	O	O
posturing	O	O
,	O	O
and	O	O
facial	O	O
twitching	O	O
.	O	O

Shifts	O	O
in	O	O
the	O	O
power	O	O
frequency	O	O
spectra	O	O
of	O	O
the	O	O
discharge	O	O
patterns	O	O
were	O	O
noted	O	O
between	O	O
quiet	O	O
and	O	O
pacing	O	O
behavioral	O	O
states	O	O
.	O	O

Hypersensitivity	B-Disease	D004342
to	O	O
various	O	O
auditory	O	O
,	O	O
tactile	O	O
,	O	O
and	O	O
visual	O	O
stimulation	O	O
was	O	O
present	O	O
and	O	O
shifts	O	O
in	O	O
the	O	O
brainstem	O	O
ambient	O	O
power	O	O
spectral	O	O
frequency	O	O
occurred	O	O
in	O	O
response	O	O
to	O	O
tactile	O	O
stimulation	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
brainstem	O	O
generates	O	O
and	O	O
propagates	O	O
pathological	O	O
discharges	O	O
that	O	O
can	O	O
be	O	O
elicited	O	O
by	O	O
mechanical	O	O
and	O	O
DC	O	O
electrical	O	O
perturbation	O	O
.	O	O

Cocaine	B-Chemical	D003042
was	O	O
found	O	O
to	O	O
activate	O	O
the	O	O
discharge	O	O
system	O	O
and	O	O
thus	O	O
induce	O	O
abnormal	O	O
behaviors	O	O
that	O	O
are	O	O
generated	O	O
at	O	O
the	O	O
discharge	O	O
site	O	O
and	O	O
at	O	O
distant	O	O
sites	O	O
to	O	O
which	O	O
the	O	O
discharge	O	O
propagates	O	O
.	O	O

Cognitive	O	O
functions	O	O
may	O	O
also	O	O
be	O	O
involved	O	O
since	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
cellular	O	O
elements	O	O
at	O	O
the	O	O
brainstem	O	O
level	O	O
are	O	O
also	O	O
implicated	O	O
.	O	O

Increased	O	O
sulfation	O	O
and	O	O
decreased	O	O
7alpha	O	O
-	O	O
hydroxylation	O	O
of	O	O
deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
in	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
-	O	O
induced	O	O
cholestasis	B-Disease	D002779
in	O	O
rats	O	O
.	O	O

Deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
conjugation	O	O
,	O	O
transport	O	O
capacity	O	O
,	O	O
and	O	O
metabolism	O	O
were	O	O
compared	O	O
in	O	O
control	O	O
and	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
-	O	O
treated	O	O
rats	O	O
.	O	O

Control	O	O
rats	O	O
were	O	O
found	O	O
to	O	O
have	O	O
a	O	O
lower	O	O
capacity	O	O
to	O	O
transport	O	O
deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
than	O	O
taurodeoxycholic	B-Chemical	D013657
acid	I-Chemical	D013657
,	O	O
and	O	O
both	O	O
were	O	O
decreased	O	O
by	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
treatment	O	O
.	O	O

During	O	O
[	O	O
24	O	O
-	O	O
14C	O	O
]	O	O
sodium	B-Chemical	D003840
deoxycholate	I-Chemical	D003840
infusion	O	O
,	O	O
[	O	O
14C	O	O
]	O	O
biliary	O	O
bile	B-Chemical	D001647
acid	I-Chemical	D001647
secretion	O	O
increased	O	O
,	O	O
but	O	O
bile	O	O
flow	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
in	O	O
either	O	O
control	O	O
or	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
-	O	O
treated	O	O
rats	O	O
.	O	O

Ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
-	O	O
treated	O	O
animals	O	O
excreted	O	O
significantly	O	O
less	O	O
14C	O	O
as	O	O
taurocholic	B-Chemical	D013656
acid	I-Chemical	D013656
than	O	O
did	O	O
control	O	O
animals	O	O
,	O	O
consistent	O	O
with	O	O
an	O	O
impairment	O	O
of	O	O
7alpha	O	O
-	O	O
hydroxylation	O	O
of	O	O
taurodeoxycholic	B-Chemical	D013657
acid	I-Chemical	D013657
.	O	O

Ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
treatment	O	O
did	O	O
not	O	O
impair	O	O
conjugation	O	O
of	O	O
deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
,	O	O
but	O	O
did	O	O
result	O	O
in	O	O
an	O	O
increase	O	O
in	O	O
sulfation	O	O
of	O	O
taurodeoxycholic	B-Chemical	D013657
acid	I-Chemical	D013657
from	O	O
1	O	O
.	O	O

5%	O	O
in	O	O
controls	O	O
to	O	O
nearly	O	O
4	O	O
.	O	O

0%	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

These	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
rat	O	O
has	O	O
a	O	O
poorer	O	O
tolerance	O	O
for	O	O
deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
than	O	O
do	O	O
certain	O	O
other	O	O
species	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
rat	O	O
converts	O	O
deoxycholic	B-Chemical	D003840
acid	I-Chemical	D003840
,	O	O
a	O	O
poor	O	O
choleretic	O	O
,	O	O
to	O	O
taurocholic	B-Chemical	D013656
acid	I-Chemical	D013656
,	O	O
a	O	O
good	O	O
choleretic	O	O
.	O	O

When	O	O
this	O	O
conversion	O	O
is	O	O
impaired	O	O
with	O	O
ethinyl	B-Chemical	D004997
estradiol	I-Chemical	D004997
treatment	O	O
,	O	O
sulfation	O	O
may	O	O
be	O	O
an	O	O
important	O	O
alternate	O	O
pathway	O	O
for	O	O
excretion	O	O
of	O	O
this	O	O
potentially	O	O
harmful	O	O
bile	B-Chemical	D001647
acid	I-Chemical	D001647
.	O	O

Effects	O	O
of	O	O
ouabain	B-Chemical	D010042
on	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
supply	O	O
and	O	O
demand	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

A	O	O
hemodynamic	O	O
,	O	O
volumetric	O	O
,	O	O
and	O	O
metabolic	O	O
study	O	O
in	O	O
patients	O	O
without	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

The	O	O
effects	O	O
of	O	O
digitalis	B-Chemical	D004071
glycosides	I-Chemical	D004071
on	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
supply	O	O
and	O	O
demand	O	O
are	O	O
of	O	O
particular	O	O
interest	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
obstructive	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
but	O	O
have	O	O
not	O	O
been	O	O
measured	O	O
previously	O	O
in	O	O
man	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
effects	O	O
of	O	O
ouabain	B-Chemical	D010042
(	O	O
0	O	O
.	O	O

015	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
on	O	O
hemodynamic	O	O
,	O	O
volumetric	O	O
,	O	O
and	O	O
metabolic	O	O
parameters	O	O
in	O	O
11	O	O
patients	O	O
with	O	O
severe	O	O
chronic	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
without	O	O
clinical	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
.	O	O

Because	O	O
the	O	O
protocol	O	O
was	O	O
long	O	O
and	O	O
involved	O	O
interventions	O	O
which	O	O
might	O	O
affect	O	O
the	O	O
determinations	O	O
,	O	O
we	O	O
also	O	O
studied	O	O
in	O	O
nine	O	O
patients	O	O
using	O	O
an	O	O
identical	O	O
protocol	O	O
except	O	O
that	O	O
ouabain	B-Chemical	D010042
administration	O	O
was	O	O
omitted	O	O
.	O	O

Left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
and	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
fell	O	O
in	O	O
each	O	O
patient	O	O
given	O	O
ouabain	B-Chemical	D010042
,	O	O
even	O	O
though	O	O
they	O	O
were	O	O
initially	O	O
elevated	O	O
in	O	O
only	O	O
two	O	O
patients	O	O
.	O	O

Left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
fell	O	O
from	O	O
11	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

4	O	O
(	O	O
mean+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
to	O	O
5	O	O
.	O	O

6+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
mm	O	O
Hg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
fell	O	O
from	O	O
100+	O	O
/	O	O
-	O	O
17	O	O
to	O	O
82+	O	O
/	O	O
-	O	O
12	O	O
ml	O	O
/	O	O
m2	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
1	O	O
h	O	O
after	O	O
ouabain	B-Chemical	D010042
infusion	O	O
was	O	O
completed	O	O
.	O	O

The	O	O
maximum	O	O
velocity	O	O
of	O	O
contractile	O	O
element	O	O
shortening	O	O
increased	O	O
from	O	O
1	O	O
.	O	O

68+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

11	O	O
ml	O	O
/	O	O
s	O	O
to	O	O
2	O	O
.	O	O

18+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

21	O	O
muscle	O	O
-	O	O
lengths	O	O
/	O	O
s	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
is	O	O
consistent	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
contractility	O	O
.	O	O

No	O	O
significant	O	O
change	O	O
in	O	O
these	O	O
parameters	O	O
occurred	O	O
in	O	O
the	O	O
control	O	O
patients	O	O
.	O	O

No	O	O
significant	O	O
change	O	O
in	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
occurred	O	O
after	O	O
ouabain	B-Chemical	D010042
administration	O	O
but	O	O
this	O	O
may	O	O
be	O	O
related	O	O
to	O	O
a	O	O
greater	O	O
decrease	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
in	O	O
the	O	O
ouabain	B-Chemical	D010042
patients	O	O
than	O	O
in	O	O
the	O	O
control	O	O
patients	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
who	O	O
are	O	O
not	O	O
in	O	O
clinical	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
left	B-Disease	D002303
ventricular	I-Disease	D002303
end	I-Disease	D002303
-	I-Disease	D002303
diastolic	I-Disease	D002303
volume	I-Disease	D002303
falls	I-Disease	D002303
after	O	O
ouabain	B-Chemical	D010042
administration	O	O
even	O	O
when	O	O
it	O	O
is	O	O
initially	O	O
normal	O	O
.	O	O

Though	O	O
this	O	O
fall	O	O
would	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
wall	O	O
tension	O	O
,	O	O
and	O	O
,	O	O
therefore	O	O
,	O	O
of	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
,	O	O
it	O	O
may	O	O
not	O	O
be	O	O
of	O	O
sufficient	O	O
magnitude	O	O
to	O	O
prevent	O	O
a	O	O
net	O	O
increase	O	O
in	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
.	O	O

Nevertheless	O	O
,	O	O
compensatory	O	O
mechanisms	O	O
prevent	O	O
a	O	O
deterioration	O	O
of	O	O
resting	O	O
myocardial	O	O
metabolism	O	O
.	O	O

Prolongation	B-Disease	D008133
of	I-Disease	D008133
the	I-Disease	D008133
QT	I-Disease	D008133
interval	I-Disease	D008133
related	O	O
to	O	O
cisapride	B-Chemical	D020117
-	O	O
diltiazem	B-Chemical	D004110
interaction	O	O
.	O	O

Cisapride	B-Chemical	D020117
,	O	O
a	O	O
cytochrome	O	O
P450	O	O
3A4	O	O
(	O	O
CYP3A4	O	O
)	O	O
substrate	O	O
,	O	O
is	O	O
widely	O	O
prescribed	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
gastrointestinal	B-Disease	D015835
motility	I-Disease	D015835
disorders	I-Disease	D015835
.	O	O

Prolongation	B-Disease	D008133
of	I-Disease	D008133
QT	I-Disease	D008133
interval	I-Disease	D008133
,	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
,	O	O
and	O	O
sudden	B-Disease	D016757
cardiac	I-Disease	D016757
death	I-Disease	D016757
have	O	O
been	O	O
reported	O	O
after	O	O
concomitant	O	O
administration	O	O
with	O	O
erythromycin	B-Chemical	D004917
or	O	O
azole	B-Chemical	D001393
antifungal	O	O
agents	O	O
,	O	O
but	O	O
not	O	O
with	O	O
other	O	O
CYP3A4	O	O
inhibitors	O	O
.	O	O

A	O	O
possible	O	O
drug	O	O
interaction	O	O
occurred	O	O
in	O	O
a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
was	O	O
taking	O	O
cisapride	B-Chemical	D020117
for	O	O
gastroesophageal	B-Disease	D005764
reflux	I-Disease	D005764
disorder	I-Disease	D005764
and	O	O
diltiazem	B-Chemical	D004110
,	O	O
an	O	O
agent	O	O
that	O	O
has	O	O
inhibitory	O	O
effect	O	O
on	O	O
CYP3A4	O	O
,	O	O
for	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
patient	O	O
was	O	O
in	O	O
near	O	O
syncope	B-Disease	D013575
and	O	O
had	O	O
QT	B-Disease	D008133
-	I-Disease	D008133
interval	I-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

After	O	O
discontinuing	O	O
cisapride	B-Chemical	D020117
,	O	O
the	O	O
QT	O	O
interval	O	O
returned	O	O
to	O	O
normal	O	O
and	O	O
symptoms	O	O
did	O	O
not	O	O
recur	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
caution	O	O
be	O	O
taken	O	O
when	O	O
cisapride	B-Chemical	D020117
is	O	O
prescribed	O	O
with	O	O
any	O	O
potent	O	O
inhibitor	O	O
of	O	O
CYP3A4	O	O
,	O	O
including	O	O
diltiazem	B-Chemical	D004110
.	O	O

Paclitaxel	B-Chemical	D017239
combined	O	O
with	O	O
carboplatin	B-Chemical	D016190
in	O	O
the	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
advanced	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

In	O	O
a	O	O
phase	O	O
I	O	O
study	O	O
to	O	O
determine	O	O
the	O	O
maximum	O	O
tolerated	O	O
dose	O	O
of	O	O
paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
;	O	O
Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
given	O	O
as	O	O
a	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
in	O	O
combination	O	O
with	O	O
carboplatin	B-Chemical	D016190
administered	O	O
every	O	O
21	O	O
days	O	O
to	O	O
women	O	O
with	O	O
advanced	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
paclitaxel	B-Chemical	D017239
doses	O	O
were	O	O
escalated	O	O
as	O	O
follows	O	O
:	O	O
level	O	O
1	O	O
,	O	O
135	O	O
mg	O	O
/	O	O
m2	O	O
;	O	O
level	O	O
2	O	O
,	O	O
160	O	O
mg	O	O
/	O	O
m2	O	O
;	O	O
level	O	O
3	O	O
,	O	O
185	O	O
mg	O	O
/	O	O
m2	O	O
;	O	O
and	O	O
level	O	O
4	O	O
,	O	O
210	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

The	O	O
fixed	O	O
dose	O	O
of	O	O
carboplatin	B-Chemical	D016190
at	O	O
levels	O	O
1	O	O
through	O	O
4	O	O
was	O	O
given	O	O
to	O	O
achieve	O	O
an	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
-	O	O
time	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
of	O	O
5	O	O
using	O	O
the	O	O
Calvert	O	O
formula	O	O
.	O	O

In	O	O
levels	O	O
5	O	O
and	O	O
6	O	O
the	O	O
carboplatin	B-Chemical	D016190
dose	O	O
was	O	O
targeted	O	O
at	O	O
AUCs	O	O
of	O	O
6	O	O
and	O	O
7	O	O
.	O	O

5	O	O
,	O	O
respectively	O	O
,	O	O
combined	O	O
with	O	O
a	O	O
fixed	O	O
paclitaxel	B-Chemical	D017239
dose	O	O
of	O	O
185	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

To	O	O
date	O	O
,	O	O
30	O	O
previously	O	O
untreated	O	O
patients	O	O
,	O	O
all	O	O
with	O	O
a	O	O
good	O	O
performance	O	O
status	O	O
(	O	O
Eastern	O	O
Cooperative	O	O
Oncology	O	O
Group	O	O
0	O	O
to	O	O
2	O	O
)	O	O
have	O	O
been	O	O
entered	O	O
into	O	O
this	O	O
ongoing	O	O
study	O	O
.	O	O

The	O	O
dose	O	O
-	O	O
limiting	O	O
toxicity	B-Disease	D064420
of	O	O
the	O	O
combination	O	O
was	O	O
myelosuppression	B-Disease	D001855
(	O	O
leukopenia	B-Disease	D007970
,	O	O
granulocytopenia	B-Disease	D000380
,	O	O
and	O	O
thrombocytopenia	B-Disease	D013921
)	O	O
.	O	O

Neurotoxicity	B-Disease	D020258
was	O	O
largely	O	O
moderate	O	O
.	O	O

So	O	O
far	O	O
,	O	O
14	O	O
patients	O	O
are	O	O
evaluable	O	O
for	O	O
response	O	O
;	O	O
of	O	O
these	O	O
,	O	O
eight	O	O
(	O	O
57%	O	O
)	O	O
showed	O	O
objective	O	O
(	O	O
complete	O	O
or	O	O
partial	O	O
)	O	O
response	O	O
and	O	O
disease	O	O
stabilized	O	O
in	O	O
six	O	O
patients	O	O
.	O	O

No	O	O
patient	O	O
had	O	O
disease	O	O
progression	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
combination	O	O
of	O	O
paclitaxel	B-Chemical	D017239
185	O	O
mg	O	O
/	O	O
m2	O	O
administered	O	O
as	O	O
a	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
followed	O	O
immediately	O	O
by	O	O
a	O	O
1	O	O
-	O	O
hour	O	O
infusion	O	O
of	O	O
carboplatin	B-Chemical	D016190
at	O	O
an	O	O
AUC	O	O
of	O	O
6	O	O
can	O	O
be	O	O
administered	O	O
safely	O	O
in	O	O
a	O	O
21	O	O
-	O	O
day	O	O
schedule	O	O
in	O	O
the	O	O
outpatient	O	O
setting	O	O
.	O	O

The	O	O
recommended	O	O
dose	O	O
for	O	O
phase	O	O
III	O	O
studies	O	O
is	O	O
paclitaxel	B-Chemical	D017239
185	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
carboplatin	B-Chemical	D016190
AUC	O	O
6	O	O
.	O	O

Treatment	O	O
of	O	O
tacrolimus	B-Chemical	D016559
-	O	O
related	O	O
adverse	O	O
effects	O	O
by	O	O
conversion	O	O
to	O	O
cyclosporine	B-Chemical	D016572
in	O	O
liver	O	O
transplant	O	O
recipients	O	O
.	O	O

When	O	O
tacrolimus	B-Chemical	D016559
side	O	O
effects	O	O
persist	O	O
despite	O	O
dose	O	O
reduction	O	O
,	O	O
conversion	O	O
to	O	O
cyclosporine	B-Chemical	D016572
-	O	O
based	O	O
immunosuppression	O	O
(	O	O
CyA	O	O
)	O	O
is	O	O
necessary	O	O
.	O	O

We	O	O
characterized	O	O
tacrolimus	B-Chemical	D016559
side	O	O
effects	O	O
that	O	O
warranted	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
,	O	O
and	O	O
outcomes	O	O
after	O	O
conversion	O	O
.	O	O

Of	O	O
388	O	O
liver	O	O
recipients	O	O
who	O	O
received	O	O
tacrolimus	B-Chemical	D016559
as	O	O
primary	O	O
immunosuppression	O	O
,	O	O
70	O	O
required	O	O
conversion	O	O
to	O	O
CyA	O	O
.	O	O

We	O	O
recorded	O	O
indication	O	O
for	O	O
conversion	O	O
,	O	O
whether	O	O
conversion	O	O
was	O	O
early	O	O
or	O	O
late	O	O
after	O	O
transplantation	O	O
,	O	O
tacrolimus	B-Chemical	D016559
dose	O	O
and	O	O
trough	O	O
blood	O	O
level	O	O
at	O	O
conversion	O	O
,	O	O
and	O	O
incidence	O	O
of	O	O
rejection	O	O
after	O	O
conversion	O	O
.	O	O

Conversion	O	O
was	O	O
early	O	O
in	O	O
29	O	O
patients	O	O
(	O	O
41	O	O
.	O	O

4%	O	O
)	O	O
and	O	O
late	O	O
in	O	O
41	O	O
(	O	O
58	O	O
.	O	O

6%	O	O
)	O	O
.	O	O

Indications	O	O
for	O	O
early	O	O
conversion	O	O
were	O	O
neurotoxicity	B-Disease	D020258
(	O	O
20	O	O
)	O	O
,	O	O
(	B-Disease	D003922
insulin	I-Disease	D003922
-	I-Disease	D003922
dependent	I-Disease	D003922
)	I-Disease	D003922
diabetes	I-Disease	D003922
mellitus	I-Disease	D003922
(	O	O
IDDM	B-Disease	D003922
)	O	O
(	O	O
5	O	O
)	O	O
,	O	O
nephrotoxicity	B-Disease	D007674
(	O	O
3	O	O
)	O	O
,	O	O
gastrointestinal	B-Disease	D005767
(	I-Disease	D005767
GI	I-Disease	D005767
)	I-Disease	D005767
toxicity	I-Disease	D005767
(	O	O
6	O	O
)	O	O
,	O	O
and	O	O
cardiomyopathy	B-Disease	D009202
(	O	O
1	O	O
)	O	O
,	O	O
and	O	O
for	O	O
late	O	O
conversion	O	O
were	O	O
neurotoxicity	B-Disease	D020258
(	O	O
15	O	O
)	O	O
,	O	O
IDDM	B-Disease	D003922
(	O	O
12	O	O
)	O	O
,	O	O
nephrotoxicity	B-Disease	D007674
(	O	O
3	O	O
)	O	O
,	O	O
GI	B-Disease	D005767
toxicity	I-Disease	D005767
(	O	O
5	O	O
)	O	O
,	O	O
hepatotoxicity	B-Disease	D056486
(	O	O
6	O	O
)	O	O
,	O	O
post	B-Disease	D008232
-	I-Disease	D008232
transplant	I-Disease	D008232
lmphoproliferate	I-Disease	D008232
disease	I-Disease	D008232
(	O	O
PTLD	B-Disease	D008232
)	O	O
(	O	O
2	O	O
)	O	O
,	O	O
cardiomyopathy	B-Disease	D009202
(	O	O
1	O	O
)	O	O
,	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
(	O	O
1	O	O
)	O	O
,	O	O
and	O	O
pruritus	B-Disease	D011537
(	O	O
1	O	O
)	O	O
.	O	O

All	O	O
early	O	O
-	O	O
conversion	O	O
patients	O	O
showed	O	O
improvement	O	O
/	O	O
resolution	O	O
of	O	O
symptoms	O	O
.	O	O

Among	O	O
late	O	O
-	O	O
conversion	O	O
patients	O	O
,	O	O
37	O	O
(	O	O
90	O	O
.	O	O

2%	O	O
)	O	O
had	O	O
improvement	O	O
/	O	O
resolution	O	O
;	O	O
in	O	O
4	O	O
(	O	O
9	O	O
.	O	O

8%	O	O
)	O	O
,	O	O
adverse	O	O
effects	O	O
persisted	O	O
.	O	O

The	O	O
overall	O	O
rejection	O	O
rate	O	O
was	O	O
30%	O	O
.	O	O

Sixty	O	O
-	O	O
two	O	O
patients	O	O
(	O	O
88	O	O
.	O	O

6%	O	O
)	O	O
are	O	O
alive	O	O
with	O	O
functioning	O	O
grafts	O	O
686	O	O
+	O	O
/	O	O
-	O	O
362	O	O
days	O	O
(	O	O
range	O	O
,	O	O
154	O	O
-	O	O
1433	O	O
days	O	O
)	O	O
after	O	O
conversion	O	O
.	O	O

When	O	O
tacrolimus	B-Chemical	D016559
side	O	O
effects	O	O
are	O	O
unresponsive	O	O
to	O	O
dose	O	O
reduction	O	O
,	O	O
conversion	O	O
to	O	O
CyA	O	O
can	O	O
be	O	O
accomplished	O	O
safely	O	O
,	O	O
with	O	O
no	O	O
increased	O	O
risk	O	O
of	O	O
rejection	O	O
and	O	O
excellent	O	O
long	O	O
-	O	O
term	O	O
outcome	O	O
.	O	O

Relative	O	O
efficacy	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
netilmicin	B-Chemical	D009428
and	O	O
tobramycin	B-Chemical	D014031
in	O	O
oncology	O	O
patients	O	O
.	O	O

We	O	O
prospectively	O	O
compared	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
netilmicin	B-Chemical	D009428
sulfate	O	O
or	O	O
tobramycin	B-Chemical	D014031
sulfate	O	O
in	O	O
conjunction	O	O
with	O	O
piperacillin	B-Chemical	D010878
sodium	I-Chemical	D010878
in	O	O
118	O	O
immunocompromised	O	O
patients	O	O
with	O	O
presumed	O	O
severe	O	O
infections	B-Disease	D007239
.	O	O

The	O	O
two	O	O
treatment	O	O
regimens	O	O
were	O	O
equally	O	O
efficacious	O	O
.	O	O

Nephrotoxicity	B-Disease	D007674
occurred	O	O
in	O	O
a	O	O
similar	O	O
proportion	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
netilmicin	B-Chemical	D009428
and	O	O
tobramycin	B-Chemical	D014031
(	O	O
17%	O	O
vs	O	O
11%	O	O
)	O	O
.	O	O

Ototoxicity	B-Disease	D006311
occurred	O	O
in	O	O
four	O	O
(	O	O
9	O	O
.	O	O

5%	O	O
)	O	O
of	O	O
42	O	O
netilmicin	B-Chemical	D009428
and	O	O
piperacillin	B-Chemical	D010878
and	O	O
in	O	O
12	O	O
(	O	O
22%	O	O
)	O	O
of	O	O
54	O	O
tobramycin	B-Chemical	D014031
and	O	O
piperacillin	B-Chemical	D010878
-	O	O
treated	O	O
patients	O	O
.	O	O

Of	O	O
those	O	O
evaluated	O	O
with	O	O
posttherapy	O	O
audiograms	O	O
,	O	O
three	O	O
of	O	O
four	O	O
netilmicin	B-Chemical	D009428
and	O	O
piperacillin	B-Chemical	D010878
-	O	O
treated	O	O
patients	O	O
had	O	O
auditory	O	O
thresholds	O	O
return	O	O
to	O	O
baseline	O	O
compared	O	O
with	O	O
one	O	O
of	O	O
nine	O	O
tobramycin	B-Chemical	D014031
and	O	O
piperacillin	B-Chemical	D010878
-	O	O
treated	O	O
patients	O	O
.	O	O

The	O	O
number	O	O
of	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
15	O	O
-	O	O
dB	O	O
increases	O	O
in	O	O
auditory	O	O
threshold	O	O
as	O	O
a	O	O
proportion	O	O
of	O	O
total	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
15	O	O
-	O	O
dB	O	O
changes	O	O
(	O	O
increases	O	O
and	O	O
decreases	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
netilmicin	B-Chemical	D009428
and	O	O
piperacillin	B-Chemical	D010878
-	O	O
vs	O	O
tobramycin	B-Chemical	D014031
and	O	O
piperacillin	B-Chemical	D010878
-	O	O
treated	O	O
patients	O	O
(	O	O
18	O	O
of	O	O
78	O	O
vs	O	O
67	O	O
of	O	O
115	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
associated	O	O
ototoxicity	B-Disease	D006311
was	O	O
less	O	O
severe	O	O
and	O	O
more	O	O
often	O	O
reversible	O	O
with	O	O
netilmicin	B-Chemical	D009428
than	O	O
with	O	O
tobramycin	B-Chemical	D014031
.	O	O

Effect	O	O
of	O	O
prostaglandin	B-Chemical	D011453
synthetase	O	O
inhibitors	O	O
on	O	O
experimentally	O	O
induced	O	O
convulsions	B-Disease	D012640
in	O	O
rats	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
relationship	O	O
of	O	O
prostaglandins	B-Chemical	D011453
(	O	O
PGs	B-Chemical	D011453
)	O	O
to	O	O
seizure	B-Disease	D012640
induction	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
six	O	O
PG	O	O
synthetase	O	O
inhibitors	O	O
on	O	O
convulsions	B-Disease	D012640
induced	O	O
by	O	O
flurothyl	B-Chemical	D005481
,	O	O
picrotoxin	B-Chemical	D010852
,	O	O
pentetrazol	B-Chemical	D010433
(	O	O
PTZ	B-Chemical	D010433
)	O	O
,	O	O
electroshock	O	O
or	O	O
bicuculline	B-Chemical	D001640
were	O	O
evaluated	O	O
.	O	O

Ibuprofen	B-Chemical	D007052
,	O	O
sulindac	B-Chemical	D013467
,	O	O
mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
,	O	O
and	O	O
low	O	O
dose	O	O
meclofenamic	B-Chemical	D008469
acid	I-Chemical	D008469
increased	O	O
the	O	O
latency	O	O
-	O	O
to	O	O
-	O	O
onset	O	O
in	O	O
the	O	O
flurothyl	B-Chemical	D005481
and	O	O
/	O	O
or	O	O
PTZ	B-Chemical	D010433
models	O	O
;	O	O
the	O	O
electroshock	O	O
,	O	O
picrotoxin	B-Chemical	D010852
and	O	O
bicuculline	B-Chemical	D001640
models	O	O
were	O	O
not	O	O
significantly	O	O
affected	O	O
by	O	O
any	O	O
of	O	O
the	O	O
pretreatment	O	O
agents	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
PGs	B-Chemical	D011453
are	O	O
involved	O	O
in	O	O
the	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
underlying	O	O
fluorthyl	B-Chemical	D005481
-	O	O
and	O	O
PTZ	B-Chemical	D010433
-	O	O
induced	O	O
convulsions	B-Disease	D012640
,	O	O
but	O	O
not	O	O
picrotoxin	B-Chemical	D010852
-	O	O
,	O	O
electroshock	O	O
-	O	O
,	O	O
or	O	O
bicuculline	B-Chemical	D001640
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

Angiotensin	O	O
-	O	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitor	O	O
-	O	O
associated	O	O
angioedema	B-Disease	D000799
of	O	O
the	O	O
stomach	O	O
and	O	O
small	O	O
intestine	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

This	O	O
is	O	O
a	O	O
case	O	O
report	O	O
on	O	O
a	O	O
45	O	O
-	O	O
year	O	O
old	O	O
African	O	O
-	O	O
American	O	O
female	O	O
with	O	O
newly	O	O
diagnosed	O	O
hypertension	B-Disease	D006973
,	O	O
who	O	O
was	O	O
started	O	O
on	O	O
a	O	O
combination	O	O
pill	O	O
of	O	O
amlodipine	B-Chemical	D017311
/	O	O
benazapril	B-Chemical	C044946
10	O	O
/	O	O
5	O	O
mg	O	O
.	O	O

The	O	O
very	O	O
next	O	O
day	O	O
,	O	O
she	O	O
presented	O	O
at	O	O
the	O	O
emergency	O	O
room	O	O
(	O	O
ER	O	O
)	O	O
with	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
,	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
.	O	O

Physical	O	O
exam	O	O
,	O	O
complete	O	O
metabolic	O	O
panel	O	O
,	O	O
and	O	O
hemogram	O	O
were	O	O
in	O	O
the	O	O
normal	O	O
range	O	O
.	O	O

She	O	O
was	O	O
discharged	O	O
from	O	O
the	O	O
ER	O	O
after	O	O
a	O	O
few	O	O
hours	O	O
of	O	O
treatment	O	O
with	O	O
fluid	O	O
and	O	O
analgesics	O	O
.	O	O

However	O	O
,	O	O
she	O	O
returned	O	O
to	O	O
the	O	O
ER	O	O
the	O	O
next	O	O
day	O	O
with	O	O
the	O	O
same	O	O
complaints	O	O
.	O	O

This	O	O
time	O	O
the	O	O
physical	O	O
exam	O	O
was	O	O
significant	O	O
for	O	O
a	O	O
distended	O	O
abdomen	O	O
with	O	O
dullness	O	O
to	O	O
percussion	O	O
.	O	O

CT	O	O
scan	O	O
of	O	O
the	O	O
abdomen	O	O
revealed	O	O
markedly	O	O
thickened	O	O
antrum	O	O
of	O	O
the	O	O
stomach	O	O
,	O	O
duodenum	O	O
and	O	O
jejunum	O	O
,	O	O
along	O	O
with	O	O
fluid	O	O
in	O	O
the	O	O
abdominal	O	O
and	O	O
pelvic	O	O
cavity	O	O
.	O	O

Angiotensin	O	O
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
(	O	O
ACEI	O	O
)	O	O
-	O	O
induced	O	O
angioedema	B-Disease	D000799
was	O	O
suspected	O	O
,	O	O
and	O	O
anti	O	O
-	O	O
hypertensive	B-Disease	D006973
medications	O	O
were	O	O
discontinued	O	O
.	O	O

Her	O	O
symptoms	O	O
improved	O	O
within	O	O
the	O	O
next	O	O
24	O	O
hours	O	O
,	O	O
and	O	O
repeat	O	O
CT	O	O
after	O	O
72	O	O
hours	O	O
revealed	O	O
marked	O	O
improvement	O	O
in	O	O
stomach	O	O
and	O	O
small	O	O
bowel	O	O
thickening	O	O
and	O	O
resolution	O	O
of	O	O
ascites	B-Disease	D001201
.	O	O

The	O	O
recognition	O	O
of	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
and	O	O
angiotensin	B-Chemical	D000809
receptor	O	O
blocker	O	O
(	O	O
ARB	O	O
)	O	O
intestinal	O	O
angioedema	B-Disease	D000799
constitutes	O	O
a	O	O
challenge	O	O
to	O	O
primary	O	O
care	O	O
physicians	O	O
,	O	O
internists	O	O
,	O	O
emergency	O	O
room	O	O
personal	O	O
and	O	O
surgeons	O	O
.	O	O

Valproic	B-Chemical	D014635
acid	I-Chemical	D014635
I	O	O
:	O	O
time	O	O
course	O	O
of	O	O
lipid	O	O
peroxidation	O	O
biomarkers	O	O
,	O	O
liver	B-Disease	D056486
toxicity	I-Disease	D056486
,	O	O
and	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
metabolite	O	O
levels	O	O
in	O	O
rats	O	O
.	O	O

A	O	O
single	O	O
dose	O	O
of	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
widely	O	O
used	O	O
antiepileptic	O	O
drug	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
oxidative	O	O
stress	O	O
in	O	O
rats	O	O
,	O	O
as	O	O
recently	O	O
demonstrated	O	O
by	O	O
elevated	O	O
levels	O	O
of	O	O
15	B-Chemical	C075750
-	I-Chemical	C075750
F	I-Chemical	C075750
(	I-Chemical	C075750
2t	I-Chemical	C075750
)	I-Chemical	C075750
-	I-Chemical	C075750
isoprostane	I-Chemical	C075750
(	O	O
15	B-Chemical	C075750
-	I-Chemical	C075750
F	I-Chemical	C075750
(	I-Chemical	C075750
2t	I-Chemical	C075750
)	I-Chemical	C075750
-	I-Chemical	C075750
IsoP	I-Chemical	C075750
)	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
there	O	O
was	O	O
a	O	O
temporal	O	O
relationship	O	O
between	O	O
VPA	B-Chemical	D014635
-	O	O
associated	O	O
oxidative	O	O
stress	O	O
and	O	O
hepatotoxicity	B-Disease	D056486
,	O	O
adult	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
treated	O	O
ip	O	O
with	O	O
VPA	B-Chemical	D014635
(	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
0	O	O
.	O	O

9%	O	O
saline	O	O
(	O	O
vehicle	O	O
)	O	O
once	O	O
daily	O	O
for	O	O
2	O	O
,	O	O
4	O	O
,	O	O
7	O	O
,	O	O
10	O	O
,	O	O
or	O	O
14	O	O
days	O	O
.	O	O

Oxidative	O	O
stress	O	O
was	O	O
assessed	O	O
by	O	O
determining	O	O
plasma	O	O
and	O	O
liver	O	O
levels	O	O
of	O	O
15	B-Chemical	C075750
-	I-Chemical	C075750
F	I-Chemical	C075750
(	I-Chemical	C075750
2t	I-Chemical	C075750
)	I-Chemical	C075750
-	I-Chemical	C075750
IsoP	I-Chemical	C075750
,	O	O
lipid	B-Chemical	D008054
hydroperoxides	I-Chemical	D008054
(	O	O
LPO	B-Chemical	D008054
)	O	O
,	O	O
and	O	O
thiobarbituric	B-Chemical	D017392
acid	I-Chemical	D017392
reactive	I-Chemical	D017392
substances	I-Chemical	D017392
(	O	O
TBARs	B-Chemical	D017392
)	O	O
.	O	O

Plasma	O	O
and	O	O
liver	O	O
15	B-Chemical	C075750
-	I-Chemical	C075750
F	I-Chemical	C075750
(	I-Chemical	C075750
2t	I-Chemical	C075750
)	I-Chemical	C075750
-	I-Chemical	C075750
IsoP	I-Chemical	C075750
were	O	O
elevated	O	O
and	O	O
reached	O	O
a	O	O
plateau	O	O
after	O	O
day	O	O
2	O	O
of	O	O
VPA	B-Chemical	D014635
treatment	O	O
compared	O	O
to	O	O
control	O	O
.	O	O

Liver	O	O
LPO	B-Chemical	D008054
levels	O	O
were	O	O
not	O	O
elevated	O	O
until	O	O
day	O	O
7	O	O
of	O	O
treatment	O	O
(	O	O
1	O	O
.	O	O

8	O	O
-	O	O
fold	O	O
versus	O	O
control	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Liver	O	O
and	O	O
plasma	O	O
TBARs	B-Chemical	D017392
were	O	O
not	O	O
increased	O	O
until	O	O
14	O	O
days	O	O
(	O	O
2	O	O
-	O	O
fold	O	O
vs	O	O
.	O	O

control	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Liver	B-Disease	D056486
toxicity	I-Disease	D056486
was	O	O
evaluated	O	O
based	O	O
on	O	O
serum	O	O
levels	O	O
of	O	O
alpha	O	O
-	O	O
glutathione	B-Chemical	D005978
S	O	O
-	O	O
transferase	O	O
(	O	O
alpha	O	O
-	O	O
GST	O	O
)	O	O
and	O	O
by	O	O
histology	O	O
.	O	O

Serum	O	O
alpha	O	O
-	O	O
GST	O	O
levels	O	O
were	O	O
significantly	O	O
elevated	O	O
by	O	O
day	O	O
4	O	O
,	O	O
which	O	O
corresponded	O	O
to	O	O
hepatotoxicity	B-Disease	D056486
as	O	O
shown	O	O
by	O	O
the	O	O
increasing	O	O
incidence	O	O
of	O	O
inflammation	B-Disease	D007249
of	O	O
the	O	O
liver	O	O
capsule	O	O
,	O	O
necrosis	B-Disease	D009336
,	O	O
and	O	O
steatosis	B-Disease	D005234
throughout	O	O
the	O	O
study	O	O
.	O	O

The	O	O
liver	O	O
levels	O	O
of	O	O
beta	O	O
-	O	O
oxidation	O	O
metabolites	O	O
of	O	O
VPA	B-Chemical	D014635
were	O	O
decreased	O	O
by	O	O
day	O	O
14	O	O
,	O	O
while	O	O
the	O	O
levels	O	O
of	O	O
4	B-Chemical	C045022
-	I-Chemical	C045022
ene	I-Chemical	C045022
-	I-Chemical	C045022
VPA	I-Chemical	C045022
and	O	O
(	O	O
E	O	O
)	O	O
-	O	O
2	B-Chemical	C556631
,	I-Chemical	C556631
4	I-Chemical	C556631
-	I-Chemical	C556631
diene	I-Chemical	C556631
-	I-Chemical	C556631
VPA	I-Chemical	C556631
were	O	O
not	O	O
elevated	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Overall	O	O
,	O	O
these	O	O
findings	O	O
indicate	O	O
that	O	O
VPA	B-Chemical	D014635
treatment	O	O
results	O	O
in	O	O
oxidative	O	O
stress	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
levels	O	O
of	O	O
15	B-Chemical	C075750
-	I-Chemical	C075750
F	I-Chemical	C075750
(	I-Chemical	C075750
2t	I-Chemical	C075750
)	I-Chemical	C075750
-	I-Chemical	C075750
IsoP	I-Chemical	C075750
,	O	O
which	O	O
precedes	O	O
the	O	O
onset	O	O
of	O	O
necrosis	B-Disease	D009336
,	O	O
steatosis	B-Disease	D005234
,	O	O
and	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	O
alpha	O	O
-	O	O
GST	O	O
.	O	O

Pheochromocytoma	B-Disease	D010673
unmasked	O	O
by	O	O
amisulpride	B-Chemical	C012052
and	O	O
tiapride	B-Chemical	D063325
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
the	O	O
unmasking	O	O
of	O	O
pheochromocytoma	B-Disease	D010673
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
amisulpride	B-Chemical	C012052
and	O	O
tiapride	B-Chemical	D063325
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
42	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
man	O	O
developed	O	O
acute	O	O
hypertension	B-Disease	D006973
with	O	O
severe	O	O
headache	B-Disease	D006261
and	O	O
vomiting	B-Disease	D014839
2	O	O
hours	O	O
after	O	O
the	O	O
first	O	O
doses	O	O
of	O	O
amisulpride	B-Chemical	C012052
100	O	O
mg	O	O
and	O	O
tiapride	B-Chemical	D063325
100	O	O
mg	O	O
.	O	O

Both	O	O
drugs	O	O
were	O	O
immediately	O	O
discontinued	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
recovered	O	O
after	O	O
subsequent	O	O
nicardipine	B-Chemical	D009529
and	O	O
verapamil	B-Chemical	D014700
treatment	O	O
.	O	O

Abdominal	O	O
ultrasound	O	O
showed	O	O
an	O	O
adrenal	O	O
mass	O	O
,	O	O
and	O	O
postoperative	O	O
histologic	O	O
examination	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
of	O	O
pheochromocytoma	B-Disease	D010673
.	O	O

DISCUSSION	O	O
:	O	O
Drug	O	O
-	O	O
induced	O	O
symptoms	O	O
of	O	O
pheochromocytoma	B-Disease	D010673
are	O	O
often	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
substituted	O	O
benzamide	B-Chemical	C037689
drugs	O	O
,	O	O
but	O	O
the	O	O
underlying	O	O
mechanism	O	O
is	O	O
unknown	O	O
.	O	O

In	O	O
our	O	O
case	O	O
,	O	O
use	O	O
of	O	O
the	O	O
Naranjo	O	O
probability	O	O
scale	O	O
indicated	O	O
a	O	O
possible	O	O
relationship	O	O
between	O	O
the	O	O
hypertensive	B-Disease	D006973
crisis	O	O
and	O	O
amisulpride	B-Chemical	C012052
and	O	O
tiapride	B-Chemical	D063325
therapy	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
As	O	O
of	O	O
March	O	O
24	O	O
,	O	O
2005	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
amisulpride	B-Chemical	C012052
-	O	O
and	O	O
tiapride	B-Chemical	D063325
-	O	O
induced	O	O
hypertensive	B-Disease	D006973
crisis	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
pheochromocytoma	B-Disease	D010673
.	O	O

Physicians	O	O
and	O	O
other	O	O
healthcare	O	O
professionals	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
adverse	O	O
effect	O	O
of	O	O
tiapride	B-Chemical	D063325
and	O	O
amisulpride	B-Chemical	C012052
.	O	O

Quantitative	O	O
drug	O	O
levels	O	O
in	O	O
stimulant	O	O
psychosis	B-Disease	D011605
:	O	O
relationship	O	O
to	O	O
symptom	O	O
severity	O	O
,	O	O
catecholamines	B-Chemical	D002395
and	O	O
hyperkinesia	B-Disease	D006948
.	O	O

To	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
quantitative	O	O
stimulant	O	O
drug	O	O
levels	O	O
,	O	O
catecholamines	B-Chemical	D002395
,	O	O
and	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
,	O	O
nineteen	O	O
patients	O	O
in	O	O
a	O	O
psychiatric	B-Disease	D001523
emergency	O	O
service	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
amphetamine	B-Chemical	D000661
-	O	O
or	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
psychosis	B-Disease	D011605
were	O	O
interviewed	O	O
,	O	O
and	O	O
plasma	O	O
and	O	O
urine	O	O
were	O	O
collected	O	O
for	O	O
quantitative	O	O
assays	O	O
of	O	O
stimulant	O	O
drug	O	O
and	O	O
catecholamine	B-Chemical	D002395
metabolite	O	O
levels	O	O
.	O	O

Methamphetamine	B-Chemical	D008694
or	O	O
amphetamine	B-Chemical	D000661
levels	O	O
were	O	O
related	O	O
to	O	O
several	O	O
psychopathology	O	O
scores	O	O
and	O	O
the	O	O
global	O	O
hyperkinesia	B-Disease	D006948
rating	O	O
.	O	O

HVA	O	O
levels	O	O
were	O	O
related	O	O
to	O	O
global	O	O
hyperkinesia	B-Disease	D006948
but	O	O
not	O	O
to	O	O
psychopathology	O	O
ratings	O	O
.	O	O

Although	O	O
many	O	O
other	O	O
factors	O	O
such	O	O
as	O	O
sensitization	O	O
may	O	O
play	O	O
a	O	O
role	O	O
,	O	O
intensity	O	O
of	O	O
stimulant	O	O
-	O	O
induced	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
and	O	O
stereotypies	B-Disease	D019956
appears	O	O
to	O	O
be	O	O
at	O	O
least	O	O
in	O	O
part	O	O
dose	O	O
-	O	O
related	O	O
.	O	O

Delayed	O	O
asystolic	B-Disease	D006323
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
after	O	O
diltiazem	B-Chemical	D004110
overdose	B-Disease	D062787
;	O	O
resuscitation	O	O
with	O	O
high	O	O
dose	O	O
intravenous	O	O
calcium	B-Chemical	D002118
.	O	O

A	O	O
51	O	O
year	O	O
old	O	O
man	O	O
took	O	O
a	O	O
mixed	O	O
overdose	B-Disease	D062787
including	O	O
1	O	O
.	O	O

8	O	O
-	O	O
3	O	O
.	O	O

6	O	O
g	O	O
of	O	O
diltiazem	B-Chemical	D004110
,	O	O
paracetamol	B-Chemical	D000082
,	O	O
aspirin	B-Chemical	D001241
,	O	O
isosorbide	B-Chemical	D007547
nitrate	B-Chemical	D009566
,	O	O
and	O	O
alcohol	B-Chemical	D000431
.	O	O

He	O	O
initially	O	O
presented	O	O
to	O	O
hospital	O	O
after	O	O
six	O	O
hours	O	O
with	O	O
mild	O	O
hypotension	B-Disease	D007022
and	O	O
was	O	O
treated	O	O
with	O	O
activated	O	O
charcoal	O	O
and	O	O
intravenous	O	O
fluids	O	O
.	O	O

Eighteen	O	O
hours	O	O
after	O	O
the	O	O
overdose	B-Disease	D062787
he	O	O
had	O	O
two	O	O
generalised	O	O
tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
seizures	I-Disease	D004830
.	O	O

The	O	O
patient	O	O
remained	O	O
unresponsive	O	O
with	O	O
junctional	O	O
bradycardia	B-Disease	D001919
,	O	O
unrecordable	O	O
blood	O	O
pressure	O	O
,	O	O
and	O	O
then	O	O
became	O	O
asystolic	B-Disease	D006323
.	O	O

He	O	O
was	O	O
resuscitated	O	O
with	O	O
high	O	O
dose	O	O
(	O	O
13	O	O
.	O	O

5	O	O
g	O	O
)	O	O
intravenous	O	O
calcium	B-Chemical	D002118
and	O	O
adrenaline	B-Chemical	D004837
(	O	O
epinephrine	B-Chemical	D004837
)	O	O
.	O	O

He	O	O
required	O	O
inotropic	O	O
support	O	O
and	O	O
temporary	O	O
pacing	O	O
over	O	O
the	O	O
next	O	O
48	O	O
hours	O	O
.	O	O

This	O	O
case	O	O
suggests	O	O
there	O	O
is	O	O
a	O	O
role	O	O
for	O	O
aggressive	O	O
high	O	O
dose	O	O
intravenous	O	O
calcium	B-Chemical	D002118
therapy	O	O
in	O	O
severe	O	O
diltiazem	B-Chemical	D004110
overdose	B-Disease	D062787
,	O	O
particularly	O	O
with	O	O
the	O	O
onset	O	O
of	O	O
asystole	B-Disease	D006323
.	O	O

It	O	O
should	O	O
be	O	O
considered	O	O
early	O	O
in	O	O
cases	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
after	O	O
diltiazem	B-Chemical	D004110
overdose	B-Disease	D062787
.	O	O

The	O	O
case	O	O
also	O	O
highlights	O	O
the	O	O
problems	O	O
with	O	O
delayed	O	O
toxicity	B-Disease	D064420
when	O	O
whole	O	O
bowel	O	O
irrigation	O	O
is	O	O
not	O	O
administered	O	O
.	O	O

Renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
due	O	O
to	O	O
naproxen	B-Chemical	D009288
.	O	O

A	O	O
31	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
,	O	O
who	O	O
had	O	O
previously	O	O
been	O	O
treated	O	O
with	O	O
sulindac	B-Chemical	D013467
,	O	O
fenoprofen	B-Chemical	D005279
calcium	I-Chemical	D005279
,	O	O
high	O	O
dose	O	O
salicylates	B-Chemical	D012459
and	O	O
gold	B-Chemical	D006046
salts	O	O
,	O	O
developed	O	O
renal	B-Disease	D007681
papillary	I-Disease	D007681
necrosis	I-Disease	D007681
(	O	O
RPN	B-Disease	D007681
)	O	O
4	O	O
months	O	O
after	O	O
institution	O	O
of	O	O
naproxen	B-Chemical	D009288
therapy	O	O
.	O	O

No	O	O
other	O	O
factor	O	O
predisposing	O	O
to	O	O
RPN	B-Disease	D007681
could	O	O
be	O	O
discovered	O	O
.	O	O

Sulindac	B-Chemical	D013467
was	O	O
substituted	O	O
for	O	O
naproxen	B-Chemical	D009288
and	O	O
no	O	O
further	O	O
adverse	O	O
renal	O	O
effects	O	O
occurred	O	O
over	O	O
the	O	O
next	O	O
12	O	O
months	O	O
.	O	O

We	O	O
review	O	O
previous	O	O
reports	O	O
linking	O	O
RPN	B-Disease	D007681
to	O	O
antiinflammatory	O	O
drug	O	O
use	O	O
and	O	O
discuss	O	O
possible	O	O
advantages	O	O
of	O	O
sulindac	B-Chemical	D013467
in	O	O
patients	O	O
who	O	O
have	O	O
experienced	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
from	O	O
other	O	O
antiinflammatory	O	O
agents	O	O
.	O	O

Adverse	O	O
interaction	O	O
between	O	O
beta	B-Chemical	D000319
-	I-Chemical	D000319
adrenergic	I-Chemical	D000319
blocking	I-Chemical	D000319
drugs	I-Chemical	D000319
and	O	O
verapamil	B-Chemical	D014700
-	O	O
-	O	O
report	O	O
of	O	O
three	O	O
cases	O	O
.	O	O

Three	O	O
patients	O	O
with	O	O
ischaemic	B-Disease	D017202
heart	I-Disease	D017202
disease	I-Disease	D017202
developed	O	O
profound	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
hypotension	B-Disease	D007022
and	O	O
bradycardia	B-Disease	D001919
during	O	O
combined	O	O
therapy	O	O
with	O	O
verapamil	B-Chemical	D014700
and	O	O
beta	B-Chemical	D000319
-	I-Chemical	D000319
adrenergic	I-Chemical	D000319
blocking	I-Chemical	D000319
drugs	I-Chemical	D000319
.	O	O

This	O	O
clinical	O	O
picture	O	O
resolved	O	O
completely	O	O
with	O	O
cessation	O	O
of	O	O
the	O	O
combined	O	O
therapy	O	O
.	O	O

Baseline	O	O
left	O	O
ventricular	O	O
function	O	O
,	O	O
assessed	O	O
by	O	O
cardiac	O	O
catheterisation	O	O
or	O	O
nuclear	O	O
angiography	O	O
,	O	O
was	O	O
normal	O	O
in	O	O
two	O	O
patients	O	O
and	O	O
only	O	O
mildly	O	O
reduced	O	O
in	O	O
the	O	O
other	O	O
.	O	O

Simultaneously	O	O
administration	O	O
of	O	O
beta	B-Chemical	D000319
-	I-Chemical	D000319
adrenergic	I-Chemical	D000319
blocking	I-Chemical	D000319
drugs	I-Chemical	D000319
and	O	O
verapamil	B-Chemical	D014700
may	O	O
result	O	O
in	O	O
profound	O	O
adverse	O	O
interactions	O	O
and	O	O
should	O	O
only	O	O
be	O	O
administered	O	O
with	O	O
great	O	O
caution	O	O
.	O	O

Adverse	O	O
reactions	O	O
to	O	O
bendrofluazide	B-Chemical	D001539
and	O	O
propranolol	B-Chemical	D011433
for	O	O
the	O	O
treatment	O	O
of	O	O
mild	O	O
hypertension	B-Disease	D006973
.	O	O

Report	O	O
of	O	O
Medical	O	O
Research	O	O
Council	O	O
Working	O	O
Party	O	O
on	O	O
Mild	O	O
to	O	O
Moderate	O	O
Hypertension	B-Disease	D006973
.	O	O

Participants	O	O
in	O	O
the	O	O
Medical	O	O
Research	O	O
Council	O	O
treatment	O	O
trial	O	O
for	O	O
mild	O	O
hypertension	B-Disease	D006973
are	O	O
randomly	O	O
allocated	O	O
to	O	O
one	O	O
of	O	O
four	O	O
treatment	O	O
groups	O	O
:	O	O
bendrofluazide	B-Chemical	D001539
,	O	O
propranolol	B-Chemical	D011433
,	O	O
or	O	O
a	O	O
placebo	O	O
for	O	O
either	O	O
of	O	O
these	O	O
drugs	O	O
.	O	O

The	O	O
trial	O	O
is	O	O
single	O	O
-	O	O
blind	O	O
.	O	O

23	O	O
582	O	O
patient	O	O
-	O	O
years	O	O
of	O	O
observation	O	O
have	O	O
been	O	O
completed	O	O
so	O	O
far	O	O
,	O	O
10	O	O
684	O	O
on	O	O
active	O	O
drugs	O	O
and	O	O
12	O	O
898	O	O
on	O	O
placebos	O	O
.	O	O

The	O	O
results	O	O
show	O	O
an	O	O
association	O	O
between	O	O
bendrofluazide	B-Chemical	D001539
treatment	O	O
and	O	O
impotence	B-Disease	D007172
,	O	O
and	O	O
impotence	B-Disease	D007172
also	O	O
occurred	O	O
more	O	O
frequently	O	O
in	O	O
patients	O	O
taking	O	O
propranolol	B-Chemical	D011433
than	O	O
in	O	O
those	O	O
taking	O	O
placebos	O	O
.	O	O

Other	O	O
adverse	O	O
reactions	O	O
significantly	O	O
linked	O	O
with	O	O
active	O	O
drugs	O	O
include	O	O
impaired	B-Disease	D018149
glucose	I-Disease	D018149
tolerance	I-Disease	D018149
in	O	O
men	O	O
and	O	O
women	O	O
and	O	O
gout	B-Disease	D006073
in	O	O
men	O	O
,	O	O
associated	O	O
with	O	O
bendrofluazide	B-Chemical	D001539
treatment	O	O
,	O	O
and	O	O
Raynaud's	B-Disease	D011928
phenomenon	I-Disease	D011928
and	O	O
dyspnoea	B-Disease	D004417
in	O	O
men	O	O
and	O	O
women	O	O
taking	O	O
propranolol	B-Chemical	D011433
.	O	O

No	O	O
corneal	B-Disease	D003316
disease	I-Disease	D003316
is	O	O
known	O	O
to	O	O
have	O	O
occurred	O	O
in	O	O
the	O	O
propranolol	B-Chemical	D011433
group	O	O
.	O	O

Mean	O	O
serum	O	O
potassium	B-Chemical	D011188
level	O	O
fell	O	O
,	O	O
and	O	O
urea	B-Chemical	D014508
and	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
levels	O	O
rose	O	O
,	O	O
in	O	O
men	O	O
and	O	O
women	O	O
taking	O	O
bendrofluazide	B-Chemical	D001539
.	O	O

In	O	O
the	O	O
propranolol	B-Chemical	D011433
group	O	O
,	O	O
serum	O	O
potassium	B-Chemical	D011188
and	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
levels	O	O
rose	O	O
in	O	O
both	O	O
sexes	O	O
,	O	O
but	O	O
the	O	O
urea	B-Chemical	D014508
level	O	O
rose	O	O
significantly	O	O
in	O	O
women	O	O
only	O	O
.	O	O

Dexmedetomidine	B-Chemical	D020927
and	O	O
cardiac	O	O
protection	O	O
for	O	O
non	O	O
-	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
of	O	O
randomised	O	O
controlled	O	O
trials	O	O
.	O	O

We	O	O
conducted	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
dexmedetomidine	B-Chemical	D020927
on	O	O
cardiac	O	O
outcomes	O	O
following	O	O
non	O	O
-	O	O
cardiac	O	O
surgery	O	O
.	O	O

We	O	O
included	O	O
prospective	O	O
,	O	O
randomised	O	O
peri	O	O
-	O	O
operative	O	O
studies	O	O
of	O	O
dexmedetomidine	B-Chemical	D020927
that	O	O
reported	O	O
mortality	O	O
,	O	O
cardiac	O	O
morbidity	O	O
or	O	O
adverse	O	O
drug	O	O
events	O	O
.	O	O

A	O	O
PubMed	O	O
Central	O	O
and	O	O
EMBASE	O	O
search	O	O
was	O	O
conducted	O	O
up	O	O
to	O	O
July	O	O
2007	O	O
.	O	O

The	O	O
reference	O	O
lists	O	O
of	O	O
identified	O	O
papers	O	O
were	O	O
examined	O	O
for	O	O
further	O	O
trials	O	O
.	O	O

Of	O	O
425	O	O
studies	O	O
identified	O	O
,	O	O
20	O	O
were	O	O
included	O	O
in	O	O
the	O	O
meta	O	O
-	O	O
analysis	O	O
(	O	O
840	O	O
patients	O	O
)	O	O
.	O	O

Dexmedetomidine	B-Chemical	D020927
was	O	O
associated	O	O
with	O	O
a	O	O
trend	O	O
towards	O	O
improved	O	O
cardiac	O	O
outcomes	O	O
;	O	O
all	O	O
-	O	O
cause	O	O
mortality	O	O
(	O	O
OR	O	O
0	O	O
.	O	O

27	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

01	O	O
-	O	O
7	O	O
.	O	O

13	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

44	O	O
)	O	O
,	O	O
non	O	O
-	O	O
fatal	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
OR	O	O
0	O	O
.	O	O

26	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

04	O	O
-	O	O
1	O	O
.	O	O

60	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

14	O	O
)	O	O
,	O	O
and	O	O
myocardial	B-Disease	D017202
ischaemia	I-Disease	D017202
(	O	O
OR	O	O
0	O	O
.	O	O

65	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

26	O	O
-	O	O
1	O	O
.	O	O

63	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

36	O	O
)	O	O
.	O	O

Peri	O	O
-	O	O
operative	O	O
hypotension	B-Disease	D007022
(	O	O
26%	O	O
,	O	O
OR	O	O
3	O	O
.	O	O

80	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

91	O	O
-	O	O
7	O	O
.	O	O

54	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
and	O	O
bradycardia	B-Disease	D001919
(	O	O
17%	O	O
,	O	O
OR	O	O
5	O	O
.	O	O

45	O	O
,	O	O
95%	O	O
CI	O	O
2	O	O
.	O	O

98	O	O
-	O	O
9	O	O
.	O	O

95	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

00001	O	O
)	O	O
were	O	O
significantly	O	O
increased	O	O
.	O	O

An	O	O
anticholinergic	O	O
did	O	O
not	O	O
reduce	O	O
the	O	O
incidence	O	O
of	O	O
bradycardia	B-Disease	D001919
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

43	O	O
)	O	O
.	O	O

A	O	O
randomised	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
of	O	O
dexmedetomidine	B-Chemical	D020927
is	O	O
warranted	O	O
.	O	O

Differential	O	O
diagnosis	O	O
of	O	O
high	O	O
serum	O	O
creatine	B-Chemical	D003401
kinase	O	O
levels	O	O
in	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
.	O	O

We	O	O
report	O	O
the	O	O
clinical	O	O
and	O	O
bioptic	O	O
findings	O	O
for	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
severe	O	O
chloroquine	B-Chemical	D002738
-	O	O
induced	O	O
myopathy	B-Disease	D009135
.	O	O

Since	O	O
1989	O	O
,	O	O
she	O	O
had	O	O
been	O	O
suffering	O	O
from	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
(	O	O
SLE	B-Disease	D008180
)	O	O
with	O	O
renal	B-Disease	D007674
involvement	I-Disease	D007674
and	O	O
undergone	O	O
periods	O	O
of	O	O
treatment	O	O
with	O	O
azathioprine	B-Chemical	D001379
and	O	O
cyclophosphamide	B-Chemical	D003520
.	O	O

Additional	O	O
therapy	O	O
with	O	O
chloroquine	B-Chemical	D002738
(	O	O
CQ	B-Chemical	D002738
)	O	O
was	O	O
started	O	O
because	O	O
of	O	O
arthralgia	B-Disease	D018771
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
slightly	O	O
increased	O	O
creatine	B-Chemical	D003401
kinase	O	O
(	O	O
CK	O	O
)	O	O
levels	O	O
were	O	O
noted	O	O
.	O	O

Myositis	B-Disease	D009220
was	O	O
suspected	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
steroids	B-Chemical	D013256
.	O	O

The	O	O
CK	O	O
increase	O	O
persisted	O	O
,	O	O
however	O	O
,	O	O
and	O	O
she	O	O
developed	O	O
progressive	O	O
muscular	B-Disease	D018908
weakness	I-Disease	D018908
and	O	O
muscular	B-Disease	D009133
atrophy	I-Disease	D009133
.	O	O

Routine	O	O
controls	O	O
revealed	O	O
markedly	O	O
elevated	O	O
CK	O	O
levels	O	O
of	O	O
1	O	O
,	O	O
700	O	O
U	O	O
/	O	O
l	O	O
.	O	O

The	O	O
neurological	O	O
and	O	O
electrophysiological	O	O
findings	O	O
were	O	O
not	O	O
typical	O	O
of	O	O
myositis	B-Disease	D009220
.	O	O

Thus	O	O
,	O	O
muscle	O	O
biopsy	O	O
of	O	O
the	O	O
deltoid	O	O
muscle	O	O
was	O	O
performed	O	O
in	O	O
order	O	O
to	O	O
exclude	O	O
polymyositis	B-Disease	D017285
or	O	O
toxic	O	O
myopathy	B-Disease	D009135
.	O	O

As	O	O
it	O	O
revealed	O	O
chloroquine	B-Chemical	D002738
-	O	O
induced	O	O
myopathy	B-Disease	D009135
,	O	O
medication	O	O
was	O	O
stopped	O	O
.	O	O

Discriminating	O	O
between	O	O
primary	O	O
SLE	B-Disease	D008180
-	O	O
induced	O	O
affection	B-Disease	D009140
of	I-Disease	D009140
the	I-Disease	D009140
musculoskeletal	I-Disease	D009140
system	I-Disease	D009140
and	O	O
drug	O	O
-	O	O
induced	O	O
side	O	O
effects	O	O
is	O	O
important	O	O
for	O	O
appropriate	O	O
treatment	O	O
of	O	O
SLE	B-Disease	D008180
patients	O	O
.	O	O

Intravenous	O	O
ribavirin	B-Chemical	D012254
treatment	O	O
for	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
in	O	O
immunocompromised	O	O
children	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Adenovirus	O	O
is	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
in	O	O
the	O	O
immunocompromised	O	O
host	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
in	O	O
pediatrics	O	O
is	O	O
increasing	O	O
in	O	O
association	O	O
with	O	O
growing	O	O
numbers	O	O
of	O	O
immunocompromised	O	O
children	O	O
,	O	O
where	O	O
case	O	O
fatality	O	O
rates	O	O
as	O	O
high	O	O
as	O	O
50%	O	O
to	O	O
80%	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

There	O	O
are	O	O
no	O	O
approved	O	O
antiviral	O	O
agents	O	O
with	O	O
proven	O	O
efficacy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
,	O	O
nor	O	O
are	O	O
there	O	O
any	O	O
prospective	O	O
randomized	O	O
,	O	O
controlled	O	O
trials	O	O
of	O	O
potentially	O	O
useful	O	O
anti	O	O
-	O	O
adenovirus	O	O
therapies	O	O
.	O	O

Apparent	O	O
clinical	O	O
success	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
is	O	O
limited	O	O
to	O	O
a	O	O
few	O	O
case	O	O
reports	O	O
and	O	O
small	O	O
series	O	O
.	O	O

Experience	O	O
is	O	O
greatest	O	O
with	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
and	O	O
cidofovir	B-Chemical	C059262
.	O	O

Ribavirin	B-Chemical	D012254
,	O	O
a	O	O
guanosine	B-Chemical	D006151
analogue	O	O
,	O	O
has	O	O
broad	O	O
antiviral	O	O
activity	O	O
against	O	O
both	O	O
RNA	O	O
and	O	O
DNA	O	O
viruses	O	O
,	O	O
including	O	O
documented	O	O
activity	O	O
against	O	O
adenovirus	O	O
in	O	O
vitro	O	O
.	O	O

Ribavirin	B-Chemical	D012254
is	O	O
licensed	O	O
in	O	O
aerosol	O	O
form	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
respiratory	B-Disease	D018357
syncytial	I-Disease	D018357
virus	I-Disease	D018357
infection	I-Disease	D018357
,	O	O
and	O	O
orally	O	O
in	O	O
combination	O	O
with	O	O
interferon	O	O
to	O	O
treat	O	O
hepatitis	B-Disease	D006526
C	I-Disease	D006526
.	O	O

Intravenous	O	O
ribavirin	B-Chemical	D012254
is	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
for	O	O
infection	B-Disease	D006482
with	I-Disease	D006482
hemorrhagic	I-Disease	D006482
fever	I-Disease	D006482
viruses	I-Disease	D006482
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
effect	O	O
of	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
is	O	O
reversible	O	O
mild	O	O
anemia	B-Disease	D000740
.	O	O

The	O	O
use	O	O
of	O	O
cidofovir	B-Chemical	C059262
in	O	O
severe	O	O
adenovirus	B-Disease	D000257
infection	I-Disease	D000257
has	O	O
been	O	O
limited	O	O
by	O	O
adverse	O	O
effects	O	O
,	O	O
the	O	O
most	O	O
significant	O	O
of	O	O
which	O	O
is	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
report	O	O
our	O	O
experience	O	O
with	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
therapy	O	O
for	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
in	O	O
a	O	O
series	O	O
of	O	O
immunocompromised	O	O
children	O	O
and	O	O
review	O	O
the	O	O
literature	O	O
.	O	O

DESIGN	O	O
/	O	O
METHODS	O	O
:	O	O
We	O	O
retrospectively	O	O
reviewed	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
5	O	O
children	O	O
treated	O	O
with	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
for	O	O
documented	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
.	O	O

Two	O	O
patients	O	O
developed	O	O
adenovirus	O	O
hemorrhagic	O	O
cystitis	O	O
after	O	O
cardiac	O	O
and	O	O
bone	O	O
marrow	O	O
transplants	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
bone	O	O
marrow	O	O
transplant	O	O
patient	O	O
also	O	O
received	O	O
intravenous	O	O
cidofovir	B-Chemical	C059262
for	O	O
progressive	O	O
disseminated	O	O
disease	O	O
.	O	O

An	O	O
additional	O	O
3	O	O
children	O	O
developed	O	O
adenovirus	O	O
pneumonia	O	O
;	O	O
2	O	O
were	O	O
neonates	O	O
,	O	O
1	O	O
of	O	O
whom	O	O
had	O	O
partial	O	O
DiGeorge	B-Disease	D004062
syndrome	I-Disease	D004062
.	O	O

The	O	O
remaining	O	O
infant	O	O
had	O	O
recently	O	O
undergone	O	O
a	O	O
cardiac	O	O
transplant	O	O
.	O	O

Intravenous	O	O
ribavirin	B-Chemical	D012254
was	O	O
administered	O	O
on	O	O
a	O	O
compassionate	O	O
-	O	O
use	O	O
protocol	O	O
.	O	O

RESULTS	O	O
:	O	O
Complete	O	O
clinical	O	O
recovery	O	O
followed	O	O
later	O	O
by	O	O
viral	O	O
clearance	O	O
was	O	O
observed	O	O
in	O	O
2	O	O
children	O	O
:	O	O
the	O	O
cardiac	O	O
transplant	O	O
recipient	O	O
with	O	O
adenovirus	O	O
hemorrhagic	O	O
cystitis	O	O
and	O	O
the	O	O
immunocompetent	O	O
neonate	O	O
with	O	O
adenovirus	O	O
pneumonia	O	O
.	O	O

The	O	O
remaining	O	O
3	O	O
children	O	O
died	O	O
of	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
.	O	O

Intravenous	O	O
ribavirin	B-Chemical	D012254
therapy	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

Use	O	O
of	O	O
cidofovir	B-Chemical	C059262
in	O	O
1	O	O
child	O	O
was	O	O
associated	O	O
with	O	O
progressive	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
and	O	O
neutropenia	B-Disease	D009503
.	O	O

DISCUSSION	O	O
:	O	O
Our	O	O
series	O	O
of	O	O
patients	O	O
is	O	O
representative	O	O
of	O	O
the	O	O
spectrum	O	O
of	O	O
immunocompromised	O	O
children	O	O
at	O	O
greatest	O	O
risk	O	O
for	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
,	O	O
namely	O	O
solid	O	O
-	O	O
organ	O	O
and	O	O
bone	O	O
marrow	O	O
transplant	O	O
recipients	O	O
,	O	O
neonates	O	O
,	O	O
and	O	O
children	O	O
with	O	O
immunodeficiency	B-Disease	D007153
.	O	O

Although	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
was	O	O
not	O	O
effective	O	O
for	O	O
all	O	O
children	O	O
with	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
in	O	O
this	O	O
series	O	O
or	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
therapy	O	O
is	O	O
unlikely	O	O
to	O	O
be	O	O
of	O	O
benefit	O	O
if	O	O
begun	O	O
late	O	O
in	O	O
the	O	O
course	O	O
of	O	O
the	O	O
infection	B-Disease	D007239
.	O	O

Early	O	O
identification	O	O
,	O	O
eg	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
of	O	O
those	O	O
patients	O	O
at	O	O
risk	O	O
of	O	O
disseminated	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
may	O	O
permit	O	O
earlier	O	O
antiviral	O	O
treatment	O	O
and	O	O
better	O	O
evaluation	O	O
of	O	O
therapeutic	O	O
response	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Two	O	O
of	O	O
5	O	O
children	O	O
with	O	O
severe	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
treated	O	O
with	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
recovered	O	O
.	O	O

The	O	O
availability	O	O
of	O	O
newer	O	O
rapid	O	O
diagnostic	O	O
techniques	O	O
,	O	O
such	O	O
as	O	O
polymerase	O	O
chain	O	O
reaction	O	O
,	O	O
may	O	O
make	O	O
earlier	O	O
,	O	O
more	O	O
effective	O	O
treatment	O	O
of	O	O
adenovirus	B-Disease	D000257
infection	I-Disease	D000257
possible	O	O
.	O	O

Given	O	O
the	O	O
seriousness	O	O
and	O	O
increasing	O	O
prevalence	O	O
of	O	O
adenovirus	B-Disease	D000257
disease	I-Disease	D000257
in	O	O
certain	O	O
hosts	O	O
,	O	O
especially	O	O
children	O	O
,	O	O
a	O	O
large	O	O
,	O	O
multicenter	O	O
clinical	O	O
trial	O	O
of	O	O
potentially	O	O
useful	O	O
anti	O	O
-	O	O
adenoviral	O	O
therapies	O	O
,	O	O
such	O	O
as	O	O
intravenous	O	O
ribavirin	B-Chemical	D012254
,	O	O
is	O	O
clearly	O	O
required	O	O
to	O	O
demonstrate	O	O
the	O	O
most	O	O
effective	O	O
and	O	O
least	O	O
toxic	O	O
therapy	O	O
.	O	O

Hepatotoxicity	B-Disease	D056486
of	O	O
amiodarone	B-Chemical	D000638
.	O	O

Amiodarone	B-Chemical	D000638
has	O	O
proved	O	O
very	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
otherwise	O	O
resistant	O	O
cardiac	O	O
tachyarrhythmias	B-Disease	D013610
.	O	O

The	O	O
use	O	O
of	O	O
amiodarone	B-Chemical	D000638
has	O	O
,	O	O
however	O	O
,	O	O
been	O	O
limited	O	O
due	O	O
to	O	O
its	O	O
serious	O	O
side	O	O
-	O	O
effects	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
cholestatic	O	O
hepatitis	O	O
due	O	O
to	O	O
amiodarone	B-Chemical	D000638
treatment	O	O
is	O	O
presented	O	O
below	O	O
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
hepatotoxicity	B-Disease	D056486
of	O	O
amiodarone	B-Chemical	D000638
is	O	O
given	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
solid	O	O
evidence	O	O
exists	O	O
of	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
due	O	O
to	O	O
amiodarone	B-Chemical	D000638
treatment	O	O
,	O	O
including	O	O
steatosis	B-Disease	D005234
,	O	O
alterations	O	O
resembling	O	O
alcoholic	B-Disease	D006519
hepatitis	I-Disease	D006519
,	O	O
cholestatic	O	O
hepatitis	O	O
and	O	O
micronodular	O	O
cirrhosis	B-Disease	D008103
of	I-Disease	D008103
the	I-Disease	D008103
liver	I-Disease	D008103
.	O	O

Patients	O	O
receiving	O	O
amiodarone	B-Chemical	D000638
should	O	O
be	O	O
regularly	O	O
screened	O	O
with	O	O
respect	O	O
to	O	O
hepatic	O	O
enzyme	O	O
levels	O	O
.	O	O

Therapy	O	O
should	O	O
be	O	O
discontinued	O	O
on	O	O
the	O	O
suspicion	O	O
of	O	O
cholestatic	B-Disease	D002779
injury	I-Disease	D002779
or	O	O
hepatomegaly	B-Disease	D006529
.	O	O

Catalepsy	B-Disease	D002375
induced	O	O
by	O	O
combinations	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
morphine	B-Chemical	D009020
:	O	O
potentiation	O	O
,	O	O
antagonism	O	O
,	O	O
tolerance	O	O
and	O	O
cross	O	O
-	O	O
tolerance	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Previous	O	O
studies	O	O
demonstrated	O	O
that	O	O
both	O	O
ketamine	B-Chemical	D007649
and	O	O
morphine	B-Chemical	D009020
induced	O	O
analgesia	B-Disease	D000699
and	O	O
catalepsy	B-Disease	D002375
in	O	O
the	O	O
rat	O	O
.	O	O

Pre	O	O
-	O	O
treatment	O	O
with	O	O
ketamine	B-Chemical	D007649
produced	O	O
cross	O	O
-	O	O
tolerance	O	O
to	O	O
morphine	B-Chemical	D009020
,	O	O
whereas	O	O
pretreatment	O	O
with	O	O
morphine	B-Chemical	D009020
did	O	O
not	O	O
induce	O	O
cross	O	O
-	O	O
tolerance	O	O
to	O	O
ketamine	B-Chemical	D007649
but	O	O
rather	O	O
augmented	O	O
the	O	O
cataleptic	B-Disease	D002375
response	O	O
;	O	O
this	O	O
augmentation	O	O
was	O	O
attributed	O	O
to	O	O
residual	O	O
morphine	B-Chemical	D009020
in	O	O
the	O	O
brain	O	O
.	O	O

The	O	O
present	O	O
studies	O	O
explored	O	O
the	O	O
duration	O	O
of	O	O
the	O	O
loss	O	O
of	O	O
righting	O	O
reflex	O	O
induced	O	O
by	O	O
sub	O	O
-	O	O
effective	O	O
doses	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
morphine	B-Chemical	D009020
,	O	O
administered	O	O
simultaneously	O	O
.	O	O

There	O	O
was	O	O
mutual	O	O
potentiation	O	O
between	O	O
sub	O	O
-	O	O
effective	O	O
doses	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
morphine	B-Chemical	D009020
,	O	O
but	O	O
sub	O	O
-	O	O
effective	O	O
doses	O	O
of	O	O
ketamine	B-Chemical	D007649
partly	O	O
antagonized	O	O
fully	O	O
-	O	O
effective	O	O
doses	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

Latency	O	O
to	O	O
the	O	O
loss	O	O
of	O	O
righting	O	O
reflex	O	O
,	O	O
rigidity	B-Disease	D009127
and	O	O
behavior	O	O
on	O	O
recovery	O	O
,	O	O
reflected	O	O
the	O	O
relative	O	O
predominance	O	O
of	O	O
ketamine	B-Chemical	D007649
or	O	O
morphine	B-Chemical	D009020
in	O	O
each	O	O
combination	O	O
.	O	O

Naloxone	B-Chemical	D009270
inhibited	O	O
the	O	O
induced	O	O
cataleptic	B-Disease	D002375
effects	O	O
.	O	O

The	O	O
degree	O	O
and	O	O
time	O	O
course	O	O
of	O	O
development	O	O
of	O	O
tolerance	O	O
to	O	O
daily	O	O
administration	O	O
of	O	O
sub	O	O
-	O	O
effective	O	O
dose	O	O
combinations	O	O
of	O	O
ketamine	B-Chemical	D007649
and	O	O
morphine	B-Chemical	D009020
were	O	O
similar	O	O
.	O	O

Rats	O	O
,	O	O
tolerant	O	O
to	O	O
ketamine	B-Chemical	D007649
-	O	O
dominant	O	O
combinations	O	O
,	O	O
were	O	O
cross	O	O
-	O	O
tolerant	O	O
to	O	O
both	O	O
drugs	O	O
,	O	O
while	O	O
those	O	O
tolerant	O	O
to	O	O
morphine	B-Chemical	D009020
-	O	O
dominant	O	O
combinations	O	O
were	O	O
cross	O	O
-	O	O
tolerant	O	O
to	O	O
morphine	B-Chemical	D009020
but	O	O
showed	O	O
either	O	O
no	O	O
cross	O	O
-	O	O
tolerance	O	O
or	O	O
an	O	O
augmented	O	O
response	O	O
to	O	O
ketamine	B-Chemical	D007649
.	O	O

While	O	O
the	O	O
mutual	O	O
potentiation	O	O
,	O	O
antagonism	O	O
and	O	O
tolerance	O	O
suggest	O	O
common	O	O
mechanisms	O	O
for	O	O
the	O	O
induced	O	O
catalepsy	B-Disease	D002375
,	O	O
differences	O	O
in	O	O
latency	O	O
,	O	O
rigidity	B-Disease	D009127
and	O	O
behavior	O	O
,	O	O
asymmetry	O	O
of	O	O
cross	O	O
-	O	O
tolerance	O	O
and	O	O
a	O	O
widely	O	O
-	O	O
different	O	O
ID50	O	O
for	O	O
naloxone	B-Chemical	D009270
would	O	O
argue	O	O
against	O	O
an	O	O
action	O	O
at	O	O
a	O	O
single	O	O
opioid	O	O
site	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
in	O	O
patients	O	O
with	O	O
AIDS	B-Disease	D000163
on	O	O
tenofovir	B-Chemical	C096918
while	O	O
receiving	O	O
prolonged	O	O
vancomycin	B-Chemical	D014640
course	O	O
for	O	O
osteomyelitis	B-Disease	D010019
.	O	O

Renal	B-Disease	D051437
failure	I-Disease	D051437
developed	O	O
after	O	O
a	O	O
prolonged	O	O
course	O	O
of	O	O
vancomycin	B-Chemical	D014640
therapy	O	O
in	O	O
2	O	O
patients	O	O
who	O	O
were	O	O
receiving	O	O
tenofovir	B-Chemical	C096918
disoproxil	O	O
fumarate	O	O
as	O	O
part	O	O
of	O	O
an	O	O
antiretroviral	O	O
regimen	O	O
.	O	O

Tenofovir	B-Chemical	C096918
has	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
development	O	O
of	O	O
Fanconi	B-Disease	D005198
syndrome	I-Disease	D005198
and	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
because	O	O
of	O	O
its	O	O
effects	O	O
on	O	O
the	O	O
proximal	O	O
renal	O	O
tubule	O	O
.	O	O

Vancomycin	B-Chemical	D014640
nephrotoxicity	B-Disease	D007674
is	O	O
infrequent	O	O
but	O	O
may	O	O
result	O	O
from	O	O
coadministration	O	O
with	O	O
a	O	O
nephrotoxic	B-Disease	D007674
agent	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
aware	O	O
that	O	O
tenofovir	B-Chemical	C096918
may	O	O
raise	O	O
the	O	O
risk	O	O
of	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
during	O	O
prolonged	O	O
administration	O	O
of	O	O
vancomycin	B-Chemical	D014640
.	O	O

Delayed	O	O
leukoencephalopathy	B-Disease	D056784
with	O	O
stroke	B-Disease	D020521
-	O	O
like	O	O
presentation	O	O
in	O	O
chemotherapy	O	O
recipients	O	O
.	O	O

BACKGROUND	O	O
:	O	O
A	O	O
transient	O	O
leukoencephalopathy	B-Disease	D056784
mimicking	O	O
cerebrovascular	B-Disease	D002544
accident	I-Disease	D002544
has	O	O
been	O	O
described	O	O
as	O	O
a	O	O
complication	O	O
of	O	O
chemotherapy	O	O
,	O	O
most	O	O
commonly	O	O
in	O	O
recipients	O	O
of	O	O
intrathecal	O	O
methotrexate	B-Chemical	D008727
for	O	O
childhood	O	O
leukaemia	B-Disease	D007938
.	O	O

Recently	O	O
published	O	O
neuroimaging	O	O
data	O	O
suggest	O	O
a	O	O
common	O	O
pathophysiology	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
chemotherapy	O	O
agents	O	O
and	O	O
modes	O	O
of	O	O
administration	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
reviewed	O	O
the	O	O
medical	O	O
literature	O	O
for	O	O
single	O	O
reports	O	O
and	O	O
case	O	O
series	O	O
of	O	O
patients	O	O
presenting	O	O
with	O	O
stroke	B-Disease	D020521
-	O	O
like	O	O
episodes	O	O
while	O	O
receiving	O	O
systemic	O	O
or	O	O
intrathecal	O	O
chemotherapy	O	O
.	O	O

We	O	O
only	O	O
included	O	O
studies	O	O
providing	O	O
detailed	O	O
neuroimaging	O	O
data	O	O
.	O	O

Patients	O	O
with	O	O
cerebrovascular	B-Disease	D002544
accidents	I-Disease	D002544
were	O	O
excluded	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
identified	O	O
27	O	O
reports	O	O
of	O	O
toxic	O	O
leukoencephalopathy	B-Disease	D056784
in	O	O
patients	O	O
treated	O	O
with	O	O
methotrexate	B-Chemical	D008727
(	O	O
intrathecal	O	O
,	O	O
systemic	O	O
)	O	O
,	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
and	O	O
its	O	O
derivative	O	O
carmofur	B-Chemical	C017367
,	O	O
and	O	O
capecitabine	B-Chemical	C110904
.	O	O

Diffusion	O	O
weighted	O	O
imaging	O	O
(	O	O
DWI	O	O
)	O	O
of	O	O
all	O	O
patients	O	O
revealed	O	O
well	O	O
demarcated	O	O
hyperintense	O	O
lesions	B-Disease	D056784
within	I-Disease	D056784
the	I-Disease	D056784
subcortical	I-Disease	D056784
white	I-Disease	D056784
matter	I-Disease	D056784
of	O	O
the	O	O
cerebral	O	O
hemispheres	O	O
and	O	O
the	O	O
corpus	O	O
callosum	O	O
,	O	O
corresponding	O	O
to	O	O
areas	O	O
of	O	O
decreased	O	O
proton	O	O
diffusion	O	O
on	O	O
apparent	O	O
diffusion	O	O
coefficient	O	O
(	O	O
ADC	O	O
)	O	O
maps	O	O
(	O	O
available	O	O
in	O	O
21	O	O
/	O	O
27	O	O
patients	O	O
)	O	O
.	O	O

Lesions	O	O
exceeded	O	O
the	O	O
confines	O	O
of	O	O
adjacent	O	O
vascular	O	O
territories	O	O
.	O	O

Complete	O	O
resolution	O	O
of	O	O
symptoms	O	O
within	O	O
1	O	O
-	O	O
4	O	O
days	O	O
was	O	O
accompanied	O	O
by	O	O
normalisation	O	O
of	O	O
ADC	O	O
abnormalities	O	O
.	O	O

However	O	O
,	O	O
fluid	O	O
attenuated	O	O
inversion	O	O
recovery	O	O
(	O	O
FLAIR	O	O
)	O	O
sequences	O	O
frequently	O	O
revealed	O	O
persistent	O	O
white	B-Disease	D056784
matter	I-Disease	D056784
abnormalities	I-Disease	D056784
.	O	O

CONCLUSIONS	O	O
:	O	O
Several	O	O
pathophysiological	O	O
models	O	O
of	O	O
delayed	O	O
leukoencephalopathy	B-Disease	D056784
after	O	O
exposure	O	O
to	O	O
intrathecal	O	O
or	O	O
systemic	O	O
chemotherapy	O	O
have	O	O
been	O	O
proposed	O	O
.	O	O

DWI	O	O
findings	O	O
in	O	O
this	O	O
cohort	O	O
are	O	O
indicative	O	O
of	O	O
cytotoxic	B-Disease	D001929
oedema	I-Disease	D001929
within	I-Disease	D001929
cerebral	I-Disease	D001929
white	I-Disease	D001929
matter	I-Disease	D001929
and	O	O
lend	O	O
support	O	O
to	O	O
an	O	O
at	O	O
least	O	O
partially	O	O
reversible	O	O
metabolic	O	O
derangement	O	O
as	O	O
the	O	O
basis	O	O
for	O	O
this	O	O
syndrome	O	O
.	O	O

Down	O	O
-	O	O
regulation	O	O
of	O	O
norepinephrine	B-Chemical	D009638
transporter	O	O
function	O	O
induced	O	O
by	O	O
chronic	O	O
administration	O	O
of	O	O
desipramine	B-Chemical	D003891
linking	O	O
to	O	O
the	O	O
alteration	O	O
of	O	O
sensitivity	O	O
of	O	O
local	O	O
-	O	O
anesthetics	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
the	O	O
counteraction	O	O
by	O	O
co	O	O
-	O	O
administration	O	O
with	O	O
local	O	O
anesthetics	O	O
.	O	O

Alterations	O	O
of	O	O
norepinephrine	B-Chemical	D009638
transporter	O	O
(	O	O
NET	O	O
)	O	O
function	O	O
by	O	O
chronic	O	O
inhibition	O	O
of	O	O
NET	O	O
in	O	O
relation	O	O
to	O	O
sensitization	O	O
to	O	O
seizures	B-Disease	D012640
induce	O	O
by	O	O
cocaine	B-Chemical	D003042
and	O	O
local	O	O
anesthetics	O	O
were	O	O
studied	O	O
in	O	O
mice	O	O
.	O	O

Daily	O	O
administration	O	O
of	O	O
desipramine	B-Chemical	D003891
,	O	O
an	O	O
inhibitor	O	O
of	O	O
the	O	O
NET	O	O
,	O	O
for	O	O
5	O	O
days	O	O
decreased	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
norepinephrine	B-Chemical	D009638
uptake	O	O
in	O	O
the	O	O
P2	O	O
fractions	O	O
of	O	O
hippocampus	O	O
but	O	O
not	O	O
cortex	O	O
,	O	O
striatum	O	O
or	O	O
amygdalae	O	O
.	O	O

Co	O	O
-	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
,	O	O
bupivacaine	B-Chemical	D002045
or	O	O
tricaine	B-Chemical	C003636
with	O	O
desipramine	B-Chemical	D003891
reversed	O	O
this	O	O
effect	O	O
.	O	O

Daily	O	O
treatment	O	O
of	O	O
cocaine	B-Chemical	D003042
increased	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
norepinephrine	B-Chemical	D009638
uptake	O	O
into	O	O
the	O	O
hippocampus	O	O
.	O	O

Daily	O	O
administration	O	O
of	O	O
desipramine	B-Chemical	D003891
increased	O	O
the	O	O
incidence	O	O
of	O	O
appearance	O	O
of	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
decreased	O	O
that	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

Co	O	O
-	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
with	O	O
desipramine	B-Chemical	D003891
reversed	O	O
the	O	O
changes	O	O
of	O	O
convulsive	B-Disease	D012640
activity	O	O
of	O	O
lidocaine	B-Chemical	D008012
and	O	O
cocaine	B-Chemical	D003042
induced	O	O
by	O	O
repeated	O	O
administration	O	O
of	O	O
desipramine	B-Chemical	D003891
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
down	O	O
-	O	O
regulation	O	O
of	O	O
hippocampal	O	O
NET	O	O
induced	O	O
by	O	O
chronic	O	O
administration	O	O
of	O	O
desipramine	B-Chemical	D003891
may	O	O
be	O	O
relevant	O	O
to	O	O
desipramine	B-Chemical	D003891
-	O	O
induced	O	O
sensitization	O	O
of	O	O
lidocaine	B-Chemical	D008012
convulsions	B-Disease	D012640
.	O	O

Inhibition	O	O
of	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
channels	O	O
by	O	O
local	O	O
anesthetics	O	O
may	O	O
regulate	O	O
desipramine	B-Chemical	D003891
-	O	O
induced	O	O
down	O	O
-	O	O
regulation	O	O
of	O	O
NET	O	O
function	O	O
.	O	O

Repeated	O	O
administration	O	O
of	O	O
cocaine	B-Chemical	D003042
induces	O	O
up	O	O
-	O	O
regulation	O	O
of	O	O
hippocampal	O	O
NET	O	O
function	O	O
.	O	O

Desipramine	B-Chemical	D003891
-	O	O
induced	O	O
sensitization	O	O
of	O	O
lidocaine	B-Chemical	D008012
seizures	B-Disease	D012640
may	O	O
have	O	O
a	O	O
mechanism	O	O
distinct	O	O
from	O	O
kindling	O	O
resulting	O	O
from	O	O
repeated	O	O
administration	O	O
of	O	O
cocaine	B-Chemical	D003042
.	O	O

Definition	O	O
and	O	O
management	O	O
of	O	O
anemia	B-Disease	D000740
in	O	O
patients	O	O
infected	B-Disease	D006526
with	I-Disease	D006526
hepatitis	I-Disease	D006526
C	I-Disease	D006526
virus	I-Disease	D006526
.	O	O

Chronic	B-Disease	D019698
infection	I-Disease	D019698
with	I-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
virus	I-Disease	D019698
(	O	O
HCV	O	O
)	O	O
can	O	O
progress	O	O
to	O	O
cirrhosis	B-Disease	D005355
,	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
,	O	O
and	O	O
end	B-Disease	D058625
-	I-Disease	D058625
stage	I-Disease	D058625
liver	I-Disease	D058625
disease	I-Disease	D058625
.	O	O

The	O	O
current	O	O
best	O	O
treatment	O	O
for	O	O
HCV	B-Disease	D006526
infection	I-Disease	D006526
is	O	O
combination	O	O
therapy	O	O
with	O	O
pegylated	O	O
interferon	B-Chemical	D007372
and	O	O
ribavirin	B-Chemical	D012254
.	O	O

Although	O	O
this	O	O
regimen	O	O
produces	O	O
sustained	O	O
virologic	O	O
responses	O	O
(	O	O
SVRs	O	O
)	O	O
in	O	O
approximately	O	O
50%	O	O
of	O	O
patients	O	O
,	O	O
it	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
a	O	O
potentially	O	O
dose	O	O
-	O	O
limiting	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

Hemoglobin	O	O
concentrations	O	O
decrease	O	O
mainly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
hemolysis	B-Disease	D006461
,	O	O
and	O	O
this	O	O
anemia	B-Disease	D000740
can	O	O
be	O	O
problematic	O	O
in	O	O
patients	O	O
with	O	O
HCV	B-Disease	D006526
infection	I-Disease	D006526
,	O	O
especially	O	O
those	O	O
who	O	O
have	O	O
comorbid	O	O
renal	O	O
or	O	O
cardiovascular	O	O
disorders	O	O
.	O	O

In	O	O
general	O	O
,	O	O
anemia	B-Disease	D000740
can	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
,	O	O
and	O	O
may	O	O
have	O	O
negative	O	O
effects	O	O
on	O	O
cerebral	O	O
function	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

Although	O	O
ribavirin	B-Chemical	D012254
-	O	O
associated	O	O
anemia	B-Disease	D000740
can	O	O
be	O	O
reversed	O	O
by	O	O
dose	O	O
reduction	O	O
or	O	O
discontinuation	O	O
,	O	O
this	O	O
approach	O	O
compromises	O	O
outcomes	O	O
by	O	O
significantly	O	O
decreasing	O	O
SVR	O	O
rates	O	O
.	O	O

Recombinant	O	O
human	O	O
erythropoietin	O	O
has	O	O
been	O	O
used	O	O
to	O	O
manage	O	O
ribavirin	B-Chemical	D012254
-	O	O
associated	O	O
anemia	B-Disease	D000740
but	O	O
has	O	O
other	O	O
potential	O	O
disadvantages	O	O
.	O	O

Viramidine	B-Chemical	C026956
,	O	O
a	O	O
liver	O	O
-	O	O
targeting	O	O
prodrug	O	O
of	O	O
ribavirin	B-Chemical	D012254
,	O	O
has	O	O
the	O	O
potential	O	O
to	O	O
maintain	O	O
the	O	O
virologic	O	O
efficacy	O	O
of	O	O
ribavirin	B-Chemical	D012254
while	O	O
decreasing	O	O
the	O	O
risk	O	O
of	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
patients	O	O
with	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
.	O	O

Calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
toxicity	B-Disease	D064420
:	O	O
the	O	O
updated	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
;	O	O
report	O	O
of	O	O
3	O	O
cases	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
3	O	O
patients	O	O
with	O	O
calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
-	O	O
induced	O	O
hypercalcemia	B-Disease	D006934
and	O	O
gain	O	O
insights	O	O
into	O	O
the	O	O
cause	O	O
and	O	O
management	O	O
of	O	O
the	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
.	O	O

METHODS	O	O
:	O	O
We	O	O
report	O	O
the	O	O
clinical	O	O
and	O	O
laboratory	O	O
data	O	O
in	O	O
3	O	O
patients	O	O
who	O	O
presented	O	O
with	O	O
severe	O	O
hypercalcemia	B-Disease	D006934
(	O	O
corrected	O	O
serum	O	O
calcium	B-Chemical	D002118
>	O	O
or	O	O
=	O	O
14	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
and	O	O
review	O	O
the	O	O
pertinent	O	O
literature	O	O
on	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
.	O	O

RESULTS	O	O
:	O	O
The	O	O
3	O	O
patients	O	O
had	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
insufficiency	I-Disease	D058186
,	O	O
relative	O	O
metabolic	B-Disease	D000471
alkalosis	I-Disease	D000471
,	O	O
and	O	O
low	O	O
parathyroid	O	O
hormone	O	O
(	O	O
PTH	O	O
)	O	O
,	O	O
PTH	O	O
-	O	O
related	O	O
peptide	O	O
,	O	O
and	O	O
1	B-Chemical	C097949
,	I-Chemical	C097949
25	I-Chemical	C097949
-	I-Chemical	C097949
dihydroxyvitamin	I-Chemical	C097949
D	I-Chemical	C097949
concentrations	O	O
.	O	O

No	O	O
malignant	O	O
lesion	O	O
was	O	O
found	O	O
.	O	O

Treatment	O	O
included	O	O
aggressive	O	O
hydration	O	O
and	O	O
varied	O	O
amounts	O	O
of	O	O
furosemide	B-Chemical	D005665
.	O	O

The	O	O
2	O	O
patients	O	O
with	O	O
the	O	O
higher	O	O
serum	O	O
calcium	B-Chemical	D002118
concentrations	O	O
received	O	O
pamidronate	B-Chemical	C019248
intravenously	O	O
(	O	O
60	O	O
and	O	O
30	O	O
mg	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
which	O	O
caused	O	O
severe	O	O
hypocalcemia	B-Disease	D006996
.	O	O

Of	O	O
the	O	O
3	O	O
patients	O	O
,	O	O
2	O	O
were	O	O
ingesting	O	O
acceptable	O	O
doses	O	O
of	O	O
elemental	O	O
calcium	B-Chemical	D002118
(	O	O
1	O	O
g	O	O
and	O	O
2	O	O
g	O	O
daily	O	O
,	O	O
respectively	O	O
)	O	O
in	O	O
the	O	O
form	O	O
of	O	O
calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
.	O	O

In	O	O
addition	O	O
to	O	O
our	O	O
highlighted	O	O
cases	O	O
,	O	O
we	O	O
review	O	O
the	O	O
history	O	O
,	O	O
classification	O	O
,	O	O
pathophysiologic	O	O
features	O	O
,	O	O
and	O	O
treatment	O	O
of	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
and	O	O
summarize	O	O
the	O	O
cases	O	O
reported	O	O
from	O	O
early	O	O
1995	O	O
to	O	O
November	O	O
2003	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
may	O	O
be	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
unexplained	O	O
hypercalcemia	B-Disease	D006934
and	O	O
can	O	O
be	O	O
precipitated	O	O
by	O	O
small	O	O
amounts	O	O
of	O	O
orally	O	O
ingested	O	O
calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
in	O	O
susceptible	O	O
persons	O	O
.	O	O

Treatment	O	O
with	O	O
hydration	O	O
,	O	O
furosemide	B-Chemical	D005665
,	O	O
and	O	O
discontinuation	O	O
of	O	O
the	O	O
calcium	B-Chemical	D002118
and	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
source	O	O
is	O	O
adequate	O	O
.	O	O

Pamidronate	B-Chemical	C019248
treatment	O	O
is	O	O
associated	O	O
with	O	O
considerable	O	O
risk	O	O
for	O	O
hypocalcemia	B-Disease	D006996
,	O	O
even	O	O
in	O	O
cases	O	O
of	O	O
initially	O	O
severe	O	O
hypercalcemia	B-Disease	D006934
.	O	O

Management	O	O
strategies	O	O
for	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
the	O	O
treatment	O	O
of	O	O
hepatitis	B-Disease	D006526
C	I-Disease	D006526
:	O	O
clinical	O	O
and	O	O
economic	O	O
implications	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Recently	O	O
published	O	O
studies	O	O
have	O	O
demonstrated	O	O
increased	O	O
efficacy	O	O
and	O	O
cost	O	O
-	O	O
effectiveness	O	O
of	O	O
combination	O	O
therapy	O	O
with	O	O
interferon	O	O
and	O	O
alpha	O	O
-	O	O
2b	O	O
/	O	O
ribavirin	B-Chemical	D012254
compared	O	O
with	O	O
interferon	B-Chemical	D016898
-	I-Chemical	D016898
alpha	I-Chemical	D016898
monotherapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
(	O	O
CHC	B-Disease	D019698
)	O	O
.	O	O

Combination	O	O
therapy	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
clinically	O	O
important	O	O
adverse	O	O
effect	O	O
:	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
(	O	O
RIHA	B-Disease	D000743
)	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
direct	O	O
health	O	O
-	O	O
care	O	O
costs	O	O
and	O	O
management	O	O
of	O	O
RIHA	B-Disease	D000743
during	O	O
treatment	O	O
of	O	O
CHC	B-Disease	D019698
in	O	O
a	O	O
clinical	O	O
trial	O	O
setting	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
systematic	O	O
literature	O	O
review	O	O
was	O	O
conducted	O	O
to	O	O
synthesize	O	O
information	O	O
on	O	O
the	O	O
incidence	O	O
and	O	O
management	O	O
of	O	O
RIHA	B-Disease	D000743
.	O	O

Decision	O	O
-	O	O
analytic	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
cost	O	O
of	O	O
treating	O	O
RIHA	B-Disease	D000743
.	O	O

Uncertainty	O	O
was	O	O
evaluated	O	O
using	O	O
sensitivity	O	O
analyses	O	O
.	O	O

RESULTS	O	O
:	O	O
RIHA	B-Disease	D000743
,	O	O
defined	O	O
as	O	O
a	O	O
reduction	O	O
in	O	O
hemoglobin	O	O
to	O	O
less	O	O
than	O	O
100	O	O
g	O	O
/	O	O
L	O	O
,	O	O
occurs	O	O
in	O	O
approximately	O	O
7%	O	O
to	O	O
9%	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
combination	O	O
therapy	O	O
.	O	O

The	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
management	O	O
of	O	O
RIHA	B-Disease	D000743
is	O	O
reduction	O	O
or	O	O
discontinuation	O	O
of	O	O
the	O	O
ribavirin	B-Chemical	D012254
dosage	O	O
.	O	O

We	O	O
estimated	O	O
the	O	O
direct	O	O
cost	O	O
of	O	O
treating	O	O
clinically	O	O
significant	O	O
RIHA	B-Disease	D000743
to	O	O
be	O	O
170	O	O
per	O	O
patient	O	O
receiving	O	O
combination	O	O
therapy	O	O
per	O	O
48	O	O
-	O	O
week	O	O
treatment	O	O
course	O	O
(	O	O
range	O	O
68	O	O
-	O	O
692	O	O
)	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
one	O	O
-	O	O
way	O	O
sensitivity	O	O
analyses	O	O
ranged	O	O
from	O	O
57	O	O
to	O	O
317	O	O
.	O	O

In	O	O
comparison	O	O
,	O	O
the	O	O
cost	O	O
of	O	O
48	O	O
weeks	O	O
of	O	O
combination	O	O
therapy	O	O
is	O	O
16	O	O
,	O	O
459	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
direct	O	O
cost	O	O
of	O	O
treating	O	O
clinically	O	O
significant	O	O
RIHA	B-Disease	D000743
is	O	O
1%	O	O
(	O	O
170	O	O
/	O	O
16	O	O
,	O	O
459	O	O
)	O	O
of	O	O
drug	O	O
treatment	O	O
costs	O	O
.	O	O

Questions	O	O
remain	O	O
about	O	O
the	O	O
optimal	O	O
dose	O	O
of	O	O
ribavirin	B-Chemical	D012254
and	O	O
the	O	O
incidence	O	O
of	O	O
RIHA	B-Disease	D000743
in	O	O
a	O	O
real	O	O
-	O	O
world	O	O
population	O	O
.	O	O

Despite	O	O
these	O	O
uncertainties	O	O
,	O	O
this	O	O
initial	O	O
evaluation	O	O
of	O	O
the	O	O
direct	O	O
cost	O	O
of	O	O
treating	O	O
RIHA	B-Disease	D000743
provides	O	O
an	O	O
estimate	O	O
of	O	O
the	O	O
cost	O	O
and	O	O
management	O	O
implications	O	O
of	O	O
this	O	O
clinically	O	O
important	O	O
adverse	O	O
effect	O	O
.	O	O

Effects	O	O
of	O	O
amine	B-Chemical	D000588
pretreatment	O	O
on	O	O
ketamine	B-Chemical	D007649
catatonia	B-Disease	D002389
in	O	O
pinealectomized	O	O
or	O	O
hypophysectomized	O	O
animals	O	O
.	O	O

The	O	O
present	O	O
studies	O	O
were	O	O
designed	O	O
to	O	O
clarify	O	O
the	O	O
role	O	O
of	O	O
catecholamines	B-Chemical	D002395
and	O	O
pineal	O	O
idolamines	O	O
on	O	O
ketamine	B-Chemical	D007649
-	O	O
induced	O	O
catatonia	B-Disease	D002389
in	O	O
the	O	O
intact	O	O
,	O	O
pinealectomized	O	O
or	O	O
hypophysectomized	O	O
chick	O	O
and	O	O
rat	O	O
.	O	O

In	O	O
the	O	O
pinealectomized	O	O
chick	O	O
,	O	O
pretreatment	O	O
with	O	O
dopamine	B-Chemical	D004298
increased	O	O
the	O	O
duration	O	O
of	O	O
catatonia	B-Disease	D002389
(	O	O
DOC	O	O
)	O	O
after	O	O
ketamine	B-Chemical	D007649
,	O	O
but	O	O
pretreatment	O	O
with	O	O
norepinephrine	B-Chemical	D009638
did	O	O
not	O	O
.	O	O

The	O	O
pineal	O	O
indolamines	O	O
exhibited	O	O
mixed	O	O
actions	O	O
.	O	O

Serotonin	B-Chemical	D012701
and	O	O
N	B-Chemical	C006389
-	I-Chemical	C006389
acetyl	I-Chemical	C006389
serotonin	I-Chemical	C006389
which	O	O
augmented	O	O
ketamine	B-Chemical	D007649
DOC	O	O
,	O	O
did	O	O
not	O	O
do	O	O
so	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
pineal	O	O
gland	O	O
,	O	O
whereas	O	O
melatonin	B-Chemical	D008550
potentiated	O	O
the	O	O
ketamine	B-Chemical	D007649
DOC	O	O
in	O	O
both	O	O
the	O	O
intact	O	O
and	O	O
pinealectomized	O	O
chick	O	O
.	O	O

Ketamine	B-Chemical	D007649
was	O	O
more	O	O
potent	O	O
in	O	O
the	O	O
hypophysectomized	O	O
chick	O	O
and	O	O
the	O	O
circadian	O	O
rhythm	O	O
noted	O	O
in	O	O
the	O	O
intact	O	O
chick	O	O
was	O	O
absent	O	O
;	O	O
furthermore	O	O
,	O	O
melatonin	B-Chemical	D008550
did	O	O
not	O	O
augment	O	O
the	O	O
ketamine	B-Chemical	D007649
DOC	O	O
whereas	O	O
dopamine	B-Chemical	D004298
continued	O	O
to	O	O
do	O	O
so	O	O
.	O	O

This	O	O
study	O	O
did	O	O
not	O	O
demonstrate	O	O
a	O	O
species	O	O
difference	O	O
regarding	O	O
the	O	O
role	O	O
of	O	O
the	O	O
amines	B-Chemical	D000588
on	O	O
the	O	O
pineal	O	O
in	O	O
spite	O	O
of	O	O
the	O	O
immature	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
in	O	O
the	O	O
young	O	O
chick	O	O
and	O	O
the	O	O
intact	O	O
barrier	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
these	O	O
data	O	O
indicate	O	O
a	O	O
direct	O	O
role	O	O
of	O	O
the	O	O
pituitary	O	O
in	O	O
the	O	O
augmentation	O	O
of	O	O
ketamine	B-Chemical	D007649
DOC	O	O
induced	O	O
by	O	O
melatonin	B-Chemical	D008550
.	O	O

Furthermore	O	O
,	O	O
dopamine	B-Chemical	D004298
appeared	O	O
to	O	O
act	O	O
on	O	O
systems	O	O
more	O	O
closely	O	O
involved	O	O
with	O	O
the	O	O
induction	O	O
of	O	O
ketamine	B-Chemical	D007649
catatonia	B-Disease	D002389
rather	O	O
than	O	O
directly	O	O
on	O	O
the	O	O
pituitary	O	O
.	O	O

Multicenter	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
multiple	O	O
-	O	O
dose	O	O
,	O	O
parallel	O	O
-	O	O
groups	O	O
efficacy	O	O
and	O	O
safety	O	O
trial	O	O
of	O	O
azelastine	B-Chemical	C020976
,	O	O
chlorpheniramine	B-Chemical	D002744
,	O	O
and	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
spring	B-Disease	D006255
allergic	I-Disease	D006255
rhinitis	I-Disease	D006255
.	O	O

Azelastine	B-Chemical	C020976
,	O	O
a	O	O
novel	O	O
antiallergic	O	O
medication	O	O
,	O	O
was	O	O
compared	O	O
with	O	O
chlorpheniramine	B-Chemical	D002744
maleate	O	O
and	O	O
placebo	O	O
for	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
spring	B-Disease	D006255
allergic	I-Disease	D006255
rhinitis	I-Disease	D006255
in	O	O
a	O	O
multicenter	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
multiple	O	O
-	O	O
dose	O	O
,	O	O
parallel	O	O
-	O	O
groups	O	O
study	O	O
.	O	O

One	O	O
hundred	O	O
fifty	O	O
-	O	O
five	O	O
subjects	O	O
participated	O	O
.	O	O

Subjects	O	O
ranged	O	O
in	O	O
age	O	O
from	O	O
18	O	O
to	O	O
60	O	O
years	O	O
of	O	O
age	O	O
and	O	O
had	O	O
at	O	O
least	O	O
a	O	O
2	O	O
-	O	O
year	O	O
history	O	O
of	O	O
spring	B-Disease	D006255
allergic	I-Disease	D006255
rhinitis	I-Disease	D006255
,	O	O
confirmed	O	O
by	O	O
positive	O	O
skin	O	O
test	O	O
to	O	O
spring	O	O
aeroallergens	O	O
.	O	O

Medications	O	O
were	O	O
given	O	O
four	O	O
times	O	O
daily	O	O
;	O	O
the	O	O
azelastine	B-Chemical	C020976
groups	O	O
received	O	O
0	O	O
.	O	O

5	O	O
,	O	O
1	O	O
.	O	O

0	O	O
,	O	O
or	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
in	O	O
the	O	O
morning	O	O
and	O	O
evening	O	O
with	O	O
placebo	O	O
in	O	O
the	O	O
early	O	O
and	O	O
late	O	O
afternoon	O	O
;	O	O
the	O	O
chlorpheniramine	B-Chemical	D002744
group	O	O
received	O	O
4	O	O
.	O	O

0	O	O
mg	O	O
four	O	O
times	O	O
daily	O	O
.	O	O

Daily	O	O
subject	O	O
symptom	O	O
cards	O	O
were	O	O
completed	O	O
during	O	O
a	O	O
screening	O	O
period	O	O
to	O	O
assess	O	O
pretreatment	O	O
symptoms	O	O
and	O	O
during	O	O
a	O	O
4	O	O
-	O	O
week	O	O
treatment	O	O
period	O	O
while	O	O
subjects	O	O
received	O	O
study	O	O
medications	O	O
.	O	O

Individual	O	O
symptoms	O	O
,	O	O
total	O	O
symptoms	O	O
,	O	O
and	O	O
major	O	O
symptoms	O	O
were	O	O
compared	O	O
to	O	O
determine	O	O
efficacy	O	O
of	O	O
medication	O	O
.	O	O

Elicited	O	O
,	O	O
volunteered	O	O
,	O	O
and	O	O
observed	O	O
adverse	O	O
experiences	O	O
were	O	O
recorded	O	O
for	O	O
each	O	O
subject	O	O
and	O	O
compared	O	O
among	O	O
groups	O	O
.	O	O

Vital	O	O
signs	O	O
,	O	O
body	O	O
weights	O	O
,	O	O
serum	O	O
chemistry	O	O
values	O	O
,	O	O
complete	O	O
blood	O	O
cell	O	O
counts	O	O
,	O	O
urine	O	O
studies	O	O
,	O	O
and	O	O
electrocardiograms	O	O
were	O	O
obtained	O	O
for	O	O
each	O	O
subject	O	O
and	O	O
compared	O	O
among	O	O
groups	O	O
.	O	O

Symptoms	O	O
relief	O	O
in	O	O
the	O	O
group	O	O
receiving	O	O
the	O	O
highest	O	O
concentration	O	O
of	O	O
azelastine	B-Chemical	C020976
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
twice	O	O
daily	O	O
)	O	O
was	O	O
statistically	O	O
greater	O	O
than	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
during	O	O
all	O	O
weeks	O	O
of	O	O
the	O	O
study	O	O
.	O	O

Lower	O	O
doses	O	O
of	O	O
azelastine	B-Chemical	C020976
were	O	O
statistically	O	O
more	O	O
effective	O	O
than	O	O
placebo	O	O
only	O	O
during	O	O
portions	O	O
of	O	O
the	O	O
first	O	O
3	O	O
weeks	O	O
of	O	O
the	O	O
study	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
although	O	O
the	O	O
chlorpheniramine	B-Chemical	D002744
group	O	O
did	O	O
have	O	O
fewer	O	O
symptoms	O	O
than	O	O
the	O	O
placebo	O	O
group	O	O
during	O	O
the	O	O
study	O	O
,	O	O
the	O	O
difference	O	O
never	O	O
reached	O	O
statistical	O	O
significance	O	O
during	O	O
any	O	O
week	O	O
of	O	O
the	O	O
study	O	O
.	O	O

There	O	O
were	O	O
no	O	O
serious	O	O
side	O	O
effects	O	O
in	O	O
any	O	O
of	O	O
the	O	O
treatment	O	O
groups	O	O
.	O	O

Drowsiness	B-Disease	D006970
and	O	O
altered	B-Disease	D013651
taste	I-Disease	D013651
perception	I-Disease	D013651
were	O	O
increased	O	O
significantly	O	O
over	O	O
placebo	O	O
only	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
azelastine	B-Chemical	C020976
group	O	O
.	O	O

Azelastine	B-Chemical	C020976
appears	O	O
to	O	O
be	O	O
a	O	O
safe	O	O
,	O	O
efficacious	O	O
medication	O	O
for	O	O
seasonal	B-Disease	D006255
allergic	I-Disease	D006255
rhinitis	I-Disease	D006255
.	O	O

Obsolete	O	O
but	O	O
dangerous	O	O
antacid	O	O
preparations	O	O
.	O	O

One	O	O
case	O	O
of	O	O
acute	O	O
hypercalcaemia	B-Disease	D006934
and	O	O
two	O	O
of	O	O
recurrent	O	O
nephrolithiasis	B-Disease	D053040
are	O	O
reported	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
regularly	O	O
consumed	O	O
large	O	O
amounts	O	O
of	O	O
calcium	B-Chemical	D002119
carbon	I-Chemical	D002119
-	I-Chemical	D002119
ate	I-Chemical	D002119
-	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
powders	O	O
for	O	O
more	O	O
than	O	O
20	O	O
years	O	O
.	O	O

The	O	O
powders	O	O
had	O	O
been	O	O
obtained	O	O
from	O	O
pharmacists	O	O
unknown	O	O
to	O	O
the	O	O
patients'	O	O
medical	O	O
practitioners	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
these	O	O
preparations	O	O
were	O	O
responsible	O	O
for	O	O
the	O	O
patient's	O	O
problems	O	O
,	O	O
and	O	O
that	O	O
such	O	O
powders	O	O
should	O	O
no	O	O
longer	O	O
be	O	O
freely	O	O
obtainable	O	O
.	O	O

Prolonged	O	O
paralysis	B-Disease	D010243
due	O	O
to	O	O
nondepolarizing	B-Chemical	D003473
neuromuscular	I-Chemical	D003473
blocking	I-Chemical	D003473
agents	I-Chemical	D003473
and	O	O
corticosteroids	B-Chemical	D000305
.	O	O

The	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
nondepolarizing	B-Chemical	D003473
neuromuscular	I-Chemical	D003473
blocking	I-Chemical	D003473
agents	I-Chemical	D003473
(	O	O
ND	B-Chemical	D003473
-	I-Chemical	D003473
NMBA	I-Chemical	D003473
)	O	O
has	O	O
recently	O	O
been	O	O
implicated	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
prolonged	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
,	O	O
although	O	O
the	O	O
site	O	O
of	O	O
the	O	O
lesion	O	O
and	O	O
the	O	O
predisposing	O	O
factors	O	O
have	O	O
been	O	O
unclear	O	O
.	O	O

We	O	O
report	O	O
3	O	O
patients	O	O
(	O	O
age	O	O
37	O	O
-	O	O
52	O	O
years	O	O
)	O	O
with	O	O
acute	O	O
respiratory	B-Disease	D012131
insufficiency	I-Disease	D012131
who	O	O
developed	O	O
prolonged	O	O
weakness	B-Disease	D018908
following	O	O
the	O	O
discontinuation	O	O
of	O	O
ND	B-Chemical	D003473
-	I-Chemical	D003473
NMBAs	I-Chemical	D003473
.	O	O

Two	O	O
patients	O	O
also	O	O
received	O	O
intravenous	O	O
corticosteroids	B-Chemical	D000305
.	O	O

Renal	O	O
function	O	O
was	O	O
normal	O	O
but	O	O
hepatic	O	O
function	O	O
was	O	O
impaired	O	O
in	O	O
all	O	O
patients	O	O
,	O	O
and	O	O
all	O	O
had	O	O
acidosis	B-Disease	D000138
.	O	O

Electrophysiologic	O	O
studies	O	O
revealed	O	O
low	O	O
amplitude	O	O
compound	O	O
motor	O	O
action	O	O
potentials	O	O
,	O	O
normal	O	O
sensory	O	O
studies	O	O
,	O	O
and	O	O
fibrillations	O	O
.	O	O

Repetitive	O	O
stimulation	O	O
at	O	O
2	O	O
Hz	O	O
showed	O	O
a	O	O
decremental	O	O
response	O	O
in	O	O
2	O	O
patients	O	O
.	O	O

The	O	O
serum	O	O
vecuronium	B-Chemical	D014673
level	O	O
measured	O	O
in	O	O
1	O	O
patient	O	O
14	O	O
days	O	O
after	O	O
the	O	O
drug	O	O
had	O	O
been	O	O
discontinued	O	O
was	O	O
172	O	O
ng	O	O
/	O	O
mL	O	O
.	O	O

A	O	O
muscle	O	O
biopsy	O	O
in	O	O
this	O	O
patient	O	O
showed	O	O
loss	B-Disease	D009135
of	I-Disease	D009135
thick	I-Disease	D009135
,	I-Disease	D009135
myosin	I-Disease	D009135
filaments	I-Disease	D009135
.	O	O

The	O	O
weakness	B-Disease	D018908
in	O	O
these	O	O
patients	O	O
is	O	O
due	O	O
to	O	O
pathology	B-Disease	D009468
at	I-Disease	D009468
both	I-Disease	D009468
the	I-Disease	D009468
neuromuscular	I-Disease	D009468
junction	I-Disease	D009468
(	O	O
most	O	O
likely	O	O
due	O	O
to	O	O
ND	B-Chemical	D003473
-	I-Chemical	D003473
NMBA	I-Chemical	D003473
)	O	O
and	O	O
muscle	O	O
(	O	O
most	O	O
likely	O	O
due	O	O
to	O	O
corticosteroids	B-Chemical	D000305
)	O	O
.	O	O

Hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
and	O	O
acidosis	B-Disease	D000138
are	O	O
contributing	O	O
risk	O	O
factors	O	O
.	O	O

Prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
-	O	O
induced	O	O
bladder	B-Disease	D053201
hyperactivity	I-Disease	D053201
in	O	O
normal	O	O
,	O	O
conscious	O	O
rats	O	O
:	O	O
involvement	O	O
of	O	O
tachykinins?	O	O
In	O	O
normal	O	O
conscious	O	O
rats	O	O
investigated	O	O
by	O	O
continuous	O	O
cystometry	O	O
,	O	O
intravesically	O	O
instilled	O	O
prostaglandin	B-Chemical	D015232
(	I-Chemical	D015232
PG	I-Chemical	D015232
)	I-Chemical	D015232
E2	I-Chemical	D015232
facilitated	O	O
micturition	O	O
and	O	O
increased	O	O
basal	O	O
intravesical	O	O
pressure	O	O
.	O	O

The	O	O
effect	O	O
was	O	O
attenuated	O	O
by	O	O
both	O	O
the	O	O
NK1	O	O
receptor	O	O
selective	O	O
antagonist	O	O
RP	B-Chemical	C071693
67	I-Chemical	C071693
,	I-Chemical	C071693
580	I-Chemical	C071693
and	O	O
the	O	O
NK2	O	O
receptor	O	O
selective	O	O
antagonist	O	O
SR	B-Chemical	C073839
48	I-Chemical	C073839
,	I-Chemical	C073839
968	I-Chemical	C073839
,	O	O
given	O	O
intra	O	O
-	O	O
arterially	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
was	O	O
mediated	O	O
by	O	O
stimulation	O	O
of	O	O
both	O	O
NK1	O	O
and	O	O
NK2	O	O
receptors	O	O
.	O	O

Intra	O	O
-	O	O
arterially	O	O
given	O	O
PGE2	B-Chemical	D015232
produced	O	O
a	O	O
distinct	O	O
increase	O	O
in	O	O
bladder	O	O
pressure	O	O
before	O	O
initiating	O	O
a	O	O
micturition	O	O
reflex	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
PG	B-Chemical	D011453
had	O	O
a	O	O
direct	O	O
contractant	O	O
effect	O	O
on	O	O
the	O	O
detrusor	O	O
smooth	O	O
muscle	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
intra	O	O
-	O	O
arterial	O	O
PGE2	B-Chemical	D015232
could	O	O
not	O	O
be	O	O
blocked	O	O
by	O	O
intra	O	O
-	O	O
arterial	O	O
RP	B-Chemical	C071693
67	I-Chemical	C071693
,	I-Chemical	C071693
580	I-Chemical	C071693
or	O	O
SR	B-Chemical	C073839
48	I-Chemical	C073839
,	I-Chemical	C073839
968	I-Chemical	C073839
,	O	O
which	O	O
opens	O	O
the	O	O
possibility	O	O
that	O	O
the	O	O
micturition	O	O
reflex	O	O
elicited	O	O
by	O	O
intra	O	O
-	O	O
arterial	O	O
PGE2	B-Chemical	D015232
was	O	O
mediated	O	O
by	O	O
pathways	O	O
other	O	O
than	O	O
the	O	O
reflex	O	O
initiated	O	O
when	O	O
the	O	O
PG	B-Chemical	D011453
was	O	O
given	O	O
intravesically	O	O
.	O	O

The	O	O
present	O	O
results	O	O
thus	O	O
suggest	O	O
that	O	O
intra	O	O
-	O	O
arterial	O	O
PGE2	B-Chemical	D015232
,	O	O
given	O	O
near	O	O
the	O	O
bladder	O	O
,	O	O
may	O	O
initiate	O	O
micturition	O	O
in	O	O
the	O	O
normal	O	O
rat	O	O
chiefly	O	O
by	O	O
directly	O	O
contracting	O	O
the	O	O
smooth	O	O
muscle	O	O
of	O	O
the	O	O
detrusor	O	O
.	O	O

However	O	O
,	O	O
when	O	O
given	O	O
intravesically	O	O
,	O	O
PGE2	B-Chemical	D015232
may	O	O
stimulate	O	O
micturition	O	O
by	O	O
releasing	O	O
tachykinins	B-Chemical	D015320
from	O	O
nerves	O	O
in	O	O
and	O	O
/	O	O
or	O	O
immediately	O	O
below	O	O
the	O	O
urothelium	O	O
.	O	O

These	O	O
tachykinins	B-Chemical	D015320
,	O	O
in	O	O
turn	O	O
,	O	O
initiate	O	O
a	O	O
micturition	O	O
reflex	O	O
by	O	O
stimulating	O	O
NK1	O	O
and	O	O
NK2	O	O
receptors	O	O
.	O	O

Prostanoids	B-Chemical	D011453
may	O	O
,	O	O
via	O	O
release	O	O
of	O	O
tachykinins	B-Chemical	D015320
,	O	O
contribute	O	O
to	O	O
both	O	O
urge	O	O
and	O	O
bladder	B-Disease	D053201
hyperactivity	I-Disease	D053201
seen	O	O
in	O	O
inflammatory	O	O
conditions	O	O
of	O	O
the	O	O
lower	O	O
urinary	O	O
tract	O	O
.	O	O

Thiazide	B-Chemical	D049971
diuretics	O	O
,	O	O
hypokalemia	B-Disease	D007008
and	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

Thiazide	B-Chemical	D049971
diuretics	O	O
are	O	O
widely	O	O
accepted	O	O
as	O	O
the	O	O
cornerstone	O	O
of	O	O
antihypertensive	O	O
treatment	O	O
programs	O	O
.	O	O

Hypokalemia	B-Disease	D007008
is	O	O
a	O	O
commonly	O	O
encountered	O	O
metabolic	O	O
consequence	O	O
of	O	O
chronic	O	O
thiazide	B-Chemical	D049971
therapy	O	O
.	O	O

We	O	O
treated	O	O
38	O	O
patients	O	O
(	O	O
22	O	O
low	O	O
renin	O	O
,	O	O
16	O	O
normal	O	O
renin	O	O
)	O	O
with	O	O
moderate	O	O
diastolic	B-Disease	C563897
hypertension	I-Disease	C563897
with	O	O
hydrochlorothiazide	B-Chemical	D006852
(	O	O
HCTC	B-Chemical	D006852
)	O	O
administered	O	O
on	O	O
a	O	O
twice	O	O
daily	O	O
schedule	O	O
.	O	O

Initial	O	O
dose	O	O
was	O	O
50	O	O
mg	O	O
and	O	O
the	O	O
dose	O	O
was	O	O
increased	O	O
at	O	O
monthly	O	O
intervals	O	O
to	O	O
100	O	O
mg	O	O
,	O	O
150	O	O
mg	O	O
and	O	O
200	O	O
mg	O	O
daily	O	O
until	O	O
blood	O	O
pressure	O	O
normalized	O	O
.	O	O

The	O	O
serum	O	O
K	B-Chemical	D011188
during	O	O
the	O	O
control	O	O
period	O	O
was	O	O
4	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
mEq	O	O
/	O	O
l	O	O
an	O	O
on	O	O
50	O	O
,	O	O
100	O	O
,	O	O
150	O	O
and	O	O
200	O	O
mg	O	O
HCTZ	B-Chemical	D006852
daily	O	O
3	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
,	O	O
3	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
,	O	O
2	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
,	O	O
and	O	O
2	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
mEq	O	O
/	O	O
l	O	O
,	O	O
respectively	O	O
.	O	O

Corresponding	O	O
figures	O	O
for	O	O
whole	O	O
body	O	O
K	B-Chemical	D011188
were	O	O
4107	O	O
+	O	O
/	O	O
-	O	O
208	O	O
,	O	O
3722	O	O
+	O	O
/	O	O
-	O	O
319	O	O
,	O	O
3628	O	O
+	O	O
/	O	O
-	O	O
257	O	O
,	O	O
3551	O	O
+	O	O
/	O	O
-	O	O
336	O	O
,	O	O
and	O	O
3269	O	O
+	O	O
/	O	O
-	O	O
380	O	O
mEq	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
13	O	O
patients	O	O
we	O	O
observed	O	O
the	O	O
effects	O	O
of	O	O
HCTZ	B-Chemical	D006852
therapy	O	O
(	O	O
100	O	O
mg	O	O
daily	O	O
)	O	O
on	O	O
the	O	O
occurrence	O	O
of	O	O
PVC's	O	O
during	O	O
rest	O	O
as	O	O
well	O	O
as	O	O
during	O	O
static	O	O
and	O	O
dynamic	O	O
exercise	O	O
.	O	O

During	O	O
rest	O	O
we	O	O
observed	O	O
0	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

08	O	O
PVC	O	O
beats	O	O
/	O	O
min	O	O
+	O	O
/	O	O
-	O	O
SEM	O	O
and	O	O
during	O	O
static	O	O
and	O	O
dynamic	O	O
exercise	O	O
0	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

06	O	O
and	O	O
0	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

15	O	O
,	O	O
respectively	O	O
.	O	O

Corresponding	O	O
figures	O	O
during	O	O
HCTZ	B-Chemical	D006852
therapy	O	O
100	O	O
mg	O	O
daily	O	O
were	O	O
1	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
,	O	O
3	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
and	O	O
5	O	O
.	O	O

7	O	O
4	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
PVC's	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
fall	O	O
in	O	O
serum	O	O
K+	O	O
observed	O	O
r	O	O
=	O	O
0	O	O
.	O	O

72	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
.	O	O

In	O	O
conclusion	O	O
we	O	O
found	O	O
that	O	O
thiazide	B-Chemical	D049971
diuretics	O	O
cause	O	O
hypokalemia	B-Disease	D007008
and	O	O
depletion	O	O
of	O	O
body	O	O
potassium	B-Chemical	D011188
.	O	O

The	O	O
more	O	O
profound	O	O
hypokalemia	B-Disease	D007008
,	O	O
the	O	O
greater	O	O
the	O	O
propensity	O	O
for	O	O
the	O	O
occurrence	O	O
of	O	O
PVC's	O	O
.	O	O

Diuretics	O	O
,	O	O
potassium	B-Chemical	D011188
and	O	O
arrhythmias	B-Disease	D001145
in	O	O
hypertensive	B-Disease	D006973
coronary	B-Disease	D003327
disease	I-Disease	D003327
.	O	O

It	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
modest	O	O
changes	O	O
in	O	O
plasma	O	O
potassium	B-Chemical	D011188
can	O	O
alter	O	O
the	O	O
tendency	O	O
towards	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

If	O	O
this	O	O
were	O	O
so	O	O
,	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
might	O	O
be	O	O
especially	O	O
susceptible	O	O
.	O	O

Thus	O	O
,	O	O
myocardial	O	O
electrical	O	O
excitability	O	O
was	O	O
measured	O	O
in	O	O
patients	O	O
with	O	O
mild	O	O
essential	O	O
hypertension	B-Disease	D006973
and	O	O
known	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
after	O	O
8	O	O
weeks	O	O
of	O	O
treatment	O	O
with	O	O
a	O	O
potassium	B-Chemical	D011188
-	O	O
conserving	O	O
diuretic	O	O
(	O	O
amiloride	B-Chemical	D000584
)	O	O
and	O	O
a	O	O
similar	O	O
period	O	O
on	O	O
a	O	O
potassium	B-Chemical	D011188
-	O	O
losing	O	O
diuretic	O	O
(	O	O
chlorthalidone	B-Chemical	D002752
)	O	O
in	O	O
a	O	O
randomised	O	O
study	O	O
.	O	O

Plasma	O	O
potassium	B-Chemical	D011188
concentrations	O	O
were	O	O
on	O	O
average	O	O
1	O	O
mmol	O	O
/	O	O
L	O	O
lower	O	O
during	O	O
the	O	O
chlorthalidone	B-Chemical	D002752
phase	O	O
compared	O	O
to	O	O
amiloride	B-Chemical	D000584
therapy	O	O
.	O	O

Blood	O	O
pressure	O	O
and	O	O
volume	O	O
states	O	O
as	O	O
assessed	O	O
by	O	O
bodyweight	O	O
,	O	O
plasma	O	O
renin	O	O
and	O	O
noradrenaline	B-Chemical	D009638
(	O	O
norepinephrine	B-Chemical	D009638
)	O	O
concentrations	O	O
were	O	O
similar	O	O
on	O	O
the	O	O
2	O	O
regimens	O	O
.	O	O

Compared	O	O
to	O	O
amiloride	B-Chemical	D000584
treatment	O	O
,	O	O
the	O	O
chlorthalidone	B-Chemical	D002752
phase	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
frequency	O	O
of	O	O
ventricular	B-Disease	D018879
ectopic	I-Disease	D018879
beats	I-Disease	D018879
(	O	O
24	O	O
-	O	O
hour	O	O
Holter	O	O
monitoring	O	O
)	O	O
and	O	O
a	O	O
higher	O	O
Lown	O	O
grading	O	O
,	O	O
increased	O	O
upslope	O	O
and	O	O
duration	O	O
of	O	O
the	O	O
monophasic	O	O
action	O	O
potential	O	O
,	O	O
prolonged	O	O
ventricular	O	O
effective	O	O
refractory	O	O
period	O	O
,	O	O
and	O	O
increased	O	O
electrical	O	O
instability	O	O
during	O	O
programmed	O	O
ventricular	O	O
stimulation	O	O
.	O	O

The	O	O
above	O	O
results	O	O
indicate	O	O
that	O	O
because	O	O
potassium	B-Chemical	D011188
-	O	O
losing	O	O
diuretic	O	O
therapy	O	O
can	O	O
increase	O	O
myocardial	O	O
electrical	O	O
excitability	O	O
in	O	O
patients	O	O
with	O	O
ischaemic	B-Disease	D017202
heart	I-Disease	D017202
disease	I-Disease	D017202
,	O	O
even	O	O
minor	O	O
falls	O	O
in	O	O
plasma	O	O
potassium	B-Chemical	D011188
concentrations	O	O
are	O	O
probably	O	O
best	O	O
avoided	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

GABA	B-Chemical	D005680
involvement	O	O
in	O	O
naloxone	B-Chemical	D009270
induced	O	O
reversal	O	O
of	O	O
respiratory	B-Disease	D012133
paralysis	I-Disease	D012133
produced	O	O
by	O	O
thiopental	B-Chemical	D013874
.	O	O

No	O	O
agent	O	O
is	O	O
yet	O	O
available	O	O
to	O	O
reverse	O	O
respiratory	B-Disease	D012133
paralysis	I-Disease	D012133
produced	O	O
by	O	O
CNS	O	O
depressants	O	O
,	O	O
such	O	O
as	O	O
general	O	O
anesthetics	O	O
.	O	O

In	O	O
this	O	O
study	O	O
naloxone	B-Chemical	D009270
reversed	O	O
respiratory	B-Disease	D012133
paralysis	I-Disease	D012133
induced	O	O
by	O	O
thiopental	B-Chemical	D013874
in	O	O
rats	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
.	O	O

thiopental	B-Chemical	D013874
produced	O	O
anesthesia	O	O
without	O	O
altering	O	O
respiratory	O	O
rate	O	O
,	O	O
increased	O	O
GABA	B-Chemical	D005680
,	O	O
decreased	O	O
glutamate	B-Chemical	D018698
,	O	O
and	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
aspartate	B-Chemical	D001224
or	O	O
glycine	B-Chemical	D005998
levels	O	O
compared	O	O
to	O	O
controls	O	O
in	O	O
rat	O	O
cortex	O	O
and	O	O
brain	O	O
stem	O	O
.	O	O

Pretreatment	O	O
of	O	O
rats	O	O
with	O	O
thiosemicarbazide	B-Chemical	C005151
for	O	O
30	O	O
minutes	O	O
abolished	O	O
the	O	O
anesthetic	O	O
action	O	O
as	O	O
well	O	O
as	O	O
the	O	O
respiratory	O	O
depressant	O	O
action	O	O
of	O	O
thiopental	B-Chemical	D013874
.	O	O

50	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
.	O	O

thiopental	B-Chemical	D013874
produced	O	O
respiratory	B-Disease	D012131
arrest	I-Disease	D012131
with	O	O
further	O	O
increase	O	O
in	O	O
GABA	B-Chemical	D005680
and	O	O
decrease	O	O
in	O	O
glutamate	B-Chemical	D018698
again	O	O
in	O	O
cortex	O	O
and	O	O
brain	O	O
stem	O	O
without	O	O
affecting	O	O
any	O	O
of	O	O
the	O	O
amino	B-Chemical	D000596
acids	I-Chemical	D000596
studied	O	O
in	O	O
four	O	O
regions	O	O
of	O	O
rat	O	O
brain	O	O
.	O	O

Naloxone	B-Chemical	D009270
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
reversed	O	O
respiratory	B-Disease	D012133
paralysis	I-Disease	D012133
,	O	O
glutamate	B-Chemical	D018698
and	O	O
GABA	B-Chemical	D005680
levels	O	O
to	O	O
control	O	O
values	O	O
in	O	O
brain	O	O
stem	O	O
and	O	O
cortex	O	O
with	O	O
no	O	O
changes	O	O
in	O	O
caudate	O	O
or	O	O
cerebellum	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
naloxone	B-Chemical	D009270
reverses	O	O
respiratory	B-Disease	D012133
paralysis	I-Disease	D012133
produced	O	O
by	O	O
thiopental	B-Chemical	D013874
and	O	O
involves	O	O
GABA	B-Chemical	D005680
in	O	O
its	O	O
action	O	O
.	O	O

National	O	O
project	O	O
on	O	O
the	O	O
prevention	O	O
of	O	O
mother	O	O
-	O	O
to	O	O
-	O	O
infant	O	O
infection	B-Disease	D006509
by	I-Disease	D006509
hepatitis	I-Disease	D006509
B	I-Disease	D006509
virus	I-Disease	D006509
in	O	O
Japan	O	O
.	O	O

In	O	O
Japan	O	O
,	O	O
a	O	O
nationwide	O	O
prevention	O	O
program	O	O
against	O	O
mother	O	O
-	O	O
to	O	O
-	O	O
infant	O	O
infection	B-Disease	D006509
by	I-Disease	D006509
hepatitis	I-Disease	D006509
B	I-Disease	D006509
virus	I-Disease	D006509
(	O	O
HBV	O	O
)	O	O
started	O	O
in	O	O
1985	O	O
.	O	O

This	O	O
program	O	O
consists	O	O
of	O	O
double	O	O
screenings	O	O
of	O	O
pregnant	O	O
women	O	O
and	O	O
prophylactic	O	O
treatment	O	O
to	O	O
the	O	O
infants	O	O
born	O	O
to	O	O
both	O	O
hepatitis	B-Chemical	D006514
B	I-Chemical	D006514
surface	I-Chemical	D006514
antigen	I-Chemical	D006514
(	O	O
HBsAg	B-Chemical	D006514
)	O	O
and	O	O
hepatitis	B-Chemical	D006513
B	I-Chemical	D006513
e	I-Chemical	D006513
antigen	I-Chemical	D006513
(	O	O
HBeAg	B-Chemical	D006513
)	O	O
positive	O	O
mothers	O	O
.	O	O

These	O	O
infants	O	O
are	O	O
treated	O	O
with	O	O
two	O	O
injections	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
(	O	O
HBIG	O	O
)	O	O
and	O	O
at	O	O
least	O	O
three	O	O
injections	O	O
of	O	O
plasma	O	O
derived	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
vaccine	O	O
.	O	O

We	O	O
sent	O	O
questionnaires	O	O
about	O	O
the	O	O
numbers	O	O
of	O	O
each	O	O
procedure	O	O
or	O	O
examination	O	O
during	O	O
nine	O	O
months	O	O
of	O	O
investigation	O	O
period	O	O
to	O	O
each	O	O
local	O	O
government	O	O
in	O	O
1986	O	O
and	O	O
1987	O	O
.	O	O

93	O	O
.	O	O

4%	O	O
pregnant	O	O
women	O	O
had	O	O
the	O	O
chance	O	O
to	O	O
be	O	O
examined	O	O
for	O	O
HBsAg	B-Chemical	D006514
,	O	O
and	O	O
the	O	O
positive	O	O
rate	O	O
was	O	O
1	O	O
.	O	O

4	O	O
to	O	O
1	O	O
.	O	O

5%	O	O
.	O	O

The	O	O
HBeAg	B-Chemical	D006513
positive	O	O
rate	O	O
in	O	O
HBsAg	B-Chemical	D006514
positive	O	O
was	O	O
23	O	O
to	O	O
26%	O	O
.	O	O

The	O	O
HBsAg	B-Chemical	D006514
positive	O	O
rate	O	O
in	O	O
neonates	O	O
and	O	O
in	O	O
infants	O	O
before	O	O
two	O	O
months	O	O
were	O	O
3%	O	O
and	O	O
2%	O	O
respectively	O	O
.	O	O

Some	O	O
problems	O	O
may	O	O
arise	O	O
,	O	O
because	O	O
27	O	O
to	O	O
30%	O	O
of	O	O
infants	O	O
need	O	O
the	O	O
fourth	O	O
vaccination	O	O
in	O	O
some	O	O
restricted	O	O
areas	O	O
.	O	O

Nociceptive	O	O
effects	O	O
induced	O	O
by	O	O
intrathecal	O	O
administration	O	O
of	O	O
prostaglandin	B-Chemical	D015230
D2	I-Chemical	D015230
,	O	O
E2	O	O
,	O	O
or	O	O
F2	O	O
alpha	O	O
to	O	O
conscious	O	O
mice	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
intrathecal	O	O
administration	O	O
of	O	O
prostaglandins	B-Chemical	D011453
on	O	O
pain	B-Disease	D010146
responses	O	O
in	O	O
conscious	O	O
mice	O	O
were	O	O
evaluated	O	O
by	O	O
using	O	O
hot	O	O
plate	O	O
and	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
writhing	O	O
tests	O	O
.	O	O

Prostaglandin	B-Chemical	D015230
D2	I-Chemical	D015230
(	O	O
0	O	O
.	O	O

5	O	O
-	O	O
3	O	O
ng	O	O
/	O	O
mouse	O	O
)	O	O
had	O	O
a	O	O
hyperalgesic	B-Disease	D006930
action	O	O
on	O	O
the	O	O
response	O	O
to	O	O
a	O	O
hot	O	O
plate	O	O
during	O	O
a	O	O
3	O	O
-	O	O
60	O	O
min	O	O
period	O	O
after	O	O
injection	O	O
.	O	O

Prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
showed	O	O
a	O	O
hyperalgesic	B-Disease	D006930
effect	O	O
at	O	O
doses	O	O
of	O	O
1	O	O
pg	B-Chemical	D011453
to	O	O
10	O	O
ng	O	O
/	O	O
mouse	O	O
,	O	O
but	O	O
the	O	O
effect	O	O
lasted	O	O
shorter	O	O
(	O	O
3	O	O
-	O	O
30	O	O
min	O	O
)	O	O
than	O	O
that	O	O
of	O	O
prostaglandin	B-Chemical	D015230
D2	I-Chemical	D015230
.	O	O

Similar	O	O
results	O	O
were	O	O
obtained	O	O
by	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
writhing	O	O
tests	O	O
.	O	O

The	O	O
hyperalgesic	B-Disease	D006930
effect	O	O
of	O	O
prostaglandin	B-Chemical	D015230
D2	I-Chemical	D015230
was	O	O
blocked	O	O
by	O	O
simultaneous	O	O
injection	O	O
of	O	O
a	O	O
substance	O	O
P	O	O
antagonist	O	O
(	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
100	O	O
ng	O	O
)	O	O
but	O	O
not	O	O
by	O	O
AH6809	B-Chemical	C053876
,	O	O
a	O	O
prostanoid	O	O
EP1	O	O
-	O	O
receptor	O	O
antagonist	O	O
.	O	O

Conversely	O	O
,	O	O
prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
was	O	O
blocked	O	O
by	O	O
AH6809	B-Chemical	C053876
(	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
500	O	O
ng	O	O
)	O	O
but	O	O
not	O	O
by	O	O
the	O	O
substance	O	O
P	O	O
antagonist	O	O
.	O	O

Prostaglandin	B-Chemical	D015237
F2	I-Chemical	D015237
alpha	I-Chemical	D015237
had	O	O
little	O	O
effect	O	O
on	O	O
pain	B-Disease	D010146
responses	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
both	O	O
prostaglandin	B-Chemical	D015230
D2	I-Chemical	D015230
and	O	O
prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
exert	O	O
hyperalgesia	B-Disease	D006930
in	O	O
the	O	O
spinal	O	O
cord	O	O
,	O	O
but	O	O
in	O	O
different	O	O
ways	O	O
.	O	O

Swallowing	O	O
-	O	O
induced	O	O
atrial	B-Disease	D013617
tachyarrhythmia	I-Disease	D013617
triggered	O	O
by	O	O
salbutamol	B-Chemical	D000420
:	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

CASE	O	O
:	O	O
A	O	O
49	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
experienced	O	O
chest	O	O
discomfort	O	O
while	O	O
swallowing	O	O
.	O	O

On	O	O
electrocardiogram	O	O
,	O	O
episodes	O	O
of	O	O
atrial	B-Disease	D013617
tachyarrhythmia	I-Disease	D013617
were	O	O
recorded	O	O
immediately	O	O
after	O	O
swallowing	O	O
;	O	O
24	O	O
-	O	O
hour	O	O
Holter	O	O
monitoring	O	O
recorded	O	O
several	O	O
events	O	O
.	O	O

The	O	O
arrhythmia	B-Disease	D001145
resolved	O	O
after	O	O
therapy	O	O
with	O	O
atenolol	B-Chemical	D001262
,	O	O
but	O	O
recurred	O	O
a	O	O
year	O	O
later	O	O
.	O	O

The	O	O
patient	O	O
noticed	O	O
that	O	O
before	O	O
these	O	O
episodes	O	O
he	O	O
had	O	O
been	O	O
using	O	O
an	O	O
inhalator	O	O
of	O	O
salbutamol	B-Chemical	D000420
.	O	O

After	O	O
stopping	O	O
the	O	O
beta	O	O
-	O	O
agonist	O	O
,	O	O
and	O	O
after	O	O
a	O	O
week	O	O
with	O	O
the	O	O
atenolol	B-Chemical	D001262
,	O	O
the	O	O
arrhythmia	B-Disease	D001145
disappeared	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Swallowing	O	O
-	O	O
induced	O	O
atrial	B-Disease	D013617
tachyarrhythmia	I-Disease	D013617
(	O	O
SIAT	B-Disease	D013617
)	O	O
is	O	O
a	O	O
rare	O	O
phenomenon	O	O
.	O	O

Fewer	O	O
than	O	O
50	O	O
cases	O	O
of	O	O
SIAT	B-Disease	D013617
have	O	O
been	O	O
described	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

This	O	O
article	O	O
summarizes	O	O
all	O	O
the	O	O
cases	O	O
published	O	O
,	O	O
creating	O	O
a	O	O
comprehensive	O	O
review	O	O
of	O	O
the	O	O
current	O	O
knowledge	O	O
and	O	O
approach	O	O
to	O	O
SIAT	B-Disease	D013617
.	O	O

It	O	O
discusses	O	O
demographics	O	O
,	O	O
clinical	O	O
characteristics	O	O
and	O	O
types	O	O
of	O	O
arrhythmia	B-Disease	D001145
,	O	O
postulated	O	O
mechanisms	O	O
of	O	O
SIAT	B-Disease	D013617
,	O	O
and	O	O
different	O	O
treatment	O	O
possibilities	O	O
such	O	O
as	O	O
medications	O	O
,	O	O
surgery	O	O
,	O	O
and	O	O
radiofrequency	O	O
catheter	O	O
ablation	O	O
(	O	O
RFCA	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Salbutamol	B-Chemical	D000420
is	O	O
presented	O	O
here	O	O
as	O	O
a	O	O
possible	O	O
trigger	O	O
for	O	O
SIAT	B-Disease	D013617
.	O	O

Although	O	O
it	O	O
is	O	O
difficult	O	O
to	O	O
define	O	O
causality	O	O
in	O	O
a	O	O
case	O	O
report	O	O
,	O	O
it	O	O
is	O	O
logical	O	O
to	O	O
think	O	O
that	O	O
a	O	O
beta	O	O
-	O	O
agonist	O	O
like	O	O
salbutamol	B-Chemical	D000420
(	O	O
known	O	O
to	O	O
induce	O	O
tachycardia	B-Disease	D013610
)	O	O
may	O	O
be	O	O
the	O	O
trigger	O	O
of	O	O
adrenergic	O	O
reflexes	O	O
originating	O	O
in	O	O
the	O	O
esophagus	O	O
while	O	O
swallowing	O	O
and	O	O
that	O	O
a	O	O
beta	O	O
-	O	O
blocker	O	O
such	O	O
as	O	O
atenolol	B-Chemical	D001262
(	O	O
that	O	O
blocks	O	O
the	O	O
adrenergic	O	O
activity	O	O
)	O	O
may	O	O
relieve	O	O
it	O	O
.	O	O

Coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
treatment	O	O
ameliorates	O	O
acute	O	O
cisplatin	B-Chemical	D002945
nephrotoxicity	B-Disease	D007674
in	O	O
mice	O	O
.	O	O

The	O	O
nephroprotective	O	O
effect	O	O
of	O	O
coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
was	O	O
investigated	O	O
in	O	O
mice	O	O
with	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
injury	I-Disease	D058186
induced	O	O
by	O	O
a	O	O
single	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injection	O	O
of	O	O
cisplatin	B-Chemical	D002945
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
treatment	O	O
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
was	O	O
applied	O	O
for	O	O
6	O	O
consecutive	O	O
days	O	O
,	O	O
starting	O	O
1	O	O
day	O	O
before	O	O
cisplatin	B-Chemical	D002945
administration	O	O
.	O	O

Coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
significantly	O	O
reduced	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
and	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
which	O	O
were	O	O
increased	O	O
by	O	O
cisplatin	B-Chemical	D002945
.	O	O

Coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
significantly	O	O
compensated	O	O
deficits	O	O
in	O	O
the	O	O
antioxidant	O	O
defense	O	O
mechanisms	O	O
(	O	O
reduced	B-Chemical	D005978
glutathione	I-Chemical	D005978
level	O	O
and	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
activity	O	O
)	O	O
,	O	O
suppressed	O	O
lipid	O	O
peroxidation	O	O
,	O	O
decreased	O	O
the	O	O
elevations	O	O
of	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
factor	O	O
-	O	O
alpha	O	O
,	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
and	O	O
platinum	B-Chemical	D010984
ion	O	O
concentration	O	O
,	O	O
and	O	O
attenuated	O	O
the	O	O
reductions	O	O
of	O	O
selenium	B-Chemical	D012643
and	O	O
zinc	B-Chemical	D015032
ions	O	O
in	O	O
renal	O	O
tissue	O	O
resulted	O	O
from	O	O
cisplatin	B-Chemical	D002945
administration	O	O
.	O	O

Also	O	O
,	O	O
histopathological	O	O
renal	B-Disease	D007674
tissue	I-Disease	D007674
damage	I-Disease	D007674
mediated	O	O
by	O	O
cisplatin	B-Chemical	D002945
was	O	O
ameliorated	O	O
by	O	O
coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
treatment	O	O
.	O	O

Immunohistochemical	O	O
analysis	O	O
revealed	O	O
that	O	O
coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
significantly	O	O
decreased	O	O
the	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
overexpression	O	O
of	O	O
inducible	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
,	O	O
nuclear	O	O
factor	O	O
-	O	O
kappaB	O	O
,	O	O
caspase	O	O
-	O	O
3	O	O
and	O	O
p53	O	O
in	O	O
renal	O	O
tissue	O	O
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
coenzyme	B-Chemical	C024989
Q10	I-Chemical	C024989
represents	O	O
a	O	O
potential	O	O
therapeutic	O	O
option	O	O
to	O	O
protect	O	O
against	O	O
acute	O	O
cisplatin	B-Chemical	D002945
nephrotoxicity	B-Disease	D007674
commonly	O	O
encountered	O	O
in	O	O
clinical	O	O
practice	O	O
.	O	O

Metformin	B-Chemical	D008687
prevents	O	O
experimental	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
by	O	O
a	O	O
mitochondria	O	O
-	O	O
dependent	O	O
pathway	O	O
.	O	O

The	O	O
antidiabetic	O	O
drug	O	O
metformin	B-Chemical	D008687
can	O	O
diminish	O	O
apoptosis	O	O
induced	O	O
by	O	O
oxidative	O	O
stress	O	O
in	O	O
endothelial	O	O
cells	O	O
and	O	O
prevent	O	O
vascular	B-Disease	D014652
dysfunction	I-Disease	D014652
even	O	O
in	O	O
nondiabetic	O	O
patients	O	O
.	O	O

Here	O	O
we	O	O
tested	O	O
whether	O	O
it	O	O
has	O	O
a	O	O
beneficial	O	O
effect	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
gentamicin	B-Chemical	D005839
toxicity	B-Disease	D064420
.	O	O

Mitochondrial	O	O
analysis	O	O
,	O	O
respiration	O	O
intensity	O	O
,	O	O
levels	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
,	O	O
permeability	O	O
transition	O	O
,	O	O
and	O	O
cytochrome	O	O
c	O	O
release	O	O
were	O	O
assessed	O	O
3	O	O
and	O	O
6	O	O
days	O	O
after	O	O
gentamicin	B-Chemical	D005839
administration	O	O
.	O	O

Metformin	B-Chemical	D008687
treatment	O	O
fully	O	O
blocked	O	O
gentamicin	B-Chemical	D005839
-	O	O
mediated	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

This	O	O
was	O	O
accompanied	O	O
by	O	O
a	O	O
lower	O	O
activity	O	O
of	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
D	O	O
-	O	O
glucosaminidase	O	O
,	O	O
together	O	O
with	O	O
a	O	O
decrease	O	O
of	O	O
lipid	O	O
peroxidation	O	O
and	O	O
increase	O	O
of	O	O
antioxidant	O	O
systems	O	O
.	O	O

Metformin	B-Chemical	D008687
also	O	O
protected	O	O
the	O	O
kidney	O	O
from	O	O
histological	O	O
damage	O	O
6	O	O
days	O	O
after	O	O
gentamicin	B-Chemical	D005839
administration	O	O
.	O	O

These	O	O
in	O	O
vivo	O	O
markers	O	O
of	O	O
kidney	B-Disease	D007674
dysfunction	I-Disease	D007674
and	O	O
their	O	O
correction	O	O
by	O	O
metformin	B-Chemical	D008687
were	O	O
complemented	O	O
by	O	O
in	O	O
vitro	O	O
studies	O	O
of	O	O
mitochondrial	O	O
function	O	O
.	O	O

We	O	O
found	O	O
that	O	O
gentamicin	B-Chemical	D005839
treatment	O	O
depleted	O	O
respiratory	O	O
components	O	O
(	O	O
cytochrome	O	O
c	O	O
,	O	O
NADH	O	O
)	O	O
,	O	O
probably	O	O
due	O	O
to	O	O
the	O	O
opening	O	O
of	O	O
mitochondrial	O	O
transition	O	O
pores	O	O
.	O	O

These	O	O
injuries	O	O
,	O	O
partly	O	O
mediated	O	O
by	O	O
a	O	O
rise	O	O
in	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
from	O	O
the	O	O
electron	O	O
transfer	O	O
chain	O	O
,	O	O
were	O	O
significantly	O	O
decreased	O	O
by	O	O
metformin	B-Chemical	D008687
.	O	O

Thus	O	O
,	O	O
our	O	O
study	O	O
suggests	O	O
that	O	O
pleiotropic	O	O
effects	O	O
of	O	O
metformin	B-Chemical	D008687
can	O	O
lessen	O	O
gentamicin	B-Chemical	D005839
nephrotoxicity	B-Disease	D007674
and	O	O
improve	O	O
mitochondrial	O	O
homeostasis	O	O
.	O	O

Sedation	O	O
depth	O	O
during	O	O
spinal	O	O
anesthesia	O	O
and	O	O
the	O	O
development	O	O
of	O	O
postoperative	O	O
delirium	B-Disease	D003693
in	O	O
elderly	O	O
patients	O	O
undergoing	O	O
hip	B-Disease	D006620
fracture	I-Disease	D006620
repair	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
whether	O	O
limiting	O	O
intraoperative	O	O
sedation	O	O
depth	O	O
during	O	O
spinal	O	O
anesthesia	O	O
for	O	O
hip	B-Disease	D006620
fracture	I-Disease	D006620
repair	O	O
in	O	O
elderly	O	O
patients	O	O
can	O	O
decrease	O	O
the	O	O
prevalence	O	O
of	O	O
postoperative	O	O
delirium	B-Disease	D003693
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
controlled	O	O
trial	O	O
at	O	O
an	O	O
academic	O	O
medical	O	O
center	O	O
of	O	O
elderly	O	O
patients	O	O
(	O	O
>or=65	O	O
years	O	O
)	O	O
without	O	O
preoperative	O	O
delirium	B-Disease	D003693
or	O	O
severe	O	O
dementia	B-Disease	D003704
who	O	O
underwent	O	O
hip	B-Disease	D006620
fracture	I-Disease	D006620
repair	O	O
under	O	O
spinal	O	O
anesthesia	O	O
with	O	O
propofol	B-Chemical	D015742
sedation	O	O
.	O	O

Sedation	O	O
depth	O	O
was	O	O
titrated	O	O
using	O	O
processed	O	O
electroencephalography	O	O
with	O	O
the	O	O
bispectral	O	O
index	O	O
(	O	O
BIS	O	O
)	O	O
,	O	O
and	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
deep	O	O
(	O	O
BIS	O	O
,	O	O
approximately	O	O
50	O	O
)	O	O
or	O	O
light	O	O
(	O	O
BIS	O	O
,	O	O
>or=80	O	O
)	O	O
sedation	O	O
.	O	O

Postoperative	O	O
delirium	B-Disease	D003693
was	O	O
assessed	O	O
as	O	O
defined	O	O
by	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	B-Disease	D001523
Disorders	I-Disease	D001523
(	O	O
Third	O	O
Edition	O	O
Revised	O	O
)	O	O
criteria	O	O
using	O	O
the	O	O
Confusion	O	O
Assessment	O	O
Method	O	O
beginning	O	O
at	O	O
any	O	O
time	O	O
from	O	O
the	O	O
second	O	O
day	O	O
after	O	O
surgery	O	O
.	O	O

RESULTS	O	O
:	O	O
From	O	O
April	O	O
2	O	O
,	O	O
2005	O	O
,	O	O
through	O	O
October	O	O
30	O	O
,	O	O
2008	O	O
,	O	O
a	O	O
total	O	O
of	O	O
114	O	O
patients	O	O
were	O	O
randomized	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
postoperative	O	O
delirium	B-Disease	D003693
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
light	O	O
sedation	O	O
group	O	O
(	O	O
11	O	O
/	O	O
57	O	O
[	O	O
19%	O	O
]	O	O
vs	O	O
23	O	O
/	O	O
57	O	O
[	O	O
40%	O	O
]	O	O
in	O	O
the	O	O
deep	O	O
sedation	O	O
group	O	O
;	O	O
P=	O	O
.	O	O

02	O	O
)	O	O
,	O	O
indicating	O	O
that	O	O
1	O	O
incident	O	O
of	O	O
delirium	B-Disease	D003693
will	O	O
be	O	O
prevented	O	O
for	O	O
every	O	O
4	O	O
.	O	O

7	O	O
patients	O	O
treated	O	O
with	O	O
light	O	O
sedation	O	O
.	O	O

The	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
number	O	O
of	O	O
days	O	O
of	O	O
delirium	B-Disease	D003693
during	O	O
hospitalization	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
light	O	O
sedation	O	O
group	O	O
than	O	O
in	O	O
the	O	O
deep	O	O
sedation	O	O
group	O	O
(	O	O
0	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5	O	O
days	O	O
vs	O	O
1	O	O
.	O	O

4+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

0	O	O
days	O	O
;	O	O
P=	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
use	O	O
of	O	O
light	O	O
propofol	B-Chemical	D015742
sedation	O	O
decreased	O	O
the	O	O
prevalence	O	O
of	O	O
postoperative	O	O
delirium	B-Disease	D003693
by	O	O
50%	O	O
compared	O	O
with	O	O
deep	O	O
sedation	O	O
.	O	O

Limiting	O	O
depth	O	O
of	O	O
sedation	O	O
during	O	O
spinal	O	O
anesthesia	O	O
is	O	O
a	O	O
simple	O	O
,	O	O
safe	O	O
,	O	O
and	O	O
cost	O	O
-	O	O
effective	O	O
intervention	O	O
for	O	O
preventing	O	O
postoperative	O	O
delirium	B-Disease	D003693
in	O	O
elderly	O	O
patients	O	O
that	O	O
could	O	O
be	O	O
widely	O	O
and	O	O
readily	O	O
adopted	O	O
.	O	O

Sorafenib	B-Chemical	C471405
-	O	O
induced	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
due	O	O
to	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
.	O	O

A	O	O
65	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
advanced	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
was	O	O
admitted	O	O
due	O	O
to	O	O
continuing	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
at	O	O
rest	O	O
.	O	O

Two	O	O
weeks	O	O
before	O	O
his	O	O
admission	O	O
,	O	O
sorafenib	B-Chemical	C471405
had	O	O
been	O	O
started	O	O
.	O	O

He	O	O
was	O	O
diagnosed	O	O
with	O	O
non	O	O
-	O	O
ST	O	O
-	O	O
elevation	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
by	O	O
laboratory	O	O
data	O	O
and	O	O
electrocardiogram	O	O
.	O	O

Enhanced	O	O
heart	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
also	O	O
showed	O	O
subendocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
no	O	O
stenosis	O	O
in	O	O
coronary	O	O
arteries	O	O
on	O	O
angiography	O	O
.	O	O

Coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
was	O	O
induced	O	O
by	O	O
a	O	O
provocative	O	O
test	O	O
.	O	O

Cessation	O	O
of	O	O
sorafenib	B-Chemical	C471405
and	O	O
administration	O	O
of	O	O
Ca	B-Chemical	D002118
-	O	O
channel	O	O
blocker	O	O
and	O	O
nitrates	B-Chemical	D009566
ameliorated	O	O
his	O	O
symptoms	O	O
,	O	O
but	O	O
relapse	O	O
occurred	O	O
after	O	O
resumption	O	O
of	O	O
sorafenib	B-Chemical	C471405
.	O	O

Addition	O	O
of	O	O
oral	O	O
nicorandil	B-Chemical	D020108
reduced	O	O
his	O	O
symptoms	O	O
and	O	O
maintained	O	O
stable	B-Disease	D060050
angina	I-Disease	D060050
status	O	O
.	O	O

We	O	O
report	O	O
the	O	O
first	O	O
case	O	O
of	O	O
sorafenib	B-Chemical	C471405
-	O	O
induced	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
.	O	O

Sorafenib	B-Chemical	C471405
is	O	O
a	O	O
multikinase	O	O
inhibitor	O	O
that	O	O
targets	O	O
signaling	O	O
pathways	O	O
necessary	O	O
for	O	O
cellular	O	O
proliferation	O	O
and	O	O
survival	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
Rho	O	O
/	O	O
ROCK	O	O
pathway	O	O
has	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
.	O	O

Our	O	O
report	O	O
may	O	O
show	O	O
an	O	O
adverse	O	O
effect	O	O
on	O	O
the	O	O
Rho	O	O
/	O	O
ROCK	O	O
pathway	O	O
by	O	O
sorafenib	B-Chemical	C471405
use	O	O
.	O	O

Anxiogenic	O	O
potential	O	O
of	O	O
ciprofloxacin	B-Chemical	D002939
and	O	O
norfloxacin	B-Chemical	D009643
in	O	O
rats	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
The	O	O
possible	O	O
anxiogenic	O	O
effects	O	O
of	O	O
fluoroquinolones	B-Chemical	D024841
,	O	O
namely	O	O
ciprofloxacin	B-Chemical	D002939
and	O	O
norfloxacin	B-Chemical	D009643
,	O	O
were	O	O
investigated	O	O
in	O	O
adult	O	O
Charles	O	O
Foster	O	O
albino	O	O
rats	O	O
of	O	O
either	O	O
sex	O	O
,	O	O
weighing	O	O
150	O	O
-	O	O
200	O	O
g	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
drugs	O	O
were	O	O
given	O	O
orally	O	O
,	O	O
in	O	O
doses	O	O
of	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
five	O	O
consecutive	O	O
days	O	O
and	O	O
the	O	O
experiments	O	O
were	O	O
performed	O	O
on	O	O
the	O	O
fifth	O	O
day	O	O
.	O	O

The	O	O
tests	O	O
included	O	O
open	O	O
-	O	O
field	O	O
exploratory	O	O
behaviour	O	O
,	O	O
elevated	O	O
plus	O	O
maze	O	O
and	O	O
elevated	O	O
zero	O	O
maze	O	O
,	O	O
social	O	O
interaction	O	O
and	O	O
novelty	O	O
-	O	O
suppressed	O	O
feeding	O	O
latency	O	O
behaviour	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
results	O	O
indicate	O	O
that	O	O
ciprofloxacin	B-Chemical	D002939
-	O	O
and	O	O
norfloxacin	B-Chemical	D009643
-	O	O
treated	O	O
rats	O	O
showed	O	O
anxious	B-Disease	D001008
behaviour	I-Disease	D001008
in	O	O
comparison	O	O
to	O	O
control	O	O
rats	O	O
in	O	O
all	O	O
the	O	O
parameters	O	O
studied	O	O
.	O	O

However	O	O
,	O	O
ciprofloxacin	B-Chemical	D002939
-	O	O
and	O	O
norfloxacin	B-Chemical	D009643
-	O	O
treated	O	O
rats	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
from	O	O
each	O	O
other	O	O
in	O	O
various	O	O
behavioural	O	O
parameters	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
present	O	O
experimental	O	O
findings	O	O
substantiate	O	O
the	O	O
clinically	O	O
observed	O	O
anxiogenic	O	O
potential	O	O
of	O	O
ciprofloxacin	B-Chemical	D002939
and	O	O
norfloxacin	B-Chemical	D009643
.	O	O

Myocardial	O	O
Fas	O	O
ligand	O	O
expression	O	O
increases	O	O
susceptibility	O	O
to	O	O
AZT	B-Chemical	D015215
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

BACKGROUND	O	O
:	O	O
Dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
(	O	O
DCM	B-Disease	D002311
)	O	O
and	O	O
myocarditis	B-Disease	D009205
occur	O	O
in	O	O
many	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
individuals	O	O
,	O	O
resulting	O	O
in	O	O
symptomatic	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
in	O	O
up	O	O
to	O	O
5%	O	O
of	O	O
patients	O	O
.	O	O

Highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
HAART	O	O
)	O	O
has	O	O
significantly	O	O
reduced	O	O
morbidity	O	O
and	O	O
mortality	O	O
of	O	O
acquired	B-Disease	D000163
immunodeficiency	I-Disease	D000163
syndrome	I-Disease	D000163
(	O	O
AIDS	B-Disease	D000163
)	O	O
,	O	O
but	O	O
has	O	O
resulted	O	O
in	O	O
an	O	O
increase	O	O
in	O	O
cardiac	B-Disease	C538496
and	I-Disease	C538496
skeletal	I-Disease	C538496
myopathies	I-Disease	C538496
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
In	O	O
order	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
HAART	O	O
component	O	O
zidovudine	B-Chemical	D015215
(	O	O
3'	B-Chemical	D015215
-	I-Chemical	D015215
azido	I-Chemical	D015215
-	I-Chemical	D015215
2'	I-Chemical	D015215
,	I-Chemical	D015215
3'	I-Chemical	D015215
-	I-Chemical	D015215
deoxythymidine	I-Chemical	D015215
;	O	O
AZT	B-Chemical	D015215
)	O	O
triggers	O	O
the	O	O
Fas	O	O
-	O	O
dependent	O	O
cell	O	O
-	O	O
death	O	O
pathway	O	O
and	O	O
cause	O	O
cytoskeletal	O	O
disruption	O	O
in	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
DCM	B-Disease	D002311
,	O	O
8	O	O
-	O	O
week	O	O
-	O	O
old	O	O
transgenic	O	O
(	O	O
expressing	O	O
Fas	O	O
ligand	O	O
in	O	O
the	O	O
myocardium	O	O
:	O	O
FasL	O	O
Tg	O	O
)	O	O
and	O	O
non	O	O
-	O	O
transgenic	O	O
(	O	O
NTg	O	O
)	O	O
mice	O	O
received	O	O
water	O	O
ad	O	O
libitum	O	O
containing	O	O
different	O	O
concentrations	O	O
of	O	O
AZT	B-Chemical	D015215
(	O	O
0	O	O
,	O	O
0	O	O
.	O	O

07	O	O
,	O	O
0	O	O
.	O	O

2	O	O
,	O	O
and	O	O
0	O	O
.	O	O

7	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

After	O	O
6	O	O
weeks	O	O
,	O	O
cardiac	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
echocardiography	O	O
and	O	O
morphology	O	O
was	O	O
assessed	O	O
by	O	O
histopathologic	O	O
and	O	O
immunohistochemical	O	O
methods	O	O
.	O	O

NTg	O	O
and	O	O
untreated	O	O
FasL	O	O
Tg	O	O
mice	O	O
showed	O	O
little	O	O
or	O	O
no	O	O
change	O	O
in	O	O
cardiac	O	O
structure	O	O
or	O	O
function	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
AZT	B-Chemical	D015215
-	O	O
treated	O	O
FasL	O	O
Tg	O	O
mice	O	O
developed	O	O
cardiac	B-Disease	D002311
dilation	I-Disease	D002311
and	O	O
depressed	O	O
cardiac	O	O
function	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
,	O	O
with	O	O
concomitant	O	O
inflammatory	O	O
infiltration	O	O
of	O	O
both	O	O
ventricles	O	O
.	O	O

These	O	O
changes	O	O
were	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
sarcolemmal	O	O
expression	O	O
of	O	O
Fas	O	O
and	O	O
FasL	O	O
,	O	O
as	O	O
well	O	O
as	O	O
increased	O	O
activation	O	O
of	O	O
caspase	O	O
3	O	O
,	O	O
translocation	O	O
of	O	O
calpain	O	O
1	O	O
to	O	O
the	O	O
sarcolemma	O	O
and	O	O
sarcomere	O	O
,	O	O
and	O	O
increased	O	O
numbers	O	O
of	O	O
cells	O	O
undergoing	O	O
apoptosis	O	O
.	O	O

These	O	O
were	O	O
associated	O	O
with	O	O
changes	O	O
in	O	O
dystrophin	O	O
and	O	O
cardiac	O	O
troponin	O	O
I	O	O
localization	O	O
,	O	O
as	O	O
well	O	O
as	O	O
loss	O	O
of	O	O
sarcolemmal	O	O
integrity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
expression	O	O
of	O	O
Fas	O	O
ligand	O	O
in	O	O
the	O	O
myocardium	O	O
,	O	O
as	O	O
identified	O	O
in	O	O
HIV	O	O
-	O	O
positive	O	O
patients	O	O
,	O	O
might	O	O
increase	O	O
the	O	O
susceptibility	O	O
to	O	O
HAART	O	O
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
due	O	O
to	O	O
activation	O	O
of	O	O
apoptotic	O	O
pathways	O	O
,	O	O
resulting	O	O
in	O	O
cardiac	B-Disease	D002311
dilation	I-Disease	D002311
and	O	O
dysfunction	O	O
.	O	O

Valproate	B-Chemical	D014635
-	O	O
induced	O	O
chorea	B-Disease	D002819
and	O	O
encephalopathy	B-Disease	D001927
in	O	O
atypical	O	O
nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
.	O	O

Nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
is	O	O
a	O	O
disorder	B-Disease	D000592
of	I-Disease	D000592
amino	I-Disease	D000592
acid	I-Disease	D000592
metabolism	I-Disease	D000592
in	O	O
which	O	O
a	O	O
defect	O	O
in	O	O
the	O	O
glycine	B-Chemical	D005998
cleavage	O	O
system	O	O
leads	O	O
to	O	O
an	O	O
accumulation	O	O
of	O	O
glycine	B-Chemical	D005998
in	O	O
the	O	O
brain	O	O
and	O	O
other	O	O
body	O	O
compartments	O	O
.	O	O

In	O	O
the	O	O
classical	O	O
form	O	O
it	O	O
presents	O	O
as	O	O
neonatal	O	O
apnea	B-Disease	D001049
,	O	O
intractable	O	O
seizures	B-Disease	D012640
,	O	O
and	O	O
hypotonia	B-Disease	D009123
,	O	O
followed	O	O
by	O	O
significant	O	O
psychomotor	B-Disease	D011596
retardation	I-Disease	D011596
.	O	O

An	O	O
important	O	O
subset	O	O
of	O	O
children	O	O
with	O	O
nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
are	O	O
atypical	O	O
variants	O	O
who	O	O
present	O	O
in	O	O
a	O	O
heterogeneous	O	O
manner	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
a	O	O
patient	O	O
with	O	O
mild	O	O
language	B-Disease	D007805
delay	I-Disease	D007805
and	O	O
mental	B-Disease	D008607
retardation	I-Disease	D008607
,	O	O
who	O	O
was	O	O
found	O	O
to	O	O
have	O	O
nonketotic	B-Disease	D020158
hyperglycinemia	I-Disease	D020158
following	O	O
her	O	O
presentation	O	O
with	O	O
acute	O	O
encephalopathy	B-Disease	D001927
and	O	O
chorea	B-Disease	D002819
shortly	O	O
after	O	O
initiation	O	O
of	O	O
valproate	B-Chemical	D014635
therapy	O	O
.	O	O

Microinjection	O	O
of	O	O
ritanserin	B-Chemical	D016713
into	O	O
the	O	O
CA1	O	O
region	O	O
of	O	O
hippocampus	O	O
improves	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
in	O	O
adult	O	O
male	O	O
rats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
ritanserin	B-Chemical	D016713
(	O	O
5	O	O
-	O	O
HT2	O	O
antagonist	O	O
)	O	O
on	O	O
scopolamine	B-Chemical	D012601
(	O	O
muscarinic	O	O
cholinergic	O	O
antagonist	O	O
)	O	O
-	O	O
induced	O	O
amnesia	B-Disease	D000647
in	O	O
Morris	O	O
water	O	O
maze	O	O
(	O	O
MWM	O	O
)	O	O
was	O	O
investigated	O	O
.	O	O

Rats	O	O
were	O	O
divided	O	O
into	O	O
eight	O	O
groups	O	O
and	O	O
bilaterally	O	O
cannulated	O	O
into	O	O
CA1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
.	O	O

One	O	O
week	O	O
later	O	O
,	O	O
they	O	O
received	O	O
repeatedly	O	O
vehicles	O	O
(	O	O
saline	O	O
,	O	O
DMSO	B-Chemical	D004121
,	O	O
saline+DMSO	O	O
)	O	O
,	O	O
scopolamine	B-Chemical	D012601
(	O	O
2	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
saline	O	O
/	O	O
side	O	O
;	O	O
30	O	O
min	O	O
before	O	O
training	O	O
)	O	O
,	O	O
ritanserin	B-Chemical	D016713
(	O	O
2	O	O
,	O	O
4	O	O
and	O	O
8	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
DMSO	B-Chemical	D004121
/	O	O
side	O	O
;	O	O
20	O	O
min	O	O
before	O	O
training	O	O
)	O	O
and	O	O
scopolamine	B-Chemical	D012601
(	O	O
2	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
;	O	O
30	O	O
min	O	O
before	O	O
ritanserin	B-Chemical	D016713
injection	O	O
)	O	O
+ritanserin	O	O
(	O	O
4	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
DMSO	B-Chemical	D004121
)	O	O
through	O	O
cannulae	O	O
each	O	O
day	O	O
.	O	O

Animals	O	O
were	O	O
tested	O	O
for	O	O
four	O	O
consecutive	O	O
days	O	O
(	O	O
4	O	O
trial	O	O
/	O	O
day	O	O
)	O	O
in	O	O
MWM	O	O
during	O	O
which	O	O
the	O	O
position	O	O
of	O	O
hidden	O	O
platform	O	O
was	O	O
unchanged	O	O
.	O	O

In	O	O
the	O	O
fifth	O	O
day	O	O
,	O	O
the	O	O
platform	O	O
was	O	O
elevated	O	O
above	O	O
the	O	O
water	O	O
surface	O	O
in	O	O
another	O	O
position	O	O
to	O	O
evaluate	O	O
the	O	O
function	O	O
of	O	O
motor	O	O
,	O	O
motivational	O	O
and	O	O
visual	O	O
systems	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
escape	O	O
latencies	O	O
and	O	O
traveled	O	O
distances	O	O
to	O	O
find	O	O
platform	O	O
in	O	O
scopolamine	B-Chemical	D012601
-	O	O
treated	O	O
group	O	O
as	O	O
compared	O	O
to	O	O
saline	O	O
group	O	O
.	O	O

Ritanserin	B-Chemical	D016713
-	O	O
treated	O	O
rats	O	O
(	O	O
4	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
/	O	O
side	O	O
)	O	O
showed	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
mentioned	O	O
parameters	O	O
as	O	O
compared	O	O
to	O	O
DMSO	B-Chemical	D004121
-	O	O
treated	O	O
group	O	O
.	O	O

However	O	O
,	O	O
scopolamine	B-Chemical	D012601
and	O	O
ritanserin	B-Chemical	D016713
co	O	O
-	O	O
administration	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
escape	O	O
latencies	O	O
and	O	O
traveled	O	O
distances	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
treated	O	O
rats	O	O
.	O	O

Our	O	O
findings	O	O
show	O	O
that	O	O
microinjection	O	O
of	O	O
ritanserin	B-Chemical	D016713
into	O	O
the	O	O
CA1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
improves	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

Hypoxia	B-Disease	D000860
in	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
with	O	O
proteinuria	B-Disease	D011507
and	O	O
/	O	O
or	O	O
glomerular	O	O
hypertension	B-Disease	D006973
.	O	O

Despite	O	O
the	O	O
increasing	O	O
need	O	O
to	O	O
identify	O	O
and	O	O
quantify	O	O
tissue	O	O
oxygenation	O	O
at	O	O
the	O	O
cellular	O	O
level	O	O
,	O	O
relatively	O	O
few	O	O
methods	O	O
have	O	O
been	O	O
available	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
developed	O	O
a	O	O
new	O	O
hypoxia	B-Disease	D000860
-	O	O
responsive	O	O
reporter	O	O
vector	O	O
using	O	O
a	O	O
hypoxia	B-Disease	D000860
-	O	O
responsive	O	O
element	O	O
of	O	O
the	O	O
5'	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
untranslated	O	O
region	O	O
and	O	O
generated	O	O
a	O	O
novel	O	O
hypoxia	B-Disease	D000860
-	O	O
sensing	O	O
transgenic	O	O
rat	O	O
.	O	O

We	O	O
then	O	O
applied	O	O
this	O	O
animal	O	O
model	O	O
to	O	O
the	O	O
detection	O	O
of	O	O
tubulointerstitial	O	O
hypoxia	B-Disease	D000860
in	O	O
the	O	O
diseased	B-Disease	D007674
kidney	I-Disease	D007674
.	O	O

With	O	O
this	O	O
model	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
identify	O	O
diffuse	O	O
cortical	O	O
hypoxia	B-Disease	D000860
in	O	O
the	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
and	O	O
focal	O	O
and	O	O
segmental	O	O
hypoxia	B-Disease	D000860
in	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
.	O	O

Expression	O	O
of	O	O
the	O	O
hypoxia	B-Disease	D000860
-	O	O
responsive	O	O
transgene	O	O
increased	O	O
throughout	O	O
the	O	O
observation	O	O
period	O	O
,	O	O
reaching	O	O
2	O	O
.	O	O

2	O	O
-	O	O
fold	O	O
at	O	O
2	O	O
weeks	O	O
in	O	O
the	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
model	O	O
and	O	O
2	O	O
.	O	O

6	O	O
-	O	O
fold	O	O
at	O	O
4	O	O
weeks	O	O
in	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
,	O	O
whereas	O	O
that	O	O
of	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
showed	O	O
a	O	O
mild	O	O
decrease	O	O
,	O	O
reflecting	O	O
distinct	O	O
behaviors	O	O
of	O	O
the	O	O
two	O	O
genes	O	O
.	O	O

The	O	O
degree	O	O
of	O	O
hypoxia	B-Disease	D000860
showed	O	O
a	O	O
positive	O	O
correlation	O	O
with	O	O
microscopic	O	O
tubulointerstitial	B-Disease	-1
injury	I-Disease	-1
in	O	O
both	O	O
models	O	O
.	O	O

Finally	O	O
,	O	O
we	O	O
identified	O	O
the	O	O
localization	O	O
of	O	O
proliferating	O	O
cell	O	O
nuclear	O	O
antigen	O	O
-	O	O
positive	O	O
,	O	O
ED	O	O
-	O	O
1	O	O
-	O	O
positive	O	O
,	O	O
and	O	O
terminal	O	O
dUTP	O	O
nick	O	O
-	O	O
end	O	O
labeled	O	O
-	O	O
positive	O	O
cells	O	O
in	O	O
the	O	O
hypoxic	B-Disease	D000860
cortical	O	O
area	O	O
in	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
.	O	O

We	O	O
propose	O	O
here	O	O
a	O	O
possible	O	O
pathological	O	O
tie	O	O
between	O	O
chronic	O	O
tubulointerstitial	O	O
hypoxia	B-Disease	D000860
and	O	O
progressive	O	O
glomerular	B-Disease	D007674
diseases	I-Disease	D007674
.	O	O

Consensus	O	O
statement	O	O
concerning	O	O
cardiotoxicity	B-Disease	D066126
occurring	O	O
during	O	O
haematopoietic	O	O
stem	O	O
cell	O	O
transplantation	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
autoimmune	B-Disease	D001327
diseases	I-Disease	D001327
,	O	O
with	O	O
special	O	O
reference	O	O
to	O	O
systemic	B-Disease	D012595
sclerosis	I-Disease	D012595
and	O	O
multiple	B-Disease	D009103
sclerosis	I-Disease	D009103
.	O	O

Autologous	O	O
haematopoietic	O	O
stem	O	O
cell	O	O
transplantation	O	O
is	O	O
now	O	O
a	O	O
feasible	O	O
and	O	O
effective	O	O
treatment	O	O
for	O	O
selected	O	O
patients	O	O
with	O	O
severe	O	O
autoimmune	B-Disease	D001327
diseases	I-Disease	D001327
.	O	O

Worldwide	O	O
,	O	O
over	O	O
650	O	O
patients	O	O
have	O	O
been	O	O
transplanted	O	O
in	O	O
the	O	O
context	O	O
of	O	O
phase	O	O
I	O	O
and	O	O
II	O	O
clinical	O	O
trials	O	O
.	O	O

The	O	O
results	O	O
are	O	O
encouraging	O	O
enough	O	O
to	O	O
begin	O	O
randomised	O	O
phase	O	O
III	O	O
trials	O	O
.	O	O

However	O	O
,	O	O
as	O	O
predicted	O	O
,	O	O
significant	O	O
transplant	O	O
-	O	O
related	O	O
morbidity	O	O
and	O	O
mortality	O	O
have	O	O
been	O	O
observed	O	O
.	O	O

This	O	O
is	O	O
primarily	O	O
due	O	O
to	O	O
complications	O	O
related	O	O
to	O	O
either	O	O
the	O	O
stage	O	O
of	O	O
the	O	O
disease	O	O
at	O	O
transplant	O	O
or	O	O
due	O	O
to	O	O
infections	B-Disease	D007239
.	O	O

The	O	O
number	O	O
of	O	O
deaths	O	O
related	O	O
to	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
is	O	O
low	O	O
.	O	O

However	O	O
,	O	O
caution	O	O
is	O	O
required	O	O
when	O	O
cyclophosphamide	B-Chemical	D003520
or	O	O
anthracyclines	B-Chemical	D018943
such	O	O
as	O	O
mitoxantrone	B-Chemical	D008942
are	O	O
used	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
possible	O	O
underlying	O	O
heart	B-Disease	D006331
damage	I-Disease	D006331
,	O	O
for	O	O
example	O	O
,	O	O
systemic	B-Disease	D012595
sclerosis	I-Disease	D012595
patients	O	O
.	O	O

In	O	O
November	O	O
2002	O	O
,	O	O
a	O	O
meeting	O	O
was	O	O
held	O	O
in	O	O
Florence	O	O
,	O	O
bringing	O	O
together	O	O
a	O	O
number	O	O
of	O	O
experts	O	O
in	O	O
various	O	O
fields	O	O
,	O	O
including	O	O
rheumatology	O	O
,	O	O
cardiology	O	O
,	O	O
neurology	O	O
,	O	O
pharmacology	O	O
and	O	O
transplantation	O	O
medicine	O	O
.	O	O

The	O	O
object	O	O
of	O	O
the	O	O
meeting	O	O
was	O	O
to	O	O
analyse	O	O
existing	O	O
data	O	O
,	O	O
both	O	O
published	O	O
or	O	O
available	O	O
,	O	O
in	O	O
the	O	O
European	O	O
Group	O	O
for	O	O
Blood	O	O
and	O	O
Marrow	O	O
Transplantation	O	O
autoimmune	B-Disease	D001327
disease	I-Disease	D001327
database	O	O
,	O	O
and	O	O
to	O	O
propose	O	O
a	O	O
safe	O	O
approach	O	O
to	O	O
such	O	O
patients	O	O
.	O	O

A	O	O
full	O	O
cardiological	O	O
assessment	O	O
before	O	O
and	O	O
during	O	O
the	O	O
transplant	O	O
emerged	O	O
as	O	O
the	O	O
major	O	O
recommendation	O	O
.	O	O

Immunohistochemical	O	O
study	O	O
on	O	O
inducible	O	O
type	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
iNOS	O	O
)	O	O
,	O	O
basic	O	O
fibroblast	O	O
growth	O	O
factor	O	O
(	O	O
bFGF	O	O
)	O	O
and	O	O
tumor	B-Disease	D009369
growth	O	O
factor	O	O
-	O	O
beta1	O	O
(	O	O
TGF	O	O
-	O	O
beta1	O	O
)	O	O
in	O	O
arteritis	B-Disease	D001167
induced	O	O
in	O	O
rats	O	O
by	O	O
fenoldopam	B-Chemical	D018818
and	O	O
theophylline	B-Chemical	D013806
,	O	O
vasodilators	O	O
.	O	O

Arteritis	B-Disease	D001167
induced	O	O
in	O	O
rats	O	O
by	O	O
vasodilators	O	O
,	O	O
fenoldopam	B-Chemical	D018818
and	O	O
theophylline	B-Chemical	D013806
,	O	O
was	O	O
examined	O	O
immunohistochemically	O	O
for	O	O
expressions	O	O
of	O	O
inducible	O	O
type	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
(	O	O
iNOS	O	O
)	O	O
,	O	O
basic	O	O
fibroblast	O	O
growth	O	O
factor	O	O
(	O	O
bFGF	O	O
)	O	O
and	O	O
tumor	B-Disease	D009369
growth	O	O
factor	O	O
-	O	O
beta1	O	O
(	O	O
TGF	O	O
-	O	O
beta1	O	O
)	O	O
.	O	O

Rats	O	O
were	O	O
administered	O	O
fenoldopam	B-Chemical	D018818
for	O	O
24	O	O
hours	O	O
by	O	O
intravenous	O	O
infusion	O	O
with	O	O
or	O	O
without	O	O
following	O	O
repeated	O	O
daily	O	O
oral	O	O
administrations	O	O
of	O	O
theophylline	B-Chemical	D013806
.	O	O

Irrespective	O	O
of	O	O
theophylline	B-Chemical	D013806
administration	O	O
,	O	O
iNOS	O	O
antigens	O	O
were	O	O
remarkably	O	O
abundant	O	O
in	O	O
ED	O	O
-	O	O
1	O	O
-	O	O
positive	O	O
cells	O	O
on	O	O
day	O	O
5	O	O
and	O	O
8	O	O
post	O	O
-	O	O
fenoldopam	B-Chemical	D018818
-	O	O
infusion	O	O
(	O	O
DPI	O	O
)	O	O
;	O	O
bFGF	O	O
antigens	O	O
were	O	O
remarkably	O	O
abundant	O	O
in	O	O
ED	O	O
-	O	O
1	O	O
-	O	O
positive	O	O
cells	O	O
on	O	O
1	O	O
and	O	O
3	O	O
DPI	O	O
;	O	O
TGF	O	O
-	O	O
beta1	O	O
antigens	O	O
were	O	O
observed	O	O
in	O	O
ED	O	O
-	O	O
1	O	O
-	O	O
positive	O	O
cells	O	O
on	O	O
and	O	O
after	O	O
5	O	O
DPI	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
peak	O	O
expression	O	O
of	O	O
iNOS	O	O
antigen	O	O
was	O	O
followed	O	O
by	O	O
that	O	O
of	O	O
bFGF	O	O
antigen	O	O
,	O	O
and	O	O
bFGF	O	O
may	O	O
have	O	O
a	O	O
suppressive	O	O
effect	O	O
on	O	O
iNOS	O	O
expression	O	O
in	O	O
these	O	O
rat	O	O
arteritis	B-Disease	D001167
models	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
TGF	O	O
-	O	O
beta1	O	O
was	O	O
not	O	O
considered	O	O
to	O	O
have	O	O
a	O	O
suppressive	O	O
effect	O	O
on	O	O
iNOS	O	O
expression	O	O
in	O	O
these	O	O
models	O	O
.	O	O

Low	B-Chemical	D006495
-	I-Chemical	D006495
molecular	I-Chemical	D006495
-	I-Chemical	D006495
weight	I-Chemical	D006495
heparin	I-Chemical	D006495
for	O	O
the	O	O
treatment	O	O
of	O	O
patients	O	O
with	O	O
mechanical	O	O
heart	O	O
valves	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
interruption	O	O
of	O	O
oral	O	O
anticoagulant	O	O
(	O	O
OAC	O	O
)	O	O
administration	O	O
is	O	O
sometimes	O	O
indicated	O	O
in	O	O
patients	O	O
with	O	O
mechanical	O	O
heart	O	O
valves	O	O
,	O	O
mainly	O	O
before	O	O
noncardiac	O	O
surgery	O	O
,	O	O
non	O	O
-	O	O
surgical	O	O
interventions	O	O
,	O	O
and	O	O
pregnancy	O	O
.	O	O

Unfractionated	B-Chemical	D006493
heparin	I-Chemical	D006493
(	O	O
UH	B-Chemical	D006493
)	O	O
is	O	O
currently	O	O
the	O	O
substitute	O	O
for	O	O
selected	O	O
patients	O	O
.	O	O

Low	B-Chemical	D006495
-	I-Chemical	D006495
molecular	I-Chemical	D006495
-	I-Chemical	D006495
weight	I-Chemical	D006495
heparin	I-Chemical	D006495
(	O	O
LMWH	B-Chemical	D006495
)	O	O
offers	O	O
theoretical	O	O
advantages	O	O
over	O	O
UH	B-Chemical	D006493
,	O	O
but	O	O
is	O	O
not	O	O
currently	O	O
considered	O	O
in	O	O
clinical	O	O
guidelines	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
UH	B-Chemical	D006493
in	O	O
patients	O	O
with	O	O
prosthetic	O	O
valves	O	O
.	O	O

HYPOTHESIS	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
review	O	O
the	O	O
data	O	O
accumulated	O	O
so	O	O
far	O	O
on	O	O
the	O	O
use	O	O
of	O	O
LMWH	B-Chemical	D006495
in	O	O
this	O	O
patient	O	O
population	O	O
and	O	O
to	O	O
discuss	O	O
its	O	O
applicability	O	O
in	O	O
common	O	O
practice	O	O
.	O	O

METHODS	O	O
:	O	O
For	O	O
this	O	O
paper	O	O
,	O	O
the	O	O
current	O	O
medical	O	O
literature	O	O
on	O	O
LMWH	B-Chemical	D006495
in	O	O
patients	O	O
with	O	O
mechanical	O	O
heart	O	O
valves	O	O
was	O	O
extensively	O	O
reviewed	O	O
.	O	O

RESULTS	O	O
:	O	O
There	O	O
were	O	O
eight	O	O
series	O	O
and	O	O
six	O	O
case	O	O
reports	O	O
.	O	O

None	O	O
of	O	O
the	O	O
studies	O	O
was	O	O
randomized	O	O
,	O	O
and	O	O
only	O	O
one	O	O
was	O	O
prospective	O	O
.	O	O

Data	O	O
to	O	O
establish	O	O
the	O	O
thromboembolic	B-Disease	D013923
risk	O	O
were	O	O
incomplete	O	O
.	O	O

After	O	O
excluding	O	O
case	O	O
reports	O	O
,	O	O
the	O	O
following	O	O
groups	O	O
were	O	O
constructed	O	O
:	O	O
(	O	O
a	O	O
)	O	O
short	O	O
-	O	O
term	O	O
administration	O	O
,	O	O
after	O	O
valve	O	O
insertion	O	O
(	O	O
n	O	O
=	O	O
212	O	O
)	O	O
;	O	O
(	O	O
b	O	O
)	O	O
short	O	O
-	O	O
term	O	O
,	O	O
perioperative	O	O
(	O	O
noncardiac	O	O
)	O	O
/	O	O
periprocedural	O	O
(	O	O
n	O	O
=	O	O
114	O	O
)	O	O
;	O	O
(	O	O
c	O	O
)	O	O
long	O	O
-	O	O
term	O	O
,	O	O
due	O	O
to	O	O
intolerance	O	O
to	O	O
OAC	O	O
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
;	O	O
(	O	O
d	O	O
)	O	O
long	O	O
-	O	O
term	O	O
,	O	O
in	O	O
pregnancy	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
rate	O	O
of	O	O
thromboembolism	B-Disease	D013923
was	O	O
0	O	O
.	O	O

9%	O	O
for	O	O
all	O	O
the	O	O
studies	O	O
and	O	O
0	O	O
.	O	O

5	O	O
,	O	O
0	O	O
,	O	O
20	O	O
,	O	O
and	O	O
0%	O	O
in	O	O
groups	O	O
a	O	O
,	O	O
b	O	O
,	O	O
c	O	O
,	O	O
and	O	O
d	O	O
,	O	O
respectively	O	O
;	O	O
for	O	O
hemorrhage	B-Disease	D006470
,	O	O
the	O	O
overall	O	O
rate	O	O
was	O	O
3	O	O
.	O	O

4%	O	O
(	O	O
3	O	O
.	O	O

8	O	O
,	O	O
2	O	O
.	O	O

6	O	O
,	O	O
10	O	O
,	O	O
and	O	O
0%	O	O
for	O	O
the	O	O
respective	O	O
groups	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
mechanical	O	O
heart	O	O
valves	O	O
,	O	O
short	O	O
-	O	O
term	O	O
LMWH	B-Chemical	D006495
therapy	O	O
compares	O	O
favorably	O	O
with	O	O
UH	B-Chemical	D006493
.	O	O

Data	O	O
on	O	O
mid	O	O
-	O	O
and	O	O
long	O	O
-	O	O
term	O	O
LMWH	B-Chemical	D006495
administration	O	O
in	O	O
these	O	O
patients	O	O
are	O	O
sparse	O	O
.	O	O

Further	O	O
randomized	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
confirm	O	O
the	O	O
safety	O	O
and	O	O
precise	O	O
indications	O	O
for	O	O
the	O	O
use	O	O
of	O	O
LMWH	B-Chemical	D006495
in	O	O
patients	O	O
with	O	O
mechanical	O	O
heart	O	O
valves	O	O
.	O	O

Topiramate	B-Chemical	C052342
-	O	O
induced	O	O
nephrolithiasis	B-Disease	D053040
.	O	O

Topiramate	B-Chemical	C052342
is	O	O
a	O	O
recently	O	O
developed	O	O
antiepileptic	O	O
medication	O	O
that	O	O
is	O	O
becoming	O	O
more	O	O
widely	O	O
prescribed	O	O
because	O	O
of	O	O
its	O	O
efficacy	O	O
in	O	O
treating	O	O
refractory	B-Disease	D004827
seizures	I-Disease	D004827
.	O	O

Urologists	O	O
should	O	O
be	O	O
aware	O	O
that	O	O
this	O	O
medication	O	O
can	O	O
cause	O	O
metabolic	B-Disease	D000138
acidosis	I-Disease	D000138
in	O	O
patients	O	O
secondary	O	O
to	O	O
inhibition	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
distal	O	O
tubular	O	O
acidification	O	O
defect	O	O
may	O	O
result	O	O
,	O	O
thus	O	O
impairing	O	O
the	O	O
normal	O	O
compensatory	O	O
drop	O	O
in	O	O
urine	O	O
pH	O	O
.	O	O

These	O	O
factors	O	O
can	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
calcium	B-Chemical	C020243
phosphate	I-Chemical	C020243
nephrolithiasis	B-Disease	D053040
.	O	O

We	O	O
report	O	O
the	O	O
first	O	O
two	O	O
cases	O	O
of	O	O
topiramate	B-Chemical	C052342
-	O	O
induced	O	O
nephrolithiasis	B-Disease	D053040
in	O	O
the	O	O
urologic	O	O
literature	O	O
.	O	O

Spironolactone	B-Chemical	D013148
:	O	O
is	O	O
it	O	O
a	O	O
novel	O	O
drug	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
-	O	O
related	O	O
hypokalemia	B-Disease	D007008
in	O	O
cancer	B-Disease	D009369
patients?	O	O
OBJECTIVE	O	O
:	O	O
Nephrotoxicity	B-Disease	D007674
is	O	O
the	O	O
major	O	O
adverse	O	O
effect	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
(	O	O
AmB	B-Chemical	D000666
)	O	O
,	O	O
often	O	O
limiting	O	O
administration	O	O
of	O	O
full	O	O
dosage	O	O
.	O	O

Selective	O	O
distal	O	O
tubular	O	O
epithelial	O	O
toxicity	B-Disease	D064420
seems	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
profound	O	O
potassium	B-Chemical	D011188
wasting	O	O
that	O	O
is	O	O
a	O	O
major	O	O
clinical	O	O
side	O	O
effect	O	O
of	O	O
treatment	O	O
with	O	O
AmB	B-Chemical	D000666
.	O	O

Potassium	B-Chemical	D011188
depletion	O	O
also	O	O
potentiates	O	O
the	O	O
tubular	O	O
toxicity	B-Disease	D064420
of	O	O
AmB	B-Chemical	D000666
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
assess	O	O
the	O	O
ability	O	O
of	O	O
spironolactone	B-Chemical	D013148
to	O	O
reduce	O	O
potassium	B-Chemical	D011188
requirements	O	O
and	O	O
to	O	O
prevent	O	O
hypokalemia	B-Disease	D007008
in	O	O
neutropenic	B-Disease	D009503
patients	O	O
on	O	O
AmB	B-Chemical	D000666
treatment	O	O
.	O	O

METHODS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
26	O	O
patients	O	O
with	O	O
various	O	O
hematological	B-Disease	D006402
disorders	I-Disease	D006402
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
intravenous	O	O
AmB	B-Chemical	D000666
alone	O	O
or	O	O
AmB	B-Chemical	D000666
and	O	O
oral	O	O
spironolactone	B-Chemical	D013148
100	O	O
mg	O	O
twice	O	O
daily	O	O
when	O	O
developing	O	O
a	O	O
proven	O	O
or	O	O
suspected	O	O
fungal	B-Disease	D009181
infection	I-Disease	D009181
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
receiving	O	O
concomitant	O	O
AmB	B-Chemical	D000666
and	O	O
spironolactone	B-Chemical	D013148
had	O	O
significantly	O	O
higher	O	O
plasma	O	O
potassium	B-Chemical	D011188
levels	O	O
than	O	O
those	O	O
receiving	O	O
AmB	B-Chemical	D000666
alone	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

0027	O	O
)	O	O
.	O	O

Those	O	O
patients	O	O
receiving	O	O
AmB	B-Chemical	D000666
and	O	O
spironolactone	B-Chemical	D013148
required	O	O
significantly	O	O
less	O	O
potassium	B-Chemical	D011188
supplementation	O	O
to	O	O
maintain	O	O
their	O	O
plasma	O	O
potassium	B-Chemical	D011188
within	O	O
the	O	O
normal	O	O
range	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

022	O	O
)	O	O
.	O	O

Moreover	O	O
,	O	O
urinary	O	O
potassium	B-Chemical	D011188
losses	O	O
were	O	O
significantly	O	O
less	O	O
in	O	O
patients	O	O
receiving	O	O
AmB	B-Chemical	D000666
and	O	O
spironolactone	B-Chemical	D013148
than	O	O
those	O	O
receiving	O	O
AmB	B-Chemical	D000666
alone	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

040	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
study	O	O
showed	O	O
that	O	O
spironolactone	B-Chemical	D013148
can	O	O
reduce	O	O
potassium	B-Chemical	D011188
requirements	O	O
and	O	O
prevent	O	O
hypokalemia	B-Disease	D007008
by	O	O
reducing	O	O
urinary	O	O
potassium	B-Chemical	D011188
loss	O	O
in	O	O
neutropenic	B-Disease	D009503
patients	O	O
on	O	O
AmB	B-Chemical	D000666
treatment	O	O
.	O	O

Dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
signaling	O	O
controls	O	O
neuronal	O	O
cell	O	O
death	O	O
induced	O	O
by	O	O
muscarinic	O	O
and	O	O
glutamatergic	O	O
drugs	O	O
.	O	O

Dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
,	O	O
through	O	O
D1	O	O
/	O	O
D2	O	O
receptor	O	O
-	O	O
mediated	O	O
signaling	O	O
,	O	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
control	O	O
of	O	O
epileptic	B-Disease	D004827
seizures	I-Disease	D004827
arising	O	O
in	O	O
the	O	O
limbic	O	O
system	O	O
.	O	O

Excitotoxicity	B-Disease	-1
leading	O	O
to	O	O
neuronal	O	O
cell	O	O
death	O	O
in	O	O
the	O	O
affected	O	O
areas	O	O
is	O	O
a	O	O
major	O	O
consequence	O	O
of	O	O
seizures	B-Disease	D012640
at	O	O
the	O	O
cellular	O	O
level	O	O
.	O	O

In	O	O
this	O	O
respect	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
role	O	O
of	O	O
DA	B-Chemical	D004298
receptors	O	O
in	O	O
the	O	O
occurrence	O	O
of	O	O
epilepsy	B-Disease	D004827
-	O	O
induced	O	O
neuronal	O	O
cell	O	O
death	O	O
.	O	O

Here	O	O
we	O	O
analyze	O	O
the	O	O
occurrence	O	O
of	O	O
seizures	B-Disease	D012640
and	O	O
neurotoxicity	B-Disease	D020258
in	O	O
D2R	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
treated	O	O
with	O	O
the	O	O
cholinergic	O	O
agonist	O	O
pilocarpine	B-Chemical	D010862
.	O	O

We	O	O
compared	O	O
these	O	O
results	O	O
with	O	O
those	O	O
previously	O	O
obtained	O	O
with	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
(	O	O
KA	B-Chemical	D007608
)	O	O
,	O	O
a	O	O
potent	O	O
glutamate	B-Chemical	D018698
agonist	O	O
.	O	O

Importantly	O	O
,	O	O
D2R	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
develop	O	O
seizures	B-Disease	D012640
at	O	O
doses	O	O
of	O	O
both	O	O
drugs	O	O
that	O	O
are	O	O
not	O	O
epileptogenic	O	O
for	O	O
WT	O	O
littermates	O	O
and	O	O
show	O	O
greater	O	O
neurotoxicity	B-Disease	D020258
.	O	O

However	O	O
,	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
result	O	O
in	O	O
a	O	O
more	O	O
widespread	O	O
neuronal	O	O
death	O	O
in	O	O
both	O	O
WT	O	O
and	O	O
D2R	O	O
-	O	O
/	O	O
-	O	O
brains	O	O
in	O	O
comparison	O	O
to	O	O
KA	B-Chemical	D007608
.	O	O

Thus	O	O
,	O	O
the	O	O
absence	O	O
of	O	O
D2R	O	O
lowers	O	O
the	O	O
threshold	O	O
for	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
both	O	O
glutamate	B-Chemical	D018698
and	O	O
acetylcholine	B-Chemical	D000109
.	O	O

Moreover	O	O
,	O	O
the	O	O
dopaminergic	O	O
control	O	O
of	O	O
epilepsy	B-Disease	D004827
-	O	O
induced	O	O
neurodegeneration	B-Disease	D019636
seems	O	O
to	O	O
be	O	O
mediated	O	O
by	O	O
distinct	O	O
interactions	O	O
of	O	O
D2R	O	O
signaling	O	O
with	O	O
these	O	O
two	O	O
neurotransmitters	O	O
.	O	O

Treatment	O	O
of	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
with	O	O
a	O	O
dopamine	B-Chemical	D004298
agonist	O	O
in	O	O
children	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Risperidone	B-Chemical	D018967
,	O	O
a	O	O
potent	O	O
antagonist	O	O
of	O	O
both	O	O
serotonergic	O	O
(	O	O
5HT2A	O	O
)	O	O
and	O	O
dopaminergic	O	O
D2	O	O
receptors	O	O
is	O	O
associated	O	O
with	O	O
hyperprolactinemia	B-Disease	D006966
in	O	O
adults	O	O
and	O	O
children	O	O
.	O	O

Chronically	O	O
elevated	O	O
prolactin	O	O
levels	O	O
in	O	O
children	O	O
with	O	O
prolactinomas	B-Disease	D015175
may	O	O
be	O	O
associated	O	O
with	O	O
arrested	O	O
growth	O	O
and	O	O
development	O	O
resulting	O	O
in	O	O
either	O	O
delayed	B-Disease	D011628
puberty	I-Disease	D011628
or	O	O
short	O	O
stature	O	O
.	O	O

These	O	O
possibilities	O	O
stress	O	O
the	O	O
importance	O	O
of	O	O
developing	O	O
a	O	O
safe	O	O
and	O	O
effective	O	O
approach	O	O
to	O	O
drug	O	O
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
in	O	O
youth	O	O
.	O	O

We	O	O
report	O	O
the	O	O
successful	O	O
treatment	O	O
of	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
with	O	O
cabergoline	B-Chemical	C047047
in	O	O
youth	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
undertook	O	O
a	O	O
retrospective	O	O
case	O	O
review	O	O
of	O	O
four	O	O
children	O	O
with	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
treated	O	O
with	O	O
cabergoline	B-Chemical	C047047
.	O	O

RESULTS	O	O
:	O	O
Four	O	O
males	O	O
(	O	O
age	O	O
6	O	O
-	O	O
11	O	O
years	O	O
)	O	O
with	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	B-Disease	D001523
Disorders	I-Disease	D001523
(	O	O
fourth	O	O
edition	O	O
)	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
or	O	O
psychoses	B-Disease	D011605
,	O	O
with	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
elevations	O	O
in	O	O
serum	O	O
prolactin	O	O
levels	O	O
(	O	O
57	O	O
.	O	O

5	O	O
-	O	O
129	O	O
ng	O	O
/	O	O
mL	O	O
,	O	O
normal	O	O
5	O	O
-	O	O
15	O	O
ng	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
were	O	O
treated	O	O
with	O	O
cabergoline	B-Chemical	C047047
(	O	O
mean	O	O
dose	O	O
2	O	O
.	O	O

13	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

09	O	O
mg	O	O
/	O	O
week	O	O
)	O	O
.	O	O

When	O	O
serum	O	O
prolactin	O	O
levels	O	O
normalized	O	O
in	O	O
all	O	O
four	O	O
subjects	O	O
(	O	O
mean	O	O
11	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
10	O	O
.	O	O

9	O	O
ng	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
the	O	O
cabergoline	B-Chemical	C047047
dose	O	O
was	O	O
reduced	O	O
to	O	O
1	O	O
mg	O	O
/	O	O
week	O	O
in	O	O
three	O	O
of	O	O
four	O	O
subjects	O	O
.	O	O

The	O	O
mean	O	O
duration	O	O
of	O	O
therapy	O	O
with	O	O
cabergoline	B-Chemical	C047047
was	O	O
523	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
129	O	O
.	O	O

7	O	O
days	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
duration	O	O
of	O	O
therapy	O	O
with	O	O
risperidone	B-Chemical	D018967
was	O	O
788	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
162	O	O
.	O	O

5	O	O
days	O	O
.	O	O

Cabergoline	B-Chemical	C047047
was	O	O
well	O	O
tolerated	O	O
without	O	O
adverse	O	O
effects	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Cabergoline	B-Chemical	C047047
may	O	O
be	O	O
useful	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
in	O	O
youth	O	O
;	O	O
however	O	O
,	O	O
further	O	O
research	O	O
is	O	O
needed	O	O
.	O	O

Cholestatic	B-Disease	D041781
jaundice	I-Disease	D041781
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
metformin	B-Chemical	D008687
.	O	O

We	O	O
report	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
cholestatic	B-Disease	D041781
jaundice	I-Disease	D041781
shortly	O	O
after	O	O
initiation	O	O
of	O	O
treatment	O	O
with	O	O
metformin	B-Chemical	D008687
hydrochloride	O	O
.	O	O

Ultrasound	O	O
of	O	O
the	O	O
liver	O	O
and	O	O
abdominal	O	O
CT	O	O
were	O	O
normal	O	O
.	O	O

An	O	O
ERCP	O	O
showed	O	O
normal	O	O
biliary	O	O
anatomy	O	O
.	O	O

A	O	O
percutaneous	O	O
liver	O	O
biopsy	O	O
was	O	O
obtained	O	O
showing	O	O
marked	O	O
cholestasis	B-Disease	D002779
,	O	O
with	O	O
portal	O	O
edema	B-Disease	D004487
,	O	O
ductular	O	O
proliferation	O	O
,	O	O
and	O	O
acute	O	O
inflammation	B-Disease	D007249
.	O	O

Metformin	B-Chemical	D008687
hydrochloride	I-Chemical	D008687
was	O	O
discontinued	O	O
,	O	O
and	O	O
the	O	O
patient's	O	O
jaundice	B-Disease	D007565
resolved	O	O
slowly	O	O
over	O	O
a	O	O
period	O	O
of	O	O
several	O	O
months	O	O
.	O	O

Given	O	O
the	O	O
onset	O	O
of	O	O
his	O	O
jaundice	B-Disease	D007565
2	O	O
wk	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
metformin	B-Chemical	D008687
,	O	O
we	O	O
believe	O	O
that	O	O
this	O	O
case	O	O
represents	O	O
an	O	O
example	O	O
of	O	O
metformin	B-Chemical	D008687
-	O	O
associated	O	O
hepatotoxicity	B-Disease	D056486
,	O	O
the	O	O
first	O	O
such	O	O
case	O	O
reported	O	O
.	O	O

Electro	O	O
-	O	O
oculography	O	O
,	O	O
electroretinography	O	O
,	O	O
visual	O	O
evoked	O	O
potentials	O	O
,	O	O
and	O	O
multifocal	O	O
electroretinography	O	O
in	O	O
patients	O	O
with	O	O
vigabatrin	B-Chemical	D020888
-	O	O
attributed	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
constriction	I-Disease	D014786
.	O	O

PURPOSE	O	O
:	O	O
Symptomatic	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
constriction	I-Disease	D014786
thought	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
vigabatrin	B-Chemical	D020888
has	O	O
been	O	O
reported	O	O
.	O	O

The	O	O
current	O	O
study	O	O
investigated	O	O
the	O	O
visual	O	O
fields	O	O
and	O	O
visual	O	O
electrophysiology	O	O
of	O	O
eight	O	O
patients	O	O
with	O	O
known	O	O
vigabatrin	B-Chemical	D020888
-	O	O
attributed	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
loss	I-Disease	D014786
,	O	O
three	O	O
of	O	O
whom	O	O
were	O	O
reported	O	O
previously	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
no	O	O
longer	O	O
receiving	O	O
vigabatrin	B-Chemical	D020888
.	O	O

METHODS	O	O
:	O	O
The	O	O
central	O	O
and	O	O
peripheral	O	O
fields	O	O
were	O	O
examined	O	O
with	O	O
the	O	O
Humphrey	O	O
Visual	O	O
Field	O	O
Analyzer	O	O
.	O	O

Full	O	O
visual	O	O
electrophysiology	O	O
,	O	O
including	O	O
flash	O	O
electroretinography	O	O
(	O	O
ERG	O	O
)	O	O
,	O	O
pattern	O	O
electroretinography	O	O
,	O	O
multifocal	O	O
ERG	O	O
using	O	O
the	O	O
VERIS	O	O
system	O	O
,	O	O
electro	O	O
-	O	O
oculography	O	O
,	O	O
and	O	O
flash	O	O
and	O	O
pattern	O	O
visual	O	O
evoked	O	O
potentials	O	O
,	O	O
was	O	O
undertaken	O	O
.	O	O

RESULTS	O	O
:	O	O
Seven	O	O
patients	O	O
showed	O	O
marked	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
constriction	I-Disease	D014786
with	O	O
some	O	O
sparing	O	O
of	O	O
the	O	O
temporal	O	O
visual	O	O
field	O	O
.	O	O

The	O	O
eighth	O	O
exhibited	O	O
concentric	O	O
constriction	O	O
.	O	O

Most	O	O
electrophysiological	O	O
responses	O	O
were	O	O
usually	O	O
just	O	O
within	O	O
normal	O	O
limits	O	O
;	O	O
two	O	O
patients	O	O
had	O	O
subnormal	O	O
Arden	O	O
electro	O	O
-	O	O
oculography	O	O
indices	O	O
;	O	O
and	O	O
one	O	O
patient	O	O
showed	O	O
an	O	O
abnormally	O	O
delayed	O	O
photopic	O	O
b	O	O
wave	O	O
.	O	O

However	O	O
,	O	O
five	O	O
patients	O	O
showed	O	O
delayed	O	O
30	O	O
-	O	O
Hz	O	O
flicker	O	O
b	O	O
waves	O	O
,	O	O
and	O	O
seven	O	O
patients	O	O
showed	O	O
delayed	O	O
oscillatory	O	O
potentials	O	O
.	O	O

Multifocal	O	O
ERG	O	O
showed	O	O
abnormalities	O	O
that	O	O
sometimes	O	O
correlated	O	O
with	O	O
the	O	O
visual	O	O
field	O	O
appearance	O	O
and	O	O
confirmed	O	O
that	O	O
the	O	O
deficit	O	O
occurs	O	O
at	O	O
the	O	O
retinal	O	O
level	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Marked	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
constriction	I-Disease	D014786
appears	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
vigabatrin	B-Chemical	D020888
therapy	O	O
.	O	O

The	O	O
field	O	O
defects	O	O
and	O	O
some	O	O
electrophysiological	O	O
abnormalities	O	O
persist	O	O
when	O	O
vigabatrin	B-Chemical	D020888
therapy	O	O
is	O	O
withdrawn	O	O
.	O	O

Conversion	O	O
to	O	O
rapamycin	B-Chemical	D020123
immunosuppression	O	O
in	O	O
renal	O	O
transplant	O	O
recipients	O	O
:	O	O
report	O	O
of	O	O
an	O	O
initial	O	O
experience	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
RAPA	B-Chemical	D020123
conversion	O	O
in	O	O
patients	O	O
undergoing	O	O
cyclosporine	B-Chemical	D016572
(	O	O
CsA	B-Chemical	D016572
)	O	O
or	O	O
tacrolimus	B-Chemical	D016559
(	O	O
Tac	B-Chemical	D016559
)	O	O
toxicity	B-Disease	D064420
.	O	O

METHODS	O	O
:	O	O
Twenty	O	O
renal	O	O
transplant	O	O
recipients	O	O
were	O	O
switched	O	O
to	O	O
fixed	O	O
dose	O	O
rapamycin	B-Chemical	D020123
(	O	O
RAPA	B-Chemical	D020123
)	O	O
(	O	O
5	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
0	O	O
to	O	O
204	O	O
months	O	O
posttransplant	O	O
.	O	O

Drug	O	O
monitoring	O	O
was	O	O
not	O	O
initially	O	O
used	O	O
to	O	O
adjust	O	O
doses	O	O
.	O	O

The	O	O
indications	O	O
for	O	O
switch	O	O
were	O	O
chronic	O	O
CsA	B-Chemical	D016572
or	O	O
Tac	B-Chemical	D016559
nephrotoxicity	B-Disease	D007674
(	O	O
12	O	O
)	O	O
,	O	O
acute	O	O
CsA	B-Chemical	D016572
or	O	O
Tac	B-Chemical	D016559
toxicity	B-Disease	D064420
(	O	O
3	O	O
)	O	O
,	O	O
severe	O	O
facial	B-Disease	-1
dysmorphism	I-Disease	-1
(	O	O
2	O	O
)	O	O
,	O	O
posttransplant	B-Disease	D008232
lymphoproliferative	I-Disease	D008232
disorder	I-Disease	D008232
(	O	O
PTLD	B-Disease	D008232
)	O	O
in	O	O
remission	O	O
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
hepatotoxicity	B-Disease	D056486
in	O	O
1	O	O
.	O	O

Follow	O	O
-	O	O
up	O	O
is	O	O
7	O	O
to	O	O
24	O	O
months	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
the	O	O
12	O	O
patients	O	O
switched	O	O
because	O	O
of	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
there	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
[	O	O
233+	O	O
/	O	O
-	O	O
34	O	O
to	O	O
210+	O	O
/	O	O
-	O	O
56	O	O
micromol	O	O
/	O	O
liter	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
at	O	O
6	O	O
months	O	O
]	O	O
.	O	O

Facial	B-Disease	-1
dysmorphism	I-Disease	-1
improved	O	O
in	O	O
two	O	O
patients	O	O
.	O	O

No	O	O
relapse	O	O
of	O	O
PTLD	B-Disease	D008232
was	O	O
observed	O	O
.	O	O

Five	O	O
patients	O	O
developed	O	O
pneumonia	B-Disease	D011014
(	O	O
two	O	O
Pneumocystis	B-Disease	D011020
carinii	I-Disease	D011020
pneumonia	I-Disease	D011020
,	O	O
one	O	O
infectious	B-Disease	D007244
mononucleosis	I-Disease	D007244
with	O	O
polyclonal	O	O
PTLD	B-Disease	D008232
lung	O	O
infiltrate	O	O
)	O	O
and	O	O
two	O	O
had	O	O
bronchiolitis	B-Disease	D001989
obliterans	I-Disease	D001989
.	O	O

There	O	O
were	O	O
no	O	O
deaths	O	O
.	O	O

RAPA	B-Chemical	D020123
was	O	O
discontinued	O	O
in	O	O
four	O	O
patients	O	O
,	O	O
because	O	O
of	O	O
pneumonia	B-Disease	D011014
in	O	O
two	O	O
,	O	O
PTLD	B-Disease	D008232
in	O	O
one	O	O
,	O	O
and	O	O
oral	O	O
aphtous	B-Disease	D013281
ulcers	I-Disease	D013281
in	O	O
one	O	O
.	O	O

RAPA	B-Chemical	D020123
levels	O	O
were	O	O
high	O	O
(	O	O
>15	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
in	O	O
7	O	O
of	O	O
13	O	O
(	O	O
54%	O	O
)	O	O
patients	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
RAPA	B-Chemical	D020123
conversion	O	O
provides	O	O
adequate	O	O
immunosuppression	O	O
to	O	O
enable	O	O
CsA	B-Chemical	D016572
withdrawal	O	O
.	O	O

However	O	O
,	O	O
when	O	O
converting	O	O
patients	O	O
to	O	O
RAPA	B-Chemical	D020123
drug	O	O
levels	O	O
should	O	O
be	O	O
monitored	O	O
to	O	O
avoid	O	O
over	O	O
-	O	O
immunosuppression	O	O
and	O	O
adequate	O	O
antiviral	O	O
and	O	O
Pneumocystis	B-Disease	D011020
carinii	I-Disease	D011020
pneumonia	I-Disease	D011020
prophylaxis	O	O
should	O	O
be	O	O
given	O	O
.	O	O

Worsening	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
by	O	O
motor	O	O
and	O	O
mental	O	O
tasks	O	O
.	O	O

Ten	O	O
patients	O	O
who	O	O
had	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
with	O	O
disabling	O	O
dyskinesia	B-Disease	D004409
were	O	O
included	O	O
in	O	O
this	O	O
study	O	O
to	O	O
evaluate	O	O
the	O	O
role	O	O
of	O	O
mental	O	O
(	O	O
mental	O	O
calculation	O	O
)	O	O
and	O	O
motor	O	O
(	O	O
flexion	O	O
/	O	O
extension	O	O
of	O	O
right	O	O
fingers	O	O
,	O	O
flexion	O	O
/	O	O
extension	O	O
of	O	O
left	O	O
fingers	O	O
,	O	O
flexion	O	O
/	O	O
extension	O	O
of	O	O
the	O	O
neck	O	O
,	O	O
speaking	O	O
aloud	O	O
)	O	O
tasks	O	O
on	O	O
the	O	O
worsening	O	O
of	O	O
peak	O	O
-	O	O
dose	O	O
dyskinesia	B-Disease	D004409
following	O	O
administration	O	O
of	O	O
an	O	O
effective	O	O
single	O	O
dose	O	O
of	O	O
apomorphine	B-Chemical	D001058
.	O	O

Compared	O	O
with	O	O
the	O	O
score	O	O
at	O	O
rest	O	O
(	O	O
1	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
)	O	O
,	O	O
a	O	O
significant	O	O
aggravation	O	O
of	O	O
the	O	O
dyskinesia	B-Disease	D004409
score	O	O
was	O	O
observed	O	O
during	O	O
speaking	O	O
aloud	O	O
(	O	O
5	O	O
.	O	O

2+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

1	O	O
,	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
movements	O	O
of	O	O
right	O	O
(	O	O
4	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
,	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
left	O	O
(	O	O
3	O	O
.	O	O

7+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
,	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
fingers	O	O
,	O	O
movements	O	O
of	O	O
the	O	O
neck	O	O
(	O	O
5	O	O
.	O	O

1+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
,	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
and	O	O
mental	O	O
calculation	O	O
(	O	O
3	O	O
.	O	O

1+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
,	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
tasks	O	O
such	O	O
as	O	O
"speaking	O	O
aloud"	O	O
could	O	O
be	O	O
used	O	O
for	O	O
objective	O	O
assessment	O	O
of	O	O
dyskinesia	B-Disease	D004409
severity	O	O
.	O	O

Structural	B-Disease	D028361
and	I-Disease	D028361
functional	I-Disease	D028361
impairment	I-Disease	D028361
of	I-Disease	D028361
mitochondria	I-Disease	D028361
in	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
in	O	O
mice	O	O
:	O	O
suppression	O	O
of	O	O
cytochrome	O	O
c	O	O
oxidase	O	O
II	O	O
gene	O	O
expression	O	O
.	O	O

The	O	O
use	O	O
of	O	O
adriamycin	B-Chemical	D004317
(	O	O
ADR	B-Chemical	D004317
)	O	O
in	O	O
cancer	B-Disease	D009369
chemotherapy	O	O
has	O	O
been	O	O
limited	O	O
due	O	O
to	O	O
its	O	O
cumulative	O	O
cardiovascular	B-Disease	D002318
toxicity	I-Disease	D002318
.	O	O

Earlier	O	O
observations	O	O
that	O	O
ADR	B-Chemical	D004317
interacts	O	O
with	O	O
mitochondrial	O	O
cytochrome	O	O
c	O	O
oxidase	O	O
(	O	O
COX	O	O
)	O	O
and	O	O
suppresses	O	O
its	O	O
enzyme	O	O
activity	O	O
led	O	O
us	O	O
to	O	O
investigate	O	O
ADR's	O	O
action	O	O
on	O	O
the	O	O
cardiovascular	O	O
functions	O	O
and	O	O
heart	O	O
mitochondrial	O	O
morphology	O	O
in	O	O
Balb	O	O
-	O	O
c	O	O
mice	O	O
i	O	O
.	O	O

p	O	O
.	O	O

treated	O	O
with	O	O
ADR	B-Chemical	D004317
for	O	O
several	O	O
weeks	O	O
.	O	O

At	O	O
various	O	O
times	O	O
during	O	O
treatment	O	O
,	O	O
the	O	O
animals	O	O
were	O	O
assessed	O	O
for	O	O
cardiovascular	O	O
functions	O	O
by	O	O
electrocardiography	O	O
and	O	O
for	O	O
heart	O	O
tissue	O	O
damage	O	O
by	O	O
electron	O	O
microscopy	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
total	O	O
RNA	O	O
was	O	O
extracted	O	O
from	O	O
samples	O	O
of	O	O
dissected	O	O
heart	O	O
and	O	O
analyzed	O	O
by	O	O
Northern	O	O
blot	O	O
hybridization	O	O
to	O	O
determine	O	O
the	O	O
steady	O	O
-	O	O
state	O	O
level	O	O
of	O	O
three	O	O
RNA	O	O
transcripts	O	O
encoded	O	O
by	O	O
the	O	O
COXII	O	O
,	O	O
COXIII	O	O
,	O	O
and	O	O
COXIV	O	O
genes	O	O
.	O	O

Similarly	O	O
,	O	O
samples	O	O
obtained	O	O
from	O	O
the	O	O
liver	O	O
of	O	O
the	O	O
same	O	O
animals	O	O
were	O	O
analyzed	O	O
for	O	O
comparative	O	O
studies	O	O
.	O	O

Our	O	O
results	O	O
indicated	O	O
that	O	O
1	O	O
)	O	O
treatment	O	O
of	O	O
mice	O	O
with	O	O
ADR	B-Chemical	D004317
caused	O	O
cardiovascular	B-Disease	D001145
arrhythmias	I-Disease	D001145
characterized	O	O
by	O	O
bradycardia	B-Disease	D001919
,	O	O
extension	O	O
of	O	O
ventricular	O	O
depolarization	O	O
time	O	O
(	O	O
tQRS	O	O
)	O	O
,	O	O
and	O	O
failure	O	O
of	O	O
QRS	O	O
at	O	O
high	O	O
concentrations	O	O
(	O	O
10	O	O
-	O	O
14	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
cumulative	O	O
dose	O	O
)	O	O
;	O	O
2	O	O
)	O	O
the	O	O
heart	O	O
mitochondria	O	O
underwent	O	O
swelling	B-Disease	D004487
,	O	O
fusion	O	O
,	O	O
dissolution	O	O
,	O	O
and	O	O
/	O	O
or	O	O
disruption	O	O
of	O	O
mitochondrial	O	O
cristae	O	O
after	O	O
several	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Such	O	O
abnormalities	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
the	O	O
mitochondria	O	O
of	O	O
liver	O	O
tissue	O	O
;	O	O
and	O	O
3	O	O
)	O	O
among	O	O
the	O	O
three	O	O
genes	O	O
of	O	O
COX	O	O
enzyme	O	O
examined	O	O
,	O	O
only	O	O
COXII	O	O
gene	O	O
expression	O	O
was	O	O
suppressed	O	O
by	O	O
ADR	B-Chemical	D004317
treatment	O	O
,	O	O
mainly	O	O
after	O	O
8	O	O
weeks	O	O
in	O	O
both	O	O
heart	O	O
and	O	O
liver	O	O
.	O	O

Knowing	O	O
that	O	O
heart	O	O
mitochondria	O	O
represent	O	O
almost	O	O
40%	O	O
of	O	O
heart	O	O
muscle	O	O
by	O	O
weight	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
the	O	O
deteriorating	O	O
effects	O	O
of	O	O
ADR	B-Chemical	D004317
on	O	O
cardiovascular	O	O
function	O	O
involve	O	O
mitochondrial	B-Disease	D028361
structural	I-Disease	D028361
and	I-Disease	D028361
functional	I-Disease	D028361
impairment	I-Disease	D028361
.	O	O

Enhanced	O	O
bradycardia	B-Disease	D001919
induced	O	O
by	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonists	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
isoniazid	B-Chemical	D007538
.	O	O

High	O	O
doses	O	O
of	O	O
isoniazid	B-Chemical	D007538
increase	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
vasodilators	O	O
and	O	O
change	O	O
the	O	O
accompanying	O	O
reflex	O	O
tachycardia	B-Disease	D013610
to	O	O
bradycardia	B-Disease	D001919
,	O	O
an	O	O
interaction	O	O
attributed	O	O
to	O	O
decreased	O	O
synthesis	O	O
of	O	O
brain	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
possible	O	O
enhancement	O	O
by	O	O
isoniazid	B-Chemical	D007538
of	O	O
bradycardia	B-Disease	D001919
induced	O	O
by	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonists	O	O
was	O	O
determined	O	O
in	O	O
rats	O	O
anaesthetised	O	O
with	O	O
chloralose	B-Chemical	D002698
-	O	O
urethane	B-Chemical	D014520
.	O	O

Isoniazid	B-Chemical	D007538
significantly	O	O
increased	O	O
bradycardia	B-Disease	D001919
after	O	O
propranolol	B-Chemical	D011433
,	O	O
pindolol	B-Chemical	D010869
,	O	O
labetalol	B-Chemical	D007741
and	O	O
atenolol	B-Chemical	D001262
,	O	O
as	O	O
well	O	O
as	O	O
after	O	O
clonidine	B-Chemical	D003000
,	O	O
but	O	O
not	O	O
after	O	O
hexamethonium	B-Chemical	D018738
or	O	O
carbachol	B-Chemical	D002217
.	O	O

Enhancement	O	O
was	O	O
not	O	O
observed	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
methylatropine	B-Chemical	C006649
or	O	O
previously	O	O
vagotomised	O	O
.	O	O

These	O	O
results	O	O
are	O	O
compatible	O	O
with	O	O
interference	O	O
by	O	O
isoniazid	B-Chemical	D007538
with	O	O
GABAergic	O	O
inhibition	O	O
of	O	O
cardiac	O	O
parasympathetic	O	O
tone	O	O
.	O	O

Such	O	O
interference	O	O
could	O	O
be	O	O
exerted	O	O
centrally	O	O
,	O	O
possibly	O	O
at	O	O
the	O	O
nucleus	O	O
ambiguus	O	O
,	O	O
or	O	O
peripherally	O	O
at	O	O
the	O	O
sinus	O	O
node	O	O
.	O	O

Epileptogenic	O	O
activity	O	O
of	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
after	O	O
drug	O	O
induces	O	O
SLE	B-Disease	D008180
(	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
and	O	O
epilepsy	B-Disease	D004827
)	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
-	O	O
containing	O	O
multivitamin	O	O
supplementation	O	O
in	O	O
epileptic	B-Disease	D004827
women	O	O
before	O	O
and	O	O
during	O	O
pregnancy	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
rate	O	O
of	O	O
structural	O	O
birth	B-Disease	D000014
defects	I-Disease	D000014
and	O	O
epilepsy	B-Disease	D004827
-	O	O
related	O	O
side	O	O
effects	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
:	O	O
First	O	O
a	O	O
randomised	O	O
trial	O	O
,	O	O
later	O	O
periconception	O	O
care	O	O
including	O	O
in	O	O
total	O	O
12225	O	O
females	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
60	O	O
epileptic	B-Disease	D004827
women	O	O
with	O	O
periconceptional	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
(	O	O
0	O	O
.	O	O

8	O	O
mg	O	O
)	O	O
-	O	O
containing	O	O
multivitamin	O	O
supplementation	O	O
,	O	O
no	O	O
one	O	O
developed	O	O
epilepsy	B-Disease	D004827
-	O	O
related	O	O
side	O	O
effects	O	O
during	O	O
the	O	O
periconception	O	O
period	O	O
.	O	O

One	O	O
epileptic	B-Disease	D004827
woman	O	O
delivered	O	O
a	O	O
newborn	O	O
with	O	O
cleft	O	O
lip	O	O
and	O	O
palate	O	O
.	O	O

Another	O	O
patient	O	O
exhibited	O	O
with	O	O
a	O	O
cluster	O	O
of	O	O
seizures	B-Disease	D012640
after	O	O
the	O	O
periconception	O	O
period	O	O
using	O	O
another	O	O
multivitamin	O	O
.	O	O

This	O	O
22	O	O
-	O	O
year	O	O
-	O	O
old	O	O
epileptic	B-Disease	D004827
woman	O	O
was	O	O
treated	O	O
continuously	O	O
by	O	O
carbamazepine	B-Chemical	D002220
and	O	O
a	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
(	O	O
1	O	O
mg	O	O
)	O	O
-	O	O
containing	O	O
multivitamin	O	O
from	O	O
the	O	O
20th	O	O
week	O	O
of	O	O
gestation	O	O
.	O	O

She	O	O
developed	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
and	O	O
later	O	O
symptoms	O	O
of	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematodes	I-Disease	D008180
.	O	O

Her	O	O
pregnancy	O	O
ended	O	O
with	O	O
stillbirth	B-Disease	D050497
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
epileptic	B-Disease	D004827
pregnant	O	O
patient's	O	O
autoimmune	B-Disease	D001327
disease	I-Disease	D001327
(	O	O
probably	O	O
drug	O	O
-	O	O
induced	O	O
lupus	B-Disease	D008180
)	O	O
could	O	O
damage	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
therefore	O	O
the	O	O
therapeutic	O	O
dose	O	O
(	O	O
>	O	O
or	O	O
=1	O	O
mg	O	O
)	O	O
of	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
triggered	O	O
a	O	O
cluster	O	O
of	O	O
seizures	B-Disease	D012640
.	O	O

Physiological	O	O
dose	O	O
(	O	O
<1	O	O
mg	O	O
)	O	O
of	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
both	O	O
in	O	O
healthy	O	O
and	O	O
60	O	O
epileptic	B-Disease	D004827
women	O	O
,	O	O
all	O	O
without	O	O
any	O	O
autoimmune	B-Disease	D001327
disease	I-Disease	D001327
,	O	O
did	O	O
not	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
epileptic	B-Disease	D004827
seizures	B-Disease	D012640
.	O	O

Effects	O	O
of	O	O
cisapride	B-Chemical	D020117
on	O	O
symptoms	O	O
and	O	O
postcibal	O	O
small	O	O
-	O	O
bowel	O	O
motor	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
irritable	B-Disease	D043183
bowel	I-Disease	D043183
syndrome	I-Disease	D043183
.	O	O

BACKGROUND	O	O
:	O	O
Irritable	B-Disease	D043183
bowel	I-Disease	D043183
syndrome	I-Disease	D043183
is	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
and	O	O
discomfort	O	O
and	O	O
may	O	O
be	O	O
related	O	O
to	O	O
disordered	B-Disease	D005767
gastrointestinal	I-Disease	D005767
motility	I-Disease	D005767
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
effects	O	O
of	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
a	O	O
prokinetic	O	O
agent	O	O
,	O	O
cisapride	B-Chemical	D020117
,	O	O
on	O	O
postprandial	O	O
jejunal	O	O
motility	O	O
and	O	O
symptoms	O	O
in	O	O
the	O	O
irritable	B-Disease	D043183
bowel	I-Disease	D043183
syndrome	I-Disease	D043183
(	O	O
IBS	B-Disease	D043183
)	O	O
.	O	O

METHODS	O	O
:	O	O
Thirty	O	O
-	O	O
eight	O	O
patients	O	O
with	O	O
IBS	B-Disease	D043183
(	O	O
constipation	B-Disease	D003248
-	O	O
predominant	O	O
,	O	O
n	O	O
=	O	O
17	O	O
;	O	O
diarrhoea	B-Disease	D003967
-	O	O
predominant	O	O
,	O	O
n	O	O
=	O	O
21	O	O
)	O	O
underwent	O	O
24	O	O
-	O	O
h	O	O
ambulatory	O	O
jejunal	O	O
manometry	O	O
before	O	O
and	O	O
after	O	O
12	O	O
week's	O	O
treatment	O	O
[	O	O
cisapride	B-Chemical	D020117
,	O	O
5	O	O
mg	O	O
three	O	O
times	O	O
daily	O	O
(	O	O
n	O	O
=	O	O
19	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
19	O	O
)	O	O
]	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
diarrhoea	B-Disease	D003967
-	O	O
predominant	O	O
patients	O	O
significant	O	O
differences	O	O
in	O	O
contraction	O	O
characteristics	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
cisapride	B-Chemical	D020117
and	O	O
placebo	O	O
groups	O	O
.	O	O

In	O	O
cisapride	B-Chemical	D020117
-	O	O
treated	O	O
diarrhoea	B-Disease	D003967
-	O	O
predominant	O	O
patients	O	O
the	O	O
mean	O	O
contraction	O	O
amplitude	O	O
was	O	O
higher	O	O
(	O	O
29	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

2	O	O
versus	O	O
24	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

6	O	O
mm	O	O
Hg	O	O
,	O	O
cisapride	B-Chemical	D020117
versus	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
pretreatment	O	O
,	O	O
25	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

0	O	O
mm	O	O
Hg	O	O
)	O	O
,	O	O
the	O	O
mean	O	O
contraction	O	O
duration	O	O
longer	O	O
(	O	O
3	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
versus	O	O
3	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
sec	O	O
,	O	O
cisapride	B-Chemical	D020117
versus	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
pretreatment	O	O
,	O	O
3	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
sec	O	O
)	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
contraction	O	O
frequency	O	O
lower	O	O
(	O	O
2	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
versus	O	O
2	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
cont	O	O
.	O	O

/	O	O
min	O	O
,	O	O
cisapride	B-Chemical	D020117
versus	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
pretreatment	O	O
,	O	O
2	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

1	O	O
cont	O	O
.	O	O

/	O	O
min	O	O
]	O	O
than	O	O
patients	O	O
treated	O	O
with	O	O
placebo	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
in	O	O
jejunal	O	O
motility	O	O
were	O	O
found	O	O
in	O	O
the	O	O
constipation	B-Disease	D003248
-	O	O
predominant	O	O
IBS	B-Disease	D043183
group	O	O
.	O	O

Symptoms	O	O
were	O	O
assessed	O	O
by	O	O
using	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
before	O	O
and	O	O
after	O	O
treatment	O	O
.	O	O

Symptom	O	O
scores	O	O
relating	O	O
to	O	O
the	O	O
severity	O	O
of	O	O
constipation	B-Disease	D003248
were	O	O
lower	O	O
in	O	O
cisapride	B-Chemical	D020117
-	O	O
treated	O	O
constipation	B-Disease	D003248
-	O	O
predominant	O	O
IBS	B-Disease	D043183
patients	O	O
[	O	O
score	O	O
,	O	O
54	O	O
+	O	O
/	O	O
-	O	O
5	O	O
versus	O	O
67	O	O
+	O	O
/	O	O
-	O	O
14	O	O
mm	O	O
,	O	O
cisapride	B-Chemical	D020117
versus	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
;	O	O
pretreatment	O	O
,	O	O
62	O	O
+	O	O
/	O	O
-	O	O
19	O	O
mm	O	O
]	O	O
.	O	O

Diarrhoea	B-Disease	D003967
-	O	O
predominant	O	O
IBS	B-Disease	D043183
patients	O	O
had	O	O
a	O	O
higher	O	O
pain	B-Disease	D010146
score	O	O
after	O	O
cisapride	B-Chemical	D020117
therapy	O	O
[	O	O
score	O	O
,	O	O
55	O	O
+	O	O
/	O	O
-	O	O
15	O	O
versus	O	O
34	O	O
+	O	O
/	O	O
-	O	O
12	O	O
mm	O	O
,	O	O
cisapride	B-Chemical	D020117
versus	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
;	O	O
pretreatment	O	O
,	O	O
67	O	O
+	O	O
/	O	O
-	O	O
19	O	O
mm	O	O
]	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Cisapride	B-Chemical	D020117
affects	O	O
jejunal	O	O
contraction	O	O
characteristics	O	O
and	O	O
some	O	O
symptoms	O	O
in	O	O
IBS	B-Disease	D043183
.	O	O

Clarithromycin	B-Chemical	D017291
-	O	O
induced	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

Clarithromycin	B-Chemical	D017291
is	O	O
a	O	O
relatively	O	O
new	O	O
macrolide	B-Chemical	D018942
antibiotic	O	O
that	O	O
offers	O	O
twice	O	O
-	O	O
daily	O	O
dosing	O	O
.	O	O

It	O	O
differs	O	O
from	O	O
erythromycin	B-Chemical	D004917
only	O	O
in	O	O
the	O	O
methylation	O	O
of	O	O
the	O	O
hydroxyl	O	O
group	O	O
at	O	O
position	O	O
6	O	O
.	O	O

Although	O	O
the	O	O
side	O	O
-	O	O
effect	O	O
profile	O	O
of	O	O
erythromycin	B-Chemical	D004917
is	O	O
established	O	O
,	O	O
including	O	O
gastroenteritis	B-Disease	D005759
and	O	O
interactions	O	O
with	O	O
other	O	O
drugs	O	O
subject	O	O
to	O	O
hepatic	O	O
mixed	O	O
-	O	O
function	O	O
oxidase	O	O
metabolism	O	O
,	O	O
experience	O	O
with	O	O
the	O	O
newer	O	O
macrolides	B-Chemical	D018942
is	O	O
still	O	O
being	O	O
recorded	O	O
.	O	O

Cardiotoxicity	B-Disease	D066126
has	O	O
been	O	O
demonstrated	O	O
after	O	O
both	O	O
intravenous	O	O
and	O	O
oral	O	O
administration	O	O
of	O	O
erythromycin	B-Chemical	D004917
but	O	O
has	O	O
never	O	O
been	O	O
reported	O	O
with	O	O
the	O	O
newer	O	O
macrolides	B-Chemical	D018942
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
ventricular	B-Disease	D001145
dysrhythmias	I-Disease	D001145
that	O	O
occurred	O	O
after	O	O
six	O	O
therapeutic	O	O
doses	O	O
of	O	O
clarithromycin	B-Chemical	D017291
.	O	O

The	O	O
dysrhythmias	B-Disease	D001145
resolved	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Persistent	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
following	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
severe	O	O
hypernatraemic	O	O
dehydration	B-Disease	D003681
following	O	O
a	O	O
head	B-Disease	D006259
injury	I-Disease	D006259
.	O	O

Ten	O	O
years	O	O
previously	O	O
he	O	O
had	O	O
been	O	O
diagnosed	O	O
to	O	O
have	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
,	O	O
and	O	O
lithium	B-Chemical	D008094
therapy	O	O
had	O	O
been	O	O
discontinued	O	O
.	O	O

He	O	O
remained	O	O
thirsty	O	O
and	O	O
polyuric	B-Disease	D011141
despite	O	O
cessation	O	O
of	O	O
lithium	B-Chemical	D008094
and	O	O
investigations	O	O
on	O	O
admission	O	O
showed	O	O
him	O	O
to	O	O
have	O	O
normal	O	O
osmoregulated	O	O
thirst	O	O
and	O	O
vasopressin	B-Chemical	D014667
secretion	O	O
,	O	O
with	O	O
clear	O	O
evidence	O	O
of	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
.	O	O

Lithium	B-Chemical	D008094
induced	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
is	O	O
considered	O	O
to	O	O
be	O	O
reversible	O	O
on	O	O
cessation	O	O
of	O	O
therapy	O	O
but	O	O
polyuria	B-Disease	D011141
persisted	O	O
in	O	O
this	O	O
patient	O	O
for	O	O
ten	O	O
years	O	O
after	O	O
lithium	B-Chemical	D008094
was	O	O
stopped	O	O
.	O	O

We	O	O
discuss	O	O
the	O	O
possible	O	O
renal	O	O
mechanisms	O	O
and	O	O
the	O	O
implications	O	O
for	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
.	O	O

Late	O	O
cardiotoxicity	B-Disease	D066126
after	O	O
treatment	O	O
for	O	O
a	O	O
malignant	O	O
bone	B-Disease	D001859
tumor	I-Disease	D001859
.	O	O

Cardiac	O	O
function	O	O
was	O	O
assessed	O	O
in	O	O
long	O	O
-	O	O
term	O	O
survivors	O	O
of	O	O
malignant	O	O
bone	B-Disease	D001859
tumors	I-Disease	D001859
who	O	O
were	O	O
treated	O	O
according	O	O
to	O	O
Rosen's	B-Chemical	C053519
T5	I-Chemical	C053519
or	I-Chemical	C053519
T10	I-Chemical	C053519
protocol	I-Chemical	C053519
,	O	O
both	O	O
including	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Thirty	O	O
-	O	O
one	O	O
patients	O	O
,	O	O
age	O	O
10	O	O
-	O	O
45	O	O
years	O	O
(	O	O
median	O	O
age	O	O
17	O	O
.	O	O

8	O	O
years	O	O
)	O	O
were	O	O
evaluated	O	O
2	O	O
.	O	O

3	O	O
-	O	O
14	O	O
.	O	O

1	O	O
years	O	O
(	O	O
median	O	O
8	O	O
.	O	O

9	O	O
years	O	O
)	O	O
following	O	O
completion	O	O
of	O	O
treatment	O	O
.	O	O

Cumulative	O	O
doses	O	O
of	O	O
doxorubicin	B-Chemical	D004317
were	O	O
225	O	O
-	O	O
550	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
median	O	O
dose	O	O
360	O	O
)	O	O
.	O	O

The	O	O
evaluation	O	O
consisted	O	O
of	O	O
a	O	O
history	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
electrocardiogram	O	O
(	O	O
ECG	O	O
)	O	O
,	O	O
signal	O	O
averaged	O	O
ECG	O	O
,	O	O
24	O	O
-	O	O
hour	O	O
ambulatory	O	O
ECG	O	O
,	O	O
echocardiography	O	O
and	O	O
radionuclide	O	O
angiography	O	O
.	O	O

Eighteen	O	O
of	O	O
31	O	O
(	O	O
58%	O	O
)	O	O
patients	O	O
showed	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
,	O	O
defined	O	O
as	O	O
having	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
following	O	O
abnormalities	O	O
:	O	O
late	O	O
potentials	O	O
,	O	O
complex	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
,	O	O
left	O	O
ventricular	B-Disease	D002311
dilation	I-Disease	D002311
,	O	O
decreased	O	O
shortening	O	O
fraction	O	O
,	O	O
or	O	O
decreased	O	O
ejection	O	O
fraction	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiac	B-Disease	D006331
abnormalities	I-Disease	D006331
increased	O	O
with	O	O
length	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
P<	O	O
or	O	O
=	O	O
.	O	O

05	O	O
)	O	O
.	O	O

No	O	O
correlation	O	O
could	O	O
be	O	O
demonstrated	O	O
between	O	O
cumulative	O	O
dose	O	O
of	O	O
doxorubicin	B-Chemical	D004317
and	O	O
cardiac	O	O
status	O	O
,	O	O
except	O	O
for	O	O
heart	O	O
rate	O	O
variability	O	O
.	O	O

When	O	O
adjusted	O	O
to	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
the	O	O
left	O	O
ventricular	O	O
posterior	O	O
wall	O	O
thickness	O	O
(	O	O
LVPW	O	O
index	O	O
)	O	O
was	O	O
decreased	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
is	O	O
high	O	O
and	O	O
increases	O	O
with	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
irrespective	O	O
of	O	O
cumulative	O	O
dose	O	O
.	O	O

Life	O	O
-	O	O
long	O	O
cardiac	O	O
follow	O	O
-	O	O
up	O	O
in	O	O
these	O	O
patients	O	O
is	O	O
warranted	O	O
.	O	O

The	O	O
results	O	O
of	O	O
our	O	O
study	O	O
suggest	O	O
that	O	O
heart	O	O
rate	O	O
variability	O	O
and	O	O
LVPW	O	O
index	O	O
could	O	O
be	O	O
sensitive	O	O
indicators	O	O
for	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Venous	B-Disease	D014652
complications	I-Disease	D014652
of	O	O
midazolam	B-Chemical	D008874
versus	O	O
diazepam	B-Chemical	D003975
.	O	O

Although	O	O
some	O	O
studies	O	O
have	O	O
suggested	O	O
fewer	O	O
venous	B-Disease	D014652
complications	I-Disease	D014652
are	O	O
associated	O	O
with	O	O
midazolam	B-Chemical	D008874
than	O	O
with	O	O
diazepam	B-Chemical	D003975
for	O	O
endoscopic	O	O
procedures	O	O
,	O	O
this	O	O
variable	O	O
has	O	O
not	O	O
been	O	O
well	O	O
documented	O	O
.	O	O

We	O	O
prospectively	O	O
evaluated	O	O
the	O	O
incidence	O	O
of	O	O
venous	B-Disease	D014652
complications	I-Disease	D014652
after	O	O
intravenous	O	O
injection	O	O
of	O	O
diazepam	B-Chemical	D003975
or	O	O
midazolam	B-Chemical	D008874
in	O	O
122	O	O
consecutive	O	O
patients	O	O
undergoing	O	O
colonoscopy	O	O
and	O	O
esophagogastroduodenoscopy	O	O
.	O	O

Overall	O	O
,	O	O
venous	B-Disease	D014652
complications	I-Disease	D014652
were	O	O
more	O	O
frequent	O	O
with	O	O
diazepam	B-Chemical	D003975
(	O	O
22	O	O
of	O	O
62	O	O
patients	O	O
)	O	O
than	O	O
with	O	O
midazolam	B-Chemical	D008874
(	O	O
4	O	O
of	O	O
60	O	O
patients	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

A	O	O
palpable	O	O
venous	O	O
cord	O	O
was	O	O
present	O	O
in	O	O
23%	O	O
(	O	O
14	O	O
of	O	O
62	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
diazepam	B-Chemical	D003975
group	O	O
,	O	O
compared	O	O
with	O	O
2%	O	O
(	O	O
1	O	O
of	O	O
60	O	O
patients	O	O
)	O	O
in	O	O
the	O	O
midazolam	B-Chemical	D008874
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

Pain	B-Disease	D010146
at	O	O
the	O	O
injection	O	O
site	O	O
occurred	O	O
in	O	O
35%	O	O
(	O	O
22	O	O
of	O	O
62	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
the	O	O
diazepam	B-Chemical	D003975
group	O	O
compared	O	O
with	O	O
7%	O	O
(	O	O
4	O	O
of	O	O
60	O	O
patients	O	O
)	O	O
in	O	O
the	O	O
midazolam	B-Chemical	D008874
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Swelling	B-Disease	D004487
and	O	O
warmth	O	O
at	O	O
the	O	O
injection	O	O
site	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Smoking	O	O
,	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
use	O	O
,	O	O
intravenous	O	O
catheter	O	O
site	O	O
,	O	O
dwell	O	O
time	O	O
of	O	O
the	O	O
needle	O	O
,	O	O
alcohol	B-Chemical	D000431
use	O	O
,	O	O
and	O	O
pain	B-Disease	D010146
during	O	O
the	O	O
injection	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
venous	B-Disease	D014652
complications	I-Disease	D014652
.	O	O

Tetany	B-Disease	D013746
and	O	O
rhabdomyolysis	B-Disease	D012206
due	O	O
to	O	O
surreptitious	O	O
furosemide	B-Chemical	D005665
-	O	O
-	O	O
importance	O	O
of	O	O
magnesium	B-Chemical	D008274
supplementation	O	O
.	O	O

Diuretics	O	O
may	O	O
induce	O	O
hypokalemia	B-Disease	D007008
,	O	O
hypocalcemia	B-Disease	D006996
and	O	O
hypomagnesemia	B-Disease	C537153
.	O	O

While	O	O
severe	O	O
hypokalemia	B-Disease	D007008
may	O	O
cause	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
,	O	O
severe	O	O
hypomagnesemia	B-Disease	C537153
is	O	O
associated	O	O
with	O	O
muscle	B-Disease	D013035
spasms	I-Disease	D013035
and	O	O
tetany	B-Disease	D013746
which	O	O
cannot	O	O
be	O	O
corrected	O	O
by	O	O
potassium	B-Chemical	D011188
and	O	O
calcium	B-Chemical	D002118
supplementation	O	O
alone	O	O
(	O	O
1	O	O
,	O	O
2	O	O
)	O	O
.	O	O

Surreptitious	O	O
diuretic	O	O
ingestion	O	O
has	O	O
been	O	O
described	O	O
,	O	O
mainly	O	O
in	O	O
women	O	O
who	O	O
are	O	O
concerned	O	O
that	O	O
they	O	O
are	O	O
obese	B-Disease	D009765
or	O	O
edematous	B-Disease	D004487
.	O	O

Symptomatic	O	O
hypokalemia	B-Disease	D007008
has	O	O
been	O	O
reported	O	O
in	O	O
such	O	O
patients	O	O
(	O	O
3	O	O
-	O	O
7	O	O
)	O	O
and	O	O
in	O	O
one	O	O
case	O	O
hypocalcemia	B-Disease	D006996
was	O	O
observed	O	O
(	O	O
8	O	O
)	O	O
,	O	O
but	O	O
the	O	O
effects	O	O
of	O	O
magnesium	B-Chemical	D008274
depletion	O	O
were	O	O
not	O	O
noted	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

Loss	O	O
of	O	O
glutamate	B-Chemical	D018698
decarboxylase	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
in	O	O
the	O	O
rat	O	O
dentate	O	O
gyrus	O	O
following	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

In	O	O
situ	O	O
hybridization	O	O
methods	O	O
were	O	O
used	O	O
to	O	O
determine	O	O
if	O	O
glutamic	B-Chemical	D018698
acid	I-Chemical	D018698
decarboxylase	O	O
(	O	O
GAD	O	O
)	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
within	O	O
the	O	O
hilus	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
are	O	O
vulnerable	O	O
to	O	O
seizure	B-Disease	D012640
-	O	O
induced	O	O
damage	O	O
in	O	O
a	O	O
model	O	O
of	O	O
chronic	O	O
seizures	B-Disease	D012640
.	O	O

Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
injected	O	O
intraperitoneally	O	O
with	O	O
pilocarpine	B-Chemical	D010862
,	O	O
and	O	O
the	O	O
hippocampal	O	O
formation	O	O
was	O	O
studied	O	O
histologically	O	O
at	O	O
1	O	O
,	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
8	O	O
week	O	O
intervals	O	O
after	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

In	O	O
situ	O	O
hybridization	O	O
histochemistry	O	O
,	O	O
using	O	O
a	O	O
digoxigenin	B-Chemical	D004076
-	O	O
labeled	O	O
GAD	O	O
cRNA	O	O
probe	O	O
,	O	O
demonstrated	O	O
a	O	O
substantial	O	O
decrease	O	O
in	O	O
the	O	O
number	O	O
of	O	O
GAD	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
in	O	O
the	O	O
hilus	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
in	O	O
the	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
rats	O	O
as	O	O
compared	O	O
to	O	O
controls	O	O
at	O	O
all	O	O
time	O	O
intervals	O	O
.	O	O

Additional	O	O
neuronanatomical	O	O
studies	O	O
,	O	O
including	O	O
cresyl	B-Chemical	C028911
violet	I-Chemical	C028911
staining	O	O
,	O	O
neuronal	B-Disease	D009410
degeneration	I-Disease	D009410
methods	O	O
,	O	O
and	O	O
histochemical	O	O
localization	O	O
of	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
suggested	O	O
that	O	O
the	O	O
decrease	O	O
in	O	O
the	O	O
number	O	O
of	O	O
GAD	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
was	O	O
related	O	O
to	O	O
neuronal	B-Disease	D009410
loss	I-Disease	D009410
rather	O	O
than	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
GAD	O	O
mRNA	O	O
levels	O	O
.	O	O

The	O	O
loss	O	O
of	O	O
GAD	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
in	O	O
the	O	O
hilus	O	O
contrasted	O	O
with	O	O
the	O	O
relative	O	O
preservation	O	O
of	O	O
labeled	O	O
putative	O	O
basket	O	O
cells	O	O
along	O	O
the	O	O
inner	O	O
margin	O	O
of	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
.	O	O

Quantitative	O	O
analyses	O	O
of	O	O
labeled	O	O
neurons	O	O
in	O	O
three	O	O
regions	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
in	O	O
the	O	O
1	O	O
and	O	O
2	O	O
week	O	O
groups	O	O
showed	O	O
statistically	O	O
significant	O	O
decreases	O	O
in	O	O
the	O	O
mean	O	O
number	O	O
of	O	O
GAD	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
in	O	O
the	O	O
hilus	O	O
of	O	O
both	O	O
groups	O	O
of	O	O
experimental	O	O
animals	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
the	O	O
molecular	O	O
layer	O	O
or	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
,	O	O
which	O	O
included	O	O
labeled	O	O
neurons	O	O
along	O	O
the	O	O
lower	O	O
margin	O	O
of	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
,	O	O
in	O	O
this	O	O
model	O	O
,	O	O
a	O	O
subpopulation	O	O
of	O	O
GAD	O	O
mRNA	O	O
-	O	O
containing	O	O
neurons	O	O
within	O	O
the	O	O
dentate	O	O
gyrus	O	O
is	O	O
selectively	O	O
vulnerable	O	O
to	O	O
seizure	B-Disease	D012640
-	O	O
induced	O	O
damage	O	O
.	O	O

Such	O	O
differential	O	O
vulnerability	O	O
appears	O	O
to	O	O
be	O	O
another	O	O
indication	O	O
of	O	O
the	O	O
heterogeneity	O	O
of	O	O
GABA	B-Chemical	D005680
neurons	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
misoprostol	B-Chemical	D016595
on	O	O
indomethacin	B-Chemical	D007213
induced	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
in	O	O
elderly	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
possible	O	O
protective	O	O
effects	O	O
of	O	O
misoprostol	B-Chemical	D016595
on	O	O
renal	O	O
function	O	O
in	O	O
hospitalized	O	O
elderly	O	O
patients	O	O
treated	O	O
with	O	O
indomethacin	B-Chemical	D007213
.	O	O

METHODS	O	O
:	O	O
Forty	O	O
-	O	O
five	O	O
hospitalized	O	O
elderly	O	O
patients	O	O
(	O	O
>	O	O
65	O	O
years	O	O
old	O	O
)	O	O
who	O	O
required	O	O
therapy	O	O
with	O	O
nonsteroidal	O	O
antiinflammatory	O	O
drugs	O	O
(	O	O
NSAID	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
either	O	O
indomethacin	B-Chemical	D007213
,	O	O
150	O	O
mg	O	O
/	O	O
day	O	O
(	O	O
Group	O	O
A	O	O
)	O	O
,	O	O
or	O	O
indomethacin	B-Chemical	D007213
150	O	O
mg	O	O
/	O	O
day	O	O
plus	O	O
misoprostol	B-Chemical	D016595
at	O	O
0	O	O
.	O	O

6	O	O
mg	O	O
/	O	O
day	O	O
(	O	O
Group	O	O
B	O	O
)	O	O
.	O	O

Laboratory	O	O
variables	O	O
of	O	O
renal	O	O
function	O	O
[	O	O
serum	O	O
creatinine	B-Chemical	D003404
,	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
(	O	O
BUN	B-Chemical	D001806
)	O	O
and	O	O
electrolytes	O	O
]	O	O
were	O	O
evaluated	O	O
before	O	O
initiation	O	O
of	O	O
therapy	O	O
and	O	O
every	O	O
2	O	O
days	O	O
,	O	O
until	O	O
termination	O	O
of	O	O
the	O	O
study	O	O
(	O	O
a	O	O
period	O	O
of	O	O
at	O	O
least	O	O
6	O	O
days	O	O
)	O	O
.	O	O

Response	O	O
to	O	O
treatment	O	O
was	O	O
estimated	O	O
by	O	O
the	O	O
visual	O	O
analog	O	O
scale	O	O
for	O	O
severity	O	O
of	O	O
pain	B-Disease	D010146
.	O	O

RESULTS	O	O
:	O	O
Forty	O	O
-	O	O
two	O	O
patients	O	O
completed	O	O
the	O	O
study	O	O
,	O	O
22	O	O
in	O	O
Group	O	O
A	O	O
and	O	O
20	O	O
in	O	O
Group	O	O
B	O	O
.	O	O

BUN	B-Chemical	D001806
and	O	O
creatinine	B-Chemical	D003404
increased	O	O
by	O	O
>	O	O
50%	O	O
of	O	O
baseline	O	O
levels	O	O
in	O	O
54	O	O
and	O	O
45%	O	O
of	O	O
Group	O	O
A	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
compared	O	O
to	O	O
only	O	O
20	O	O
and	O	O
10%	O	O
of	O	O
Group	O	O
B	O	O
patients	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Potassium	B-Chemical	D011188
(	O	O
K	B-Chemical	D011188
)	O	O
increment	O	O
of	O	O
0	O	O
.	O	O

6	O	O
mEq	O	O
/	O	O
l	O	O
or	O	O
more	O	O
was	O	O
observed	O	O
in	O	O
50%	O	O
of	O	O
Group	O	O
A	O	O
,	O	O
but	O	O
in	O	O
only	O	O
15%	O	O
of	O	O
Group	O	O
B	O	O
patients	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
increments	O	O
in	O	O
BUN	B-Chemical	D001806
,	O	O
creatinine	B-Chemical	D003404
,	O	O
and	O	O
K	B-Chemical	D011188
were	O	O
reduced	O	O
by	O	O
63	O	O
,	O	O
80	O	O
,	O	O
and	O	O
42%	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
Group	O	O
B	O	O
patients	O	O
compared	O	O
to	O	O
Group	O	O
A	O	O
.	O	O

Response	O	O
to	O	O
treatment	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Hospitalized	O	O
elderly	O	O
patients	O	O
are	O	O
at	O	O
risk	O	O
for	O	O
developing	O	O
indomethacin	B-Chemical	D007213
related	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

Addition	O	O
of	O	O
misoprostol	B-Chemical	D016595
can	O	O
minimize	O	O
this	O	O
renal	B-Disease	D007674
impairment	I-Disease	D007674
without	O	O
affecting	O	O
pain	B-Disease	D010146
control	O	O
.	O	O

Nephrotoxic	B-Disease	D007674
effects	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
treatment	O	O
on	O	O
renal	O	O
protein	O	O
reabsorption	O	O
and	O	O
accumulation	O	O
.	O	O

To	O	O
quantify	O	O
the	O	O
effects	O	O
of	O	O
gentamicin	B-Chemical	D005839
,	O	O
kanamycin	B-Chemical	D007612
and	O	O
netilmicin	B-Chemical	D009428
on	O	O
renal	O	O
protein	O	O
reabsorption	O	O
and	O	O
accumulation	O	O
,	O	O
these	O	O
drugs	O	O
were	O	O
administered	O	O
to	O	O
rats	O	O
intraperitoneally	O	O
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
for	O	O
7	O	O
,	O	O
14	O	O
or	O	O
21	O	O
days	O	O
.	O	O

Scanning	O	O
electron	O	O
microscopy	O	O
of	O	O
the	O	O
glomerular	O	O
endothelia	O	O
,	O	O
urinary	O	O
measurements	O	O
of	O	O
sodium	B-Chemical	D012964
,	O	O
potassium	B-Chemical	D011188
,	O	O
endogenous	O	O
lysozyme	O	O
,	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
D	O	O
-	O	O
glucosaminidase	O	O
(	O	O
NAG	O	O
)	O	O
as	O	O
well	O	O
as	O	O
clearance	O	O
and	O	O
accumulation	O	O
experiments	O	O
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
of	O	O
egg	O	O
-	O	O
white	O	O
lysozyme	O	O
and	O	O
measurements	O	O
of	O	O
inulin	O	O
clearance	O	O
(	O	O
GFR	O	O
)	O	O
were	O	O
done	O	O
in	O	O
each	O	O
treatment	O	O
group	O	O
.	O	O

Gentamicin	B-Chemical	D005839
administration	O	O
decreased	O	O
diameter	O	O
,	O	O
density	O	O
and	O	O
shape	O	O
of	O	O
endothelial	O	O
fenestrae	O	O
.	O	O

Kanamycin	B-Chemical	D007612
and	O	O
netilmicin	B-Chemical	D009428
appeared	O	O
to	O	O
have	O	O
no	O	O
effect	O	O
at	O	O
the	O	O
dose	O	O
used	O	O
.	O	O

All	O	O
three	O	O
aminoglycosides	B-Chemical	D000617
decreased	O	O
GFR	O	O
and	O	O
increased	O	O
urinary	O	O
excretion	O	O
of	O	O
sodium	B-Chemical	D012964
and	O	O
potassium	B-Chemical	D011188
.	O	O

While	O	O
gentamicin	B-Chemical	D005839
and	O	O
kanamycin	B-Chemical	D007612
decreased	O	O
the	O	O
percentage	O	O
reabsorption	O	O
and	O	O
accumulation	O	O
of	O	O
lysozyme	O	O
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
of	O	O
egg	O	O
-	O	O
white	O	O
lysozyme	O	O
netilmicin	B-Chemical	D009428
had	O	O
no	O	O
effect	O	O
.	O	O

Daily	O	O
excretion	O	O
of	O	O
total	O	O
protein	O	O
,	O	O
endogenous	O	O
lysozyme	O	O
and	O	O
NAG	O	O
increased	O	O
only	O	O
after	O	O
treatment	O	O
with	O	O
kanamycin	B-Chemical	D007612
and	O	O
gentamicin	B-Chemical	D005839
.	O	O

Thus	O	O
,	O	O
aminoglycosides	B-Chemical	D000617
may	O	O
act	O	O
as	O	O
nephrotoxicants	O	O
at	O	O
glomerular	O	O
and	O	O
/	O	O
or	O	O
tubular	O	O
level	O	O
inducing	O	O
impairment	B-Disease	D007674
of	I-Disease	D007674
renal	I-Disease	D007674
reabsorption	I-Disease	D007674
and	O	O
accumulation	O	O
of	O	O
proteins	O	O
.	O	O

Pharmacology	O	O
of	O	O
GYKI	B-Chemical	C025725
-	I-Chemical	C025725
41	I-Chemical	C025725
099	I-Chemical	C025725
(	O	O
chlorpropanol	B-Chemical	C025725
,	O	O
Tobanum	B-Chemical	C025725
)	O	O
a	O	O
new	O	O
potent	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
.	O	O

The	O	O
compound	O	O
GYKI	B-Chemical	C025725
-	I-Chemical	C025725
41	I-Chemical	C025725
099	I-Chemical	C025725
,	O	O
as	O	O
a	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
,	O	O
is	O	O
3	O	O
-	O	O
8	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
propranolol	B-Chemical	D011433
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

Its	O	O
antiarrhythmic	O	O
effectiveness	O	O
surpasses	O	O
that	O	O
of	O	O
propranolol	B-Chemical	D011433
and	O	O
pindolol	B-Chemical	D010869
inhibiting	O	O
the	O	O
ouabain	B-Chemical	D010042
arrhythmia	B-Disease	D001145
in	O	O
dogs	O	O
and	O	O
cats	O	O
.	O	O

GYKI	B-Chemical	-1
-	I-Chemical	-1
41	I-Chemical	-1
900	I-Chemical	-1
has	O	O
a	O	O
negligible	O	O
cardiodepressant	O	O
activity	O	O
;	O	O
it	O	O
is	O	O
not	O	O
cardioselective	O	O
.	O	O

The	O	O
compound	O	O
shows	O	O
a	O	O
rapid	O	O
and	O	O
long	O	O
lasting	O	O
effect	O	O
.	O	O

There	O	O
was	O	O
a	O	O
prolonged	O	O
elimination	O	O
of	O	O
the	O	O
radioactivity	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
14C	B-Chemical	-1
-	I-Chemical	-1
41	I-Chemical	-1
099	I-Chemical	-1
to	O	O
rats	O	O
and	O	O
dogs	O	O
.	O	O

The	O	O
half	O	O
life	O	O
of	O	O
the	O	O
unlabeled	O	O
substance	O	O
in	O	O
humans	O	O
was	O	O
more	O	O
than	O	O
10	O	O
hours	O	O
.	O	O

Chorea	B-Disease	D002819
associated	O	O
with	O	O
oral	B-Chemical	D003276
contraception	I-Chemical	D003276
.	O	O

Three	O	O
patients	O	O
developed	O	O
chorea	B-Disease	D002819
while	O	O
receiving	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

Two	O	O
were	O	O
young	O	O
patients	O	O
whose	O	O
chorea	B-Disease	D002819
developed	O	O
long	O	O
after	O	O
treatment	O	O
had	O	O
been	O	O
started	O	O
and	O	O
disappeared	O	O
soon	O	O
after	O	O
it	O	O
had	O	O
been	O	O
discontinued	O	O
.	O	O

The	O	O
third	O	O
patient	O	O
had	O	O
acute	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
chorea	B-Disease	D002819
after	O	O
prolonged	O	O
oral	B-Chemical	D003276
contraception	I-Chemical	D003276
.	O	O

Prolonged	O	O
administration	O	O
of	O	O
female	O	O
sex	O	O
hormones	O	O
is	O	O
a	O	O
possible	O	O
cause	O	O
of	O	O
chorea	B-Disease	D002819
in	O	O
women	O	O
who	O	O
have	O	O
not	O	O
previously	O	O
had	O	O
chorea	B-Disease	D002819
or	O	O
rheumatic	B-Disease	D012213
fever	I-Disease	D012213
.	O	O

Reversal	O	O
of	O	O
ammonia	B-Chemical	D000641
coma	B-Disease	D003128
in	O	O
rats	O	O
by	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
:	O	O
a	O	O
peripheral	O	O
effect	O	O
.	O	O

Ammonia	B-Chemical	D000641
coma	B-Disease	D003128
was	O	O
produced	O	O
in	O	O
rats	O	O
within	O	O
10	O	O
to	O	O
15	O	O
minutes	O	O
of	O	O
an	O	O
intraperitonealinjection	O	O
of	O	O
1	O	O
.	O	O

7	O	O
mmol	O	O
NH4CL	B-Chemical	D000643
.	O	O

This	O	O
coma	B-Disease	D003128
was	O	O
prevented	O	O
with	O	O
1	O	O
.	O	O

68	O	O
mmol	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
given	O	O
by	O	O
gastric	O	O
intubation	O	O
15	O	O
minutes	O	O
before	O	O
the	O	O
ammonium	B-Chemical	D064751
salt	I-Chemical	D064751
injection	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
was	O	O
correlated	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
blood	O	O
and	O	O
brain	O	O
ammonia	B-Chemical	D000641
,	O	O
an	O	O
increase	O	O
in	O	O
brain	O	O
dopamine	B-Chemical	D004298
,	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
renal	O	O
excretion	O	O
of	O	O
ammonia	B-Chemical	D000641
and	O	O
urea	B-Chemical	D014508
.	O	O

Intraventricular	O	O
infusion	O	O
of	O	O
dopamine	B-Chemical	D004298
sufficient	O	O
to	O	O
raise	O	O
the	O	O
brain	O	O
dopamine	B-Chemical	D004298
to	O	O
the	O	O
same	O	O
extent	O	O
did	O	O
not	O	O
prevent	O	O
the	O	O
ammonia	B-Chemical	D000641
coma	B-Disease	D003128
nor	O	O
affect	O	O
the	O	O
blood	O	O
and	O	O
brain	O	O
ammonia	B-Chemical	D000641
concentrations	O	O
.	O	O

Bilateral	O	O
nephrectomy	O	O
eliminated	O	O
the	O	O
beneficial	O	O
effect	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
on	O	O
blood	O	O
and	O	O
brain	O	O
ammonia	B-Chemical	D000641
and	O	O
the	O	O
ammonia	B-Chemical	D000641
coma	B-Disease	D003128
was	O	O
not	O	O
prevented	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
reduction	O	O
in	O	O
blood	O	O
and	O	O
brain	O	O
ammonia	B-Chemical	D000641
and	O	O
the	O	O
prevention	O	O
of	O	O
ammonia	B-Chemical	D000641
coma	B-Disease	D003128
after	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
,	O	O
can	O	O
be	O	O
accounted	O	O
for	O	O
by	O	O
the	O	O
peripheral	O	O
effect	O	O
of	O	O
dopamine	B-Chemical	D004298
on	O	O
renal	O	O
function	O	O
rather	O	O
than	O	O
its	O	O
central	O	O
action	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
a	O	O
reasonable	O	O
explanation	O	O
for	O	O
the	O	O
beneficial	O	O
effects	O	O
observed	O	O
in	O	O
some	O	O
encephalopathic	B-Disease	D001927
patients	O	O
receiving	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
after	O	O
liver	O	O
transplantation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Unfractionated	B-Chemical	D006493
heparin	I-Chemical	D006493
sodium	I-Chemical	D006493
(	O	O
UFH	B-Chemical	D006493
)	O	O
or	O	O
low	B-Chemical	D006495
-	I-Chemical	D006495
molecular	I-Chemical	D006495
weight	I-Chemical	D006495
heparin	I-Chemical	D006495
(	O	O
LMWH	O	O
)	O	O
is	O	O
used	O	O
in	O	O
anticoagulant	O	O
protocols	O	O
at	O	O
several	O	O
institutions	O	O
to	O	O
prevent	O	O
thrombosis	B-Disease	D013927
after	O	O
liver	O	O
transplantation	O	O
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
HIT	B-Disease	D013921
)	O	O
is	O	O
an	O	O
adverse	O	O
immune	O	O
-	O	O
mediated	O	O
reaction	O	O
to	O	O
heparin	B-Chemical	D006493
,	O	O
resulting	O	O
in	O	O
platelet	O	O
count	O	O
decreases	O	O
of	O	O
more	O	O
than	O	O
50%	O	O
.	O	O

The	O	O
frequencies	O	O
of	O	O
HIT	B-Disease	D013921
after	O	O
liver	O	O
transplantation	O	O
and	O	O
platelet	O	O
factor	O	O
4	O	O
/	O	O
heparin	B-Chemical	D006493
-	O	O
reactive	O	O
antibody	O	O
(	O	O
HIT	B-Disease	D013921
antibody	O	O
)	O	O
positivity	O	O
in	O	O
liver	O	O
transplantation	O	O
patients	O	O
,	O	O
however	O	O
,	O	O
are	O	O
unknown	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
32	O	O
men	O	O
and	O	O
20	O	O
women	O	O
underwent	O	O
living	O	O
donor	O	O
liver	O	O
transplantation	O	O
.	O	O

We	O	O
started	O	O
LMWH	O	O
(	O	O
25	O	O
IU	O	O
/	O	O
kg	O	O
/	O	O
h	O	O
)	O	O
on	O	O
postoperative	O	O
day	O	O
(	O	O
POD	O	O
)	O	O
1	O	O
,	O	O
switching	O	O
to	O	O
UFH	B-Chemical	D006493
(	O	O
5000	O	O
U	O	O
/	O	O
d	O	O
)	O	O
on	O	O
POD	O	O
2	O	O
or	O	O
3	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
UFH	B-Chemical	D006493
was	O	O
changed	O	O
according	O	O
to	O	O
the	O	O
activated	O	O
clotting	O	O
time	O	O
level	O	O
.	O	O

HIT	B-Disease	D013921
antibody	O	O
levels	O	O
were	O	O
measured	O	O
the	O	O
day	O	O
before	O	O
surgery	O	O
and	O	O
on	O	O
POD	O	O
7	O	O
and	O	O
14	O	O
.	O	O

Platelet	O	O
count	O	O
was	O	O
measured	O	O
daily	O	O
for	O	O
3	O	O
weeks	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
average	O	O
platelet	O	O
counts	O	O
preoperatively	O	O
,	O	O
and	O	O
on	O	O
POD	O	O
7	O	O
,	O	O
14	O	O
,	O	O
and	O	O
21	O	O
were	O	O
65	O	O
,	O	O
88	O	O
,	O	O
149	O	O
,	O	O
and	O	O
169	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
,	O	O
respectively	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
hepatic	O	O
artery	O	O
thrombosis	B-Disease	D013927
on	O	O
POD	O	O
11	O	O
and	O	O
19	O	O
,	O	O
respectively	O	O
,	O	O
although	O	O
they	O	O
were	O	O
HIT	B-Disease	D013921
antibody	O	O
-	O	O
negative	O	O
and	O	O
their	O	O
platelet	O	O
counts	O	O
were	O	O
stable	O	O
.	O	O

In	O	O
2	O	O
other	O	O
patients	O	O
,	O	O
the	O	O
platelet	O	O
count	O	O
decreased	O	O
suddenly	O	O
from	O	O
107	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
on	O	O
POD	O	O
4	O	O
to	O	O
65	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
on	O	O
POD	O	O
6	O	O
and	O	O
from	O	O
76	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
on	O	O
POD	O	O
7	O	O
to	O	O
33	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
/	O	O
L	O	O
on	O	O
POD	O	O
9	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
test	O	O
was	O	O
negative	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
HIT	B-Disease	D013921
antibody	O	O
-	O	O
positive	O	O
patients	O	O
was	O	O
0	O	O
.	O	O

5%	O	O
preoperatively	O	O
,	O	O
5	O	O
.	O	O

6%	O	O
on	O	O
POD	O	O
7	O	O
,	O	O
and	O	O
5	O	O
.	O	O

6%	O	O
on	O	O
POD	O	O
14	O	O
.	O	O

None	O	O
of	O	O
the	O	O
subjects	O	O
/	O	O
patients	O	O
developed	O	O
UFH	B-Chemical	D006493
-	O	O
related	O	O
HIT	B-Disease	D013921
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
our	O	O
series	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
HIT	B-Disease	D013921
after	O	O
liver	O	O
transplantation	O	O
was	O	O
uncommon	O	O
.	O	O

PTU	B-Chemical	D011441
-	O	O
associated	O	O
vasculitis	B-Disease	D014657
in	O	O
a	O	O
girl	O	O
with	O	O
Turner	B-Disease	D014424
Syndrome	I-Disease	D014424
and	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
.	O	O

Palpable	O	O
purpura	B-Disease	D011693
is	O	O
a	O	O
concerning	O	O
clinical	O	O
finding	O	O
in	O	O
pediatric	O	O
patients	O	O
and	O	O
can	O	O
have	O	O
many	O	O
causes	O	O
,	O	O
including	O	O
infectious	O	O
and	O	O
autoimmune	O	O
processes	O	O
.	O	O

A	O	O
rare	O	O
cause	O	O
,	O	O
drug	O	O
-	O	O
induced	O	O
vasculitis	B-Disease	D014657
,	O	O
may	O	O
result	O	O
from	O	O
the	O	O
production	O	O
of	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibodies	O	O
(	O	O
ANCAs	O	O
)	O	O
in	O	O
response	O	O
to	O	O
a	O	O
medication	O	O
.	O	O

We	O	O
report	O	O
a	O	O
girl	O	O
with	O	O
Turner	B-Disease	D014424
syndrome	I-Disease	D014424
and	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
who	O	O
presented	O	O
with	O	O
palpable	O	O
purpuric	B-Disease	D011693
lesions	I-Disease	D011693
.	O	O

The	O	O
diagnosis	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
(	O	O
PTU	B-Chemical	D011441
)	O	O
-	O	O
associated	O	O
vasculitis	B-Disease	D014657
was	O	O
made	O	O
by	O	O
observation	O	O
of	O	O
consistent	O	O
clinical	O	O
features	O	O
,	O	O
the	O	O
detection	O	O
of	O	O
elevated	O	O
ANA	O	O
and	O	O
ANCA	O	O
in	O	O
the	O	O
blood	O	O
,	O	O
and	O	O
the	O	O
observed	O	O
clinical	O	O
resolution	O	O
of	O	O
symptoms	O	O
following	O	O
withdrawal	O	O
of	O	O
PTU	B-Chemical	D011441
.	O	O

Subsequent	O	O
treatment	O	O
of	O	O
persistent	O	O
hyperthyroidism	B-Disease	D006980
with	O	O
radioablation	O	O
did	O	O
not	O	O
result	O	O
in	O	O
an	O	O
exacerbation	O	O
of	O	O
the	O	O
vasculitis	B-Disease	D014657
,	O	O
a	O	O
complication	O	O
described	O	O
in	O	O
prior	O	O
case	O	O
reports	O	O
.	O	O

Succinylcholine	B-Chemical	D013390
-	O	O
induced	O	O
masseter	B-Disease	D014313
muscle	I-Disease	D014313
rigidity	I-Disease	D014313
during	O	O
bronchoscopic	O	O
removal	O	O
of	O	O
a	O	O
tracheal	O	O
foreign	O	O
body	O	O
.	O	O

Masseter	B-Disease	D014313
muscle	I-Disease	D014313
rigidity	I-Disease	D014313
during	O	O
general	O	O
anesthesia	O	O
is	O	O
considered	O	O
an	O	O
early	O	O
warning	O	O
sign	O	O
of	O	O
a	O	O
possible	O	O
episode	O	O
of	O	O
malignant	B-Disease	D008305
hyperthermia	I-Disease	D008305
.	O	O

The	O	O
decision	O	O
whether	O	O
to	O	O
continue	O	O
or	O	O
discontinue	O	O
the	O	O
procedure	O	O
depends	O	O
on	O	O
the	O	O
urgency	O	O
of	O	O
the	O	O
surgery	O	O
and	O	O
severity	O	O
of	O	O
masseter	B-Disease	D014313
muscle	I-Disease	D014313
rigidity	I-Disease	D014313
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
severe	O	O
masseter	B-Disease	D014313
muscle	I-Disease	D014313
rigidity	I-Disease	D014313
(	O	O
jaw	B-Disease	D014313
of	I-Disease	D014313
steel	I-Disease	D014313
)	O	O
after	O	O
succinylcholine	B-Chemical	D013390
(	O	O
Sch	B-Chemical	D013390
)	O	O
administration	O	O
during	O	O
general	O	O
anesthetic	O	O
management	O	O
for	O	O
rigid	O	O
bronchoscopic	O	O
removal	O	O
of	O	O
a	O	O
tracheal	O	O
foreign	O	O
body	O	O
.	O	O

Anesthesia	O	O
was	O	O
continued	O	O
uneventfully	O	O
with	O	O
propofol	B-Chemical	D015742
infusion	O	O
while	O	O
all	O	O
facilities	O	O
were	O	O
available	O	O
to	O	O
detect	O	O
and	O	O
treat	O	O
malignant	B-Disease	D008305
hyperthermia	I-Disease	D008305
.	O	O

Minor	O	O
neurological	B-Disease	D009422
dysfunction	I-Disease	D009422
,	O	O
cognitive	O	O
development	O	O
,	O	O
and	O	O
somatic	O	O
development	O	O
at	O	O
the	O	O
age	O	O
of	O	O
3	O	O
to	O	O
7	O	O
years	O	O
after	O	O
dexamethasone	B-Chemical	D003907
treatment	O	O
in	O	O
very	O	O
-	O	O
low	O	O
birth	O	O
-	O	O
weight	O	O
infants	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
minor	O	O
neurological	B-Disease	D009422
dysfunction	I-Disease	D009422
,	O	O
cognitive	O	O
development	O	O
,	O	O
and	O	O
somatic	O	O
development	O	O
after	O	O
dexamethasone	B-Chemical	D003907
therapy	O	O
in	O	O
very	O	O
-	O	O
low	O	O
-	O	O
birthweight	O	O
infants	O	O
.	O	O

Thirty	O	O
-	O	O
three	O	O
children	O	O
after	O	O
dexamethasone	B-Chemical	D003907
treatment	O	O
were	O	O
matched	O	O
to	O	O
33	O	O
children	O	O
without	O	O
dexamethasone	B-Chemical	D003907
treatment	O	O
.	O	O

Data	O	O
were	O	O
assessed	O	O
at	O	O
the	O	O
age	O	O
of	O	O
3	O	O
-	O	O
7	O	O
years	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
was	O	O
started	O	O
between	O	O
the	O	O
7th	O	O
and	O	O
the	O	O
28th	O	O
day	O	O
of	O	O
life	O	O
over	O	O
7	O	O
days	O	O
with	O	O
a	O	O
total	O	O
dose	O	O
of	O	O
2	O	O
.	O	O

35	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
asphyxia	B-Disease	D001237
,	O	O
malformations	B-Disease	D000014
,	O	O
major	O	O
surgical	O	O
interventions	O	O
,	O	O
small	O	O
for	O	O
gestational	O	O
age	O	O
,	O	O
intraventricular	O	O
haemorrhage	B-Disease	D006470
grades	O	O
III	O	O
and	O	O
IV	O	O
,	O	O
periventricular	B-Disease	D007969
leukomalacia	I-Disease	D007969
,	O	O
and	O	O
severe	O	O
psychomotor	B-Disease	D011596
retardation	I-Disease	D011596
.	O	O

Each	O	O
child	O	O
was	O	O
examined	O	O
by	O	O
a	O	O
neuropediatrician	O	O
for	O	O
minor	O	O
neurological	B-Disease	D009422
dysfunctions	I-Disease	D009422
and	O	O
tested	O	O
by	O	O
a	O	O
psychologist	O	O
for	O	O
cognitive	O	O
development	O	O
with	O	O
a	O	O
Kaufman	O	O
Assessment	O	O
Battery	O	O
for	O	O
Children	O	O
and	O	O
a	O	O
Draw	O	O
-	O	O
a	O	O
-	O	O
Man	O	O
Test	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
demographic	O	O
data	O	O
,	O	O
growth	O	O
,	O	O
and	O	O
socio	O	O
-	O	O
economic	O	O
status	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Fine	O	O
motor	O	O
skills	O	O
and	O	O
gross	O	O
motor	O	O
function	O	O
were	O	O
significantly	O	O
better	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
p<0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Draw	O	O
-	O	O
a	O	O
-	O	O
Man	O	O
Test	O	O
,	O	O
the	O	O
control	O	O
group	O	O
showed	O	O
better	O	O
results	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
development	O	O
of	O	O
speech	O	O
,	O	O
social	O	O
development	O	O
,	O	O
and	O	O
the	O	O
Kaufman	O	O
Assessment	O	O
Battery	O	O
for	O	O
Children	O	O
.	O	O

After	O	O
dexamethasone	B-Chemical	D003907
treatment	O	O
,	O	O
children	O	O
showed	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
minor	O	O
neurological	B-Disease	D009422
dysfunctions	I-Disease	D009422
.	O	O

Neurological	O	O
development	O	O
was	O	O
affected	O	O
even	O	O
without	O	O
neurological	O	O
diagnosis	O	O
.	O	O

Further	O	O
long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
studies	O	O
will	O	O
be	O	O
necessary	O	O
to	O	O
fully	O	O
evaluate	O	O
the	O	O
impact	O	O
of	O	O
dexamethasone	B-Chemical	D003907
on	O	O
neurological	O	O
and	O	O
cognitive	O	O
development	O	O
.	O	O

Force	O	O
overflow	O	O
and	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

We	O	O
assessed	O	O
force	O	O
coordination	O	O
of	O	O
the	O	O
hand	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
and	O	O
its	O	O
relationship	O	O
to	O	O
motor	O	O
complications	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
,	O	O
particularly	O	O
to	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
(	O	O
LID	B-Disease	D004409
)	O	O
.	O	O

We	O	O
studied	O	O
two	O	O
groups	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
patients	O	O
with	O	O
(	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
+	O	O
LID	B-Disease	D004409
,	O	O
n	O	O
=	O	O
23	O	O
)	O	O
and	O	O
without	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
(	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
-	O	O
LID	B-Disease	D004409
,	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
and	O	O
age	O	O
-	O	O
matched	O	O
healthy	O	O
controls	O	O
.	O	O

The	O	O
motor	O	O
score	O	O
of	O	O
the	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
,	O	O
a	O	O
dyskinesia	B-Disease	D004409
score	O	O
and	O	O
force	O	O
in	O	O
a	O	O
grip	O	O
-	O	O
lift	O	O
paradigm	O	O
were	O	O
assessed	O	O
ON	O	O
and	O	O
OFF	O	O
levodopa	B-Chemical	D007980
.	O	O

A	O	O
pathological	O	O
increase	O	O
of	O	O
forces	O	O
was	O	O
seen	O	O
in	O	O
ON	O	O
-	O	O
state	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
+	O	O
LID	B-Disease	D004409
only	O	O
.	O	O

In	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
+	O	O
LID	B-Disease	D004409
,	O	O
the	O	O
force	O	O
involved	O	O
in	O	O
pressing	O	O
down	O	O
the	O	O
object	O	O
before	O	O
lifting	O	O
was	O	O
significantly	O	O
increased	O	O
by	O	O
levodopa	B-Chemical	D007980
(	O	O
by	O	O
61%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

An	O	O
overshooting	O	O
of	O	O
peak	O	O
grip	O	O
force	O	O
by	O	O
51%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
of	O	O
static	O	O
grip	O	O
force	O	O
by	O	O
45%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
ON	O	O
-	O	O
compared	O	O
with	O	O
the	O	O
OFF	O	O
-	O	O
drug	O	O
condition	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
no	O	O
excessive	O	O
force	O	O
was	O	O
found	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
-	O	O
LID	B-Disease	D004409
.	O	O

Peak	O	O
grip	O	O
force	O	O
in	O	O
ON	O	O
-	O	O
state	O	O
was	O	O
140%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
higher	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
+	O	O
LID	B-Disease	D004409
than	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
-	O	O
LID	B-Disease	D004409
,	O	O
while	O	O
static	O	O
grip	O	O
force	O	O
was	O	O
increased	O	O
by	O	O
138%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
between	O	O
groups	O	O
.	O	O

Severity	O	O
of	O	O
peak	O	O
-	O	O
dose	O	O
dyskinesias	B-Disease	D004409
was	O	O
strongly	O	O
correlated	O	O
with	O	O
grip	O	O
force	O	O
in	O	O
ON	O	O
-	O	O
state	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

79	O	O
with	O	O
peak	O	O
force	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
forces	O	O
and	O	O
the	O	O
motor	O	O
score	O	O
as	O	O
well	O	O
as	O	O
with	O	O
the	O	O
daily	O	O
dose	O	O
of	O	O
dopaminergic	O	O
medication	O	O
.	O	O

Force	O	O
excess	O	O
was	O	O
only	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
LID	B-Disease	D004409
and	O	O
motor	O	O
fluctuations	O	O
.	O	O

A	O	O
close	O	O
relationship	O	O
was	O	O
seen	O	O
between	O	O
the	O	O
overshooting	O	O
of	O	O
forces	O	O
and	O	O
dyskinesias	B-Disease	D004409
in	O	O
the	O	O
ON	O	O
-	O	O
drug	O	O
condition	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
both	O	O
LID	B-Disease	D004409
and	O	O
grip	O	O
force	O	O
excess	O	O
share	O	O
common	O	O
pathophysiological	O	O
mechanisms	O	O
related	O	O
to	O	O
motor	O	O
fluctuations	O	O
.	O	O

Postinfarction	O	O
ventricular	B-Disease	D018658
septal	I-Disease	D018658
defect	I-Disease	D018658
associated	O	O
with	O	O
long	O	O
-	O	O
term	O	O
steroid	B-Chemical	D013256
therapy	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
postinfarction	O	O
ventricular	B-Disease	D018658
septal	I-Disease	D018658
rupture	I-Disease	D018658
in	O	O
patients	O	O
on	O	O
long	O	O
-	O	O
term	O	O
steroid	B-Chemical	D013256
therapy	O	O
are	O	O
presented	O	O
and	O	O
the	O	O
favourable	O	O
outcome	O	O
in	O	O
both	O	O
cases	O	O
described	O	O
.	O	O

A	O	O
possible	O	O
association	O	O
between	O	O
steroid	B-Chemical	D013256
therapy	O	O
and	O	O
subsequent	O	O
postinfarction	O	O
septal	B-Disease	D018658
rupture	I-Disease	D018658
is	O	O
discussed	O	O
.	O	O

Angioedema	B-Disease	D000799
associated	O	O
with	O	O
droperidol	B-Chemical	D004329
administration	O	O
.	O	O

Angioedema	B-Disease	D000799
,	O	O
also	O	O
known	O	O
as	O	O
angioneurotic	B-Disease	D000799
edema	I-Disease	D000799
or	O	O
Quincke's	B-Disease	D000799
disease	I-Disease	D000799
,	O	O
is	O	O
a	O	O
well	O	O
-	O	O
demarcated	O	O
,	O	O
localized	O	O
edema	B-Disease	D004487
involving	O	O
the	O	O
subcutaneous	O	O
tissues	O	O
that	O	O
may	O	O
cause	O	O
upper	B-Disease	D000402
-	I-Disease	D000402
airway	I-Disease	D000402
obstruction	I-Disease	D000402
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
previously	O	O
healthy	O	O
19	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
no	O	O
known	O	O
drug	B-Disease	D004342
allergies	I-Disease	D004342
in	O	O
whom	O	O
angioedema	B-Disease	D000799
with	O	O
significant	O	O
tongue	O	O
swelling	O	O
and	O	O
protrusion	O	O
developed	O	O
within	O	O
10	O	O
minutes	O	O
of	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
single	O	O
IV	O	O
dose	O	O
of	O	O
droperidol	B-Chemical	D004329
.	O	O

Clarithromycin	B-Chemical	D017291
-	O	O
associated	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
on	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

Visual	B-Disease	D006212
hallucinations	I-Disease	D006212
are	O	O
a	O	O
rare	O	O
event	O	O
in	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
and	O	O
not	O	O
related	O	O
to	O	O
uremia	B-Disease	D014511
per	O	O
se	O	O
.	O	O

Unreported	O	O
in	O	O
the	O	O
literature	O	O
is	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
occurring	O	O
in	O	O
association	O	O
with	O	O
the	O	O
new	O	O
macrolide	B-Chemical	D018942
antibiotic	O	O
,	O	O
clarithromycin	B-Chemical	D017291
.	O	O

We	O	O
describe	O	O
such	O	O
a	O	O
case	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
(	O	O
ESRD	B-Disease	D007676
)	O	O
maintained	O	O
on	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
.	O	O

The	O	O
combination	O	O
of	O	O
a	O	O
relatively	O	O
high	O	O
dose	O	O
of	O	O
clarithromycin	B-Chemical	D017291
in	O	O
face	O	O
of	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
in	O	O
a	O	O
functionally	O	O
anephric	O	O
patient	O	O
,	O	O
with	O	O
underlying	O	O
aluminum	B-Chemical	D000535
intoxication	O	O
,	O	O
may	O	O
have	O	O
facilitated	O	O
the	O	O
appearance	O	O
of	O	O
this	O	O
neurotoxic	B-Disease	D020258
side	O	O
effect	O	O
.	O	O

It	O	O
is	O	O
important	O	O
to	O	O
understand	O	O
the	O	O
pharmacokinetics	O	O
of	O	O
medications	O	O
in	O	O
face	O	O
of	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
,	O	O
the	O	O
possibility	O	O
of	O	O
drug	O	O
interactions	O	O
,	O	O
and	O	O
how	O	O
these	O	O
factors	O	O
should	O	O
help	O	O
guide	O	O
medication	O	O
therapy	O	O
in	O	O
the	O	O
ESRD	B-Disease	D007676
patient	O	O
.	O	O

Acute	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
adriamycin	B-Chemical	D004317
)	O	O
-	O	O
loaded	O	O
cyanoacrylate	B-Chemical	D003487
nanoparticles	O	O
.	O	O

Acute	O	O
doxorubicin	B-Chemical	D004317
-	O	O
loaded	O	O
nanoparticle	O	O
(	O	O
DXNP	O	O
)	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
was	O	O
explored	O	O
in	O	O
both	O	O
normal	O	O
rats	O	O
and	O	O
rats	O	O
with	O	O
experimental	O	O
glomerulonephritis	B-Disease	D005921
.	O	O

In	O	O
normal	O	O
rats	O	O
,	O	O
2	O	O
/	O	O
6	O	O
rats	O	O
given	O	O
free	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DX	B-Chemical	D004317
)	O	O
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
died	O	O
within	O	O
one	O	O
week	O	O
,	O	O
whereas	O	O
all	O	O
control	O	O
animals	O	O
and	O	O
all	O	O
rats	O	O
having	O	O
received	O	O
free	O	O
NP	O	O
or	O	O
DXNP	O	O
survived	O	O
.	O	O

A	O	O
3	O	O
times	O	O
higher	O	O
proteinuria	B-Disease	D011507
appeared	O	O
in	O	O
animals	O	O
treated	O	O
with	O	O
DXNP	O	O
than	O	O
in	O	O
those	O	O
treated	O	O
with	O	O
DX	B-Chemical	D004317
.	O	O

Free	O	O
NP	O	O
did	O	O
not	O	O
provoke	O	O
any	O	O
proteinuria	B-Disease	D011507
.	O	O

Two	O	O
hr	O	O
post	O	O
-	O	O
injection	O	O
,	O	O
DXNP	O	O
was	O	O
2	O	O
.	O	O

7	O	O
times	O	O
more	O	O
concentrated	O	O
in	O	O
kidneys	O	O
than	O	O
free	O	O
DX	B-Chemical	D004317
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

025	O	O
)	O	O
.	O	O

In	O	O
rats	O	O
with	O	O
immune	O	O
experimental	O	O
glomerulonephritis	B-Disease	D005921
,	O	O
5	O	O
/	O	O
6	O	O
rats	O	O
given	O	O
DX	B-Chemical	D004317
died	O	O
within	O	O
7	O	O
days	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
animals	O	O
treated	O	O
by	O	O
DXNP	O	O
,	O	O
NP	O	O
,	O	O
or	O	O
untreated	O	O
,	O	O
which	O	O
all	O	O
survived	O	O
.	O	O

Proteinuria	B-Disease	D011507
appeared	O	O
in	O	O
all	O	O
series	O	O
,	O	O
but	O	O
was	O	O
2	O	O
-	O	O
5	O	O
times	O	O
more	O	O
intense	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
prolonged	O	O
after	O	O
doxorubicin	B-Chemical	D004317
treatment	O	O
(	O	O
400	O	O
-	O	O
700	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
,	O	O
without	O	O
significant	O	O
difference	O	O
between	O	O
DXNP	O	O
and	O	O
DX	B-Chemical	D004317
.	O	O

Rats	O	O
treated	O	O
by	O	O
unloaded	O	O
NP	O	O
behaved	O	O
as	O	O
controls	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
,	O	O
in	O	O
these	O	O
experimental	O	O
conditions	O	O
,	O	O
DXNP	O	O
killed	O	O
less	O	O
animals	O	O
than	O	O
free	O	O
DX	B-Chemical	D004317
,	O	O
despite	O	O
of	O	O
an	O	O
enhanced	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
of	O	O
the	O	O
former	O	O
.	O	O

Both	O	O
effects	O	O
(	O	O
better	O	O
survival	O	O
and	O	O
nephrosis	B-Disease	D009401
)	O	O
are	O	O
most	O	O
probably	O	O
related	O	O
to	O	O
an	O	O
enhanced	O	O
capture	O	O
of	O	O
DXNP	O	O
by	O	O
cells	O	O
of	O	O
the	O	O
mononuclear	O	O
phagocyte	O	O
system	O	O
,	O	O
including	O	O
mesangial	O	O
cells	O	O
.	O	O

Etoposide	B-Chemical	D005047
-	O	O
related	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
occurrence	O	O
of	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
is	O	O
reported	O	O
after	O	O
chemotherapy	O	O
containing	O	O
etoposide	B-Chemical	D005047
,	O	O
in	O	O
a	O	O
man	O	O
with	O	O
no	O	O
risk	O	O
factors	O	O
for	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
.	O	O

Possible	O	O
causal	O	O
mechanisms	O	O
are	O	O
discussed	O	O
.	O	O

Subjective	O	O
assessment	O	O
of	O	O
sexual	B-Disease	D020018
dysfunction	I-Disease	D020018
of	O	O
patients	O	O
on	O	O
long	O	O
-	O	O
term	O	O
administration	O	O
of	O	O
digoxin	B-Chemical	D004077
.	O	O

Various	O	O
data	O	O
suggest	O	O
that	O	O
male	O	O
patients	O	O
who	O	O
have	O	O
received	O	O
digoxin	B-Chemical	D004077
on	O	O
a	O	O
longterm	O	O
basis	O	O
have	O	O
increased	O	O
levels	O	O
of	O	O
serum	O	O
estrogen	B-Chemical	D004967
and	O	O
decreased	O	O
levels	O	O
of	O	O
plasma	O	O
testosterone	B-Chemical	D013739
and	O	O
luteinizing	O	O
hormone	O	O
(	O	O
LH	O	O
)	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
investigate	O	O
the	O	O
links	O	O
between	O	O
the	O	O
long	O	O
-	O	O
term	O	O
administration	O	O
of	O	O
digoxin	B-Chemical	D004077
therapy	O	O
and	O	O
sexual	O	O
behavior	O	O
,	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
digoxin	B-Chemical	D004077
on	O	O
plasma	O	O
levels	O	O
of	O	O
estradiol	B-Chemical	D004958
,	O	O
testosterone	B-Chemical	D013739
,	O	O
and	O	O
LH	O	O
.	O	O

The	O	O
patients	O	O
of	O	O
the	O	O
study	O	O
and	O	O
control	O	O
group	O	O
(	O	O
without	O	O
digoxin	B-Chemical	D004077
)	O	O
were	O	O
of	O	O
similar	O	O
cardiac	O	O
functional	O	O
capacity	O	O
and	O	O
age	O	O
(	O	O
25	O	O
-	O	O
40	O	O
years	O	O
)	O	O
and	O	O
were	O	O
randomly	O	O
selected	O	O
from	O	O
the	O	O
rheumatic	B-Disease	D012214
heart	I-Disease	D012214
disease	I-Disease	D012214
patients	O	O
.	O	O

A	O	O
subjective	O	O
assessment	O	O
of	O	O
sexual	O	O
behavior	O	O
in	O	O
the	O	O
study	O	O
and	O	O
control	O	O
groups	O	O
was	O	O
carried	O	O
out	O	O
,	O	O
using	O	O
parameters	O	O
such	O	O
as	O	O
sexual	O	O
desire	O	O
,	O	O
sexual	O	O
excitement	O	O
,	O	O
and	O	O
frequency	O	O
of	O	O
sexual	O	O
relations	O	O
.	O	O

Personal	O	O
interviews	O	O
and	O	O
a	O	O
questionnaire	O	O
were	O	O
also	O	O
used	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
sexual	O	O
behavior	O	O
.	O	O

The	O	O
findings	O	O
support	O	O
the	O	O
reports	O	O
concerning	O	O
digoxin	B-Chemical	D004077
effect	O	O
on	O	O
plasma	O	O
estradiol	B-Chemical	D004958
,	O	O
testosterone	B-Chemical	D013739
,	O	O
and	O	O
LH	O	O
.	O	O

The	O	O
differences	O	O
in	O	O
the	O	O
means	O	O
were	O	O
significant	O	O
.	O	O

Tests	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
changes	O	O
in	O	O
sexual	O	O
behavior	O	O
showed	O	O
a	O	O
significant	O	O
decrease	B-Disease	D020018
in	I-Disease	D020018
sexual	I-Disease	D020018
desire	I-Disease	D020018
,	O	O
sexual	O	O
excitement	O	O
phase	O	O
(	O	O
erection	O	O
)	O	O
,	O	O
and	O	O
frequency	O	O
of	O	O
sexual	O	O
relations	O	O
in	O	O
the	O	O
study	O	O
group	O	O
.	O	O

Fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
due	O	O
to	O	O
indomethacin	B-Chemical	D007213
-	O	O
-	O	O
lymphocyte	O	O
transformation	O	O
tests	O	O
in	O	O
vitro	O	O
.	O	O

Although	O	O
indomethacin	B-Chemical	D007213
has	O	O
been	O	O
implicated	O	O
as	O	O
a	O	O
possible	O	O
cause	O	O
of	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
on	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
few	O	O
clinical	O	O
observations	O	O
,	O	O
its	O	O
role	O	O
has	O	O
not	O	O
been	O	O
definitely	O	O
established	O	O
.	O	O

A	O	O
case	O	O
of	O	O
fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
is	O	O
described	O	O
in	O	O
which	O	O
no	O	O
drugs	O	O
other	O	O
than	O	O
allopurinol	B-Chemical	D000493
and	O	O
indomethacin	B-Chemical	D007213
were	O	O
given	O	O
.	O	O

Indomethacin	B-Chemical	D007213
was	O	O
first	O	O
given	O	O
four	O	O
weeks	O	O
prior	O	O
to	O	O
the	O	O
onset	O	O
of	O	O
symptoms	O	O
.	O	O

A	O	O
positive	O	O
lymphocyte	O	O
transformation	O	O
test	O	O
with	O	O
indomethacin	B-Chemical	D007213
in	O	O
vitro	O	O
further	O	O
substantiates	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
this	O	O
drug	O	O
in	O	O
causing	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
in	O	O
a	O	O
susceptible	O	O
patient	O	O
.	O	O

Fortunately	O	O
,	O	O
this	O	O
seems	O	O
to	O	O
be	O	O
a	O	O
very	O	O
rare	O	O
complication	O	O
.	O	O

Plasma	O	O
and	O	O
urinary	O	O
lipids	O	O
and	O	O
lipoproteins	O	O
during	O	O
the	O	O
development	O	O
of	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
induced	O	O
in	O	O
the	O	O
rat	O	O
by	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
ascertain	O	O
whether	O	O
the	O	O
alterations	O	O
of	O	O
plasma	O	O
lipoproteins	O	O
found	O	O
in	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
induced	O	O
by	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
were	O	O
due	O	O
to	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
per	O	O
se	O	O
,	O	O
or	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
to	O	O
the	O	O
aminonucleoside	B-Chemical	D011692
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
changes	O	O
in	O	O
plasma	O	O
and	O	O
urinary	O	O
lipoproteins	O	O
during	O	O
the	O	O
administration	O	O
of	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
7	O	O
days	O	O
)	O	O
and	O	O
the	O	O
subsequent	O	O
development	O	O
of	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Since	O	O
massive	O	O
albuminuria	B-Disease	D000419
occurred	O	O
after	O	O
6	O	O
days	O	O
of	O	O
treatment	O	O
,	O	O
the	O	O
time	O	O
-	O	O
course	O	O
study	O	O
was	O	O
divided	O	O
into	O	O
two	O	O
stages	O	O
:	O	O
pre	O	O
-	O	O
nephrotic	B-Disease	D009404
stage	O	O
(	O	O
day	O	O
1	O	O
-	O	O
5	O	O
)	O	O
and	O	O
nephrotic	B-Disease	D009404
stage	O	O
(	O	O
day	O	O
6	O	O
-	O	O
11	O	O
)	O	O
.	O	O

In	O	O
pre	O	O
-	O	O
nephrotic	B-Disease	D009404
stage	O	O
the	O	O
plasma	O	O
level	O	O
of	O	O
fatty	B-Chemical	D005227
acids	I-Chemical	D005227
,	O	O
triacylglycerol	B-Chemical	D014280
and	O	O
VLDL	O	O
decreased	O	O
while	O	O
that	O	O
of	O	O
phospholipid	O	O
,	O	O
cholesteryl	B-Chemical	D002788
esters	I-Chemical	D002788
and	O	O
HDL	O	O
remained	O	O
constant	O	O
.	O	O

Plasma	O	O
apolipoprotein	O	O
A	O	O
-	O	O
I	O	O
tended	O	O
to	O	O
increase	O	O
(	O	O
40%	O	O
increase	O	O
at	O	O
day	O	O
5	O	O
)	O	O
.	O	O

At	O	O
the	O	O
beginning	O	O
of	O	O
nephrotic	B-Disease	D009404
stage	O	O
(	O	O
day	O	O
6	O	O
)	O	O
the	O	O
concentration	O	O
of	O	O
plasma	O	O
albumin	O	O
dropped	O	O
to	O	O
a	O	O
very	O	O
low	O	O
level	O	O
,	O	O
while	O	O
that	O	O
of	O	O
apolipoprotein	O	O
A	O	O
-	O	O
I	O	O
increased	O	O
abruptly	O	O
(	O	O
4	O	O
-	O	O
fold	O	O
increase	O	O
)	O	O
and	O	O
continued	O	O
to	O	O
rise	O	O
,	O	O
although	O	O
less	O	O
steeply	O	O
,	O	O
in	O	O
the	O	O
following	O	O
days	O	O
.	O	O

The	O	O
plasma	O	O
concentration	O	O
of	O	O
HDL	O	O
followed	O	O
the	O	O
same	O	O
pattern	O	O
.	O	O

Plasma	O	O
VLDL	O	O
and	O	O
LDL	O	O
increased	O	O
at	O	O
a	O	O
later	O	O
stage	O	O
(	O	O
day	O	O
9	O	O
)	O	O
.	O	O

Plasma	O	O
apolipoprotein	O	O
A	O	O
-	O	O
I	O	O
was	O	O
found	O	O
not	O	O
only	O	O
in	O	O
HDL	O	O
(	O	O
1	O	O
.	O	O

063	O	O
-	O	O
1	O	O
.	O	O

210	O	O
g	O	O
/	O	O
ml	O	O
)	O	O
but	O	O
also	O	O
in	O	O
the	O	O
LDL	O	O
density	O	O
class	O	O
(	O	O
1	O	O
.	O	O

025	O	O
-	O	O
1	O	O
.	O	O

050	O	O
g	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

In	O	O
the	O	O
pre	O	O
-	O	O
nephrotic	B-Disease	D009404
stage	O	O
lipoproteinuria	O	O
was	O	O
negligible	O	O
,	O	O
while	O	O
in	O	O
the	O	O
early	O	O
nephrotic	B-Disease	D009404
stage	O	O
the	O	O
urinary	O	O
loss	O	O
of	O	O
plasma	O	O
lipoproteins	O	O
consisted	O	O
mainly	O	O
of	O	O
HDL	O	O
.	O	O

These	O	O
observations	O	O
indicate	O	O
that	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
alters	O	O
plasma	O	O
lipoproteins	O	O
by	O	O
lowering	O	O
VLDL	O	O
and	O	O
increasing	O	O
HDL	O	O
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
early	O	O
and	O	O
striking	O	O
increase	O	O
of	O	O
plasma	O	O
HDL	O	O
found	O	O
in	O	O
nephrotic	B-Disease	D009404
rats	O	O
is	O	O
related	O	O
to	O	O
a	O	O
direct	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
HDL	O	O
metabolism	O	O
.	O	O

Circulating	O	O
lysosomal	O	O
enzymes	O	O
and	O	O
acute	B-Disease	D017114
hepatic	I-Disease	D017114
necrosis	I-Disease	D017114
.	O	O

The	O	O
activities	O	O
of	O	O
the	O	O
lysosomal	O	O
enzymes	O	O
acid	O	O
and	O	O
neutral	O	O
protease	O	O
,	O	O
N	O	O
-	O	O
acetylglucosaminidase	O	O
,	O	O
and	O	O
acid	O	O
phosphatase	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
serum	O	O
of	O	O
patients	O	O
with	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

Acid	O	O
protease	O	O
(	O	O
cathepsin	O	O
D	O	O
)	O	O
activity	O	O
was	O	O
increased	O	O
about	O	O
tenfold	O	O
in	O	O
patients	O	O
who	O	O
died	O	O
and	O	O
nearly	O	O
fourfold	O	O
in	O	O
those	O	O
who	O	O
survived	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
after	O	O
paracetamol	B-Chemical	D000082
overdose	B-Disease	D062787
,	O	O
whereas	O	O
activities	O	O
were	O	O
increased	O	O
equally	O	O
in	O	O
patients	O	O
with	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
due	O	O
to	O	O
viral	B-Disease	D006525
hepatitis	I-Disease	D006525
whether	O	O
or	O	O
not	O	O
they	O	O
survived	O	O
.	O	O

A	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
serum	O	O
acid	O	O
protease	O	O
activity	O	O
and	O	O
prothrombin	O	O
time	O	O
,	O	O
and	O	O
the	O	O
increase	O	O
in	O	O
cathepsin	O	O
D	O	O
activity	O	O
was	O	O
sustained	O	O
over	O	O
several	O	O
days	O	O
compared	O	O
with	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
,	O	O
which	O	O
showed	O	O
a	O	O
sharp	O	O
early	O	O
peak	O	O
and	O	O
then	O	O
a	O	O
fall	O	O
.	O	O

Circulating	O	O
lysosomal	O	O
proteases	O	O
can	O	O
damage	O	O
other	O	O
organs	O	O
,	O	O
and	O	O
measurement	O	O
of	O	O
their	O	O
activity	O	O
may	O	O
therefore	O	O
be	O	O
of	O	O
added	O	O
value	O	O
in	O	O
assessing	O	O
prognosis	O	O
in	O	O
this	O	O
condition	O	O
.	O	O

Transketolase	O	O
abnormality	O	O
in	O	O
tolazamide	B-Chemical	D014042
-	O	O
induced	O	O
Wernicke's	B-Disease	D014899
encephalopathy	I-Disease	D014899
.	O	O

We	O	O
studied	O	O
a	O	O
thiamine	B-Chemical	D013831
-	O	O
dependent	O	O
enzyme	O	O
,	O	O
transketolase	O	O
,	O	O
from	O	O
fibroblasts	O	O
of	O	O
a	O	O
diabetic	B-Disease	D003920
patient	O	O
who	O	O
developed	O	O
Wernicke's	B-Disease	D014899
encephalopathy	I-Disease	D014899
when	O	O
treated	O	O
with	O	O
tolazamide	B-Chemical	D014042
,	O	O
in	O	O
order	O	O
to	O	O
delineate	O	O
if	O	O
this	O	O
patient	O	O
also	O	O
had	O	O
transketolase	O	O
abnormality	O	O
[	O	O
high	O	O
Km	O	O
for	O	O
thiamine	B-Chemical	D013831
pyrophosphate	O	O
(	O	O
TPP	B-Chemical	D013835
)	O	O
]	O	O
,	O	O
as	O	O
previously	O	O
reported	O	O
in	O	O
postalcoholic	O	O
Wernicke	B-Disease	D020915
-	I-Disease	D020915
Korsakoff	I-Disease	D020915
syndrome	I-Disease	D020915
.	O	O

In	O	O
addition	O	O
to	O	O
this	O	O
patient	O	O
,	O	O
we	O	O
also	O	O
studied	O	O
this	O	O
enzyme	O	O
from	O	O
three	O	O
diabetic	B-Disease	D003920
kindreds	O	O
without	O	O
any	O	O
history	O	O
of	O	O
Wernicke's	B-Disease	D014899
encephalopathy	I-Disease	D014899
and	O	O
from	O	O
four	O	O
normal	O	O
controls	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
above	O	O
-	O	O
mentioned	O	O
patient	O	O
and	O	O
one	O	O
of	O	O
the	O	O
diabetic	B-Disease	D003920
kindreds	O	O
with	O	O
no	O	O
history	O	O
of	O	O
Wernicke's	B-Disease	D014899
encephalopathy	I-Disease	D014899
had	O	O
abnormal	O	O
transketolase	O	O
as	O	O
determined	O	O
by	O	O
its	O	O
Km	O	O
for	O	O
TPP	B-Chemical	D013835
.	O	O

These	O	O
data	O	O
suggest	O	O
a	O	O
similarity	O	O
between	O	O
postalcoholic	O	O
Wernicke	B-Disease	D020915
-	I-Disease	D020915
Korsakoff	I-Disease	D020915
syndrome	I-Disease	D020915
and	O	O
the	O	O
patient	O	O
with	O	O
tolazamide	B-Chemical	D014042
-	O	O
induced	O	O
Wernicke's	B-Disease	D014899
encephalopathy	I-Disease	D014899
from	O	O
the	O	O
standpoint	O	O
of	O	O
transketolase	O	O
abnormality	O	O
.	O	O

Mechanisms	O	O
of	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
induced	O	O
by	O	O
epinephrine	B-Chemical	D004837
:	O	O
comparison	O	O
with	O	O
exercise	O	O
-	O	O
induced	O	O
ischemia	B-Disease	D007511
.	O	O

The	O	O
role	O	O
of	O	O
epinephrine	B-Chemical	D004837
in	O	O
eliciting	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
was	O	O
examined	O	O
in	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

Objective	O	O
signs	O	O
of	O	O
ischemia	B-Disease	D007511
and	O	O
factors	O	O
increasing	O	O
myocardial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
were	O	O
compared	O	O
during	O	O
epinephrine	B-Chemical	D004837
infusion	O	O
and	O	O
supine	O	O
bicycle	O	O
exercise	O	O
.	O	O

Both	O	O
epinephrine	B-Chemical	D004837
and	O	O
exercise	O	O
produced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
as	O	O
evidenced	O	O
by	O	O
ST	O	O
segment	O	O
depression	B-Disease	D003866
and	O	O
angina	B-Disease	D000787
.	O	O

However	O	O
,	O	O
the	O	O
mechanisms	O	O
of	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
induced	O	O
by	O	O
epinephrine	B-Chemical	D004837
were	O	O
significantly	O	O
different	O	O
from	O	O
those	O	O
of	O	O
exercise	O	O
.	O	O

Exercise	O	O
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
was	O	O
marked	O	O
predominantly	O	O
by	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
rate	O	O
-	O	O
pressure	O	O
product	O	O
with	O	O
a	O	O
minor	O	O
contribution	O	O
of	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
,	O	O
while	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
ischemia	B-Disease	D007511
was	O	O
characterized	O	O
by	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
contractility	O	O
and	O	O
a	O	O
less	O	O
pronounced	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
and	O	O
rate	O	O
-	O	O
pressure	O	O
product	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
ischemia	B-Disease	D007511
produced	O	O
by	O	O
epinephrine	B-Chemical	D004837
,	O	O
as	O	O
may	O	O
occur	O	O
during	O	O
states	O	O
of	O	O
emotional	O	O
distress	O	O
,	O	O
has	O	O
a	O	O
mechanism	O	O
distinct	O	O
from	O	O
that	O	O
due	O	O
to	O	O
physical	O	O
exertion	O	O
.	O	O

Transient	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
following	O	O
unilateral	O	O
substantia	B-Disease	-1
nigra	I-Disease	-1
lesion	I-Disease	-1
reflects	O	O
susceptibility	O	O
of	O	O
the	O	O
nigrostriatal	O	O
system	O	O
to	O	O
exhaustion	O	O
by	O	O
amphetamine	B-Chemical	D000661
.	O	O

Following	O	O
unilateral	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
induced	O	O
SN	B-Disease	-1
lesion	I-Disease	-1
,	O	O
a	O	O
transient	O	O
period	O	O
of	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
has	O	O
been	O	O
reported	O	O
to	O	O
precede	O	O
the	O	O
predominant	O	O
ipsilateral	B-Disease	D009069
circling	I-Disease	D009069
.	O	O

In	O	O
order	O	O
to	O	O
clarify	O	O
the	O	O
nature	O	O
of	O	O
this	O	O
initial	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
we	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
duration	O	O
of	O	O
recovery	O	O
period	O	O
after	O	O
the	O	O
lesion	O	O
,	O	O
on	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
rotational	B-Disease	D009069
behavior	I-Disease	D009069
.	O	O

Three	O	O
days	O	O
post	O	O
lesion	O	O
,	O	O
most	O	O
rats	O	O
circled	O	O
predominantly	O	O
contralaterally	O	O
to	O	O
the	O	O
lesion	O	O
.	O	O

Such	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
may	O	O
result	O	O
from	O	O
either	O	O
degeneration	O	O
-	O	O
induced	O	O
breakdown	O	O
of	O	O
the	O	O
DA	O	O
pool	O	O
,	O	O
or	O	O
lesion	O	O
-	O	O
induced	O	O
increase	O	O
of	O	O
DA	O	O
turnover	O	O
in	O	O
the	O	O
spared	O	O
neurons	O	O
.	O	O

A	O	O
substantial	O	O
degree	O	O
of	O	O
contralateral	O	O
preference	O	O
was	O	O
still	O	O
evident	O	O
when	O	O
amphetamine	B-Chemical	D000661
was	O	O
administered	O	O
for	O	O
the	O	O
first	O	O
time	O	O
24	O	O
days	O	O
after	O	O
lesioning	O	O
,	O	O
indicating	O	O
involvement	O	O
of	O	O
spared	O	O
cells	O	O
in	O	O
the	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
.	O	O

However	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
duration	O	O
of	O	O
recovery	O	O
(	O	O
and	O	O
irrespective	O	O
of	O	O
either	O	O
lesion	O	O
volume	O	O
,	O	O
amphetamine	B-Chemical	D000661
dose	O	O
,	O	O
or	O	O
post	O	O
-	O	O
lesion	O	O
motor	O	O
exercise	O	O
)	O	O
,	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
rotation	B-Disease	D009069
tended	O	O
to	O	O
become	O	O
gradually	O	O
more	O	O
ipsilateral	O	O
as	O	O
the	O	O
observation	O	O
session	O	O
progressed	O	O
,	O	O
and	O	O
all	O	O
rats	O	O
circled	O	O
ipsilaterally	O	O
to	O	O
the	O	O
lesion	O	O
in	O	O
response	O	O
to	O	O
further	O	O
amphetamine	B-Chemical	D000661
injections	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
amphetamine	B-Chemical	D000661
has	O	O
an	O	O
irreversible	O	O
effect	O	O
on	O	O
the	O	O
post	O	O
-	O	O
lesion	O	O
DA	O	O
pool	O	O
contributing	O	O
to	O	O
contralateral	B-Disease	D009069
rotation	I-Disease	D009069
.	O	O

Thyroid	O	O
function	O	O
and	O	O
urine	O	O
-	O	O
concentrating	O	O
ability	O	O
during	O	O
lithium	B-Chemical	D008094
treatment	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
adenylate	O	O
cyclase	O	O
inhibition	O	O
may	O	O
be	O	O
important	O	O
in	O	O
the	O	O
development	O	O
of	O	O
both	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
and	O	O
hypothyroidism	B-Disease	D007037
during	O	O
lithium	B-Chemical	D008094
treatment	O	O
.	O	O

We	O	O
measured	O	O
serum	O	O
thyroxine	B-Chemical	D013974
and	O	O
urine	O	O
-	O	O
concentrating	O	O
ability	O	O
(	O	O
Umax	O	O
)	O	O
in	O	O
response	O	O
to	O	O
desmopressin	O	O
(	O	O
DDAVP	O	O
)	O	O
in	O	O
85	O	O
patients	O	O
receiving	O	O
lithium	B-Chemical	D008094
.	O	O

Hypothyroidism	B-Disease	D007037
developed	O	O
in	O	O
eight	O	O
patients	O	O
while	O	O
they	O	O
were	O	O
taking	O	O
lithium	B-Chemical	D008094
.	O	O

Impaired	O	O
Umax	O	O
was	O	O
found	O	O
in	O	O
both	O	O
euthyroid	O	O
and	O	O
hypothyroid	B-Disease	D007037
patients	O	O
while	O	O
some	O	O
hypothyroid	B-Disease	D007037
patients	O	O
concentrated	O	O
their	O	O
urine	O	O
well	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
the	O	O
dominant	O	O
mechanisms	O	O
by	O	O
which	O	O
lithium	B-Chemical	D008094
exerts	O	O
these	O	O
two	O	O
effects	O	O
are	O	O
different	O	O
.	O	O

Sensitivity	O	O
of	O	O
erythroid	O	O
progenitor	O	O
colonies	O	O
to	O	O
erythropoietin	O	O
in	O	O
azidothymidine	B-Chemical	D015215
treated	O	O
immunodeficient	B-Disease	C565469
mice	O	O
.	O	O

The	O	O
anaemia	B-Disease	D000740
induced	O	O
by	O	O
3'	B-Chemical	D015215
-	I-Chemical	D015215
azido	I-Chemical	D015215
-	I-Chemical	D015215
3'dideoxythymidine	I-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
have	O	O
used	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
AIDS	B-Disease	D000163
,	O	O
infection	B-Disease	D007239
of	O	O
female	O	O
C57BL	O	O
/	O	O
6	O	O
mice	O	O
with	O	O
LP	O	O
-	O	O
BM5	O	O
murine	O	O
leukaemia	B-Disease	D007938
(	O	O
MuLV	O	O
)	O	O
virus	O	O
,	O	O
to	O	O
determine	O	O
if	O	O
AZT	B-Chemical	D015215
-	O	O
induced	O	O
anaemia	B-Disease	D000740
is	O	O
due	O	O
,	O	O
in	O	O
part	O	O
,	O	O
to	O	O
decreased	O	O
responsiveness	O	O
of	O	O
erythropoietic	O	O
precursors	O	O
(	O	O
BFU	O	O
-	O	O
e	O	O
)	O	O
to	O	O
erythropoietin	O	O
(	O	O
EPO	O	O
)	O	O
.	O	O

Mice	O	O
in	O	O
the	O	O
early	O	O
stage	O	O
of	O	O
LP	O	O
-	O	O
BM5	O	O
MuLV	O	O
disease	O	O
were	O	O
given	O	O
AZT	B-Chemical	D015215
in	O	O
their	O	O
drinking	O	O
water	O	O
at	O	O
1	O	O
.	O	O

0	O	O
and	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
ml	O	O
.	O	O

AZT	B-Chemical	D015215
produced	O	O
anaemia	B-Disease	D000740
in	O	O
both	O	O
groups	O	O
,	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
fashion	O	O
.	O	O

Despite	O	O
the	O	O
anaemia	B-Disease	D000740
,	O	O
the	O	O
number	O	O
of	O	O
splenic	O	O
and	O	O
bone	O	O
marrow	O	O
BFU	O	O
-	O	O
e	O	O
in	O	O
AZT	B-Chemical	D015215
treated	O	O
mice	O	O
increased	O	O
up	O	O
to	O	O
five	O	O
-	O	O
fold	O	O
over	O	O
levels	O	O
observed	O	O
in	O	O
infected	O	O
untreated	O	O
animals	O	O
after	O	O
15	O	O
d	O	O
of	O	O
treatment	O	O
.	O	O

Colony	O	O
formation	O	O
by	O	O
splenic	O	O
and	O	O
bone	O	O
marrow	O	O
BFUe	O	O
was	O	O
stimulated	O	O
at	O	O
lower	O	O
concentrations	O	O
of	O	O
EPO	O	O
in	O	O
mice	O	O
receiving	O	O
AZT	B-Chemical	D015215
for	O	O
15	O	O
d	O	O
than	O	O
for	O	O
infected	O	O
,	O	O
untreated	O	O
mice	O	O
.	O	O

By	O	O
day	O	O
30	O	O
,	O	O
sensitivity	O	O
of	O	O
both	O	O
splenic	O	O
and	O	O
bone	O	O
marrow	O	O
BFU	O	O
-	O	O
e	O	O
of	O	O
treated	O	O
animals	O	O
returned	O	O
to	O	O
that	O	O
observed	O	O
from	O	O
cells	O	O
of	O	O
infected	O	O
untreated	O	O
animals	O	O
.	O	O

The	O	O
mean	O	O
plasma	O	O
levels	O	O
of	O	O
EPO	O	O
observed	O	O
in	O	O
AZT	B-Chemical	D015215
treated	O	O
mice	O	O
were	O	O
appropriate	O	O
for	O	O
the	O	O
degree	O	O
of	O	O
anaemia	B-Disease	D000740
observed	O	O
when	O	O
compared	O	O
with	O	O
phenylhydrazine	B-Chemical	C030299
(	O	O
PHZ	B-Chemical	C030299
)	O	O
treated	O	O
mice	O	O
.	O	O

The	O	O
numbers	O	O
of	O	O
BFU	O	O
-	O	O
e	O	O
and	O	O
the	O	O
percentage	O	O
of	O	O
bone	O	O
marrow	O	O
erythroblasts	O	O
observed	O	O
were	O	O
comparable	O	O
in	O	O
AZT	B-Chemical	D015215
and	O	O
PHZ	B-Chemical	C030299
treated	O	O
mice	O	O
with	O	O
similar	O	O
degrees	O	O
of	O	O
anaemia	B-Disease	D000740
.	O	O

However	O	O
,	O	O
reticulocytosis	B-Disease	D045262
was	O	O
inappropriate	O	O
for	O	O
the	O	O
degree	O	O
of	O	O
anaemia	B-Disease	D000740
observed	O	O
in	O	O
AZT	B-Chemical	D015215
treated	O	O
infected	O	O
mice	O	O
.	O	O

AZT	B-Chemical	D015215
-	O	O
induced	O	O
peripheral	O	O
anaemia	B-Disease	D000740
in	O	O
the	O	O
face	O	O
of	O	O
increased	O	O
numbers	O	O
of	O	O
BFU	O	O
-	O	O
e	O	O
and	O	O
increased	O	O
levels	O	O
of	O	O
plasma	O	O
EPO	O	O
suggest	O	O
a	O	O
lesion	O	O
in	O	O
terminal	O	O
differentiation	O	O
.	O	O

Detection	O	O
of	O	O
abnormal	O	O
cardiac	O	O
adrenergic	O	O
neuron	O	O
activity	O	O
in	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
with	O	O
iodine	B-Chemical	D019797
-	I-Chemical	D019797
125	I-Chemical	D019797
-	I-Chemical	D019797
metaiodobenzylguanidine	I-Chemical	D019797
.	O	O

Radiolabeled	B-Chemical	D019797
metaiodobenzylguanidine	I-Chemical	D019797
(	O	O
MIBG	B-Chemical	D019797
)	O	O
,	O	O
an	O	O
analog	O	O
of	O	O
norepinephrine	B-Chemical	D009638
(	O	O
NE	B-Chemical	D009638
)	O	O
,	O	O
serves	O	O
as	O	O
an	O	O
index	O	O
of	O	O
adrenergic	O	O
neuron	O	O
integrity	O	O
and	O	O
function	O	O
.	O	O

Using	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
we	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
abnormal	O	O
cardiac	O	O
adrenergic	O	O
neuron	O	O
activity	O	O
may	O	O
appear	O	O
and	O	O
be	O	O
exacerbated	O	O
dose	O	O
-	O	O
dependently	O	O
in	O	O
adriamycin	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
.	O	O

The	O	O
degree	O	O
of	O	O
vacuolar	B-Disease	C536522
degeneration	I-Disease	C536522
of	I-Disease	C536522
myocardial	I-Disease	C536522
cells	I-Disease	C536522
was	O	O
analyzed	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
duration	O	O
of	O	O
adriamycin	B-Chemical	D004317
treatment	O	O
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
once	O	O
a	O	O
week	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
abnormalities	O	O
or	O	O
only	O	O
isolated	O	O
degeneration	O	O
in	O	O
the	O	O
1	O	O
-	O	O
or	O	O
2	O	O
-	O	O
wk	O	O
treatment	O	O
groups	O	O
,	O	O
isolated	O	O
or	O	O
scattered	O	O
degeneration	O	O
in	O	O
half	O	O
of	O	O
the	O	O
3	O	O
-	O	O
wk	O	O
group	O	O
,	O	O
frequent	O	O
scattered	O	O
degeneration	O	O
in	O	O
the	O	O
4	O	O
-	O	O
wk	O	O
group	O	O
,	O	O
scattered	O	O
or	O	O
focal	O	O
degeneration	O	O
in	O	O
the	O	O
5	O	O
-	O	O
wk	O	O
group	O	O
,	O	O
and	O	O
extensive	O	O
degeneration	O	O
in	O	O
the	O	O
8	O	O
-	O	O
wk	O	O
group	O	O
.	O	O

Myocardial	O	O
accumulation	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
MIBG	B-Chemical	D019797
4	O	O
hr	O	O
after	O	O
intravenous	O	O
injection	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
the	O	O
controls	O	O
and	O	O
the	O	O
groups	O	O
treated	O	O
3	O	O
wk	O	O
or	O	O
less	O	O
.	O	O

However	O	O
,	O	O
the	O	O
4	O	O
-	O	O
wk	O	O
group	O	O
had	O	O
a	O	O
slightly	O	O
lower	O	O
accumulation	O	O
in	O	O
the	O	O
right	O	O
ventricular	O	O
wall	O	O
(	O	O
82%	O	O
of	O	O
the	O	O
control	O	O
)	O	O
and	O	O
significantly	O	O
lower	O	O
accumulation	O	O
in	O	O
the	O	O
left	O	O
ventricular	O	O
wall	O	O
(	O	O
about	O	O
66%	O	O
of	O	O
the	O	O
control	O	O
:	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

In	O	O
the	O	O
5	O	O
-	O	O
wk	O	O
group	O	O
,	O	O
MIBG	B-Chemical	D019797
accumulation	O	O
in	O	O
the	O	O
right	O	O
and	O	O
left	O	O
ventricular	O	O
wall	O	O
was	O	O
35%	O	O
and	O	O
27%	O	O
of	O	O
that	O	O
in	O	O
controls	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
8	O	O
-	O	O
wk	O	O
group	O	O
,	O	O
MIBG	B-Chemical	D019797
accumulation	O	O
in	O	O
the	O	O
right	O	O
and	O	O
left	O	O
ventricular	O	O
wall	O	O
was	O	O
18%	O	O
and	O	O
14%	O	O
of	O	O
that	O	O
in	O	O
controls	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
MIBG	B-Chemical	D019797
accumulation	O	O
in	O	O
the	O	O
myocardium	O	O
decreased	O	O
in	O	O
an	O	O
adriamycin	B-Chemical	D004317
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

The	O	O
appearance	O	O
of	O	O
impaired	O	O
cardiac	O	O
adrenergic	O	O
neuron	O	O
activity	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
slight	O	O
myocardial	B-Disease	D009202
impairment	I-Disease	D009202
(	O	O
scattered	O	O
or	O	O
focal	O	O
vacuolar	B-Disease	C536522
degeneration	I-Disease	C536522
)	O	O
indicates	O	O
that	O	O
MIBG	B-Chemical	D019797
scintigraphy	O	O
may	O	O
be	O	O
a	O	O
useful	O	O
method	O	O
for	O	O
detection	O	O
of	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

Amnestic	B-Disease	D000647
syndrome	I-Disease	D000647
associated	O	O
with	O	O
propranolol	B-Chemical	D011433
toxicity	B-Disease	D064420
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

An	O	O
elderly	O	O
woman	O	O
developed	O	O
an	O	O
Alzheimer	B-Disease	D000544
-	O	O
like	O	O
subacute	O	O
dementia	B-Disease	D003704
as	O	O
a	O	O
result	O	O
of	O	O
propranolol	B-Chemical	D011433
toxicity	B-Disease	D064420
.	O	O

Analysis	O	O
of	O	O
the	O	O
manifestations	O	O
showed	O	O
that	O	O
severe	O	O
impairment	O	O
of	O	O
memory	O	O
accounted	O	O
for	O	O
virtually	O	O
all	O	O
of	O	O
the	O	O
abnormalities	O	O
.	O	O

There	O	O
is	O	O
evidence	O	O
that	O	O
cerebral	O	O
reactions	O	O
to	O	O
drug	O	O
toxicity	B-Disease	D064420
can	O	O
exhibit	O	O
patterns	O	O
that	O	O
suggest	O	O
highly	O	O
selective	O	O
involvement	O	O
of	O	O
functional	O	O
subdivisions	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

Biphasic	O	O
response	O	O
of	O	O
the	O	O
SA	O	O
node	O	O
of	O	O
the	O	O
dog	O	O
heart	O	O
in	O	O
vivo	O	O
to	O	O
selective	O	O
administration	O	O
of	O	O
ketamine	B-Chemical	D007649
.	O	O

Effect	O	O
of	O	O
ketamine	B-Chemical	D007649
on	O	O
the	O	O
SA	O	O
node	O	O
of	O	O
the	O	O
dog	O	O
heart	O	O
was	O	O
studied	O	O
in	O	O
vivo	O	O
using	O	O
a	O	O
selective	O	O
perfusion	O	O
technique	O	O
of	O	O
the	O	O
SA	O	O
node	O	O
artery	O	O
.	O	O

Injections	O	O
of	O	O
ketamine	B-Chemical	D007649
in	O	O
doses	O	O
from	O	O
100	O	O
microgram	O	O
to	O	O
3	O	O
mg	O	O
into	O	O
the	O	O
artery	O	O
produced	O	O
a	O	O
depression	B-Disease	D003866
of	O	O
the	O	O
SA	O	O
nodal	O	O
activity	O	O
by	O	O
a	O	O
direct	O	O
action	O	O
.	O	O

This	O	O
depression	B-Disease	D003866
was	O	O
followed	O	O
by	O	O
the	O	O
sudden	O	O
appearance	O	O
of	O	O
a	O	O
stimulatory	O	O
phase	O	O
.	O	O

Bilateral	O	O
vagotomy	O	O
and	O	O
sympathectomy	O	O
or	O	O
prior	O	O
administration	O	O
of	O	O
a	O	O
ganglion	O	O
blocker	O	O
failed	O	O
to	O	O
inhibit	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
ketamine	B-Chemical	D007649
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
,	O	O
while	O	O
it	O	O
was	O	O
completely	O	O
abolished	O	O
in	O	O
the	O	O
reserpinized	O	O
dogs	O	O
or	O	O
by	O	O
a	O	O
prior	O	O
injection	O	O
of	O	O
a	O	O
beta	O	O
-	O	O
blocking	O	O
agent	O	O
into	O	O
the	O	O
SA	O	O
node	O	O
artery	O	O
.	O	O

This	O	O
may	O	O
indicate	O	O
that	O	O
an	O	O
activation	O	O
of	O	O
the	O	O
peripheral	O	O
adrenergic	O	O
mechanism	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
the	O	O
excitatory	O	O
effect	O	O
of	O	O
ketamine	B-Chemical	D007649
injected	O	O
in	O	O
the	O	O
SA	O	O
node	O	O
artery	O	O
.	O	O

The	O	O
use	O	O
of	O	O
serum	O	O
cholinesterase	O	O
in	O	O
succinylcholine	B-Chemical	D013390
apnoea	B-Disease	D001049
.	O	O

Fifteen	O	O
patients	O	O
demonstrating	O	O
unexpected	O	O
prolonged	O	O
apnoea	B-Disease	D001049
lasting	O	O
several	O	O
hours	O	O
after	O	O
succinylcholine	B-Chemical	D013390
have	O	O
been	O	O
treated	O	O
by	O	O
a	O	O
new	O	O
preparation	O	O
of	O	O
human	O	O
serum	O	O
cholinesterase	O	O
.	O	O

Adequate	O	O
spontaneous	O	O
respiration	O	O
was	O	O
re	O	O
-	O	O
established	O	O
in	O	O
an	O	O
average	O	O
period	O	O
of	O	O
ten	O	O
minutes	O	O
after	O	O
the	O	O
injection	O	O
.	O	O

In	O	O
12	O	O
patients	O	O
biochemical	O	O
genetic	O	O
examinations	O	O
confirmed	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
atypical	O	O
serum	O	O
cholinesterase	O	O
.	O	O

In	O	O
three	O	O
patients	O	O
none	O	O
of	O	O
the	O	O
usual	O	O
variants	O	O
were	O	O
found	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
supposed	O	O
that	O	O
other	O	O
unknown	O	O
variants	O	O
of	O	O
serum	O	O
cholinesterase	O	O
exist	O	O
which	O	O
cannot	O	O
hydrolyze	O	O
succinylcholine	B-Chemical	D013390
.	O	O

The	O	O
use	O	O
of	O	O
serum	O	O
cholinesterase	O	O
in	O	O
succinylcholine	B-Chemical	D013390
apnoea	B-Disease	D001049
provided	O	O
considerable	O	O
relief	O	O
to	O	O
both	O	O
patient	O	O
and	O	O
anaesthetist	O	O
.	O	O

Orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
occurs	O	O
following	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
blockade	O	O
in	O	O
chronic	O	O
prazosin	B-Chemical	D011224
-	O	O
pretreated	O	O
conscious	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

1	O	O
.	O	O

Studies	O	O
were	O	O
performed	O	O
to	O	O
evaluate	O	O
whether	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treatment	O	O
alters	O	O
the	O	O
alpha	O	O
2	O	O
-	O	O
adrenoceptor	O	O
function	O	O
for	O	O
orthostatic	O	O
control	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
in	O	O
conscious	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
(	O	O
SHR	O	O
)	O	O
.	O	O

2	O	O
.	O	O

Conscious	O	O
SHR	O	O
(	O	O
male	O	O
300	O	O
-	O	O
350	O	O
g	O	O
)	O	O
were	O	O
subjected	O	O
to	O	O
90	O	O
degrees	O	O
head	O	O
-	O	O
up	O	O
tilts	O	O
for	O	O
60	O	O
s	O	O
following	O	O
acute	O	O
administration	O	O
of	O	O
prazosin	B-Chemical	D011224
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
or	O	O
rauwolscine	B-Chemical	D015016
(	O	O
3	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
.	O	O

Orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
was	O	O
determined	O	O
by	O	O
the	O	O
average	O	O
decrease	O	O
(	O	O
%	O	O
)	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
femoral	O	O
)	O	O
over	O	O
the	O	O
60	O	O
-	O	O
s	O	O
tilt	O	O
period	O	O
.	O	O

The	O	O
basal	O	O
MAP	O	O
of	O	O
conscious	O	O
SHR	O	O
was	O	O
reduced	O	O
to	O	O
a	O	O
similar	O	O
extent	O	O
by	O	O
prazosin	B-Chemical	D011224
(	O	O
-	O	O
23%	O	O
(	O	O
-	O	O
)	O	O
-	O	O
26%	O	O
MAP	O	O
)	O	O
and	O	O
rauwolscine	B-Chemical	D015016
(	O	O
-	O	O
16%	O	O
(	O	O
-	O	O
)	O	O
-	O	O
33%	O	O
MAP	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
head	O	O
-	O	O
up	O	O
tilt	O	O
induced	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
in	O	O
the	O	O
SHR	O	O
treated	O	O
with	O	O
prazosin	B-Chemical	D011224
(	O	O
-	O	O
16%	O	O
MAP	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
SHR	O	O
treated	O	O
with	O	O
rauwolscine	B-Chemical	D015016
(	O	O
less	O	O
than	O	O
+2%	O	O
MAP	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
.	O	O

3	O	O
.	O	O

Conscious	O	O
SHR	O	O
were	O	O
treated	O	O
for	O	O
4	O	O
days	O	O
with	O	O
prazosin	B-Chemical	D011224
at	O	O
2	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
day	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

for	O	O
chronic	O	O
alpha	O	O
1	O	O
-	O	O
adrenoceptor	O	O
blockade	O	O
.	O	O

MAP	O	O
in	O	O
conscious	O	O
SHR	O	O
after	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treatment	O	O
was	O	O
14%	O	O
lower	O	O
than	O	O
in	O	O
the	O	O
untreated	O	O
SHR	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
.	O	O

Head	O	O
-	O	O
up	O	O
tilts	O	O
in	O	O
these	O	O
rats	O	O
did	O	O
not	O	O
produce	O	O
orthostatic	B-Disease	D007024
hypotension	I-Disease	D007024
when	O	O
performed	O	O
either	O	O
prior	O	O
to	O	O
or	O	O
after	O	O
acute	O	O
dosing	O	O
of	O	O
prazosin	B-Chemical	D011224
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

Conversely	O	O
,	O	O
administration	O	O
of	O	O
rauwolscine	B-Chemical	D015016
(	O	O
3	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
in	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treated	O	O
SHR	O	O
decreased	O	O
the	O	O
basal	O	O
MAP	O	O
by	O	O
12	O	O
-	O	O
31%	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
,	O	O
and	O	O
subsequent	O	O
tilts	O	O
induced	O	O
further	O	O
drops	O	O
of	O	O
MAP	O	O
by	O	O
19	O	O
-	O	O
23%	O	O
in	O	O
these	O	O
rats	O	O
.	O	O

4	O	O
.	O	O

The	O	O
pressor	O	O
responses	O	O
and	O	O
bradycardia	B-Disease	D001919
to	O	O
the	O	O
alpha	O	O
1	O	O
-	O	O
agonist	O	O
cirazoline	B-Chemical	C014282
(	O	O
0	O	O
.	O	O

6	O	O
and	O	O
2	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
,	O	O
the	O	O
alpha	O	O
2	O	O
-	O	O
agonist	O	O
Abbott	B-Chemical	C056299
-	I-Chemical	C056299
53693	I-Chemical	C056299
(	O	O
1	O	O
and	O	O
3	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
,	O	O
and	O	O
noradrenaline	B-Chemical	D009638
(	O	O
0	O	O
.	O	O

1	O	O
and	O	O
1	O	O
.	O	O

0	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
were	O	O
determined	O	O
in	O	O
conscious	O	O
SHR	O	O
with	O	O
and	O	O
without	O	O
chronic	O	O
prazosin	B-Chemical	D011224
pretreatment	O	O
.	O	O

Both	O	O
the	O	O
pressor	O	O
and	O	O
bradycardia	B-Disease	D001919
effects	O	O
of	O	O
cirazoline	B-Chemical	C014282
were	O	O
abolished	O	O
in	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treated	O	O
SHR	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
untreated	O	O
SHR	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
pressor	O	O
effects	O	O
of	O	O
Abbott	B-Chemical	C056299
-	I-Chemical	C056299
53693	I-Chemical	C056299
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
SHR	O	O
,	O	O
but	O	O
the	O	O
accompanying	O	O
bradycardia	B-Disease	D001919
was	O	O
greater	O	O
in	O	O
SHR	O	O
with	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treatment	O	O
than	O	O
without	O	O
such	O	O
treatment	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
bradycardia	B-Disease	D001919
that	O	O
accompanied	O	O
the	O	O
noradrenaline	B-Chemical	D009638
-	O	O
induced	O	O
pressor	O	O
effect	O	O
in	O	O
SHR	O	O
was	O	O
similar	O	O
with	O	O
and	O	O
without	O	O
chronic	O	O
prazosin	B-Chemical	D011224
treatment	O	O
despite	O	O
a	O	O
47	O	O
-	O	O
71%	O	O
reduction	O	O
of	O	O
the	O	O
pressor	O	O
effect	O	O
in	O	O
chronic	O	O
alpha	O	O
1	O	O
-	O	O
receptor	O	O
blocked	O	O
SHR	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
Coexistence	O	O
of	O	O
cerebral	O	O
venous	O	O
sinus	O	O
and	O	O
internal	O	O
carotid	O	O
artery	O	O
thrombosis	O	O
associated	O	O
with	O	O
exogenous	O	O
sex	O	O
hormones	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

A	O	O
forty	O	O
-	O	O
six	O	O
year	O	O
-	O	O
old	O	O
premenopausal	O	O
woman	O	O
developed	O	O
headache	B-Disease	D006261
,	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
,	O	O
left	O	O
hemiparesis	B-Disease	D010291
and	O	O
seizure	B-Disease	D012640
two	O	O
days	O	O
after	O	O
parenteral	O	O
use	O	O
of	O	O
progesterone	B-Chemical	D011374
and	O	O
estradiol	B-Chemical	D004958
.	O	O

Diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
(	O	O
DM	B-Disease	D003920
)	O	O
was	O	O
found	O	O
during	O	O
admission	O	O
.	O	O

Computed	O	O
tomography	O	O
showed	O	O
a	O	O
hemorrhagic	O	O
infarct	O	O
in	O	O
the	O	O
right	O	O
frontal	O	O
lobe	O	O
and	O	O
increased	O	O
density	O	O
in	O	O
the	O	O
superior	O	O
sagittal	O	O
sinus	O	O
(	O	O
SSS	O	O
)	O	O
.	O	O

Left	O	O
carotid	O	O
angiography	O	O
found	O	O
occlusion	B-Disease	D001157
of	I-Disease	D001157
the	I-Disease	D001157
left	I-Disease	D001157
internal	I-Disease	D001157
carotid	I-Disease	D001157
artery	I-Disease	D001157
(	O	O
ICA	O	O
)	O	O
.	O	O

Right	O	O
carotid	O	O
angiograms	O	O
failed	O	O
to	O	O
show	O	O
the	O	O
SSS	O	O
and	O	O
inferior	O	O
sagittal	O	O
sinus	O	O
,	O	O
suggestive	O	O
of	O	O
venous	B-Disease	D012851
sinus	I-Disease	D012851
thrombosis	I-Disease	D012851
.	O	O

Coexistence	O	O
of	O	O
the	O	O
cerebral	O	O
artery	O	O
and	O	O
the	O	O
venous	O	O
sinus	O	O
occlusion	O	O
has	O	O
been	O	O
described	O	O
infrequently	O	O
.	O	O

In	O	O
this	O	O
case	O	O
,	O	O
the	O	O
authors	O	O
postulate	O	O
that	O	O
the	O	O
use	O	O
of	O	O
estradiol	B-Chemical	D004958
and	O	O
progesterone	B-Chemical	D011374
and	O	O
the	O	O
underlying	O	O
DM	B-Disease	D003920
increased	O	O
vascular	O	O
thrombogenicity	O	O
,	O	O
which	O	O
provided	O	O
a	O	O
common	O	O
denominator	O	O
for	O	O
thrombosis	O	O
of	O	O
both	O	O
the	O	O
ICA	O	O
and	O	O
the	O	O
venous	O	O
sinus	O	O
.	O	O

Chloroquine	B-Chemical	D002738
related	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
with	O	O
blindness	B-Disease	D001766
:	O	O
case	O	O
report	O	O
.	O	O

A	O	O
27	O	O
-	O	O
year	O	O
old	O	O
African	O	O
woman	O	O
with	O	O
history	O	O
of	O	O
regular	O	O
chloroquine	B-Chemical	D002738
ingestion	O	O
presented	O	O
with	O	O
progressive	O	O
deterioration	B-Disease	D015354
of	I-Disease	D015354
vision	I-Disease	D015354
,	O	O
easy	O	O
fatiguability	B-Disease	D005221
,	O	O
dyspnoea	B-Disease	D004417
,	O	O
dizziness	B-Disease	D004244
progressing	O	O
to	O	O
syncopal	B-Disease	D013575
attacks	I-Disease	D013575
.	O	O

Ophthalmological	O	O
assessment	O	O
revealed	O	O
features	O	O
of	O	O
chloroquine	B-Chemical	D002738
retinopathy	B-Disease	D012164
,	O	O
cardiac	O	O
assessment	O	O
revealed	O	O
features	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
and	O	O
a	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
with	O	O
right	B-Disease	D002037
bundle	I-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
pattern	O	O
.	O	O

The	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
was	O	O
treated	O	O
by	O	O
pacemaker	O	O
insertion	O	O
and	O	O
the	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
resolved	O	O
spontaneously	O	O
following	O	O
chloroquine	B-Chemical	D002738
discontinuation	O	O
.	O	O

She	O	O
however	O	O
remains	O	O
blind	B-Disease	D001766
.	O	O

Systemic	O	O
toxicity	B-Disease	D064420
and	O	O
resuscitation	O	O
in	O	O
bupivacaine	B-Chemical	D002045
-	O	O
,	O	O
levobupivacaine	B-Chemical	C476513
-	O	O
,	O	O
or	O	O
ropivacaine	B-Chemical	C037663
-	O	O
infused	O	O
rats	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
systemic	O	O
toxicity	B-Disease	D064420
of	O	O
bupivacaine	B-Chemical	D002045
,	O	O
levobupivacaine	B-Chemical	C476513
,	O	O
and	O	O
ropivacaine	B-Chemical	C037663
in	O	O
anesthetized	O	O
rats	O	O
.	O	O

We	O	O
also	O	O
compared	O	O
the	O	O
ability	O	O
to	O	O
resuscitate	O	O
rats	O	O
after	O	O
lethal	O	O
doses	O	O
of	O	O
these	O	O
local	O	O
anesthetics	O	O
.	O	O

Bupivacaine	B-Chemical	D002045
,	O	O
levobupivacaine	B-Chemical	C476513
,	O	O
or	O	O
ropivacaine	B-Chemical	C037663
was	O	O
infused	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
2	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

min	O	O
(	O	O
-	O	O
1	O	O
)	O	O
while	O	O
electrocardiogram	O	O
,	O	O
electroencephalogram	O	O
,	O	O
and	O	O
arterial	O	O
pressure	O	O
were	O	O
continuously	O	O
monitored	O	O
.	O	O

When	O	O
asystole	B-Disease	D006323
was	O	O
recorded	O	O
,	O	O
drug	O	O
infusion	O	O
was	O	O
stopped	O	O
and	O	O
a	O	O
resuscitation	O	O
sequence	O	O
was	O	O
begun	O	O
.	O	O

Epinephrine	B-Chemical	D004837
0	O	O
.	O	O

01	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
administered	O	O
at	O	O
1	O	O
-	O	O
min	O	O
intervals	O	O
while	O	O
external	O	O
cardiac	O	O
compressions	O	O
were	O	O
applied	O	O
.	O	O

Resuscitation	O	O
was	O	O
considered	O	O
successful	O	O
when	O	O
a	O	O
systolic	O	O
arterial	O	O
pressure	O	O
>	O	O
or	O	O
=100	O	O
mm	O	O
Hg	O	O
was	O	O
achieved	O	O
within	O	O
5	O	O
min	O	O
.	O	O

The	O	O
cumulative	O	O
doses	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
and	O	O
ropivacaine	B-Chemical	C037663
that	O	O
produced	O	O
seizures	B-Disease	D012640
were	O	O
similar	O	O
and	O	O
were	O	O
larger	O	O
than	O	O
those	O	O
of	O	O
bupivacaine	B-Chemical	D002045
.	O	O

The	O	O
cumulative	O	O
doses	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
that	O	O
produced	O	O
dysrhythmias	B-Disease	D001145
and	O	O
asystole	B-Disease	D006323
were	O	O
smaller	O	O
than	O	O
the	O	O
corresponding	O	O
doses	O	O
of	O	O
ropivacaine	B-Chemical	C037663
,	O	O
but	O	O
they	O	O
were	O	O
larger	O	O
than	O	O
those	O	O
of	O	O
bupivacaine	B-Chemical	D002045
.	O	O

The	O	O
number	O	O
of	O	O
successful	O	O
resuscitations	O	O
did	O	O
not	O	O
differ	O	O
among	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
a	O	O
smaller	O	O
dose	O	O
of	O	O
epinephrine	B-Chemical	D004837
was	O	O
required	O	O
in	O	O
the	O	O
Ropivacaine	B-Chemical	C037663
group	O	O
than	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
systemic	O	O
toxicity	B-Disease	D064420
of	O	O
levobupivacaine	B-Chemical	C476513
is	O	O
intermediate	O	O
between	O	O
that	O	O
of	O	O
ropivacaine	B-Chemical	C037663
and	O	O
bupivacaine	B-Chemical	D002045
when	O	O
administered	O	O
at	O	O
the	O	O
same	O	O
rate	O	O
and	O	O
that	O	O
ropivacaine	B-Chemical	C037663
-	O	O
induced	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
appears	O	O
to	O	O
be	O	O
more	O	O
susceptible	O	O
to	O	O
treatment	O	O
than	O	O
that	O	O
induced	O	O
by	O	O
bupivacaine	B-Chemical	D002045
or	O	O
levobupivacaine	B-Chemical	C476513
.	O	O

22	B-Chemical	C051883
-	I-Chemical	C051883
oxacalcitriol	I-Chemical	C051883
suppresses	O	O
secondary	B-Disease	D006962
hyperparathyroidism	I-Disease	D006962
without	O	O
inducing	O	O
low	B-Disease	D001851
bone	I-Disease	D001851
turnover	I-Disease	D001851
in	O	O
dogs	O	O
with	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

BACKGROUND	O	O
:	O	O
Calcitriol	B-Chemical	D002117
therapy	O	O
suppresses	O	O
serum	O	O
levels	O	O
of	O	O
parathyroid	O	O
hormone	O	O
(	O	O
PTH	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
but	O	O
has	O	O
several	O	O
drawbacks	O	O
,	O	O
including	O	O
hypercalcemia	B-Disease	D006934
and	O	O
/	O	O
or	O	O
marked	O	O
suppression	B-Disease	D001851
of	I-Disease	D001851
bone	I-Disease	D001851
turnover	I-Disease	D001851
,	O	O
which	O	O
may	O	O
lead	O	O
to	O	O
adynamic	B-Disease	D001851
bone	I-Disease	D001851
disease	I-Disease	D001851
.	O	O

A	O	O
new	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
analogue	O	O
,	O	O
22	B-Chemical	C051883
-	I-Chemical	C051883
oxacalcitriol	I-Chemical	C051883
(	O	O
OCT	B-Chemical	C051883
)	O	O
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
promising	O	O
characteristics	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
OCT	B-Chemical	C051883
on	O	O
serum	O	O
PTH	O	O
levels	O	O
and	O	O
bone	O	O
turnover	O	O
in	O	O
states	O	O
of	O	O
normal	O	O
or	O	O
impaired	B-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
.	O	O

METHODS	O	O
:	O	O
Sixty	O	O
dogs	O	O
were	O	O
either	O	O
nephrectomized	O	O
(	O	O
Nx	O	O
,	O	O
N	O	O
=	O	O
38	O	O
)	O	O
or	O	O
sham	O	O
-	O	O
operated	O	O
(	O	O
Sham	O	O
,	O	O
N	O	O
=	O	O
22	O	O
)	O	O
.	O	O

The	O	O
animals	O	O
received	O	O
supplemental	O	O
phosphate	B-Chemical	D010710
to	O	O
enhance	O	O
PTH	O	O
secretion	O	O
.	O	O

Fourteen	O	O
weeks	O	O
after	O	O
the	O	O
start	O	O
of	O	O
phosphate	B-Chemical	D010710
supplementation	O	O
,	O	O
half	O	O
of	O	O
the	O	O
Nx	O	O
and	O	O
Sham	O	O
dogs	O	O
received	O	O
doses	O	O
of	O	O
OCT	B-Chemical	C051883
(	O	O
three	O	O
times	O	O
per	O	O
week	O	O
)	O	O
;	O	O
the	O	O
other	O	O
half	O	O
were	O	O
given	O	O
vehicle	O	O
for	O	O
60	O	O
weeks	O	O
.	O	O

Thereafter	O	O
,	O	O
the	O	O
treatment	O	O
modalities	O	O
for	O	O
a	O	O
subset	O	O
of	O	O
animals	O	O
were	O	O
crossed	O	O
over	O	O
for	O	O
an	O	O
additional	O	O
eight	O	O
months	O	O
.	O	O

Biochemical	O	O
and	O	O
hormonal	O	O
indices	O	O
of	O	O
calcium	B-Chemical	D002118
and	O	O
bone	O	O
metabolism	O	O
were	O	O
measured	O	O
throughout	O	O
the	O	O
study	O	O
,	O	O
and	O	O
bone	O	O
biopsies	O	O
were	O	O
done	O	O
at	O	O
baseline	O	O
,	O	O
60	O	O
weeks	O	O
after	O	O
OCT	B-Chemical	C051883
or	O	O
vehicle	O	O
treatment	O	O
,	O	O
and	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
crossover	O	O
period	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
Nx	O	O
dogs	O	O
,	O	O
OCT	B-Chemical	C051883
significantly	O	O
decreased	O	O
serum	O	O
PTH	O	O
levels	O	O
soon	O	O
after	O	O
the	O	O
induction	O	O
of	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
.	O	O

In	O	O
long	O	O
-	O	O
standing	O	O
secondary	B-Disease	D006962
hyperparathyroidism	I-Disease	D006962
,	O	O
OCT	B-Chemical	C051883
(	O	O
0	O	O
.	O	O

03	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
stabilized	O	O
serum	O	O
PTH	O	O
levels	O	O
during	O	O
the	O	O
first	O	O
months	O	O
.	O	O

Serum	O	O
PTH	O	O
levels	O	O
rose	O	O
thereafter	O	O
,	O	O
but	O	O
the	O	O
rise	O	O
was	O	O
less	O	O
pronounced	O	O
compared	O	O
with	O	O
baseline	O	O
than	O	O
the	O	O
rise	O	O
seen	O	O
in	O	O
Nx	O	O
control	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
accompanied	O	O
by	O	O
episodes	O	O
of	O	O
hypercalcemia	B-Disease	D006934
and	O	O
hyperphosphatemia	B-Disease	D054559
.	O	O

In	O	O
animals	O	O
with	O	O
normal	O	O
renal	O	O
function	O	O
,	O	O
OCT	B-Chemical	C051883
induced	O	O
a	O	O
transient	O	O
decrease	O	O
in	O	O
serum	O	O
PTH	O	O
levels	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

1	O	O
microg	O	O
/	O	O
kg	O	O
,	O	O
which	O	O
was	O	O
not	O	O
sustained	O	O
with	O	O
lowering	O	O
of	O	O
the	O	O
doses	O	O
.	O	O

In	O	O
Nx	O	O
dogs	O	O
,	O	O
OCT	B-Chemical	C051883
reversed	O	O
abnormal	O	O
bone	O	O
formation	O	O
,	O	O
such	O	O
as	O	O
woven	B-Disease	-1
osteoid	I-Disease	-1
and	O	O
fibrosis	B-Disease	D005355
,	O	O
but	O	O
did	O	O
not	O	O
significantly	O	O
alter	O	O
the	O	O
level	O	O
of	O	O
bone	O	O
turnover	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
OCT	B-Chemical	C051883
improved	O	O
mineralization	O	O
lag	O	O
time	O	O
,	O	O
(	O	O
that	O	O
is	O	O
,	O	O
the	O	O
rate	O	O
at	O	O
which	O	O
osteoid	O	O
mineralizes	O	O
)	O	O
in	O	O
both	O	O
Nx	O	O
and	O	O
Sham	O	O
dogs	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
indicate	O	O
that	O	O
even	O	O
though	O	O
OCT	B-Chemical	C051883
does	O	O
not	O	O
completely	O	O
prevent	O	O
the	O	O
occurrence	O	O
of	O	O
hypercalcemia	B-Disease	D006934
in	O	O
experimental	O	O
dogs	O	O
with	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
,	O	O
it	O	O
may	O	O
be	O	O
of	O	O
use	O	O
in	O	O
the	O	O
management	O	O
of	O	O
secondary	B-Disease	D006962
hyperparathyroidism	I-Disease	D006962
because	O	O
it	O	O
does	O	O
not	O	O
induce	O	O
low	B-Disease	D001851
bone	I-Disease	D001851
turnover	I-Disease	D001851
and	O	O
,	O	O
therefore	O	O
,	O	O
does	O	O
not	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
adynamic	B-Disease	D001851
bone	I-Disease	D001851
disease	I-Disease	D001851
.	O	O

Chemotherapy	O	O
of	O	O
advanced	O	O
inoperable	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
with	O	O
paclitaxel	B-Chemical	D017239
:	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
;	O	O
Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
has	O	O
demonstrated	O	O
significant	O	O
antineoplastic	O	O
activity	O	O
against	O	O
different	O	O
tumor	B-Disease	D009369
types	O	O
,	O	O
notably	O	O
ovarian	O	O
and	O	O
breast	O	O
carcinoma	O	O
.	O	O

Two	O	O
phase	O	O
II	O	O
trials	O	O
of	O	O
24	O	O
-	O	O
hour	O	O
paclitaxel	B-Chemical	D017239
infusions	O	O
in	O	O
chemotherapy	O	O
-	O	O
naive	O	O
patients	O	O
with	O	O
stage	O	O
IIIB	O	O
or	O	O
IV	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
(	O	O
NSCLC	B-Disease	D002289
)	O	O
reported	O	O
response	O	O
rates	O	O
of	O	O
21%	O	O
and	O	O
24%	O	O
.	O	O

Leukopenia	B-Disease	D007970
was	O	O
dose	O	O
limiting	O	O
:	O	O
as	O	O
many	O	O
as	O	O
62	O	O
.	O	O

5%	O	O
of	O	O
patients	O	O
experienced	O	O
grade	O	O
4	O	O
leukopenia	B-Disease	D007970
.	O	O

We	O	O
investigated	O	O
the	O	O
efficacy	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
a	O	O
3	O	O
-	O	O
hour	O	O
paclitaxel	B-Chemical	D017239
infusion	O	O
in	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
inoperable	O	O
stage	O	O
IIIB	O	O
or	O	O
IV	O	O
NSCLC	B-Disease	D002289
.	O	O

The	O	O
58	O	O
patients	O	O
treated	O	O
(	O	O
41	O	O
men	O	O
and	O	O
17	O	O
women	O	O
)	O	O
had	O	O
a	O	O
median	O	O
age	O	O
of	O	O
59	O	O
years	O	O
(	O	O
age	O	O
range	O	O
,	O	O
25	O	O
to	O	O
75	O	O
)	O	O
and	O	O
a	O	O
performance	O	O
status	O	O
of	O	O
0	O	O
through	O	O
2	O	O
.	O	O

Most	O	O
patients	O	O
(	O	O
72	O	O
.	O	O

4%	O	O
)	O	O
had	O	O
stage	O	O
IV	O	O
NSCLC	B-Disease	D002289
.	O	O

Paclitaxel	B-Chemical	D017239
225	O	O
mg	O	O
/	O	O
m2	O	O
was	O	O
infused	O	O
over	O	O
3	O	O
hours	O	O
every	O	O
3	O	O
weeks	O	O
with	O	O
standard	O	O
prophylactic	O	O
premedication	O	O
.	O	O

Of	O	O
50	O	O
patients	O	O
evaluable	O	O
for	O	O
response	O	O
,	O	O
12	O	O
(	O	O
24%	O	O
)	O	O
had	O	O
partial	O	O
remission	O	O
,	O	O
26	O	O
(	O	O
52%	O	O
)	O	O
had	O	O
no	O	O
change	O	O
,	O	O
and	O	O
12	O	O
had	O	O
disease	O	O
progression	O	O
(	O	O
24%	O	O
)	O	O
.	O	O

Hematologic	O	O
toxicities	B-Disease	D064420
were	O	O
mild	O	O
:	O	O
only	O	O
one	O	O
patient	O	O
(	O	O
2%	O	O
)	O	O
developed	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
neutropenia	B-Disease	D009503
,	O	O
while	O	O
29%	O	O
had	O	O
grade	O	O
1	O	O
or	O	O
2	O	O
.	O	O

Grade	O	O
1	O	O
or	O	O
2	O	O
polyneuropathy	B-Disease	D011115
affected	O	O
56%	O	O
of	O	O
patients	O	O
while	O	O
only	O	O
one	O	O
(	O	O
2%	O	O
)	O	O
experienced	O	O
severe	O	O
polyneuropathy	B-Disease	D011115
.	O	O

Similarly	O	O
,	O	O
grade	O	O
1	O	O
or	O	O
2	O	O
myalgia	B-Disease	D063806
/	O	O
arthralgia	B-Disease	D018771
was	O	O
observed	O	O
in	O	O
63	O	O
.	O	O

2%	O	O
of	O	O
patients	O	O
,	O	O
but	O	O
only	O	O
14	O	O
.	O	O

3%	O	O
experienced	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
.	O	O

Nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
were	O	O
infrequent	O	O
,	O	O
with	O	O
14%	O	O
of	O	O
patients	O	O
experiencing	O	O
grade	O	O
1	O	O
or	O	O
2	O	O
and	O	O
only	O	O
2%	O	O
experiencing	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
is	O	O
thus	O	O
an	O	O
active	O	O
single	O	O
agent	O	O
in	O	O
this	O	O
patient	O	O
population	O	O
,	O	O
with	O	O
a	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
proving	O	O
comparably	O	O
effective	O	O
to	O	O
a	O	O
24	O	O
-	O	O
hour	O	O
infusion	O	O
and	O	O
superior	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
incidence	O	O
of	O	O
hematologic	O	O
and	O	O
nonhematologic	O	O
toxicity	B-Disease	D064420
.	O	O

Further	O	O
phase	O	O
II	O	O
studies	O	O
with	O	O
paclitaxel	B-Chemical	D017239
combined	O	O
with	O	O
other	O	O
drugs	O	O
active	O	O
against	O	O
NSCLC	B-Disease	D002289
are	O	O
indicated	O	O
,	O	O
and	O	O
phase	O	O
III	O	O
studies	O	O
comparing	O	O
paclitaxel	B-Chemical	D017239
with	O	O
standard	O	O
chemotherapy	O	O
remain	O	O
to	O	O
be	O	O
completed	O	O
.	O	O

Cerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
associated	O	O
with	O	O
phenylpropanolamine	B-Chemical	D010665
in	O	O
combination	O	O
with	O	O
caffeine	B-Chemical	D002110
.	O	O

Phenylpropanolamine	B-Chemical	D010665
(	O	O
PPA	B-Chemical	D010665
)	O	O
is	O	O
a	O	O
drug	O	O
that	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
serious	O	O
side	O	O
effects	O	O
including	O	O
stroke	B-Disease	D020521
.	O	O

It	O	O
is	O	O
often	O	O
combined	O	O
with	O	O
caffeine	B-Chemical	D002110
in	O	O
diet	O	O
preparations	O	O
and	O	O
"look	O	O
-	O	O
alike"	O	O
pills	O	O
.	O	O

In	O	O
order	O	O
to	O	O
determine	O	O
if	O	O
PPA	B-Chemical	D010665
/	O	O
caffeine	B-Chemical	D002110
can	O	O
lead	O	O
to	O	O
stroke	B-Disease	D020521
in	O	O
normotensive	O	O
and	O	O
/	O	O
or	O	O
hypertensive	B-Disease	D006973
rats	O	O
,	O	O
we	O	O
administered	O	O
the	O	O
combination	O	O
in	O	O
six	O	O
times	O	O
the	O	O
allowed	O	O
human	O	O
dose	O	O
calculated	O	O
on	O	O
a	O	O
per	O	O
weight	O	O
basis	O	O
for	O	O
the	O	O
rats	O	O
two	O	O
times	O	O
per	O	O
day	O	O
for	O	O
five	O	O
days	O	O
.	O	O

Subarachnoid	O	O
and	O	O
cerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
was	O	O
noted	O	O
in	O	O
18%	O	O
of	O	O
the	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

A	O	O
single	O	O
PPA	B-Chemical	D010665
/	O	O
caffeine	B-Chemical	D002110
administration	O	O
(	O	O
same	O	O
dose	O	O
)	O	O
lead	O	O
to	O	O
acute	O	O
hypertension	B-Disease	D006973
in	O	O
both	O	O
the	O	O
normotensive	O	O
and	O	O
hypertensive	B-Disease	D006973
animals	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
PPA	B-Chemical	D010665
/	O	O
caffeine	B-Chemical	D002110
can	O	O
lead	O	O
to	O	O
cerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
in	O	O
previously	O	O
hypertensive	B-Disease	D006973
animals	O	O
when	O	O
administered	O	O
in	O	O
greater	O	O
than	O	O
the	O	O
allowed	O	O
dosage	O	O
.	O	O

An	O	O
acute	O	O
elevation	O	O
in	O	O
blood	O	O
pressure	O	O
may	O	O
be	O	O
a	O	O
contributing	O	O
factor	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
efficacy	O	O
and	O	O
toxicity	B-Disease	D064420
of	O	O
high	O	O
-	O	O
dose	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
for	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
or	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
.	O	O

Amiodarone	B-Chemical	D000638
was	O	O
administered	O	O
to	O	O
154	O	O
patients	O	O
who	O	O
had	O	O
sustained	O	O
,	O	O
symptomatic	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
(	O	O
VT	B-Disease	D017180
)	O	O
(	O	O
n	O	O
=	O	O
118	O	O
)	O	O
or	O	O
a	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
(	O	O
n	O	O
=	O	O
36	O	O
)	O	O
and	O	O
who	O	O
were	O	O
refractory	O	O
to	O	O
conventional	O	O
antiarrhythmic	O	O
drugs	O	O
.	O	O

The	O	O
loading	O	O
dose	O	O
was	O	O
800	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
6	O	O
weeks	O	O
and	O	O
the	O	O
maintenance	O	O
dose	O	O
was	O	O
600	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

Sixty	O	O
-	O	O
nine	O	O
percent	O	O
of	O	O
patients	O	O
continued	O	O
treatment	O	O
with	O	O
amiodarone	B-Chemical	D000638
and	O	O
had	O	O
no	O	O
recurrence	O	O
of	O	O
symptomatic	O	O
VT	B-Disease	D017180
or	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
(	O	O
VF	B-Disease	D014693
)	O	O
over	O	O
a	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
6	O	O
to	O	O
52	O	O
months	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
standard	O	O
deviation	O	O
14	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

2	O	O
)	O	O
.	O	O

Six	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
a	O	O
nonfatal	O	O
recurrence	O	O
of	O	O
VT	B-Disease	D017180
and	O	O
were	O	O
successfully	O	O
managed	O	O
by	O	O
continuing	O	O
amiodarone	B-Chemical	D000638
at	O	O
a	O	O
higher	O	O
dose	O	O
or	O	O
by	O	O
the	O	O
addition	O	O
of	O	O
a	O	O
conventional	O	O
antiarrhythmic	O	O
drug	O	O
.	O	O

One	O	O
or	O	O
more	O	O
adverse	O	O
drug	O	O
reactions	O	O
occurred	O	O
in	O	O
51%	O	O
of	O	O
patients	O	O
.	O	O

Adverse	O	O
effects	O	O
forced	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
amiodarone	B-Chemical	D000638
in	O	O
41%	O	O
and	O	O
discontinuation	O	O
of	O	O
amiodarone	B-Chemical	D000638
in	O	O
10%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
most	O	O
common	O	O
symptomatic	O	O
adverse	O	O
reactions	O	O
were	O	O
tremor	B-Disease	D014202
or	O	O
ataxia	B-Disease	D001259
(	O	O
35%	O	O
)	O	O
,	O	O
nausea	B-Disease	D009325
and	O	O
anorexia	B-Disease	D000855
(	O	O
8%	O	O
)	O	O
,	O	O
visual	B-Disease	D014786
halos	I-Disease	D014786
or	I-Disease	D014786
blurring	I-Disease	D014786
(	O	O
6%	O	O
)	O	O
,	O	O
thyroid	B-Disease	D013959
function	I-Disease	D013959
abnormalities	I-Disease	D013959
(	O	O
6%	O	O
)	O	O
and	O	O
pulmonary	B-Disease	-1
interstitial	I-Disease	-1
infiltrates	I-Disease	-1
(	O	O
5%	O	O
)	O	O
.	O	O

Although	O	O
large	O	O
-	O	O
dose	O	O
amiodarone	B-Chemical	D000638
is	O	O
highly	O	O
effective	O	O
in	O	O
the	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
of	O	O
VT	B-Disease	D017180
or	O	O
VF	B-Disease	D014693
refractory	O	O
to	O	O
conventional	O	O
antiarrhythmic	O	O
drugs	O	O
,	O	O
it	O	O
causes	O	O
significant	O	O
toxicity	B-Disease	D064420
in	O	O
approximately	O	O
50%	O	O
of	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
when	O	O
the	O	O
dose	O	O
is	O	O
adjusted	O	O
based	O	O
on	O	O
clinical	O	O
response	O	O
or	O	O
the	O	O
development	O	O
of	O	O
adverse	O	O
effects	O	O
,	O	O
75%	O	O
of	O	O
patients	O	O
with	O	O
VT	B-Disease	D017180
or	O	O
VF	B-Disease	D014693
can	O	O
be	O	O
successfully	O	O
managed	O	O
with	O	O
amiodarone	B-Chemical	D000638
.	O	O

Effect	O	O
of	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
therapy	O	O
on	O	O
desipramine	B-Chemical	D003891
toxicity	B-Disease	D064420
in	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Hypotension	B-Disease	D007022
is	O	O
a	O	O
major	O	O
contributor	O	O
to	O	O
mortality	O	O
in	O	O
tricyclic	O	O
antidepressant	O	O
overdose	B-Disease	D062787
.	O	O

Recent	O	O
data	O	O
suggest	O	O
that	O	O
tricyclic	O	O
antidepressants	O	O
inhibit	O	O
calcium	B-Chemical	D002118
influx	O	O
in	O	O
some	O	O
tissues	O	O
.	O	O

This	O	O
study	O	O
addressed	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blockade	O	O
in	O	O
tricyclic	O	O
antidepressant	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

METHODS	O	O
:	O	O
Two	O	O
interventions	O	O
were	O	O
studied	O	O
that	O	O
have	O	O
been	O	O
shown	O	O
previously	O	O
to	O	O
improve	O	O
blood	O	O
pressure	O	O
with	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
overdose	B-Disease	D062787
.	O	O

CaCl2	B-Chemical	D002122
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
.	O	O

Anesthetized	O	O
rats	O	O
received	O	O
the	O	O
tricyclic	O	O
antidepressant	O	O
desipramine	B-Chemical	D003891
IP	O	O
to	O	O
produce	O	O
hypotension	B-Disease	D007022
,	O	O
QRS	O	O
prolongation	O	O
,	O	O
and	O	O
bradycardia	B-Disease	D001919
.	O	O

Fifteen	O	O
min	O	O
later	O	O
,	O	O
animals	O	O
received	O	O
CaCl2	B-Chemical	D002122
,	O	O
NaHCO3	B-Chemical	D017693
,	O	O
or	O	O
saline	O	O
.	O	O

In	O	O
a	O	O
second	O	O
experiment	O	O
,	O	O
rats	O	O
received	O	O
tricyclic	O	O
antidepressant	O	O
desipramine	B-Chemical	D003891
IP	O	O
followed	O	O
in	O	O
15	O	O
min	O	O
by	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
or	O	O
saline	O	O
.	O	O

RESULTS	O	O
:	O	O
NaHCO3	B-Chemical	D017693
briefly	O	O
(	O	O
5	O	O
min	O	O
)	O	O
reversed	O	O
hypotension	B-Disease	D007022
and	O	O
QRS	O	O
prolongation	O	O
.	O	O

CaCl2	B-Chemical	D002122
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
failed	O	O
to	O	O
improve	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

004	O	O
)	O	O
and	O	O
seizures	B-Disease	D012640
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
in	O	O
the	O	O
CaCl2	B-Chemical	D002122
group	O	O
was	O	O
higher	O	O
than	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
administration	O	O
of	O	O
CaCl2	B-Chemical	D002122
or	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
did	O	O
not	O	O
reverse	O	O
tricyclic	O	O
antidepressant	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
rats	O	O
.	O	O

CaCl2	B-Chemical	D002122
therapy	O	O
may	O	O
possibly	O	O
worsen	O	O
both	O	O
cardiovascular	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
toxicity	B-Disease	D064420
.	O	O

These	O	O
findings	O	O
do	O	O
not	O	O
support	O	O
a	O	O
role	O	O
for	O	O
calcium	B-Chemical	D002118
channel	O	O
inhibition	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
tricyclic	O	O
antidepressant	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Phase	O	O
I	O	O
trial	O	O
of	O	O
13	B-Chemical	D015474
-	I-Chemical	D015474
cis	I-Chemical	D015474
-	I-Chemical	D015474
retinoic	I-Chemical	D015474
acid	I-Chemical	D015474
in	O	O
children	O	O
with	O	O
neuroblastoma	B-Disease	D009447
following	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O

PURPOSE	O	O
:	O	O
Treatment	O	O
of	O	O
neuroblastoma	B-Disease	D009447
cell	O	O
lines	O	O
with	O	O
13	B-Chemical	D015474
-	I-Chemical	D015474
cis	I-Chemical	D015474
-	I-Chemical	D015474
retinoic	I-Chemical	D015474
acid	I-Chemical	D015474
(	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
)	O	O
can	O	O
cause	O	O
sustained	O	O
inhibition	O	O
of	O	O
proliferation	O	O
.	O	O

Since	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
has	O	O
demonstrated	O	O
clinical	O	O
responses	O	O
in	O	O
neuroblastoma	B-Disease	D009447
patients	O	O
,	O	O
it	O	O
may	O	O
be	O	O
effective	O	O
in	O	O
preventing	O	O
relapse	O	O
after	O	O
cytotoxic	O	O
therapy	O	O
.	O	O

This	O	O
phase	O	O
I	O	O
trial	O	O
was	O	O
designed	O	O
to	O	O
determine	O	O
the	O	O
maximal	O	O
-	O	O
tolerated	O	O
dosage	O	O
(	O	O
MTD	O	O
)	O	O
,	O	O
toxicities	B-Disease	D064420
,	O	O
and	O	O
pharmacokinetics	O	O
of	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
administered	O	O
on	O	O
an	O	O
intermittent	O	O
schedule	O	O
in	O	O
children	O	O
with	O	O
neuroblastoma	B-Disease	D009447
following	O	O
bone	O	O
marrow	O	O
transplantation	O	O
(	O	O
BMT	O	O
)	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Fifty	O	O
-	O	O
one	O	O
assessable	O	O
patients	O	O
,	O	O
2	O	O
to	O	O
12	O	O
years	O	O
of	O	O
age	O	O
,	O	O
were	O	O
treated	O	O
with	O	O
oral	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
administered	O	O
in	O	O
two	O	O
equally	O	O
divided	O	O
doses	O	O
daily	O	O
for	O	O
2	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
2	O	O
-	O	O
week	O	O
rest	O	O
period	O	O
,	O	O
for	O	O
up	O	O
to	O	O
12	O	O
courses	O	O
.	O	O

The	O	O
dose	O	O
was	O	O
escalated	O	O
from	O	O
100	O	O
to	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
until	O	O
dose	O	O
-	O	O
limiting	O	O
toxicity	B-Disease	D064420
(	O	O
DLT	O	O
)	O	O
was	O	O
observed	O	O
.	O	O

A	O	O
single	O	O
intrapatient	O	O
dose	O	O
escalation	O	O
was	O	O
permitted	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
MTD	O	O
of	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
was	O	O
160	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

Dose	O	O
-	O	O
limiting	O	O
toxicities	B-Disease	D064420
in	O	O
six	O	O
of	O	O
nine	O	O
patients	O	O
at	O	O
200	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
included	O	O
hypercalcemia	B-Disease	D006934
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
rash	B-Disease	D005076
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
and	O	O
anemia	B-Disease	D000740
/	O	O
thrombocytopenia	B-Disease	D013921
/	O	O
emesis	B-Disease	D014839
/	O	O
rash	B-Disease	D005076
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
.	O	O

All	O	O
toxicities	B-Disease	D064420
resolved	O	O
after	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
was	O	O
discontinued	O	O
.	O	O

Three	O	O
complete	O	O
responses	O	O
were	O	O
observed	O	O
in	O	O
marrow	O	O
metastases	B-Disease	D009362
.	O	O

Serum	O	O
levels	O	O
of	O	O
7	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

0	O	O
mumol	O	O
/	O	O
L	O	O
(	O	O
peak	O	O
)	O	O
and	O	O
4	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

8	O	O
mumol	O	O
/	O	O
L	O	O
(	O	O
trough	O	O
)	O	O
at	O	O
the	O	O
MTD	O	O
were	O	O
maintained	O	O
during	O	O
14	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

The	O	O
DLT	O	O
correlated	O	O
with	O	O
serum	O	O
levels	O	O
>	O	O
or	O	O
=	O	O
10	O	O
mumol	O	O
/	O	O
L	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
MTD	O	O
of	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
given	O	O
on	O	O
this	O	O
intermittent	O	O
schedule	O	O
was	O	O
160	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

Serum	O	O
levels	O	O
known	O	O
to	O	O
be	O	O
effective	O	O
against	O	O
neuroblastoma	B-Disease	D009447
in	O	O
vitro	O	O
were	O	O
achieved	O	O
at	O	O
this	O	O
dose	O	O
.	O	O

The	O	O
DLT	O	O
included	O	O
hypercalcemia	B-Disease	D006934
,	O	O
and	O	O
may	O	O
be	O	O
predicted	O	O
by	O	O
serum	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
levels	O	O
.	O	O

Monitoring	O	O
of	O	O
serum	O	O
calcium	B-Chemical	D002118
and	O	O
cis	B-Chemical	D015474
-	I-Chemical	D015474
RA	I-Chemical	D015474
levels	O	O
is	O	O
indicated	O	O
in	O	O
future	O	O
trials	O	O
.	O	O

Effect	O	O
of	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
on	O	O
gross	O	O
behavioural	O	O
changes	O	O
produced	O	O
by	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
in	O	O
cats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
injected	O	O
into	O	O
the	O	O
cerebral	O	O
ventricles	O	O
of	O	O
group	O	O
-	O	O
housed	O	O
unanaesthetized	O	O
cats	O	O
upon	O	O
vocalization	O	O
(	O	O
rage	O	O
,	O	O
hissing	O	O
and	O	O
snarling	O	O
)	O	O
,	O	O
fighting	O	O
(	O	O
attack	O	O
with	O	O
paws	O	O
and	O	O
claws	O	O
,	O	O
defense	O	O
with	O	O
paws	O	O
and	O	O
claws	O	O
and	O	O
biting	O	O
)	O	O
,	O	O
mydriasis	B-Disease	D015878
,	O	O
tremor	B-Disease	D014202
and	O	O
clonic	B-Disease	D004830
-	I-Disease	D004830
tonic	I-Disease	D004830
convulsions	I-Disease	D004830
produced	O	O
by	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
injected	O	O
similarly	O	O
was	O	O
investigated	O	O
.	O	O

Calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
depressed	O	O
or	O	O
almost	O	O
completely	O	O
abolished	O	O
the	O	O
vocalization	O	O
and	O	O
fighting	O	O
due	O	O
to	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
mydriasis	B-Disease	D015878
,	O	O
tremor	B-Disease	D014202
and	O	O
clonic	B-Disease	D004830
-	I-Disease	D004830
tonic	I-Disease	D004830
convulsions	I-Disease	D004830
evoked	O	O
by	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
were	O	O
not	O	O
significantly	O	O
changed	O	O
by	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
.	O	O

It	O	O
is	O	O
apparent	O	O
that	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
can	O	O
"dissociate"	O	O
vocalization	O	O
and	O	O
fighting	O	O
from	O	O
autonomic	O	O
and	O	O
motor	O	O
phenomena	O	O
such	O	O
as	O	O
mydriasis	B-Disease	D015878
,	O	O
tremor	B-Disease	D014202
and	O	O
clonic	B-Disease	D004830
-	I-Disease	D004830
tonic	I-Disease	D004830
convulsions	I-Disease	D004830
caused	O	O
by	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
.	O	O

Calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
inhibited	O	O
the	O	O
vocalization	O	O
and	O	O
fighting	O	O
produced	O	O
by	O	O
carbachol	B-Chemical	D002217
and	O	O
eserine	B-Chemical	D010830
most	O	O
probably	O	O
by	O	O
a	O	O
nonspecific	O	O
stabilizing	O	O
action	O	O
on	O	O
central	O	O
muscarinic	O	O
cholinoceptive	O	O
sites	O	O
.	O	O

These	O	O
results	O	O
further	O	O
support	O	O
the	O	O
view	O	O
that	O	O
calcium	B-Chemical	D002118
ions	O	O
in	O	O
excess	O	O
have	O	O
an	O	O
atropine	B-Chemical	D001285
-	O	O
like	O	O
action	O	O
also	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Multiple	O	O
side	O	O
effects	O	O
of	O	O
penicillamine	B-Chemical	D010396
therapy	O	O
in	O	O
one	O	O
patient	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

Skin	B-Disease	D005076
rashes	I-Disease	D005076
,	O	O
proteinuria	B-Disease	D011507
,	O	O
systemic	B-Disease	D008180
lupus	I-Disease	D008180
erythematosus	I-Disease	D008180
,	O	O
polymyositis	B-Disease	D017285
and	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
have	O	O
all	O	O
been	O	O
recorded	O	O
as	O	O
complications	O	O
of	O	O
penicillamine	B-Chemical	D010396
therapy	O	O
in	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

A	O	O
patient	O	O
who	O	O
had	O	O
developed	O	O
all	O	O
5	O	O
is	O	O
now	O	O
described	O	O
.	O	O

The	O	O
skin	B-Disease	D012871
lesion	I-Disease	D012871
resembled	O	O
elastosis	B-Disease	C536202
perforans	I-Disease	C536202
serpiginosa	I-Disease	C536202
,	O	O
which	O	O
has	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
rare	O	O
side	O	O
effect	O	O
in	O	O
patients	O	O
with	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
but	O	O
not	O	O
in	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
treated	O	O
with	O	O
penicillamine	B-Chemical	D010396
.	O	O

Electrocardiographic	O	O
changes	O	O
and	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
in	O	O
patients	O	O
receiving	O	O
psychotropic	O	O
drugs	O	O
.	O	O

Eight	O	O
patients	O	O
had	O	O
cardiac	O	O
manifestations	O	O
that	O	O
were	O	O
life	O	O
-	O	O
threatening	O	O
in	O	O
five	O	O
while	O	O
taking	O	O
psychotropic	O	O
drugs	O	O
,	O	O
either	O	O
phenothiazines	B-Chemical	D010640
or	O	O
tricyclic	O	O
antidepressants	O	O
.	O	O

Although	O	O
most	O	O
patients	O	O
were	O	O
receiving	O	O
several	O	O
drugs	O	O
,	O	O
Mellaril	B-Chemical	D013881
(	O	O
thioridazine	B-Chemical	D013881
)	O	O
appeared	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
five	O	O
cases	O	O
of	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
,	O	O
one	O	O
of	O	O
which	O	O
was	O	O
fatal	O	O
in	O	O
a	O	O
35	O	O
year	O	O
old	O	O
woman	O	O
.	O	O

Supraventricular	B-Disease	D013617
tachycardia	I-Disease	D013617
developed	O	O
in	O	O
one	O	O
patient	O	O
receiving	O	O
Thorazine	B-Chemical	D002746
(	O	O
chlorpromazine	B-Chemical	D002746
)	O	O
.	O	O

Aventyl	B-Chemical	D009661
(	O	O
nortriptyline	B-Chemical	D009661
)	O	O
and	O	O
Elavil	B-Chemical	D000639
(	O	O
amitriptyline	B-Chemical	D000639
)	O	O
each	O	O
produced	O	O
left	B-Disease	D002037
bundle	I-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
in	O	O
a	O	O
73	O	O
year	O	O
old	O	O
woman	O	O
.	O	O

Electrocardiographic	O	O
T	O	O
and	O	O
U	O	O
wave	O	O
abnormalities	O	O
were	O	O
present	O	O
in	O	O
most	O	O
patients	O	O
.	O	O

The	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
responded	O	O
to	O	O
intravenous	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
and	O	O
to	O	O
direct	O	O
current	O	O
electric	O	O
shock	O	O
;	O	O
ventricular	O	O
pacing	O	O
was	O	O
required	O	O
in	O	O
some	O	O
instances	O	O
and	O	O
intravenous	O	O
administration	O	O
of	O	O
propranolol	B-Chemical	D011433
combined	O	O
with	O	O
ventricular	O	O
pacing	O	O
in	O	O
one	O	O
.	O	O

The	O	O
tachyarrhythmias	B-Disease	D013610
generally	O	O
subsided	O	O
within	O	O
48	O	O
hours	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drugs	O	O
was	O	O
stopped	O	O
.	O	O

Five	O	O
of	O	O
the	O	O
eight	O	O
patients	O	O
were	O	O
50	O	O
years	O	O
of	O	O
age	O	O
or	O	O
younger	O	O
;	O	O
only	O	O
one	O	O
clearly	O	O
had	O	O
antecedent	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
.	O	O

Major	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
are	O	O
a	O	O
potential	O	O
hazard	O	O
in	O	O
patients	O	O
without	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
who	O	O
are	O	O
receiving	O	O
customary	O	O
therapeutic	O	O
doses	O	O
of	O	O
psychotropic	O	O
drugs	O	O
.	O	O

A	O	O
prospective	O	O
clinical	O	O
trial	O	O
is	O	O
suggested	O	O
to	O	O
quantify	O	O
the	O	O
risk	O	O
of	O	O
cardiac	B-Disease	D005117
complications	I-Disease	D005117
to	O	O
patients	O	O
receiving	O	O
phenothiazines	B-Chemical	D010640
or	O	O
tricyclic	O	O
antidepressant	O	O
drugs	O	O
.	O	O

Serotonergic	O	O
drugs	O	O
,	O	O
benzodiazepines	B-Chemical	D001569
and	O	O
baclofen	B-Chemical	D001418
block	O	O
muscimol	B-Chemical	D009118
-	O	O
induced	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
in	O	O
a	O	O
strain	O	O
of	O	O
mice	O	O
.	O	O

In	O	O
male	O	O
Swiss	O	O
mice	O	O
,	O	O
muscimol	B-Chemical	D009118
produced	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
.	O	O

A	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
dose	O	O
induced	O	O
this	O	O
response	O	O
in	O	O
all	O	O
of	O	O
the	O	O
mice	O	O
tested	O	O
and	O	O
the	O	O
peak	O	O
response	O	O
of	O	O
73	O	O
jerks	O	O
per	O	O
min	O	O
was	O	O
observed	O	O
between	O	O
27	O	O
and	O	O
45	O	O
min	O	O
.	O	O

Increasing	O	O
the	O	O
brain	O	O
serotonin	B-Chemical	D012701
levels	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
5	B-Chemical	D006916
-	I-Chemical	D006916
hydroxytryptophan	I-Chemical	D006916
(	O	O
80	O	O
-	O	O
160	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
a	O	O
peripheral	O	O
decarboxylase	O	O
inhibitor	O	O
resulted	O	O
in	O	O
an	O	O
inhibition	O	O
of	O	O
the	O	O
muscimol	B-Chemical	D009118
effect	O	O
.	O	O

However	O	O
,	O	O
in	O	O
a	O	O
similar	O	O
experiment	O	O
l	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
(	O	O
80	O	O
-	O	O
160	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
without	O	O
effect	O	O
.	O	O

In	O	O
doses	O	O
of	O	O
3	O	O
-	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
the	O	O
serotonin	B-Chemical	D012701
receptor	O	O
agonist	O	O
MK	B-Chemical	C014896
-	I-Chemical	C014896
212	I-Chemical	C014896
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
blockade	O	O
of	O	O
the	O	O
response	O	O
of	O	O
muscimol	B-Chemical	D009118
.	O	O

Of	O	O
the	O	O
benzodiazepines	B-Chemical	D001569
,	O	O
clonazepam	B-Chemical	D002998
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
0	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
found	O	O
to	O	O
be	O	O
several	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
diazepam	B-Chemical	D003975
(	O	O
0	O	O
.	O	O

3	O	O
-	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
blocking	O	O
the	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
.	O	O

While	O	O
(	O	O
-	O	O
)	O	O
-	O	O
baclofen	B-Chemical	D001418
(	O	O
1	O	O
-	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
proved	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
antagonist	O	O
of	O	O
muscimol	B-Chemical	D009118
,	O	O
its	O	O
(	O	O
+	O	O
)	O	O
-	O	O
isomer	O	O
(	O	O
5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
lacked	O	O
this	O	O
property	O	O
.	O	O

Considering	O	O
the	O	O
fact	O	O
that	O	O
5	B-Chemical	D006916
-	I-Chemical	D006916
HTP	I-Chemical	D006916
and	O	O
the	O	O
benzodiazepines	B-Chemical	D001569
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
beneficial	O	O
in	O	O
the	O	O
management	O	O
of	O	O
clinical	O	O
myoclonus	B-Disease	D009207
,	O	O
the	O	O
muscimol	B-Chemical	D009118
-	O	O
induced	O	O
myoclonus	B-Disease	D009207
seems	O	O
to	O	O
be	O	O
a	O	O
satisfactory	O	O
animal	O	O
model	O	O
that	O	O
may	O	O
prove	O	O
useful	O	O
for	O	O
the	O	O
development	O	O
of	O	O
new	O	O
drug	O	O
treatments	O	O
for	O	O
this	O	O
condition	O	O
.	O	O

Our	O	O
present	O	O
study	O	O
indicated	O	O
the	O	O
possible	O	O
value	O	O
of	O	O
MK	B-Chemical	C014896
-	I-Chemical	C014896
212	I-Chemical	C014896
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
baclofen	B-Chemical	D001418
in	O	O
the	O	O
management	O	O
of	O	O
clinical	O	O
myoclonus	B-Disease	D009207
.	O	O

Hyperglycemic	O	O
acidotic	O	O
coma	B-Disease	D003128
and	O	O
death	O	O
in	O	O
Kearns	B-Disease	D007625
-	I-Disease	D007625
Sayre	I-Disease	D007625
syndrome	I-Disease	D007625
.	O	O

This	O	O
paper	O	O
presents	O	O
the	O	O
clinical	O	O
and	O	O
metabolic	O	O
findings	O	O
in	O	O
two	O	O
young	O	O
boys	O	O
with	O	O
long	O	O
-	O	O
standing	O	O
Kearns	B-Disease	D007625
-	I-Disease	D007625
Sayre	I-Disease	D007625
syndrome	I-Disease	D007625
.	O	O

Following	O	O
short	O	O
exposure	O	O
to	O	O
oral	O	O
prednisone	B-Chemical	D011241
,	O	O
both	O	O
boys	O	O
developed	O	O
lethargy	B-Disease	D053609
,	O	O
increasing	O	O
somnolence	B-Disease	D006970
,	O	O
polydipsia	B-Disease	D059606
,	O	O
polyphagia	B-Disease	D006963
,	O	O
and	O	O
polyuria	B-Disease	D011141
.	O	O

Both	O	O
presented	O	O
in	O	O
the	O	O
emergency	O	O
room	O	O
with	O	O
profound	O	O
coma	B-Disease	D003128
,	O	O
hypotension	B-Disease	D007022
,	O	O
severe	O	O
hyperglycemia	B-Disease	D006943
,	O	O
and	O	O
acidosis	B-Disease	D000138
.	O	O

Nonketotic	O	O
lactic	B-Disease	D000140
acidosis	I-Disease	D000140
was	O	O
present	O	O
in	O	O
one	O	O
and	O	O
ketosis	B-Disease	D007662
without	O	O
a	O	O
known	O	O
serum	O	O
lactate	B-Chemical	D019344
level	O	O
was	O	O
present	O	O
in	O	O
the	O	O
other	O	O
.	O	O

Respiratory	B-Disease	D012131
failure	I-Disease	D012131
rapidly	O	O
ensued	O	O
and	O	O
both	O	O
patients	O	O
expired	O	O
in	O	O
spite	O	O
of	O	O
efforts	O	O
at	O	O
resuscitation	O	O
.	O	O

We	O	O
believe	O	O
these	O	O
two	O	O
cases	O	O
represent	O	O
a	O	O
newly	O	O
described	O	O
and	O	O
catastrophic	O	O
metabolic	B-Disease	-1
-	I-Disease	-1
endocrine	I-Disease	-1
failure	I-Disease	-1
in	O	O
the	O	O
Kearns	B-Disease	D007625
-	I-Disease	D007625
Sayre	I-Disease	D007625
syndrome	I-Disease	D007625
.	O	O

Effects	O	O
of	O	O
active	O	O
constituents	O	O
of	O	O
Crocus	O	O
sativus	O	O
L	O	O
.	O	O

,	O	O
crocin	B-Chemical	C029036
on	O	O
streptozocin	B-Chemical	D013311
-	O	O
induced	O	O
model	O	O
of	O	O
sporadic	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
in	O	O
male	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
involvement	O	O
of	O	O
water	O	O
-	O	O
soluble	O	O
carotenoids	B-Chemical	D002338
,	O	O
crocins	B-Chemical	C029036
,	O	O
as	O	O
the	O	O
main	O	O
and	O	O
active	O	O
components	O	O
of	O	O
Crocus	O	O
sativus	O	O
L	O	O
.	O	O

extract	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
processes	O	O
has	O	O
been	O	O
proposed	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
crocins	B-Chemical	C029036
on	O	O
sporadic	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
induced	O	O
by	O	O
intracerebroventricular	O	O
(	O	O
icv	O	O
)	O	O
streptozocin	B-Chemical	D013311
(	O	O
STZ	B-Chemical	D013311
)	O	O
in	O	O
male	O	O
rats	O	O
was	O	O
investigated	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
adult	O	O
Wistar	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
90	O	O
and	O	O
260	O	O
-	O	O
290	O	O
g	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
1	O	O
,	O	O
control	O	O
;	O	O
2	O	O
and	O	O
3	O	O
,	O	O
crocins	B-Chemical	C029036
(	O	O
15	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
;	O	O
4	O	O
,	O	O
STZ	B-Chemical	D013311
;	O	O
5	O	O
and	O	O
6	O	O
,	O	O
STZ	B-Chemical	D013311
+	O	O
crocins	B-Chemical	C029036
(	O	O
15	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
groups	O	O
.	O	O

In	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
groups	O	O
,	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
bilaterally	O	O
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
first	O	O
day	O	O
and	O	O
3	O	O
days	O	O
later	O	O
,	O	O
a	O	O
similar	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
application	O	O
was	O	O
repeated	O	O
.	O	O

In	O	O
STZ	B-Chemical	D013311
+	O	O
crocin	B-Chemical	C029036
animal	O	O
groups	O	O
,	O	O
crocin	B-Chemical	C029036
was	O	O
applied	O	O
in	O	O
doses	O	O
of	O	O
15	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
one	O	O
day	O	O
pre	O	O
-	O	O
surgery	O	O
and	O	O
continued	O	O
for	O	O
three	O	O
weeks	O	O
.	O	O

Prescription	O	O
of	O	O
crocin	B-Chemical	C029036
in	O	O
each	O	O
dose	O	O
was	O	O
repeated	O	O
once	O	O
for	O	O
two	O	O
days	O	O
.	O	O

However	O	O
,	O	O
the	O	O
learning	O	O
and	O	O
memory	O	O
performance	O	O
was	O	O
assessed	O	O
using	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
,	O	O
and	O	O
for	O	O
spatial	O	O
cognition	O	O
evaluation	O	O
,	O	O
Y	O	O
-	O	O
maze	O	O
task	O	O
was	O	O
used	O	O
.	O	O

RESULTS	O	O
:	O	O
It	O	O
was	O	O
found	O	O
out	O	O
that	O	O
crocin	B-Chemical	C029036
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
-	O	O
treated	O	O
STZ	B-Chemical	D013311
-	O	O
injected	O	O
rats	O	O
show	O	O
higher	O	O
correct	O	O
choices	O	O
and	O	O
lower	O	O
errors	O	O
in	O	O
Y	O	O
-	O	O
maze	O	O
than	O	O
vehicle	O	O
-	O	O
treated	O	O
STZ	B-Chemical	D013311
-	O	O
injected	O	O
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
crocin	B-Chemical	C029036
in	O	O
the	O	O
mentioned	O	O
dose	O	O
could	O	O
significantly	O	O
attenuated	O	O
learning	O	O
and	O	O
memory	O	O
impairment	O	O
in	O	O
treated	O	O
STZ	B-Chemical	D013311
-	O	O
injected	O	O
group	O	O
in	O	O
passive	O	O
avoidance	O	O
test	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Therefore	O	O
,	O	O
these	O	O
results	O	O
demonstrate	O	O
the	O	O
effectiveness	O	O
of	O	O
crocin	B-Chemical	C029036
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
antagonizing	O	O
the	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
caused	O	O
by	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
in	O	O
rats	O	O
and	O	O
its	O	O
potential	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
neurodegenerative	B-Disease	D019636
diseases	I-Disease	D019636
such	O	O
as	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

Rosaceiform	O	O
dermatitis	B-Disease	D003872
associated	O	O
with	O	O
topical	O	O
tacrolimus	B-Chemical	D016559
treatment	O	O
.	O	O

We	O	O
describe	O	O
herein	O	O
3	O	O
patients	O	O
who	O	O
developed	O	O
rosacea	B-Disease	D012393
-	O	O
like	O	O
dermatitis	B-Disease	D003872
eruptions	B-Disease	D003875
while	O	O
using	O	O
0	O	O
.	O	O

03%	O	O
or	O	O
0	O	O
.	O	O

1%	O	O
tacrolimus	B-Chemical	D016559
ointment	O	O
for	O	O
facial	B-Disease	D005148
dermatitis	I-Disease	D005148
.	O	O

Skin	O	O
biopsy	O	O
specimens	O	O
showed	O	O
telangiectasia	B-Disease	D013684
and	O	O
noncaseating	O	O
epithelioid	O	O
granulomatous	O	O
tissue	O	O
formation	O	O
in	O	O
the	O	O
papillary	O	O
to	O	O
mid	O	O
dermis	O	O
.	O	O

Continuous	O	O
topical	O	O
use	O	O
of	O	O
immunomodulators	O	O
such	O	O
as	O	O
tacrolimus	B-Chemical	D016559
or	O	O
pimecrolimus	B-Chemical	C117268
should	O	O
be	O	O
regarded	O	O
as	O	O
a	O	O
potential	O	O
cause	O	O
of	O	O
rosaceiform	O	O
dermatitis	B-Disease	D003872
,	O	O
although	O	O
many	O	O
cases	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

A	O	O
novel	O	O
animal	O	O
model	O	O
to	O	O
evaluate	O	O
the	O	O
ability	O	O
of	O	O
a	O	O
drug	O	O
delivery	O	O
system	O	O
to	O	O
promote	O	O
the	O	O
passage	O	O
through	O	O
the	O	O
BBB	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
explore	O	O
the	O	O
potentiality	O	O
of	O	O
a	O	O
novel	O	O
animal	O	O
model	O	O
to	O	O
be	O	O
used	O	O
for	O	O
the	O	O
in	O	O
vivo	O	O
evaluation	O	O
of	O	O
the	O	O
ability	O	O
of	O	O
a	O	O
drug	O	O
delivery	O	O
system	O	O
to	O	O
promote	O	O
the	O	O
passage	O	O
through	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
(	O	O
BBB	O	O
)	O	O
and	O	O
/	O	O
or	O	O
to	O	O
improve	O	O
the	O	O
brain	O	O
localization	O	O
of	O	O
a	O	O
bioactive	O	O
compound	O	O
.	O	O

A	O	O
Tween	O	O
80	O	O
-	O	O
coated	O	O
poly	B-Chemical	-1
-	I-Chemical	-1
L	I-Chemical	-1
-	I-Chemical	-1
lactid	I-Chemical	-1
acid	I-Chemical	-1
nanoparticles	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
of	O	O
colloidal	O	O
drug	O	O
delivery	O	O
system	O	O
,	O	O
able	O	O
to	O	O
trespass	O	O
the	O	O
BBB	O	O
.	O	O

Tacrine	B-Chemical	D013619
,	O	O
administered	O	O
in	O	O
LiCl	B-Chemical	D018021
pre	O	O
-	O	O
treated	O	O
rats	O	O
,	O	O
induces	O	O
electrocorticographic	O	O
seizures	B-Disease	D012640
and	O	O
delayed	O	O
hippocampal	B-Disease	D001930
damage	I-Disease	D001930
.	O	O

The	O	O
toxic	O	O
effects	O	O
of	O	O
tacrine	B-Chemical	D013619
-	O	O
loaded	O	O
poly	B-Chemical	-1
-	I-Chemical	-1
L	I-Chemical	-1
-	I-Chemical	-1
lactid	I-Chemical	-1
acid	I-Chemical	-1
nanoparticles	O	O
(	O	O
5mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
a	O	O
saline	O	O
solution	O	O
of	O	O
tacrine	B-Chemical	D013619
(	O	O
5mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
an	O	O
empty	O	O
colloidal	O	O
nanoparticle	O	O
suspension	O	O
were	O	O
compared	O	O
following	O	O
i	O	O
.	O	O

p	O	O
.	O	O

administration	O	O
in	O	O
LiCl	B-Chemical	D018021
-	O	O
pre	O	O
-	O	O
treated	O	O
Wistar	O	O
rats	O	O
.	O	O

All	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
tacrine	B-Chemical	D013619
-	O	O
loaded	O	O
nanoparticles	O	O
showed	O	O
an	O	O
earlier	O	O
outcome	O	O
of	O	O
CNS	O	O
adverse	O	O
symptoms	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

epileptic	B-Disease	D004827
onset	O	O
,	O	O
with	O	O
respect	O	O
to	O	O
those	O	O
animals	O	O
treated	O	O
with	O	O
the	O	O
free	O	O
compound	O	O
(	O	O
10	O	O
min	O	O
vs	O	O
.	O	O

22	O	O
min	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
tacrine	B-Chemical	D013619
-	O	O
loaded	O	O
nanoparticles	O	O
administration	O	O
induced	O	O
damage	B-Disease	D001930
of	I-Disease	D001930
neuronal	I-Disease	D001930
cells	I-Disease	D001930
in	O	O
CA1	O	O
field	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
all	O	O
treated	O	O
animals	O	O
,	O	O
while	O	O
the	O	O
saline	O	O
solution	O	O
of	O	O
tacrine	B-Chemical	D013619
only	O	O
in	O	O
60%	O	O
of	O	O
animals	O	O
.	O	O

Empty	O	O
nanoparticles	O	O
provided	O	O
similar	O	O
results	O	O
to	O	O
control	O	O
(	O	O
saline	O	O
-	O	O
treated	O	O
)	O	O
group	O	O
of	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
evaluation	O	O
of	O	O
time	O	O
-	O	O
to	O	O
-	O	O
onset	O	O
of	O	O
symptoms	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
neurodegenerative	O	O
processes	O	O
induced	O	O
by	O	O
the	O	O
tacrine	B-Chemical	D013619
-	O	O
lithium	B-Chemical	D008094
model	O	O
of	O	O
epilepsy	B-Disease	D004827
in	O	O
the	O	O
rat	O	O
,	O	O
could	O	O
be	O	O
used	O	O
to	O	O
evaluate	O	O
preliminarily	O	O
the	O	O
capability	O	O
of	O	O
a	O	O
drug	O	O
delivery	O	O
system	O	O
to	O	O
trespass	O	O
(	O	O
or	O	O
not	O	O
)	O	O
the	O	O
BBB	O	O
in	O	O
vivo	O	O
.	O	O

The	O	O
antiarrhythmic	O	O
effect	O	O
and	O	O
possible	O	O
ionic	O	O
mechanisms	O	O
of	O	O
pilocarpine	B-Chemical	D010862
on	O	O
animal	O	O
models	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
pilocarpine	B-Chemical	D010862
and	O	O
explore	O	O
the	O	O
underlying	O	O
ionic	O	O
mechanism	O	O
,	O	O
using	O	O
both	O	O
aconitine	B-Chemical	D000157
-	O	O
induced	O	O
rat	O	O
and	O	O
ouabain	B-Chemical	D010042
-	O	O
induced	O	O
guinea	O	O
pig	O	O
arrhythmia	B-Disease	D001145
models	O	O
.	O	O

Confocal	O	O
microscopy	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
intracellular	O	O
free	O	O
-	O	O
calcium	B-Chemical	D002118
concentrations	O	O
(	O	O
[	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
]	O	O
(	O	O
i	O	O
)	O	O
)	O	O
in	O	O
isolated	O	O
myocytes	O	O
.	O	O

The	O	O
current	O	O
data	O	O
showed	O	O
that	O	O
pilocarpine	B-Chemical	D010862
significantly	O	O
delayed	O	O
onset	O	O
of	O	O
arrhythmias	B-Disease	D001145
,	O	O
decreased	O	O
the	O	O
time	O	O
course	O	O
of	O	O
ventricular	O	O
tachycardia	O	O
and	O	O
fibrillation	O	O
,	O	O
reduced	O	O
arrhythmia	B-Disease	D001145
score	O	O
,	O	O
and	O	O
increased	O	O
the	O	O
survival	O	O
time	O	O
of	O	O
arrhythmic	B-Disease	D001145
rats	O	O
and	O	O
guinea	O	O
pigs	O	O
.	O	O

[	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
]	O	O
(	O	O
i	O	O
)	O	O
overload	O	O
induced	O	O
by	O	O
aconitine	B-Chemical	D000157
or	O	O
ouabain	B-Chemical	D010042
was	O	O
reduced	O	O
in	O	O
isolated	O	O
myocytes	O	O
pretreated	O	O
with	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Moreover	O	O
,	O	O
M	O	O
(	O	O
3	O	O
)	O	O
-	O	O
muscarinic	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
(	O	O
mAChR	O	O
)	O	O
antagonist	O	O
4	B-Chemical	C042375
-	I-Chemical	C042375
DAMP	I-Chemical	C042375
(	O	O
4	B-Chemical	C042375
-	I-Chemical	C042375
diphenylacetoxy	I-Chemical	C042375
-	I-Chemical	C042375
N	I-Chemical	C042375
-	I-Chemical	C042375
methylpiperidine	I-Chemical	C042375
-	I-Chemical	C042375
methiodide	I-Chemical	C042375
)	O	O
partially	O	O
abolished	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
pilocarpine	B-Chemical	D010862
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
pilocarpine	B-Chemical	D010862
produced	O	O
antiarrhythmic	O	O
actions	O	O
on	O	O
arrhythmic	B-Disease	D001145
rat	O	O
and	O	O
guinea	O	O
pig	O	O
models	O	O
induced	O	O
by	O	O
aconitine	B-Chemical	D000157
or	O	O
ouabain	B-Chemical	D010042
via	O	O
stimulating	O	O
the	O	O
cardiac	O	O
M	O	O
(	O	O
3	O	O
)	O	O
-	O	O
mAChR	O	O
.	O	O

The	O	O
mechanism	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
improvement	O	O
of	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
handling	O	O
.	O	O

Disulfiram	B-Chemical	D004221
-	O	O
induced	O	O
transient	O	O
optic	O	O
and	O	O
peripheral	O	O
neuropathy	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

AIM	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
optic	O	O
and	O	O
peripheral	O	O
neuropathy	O	O
after	O	O
chronic	O	O
use	O	O
of	O	O
disulfiram	B-Chemical	D004221
for	O	O
alcohol	B-Disease	D000437
dependence	I-Disease	D000437
management	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
case	O	O
report	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
presented	O	O
with	O	O
gradual	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
vision	I-Disease	D014786
in	O	O
both	O	O
eyes	O	O
with	O	O
intermittent	O	O
headaches	B-Disease	D006261
for	O	O
2	O	O
months	O	O
.	O	O

He	O	O
also	O	O
complained	O	O
of	O	O
paraesthesia	B-Disease	D010292
with	O	O
numbness	B-Disease	D006987
in	O	O
both	O	O
feet	O	O
.	O	O

His	O	O
vision	O	O
was	O	O
6	O	O
/	O	O
15	O	O
and	O	O
2	O	O
/	O	O
60	O	O
in	O	O
the	O	O
right	O	O
and	O	O
left	O	O
eyes	O	O
,	O	O
respectively	O	O
.	O	O

Fundoscopy	O	O
revealed	O	O
bilaterally	O	O
swollen	O	O
optic	O	O
nerve	O	O
heads	O	O
.	O	O

Visual	O	O
field	O	O
testing	O	O
confirmed	O	O
bilateral	O	O
central	O	O
-	O	O
caecal	O	O
scotomata	B-Disease	D012607
.	O	O

He	O	O
had	O	O
been	O	O
taking	O	O
disulfiram	B-Chemical	D004221
for	O	O
alcohol	B-Disease	D000437
dependence	I-Disease	D000437
for	O	O
the	O	O
preceding	O	O
3	O	O
years	O	O
.	O	O

Disulfiram	B-Chemical	D004221
discontinuation	O	O
lead	O	O
to	O	O
an	O	O
immediate	O	O
symptomatic	O	O
improvement	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Physicians	O	O
initiating	O	O
long	O	O
-	O	O
term	O	O
disulfiram	B-Chemical	D004221
therapy	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
these	O	O
adverse	O	O
effects	O	O
.	O	O

They	O	O
should	O	O
recommend	O	O
annual	O	O
ophthalmic	O	O
reviews	O	O
with	O	O
visual	O	O
field	O	O
testing	O	O
.	O	O

Patients	O	O
should	O	O
be	O	O
reassured	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
reversibility	O	O
of	O	O
these	O	O
adverse	O	O
effects	O	O
.	O	O

Sustained	O	O
clinical	O	O
improvement	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
decompensated	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
-	O	O
related	O	O
cirrhosis	B-Disease	D005355
after	O	O
treatment	O	O
with	O	O
lamivudine	B-Chemical	D019259
monotherapy	O	O
.	O	O

Hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	I-Disease	D006509
(	I-Disease	D006509
HBV	I-Disease	D006509
)	I-Disease	D006509
infection	I-Disease	D006509
,	O	O
which	O	O
causes	O	O
liver	B-Disease	D008103
cirrhosis	I-Disease	D008103
and	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
,	O	O
remains	O	O
a	O	O
major	O	O
health	O	O
problem	O	O
in	O	O
Asian	O	O
countries	O	O
.	O	O

Recent	O	O
development	O	O
of	O	O
vaccine	O	O
for	O	O
prevention	O	O
is	O	O
reported	O	O
to	O	O
be	O	O
successful	O	O
in	O	O
reducing	O	O
the	O	O
size	O	O
of	O	O
chronically	O	O
infected	O	O
carriers	O	O
,	O	O
although	O	O
the	O	O
standard	O	O
medical	O	O
therapies	O	O
have	O	O
not	O	O
been	O	O
established	O	O
up	O	O
to	O	O
now	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
encountered	O	O
a	O	O
patient	O	O
with	O	O
decompensated	O	O
HBV	O	O
-	O	O
related	O	O
cirrhosis	B-Disease	D005355
who	O	O
exhibited	O	O
the	O	O
dramatic	O	O
improvements	O	O
after	O	O
antiviral	O	O
therapy	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
a	O	O
50	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
.	O	O

Previous	O	O
conventional	O	O
medical	O	O
treatments	O	O
were	O	O
not	O	O
effective	O	O
for	O	O
this	O	O
patient	O	O
,	O	O
thus	O	O
this	O	O
patient	O	O
had	O	O
been	O	O
referred	O	O
to	O	O
our	O	O
hospital	O	O
.	O	O

However	O	O
,	O	O
the	O	O
administration	O	O
of	O	O
lamivudine	B-Chemical	D019259
,	O	O
a	O	O
reverse	O	O
transcriptase	O	O
inhibitor	O	O
,	O	O
for	O	O
23	O	O
months	O	O
dramatically	O	O
improved	O	O
her	O	O
liver	O	O
severity	O	O
.	O	O

During	O	O
this	O	O
period	O	O
,	O	O
no	O	O
drug	O	O
resistant	O	O
mutant	O	O
HBV	O	O
emerged	O	O
,	O	O
and	O	O
the	O	O
serum	O	O
HBV	O	O
-	O	O
DNA	O	O
level	O	O
was	O	O
continuously	O	O
suppressed	O	O
.	O	O

These	O	O
virological	O	O
responses	O	O
were	O	O
also	O	O
maintained	O	O
even	O	O
after	O	O
the	O	O
antiviral	O	O
therapy	O	O
was	O	O
discontinued	O	O
.	O	O

Moreover	O	O
,	O	O
both	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
and	O	O
e	O	O
antigen	O	O
were	O	O
observed	O	O
to	O	O
have	O	O
disappeared	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
lamivudine	B-Chemical	D019259
to	O	O
patients	O	O
with	O	O
HBV	O	O
-	O	O
related	O	O
cirrhosis	B-Disease	D005355
,	O	O
like	O	O
our	O	O
present	O	O
case	O	O
,	O	O
should	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
initial	O	O
medical	O	O
therapeutic	O	O
option	O	O
,	O	O
especially	O	O
in	O	O
countries	O	O
where	O	O
liver	O	O
transplantation	O	O
is	O	O
not	O	O
reliably	O	O
available	O	O
.	O	O

Dual	O	O
effects	O	O
of	O	O
melatonin	B-Chemical	D008550
on	O	O
barbiturate	B-Chemical	C032232
-	O	O
induced	O	O
narcosis	B-Disease	D053608
in	O	O
rats	O	O
.	O	O

Melatonin	B-Chemical	D008550
affects	O	O
the	O	O
circadian	O	O
sleep	O	O
/	O	O
wake	O	O
cycle	O	O
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
it	O	O
may	O	O
influence	O	O
drug	O	O
-	O	O
induced	O	O
narcosis	B-Disease	D053608
.	O	O

Sodium	B-Chemical	D013874
thiopenthal	I-Chemical	D013874
was	O	O
administered	O	O
intraperitoneally	O	O
into	O	O
male	O	O
rats	O	O
pre	O	O
-	O	O
treated	O	O
with	O	O
melatonin	B-Chemical	D008550
(	O	O
0	O	O
.	O	O

05	O	O
,	O	O
0	O	O
.	O	O

5	O	O
,	O	O
5	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Melatonin	B-Chemical	D008550
pre	O	O
-	O	O
treatment	O	O
affected	O	O
in	O	O
a	O	O
dual	O	O
manner	O	O
barbiturate	B-Chemical	C032232
narcosis	B-Disease	D053608
,	O	O
however	O	O
,	O	O
no	O	O
dose	O	O
-	O	O
effect	O	O
correlation	O	O
was	O	O
found	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
low	O	O
doses	O	O
reduced	O	O
the	O	O
latency	O	O
to	O	O
and	O	O
prolonged	O	O
the	O	O
duration	O	O
of	O	O
barbiturate	B-Chemical	C032232
narcosis	B-Disease	D053608
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
highest	O	O
dose	O	O
of	O	O
melatonin	B-Chemical	D008550
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
caused	O	O
a	O	O
paradoxical	O	O
increase	O	O
in	O	O
the	O	O
latency	O	O
and	O	O
produced	O	O
a	O	O
sustained	O	O
reduction	O	O
of	O	O
the	O	O
duration	O	O
of	O	O
narcosis	B-Disease	D053608
,	O	O
and	O	O
a	O	O
reduction	O	O
in	O	O
mortality	O	O
rate	O	O
.	O	O

Melatonin	B-Chemical	D008550
0	O	O
.	O	O

5	O	O
and	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
influenced	O	O
the	O	O
duration	O	O
but	O	O
not	O	O
the	O	O
latency	O	O
of	O	O
ketamine	B-Chemical	D007649
-	O	O
or	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
narcosis	B-Disease	D053608
.	O	O

Thus	O	O
,	O	O
the	O	O
dual	O	O
action	O	O
of	O	O
melatonin	B-Chemical	D008550
on	O	O
pharmacological	O	O
narcosis	B-Disease	D053608
seems	O	O
to	O	O
be	O	O
specific	O	O
for	O	O
the	O	O
barbiturate	B-Chemical	C032232
mechanism	O	O
of	O	O
action	O	O
.	O	O

Effects	O	O
of	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
on	O	O
cholinesterase	O	O
and	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

The	O	O
effects	O	O
of	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
on	O	O
cholinesterase	O	O
,	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
and	O	O
spontaneous	O	O
movement	O	O
were	O	O
examined	O	O
and	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
the	O	O
well	O	O
-	O	O
known	O	O
cholinesterase	O	O
inhibitors	O	O
tacrine	B-Chemical	D013619
and	O	O
E	B-Chemical	C076946
-	I-Chemical	C076946
2020	I-Chemical	C076946
.	O	O

NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
,	O	O
tacrine	B-Chemical	D013619
and	O	O
E	B-Chemical	C076946
-	I-Chemical	C076946
2020	I-Chemical	C076946
all	O	O
strongly	O	O
inhibited	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
in	O	O
human	O	O
red	O	O
blood	O	O
cells	O	O
(	O	O
IC50s	O	O
=	O	O
1	O	O
.	O	O

0	O	O
x	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
,	O	O
2	O	O
.	O	O

9	O	O
x	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
and	O	O
3	O	O
.	O	O

7	O	O
x	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
and	O	O
tacrine	B-Chemical	D013619
,	O	O
but	O	O
not	O	O
E	B-Chemical	C076946
-	I-Chemical	C076946
2020	I-Chemical	C076946
,	O	O
strongly	O	O
inhibited	O	O
butyrylcholinestrase	O	O
(	O	O
BuChE	O	O
)	O	O
in	O	O
human	O	O
serum	O	O
.	O	O

All	O	O
three	O	O
drugs	O	O
produced	O	O
mixed	O	O
inhibition	O	O
of	O	O
AChE	O	O
activity	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
on	O	O
AChE	O	O
was	O	O
reversible	O	O
.	O	O

All	O	O
compounds	O	O
at	O	O
0	O	O
.	O	O

1	O	O
-	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

significantly	O	O
improved	O	O
the	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
in	O	O
rats	O	O
performing	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
.	O	O

The	O	O
three	O	O
compounds	O	O
at	O	O
1	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

did	O	O
not	O	O
significantly	O	O
decrease	O	O
spontaneous	O	O
movement	O	O
by	O	O
rats	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
at	O	O
a	O	O
low	O	O
dose	O	O
(	O	O
0	O	O
.	O	O

1	O	O
-	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
improves	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
but	O	O
does	O	O
not	O	O
affect	O	O
spontaneous	O	O
movement	O	O
.	O	O

The	O	O
findings	O	O
suggest	O	O
that	O	O
NIK	B-Chemical	C049860
-	I-Chemical	C049860
247	I-Chemical	C049860
may	O	O
be	O	O
a	O	O
useful	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
.	O	O

Nightmares	O	O
and	O	O
hallucinations	B-Disease	D006212
after	O	O
long	O	O
-	O	O
term	O	O
intake	O	O
of	O	O
tramadol	B-Chemical	D014147
combined	O	O
with	O	O
antidepressants	O	O
.	O	O

Tramadol	B-Chemical	D014147
is	O	O
a	O	O
weak	O	O
opioid	O	O
with	O	O
effects	O	O
on	O	O
adrenergic	O	O
and	O	O
serotonergic	O	O
neurotransmission	O	O
that	O	O
is	O	O
used	O	O
to	O	O
treat	O	O
cancer	B-Disease	D009369
pain	B-Disease	D010146
and	O	O
chronic	O	O
non	O	O
malignant	O	O
pain	B-Disease	D010146
.	O	O

This	O	O
drug	O	O
was	O	O
initiated	O	O
in	O	O
association	O	O
with	O	O
paroxetine	B-Chemical	D017374
and	O	O
dosulepine	B-Chemical	D004308
hydrochloride	I-Chemical	D004308
in	O	O
a	O	O
tetraparetic	B-Disease	-1
patient	O	O
with	O	O
chronic	B-Disease	D059350
pain	I-Disease	D059350
.	O	O

Fifty	O	O
-	O	O
six	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
the	O	O
treatment	O	O
the	O	O
patient	O	O
presented	O	O
hallucinations	B-Disease	D006212
that	O	O
only	O	O
stopped	O	O
after	O	O
the	O	O
withdrawal	O	O
of	O	O
psycho	O	O
-	O	O
active	O	O
drugs	O	O
and	O	O
tramadol	B-Chemical	D014147
.	O	O

The	O	O
case	O	O
report	O	O
questions	O	O
the	O	O
long	O	O
term	O	O
use	O	O
of	O	O
pain	B-Disease	D010146
killers	O	O
combined	O	O
with	O	O
psycho	O	O
-	O	O
active	O	O
drugs	O	O
in	O	O
chronic	O	O
non	O	O
malignant	O	O
pain	B-Disease	D010146
,	O	O
especially	O	O
if	O	O
pain	B-Disease	D010146
is	O	O
under	O	O
control	O	O
.	O	O

Apparent	O	O
cure	O	O
of	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
by	O	O
bone	O	O
marrow	O	O
transplantation	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
induction	O	O
of	O	O
sustained	O	O
remissions	O	O
and	O	O
possible	O	O
cure	O	O
of	O	O
severe	O	O
erosive	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
(	O	O
RA	B-Disease	D001172
)	O	O
by	O	O
bone	O	O
marrow	O	O
transplantation	O	O
(	O	O
BMT	O	O
)	O	O
in	O	O
2	O	O
patients	O	O
.	O	O

BMT	O	O
was	O	O
used	O	O
to	O	O
treat	O	O
severe	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
which	O	O
was	O	O
caused	O	O
by	O	O
gold	B-Chemical	D006046
in	O	O
one	O	O
case	O	O
and	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
in	O	O
the	O	O
other	O	O
.	O	O

In	O	O
the	O	O
8	O	O
and	O	O
6	O	O
years	O	O
since	O	O
the	O	O
transplants	O	O
(	O	O
representing	O	O
8	O	O
and	O	O
4	O	O
years	O	O
since	O	O
cessation	O	O
of	O	O
all	O	O
immunosuppressive	O	O
therapy	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
the	O	O
RA	B-Disease	D001172
in	O	O
each	O	O
case	O	O
has	O	O
been	O	O
completely	O	O
quiescent	O	O
.	O	O

Although	O	O
short	O	O
term	O	O
remission	O	O
of	O	O
severe	O	O
RA	B-Disease	D001172
following	O	O
BMT	O	O
has	O	O
been	O	O
reported	O	O
,	O	O
these	O	O
are	O	O
the	O	O
first	O	O
cases	O	O
for	O	O
which	O	O
prolonged	O	O
followup	O	O
has	O	O
been	O	O
available	O	O
.	O	O

This	O	O
experience	O	O
raises	O	O
the	O	O
question	O	O
of	O	O
the	O	O
role	O	O
of	O	O
BMT	O	O
itself	O	O
as	O	O
a	O	O
therapeutic	O	O
option	O	O
for	O	O
patients	O	O
with	O	O
uncontrolled	O	O
destructive	O	O
synovitis	B-Disease	D013585
.	O	O

Urinary	O	O
enzymes	O	O
and	O	O
protein	O	O
patterns	O	O
as	O	O
indicators	O	O
of	O	O
injury	B-Disease	D007674
to	I-Disease	D007674
different	I-Disease	D007674
regions	I-Disease	D007674
of	I-Disease	D007674
the	I-Disease	D007674
kidney	I-Disease	D007674
.	O	O

Acute	B-Disease	D058186
experimental	I-Disease	D058186
models	I-Disease	D058186
of	I-Disease	D058186
renal	I-Disease	D058186
damage	I-Disease	D058186
to	O	O
the	O	O
proximal	O	O
tubular	O	O
,	O	O
glomerular	O	O
,	O	O
and	O	O
papillary	O	O
regions	O	O
of	O	O
the	O	O
rat	O	O
were	O	O
produced	O	O
by	O	O
administration	O	O
of	O	O
hexachloro	B-Chemical	C001335
-	I-Chemical	C001335
1	I-Chemical	C001335
:	I-Chemical	C001335
3	I-Chemical	C001335
-	I-Chemical	C001335
butadiene	I-Chemical	C001335
(	O	O
HCBD	B-Chemical	C001335
)	O	O
,	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
,	O	O
and	O	O
2	B-Chemical	C004504
-	I-Chemical	C004504
bromoethylamine	I-Chemical	C004504
(	O	O
BEA	B-Chemical	C004504
)	O	O
,	O	O
respectively	O	O
.	O	O

Several	O	O
routine	O	O
indicators	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
the	O	O
enzymes	O	O
alkaline	O	O
phosphatase	O	O
and	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
glucosaminidase	O	O
,	O	O
and	O	O
the	O	O
molecular	O	O
weight	O	O
of	O	O
protein	B-Disease	D011507
excretion	I-Disease	D011507
were	O	O
determined	O	O
on	O	O
urine	O	O
samples	O	O
.	O	O

Tubular	O	O
damage	O	O
produced	O	O
by	O	O
HCBD	B-Chemical	C001335
or	O	O
BEA	B-Chemical	C004504
was	O	O
discriminated	O	O
both	O	O
quantitatively	O	O
and	O	O
qualitatively	O	O
from	O	O
glomerular	B-Disease	D007674
damage	I-Disease	D007674
produced	O	O
by	O	O
PAN	B-Chemical	D011692
.	O	O

The	O	O
latter	O	O
was	O	O
characterized	O	O
by	O	O
a	O	O
pronounced	O	O
increase	O	O
in	O	O
protein	B-Disease	D011507
excretion	I-Disease	D011507
,	O	O
especially	O	O
proteins	O	O
with	O	O
molecular	O	O
weight	O	O
greater	O	O
than	O	O
40	O	O
,	O	O
000	O	O
Da	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
protein	B-Disease	D011507
excretion	I-Disease	D011507
in	O	O
tubular	O	O
damage	O	O
was	O	O
raised	O	O
only	O	O
slightly	O	O
and	O	O
characterized	O	O
by	O	O
excretion	B-Disease	D011507
of	I-Disease	D011507
proteins	I-Disease	D011507
of	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
molecular	O	O
weights	O	O
.	O	O

Proximal	O	O
tubular	O	O
damage	O	O
caused	O	O
by	O	O
HCBD	B-Chemical	C001335
and	O	O
papillary	O	O
damage	O	O
caused	O	O
by	O	O
BEA	B-Chemical	C004504
were	O	O
distinguished	O	O
both	O	O
by	O	O
conventional	O	O
urinalysis	O	O
(	O	O
volume	O	O
and	O	O
specific	O	O
gravity	O	O
)	O	O
and	O	O
by	O	O
measurement	O	O
of	O	O
the	O	O
two	O	O
urinary	O	O
enzymes	O	O
.	O	O

Alkaline	O	O
phosphatase	O	O
and	O	O
glucose	B-Chemical	D005947
were	O	O
markedly	O	O
and	O	O
transiently	O	O
elevated	O	O
in	O	O
proximal	O	O
tubular	O	O
damage	O	O
and	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
glucosaminidase	O	O
showed	O	O
a	O	O
sustained	O	O
elevation	O	O
in	O	O
papillary	O	O
damage	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
both	O	O
selective	O	O
urinary	O	O
enzymes	O	O
and	O	O
the	O	O
molecular	O	O
weight	O	O
pattern	O	O
of	O	O
urinary	O	O
proteins	O	O
can	O	O
be	O	O
used	O	O
to	O	O
provide	O	O
diagnostic	O	O
information	O	O
about	O	O
the	O	O
possible	O	O
site	O	O
of	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
.	O	O

Neuromuscular	B-Disease	D020879
blockade	I-Disease	D020879
with	O	O
magnesium	B-Chemical	D008278
sulfate	I-Chemical	D008278
and	O	O
nifedipine	B-Chemical	D009543
.	O	O

A	O	O
patient	O	O
who	O	O
received	O	O
tocolysis	O	O
with	O	O
nifedipine	B-Chemical	D009543
developed	O	O
neuromuscular	B-Disease	D020879
blockade	I-Disease	D020879
after	O	O
500	O	O
mg	O	O
of	O	O
magnesium	B-Chemical	D008278
sulfate	I-Chemical	D008278
was	O	O
administered	O	O
.	O	O

This	O	O
reaction	O	O
demonstrates	O	O
that	O	O
nifedipine	B-Chemical	D009543
can	O	O
seriously	O	O
potentiate	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
magnesium	B-Chemical	D008274
.	O	O

Caution	O	O
should	O	O
be	O	O
exercised	O	O
when	O	O
these	O	O
two	O	O
tocolytics	O	O
are	O	O
combined	O	O
.	O	O

Ifosfamide	B-Chemical	D007069
continuous	O	O
infusion	O	O
without	O	O
mesna	B-Chemical	D015080
.	O	O

A	O	O
phase	O	O
I	O	O
trial	O	O
of	O	O
a	O	O
14	O	O
-	O	O
day	O	O
cycle	O	O
.	O	O

Twenty	O	O
patients	O	O
received	O	O
27	O	O
courses	O	O
of	O	O
ifosfamide	B-Chemical	D007069
administered	O	O
as	O	O
a	O	O
24	O	O
-	O	O
hour	O	O
continuous	O	O
infusion	O	O
for	O	O
14	O	O
days	O	O
without	O	O
Mesna	B-Chemical	D015080
.	O	O

The	O	O
goal	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
deliver	O	O
a	O	O
dose	O	O
rate	O	O
and	O	O
total	O	O
cumulative	O	O
dose	O	O
of	O	O
ifosfamide	B-Chemical	D007069
that	O	O
would	O	O
be	O	O
comparable	O	O
to	O	O
standard	O	O
bolus	O	O
or	O	O
short	O	O
-	O	O
term	O	O
infusions	O	O
administered	O	O
with	O	O
Mesna	B-Chemical	D015080
.	O	O

Dose	O	O
escalations	O	O
proceeded	O	O
from	O	O
200	O	O
to	O	O
300	O	O
,	O	O
400	O	O
,	O	O
450	O	O
,	O	O
500	O	O
,	O	O
and	O	O
550	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

Four	O	O
patients	O	O
developed	O	O
transient	O	O
microscopic	O	O
hematuria	B-Disease	D006417
at	O	O
400	O	O
,	O	O
450	O	O
,	O	O
and	O	O
500	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

There	O	O
were	O	O
no	O	O
instances	O	O
of	O	O
macroscopic	O	O
hematuria	B-Disease	D006417
.	O	O

At	O	O
550	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
,	O	O
three	O	O
patients	O	O
experienced	O	O
nonurologic	O	O
toxicity	B-Disease	D064420
;	O	O
confusion	B-Disease	D003221
(	O	O
1	O	O
)	O	O
,	O	O
nausea	B-Disease	D009325
(	O	O
1	O	O
)	O	O
,	O	O
and	O	O
Grade	O	O
2	O	O
leukopenia	B-Disease	D007970
(	O	O
1	O	O
)	O	O
.	O	O

The	O	O
recommended	O	O
dose	O	O
of	O	O
500	O	O
mg	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
delivers	O	O
a	O	O
total	O	O
dose	O	O
of	O	O
7	O	O
g	O	O
/	O	O
m2	O	O
per	O	O
cycle	O	O
,	O	O
which	O	O
is	O	O
comparable	O	O
to	O	O
that	O	O
delivered	O	O
in	O	O
clinical	O	O
practice	O	O
for	O	O
bolus	O	O
or	O	O
short	O	O
-	O	O
term	O	O
infusion	O	O
.	O	O

Because	O	O
few	O	O
patients	O	O
received	O	O
multiple	O	O
courses	O	O
over	O	O
time	O	O
,	O	O
the	O	O
cumulative	O	O
effects	O	O
are	O	O
indeterminate	O	O
in	O	O
the	O	O
present	O	O
trial	O	O
.	O	O

The	O	O
frequency	O	O
and	O	O
predictability	O	O
of	O	O
hematuria	B-Disease	D006417
are	O	O
not	O	O
precise	O	O
,	O	O
and	O	O
at	O	O
least	O	O
daily	O	O
monitoring	O	O
by	O	O
urine	O	O
Hematest	O	O
is	O	O
essential	O	O
,	O	O
adding	O	O
Mesna	B-Chemical	D015080
to	O	O
the	O	O
infusate	O	O
in	O	O
patients	O	O
with	O	O
persistent	O	O
hematuria	B-Disease	D006417
.	O	O

The	O	O
protracted	O	O
infusion	O	O
schedule	O	O
for	O	O
ifosfamide	B-Chemical	D007069
permits	O	O
convenient	O	O
outpatient	O	O
administration	O	O
without	O	O
Mesna	B-Chemical	D015080
and	O	O
reduces	O	O
the	O	O
drug	O	O
cost	O	O
of	O	O
clinical	O	O
usage	O	O
of	O	O
this	O	O
agent	O	O
by	O	O
up	O	O
to	O	O
890	O	O
per	O	O
cycle	O	O
.	O	O

Clinical	O	O
activity	O	O
was	O	O
demonstrated	O	O
in	O	O
a	O	O
single	O	O
patient	O	O
,	O	O
but	O	O
a	O	O
comparative	O	O
trial	O	O
of	O	O
standard	O	O
bolus	O	O
schedules	O	O
with	O	O
the	O	O
protracted	O	O
infusion	O	O
schedule	O	O
will	O	O
be	O	O
necessary	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
clinical	O	O
effectiveness	O	O
of	O	O
the	O	O
drug	O	O
is	O	O
maintained	O	O
.	O	O

Myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
pregnancy	O	O
associated	O	O
with	O	O
clomiphene	B-Chemical	D002996
citrate	I-Chemical	D002996
for	O	O
ovulation	O	O
induction	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Clomiphene	B-Chemical	D002996
citrate	I-Chemical	D002996
(	O	O
CC	B-Chemical	D002996
)	O	O
is	O	O
commonly	O	O
prescribed	O	O
for	O	O
ovulation	O	O
induction	O	O
.	O	O

It	O	O
is	O	O
considered	O	O
safe	O	O
,	O	O
with	O	O
minimal	O	O
side	O	O
effects	O	O
.	O	O

Thromboembolism	B-Disease	D013923
is	O	O
a	O	O
rare	O	O
but	O	O
life	O	O
-	O	O
threatening	O	O
complication	O	O
that	O	O
has	O	O
been	O	O
reported	O	O
after	O	O
ovulation	O	O
induction	O	O
with	O	O
CC	B-Chemical	D002996
.	O	O

Spontaneous	O	O
coronary	B-Disease	D003328
thrombosis	I-Disease	D003328
or	O	O
thromboembolism	B-Disease	D013923
with	O	O
subsequent	O	O
clot	O	O
lysis	O	O
has	O	O
been	O	O
suggested	O	O
as	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
causes	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
during	O	O
pregnancy	O	O
,	O	O
with	O	O
a	O	O
subsequently	O	O
normal	O	O
coronary	O	O
angiogram	O	O
.	O	O

CASE	O	O
:	O	O
A	O	O
33	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
5	O	O
-	O	O
week	O	O
gestation	O	O
had	O	O
recently	O	O
received	O	O
CC	B-Chemical	D002996
for	O	O
ovulation	O	O
induction	O	O
and	O	O
presented	O	O
with	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

An	O	O
electrocardiogram	O	O
showed	O	O
a	O	O
lateral	O	O
and	O	O
anterior	O	O
wall	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Cardiac	O	O
enzymes	O	O
showed	O	O
a	O	O
peak	O	O
rise	O	O
in	O	O
troponin	O	O
I	O	O
to	O	O
9	O	O
.	O	O

10	O	O
ng	O	O
/	O	O
mL	O	O
.	O	O

An	O	O
initial	O	O
exercise	O	O
stress	O	O
test	O	O
was	O	O
normal	O	O
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
admission	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
at	O	O
high	O	O
risk	O	O
of	O	O
radiation	B-Disease	D011832
injury	I-Disease	D011832
to	O	O
the	O	O
fetus	O	O
,	O	O
so	O	O
a	O	O
coronary	O	O
angiogram	O	O
was	O	O
postponed	O	O
until	O	O
the	O	O
second	O	O
trimester	O	O
.	O	O

It	O	O
showed	O	O
normal	O	O
coronary	O	O
vessels	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
documenting	O	O
a	O	O
possible	O	O
association	O	O
between	O	O
CC	B-Chemical	D002996
and	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Thrombosis	B-Disease	D013927
might	O	O
be	O	O
a	O	O
rare	O	O
but	O	O
hazardous	O	O
complication	O	O
of	O	O
CC	B-Chemical	D002996
.	O	O

Given	O	O
this	O	O
life	O	O
-	O	O
threatening	O	O
complication	O	O
,	O	O
appropriate	O	O
prophylactic	O	O
measures	O	O
should	O	O
be	O	O
used	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
woman	O	O
undergoing	O	O
ovarian	O	O
stimulation	O	O
.	O	O

Hepatonecrosis	B-Disease	-1
and	O	O
cholangitis	B-Disease	D002761
related	O	O
to	O	O
long	O	O
-	O	O
term	O	O
phenobarbital	B-Chemical	D010634
therapy	O	O
:	O	O
an	O	O
autopsy	O	O
report	O	O
of	O	O
two	O	O
patients	O	O
.	O	O

Phenobarbital	B-Chemical	D010634
(	O	O
PB	B-Chemical	D010634
)	O	O
has	O	O
a	O	O
reputation	O	O
for	O	O
safety	O	O
,	O	O
and	O	O
it	O	O
is	O	O
commonly	O	O
believed	O	O
that	O	O
PB	B-Chemical	D010634
-	O	O
related	O	O
increases	O	O
in	O	O
serum	O	O
aminotransferase	O	O
levels	O	O
do	O	O
not	O	O
indicate	O	O
or	O	O
predict	O	O
the	O	O
development	O	O
of	O	O
significant	O	O
chronic	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

Here	O	O
we	O	O
report	O	O
of	O	O
two	O	O
adult	O	O
patients	O	O
with	O	O
a	O	O
long	O	O
history	O	O
of	O	O
epilepsy	B-Disease	D004827
treated	O	O
with	O	O
PB	B-Chemical	D010634
who	O	O
died	O	O
suddenly	O	O
:	O	O
one	O	O
as	O	O
consequence	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
,	O	O
the	O	O
other	O	O
of	O	O
acute	O	O
bronchopneumonia	B-Disease	D001996
.	O	O

At	O	O
autopsy	O	O
,	O	O
analysis	O	O
of	O	O
liver	O	O
parenchyma	O	O
revealed	O	O
rich	O	O
portal	O	O
inflammatory	O	O
infiltrate	O	O
,	O	O
which	O	O
consisted	O	O
of	O	O
mixed	O	O
eosinophil	O	O
and	O	O
monocyte	O	O
cells	O	O
,	O	O
associated	O	O
with	O	O
several	O	O
foci	O	O
of	O	O
necrosis	B-Disease	D009336
surrounded	O	O
by	O	O
a	O	O
hard	O	O
ring	O	O
of	O	O
non	O	O
-	O	O
specific	O	O
granulomatous	O	O
tissue	O	O
.	O	O

Inflammatory	O	O
reactions	O	O
of	O	O
internal	O	O
and	O	O
external	O	O
hepatic	O	O
biliary	O	O
ducts	O	O
were	O	O
also	O	O
seen	O	O
.	O	O

Our	O	O
findings	O	O
illustrate	O	O
that	O	O
PB	B-Chemical	D010634
may	O	O
be	O	O
associated	O	O
with	O	O
chronic	O	O
liver	B-Disease	D008107
damage	I-Disease	D008107
,	O	O
which	O	O
may	O	O
lead	O	O
to	O	O
more	O	O
serious	O	O
and	O	O
deleterious	O	O
consequences	O	O
.	O	O

For	O	O
this	O	O
reason	O	O
,	O	O
each	O	O
clinician	O	O
should	O	O
recognize	O	O
this	O	O
entity	O	O
in	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
PB	B-Chemical	D010634
-	O	O
related	O	O
asymptomatic	O	O
chronic	B-Disease	D056487
hepatic	I-Disease	D056487
enzyme	I-Disease	D056487
dysfunction	I-Disease	D056487
.	O	O

Ethambutol	B-Chemical	D004977
-	O	O
associated	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

INTRODUCTION	O	O
:	O	O
Ethambutol	B-Chemical	D004977
is	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
tuberculosis	B-Disease	D014376
,	O	O
which	O	O
is	O	O
still	O	O
prevalent	O	O
in	O	O
Southeast	O	O
Asia	O	O
,	O	O
and	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
permanent	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
.	O	O

We	O	O
report	O	O
3	O	O
cases	O	O
which	O	O
presented	O	O
with	O	O
bitemporal	B-Disease	D006423
hemianopia	I-Disease	D006423
.	O	O

CLINICAL	O	O
PICTURE	O	O
:	O	O
Three	O	O
patients	O	O
with	O	O
ethambutol	B-Chemical	D004977
-	O	O
associated	O	O
toxic	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
are	O	O
described	O	O
.	O	O

All	O	O
3	O	O
patients	O	O
had	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
central	I-Disease	D014786
visual	I-Disease	D014786
acuity	I-Disease	D014786
,	I-Disease	D014786
colour	I-Disease	D014786
vision	I-Disease	D014786
(	I-Disease	D014786
Ishihara	I-Disease	D014786
)	I-Disease	D014786
and	I-Disease	D014786
visual	I-Disease	D014786
field	I-Disease	D014786
.	O	O

The	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
loss	I-Disease	D014786
had	O	O
a	O	O
bitemporal	O	O
flavour	O	O
,	O	O
suggesting	O	O
involvement	O	O
of	O	O
the	O	O
optic	O	O
chiasm	O	O
.	O	O

TREATMENT	O	O
:	O	O
Despite	O	O
stopping	O	O
ethambutol	B-Chemical	D004977
on	O	O
diagnosis	O	O
,	O	O
visual	O	O
function	O	O
continued	O	O
to	O	O
deteriorate	O	O
for	O	O
a	O	O
few	O	O
months	O	O
.	O	O

Subsequent	O	O
improvement	O	O
was	O	O
mild	O	O
in	O	O
2	O	O
cases	O	O
.	O	O

In	O	O
the	O	O
third	O	O
case	O	O
,	O	O
visual	O	O
acuity	O	O
and	O	O
colour	O	O
vision	O	O
normalised	O	O
but	O	O
the	O	O
optic	O	O
discs	O	O
were	O	O
pale	O	O
.	O	O

OUTCOME	O	O
:	O	O
All	O	O
3	O	O
patients	O	O
had	O	O
some	O	O
permanent	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
visual	I-Disease	D014786
function	I-Disease	D014786
.	O	O

CONCLUSIONS	O	O
:	O	O
Ethambutol	B-Chemical	D004977
usage	O	O
is	O	O
associated	O	O
with	O	O
permanent	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
and	O	O
should	O	O
be	O	O
avoided	O	O
if	O	O
possible	O	O
or	O	O
used	O	O
with	O	O
caution	O	O
and	O	O
proper	O	O
ophthalmological	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

The	O	O
author	O	O
postulates	O	O
that	O	O
in	O	O
cases	O	O
of	O	O
ethambutol	B-Chemical	D004977
associated	O	O
chiasmopathy	O	O
,	O	O
ethambutol	B-Chemical	D004977
may	O	O
initially	O	O
affect	O	O
the	O	O
optic	O	O
nerves	O	O
and	O	O
subsequently	O	O
progress	O	O
to	O	O
involve	O	O
the	O	O
optic	O	O
chiasm	O	O
.	O	O

Tolerability	O	O
of	O	O
nimesulide	B-Chemical	C012655
and	O	O
paracetamol	B-Chemical	D000082
in	O	O
patients	O	O
with	O	O
NSAID	B-Chemical	D000894
-	O	O
induced	O	O
urticaria	B-Disease	D014581
/	O	O
angioedema	B-Disease	D000799
.	O	O

Previous	O	O
studies	O	O
evaluated	O	O
the	O	O
tolerance	O	O
of	O	O
nimesulide	B-Chemical	C012655
and	O	O
paracetamol	B-Chemical	D000082
in	O	O
subjects	O	O
with	O	O
cutaneous	O	O
,	O	O
respiratory	O	O
and	O	O
anaphylactoid	O	O
reactions	O	O
induced	O	O
by	O	O
nonsteroidal	B-Chemical	D000894
anti	I-Chemical	D000894
-	I-Chemical	D000894
inflammatory	I-Chemical	D000894
drugs	I-Chemical	D000894
(	O	O
NSAIDs	B-Chemical	D000894
)	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
investigated	O	O
tolerability	O	O
and	O	O
reliability	O	O
of	O	O
nimesulide	B-Chemical	C012655
and	O	O
paracetamol	B-Chemical	D000082
in	O	O
a	O	O
very	O	O
large	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
an	O	O
exclusive	O	O
well	O	O
-	O	O
documented	O	O
history	O	O
of	O	O
NSAID	B-Chemical	D000894
-	O	O
induced	O	O
urticaria	B-Disease	D014581
/	O	O
angioedema	B-Disease	D000799
.	O	O

Furthermore	O	O
,	O	O
we	O	O
evaluated	O	O
whether	O	O
some	O	O
factors	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
reaction	O	O
to	O	O
paracetamol	B-Chemical	D000082
and	O	O
nimesulide	B-Chemical	C012655
.	O	O

A	O	O
single	O	O
-	O	O
placebo	O	O
-	O	O
controlled	O	O
oral	O	O
challenge	O	O
procedure	O	O
with	O	O
nimesulide	B-Chemical	C012655
or	O	O
paracetamol	B-Chemical	D000082
was	O	O
applied	O	O
to	O	O
829	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
NSAID	B-Chemical	D000894
-	O	O
induced	O	O
urticaria	B-Disease	D014581
/	O	O
angioedema	B-Disease	D000799
.	O	O

A	O	O
total	O	O
of	O	O
75	O	O
/	O	O
829	O	O
(	O	O
9	O	O
.	O	O

4%	O	O
)	O	O
patients	O	O
experienced	O	O
reactions	O	O
to	O	O
nimesulide	B-Chemical	C012655
or	O	O
paracetamol	B-Chemical	D000082
.	O	O

Of	O	O
the	O	O
715	O	O
patients	O	O
tested	O	O
with	O	O
nimesulide	B-Chemical	C012655
62	O	O
(	O	O
8	O	O
.	O	O

6%	O	O
)	O	O
showed	O	O
a	O	O
positive	O	O
test	O	O
,	O	O
while	O	O
of	O	O
114	O	O
subjects	O	O
submitted	O	O
to	O	O
the	O	O
challenge	O	O
with	O	O
paracetamol	B-Chemical	D000082
,	O	O
13	O	O
(	O	O
9	O	O
.	O	O

6%	O	O
)	O	O
did	O	O
not	O	O
tolerate	O	O
this	O	O
drug	O	O
.	O	O

Furthermore	O	O
,	O	O
18	O	O
.	O	O

28%	O	O
of	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
chronic	O	O
urticaria	B-Disease	D014581
and	O	O
11	O	O
.	O	O

8%	O	O
of	O	O
subjects	O	O
with	O	O
an	O	O
history	O	O
of	O	O
NSAID	B-Chemical	D000894
-	O	O
induced	O	O
urticaria	B-Disease	D014581
/	O	O
angioedema	B-Disease	D000799
or	O	O
angioedema	B-Disease	D000799
alone	O	O
(	O	O
with	O	O
or	O	O
without	O	O
chronic	O	O
urticaria	B-Disease	D014581
)	O	O
resulted	O	O
to	O	O
be	O	O
intolerant	O	O
to	O	O
alternative	O	O
drugs	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
results	O	O
confirm	O	O
the	O	O
good	O	O
tolerability	O	O
of	O	O
nimesulide	B-Chemical	C012655
and	O	O
paracetamol	B-Chemical	D000082
in	O	O
patients	O	O
who	O	O
experienced	O	O
urticaria	B-Disease	D014581
/	O	O
angioedema	B-Disease	D000799
caused	O	O
by	O	O
NSAIDs	B-Chemical	D000894
.	O	O

However	O	O
,	O	O
the	O	O
risk	O	O
of	O	O
reaction	O	O
to	O	O
these	O	O
alternative	O	O
study	O	O
drugs	O	O
is	O	O
statistically	O	O
increased	O	O
by	O	O
a	O	O
history	O	O
of	O	O
chronic	O	O
urticaria	B-Disease	D014581
and	O	O
,	O	O
above	O	O
all	O	O
,	O	O
by	O	O
a	O	O
history	O	O
of	O	O
NSAID	B-Chemical	D000894
-	O	O
induced	O	O
angioedema	B-Disease	D000799
.	O	O

Effects	O	O
of	O	O
verapamil	B-Chemical	D014700
on	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
and	O	O
its	O	O
electrophysiological	O	O
determinants	O	O
in	O	O
dogs	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Atrial	B-Disease	D013617
tachycardia	I-Disease	D013617
-	O	O
induced	O	O
remodeling	O	O
promotes	O	O
the	O	O
occurrence	O	O
and	O	O
maintenance	O	O
of	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
(	O	O
AF	B-Disease	D001281
)	O	O
and	O	O
decreases	O	O
L	O	O
-	O	O
type	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
current	O	O
.	O	O

There	O	O
is	O	O
also	O	O
a	O	O
clinical	O	O
suggestion	O	O
that	O	O
acute	O	O
L	O	O
-	O	O
type	O	O
Ca	B-Chemical	D002118
(	O	O
2	O	O
)	O	O
channel	O	O
blockade	O	O
can	O	O
promote	O	O
AF	B-Disease	D001281
,	O	O
consistent	O	O
with	O	O
an	O	O
AF	B-Disease	D001281
promoting	O	O
effect	O	O
of	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
channel	O	O
inhibition	O	O
.	O	O

METHODS	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
potential	O	O
mechanisms	O	O
of	O	O
AF	B-Disease	D001281
promotion	O	O
by	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
channel	O	O
blockers	O	O
,	O	O
we	O	O
administered	O	O
verapamil	B-Chemical	D014700
to	O	O
morphine	B-Chemical	D009020
-	O	O
chloralose	B-Chemical	D002698
anesthetized	O	O
dogs	O	O
.	O	O

Diltiazem	B-Chemical	D004110
was	O	O
used	O	O
as	O	O
a	O	O
comparison	O	O
drug	O	O
and	O	O
autonomic	O	O
blockade	O	O
with	O	O
atropine	B-Chemical	D001285
and	O	O
nadolol	B-Chemical	D009248
was	O	O
applied	O	O
in	O	O
some	O	O
experiments	O	O
.	O	O

Epicardial	O	O
mapping	O	O
with	O	O
240	O	O
epicardial	O	O
electrodes	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
activation	O	O
during	O	O
AF	B-Disease	D001281
.	O	O

RESULTS	O	O
:	O	O
Verapamil	B-Chemical	D014700
caused	O	O
AF	B-Disease	D001281
promotion	O	O
in	O	O
six	O	O
dogs	O	O
,	O	O
increasing	O	O
mean	O	O
duration	O	O
of	O	O
AF	B-Disease	D001281
induced	O	O
by	O	O
burst	O	O
pacing	O	O
,	O	O
from	O	O
8+	O	O
/	O	O
-	O	O
4	O	O
s	O	O
(	O	O
mean+	O	O
/	O	O
-	O	O
S	O	O
.	O	O

E	O	O
.	O	O

)	O	O
to	O	O
95+	O	O
/	O	O
-	O	O
39	O	O
s	O	O
(	O	O
P<0	O	O
.	O	O

01	O	O
vs	O	O
.	O	O

control	O	O
)	O	O
at	O	O
a	O	O
loading	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
228+	O	O
/	O	O
-	O	O
101	O	O
s	O	O
(	O	O
P<0	O	O
.	O	O

0005	O	O
vs	O	O
.	O	O

control	O	O
)	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Underlying	O	O
electrophysiological	O	O
mechanisms	O	O
were	O	O
studied	O	O
in	O	O
detail	O	O
in	O	O
five	O	O
additional	O	O
dogs	O	O
under	O	O
control	O	O
conditions	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
verapamil	B-Chemical	D014700
.	O	O

In	O	O
these	O	O
experiments	O	O
,	O	O
verapamil	B-Chemical	D014700
shortened	O	O
mean	O	O
effective	O	O
refractory	O	O
period	O	O
(	O	O
ERP	O	O
)	O	O
from	O	O
122+	O	O
/	O	O
-	O	O
5	O	O
to	O	O
114+	O	O
/	O	O
-	O	O
4	O	O
ms	O	O
(	O	O
P<0	O	O
.	O	O

02	O	O
)	O	O
at	O	O
a	O	O
cycle	O	O
length	O	O
of	O	O
300	O	O
ms	O	O
,	O	O
decreased	O	O
ERP	O	O
heterogeneity	O	O
(	O	O
from	O	O
15+	O	O
/	O	O
-	O	O
1	O	O
to	O	O
10+	O	O
/	O	O
-	O	O
1%	O	O
,	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
heterogeneously	O	O
accelerated	O	O
atrial	O	O
conduction	O	O
and	O	O
decreased	O	O
the	O	O
cycle	O	O
length	O	O
of	O	O
AF	B-Disease	D001281
(	O	O
94+	O	O
/	O	O
-	O	O
4	O	O
to	O	O
84+	O	O
/	O	O
-	O	O
3	O	O
ms	O	O
,	O	O
P<0	O	O
.	O	O

005	O	O
)	O	O
.	O	O

Diltiazem	B-Chemical	D004110
did	O	O
not	O	O
affect	O	O
ERP	O	O
,	O	O
AF	B-Disease	D001281
cycle	O	O
length	O	O
or	O	O
AF	B-Disease	D001281
duration	O	O
,	O	O
but	O	O
produced	O	O
conduction	O	O
acceleration	O	O
similar	O	O
to	O	O
that	O	O
caused	O	O
by	O	O
verapamil	B-Chemical	D014700
(	O	O
n=5	O	O
)	O	O
.	O	O

In	O	O
the	O	O
presence	O	O
of	O	O
autonomic	O	O
blockade	O	O
,	O	O
verapamil	B-Chemical	D014700
failed	O	O
to	O	O
promote	O	O
AF	B-Disease	D001281
and	O	O
increased	O	O
,	O	O
rather	O	O
than	O	O
decreasing	O	O
,	O	O
refractoriness	O	O
.	O	O

Neither	O	O
verapamil	B-Chemical	D014700
nor	O	O
diltiazem	B-Chemical	D004110
affected	O	O
atrial	O	O
conduction	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
autonomic	O	O
blockade	O	O
.	O	O

Epicardial	O	O
mapping	O	O
suggested	O	O
that	O	O
verapamil	B-Chemical	D014700
promoted	O	O
AF	B-Disease	D001281
by	O	O
increasing	O	O
the	O	O
number	O	O
of	O	O
simultaneous	O	O
wavefronts	O	O
reflected	O	O
by	O	O
separate	O	O
zones	O	O
of	O	O
reactivation	O	O
in	O	O
each	O	O
cycle	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Verapamil	B-Chemical	D014700
promotes	O	O
AF	B-Disease	D001281
in	O	O
normal	O	O
dogs	O	O
by	O	O
promoting	O	O
multiple	O	O
circuit	O	O
reentry	O	O
,	O	O
an	O	O
effect	O	O
dependent	O	O
on	O	O
intact	O	O
autonomic	O	O
tone	O	O
and	O	O
not	O	O
shared	O	O
by	O	O
diltiazem	B-Chemical	D004110
.	O	O

Hypotension	B-Disease	D007022
,	O	O
bradycardia	B-Disease	D001919
,	O	O
and	O	O
asystole	B-Disease	D006323
after	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
methylprednisolone	B-Chemical	D008775
in	O	O
a	O	O
monitored	O	O
patient	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
hypotension	B-Disease	D007022
,	O	O
bradycardia	B-Disease	D001919
,	O	O
and	O	O
asystole	B-Disease	D006323
after	O	O
intravenous	O	O
administration	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-Chemical	D008775
in	O	O
a	O	O
73	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
who	O	O
underwent	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
monitoring	O	O
throughout	O	O
the	O	O
episode	O	O
.	O	O

There	O	O
was	O	O
a	O	O
history	O	O
of	O	O
ischemic	B-Disease	D007511
cardiac	B-Disease	D006331
disease	I-Disease	D006331
9	O	O
years	O	O
earlier	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
admitted	O	O
with	O	O
a	O	O
pulmonary	B-Disease	C538458
-	I-Disease	C538458
renal	I-Disease	C538458
syndrome	I-Disease	C538458
with	O	O
hemoptysis	B-Disease	D006469
,	O	O
rapidly	O	O
progressive	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
and	O	O
hypoxemia	B-Disease	D000860
that	O	O
required	O	O
mechanical	O	O
ventilation	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

After	O	O
receiving	O	O
advanced	O	O
cardiopulmonary	O	O
resuscitation	O	O
,	O	O
the	O	O
patient	O	O
recovered	O	O
cardiac	O	O
rhythm	O	O
.	O	O

The	O	O
ECG	O	O
showed	O	O
a	O	O
junctional	O	O
rhythm	O	O
without	O	O
ventricular	B-Disease	D001145
arrhythmia	I-Disease	D001145
.	O	O

This	O	O
study	O	O
reviews	O	O
the	O	O
current	O	O
proposed	O	O
mechanisms	O	O
of	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
after	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
intravenous	O	O
methylprednisolone	B-Chemical	D008775
(	O	O
IVMP	B-Chemical	D008775
)	O	O
.	O	O

These	O	O
mechanisms	O	O
are	O	O
not	O	O
well	O	O
understood	O	O
because	O	O
,	O	O
in	O	O
most	O	O
cases	O	O
,	O	O
the	O	O
patients	O	O
were	O	O
not	O	O
monitored	O	O
at	O	O
the	O	O
moment	O	O
of	O	O
the	O	O
event	O	O
.	O	O

Rapid	O	O
infusion	O	O
and	O	O
underlying	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
were	O	O
important	O	O
risk	O	O
factors	O	O
in	O	O
the	O	O
case	O	O
reported	O	O
here	O	O
,	O	O
and	O	O
the	O	O
authors	O	O
discount	O	O
ventricular	B-Disease	D001145
arrhythmia	I-Disease	D001145
as	O	O
the	O	O
main	O	O
mechanism	O	O
.	O	O

Lifetime	O	O
treatment	O	O
of	O	O
mice	O	O
with	O	O
azidothymidine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
produces	O	O
myelodysplasia	B-Disease	D009190
.	O	O

AZT	B-Chemical	D015215
has	O	O
induced	O	O
a	O	O
macrocytic	B-Disease	D000748
anemia	I-Disease	D000748
in	O	O
AIDS	B-Disease	D000163
patients	O	O
on	O	O
long	O	O
term	O	O
AZT	B-Chemical	D015215
therapy	O	O
.	O	O

It	O	O
is	O	O
generally	O	O
assumed	O	O
that	O	O
DNA	O	O
elongation	O	O
is	O	O
stopped	O	O
by	O	O
the	O	O
insertion	O	O
of	O	O
AZT	B-Chemical	D015215
into	O	O
the	O	O
chain	O	O
in	O	O
place	O	O
of	O	O
thymidine	B-Chemical	D013936
thus	O	O
preventing	O	O
the	O	O
phosphate	B-Chemical	D010710
hydroxyl	O	O
linkages	O	O
and	O	O
therefore	O	O
suppresses	O	O
hemopoietic	O	O
progenitor	O	O
cell	O	O
proliferation	O	O
in	O	O
an	O	O
early	O	O
stage	O	O
of	O	O
differentiation	O	O
.	O	O

CBA	O	O
/	O	O
Ca	O	O
male	O	O
mice	O	O
started	O	O
on	O	O
AZT	B-Chemical	D015215
0	O	O
.	O	O

75	O	O
mg	O	O
/	O	O
ml	O	O
H2O	O	O
at	O	O
84	O	O
days	O	O
of	O	O
age	O	O
and	O	O
kept	O	O
on	O	O
it	O	O
for	O	O
687	O	O
days	O	O
when	O	O
dosage	O	O
reduced	O	O
to	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
ml	O	O
H2O	O	O
for	O	O
a	O	O
group	O	O
,	O	O
another	O	O
group	O	O
removed	O	O
from	O	O
AZT	B-Chemical	D015215
to	O	O
see	O	O
recovery	O	O
,	O	O
and	O	O
third	O	O
group	O	O
remained	O	O
on	O	O
0	O	O
.	O	O

75	O	O
mg	O	O
.	O	O

At	O	O
687	O	O
days	O	O
mice	O	O
that	O	O
had	O	O
been	O	O
on	O	O
0	O	O
.	O	O

75	O	O
mg	O	O
had	O	O
average	O	O
platelet	O	O
counts	O	O
of	O	O
2	O	O
.	O	O

5	O	O
x	O	O
10	O	O
(	O	O
6	O	O
)	O	O
.	O	O

Histological	O	O
examination	O	O
on	O	O
9	O	O
of	O	O
10	O	O
mice	O	O
with	O	O
such	O	O
thrombocytopenia	B-Disease	D013921
showed	O	O
changes	O	O
compatible	O	O
with	O	O
myelodysplastic	B-Disease	D009190
syndrome	I-Disease	D009190
(	O	O
MDS	B-Disease	D009190
)	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
histological	O	O
patterns	O	O
was	O	O
observed	O	O
.	O	O

There	O	O
were	O	O
two	O	O
cases	O	O
of	O	O
hypocellular	O	O
myelodysplasia	B-Disease	D009190
,	O	O
two	O	O
cases	O	O
of	O	O
hypersegmented	O	O
myelodysplastic	B-Disease	D009190
granulocytosis	O	O
,	O	O
two	O	O
cases	O	O
of	O	O
hypercellular	O	O
marrow	O	O
with	O	O
abnormal	O	O
megakaryocytes	O	O
with	O	O
bizarre	O	O
nuclei	O	O
,	O	O
one	O	O
case	O	O
of	O	O
megakaryocytic	O	O
myelosis	O	O
associated	O	O
with	O	O
a	O	O
hyperplastic	B-Disease	D001855
marrow	I-Disease	D001855
,	O	O
dysmyelopoiesis	B-Disease	D009190
and	O	O
a	O	O
hypocellular	B-Disease	D001855
marrow	I-Disease	D001855
and	O	O
two	O	O
cases	O	O
of	O	O
myelodysplasia	B-Disease	D009190
with	O	O
dyserythropoiesis	B-Disease	-1
,	O	O
hemosiderosis	B-Disease	D006486
and	O	O
a	O	O
hypocellular	B-Disease	D001855
marrow	I-Disease	D001855
.	O	O

Above	O	O
mentioned	O	O
AZT	B-Chemical	D015215
incorporation	O	O
may	O	O
have	O	O
induced	O	O
an	O	O
ineffective	O	O
hemopoiesis	O	O
in	O	O
the	O	O
primitive	O	O
hemopoietic	O	O
progenitor	O	O
cells	O	O
,	O	O
which	O	O
is	O	O
known	O	O
to	O	O
be	O	O
seen	O	O
commonly	O	O
in	O	O
the	O	O
myelodysplastic	B-Disease	D009190
syndrome	I-Disease	D009190
.	O	O

Influence	O	O
of	O	O
diet	O	O
free	O	O
of	O	O
NAD	B-Chemical	D009243
-	O	O
precursors	O	O
on	O	O
acetaminophen	B-Chemical	D000082
hepatotoxicity	B-Disease	D056486
in	O	O
mice	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
demonstrated	O	O
the	O	O
hepatoprotective	O	O
effects	O	O
of	O	O
nicotinic	B-Chemical	D009536
acid	I-Chemical	D009536
amide	I-Chemical	D009536
,	O	O
a	O	O
selective	O	O
inhibitor	O	O
of	O	O
poly	B-Chemical	D011064
(	I-Chemical	D011064
ADP	I-Chemical	D011064
-	I-Chemical	D011064
ribose	I-Chemical	D011064
)	I-Chemical	D011064
polymerase	O	O
(	O	O
PARP	O	O
;	O	O
EC	O	O
2	O	O
.	O	O

4	O	O
.	O	O

2	O	O
.	O	O

30	O	O
)	O	O
on	O	O
mice	O	O
suffering	O	O
from	O	O
acetaminophen	B-Chemical	D000082
(	O	O
AAP	B-Chemical	D000082
)	O	O
-	O	O
hepatitis	B-Disease	D056486
,	O	O
suggesting	O	O
that	O	O
the	O	O
AAP	B-Chemical	D000082
-	O	O
induced	O	O
liver	B-Disease	D056486
injury	I-Disease	D056486
involves	O	O
a	O	O
step	O	O
which	O	O
depends	O	O
on	O	O
adenoribosylation	O	O
.	O	O

The	O	O
present	O	O
study	O	O
investigates	O	O
the	O	O
effects	O	O
of	O	O
a	O	O
diet	O	O
free	O	O
of	O	O
precursors	O	O
of	O	O
NAD	B-Chemical	D009243
,	O	O
the	O	O
substrate	O	O
on	O	O
which	O	O
PARP	O	O
acts	O	O
,	O	O
in	O	O
female	O	O
NMRI	O	O
mice	O	O
with	O	O
AAP	B-Chemical	D000082
hepatitis	B-Disease	D056486
and	O	O
evaluates	O	O
the	O	O
influence	O	O
of	O	O
simultaneous	O	O
ethanol	B-Chemical	D000431
consumption	O	O
in	O	O
these	O	O
animals	O	O
.	O	O

Liver	B-Disease	D056486
injuries	I-Disease	D056486
were	O	O
quantified	O	O
as	O	O
serum	O	O
activities	O	O
of	O	O
glutamate	B-Chemical	D018698
-	O	O
oxaloacetate	B-Chemical	D062907
transaminase	O	O
(	O	O
GOT	O	O
)	O	O
and	O	O
glutamate	B-Chemical	D018698
-	O	O
pyruvate	B-Chemical	D019289
transaminase	O	O
(	O	O
GPT	O	O
)	O	O
.	O	O

While	O	O
AAP	B-Chemical	D000082
caused	O	O
a	O	O
117	O	O
-	O	O
fold	O	O
elevation	O	O
of	O	O
serum	O	O
transaminase	O	O
activities	O	O
in	O	O
mice	O	O
kept	O	O
on	O	O
a	O	O
standard	O	O
laboratory	O	O
diet	O	O
,	O	O
which	O	O
was	O	O
significantly	O	O
exacerbated	O	O
by	O	O
ethanol	B-Chemical	D000431
and	O	O
inhibited	O	O
by	O	O
nicotinic	B-Chemical	D009536
acid	I-Chemical	D009536
amide	I-Chemical	D009536
(	O	O
NAA	B-Chemical	D009536
)	O	O
,	O	O
adverse	O	O
effects	O	O
were	O	O
noted	O	O
in	O	O
animals	O	O
fed	O	O
a	O	O
diet	O	O
free	O	O
of	O	O
precursors	O	O
of	O	O
NAD	B-Chemical	D009243
.	O	O

In	O	O
these	O	O
animals	O	O
,	O	O
only	O	O
minor	O	O
increases	O	O
of	O	O
serum	O	O
transaminase	O	O
activities	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
AAP	B-Chemical	D000082
,	O	O
and	O	O
unlike	O	O
the	O	O
exacerbation	O	O
caused	O	O
by	O	O
ethanol	B-Chemical	D000431
in	O	O
mice	O	O
on	O	O
a	O	O
standard	O	O
diet	O	O
,	O	O
the	O	O
liver	B-Disease	D056486
damage	I-Disease	D056486
was	O	O
inhibited	O	O
by	O	O
50%	O	O
by	O	O
ethanol	B-Chemical	D000431
.	O	O

A	O	O
further	O	O
64%	O	O
reduction	O	O
of	O	O
hepatitis	B-Disease	D056486
was	O	O
observed	O	O
,	O	O
when	O	O
NAA	B-Chemical	D009536
was	O	O
given	O	O
to	O	O
ethanol	B-Chemical	D000431
/	O	O
AAP	B-Chemical	D000082
-	O	O
mice	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
evidence	O	O
that	O	O
the	O	O
AAP	B-Chemical	D000082
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
and	O	O
its	O	O
exacerbation	O	O
by	O	O
ethanol	B-Chemical	D000431
can	O	O
either	O	O
be	O	O
reduced	O	O
by	O	O
end	O	O
-	O	O
product	O	O
inhibition	O	O
of	O	O
PARP	O	O
by	O	O
NAA	B-Chemical	D009536
or	O	O
by	O	O
dietary	O	O
depletion	O	O
of	O	O
the	O	O
enzyme's	O	O
substrate	O	O
NAD	B-Chemical	D009243
.	O	O

We	O	O
see	O	O
the	O	O
main	O	O
application	O	O
of	O	O
NAA	B-Chemical	D009536
as	O	O
for	O	O
the	O	O
combinational	O	O
use	O	O
in	O	O
pharmaceutical	O	O
preparations	O	O
of	O	O
acetaminophen	B-Chemical	D000082
in	O	O
order	O	O
to	O	O
avoid	O	O
hepatic	B-Disease	D056486
damage	I-Disease	D056486
in	O	O
patients	O	O
treated	O	O
with	O	O
this	O	O
widely	O	O
used	O	O
analgesic	O	O
.	O	O

Antiarrhythmic	O	O
plasma	O	O
concentrations	O	O
of	O	O
cibenzoline	B-Chemical	C032151
on	O	O
canine	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

Using	O	O
two	O	O
-	O	O
stage	O	O
coronary	O	O
ligation	O	O
-	O	O
,	O	O
digitalis	B-Chemical	D004071
-	O	O
,	O	O
and	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
canine	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
,	O	O
antiarrhythmic	O	O
effects	O	O
of	O	O
cibenzoline	B-Chemical	C032151
were	O	O
examined	O	O
and	O	O
the	O	O
minimum	O	O
effective	O	O
plasma	O	O
concentration	O	O
for	O	O
each	O	O
arrhythmia	B-Disease	D001145
model	O	O
was	O	O
determined	O	O
.	O	O

Cibenzoline	B-Chemical	C032151
suppressed	O	O
all	O	O
the	O	O
arrhythmias	B-Disease	D001145
,	O	O
and	O	O
the	O	O
minimum	O	O
effective	O	O
plasma	O	O
concentrations	O	O
for	O	O
arrhythmias	B-Disease	D001145
induced	O	O
by	O	O
24	O	O
-	O	O
h	O	O
coronary	O	O
ligation	O	O
,	O	O
48	O	O
-	O	O
h	O	O
coronary	O	O
ligation	O	O
,	O	O
digitalis	B-Chemical	D004071
,	O	O
and	O	O
adrenaline	B-Chemical	D004837
were	O	O
1	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
(	O	O
by	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
,	O	O
1	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
(	O	O
by	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
,	O	O
0	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
(	O	O
by	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
,	O	O
and	O	O
3	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
(	O	O
by	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
micrograms	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SDM	O	O
,	O	O
n	O	O
=	O	O
6	O	O
-	O	O
7	O	O
)	O	O
.	O	O

The	O	O
concentration	O	O
for	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
arrhythmia	B-Disease	D001145
was	O	O
significantly	O	O
higher	O	O
than	O	O
those	O	O
for	O	O
the	O	O
other	O	O
types	O	O
of	O	O
arrhythmias	B-Disease	D001145
.	O	O

This	O	O
pharmacological	O	O
profile	O	O
is	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
mexiletine	B-Chemical	D008801
and	O	O
tocainide	B-Chemical	D016677
,	O	O
and	O	O
all	O	O
three	O	O
drugs	O	O
have	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
stimulant	O	O
action	O	O
.	O	O

Because	O	O
cibenzoline	B-Chemical	C032151
had	O	O
only	O	O
weak	O	O
hypotensive	B-Disease	D007022
and	O	O
sinus	O	O
node	O	O
depressive	B-Disease	D003866
effects	O	O
and	O	O
was	O	O
found	O	O
to	O	O
be	O	O
orally	O	O
active	O	O
when	O	O
given	O	O
to	O	O
coronary	O	O
ligation	O	O
arrhythmia	B-Disease	D001145
dogs	O	O
,	O	O
its	O	O
clinical	O	O
usefulness	O	O
is	O	O
expected	O	O
.	O	O

Immunopathology	O	O
of	O	O
penicillamine	B-Chemical	D010396
-	O	O
induced	O	O
glomerular	B-Disease	D007674
disease	I-Disease	D007674
.	O	O

Four	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
developed	O	O
heavy	O	O
proteinuria	B-Disease	D011507
after	O	O
five	O	O
to	O	O
12	O	O
months	O	O
of	O	O
treatment	O	O
with	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
.	O	O

Light	O	O
microscopy	O	O
of	O	O
renal	O	O
biopsy	O	O
samples	O	O
showed	O	O
minimal	O	O
glomerular	O	O
capillary	O	O
wall	O	O
thickening	O	O
and	O	O
mesangial	O	O
matrix	O	O
increase	O	O
,	O	O
or	O	O
no	O	O
departure	O	O
from	O	O
normal	O	O
.	O	O

Electron	O	O
microscopy	O	O
,	O	O
however	O	O
,	O	O
revealed	O	O
subepithelial	O	O
electron	O	O
-	O	O
dense	O	O
deposits	O	O
,	O	O
fusion	O	O
of	O	O
epithelial	O	O
cell	O	O
foot	O	O
processes	O	O
,	O	O
and	O	O
evidence	O	O
of	O	O
mesangial	O	O
cell	O	O
hyperactivity	O	O
.	O	O

Immunofluorescence	O	O
microscopy	O	O
demonstrated	O	O
granular	O	O
capillary	O	O
wall	O	O
deposits	O	O
of	O	O
IgG	O	O
and	O	O
C3	O	O
.	O	O

The	O	O
findings	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
in	O	O
early	O	O
membranous	B-Disease	D015433
glomerulonephritis	I-Disease	D015433
,	O	O
differences	O	O
being	O	O
observed	O	O
however	O	O
in	O	O
the	O	O
results	O	O
of	O	O
staining	O	O
for	O	O
the	O	O
early	O	O
-	O	O
acting	O	O
complement	O	O
components	O	O
C1q	O	O
and	O	O
C4	O	O
.	O	O

It	O	O
is	O	O
tentatively	O	O
concluded	O	O
that	O	O
complement	O	O
was	O	O
activated	O	O
by	O	O
the	O	O
classical	O	O
pathway	O	O
.	O	O

Ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
from	O	O
diatrizoate	B-Chemical	D003973
with	O	O
and	O	O
without	O	O
chelating	O	O
agents	O	O
.	O	O

The	O	O
toxicity	B-Disease	D064420
of	O	O
Renografin	B-Chemical	C027278
76%	I-Chemical	C027278
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
Hypaque	B-Chemical	C027278
76%	I-Chemical	C027278
by	O	O
selective	O	O
injection	O	O
of	O	O
each	O	O
into	O	O
the	O	O
right	O	O
coronary	O	O
artery	O	O
of	O	O
dogs	O	O
.	O	O

Renografin	B-Chemical	D003974
contains	O	O
the	O	O
chelating	O	O
agents	O	O
sodium	B-Chemical	C102006
citrate	I-Chemical	C102006
and	O	O
disodium	B-Chemical	D004492
edetate	I-Chemical	D004492
,	O	O
while	O	O
Hypaque	B-Chemical	D003973
contains	O	O
calcium	B-Chemical	D004492
disodium	I-Chemical	D004492
edetate	I-Chemical	D004492
and	O	O
no	O	O
sodium	B-Chemical	C102006
citrate	I-Chemical	C102006
.	O	O

Ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
occurred	O	O
significantly	O	O
more	O	O
often	O	O
with	O	O
Renografin	B-Chemical	D003974
,	O	O
suggesting	O	O
that	O	O
chelating	O	O
agents	O	O
contribute	O	O
to	O	O
toxicity	B-Disease	D064420
in	O	O
coronary	O	O
angiography	O	O
.	O	O

Rapid	O	O
reversal	O	O
of	O	O
anticoagulation	O	O
reduces	O	O
hemorrhage	B-Disease	D006470
volume	O	O
in	O	O
a	O	O
mouse	O	O
model	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
associated	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
.	O	O

Warfarin	B-Chemical	D014859
-	O	O
associated	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
(	O	O
W	O	O
-	O	O
ICH	B-Disease	D002543
)	O	O
is	O	O
a	O	O
severe	O	O
type	O	O
of	O	O
stroke	B-Disease	D020521
.	O	O

There	O	O
is	O	O
no	O	O
consensus	O	O
on	O	O
the	O	O
optimal	O	O
treatment	O	O
for	O	O
W	O	O
-	O	O
ICH	B-Disease	D002543
.	O	O

Using	O	O
a	O	O
mouse	O	O
model	O	O
,	O	O
we	O	O
tested	O	O
whether	O	O
the	O	O
rapid	O	O
reversal	O	O
of	O	O
anticoagulation	O	O
using	O	O
human	O	O
prothrombin	B-Chemical	C025667
complex	I-Chemical	C025667
concentrate	I-Chemical	C025667
(	O	O
PCC	B-Chemical	C025667
)	O	O
can	O	O
reduce	O	O
hemorrhagic	O	O
blood	O	O
volume	O	O
.	O	O

Male	O	O
CD	O	O
-	O	O
1	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
warfarin	B-Chemical	D014859
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
over	O	O
24	O	O
h	O	O
)	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
s	O	O
.	O	O

d	O	O
.	O	O

)	O	O
International	O	O
Normalized	O	O
Ratio	O	O
of	O	O
3	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
.	O	O

First	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
an	O	O
intravenous	O	O
administration	O	O
of	O	O
human	O	O
PCC	B-Chemical	C025667
rapidly	O	O
reversed	O	O
anticoagulation	O	O
in	O	O
mice	O	O
.	O	O

Second	O	O
,	O	O
a	O	O
stereotactic	O	O
injection	O	O
of	O	O
collagenase	O	O
was	O	O
administered	O	O
to	O	O
induce	O	O
hemorrhage	B-Disease	D006470
in	O	O
the	O	O
right	O	O
striatum	O	O
.	O	O

Forty	O	O
-	O	O
five	O	O
minutes	O	O
later	O	O
,	O	O
the	O	O
animals	O	O
were	O	O
randomly	O	O
treated	O	O
with	O	O
PCC	B-Chemical	C025667
(	O	O
100	O	O
U	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
saline	O	O
i	O	O
.	O	O

v	O	O
.	O	O

(	O	O
n=12	O	O
per	O	O
group	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
hours	O	O
after	O	O
hemorrhage	B-Disease	D006470
induction	O	O
,	O	O
hemorrhagic	O	O
blood	O	O
volume	O	O
was	O	O
quantified	O	O
using	O	O
a	O	O
photometric	O	O
hemoglobin	O	O
assay	O	O
.	O	O

The	O	O
mean	O	O
hemorrhagic	O	O
blood	O	O
volume	O	O
was	O	O
reduced	O	O
in	O	O
PCC	B-Chemical	C025667
-	O	O
treated	O	O
animals	O	O
(	O	O
6	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

1	O	O
microL	O	O
)	O	O
compared	O	O
with	O	O
saline	O	O
controls	O	O
(	O	O
15	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
11	O	O
.	O	O

2	O	O
microL	O	O
,	O	O
P=0	O	O
.	O	O

015	O	O
)	O	O
.	O	O

In	O	O
the	O	O
saline	O	O
group	O	O
,	O	O
45%	O	O
of	O	O
the	O	O
mice	O	O
developed	O	O
large	O	O
hematomas	B-Disease	D006406
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
>15	O	O
microL	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
such	O	O
extensive	O	O
lesions	O	O
were	O	O
never	O	O
found	O	O
in	O	O
the	O	O
PCC	B-Chemical	C025667
group	O	O
.	O	O

We	O	O
provide	O	O
experimental	O	O
data	O	O
suggesting	O	O
PCC	B-Chemical	C025667
to	O	O
be	O	O
an	O	O
effective	O	O
acute	O	O
treatment	O	O
for	O	O
W	O	O
-	O	O
ICH	B-Disease	D002543
in	O	O
terms	O	O
of	O	O
reducing	O	O
hemorrhagic	O	O
blood	O	O
volume	O	O
.	O	O

Future	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
assess	O	O
the	O	O
therapeutic	O	O
potential	O	O
emerging	O	O
from	O	O
our	O	O
finding	O	O
for	O	O
human	O	O
W	O	O
-	O	O
ICH	B-Disease	D002543
.	O	O

Impact	O	O
of	O	O
alcohol	B-Chemical	D000431
exposure	O	O
after	O	O
pregnancy	O	O
recognition	O	O
on	O	O
ultrasonographic	O	O
fetal	O	O
growth	O	O
measures	O	O
.	O	O

BACKGROUND	O	O
:	O	O
More	O	O
than	O	O
3	O	O
decades	O	O
after	O	O
Jones	O	O
and	O	O
Smith	O	O
(	O	O
1973	O	O
)	O	O
reported	O	O
on	O	O
the	O	O
devastation	O	O
caused	O	O
by	O	O
alcohol	B-Chemical	D000431
exposure	O	O
on	O	O
fetal	O	O
development	O	O
,	O	O
the	O	O
rates	O	O
of	O	O
heavy	O	O
drinking	O	O
during	O	O
pregnancy	O	O
remain	O	O
relatively	O	O
unchanged	O	O
.	O	O

Early	O	O
identification	O	O
of	O	O
fetal	O	O
alcohol	B-Chemical	D000431
exposure	O	O
and	O	O
maternal	O	O
abstinence	O	O
led	O	O
to	O	O
better	O	O
infant	O	O
outcomes	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
utility	O	O
of	O	O
biometry	O	O
for	O	O
detecting	O	O
alcohol	B-Chemical	D000431
-	O	O
related	O	O
fetal	O	O
growth	B-Disease	D006130
impairment	I-Disease	D006130
.	O	O

METHODS	O	O
:	O	O
We	O	O
obtained	O	O
fetal	O	O
ultrasound	O	O
measures	O	O
from	O	O
routine	O	O
ultrasound	O	O
examinations	O	O
for	O	O
167	O	O
pregnant	O	O
hazardous	O	O
drinkers	O	O
who	O	O
were	O	O
enrolled	O	O
in	O	O
a	O	O
brief	O	O
alcohol	B-Chemical	D000431
intervention	O	O
study	O	O
.	O	O

The	O	O
fetal	O	O
measures	O	O
for	O	O
women	O	O
who	O	O
quit	O	O
after	O	O
learning	O	O
of	O	O
their	O	O
pregnancies	O	O
were	O	O
compared	O	O
with	O	O
measures	O	O
for	O	O
women	O	O
who	O	O
continued	O	O
some	O	O
drinking	O	O
throughout	O	O
the	O	O
course	O	O
of	O	O
their	O	O
pregnancies	O	O
.	O	O

Because	O	O
intensity	O	O
of	O	O
alcohol	B-Chemical	D000431
consumption	O	O
is	O	O
associated	O	O
with	O	O
poorer	O	O
fetal	O	O
outcomes	O	O
,	O	O
separate	O	O
analyses	O	O
were	O	O
conducted	O	O
for	O	O
the	O	O
heavy	O	O
(	O	O
average	O	O
of	O	O
>or=5	O	O
drinks	O	O
per	O	O
drinking	O	O
day	O	O
)	O	O
alcohol	B-Chemical	D000431
consumers	O	O
.	O	O

Fetal	O	O
measures	O	O
from	O	O
the	O	O
heavy	O	O
-	O	O
exposed	O	O
fetuses	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
measures	O	O
from	O	O
a	O	O
nondrinking	O	O
group	O	O
that	O	O
was	O	O
representative	O	O
of	O	O
normal	O	O
,	O	O
uncomplicated	O	O
pregnancies	O	O
from	O	O
our	O	O
clinics	O	O
.	O	O

Analyses	O	O
of	O	O
covariance	O	O
were	O	O
used	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
were	O	O
differences	O	O
between	O	O
groups	O	O
after	O	O
controlling	O	O
for	O	O
influences	O	O
of	O	O
gestational	O	O
age	O	O
and	O	O
drug	B-Disease	D019966
abuse	I-Disease	D019966
.	O	O

RESULTS	O	O
:	O	O
Nearly	O	O
half	O	O
of	O	O
the	O	O
pregnant	O	O
drinkers	O	O
abstained	O	O
after	O	O
learning	O	O
of	O	O
their	O	O
pregnancies	O	O
.	O	O

When	O	O
women	O	O
reportedly	O	O
quit	O	O
drinking	O	O
early	O	O
in	O	O
their	O	O
pregnancies	O	O
,	O	O
fetal	O	O
growth	O	O
measures	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
from	O	O
a	O	O
non	O	O
-	O	O
alcohol	B-Chemical	D000431
-	O	O
exposed	O	O
group	O	O
,	O	O
regardless	O	O
of	O	O
prior	O	O
drinking	O	O
patterns	O	O
.	O	O

Any	O	O
alcohol	B-Chemical	D000431
consumption	O	O
postpregnancy	O	O
recognition	O	O
among	O	O
the	O	O
heavy	O	O
drinkers	O	O
resulted	O	O
in	O	O
reduced	B-Disease	D006130
cerebellar	I-Disease	D006130
growth	I-Disease	D006130
as	O	O
well	O	O
as	O	O
decreased	B-Disease	D006130
cranial	I-Disease	D006130
to	I-Disease	D006130
body	I-Disease	D006130
growth	I-Disease	D006130
in	O	O
comparison	O	O
with	O	O
women	O	O
who	O	O
either	O	O
quit	O	O
drinking	O	O
or	O	O
who	O	O
were	O	O
nondrinkers	O	O
.	O	O

Amphetamine	B-Chemical	D000661
abuse	O	O
was	O	O
predictive	O	O
of	O	O
larger	O	O
cranial	O	O
to	O	O
body	O	O
growth	O	O
ratios	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Alterations	O	O
in	O	O
fetal	O	O
biometric	O	O
measurements	O	O
were	O	O
observed	O	O
among	O	O
the	O	O
heavy	O	O
drinkers	O	O
only	O	O
when	O	O
they	O	O
continued	O	O
drinking	O	O
after	O	O
becoming	O	O
aware	O	O
of	O	O
their	O	O
pregnancies	O	O
.	O	O

Although	O	O
the	O	O
reliance	O	O
on	O	O
self	O	O
-	O	O
reported	O	O
drinking	O	O
is	O	O
a	O	O
limitation	O	O
in	O	O
this	O	O
study	O	O
,	O	O
these	O	O
findings	O	O
support	O	O
the	O	O
benefits	O	O
of	O	O
early	O	O
abstinence	O	O
and	O	O
the	O	O
potential	O	O
for	O	O
ultrasound	O	O
examinations	O	O
in	O	O
the	O	O
detection	O	O
of	O	O
fetal	O	O
alcohol	B-Chemical	D000431
effects	O	O
.	O	O

Urinary	O	O
symptoms	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
changes	O	O
in	O	O
Thai	O	O
women	O	O
with	O	O
overactive	B-Disease	D053201
bladder	I-Disease	D053201
after	O	O
tolterodine	B-Chemical	C099041
treatment	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
study	O	O
the	O	O
urinary	O	O
symptoms	O	O
and	O	O
quality	O	O
of	O	O
life	O	O
changes	O	O
in	O	O
Thai	O	O
women	O	O
with	O	O
overactive	B-Disease	D053201
bladder	I-Disease	D053201
(	O	O
OAB	B-Disease	D053201
)	O	O
after	O	O
tolterodine	B-Chemical	C099041
treatment	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHOD	O	O
:	O	O
Thirty	O	O
women	O	O
(	O	O
aged	O	O
30	O	O
-	O	O
77	O	O
years	O	O
)	O	O
diagnosed	O	O
as	O	O
having	O	O
OAB	B-Disease	D053201
at	O	O
the	O	O
Gynecology	O	O
Clinic	O	O
,	O	O
King	O	O
Chulalongkorn	O	O
Memorial	O	O
Hospital	O	O
from	O	O
January	O	O
to	O	O
April	O	O
2004	O	O
were	O	O
included	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

Tolterodine	B-Chemical	C099041
2	O	O
mg	O	O
,	O	O
twice	O	O
daily	O	O
was	O	O
given	O	O
.	O	O

After	O	O
8	O	O
weeks	O	O
treatment	O	O
,	O	O
changes	O	O
in	O	O
micturition	O	O
diary	O	O
variables	O	O
and	O	O
tolerability	O	O
were	O	O
determined	O	O
.	O	O

Short	O	O
form	O	O
36	O	O
(	O	O
SF36	O	O
)	O	O
questionaires	O	O
(	O	O
Thai	O	O
version	O	O
)	O	O
were	O	O
given	O	O
before	O	O
and	O	O
after	O	O
8	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

RESULTS	O	O
:	O	O
At	O	O
8	O	O
weeks	O	O
,	O	O
all	O	O
micturition	O	O
per	O	O
day	O	O
decreased	O	O
from	O	O
16	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

3	O	O
to	O	O
6	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

4	O	O
times	O	O
per	O	O
day	O	O
.	O	O

The	O	O
number	O	O
of	O	O
nocturia	B-Disease	D053158
episodes	O	O
decreased	O	O
from	O	O
5	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

2	O	O
to	O	O
1	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
times	O	O
per	O	O
night	O	O
.	O	O

The	O	O
most	O	O
common	O	O
side	O	O
effect	O	O
was	O	O
dry	B-Disease	D014987
month	I-Disease	D014987
in	O	O
5	O	O
cases	O	O
(	O	O
16	O	O
.	O	O

7%	O	O
)	O	O
with	O	O
2	O	O
cases	O	O
reporting	O	O
a	O	O
moderate	O	O
degree	O	O
and	O	O
1	O	O
case	O	O
with	O	O
severe	O	O
degree	O	O
.	O	O

Only	O	O
one	O	O
case	O	O
(	O	O
3	O	O
.	O	O

3%	O	O
)	O	O
withdrew	O	O
from	O	O
the	O	O
present	O	O
study	O	O
due	O	O
to	O	O
a	O	O
severe	O	O
dry	B-Disease	D014987
mouth	I-Disease	D014987
.	O	O

The	O	O
SF	O	O
-	O	O
36	O	O
scores	O	O
changed	O	O
significantly	O	O
in	O	O
the	O	O
domains	O	O
of	O	O
physical	O	O
functioning	O	O
,	O	O
role	O	O
function	O	O
emotional	O	O
,	O	O
social	O	O
function	O	O
and	O	O
mental	O	O
heath	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Tolterodine	B-Chemical	C099041
was	O	O
well	O	O
tolerated	O	O
and	O	O
its	O	O
effects	O	O
improved	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
in	O	O
Thai	O	O
women	O	O
with	O	O
OAB	B-Disease	D053201
.	O	O

Absence	O	O
of	O	O
acute	O	O
cerebral	O	O
vasoconstriction	O	O
after	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
.	O	O

INTRODUCTION	O	O
:	O	O
Cocaine	B-Chemical	D003042
use	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
neurovascular	B-Disease	D013901
complications	I-Disease	D013901
,	O	O
including	O	O
arterial	O	O
vasoconstriction	O	O
and	O	O
vasculitis	B-Disease	D014657
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
few	O	O
studies	O	O
of	O	O
angiographic	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
on	O	O
human	O	O
cerebral	O	O
arteries	O	O
.	O	O

Information	O	O
on	O	O
these	O	O
effects	O	O
could	O	O
be	O	O
obtained	O	O
from	O	O
angiograms	O	O
of	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
(	O	O
SAH	B-Disease	D013345
)	O	O
who	O	O
underwent	O	O
angiography	O	O
shortly	O	O
after	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
screened	O	O
patients	O	O
with	O	O
SAH	B-Disease	D013345
retrospectively	O	O
and	O	O
identified	O	O
those	O	O
with	O	O
positive	O	O
urine	O	O
toxicology	O	O
for	O	O
cocaine	B-Chemical	D003042
or	O	O
its	O	O
metabolites	O	O
.	O	O

Quantitative	O	O
arterial	O	O
diameter	O	O
measurements	O	O
from	O	O
angiograms	O	O
of	O	O
these	O	O
patients	O	O
were	O	O
compared	O	O
to	O	O
measurements	O	O
from	O	O
control	O	O
patients	O	O
with	O	O
SAH	B-Disease	D013345
who	O	O
were	O	O
matched	O	O
for	O	O
factors	O	O
known	O	O
to	O	O
influence	O	O
arterial	O	O
diameter	O	O
.	O	O

Qualitative	O	O
comparisons	O	O
of	O	O
small	O	O
artery	O	O
changes	O	O
also	O	O
were	O	O
made	O	O
.	O	O

RESULTS	O	O
:	O	O
Thirteen	O	O
patients	O	O
with	O	O
positive	O	O
cocaine	B-Chemical	D003042
toxicology	O	O
were	O	O
compared	O	O
to	O	O
26	O	O
controls	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
in	O	O
the	O	O
mean	O	O
diameters	O	O
of	O	O
the	O	O
intradural	O	O
internal	O	O
carotid	O	O
,	O	O
sphenoidal	O	O
segment	O	O
of	O	O
the	O	O
middle	O	O
cerebral	O	O
,	O	O
precommunicating	O	O
segment	O	O
of	O	O
the	O	O
anterior	O	O
cerebral	O	O
,	O	O
or	O	O
basilar	O	O
arteries	O	O
(	O	O
p	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

05	O	O
for	O	O
all	O	O
comparisons	O	O
,	O	O
unpaired	O	O
t	O	O
-	O	O
tests	O	O
)	O	O
.	O	O

There	O	O
also	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
groups	O	O
when	O	O
expressing	O	O
diameters	O	O
as	O	O
the	O	O
sum	O	O
of	O	O
the	O	O
precommunicating	O	O
segment	O	O
of	O	O
the	O	O
anterior	O	O
cerebral	O	O
+	O	O
sphenoidal	O	O
segment	O	O
of	O	O
the	O	O
middle	O	O
cerebral	O	O
+	O	O
supraclinoid	O	O
internal	O	O
carotid	O	O
artery	O	O
+	O	O
basilar	O	O
artery	O	O
divided	O	O
by	O	O
the	O	O
diameter	O	O
of	O	O
the	O	O
petrous	O	O
internal	O	O
carotid	O	O
artery	O	O
(	O	O
p	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

05	O	O
,	O	O
unpaired	O	O
t	O	O
-	O	O
tests	O	O
)	O	O
.	O	O

Qualitative	O	O
assessments	O	O
showed	O	O
two	O	O
arterial	O	O
irregularities	O	O
in	O	O
the	O	O
distal	O	O
vasculature	O	O
in	O	O
each	O	O
group	O	O
.	O	O

CONCLUSION	O	O
:	O	O
No	O	O
quantitative	O	O
evidence	O	O
for	O	O
narrowing	O	O
of	O	O
large	O	O
cerebral	O	O
arteries	O	O
or	O	O
qualitative	O	O
angiographic	O	O
evidence	O	O
for	O	O
distal	O	O
narrowing	O	O
or	O	O
vasculitis	B-Disease	D014657
could	O	O
be	O	O
found	O	O
in	O	O
patients	O	O
who	O	O
underwent	O	O
angiography	O	O
after	O	O
aneurysmal	B-Disease	D017542
SAH	B-Disease	D013345
associated	O	O
with	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

Atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
following	O	O
chemotherapy	O	O
for	O	O
stage	O	O
IIIE	O	O
diffuse	O	O
large	O	O
B	O	O
-	O	O
cell	O	O
gastric	B-Disease	C535648
lymphoma	I-Disease	C535648
in	O	O
a	O	O
patient	O	O
with	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
(	O	O
Steinert's	B-Disease	D009223
disease	I-Disease	D009223
)	O	O
.	O	O

The	O	O
authors	O	O
describe	O	O
the	O	O
unusual	O	O
association	O	O
between	O	O
diffuse	O	O
B	O	O
-	O	O
cell	O	O
gastric	B-Disease	C535648
lymphoma	I-Disease	C535648
and	O	O
myotonic	B-Disease	D009223
dystrophy	I-Disease	D009223
,	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
adult	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
,	O	O
and	O	O
sudden	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
following	O	O
one	O	O
cycle	O	O
of	O	O
doxorubicin	B-Chemical	D004317
-	O	O
based	O	O
chemotherapy	O	O
in	O	O
the	O	O
same	O	O
patient	O	O
.	O	O

Atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
or	O	O
other	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
are	O	O
unusual	O	O
complications	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
chemotherapy	O	O
.	O	O

The	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
intrinsically	O	O
associated	O	O
with	O	O
the	O	O
aggressive	O	O
chemotherapy	O	O
employed	O	O
could	O	O
function	O	O
as	O	O
a	O	O
triggering	O	O
factor	O	O
for	O	O
the	O	O
arrhythmia	B-Disease	D001145
in	O	O
the	O	O
predisposed	O	O
myocardium	O	O
of	O	O
this	O	O
patient	O	O
.	O	O

A	O	O
phase	O	O
II	O	O
study	O	O
of	O	O
thalidomide	B-Chemical	D013792
in	O	O
advanced	O	O
metastatic	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
toxicity	B-Disease	D064420
and	O	O
activity	O	O
of	O	O
thalidomide	B-Chemical	D013792
in	O	O
patients	O	O
with	O	O
advanced	O	O
metastatic	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
cancer	I-Disease	D002292
and	O	O
to	O	O
measure	O	O
changes	O	O
of	O	O
one	O	O
angiogenic	O	O
factor	O	O
,	O	O
vascular	O	O
endothelial	O	O
growth	O	O
factor	O	O
(	O	O
VEGF	O	O
)	O	O
165	O	O
,	O	O
with	O	O
therapy	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
29	O	O
patients	O	O
were	O	O
enrolled	O	O
on	O	O
a	O	O
study	O	O
of	O	O
thalidomide	B-Chemical	D013792
using	O	O
an	O	O
intra	O	O
-	O	O
patient	O	O
dose	O	O
escalation	O	O
schedule	O	O
.	O	O

Patients	O	O
began	O	O
thalidomide	B-Chemical	D013792
at	O	O
400	O	O
mg	O	O
/	O	O
d	O	O
and	O	O
escalated	O	O
as	O	O
tolerated	O	O
to	O	O
1200	O	O
mg	O	O
/	O	O
d	O	O
by	O	O
day	O	O
54	O	O
.	O	O

Fifty	O	O
-	O	O
nine	O	O
per	O	O
cent	O	O
of	O	O
patients	O	O
had	O	O
had	O	O
previous	O	O
therapy	O	O
with	O	O
IL	O	O
-	O	O
2	O	O
and	O	O
52%	O	O
were	O	O
performance	O	O
status	O	O
2	O	O
or	O	O
3	O	O
.	O	O

Systemic	O	O
plasma	O	O
VEGF165	O	O
levels	O	O
were	O	O
measured	O	O
by	O	O
dual	O	O
monoclonal	O	O
ELISA	O	O
in	O	O
8	O	O
patients	O	O
.	O	O

RESULTS	O	O
:	O	O
24	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
response	O	O
with	O	O
one	O	O
partial	O	O
response	O	O
of	O	O
11	O	O
months	O	O
duration	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
hepatic	O	O
and	O	O
pulmonary	O	O
metastases	B-Disease	D009362
(	O	O
4%	O	O
)	O	O
,	O	O
one	O	O
minor	O	O
response	O	O
,	O	O
and	O	O
2	O	O
patients	O	O
stable	O	O
for	O	O
over	O	O
6	O	O
months	O	O
.	O	O

Somnolence	B-Disease	D006970
and	O	O
constipation	B-Disease	D003248
were	O	O
prominent	O	O
toxicities	B-Disease	D064420
and	O	O
most	O	O
patients	O	O
could	O	O
not	O	O
tolerate	O	O
the	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
dose	O	O
level	O	O
.	O	O

Systemic	O	O
plasma	O	O
VEGF165	O	O
levels	O	O
did	O	O
not	O	O
change	O	O
with	O	O
therapy	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
low	O	O
level	O	O
of	O	O
activity	O	O
of	O	O
thalidomide	B-Chemical	D013792
in	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
.	O	O

Administration	O	O
of	O	O
doses	O	O
over	O	O
800	O	O
mg	O	O
/	O	O
day	O	O
was	O	O
difficult	O	O
to	O	O
achieve	O	O
in	O	O
this	O	O
patient	O	O
population	O	O
,	O	O
however	O	O
lower	O	O
doses	O	O
were	O	O
practical	O	O
.	O	O

The	O	O
dose	O	O
-	O	O
response	O	O
relationship	O	O
,	O	O
if	O	O
any	O	O
,	O	O
of	O	O
thalidomide	B-Chemical	D013792
for	O	O
renal	B-Disease	D002292
cell	I-Disease	D002292
carcinoma	I-Disease	D002292
is	O	O
unclear	O	O
.	O	O

The	O	O
striatum	O	O
as	O	O
a	O	O
target	O	O
for	O	O
anti	O	O
-	O	O
rigor	O	O
effects	O	O
of	O	O
an	O	O
antagonist	O	O
of	O	O
mGluR1	O	O
,	O	O
but	O	O
not	O	O
an	O	O
agonist	O	O
of	O	O
group	O	O
II	O	O
metabotropic	O	O
glutamate	B-Chemical	D018698
receptors	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
find	O	O
out	O	O
whether	O	O
the	O	O
metabotropic	O	O
receptor	O	O
1	O	O
(	O	O
mGluR1	O	O
)	O	O
and	O	O
group	O	O
II	O	O
mGluRs	O	O
,	O	O
localized	O	O
in	O	O
the	O	O
striatum	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
antiparkinsonian	O	O
-	O	O
like	O	O
effects	O	O
in	O	O
rats	O	O
.	O	O

Haloperidol	B-Chemical	D006220
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
induced	O	O
parkinsonian	B-Disease	D010300
-	O	O
like	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
,	O	O
measured	O	O
as	O	O
an	O	O
increased	O	O
resistance	O	O
of	O	O
a	O	O
rat's	O	O
hind	O	O
foot	O	O
to	O	O
passive	O	O
flexion	O	O
and	O	O
extension	O	O
at	O	O
the	O	O
ankle	O	O
joint	O	O
.	O	O

(	B-Chemical	C095756
RS	I-Chemical	C095756
)	I-Chemical	C095756
-	I-Chemical	C095756
1	I-Chemical	C095756
-	I-Chemical	C095756
aminoindan	I-Chemical	C095756
-	I-Chemical	C095756
1	I-Chemical	C095756
,	I-Chemical	C095756
5	I-Chemical	C095756
-	I-Chemical	C095756
dicarboxylic	I-Chemical	C095756
acid	I-Chemical	C095756
(	O	O
AIDA	B-Chemical	C095756
;	O	O
0	O	O
.	O	O

5	O	O
-	O	O
15	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
)	O	O
,	O	O
a	O	O
potent	O	O
and	O	O
selective	O	O
mGluR1	O	O
antagonist	O	O
,	O	O
or	O	O
(	B-Chemical	C097299
2R	I-Chemical	C097299
,	I-Chemical	C097299
4R	I-Chemical	C097299
)	I-Chemical	C097299
-	I-Chemical	C097299
4	I-Chemical	C097299
-	I-Chemical	C097299
aminopyrrolidine	I-Chemical	C097299
-	I-Chemical	C097299
2	I-Chemical	C097299
,	I-Chemical	C097299
4	I-Chemical	C097299
-	I-Chemical	C097299
dicarboxylate	I-Chemical	C097299
(	O	O
2R	B-Chemical	C097299
,	I-Chemical	C097299
4R	I-Chemical	C097299
-	I-Chemical	C097299
APDC	I-Chemical	C097299
;	O	O
7	O	O
.	O	O

5	O	O
-	O	O
15	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
)	O	O
,	O	O
a	O	O
selective	O	O
group	O	O
II	O	O
agonist	O	O
,	O	O
was	O	O
injected	O	O
bilaterally	O	O
into	O	O
the	O	O
striatum	O	O
of	O	O
haloperidol	B-Chemical	D006220
-	O	O
treated	O	O
animals	O	O
.	O	O

AIDA	B-Chemical	C095756
in	O	O
doses	O	O
of	O	O
7	O	O
.	O	O

5	O	O
-	O	O
15	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
diminished	O	O
the	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
.	O	O

In	O	O
contrast	O	O
,	O	O
2R	B-Chemical	C097299
,	I-Chemical	C097299
4R	I-Chemical	C097299
-	I-Chemical	C097299
APDC	I-Chemical	C097299
injections	O	O
were	O	O
ineffective	O	O
.	O	O

The	O	O
present	O	O
results	O	O
may	O	O
suggest	O	O
that	O	O
the	O	O
blockade	O	O
of	O	O
striatal	O	O
mGluR1	O	O
,	O	O
but	O	O
not	O	O
the	O	O
stimulation	O	O
of	O	O
group	O	O
II	O	O
mGluRs	O	O
,	O	O
may	O	O
ameliorate	O	O
parkinsonian	B-Disease	D010300
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
.	O	O

Acute	O	O
cholestatic	O	O
hepatitis	B-Disease	D056486
after	O	O
exposure	O	O
to	O	O
isoflurane	B-Chemical	D007530
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
cholestatic	O	O
hepatitis	B-Disease	D056486
following	O	O
exposure	O	O
to	O	O
the	O	O
inhalational	O	O
anesthetic	O	O
isoflurane	B-Chemical	D007530
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
70	O	O
-	O	O
year	O	O
-	O	O
old	O	O
healthy	O	O
woman	O	O
from	O	O
Iraq	O	O
developed	O	O
acute	O	O
cholestatic	O	O
hepatitis	B-Disease	D056486
3	O	O
weeks	O	O
following	O	O
repair	O	O
of	O	O
the	O	O
right	O	O
rotator	O	O
cuff	O	O
under	O	O
general	O	O
anesthesia	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
for	O	O
viral	O	O
,	O	O
autoimmune	O	O
,	O	O
or	O	O
metabolic	O	O
causes	O	O
of	O	O
hepatitis	B-Disease	D056486
.	O	O

No	O	O
other	O	O
medications	O	O
were	O	O
involved	O	O
except	O	O
for	O	O
dipyrone	B-Chemical	D004177
for	O	O
analgesia	B-Disease	D000699
.	O	O

The	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
was	O	O
elevated	O	O
to	O	O
a	O	O
peak	O	O
concentration	O	O
of	O	O
1533	O	O
U	O	O
/	O	O
L	O	O
and	O	O
the	O	O
serum	O	O
bilirubin	B-Chemical	D001663
reached	O	O
a	O	O
peak	O	O
of	O	O
17	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
dL	O	O
.	O	O

There	O	O
was	O	O
slow	O	O
improvement	O	O
over	O	O
4	O	O
months	O	O
.	O	O

Accidental	O	O
reexposure	O	O
by	O	O
the	O	O
patient	O	O
to	O	O
dipyrone	B-Chemical	D004177
was	O	O
uneventful	O	O
.	O	O

DISCUSSION	O	O
:	O	O
The	O	O
clinical	O	O
and	O	O
histologic	O	O
picture	O	O
of	O	O
this	O	O
case	O	O
resembles	O	O
halothane	B-Disease	C562477
hepatitis	I-Disease	C562477
,	O	O
which	O	O
has	O	O
a	O	O
significant	O	O
mortality	O	O
rate	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Isoflurane	B-Chemical	D007530
,	O	O
a	O	O
common	O	O
anesthetic	O	O
agent	O	O
,	O	O
can	O	O
cause	O	O
severe	O	O
cholestatic	O	O
hepatitis	B-Disease	D056486
.	O	O

Calcitonin	O	O
gene	O	O
-	O	O
related	O	O
peptide	O	O
levels	O	O
during	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
-	O	O
induced	O	O
headache	B-Disease	D006261
in	O	O
patients	O	O
with	O	O
chronic	O	O
tension	B-Disease	D018781
-	I-Disease	D018781
type	I-Disease	D018781
headache	I-Disease	D018781
.	O	O

It	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
induced	O	O
headache	B-Disease	D006261
in	O	O
primary	B-Disease	D051270
headaches	I-Disease	D051270
may	O	O
be	O	O
associated	O	O
with	O	O
release	O	O
of	O	O
calcitonin	O	O
gene	O	O
-	O	O
related	O	O
peptide	O	O
(	O	O
CGRP	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
investigate	O	O
plasma	O	O
levels	O	O
of	O	O
CGRP	O	O
during	O	O
headache	B-Disease	D006261
induced	O	O
by	O	O
the	O	O
NO	B-Chemical	D009569
donor	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
(	O	O
GTN	B-Chemical	D005996
)	O	O
in	O	O
16	O	O
patients	O	O
with	O	O
chronic	O	O
tension	B-Disease	D018781
-	I-Disease	D018781
type	I-Disease	D018781
headache	I-Disease	D018781
and	O	O
16	O	O
healthy	O	O
controls	O	O
.	O	O

The	O	O
subjects	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
0	O	O
.	O	O

5	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
GTN	B-Chemical	D005996
or	O	O
placebo	O	O
over	O	O
20	O	O
min	O	O
on	O	O
two	O	O
headache	B-Disease	D006261
-	O	O
free	O	O
days	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
collected	O	O
at	O	O
baseline	O	O
,	O	O
10	O	O
,	O	O
20	O	O
and	O	O
60	O	O
min	O	O
after	O	O
start	O	O
of	O	O
infusion	O	O
.	O	O

Both	O	O
patients	O	O
and	O	O
controls	O	O
developed	O	O
significantly	O	O
stronger	O	O
immediate	O	O
headache	B-Disease	D006261
on	O	O
the	O	O
GTN	B-Chemical	D005996
day	O	O
than	O	O
on	O	O
the	O	O
placebo	O	O
day	O	O
and	O	O
the	O	O
headache	B-Disease	D006261
was	O	O
significantly	O	O
more	O	O
pronounced	O	O
in	O	O
patients	O	O
than	O	O
in	O	O
controls	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
between	O	O
the	O	O
area	O	O
under	O	O
the	O	O
CGRP	O	O
curve	O	O
(	O	O
AUCCGRP	O	O
)	O	O
on	O	O
GTN	B-Chemical	D005996
vs	O	O
.	O	O

placebo	O	O
day	O	O
in	O	O
either	O	O
patients	O	O
(	O	O
P=0	O	O
.	O	O

65	O	O
)	O	O
or	O	O
controls	O	O
(	O	O
P=0	O	O
.	O	O

48	O	O
)	O	O
.	O	O

The	O	O
AUCCGRP	O	O
recorded	O	O
on	O	O
the	O	O
GTN	B-Chemical	D005996
day	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
patients	O	O
and	O	O
controls	O	O
(	O	O
P=0	O	O
.	O	O

36	O	O
)	O	O
.	O	O

Both	O	O
in	O	O
patients	O	O
and	O	O
controls	O	O
,	O	O
CGRP	O	O
levels	O	O
changed	O	O
significantly	O	O
over	O	O
time	O	O
,	O	O
on	O	O
both	O	O
the	O	O
GTN	B-Chemical	D005996
and	O	O
placebo	O	O
days	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
present	O	O
study	O	O
indicates	O	O
that	O	O
NO	B-Chemical	D009569
-	O	O
induced	O	O
immediate	O	O
headache	B-Disease	D006261
is	O	O
not	O	O
associated	O	O
with	O	O
release	O	O
of	O	O
CGRP	O	O
.	O	O

Myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
due	O	O
to	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
during	O	O
dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
.	O	O

Dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
(	O	O
DSE	O	O
)	O	O
is	O	O
a	O	O
useful	O	O
and	O	O
safe	O	O
provocation	O	O
test	O	O
for	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

Until	O	O
now	O	O
,	O	O
the	O	O
test	O	O
has	O	O
been	O	O
focused	O	O
only	O	O
on	O	O
the	O	O
organic	O	O
lesion	O	O
in	O	O
the	O	O
coronary	O	O
artery	O	O
,	O	O
and	O	O
positive	O	O
DSE	O	O
has	O	O
indicated	O	O
the	O	O
presence	O	O
of	O	O
significant	O	O
fixed	O	O
coronary	B-Disease	D023921
artery	I-Disease	D023921
stenosis	I-Disease	D023921
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
is	O	O
to	O	O
examine	O	O
whether	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
due	O	O
to	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
is	O	O
induced	O	O
by	O	O
dobutamine	B-Chemical	D004280
.	O	O

We	O	O
performed	O	O
DSE	O	O
on	O	O
51	O	O
patients	O	O
with	O	O
coronary	B-Disease	D000788
spastic	I-Disease	D000788
angina	I-Disease	D000788
but	O	O
without	O	O
significant	O	O
fixed	O	O
coronary	B-Disease	D023921
artery	I-Disease	D023921
stenosis	I-Disease	D023921
.	O	O

All	O	O
patients	O	O
had	O	O
anginal	B-Disease	D000787
attacks	O	O
at	O	O
rest	O	O
with	O	O
ST	O	O
elevation	O	O
on	O	O
the	O	O
electrocardiogram	O	O
(	O	O
variant	B-Disease	D000788
angina	I-Disease	D000788
)	O	O
.	O	O

Coronary	O	O
spasm	O	O
was	O	O
induced	O	O
by	O	O
intracoronary	O	O
injection	O	O
of	O	O
acetylcholine	B-Chemical	D000109
,	O	O
and	O	O
no	O	O
fixed	O	O
coronary	B-Disease	D023921
artery	I-Disease	D023921
stenosis	I-Disease	D023921
was	O	O
documented	O	O
on	O	O
angiograms	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

DSE	O	O
was	O	O
performed	O	O
with	O	O
intravenous	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
with	O	O
an	O	O
incremental	O	O
doses	O	O
of	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
30	O	O
,	O	O
and	O	O
40	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
every	O	O
5	O	O
minutes	O	O
.	O	O

Of	O	O
the	O	O
51	O	O
patients	O	O
,	O	O
7	O	O
patients	O	O
showed	O	O
asynergy	O	O
with	O	O
ST	O	O
elevation	O	O
.	O	O

All	O	O
7	O	O
patients	O	O
(	O	O
13	O	O
.	O	O

7%	O	O
)	O	O
had	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
during	O	O
asynergy	O	O
,	O	O
and	O	O
both	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
electrocardiographic	O	O
changes	O	O
were	O	O
preceded	O	O
by	O	O
asynergy	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
dobutamine	B-Chemical	D004280
can	O	O
provoke	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
in	O	O
some	O	O
patients	O	O
with	O	O
coronary	B-Disease	D000788
spastic	I-Disease	D000788
angina	I-Disease	D000788
.	O	O

When	O	O
DSE	O	O
is	O	O
performed	O	O
to	O	O
evaluate	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
not	O	O
only	O	O
fixed	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
,	O	O
but	O	O
also	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
should	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
genesis	O	O
of	O	O
asynergy	O	O
.	O	O

Nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
expression	O	O
in	O	O
the	O	O
course	O	O
of	O	O
lead	B-Chemical	D007854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

We	O	O
recently	O	O
showed	O	O
elevated	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
(	O	O
ROS	O	O
)	O	O
,	O	O
reduced	O	O
urinary	O	O
excretion	O	O
of	O	O
NO	B-Chemical	D009569
metabolites	O	O
(	O	O
NOx	O	O
)	O	O
,	O	O
and	O	O
increased	O	O
NO	B-Chemical	D009569
sequestration	O	O
as	O	O
nitrotyrosine	B-Chemical	C002744
in	O	O
various	O	O
tissues	O	O
in	O	O
rats	O	O
with	O	O
lead	B-Chemical	D007854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
discern	O	O
whether	O	O
the	O	O
reduction	O	O
in	O	O
urinary	O	O
NOx	O	O
in	O	O
lead	B-Chemical	D007854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
is	O	O
,	O	O
in	O	O
part	O	O
,	O	O
due	O	O
to	O	O
depressed	O	O
NO	B-Chemical	D009569
synthase	O	O
(	O	O
NOS	O	O
)	O	O
expression	O	O
.	O	O

Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
a	O	O
lead	B-Chemical	D007854
-	O	O
treated	O	O
group	O	O
(	O	O
given	O	O
lead	B-Chemical	D007854
acetate	O	O
,	O	O
100	O	O
ppm	O	O
,	O	O
in	O	O
drinking	O	O
water	O	O
and	O	O
regular	O	O
rat	O	O
chow	O	O
)	O	O
,	O	O
a	O	O
group	O	O
given	O	O
lead	B-Chemical	D007854
and	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
-	O	O
fortified	O	O
chow	O	O
,	O	O
or	O	O
a	O	O
normal	O	O
control	O	O
group	O	O
given	O	O
either	O	O
regular	O	O
food	O	O
and	O	O
water	O	O
or	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
-	O	O
fortified	O	O
food	O	O
for	O	O
12	O	O
weeks	O	O
.	O	O

Tail	O	O
blood	O	O
pressure	O	O
,	O	O
urinary	O	O
NOx	O	O
excretion	O	O
,	O	O
plasma	O	O
malondialdehyde	B-Chemical	D008315
(	O	O
MDA	B-Chemical	D008315
)	O	O
,	O	O
and	O	O
endothelial	O	O
and	O	O
inducible	O	O
NOS	O	O
(	O	O
eNOS	O	O
and	O	O
iNOS	O	O
)	O	O
isotypes	O	O
in	O	O
the	O	O
aorta	O	O
and	O	O
kidney	O	O
were	O	O
measured	O	O
.	O	O

The	O	O
lead	B-Chemical	D007854
-	O	O
treated	O	O
group	O	O
exhibited	O	O
a	O	O
rise	O	O
in	O	O
blood	O	O
pressure	O	O
and	O	O
plasma	O	O
MDA	B-Chemical	D008315
concentration	O	O
,	O	O
a	O	O
fall	O	O
in	O	O
urinary	O	O
NOx	O	O
excretion	O	O
,	O	O
and	O	O
a	O	O
paradoxical	O	O
rise	O	O
in	O	O
vascular	O	O
and	O	O
renal	O	O
tissue	O	O
eNOS	O	O
and	O	O
iNOS	O	O
expression	O	O
.	O	O

Vitamin	B-Chemical	D014810
E	I-Chemical	D014810
supplementation	O	O
ameliorated	O	O
hypertension	B-Disease	D006973
,	O	O
lowered	O	O
plasma	O	O
MDA	B-Chemical	D008315
concentration	O	O
,	O	O
and	O	O
raised	O	O
urinary	O	O
NOx	O	O
excretion	O	O
while	O	O
significantly	O	O
lowering	O	O
vascular	O	O
,	O	O
but	O	O
not	O	O
renal	O	O
,	O	O
tissue	O	O
eNOS	O	O
and	O	O
iNOS	O	O
expression	O	O
.	O	O

Vitamin	B-Chemical	D014810
E	I-Chemical	D014810
supplementation	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
either	O	O
blood	O	O
pressure	O	O
,	O	O
plasma	O	O
MDA	B-Chemical	D008315
,	O	O
or	O	O
NOS	O	O
expression	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

The	O	O
study	O	O
also	O	O
revealed	O	O
significant	O	O
inhibition	O	O
of	O	O
NOS	O	O
enzymatic	O	O
activity	O	O
by	O	O
lead	B-Chemical	D007854
in	O	O
cell	O	O
-	O	O
free	O	O
preparations	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
lead	B-Chemical	D007854
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
this	O	O
model	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
compensatory	O	O
upregulation	O	O
of	O	O
renal	O	O
and	O	O
vascular	O	O
eNOS	O	O
and	O	O
iNOS	O	O
expression	O	O
.	O	O

This	O	O
is	O	O
,	O	O
in	O	O
part	O	O
,	O	O
due	O	O
to	O	O
ROS	O	O
-	O	O
mediated	O	O
NO	B-Chemical	D009569
inactivation	O	O
,	O	O
lead	B-Chemical	D007854
-	O	O
associated	O	O
inhibition	O	O
of	O	O
NOS	O	O
activity	O	O
,	O	O
and	O	O
perhaps	O	O
stimulatory	O	O
actions	O	O
of	O	O
increased	O	O
shear	O	O
stress	O	O
associated	O	O
with	O	O
hypertension	B-Disease	D006973
.	O	O

Risk	O	O
for	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
among	O	O
users	O	O
of	O	O
fenfluramine	B-Chemical	D005277
and	O	O
dexfenfluramine	B-Chemical	D020372
who	O	O
underwent	O	O
echocardiography	O	O
before	O	O
use	O	O
of	O	O
medication	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Because	O	O
uncontrolled	O	O
echocardiographic	O	O
surveys	O	O
suggested	O	O
that	O	O
up	O	O
to	O	O
30%	O	O
to	O	O
38%	O	O
of	O	O
users	O	O
of	O	O
fenfluramine	B-Chemical	D005277
and	O	O
dexfenfluramine	B-Chemical	D020372
had	O	O
valvular	B-Disease	D006349
disease	I-Disease	D006349
,	O	O
these	O	O
drugs	O	O
were	O	O
withdrawn	O	O
from	O	O
the	O	O
market	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
risk	O	O
for	O	O
new	O	O
or	O	O
worsening	O	O
valvular	B-Disease	D006349
abnormalities	I-Disease	D006349
among	O	O
users	O	O
of	O	O
fenfluramine	B-Chemical	D005277
or	O	O
dexfenfluramine	B-Chemical	D020372
who	O	O
underwent	O	O
echocardiography	O	O
before	O	O
they	O	O
began	O	O
to	O	O
take	O	O
these	O	O
medications	O	O
.	O	O

DESIGN	O	O
:	O	O
Cohort	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Academic	O	O
primary	O	O
care	O	O
practices	O	O
.	O	O

PATIENTS	O	O
:	O	O
46	O	O
patients	O	O
who	O	O
used	O	O
fenfluramine	B-Chemical	D005277
or	O	O
dexfenfluramine	B-Chemical	D020372
for	O	O
14	O	O
days	O	O
or	O	O
more	O	O
and	O	O
had	O	O
echocardiograms	O	O
obtained	O	O
before	O	O
therapy	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Follow	O	O
-	O	O
up	O	O
echocardiography	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
new	O	O
or	O	O
worsening	O	O
valvulopathy	B-Disease	D006349
,	O	O
defined	O	O
as	O	O
progression	O	O
of	O	O
either	O	O
aortic	O	O
or	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
by	O	O
at	O	O
least	O	O
one	O	O
degree	O	O
of	O	O
severity	O	O
and	O	O
disease	O	O
that	O	O
met	O	O
U	O	O
.	O	O

S	O	O
.	O	O

Food	O	O
and	O	O
Drug	O	O
Administration	O	O
criteria	O	O
(	O	O
at	O	O
least	O	O
mild	O	O
aortic	B-Disease	D001022
regurgitation	I-Disease	D001022
or	O	O
moderate	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
patients	O	O
(	O	O
4	O	O
.	O	O

3%	O	O
[	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
.	O	O

6%	O	O
to	O	O
14	O	O
.	O	O

8%	O	O
]	O	O
)	O	O
receiving	O	O
fenfluramine	B-Chemical	D005277
-	O	O
phentermine	B-Chemical	D010645
developed	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
.	O	O

One	O	O
had	O	O
baseline	O	O
bicuspid	B-Disease	C562388
aortic	I-Disease	C562388
valve	I-Disease	C562388
and	O	O
mild	O	O
aortic	B-Disease	D001022
regurgitation	I-Disease	D001022
that	O	O
progressed	O	O
to	O	O
moderate	O	O
regurgitation	O	O
.	O	O

The	O	O
second	O	O
patient	O	O
developed	O	O
new	O	O
moderate	O	O
aortic	B-Disease	D001022
insufficiency	I-Disease	D001022
.	O	O

CONCLUSION	O	O
:	O	O
Users	O	O
of	O	O
diet	O	O
medications	O	O
are	O	O
at	O	O
risk	O	O
for	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
.	O	O

However	O	O
,	O	O
the	O	O
incidence	O	O
may	O	O
be	O	O
lower	O	O
than	O	O
that	O	O
reported	O	O
previously	O	O
.	O	O

Carboplatin	B-Chemical	D016190
toxic	O	O
effects	O	O
on	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
of	O	O
the	O	O
rat	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
most	O	O
striking	O	O
of	O	O
carboplatin's	O	O
advantages	O	O
(	O	O
CBDCA	B-Chemical	D016190
)	O	O
over	O	O
cisplatin	B-Chemical	D002945
(	O	O
CDDP	B-Chemical	D002945
)	O	O
is	O	O
its	O	O
markedly	O	O
reduced	O	O
rate	O	O
of	O	O
neurotoxic	B-Disease	D020258
effects	O	O
.	O	O

However	O	O
,	O	O
the	O	O
use	O	O
of	O	O
CBDCA	B-Chemical	D016190
higher	O	O
-	O	O
intensity	O	O
schedules	O	O
and	O	O
the	O	O
association	O	O
with	O	O
other	O	O
neurotoxic	B-Disease	D020258
drugs	O	O
in	O	O
polychemotherapy	O	O
may	O	O
cause	O	O
some	O	O
concern	O	O
about	O	O
its	O	O
safety	O	O
with	O	O
respect	O	O
to	O	O
peripheral	B-Disease	D010523
nervous	I-Disease	D010523
system	I-Disease	D010523
damage	I-Disease	D010523
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Two	O	O
different	O	O
schedules	O	O
of	O	O
CBDCA	B-Chemical	D016190
administration	O	O
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

twice	O	O
a	O	O
week	O	O
for	O	O
nine	O	O
times	O	O
)	O	O
were	O	O
evaluated	O	O
in	O	O
Wistar	O	O
rats	O	O
.	O	O

Neurotoxicity	B-Disease	D020258
was	O	O
assessed	O	O
for	O	O
behavioral	O	O
(	O	O
tail	O	O
-	O	O
flick	O	O
test	O	O
)	O	O
,	O	O
neurophysiological	O	O
(	O	O
nerve	O	O
conduction	O	O
velocity	O	O
in	O	O
the	O	O
tail	O	O
nerve	O	O
)	O	O
,	O	O
morphological	O	O
,	O	O
morphometrical	O	O
and	O	O
analytical	O	O
effects	O	O
.	O	O

RESULTS	O	O
:	O	O
CBDCA	B-Chemical	D016190
administration	O	O
induced	O	O
dose	O	O
-	O	O
dependent	O	O
peripheral	B-Disease	D010523
neurotoxicity	I-Disease	D010523
.	O	O

Pain	B-Disease	D010146
perception	O	O
and	O	O
nerve	O	O
conduction	O	O
velocity	O	O
in	O	O
the	O	O
tail	O	O
were	O	O
significantly	O	O
impaired	O	O
,	O	O
particularly	O	O
after	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
treatment	O	O
.	O	O

The	O	O
dorsal	O	O
root	O	O
ganglia	O	O
sensory	O	O
neurons	O	O
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
,	O	O
satellite	O	O
cells	O	O
showed	O	O
the	O	O
same	O	O
changes	O	O
as	O	O
those	O	O
induced	O	O
by	O	O
CDDP	B-Chemical	D002945
,	O	O
mainly	O	O
affecting	O	O
the	O	O
nucleus	O	O
and	O	O
nucleolus	O	O
of	O	O
ganglionic	O	O
sensory	O	O
neurons	O	O
.	O	O

Moreover	O	O
,	O	O
significant	O	O
amounts	O	O
of	O	O
platinum	B-Chemical	D010984
were	O	O
detected	O	O
in	O	O
the	O	O
dorsal	O	O
root	O	O
ganglia	O	O
and	O	O
kidney	O	O
after	O	O
CBDCA	B-Chemical	D016190
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
CBDCA	B-Chemical	D016190
is	O	O
neurotoxic	B-Disease	D020258
in	O	O
our	O	O
model	O	O
,	O	O
and	O	O
the	O	O
type	O	O
of	O	O
pathological	O	O
changes	O	O
it	O	O
induces	O	O
are	O	O
so	O	O
closely	O	O
similar	O	O
to	O	O
those	O	O
caused	O	O
by	O	O
CDDP	B-Chemical	D002945
that	O	O
it	O	O
is	O	O
probable	O	O
that	O	O
neurotoxicity	B-Disease	D020258
is	O	O
induced	O	O
in	O	O
the	O	O
two	O	O
drugs	O	O
by	O	O
the	O	O
same	O	O
mechanism	O	O
.	O	O

This	O	O
model	O	O
can	O	O
be	O	O
used	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
drugs	O	O
to	O	O
explore	O	O
the	O	O
effect	O	O
of	O	O
CBDCA	B-Chemical	D016190
on	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
.	O	O

Iatrogenic	O	O
risks	O	O
of	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
after	O	O
treatment	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
a	O	O
large	O	O
French	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

F	O	O
d	O	O
ration	O	O
Nationale	O	O
des	O	O
Centres	O	O
de	O	O
Lutte	O	O
Contre	O	O
le	O	O
Cancer	O	O
(	O	O
FNCLCC	O	O
)	O	O
.	O	O

Since	O	O
tamoxifen	B-Chemical	D013629
is	O	O
widely	O	O
used	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
treatment	O	O
and	O	O
has	O	O
been	O	O
proposed	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
its	O	O
endometrial	O	O
iatrogenic	O	O
effects	O	O
must	O	O
be	O	O
carefully	O	O
examined	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
association	O	O
between	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
and	O	O
tamoxifen	B-Chemical	D013629
use	O	O
or	O	O
other	O	O
treatments	O	O
in	O	O
women	O	O
treated	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
in	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

Cases	O	O
of	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
diagnosed	O	O
after	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
(	O	O
n	O	O
=	O	O
135	O	O
)	O	O
and	O	O
467	O	O
controls	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
year	O	O
of	O	O
diagnosis	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
and	O	O
hospital	O	O
and	O	O
survival	O	O
time	O	O
with	O	O
an	O	O
intact	O	O
uterus	O	O
were	O	O
included	O	O
.	O	O

Women	O	O
who	O	O
had	O	O
received	O	O
tamoxifen	B-Chemical	D013629
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
diagnosed	O	O
than	O	O
those	O	O
who	O	O
had	O	O
not	O	O
(	O	O
crude	O	O
relative	O	O
risk	O	O
=	O	O
4	O	O
.	O	O

9	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Univariate	O	O
and	O	O
adjusted	O	O
analyses	O	O
showed	O	O
that	O	O
the	O	O
risk	O	O
increased	O	O
with	O	O
the	O	O
length	O	O
of	O	O
treatment	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
or	O	O
the	O	O
cumulative	O	O
dose	O	O
of	O	O
tamoxifen	B-Chemical	D013629
received	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
daily	O	O
dose	O	O
.	O	O

Women	O	O
who	O	O
had	O	O
undergone	O	O
pelvic	O	O
radiotherapy	O	O
also	O	O
had	O	O
a	O	O
higher	O	O
risk	O	O
(	O	O
crude	O	O
relative	O	O
risk	O	O
=	O	O
7	O	O
.	O	O

8	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

After	O	O
adjusting	O	O
for	O	O
confounding	O	O
factors	O	O
,	O	O
the	O	O
risk	O	O
was	O	O
higher	O	O
for	O	O
tamoxifen	B-Chemical	D013629
users	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0012	O	O
)	O	O
,	O	O
treatment	O	O
for	O	O
more	O	O
than	O	O
3	O	O
years	O	O
(	O	O
all	O	O
p	O	O
<	O	O
0	O	O
.	O	O

03	O	O
)	O	O
and	O	O
pelvic	O	O
radiotherapy	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

012	O	O
)	O	O
.	O	O

Women	O	O
who	O	O
had	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
and	O	O
had	O	O
received	O	O
tamoxifen	B-Chemical	D013629
had	O	O
more	O	O
advanced	B-Disease	D020178
disease	I-Disease	D020178
and	O	O
poorer	O	O
prognosis	O	O
than	O	O
those	O	O
with	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
who	O	O
had	O	O
not	O	O
received	O	O
this	O	O
treatment	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
a	O	O
causal	O	O
role	O	O
of	O	O
tamoxifen	B-Chemical	D013629
in	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
,	O	O
particularly	O	O
when	O	O
used	O	O
as	O	O
currently	O	O
proposed	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
prevention	O	O
.	O	O

Pelvic	O	O
radiotherapy	O	O
may	O	O
be	O	O
an	O	O
additional	O	O
iatrogenic	O	O
factor	O	O
for	O	O
women	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Endometrial	B-Disease	D016889
cancers	I-Disease	D016889
diagnosed	O	O
in	O	O
women	O	O
treated	O	O
with	O	O
tamoxifen	B-Chemical	D013629
have	O	O
poorer	O	O
prognosis	O	O
.	O	O

Women	O	O
who	O	O
receive	O	O
tamoxifen	B-Chemical	D013629
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
should	O	O
be	O	O
offered	O	O
gynaecological	O	O
surveillance	O	O
during	O	O
and	O	O
after	O	O
treatment	O	O
.	O	O

A	O	O
long	O	O
-	O	O
term	O	O
evaluation	O	O
of	O	O
the	O	O
risk	O	O
-	O	O
benefit	O	O
ratio	O	O
of	O	O
tamoxifen	B-Chemical	D013629
as	O	O
a	O	O
preventive	O	O
treatment	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
is	O	O
clearly	O	O
warranted	O	O
.	O	O

Granulosa	B-Disease	C537296
cell	I-Disease	C537296
tumor	I-Disease	C537296
of	I-Disease	C537296
the	I-Disease	C537296
ovary	I-Disease	C537296
associated	O	O
with	O	O
antecedent	O	O
tamoxifen	B-Chemical	D013629
use	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Increased	O	O
attention	O	O
has	O	O
been	O	O
focused	O	O
recently	O	O
on	O	O
the	O	O
estrogenic	O	O
effects	O	O
of	O	O
tamoxifen	B-Chemical	D013629
.	O	O

Review	O	O
of	O	O
the	O	O
literature	O	O
reveals	O	O
an	O	O
association	O	O
between	O	O
tamoxifen	B-Chemical	D013629
use	O	O
and	O	O
gynecologic	O	O
tumors	B-Disease	D009369
.	O	O

CASE	O	O
:	O	O
A	O	O
52	O	O
-	O	O
year	O	O
-	O	O
old	O	O
postmenopausal	O	O
woman	O	O
was	O	O
treated	O	O
with	O	O
tamoxifen	B-Chemical	D013629
for	O	O
stage	O	O
II	O	O
estrogen	B-Chemical	D004967
receptor	O	O
-	O	O
positive	O	O
breast	B-Disease	D001943
carcinoma	I-Disease	D001943
.	O	O

Her	O	O
aspartate	B-Chemical	D001224
transaminase	O	O
and	O	O
alanine	B-Chemical	D000409
transaminase	O	O
levels	O	O
increase	O	O
markedly	O	O
after	O	O
6	O	O
months	O	O
of	O	O
tamoxifen	B-Chemical	D013629
use	O	O
.	O	O

After	O	O
an	O	O
additional	O	O
17	O	O
months	O	O
of	O	O
elevated	O	O
serum	O	O
transaminases	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
stage	O	O
Ic	O	O
granulosa	B-Disease	C537296
cell	I-Disease	C537296
tumor	I-Disease	C537296
of	I-Disease	C537296
the	I-Disease	C537296
ovary	I-Disease	C537296
.	O	O

CONCLUSION	O	O
:	O	O
Patients	O	O
with	O	O
tamoxifen	B-Chemical	D013629
-	O	O
induced	O	O
liver	B-Disease	D017093
dysfunction	I-Disease	D017093
may	O	O
be	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
granulosa	B-Disease	D006106
cell	I-Disease	D006106
tumors	I-Disease	D006106
because	O	O
of	O	O
alterations	O	O
in	O	O
tamoxifen	B-Chemical	D013629
metabolism	O	O
.	O	O

A	O	O
murine	O	O
model	O	O
of	O	O
adenomyosis	B-Disease	D062788
:	O	O
the	O	O
effects	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
induced	O	O
by	O	O
fluoxetine	B-Chemical	D005473
hydrochloride	I-Chemical	D005473
,	O	O
a	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
,	O	O
on	O	O
adenomyosis	B-Disease	D062788
induction	O	O
in	O	O
Wistar	O	O
albino	O	O
rats	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
fluoxetine	B-Chemical	D005473
given	O	O
to	O	O
castrated	O	O
and	O	O
noncastrated	O	O
rats	O	O
caused	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
its	O	O
effects	O	O
with	O	O
respect	O	O
to	O	O
adenomyosis	B-Disease	D062788
.	O	O

DESIGN	O	O
:	O	O
Fluoxetine	B-Chemical	D005473
,	O	O
a	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
,	O	O
was	O	O
given	O	O
to	O	O
Wistar	O	O
Albino	O	O
rats	O	O
for	O	O
98	O	O
days	O	O
to	O	O
produce	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

The	O	O
drug	O	O
was	O	O
given	O	O
to	O	O
two	O	O
groups	O	O
consisting	O	O
of	O	O
castrated	O	O
and	O	O
noncastrated	O	O
rats	O	O
and	O	O
compared	O	O
to	O	O
two	O	O
groups	O	O
of	O	O
castrated	O	O
and	O	O
noncastrated	O	O
controls	O	O
.	O	O

Prolactin	O	O
levels	O	O
were	O	O
measured	O	O
and	O	O
the	O	O
uteri	O	O
of	O	O
the	O	O
rats	O	O
were	O	O
removed	O	O
for	O	O
histopathological	O	O
analysis	O	O
at	O	O
the	O	O
end	O	O
of	O	O
98	O	O
days	O	O
.	O	O

SETTING	O	O
:	O	O
Marmara	O	O
University	O	O
School	O	O
of	O	O
Medicine	O	O
,	O	O
Department	O	O
of	O	O
Histology	O	O
and	O	O
Embryology	O	O
,	O	O
Zeynep	O	O
Kamil	O	O
Women	O	O
and	O	O
Children's	O	O
Hospital	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
:	O	O
Serum	O	O
prolactin	O	O
levels	O	O
,	O	O
uterine	O	O
histopathology	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
prolactin	O	O
levels	O	O
of	O	O
castrated	O	O
and	O	O
noncastrated	O	O
groups	O	O
treated	O	O
with	O	O
fluoxetine	B-Chemical	D005473
were	O	O
statistically	O	O
significantly	O	O
higher	O	O
when	O	O
compared	O	O
to	O	O
their	O	O
respective	O	O
control	O	O
groups	O	O
.	O	O

Histological	O	O
studies	O	O
revealed	O	O
11	O	O
cases	O	O
of	O	O
adenomyosis	B-Disease	D062788
,	O	O
all	O	O
within	O	O
the	O	O
noncastrated	O	O
group	O	O
receiving	O	O
fluoxetine	B-Chemical	D005473
.	O	O

CONCLUSION	O	O
:	O	O
It	O	O
was	O	O
suggested	O	O
that	O	O
high	O	O
serum	O	O
prolactin	O	O
levels	O	O
cause	O	O
degeneration	O	O
of	O	O
myometrial	O	O
cells	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
ovarian	O	O
steroids	B-Chemical	D013256
that	O	O
results	O	O
in	O	O
a	O	O
myometrial	O	O
invasion	O	O
by	O	O
endometrial	O	O
stroma	O	O
.	O	O

This	O	O
invasion	O	O
eventually	O	O
progresses	O	O
to	O	O
adenomyosis	B-Disease	D062788
.	O	O

Effects	O	O
of	O	O
deliberate	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
labetalol	B-Chemical	D007741
with	O	O
isoflurane	B-Chemical	D007530
on	O	O
neuropsychological	O	O
function	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
deliberate	O	O
hypotension	B-Disease	D007022
on	O	O
brain	O	O
function	O	O
measured	O	O
by	O	O
neuropsychological	O	O
tests	O	O
was	O	O
studied	O	O
in	O	O
41	O	O
adult	O	O
patients	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
patients	O	O
were	O	O
anaesthetized	O	O
for	O	O
middle	O	O
-	O	O
ear	O	O
surgery	O	O
with	O	O
deliberate	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
labetalol	B-Chemical	D007741
with	O	O
isoflurane	B-Chemical	D007530
(	O	O
hypotensive	B-Disease	D007022
group	O	O
)	O	O
.	O	O

Seventeen	O	O
patients	O	O
without	O	O
hypotension	B-Disease	D007022
served	O	O
as	O	O
a	O	O
control	O	O
group	O	O
.	O	O

The	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
77	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mmHg	O	O
(	O	O
10	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
kPa	O	O
)	O	O
before	O	O
hypotension	B-Disease	D007022
and	O	O
50	O	O
+	O	O
/	O	O
-	O	O
0	O	O
mmHg	O	O
(	O	O
6	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

0	O	O
kPa	O	O
)	O	O
during	O	O
hypotension	B-Disease	D007022
in	O	O
the	O	O
hypotensive	B-Disease	D007022
group	O	O
,	O	O
and	O	O
86	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mmHg	O	O
(	O	O
11	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
kPa	O	O
)	O	O
during	O	O
anaesthesia	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

The	O	O
following	O	O
psychological	O	O
tests	O	O
were	O	O
performed	O	O
:	O	O
four	O	O
subtests	O	O
of	O	O
the	O	O
Wechsler	O	O
Adult	O	O
Intelligence	O	O
Scale	O	O
(	O	O
similarities	O	O
,	O	O
digit	O	O
span	O	O
,	O	O
vocabulary	O	O
and	O	O
digit	O	O
symbol	O	O
)	O	O
,	O	O
Trail	O	O
-	O	O
Making	O	O
tests	O	O
A	O	O
and	O	O
B	O	O
,	O	O
Zung	O	O
tests	O	O
(	O	O
self	O	O
-	O	O
rating	O	O
anxiety	B-Disease	D001008
scale	O	O
and	O	O
self	O	O
-	O	O
rating	O	O
depression	B-Disease	D003866
scale	O	O
)	O	O
and	O	O
two	O	O
-	O	O
part	O	O
memory	O	O
test	O	O
battery	O	O
with	O	O
immediate	O	O
and	O	O
delayed	O	O
recall	O	O
.	O	O

The	O	O
tests	O	O
were	O	O
performed	O	O
preoperatively	O	O
and	O	O
2	O	O
days	O	O
postoperatively	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
in	O	O
any	O	O
of	O	O
the	O	O
tests	O	O
in	O	O
the	O	O
changes	O	O
from	O	O
preoperative	O	O
value	O	O
to	O	O
postoperative	O	O
value	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
labetalol	B-Chemical	D007741
with	O	O
isoflurane	B-Chemical	D007530
has	O	O
no	O	O
significant	O	O
harmful	O	O
effects	O	O
on	O	O
mental	O	O
functions	O	O
compared	O	O
to	O	O
normotensive	O	O
anaesthesia	O	O
.	O	O

Auditory	O	O
disturbance	O	O
associated	O	O
with	O	O
interscalene	O	O
brachial	O	O
plexus	O	O
block	O	O
.	O	O

We	O	O
performed	O	O
an	O	O
audiometric	O	O
study	O	O
in	O	O
20	O	O
patients	O	O
who	O	O
underwent	O	O
surgery	O	O
of	O	O
the	O	O
shoulder	O	O
region	O	O
under	O	O
an	O	O
interscalene	O	O
brachial	O	O
plexus	O	O
block	O	O
(	O	O
IBPB	O	O
)	O	O
.	O	O

Bupivacaine	B-Chemical	D002045
0	O	O
.	O	O

75%	O	O
with	O	O
adrenaline	B-Chemical	D004837
was	O	O
given	O	O
followed	O	O
by	O	O
a	O	O
24	O	O
-	O	O
hr	O	O
continuous	O	O
infusion	O	O
of	O	O
0	O	O
.	O	O

25%	O	O
bupivacaine	B-Chemical	D002045
.	O	O

Three	O	O
audiometric	O	O
threshold	O	O
measurements	O	O
(	O	O
0	O	O
.	O	O

25	O	O
-	O	O
18	O	O
kHz	O	O
)	O	O
were	O	O
made	O	O
:	O	O
the	O	O
first	O	O
before	O	O
IBPB	O	O
,	O	O
the	O	O
second	O	O
2	O	O
-	O	O
6	O	O
h	O	O
after	O	O
surgery	O	O
and	O	O
the	O	O
third	O	O
on	O	O
the	O	O
first	O	O
day	O	O
after	O	O
operation	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
hearing	B-Disease	D034381
impairment	I-Disease	D034381
on	O	O
the	O	O
side	O	O
of	O	O
the	O	O
block	O	O
was	O	O
demonstrated	O	O
after	O	O
operation	O	O
,	O	O
in	O	O
three	O	O
measurements	O	O
on	O	O
the	O	O
day	O	O
of	O	O
surgery	O	O
and	O	O
in	O	O
one	O	O
on	O	O
the	O	O
following	O	O
day	O	O
.	O	O

The	O	O
frequencies	O	O
at	O	O
which	O	O
the	O	O
impairment	O	O
occurred	O	O
varied	O	O
between	O	O
patients	O	O
;	O	O
in	O	O
one	O	O
only	O	O
low	O	O
frequencies	O	O
(	O	O
0	O	O
.	O	O

25	O	O
-	O	O
0	O	O
.	O	O

5	O	O
kHz	O	O
)	O	O
were	O	O
involved	O	O
.	O	O

The	O	O
maximum	O	O
change	O	O
in	O	O
threshold	O	O
was	O	O
35	O	O
dB	O	O
at	O	O
6	O	O
kHz	O	O
measured	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
continuous	O	O
infusion	O	O
of	O	O
bupivacaine	B-Chemical	D002045
.	O	O

This	O	O
patient	O	O
had	O	O
hearing	O	O
threshold	O	O
changes	O	O
(	O	O
15	O	O
-	O	O
20	O	O
dB	O	O
)	O	O
at	O	O
6	O	O
-	O	O
10	O	O
kHz	O	O
on	O	O
the	O	O
opposite	O	O
side	O	O
also	O	O
.	O	O

IBPB	O	O
may	O	O
cause	O	O
transient	O	O
auditory	B-Disease	D006311
dysfunction	I-Disease	D006311
in	O	O
the	O	O
ipsilateral	O	O
ear	O	O
,	O	O
possibly	O	O
via	O	O
an	O	O
effect	O	O
on	O	O
sympathetic	O	O
innervation	O	O
.	O	O

Midazolam	B-Chemical	D008874
compared	O	O
with	O	O
thiopentone	B-Chemical	D013874
as	O	O
an	O	O
induction	O	O
agent	O	O
.	O	O

In	O	O
patients	O	O
premedicated	O	O
with	O	O
scopolamine	B-Chemical	D012601
+	O	O
morphine	B-Chemical	D009020
(	O	O
+5	O	O
mg	O	O
nitrazepam	B-Chemical	D009567
the	O	O
evening	O	O
before	O	O
surgery	O	O
)	O	O
,	O	O
the	O	O
sleep	O	O
-	O	O
inducing	O	O
effect	O	O
of	O	O
midazolam	B-Chemical	D008874
0	O	O
.	O	O

15	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

was	O	O
clearly	O	O
slower	O	O
in	O	O
onset	O	O
than	O	O
that	O	O
of	O	O
thiopentone	B-Chemical	D013874
4	O	O
.	O	O

67	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

Somewhat	O	O
fewer	O	O
cardiovascular	O	O
and	O	O
local	O	O
sequelae	O	O
were	O	O
found	O	O
in	O	O
the	O	O
midazolam	B-Chemical	D008874
group	O	O
,	O	O
but	O	O
,	O	O
although	O	O
apnoea	B-Disease	D001049
occurred	O	O
less	O	O
often	O	O
in	O	O
the	O	O
midazolam	B-Chemical	D008874
group	O	O
it	O	O
lasted	O	O
longer	O	O
.	O	O

On	O	O
the	O	O
whole	O	O
,	O	O
the	O	O
differences	O	O
between	O	O
midazolam	B-Chemical	D008874
and	O	O
thiopentone	B-Chemical	D013874
had	O	O
no	O	O
apparent	O	O
clinical	O	O
consequences	O	O
.	O	O

Midazolam	B-Chemical	D008874
is	O	O
a	O	O
new	O	O
alternative	O	O
agent	O	O
for	O	O
induction	O	O
in	O	O
combination	O	O
anaesthesia	O	O
.	O	O

Cardiotoxic	B-Disease	D066126
and	O	O
possible	O	O
leukemogenic	O	O
effects	O	O
of	O	O
adriamycin	B-Chemical	D004317
in	O	O
nonhuman	O	O
primates	O	O
.	O	O

10	O	O
monkeys	O	O
(	O	O
macaques	O	O
)	O	O
received	O	O
adriamycin	B-Chemical	D004317
by	O	O
monthly	O	O
intravenous	O	O
injections	O	O
at	O	O
12	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

8	O	O
of	O	O
the	O	O
10	O	O
monkeys	O	O
developed	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
at	O	O
an	O	O
average	O	O
cumulative	O	O
adriamycin	B-Chemical	D004317
dose	O	O
(	O	O
310	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
well	O	O
below	O	O
that	O	O
considered	O	O
the	O	O
safe	O	O
upper	O	O
limit	O	O
(	O	O
550	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
in	O	O
man	O	O
.	O	O

Histologically	O	O
,	O	O
the	O	O
myocardial	B-Disease	D001768
lesions	I-Disease	D001768
resembled	O	O
those	O	O
found	O	O
in	O	O
human	O	O
anthracycline	B-Chemical	D018943
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

1	O	O
of	O	O
the	O	O
10	O	O
monkeys	O	O
developed	O	O
acute	B-Disease	D015470
myeloblastic	I-Disease	D015470
leukemia	I-Disease	D015470
after	O	O
receiving	O	O
324	O	O
mg	O	O
/	O	O
m2	O	O
of	O	O
adriamycin	B-Chemical	D004317
;	O	O
the	O	O
10th	O	O
monkey	O	O
is	O	O
alive	O	O
and	O	O
well	O	O
26	O	O
months	O	O
after	O	O
the	O	O
last	O	O
dose	O	O
of	O	O
drug	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
adriamycin	B-Chemical	D004317
is	O	O
a	O	O
more	O	O
potent	O	O
cardiotoxin	O	O
in	O	O
monkeys	O	O
than	O	O
in	O	O
man	O	O
,	O	O
and	O	O
that	O	O
leukemia	B-Disease	D007938
may	O	O
be	O	O
a	O	O
consequence	O	O
of	O	O
prolonged	O	O
treatment	O	O
with	O	O
this	O	O
drug	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
in	O	O
children	O	O
with	O	O
left	O	O
-	O	O
sided	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
.	O	O

Two	O	O
children	O	O
with	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
of	O	O
the	O	O
left	O	O
kidney	O	O
experienced	O	O
severe	O	O
anthracycline	B-Chemical	D018943
cardiomyopathy	B-Disease	D009202
after	O	O
irradiation	O	O
to	O	O
the	O	O
tumor	B-Disease	D009369
bed	O	O
and	O	O
conventional	O	O
dosage	O	O
of	O	O
doxorubicin	B-Chemical	D004317
.	O	O

The	O	O
cardiomyopathy	B-Disease	D009202
is	O	O
attributed	O	O
1	O	O
)	O	O
to	O	O
the	O	O
fact	O	O
that	O	O
radiation	O	O
fields	O	O
for	O	O
left	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
include	O	O
the	O	O
lower	O	O
portion	O	O
of	O	O
the	O	O
heart	O	O
and	O	O
2	O	O
)	O	O
to	O	O
the	O	O
interaction	O	O
of	O	O
doxorubicin	B-Chemical	D004317
and	O	O
irradiation	O	O
on	O	O
cardiac	O	O
muscle	O	O
.	O	O

It	O	O
is	O	O
recommended	O	O
that	O	O
doxorubicin	B-Chemical	D004317
dosage	O	O
be	O	O
sharply	O	O
restricted	O	O
in	O	O
children	O	O
with	O	O
Wilms	B-Disease	D009396
tumor	I-Disease	D009396
of	O	O
the	O	O
left	O	O
kidney	O	O
who	O	O
receive	O	O
postoperative	O	O
irradiation	O	O
.	O	O

Promotional	O	O
effects	O	O
of	O	O
testosterone	B-Chemical	D013739
and	O	O
dietary	O	O
fat	O	O
on	O	O
prostate	O	O
carcinogenesis	B-Disease	D063646
in	O	O
genetically	O	O
susceptible	O	O
rats	O	O
.	O	O

Germfree	O	O
(	O	O
GF	O	O
)	O	O
Lobund	O	O
strain	O	O
Wistar	O	O
(	O	O
LW	O	O
)	O	O
rats	O	O
,	O	O
fed	O	O
vegetable	O	O
diet	O	O
L	O	O
-	O	O
485	O	O
,	O	O
have	O	O
developed	O	O
prostate	B-Disease	D011471
adenocarcinomas	I-Disease	D011471
spontaneously	O	O
(	O	O
10%	O	O
incidence	O	O
)	O	O
at	O	O
average	O	O
age	O	O
34	O	O
months	O	O
.	O	O

Conventional	O	O
LW	O	O
rats	O	O
,	O	O
implanted	O	O
with	O	O
testosterone	B-Chemical	D013739
at	O	O
age	O	O
4	O	O
months	O	O
,	O	O
developed	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
after	O	O
an	O	O
average	O	O
interval	O	O
of	O	O
14	O	O
months	O	O
:	O	O
24%	O	O
had	O	O
developed	O	O
gross	O	O
tumors	B-Disease	D009369
,	O	O
and	O	O
40%	O	O
when	O	O
it	O	O
included	O	O
microscopic	O	O
tumors	B-Disease	D009369
.	O	O

Preliminary	O	O
results	O	O
indicate	O	O
that	O	O
testosterone	B-Chemical	D013739
-	O	O
treated	O	O
LW	O	O
rats	O	O
that	O	O
were	O	O
fed	O	O
the	O	O
same	O	O
diet	O	O
,	O	O
which	O	O
was	O	O
supplemented	O	O
with	O	O
corn	O	O
oil	O	O
up	O	O
to	O	O
20%	O	O
fat	O	O
,	O	O
developed	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
after	O	O
intervals	O	O
of	O	O
6	O	O
-	O	O
12	O	O
months	O	O
.	O	O

Aged	O	O
GF	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
have	O	O
not	O	O
developed	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
spontaneously	O	O
.	O	O

Conventional	O	O
SD	O	O
rats	O	O
fed	O	O
diet	O	O
L	O	O
-	O	O
485	O	O
and	O	O
treated	O	O
with	O	O
testosterone	B-Chemical	D013739
developed	O	O
only	O	O
prostatitis	B-Disease	D011472
.	O	O

Experimental	O	O
designs	O	O
should	O	O
consider	O	O
genetic	O	O
susceptibility	O	O
as	O	O
a	O	O
basic	O	O
prerequisite	O	O
for	O	O
studies	O	O
on	O	O
experimental	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

Mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
associated	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

Mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
associated	O	O
Hemolytic	B-Disease	D006463
Uremic	I-Disease	D006463
Syndrome	I-Disease	D006463
(	O	O
HUS	B-Disease	D006463
)	O	O
is	O	O
a	O	O
potentially	O	O
fatal	O	O
but	O	O
uncommon	O	O
condition	O	O
that	O	O
is	O	O
not	O	O
yet	O	O
widely	O	O
recognised	O	O
.	O	O

It	O	O
consists	O	O
of	O	O
microangiopathic	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
,	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
progressive	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
associated	O	O
with	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
treatment	O	O
and	O	O
affects	O	O
about	O	O
10%	O	O
of	O	O
patients	O	O
treated	O	O
with	O	O
this	O	O
agent	O	O
.	O	O

The	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
usually	O	O
develops	O	O
about	O	O
8	O	O
-	O	O
10	O	O
mth	O	O
after	O	O
start	O	O
of	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
treatment	O	O
and	O	O
the	O	O
mortality	O	O
is	O	O
approximately	O	O
60%	O	O
from	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
or	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
.	O	O

Renal	B-Disease	D051437
lesions	I-Disease	D051437
are	O	O
similar	O	O
to	O	O
those	O	O
seen	O	O
in	O	O
idiopathic	O	O
HUS	B-Disease	D006463
and	O	O
include	O	O
arteriolar	O	O
fibrin	O	O
thrombi	B-Disease	D013927
,	O	O
expanded	O	O
subendothelial	O	O
zones	O	O
in	O	O
glomerular	O	O
capillary	O	O
walls	O	O
,	O	O
ischemic	B-Disease	D007511
wrinkling	O	O
of	O	O
glomerular	O	O
basement	O	O
membranes	O	O
and	O	O
mesangiolysis	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
postulated	O	O
as	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
-	O	O
induced	O	O
endothelial	O	O
cell	O	O
damage	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
clinical	O	O
course	O	O
and	O	O
pathological	O	O
findings	O	O
in	O	O
a	O	O
65	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
with	O	O
gastric	B-Disease	D013274
adenocarcinoma	I-Disease	D013274
who	O	O
developed	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
thrombocytopenia	B-Disease	D013921
while	O	O
on	O	O
treatment	O	O
with	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
and	O	O
died	O	O
in	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
.	O	O

Continuous	O	O
ambulatory	O	O
ECG	O	O
monitoring	O	O
during	O	O
fluorouracil	B-Chemical	D005472
therapy	O	O
:	O	O
a	O	O
prospective	O	O
study	O	O
.	O	O

Although	O	O
there	O	O
have	O	O
been	O	O
anecdotal	O	O
reports	O	O
of	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
associated	O	O
with	O	O
fluorouracil	B-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
therapy	O	O
,	O	O
this	O	O
phenomenon	O	O
has	O	O
not	O	O
been	O	O
studied	O	O
in	O	O
a	O	O
systematic	O	O
fashion	O	O
.	O	O

We	O	O
prospectively	O	O
performed	O	O
continuous	O	O
ambulatory	O	O
ECG	O	O
monitoring	O	O
on	O	O
25	O	O
patients	O	O
undergoing	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
for	O	O
treatment	O	O
of	O	O
solid	O	O
tumors	B-Disease	D009369
in	O	O
order	O	O
to	O	O
assess	O	O
the	O	O
incidence	O	O
of	O	O
ischemic	B-Disease	D007511
ST	O	O
changes	O	O
.	O	O

Patients	O	O
were	O	O
monitored	O	O
for	O	O
23	O	O
+	O	O
/	O	O
-	O	O
4	O	O
hours	O	O
before	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
,	O	O
and	O	O
98	O	O
+	O	O
/	O	O
-	O	O
9	O	O
hours	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
.	O	O

Anginal	B-Disease	D000787
episodes	O	O
were	O	O
rare	O	O
:	O	O
only	O	O
one	O	O
patient	O	O
had	O	O
angina	B-Disease	D000787
(	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
)	O	O
.	O	O

However	O	O
,	O	O
asymptomatic	O	O
ST	O	O
changes	O	O
(	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
1	O	O
mm	O	O
ST	O	O
deviation	O	O
)	O	O
were	O	O
common	O	O
:	O	O
six	O	O
of	O	O
25	O	O
patients	O	O
(	O	O
24%	O	O
)	O	O
had	O	O
ST	O	O
changes	O	O
before	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
v	O	O
17	O	O
(	O	O
68%	O	O
)	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

002	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
ischemic	B-Disease	D007511
episodes	O	O
per	O	O
patient	O	O
per	O	O
hour	O	O
was	O	O
0	O	O
.	O	O

05	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

02	O	O
prior	O	O
to	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
v	O	O
0	O	O
.	O	O

13	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

03	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

001	O	O
)	O	O
;	O	O
the	O	O
duration	O	O
of	O	O
ECG	O	O
changes	O	O
was	O	O
0	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
minutes	O	O
per	O	O
patient	O	O
per	O	O
hour	O	O
before	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
v	O	O
1	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
minutes	O	O
per	O	O
patient	O	O
per	O	O
hour	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

01	O	O
)	O	O
.	O	O

ECG	O	O
changes	O	O
were	O	O
more	O	O
common	O	O
among	O	O
patients	O	O
with	O	O
known	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

There	O	O
were	O	O
two	O	O
cases	O	O
of	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
,	O	O
both	O	O
of	O	O
which	O	O
occurred	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
chemotherapy	O	O
course	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
infusion	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
silent	O	O
ST	O	O
segment	O	O
deviation	O	O
suggestive	O	O
of	O	O
ischemia	B-Disease	D007511
,	O	O
particularly	O	O
among	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

The	O	O
mechanism	O	O
and	O	O
clinical	O	O
significance	O	O
of	O	O
these	O	O
ECG	O	O
changes	O	O
remain	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

Lethal	O	O
anuria	B-Disease	D001002
complicating	O	O
high	O	O
dose	O	O
ifosfamide	B-Chemical	D007069
chemotherapy	O	O
in	O	O
a	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patient	O	O
with	O	O
an	O	O
impaired	B-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
.	O	O

A	O	O
sixty	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
advanced	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
previously	O	O
treated	O	O
with	O	O
cisplatin	B-Chemical	D002945
,	O	O
developed	O	O
an	O	O
irreversible	O	O
lethal	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
with	O	O
anuria	B-Disease	D001002
,	O	O
the	O	O
day	O	O
after	O	O
5	O	O
g	O	O
/	O	O
m2	O	O
bolus	O	O
ifosfamide	B-Chemical	D007069
.	O	O

Postrenal	B-Disease	D007674
failure	I-Disease	D007674
was	O	O
excluded	O	O
by	O	O
echography	O	O
.	O	O

A	O	O
prerenal	O	O
component	O	O
could	O	O
have	O	O
contributed	O	O
to	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
because	O	O
of	O	O
a	O	O
transient	O	O
hypotension	B-Disease	D007022
,	O	O
due	O	O
to	O	O
an	O	O
increasing	O	O
ascitis	O	O
,	O	O
occurring	O	O
just	O	O
before	O	O
anuria	B-Disease	D001002
.	O	O

However	O	O
,	O	O
correction	O	O
of	O	O
the	O	O
hemodynamic	O	O
parameters	O	O
did	O	O
not	O	O
improve	O	O
renal	O	O
function	O	O
.	O	O

Ifosfamide	B-Chemical	D007069
is	O	O
a	O	O
known	O	O
nephrotoxic	B-Disease	D007674
drug	O	O
with	O	O
demonstrated	O	O
tubulopathies	B-Disease	D007674
.	O	O

We	O	O
strongly	O	O
suspect	O	O
that	O	O
this	O	O
lethal	O	O
anuria	B-Disease	D001002
was	O	O
mainly	O	O
due	O	O
to	O	O
ifosfamide	B-Chemical	D007069
,	O	O
occurring	O	O
in	O	O
a	O	O
patient	O	O
having	O	O
received	O	O
previous	O	O
cisplatin	B-Chemical	D002945
chemotherapy	O	O
and	O	O
with	O	O
poor	O	O
kidney	O	O
perfusion	O	O
due	O	O
to	O	O
transient	O	O
hypotension	B-Disease	D007022
.	O	O

We	O	O
recommend	O	O
careful	O	O
use	O	O
of	O	O
ifosfamide	B-Chemical	D007069
in	O	O
patients	O	O
pretreated	O	O
with	O	O
nephrotoxic	B-Disease	D007674
chemotherapy	O	O
and	O	O
inadequate	O	O
renal	O	O
perfusion	O	O
.	O	O

Central	O	O
vein	B-Disease	D020246
thrombosis	I-Disease	D020246
and	O	O
topical	O	O
dipivalyl	B-Chemical	C015173
epinephrine	I-Chemical	C015173
.	O	O

A	O	O
report	O	O
is	O	O
given	O	O
on	O	O
an	O	O
83	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
who	O	O
acquired	O	O
central	O	O
vein	B-Disease	D020246
thrombosis	I-Disease	D020246
in	O	O
her	O	O
seeing	O	O
eye	O	O
one	O	O
day	O	O
after	O	O
having	O	O
started	O	O
topical	O	O
medication	O	O
with	O	O
dipivalyl	B-Chemical	C015173
epinephrine	I-Chemical	C015173
for	O	O
advanced	O	O
glaucoma	B-Disease	D005901
discovered	O	O
in	O	O
the	O	O
other	O	O
eye	O	O
.	O	O

From	O	O
present	O	O
knowledge	O	O
about	O	O
the	O	O
effects	O	O
of	O	O
adrenergic	O	O
eye	O	O
drops	O	O
on	O	O
ocular	O	O
blood	O	O
circulation	O	O
,	O	O
it	O	O
is	O	O
difficult	O	O
to	O	O
suggest	O	O
an	O	O
association	O	O
between	O	O
the	O	O
two	O	O
events	O	O
,	O	O
which	O	O
may	O	O
be	O	O
coincidental	O	O
only	O	O
.	O	O

Amelioration	O	O
of	O	O
bendrofluazide	B-Chemical	D001539
-	O	O
induced	O	O
hypokalemia	B-Disease	D007008
by	O	O
timolol	B-Chemical	D013999
.	O	O

The	O	O
beta	O	O
adrenergic	O	O
blocking	O	O
drug	O	O
,	O	O
timolol	B-Chemical	D013999
,	O	O
tended	O	O
to	O	O
correct	O	O
the	O	O
hypokalemia	B-Disease	D007008
of	O	O
short	O	O
-	O	O
term	O	O
bendrofluazide	B-Chemical	D001539
treatment	O	O
in	O	O
6	O	O
healthy	O	O
male	O	O
subjects	O	O
and	O	O
although	O	O
the	O	O
effect	O	O
was	O	O
small	O	O
it	O	O
was	O	O
significant	O	O
.	O	O

Timolol	B-Chemical	D013999
also	O	O
reduced	O	O
the	O	O
rise	O	O
in	O	O
plasma	O	O
aldosterone	B-Chemical	D000450
and	O	O
urine	O	O
potassium	B-Chemical	D011188
excretion	O	O
following	O	O
bendrofluazide	B-Chemical	D001539
and	O	O
increased	O	O
the	O	O
urine	O	O
sodium	B-Chemical	D012964
/	O	O
potassium	B-Chemical	D011188
ratio	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
a	O	O
shift	O	O
of	O	O
potassium	B-Chemical	D011188
from	O	O
the	O	O
intracellular	O	O
to	O	O
the	O	O
extracellular	O	O
space	O	O
.	O	O

A	O	O
cross	O	O
-	O	O
sectional	O	O
evaluation	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
risperidone	B-Chemical	D018967
and	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
on	O	O
bone	O	O
mineral	O	O
density	O	O
in	O	O
boys	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
on	O	O
trabecular	O	O
bone	O	O
mineral	O	O
density	O	O
(	O	O
BMD	O	O
)	O	O
in	O	O
children	O	O
and	O	O
adolescents	O	O
.	O	O

METHOD	O	O
:	O	O
Medically	O	O
healthy	O	O
7	O	O
-	O	O
to	O	O
17	O	O
-	O	O
year	O	O
-	O	O
old	O	O
males	O	O
chronically	O	O
treated	O	O
,	O	O
in	O	O
a	O	O
naturalistic	O	O
setting	O	O
,	O	O
with	O	O
risperidone	B-Chemical	D018967
were	O	O
recruited	O	O
for	O	O
this	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
through	O	O
child	O	O
psychiatry	O	O
outpatient	O	O
clinics	O	O
between	O	O
November	O	O
2005	O	O
and	O	O
June	O	O
2007	O	O
.	O	O

Anthropometric	O	O
measurements	O	O
and	O	O
laboratory	O	O
testing	O	O
were	O	O
conducted	O	O
.	O	O

The	O	O
clinical	O	O
diagnoses	O	O
were	O	O
based	O	O
on	O	O
chart	O	O
review	O	O
,	O	O
and	O	O
developmental	O	O
and	O	O
treatment	O	O
history	O	O
was	O	O
obtained	O	O
from	O	O
the	O	O
medical	O	O
record	O	O
.	O	O

Volumetric	O	O
BMD	O	O
of	O	O
the	O	O
ultradistal	O	O
radius	O	O
was	O	O
measured	O	O
using	O	O
peripheral	O	O
quantitative	O	O
computed	O	O
tomography	O	O
,	O	O
and	O	O
areal	O	O
BMD	O	O
of	O	O
the	O	O
lumbar	O	O
spine	O	O
was	O	O
estimated	O	O
using	O	O
dual	O	O
-	O	O
energy	O	O
x	O	O
-	O	O
ray	O	O
absorptiometry	O	O
.	O	O

RESULTS	O	O
:	O	O
Hyperprolactinemia	B-Disease	D006966
was	O	O
present	O	O
in	O	O
49%	O	O
of	O	O
83	O	O
boys	O	O
(	O	O
n	O	O
=	O	O
41	O	O
)	O	O
treated	O	O
with	O	O
risperidone	B-Chemical	D018967
for	O	O
a	O	O
mean	O	O
of	O	O
2	O	O
.	O	O

9	O	O
years	O	O
.	O	O

Serum	O	O
testosterone	B-Chemical	D013739
concentration	O	O
increased	O	O
with	O	O
pubertal	O	O
status	O	O
but	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

As	O	O
expected	O	O
,	O	O
bone	O	O
mineral	O	O
content	O	O
and	O	O
BMD	O	O
increased	O	O
with	O	O
sexual	O	O
maturity	O	O
.	O	O

After	O	O
adjusting	O	O
for	O	O
the	O	O
stage	O	O
of	O	O
sexual	O	O
development	O	O
and	O	O
height	O	O
and	O	O
BMI	O	O
z	O	O
scores	O	O
,	O	O
serum	O	O
prolactin	O	O
was	O	O
negatively	O	O
associated	O	O
with	O	O
trabecular	O	O
volumetric	O	O
BMD	O	O
at	O	O
the	O	O
ultradistal	O	O
radius	O	O
(	O	O
P	O	O
<	O	O
.	O	O

03	O	O
)	O	O
.	O	O

Controlling	O	O
for	O	O
relevant	O	O
covariates	O	O
,	O	O
we	O	O
also	O	O
found	O	O
treatment	O	O
with	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
(	O	O
SSRIs	O	O
)	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
lower	O	O
trabecular	O	O
BMD	O	O
at	O	O
the	O	O
radius	O	O
(	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
and	O	O
BMD	O	O
z	O	O
score	O	O
at	O	O
the	O	O
lumbar	O	O
spine	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
.	O	O

These	O	O
findings	O	O
became	O	O
more	O	O
marked	O	O
when	O	O
the	O	O
analysis	O	O
was	O	O
restricted	O	O
to	O	O
non	O	O
-	O	O
Hispanic	O	O
white	O	O
patients	O	O
.	O	O

Of	O	O
13	O	O
documented	O	O
fractures	B-Disease	D050723
,	O	O
3	O	O
occurred	O	O
after	O	O
risperidone	B-Chemical	D018967
and	O	O
SSRIs	O	O
were	O	O
started	O	O
,	O	O
and	O	O
none	O	O
occurred	O	O
in	O	O
patients	O	O
with	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
link	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
SSRI	O	O
treatment	O	O
to	O	O
lower	O	O
BMD	O	O
in	O	O
children	O	O
and	O	O
adolescents	O	O
.	O	O

Future	O	O
research	O	O
should	O	O
evaluate	O	O
the	O	O
longitudinal	O	O
course	O	O
of	O	O
this	O	O
adverse	O	O
event	O	O
to	O	O
determine	O	O
its	O	O
temporal	O	O
stability	O	O
and	O	O
whether	O	O
a	O	O
higher	O	O
fracture	O	O
rate	O	O
ensues	O	O
.	O	O

Seizures	B-Disease	D012640
associated	O	O
with	O	O
levofloxacin	B-Chemical	D064704
:	O	O
case	O	O
presentation	O	O
and	O	O
literature	O	O
review	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
seizures	B-Disease	D012640
shortly	O	O
after	O	O
initiating	O	O
treatment	O	O
with	O	O
levofloxacin	B-Chemical	D064704
and	O	O
to	O	O
discuss	O	O
the	O	O
potential	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
related	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
cytochrome	O	O
P450	O	O
(	O	O
CYP	O	O
)	O	O
1A2	O	O
in	O	O
this	O	O
case	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
other	O	O
cases	O	O
,	O	O
of	O	O
levofloxacin	B-Chemical	D064704
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

METHODS	O	O
:	O	O
Several	O	O
biomedical	O	O
databases	O	O
were	O	O
searched	O	O
including	O	O
MEDLINE	O	O
,	O	O
Cochrane	O	O
and	O	O
Ovid	O	O
.	O	O

The	O	O
main	O	O
search	O	O
terms	O	O
utilized	O	O
were	O	O
case	O	O
report	O	O
and	O	O
levofloxacin	B-Chemical	D064704
.	O	O

The	O	O
search	O	O
was	O	O
limited	O	O
to	O	O
studies	O	O
published	O	O
in	O	O
English	O	O
.	O	O

RESULTS	O	O
:	O	O
Six	O	O
cases	O	O
of	O	O
levofloxacin	B-Chemical	D064704
-	O	O
induced	O	O
seizures	B-Disease	D012640
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Drug	O	O
-	O	O
drug	O	O
interactions	O	O
related	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
CYP1A2	O	O
by	O	O
levofloxacin	B-Chemical	D064704
are	O	O
likely	O	O
involved	O	O
in	O	O
the	O	O
clinical	O	O
outcome	O	O
of	O	O
these	O	O
cases	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinicians	O	O
are	O	O
exhorted	O	O
to	O	O
pay	O	O
close	O	O
attention	O	O
when	O	O
initiating	O	O
levofloxacin	B-Chemical	D064704
therapy	O	O
in	O	O
patients	O	O
taking	O	O
medications	O	O
with	O	O
epileptogenic	O	O
properties	O	O
that	O	O
are	O	O
CYP1A2	O	O
substrates	O	O
.	O	O

Mice	O	O
lacking	O	O
mPGES	O	O
-	O	O
1	O	O
are	O	O
resistant	O	O
to	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
.	O	O

Cyclooxygenase	O	O
-	O	O
2	O	O
activity	O	O
is	O	O
required	O	O
for	O	O
the	O	O
development	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
.	O	O

However	O	O
,	O	O
the	O	O
involvement	O	O
of	O	O
a	O	O
specific	O	O
,	O	O
terminal	O	O
prostaglandin	B-Chemical	D011453
(	O	O
PG	B-Chemical	D011453
)	O	O
isomerase	O	O
has	O	O
not	O	O
been	O	O
evaluated	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
assess	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
in	O	O
mice	O	O
deficient	O	O
in	O	O
microsomal	O	O
prostaglandin	B-Chemical	D011453
E	O	O
synthase	O	O
-	O	O
1	O	O
(	O	O
mPGES	O	O
-	O	O
1	O	O
)	O	O
.	O	O

A	O	O
2	O	O
-	O	O
wk	O	O
administration	O	O
of	O	O
LiCl	B-Chemical	D018021
(	O	O
4	O	O
mmol	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
ip	O	O
)	O	O
in	O	O
mPGES	O	O
-	O	O
1	O	O
+	O	O
/	O	O
+	O	O
mice	O	O
led	O	O
to	O	O
a	O	O
marked	O	O
polyuria	B-Disease	D011141
with	O	O
hyposmotic	O	O
urine	O	O
.	O	O

This	O	O
was	O	O
associated	O	O
with	O	O
elevated	O	O
renal	O	O
mPGES	O	O
-	O	O
1	O	O
protein	O	O
expression	O	O
and	O	O
increased	O	O
urine	O	O
PGE	B-Chemical	D015232
(	I-Chemical	D015232
2	I-Chemical	D015232
)	I-Chemical	D015232
excretion	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
mPGES	O	O
-	O	O
1	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
largely	O	O
resistant	O	O
to	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
and	O	O
a	O	O
urine	O	O
concentrating	O	O
defect	O	O
,	O	O
accompanied	O	O
by	O	O
nearly	O	O
complete	O	O
blockade	O	O
of	O	O
high	O	O
urine	O	O
PGE	B-Chemical	D015232
(	I-Chemical	D015232
2	I-Chemical	D015232
)	I-Chemical	D015232
and	O	O
cAMP	O	O
output	O	O
.	O	O

Immunoblotting	O	O
,	O	O
immunohistochemistry	O	O
,	O	O
and	O	O
quantitative	O	O
(	O	O
q	O	O
)	O	O
RT	O	O
-	O	O
PCR	O	O
consistently	O	O
detected	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
aquaporin	O	O
-	O	O
2	O	O
(	O	O
AQP2	O	O
)	O	O
protein	O	O
expression	O	O
in	O	O
both	O	O
the	O	O
renal	O	O
cortex	O	O
and	O	O
medulla	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
+	O	O
/	O	O
+	O	O
mice	O	O
.	O	O

This	O	O
decrease	O	O
was	O	O
significantly	O	O
attenuated	O	O
in	O	O
the	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
.	O	O

qRT	O	O
-	O	O
PCR	O	O
detected	O	O
similar	O	O
patterns	O	O
of	O	O
changes	O	O
in	O	O
AQP2	O	O
mRNA	O	O
in	O	O
the	O	O
medulla	O	O
but	O	O
not	O	O
in	O	O
the	O	O
cortex	O	O
.	O	O

Similarly	O	O
,	O	O
the	O	O
total	O	O
protein	O	O
abundance	O	O
of	O	O
the	O	O
Na	B-Chemical	D012964
-	O	O
K	B-Chemical	D011188
-	O	O
2Cl	O	O
cotransporter	O	O
(	O	O
NKCC2	O	O
)	O	O
in	O	O
the	O	O
medulla	O	O
but	O	O
not	O	O
in	O	O
the	O	O
cortex	O	O
of	O	O
the	O	O
+	O	O
/	O	O
+	O	O
mice	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
lithium	B-Chemical	D008094
treatment	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
dowregulation	O	O
of	O	O
renal	O	O
medullary	O	O
NKCC2	O	O
expression	O	O
was	O	O
significantly	O	O
attenuated	O	O
in	O	O
the	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
mPGES	O	O
-	O	O
1	O	O
-	O	O
derived	O	O
PGE	B-Chemical	D015232
(	I-Chemical	D015232
2	I-Chemical	D015232
)	I-Chemical	D015232
mediates	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
likely	O	O
via	O	O
inhibition	O	O
of	O	O
AQP2	O	O
and	O	O
NKCC2	O	O
expression	O	O
.	O	O

Identification	O	O
of	O	O
a	O	O
simple	O	O
and	O	O
sensitive	O	O
microplate	O	O
method	O	O
for	O	O
the	O	O
detection	O	O
of	O	O
oversulfated	O	O
chondroitin	B-Chemical	D002809
sulfate	I-Chemical	D002809
in	O	O
heparin	B-Chemical	D006493
products	O	O
.	O	O

Heparin	B-Chemical	D006493
is	O	O
a	O	O
commonly	O	O
implemented	O	O
anticoagulant	O	O
used	O	O
to	O	O
treat	O	O
critically	O	O
ill	O	O
patients	O	O
.	O	O

Recently	O	O
,	O	O
a	O	O
number	O	O
of	O	O
commercial	O	O
lots	O	O
of	O	O
heparin	B-Chemical	D006493
products	O	O
were	O	O
found	O	O
to	O	O
be	O	O
contaminated	O	O
with	O	O
an	O	O
oversulfated	O	O
chondroitin	B-Chemical	D002809
sulfate	I-Chemical	D002809
(	O	O
OSCS	O	O
)	O	O
derivative	O	O
that	O	O
could	O	O
elicit	O	O
a	O	O
hypotensive	B-Disease	D007022
response	O	O
in	O	O
pigs	O	O
following	O	O
a	O	O
single	O	O
high	O	O
-	O	O
dose	O	O
infusion	O	O
.	O	O

Using	O	O
both	O	O
contaminated	O	O
heparin	B-Chemical	D006493
products	O	O
and	O	O
the	O	O
synthetically	O	O
produced	O	O
derivative	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
the	O	O
OSCS	O	O
produces	O	O
dose	O	O
-	O	O
dependent	O	O
hypotension	B-Disease	D007022
in	O	O
pigs	O	O
.	O	O

The	O	O
no	O	O
observed	O	O
effect	O	O
level	O	O
(	O	O
NOEL	O	O
)	O	O
for	O	O
this	O	O
contaminant	O	O
appears	O	O
to	O	O
be	O	O
approximately	O	O
1mg	O	O
/	O	O
kg	O	O
,	O	O
corresponding	O	O
to	O	O
a	O	O
contamination	O	O
level	O	O
of	O	O
approximately	O	O
3%	O	O
.	O	O

We	O	O
also	O	O
demonstrated	O	O
that	O	O
OSCS	O	O
can	O	O
be	O	O
identified	O	O
in	O	O
heparin	B-Chemical	D006493
products	O	O
using	O	O
a	O	O
simple	O	O
,	O	O
inexpensive	O	O
,	O	O
commercially	O	O
available	O	O
heparin	B-Chemical	D006493
enzyme	O	O
immunoassay	O	O
(	O	O
EIA	O	O
)	O	O
kit	O	O
that	O	O
has	O	O
a	O	O
limit	O	O
of	O	O
detection	O	O
of	O	O
approximately	O	O
0	O	O
.	O	O

1%	O	O
,	O	O
well	O	O
below	O	O
the	O	O
NOEL	O	O
.	O	O

This	O	O
kit	O	O
may	O	O
provide	O	O
a	O	O
useful	O	O
method	O	O
to	O	O
test	O	O
heparin	B-Chemical	D006493
products	O	O
for	O	O
contamination	O	O
with	O	O
oversulfated	O	O
GAG	O	O
derivatives	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
-	O	O
induced	O	O
inflammation	B-Disease	D007249
and	O	O
apoptosis	O	O
are	O	O
attenuated	O	O
by	O	O
gene	O	O
deletion	O	O
of	O	O
the	O	O
kinin	O	O
B1	O	O
receptor	O	O
.	O	O

Clinical	O	O
use	O	O
of	O	O
the	O	O
anthracycline	B-Chemical	D018943
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
is	O	O
limited	O	O
by	O	O
its	O	O
cardiotoxic	B-Disease	D066126
effects	O	O
,	O	O
which	O	O
are	O	O
attributed	O	O
to	O	O
the	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
possible	O	O
role	O	O
of	O	O
the	O	O
kinin	O	O
B1	O	O
receptor	O	O
(	O	O
B1R	O	O
)	O	O
during	O	O
the	O	O
development	O	O
of	O	O
DOX	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
,	O	O
we	O	O
studied	O	O
B1R	O	O
knockout	O	O
mice	O	O
(	O	O
B1R	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
)	O	O
by	O	O
investigating	O	O
cardiac	O	O
inflammation	B-Disease	D007249
and	O	O
apoptosis	O	O
after	O	O
induction	O	O
of	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

DOX	B-Chemical	D004317
control	O	O
mice	O	O
showed	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
measured	O	O
by	O	O
pressure	O	O
-	O	O
volume	O	O
loops	O	O
in	O	O
vivo	O	O
.	O	O

This	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
reduced	O	O
activation	O	O
state	O	O
of	O	O
AKT	O	O
,	O	O
as	O	O
well	O	O
as	O	O
an	O	O
increased	O	O
bax	O	O
/	O	O
bcl2	O	O
ratio	O	O
in	O	O
Western	O	O
blots	O	O
,	O	O
indicating	O	O
cardiac	B-Disease	D006331
apoptosis	I-Disease	D006331
.	O	O

Furthermore	O	O
,	O	O
mRNA	O	O
levels	O	O
of	O	O
the	O	O
proinflammatory	O	O
cytokine	O	O
interleukin	O	O
6	O	O
were	O	O
increased	O	O
in	O	O
the	O	O
cardiac	O	O
tissue	O	O
.	O	O

In	O	O
DOX	B-Chemical	D004317
B1R	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
was	O	O
improved	O	O
compared	O	O
to	O	O
DOX	B-Chemical	D004317
control	O	O
mice	O	O
,	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
normalization	O	O
of	O	O
the	O	O
bax	O	O
/	O	O
bcl	O	O
-	O	O
2	O	O
ratio	O	O
and	O	O
interleukin	O	O
6	O	O
,	O	O
as	O	O
well	O	O
as	O	O
AKT	O	O
activation	O	O
state	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
B1R	O	O
is	O	O
detrimental	O	O
in	O	O
DOX	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
in	O	O
that	O	O
it	O	O
mediates	O	O
the	O	O
inflammatory	O	O
response	O	O
and	O	O
apoptosis	O	O
.	O	O

These	O	O
insights	O	O
might	O	O
have	O	O
useful	O	O
implications	O	O
for	O	O
future	O	O
studies	O	O
utilizing	O	O
B1R	O	O
antagonists	O	O
for	O	O
treatment	O	O
of	O	O
human	O	O
DOX	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
.	O	O

Hepatotoxicity	B-Disease	D056486
associated	O	O
with	O	O
sulfasalazine	B-Chemical	D012460
in	O	O
inflammatory	O	O
arthritis	B-Disease	D001168
:	O	O
A	O	O
case	O	O
series	O	O
from	O	O
a	O	O
local	O	O
surveillance	O	O
of	O	O
serious	O	O
adverse	O	O
events	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Spontaneous	O	O
reporting	O	O
systems	O	O
for	O	O
adverse	O	O
drug	O	O
reactions	O	O
(	O	O
ADRs	O	O
)	O	O
are	O	O
handicapped	O	O
by	O	O
under	O	O
-	O	O
reporting	O	O
and	O	O
limited	O	O
detail	O	O
on	O	O
individual	O	O
cases	O	O
.	O	O

We	O	O
report	O	O
an	O	O
investigation	O	O
from	O	O
a	O	O
local	O	O
surveillance	O	O
for	O	O
serious	O	O
adverse	O	O
drug	O	O
reactions	O	O
associated	O	O
with	O	O
disease	O	O
modifying	O	O
anti	O	O
-	O	O
rheumatic	O	O
drugs	O	O
that	O	O
was	O	O
triggered	O	O
by	O	O
the	O	O
occurrence	O	O
of	O	O
liver	B-Disease	D017093
failure	I-Disease	D017093
in	O	O
two	O	O
of	O	O
our	O	O
patients	O	O
.	O	O

METHODS	O	O
:	O	O
Serious	O	O
ADR	O	O
reports	O	O
have	O	O
been	O	O
solicited	O	O
from	O	O
local	O	O
clinicians	O	O
by	O	O
regular	O	O
postcards	O	O
over	O	O
the	O	O
past	O	O
seven	O	O
years	O	O
.	O	O

Patients'	O	O
,	O	O
who	O	O
had	O	O
hepatotoxicity	B-Disease	D056486
on	O	O
sulfasalazine	B-Chemical	D012460
and	O	O
met	O	O
a	O	O
definition	O	O
of	O	O
a	O	O
serious	O	O
ADR	O	O
,	O	O
were	O	O
identified	O	O
.	O	O

Two	O	O
clinicians	O	O
reviewed	O	O
structured	O	O
case	O	O
reports	O	O
and	O	O
assessed	O	O
causality	O	O
by	O	O
consensus	O	O
and	O	O
by	O	O
using	O	O
a	O	O
causality	O	O
assessment	O	O
instrument	O	O
.	O	O

The	O	O
likely	O	O
frequency	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
with	O	O
sulfasalazine	B-Chemical	D012460
was	O	O
estimated	O	O
by	O	O
making	O	O
a	O	O
series	O	O
of	O	O
conservative	O	O
assumptions	O	O
.	O	O

RESULTS	O	O
:	O	O
Ten	O	O
cases	O	O
were	O	O
identified	O	O
:	O	O
eight	O	O
occurred	O	O
during	O	O
surveillance	O	O
.	O	O

Eight	O	O
patients	O	O
were	O	O
hospitalised	O	O
,	O	O
two	O	O
in	O	O
hepatic	B-Disease	D017093
failure	I-Disease	D017093
-	O	O
one	O	O
died	O	O
after	O	O
a	O	O
liver	O	O
transplant	O	O
.	O	O

All	O	O
but	O	O
one	O	O
event	O	O
occurred	O	O
within	O	O
6	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

Seven	O	O
patients	O	O
had	O	O
a	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
three	O	O
eosinophilia	B-Disease	D004802
and	O	O
one	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
.	O	O

Five	O	O
patients	O	O
were	O	O
of	O	O
Black	O	O
British	O	O
of	O	O
African	O	O
or	O	O
Caribbean	O	O
descent	O	O
.	O	O

Liver	O	O
enzymes	O	O
showed	O	O
a	O	O
hepatocellular	O	O
pattern	O	O
in	O	O
four	O	O
cases	O	O
and	O	O
a	O	O
mixed	O	O
pattern	O	O
in	O	O
six	O	O
.	O	O

Drug	O	O
-	O	O
related	O	O
hepatotoxicity	B-Disease	D056486
was	O	O
judged	O	O
probable	O	O
or	O	O
highly	O	O
probable	O	O
in	O	O
8	O	O
patients	O	O
.	O	O

The	O	O
likely	O	O
frequency	O	O
of	O	O
serious	O	O
hepatotoxicity	B-Disease	D056486
with	O	O
sulfasalazine	B-Chemical	D012460
was	O	O
estimated	O	O
at	O	O
0	O	O
.	O	O

4%	O	O
of	O	O
treated	O	O
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Serious	O	O
hepatotoxicity	B-Disease	D056486
associated	O	O
with	O	O
sulfasalazine	B-Chemical	D012460
appears	O	O
to	O	O
be	O	O
under	O	O
-	O	O
appreciated	O	O
and	O	O
intensive	O	O
monitoring	O	O
and	O	O
vigilance	O	O
in	O	O
the	O	O
first	O	O
6	O	O
weeks	O	O
of	O	O
treatment	O	O
is	O	O
especially	O	O
important	O	O
.	O	O

An	O	O
evaluation	O	O
of	O	O
amikacin	B-Chemical	D000583
nephrotoxicity	B-Disease	D007674
in	O	O
the	O	O
hematology	O	O
/	O	O
oncology	O	O
population	O	O
.	O	O

Amikacin	B-Chemical	D000583
is	O	O
an	O	O
aminoglycoside	B-Chemical	D000617
commonly	O	O
used	O	O
to	O	O
provide	O	O
empirical	O	O
double	O	O
gram	O	O
-	O	O
negative	O	O
treatment	O	O
for	O	O
febrile	B-Disease	D009503
neutropenia	I-Disease	D009503
and	O	O
other	O	O
suspected	O	O
infections	B-Disease	D007239
.	O	O

Strategies	O	O
of	O	O
extended	O	O
-	O	O
interval	O	O
and	O	O
conventional	O	O
dosing	O	O
have	O	O
been	O	O
utilized	O	O
extensively	O	O
in	O	O
the	O	O
general	O	O
medical	O	O
population	O	O
;	O	O
however	O	O
,	O	O
data	O	O
are	O	O
lacking	O	O
to	O	O
support	O	O
a	O	O
dosing	O	O
strategy	O	O
in	O	O
the	O	O
hematology	O	O
/	O	O
oncology	O	O
population	O	O
.	O	O

To	O	O
evaluate	O	O
amikacin	B-Chemical	D000583
-	O	O
associated	O	O
nephrotoxicity	B-Disease	D007674
in	O	O
an	O	O
adult	O	O
hematology	O	O
/	O	O
oncology	O	O
population	O	O
,	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
was	O	O
conducted	O	O
at	O	O
a	O	O
university	O	O
-	O	O
affiliated	O	O
medical	O	O
center	O	O
.	O	O

Forty	O	O
patients	O	O
with	O	O
a	O	O
diagnosis	O	O
consistent	O	O
with	O	O
a	O	O
hematologic	O	O
/	O	O
oncologic	O	O
disorder	O	O
that	O	O
required	O	O
treatment	O	O
with	O	O
an	O	O
aminoglycoside	B-Chemical	D000617
were	O	O
randomized	O	O
to	O	O
either	O	O
conventional	O	O
or	O	O
extended	O	O
-	O	O
interval	O	O
amikacin	B-Chemical	D000583
.	O	O

The	O	O
occurrence	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
by	O	O
means	O	O
of	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
and	O	O
evaluation	O	O
of	O	O
efficacy	O	O
via	O	O
amikacin	B-Chemical	D000583
serum	O	O
concentrations	O	O
with	O	O
respective	O	O
pathogens	O	O
were	O	O
assessed	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
was	O	O
similar	O	O
between	O	O
the	O	O
conventional	O	O
and	O	O
extended	O	O
-	O	O
interval	O	O
groups	O	O
,	O	O
at	O	O
10%	O	O
and	O	O
5%	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
=	O	O
1	O	O
.	O	O

00	O	O
)	O	O
.	O	O

Six	O	O
patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
had	O	O
a	O	O
positive	O	O
culture	O	O
,	O	O
compared	O	O
with	O	O
none	O	O
in	O	O
the	O	O
extended	O	O
-	O	O
interval	O	O
group	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

The	O	O
occurrence	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
was	O	O
similar	O	O
between	O	O
the	O	O
two	O	O
dosing	O	O
regimens	O	O
,	O	O
but	O	O
the	O	O
distribution	O	O
of	O	O
risk	O	O
factors	O	O
was	O	O
variable	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Efficacy	O	O
could	O	O
not	O	O
be	O	O
assessed	O	O
.	O	O

Memory	O	O
function	O	O
and	O	O
serotonin	B-Chemical	D012701
transporter	O	O
promoter	O	O
gene	O	O
polymorphism	O	O
in	O	O
ecstasy	B-Chemical	D018817
(	O	O
MDMA	B-Chemical	D018817
)	O	O
users	O	O
.	O	O

Although	O	O
3	B-Chemical	D018817
,	I-Chemical	D018817
4	I-Chemical	D018817
-	I-Chemical	D018817
methylenedioxymethamphetamine	I-Chemical	D018817
(	O	O
MDMA	B-Chemical	D018817
or	O	O
ecstasy	B-Chemical	D018817
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
damage	O	O
brain	O	O
serotonin	B-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
neurons	O	O
in	O	O
animals	O	O
and	O	O
possibly	O	O
humans	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
long	O	O
-	O	O
term	O	O
consequences	O	O
of	O	O
MDMA	B-Chemical	D018817
-	O	O
induced	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
neurotoxic	B-Disease	D020258
lesions	I-Disease	D020258
on	O	O
functions	O	O
in	O	O
which	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
is	O	O
involved	O	O
,	O	O
such	O	O
as	O	O
cognitive	O	O
function	O	O
.	O	O

Because	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
transporters	O	O
play	O	O
a	O	O
key	O	O
element	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
synaptic	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
transmission	O	O
it	O	O
may	O	O
be	O	O
important	O	O
to	O	O
control	O	O
for	O	O
the	O	O
potential	O	O
covariance	O	O
effect	O	O
of	O	O
a	O	O
polymorphism	O	O
in	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
transporter	O	O
promoter	O	O
gene	O	O
region	O	O
(	O	O
5	O	O
-	O	O
HTTLPR	O	O
)	O	O
when	O	O
studying	O	O
the	O	O
effects	O	O
of	O	O
MDMA	B-Chemical	D018817
as	O	O
well	O	O
as	O	O
cognitive	O	O
functioning	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
moderate	O	O
and	O	O
heavy	O	O
MDMA	B-Chemical	D018817
use	O	O
on	O	O
cognitive	O	O
function	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
effects	O	O
of	O	O
long	O	O
-	O	O
term	O	O
abstention	O	O
from	O	O
MDMA	B-Chemical	D018817
,	O	O
in	O	O
subjects	O	O
genotyped	O	O
for	O	O
5	O	O
-	O	O
HTTLPR	O	O
.	O	O

A	O	O
second	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
these	O	O
effects	O	O
differ	O	O
for	O	O
females	O	O
and	O	O
males	O	O
.	O	O

Fifteen	O	O
moderate	O	O
MDMA	B-Chemical	D018817
users	O	O
(	O	O
<55	O	O
lifetime	O	O
tablets	O	O
)	O	O
,	O	O
22	O	O
heavy	O	O
MDMA+	O	O
users	O	O
(	O	O
>55	O	O
lifetime	O	O
tablets	O	O
)	O	O
,	O	O
16	O	O
ex	O	O
-	O	O
MDMA+	O	O
users	O	O
(	O	O
last	O	O
tablet	O	O
>	O	O
1	O	O
year	O	O
ago	O	O
)	O	O
and	O	O
13	O	O
controls	O	O
were	O	O
compared	O	O
on	O	O
a	O	O
battery	O	O
of	O	O
neuropsychological	O	O
tests	O	O
.	O	O

DNA	O	O
from	O	O
peripheral	O	O
nuclear	O	O
blood	O	O
cells	O	O
was	O	O
genotyped	O	O
for	O	O
5	O	O
-	O	O
HTTLPR	O	O
using	O	O
standard	O	O
polymerase	O	O
chain	O	O
reaction	O	O
methods	O	O
.	O	O

A	O	O
significant	O	O
group	O	O
effect	O	O
was	O	O
observed	O	O
only	O	O
on	O	O
memory	O	O
function	O	O
tasks	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

04	O	O
)	O	O
but	O	O
not	O	O
on	O	O
reaction	O	O
times	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

61	O	O
)	O	O
or	O	O
attention	O	O
/	O	O
executive	O	O
functioning	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

59	O	O
)	O	O
.	O	O

Heavy	O	O
and	O	O
ex	O	O
-	O	O
MDMA+	O	O
users	O	O
performed	O	O
significantly	O	O
poorer	O	O
on	O	O
memory	O	O
tasks	O	O
than	O	O
controls	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
no	O	O
evidence	O	O
of	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
was	O	O
observed	O	O
in	O	O
moderate	O	O
MDMA	B-Chemical	D018817
users	O	O
.	O	O

No	O	O
significant	O	O
effect	O	O
of	O	O
5	O	O
-	O	O
HTTLPR	O	O
or	O	O
gender	O	O
was	O	O
observed	O	O
.	O	O

While	O	O
the	O	O
use	O	O
of	O	O
MDMA	B-Chemical	D018817
in	O	O
quantities	O	O
that	O	O
may	O	O
be	O	O
considered	O	O
"moderate"	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
impaired	B-Disease	D008569
memory	I-Disease	D008569
functioning	I-Disease	D008569
,	O	O
heavy	O	O
use	O	O
of	O	O
MDMA	B-Chemical	D018817
use	O	O
may	O	O
lead	O	O
to	O	O
long	O	O
lasting	O	O
memory	B-Disease	D008569
impairments	I-Disease	D008569
.	O	O

No	O	O
effect	O	O
of	O	O
5	O	O
-	O	O
HTTLPR	O	O
or	O	O
gender	O	O
on	O	O
memory	O	O
function	O	O
or	O	O
MDMA	B-Chemical	D018817
use	O	O
was	O	O
observed	O	O
.	O	O

Aging	O	O
process	O	O
of	O	O
epithelial	O	O
cells	O	O
of	O	O
the	O	O
rat	O	O
prostate	O	O
lateral	O	O
lobe	O	O
in	O	O
experimental	O	O
hyperprolactinemia	B-Disease	D006966
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
influence	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
,	O	O
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
(	O	O
HAL	B-Chemical	D006220
)	O	O
on	O	O
age	O	O
related	O	O
morphology	O	O
and	O	O
function	O	O
changes	O	O
of	O	O
epithelial	O	O
cells	O	O
in	O	O
rat	O	O
prostate	O	O
lateral	O	O
lobe	O	O
.	O	O

The	O	O
study	O	O
was	O	O
performed	O	O
on	O	O
sexually	O	O
mature	O	O
male	O	O
rats	O	O
.	O	O

Serum	O	O
concentrations	O	O
of	O	O
prolactin	O	O
(	O	O
PRL	B-Chemical	D011388
)	O	O
and	O	O
testosterone	B-Chemical	D013739
(	O	O
T	B-Chemical	D013739
)	O	O
were	O	O
measured	O	O
.	O	O

Tissue	O	O
sections	O	O
were	O	O
evaluated	O	O
with	O	O
light	O	O
and	O	O
electron	O	O
microscopy	O	O
.	O	O

Immunohistochemical	O	O
reactions	O	O
for	O	O
Anti	O	O
-	O	O
Proliferating	O	O
Cell	O	O
Nuclear	O	O
Antigen	O	O
(	O	O
PCNA	O	O
)	O	O
were	O	O
performed	O	O
.	O	O

In	O	O
rats	O	O
of	O	O
the	O	O
experimental	O	O
group	O	O
,	O	O
the	O	O
mean	O	O
concentration	O	O
of	O	O
:	O	O
PRL	B-Chemical	D011388
was	O	O
more	O	O
than	O	O
twice	O	O
higher	O	O
,	O	O
whereas	O	O
T	B-Chemical	D013739
concentration	O	O
was	O	O
almost	O	O
twice	O	O
lower	O	O
than	O	O
that	O	O
in	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Light	O	O
microscopy	O	O
visualized	O	O
the	O	O
following	O	O
:	O	O
hypertrophy	B-Disease	D006984
and	O	O
epithelium	O	O
hyperplasia	B-Disease	D006965
of	O	O
the	O	O
glandular	O	O
ducts	O	O
,	O	O
associated	O	O
with	O	O
increased	O	O
PCNA	O	O
expression	O	O
.	O	O

Electron	O	O
microscopy	O	O
revealed	O	O
changes	O	O
in	O	O
columnar	O	O
epithelial	O	O
cells	O	O
,	O	O
concerning	O	O
organelles	O	O
,	O	O
engaged	O	O
in	O	O
protein	O	O
synthesis	O	O
and	O	O
secretion	O	O
.	O	O

Does	O	O
supplemental	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
increase	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
risk	O	O
in	O	O
women	O	O
with	O	O
diabetes?	O	O
BACKGROUND	O	O
:	O	O
Vitamin	B-Chemical	D001205
C	I-Chemical	D001205
acts	O	O
as	O	O
a	O	O
potent	O	O
antioxidant	O	O
;	O	O
however	O	O
,	O	O
it	O	O
can	O	O
also	O	O
be	O	O
a	O	O
prooxidant	O	O
and	O	O
glycate	O	O
protein	O	O
under	O	O
certain	O	O
circumstances	O	O
in	O	O
vitro	O	O
.	O	O

These	O	O
observations	O	O
led	O	O
us	O	O
to	O	O
hypothesize	O	O
that	O	O
a	O	O
high	O	O
intake	O	O
of	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
in	O	O
diabetic	B-Disease	D003920
persons	O	O
might	O	O
promote	O	O
atherosclerosis	B-Disease	D050197
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
relation	O	O
between	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
intake	O	O
and	O	O
mortality	O	O
from	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
.	O	O

DESIGN	O	O
:	O	O
We	O	O
studied	O	O
the	O	O
relation	O	O
between	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
intake	O	O
and	O	O
mortality	O	O
from	O	O
total	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
(	O	O
n	O	O
=	O	O
281	O	O
)	O	O
,	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
(	O	O
n	O	O
=	O	O
175	O	O
)	O	O
,	O	O
and	O	O
stroke	B-Disease	D020521
(	O	O
n	O	O
=	O	O
57	O	O
)	O	O
in	O	O
1923	O	O
postmenopausal	O	O
women	O	O
who	O	O
reported	O	O
being	O	O
diabetic	B-Disease	D003920
at	O	O
baseline	O	O
.	O	O

Diet	O	O
was	O	O
assessed	O	O
with	O	O
a	O	O
food	O	O
-	O	O
frequency	O	O
questionnaire	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
subjects	O	O
initially	O	O
free	O	O
of	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
were	O	O
prospectively	O	O
followed	O	O
for	O	O
15	O	O
y	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
adjustment	O	O
for	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
risk	O	O
factors	O	O
,	O	O
type	O	O
of	O	O
diabetes	B-Disease	D003920
medication	O	O
used	O	O
,	O	O
duration	O	O
of	O	O
diabetes	B-Disease	D003920
,	O	O
and	O	O
intakes	O	O
of	O	O
folate	B-Chemical	D005492
,	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
,	O	O
and	O	O
beta	B-Chemical	D019207
-	I-Chemical	D019207
carotene	I-Chemical	D019207
,	O	O
the	O	O
adjusted	O	O
relative	O	O
risks	O	O
of	O	O
total	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
mortality	O	O
were	O	O
1	O	O
.	O	O

0	O	O
,	O	O
0	O	O
.	O	O

97	O	O
,	O	O
1	O	O
.	O	O

11	O	O
,	O	O
1	O	O
.	O	O

47	O	O
,	O	O
and	O	O
1	O	O
.	O	O

84	O	O
(	O	O
P	O	O
for	O	O
trend	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
across	O	O
quintiles	O	O
of	O	O
total	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
intake	O	O
from	O	O
food	O	O
and	O	O
supplements	O	O
.	O	O

Adjusted	O	O
relative	O	O
risks	O	O
of	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
were	O	O
1	O	O
.	O	O

0	O	O
,	O	O
0	O	O
.	O	O

81	O	O
,	O	O
0	O	O
.	O	O

99	O	O
,	O	O
1	O	O
.	O	O

26	O	O
,	O	O
and	O	O
1	O	O
.	O	O

91	O	O
(	O	O
P	O	O
for	O	O
trend	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
of	O	O
stroke	B-Disease	D020521
were	O	O
1	O	O
.	O	O

0	O	O
,	O	O
0	O	O
.	O	O

52	O	O
,	O	O
1	O	O
.	O	O

23	O	O
,	O	O
2	O	O
.	O	O

22	O	O
,	O	O
and	O	O
2	O	O
.	O	O

57	O	O
(	O	O
P	O	O
for	O	O
trend	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

When	O	O
dietary	O	O
and	O	O
supplemental	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
were	O	O
analyzed	O	O
separately	O	O
,	O	O
only	O	O
supplemental	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
showed	O	O
a	O	O
positive	O	O
association	O	O
with	O	O
mortality	O	O
endpoints	O	O
.	O	O

Vitamin	B-Chemical	D001205
C	I-Chemical	D001205
intake	O	O
was	O	O
unrelated	O	O
to	O	O
mortality	O	O
from	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
in	O	O
the	O	O
nondiabetic	O	O
subjects	O	O
at	O	O
baseline	O	O
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
high	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
intake	O	O
from	O	O
supplements	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
mortality	O	O
in	O	O
postmenopausal	O	O
women	O	O
with	O	O
diabetes	B-Disease	D003920
.	O	O

Absolute	O	O
and	O	O
attributable	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
in	O	O
women	O	O
on	O	O
combined	O	O
cyproterone	B-Chemical	D017373
acetate	I-Chemical	D017373
and	O	O
ethinylestradiol	B-Chemical	D004997
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
achieve	O	O
absolute	O	O
risk	O	O
estimates	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
VTE	B-Disease	D054556
)	O	O
among	O	O
women	O	O
on	O	O
cyproterone	B-Chemical	D017373
acetate	I-Chemical	D017373
plus	O	O
ethinylestradiol	B-Chemical	D004997
(	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
)	O	O
,	O	O
and	O	O
among	O	O
women	O	O
on	O	O
combined	B-Chemical	D003277
oral	I-Chemical	D003277
contraceptives	I-Chemical	D003277
(	O	O
COCs	B-Chemical	D003277
)	O	O
.	O	O

METHODS	O	O
:	O	O
From	O	O
the	O	O
Danish	O	O
National	O	O
Register	O	O
of	O	O
Patients	O	O
(	O	O
NRP	O	O
)	O	O
,	O	O
1996	O	O
to	O	O
1998	O	O
,	O	O
the	O	O
records	O	O
of	O	O
1	O	O
.	O	O

1	O	O
million	O	O
Danish	O	O
women	O	O
,	O	O
ages	O	O
15	O	O
to	O	O
44	O	O
years	O	O
,	O	O
were	O	O
searched	O	O
for	O	O
evidence	O	O
of	O	O
VTE	B-Disease	D054556
.	O	O

COC	B-Chemical	D003277
use	O	O
was	O	O
ascertained	O	O
through	O	O
mailed	O	O
questionnaires	O	O
.	O	O

Sales	O	O
statistics	O	O
of	O	O
COCs	B-Chemical	D003277
and	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
were	O	O
provided	O	O
through	O	O
Danish	O	O
Drug	O	O
Statistics	O	O
.	O	O

RESULTS	O	O
:	O	O
During	O	O
the	O	O
time	O	O
frame	O	O
of	O	O
the	O	O
study	O	O
,	O	O
330	O	O
women	O	O
were	O	O
found	O	O
to	O	O
have	O	O
had	O	O
VTE	B-Disease	D054556
while	O	O
on	O	O
COCs	B-Chemical	D003277
.	O	O

Of	O	O
these	O	O
women	O	O
,	O	O
67	O	O
were	O	O
on	O	O
levonorgestrel	B-Chemical	D016912
-	O	O
containing	O	O
COCs	B-Chemical	D003277
.	O	O

Eleven	O	O
were	O	O
on	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
.	O	O

The	O	O
corresponding	O	O
absolute	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
was	O	O
3	O	O
.	O	O

4	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O

1	O	O
-	O	O
3	O	O
.	O	O

8	O	O
)	O	O
per	O	O
10	O	O
000	O	O
women	O	O
years	O	O
among	O	O
the	O	O
women	O	O
on	O	O
COCs	B-Chemical	D003277
,	O	O
4	O	O
.	O	O

2	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O

2	O	O
-	O	O
5	O	O
.	O	O

2	O	O
)	O	O
per	O	O
10	O	O
000	O	O
women	O	O
years	O	O
among	O	O
women	O	O
on	O	O
levonorgestrel	B-Chemical	D016912
-	O	O
containing	O	O
COCs	B-Chemical	D003277
,	O	O
and	O	O
3	O	O
.	O	O

1	O	O
(	O	O
range	O	O
,	O	O
1	O	O
.	O	O

3	O	O
-	O	O
4	O	O
.	O	O

9	O	O
)	O	O
per	O	O
10	O	O
000	O	O
women	O	O
years	O	O
among	O	O
the	O	O
women	O	O
on	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
suggest	O	O
the	O	O
absolute	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
among	O	O
Danish	O	O
women	O	O
on	O	O
COCs	B-Chemical	D003277
is	O	O
similar	O	O
to	O	O
that	O	O
among	O	O
women	O	O
taking	O	O
CPA	B-Chemical	D017373
/	O	O
EE	B-Chemical	D004997
.	O	O

Effect	O	O
of	O	O
lindane	B-Chemical	D001556
on	O	O
hepatic	O	O
and	O	O
brain	O	O
cytochrome	O	O
P450s	O	O
and	O	O
influence	O	O
of	O	O
P450	O	O
modulation	O	O
in	O	O
lindane	B-Chemical	D001556
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Oral	O	O
administration	O	O
of	O	O
lindane	B-Chemical	D001556
(	O	O
2	O	O
.	O	O

5	O	O
,	O	O
5	O	O
,	O	O
10	O	O
and	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
body	O	O
weight	O	O
)	O	O
for	O	O
5	O	O
days	O	O
was	O	O
found	O	O
to	O	O
produce	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
increase	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
P450	O	O
dependent	O	O
7	O	O
-	O	O
ethoxyresorufin	O	O
-	O	O
O	O	O
-	O	O
deethylase	O	O
(	O	O
EROD	O	O
)	O	O
,	O	O
7	O	O
-	O	O
pentoxyresorufin	O	O
-	O	O
O	O	O
-	O	O
dealkylase	O	O
(	O	O
PROD	O	O
)	O	O
and	O	O
N	B-Chemical	D004128
-	I-Chemical	D004128
nitrosodimethylamine	I-Chemical	D004128
demethylase	O	O
(	O	O
NDMA	B-Chemical	D004128
-	O	O
d	O	O
)	O	O
in	O	O
rat	O	O
brain	O	O
and	O	O
liver	O	O
.	O	O

A	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
hepatic	O	O
and	O	O
brain	O	O
P450	O	O
monooxygenases	O	O
was	O	O
also	O	O
observed	O	O
when	O	O
the	O	O
duration	O	O
of	O	O
exposure	O	O
of	O	O
low	O	O
dose	O	O
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
lindane	B-Chemical	D001556
was	O	O
increased	O	O
from	O	O
5	O	O
days	O	O
to	O	O
15	O	O
or	O	O
21	O	O
days	O	O
.	O	O

As	O	O
observed	O	O
with	O	O
different	O	O
doses	O	O
,	O	O
the	O	O
magnitude	O	O
of	O	O
induction	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
P450	O	O
monooxygenases	O	O
was	O	O
several	O	O
fold	O	O
higher	O	O
in	O	O
liver	O	O
microsomes	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
brain	O	O
.	O	O

Western	O	O
blotting	O	O
studies	O	O
have	O	O
indicated	O	O
that	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
P450	O	O
enzymes	O	O
could	O	O
be	O	O
due	O	O
to	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
P450	O	O
1A1	O	O
/	O	O
1A2	O	O
,	O	O
2B1	O	O
/	O	O
2B2	O	O
and	O	O
2E1	O	O
isoenzymes	O	O
.	O	O

In	O	O
vitro	O	O
studies	O	O
using	O	O
organic	O	O
inhibitors	O	O
specific	O	O
for	O	O
individual	O	O
P450	O	O
isoenzymes	O	O
and	O	O
antibody	O	O
inhibition	O	O
experiments	O	O
have	O	O
further	O	O
demonstrated	O	O
that	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
PROD	O	O
,	O	O
EROD	O	O
and	O	O
NDMA	B-Chemical	D004128
-	O	O
d	O	O
are	O	O
due	O	O
to	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
P450	O	O
2B1	O	O
/	O	O
2B2	O	O
,	O	O
1A1	O	O
/	O	O
1A2	O	O
and	O	O
2E1	O	O
isoenzymes	O	O
,	O	O
respectively	O	O
.	O	O

Induction	O	O
studies	O	O
have	O	O
further	O	O
shown	O	O
that	O	O
while	O	O
pretreatment	O	O
of	O	O
3	B-Chemical	D008748
-	I-Chemical	D008748
methylcholanthrene	I-Chemical	D008748
(	O	O
MC	B-Chemical	D008748
)	O	O
,	O	O
an	O	O
inducer	O	O
of	O	O
P4501A1	O	O
/	O	O
1A2	O	O
,	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
significant	O	O
effect	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
lindane	B-Chemical	D001556
induced	O	O
convulsions	B-Disease	D012640
,	O	O
pretreatment	O	O
with	O	O
phenobarbital	B-Chemical	D010634
(	O	O
PB	O	O
)	O	O
,	O	O
an	O	O
inducer	O	O
of	O	O
P450	O	O
2B1	O	O
/	O	O
2B2	O	O
or	O	O
ethanol	B-Chemical	D000431
,	O	O
an	O	O
inducer	O	O
of	O	O
P450	O	O
2E1	O	O
catalysed	O	O
reactions	O	O
,	O	O
significantly	O	O
increased	O	O
the	O	O
incidence	O	O
of	O	O
lindane	B-Chemical	D001556
induced	O	O
convulsions	B-Disease	D012640
.	O	O

Similarly	O	O
,	O	O
when	O	O
the	O	O
P450	O	O
-	O	O
mediated	O	O
metabolism	O	O
of	O	O
lindane	B-Chemical	D001556
was	O	O
blocked	O	O
by	O	O
cobalt	B-Chemical	C018021
chloride	I-Chemical	C018021
incidence	O	O
of	O	O
convulsions	B-Disease	D012640
was	O	O
increased	O	O
in	O	O
animals	O	O
treated	O	O
with	O	O
lindane	B-Chemical	D001556
indicating	O	O
that	O	O
lindane	B-Chemical	D001556
per	O	O
se	O	O
or	O	O
its	O	O
metabolites	O	O
formed	O	O
by	O	O
PB	O	O
or	O	O
ethanol	B-Chemical	D000431
inducible	O	O
P450	O	O
isoenzymes	O	O
are	O	O
involved	O	O
in	O	O
its	O	O
neurobehavioral	O	O
toxicity	B-Disease	D064420
.	O	O

Seizure	B-Disease	D012640
associated	O	O
with	O	O
sleep	B-Disease	D012892
deprivation	I-Disease	D012892
and	O	O
sustained	O	O
-	O	O
release	O	O
bupropion	B-Chemical	D016642
.	O	O

This	O	O
case	O	O
report	O	O
describes	O	O
a	O	O
generalized	O	O
seizure	B-Disease	D012640
associated	O	O
with	O	O
sustained	O	O
-	O	O
release	O	O
bupropion	B-Chemical	D016642
use	O	O
and	O	O
sleep	B-Disease	D012892
deprivation	I-Disease	D012892
.	O	O

The	O	O
subject	O	O
,	O	O
a	O	O
31	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
smoker	O	O
,	O	O
was	O	O
participating	O	O
in	O	O
a	O	O
clinical	O	O
trial	O	O
evaluating	O	O
an	O	O
investigational	O	O
medication	O	O
for	O	O
smoking	O	O
cessation	O	O
that	O	O
used	O	O
sustained	O	O
-	O	O
release	O	O
bupropion	B-Chemical	D016642
as	O	O
an	O	O
active	O	O
control	O	O
.	O	O

After	O	O
5	O	O
weeks	O	O
of	O	O
bupropion	B-Chemical	D016642
use	O	O
,	O	O
the	O	O
subject	O	O
experienced	O	O
a	O	O
generalized	O	O
tonic	O	O
clonic	O	O
seizure	B-Disease	D012640
after	O	O
staying	O	O
up	O	O
nearly	O	O
all	O	O
night	O	O
packing	O	O
and	O	O
moving	O	O
to	O	O
a	O	O
new	O	O
residence	O	O
.	O	O

The	O	O
patient	O	O
had	O	O
no	O	O
other	O	O
risk	O	O
factors	O	O
for	O	O
seizures	B-Disease	D012640
.	O	O

We	O	O
suggest	O	O
that	O	O
sleep	B-Disease	D012892
deprivation	I-Disease	D012892
may	O	O
add	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
bupropion	B-Chemical	D016642
-	O	O
associated	O	O
seizures	B-Disease	D012640
.	O	O

Nephrotoxic	B-Disease	D007674
effects	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
undergoing	O	O
angiography	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
use	O	O
of	O	O
iodinated	O	O
contrast	O	O
medium	O	O
can	O	O
result	O	O
in	O	O
nephropathy	B-Disease	D007674
.	O	O

Whether	O	O
iso	O	O
-	O	O
osmolar	O	O
contrast	O	O
medium	O	O
is	O	O
less	O	O
nephrotoxic	B-Disease	D007674
than	O	O
low	O	O
-	O	O
osmolar	O	O
contrast	O	O
medium	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
is	O	O
uncertain	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
prospective	O	O
,	O	O
multicenter	O	O
study	O	O
comparing	O	O
the	O	O
nephrotoxic	B-Disease	D007674
effects	O	O
of	O	O
an	O	O
iso	O	O
-	O	O
osmolar	O	O
,	O	O
dimeric	O	O
,	O	O
nonionic	O	O
contrast	O	O
medium	O	O
,	O	O
iodixanol	B-Chemical	C044834
,	O	O
with	O	O
those	O	O
of	O	O
a	O	O
low	O	O
-	O	O
osmolar	O	O
,	O	O
nonionic	O	O
,	O	O
monomeric	O	O
contrast	O	O
medium	O	O
,	O	O
iohexol	B-Chemical	D007472
.	O	O

The	O	O
study	O	O
involved	O	O
129	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
with	O	O
serum	O	O
creatinine	B-Chemical	D003404
concentrations	O	O
of	O	O
1	O	O
.	O	O

5	O	O
to	O	O
3	O	O
.	O	O

5	O	O
mg	O	O
per	O	O
deciliter	O	O
who	O	O
underwent	O	O
coronary	O	O
or	O	O
aortofemoral	O	O
angiography	O	O
.	O	O

The	O	O
primary	O	O
end	O	O
point	O	O
was	O	O
the	O	O
peak	O	O
increase	O	O
from	O	O
base	O	O
line	O	O
in	O	O
the	O	O
creatinine	B-Chemical	D003404
concentration	O	O
during	O	O
the	O	O
three	O	O
days	O	O
after	O	O
angiography	O	O
.	O	O

Other	O	O
end	O	O
points	O	O
were	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
creatinine	B-Chemical	D003404
concentration	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
per	O	O
deciliter	O	O
or	O	O
more	O	O
,	O	O
an	O	O
increase	O	O
of	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
per	O	O
deciliter	O	O
or	O	O
more	O	O
,	O	O
and	O	O
a	O	O
change	O	O
in	O	O
the	O	O
creatinine	B-Chemical	D003404
concentration	O	O
from	O	O
day	O	O
0	O	O
to	O	O
day	O	O
7	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
creatinine	B-Chemical	D003404
concentration	O	O
increased	O	O
significantly	O	O
less	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
iodixanol	B-Chemical	C044834
.	O	O

From	O	O
day	O	O
0	O	O
to	O	O
day	O	O
3	O	O
,	O	O
the	O	O
mean	O	O
peak	O	O
increase	O	O
in	O	O
creatinine	B-Chemical	D003404
was	O	O
0	O	O
.	O	O

13	O	O
mg	O	O
per	O	O
deciliter	O	O
in	O	O
the	O	O
iodixanol	B-Chemical	C044834
group	O	O
and	O	O
0	O	O
.	O	O

55	O	O
mg	O	O
per	O	O
deciliter	O	O
in	O	O
the	O	O
iohexol	B-Chemical	D007472
group	O	O
(	O	O
P=0	O	O
.	O	O

001	O	O
;	O	O
the	O	O
increase	O	O
with	O	O
iodixanol	B-Chemical	C044834
minus	O	O
the	O	O
increase	O	O
with	O	O
iohexol	B-Chemical	D007472
,	O	O
-	O	O
0	O	O
.	O	O

42	O	O
mg	O	O
per	O	O
deciliter	O	O
[	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
-	O	O
0	O	O
.	O	O

73	O	O
to	O	O
-	O	O
0	O	O
.	O	O

22	O	O
]	O	O
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
64	O	O
patients	O	O
in	O	O
the	O	O
iodixanol	B-Chemical	C044834
group	O	O
(	O	O
3	O	O
percent	O	O
)	O	O
had	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
creatinine	B-Chemical	D003404
concentration	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
per	O	O
deciliter	O	O
or	O	O
more	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
17	O	O
of	O	O
the	O	O
65	O	O
patients	O	O
in	O	O
the	O	O
iohexol	B-Chemical	D007472
group	O	O
(	O	O
26	O	O
percent	O	O
)	O	O
(	O	O
P=0	O	O
.	O	O

002	O	O
;	O	O
odds	O	O
ratio	O	O
for	O	O
such	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
iodixanol	B-Chemical	C044834
group	O	O
,	O	O
0	O	O
.	O	O

09	O	O
[	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

02	O	O
to	O	O
0	O	O
.	O	O

41	O	O
]	O	O
)	O	O
.	O	O

No	O	O
patient	O	O
receiving	O	O
iodixanol	B-Chemical	C044834
had	O	O
an	O	O
increase	O	O
of	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
per	O	O
deciliter	O	O
or	O	O
more	O	O
,	O	O
but	O	O
10	O	O
patients	O	O
in	O	O
the	O	O
iohexol	B-Chemical	D007472
group	O	O
(	O	O
15	O	O
percent	O	O
)	O	O
did	O	O
.	O	O

The	O	O
mean	O	O
change	O	O
in	O	O
the	O	O
creatinine	B-Chemical	D003404
concentration	O	O
from	O	O
day	O	O
0	O	O
to	O	O
day	O	O
7	O	O
was	O	O
0	O	O
.	O	O

07	O	O
mg	O	O
per	O	O
deciliter	O	O
in	O	O
the	O	O
iodixanol	B-Chemical	C044834
group	O	O
and	O	O
0	O	O
.	O	O

24	O	O
mg	O	O
per	O	O
deciliter	O	O
in	O	O
the	O	O
iohexol	B-Chemical	D007472
group	O	O
(	O	O
P=0	O	O
.	O	O

003	O	O
;	O	O
value	O	O
in	O	O
the	O	O
iodixanol	B-Chemical	C044834
group	O	O
minus	O	O
the	O	O
value	O	O
in	O	O
the	O	O
iohexol	B-Chemical	D007472
group	O	O
,	O	O
-	O	O
0	O	O
.	O	O

17	O	O
mg	O	O
per	O	O
deciliter	O	O
[	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
-	O	O
0	O	O
.	O	O

34	O	O
to	O	O
-	O	O
0	O	O
.	O	O

07	O	O
]	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Nephropathy	B-Disease	D007674
induced	O	O
by	O	O
contrast	O	O
medium	O	O
may	O	O
be	O	O
less	O	O
likely	O	O
to	O	O
develop	O	O
in	O	O
high	O	O
-	O	O
risk	O	O
patients	O	O
when	O	O
iodixanol	B-Chemical	C044834
is	O	O
used	O	O
rather	O	O
than	O	O
a	O	O
low	O	O
-	O	O
osmolar	O	O
,	O	O
nonionic	O	O
contrast	O	O
medium	O	O
.	O	O

Experimental	O	O
cranial	O	O
pain	B-Disease	D010146
elicited	O	O
by	O	O
capsaicin	B-Chemical	D002211
:	O	O
a	O	O
PET	O	O
study	O	O
.	O	O

Using	O	O
a	O	O
positron	O	O
emission	O	O
tomography	O	O
(	O	O
PET	O	O
)	O	O
study	O	O
it	O	O
was	O	O
shown	O	O
recently	O	O
that	O	O
in	O	O
migraine	B-Disease	D008881
without	O	O
aura	O	O
certain	O	O
areas	O	O
in	O	O
the	O	O
brain	O	O
stem	O	O
were	O	O
activated	O	O
during	O	O
the	O	O
headache	B-Disease	D006261
state	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
headache	B-Disease	D006261
free	O	O
interval	O	O
.	O	O

It	O	O
was	O	O
suggested	O	O
that	O	O
this	O	O
brain	O	O
stem	O	O
activation	O	O
is	O	O
inherent	O	O
to	O	O
the	O	O
migraine	B-Disease	D008881
attack	O	O
itself	O	O
and	O	O
represents	O	O
the	O	O
so	O	O
called	O	O
'migraine	O	O
generator'	O	O
.	O	O

To	O	O
test	O	O
this	O	O
hypothesis	O	O
we	O	O
performed	O	O
an	O	O
experimental	O	O
pain	B-Disease	D010146
study	O	O
in	O	O
seven	O	O
healthy	O	O
volunteers	O	O
,	O	O
using	O	O
the	O	O
same	O	O
positioning	O	O
in	O	O
the	O	O
PET	O	O
scanner	O	O
as	O	O
in	O	O
the	O	O
migraine	B-Disease	D008881
patients	O	O
.	O	O

A	O	O
small	O	O
amount	O	O
of	O	O
capsaicin	B-Chemical	D002211
was	O	O
administered	O	O
subcutaneously	O	O
in	O	O
the	O	O
right	O	O
forehead	O	O
to	O	O
evoke	O	O
a	O	O
burning	O	O
painful	B-Disease	D010146
sensation	O	O
in	O	O
the	O	O
first	O	O
division	O	O
of	O	O
the	O	O
trigeminal	O	O
nerve	O	O
.	O	O

Increases	O	O
of	O	O
regional	O	O
cerebral	O	O
blood	O	O
flow	O	O
(	O	O
rCBF	O	O
)	O	O
were	O	O
found	O	O
bilaterally	O	O
in	O	O
the	O	O
insula	O	O
,	O	O
in	O	O
the	O	O
anterior	O	O
cingulate	O	O
cortex	O	O
,	O	O
the	O	O
cavernous	O	O
sinus	O	O
and	O	O
the	O	O
cerebellum	O	O
.	O	O

Using	O	O
the	O	O
same	O	O
stereotactic	O	O
space	O	O
limits	O	O
as	O	O
in	O	O
the	O	O
above	O	O
mentioned	O	O
migraine	B-Disease	D008881
study	O	O
no	O	O
brain	O	O
stem	O	O
activation	O	O
was	O	O
found	O	O
in	O	O
the	O	O
acute	O	O
pain	B-Disease	D010146
state	O	O
compared	O	O
to	O	O
the	O	O
pain	B-Disease	D010146
free	O	O
state	O	O
.	O	O

The	O	O
increase	O	O
of	O	O
activation	O	O
in	O	O
the	O	O
region	O	O
of	O	O
the	O	O
cavernous	O	O
sinus	O	O
however	O	O
,	O	O
suggests	O	O
that	O	O
this	O	O
structure	O	O
is	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
trigeminal	O	O
transmitted	O	O
pain	B-Disease	D010146
as	O	O
such	O	O
,	O	O
rather	O	O
than	O	O
in	O	O
a	O	O
specific	O	O
type	O	O
of	O	O
headache	B-Disease	D006261
as	O	O
was	O	O
suggested	O	O
for	O	O
cluster	B-Disease	D003027
headache	I-Disease	D003027
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
with	O	O
risperidone	B-Chemical	D018967
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
is	O	O
thought	O	O
to	O	O
be	O	O
a	O	O
result	O	O
of	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
blockade	O	O
in	O	O
the	O	O
striatum	O	O
of	O	O
the	O	O
basal	O	O
ganglia	O	O
.	O	O

Risperidone	B-Chemical	D018967
,	O	O
a	O	O
benzisoxazole	B-Chemical	C441200
derivative	O	O
antipsychotic	O	O
,	O	O
has	O	O
high	O	O
serotonin	B-Chemical	D012701
5	O	O
-	O	O
HT2	O	O
receptor	O	O
blockade	O	O
and	O	O
dose	O	O
-	O	O
related	O	O
D2	O	O
receptor	O	O
blockade	O	O
.	O	O

The	O	O
high	O	O
ratio	O	O
is	O	O
believed	O	O
to	O	O
impart	O	O
the	O	O
low	O	O
frequency	O	O
of	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
with	O	O
risperidone	B-Chemical	D018967
at	O	O
low	O	O
dosages	O	O
.	O	O

With	O	O
this	O	O
low	O	O
frequency	O	O
of	O	O
extrapyramidal	B-Disease	D001480
symptoms	I-Disease	D001480
,	O	O
it	O	O
was	O	O
thought	O	O
the	O	O
frequency	O	O
of	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
might	O	O
also	O	O
be	O	O
lowered	O	O
.	O	O

A	O	O
73	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
developed	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
after	O	O
monotherapy	O	O
with	O	O
risperidone	B-Chemical	D018967
.	O	O

The	O	O
syndrome	O	O
reversed	O	O
after	O	O
discontinuing	O	O
risperidone	B-Chemical	D018967
and	O	O
starting	O	O
treatment	O	O
with	O	O
dantrolene	B-Chemical	D003620
and	O	O
bromocriptine	B-Chemical	D001971
.	O	O

It	O	O
appears	O	O
that	O	O
the	O	O
protection	O	O
from	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
observed	O	O
with	O	O
risperidone	B-Chemical	D018967
does	O	O
not	O	O
ensure	O	O
protection	O	O
from	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
.	O	O

Hepatic	O	O
and	O	O
extrahepatic	O	O
angiotensinogen	O	O
gene	O	O
expression	O	O
in	O	O
rats	O	O
with	O	O
acute	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

Plasma	O	O
concentration	O	O
and	O	O
urine	O	O
excretion	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
proteins	O	O
are	O	O
altered	O	O
in	O	O
rats	O	O
with	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
(	O	O
NS	B-Disease	D009404
)	O	O
.	O	O

In	O	O
this	O	O
work	O	O
the	O	O
messenger	O	O
ribonucleic	O	O
acid	O	O
(	O	O
mRNA	O	O
)	O	O
levels	O	O
of	O	O
angiotensinogen	O	O
(	O	O
Ao	O	O
)	O	O
were	O	O
analyzed	O	O
with	O	O
the	O	O
slot	O	O
-	O	O
blot	O	O
hybridization	O	O
technique	O	O
in	O	O
liver	O	O
and	O	O
other	O	O
extrahepatic	O	O
tissues	O	O
:	O	O
kidney	O	O
,	O	O
heart	O	O
,	O	O
brain	O	O
,	O	O
and	O	O
adrenal	O	O
gland	O	O
from	O	O
control	O	O
,	O	O
nephrotic	B-Disease	D009404
,	O	O
and	O	O
pair	O	O
-	O	O
fed	O	O
(	O	O
PF	O	O
)	O	O
rats	O	O
.	O	O

NS	B-Disease	D009404
was	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
puromycin	B-Chemical	D011692
amino	I-Chemical	D011692
-	I-Chemical	D011692
nucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
.	O	O

Although	O	O
a	O	O
great	O	O
urinary	O	O
excretion	O	O
and	O	O
half	O	O
-	O	O
normal	O	O
plasma	O	O
levels	O	O
of	O	O
Ao	O	O
were	O	O
observed	O	O
on	O	O
day	O	O
6	O	O
after	O	O
PAN	B-Chemical	D011692
injection	O	O
,	O	O
when	O	O
NS	B-Disease	D009404
was	O	O
clearly	O	O
established	O	O
,	O	O
hepatic	O	O
Ao	O	O
mRNA	O	O
levels	O	O
did	O	O
not	O	O
change	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
Ao	O	O
mRNA	O	O
levels	O	O
did	O	O
not	O	O
change	O	O
in	O	O
any	O	O
of	O	O
the	O	O
extrahepatic	O	O
tissues	O	O
studied	O	O
on	O	O
day	O	O
6	O	O
,	O	O
nor	O	O
did	O	O
its	O	O
hepatic	O	O
levels	O	O
at	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
,	O	O
or	O	O
7	O	O
after	O	O
PAN	B-Chemical	D011692
injection	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
hepatic	O	O
and	O	O
extrahepatic	O	O
Ao	O	O
mRNA	O	O
levels	O	O
are	O	O
unaltered	O	O
during	O	O
the	O	O
development	O	O
of	O	O
the	O	O
acute	O	O
NS	B-Disease	D009404
induced	O	O
by	O	O
PAN	B-Chemical	D011692
.	O	O

Cyclophosphamide	B-Chemical	D003520
associated	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
-	O	O
-	O	O
a	O	O
highly	O	O
aggressive	O	O
disease	O	O
:	O	O
analysis	O	O
of	O	O
12	O	O
cases	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
gained	O	O
knowledge	O	O
of	O	O
the	O	O
etiology	O	O
,	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
associated	O	O
urothelial	B-Disease	D014523
cancer	I-Disease	D014523
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
medical	O	O
records	O	O
of	O	O
6	O	O
men	O	O
and	O	O
6	O	O
women	O	O
(	O	O
mean	O	O
age	O	O
55	O	O
years	O	O
)	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
associated	O	O
bladder	B-Disease	D001749
cancer	I-Disease	D001749
were	O	O
reviewed	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
tumors	B-Disease	D009369
were	O	O
grade	O	O
3	O	O
or	O	O
4	O	O
transitional	O	O
cell	O	O
carcinoma	B-Disease	D002277
.	O	O

Of	O	O
the	O	O
5	O	O
patients	O	O
initially	O	O
treated	O	O
with	O	O
endoscopic	O	O
resection	O	O
alone	O	O
only	O	O
1	O	O
is	O	O
alive	O	O
without	O	O
disease	O	O
.	O	O

Of	O	O
the	O	O
6	O	O
patients	O	O
who	O	O
underwent	O	O
early	O	O
cystectomy	O	O
4	O	O
were	O	O
alive	O	O
at	O	O
24	O	O
to	O	O
111	O	O
months	O	O
.	O	O

The	O	O
remaining	O	O
patient	O	O
with	O	O
extensive	O	O
cancer	B-Disease	D009369
underwent	O	O
partial	O	O
cystectomy	O	O
for	O	O
palliation	O	O
and	O	O
died	O	O
3	O	O
months	O	O
later	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Cyclophosphamide	B-Chemical	D003520
associated	O	O
bladder	B-Disease	D001749
tumor	I-Disease	D001749
is	O	O
an	O	O
aggressive	O	O
disease	O	O
.	O	O

However	O	O
,	O	O
long	O	O
-	O	O
term	O	O
survival	O	O
is	O	O
possible	O	O
when	O	O
radical	O	O
cystectomy	O	O
is	O	O
performed	O	O
for	O	O
bladder	B-Disease	D001749
tumors	I-Disease	D001749
with	O	O
any	O	O
sign	O	O
of	O	O
invasion	O	O
and	O	O
for	O	O
recurrent	O	O
high	O	O
grade	O	O
disease	O	O
,	O	O
even	O	O
when	O	O
noninvasive	O	O
.	O	O

Leg	B-Disease	D001416
and	I-Disease	D001416
back	I-Disease	D001416
pain	I-Disease	D001416
after	O	O
spinal	O	O
anaesthesia	O	O
involving	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
.	O	O

Fifty	O	O
-	O	O
four	O	O
patients	O	O
,	O	O
aged	O	O
27	O	O
-	O	O
90	O	O
years	O	O
,	O	O
who	O	O
were	O	O
given	O	O
lignocaine	B-Chemical	D008012
5%	O	O
in	O	O
6	O	O
.	O	O

8%	O	O
glucose	B-Chemical	D005947
solution	O	O
for	O	O
spinal	O	O
anaesthesia	O	O
were	O	O
studied	O	O
.	O	O

Thirteen	O	O
of	O	O
these	O	O
patients	O	O
experienced	O	O
pain	B-Disease	D001416
in	I-Disease	D001416
the	I-Disease	D001416
legs	I-Disease	D001416
and	I-Disease	D001416
/	I-Disease	D001416
or	I-Disease	D001416
back	I-Disease	D001416
after	O	O
recovery	O	O
from	O	O
anaesthesia	O	O
.	O	O

The	O	O
patients	O	O
affected	O	O
were	O	O
younger	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
the	O	O
site	O	O
of	O	O
the	O	O
dural	O	O
puncture	O	O
was	O	O
higher	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
than	O	O
those	O	O
individuals	O	O
without	O	O
pain	B-Disease	D010146
.	O	O

Five	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
(	O	O
38%	O	O
)	O	O
with	O	O
pain	B-Disease	D010146
and	O	O
seven	O	O
of	O	O
the	O	O
41	O	O
patients	O	O
(	O	O
17%	O	O
)	O	O
without	O	O
pain	B-Disease	D010146
admitted	O	O
to	O	O
a	O	O
high	O	O
alcohol	B-Chemical	D000431
intake	O	O
,	O	O
which	O	O
might	O	O
be	O	O
a	O	O
contributing	O	O
factor	O	O
.	O	O

Leg	B-Disease	D001416
and	I-Disease	D001416
/	I-Disease	D001416
or	I-Disease	D001416
back	I-Disease	D001416
pain	I-Disease	D001416
is	O	O
associated	O	O
with	O	O
the	O	O
intrathecal	O	O
use	O	O
of	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
.	O	O

Acute	O	O
blood	O	O
pressure	O	O
elevations	O	O
with	O	O
caffeine	B-Chemical	D002110
in	O	O
men	O	O
with	O	O
borderline	O	O
systemic	O	O
hypertension	B-Disease	D006973
.	O	O

Whether	O	O
the	O	O
vasoconstrictive	O	O
actions	O	O
of	O	O
caffeine	B-Chemical	D002110
are	O	O
enhanced	O	O
in	O	O
hypertensive	B-Disease	D006973
persons	O	O
has	O	O
not	O	O
been	O	O
demonstrated	O	O
.	O	O

Thus	O	O
,	O	O
caffeine	B-Chemical	D002110
(	O	O
3	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
versus	O	O
placebo	O	O
was	O	O
tested	O	O
in	O	O
48	O	O
healthy	O	O
men	O	O
(	O	O
aged	O	O
20	O	O
to	O	O
35	O	O
years	O	O
)	O	O
selected	O	O
after	O	O
screening	O	O
on	O	O
2	O	O
separate	O	O
occasions	O	O
.	O	O

Borderline	O	O
hypertensive	B-Disease	D006973
men	O	O
(	O	O
n	O	O
=	O	O
24	O	O
)	O	O
were	O	O
selected	O	O
with	O	O
screening	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
of	O	O
140	O	O
to	O	O
160	O	O
mm	O	O
Hg	O	O
and	O	O
/	O	O
or	O	O
diastolic	O	O
BP	O	O
90	O	O
to	O	O
99	O	O
mm	O	O
Hg	O	O
.	O	O

Low	O	O
-	O	O
risk	O	O
controls	O	O
(	O	O
n	O	O
=	O	O
24	O	O
)	O	O
reported	O	O
no	O	O
parental	O	O
history	O	O
of	O	O
hypertension	B-Disease	D006973
and	O	O
had	O	O
screening	O	O
BP	O	O
<	O	O
130	O	O
/	O	O
85	O	O
mm	O	O
Hg	O	O
.	O	O

Participants	O	O
were	O	O
then	O	O
tested	O	O
on	O	O
2	O	O
occasions	O	O
after	O	O
12	O	O
-	O	O
hour	O	O
abstinence	O	O
from	O	O
caffeine	B-Chemical	D002110
in	O	O
each	O	O
of	O	O
2	O	O
protocols	O	O
;	O	O
this	O	O
required	O	O
a	O	O
total	O	O
of	O	O
4	O	O
laboratory	O	O
visits	O	O
.	O	O

Caffeine	B-Chemical	D002110
-	O	O
induced	O	O
changes	O	O
in	O	O
diastolic	O	O
BP	O	O
were	O	O
2	O	O
to	O	O
3	O	O
times	O	O
larger	O	O
in	O	O
borderline	O	O
subjects	O	O
than	O	O
in	O	O
controls	O	O
(	O	O
+8	O	O
.	O	O

4	O	O
vs	O	O
+3	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
and	O	O
were	O	O
attributable	O	O
to	O	O
larger	O	O
changes	O	O
in	O	O
impedance	O	O
-	O	O
derived	O	O
measures	O	O
of	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
+135	O	O
vs	O	O
+45	O	O
dynes	O	O
.	O	O

s	O	O
.	O	O

cm	O	O
-	O	O
5	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

004	O	O
)	O	O
.	O	O

These	O	O
findings	O	O
were	O	O
consistent	O	O
and	O	O
reached	O	O
significance	O	O
in	O	O
both	O	O
protocols	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
borderline	O	O
subjects	O	O
in	O	O
whom	O	O
diastolic	O	O
BP	O	O
changes	O	O
exceeded	O	O
the	O	O
median	O	O
control	O	O
response	O	O
was	O	O
96%	O	O
.	O	O

Consequently	O	O
,	O	O
whereas	O	O
all	O	O
participants	O	O
exhibited	O	O
normotensive	O	O
levels	O	O
during	O	O
the	O	O
resting	O	O
predrug	O	O
baseline	O	O
,	O	O
33%	O	O
of	O	O
borderline	O	O
subjects	O	O
achieved	O	O
hypertensive	B-Disease	D006973
BP	O	O
levels	O	O
after	O	O
caffeine	B-Chemical	D002110
ingestion	O	O
.	O	O

Thus	O	O
,	O	O
in	O	O
borderline	O	O
hypertensive	B-Disease	D006973
men	O	O
,	O	O
exaggerated	O	O
responses	O	O
to	O	O
caffeine	B-Chemical	D002110
were	O	O
:	O	O
selective	O	O
for	O	O
diastolic	O	O
BP	O	O
,	O	O
consistent	O	O
with	O	O
greater	O	O
vasoconstriction	O	O
,	O	O
replicated	O	O
in	O	O
2	O	O
protocols	O	O
,	O	O
and	O	O
representative	O	O
of	O	O
nearly	O	O
all	O	O
borderline	O	O
hypertensives	B-Disease	D006973
.	O	O

We	O	O
suspect	O	O
that	O	O
the	O	O
potential	O	O
for	O	O
caffeine	B-Chemical	D002110
to	O	O
stabilize	O	O
high	O	O
resistance	O	O
states	O	O
in	O	O
susceptible	O	O
persons	O	O
suggests	O	O
that	O	O
its	O	O
use	O	O
may	O	O
facilitate	O	O
their	O	O
disease	O	O
progression	O	O
,	O	O
as	O	O
well	O	O
as	O	O
hinder	O	O
accurate	O	O
diagnosis	O	O
and	O	O
treatment	O	O
.	O	O

Hallucinations	B-Disease	D006212
and	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

BACKGROUND	O	O
:	O	O
Hallucinations	B-Disease	D006212
as	O	O
a	O	O
symptom	O	O
of	O	O
central	O	O
neurotoxicity	B-Disease	D020258
are	O	O
a	O	O
known	O	O
but	O	O
poorly	O	O
described	O	O
side	O	O
effect	O	O
of	O	O
ifosfamide	B-Chemical	D007069
.	O	O

Most	O	O
cases	O	O
of	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
hallucinations	B-Disease	D006212
have	O	O
been	O	O
reported	O	O
with	O	O
other	O	O
mental	O	O
status	O	O
changes	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
authors	O	O
interviewed	O	O
six	O	O
persons	O	O
with	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
hallucinations	B-Disease	D006212
in	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
clear	O	O
sensorium	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
ifosfamide	B-Chemical	D007069
as	O	O
part	O	O
of	O	O
their	O	O
bone	O	O
marrow	O	O
transplant	O	O
procedure	O	O
.	O	O

RESULTS	O	O
:	O	O
Hallucinations	B-Disease	D006212
occurred	O	O
only	O	O
when	O	O
the	O	O
patient's	O	O
eyes	O	O
were	O	O
closed	O	O
and	O	O
,	O	O
in	O	O
all	O	O
but	O	O
one	O	O
case	O	O
,	O	O
were	O	O
reported	O	O
as	O	O
disturbing	O	O
or	O	O
frightening	O	O
.	O	O

Underreporting	O	O
of	O	O
these	O	O
hallucinations	B-Disease	D006212
by	O	O
patients	O	O
is	O	O
likely	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Hallucinations	B-Disease	D006212
may	O	O
be	O	O
the	O	O
sole	O	O
or	O	O
first	O	O
manifestation	O	O
of	O	O
neurotoxicity	B-Disease	D020258
.	O	O

The	O	O
incidence	O	O
may	O	O
be	O	O
dose	O	O
and	O	O
infusion	O	O
-	O	O
time	O	O
related	O	O
.	O	O

The	O	O
clinician	O	O
should	O	O
be	O	O
alerted	O	O
for	O	O
possible	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
hallucinations	B-Disease	D006212
,	O	O
which	O	O
may	O	O
occur	O	O
without	O	O
other	O	O
signs	O	O
of	O	O
neurotoxicity	B-Disease	D020258
.	O	O

"Eyes	O	O
-	O	O
closed"	O	O
hallucinatory	B-Disease	D006212
experiences	O	O
appear	O	O
to	O	O
be	O	O
an	O	O
unusual	O	O
feature	O	O
of	O	O
this	O	O
presentation	O	O
.	O	O

Patients	O	O
anxious	O	O
about	O	O
this	O	O
experience	O	O
respond	O	O
well	O	O
to	O	O
support	O	O
and	O	O
education	O	O
about	O	O
this	O	O
occurrence	O	O
.	O	O

Optimal	O	O
pharmacologic	O	O
management	O	O
of	O	O
disturbed	O	O
patients	O	O
is	O	O
unclear	O	O
.	O	O

If	O	O
agitation	B-Disease	D011595
becomes	O	O
marked	O	O
,	O	O
high	O	O
-	O	O
potency	O	O
neuroleptics	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
haloperidol	B-Chemical	D006220
)	O	O
may	O	O
be	O	O
effective	O	O
.	O	O

Chlorpropamide	B-Chemical	D002747
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

A	O	O
65	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
adult	B-Disease	D003924
-	I-Disease	D003924
onset	I-Disease	D003924
diabetes	I-Disease	D003924
treated	O	O
with	O	O
chlorpropamide	B-Chemical	D002747
(	O	O
Diabenese	B-Chemical	D002747
)	O	O
had	O	O
a	O	O
toxic	B-Disease	D009901
optic	I-Disease	D009901
neuropathy	I-Disease	D009901
that	O	O
resolved	O	O
with	O	O
discontinuation	O	O
of	O	O
chlorpropamide	B-Chemical	D002747
therapy	O	O
.	O	O

Visual	B-Disease	D014786
loss	I-Disease	D014786
occurs	O	O
in	O	O
diabetics	B-Disease	D003920
for	O	O
a	O	O
variety	O	O
of	O	O
reasons	O	O
,	O	O
and	O	O
accurate	O	O
diagnosis	O	O
is	O	O
necessary	O	O
to	O	O
institute	O	O
appropriate	O	O
therapy	O	O
.	O	O

The	O	O
possibility	O	O
of	O	O
a	O	O
drug	O	O
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
should	O	O
be	O	O
considered	O	O
in	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
in	O	O
diabetics	B-Disease	D003920
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
and	O	O
thalamotomy	O	O
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
of	O	O
the	O	O
limbs	O	O
in	O	O
thirteen	O	O
cases	O	O
of	O	O
Parkinsonism	B-Disease	D010302
,	O	O
which	O	O
was	O	O
choreic	O	O
,	O	O
ballistic	O	O
or	O	O
dystonic	B-Disease	D020821
in	O	O
type	O	O
,	O	O
was	O	O
alleviated	O	O
almost	O	O
completely	O	O
by	O	O
stereotaxic	O	O
surgery	O	O
using	O	O
a	O	O
microelectrode	O	O
technique	O	O
for	O	O
the	O	O
ventralis	O	O
oralis	O	O
anterior	O	O
and	O	O
posterior	O	O
nuclei	O	O
of	O	O
the	O	O
thalamus	O	O
,	O	O
but	O	O
much	O	O
less	O	O
by	O	O
the	O	O
ventralis	O	O
intermedius	O	O
nucleus	O	O
.	O	O

Control	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
by	O	O
thalamic	B-Disease	D013786
lesions	I-Disease	D013786
in	O	O
the	O	O
course	O	O
of	O	O
routine	O	O
treatment	O	O
of	O	O
Parkinsonism	B-Disease	D010302
is	O	O
discussed	O	O
.	O	O

Factors	O	O
associated	O	O
with	O	O
nephrotoxicity	B-Disease	D007674
and	O	O
clinical	O	O
outcome	O	O
in	O	O
patients	O	O
receiving	O	O
amikacin	B-Chemical	D000583
.	O	O

Data	O	O
from	O	O
60	O	O
patients	O	O
treated	O	O
with	O	O
amikacin	B-Chemical	D000583
were	O	O
analyzed	O	O
for	O	O
factors	O	O
associated	O	O
with	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

In	O	O
42	O	O
of	O	O
these	O	O
patients	O	O
,	O	O
data	O	O
were	O	O
examined	O	O
for	O	O
factors	O	O
associated	O	O
with	O	O
clinical	O	O
outcome	O	O
.	O	O

Variables	O	O
evaluated	O	O
included	O	O
patient	O	O
weight	O	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
serum	O	O
creatinine	B-Chemical	D003404
level	O	O
,	O	O
creatinine	B-Chemical	D003404
clearance	O	O
,	O	O
duration	O	O
of	O	O
therapy	O	O
,	O	O
total	O	O
dose	O	O
,	O	O
mean	O	O
daily	O	O
dose	O	O
,	O	O
organism	O	O
minimum	O	O
inhibitory	O	O
concentration	O	O
(	O	O
MIC	O	O
)	O	O
,	O	O
mean	O	O
peak	O	O
levels	O	O
,	O	O
mean	O	O
trough	O	O
levels	O	O
,	O	O
mean	O	O
area	O	O
under	O	O
the	O	O
serum	O	O
concentration	O	O
-	O	O
time	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
,	O	O
total	O	O
AUC	O	O
,	O	O
mean	O	O
AUC	O	O
greater	O	O
than	O	O
MIC	O	O
,	O	O
total	O	O
AUC	O	O
greater	O	O
than	O	O
MIC	O	O
,	O	O
mean	O	O
Schumacher's	O	O
intensity	O	O
factor	O	O
(	O	O
IF	O	O
)	O	O
,	O	O
total	O	O
IF	O	O
,	O	O
In	O	O
(	O	O
mean	O	O
maximum	O	O
concentration	O	O
[	O	O
Cmax	O	O
]	O	O
/	O	O
MIC	O	O
)	O	O
.	O	O

Model	O	O
-	O	O
dependent	O	O
pharmacokinetic	O	O
parameters	O	O
were	O	O
calculated	O	O
by	O	O
computer	O	O
based	O	O
on	O	O
a	O	O
one	O	O
-	O	O
compartment	O	O
model	O	O
.	O	O

When	O	O
the	O	O
parameters	O	O
were	O	O
examined	O	O
individually	O	O
,	O	O
duration	O	O
of	O	O
therapy	O	O
and	O	O
total	O	O
AUC	O	O
correlated	O	O
significantly	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

05	O	O
)	O	O
with	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
stepwise	O	O
discriminant	O	O
function	O	O
analysis	O	O
identified	O	O
only	O	O
duration	O	O
of	O	O
therapy	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

001	O	O
)	O	O
as	O	O
an	O	O
important	O	O
factor	O	O
.	O	O

Based	O	O
on	O	O
this	O	O
model	O	O
and	O	O
on	O	O
Bayes'	O	O
theorem	O	O
,	O	O
the	O	O
predictive	O	O
accuracy	O	O
of	O	O
identifying	O	O
"nephrotoxic"	O	O
patients	O	O
increased	O	O
from	O	O
0	O	O
.	O	O

17	O	O
to	O	O
0	O	O
.	O	O

39	O	O
.	O	O

When	O	O
examined	O	O
individually	O	O
,	O	O
mean	O	O
IF	O	O
,	O	O
MIC	O	O
,	O	O
total	O	O
dose	O	O
,	O	O
mean	O	O
daily	O	O
dose	O	O
,	O	O
and	O	O
ln	O	O
(	O	O
mean	O	O
Cmax	O	O
/	O	O
MIC	O	O
)	O	O
correlated	O	O
significantly	O	O
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

05	O	O
)	O	O
with	O	O
cure	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
simultaneous	O	O
multivariable	O	O
analysis	O	O
identified	O	O
IF	O	O
,	O	O
MIC	O	O
,	O	O
and	O	O
total	O	O
dose	O	O
according	O	O
to	O	O
one	O	O
model	O	O
and	O	O
ln	O	O
(	O	O
mean	O	O
Cmax	O	O
/	O	O
MIC	O	O
)	O	O
according	O	O
to	O	O
a	O	O
second	O	O
statistical	O	O
model	O	O
of	O	O
parameters	O	O
selected	O	O
to	O	O
have	O	O
the	O	O
greatest	O	O
prospective	O	O
value	O	O
.	O	O

Based	O	O
on	O	O
Bayes'	O	O
theorem	O	O
and	O	O
the	O	O
first	O	O
model	O	O
,	O	O
the	O	O
predictive	O	O
accuracy	O	O
of	O	O
identifying	O	O
patients	O	O
not	O	O
cured	O	O
increased	O	O
from	O	O
0	O	O
.	O	O

19	O	O
to	O	O
0	O	O
.	O	O

83	O	O
.	O	O

For	O	O
the	O	O
second	O	O
model	O	O
,	O	O
the	O	O
predictive	O	O
accuracy	O	O
increased	O	O
from	O	O
0	O	O
.	O	O

19	O	O
to	O	O
0	O	O
.	O	O

50	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Cardiac	O	O
transplantation	O	O
:	O	O
improved	O	O
quality	O	O
of	O	O
survival	O	O
with	O	O
a	O	O
modified	O	O
immunosuppressive	O	O
protocol	O	O
.	O	O

The	O	O
effects	O	O
on	O	O
renal	O	O
function	O	O
on	O	O
two	O	O
different	O	O
immunosuppressive	O	O
protocols	O	O
were	O	O
evaluated	O	O
retrospectively	O	O
in	O	O
two	O	O
subsequent	O	O
groups	O	O
of	O	O
heart	O	O
transplant	O	O
recipients	O	O
.	O	O

In	O	O
group	O	O
I	O	O
,	O	O
cyclosporine	B-Chemical	D016572
was	O	O
given	O	O
before	O	O
the	O	O
procedure	O	O
at	O	O
a	O	O
loading	O	O
dose	O	O
of	O	O
17	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
then	O	O
continued	O	O
after	O	O
the	O	O
procedure	O	O
to	O	O
keep	O	O
a	O	O
whole	O	O
blood	O	O
level	O	O
about	O	O
1000	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

In	O	O
group	O	O
II	O	O
,	O	O
cyclosporine	B-Chemical	D016572
was	O	O
started	O	O
only	O	O
after	O	O
the	O	O
procedure	O	O
at	O	O
a	O	O
lower	O	O
dosage	O	O
and	O	O
was	O	O
complemented	O	O
by	O	O
azathioprine	B-Chemical	D001379
,	O	O
which	O	O
was	O	O
used	O	O
for	O	O
the	O	O
first	O	O
postoperative	O	O
week	O	O
.	O	O

Group	O	O
II	O	O
showed	O	O
a	O	O
better	O	O
perioperative	O	O
renal	O	O
function	O	O
as	O	O
determined	O	O
by	O	O
serum	O	O
blood	O	O
urea	B-Chemical	D001806
nitrogen	I-Chemical	D001806
and	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
.	O	O

Group	O	O
II	O	O
also	O	O
showed	O	O
a	O	O
significant	O	O
decrease	O	O
of	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
secondary	O	O
to	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
cyclosporine	B-Chemical	D016572
.	O	O

Despite	O	O
this	O	O
improvement	O	O
in	O	O
late	O	O
renal	O	O
function	O	O
,	O	O
group	O	O
II	O	O
still	O	O
shows	O	O
a	O	O
slow	O	O
rise	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
.	O	O

We	O	O
think	O	O
that	O	O
even	O	O
these	O	O
lower	O	O
dosages	O	O
of	O	O
cyclosporine	B-Chemical	D016572
can	O	O
cause	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
and	O	O
that	O	O
further	O	O
modification	O	O
of	O	O
the	O	O
immunosuppressive	O	O
regimen	O	O
is	O	O
required	O	O
to	O	O
completely	O	O
abolish	O	O
this	O	O
toxic	O	O
side	O	O
effect	O	O
.	O	O

Reversible	O	O
cholestasis	B-Disease	D002779
with	O	O
bile	B-Disease	D002779
duct	I-Disease	D002779
injury	I-Disease	D002779
following	O	O
azathioprine	B-Chemical	D001379
therapy	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

A	O	O
67	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
,	O	O
with	O	O
primary	O	O
polymyositis	B-Disease	D017285
and	O	O
without	O	O
previous	O	O
evidence	O	O
of	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
,	O	O
developed	O	O
clinical	O	O
and	O	O
biochemical	O	O
features	O	O
of	O	O
severe	O	O
cholestasis	B-Disease	D002779
3	O	O
months	O	O
after	O	O
initiation	O	O
of	O	O
azathioprine	B-Chemical	D001379
therapy	O	O
.	O	O

Liver	O	O
biopsy	O	O
showed	O	O
cholestasis	B-Disease	D002779
with	O	O
both	O	O
cytological	O	O
and	O	O
architectural	O	O
alterations	O	O
of	O	O
interlobular	O	O
bile	O	O
ducts	O	O
.	O	O

Azathioprine	B-Chemical	D001379
withdrawal	O	O
resulted	O	O
after	O	O
7	O	O
weeks	O	O
in	O	O
the	O	O
resolution	O	O
of	O	O
clinical	O	O
and	O	O
biochemical	O	O
abnormalities	O	O
.	O	O

It	O	O
is	O	O
believed	O	O
that	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
reversible	O	O
azathioprine	B-Chemical	D001379
-	O	O
induced	O	O
cholestasis	B-Disease	D002779
associated	O	O
with	O	O
histological	O	O
evidence	O	O
of	O	O
bile	B-Disease	D002779
duct	I-Disease	D002779
injury	I-Disease	D002779
.	O	O

Renal	O	O
function	O	O
and	O	O
hemodynamics	O	O
during	O	O
prolonged	O	O
isoflurane	B-Chemical	D007530
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
humans	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
isoflurane	B-Chemical	D007530
-	O	O
induced	O	O
hypotension	B-Disease	D007022
on	O	O
glomerular	O	O
function	O	O
and	O	O
renal	O	O
blood	O	O
flow	O	O
was	O	O
investigated	O	O
in	O	O
20	O	O
human	O	O
subjects	O	O
.	O	O

Glomerular	O	O
filtration	O	O
rate	O	O
(	O	O
GFR	O	O
)	O	O
and	O	O
effective	O	O
renal	O	O
plasma	O	O
flow	O	O
(	O	O
ERPF	O	O
)	O	O
were	O	O
measured	O	O
by	O	O
inulin	O	O
and	O	O
para	B-Chemical	D010130
-	I-Chemical	D010130
aminohippurate	I-Chemical	D010130
(	O	O
PAH	B-Chemical	D010130
)	O	O
clearance	O	O
,	O	O
respectively	O	O
.	O	O

Anesthesia	O	O
was	O	O
maintained	O	O
with	O	O
fentanyl	B-Chemical	D005283
,	O	O
nitrous	B-Chemical	D009609
oxide	I-Chemical	D009609
,	O	O
oxygen	B-Chemical	D010100
,	O	O
and	O	O
isoflurane	B-Chemical	D007530
.	O	O

Hypotension	B-Disease	D007022
was	O	O
induced	O	O
for	O	O
236	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
15	O	O
.	O	O

1	O	O
min	O	O
by	O	O
increasing	O	O
the	O	O
isoflurane	B-Chemical	D007530
inspired	O	O
concentration	O	O
to	O	O
maintain	O	O
a	O	O
mean	O	O
arterial	O	O
pressure	O	O
of	O	O
59	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
mmHg	O	O
.	O	O

GFR	O	O
and	O	O
ERPF	O	O
decreased	O	O
with	O	O
the	O	O
induction	O	O
of	O	O
anesthesia	O	O
but	O	O
not	O	O
significantly	O	O
more	O	O
during	O	O
hypotension	B-Disease	D007022
.	O	O

Postoperatively	O	O
,	O	O
ERPF	O	O
returned	O	O
to	O	O
preoperative	O	O
values	O	O
,	O	O
whereas	O	O
GFR	O	O
was	O	O
higher	O	O
than	O	O
preoperative	O	O
values	O	O
.	O	O

Renal	O	O
vascular	O	O
resistance	O	O
increased	O	O
during	O	O
anesthesia	O	O
but	O	O
decreased	O	O
when	O	O
hypotension	B-Disease	D007022
was	O	O
induced	O	O
,	O	O
allowing	O	O
the	O	O
maintenance	O	O
of	O	O
renal	O	O
blood	O	O
flow	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
renal	O	O
compensatory	O	O
mechanisms	O	O
are	O	O
preserved	O	O
during	O	O
isoflurane	B-Chemical	D007530
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
that	O	O
renal	O	O
function	O	O
and	O	O
hemodynamics	O	O
quickly	O	O
return	O	O
to	O	O
normal	O	O
when	O	O
normotension	O	O
is	O	O
resumed	O	O
.	O	O

Debrisoquine	B-Chemical	D003647
phenotype	O	O
and	O	O
the	O	O
pharmacokinetics	O	O
and	O	O
beta	O	O
-	O	O
2	O	O
receptor	O	O
pharmacodynamics	O	O
of	O	O
metoprolol	B-Chemical	D008790
and	O	O
its	O	O
enantiomers	O	O
.	O	O

The	O	O
metabolism	O	O
of	O	O
the	O	O
cardioselective	O	O
beta	O	O
-	O	O
blocker	O	O
metoprolol	B-Chemical	D008790
is	O	O
under	O	O
genetic	O	O
control	O	O
of	O	O
the	O	O
debrisoquine	B-Chemical	D003647
/	O	O
sparteine	B-Chemical	D013034
type	O	O
.	O	O

The	O	O
two	O	O
metabolic	O	O
phenotypes	O	O
,	O	O
extensive	O	O
(	O	O
EM	O	O
)	O	O
and	O	O
poor	O	O
metabolizers	O	O
(	O	O
PM	O	O
)	O	O
,	O	O
show	O	O
different	O	O
stereoselective	O	O
metabolism	O	O
,	O	O
resulting	O	O
in	O	O
apparently	O	O
higher	O	O
beta	O	O
-	O	O
1	O	O
adrenoceptor	O	O
antagonistic	O	O
potency	O	O
of	O	O
racemic	O	O
metoprolol	B-Chemical	D008790
in	O	O
EMs	O	O
.	O	O

We	O	O
investigated	O	O
if	O	O
the	O	O
latter	O	O
also	O	O
applies	O	O
to	O	O
the	O	O
beta	O	O
-	O	O
2	O	O
adrenoceptor	O	O
antagonism	O	O
by	O	O
metoprolol	B-Chemical	D008790
.	O	O

The	O	O
drug	O	O
effect	O	O
studied	O	O
was	O	O
the	O	O
antagonism	O	O
by	O	O
metoprolol	B-Chemical	D008790
of	O	O
terbutaline	B-Chemical	D013726
-	O	O
induced	O	O
hypokalemia	B-Disease	D007008
.	O	O

By	O	O
using	O	O
pharmacokinetic	O	O
pharmacodynamic	O	O
modeling	O	O
the	O	O
pharmacodynamics	O	O
of	O	O
racemic	O	O
metoprolol	B-Chemical	D008790
and	O	O
the	O	O
active	O	O
S	O	O
-	O	O
isomer	O	O
,	O	O
were	O	O
quantitated	O	O
in	O	O
EMs	O	O
and	O	O
PMs	O	O
in	O	O
terms	O	O
of	O	O
IC50	O	O
values	O	O
,	O	O
representing	O	O
metoprolol	B-Chemical	D008790
plasma	O	O
concentrations	O	O
resulting	O	O
in	O	O
half	O	O
-	O	O
maximum	O	O
receptor	O	O
occupancy	O	O
.	O	O

Six	O	O
EMs	O	O
received	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
of	O	O
terbutaline	B-Chemical	D013726
s	O	O
.	O	O

c	O	O
.	O	O

on	O	O
two	O	O
different	O	O
occasions	O	O
:	O	O
1	O	O
)	O	O
1	O	O
hr	O	O
after	O	O
administration	O	O
of	O	O
a	O	O
placebo	O	O
and	O	O
2	O	O
)	O	O
1	O	O
hr	O	O
after	O	O
150	O	O
mg	O	O
of	O	O
metoprolol	B-Chemical	D008790
p	O	O
.	O	O

o	O	O
.	O	O

Five	O	O
PMs	O	O
were	O	O
studied	O	O
according	O	O
to	O	O
the	O	O
same	O	O
protocol	O	O
,	O	O
except	O	O
for	O	O
a	O	O
higher	O	O
terbutaline	B-Chemical	D013726
dose	O	O
(	O	O
0	O	O
.	O	O

75	O	O
mg	O	O
)	O	O
on	O	O
day	O	O
2	O	O
.	O	O

Blood	O	O
samples	O	O
for	O	O
the	O	O
analysis	O	O
of	O	O
plasma	O	O
potassium	B-Chemical	D011188
,	O	O
terbutaline	B-Chemical	D013726
,	O	O
metoprolol	B-Chemical	D008790
(	O	O
racemic	O	O
,	O	O
R	O	O
-	O	O
and	O	O
S	O	O
-	O	O
isomer	O	O
)	O	O
,	O	O
and	O	O
alpha	B-Chemical	C029504
-	I-Chemical	C029504
hydroxymetoprolol	I-Chemical	C029504
concentrations	O	O
were	O	O
taken	O	O
at	O	O
regular	O	O
time	O	O
intervals	O	O
,	O	O
during	O	O
8	O	O
hr	O	O
after	O	O
metoprolol	B-Chemical	D008790
.	O	O

In	O	O
PMs	O	O
,	O	O
metoprolol	B-Chemical	D008790
increased	O	O
the	O	O
terbutaline	B-Chemical	D013726
area	O	O
under	O	O
the	O	O
plasma	O	O
concentration	O	O
vs	O	O
.	O	O

time	O	O
curve	O	O
(	O	O
+67%	O	O
)	O	O
.	O	O

Higher	O	O
metoprolol	B-Chemical	D008790
/	O	O
alpha	B-Chemical	C029504
-	I-Chemical	C029504
hydroxymetoprolol	I-Chemical	C029504
ratios	O	O
in	O	O
PMs	O	O
were	O	O
predictive	O	O
for	O	O
higher	O	O
R	O	O
-	O	O
/	O	O
S	O	O
-	O	O
isomer	O	O
ratios	O	O
of	O	O
unchanged	O	O
drug	O	O
.	O	O

There	O	O
was	O	O
a	O	O
difference	O	O
in	O	O
metoprolol	B-Chemical	D008790
potency	O	O
with	O	O
higher	O	O
racemic	O	O
metoprolol	B-Chemical	D008790
IC50	O	O
values	O	O
in	O	O
PMs	O	O
(	O	O
72	O	O
+	O	O
/	O	O
-	O	O
7	O	O
ng	O	O
.	O	O

ml	O	O
-	O	O
1	O	O
)	O	O
than	O	O
EMs	O	O
(	O	O
42	O	O
+	O	O
/	O	O
-	O	O
8	O	O
ng	O	O
.	O	O

ml	O	O
-	O	O
1	O	O
,	O	O
P	O	O
less	O	O
than	O	O
.	O	O

001	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Cefotetan	B-Chemical	D015313
-	O	O
induced	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

Immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
due	O	O
to	O	O
a	O	O
drug	O	O
-	O	O
adsorption	O	O
mechanism	O	O
has	O	O
been	O	O
described	O	O
primarily	O	O
in	O	O
patients	O	O
receiving	O	O
penicillins	B-Chemical	D010406
and	O	O
first	O	O
-	O	O
generation	O	O
cephalosporins	B-Chemical	D002511
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
anemia	B-Disease	D000740
while	O	O
receiving	O	O
intravenous	O	O
cefotetan	B-Chemical	D015313
.	O	O

Cefotetan	B-Chemical	D015313
-	O	O
dependent	O	O
antibodies	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
patient's	O	O
serum	O	O
and	O	O
in	O	O
an	O	O
eluate	O	O
prepared	O	O
from	O	O
his	O	O
red	O	O
blood	O	O
cells	O	O
.	O	O

The	O	O
eluate	O	O
also	O	O
reacted	O	O
weakly	O	O
with	O	O
red	O	O
blood	O	O
cells	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
cefotetan	B-Chemical	D015313
,	O	O
suggesting	O	O
the	O	O
concomitant	O	O
formation	O	O
of	O	O
warm	O	O
-	O	O
reactive	O	O
autoantibodies	O	O
.	O	O

These	O	O
observations	O	O
,	O	O
in	O	O
conjunction	O	O
with	O	O
clinical	O	O
and	O	O
laboratory	O	O
evidence	O	O
of	O	O
extravascular	O	O
hemolysis	B-Disease	D006461
,	O	O
are	O	O
consistent	O	O
with	O	O
drug	O	O
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
,	O	O
possibly	O	O
involving	O	O
both	O	O
drug	O	O
-	O	O
adsorption	O	O
and	O	O
autoantibody	O	O
formation	O	O
mechanisms	O	O
.	O	O

This	O	O
case	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
increased	O	O
awareness	O	O
of	O	O
hemolytic	O	O
reactions	O	O
to	O	O
all	O	O
cephalosporins	B-Chemical	D002511
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
subsequent	O	O
to	O	O
the	O	O
administration	O	O
of	O	O
rifampicin	B-Chemical	D012293
.	O	O

A	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
of	O	O
cases	O	O
reported	O	O
earlier	O	O
.	O	O

A	O	O
clinical	O	O
presentation	O	O
is	O	O
made	O	O
of	O	O
a	O	O
2	O	O
-	O	O
3	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
six	O	O
cases	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
that	O	O
have	O	O
been	O	O
reported	O	O
earlier	O	O
.	O	O

The	O	O
patients	O	O
had	O	O
developed	O	O
transient	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
after	O	O
the	O	O
intermittent	O	O
administration	O	O
of	O	O
rifampicin	B-Chemical	D012293
.	O	O

The	O	O
stage	O	O
of	O	O
olig	O	O
-	O	O
anuria	B-Disease	D001002
lasted	O	O
for	O	O
1	O	O
-	O	O
3	O	O
weeks	O	O
,	O	O
and	O	O
five	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
treated	O	O
by	O	O
hemodialysis	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
patients	O	O
died	O	O
due	O	O
to	O	O
unrelated	O	O
causes	O	O
during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
.	O	O

The	O	O
four	O	O
patients	O	O
re	O	O
-	O	O
examined	O	O
were	O	O
clinically	O	O
cured	O	O
.	O	O

Pathologic	O	O
findings	O	O
by	O	O
light	O	O
microscopy	O	O
and	O	O
immunofluorescence	O	O
at	O	O
biopsy	O	O
were	O	O
scarce	O	O
.	O	O

Nothing	O	O
abnormal	O	O
was	O	O
seen	O	O
by	O	O
electron	O	O
microscopy	O	O
in	O	O
two	O	O
of	O	O
the	O	O
cases	O	O
studied	O	O
.	O	O

Renal	O	O
function	O	O
was	O	O
normal	O	O
.	O	O

In	O	O
three	O	O
cases	O	O
the	O	O
excretion	O	O
at	O	O
131I	O	O
-	O	O
hippuran	O	O
renography	O	O
was	O	O
slightly	O	O
slowed	O	O
.	O	O

Although	O	O
in	O	O
the	O	O
acute	O	O
stage	O	O
the	O	O
renal	B-Disease	D007674
lesions	I-Disease	D007674
histologically	O	O
appeared	O	O
toxic	O	O
,	O	O
evidence	O	O
suggestive	O	O
of	O	O
an	O	O
immunological	O	O
mechanism	O	O
cannot	O	O
be	O	O
excluded	O	O
.	O	O

Type	B-Disease	D006509
B	I-Disease	D006509
hepatitis	I-Disease	D006509
after	O	O
needle	O	O
-	O	O
stick	O	O
exposure	O	O
:	O	O
prevention	O	O
with	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
.	O	O

Final	O	O
report	O	O
of	O	O
the	O	O
Veterans	O	O
Administration	O	O
Cooperative	O	O
Study	O	O
.	O	O

Hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
(	O	O
HBIG	O	O
)	O	O
and	O	O
immune	O	O
serum	O	O
globulin	O	O
(	O	O
ISG	O	O
)	O	O
were	O	O
examined	O	O
in	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
to	O	O
assess	O	O
their	O	O
relative	O	O
efficacies	O	O
in	O	O
preventing	O	O
type	B-Disease	D006509
B	I-Disease	D006509
hepatitis	I-Disease	D006509
after	O	O
needle	O	O
-	O	O
stick	O	O
exposure	O	O
to	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
(	O	O
HBsAG	B-Chemical	D006514
)	O	O
-	O	O
positive	O	O
donors	O	O
.	O	O

Clinical	O	O
hepatitis	B-Disease	D056486
developed	O	O
in	O	O
1	O	O
.	O	O

4%	O	O
of	O	O
HBIG	O	O
and	O	O
in	O	O
5	O	O
.	O	O

9%	O	O
of	O	O
ISG	O	O
recipients	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

016	O	O
)	O	O
,	O	O
and	O	O
seroconversion	O	O
(	O	O
anti	O	O
-	O	O
HBs	O	O
)	O	O
occurred	O	O
in	O	O
5	O	O
.	O	O

6%	O	O
and	O	O
20	O	O
.	O	O

7%	O	O
of	O	O
them	O	O
respectively	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Mild	O	O
and	O	O
transient	O	O
side	O	O
-	O	O
effects	O	O
were	O	O
noted	O	O
in	O	O
3	O	O
.	O	O

0%	O	O
of	O	O
ISG	O	O
and	O	O
in	O	O
3	O	O
.	O	O

2%	O	O
of	O	O
HBIG	O	O
recipients	O	O
.	O	O

Available	O	O
donor	O	O
sera	O	O
were	O	O
examined	O	O
for	O	O
DNA	O	O
polymerase	O	O
(	O	O
DNAP	O	O
)	O	O
and	O	O
e	O	O
antigen	O	O
and	O	O
antibody	O	O
(	O	O
HBeAg	B-Chemical	D006513
;	O	O
anti	O	O
-	O	O
HBE	O	O
)	O	O
.	O	O

Both	O	O
DNAP	O	O
and	O	O
HBeAg	B-Chemical	D006513
showed	O	O
a	O	O
highly	O	O
statistically	O	O
significant	O	O
correlation	O	O
with	O	O
the	O	O
infectivity	O	O
of	O	O
HBsAg	B-Chemical	D006514
-	O	O
positive	O	O
donors	O	O
.	O	O

Hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
remained	O	O
significantly	O	O
superior	O	O
to	O	O
ISG	O	O
in	O	O
preventing	O	O
type	B-Disease	D006509
B	I-Disease	D006509
hepatitis	I-Disease	D006509
even	O	O
when	O	O
the	O	O
analysis	O	O
was	O	O
confined	O	O
to	O	O
these	O	O
two	O	O
high	O	O
-	O	O
risk	O	O
subgroups	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
ISG	O	O
in	O	O
preventing	O	O
type	B-Disease	D006509
B	I-Disease	D006509
hepatitis	I-Disease	D006509
cannot	O	O
be	O	O
ascertained	O	O
because	O	O
a	O	O
true	O	O
placebo	O	O
group	O	O
was	O	O
not	O	O
included	O	O
.	O	O

Serotonin	B-Disease	D020230
syndrome	I-Disease	D020230
from	O	O
venlafaxine	B-Chemical	C047426
-	O	O
tranylcypromine	B-Chemical	D014191
interaction	O	O
.	O	O

Excessive	O	O
stimulation	O	O
of	O	O
serotonin	B-Chemical	D012701
5HT1A	O	O
receptors	O	O
causes	O	O
a	O	O
syndrome	O	O
of	O	O
serotonin	B-Chemical	D012701
excess	O	O
that	O	O
consists	O	O
of	O	O
shivering	O	O
,	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
,	O	O
salivation	B-Disease	D012798
,	O	O
confusion	B-Disease	D003221
,	O	O
agitation	B-Disease	D011595
and	O	O
hyperthermia	B-Disease	D005334
.	O	O

The	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
this	O	O
syndrome	O	O
is	O	O
an	O	O
interaction	O	O
between	O	O
a	O	O
monoamine	O	O
oxidase	O	O
inhibitor	O	O
(	O	O
MAOI	O	O
)	O	O
and	O	O
a	O	O
specific	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
.	O	O

Venlafaxine	B-Chemical	C047426
is	O	O
a	O	O
new	O	O
antidepressant	O	O
agent	O	O
that	O	O
inhibits	O	O
the	O	O
reuptake	O	O
of	O	O
serotonin	B-Chemical	D012701
and	O	O
norepinephrine	B-Chemical	D009638
.	O	O

We	O	O
report	O	O
a	O	O
venlafaxine	B-Chemical	C047426
-	O	O
MAOI	O	O
interaction	O	O
that	O	O
resulted	O	O
in	O	O
the	O	O
serotonin	B-Chemical	D012701
syndrome	O	O
in	O	O
a	O	O
23	O	O
-	O	O
y	O	O
-	O	O
old	O	O
male	O	O
who	O	O
was	O	O
taking	O	O
tranylcypromine	B-Chemical	D014191
for	O	O
depression	B-Disease	D003866
.	O	O

He	O	O
had	O	O
been	O	O
well	O	O
until	O	O
the	O	O
morning	O	O
of	O	O
presentation	O	O
when	O	O
he	O	O
took	O	O
1	O	O
/	O	O
2	O	O
tab	O	O
of	O	O
venlafaxine	B-Chemical	C047426
.	O	O

Within	O	O
2	O	O
h	O	O
he	O	O
became	O	O
confused	O	O
with	O	O
jerking	O	O
movements	O	O
of	O	O
his	O	O
extremities	O	O
,	O	O
tremors	B-Disease	D014202
and	O	O
rigidity	B-Disease	D009127
.	O	O

He	O	O
was	O	O
brought	O	O
directly	O	O
to	O	O
a	O	O
hospital	O	O
where	O	O
he	O	O
was	O	O
found	O	O
to	O	O
be	O	O
agitated	O	O
and	O	O
confused	O	O
with	O	O
shivering	O	O
,	O	O
myoclonic	B-Disease	D009207
jerks	I-Disease	D009207
,	O	O
rigidity	B-Disease	D009127
,	O	O
salivation	B-Disease	D012798
and	O	O
diaphoresis	O	O
.	O	O

His	O	O
pupils	O	O
were	O	O
7	O	O
mm	O	O
and	O	O
sluggishly	O	O
reactive	O	O
to	O	O
light	O	O
.	O	O

Vital	O	O
signs	O	O
were	O	O
:	O	O
blood	O	O
pressure	O	O
120	O	O
/	O	O
67	O	O
mm	O	O
Hg	O	O
,	O	O
heart	O	O
rate	O	O
127	O	O
/	O	O
min	O	O
,	O	O
respiratory	O	O
rate	O	O
28	O	O
/	O	O
min	O	O
,	O	O
and	O	O
temperature	O	O
97	O	O
F	O	O
.	O	O

After	O	O
180	O	O
mg	O	O
of	O	O
diazepam	B-Chemical	D003975
i	O	O
.	O	O

v	O	O
.	O	O

he	O	O
remained	O	O
tremulous	O	O
with	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
and	O	O
clenched	O	O
jaws	O	O
.	O	O

He	O	O
was	O	O
intubated	O	O
for	O	O
airway	O	O
protection	O	O
and	O	O
because	O	O
of	O	O
hypoventilation	B-Disease	D007040
,	O	O
and	O	O
was	O	O
paralyzed	B-Disease	D010243
to	O	O
control	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
.	O	O

His	O	O
subsequent	O	O
course	O	O
was	O	O
remarkable	O	O
for	O	O
non	O	O
-	O	O
immune	O	O
thrombocytopenia	B-Disease	D013921
which	O	O
resolved	O	O
.	O	O

The	O	O
patient's	O	O
maximal	O	O
temperature	O	O
was	O	O
101	O	O
.	O	O

2	O	O
F	O	O
and	O	O
his	O	O
CPK	O	O
remained	O	O
<	O	O
500	O	O
units	O	O
/	O	O
L	O	O
with	O	O
no	O	O
other	O	O
evidence	O	O
of	O	O
rhabdomyolysis	B-Disease	D012206
.	O	O

His	O	O
mental	O	O
status	O	O
normalized	O	O
and	O	O
he	O	O
was	O	O
transferred	O	O
to	O	O
a	O	O
psychiatry	O	O
ward	O	O
.	O	O

This	O	O
patient	O	O
survived	O	O
without	O	O
sequelae	O	O
due	O	O
to	O	O
the	O	O
aggressive	O	O
sedation	O	O
and	O	O
neuromuscular	O	O
paralysis	B-Disease	D010243
.	O	O

Effect	O	O
of	O	O
nondopaminergic	O	O
drugs	O	O
on	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
in	O	O
MPTP	B-Chemical	D015632
-	O	O
treated	O	O
monkeys	O	O
.	O	O

A	O	O
group	O	O
of	O	O
four	O	O
monkeys	O	O
was	O	O
rendered	O	O
parkinsonian	B-Disease	D020734
with	O	O
the	O	O
toxin	O	O
MPTP	B-Chemical	D015632
.	O	O

They	O	O
were	O	O
then	O	O
treated	O	O
chronically	O	O
with	O	O
L	B-Chemical	C005177
-	I-Chemical	C005177
DOPA	I-Chemical	C005177
/	I-Chemical	C005177
benserazide	I-Chemical	C005177
50	O	O
/	O	O
12	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
given	O	O
orally	O	O
daily	O	O
for	O	O
2	O	O
months	O	O
.	O	O

This	O	O
dose	O	O
produced	O	O
a	O	O
striking	O	O
antiparkinsonian	O	O
effect	O	O
,	O	O
but	O	O
all	O	O
animals	O	O
manifested	O	O
dyskinesia	B-Disease	D004409
.	O	O

A	O	O
series	O	O
of	O	O
agents	O	O
acting	O	O
primarily	O	O
on	O	O
neurotransmitters	O	O
other	O	O
than	O	O
dopamine	B-Chemical	D004298
were	O	O
then	O	O
tested	O	O
in	O	O
combination	O	O
with	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
to	O	O
see	O	O
if	O	O
the	O	O
dyskinetic	B-Disease	D004409
movements	O	O
would	O	O
be	O	O
modified	O	O
.	O	O

Several	O	O
drugs	O	O
,	O	O
including	O	O
clonidine	B-Chemical	D003000
,	O	O
physostigmine	B-Chemical	D010830
,	O	O
methysergide	B-Chemical	D008784
,	O	O
5	B-Chemical	-1
-	I-Chemical	-1
MDOT	I-Chemical	-1
,	O	O
propranolol	B-Chemical	D011433
,	O	O
and	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
,	O	O
markedly	O	O
reduced	O	O
the	O	O
dyskinetic	B-Disease	D004409
movements	O	O
but	O	O
at	O	O
the	O	O
cost	O	O
of	O	O
a	O	O
return	O	O
of	O	O
parkinsonian	B-Disease	D020734
symptomatology	O	O
.	O	O

However	O	O
,	O	O
yohimbine	B-Chemical	D015016
and	O	O
meperidine	B-Chemical	D008614
reduced	O	O
predominantly	O	O
the	O	O
dyskinetic	B-Disease	D004409
movements	O	O
.	O	O

Baclofen	B-Chemical	D001418
was	O	O
also	O	O
useful	O	O
in	O	O
one	O	O
monkey	O	O
against	O	O
a	O	O
more	O	O
dystonic	B-Disease	D020821
form	O	O
of	O	O
dyskinesia	B-Disease	D004409
.	O	O

Atropine	B-Chemical	D001285
converted	O	O
the	O	O
dystonic	B-Disease	D020821
movements	O	O
into	O	O
chorea	B-Disease	D002819
.	O	O

CCNU	B-Chemical	D008130
(	O	O
lomustine	B-Chemical	D008130
)	O	O
toxicity	B-Disease	D064420
in	O	O
dogs	O	O
:	O	O
a	O	O
retrospective	O	O
study	O	O
(	O	O
2002	O	O
-	O	O
07	O	O
)	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
the	O	O
incidence	O	O
of	O	O
haematological	O	O
,	O	O
renal	O	O
,	O	O
hepatic	O	O
and	O	O
gastrointestinal	O	O
toxicities	O	O
in	O	O
tumour	O	O
-	O	O
bearing	O	O
dogs	O	O
receiving	O	O
1	B-Chemical	D008130
-	I-Chemical	D008130
(	I-Chemical	D008130
2	I-Chemical	D008130
-	I-Chemical	D008130
chloroethyl	I-Chemical	D008130
)	I-Chemical	D008130
-	I-Chemical	D008130
3	I-Chemical	D008130
-	I-Chemical	D008130
cyclohexyl	I-Chemical	D008130
-	I-Chemical	D008130
1	I-Chemical	D008130
-	I-Chemical	D008130
nitrosourea	I-Chemical	D008130
(	O	O
CCNU	B-Chemical	D008130
)	O	O
.	O	O

DESIGN	O	O
:	O	O
The	O	O
medical	O	O
records	O	O
of	O	O
206	O	O
dogs	O	O
that	O	O
were	O	O
treated	O	O
with	O	O
CCNU	B-Chemical	D008130
at	O	O
the	O	O
Melbourne	O	O
Veterinary	O	O
Specialist	O	O
Centre	O	O
between	O	O
February	O	O
2002	O	O
and	O	O
December	O	O
2007	O	O
were	O	O
retrospectively	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
206	O	O
dogs	O	O
treated	O	O
with	O	O
CCNU	B-Chemical	D008130
,	O	O
185	O	O
met	O	O
the	O	O
inclusion	O	O
criteria	O	O
for	O	O
at	O	O
least	O	O
one	O	O
class	O	O
of	O	O
toxicity	B-Disease	D064420
.	O	O

CCNU	B-Chemical	D008130
was	O	O
used	O	O
most	O	O
commonly	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
lymphoma	B-Disease	D008223
,	O	O
mast	B-Disease	D034801
cell	I-Disease	D034801
tumour	I-Disease	D034801
,	O	O
brain	B-Disease	D001932
tumour	I-Disease	D001932
,	O	O
histiocytic	B-Disease	D015620
tumours	I-Disease	D015620
and	O	O
epitheliotropic	B-Disease	D008223
lymphoma	I-Disease	D008223
.	O	O

Throughout	O	O
treatment	O	O
,	O	O
56	O	O
.	O	O

9%	O	O
of	O	O
dogs	O	O
experienced	O	O
neutropenia	B-Disease	D009503
,	O	O
34	O	O
.	O	O

2%	O	O
experienced	O	O
anaemia	B-Disease	D000740
and	O	O
14	O	O
.	O	O

2%	O	O
experienced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

Gastrointestinal	B-Disease	D005767
toxicosis	I-Disease	D005767
was	O	O
detected	O	O
in	O	O
37	O	O
.	O	O

8%	O	O
of	O	O
dogs	O	O
,	O	O
the	O	O
most	O	O
common	O	O
sign	O	O
of	O	O
which	O	O
was	O	O
vomiting	B-Disease	D014839
(	O	O
24	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

Potential	O	O
renal	O	O
toxicity	B-Disease	D064420
and	O	O
elevated	O	O
alanine	B-Chemical	D000409
transaminase	O	O
(	O	O
ALT	O	O
)	O	O
concentration	O	O
were	O	O
reported	O	O
in	O	O
12	O	O
.	O	O

2%	O	O
and	O	O
48	O	O
.	O	O

8%	O	O
of	O	O
dogs	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
hepatic	B-Disease	D017093
failure	I-Disease	D017093
was	O	O
1	O	O
.	O	O

2%	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
CCNU	B-Chemical	D008130
-	O	O
associated	O	O
toxicity	B-Disease	D064420
in	O	O
dogs	O	O
is	O	O
common	O	O
,	O	O
but	O	O
is	O	O
usually	O	O
not	O	O
life	O	O
threatening	O	O
.	O	O

Neuroactive	O	O
steroids	B-Chemical	D013256
protect	O	O
against	O	O
pilocarpine	B-Chemical	D010862
-	O	O
and	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
-	O	O
induced	O	O
limbic	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
mice	O	O
.	O	O

Several	O	O
structurally	O	O
related	O	O
metabolites	O	O
of	O	O
progesterone	B-Chemical	D011374
(	O	O
3	B-Chemical	D011374
alpha	I-Chemical	D011374
-	I-Chemical	D011374
hydroxy	I-Chemical	D011374
pregnane	I-Chemical	D011374
-	I-Chemical	D011374
20	I-Chemical	D011374
-	I-Chemical	D011374
ones	I-Chemical	D011374
)	O	O
and	O	O
deoxycorticosterone	B-Chemical	D003900
(	O	O
3	B-Chemical	D003900
alpha	I-Chemical	D003900
-	I-Chemical	D003900
hydroxy	I-Chemical	D003900
pregnane	I-Chemical	D003900
-	I-Chemical	D003900
21	I-Chemical	D003900
-	I-Chemical	D003900
diol	I-Chemical	D003900
-	I-Chemical	D003900
20	I-Chemical	D003900
-	I-Chemical	D003900
ones	I-Chemical	D003900
)	O	O
and	O	O
their	O	O
3	O	O
beta	O	O
-	O	O
epimers	O	O
were	O	O
evaluated	O	O
for	O	O
protective	O	O
activity	O	O
against	O	O
pilocarpine	B-Chemical	D010862
-	O	O
,	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
-	O	O
and	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
mice	O	O
.	O	O

Steroids	B-Chemical	D013256
with	O	O
the	O	O
3	O	O
-	O	O
hydroxy	O	O
group	O	O
in	O	O
the	O	O
alpha	O	O
-	O	O
position	O	O
and	O	O
5	O	O
-	O	O
H	O	O
in	O	O
the	O	O
alpha	O	O
-	O	O
or	O	O
beta	O	O
-	O	O
configurations	O	O
were	O	O
highly	O	O
effective	O	O
in	O	O
protecting	O	O
against	O	O
pilocarpine	B-Chemical	D010862
(	O	O
416	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
-	O	O
induced	O	O
limbic	O	O
motor	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
ED50	O	O
values	O	O
,	O	O
7	O	O
.	O	O

0	O	O
-	O	O
18	O	O
.	O	O

7	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

The	O	O
corresponding	O	O
epimers	O	O
with	O	O
the	O	O
3	O	O
-	O	O
hydroxy	O	O
group	O	O
in	O	O
the	O	O
beta	O	O
-	O	O
position	O	O
were	O	O
also	O	O
effective	O	O
but	O	O
less	O	O
potent	O	O
(	O	O
ED50	O	O
values	O	O
,	O	O
33	O	O
.	O	O

8	O	O
-	O	O
63	O	O
.	O	O

5	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

Although	O	O
the	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
were	O	O
considerably	O	O
less	O	O
potent	O	O
than	O	O
the	O	O
benzodiazepine	B-Chemical	D001569
clonazepam	B-Chemical	D002998
in	O	O
protecting	O	O
against	O	O
pilocarpine	B-Chemical	D010862
seizures	B-Disease	D012640
,	O	O
steroids	B-Chemical	D013256
with	O	O
the	O	O
5	O	O
alpha	O	O
,	O	O
3	O	O
alpha	O	O
-	O	O
configuration	O	O
had	O	O
comparable	O	O
or	O	O
higher	O	O
protective	O	O
index	O	O
values	O	O
(	O	O
TD50	O	O
for	O	O
motor	O	O
impairment	O	O
divided	O	O
by	O	O
ED50	O	O
for	O	O
seizure	B-Disease	D012640
protection	O	O
)	O	O
than	O	O
clonazepam	B-Chemical	D002998
,	O	O
indicating	O	O
that	O	O
some	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
may	O	O
have	O	O
lower	O	O
relative	O	O
toxicity	B-Disease	D064420
.	O	O

Steroids	B-Chemical	D013256
with	O	O
the	O	O
5	O	O
alpha	O	O
,	O	O
3	O	O
alpha	O	O
-	O	O
or	O	O
5	O	O
beta	O	O
,	O	O
3	O	O
alpha	O	O
-	O	O
configurations	O	O
also	O	O
produced	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
delay	O	O
in	O	O
the	O	O
onset	O	O
of	O	O
limbic	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
(	O	O
32	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
,	O	O
but	O	O
did	O	O
not	O	O
completely	O	O
protect	O	O
against	O	O
the	O	O
seizures	B-Disease	D012640
.	O	O

However	O	O
,	O	O
when	O	O
a	O	O
second	O	O
dose	O	O
of	O	O
the	O	O
steroid	B-Chemical	D013256
was	O	O
administered	O	O
1	O	O
hr	O	O
after	O	O
the	O	O
first	O	O
dose	O	O
,	O	O
complete	O	O
protection	O	O
from	O	O
the	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
-	O	O
induced	O	O
limbic	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
was	O	O
obtained	O	O
.	O	O

The	O	O
steroids	B-Chemical	D013256
also	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
delay	O	O
in	O	O
NMDA	B-Chemical	D016202
(	O	O
257	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
-	O	O
induced	O	O
lethality	O	O
,	O	O
but	O	O
did	O	O
not	O	O
completely	O	O
protect	O	O
against	O	O
NMDA	B-Chemical	D016202
seizures	B-Disease	D012640
or	O	O
lethality	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
are	O	O
highly	O	O
effective	O	O
in	O	O
protecting	O	O
against	O	O
pilocarpine	B-Chemical	D010862
-	O	O
and	O	O
kainic	B-Chemical	D007608
acid	I-Chemical	D007608
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
mice	O	O
,	O	O
and	O	O
may	O	O
be	O	O
of	O	O
utility	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
some	O	O
forms	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
humans	O	O
.	O	O

The	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
combination	O	O
N	B-Chemical	C059896
-	I-Chemical	C059896
butyl	I-Chemical	C059896
-	I-Chemical	C059896
deoxynojirimycin	I-Chemical	C059896
(	O	O
SC	B-Chemical	C059896
-	I-Chemical	C059896
48334	I-Chemical	C059896
)	O	O
and	O	O
zidovudine	B-Chemical	D015215
in	O	O
patients	O	O
with	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
1	I-Disease	D015658
infection	I-Disease	D015658
and	O	O
200	O	O
-	O	O
500	O	O
CD4	O	O
cells	O	O
/	O	O
mm3	O	O
.	O	O

We	O	O
conducted	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
phase	O	O
II	O	O
study	O	O
to	O	O
evaluate	O	O
the	O	O
safety	O	O
and	O	O
activity	O	O
of	O	O
combination	O	O
therapy	O	O
with	O	O
N	B-Chemical	C059896
-	I-Chemical	C059896
butyl	I-Chemical	C059896
-	I-Chemical	C059896
deoxynojirimycin	I-Chemical	C059896
(	O	O
SC	B-Chemical	C059896
-	I-Chemical	C059896
48334	I-Chemical	C059896
)	O	O
(	O	O
an	O	O
alpha	O	O
-	O	O
glucosidase	O	O
I	O	O
inhibitor	O	O
)	O	O
and	O	O
zidovudine	B-Chemical	D015215
versus	O	O
zidovudine	B-Chemical	D015215
alone	O	O
.	O	O

Patients	O	O
with	O	O
200	O	O
to	O	O
500	O	O
CD4	O	O
cells	O	O
/	O	O
mm3	O	O
who	O	O
tolerated	O	O
<	O	O
or	O	O
=	O	O
12	O	O
weeks	O	O
of	O	O
prior	O	O
zidovudine	B-Chemical	D015215
therapy	O	O
received	O	O
SC	B-Chemical	C059896
-	I-Chemical	C059896
48334	I-Chemical	C059896
(	O	O
1000	O	O
mg	O	O
every	O	O
8	O	O
h	O	O
)	O	O
and	O	O
zidovudine	B-Chemical	D015215
(	O	O
100	O	O
mg	O	O
every	O	O
8	O	O
h	O	O
)	O	O
or	O	O
zidovudine	B-Chemical	D015215
and	O	O
placebo	O	O
.	O	O

Sixty	O	O
patients	O	O
received	O	O
combination	O	O
therapy	O	O
and	O	O
58	O	O
,	O	O
zidovudine	B-Chemical	D015215
and	O	O
placebo	O	O
.	O	O

Twenty	O	O
-	O	O
three	O	O
patients	O	O
(	O	O
38%	O	O
)	O	O
and	O	O
15	O	O
(	O	O
26%	O	O
)	O	O
,	O	O
in	O	O
the	O	O
combination	O	O
and	O	O
zidovudine	B-Chemical	D015215
groups	O	O
,	O	O
respectively	O	O
,	O	O
discontinued	O	O
therapy	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

15	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
SC	B-Chemical	C059896
-	I-Chemical	C059896
48334	I-Chemical	C059896
steady	O	O
-	O	O
state	O	O
trough	O	O
level	O	O
(	O	O
4	O	O
.	O	O

04	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

99	O	O
micrograms	O	O
/	O	O
ml	O	O
)	O	O
was	O	O
below	O	O
the	O	O
in	O	O
vitro	O	O
inhibitory	O	O
concentration	O	O
for	O	O
human	O	O
immunodeficiency	B-Disease	D007153
virus	O	O
(	O	O
HIV	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
increase	O	O
in	O	O
CD4	O	O
cells	O	O
at	O	O
week	O	O
4	O	O
was	O	O
73	O	O
.	O	O

8	O	O
cells	O	O
/	O	O
mm3	O	O
and	O	O
52	O	O
.	O	O

4	O	O
cells	O	O
/	O	O
mm3	O	O
for	O	O
the	O	O
combination	O	O
and	O	O
zidovudine	B-Chemical	D015215
groups	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O

36	O	O
)	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
prior	O	O
zidovudine	B-Chemical	D015215
therapy	O	O
,	O	O
the	O	O
mean	O	O
change	O	O
in	O	O
CD4	O	O
cells	O	O
in	O	O
the	O	O
combination	O	O
and	O	O
zidovudine	B-Chemical	D015215
groups	O	O
was	O	O
63	O	O
.	O	O

7	O	O
cells	O	O
/	O	O
mm3	O	O
and	O	O
4	O	O
.	O	O

9	O	O
cells	O	O
/	O	O
mm3	O	O
at	O	O
week	O	O
8	O	O
and	O	O
6	O	O
.	O	O

8	O	O
cells	O	O
/	O	O
mm3	O	O
and	O	O
-	O	O
45	O	O
.	O	O

1	O	O
cells	O	O
/	O	O
mm3	O	O
at	O	O
week	O	O
16	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
suppression	O	O
of	O	O
HIV	O	O
p24	O	O
antigenemia	O	O
in	O	O
the	O	O
combination	O	O
and	O	O
zidovudine	B-Chemical	D015215
groups	O	O
was	O	O
six	O	O
(	O	O
40%	O	O
)	O	O
and	O	O
two	O	O
(	O	O
11%	O	O
)	O	O
at	O	O
week	O	O
4	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

10	O	O
)	O	O
and	O	O
five	O	O
(	O	O
45%	O	O
)	O	O
and	O	O
two	O	O
(	O	O
14%	O	O
)	O	O
at	O	O
week	O	O
24	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

08	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Diarrhea	B-Disease	D003967
,	O	O
flatulence	B-Disease	D005414
,	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
,	O	O
and	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
were	O	O
common	O	O
for	O	O
combination	O	O
recipients	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Recent	O	O
preclinical	O	O
and	O	O
clinical	O	O
studies	O	O
with	O	O
the	O	O
thymidylate	O	O
synthase	O	O
inhibitor	O	O
N10	B-Chemical	C031662
-	I-Chemical	C031662
propargyl	I-Chemical	C031662
-	I-Chemical	C031662
5	I-Chemical	C031662
,	I-Chemical	C031662
8	I-Chemical	C031662
-	I-Chemical	C031662
dideazafolic	I-Chemical	C031662
acid	I-Chemical	C031662
(	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
)	O	O
.	O	O

CB	B-Chemical	C031662
3717	I-Chemical	C031662
,	O	O
N10	B-Chemical	C031662
-	I-Chemical	C031662
propargyl	I-Chemical	C031662
-	I-Chemical	C031662
5	I-Chemical	C031662
,	I-Chemical	C031662
8	I-Chemical	C031662
-	I-Chemical	C031662
dideazafolic	I-Chemical	C031662
acid	I-Chemical	C031662
,	O	O
is	O	O
a	O	O
tight	O	O
-	O	O
binding	O	O
inhibitor	O	O
of	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
whose	O	O
cytotoxicity	B-Disease	D064420
is	O	O
mediated	O	O
solely	O	O
through	O	O
the	O	O
inhibition	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O

Recent	O	O
preclinical	O	O
studies	O	O
have	O	O
focused	O	O
on	O	O
the	O	O
intracellular	O	O
formation	O	O
of	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
polyglutamates	O	O
.	O	O

Following	O	O
a	O	O
12	O	O
-	O	O
hour	O	O
exposure	O	O
of	O	O
L1210	O	O
cells	O	O
to	O	O
50	O	O
microM	O	O
[	O	O
3H	O	O
]	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
,	O	O
30%	O	O
of	O	O
the	O	O
extractable	O	O
radioactivity	O	O
could	O	O
be	O	O
accounted	O	O
for	O	O
as	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
tetra	O	O
-	O	O
and	O	O
pentaglutamate	O	O
,	O	O
as	O	O
determined	O	O
by	O	O
high	O	O
-	O	O
pressure	O	O
liquid	O	O
chromatography	O	O
(	O	O
HPLC	O	O
)	O	O
analyses	O	O
.	O	O

As	O	O
inhibitors	O	O
of	O	O
isolated	O	O
L1210	O	O
TS	O	O
,	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
di	O	O
-	O	O
,	O	O
tri	O	O
-	O	O
,	O	O
tetra	O	O
-	O	O
and	O	O
pentaglutamate	O	O
are	O	O
26	O	O
-	O	O
,	O	O
87	O	O
-	O	O
,	O	O
119	O	O
-	O	O
and	O	O
114	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
,	O	O
respectively	O	O
,	O	O
and	O	O
their	O	O
formation	O	O
may	O	O
,	O	O
therefore	O	O
,	O	O
be	O	O
an	O	O
important	O	O
determinant	O	O
of	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
cytotoxicity	B-Disease	D064420
.	O	O

In	O	O
early	O	O
clinical	O	O
studies	O	O
with	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
,	O	O
activity	O	O
has	O	O
been	O	O
seen	O	O
in	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
hepatoma	B-Disease	D006528
,	O	O
and	O	O
mesothelioma	B-Disease	D008654
.	O	O

Toxicities	B-Disease	D064420
included	O	O
hepatotoxicity	B-Disease	D056486
,	O	O
malaise	B-Disease	D005221
,	O	O
and	O	O
dose	O	O
-	O	O
limiting	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

This	O	O
latter	O	O
effect	O	O
is	O	O
thought	O	O
to	O	O
be	O	O
due	O	O
to	O	O
drug	O	O
precipitation	O	O
within	O	O
the	O	O
renal	O	O
tubule	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
poor	O	O
solubility	O	O
of	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
under	O	O
acidic	O	O
conditions	O	O
.	O	O

In	O	O
an	O	O
attempt	O	O
to	O	O
overcome	O	O
this	O	O
problem	O	O
,	O	O
a	O	O
clinical	O	O
trial	O	O
of	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
administered	O	O
with	O	O
alkaline	O	O
diuresis	O	O
is	O	O
under	O	O
way	O	O
.	O	O

Preliminary	O	O
results	O	O
at	O	O
400	O	O
and	O	O
500	O	O
mg	O	O
/	O	O
m2	O	O
suggest	O	O
that	O	O
a	O	O
reduction	O	O
in	O	O
nephrotoxicity	B-Disease	D007674
may	O	O
have	O	O
been	O	O
achieved	O	O
with	O	O
only	O	O
1	O	O
instance	O	O
of	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
in	O	O
10	O	O
patients	O	O
.	O	O

Hepatotoxicity	B-Disease	D056486
and	O	O
malaise	B-Disease	D005221
are	O	O
again	O	O
the	O	O
most	O	O
frequent	O	O
side	O	O
effects	O	O
.	O	O

Evidence	O	O
of	O	O
antitumor	O	O
activity	O	O
has	O	O
been	O	O
seen	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

Pharmacokinetic	O	O
investigations	O	O
have	O	O
shown	O	O
that	O	O
alkaline	O	O
diuresis	O	O
does	O	O
not	O	O
alter	O	O
CB	B-Chemical	C031662
3717	I-Chemical	C031662
plasma	O	O
levels	O	O
or	O	O
urinary	O	O
excretion	O	O
and	O	O
that	O	O
satisfactory	O	O
urinary	O	O
alkalinization	O	O
can	O	O
be	O	O
readily	O	O
achieved	O	O
.	O	O

Ethopropazine	B-Chemical	C084820
and	O	O
benztropine	B-Chemical	D001590
in	O	O
neuroleptic	O	O
-	O	O
induced	O	O
parkinsonism	B-Disease	D010302
.	O	O

In	O	O
a	O	O
12	O	O
-	O	O
week	O	O
controlled	O	O
study	O	O
ethopropazine	B-Chemical	C084820
was	O	O
compared	O	O
to	O	O
benztropine	B-Chemical	D001590
in	O	O
the	O	O
treatment	O	O
of	O	O
parkinsonism	B-Disease	D010302
induced	O	O
by	O	O
fluphenazine	B-Chemical	C017610
enanthate	I-Chemical	C017610
in	O	O
60	O	O
schizophrenic	B-Disease	D012559
outpatients	O	O
.	O	O

Ethopropazine	B-Chemical	C084820
and	O	O
benztropine	B-Chemical	D001590
were	O	O
found	O	O
to	O	O
be	O	O
equally	O	O
effective	O	O
in	O	O
controlling	O	O
parkinsonian	B-Disease	D010302
symptoms	I-Disease	D010302
and	O	O
were	O	O
as	O	O
efficacious	O	O
as	O	O
procyclidine	B-Chemical	D011352
,	O	O
their	O	O
previous	O	O
antiparkinsonian	O	O
drug	O	O
.	O	O

However	O	O
,	O	O
benztropine	B-Chemical	D001590
treated	O	O
patients	O	O
had	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
compared	O	O
to	O	O
their	O	O
condition	O	O
during	O	O
procyclindine	B-Chemical	D011352
treatment	O	O
,	O	O
and	O	O
significantly	O	O
more	O	O
anxiety	B-Disease	D001008
and	O	O
depression	B-Disease	D003866
than	O	O
ethopropazine	B-Chemical	C084820
treated	O	O
patients	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
benztropine	B-Chemical	D001590
is	O	O
not	O	O
the	O	O
anticholinergic	O	O
drug	O	O
of	O	O
choice	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
neuroleptic	O	O
-	O	O
induced	O	O
parkinsonian	B-Disease	D010302
symptoms	I-Disease	D010302
,	O	O
because	O	O
of	O	O
its	O	O
more	O	O
toxic	O	O
central	O	O
and	O	O
peripheral	O	O
atropinic	O	O
effect	O	O
.	O	O

Effect	O	O
of	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
tocopherol	I-Chemical	D024502
and	O	O
deferoxamine	B-Chemical	D003676
on	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Methamphetamine	B-Chemical	D008694
(	O	O
MA	B-Chemical	D008694
)	O	O
-	O	O
induced	O	O
dopaminergic	O	O
neurotoxicity	B-Disease	D020258
is	O	O
believed	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
increased	O	O
formation	O	O
of	O	O
free	O	O
radicals	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
tocopherol	I-Chemical	D024502
(	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
)	O	O
,	O	O
a	O	O
scavenger	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
,	O	O
and	O	O
deferoxamine	B-Chemical	D003676
(	O	O
DFO	B-Chemical	D003676
)	O	O
,	O	O
an	O	O
iron	B-Chemical	D007501
chelator	O	O
,	O	O
on	O	O
the	O	O
MA	B-Chemical	D008694
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Male	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
MA	B-Chemical	D008694
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
every	O	O
2	O	O
h	O	O
for	O	O
four	O	O
injections	O	O
)	O	O
.	O	O

The	O	O
rat	O	O
received	O	O
either	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
intraperitoneally	O	O
for	O	O
3	O	O
days	O	O
and	O	O
30	O	O
min	O	O
prior	O	O
to	O	O
MA	B-Chemical	D008694
administration	O	O
or	O	O
DFO	B-Chemical	D003676
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
subcutaneously	O	O
30	O	O
min	O	O
before	O	O
MA	B-Chemical	D008694
administration	O	O
.	O	O

The	O	O
concentrations	O	O
of	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
,	O	O
serotonin	B-Chemical	D012701
and	O	O
their	O	O
metabolites	O	O
decreased	O	O
significantly	O	O
after	O	O
MA	B-Chemical	D008694
administration	O	O
,	O	O
which	O	O
was	O	O
inhibited	O	O
by	O	O
the	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
and	O	O
DFO	B-Chemical	D003676
pretreatment	O	O
.	O	O

alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
and	O	O
DFO	B-Chemical	D003676
attenuated	O	O
the	O	O
MA	B-Chemical	D008694
-	O	O
induced	O	O
hyperthermia	B-Disease	D005334
as	O	O
well	O	O
as	O	O
the	O	O
alterations	O	O
in	O	O
the	O	O
locomotor	O	O
activity	O	O
.	O	O

The	O	O
level	O	O
of	O	O
lipid	O	O
peroxidation	O	O
was	O	O
higher	O	O
and	O	O
the	O	O
reduced	O	O
glutathione	B-Chemical	D005978
concentration	O	O
was	O	O
lower	O	O
in	O	O
the	O	O
MA	B-Chemical	D008694
-	O	O
treated	O	O
rats	O	O
.	O	O

These	O	O
changes	O	O
were	O	O
significantly	O	O
attenuated	O	O
by	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
and	O	O
DFO	B-Chemical	D003676
.	O	O

This	O	O
suggests	O	O
that	O	O
alpha	B-Chemical	D024502
-	I-Chemical	D024502
TC	I-Chemical	D024502
and	O	O
DFO	B-Chemical	D003676
ameliorate	O	O
the	O	O
MA	B-Chemical	D008694
-	O	O
induced	O	O
neuronal	B-Disease	D009422
damage	I-Disease	D009422
by	O	O
decreasing	O	O
the	O	O
level	O	O
of	O	O
oxidative	O	O
stress	O	O
.	O	O

Use	O	O
of	O	O
dexamethasone	B-Chemical	D003907
with	O	O
mesna	B-Chemical	D015080
for	O	O
the	O	O
prevention	O	O
of	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

AIM	O	O
:	O	O
Hemorrhagic	O	O
cystitis	O	O
(	O	O
HC	B-Disease	D006470
)	O	O
is	O	O
a	O	O
limiting	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
chemotherapy	O	O
with	O	O
ifosfamide	B-Chemical	D007069
(	O	O
IFS	B-Chemical	D007069
)	O	O
.	O	O

In	O	O
the	O	O
study	O	O
presented	O	O
here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
use	O	O
of	O	O
dexamethasone	B-Chemical	D003907
in	O	O
combination	O	O
with	O	O
mesna	B-Chemical	D015080
for	O	O
the	O	O
prevention	O	O
of	O	O
IFS	B-Chemical	D007069
-	O	O
induced	O	O
HC	B-Disease	D006470
.	O	O

METHODS	O	O
:	O	O
Male	O	O
Wistar	O	O
rats	O	O
(	O	O
150	O	O
-	O	O
200	O	O
g	O	O
;	O	O
6	O	O
rats	O	O
per	O	O
group	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
saline	O	O
or	O	O
mesna	B-Chemical	D015080
5	O	O
min	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
before	O	O
and	O	O
2	O	O
and	O	O
6	O	O
h	O	O
after	O	O
(	O	O
v	O	O
.	O	O

o	O	O
.	O	O

)	O	O
administration	O	O
of	O	O
IFS	B-Chemical	D007069
.	O	O

One	O	O
,	O	O
two	O	O
or	O	O
three	O	O
doses	O	O
of	O	O
mesna	B-Chemical	D015080
were	O	O
replaced	O	O
with	O	O
dexamethasone	B-Chemical	D003907
alone	O	O
or	O	O
with	O	O
dexamethasone	B-Chemical	D003907
plus	O	O
mesna	B-Chemical	D015080
.	O	O

Cystitis	B-Disease	D003556
was	O	O
evaluated	O	O
24	O	O
h	O	O
after	O	O
its	O	O
induction	O	O
by	O	O
the	O	O
changes	O	O
in	O	O
bladder	O	O
wet	O	O
weight	O	O
and	O	O
by	O	O
macroscopic	O	O
and	O	O
microscopic	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
replacement	O	O
of	O	O
the	O	O
last	O	O
dose	O	O
or	O	O
the	O	O
last	O	O
two	O	O
doses	O	O
of	O	O
mesna	B-Chemical	D015080
with	O	O
dexamethasone	B-Chemical	D003907
reduced	O	O
the	O	O
increase	O	O
in	O	O
bladder	O	O
wet	O	O
weight	O	O
induced	O	O
by	O	O
IFS	B-Chemical	D007069
by	O	O
84	O	O
.	O	O

79%	O	O
and	O	O
89	O	O
.	O	O

13%	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
it	O	O
almost	O	O
abolished	O	O
the	O	O
macroscopic	O	O
and	O	O
microscopic	O	O
alterations	O	O
induced	O	O
by	O	O
IFS	B-Chemical	D007069
.	O	O

Moreover	O	O
,	O	O
the	O	O
addition	O	O
of	O	O
dexamethasone	B-Chemical	D003907
to	O	O
the	O	O
last	O	O
two	O	O
doses	O	O
of	O	O
mesna	B-Chemical	D015080
was	O	O
more	O	O
efficient	O	O
than	O	O
three	O	O
doses	O	O
of	O	O
mesna	B-Chemical	D015080
alone	O	O
when	O	O
evaluated	O	O
microscopically	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Dexamethasone	B-Chemical	D003907
in	O	O
combination	O	O
with	O	O
mesna	B-Chemical	D015080
was	O	O
efficient	O	O
in	O	O
blocking	O	O
IFS	B-Chemical	D007069
-	O	O
induced	O	O
HC	B-Disease	D006470
.	O	O

However	O	O
,	O	O
the	O	O
replacement	O	O
of	O	O
last	O	O
two	O	O
doses	O	O
of	O	O
mesna	B-Chemical	D015080
with	O	O
saline	O	O
or	O	O
all	O	O
of	O	O
the	O	O
mesna	B-Chemical	D015080
doses	O	O
with	O	O
dexamethasone	B-Chemical	D003907
did	O	O
not	O	O
prevent	O	O
HC	B-Disease	D006470
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
on	O	O
reserpine	B-Chemical	D012110
-	O	O
treated	O	O
mice	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
dizocilpine	B-Chemical	D016291
(	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
)	O	O
,	O	O
a	O	O
noncompetitive	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
were	O	O
studied	O	O
on	O	O
dopamine	B-Chemical	D004298
-	O	O
related	O	O
behaviors	O	O
induced	O	O
by	O	O
reserpine	B-Chemical	D012110
treatments	O	O
.	O	O

This	O	O
study	O	O
focuses	O	O
on	O	O
behavioral	O	O
syndromes	O	O
that	O	O
may	O	O
used	O	O
as	O	O
models	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
or	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
,	O	O
and	O	O
its	O	O
response	O	O
after	O	O
glutamatergic	O	O
blockage	O	O
.	O	O

Reserpine	B-Chemical	D012110
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
administered	O	O
once	O	O
every	O	O
other	O	O
day	O	O
for	O	O
4	O	O
days	O	O
,	O	O
produced	O	O
increases	O	O
in	O	O
orofacial	B-Disease	D009069
dyskinesia	I-Disease	D009069
,	O	O
tongue	O	O
protrusion	O	O
and	O	O
vacuous	O	O
chewing	O	O
in	O	O
mice	O	O
,	O	O
which	O	O
are	O	O
signs	O	O
indicative	O	O
of	O	O
tardive	B-Disease	D004409
dyskinesia	I-Disease	D004409
.	O	O

Reserpine	B-Chemical	D012110
also	O	O
produced	O	O
tremor	B-Disease	D014202
and	O	O
catalepsy	B-Disease	D002375
,	O	O
which	O	O
are	O	O
signs	O	O
suggestive	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
administered	O	O
30	O	O
min	O	O
before	O	O
the	O	O
observation	O	O
test	O	O
,	O	O
prevented	O	O
the	O	O
vacuous	O	O
chewing	O	O
movements	O	O
,	O	O
tongue	O	O
protrusions	O	O
and	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
reserpine	B-Chemical	D012110
.	O	O

However	O	O
,	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
injection	O	O
produced	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
tremor	B-Disease	D014202
in	O	O
reserpine	B-Chemical	D012110
-	O	O
treated	O	O
mice	O	O
.	O	O

Reserpine	B-Chemical	D012110
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
administered	O	O
90	O	O
min	O	O
before	O	O
the	O	O
test	O	O
and	O	O
followed	O	O
by	O	O
apomophine	B-Chemical	D001058
injection	O	O
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
5	O	O
min	O	O
before	O	O
the	O	O
test	O	O
,	O	O
did	O	O
not	O	O
produce	O	O
oral	B-Disease	D009069
dyskinesia	I-Disease	D009069
in	O	O
mice	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
reserpine	B-Chemical	D012110
induced	O	O
increases	O	O
in	O	O
tremor	B-Disease	D014202
and	O	O
catalepsy	B-Disease	D002375
compared	O	O
to	O	O
control	O	O
mice	O	O
.	O	O

MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
administration	O	O
attenuated	O	O
the	O	O
catalepsy	B-Disease	D002375
and	O	O
tremor	B-Disease	D014202
induced	O	O
by	O	O
reserpine	B-Chemical	D012110
.	O	O

Pretreatment	O	O
with	O	O
reserpine	B-Chemical	D012110
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
24	O	O
h	O	O
before	O	O
the	O	O
observation	O	O
test	O	O
produced	O	O
increases	O	O
in	O	O
vacuous	O	O
chewing	O	O
movements	O	O
and	O	O
tongue	O	O
protrusion	O	O
,	O	O
as	O	O
well	O	O
as	O	O
increases	O	O
in	O	O
tremor	B-Disease	D014202
and	O	O
catalepsy	B-Disease	D002375
,	O	O
whereas	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
injection	O	O
90	O	O
min	O	O
before	O	O
the	O	O
test	O	O
reversed	O	O
the	O	O
effects	O	O
of	O	O
reserpine	B-Chemical	D012110
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
reserpine	B-Chemical	D012110
produces	O	O
different	O	O
and	O	O
abnormal	B-Disease	D004409
movements	I-Disease	D004409
,	O	O
which	O	O
are	O	O
related	O	O
to	O	O
dose	O	O
and	O	O
schedule	O	O
employed	O	O
and	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
parkinsonian	B-Disease	D010300
-	O	O
like	O	O
and	O	O
tardive	B-Disease	D004409
dsykinesia	I-Disease	D004409
signs	O	O
.	O	O

The	O	O
glutamatergic	O	O
blockage	O	O
produced	O	O
by	O	O
NMDA	B-Chemical	D016202
can	O	O
restore	O	O
these	O	O
signs	O	O
,	O	O
such	O	O
as	O	O
vacuous	O	O
chewing	O	O
movements	O	O
,	O	O
tongue	O	O
protrusions	O	O
,	O	O
catalepsy	B-Disease	D002375
and	O	O
tremor	B-Disease	D014202
according	O	O
to	O	O
the	O	O
employed	O	O
model	O	O
.	O	O

Effect	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
on	O	O
the	O	O
sphincter	O	O
of	O	O
Oddi	O	O
spasm	B-Disease	D013035
evoked	O	O
by	O	O
prostigmine	B-Chemical	D009388
-	O	O
morphine	B-Chemical	D009020
administration	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
In	O	O
this	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
on	O	O
the	O	O
prostigmine	B-Chemical	D009388
-	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
sphincter	O	O
of	O	O
Oddi	O	O
spasm	B-Disease	D013035
was	O	O
evaluated	O	O
in	O	O
nine	O	O
female	O	O
patients	O	O
with	O	O
sphincter	B-Disease	D046628
of	I-Disease	D046628
Oddi	I-Disease	D046628
dyskinesia	I-Disease	D046628
.	O	O

METHOD	O	O
:	O	O
Sphincter	O	O
of	O	O
Oddi	O	O
spasm	B-Disease	D013035
was	O	O
induced	O	O
by	O	O
prostigmine	B-Chemical	D009388
-	O	O
morphine	B-Chemical	D009020
administration	O	O
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
prostigmine	B-Chemical	D009388
intramuscularly	O	O
and	O	O
10	O	O
mg	O	O
morphine	B-Chemical	D009020
subcutaneously	O	O
)	O	O
and	O	O
visualized	O	O
by	O	O
quantitative	O	O
hepatobiliary	O	O
scintigraphy	O	O
.	O	O

The	O	O
entire	O	O
procedure	O	O
was	O	O
repeated	O	O
during	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
infusion	O	O
(	O	O
Nitrolingual	B-Chemical	D005996
1	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
for	O	O
120	O	O
min	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Prostigmine	B-Chemical	D009388
-	O	O
morphine	B-Chemical	D009020
provocation	O	O
caused	O	O
significant	O	O
increases	O	O
in	O	O
the	O	O
time	O	O
to	O	O
peak	O	O
activity	O	O
(	O	O
Tmax	O	O
)	O	O
over	O	O
the	O	O
hepatic	O	O
hilum	O	O
(	O	O
HH	O	O
:	O	O
34	O	O
.	O	O

33	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

05	O	O
vs	O	O
.	O	O

22	O	O
.	O	O

77	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

26	O	O
)	O	O
and	O	O
the	O	O
common	O	O
bile	O	O
duct	O	O
(	O	O
CBD	O	O
:	O	O
60	O	O
.	O	O

44	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

99	O	O
vs	O	O
.	O	O

40	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

88	O	O
)	O	O
and	O	O
in	O	O
the	O	O
half	O	O
-	O	O
time	O	O
of	O	O
excretion	O	O
(	O	O
T1	O	O
/	O	O
2	O	O
)	O	O
over	O	O
the	O	O
liver	O	O
parenchyma	O	O
(	O	O
LP	O	O
:	O	O
120	O	O
.	O	O

04	O	O
+	O	O
/	O	O
-	O	O
16	O	O
.	O	O

01	O	O
vs	O	O
.	O	O

27	O	O
.	O	O

37	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

19	O	O
)	O	O
,	O	O
HH	O	O
(	O	O
117	O	O
.	O	O

61	O	O
+	O	O
/	O	O
-	O	O
14	O	O
.	O	O

71	O	O
vs	O	O
.	O	O

31	O	O
.	O	O

85	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

99	O	O
)	O	O
and	O	O
CBD	O	O
(	O	O
158	O	O
.	O	O

11	O	O
+	O	O
/	O	O
-	O	O
9	O	O
.	O	O

18	O	O
vs	O	O
.	O	O

40	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

24	O	O
)	O	O
,	O	O
indicating	O	O
a	O	O
complete	O	O
spasm	B-Disease	D013035
at	O	O
the	O	O
level	O	O
of	O	O
the	O	O
sphincter	O	O
of	O	O
Oddi	O	O
.	O	O

Glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
infusion	O	O
completely	O	O
normalized	O	O
the	O	O
prostigmine	B-Chemical	D009388
-	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
alterations	O	O
in	O	O
these	O	O
quantitative	O	O
parameters	O	O
(	O	O
TmaX	O	O
over	O	O
the	O	O
LP	O	O
:	O	O
11	O	O
.	O	O

33	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

13	O	O
;	O	O
over	O	O
the	O	O
HH	O	O
:	O	O
18	O	O
.	O	O

88	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

48	O	O
;	O	O
and	O	O
over	O	O
the	O	O
CBD	O	O
:	O	O
36	O	O
.	O	O

22	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

92	O	O
;	O	O
and	O	O
T1	O	O
/	O	O
2	O	O
over	O	O
the	O	O
LP	O	O
:	O	O
28	O	O
.	O	O

21	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

83	O	O
;	O	O
over	O	O
the	O	O
HH	O	O
:	O	O
33	O	O
.	O	O

42	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

10	O	O
;	O	O
and	O	O
over	O	O
the	O	O
CBD	O	O
:	O	O
41	O	O
.	O	O

66	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

33	O	O
)	O	O
,	O	O
suggesting	O	O
an	O	O
effective	O	O
sphincter	O	O
-	O	O
relaxing	O	O
effect	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
results	O	O
provide	O	O
the	O	O
first	O	O
evidence	O	O
of	O	O
the	O	O
effectiveness	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
on	O	O
the	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
sphincter	O	O
of	O	O
Oddi	O	O
spasm	B-Disease	D013035
in	O	O
humans	O	O
.	O	O

Since	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
is	O	O
able	O	O
to	O	O
overcome	O	O
even	O	O
the	O	O
drastic	O	O
effect	O	O
of	O	O
morphine	B-Chemical	D009020
,	O	O
it	O	O
might	O	O
be	O	O
of	O	O
relevance	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
sphincter	B-Disease	D046628
of	I-Disease	D046628
Oddi	I-Disease	D046628
dyskinesia	I-Disease	D046628
.	O	O

Effects	O	O
of	O	O
acute	O	O
steroid	B-Chemical	D013256
administration	O	O
on	O	O
ventilatory	O	O
and	O	O
peripheral	O	O
muscles	O	O
in	O	O
rats	O	O
.	O	O

Occasional	O	O
case	O	O
reports	O	O
have	O	O
shown	O	O
that	O	O
acute	O	O
myopathy	B-Disease	D009135
may	O	O
occur	O	O
in	O	O
patients	O	O
treated	O	O
with	O	O
massive	O	O
doses	O	O
of	O	O
corticosteroids	B-Chemical	D000305
.	O	O

The	O	O
mechanism	O	O
of	O	O
this	O	O
myopathy	B-Disease	D009135
is	O	O
poorly	O	O
understood	O	O
.	O	O

Therefore	O	O
,	O	O
60	O	O
male	O	O
rats	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
daily	O	O
injection	O	O
of	O	O
saline	O	O
(	O	O
C	O	O
)	O	O
,	O	O
methylprednisolone	B-Chemical	D008775
(	O	O
M	B-Chemical	D008775
)	O	O
,	O	O
or	O	O
triamcinolone	B-Chemical	D014221
(	O	O
T	B-Chemical	D014221
)	O	O
80	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
d	O	O
for	O	O
5	O	O
d	O	O
.	O	O

Nutritional	O	O
intake	O	O
,	O	O
measured	O	O
daily	O	O
in	O	O
15	O	O
animals	O	O
,	O	O
showed	O	O
a	O	O
significant	O	O
reduction	B-Disease	D000855
of	I-Disease	D000855
food	I-Disease	D000855
intake	I-Disease	D000855
in	O	O
the	O	O
steroid	B-Chemical	D013256
-	O	O
treated	O	O
groups	O	O
(	O	O
-	O	O
50	O	O
and	O	O
-	O	O
79%	O	O
in	O	O
M	B-Chemical	D008775
and	O	O
T	B-Chemical	D014221
,	O	O
respectively	O	O
)	O	O
.	O	O

This	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
similar	O	O
loss	B-Disease	D015431
in	I-Disease	D015431
body	I-Disease	D015431
weight	I-Disease	D015431
.	O	O

In	O	O
the	O	O
45	O	O
remaining	O	O
animals	O	O
,	O	O
diaphragm	O	O
contractility	O	O
and	O	O
histopathologic	O	O
features	O	O
of	O	O
several	O	O
muscles	O	O
were	O	O
studied	O	O
.	O	O

Weights	O	O
of	O	O
respiratory	O	O
and	O	O
peripheral	O	O
muscles	O	O
were	O	O
similarly	O	O
decreased	O	O
after	O	O
steroid	B-Chemical	D013256
treatment	O	O
.	O	O

Maximal	O	O
twitches	O	O
of	O	O
the	O	O
diaphragm	O	O
were	O	O
lower	O	O
in	O	O
the	O	O
C	O	O
group	O	O
(	O	O
653	O	O
+	O	O
/	O	O
-	O	O
174	O	O
g	O	O
/	O	O
cm	O	O
(	O	O
2	O	O
)	O	O
)	O	O
than	O	O
in	O	O
the	O	O
M	B-Chemical	D008775
group	O	O
(	O	O
837	O	O
+	O	O
/	O	O
-	O	O
171	O	O
g	O	O
/	O	O
cm	O	O
(	O	O
2	O	O
)	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
the	O	O
T	B-Chemical	D014221
group	O	O
(	O	O
765	O	O
+	O	O
/	O	O
-	O	O
145	O	O
g	O	O
/	O	O
cm	O	O
(	O	O
2	O	O
)	O	O
,	O	O
NS	O	O
)	O	O
.	O	O

Half	O	O
-	O	O
relaxation	O	O
time	O	O
was	O	O
prolonged	O	O
in	O	O
both	O	O
steroid	B-Chemical	D013256
groups	O	O
,	O	O
and	O	O
time	O	O
to	O	O
peak	O	O
tension	O	O
was	O	O
longer	O	O
with	O	O
M	B-Chemical	D008775
,	O	O
whereas	O	O
tetanic	B-Disease	D013746
tensions	O	O
were	O	O
similar	O	O
.	O	O

Steroid	B-Chemical	D013256
treatment	O	O
also	O	O
induced	O	O
a	O	O
leftward	O	O
shift	O	O
of	O	O
the	O	O
force	O	O
-	O	O
frequency	O	O
curve	O	O
at	O	O
25	O	O
and	O	O
50	O	O
Hz	O	O
when	O	O
compared	O	O
with	O	O
saline	O	O
treatment	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

ATPase	O	O
staining	O	O
of	O	O
the	O	O
diaphragm	O	O
,	O	O
scalenus	O	O
medius	O	O
,	O	O
and	O	O
gastrocnemius	O	O
showed	O	O
type	O	O
IIb	O	O
fiber	O	O
atrophy	B-Disease	D009133
in	O	O
the	O	O
steroid	B-Chemical	D013256
groups	O	O
and	O	O
also	O	O
diaphragmatic	O	O
type	O	O
IIa	O	O
atrophy	B-Disease	D009133
with	O	O
T	B-Chemical	D014221
,	O	O
whereas	O	O
histologic	O	O
examinations	O	O
revealed	O	O
a	O	O
normal	O	O
muscular	O	O
pattern	O	O
with	O	O
absence	O	O
of	O	O
necrosis	B-Disease	D009336
.	O	O

Finally	O	O
,	O	O
a	O	O
pair	O	O
-	O	O
fed	O	O
(	O	O
PF	O	O
)	O	O
study	O	O
,	O	O
performed	O	O
in	O	O
18	O	O
rats	O	O
(	O	O
C	O	O
,	O	O
T	B-Chemical	D014221
,	O	O
and	O	O
PF	O	O
)	O	O
,	O	O
showed	O	O
that	O	O
muscle	B-Disease	D009133
atrophy	I-Disease	D009133
was	O	O
considerably	O	O
less	O	O
pronounced	O	O
in	O	O
PF	O	O
animals	O	O
than	O	O
in	O	O
T	B-Chemical	D014221
-	O	O
treated	O	O
animals	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
(	O	O
1	O	O
)	O	O
short	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
massive	O	O
doses	O	O
of	O	O
steroids	B-Chemical	D013256
induced	O	O
severe	O	O
respiratory	O	O
and	O	O
limb	O	O
muscle	O	O
wasting	O	O
;	O	O
(	O	O
2	O	O
)	O	O
both	O	O
types	O	O
of	O	O
steroids	B-Chemical	D013256
induced	O	O
predominantly	O	O
type	O	O
IIb	O	O
atrophy	B-Disease	D009133
,	O	O
resulting	O	O
in	O	O
the	O	O
expected	O	O
alterations	O	O
in	O	O
diaphragm	O	O
contractile	O	O
properties	O	O
;	O	O
(	O	O
3	O	O
)	O	O
neither	O	O
steroid	B-Chemical	D013256
caused	O	O
muscle	O	O
necrosis	B-Disease	D009336
;	O	O
(	O	O
4	O	O
)	O	O
type	O	O
IIb	O	O
atrophy	B-Disease	D009133
was	O	O
not	O	O
caused	O	O
by	O	O
acute	O	O
nutritional	O	O
deprivation	O	O
alone	O	O
.	O	O

Refractory	O	O
cardiogenic	B-Disease	D012770
shock	I-Disease	D012770
and	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
after	O	O
verapamil	B-Chemical	D014700
SR	O	O
and	O	O
metoprolol	B-Chemical	D008790
treatment	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

A	O	O
seventy	O	O
-	O	O
eight	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
and	O	O
refractory	O	O
hypotension	B-Disease	D007022
two	O	O
days	O	O
after	O	O
a	O	O
therapeutic	O	O
dose	O	O
of	O	O
sustained	O	O
-	O	O
release	O	O
verapamil	B-Chemical	D014700
with	O	O
concomitant	O	O
use	O	O
of	O	O
metoprolol	B-Chemical	D008790
.	O	O

The	O	O
patient	O	O
continued	O	O
to	O	O
remain	O	O
hypotensive	B-Disease	D007022
with	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
,	O	O
even	O	O
with	O	O
multiple	O	O
uses	O	O
of	O	O
intravenous	O	O
atropine	B-Chemical	D001285
as	O	O
well	O	O
as	O	O
high	O	O
doses	O	O
of	O	O
pressor	O	O
agents	O	O
such	O	O
as	O	O
dopamine	B-Chemical	D004298
and	O	O
dobutamine	B-Chemical	D004280
.	O	O

However	O	O
,	O	O
shortly	O	O
after	O	O
the	O	O
use	O	O
of	O	O
intravenous	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
,	O	O
the	O	O
refractory	O	O
hypotension	B-Disease	D007022
and	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
resolved	O	O
.	O	O

A	O	O
phase	O	O
I	O	O
clinical	O	O
study	O	O
of	O	O
the	O	O
antipurine	B-Chemical	D000983
antifolate	O	O
lometrexol	B-Chemical	C045894
(	O	O
DDATHF	B-Chemical	C045894
)	O	O
given	O	O
with	O	O
oral	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
.	O	O

Lometrexol	B-Chemical	C045894
is	O	O
an	O	O
antifolate	O	O
which	O	O
inhibits	O	O
glycinamide	B-Chemical	C402896
ribonucleotide	I-Chemical	C402896
formyltransferase	O	O
(	O	O
GARFT	O	O
)	O	O
,	O	O
an	O	O
enzyme	O	O
essential	O	O
for	O	O
de	O	O
novo	O	O
purine	B-Chemical	D011687
synthesis	O	O
.	O	O

Extensive	O	O
experimental	O	O
and	O	O
limited	O	O
clinical	O	O
data	O	O
have	O	O
shown	O	O
that	O	O
lometrexol	B-Chemical	C045894
has	O	O
activity	O	O
against	O	O
tumours	B-Disease	D009369
which	O	O
are	O	O
refractory	O	O
to	O	O
other	O	O
drugs	O	O
,	O	O
notably	O	O
methotrexate	B-Chemical	D008727
.	O	O

However	O	O
,	O	O
the	O	O
initial	O	O
clinical	O	O
development	O	O
of	O	O
lometrexol	B-Chemical	C045894
was	O	O
curtailed	O	O
because	O	O
of	O	O
severe	O	O
and	O	O
cumulative	O	O
antiproliferative	O	O
toxicities	B-Disease	D064420
.	O	O

Preclinical	O	O
murine	O	O
studies	O	O
demonstrated	O	O
that	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
lometrexol	B-Chemical	C045894
can	O	O
be	O	O
prevented	O	O
by	O	O
low	O	O
dose	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
administration	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

for	O	O
7	O	O
days	O	O
prior	O	O
to	O	O
and	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
bolus	O	O
dose	O	O
.	O	O

This	O	O
observation	O	O
prompted	O	O
a	O	O
Phase	O	O
I	O	O
clinical	O	O
study	O	O
of	O	O
lometrexol	B-Chemical	C045894
given	O	O
with	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
supplementation	O	O
which	O	O
has	O	O
confirmed	O	O
that	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
lometrexol	B-Chemical	C045894
can	O	O
be	O	O
markedly	O	O
reduced	O	O
by	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
supplementation	O	O
.	O	O

Thrombocytopenia	B-Disease	D013921
and	O	O
mucositis	B-Disease	D052016
were	O	O
the	O	O
major	O	O
toxicities	B-Disease	D064420
.	O	O

There	O	O
was	O	O
no	O	O
clear	O	O
relationship	O	O
between	O	O
clinical	O	O
toxicity	B-Disease	D064420
and	O	O
the	O	O
extent	O	O
of	O	O
plasma	O	O
folate	B-Chemical	D005492
elevation	O	O
.	O	O

Associated	O	O
studies	O	O
demonstrated	O	O
that	O	O
lometrexol	B-Chemical	C045894
plasma	O	O
pharmacokinetics	O	O
were	O	O
not	O	O
altered	O	O
by	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
administration	O	O
indicating	O	O
that	O	O
supplementation	O	O
is	O	O
unlikely	O	O
to	O	O
reduce	O	O
toxicity	B-Disease	D064420
by	O	O
enhancing	O	O
lometrexol	B-Chemical	C045894
plasma	O	O
clearance	O	O
.	O	O

The	O	O
work	O	O
described	O	O
in	O	O
this	O	O
report	O	O
has	O	O
identified	O	O
for	O	O
the	O	O
first	O	O
time	O	O
a	O	O
clinically	O	O
acceptable	O	O
schedule	O	O
for	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
GARFT	O	O
inhibitor	O	O
.	O	O

This	O	O
information	O	O
will	O	O
facilitate	O	O
the	O	O
future	O	O
evaluation	O	O
of	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
in	O	O
cancer	B-Disease	D009369
therapy	O	O
.	O	O

Involvement	O	O
of	O	O
the	O	O
mu	O	O
-	O	O
opiate	O	O
receptor	O	O
in	O	O
peripheral	O	O
analgesia	B-Disease	D000699
.	O	O

The	O	O
intradermal	O	O
injection	O	O
of	O	O
mu	O	O
(	O	O
morphine	B-Chemical	D009020
,	O	O
Tyr	B-Chemical	D020875
-	I-Chemical	D020875
D	I-Chemical	D020875
-	I-Chemical	D020875
Ala	I-Chemical	D020875
-	I-Chemical	D020875
Gly	I-Chemical	D020875
-	I-Chemical	D020875
NMe	I-Chemical	D020875
-	I-Chemical	D020875
Phe	I-Chemical	D020875
-	I-Chemical	D020875
Gly	I-Chemical	D020875
-	I-Chemical	D020875
ol	I-Chemical	D020875
and	O	O
morphiceptin	B-Chemical	C028889
)	O	O
,	O	O
kappa	O	O
(	O	O
trans	B-Chemical	D019900
-	I-Chemical	D019900
3	I-Chemical	D019900
,	I-Chemical	D019900
4	I-Chemical	D019900
-	I-Chemical	D019900
dichloro	I-Chemical	D019900
-	I-Chemical	D019900
N	I-Chemical	D019900
-	I-Chemical	D019900
methyl	I-Chemical	D019900
-	I-Chemical	D019900
N	I-Chemical	D019900
[	I-Chemical	D019900
2	I-Chemical	D019900
-	I-Chemical	D019900
(	I-Chemical	D019900
1	I-Chemical	D019900
-	I-Chemical	D019900
pyrrolidinyl	I-Chemical	D019900
)	I-Chemical	D019900
cyclohexyl	I-Chemical	D019900
]	I-Chemical	D019900
benzeneactemide	I-Chemical	D019900
)	O	O
and	O	O
delta	O	O
(	O	O
[	B-Chemical	D020881
D	I-Chemical	D020881
-	I-Chemical	D020881
Pen2	I-Chemical	D020881
.	I-Chemical	D020881

5	I-Chemical	D020881
]	I-Chemical	D020881
-	I-Chemical	D020881
enkephalin	I-Chemical	D020881
and	O	O
[	B-Chemical	C034318
D	I-Chemical	C034318
-	I-Chemical	C034318
Ser2	I-Chemical	C034318
]	I-Chemical	C034318
-	I-Chemical	C034318
[	I-Chemical	C034318
Leu	I-Chemical	C034318
]	I-Chemical	C034318
enkephalin	I-Chemical	C034318
-	I-Chemical	C034318
Thr	I-Chemical	C034318
)	O	O
selective	O	O
opioid	O	O
-	O	O
agonists	O	O
,	O	O
by	O	O
themselves	O	O
,	O	O
did	O	O
not	O	O
significantly	O	O
affect	O	O
the	O	O
mechanical	O	O
nociceptive	O	O
threshold	O	O
in	O	O
the	O	O
hindpaw	O	O
of	O	O
the	O	O
rat	O	O
.	O	O

Intradermal	O	O
injection	O	O
of	O	O
mu	O	O
,	O	O
but	O	O
not	O	O
delta	O	O
or	O	O
kappa	O	O
opioid	O	O
-	O	O
agonists	O	O
,	O	O
however	O	O
,	O	O
produced	O	O
dose	O	O
-	O	O
dependent	O	O
inhibition	O	O
of	O	O
prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
.	O	O

The	O	O
analgesic	O	O
effect	O	O
of	O	O
the	O	O
mu	O	O
-	O	O
agonist	O	O
morphine	B-Chemical	D009020
was	O	O
dose	O	O
-	O	O
dependently	O	O
antagonized	O	O
by	O	O
naloxone	B-Chemical	D009270
and	O	O
prevented	O	O
by	O	O
co	O	O
-	O	O
injection	O	O
of	O	O
pertussis	O	O
toxin	O	O
.	O	O

Morphine	B-Chemical	D009020
did	O	O
not	O	O
,	O	O
however	O	O
,	O	O
alter	O	O
the	O	O
hyperalgesia	B-Disease	D006930
induced	O	O
by	O	O
8	B-Chemical	D015124
-	I-Chemical	D015124
bromo	I-Chemical	D015124
cyclic	I-Chemical	D015124
adenosine	I-Chemical	D015124
monophosphate	I-Chemical	D015124
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
analgesic	O	O
action	O	O
of	O	O
opioids	O	O
on	O	O
the	O	O
peripheral	O	O
terminals	O	O
of	O	O
primary	O	O
afferents	O	O
is	O	O
via	O	O
a	O	O
binding	O	O
site	O	O
with	O	O
characteristics	O	O
of	O	O
the	O	O
mu	O	O
-	O	O
opioid	O	O
receptor	O	O
and	O	O
that	O	O
this	O	O
action	O	O
is	O	O
mediated	O	O
by	O	O
inhibition	O	O
of	O	O
the	O	O
cyclic	B-Chemical	D000242
adenosine	I-Chemical	D000242
monophosphate	I-Chemical	D000242
second	O	O
messenger	O	O
system	O	O
.	O	O

Adequate	O	O
timing	O	O
of	O	O
ribavirin	B-Chemical	D012254
reduction	O	O
in	O	O
patients	O	O
with	O	O
hemolysis	B-Disease	D006461
during	O	O
combination	O	O
therapy	O	O
of	O	O
interferon	B-Chemical	D007372
and	O	O
ribavirin	B-Chemical	D012254
for	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
.	O	O

BACKGROUND	O	O
:	O	O
Hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
is	O	O
one	O	O
of	O	O
the	O	O
major	O	O
adverse	O	O
events	O	O
of	O	O
the	O	O
combination	O	O
therapy	O	O
of	O	O
interferon	B-Chemical	D007372
and	O	O
ribavirin	B-Chemical	D012254
.	O	O

Because	O	O
of	O	O
ribavirin	B-Chemical	D012254
-	O	O
related	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
,	O	O
dose	O	O
reduction	O	O
is	O	O
a	O	O
common	O	O
event	O	O
in	O	O
this	O	O
therapy	O	O
.	O	O

In	O	O
this	O	O
clinical	O	O
retrospective	O	O
cohort	O	O
study	O	O
we	O	O
have	O	O
examined	O	O
the	O	O
suitable	O	O
timing	O	O
of	O	O
ribavirin	B-Chemical	D012254
reduction	O	O
in	O	O
patients	O	O
with	O	O
hemolysis	B-Disease	D006461
during	O	O
combination	O	O
therapy	O	O
.	O	O

METHODS	O	O
:	O	O
Thirty	O	O
-	O	O
seven	O	O
of	O	O
160	O	O
patients	O	O
who	O	O
had	O	O
HCV	O	O
-	O	O
genotype	O	O
1b	O	O
,	O	O
had	O	O
high	O	O
virus	O	O
load	O	O
,	O	O
and	O	O
received	O	O
24	O	O
-	O	O
week	O	O
combination	O	O
therapy	O	O
developed	O	O
anemia	B-Disease	D000740
with	O	O
hemoglobin	O	O
level	O	O
<10	O	O
g	O	O
/	O	O
dl	O	O
or	O	O
anemia	B-Disease	D000740
-	O	O
related	O	O
signs	O	O
during	O	O
therapy	O	O
.	O	O

After	O	O
that	O	O
,	O	O
these	O	O
37	O	O
patients	O	O
were	O	O
reduced	O	O
one	O	O
tablet	O	O
of	O	O
ribavirin	B-Chemical	D012254
(	O	O
200	O	O
mg	O	O
)	O	O
per	O	O
day	O	O
.	O	O

After	O	O
reduction	O	O
of	O	O
ribavirin	B-Chemical	D012254
,	O	O
27	O	O
of	O	O
37	O	O
patients	O	O
could	O	O
continue	O	O
combination	O	O
therapy	O	O
for	O	O
a	O	O
total	O	O
of	O	O
24	O	O
weeks	O	O
(	O	O
group	O	O
A	O	O
)	O	O
.	O	O

However	O	O
,	O	O
10	O	O
of	O	O
37	O	O
patients	O	O
with	O	O
reduction	O	O
of	O	O
ribavirin	B-Chemical	D012254
could	O	O
not	O	O
continue	O	O
combination	O	O
therapy	O	O
because	O	O
their	O	O
<8	O	O
.	O	O

5	O	O
g	O	O
/	O	O
dl	O	O
hemoglobin	O	O
values	O	O
decreased	O	O
to	O	O
or	O	O
anemia	B-Disease	D000740
-	O	O
related	O	O
severe	O	O
side	O	O
effects	O	O
occurred	O	O
(	O	O
group	O	O
B	O	O
)	O	O
.	O	O

We	O	O
assessed	O	O
the	O	O
final	O	O
efficacy	O	O
and	O	O
safety	O	O
after	O	O
reduction	O	O
of	O	O
ribavirin	B-Chemical	D012254
in	O	O
groups	O	O
A	O	O
and	O	O
B	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
sustained	O	O
virological	O	O
response	O	O
(	O	O
SVR	O	O
)	O	O
was	O	O
29	O	O
.	O	O

6%	O	O
(	O	O
8	O	O
/	O	O
27	O	O
)	O	O
in	O	O
group	O	O
A	O	O
and	O	O
10%	O	O
(	O	O
1	O	O
/	O	O
10	O	O
)	O	O
in	O	O
group	O	O
B	O	O
,	O	O
respectively	O	O
.	O	O

A	O	O
34	O	O
.	O	O

4%	O	O
(	O	O
12	O	O
/	O	O
27	O	O
)	O	O
of	O	O
SVR	O	O
+	O	O
biological	O	O
response	O	O
in	O	O
group	O	O
A	O	O
was	O	O
higher	O	O
than	O	O
10%	O	O
(	O	O
1	O	O
/	O	O
10	O	O
)	O	O
in	O	O
group	O	O
B	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

051	O	O
)	O	O
,	O	O
with	O	O
slight	O	O
significance	O	O
.	O	O

With	O	O
respect	O	O
to	O	O
hemoglobin	O	O
level	O	O
at	O	O
the	O	O
time	O	O
of	O	O
ribavirin	B-Chemical	D012254
reduction	O	O
,	O	O
a	O	O
rate	O	O
of	O	O
continuation	O	O
of	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
>	O	O
or	O	O
=10	O	O
g	O	O
/	O	O
dl	O	O
hemoglobin	O	O
was	O	O
higher	O	O
than	O	O
that	O	O
in	O	O
patients	O	O
with	O	O
<10	O	O
g	O	O
/	O	O
dl	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

036	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Reduction	O	O
of	O	O
ribavirin	B-Chemical	D012254
at	O	O
hemoglobin	O	O
level	O	O
>	O	O
or	O	O
=10	O	O
g	O	O
/	O	O
dl	O	O
is	O	O
suitable	O	O
in	O	O
terms	O	O
of	O	O
efficacy	O	O
and	O	O
side	O	O
effects	O	O
.	O	O

Increased	O	O
expression	O	O
and	O	O
apical	O	O
targeting	O	O
of	O	O
renal	O	O
ENaC	O	O
subunits	O	O
in	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
in	O	O
rats	O	O
.	O	O

Nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
is	O	O
often	O	O
accompanied	O	O
by	O	O
sodium	B-Chemical	D012964
retention	O	O
and	O	O
generalized	O	O
edema	B-Disease	D004487
.	O	O

However	O	O
,	O	O
the	O	O
molecular	O	O
basis	O	O
for	O	O
the	O	O
decreased	O	O
renal	O	O
sodium	B-Chemical	D012964
excretion	O	O
remains	O	O
undefined	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
epithelial	O	O
Na	B-Chemical	D012964
channel	O	O
(	O	O
ENaC	O	O
)	O	O
subunit	O	O
dysregulation	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
increased	O	O
sodium	B-Chemical	D012964
retention	O	O
.	O	O

An	O	O
experimental	O	O
group	O	O
of	O	O
rats	O	O
was	O	O
treated	O	O
with	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
;	O	O
180	O	O
mg	O	O
/	O	O
kg	O	O
iv	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
control	O	O
group	O	O
received	O	O
only	O	O
vehicle	O	O
.	O	O

After	O	O
7	O	O
days	O	O
,	O	O
PAN	B-Chemical	D011692
treatment	O	O
induced	O	O
significant	O	O
proteinuria	B-Disease	D011507
,	O	O
hypoalbuminemia	B-Disease	D034141
,	O	O
decreased	O	O
urinary	O	O
sodium	B-Chemical	D012964
excretion	O	O
,	O	O
and	O	O
extensive	O	O
ascites	B-Disease	D001201
.	O	O

The	O	O
protein	O	O
abundance	O	O
of	O	O
alpha	O	O
-	O	O
ENaC	O	O
and	O	O
beta	O	O
-	O	O
ENaC	O	O
was	O	O
increased	O	O
in	O	O
the	O	O
inner	O	O
stripe	O	O
of	O	O
the	O	O
outer	O	O
medulla	O	O
(	O	O
ISOM	O	O
)	O	O
and	O	O
in	O	O
the	O	O
inner	O	O
medulla	O	O
(	O	O
IM	O	O
)	O	O
but	O	O
was	O	O
not	O	O
altered	O	O
in	O	O
the	O	O
cortex	O	O
.	O	O

gamma	O	O
-	O	O
ENaC	O	O
abundance	O	O
was	O	O
increased	O	O
in	O	O
the	O	O
cortex	O	O
,	O	O
ISOM	O	O
,	O	O
and	O	O
IM	O	O
.	O	O

Immunoperoxidase	O	O
brightfield	O	O
-	O	O
and	O	O
laser	O	O
-	O	O
scanning	O	O
confocal	O	O
fluorescence	O	O
microscopy	O	O
demonstrated	O	O
increased	O	O
targeting	O	O
of	O	O
alpha	O	O
-	O	O
ENaC	O	O
,	O	O
beta	O	O
-	O	O
ENaC	O	O
,	O	O
and	O	O
gamma	O	O
-	O	O
ENaC	O	O
subunits	O	O
to	O	O
the	O	O
apical	O	O
plasma	O	O
membrane	O	O
in	O	O
the	O	O
distal	O	O
convoluted	O	O
tubule	O	O
(	O	O
DCT2	O	O
)	O	O
,	O	O
connecting	O	O
tubule	O	O
,	O	O
and	O	O
cortical	O	O
and	O	O
medullary	O	O
collecting	O	O
duct	O	O
segments	O	O
.	O	O

Immunoelectron	O	O
microscopy	O	O
further	O	O
revealed	O	O
an	O	O
increased	O	O
labeling	O	O
of	O	O
alpha	O	O
-	O	O
ENaC	O	O
in	O	O
the	O	O
apical	O	O
plasma	O	O
membrane	O	O
of	O	O
cortical	O	O
collecting	O	O
duct	O	O
principal	O	O
cells	O	O
of	O	O
PAN	B-Chemical	D011692
-	O	O
treated	O	O
rats	O	O
,	O	O
indicating	O	O
enhanced	O	O
apical	O	O
targeting	O	O
of	O	O
alpha	O	O
-	O	O
ENaC	O	O
subunits	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
protein	O	O
abundances	O	O
of	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
/	O	O
H	B-Chemical	D006859
(	O	O
+	O	O
)	O	O
exchanger	O	O
type	O	O
3	O	O
(	O	O
NHE3	O	O
)	O	O
,	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
-	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
2Cl	O	O
(	O	O
-	O	O
)	O	O
cotransporter	O	O
(	O	O
BSC	O	O
-	O	O
1	O	O
)	O	O
,	O	O
and	O	O
thiazide	B-Chemical	D049971
-	O	O
sensitive	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
-	O	O
Cl	B-Chemical	D002713
(	O	O
-	O	O
)	O	O
cotransporter	O	O
(	O	O
TSC	O	O
)	O	O
were	O	O
decreased	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
abundance	O	O
of	O	O
the	O	O
alpha	O	O
(	O	O
1	O	O
)	O	O
-	O	O
subunit	O	O
of	O	O
the	O	O
Na	B-Chemical	D012964
-	O	O
K	B-Chemical	D011188
-	O	O
ATPase	O	O
was	O	O
decreased	O	O
in	O	O
the	O	O
cortex	O	O
and	O	O
ISOM	O	O
,	O	O
but	O	O
it	O	O
remained	O	O
unchanged	O	O
in	O	O
the	O	O
IM	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
increased	O	O
or	O	O
sustained	O	O
expression	O	O
of	O	O
ENaC	O	O
subunits	O	O
combined	O	O
with	O	O
increased	O	O
apical	O	O
targeting	O	O
in	O	O
the	O	O
DCT2	O	O
,	O	O
connecting	O	O
tubule	O	O
,	O	O
and	O	O
collecting	O	O
duct	O	O
are	O	O
likely	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
sodium	B-Chemical	D012964
retention	O	O
associated	O	O
with	O	O
PAN	B-Chemical	D011692
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
.	O	O

The	O	O
decreased	O	O
abundance	O	O
of	O	O
NHE3	O	O
,	O	O
BSC	O	O
-	O	O
1	O	O
,	O	O
TSC	O	O
,	O	O
and	O	O
Na	B-Chemical	D012964
-	O	O
K	B-Chemical	D011188
-	O	O
ATPase	O	O
may	O	O
play	O	O
a	O	O
compensatory	O	O
role	O	O
to	O	O
promote	O	O
sodium	B-Chemical	D012964
excretion	O	O
.	O	O

Does	O	O
hormone	O	O
therapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
have	O	O
a	O	O
detrimental	O	O
effect	O	O
on	O	O
memory	O	O
and	O	O
cognition?	O	O
A	O	O
pilot	O	O
study	O	O
.	O	O

This	O	O
pilot	O	O
study	O	O
examines	O	O
whether	O	O
hormone	O	O
therapy	O	O
for	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
affects	O	O
cognition	O	O
.	O	O

Patients	O	O
participating	O	O
in	O	O
a	O	O
randomised	O	O
trial	O	O
of	O	O
anastrozole	B-Chemical	C090450
,	O	O
tamoxifen	B-Chemical	D013629
alone	O	O
or	O	O
combined	O	O
(	O	O
ATAC	O	O
)	O	O
(	O	O
n=94	O	O
)	O	O
and	O	O
a	O	O
group	O	O
of	O	O
women	O	O
without	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
(	O	O
n=35	O	O
)	O	O
completed	O	O
a	O	O
battery	O	O
of	O	O
neuropsychological	O	O
measures	O	O
.	O	O

Compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
the	O	O
patients	O	O
were	O	O
impaired	O	O
on	O	O
a	O	O
processing	O	O
speed	O	O
task	O	O
(	O	O
p=0	O	O
.	O	O

032	O	O
)	O	O
and	O	O
on	O	O
a	O	O
measure	O	O
of	O	O
immediate	O	O
verbal	O	O
memory	O	O
(	O	O
p=0	O	O
.	O	O

026	O	O
)	O	O
after	O	O
controlling	O	O
for	O	O
the	O	O
use	O	O
of	O	O
hormone	O	O
replacement	O	O
therapy	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Patient	O	O
group	O	O
performance	O	O
was	O	O
not	O	O
significantly	O	O
related	O	O
to	O	O
length	O	O
of	O	O
treatment	O	O
or	O	O
measures	O	O
of	O	O
psychological	O	O
morbidity	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
specific	O	O
impairments	O	O
in	O	O
processing	O	O
speed	O	O
and	O	O
verbal	O	O
memory	O	O
in	O	O
women	O	O
receiving	O	O
hormonal	O	O
therapy	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Verbal	O	O
memory	O	O
may	O	O
be	O	O
especially	O	O
sensitive	O	O
to	O	O
changes	O	O
in	O	O
oestrogen	B-Chemical	D004967
levels	O	O
,	O	O
a	O	O
finding	O	O
commonly	O	O
reported	O	O
in	O	O
studies	O	O
of	O	O
hormone	O	O
replacement	O	O
therapy	O	O
in	O	O
healthy	O	O
women	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
increased	O	O
use	O	O
of	O	O
hormone	O	O
therapies	O	O
in	O	O
an	O	O
adjuvant	O	O
and	O	O
preventative	O	O
setting	O	O
their	O	O
impact	O	O
on	O	O
cognitive	O	O
functioning	O	O
should	O	O
be	O	O
investigated	O	O
more	O	O
thoroughly	O	O
.	O	O

Association	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
production	O	O
and	O	O
apoptosis	O	O
in	O	O
a	O	O
model	O	O
of	O	O
experimental	O	O
nephropathy	B-Disease	D007674
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
recent	O	O
studies	O	O
increased	O	O
amounts	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
and	O	O
apoptosis	O	O
have	O	O
been	O	O
implicated	O	O
in	O	O
various	O	O
pathological	O	O
conditions	O	O
in	O	O
the	O	O
kidney	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
role	O	O
of	O	O
NO	B-Chemical	D009569
and	O	O
its	O	O
association	O	O
with	O	O
apoptosis	O	O
in	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
adriamycin	B-Chemical	D004317
(	O	O
ADR	B-Chemical	D004317
)	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
alteration	O	O
in	O	O
the	O	O
NO	B-Chemical	D009569
pathway	O	O
was	O	O
assessed	O	O
by	O	O
measuring	O	O
nitrite	B-Chemical	D009573
levels	O	O
in	O	O
serum	O	O
/	O	O
urine	O	O
and	O	O
by	O	O
evaluating	O	O
the	O	O
changes	O	O
in	O	O
vascular	O	O
reactivity	O	O
of	O	O
the	O	O
isolated	O	O
perfused	O	O
rat	O	O
kidney	O	O
(	O	O
IPRK	O	O
)	O	O
system	O	O
.	O	O

Rats	O	O
were	O	O
stratified	O	O
into	O	O
control	O	O
groups	O	O
and	O	O
ADR	B-Chemical	D004317
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
groups	O	O
.	O	O

These	O	O
two	O	O
groups	O	O
were	O	O
then	O	O
divided	O	O
into	O	O
:	O	O
group	O	O
1	O	O
,	O	O
animals	O	O
receiving	O	O
saline	O	O
;	O	O
and	O	O
group	O	O
2	O	O
,	O	O
animals	O	O
receiving	O	O
aminoguanidine	B-Chemical	C004479
(	O	O
AG	B-Chemical	C004479
)	O	O
which	O	O
is	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
inducible	O	O
-	O	O
NO	B-Chemical	D009569
synthase	O	O
.	O	O

On	O	O
day	O	O
21	O	O
,	O	O
rats	O	O
were	O	O
sacrificed	O	O
after	O	O
obtaining	O	O
material	O	O
for	O	O
biochemical	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
Histopathological	O	O
examination	O	O
of	O	O
the	O	O
kidneys	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
ADR	B-Chemical	D004317
revealed	O	O
focal	O	O
areas	O	O
of	O	O
mesangial	B-Disease	C537346
proliferation	I-Disease	C537346
and	O	O
mild	O	O
tubulointerstitial	B-Disease	D009395
inflammation	I-Disease	D009395
.	O	O

They	O	O
also	O	O
had	O	O
significantly	O	O
higher	O	O
levels	O	O
of	O	O
proteinuria	B-Disease	D011507
compared	O	O
with	O	O
control	O	O
and	O	O
treatment	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Urine	O	O
nitrite	B-Chemical	D009573
levels	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
the	O	O
ADR	B-Chemical	D004317
-	O	O
nephropathy	B-Disease	D007674
group	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

In	O	O
the	O	O
IPRK	O	O
phenylephrine	B-Chemical	D010656
and	O	O
acetylcholine	B-Chemical	D000109
related	O	O
responses	O	O
were	O	O
significantly	O	O
impaired	O	O
in	O	O
the	O	O
ADR	B-Chemical	D004317
-	O	O
nephropathy	B-Disease	D007674
group	O	O
.	O	O

Apoptosis	O	O
was	O	O
not	O	O
detected	O	O
in	O	O
controls	O	O
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
ADR	B-Chemical	D004317
-	O	O
nephropathy	B-Disease	D007674
group	O	O
,	O	O
numerous	O	O
apoptotic	O	O
cells	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
tubulointerstitial	O	O
areas	O	O
.	O	O

Double	O	O
staining	O	O
revealed	O	O
numerous	O	O
interstitial	O	O
apoptotic	O	O
cells	O	O
to	O	O
stain	O	O
for	O	O
ED1	O	O
,	O	O
a	O	O
marker	O	O
for	O	O
monocytes	O	O
/	O	O
macrophages	O	O
.	O	O

Treatment	O	O
with	O	O
AG	B-Chemical	C004479
prevented	O	O
the	O	O
impairment	O	O
of	O	O
renal	O	O
vascular	O	O
bed	O	O
responses	O	O
and	O	O
reduced	O	O
both	O	O
urine	O	O
nitrite	B-Chemical	D009573
levels	O	O
and	O	O
apoptosis	O	O
to	O	O
control	O	O
levels	O	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
suggest	O	O
that	O	O
interactions	O	O
between	O	O
NO	B-Chemical	D009569
and	O	O
apoptosis	O	O
are	O	O
important	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
the	O	O
ADR	B-Chemical	D004317
-	O	O
induced	O	O
nephrosis	B-Disease	D009401
.	O	O

The	O	O
attenuating	O	O
effect	O	O
of	O	O
carteolol	B-Chemical	D002354
hydrochloride	I-Chemical	D002354
,	O	O
a	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonist	O	O
,	O	O
on	O	O
neuroleptic	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
rats	O	O
.	O	O

It	O	O
is	O	O
known	O	O
that	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonists	O	O
are	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
akathisia	B-Disease	D017109
,	O	O
one	O	O
of	O	O
the	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
that	O	O
occur	O	O
during	O	O
neuroleptic	O	O
treatment	O	O
.	O	O

Neuroleptic	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
,	O	O
a	O	O
model	O	O
of	O	O
neuroleptic	O	O
-	O	O
induced	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
,	O	O
was	O	O
considered	O	O
suitable	O	O
as	O	O
a	O	O
model	O	O
for	O	O
predicting	O	O
neuroleptic	O	O
-	O	O
induced	O	O
akathisia	B-Disease	D017109
in	O	O
humans	O	O
,	O	O
although	O	O
neuroleptic	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
was	O	O
not	O	O
considered	O	O
a	O	O
specific	O	O
test	O	O
for	O	O
neuroleptic	O	O
-	O	O
induced	O	O
akathisia	B-Disease	D017109
.	O	O

Therefore	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
carteolol	B-Chemical	D002354
,	O	O
a	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonist	O	O
,	O	O
on	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
rats	O	O
were	O	O
behaviorally	O	O
studied	O	O
and	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
propranolol	B-Chemical	D011433
and	O	O
biperiden	B-Chemical	D001712
,	O	O
a	O	O
muscarinic	O	O
receptor	O	O
antagonist	O	O
.	O	O

Carteolol	B-Chemical	D002354
,	O	O
as	O	O
well	O	O
as	O	O
propranolol	B-Chemical	D011433
and	O	O
biperiden	B-Chemical	D001712
,	O	O
inhibited	O	O
the	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

The	O	O
inhibitory	O	O
effect	O	O
of	O	O
carteolol	B-Chemical	D002354
was	O	O
almost	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
propranolol	B-Chemical	D011433
,	O	O
but	O	O
was	O	O
weaker	O	O
than	O	O
that	O	O
of	O	O
biperiden	B-Chemical	D001712
.	O	O

Carteolol	B-Chemical	D002354
did	O	O
not	O	O
evoke	O	O
postsynaptic	O	O
dopamine	B-Chemical	D004298
receptor	O	O
-	O	O
stimulating	O	O
behavioral	O	O
signs	O	O
such	O	O
as	O	O
stereotypy	O	O
and	O	O
hyperlocomotion	B-Disease	D009069
in	O	O
rats	O	O
.	O	O

Carteolol	B-Chemical	D002354
did	O	O
not	O	O
antagonize	O	O
the	O	O
inhibitory	O	O
effects	O	O
of	O	O
haloperidol	B-Chemical	D006220
on	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
stereotypy	O	O
and	O	O
locomotor	O	O
activity	O	O
in	O	O
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
carteolol	B-Chemical	D002354
did	O	O
not	O	O
evoke	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
-	O	O
stimulating	O	O
behavioral	O	O
signs	O	O
such	O	O
as	O	O
flat	O	O
body	O	O
posture	O	O
and	O	O
forepaw	O	O
treading	O	O
and	O	O
did	O	O
not	O	O
inhibit	O	O
5	B-Chemical	D006916
-	I-Chemical	D006916
hydroxytryptophan	I-Chemical	D006916
-	O	O
induced	O	O
head	O	O
twitch	O	O
in	O	O
rats	O	O
.	O	O

Finally	O	O
,	O	O
carteolol	B-Chemical	D002354
did	O	O
not	O	O
inhibit	O	O
physostigmine	B-Chemical	D010830
-	O	O
induced	O	O
lethality	O	O
in	O	O
rats	O	O
.	O	O

These	O	O
results	O	O
strongly	O	O
suggest	O	O
that	O	O
carteolol	B-Chemical	D002354
improves	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
via	O	O
its	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
antagonistic	O	O
activity	O	O
and	O	O
is	O	O
expected	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
akathisia	B-Disease	D017109
without	O	O
attenuating	O	O
neuroleptic	O	O
-	O	O
induced	O	O
antipsychotic	O	O
effects	O	O
due	O	O
to	O	O
its	O	O
postsynaptic	O	O
dopamine	B-Chemical	D004298
receptor	O	O
antagonistic	O	O
activity	O	O
.	O	O

Penicillamine	B-Chemical	D010396
-	O	O
induced	O	O
rapidly	O	O
progressive	O	O
glomerulonephritis	B-Disease	D005921
in	O	O
a	O	O
patient	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

A	O	O
67	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
presented	O	O
rapidly	O	O
progressive	O	O
glomerulonephritis	B-Disease	D005921
(	O	O
RPGN	B-Disease	D005921
)	O	O
after	O	O
5	O	O
months	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
(	O	O
250	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
treatment	O	O
.	O	O

Light	O	O
microscopy	O	O
study	O	O
showed	O	O
severe	O	O
glomerulonephritis	B-Disease	D005921
with	O	O
crescent	O	O
formation	O	O
in	O	O
60%	O	O
of	O	O
the	O	O
glomeruli	O	O
and	O	O
infiltration	O	O
of	O	O
inflammatory	O	O
cells	O	O
in	O	O
the	O	O
wall	O	O
of	O	O
an	O	O
arteriole	O	O
.	O	O

Immunofluorescence	O	O
revealed	O	O
scanty	O	O
granular	O	O
IgG	O	O
,	O	O
IgA	O	O
and	O	O
C3	O	O
deposits	O	O
along	O	O
the	O	O
capillary	O	O
walls	O	O
and	O	O
mesangium	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
steroid	B-Chemical	D013256
pulse	O	O
,	O	O
plasmapheresis	O	O
,	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
antiplatelet	B-Chemical	D010975
agents	I-Chemical	D010975
.	O	O

A	O	O
complete	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
was	O	O
achieved	O	O
in	O	O
a	O	O
few	O	O
weeks	O	O
.	O	O

This	O	O
new	O	O
case	O	O
of	O	O
RPGN	B-Disease	D005921
in	O	O
the	O	O
course	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
treatment	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
frequent	O	O
monitoring	O	O
of	O	O
renal	O	O
function	O	O
and	O	O
evaluation	O	O
of	O	O
urinary	O	O
sediment	O	O
and	O	O
proteinuria	B-Disease	D011507
in	O	O
these	O	O
patients	O	O
.	O	O

The	O	O
prompt	O	O
discontinuation	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
and	O	O
vigorous	O	O
treatment	O	O
measures	O	O
could	O	O
allow	O	O
for	O	O
a	O	O
good	O	O
prognosis	O	O
as	O	O
in	O	O
this	O	O
case	O	O
.	O	O

Nature	O	O
,	O	O
time	O	O
course	O	O
and	O	O
dose	O	O
dependence	O	O
of	O	O
zidovudine	B-Chemical	D015215
-	O	O
related	O	O
side	O	O
effects	O	O
:	O	O
results	O	O
from	O	O
the	O	O
Multicenter	O	O
Canadian	O	O
Azidothymidine	B-Chemical	D015215
Trial	O	O
.	O	O

To	O	O
characterize	O	O
the	O	O
nature	O	O
,	O	O
time	O	O
course	O	O
and	O	O
dose	O	O
dependency	O	O
of	O	O
zidovudine	B-Chemical	D015215
-	O	O
related	O	O
side	O	O
effects	O	O
,	O	O
we	O	O
undertook	O	O
a	O	O
multicenter	O	O
,	O	O
prospective	O	O
,	O	O
dose	O	O
-	O	O
range	O	O
finding	O	O
study	O	O
.	O	O

Our	O	O
study	O	O
group	O	O
consisted	O	O
of	O	O
74	O	O
HIV	O	O
-	O	O
positive	O	O
homosexual	O	O
men	O	O
belonging	O	O
to	O	O
groups	O	O
II	O	O
B	O	O
,	O	O
III	O	O
and	O	O
IV	O	O
C2	O	O
from	O	O
the	O	O
Centers	O	O
for	O	O
Disease	O	O
Control	O	O
(	O	O
CDC	O	O
)	O	O
classification	O	O
of	O	O
HIV	B-Disease	D015658
disease	I-Disease	D015658
.	O	O

Following	O	O
a	O	O
3	O	O
-	O	O
week	O	O
observation	O	O
period	O	O
,	O	O
volunteers	O	O
were	O	O
treated	O	O
with	O	O
zidovudine	B-Chemical	D015215
600	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
18	O	O
weeks	O	O
,	O	O
900	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
9	O	O
weeks	O	O
and	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
9	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
washout	O	O
period	O	O
of	O	O
6	O	O
weeks	O	O
after	O	O
which	O	O
they	O	O
were	O	O
re	O	O
-	O	O
started	O	O
on	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
or	O	O
the	O	O
highest	O	O
tolerated	O	O
dose	O	O
at	O	O
8	O	O
-	O	O
hourly	O	O
intervals	O	O
.	O	O

Subjects	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
4	O	O
-	O	O
hourly	O	O
or	O	O
8	O	O
-	O	O
hourly	O	O
regimens	O	O
within	O	O
CDC	O	O
groups	O	O
while	O	O
taking	O	O
600	O	O
and	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

Clinical	O	O
and	O	O
laboratory	O	O
evaluations	O	O
were	O	O
performed	O	O
at	O	O
3	O	O
-	O	O
week	O	O
intervals	O	O
.	O	O

Symptomatic	O	O
adverse	O	O
effects	O	O
were	O	O
present	O	O
in	O	O
96%	O	O
of	O	O
subjects	O	O
,	O	O
most	O	O
commonly	O	O
nausea	B-Disease	D009325
(	O	O
64%	O	O
)	O	O
,	O	O
fatigue	B-Disease	D005221
(	O	O
55%	O	O
)	O	O
and	O	O
headache	B-Disease	D006261
(	O	O
49%	O	O
)	O	O
.	O	O

These	O	O
were	O	O
generally	O	O
self	O	O
-	O	O
limited	O	O
,	O	O
reappearing	O	O
briefly	O	O
at	O	O
each	O	O
dose	O	O
increment	O	O
.	O	O

A	O	O
decrease	O	O
in	O	O
hemoglobin	O	O
occurred	O	O
shortly	O	O
after	O	O
initiation	O	O
of	O	O
therapy	O	O
.	O	O

This	O	O
was	O	O
not	O	O
dose	O	O
dependent	O	O
and	O	O
reversed	O	O
rapidly	O	O
upon	O	O
discontinuation	O	O
of	O	O
treatment	O	O
.	O	O

A	O	O
red	O	O
blood	O	O
cell	O	O
count	O	O
decrease	O	O
,	O	O
a	O	O
mean	O	O
cell	O	O
volume	O	O
increase	O	O
and	O	O
a	O	O
granulocyte	O	O
count	O	O
decrease	O	O
developed	O	O
early	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
independent	O	O
fashion	O	O
,	O	O
reverting	O	O
at	O	O
least	O	O
partially	O	O
during	O	O
the	O	O
washout	O	O
phase	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
reticulocyte	O	O
count	O	O
was	O	O
dose	O	O
related	O	O
between	O	O
600	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
day	O	O
with	O	O
no	O	O
further	O	O
change	O	O
when	O	O
the	O	O
dose	O	O
was	O	O
escalated	O	O
to	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

Bone	O	O
marrow	O	O
changes	O	O
occurred	O	O
rapidly	O	O
as	O	O
demonstrated	O	O
by	O	O
megaloblastosis	B-Disease	-1
in	O	O
95%	O	O
of	O	O
65	O	O
specimens	O	O
at	O	O
week	O	O
18	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Bilateral	B-Disease	D009901
optic	I-Disease	D009901
neuropathy	I-Disease	D009901
due	O	O
to	O	O
combined	O	O
ethambutol	B-Chemical	D004977
and	O	O
isoniazid	B-Chemical	D007538
treatment	O	O
.	O	O

The	O	O
case	O	O
of	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
who	O	O
underwent	O	O
an	O	O
unsuccessful	O	O
cadaver	O	O
kidney	O	O
transplantation	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
ethambutol	B-Chemical	D004977
and	O	O
isoniazid	B-Chemical	D007538
is	O	O
reported	O	O
.	O	O

A	O	O
bilateral	B-Disease	D009901
retrobulbar	I-Disease	D009901
neuropathy	I-Disease	D009901
with	O	O
an	O	O
unusual	O	O
central	O	O
bitemporal	O	O
hemianopic	O	O
scotoma	B-Disease	D012607
was	O	O
found	O	O
.	O	O

Ethambutol	B-Chemical	D004977
was	O	O
stopped	O	O
and	O	O
only	O	O
small	O	O
improvement	O	O
of	O	O
the	O	O
visual	O	O
acuity	O	O
followed	O	O
.	O	O

Isoniazid	B-Chemical	D007538
was	O	O
discontinued	O	O
later	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
dramatic	O	O
improvement	O	O
in	O	O
the	O	O
visual	O	O
acuity	O	O
.	O	O

The	O	O
hazards	O	O
of	O	O
optic	O	O
nerve	O	O
toxicity	B-Disease	D064420
due	O	O
to	O	O
ethambutol	B-Chemical	D004977
are	O	O
known	O	O
.	O	O

We	O	O
emphasize	O	O
the	O	O
potential	O	O
danger	O	O
in	O	O
the	O	O
use	O	O
of	O	O
ethambutol	B-Chemical	D004977
and	O	O
isoniazid	B-Chemical	D007538
.	O	O

Progestational	O	O
agents	O	O
and	O	O
blood	B-Disease	D001778
coagulation	I-Disease	D001778
.	O	O

VII	O	O
.	O	O

Thromboembolic	B-Disease	D013923
and	O	O
other	O	O
complications	O	O
of	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
therapy	O	O
in	O	O
relationship	O	O
to	O	O
pretreatment	O	O
levels	O	O
of	O	O
blood	B-Disease	D001778
coagulation	I-Disease	D001778
factors	O	O
:	O	O
summary	O	O
report	O	O
of	O	O
a	O	O
ten	O	O
-	O	O
year	O	O
study	O	O
.	O	O

During	O	O
a	O	O
ten	O	O
-	O	O
year	O	O
period	O	O
,	O	O
348	O	O
women	O	O
were	O	O
studied	O	O
for	O	O
a	O	O
total	O	O
of	O	O
5	O	O
,	O	O
877	O	O
patient	O	O
months	O	O
in	O	O
four	O	O
separate	O	O
studies	O	O
relating	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
to	O	O
changes	O	O
in	O	O
hematologic	O	O
parameters	O	O
.	O	O

Significant	O	O
increases	O	O
in	O	O
certain	O	O
factors	O	O
of	O	O
the	O	O
blood	B-Disease	D001778
coagulation	I-Disease	D001778
and	O	O
fibrinolysin	O	O
systems	O	O
(	O	O
factors	O	O
I	O	O
,	O	O
II	O	O
,	O	O
VII	O	O
,	O	O
VIII	O	O
,	O	O
IX	O	O
,	O	O
and	O	O
X	O	O
and	O	O
plasminogen	O	O
)	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
treated	O	O
groups	O	O
.	O	O

Severe	O	O
complications	O	O
developed	O	O
in	O	O
four	O	O
patients	O	O
.	O	O

All	O	O
four	O	O
had	O	O
an	O	O
abnormal	O	O
blood	B-Disease	D001778
coagulation	I-Disease	D001778
profile	O	O
,	O	O
suggesting	O	O
"hypercoagulability"	O	O
before	O	O
initiation	O	O
of	O	O
therapy	O	O
.	O	O

Some	O	O
of	O	O
these	O	O
findings	O	O
represented	O	O
the	O	O
most	O	O
extreme	O	O
abnormalities	O	O
seen	O	O
in	O	O
the	O	O
entire	O	O
group	O	O
of	O	O
patients	O	O
;	O	O
some	O	O
increased	O	O
further	O	O
during	O	O
therapy	O	O
.	O	O

One	O	O
of	O	O
these	O	O
patients	O	O
developed	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
before	O	O
receiving	O	O
any	O	O
medication	O	O
,	O	O
shortly	O	O
after	O	O
the	O	O
base	O	O
-	O	O
line	O	O
values	O	O
were	O	O
obtained	O	O
.	O	O

One	O	O
patient	O	O
developed	O	O
retinopathy	B-Disease	D012164
19	O	O
months	O	O
after	O	O
she	O	O
began	O	O
therapy	O	O
,	O	O
and	O	O
another	O	O
developed	O	O
thrombophlebitis	B-Disease	D013924
after	O	O
27	O	O
months	O	O
of	O	O
therapy	O	O
.	O	O

The	O	O
fourth	O	O
patient	O	O
developed	O	O
thrombophlebitis	B-Disease	D013924
14	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
contraceptive	O	O
therapy	O	O
.	O	O

All	O	O
four	O	O
patients	O	O
were	O	O
of	O	O
the	O	O
A	O	O
or	O	O
AB	O	O
blood	O	O
group	O	O
.	O	O

Previous	O	O
studies	O	O
suggested	O	O
the	O	O
possiblility	O	O
of	O	O
increased	O	O
propensity	O	O
for	O	O
thromboembolic	B-Disease	D013923
episodes	I-Disease	D013923
in	O	O
patients	O	O
possessing	O	O
the	O	O
A	O	O
antigen	O	O
.	O	O

It	O	O
appears	O	O
from	O	O
these	O	O
data	O	O
that	O	O
hematologic	O	O
work	O	O
-	O	O
ups	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
women	O	O
who	O	O
are	O	O
about	O	O
to	O	O
start	O	O
long	O	O
-	O	O
term	O	O
oral	B-Chemical	D003276
contraceptive	I-Chemical	D003276
therapy	O	O
.	O	O

Cardiac	B-Disease	D006323
arrest	I-Disease	D006323
in	O	O
a	O	O
child	O	O
with	O	O
cerebral	B-Disease	D002547
palsy	I-Disease	D002547
undergoing	O	O
sevoflurane	B-Chemical	C009250
induction	O	O
of	O	O
anesthesia	O	O
after	O	O
preoperative	O	O
clonidine	B-Chemical	D003000
.	O	O

Clonidine	B-Chemical	D003000
is	O	O
a	O	O
frequently	O	O
administered	O	O
alpha2	O	O
-	O	O
adrenergic	O	O
agonist	O	O
which	O	O
can	O	O
decrease	O	O
heart	O	O
rate	O	O
and	O	O
blood	O	O
pressure	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
child	O	O
with	O	O
cerebral	B-Disease	D002547
palsy	I-Disease	D002547
and	O	O
seizure	B-Disease	D004827
disorder	I-Disease	D004827
,	O	O
receiving	O	O
clonidine	B-Chemical	D003000
for	O	O
restlessness	B-Disease	D011595
,	O	O
who	O	O
presented	O	O
for	O	O
placement	O	O
of	O	O
a	O	O
baclofen	B-Chemical	D001418
pump	O	O
.	O	O

Without	O	O
the	O	O
knowledge	O	O
of	O	O
the	O	O
medical	O	O
personnel	O	O
,	O	O
the	O	O
patient's	O	O
mother	O	O
administered	O	O
three	O	O
doses	O	O
of	O	O
clonidine	B-Chemical	D003000
during	O	O
the	O	O
evening	O	O
before	O	O
and	O	O
morning	O	O
of	O	O
surgery	O	O
to	O	O
reduce	O	O
anxiety	B-Disease	D001008
.	O	O

During	O	O
induction	O	O
of	O	O
anesthesia	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
bradycardia	B-Disease	D001919
and	O	O
hypotension	B-Disease	D007022
requiring	O	O
cardiac	O	O
resuscitation	O	O
.	O	O

There	O	O
are	O	O
no	O	O
previous	O	O
reports	O	O
of	O	O
clonidine	B-Chemical	D003000
-	O	O
associated	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
in	O	O
a	O	O
child	O	O
undergoing	O	O
induction	O	O
of	O	O
anesthesia	O	O
.	O	O

Effects	O	O
of	O	O
UMB24	B-Chemical	C519696
and	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
SM	B-Chemical	C107044
21	I-Chemical	C107044
,	O	O
putative	O	O
sigma2	O	O
-	O	O
preferring	O	O
antagonists	O	O
,	O	O
on	O	O
behavioral	O	O
toxic	O	O
and	O	O
stimulant	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
in	O	O
mice	O	O
.	O	O

Earlier	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
antagonism	O	O
of	O	O
sigma1	O	O
receptors	O	O
attenuates	O	O
the	O	O
convulsive	B-Disease	D012640
,	O	O
lethal	O	O
,	O	O
locomotor	O	O
stimulatory	O	O
and	O	O
rewarding	O	O
actions	O	O
of	O	O
cocaine	B-Chemical	D003042
in	O	O
mice	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
contribution	O	O
of	O	O
sigma2	O	O
receptors	O	O
is	O	O
unclear	O	O
because	O	O
experimental	O	O
tools	O	O
to	O	O
selectively	O	O
target	O	O
this	O	O
subtype	O	O
are	O	O
unavailable	O	O
.	O	O

To	O	O
begin	O	O
addressing	O	O
this	O	O
need	O	O
,	O	O
we	O	O
characterized	O	O
UMB24	B-Chemical	C519696
(	O	O
1	B-Chemical	C519696
-	I-Chemical	C519696
(	I-Chemical	C519696
2	I-Chemical	C519696
-	I-Chemical	C519696
phenethyl	I-Chemical	C519696
)	I-Chemical	C519696
-	I-Chemical	C519696
4	I-Chemical	C519696
-	I-Chemical	C519696
(	I-Chemical	C519696
2	I-Chemical	C519696
-	I-Chemical	C519696
pyridyl	I-Chemical	C519696
)	I-Chemical	C519696
-	I-Chemical	C519696
piperazine	I-Chemical	C519696
)	O	O
and	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
SM	B-Chemical	C107044
21	I-Chemical	C107044
(	O	O
3alpha	B-Chemical	C107044
-	I-Chemical	C107044
tropanyl	I-Chemical	C107044
-	I-Chemical	C107044
2	I-Chemical	C107044
-	I-Chemical	C107044
(	I-Chemical	C107044
4	I-Chemical	C107044
-	I-Chemical	C107044
chorophenoxy	I-Chemical	C107044
)	I-Chemical	C107044
butyrate	I-Chemical	C107044
)	O	O
in	O	O
receptor	O	O
binding	O	O
and	O	O
behavioral	O	O
studies	O	O
.	O	O

Receptor	O	O
binding	O	O
studies	O	O
confirmed	O	O
that	O	O
UMB24	B-Chemical	C519696
and	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
SM	B-Chemical	C107044
21	I-Chemical	C107044
display	O	O
preferential	O	O
affinity	O	O
for	O	O
sigma2	O	O
over	O	O
sigma1	O	O
receptors	O	O
.	O	O

In	O	O
behavioral	O	O
studies	O	O
,	O	O
pretreatment	O	O
of	O	O
Swiss	O	O
Webster	O	O
mice	O	O
with	O	O
UMB24	B-Chemical	C519696
or	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
SM	B-Chemical	C107044
21	I-Chemical	C107044
significantly	O	O
attenuated	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
locomotor	O	O
activity	O	O
,	O	O
but	O	O
not	O	O
lethality	O	O
.	O	O

When	O	O
administered	O	O
alone	O	O
,	O	O
(	O	O
+	O	O
/	O	O
-	O	O
)	O	O
-	O	O
SM	B-Chemical	C107044
21	I-Chemical	C107044
produced	O	O
no	O	O
significant	O	O
effects	O	O
compared	O	O
to	O	O
control	O	O
injections	O	O
of	O	O
saline	O	O
,	O	O
but	O	O
UMB24	B-Chemical	C519696
had	O	O
locomotor	O	O
depressant	O	O
actions	O	O
.	O	O

Together	O	O
,	O	O
the	O	O
data	O	O
suggest	O	O
that	O	O
sigma2	O	O
receptor	O	O
antagonists	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
attenuate	O	O
some	O	O
of	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
,	O	O
and	O	O
further	O	O
development	O	O
of	O	O
more	O	O
selective	O	O
,	O	O
high	O	O
affinity	O	O
ligands	O	O
are	O	O
warranted	O	O
.	O	O

Methimazole	B-Chemical	D008713
-	O	O
induced	O	O
cholestatic	B-Disease	D041781
jaundice	I-Disease	D041781
.	O	O

Methimazole	B-Chemical	D008713
is	O	O
a	O	O
widely	O	O
used	O	O
and	O	O
generally	O	O
well	O	O
-	O	O
tolerated	O	O
antithyroid	O	O
agent	O	O
.	O	O

A	O	O
43	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
had	O	O
severe	O	O
jaundice	B-Disease	D007565
and	O	O
itching	B-Disease	D011537
1	O	O
month	O	O
after	O	O
receiving	O	O
methimazole	B-Chemical	D008713
(	O	O
10	O	O
mg	O	O
tid	O	O
)	O	O
and	O	O
propranolol	B-Chemical	D011433
(	O	O
20	O	O
mg	O	O
tid	O	O
)	O	O
for	O	O
treatment	O	O
of	O	O
hyperthyroidism	B-Disease	D006980
.	O	O

The	O	O
patient	O	O
continued	O	O
treatment	O	O
for	O	O
another	O	O
4	O	O
days	O	O
after	O	O
the	O	O
appearance	O	O
of	O	O
jaundice	B-Disease	D007565
until	O	O
she	O	O
finished	O	O
both	O	O
medications	O	O
.	O	O

When	O	O
seen	O	O
at	O	O
the	O	O
emergency	O	O
department	O	O
2	O	O
weeks	O	O
later	O	O
,	O	O
she	O	O
still	O	O
had	O	O
severe	O	O
icterus	B-Disease	D007565
,	O	O
pruritus	B-Disease	D011537
,	O	O
and	O	O
hyperbilirubinemia	B-Disease	D006932
,	O	O
formed	O	O
mainly	O	O
of	O	O
the	O	O
conjugated	O	O
fraction	O	O
.	O	O

Methimazole	B-Chemical	D008713
-	O	O
induced	O	O
cholestasis	B-Disease	D002779
was	O	O
diagnosed	O	O
,	O	O
and	O	O
propranolol	B-Chemical	D011433
therapy	O	O
was	O	O
resumed	O	O
.	O	O

Over	O	O
the	O	O
following	O	O
9	O	O
days	O	O
,	O	O
the	O	O
symptoms	O	O
improved	O	O
and	O	O
plasma	O	O
bilirubin	B-Chemical	D001663
levels	O	O
were	O	O
normal	O	O
after	O	O
12	O	O
weeks	O	O
without	O	O
methimazole	B-Chemical	D008713
.	O	O

In	O	O
rare	O	O
cases	O	O
within	O	O
the	O	O
first	O	O
few	O	O
weeks	O	O
of	O	O
therapy	O	O
,	O	O
this	O	O
drug	O	O
can	O	O
cause	O	O
severe	O	O
and	O	O
reversible	O	O
cholestatic	B-Disease	D041781
jaundice	I-Disease	D041781
.	O	O

Physicians	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
adverse	O	O
effect	O	O
so	O	O
that	O	O
,	O	O
upon	O	O
occurrence	O	O
,	O	O
they	O	O
can	O	O
discontinue	O	O
methimazole	B-Chemical	D008713
therapy	O	O
and	O	O
avoid	O	O
unnecessary	O	O
invasive	O	O
procedures	O	O
.	O	O

Ciprofloxacin	B-Chemical	D002939
-	O	O
induced	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
and	O	O
autoimmune	B-Disease	D000744
hemolytic	I-Disease	D000744
anemia	I-Disease	D000744
.	O	O

Ciprofloxacin	B-Chemical	D002939
has	O	O
been	O	O
associated	O	O
with	O	O
several	O	O
side	O	O
effects	O	O
including	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
and	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

The	O	O
combination	O	O
of	O	O
both	O	O
side	O	O
effects	O	O
is	O	O
extremely	O	O
rare	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
ciprofloxacin	B-Chemical	D002939
-	O	O
induced	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
and	O	O
autoimmune	B-Disease	D000744
hemolytic	I-Disease	D000744
anemia	I-Disease	D000744
.	O	O

Hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
improved	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
and	O	O
initiation	O	O
of	O	O
steroid	B-Chemical	D013256
therapy	O	O
.	O	O

Unfortunately	O	O
,	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
was	O	O
irreversible	O	O
and	O	O
the	O	O
patient	O	O
developed	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
.	O	O

Contribution	O	O
of	O	O
sodium	B-Chemical	D014635
valproate	I-Chemical	D014635
to	O	O
the	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
secretion	I-Disease	D007177
of	I-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
62	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
was	O	O
administered	O	O
sodium	B-Chemical	D014635
valproate	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
and	O	O
who	O	O
subsequently	O	O
developed	O	O
the	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
secretion	I-Disease	D007177
of	I-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
(	O	O
SIADH	B-Disease	D007177
)	O	O
.	O	O

He	O	O
had	O	O
been	O	O
taking	O	O
VPA	B-Chemical	D014635
for	O	O
treatment	O	O
of	O	O
idiopathic	O	O
generalized	O	O
tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
convulsions	I-Disease	D004830
since	O	O
he	O	O
was	O	O
56	O	O
years	O	O
old	O	O
.	O	O

After	O	O
substituting	O	O
VPA	B-Chemical	D014635
with	O	O
zonisamide	B-Chemical	C022189
,	O	O
the	O	O
serum	O	O
sodium	B-Chemical	D012964
level	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

We	O	O
consider	O	O
this	O	O
episode	O	O
of	O	O
SIADH	B-Disease	D007177
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
a	O	O
combination	O	O
of	O	O
factors	O	O
including	O	O
a	O	O
weakness	B-Disease	D002493
of	I-Disease	D002493
the	I-Disease	D002493
central	I-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
and	O	O
the	O	O
long	O	O
-	O	O
term	O	O
administration	O	O
of	O	O
VPA	B-Chemical	D014635
.	O	O

Vasopressin	B-Chemical	D014667
in	O	O
the	O	O
treatment	O	O
of	O	O
milrinone	B-Chemical	D020105
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
severe	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

The	O	O
use	O	O
of	O	O
phosphodiesterase	O	O
inhibitors	O	O
such	O	O
as	O	O
milrinone	B-Chemical	D020105
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
is	O	O
frequently	O	O
restricted	O	O
because	O	O
they	O	O
cause	O	O
vasodilation	O	O
and	O	O
hypotension	B-Disease	D007022
.	O	O

In	O	O
patients	O	O
with	O	O
decompensated	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
with	O	O
hypotension	B-Disease	D007022
after	O	O
treatment	O	O
with	O	O
milrinone	B-Chemical	D020105
,	O	O
low	O	O
doses	O	O
of	O	O
vasopressin	B-Chemical	D014667
restored	O	O
blood	O	O
pressure	O	O
without	O	O
inhibiting	O	O
the	O	O
inotropic	O	O
effect	O	O
of	O	O
milrinone	B-Chemical	D020105
.	O	O

Halogenated	O	O
anesthetics	O	O
form	O	O
liver	O	O
adducts	O	O
and	O	O
antigens	O	O
that	O	O
cross	O	O
-	O	O
react	O	O
with	O	O
halothane	B-Chemical	D006221
-	O	O
induced	O	O
antibodies	O	O
.	O	O

Two	O	O
halogenated	O	O
anesthetics	O	O
,	O	O
enflurane	B-Chemical	D004737
and	O	O
isoflurane	B-Chemical	D007530
,	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
an	O	O
allergic	O	O
-	O	O
type	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
both	O	O
alone	O	O
and	O	O
following	O	O
previous	O	O
exposure	O	O
to	O	O
halothane	B-Chemical	D006221
.	O	O

Halothane	B-Chemical	D006221
hepatitis	B-Disease	D056486
appears	O	O
to	O	O
involve	O	O
an	O	O
aberrant	O	O
immune	O	O
response	O	O
.	O	O

An	O	O
antibody	O	O
response	O	O
to	O	O
a	O	O
protein	O	O
-	O	O
bound	O	O
biotransformation	O	O
product	O	O
(	O	O
trifluoroacetyl	B-Chemical	D014269
adduct	O	O
)	O	O
has	O	O
been	O	O
detected	O	O
on	O	O
halothane	B-Chemical	D006221
hepatitis	B-Disease	D056486
patients	O	O
.	O	O

This	O	O
study	O	O
was	O	O
performed	O	O
to	O	O
determine	O	O
cross	O	O
-	O	O
reactivity	O	O
between	O	O
enflurane	B-Chemical	D004737
and	O	O
isoflurane	B-Chemical	D007530
with	O	O
the	O	O
hypersensitivity	B-Disease	D004342
induced	O	O
by	O	O
halothane	B-Chemical	D006221
.	O	O

The	O	O
subcellular	O	O
and	O	O
lobular	O	O
production	O	O
of	O	O
hepatic	O	O
neoantigens	O	O
recognized	O	O
by	O	O
halothane	B-Chemical	D006221
-	O	O
induced	O	O
antibodies	O	O
following	O	O
enflurane	B-Chemical	D004737
and	O	O
isoflurane	B-Chemical	D007530
,	O	O
and	O	O
the	O	O
biochemical	O	O
nature	O	O
of	O	O
these	O	O
neoantigens	O	O
was	O	O
investigated	O	O
in	O	O
two	O	O
animal	O	O
models	O	O
.	O	O

Enflurane	B-Chemical	D004737
administration	O	O
resulted	O	O
in	O	O
neoantigens	O	O
detected	O	O
in	O	O
both	O	O
the	O	O
microsomal	O	O
and	O	O
cytosolic	O	O
fraction	O	O
of	O	O
liver	O	O
homogenates	O	O
and	O	O
in	O	O
the	O	O
centrilobular	O	O
region	O	O
of	O	O
the	O	O
liver	O	O
.	O	O

In	O	O
the	O	O
same	O	O
liver	O	O
,	O	O
biochemical	O	O
analysis	O	O
detected	O	O
fluorinated	O	O
liver	O	O
adducts	O	O
that	O	O
were	O	O
up	O	O
to	O	O
20	O	O
-	O	O
fold	O	O
greater	O	O
in	O	O
guinea	O	O
pigs	O	O
than	O	O
in	O	O
rats	O	O
.	O	O

This	O	O
supports	O	O
and	O	O
extends	O	O
previous	O	O
evidence	O	O
for	O	O
a	O	O
mechanism	O	O
by	O	O
which	O	O
enflurane	B-Chemical	D004737
and	O	O
/	O	O
or	O	O
isoflurane	B-Chemical	D007530
could	O	O
produce	O	O
a	O	O
hypersensitivity	B-Disease	D004342
condition	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
halothane	B-Chemical	D006221
hepatitis	B-Disease	D056486
either	O	O
alone	O	O
or	O	O
subsequent	O	O
to	O	O
halothane	B-Chemical	D006221
administration	O	O
.	O	O

The	O	O
guinea	O	O
pig	O	O
would	O	O
appear	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
model	O	O
for	O	O
further	O	O
investigations	O	O
of	O	O
the	O	O
immunological	O	O
response	O	O
to	O	O
these	O	O
antigens	O	O
.	O	O

Induction	O	O
by	O	O
paracetamol	B-Chemical	D000082
of	O	O
bladder	O	O
and	O	O
liver	O	O
tumours	B-Disease	D009369
in	O	O
the	O	O
rat	O	O
.	O	O

Effects	O	O
on	O	O
hepatocyte	O	O
fine	O	O
structure	O	O
.	O	O

Groups	O	O
of	O	O
male	O	O
and	O	O
female	O	O
inbred	O	O
Leeds	O	O
strain	O	O
rats	O	O
were	O	O
fed	O	O
diets	O	O
containing	O	O
either	O	O
0	O	O
.	O	O

5%	O	O
or	O	O
1	O	O
.	O	O

0%	O	O
paracetamol	B-Chemical	D000082
by	O	O
weight	O	O
for	O	O
up	O	O
to	O	O
18	O	O
months	O	O
.	O	O

At	O	O
the	O	O
1	O	O
.	O	O

0%	O	O
dosage	O	O
level	O	O
,	O	O
20%	O	O
of	O	O
rats	O	O
of	O	O
both	O	O
sexes	O	O
developed	O	O
neoplastic	O	O
nodules	O	O
of	O	O
the	O	O
liver	O	O
,	O	O
a	O	O
statistically	O	O
significant	O	O
incidence	O	O
.	O	O

These	O	O
rats	O	O
also	O	O
showed	O	O
gross	O	O
enlargement	O	O
of	O	O
their	O	O
livers	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
foci	O	O
of	O	O
cellular	O	O
alteration	O	O
,	O	O
the	O	O
latter	O	O
also	O	O
being	O	O
observed	O	O
in	O	O
the	O	O
low	O	O
dosage	O	O
male	O	O
rats	O	O
.	O	O

Papillomas	B-Disease	D010212
of	O	O
the	O	O
transitional	O	O
epithelium	O	O
of	O	O
the	O	O
bladder	O	O
developed	O	O
in	O	O
all	O	O
paracetamol	B-Chemical	D000082
-	O	O
treated	O	O
groups	O	O
,	O	O
and	O	O
three	O	O
rats	O	O
bore	O	O
bladder	B-Disease	D001749
carcinomas	I-Disease	D001749
.	O	O

However	O	O
,	O	O
significant	O	O
yields	O	O
of	O	O
bladder	B-Disease	D001749
tumours	I-Disease	D001749
were	O	O
only	O	O
obtained	O	O
from	O	O
low	O	O
dosage	O	O
females	O	O
and	O	O
high	O	O
dosage	O	O
males	O	O
.	O	O

Additionally	O	O
,	O	O
20	O	O
to	O	O
25%	O	O
of	O	O
paracetamol	B-Chemical	D000082
-	O	O
treated	O	O
rats	O	O
developed	O	O
hyperplasia	B-Disease	D006965
of	O	O
the	O	O
bladder	O	O
epithelium	O	O
,	O	O
which	O	O
was	O	O
not	O	O
coincident	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
bladder	B-Disease	D001744
calculi	I-Disease	D001744
.	O	O

A	O	O
low	O	O
yield	O	O
of	O	O
tumours	B-Disease	D009369
at	O	O
various	O	O
other	O	O
sites	O	O
also	O	O
arose	O	O
following	O	O
paracetamol	B-Chemical	D000082
feeding	O	O
.	O	O

An	O	O
electron	O	O
microscope	O	O
study	O	O
of	O	O
the	O	O
livers	O	O
of	O	O
paracetamol	B-Chemical	D000082
-	O	O
treated	O	O
rats	O	O
revealed	O	O
ultrastructural	O	O
changes	O	O
in	O	O
the	O	O
hepatocytes	O	O
that	O	O
resemble	O	O
those	O	O
that	O	O
result	O	O
from	O	O
exposure	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
known	O	O
hepatocarcinogens	B-Disease	D008113
.	O	O

Rat	O	O
extraocular	O	O
muscle	O	O
regeneration	O	O
.	O	O

Repair	O	O
of	O	O
local	O	O
anesthetic	O	O
-	O	O
induced	O	O
damage	O	O
.	O	O

Local	O	O
anesthetics	O	O
that	O	O
are	O	O
commonly	O	O
used	O	O
in	O	O
ophthalmic	O	O
surgery	O	O
(	O	O
0	O	O
.	O	O

75%	O	O
bupivacaine	B-Chemical	D002045
hydrochloride	I-Chemical	D002045
,	O	O
2	O	O
.	O	O

0%	O	O
mepivacaine	B-Chemical	D008619
hydrochloride	I-Chemical	D008619
,	O	O
and	O	O
2	O	O
.	O	O

0%	O	O
lidocaine	B-Chemical	D008012
hydrochloride	I-Chemical	D008012
plus	O	O
1	O	O
:	O	O
100	O	O
,	O	O
000	O	O
epinephrine	B-Chemical	D004837
)	O	O
were	O	O
injected	O	O
into	O	O
the	O	O
retrobulbar	O	O
area	O	O
of	O	O
rat	O	O
eyes	O	O
.	O	O

Controls	O	O
were	O	O
injected	O	O
with	O	O
physiological	O	O
saline	O	O
.	O	O

All	O	O
three	O	O
anesthetics	O	O
produced	O	O
massive	O	O
degeneration	O	O
of	O	O
the	O	O
extraocular	O	O
muscles	O	O
.	O	O

Muscle	B-Disease	D009135
degeneration	I-Disease	D009135
is	O	O
followed	O	O
by	O	O
regeneration	O	O
of	O	O
the	O	O
damaged	O	O
muscle	O	O
fibers	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
muscle	B-Disease	D009135
damage	I-Disease	D009135
,	O	O
severe	O	O
damage	O	O
was	O	O
also	O	O
seen	O	O
in	O	O
harderian	O	O
glands	O	O
,	O	O
especially	O	O
after	O	O
exposure	O	O
to	O	O
mepivacaine	B-Chemical	D008619
and	O	O
lidocaine	B-Chemical	D008012
plus	O	O
epinephrine	B-Chemical	D004837
.	O	O

With	O	O
these	O	O
findings	O	O
in	O	O
rats	O	O
,	O	O
it	O	O
is	O	O
hypothesized	O	O
that	O	O
the	O	O
temporary	O	O
diplopia	B-Disease	D004172
sometimes	O	O
seen	O	O
in	O	O
patients	O	O
after	O	O
ophthalmic	O	O
surgery	O	O
might	O	O
be	O	O
due	O	O
to	O	O
anesthetic	O	O
-	O	O
induced	O	O
damage	O	O
to	O	O
the	O	O
extraocular	O	O
muscles	O	O
.	O	O

Reversal	O	O
of	O	O
neuroleptic	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
by	O	O
novel	O	O
aryl	B-Chemical	-1
-	I-Chemical	-1
piperazine	I-Chemical	-1
anxiolytic	O	O
drugs	O	O
.	O	O

The	O	O
novel	O	O
anxiolytic	O	O
drug	O	O
,	O	O
buspirone	B-Chemical	D002065
,	O	O
reverses	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
.	O	O

A	O	O
series	O	O
of	O	O
aryl	B-Chemical	-1
-	I-Chemical	-1
piperazine	I-Chemical	-1
analogues	O	O
of	O	O
buspirone	B-Chemical	D002065
and	O	O
other	O	O
5	B-Chemical	D058825
-	I-Chemical	D058825
hydroxytryptaminergic	I-Chemical	D058825
agonists	I-Chemical	D058825
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
reverse	O	O
haloperidol	B-Chemical	D006220
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

Those	O	O
drugs	O	O
with	O	O
strong	O	O
affinity	O	O
for	O	O
5	O	O
-	O	O
hydroxytryptamine1a	O	O
receptors	O	O
were	O	O
able	O	O
to	O	O
reverse	O	O
catalepsy	B-Disease	D002375
.	O	O

Drugs	O	O
with	O	O
affinity	O	O
for	O	O
other	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
receptors	O	O
or	O	O
weak	O	O
affinity	O	O
were	O	O
ineffective	O	O
.	O	O

However	O	O
,	O	O
inhibition	O	O
of	O	O
postsynaptic	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
receptors	O	O
neither	O	O
inhibited	O	O
nor	O	O
potentiated	O	O
reversal	O	O
of	O	O
catalepsy	B-Disease	D002375
and	O	O
leaves	O	O
open	O	O
the	O	O
question	O	O
as	O	O
to	O	O
the	O	O
site	O	O
or	O	O
mechanism	O	O
for	O	O
this	O	O
effect	O	O
.	O	O

Diazepam	B-Chemical	D003975
facilitates	O	O
reflex	O	O
bradycardia	B-Disease	D001919
in	O	O
conscious	O	O
rats	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
diazepam	B-Chemical	D003975
on	O	O
cardiovascular	O	O
function	O	O
were	O	O
assessed	O	O
in	O	O
conscious	O	O
rats	O	O
.	O	O

Intravenous	O	O
administration	O	O
of	O	O
diazepam	B-Chemical	D003975
(	O	O
1	O	O
-	O	O
30	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
)	O	O
produced	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
both	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
and	O	O
the	O	O
heart	O	O
rate	O	O
.	O	O

Also	O	O
,	O	O
reflex	O	O
bradycardia	B-Disease	D001919
was	O	O
produced	O	O
in	O	O
rats	O	O
by	O	O
intravenous	O	O
infusion	O	O
of	O	O
adrenaline	B-Chemical	D004837
(	O	O
1	O	O
.	O	O

25	O	O
-	O	O
2	O	O
.	O	O

5	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Intravenous	O	O
pretreatment	O	O
of	O	O
the	O	O
rats	O	O
with	O	O
diazepam	B-Chemical	D003975
,	O	O
although	O	O
causing	O	O
no	O	O
change	O	O
in	O	O
the	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
pressor	O	O
effect	O	O
,	O	O
did	O	O
enhance	O	O
the	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
reflex	O	O
bradycardia	B-Disease	D001919
.	O	O

However	O	O
,	O	O
the	O	O
diazepam	B-Chemical	D003975
enhancement	O	O
of	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
reflex	O	O
bradycardia	B-Disease	D001919
was	O	O
antagonized	O	O
by	O	O
pretreatment	O	O
of	O	O
rats	O	O
with	O	O
an	O	O
intravenous	O	O
dose	O	O
of	O	O
picrotoxin	B-Chemical	D010852
(	O	O
an	O	O
agent	O	O
blocks	O	O
chloride	B-Chemical	D002712
channels	O	O
by	O	O
binding	O	O
to	O	O
sites	O	O
associated	O	O
with	O	O
the	O	O
benzodiazepine	B-Chemical	D001569
-	O	O
GABA	B-Chemical	D005680
-	O	O
chloride	B-Chemical	D002712
channel	O	O
macromolecular	O	O
complex	O	O
)	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
diazepam	B-Chemical	D003975
acts	O	O
through	O	O
the	O	O
benzodiazepine	B-Chemical	D001569
-	O	O
GABA	B-Chemical	D005680
-	O	O
chloride	B-Chemical	D002712
channel	O	O
macromolecular	O	O
complex	O	O
within	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
to	O	O
facilitate	O	O
reflex	O	O
bradycardia	B-Disease	D001919
mediated	O	O
through	O	O
baroreceptor	O	O
reflexes	O	O
in	O	O
response	O	O
to	O	O
an	O	O
acute	O	O
increase	O	O
in	O	O
arterial	O	O
pressure	O	O
.	O	O

Chronic	O	O
carbamazepine	B-Chemical	D002220
inhibits	O	O
the	O	O
development	O	O
of	O	O
local	O	O
anesthetic	O	O
seizures	B-Disease	D012640
kindled	O	O
by	O	O
cocaine	B-Chemical	D003042
and	O	O
lidocaine	B-Chemical	D008012
.	O	O

The	O	O
effects	O	O
of	O	O
carbamazepine	B-Chemical	D002220
(	O	O
CBZ	B-Chemical	D002220
)	O	O
treatment	O	O
on	O	O
local	O	O
anesthetic	O	O
-	O	O
kindled	O	O
seizures	B-Disease	D012640
and	O	O
lethality	O	O
were	O	O
evaluated	O	O
in	O	O
different	O	O
stages	O	O
of	O	O
the	O	O
kindling	O	O
process	O	O
and	O	O
under	O	O
different	O	O
methods	O	O
of	O	O
CBZ	B-Chemical	D002220
administration	O	O
.	O	O

Chronic	O	O
oral	O	O
CBZ	B-Chemical	D002220
inhibited	O	O
the	O	O
development	O	O
of	O	O
both	O	O
lidocaine	B-Chemical	D008012
-	O	O
and	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
,	O	O
but	O	O
had	O	O
little	O	O
effect	O	O
on	O	O
the	O	O
fully	O	O
developed	O	O
local	O	O
anesthetic	O	O
seizures	B-Disease	D012640
.	O	O

Chronic	O	O
CBZ	B-Chemical	D002220
also	O	O
decreased	O	O
the	O	O
incidence	O	O
of	O	O
seizure	B-Disease	D012640
-	O	O
related	O	O
mortality	O	O
in	O	O
the	O	O
cocaine	B-Chemical	D003042
-	O	O
injected	O	O
rats	O	O
.	O	O

Acute	O	O
CBZ	B-Chemical	D002220
over	O	O
a	O	O
range	O	O
of	O	O
doses	O	O
(	O	O
15	O	O
-	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
completed	O	O
lidocaine	B-Chemical	D008012
-	O	O
kindled	O	O
or	O	O
acute	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Repeated	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injection	O	O
of	O	O
CBZ	B-Chemical	D002220
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
also	O	O
was	O	O
without	O	O
effect	O	O
on	O	O
the	O	O
development	O	O
of	O	O
lidocaine	B-Chemical	D008012
-	O	O
or	O	O
cocaine	B-Chemical	D003042
-	O	O
kindled	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
differential	O	O
effects	O	O
of	O	O
CBZ	B-Chemical	D002220
depending	O	O
upon	O	O
stage	O	O
of	O	O
seizure	B-Disease	D012640
development	O	O
suggest	O	O
that	O	O
distinct	O	O
mechanisms	O	O
underlie	O	O
the	O	O
development	O	O
versus	O	O
maintenance	O	O
of	O	O
local	O	O
anesthetic	O	O
-	O	O
kindled	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
effectiveness	O	O
of	O	O
chronic	O	O
but	O	O
not	O	O
repeated	O	O
,	O	O
intermittent	O	O
injections	O	O
of	O	O
CBZ	B-Chemical	D002220
suggests	O	O
that	O	O
different	O	O
biochemical	O	O
consequences	O	O
result	O	O
from	O	O
the	O	O
different	O	O
treatment	O	O
regimens	O	O
.	O	O

The	O	O
possible	O	O
utility	O	O
of	O	O
chronic	O	O
CBZ	B-Chemical	D002220
in	O	O
preventing	O	O
the	O	O
development	O	O
of	O	O
toxic	O	O
side	O	O
effects	O	O
in	O	O
human	O	O
cocaine	B-Chemical	D003042
users	O	O
is	O	O
suggested	O	O
by	O	O
these	O	O
data	O	O
,	O	O
but	O	O
remains	O	O
to	O	O
be	O	O
directly	O	O
evaluated	O	O
.	O	O

D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
in	O	O
the	O	O
treatment	O	O
of	O	O
localized	B-Disease	D012594
scleroderma	I-Disease	D012594
.	O	O

Localized	B-Disease	D012594
scleroderma	I-Disease	D012594
has	O	O
no	O	O
recognized	O	O
internal	O	O
organ	O	O
involvement	O	O
but	O	O
may	O	O
be	O	O
disfiguring	O	O
and	O	O
disabling	O	O
when	O	O
the	O	O
cutaneous	O	O
lesions	O	O
are	O	O
extensive	O	O
or	O	O
affect	O	O
children	O	O
.	O	O

There	O	O
is	O	O
no	O	O
accepted	O	O
or	O	O
proven	O	O
treatment	O	O
for	O	O
localized	B-Disease	D012594
scleroderma	I-Disease	D012594
.	O	O

Case	O	O
reports	O	O
of	O	O
11	O	O
patients	O	O
with	O	O
severe	O	O
,	O	O
extensive	O	O
localized	B-Disease	D012594
scleroderma	I-Disease	D012594
who	O	O
were	O	O
treated	O	O
with	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
are	O	O
summarized	O	O
in	O	O
this	O	O
article	O	O
.	O	O

This	O	O
drug	O	O
was	O	O
judged	O	O
to	O	O
have	O	O
a	O	O
favorable	O	O
effect	O	O
on	O	O
the	O	O
disease	O	O
course	O	O
in	O	O
7	O	O
(	O	O
64%	O	O
)	O	O
of	O	O
11	O	O
patients	O	O
.	O	O

Improvement	O	O
began	O	O
within	O	O
3	O	O
to	O	O
6	O	O
months	O	O
and	O	O
consisted	O	O
of	O	O
cessation	O	O
of	O	O
active	O	O
cutaneous	O	O
lesions	O	O
in	O	O
all	O	O
7	O	O
patients	O	O
,	O	O
skin	O	O
softening	O	O
in	O	O
5	O	O
,	O	O
and	O	O
more	O	O
normal	O	O
growth	O	O
of	O	O
the	O	O
affected	O	O
limb	O	O
in	O	O
2	O	O
of	O	O
3	O	O
children	O	O
.	O	O

Joint	O	O
stiffness	O	O
and	O	O
contractures	B-Disease	D003286
also	O	O
improved	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
associated	O	O
with	O	O
a	O	O
favorable	O	O
response	O	O
was	O	O
as	O	O
low	O	O
as	O	O
2	O	O
to	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
given	O	O
over	O	O
a	O	O
period	O	O
ranging	O	O
from	O	O
15	O	O
to	O	O
53	O	O
months	O	O
.	O	O

D	B-Chemical	D010396
-	I-Chemical	D010396
Penicillamine	I-Chemical	D010396
caused	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
in	O	O
1	O	O
patient	O	O
and	O	O
milder	O	O
reversible	O	O
proteinuria	B-Disease	D011507
in	O	O
3	O	O
other	O	O
patients	O	O
;	O	O
none	O	O
developed	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
may	O	O
be	O	O
effective	O	O
in	O	O
severe	O	O
cases	O	O
of	O	O
localized	B-Disease	D012594
scleroderma	I-Disease	D012594
.	O	O

Preservation	O	O
of	O	O
renal	O	O
blood	O	O
flow	O	O
during	O	O
hypotension	B-Disease	D007022
induced	O	O
with	O	O
fenoldopam	B-Chemical	D018818
in	O	O
dogs	O	O
.	O	O

The	O	O
introduction	O	O
of	O	O
drugs	O	O
that	O	O
could	O	O
induce	O	O
hypotension	B-Disease	D007022
with	O	O
different	O	O
pharmacological	O	O
actions	O	O
would	O	O
be	O	O
advantageous	O	O
because	O	O
side	O	O
effects	O	O
unique	O	O
to	O	O
a	O	O
specific	O	O
drug	O	O
could	O	O
be	O	O
minimized	O	O
by	O	O
selecting	O	O
appropriate	O	O
therapy	O	O
.	O	O

Specific	O	O
dopamine	B-Chemical	D004298
-	O	O
1	O	O
,	O	O
(	O	O
DA1	O	O
)	O	O
and	O	O
dopamine	B-Chemical	D004298
-	O	O
2	O	O
(	O	O
DA2	O	O
)	O	O
receptor	O	O
agonists	O	O
are	O	O
now	O	O
under	O	O
clinical	O	O
investigation	O	O
.	O	O

Fenoldopam	B-Chemical	D018818
mesylate	I-Chemical	D018818
is	O	O
a	O	O
specific	O	O
DA1	O	O
receptor	O	O
agonist	O	O
that	O	O
lowers	O	O
blood	O	O
pressure	O	O
by	O	O
vasodilatation	O	O
.	O	O

The	O	O
hypothesis	O	O
that	O	O
fenoldopam	B-Chemical	D018818
could	O	O
be	O	O
used	O	O
to	O	O
induce	O	O
hypotension	B-Disease	D007022
and	O	O
preserve	O	O
blood	O	O
flow	O	O
to	O	O
the	O	O
kidney	O	O
was	O	O
tested	O	O
.	O	O

Systemic	O	O
aortic	O	O
blood	O	O
pressure	O	O
and	O	O
renal	O	O
blood	O	O
flow	O	O
were	O	O
measured	O	O
continuously	O	O
with	O	O
a	O	O
carotid	O	O
arterial	O	O
catheter	O	O
and	O	O
an	O	O
electromagnetic	O	O
flow	O	O
probe	O	O
respectively	O	O
,	O	O
in	O	O
order	O	O
to	O	O
compare	O	O
the	O	O
cardiovascular	O	O
and	O	O
renal	O	O
vascular	O	O
effects	O	O
of	O	O
fenoldopam	B-Chemical	D018818
and	O	O
sodium	B-Chemical	D012964
nitroprusside	B-Chemical	D009599
in	O	O
ten	O	O
dogs	O	O
under	O	O
halothane	B-Chemical	D006221
general	O	O
anaesthesia	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
was	O	O
decreased	O	O
30	O	O
+	O	O
/	O	O
-	O	O
8	O	O
per	O	O
cent	O	O
from	O	O
control	O	O
with	O	O
infusion	O	O
of	O	O
fenoldopam	B-Chemical	D018818
(	O	O
3	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

0	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
)	O	O
and	O	O
34	O	O
+	O	O
/	O	O
-	O	O
4	O	O
per	O	O
cent	O	O
with	O	O
infusion	O	O
of	O	O
sodium	B-Chemical	D012964
nitroprusside	B-Chemical	D009599
(	O	O
5	O	O
.	O	O

9	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
)	O	O
(	O	O
NS	O	O
)	O	O
.	O	O

Renal	O	O
blood	O	O
flow	O	O
(	O	O
RBF	O	O
)	O	O
increased	O	O
during	O	O
fenoldopam	B-Chemical	D018818
-	O	O
induced	O	O
hypotension	B-Disease	D007022
11	O	O
+	O	O
/	O	O
-	O	O
7	O	O
per	O	O
cent	O	O
and	O	O
decreased	O	O
21	O	O
+	O	O
/	O	O
-	O	O
8	O	O
per	O	O
cent	O	O
during	O	O
sodium	B-Chemical	D012964
nitroprusside	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Sodium	O	O
nitroprusside	B-Chemical	D009599
is	O	O
a	O	O
non	O	O
-	O	O
selective	O	O
arteriolar	O	O
and	O	O
venous	O	O
vasodilator	O	O
that	O	O
can	O	O
produce	O	O
redistribution	O	O
of	O	O
blood	O	O
flow	O	O
away	O	O
from	O	O
the	O	O
kidney	O	O
during	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Fenoldopam	O	O
is	O	O
a	O	O
selective	O	O
dopamine	B-Chemical	D004298
-	O	O
1	O	O
(	O	O
DA1	O	O
)	O	O
receptor	O	O
agonist	O	O
that	O	O
causes	O	O
vasodilatation	O	O
to	O	O
the	O	O
kidney	O	O
and	O	O
other	O	O
organs	O	O
with	O	O
DA1	O	O
receptors	O	O
and	O	O
preserves	O	O
blood	O	O
flow	O	O
to	O	O
the	O	O
kidney	O	O
during	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

Antiarrhythmic	O	O
effects	O	O
of	O	O
optical	O	O
isomers	O	O
of	O	O
cibenzoline	B-Chemical	C032151
on	O	O
canine	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

Antiarrhythmic	O	O
effects	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
and	O	O
(	O	O
-	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
were	O	O
examined	O	O
using	O	O
two	O	O
canine	O	O
ventricular	B-Disease	D001145
arrhythmia	I-Disease	D001145
models	O	O
.	O	O

Digitalis	B-Chemical	D004070
arrhythmia	B-Disease	D001145
,	O	O
which	O	O
is	O	O
suppressed	O	O
by	O	O
Na	B-Chemical	D012964
channel	O	O
blockers	O	O
,	O	O
was	O	O
induced	O	O
by	O	O
intermittent	O	O
intravenous	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
injection	O	O
of	O	O
ouabain	B-Chemical	D010042
in	O	O
pentobarbital	B-Chemical	D010424
-	O	O
anesthetized	O	O
dogs	O	O
.	O	O

Adrenaline	B-Disease	D001145
arrhythmia	I-Disease	D001145
,	O	O
which	O	O
is	O	O
suppressed	O	O
by	O	O
Ca	B-Chemical	D002118
channel	O	O
blockers	O	O
,	O	O
was	O	O
induced	O	O
by	O	O
adrenaline	B-Chemical	D004837
infusion	O	O
in	O	O
halothane	B-Chemical	D006221
-	O	O
anesthetized	O	O
dogs	O	O
.	O	O

Ten	O	O
and	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

(	O	O
+	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
suppressed	O	O
digitalis	B-Chemical	D004070
-	O	O
and	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
arrhythmias	B-Disease	D001145
,	O	O
respectively	O	O
.	O	O

The	O	O
minimum	O	O
effective	O	O
plasma	O	O
concentrations	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
for	O	O
digitalis	B-Chemical	D004070
-	O	O
and	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
arrhythmias	B-Disease	D001145
were	O	O
1	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
and	O	O
2	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
micrograms	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
.	O	O

A	O	O
lower	O	O
dose	O	O
of	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
suppressed	O	O
the	O	O
digitalis	B-Chemical	D004070
-	O	O
induced	O	O
arrhythmia	B-Disease	D001145
,	O	O
whereas	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

was	O	O
needed	O	O
to	O	O
suppress	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
arrhythmias	B-Disease	D001145
.	O	O

The	O	O
minimum	O	O
effective	O	O
plasma	O	O
concentrations	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
for	O	O
digitalis	B-Chemical	D004070
-	O	O
and	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
arrhythmia	B-Disease	D001145
were	O	O
0	O	O
.	O	O

06	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

04	O	O
and	O	O
0	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
micrograms	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
.	O	O

The	O	O
stronger	O	O
antiarrhythmic	O	O
effect	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
cibenzoline	B-Chemical	C032151
indicates	O	O
that	O	O
(	O	O
-	O	O
)	O	O
-	O	O
isomer	O	O
may	O	O
have	O	O
an	O	O
effect	O	O
nearly	O	O
5	O	O
-	O	O
20	O	O
times	O	O
stronger	O	O
in	O	O
suppressing	O	O
Na	B-Chemical	D012964
channels	O	O
,	O	O
but	O	O
effects	O	O
of	O	O
both	O	O
drugs	O	O
on	O	O
Ca	B-Chemical	D002118
channels	O	O
may	O	O
be	O	O
almost	O	O
equipotent	O	O
.	O	O

Effect	O	O
of	O	O
Hibiscus	B-Chemical	D010936
rosa	I-Chemical	D010936
sinensis	I-Chemical	D010936
on	O	O
reserpine	B-Chemical	D012110
-	O	O
induced	O	O
neurobehavioral	O	O
and	O	O
biochemical	O	O
alterations	O	O
in	O	O
rats	O	O
.	O	O

Effect	O	O
of	O	O
methanolic	O	O
extract	O	O
of	O	O
Hibiscus	B-Chemical	D010936
rosa	I-Chemical	D010936
sinensis	I-Chemical	D010936
(	O	O
100	O	O
-	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
studied	O	O
on	O	O
reserpine	B-Chemical	D012110
-	O	O
induced	O	O
orofacial	O	O
dyskinesia	B-Disease	D004409
and	O	O
neurochemical	O	O
alterations	O	O
.	O	O

The	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
intraperitoneal	O	O
reserpine	B-Chemical	D012110
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
ip	O	O
)	O	O
for	O	O
3	O	O
days	O	O
every	O	O
other	O	O
day	O	O
.	O	O

On	O	O
day	O	O
5	O	O
,	O	O
vacuous	O	O
chewing	O	O
movements	O	O
and	O	O
tongue	O	O
protrusions	O	O
were	O	O
counted	O	O
for	O	O
5	O	O
min	O	O
.	O	O

Reserpine	B-Chemical	D012110
treated	O	O
rats	O	O
significantly	O	O
developed	O	O
vacuous	O	O
chewing	O	O
movements	O	O
and	O	O
tongue	O	O
protrusions	O	O
however	O	O
,	O	O
coadministration	O	O
of	O	O
Hibiscus	B-Chemical	D010936
rosa	I-Chemical	D010936
sinensis	I-Chemical	D010936
roots	O	O
extract	O	O
(	O	O
100	O	O
,	O	O
200	O	O
and	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
per	O	O
orally	O	O
)	O	O
attenuated	O	O
the	O	O
effects	O	O
.	O	O

Biochemical	O	O
analysis	O	O
of	O	O
brain	O	O
revealed	O	O
that	O	O
the	O	O
reserpine	B-Chemical	D012110
treatment	O	O
significantly	O	O
increased	O	O
lipid	O	O
peroxidation	O	O
and	O	O
decreased	O	O
levels	O	O
of	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
,	O	O
catalase	O	O
(	O	O
CAT	O	O
)	O	O
and	O	O
glutathione	B-Chemical	D005978
reductase	O	O
(	O	O
GSH	O	O
)	O	O
,	O	O
an	O	O
index	O	O
of	O	O
oxidative	O	O
stress	O	O
process	O	O
.	O	O

Coadministration	O	O
of	O	O
extract	O	O
significantly	O	O
reduced	O	O
the	O	O
lipid	O	O
peroxidation	O	O
and	O	O
reversed	O	O
the	O	O
decrease	O	O
in	O	O
brain	O	O
SOD	O	O
,	O	O
CAT	O	O
and	O	O
GSH	O	O
levels	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggested	O	O
that	O	O
Hibiscus	B-Chemical	D010936
rosa	I-Chemical	D010936
sinensis	I-Chemical	D010936
had	O	O
a	O	O
protective	O	O
role	O	O
against	O	O
reserpine	B-Chemical	D012110
-	O	O
induced	O	O
orofacial	O	O
dyskinesia	B-Disease	D004409
and	O	O
oxidative	O	O
stress	O	O
.	O	O

Comparison	O	O
of	O	O
aqueous	O	O
and	O	O
gellan	O	O
ophthalmic	O	O
timolol	B-Chemical	D013999
with	O	O
placebo	O	O
on	O	O
the	O	O
24	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
response	O	O
in	O	O
patients	O	O
on	O	O
treatment	O	O
for	O	O
glaucoma	B-Disease	D005901
.	O	O

PURPOSE	O	O
:	O	O
Topical	O	O
beta	O	O
-	O	O
blocker	O	O
treatment	O	O
is	O	O
routine	O	O
therapy	O	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
glaucoma	B-Disease	D005901
.	O	O

Therapy	O	O
results	O	O
in	O	O
systemic	O	O
absorption	O	O
,	O	O
however	O	O
,	O	O
the	O	O
degree	O	O
of	O	O
reduction	O	O
of	O	O
resting	O	O
and	O	O
peak	O	O
heart	O	O
rate	O	O
has	O	O
not	O	O
been	O	O
quantified	O	O
.	O	O

DESIGN	O	O
:	O	O
This	O	O
trial	O	O
evaluated	O	O
the	O	O
effect	O	O
of	O	O
placebo	O	O
,	O	O
0	O	O
.	O	O

5%	O	O
aqueous	O	O
timolol	B-Chemical	D013999
(	O	O
timolol	B-Chemical	D013999
solution	O	O
)	O	O
and	O	O
a	O	O
0	O	O
.	O	O

5%	O	O
timolol	B-Chemical	D013999
suspension	O	O
that	O	O
forms	O	O
a	O	O
gel	O	O
on	O	O
application	O	O
to	O	O
the	O	O
conjunctiva	O	O
(	O	O
timolol	B-Chemical	D013999
gellan	O	O
)	O	O
on	O	O
the	O	O
24	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
in	O	O
patients	O	O
currently	O	O
being	O	O
treated	O	O
for	O	O
glaucoma	B-Disease	D005901
to	O	O
quantify	O	O
the	O	O
reduction	O	O
in	O	O
mean	O	O
heart	O	O
rate	O	O
.	O	O

METHODS	O	O
:	O	O
Forty	O	O
-	O	O
three	O	O
Caucasian	O	O
patients	O	O
with	O	O
primary	O	O
open	B-Disease	D005902
-	I-Disease	D005902
angle	I-Disease	D005902
glaucoma	I-Disease	D005902
or	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
with	O	O
a	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
age	O	O
of	O	O
63	O	O
(	O	O
+	O	O
/	O	O
-	O	O
8	O	O
)	O	O
years	O	O
were	O	O
randomized	O	O
and	O	O
crossed	O	O
over	O	O
in	O	O
a	O	O
double	O	O
-	O	O
masked	O	O
manner	O	O
to	O	O
14	O	O
days	O	O
of	O	O
treatment	O	O
with	O	O
placebo	O	O
(	O	O
morning	O	O
and	O	O
evening	O	O
in	O	O
both	O	O
eyes	O	O
)	O	O
,	O	O
timolol	B-Chemical	D013999
solution	O	O
(	O	O
morning	O	O
and	O	O
evening	O	O
in	O	O
both	O	O
eyes	O	O
)	O	O
,	O	O
or	O	O
timolol	B-Chemical	D013999
gellan	O	O
(	O	O
morning	O	O
in	O	O
both	O	O
eyes	O	O
with	O	O
placebo	O	O
in	O	O
the	O	O
evening	O	O
)	O	O
.	O	O

On	O	O
the	O	O
13th	O	O
day	O	O
of	O	O
each	O	O
period	O	O
,	O	O
heart	O	O
rate	O	O
was	O	O
recorded	O	O
continuously	O	O
during	O	O
a	O	O
typical	O	O
,	O	O
ambulant	O	O
24	O	O
-	O	O
hour	O	O
period	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
timolol	B-Chemical	D013999
solution	O	O
and	O	O
timolol	B-Chemical	D013999
gellan	O	O
reduced	O	O
the	O	O
mean	O	O
24	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
compared	O	O
with	O	O
placebo	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
this	O	O
reduction	O	O
was	O	O
most	O	O
pronounced	O	O
during	O	O
the	O	O
daytime	O	O
(	O	O
-	O	O
7	O	O
.	O	O

5%	O	O
change	O	O
in	O	O
mean	O	O
heart	O	O
rate	O	O
,	O	O
-	O	O
5	O	O
.	O	O

7	O	O
beats	O	O
/	O	O
min	O	O
)	O	O
.	O	O

Timolol	B-Chemical	D013999
gellan	O	O
showed	O	O
a	O	O
numerically	O	O
but	O	O
not	O	O
significantly	O	O
smaller	O	O
reduction	O	O
in	O	O
24	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
,	O	O
compared	O	O
with	O	O
timolol	B-Chemical	D013999
solution	O	O
.	O	O

During	O	O
the	O	O
night	O	O
,	O	O
the	O	O
mean	O	O
12	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
on	O	O
placebo	O	O
and	O	O
timolol	B-Chemical	D013999
gellan	O	O
were	O	O
both	O	O
significantly	O	O
less	O	O
than	O	O
on	O	O
timolol	B-Chemical	D013999
solution	O	O
;	O	O
the	O	O
difference	O	O
between	O	O
solution	O	O
and	O	O
gellan	O	O
treatments	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Both	O	O
timolol	B-Chemical	D013999
solution	O	O
and	O	O
timolol	B-Chemical	D013999
gellan	O	O
decrease	O	O
the	O	O
mean	O	O
24	O	O
-	O	O
hour	O	O
heart	O	O
rate	O	O
compared	O	O
with	O	O
placebo	O	O
.	O	O

This	O	O
response	O	O
was	O	O
most	O	O
pronounced	O	O
during	O	O
the	O	O
active	O	O
daytime	O	O
period	O	O
.	O	O

These	O	O
data	O	O
quantify	O	O
the	O	O
modest	O	O
bradycardia	B-Disease	D001919
associated	O	O
with	O	O
ophthalmic	O	O
beta	O	O
-	O	O
blocker	O	O
therapy	O	O
in	O	O
a	O	O
typical	O	O
patient	O	O
population	O	O
on	O	O
therapy	O	O
for	O	O
glaucoma	B-Disease	D005901
.	O	O

Although	O	O
exercise	O	O
performance	O	O
was	O	O
not	O	O
assessed	O	O
in	O	O
this	O	O
trial	O	O
,	O	O
reductions	O	O
of	O	O
this	O	O
magnitude	O	O
should	O	O
not	O	O
have	O	O
substantial	O	O
clinical	O	O
consequences	O	O
.	O	O

5	B-Chemical	D005472
flourouracil	I-Chemical	D005472
-	O	O
induced	O	O
apical	B-Disease	D054549
ballooning	I-Disease	D054549
syndrome	I-Disease	D054549
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

The	O	O
apical	B-Disease	D054549
ballooning	I-Disease	D054549
syndrome	I-Disease	D054549
(	O	O
ABS	B-Disease	D054549
)	O	O
is	O	O
a	O	O
recently	O	O
described	O	O
stress	O	O
-	O	O
mediated	O	O
acute	B-Disease	D006331
cardiac	I-Disease	D006331
syndrome	I-Disease	D006331
characterized	O	O
by	O	O
transient	O	O
wall	O	O
-	O	O
motion	O	O
abnormalities	O	O
involving	O	O
the	O	O
apex	O	O
and	O	O
midventricle	O	O
with	O	O
hyperkinesis	B-Disease	D006948
of	O	O
the	O	O
basal	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
segments	O	O
without	O	O
obstructive	O	O
epicardial	B-Disease	D003327
coronary	I-Disease	D003327
disease	I-Disease	D003327
.	O	O

Cardiotoxicity	B-Disease	D066126
is	O	O
not	O	O
an	O	O
uncommon	O	O
adverse	O	O
effect	O	O
of	O	O
chemotherapeutic	O	O
agents	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O	O
of	O	O
ABS	B-Disease	D054549
secondary	O	O
to	O	O
chemotherapeutic	O	O
agents	O	O
.	O	O

We	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
who	O	O
developed	O	O
the	O	O
syndrome	O	O
after	O	O
chemotherapy	O	O
for	O	O
metastatic	O	O
cancer	B-Disease	D009369
.	O	O

A	O	O
79	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
typical	O	O
ischemic	B-Disease	D007511
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
elevated	O	O
cardiac	O	O
enzymes	O	O
with	O	O
significant	O	O
ST	O	O
-	O	O
segment	O	O
abnormalities	O	O
on	O	O
her	O	O
electrocardiogram	O	O
.	O	O

She	O	O
underwent	O	O
recent	O	O
chemotherapy	O	O
with	O	O
fluorouracil	B-Chemical	D005472
for	O	O
metastatic	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
.	O	O

Echocardiography	O	O
revealed	O	O
a	O	O
wall	O	O
-	O	O
motion	O	O
abnormality	O	O
involving	O	O
the	O	O
apical	O	O
and	O	O
periapical	O	O
segments	O	O
which	O	O
appeared	O	O
akinetic	B-Disease	D018476
.	O	O

Coronary	O	O
angiography	O	O
revealed	O	O
no	O	O
obstructive	O	O
coronary	O	O
lesions	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
stabilized	O	O
with	O	O
medical	O	O
therapy	O	O
.	O	O

Four	O	O
weeks	O	O
later	O	O
she	O	O
remained	O	O
completely	O	O
asymptomatic	O	O
.	O	O

Echocardiogram	O	O
revealed	O	O
a	O	O
normal	O	O
ejection	O	O
fraction	O	O
and	O	O
a	O	O
resolution	O	O
of	O	O
the	O	O
apical	O	O
akinesis	B-Disease	D018476
.	O	O

Pathogenetic	O	O
mechanisms	O	O
of	O	O
cardiac	B-Disease	D005117
complications	I-Disease	D005117
in	O	O
cancer	B-Disease	D009369
patients	O	O
undergoing	O	O
chemotherapy	O	O
include	O	O
coronary	B-Disease	D003329
vasospasm	I-Disease	D003329
,	O	O
endothelial	O	O
damage	O	O
and	O	O
consequent	O	O
thrombus	B-Disease	D013927
formation	O	O
.	O	O

In	O	O
our	O	O
patient	O	O
,	O	O
both	O	O
supraphysiologic	O	O
levels	O	O
of	O	O
plasma	O	O
catecholamines	B-Chemical	D002395
and	O	O
stress	O	O
related	O	O
neuropeptides	O	O
caused	O	O
by	O	O
cancer	B-Disease	D009369
diagnosis	O	O
as	O	O
well	O	O
as	O	O
chemotherapy	O	O
may	O	O
have	O	O
contributed	O	O
the	O	O
development	O	O
of	O	O
ABS	B-Disease	D054549
.	O	O

Reduction	O	O
of	O	O
pain	B-Disease	D010146
during	O	O
induction	O	O
with	O	O
target	O	O
-	O	O
controlled	O	O
propofol	B-Chemical	D015742
and	O	O
remifentanil	B-Chemical	C071741
.	O	O

BACKGROUND	O	O
:	O	O
Pain	B-Disease	D010146
on	O	O
injection	O	O
of	O	O
propofol	B-Chemical	D015742
is	O	O
unpleasant	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
propofol	B-Chemical	D015742
infusion	O	O
pain	B-Disease	D010146
might	O	O
be	O	O
prevented	O	O
by	O	O
infusing	O	O
remifentanil	B-Chemical	C071741
before	O	O
starting	O	O
the	O	O
propofol	B-Chemical	D015742
infusion	O	O
in	O	O
a	O	O
clinical	O	O
setting	O	O
where	O	O
target	O	O
-	O	O
controlled	O	O
infusions	O	O
(	O	O
TCI	O	O
)	O	O
of	O	O
both	O	O
drugs	O	O
were	O	O
used	O	O
.	O	O

A	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
was	O	O
performed	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
-	O	O
site	O	O
concentration	O	O
(	O	O
Ce	O	O
)	O	O
of	O	O
remifentanil	B-Chemical	C071741
to	O	O
prevent	O	O
the	O	O
pain	B-Disease	D010146
without	O	O
producing	O	O
complications	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
128	O	O
patients	O	O
undergoing	O	O
general	O	O
surgery	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
normal	O	O
saline	O	O
(	O	O
control	O	O
)	O	O
or	O	O
remifentanil	B-Chemical	C071741
to	O	O
a	O	O
target	O	O
Ce	O	O
of	O	O
2	O	O
ng	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
R2	O	O
)	O	O
,	O	O
4	O	O
ng	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
R4	O	O
)	O	O
,	O	O
or	O	O
6	O	O
ng	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
R6	O	O
)	O	O
administered	O	O
via	O	O
TCI	O	O
.	O	O

After	O	O
the	O	O
target	O	O
Ce	O	O
was	O	O
achieved	O	O
,	O	O
the	O	O
infusion	O	O
of	O	O
propofol	B-Chemical	D015742
was	O	O
started	O	O
.	O	O

Remifentanil	B-Chemical	C071741
-	O	O
related	O	O
complications	O	O
were	O	O
assessed	O	O
during	O	O
the	O	O
remifentanil	B-Chemical	C071741
infusion	O	O
,	O	O
and	O	O
pain	B-Disease	D010146
caused	O	O
by	O	O
propofol	B-Chemical	D015742
was	O	O
evaluated	O	O
using	O	O
a	O	O
four	O	O
-	O	O
point	O	O
scale	O	O
during	O	O
the	O	O
propofol	B-Chemical	D015742
infusion	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
pain	B-Disease	D010146
was	O	O
significantly	O	O
lower	O	O
in	O	O
Groups	O	O
R4	O	O
and	O	O
R6	O	O
than	O	O
in	O	O
the	O	O
control	O	O
and	O	O
R2	O	O
groups	O	O
(	O	O
12	O	O
/	O	O
32	O	O
and	O	O
6	O	O
/	O	O
31	O	O
vs	O	O
26	O	O
/	O	O
31	O	O
and	O	O
25	O	O
/	O	O
32	O	O
,	O	O
respectively	O	O
,	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Pain	B-Disease	D010146
was	O	O
less	O	O
severe	O	O
in	O	O
Groups	O	O
R4	O	O
and	O	O
R6	O	O
than	O	O
in	O	O
the	O	O
control	O	O
and	O	O
R2	O	O
groups	O	O
(	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

However	O	O
,	O	O
both	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
pain	B-Disease	D010146
were	O	O
not	O	O
different	O	O
between	O	O
Groups	O	O
R4	O	O
and	O	O
R6	O	O
.	O	O

No	O	O
significant	O	O
complications	O	O
were	O	O
observed	O	O
during	O	O
the	O	O
study	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
During	O	O
induction	O	O
of	O	O
anaesthesia	O	O
with	O	O
TCI	O	O
of	O	O
propofol	B-Chemical	D015742
and	O	O
remifentanil	B-Chemical	C071741
,	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
propofol	B-Chemical	D015742
infusion	O	O
pain	B-Disease	D010146
was	O	O
achieved	O	O
without	O	O
significant	O	O
complications	O	O
by	O	O
prior	O	O
administration	O	O
of	O	O
remifentanil	B-Chemical	C071741
at	O	O
a	O	O
target	O	O
Ce	O	O
of	O	O
4	O	O
ng	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Prenatal	O	O
exposure	O	O
to	O	O
fluoxetine	B-Chemical	D005473
induces	O	O
fetal	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
in	O	O
the	O	O
rat	O	O
.	O	O

RATIONALE	O	O
:	O	O
Fluoxetine	B-Chemical	D005473
is	O	O
a	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
antidepressant	O	O
widely	O	O
used	O	O
by	O	O
pregnant	O	O
women	O	O
.	O	O

Epidemiological	O	O
data	O	O
suggest	O	O
that	O	O
fluoxetine	B-Chemical	D005473
exposure	O	O
prenatally	O	O
increases	O	O
the	O	O
prevalence	O	O
of	O	O
persistent	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
syndrome	I-Disease	D006976
of	O	O
the	O	O
newborn	O	O
.	O	O

The	O	O
mechanism	O	O
responsible	O	O
for	O	O
this	O	O
effect	O	O
is	O	O
unclear	O	O
and	O	O
paradoxical	O	O
,	O	O
considering	O	O
the	O	O
current	O	O
evidence	O	O
of	O	O
a	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
protective	O	O
fluoxetine	B-Chemical	D005473
effect	O	O
in	O	O
adult	O	O
rodents	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
fluoxetine	B-Chemical	D005473
effect	O	O
on	O	O
fetal	O	O
rat	O	O
pulmonary	O	O
vascular	O	O
smooth	O	O
muscle	O	O
mechanical	O	O
properties	O	O
and	O	O
cell	O	O
proliferation	O	O
rate	O	O
.	O	O

METHODS	O	O
:	O	O
Pregnant	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
fluoxetine	B-Chemical	D005473
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
from	O	O
Day	O	O
11	O	O
through	O	O
Day	O	O
21	O	O
of	O	O
gestation	O	O
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
Fetuses	O	O
were	O	O
delivered	O	O
by	O	O
cesarean	O	O
section	O	O
.	O	O

As	O	O
compared	O	O
with	O	O
controls	O	O
,	O	O
fluoxetine	B-Chemical	D005473
exposure	O	O
resulted	O	O
in	O	O
fetal	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
as	O	O
evidenced	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
weight	O	O
ratio	O	O
of	O	O
the	O	O
right	O	O
ventricle	O	O
to	O	O
the	O	O
left	O	O
ventricle	O	O
plus	O	O
septum	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
and	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
pulmonary	O	O
arterial	O	O
medial	O	O
thickness	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Postnatal	O	O
mortality	O	O
was	O	O
increased	O	O
among	O	O
experimental	O	O
animals	O	O
,	O	O
and	O	O
arterial	O	O
oxygen	B-Chemical	D010100
saturation	O	O
was	O	O
96	O	O
+	O	O
/	O	O
-	O	O
1%	O	O
in	O	O
1	O	O
-	O	O
day	O	O
-	O	O
old	O	O
control	O	O
animals	O	O
and	O	O
significantly	O	O
lower	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
in	O	O
fluoxetine	B-Chemical	D005473
-	O	O
exposed	O	O
pups	O	O
(	O	O
79	O	O
+	O	O
/	O	O
-	O	O
2%	O	O
)	O	O
.	O	O

In	O	O
vitro	O	O
,	O	O
fluoxetine	B-Chemical	D005473
induced	O	O
pulmonary	O	O
arterial	O	O
muscle	O	O
contraction	O	O
in	O	O
fetal	O	O
,	O	O
but	O	O
not	O	O
adult	O	O
,	O	O
animals	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
reduced	O	O
serotonin	B-Chemical	D012701
-	O	O
induced	O	O
contraction	O	O
at	O	O
both	O	O
ages	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

After	O	O
in	O	O
utero	O	O
exposure	O	O
to	O	O
a	O	O
low	O	O
fluoxetine	B-Chemical	D005473
concentration	O	O
the	O	O
pulmonary	O	O
arterial	O	O
smooth	O	O
muscle	O	O
cell	O	O
proliferation	O	O
rate	O	O
was	O	O
significantly	O	O
increased	O	O
in	O	O
fetal	O	O
,	O	O
but	O	O
not	O	O
adult	O	O
,	O	O
cells	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
contrast	O	O
to	O	O
the	O	O
adult	O	O
,	O	O
fluoxetine	B-Chemical	D005473
exposure	O	O
in	O	O
utero	O	O
induces	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
in	O	O
the	O	O
fetal	O	O
rat	O	O
as	O	O
a	O	O
result	O	O
of	O	O
a	O	O
developmentally	O	O
regulated	O	O
increase	O	O
in	O	O
pulmonary	O	O
vascular	O	O
smooth	O	O
muscle	O	O
proliferation	O	O
.	O	O

Syncope	B-Disease	D013575
and	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
among	O	O
patients	O	O
treated	O	O
with	O	O
methadone	B-Chemical	D008691
for	O	O
heroin	B-Chemical	D003932
dependence	O	O
in	O	O
the	O	O
city	O	O
of	O	O
Copenhagen	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Methadone	B-Chemical	D008691
is	O	O
prescribed	O	O
to	O	O
heroin	B-Chemical	D003932
addicts	O	O
to	O	O
decrease	O	O
illicit	O	O
opioid	O	O
use	O	O
.	O	O

Prolongation	O	O
of	O	O
the	O	O
QT	O	O
interval	O	O
in	O	O
the	O	O
ECG	O	O
of	O	O
patients	O	O
with	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TdP	B-Disease	D016171
)	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
methadone	B-Chemical	D008691
users	O	O
.	O	O

As	O	O
heroin	B-Chemical	D003932
addicts	O	O
sometimes	O	O
faint	O	O
while	O	O
using	O	O
illicit	O	O
drugs	O	O
,	O	O
doctors	O	O
might	O	O
attribute	O	O
too	O	O
many	O	O
episodes	O	O
of	O	O
syncope	B-Disease	D013575
to	O	O
illicit	O	O
drug	O	O
use	O	O
and	O	O
thereby	O	O
underestimate	O	O
the	O	O
incidence	O	O
of	O	O
TdP	B-Disease	D016171
in	O	O
this	O	O
special	O	O
population	O	O
,	O	O
and	O	O
the	O	O
high	O	O
mortality	O	O
in	O	O
this	O	O
population	O	O
may	O	O
,	O	O
in	O	O
part	O	O
,	O	O
be	O	O
caused	O	O
by	O	O
the	O	O
proarrhythmic	O	O
effect	O	O
of	O	O
methadone	B-Chemical	D008691
.	O	O

METHODS	O	O
:	O	O
In	O	O
this	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
interview	O	O
,	O	O
ECGs	O	O
and	O	O
blood	O	O
samples	O	O
were	O	O
collected	O	O
in	O	O
a	O	O
population	O	O
of	O	O
adult	O	O
heroin	B-Chemical	D003932
addicts	O	O
treated	O	O
with	O	O
methadone	B-Chemical	D008691
or	O	O
buprenorphine	B-Chemical	D002047
on	O	O
a	O	O
daily	O	O
basis	O	O
.	O	O

Of	O	O
the	O	O
patients	O	O
at	O	O
the	O	O
Drug	O	O
Addiction	O	O
Service	O	O
in	O	O
the	O	O
municipal	O	O
of	O	O
Copenhagen	O	O
,	O	O
450	O	O
(	O	O
approximately	O	O
52%	O	O
)	O	O
were	O	O
included	O	O
.	O	O

The	O	O
QT	O	O
interval	O	O
was	O	O
estimated	O	O
from	O	O
12	O	O
lead	O	O
ECGs	O	O
.	O	O

All	O	O
participants	O	O
were	O	O
interviewed	O	O
about	O	O
any	O	O
experience	O	O
of	O	O
syncope	B-Disease	D013575
.	O	O

The	O	O
association	O	O
between	O	O
opioid	O	O
dose	O	O
and	O	O
QT	O	O
,	O	O
and	O	O
methadone	B-Chemical	D008691
dose	O	O
and	O	O
reporting	O	O
of	O	O
syncope	B-Disease	D013575
was	O	O
assessed	O	O
using	O	O
multivariate	O	O
linear	O	O
regression	O	O
and	O	O
logistic	O	O
regression	O	O
,	O	O
respectively	O	O
.	O	O

RESULTS	O	O
:	O	O
Methadone	B-Chemical	D008691
dose	O	O
was	O	O
associated	O	O
with	O	O
longer	O	O
QT	O	O
interval	O	O
of	O	O
0	O	O
.	O	O

140	O	O
ms	O	O
/	O	O
mg	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

No	O	O
association	O	O
between	O	O
buprenorphine	B-Chemical	D002047
and	O	O
QTc	O	O
was	O	O
found	O	O
.	O	O

Among	O	O
the	O	O
subjects	O	O
treated	O	O
with	O	O
methadone	B-Chemical	D008691
,	O	O
28%	O	O
men	O	O
and	O	O
32%	O	O
women	O	O
had	O	O
prolonged	B-Disease	D008133
QTc	I-Disease	D008133
interval	I-Disease	D008133
.	O	O

None	O	O
of	O	O
the	O	O
subjects	O	O
treated	O	O
with	O	O
buprenorphine	B-Chemical	D002047
had	O	O
QTc	O	O
interval	O	O
>0	O	O
.	O	O

440	O	O
s	O	O
(	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
)	O	O
.	O	O

A	O	O
50	O	O
mg	O	O
higher	O	O
methadone	B-Chemical	D008691
dose	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
1	O	O
.	O	O

2	O	O
(	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

1	O	O
to	O	O
1	O	O
.	O	O

4	O	O
)	O	O
times	O	O
higher	O	O
odds	O	O
for	O	O
syncope	B-Disease	D013575
.	O	O

CONCLUSIONS	O	O
:	O	O
Methadone	B-Chemical	D008691
is	O	O
associated	O	O
with	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
and	O	O
higher	O	O
reporting	O	O
of	O	O
syncope	B-Disease	D013575
in	O	O
a	O	O
population	O	O
of	O	O
heroin	B-Chemical	D003932
addicts	O	O
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
caused	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B-Disease	D015470
myeloid	I-Disease	D015470
leukemia	I-Disease	D015470
.	O	O

The	O	O
central	O	O
nervous	O	O
system	O	O
toxicity	B-Disease	D064420
of	O	O
high	O	O
-	O	O
dose	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
is	O	O
well	O	O
recognized	O	O
,	O	O
but	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
in	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
has	O	O
been	O	O
infrequently	O	O
reported	O	O
.	O	O

A	O	O
49	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Japanese	O	O
man	O	O
was	O	O
diagnosed	O	O
with	O	O
acute	B-Disease	D015470
myeloid	I-Disease	D015470
leukemia	I-Disease	D015470
.	O	O

After	O	O
he	O	O
achieved	O	O
complete	O	O
remission	O	O
,	O	O
he	O	O
received	O	O
high	O	O
-	O	O
dose	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
treatment	O	O
(	O	O
2	O	O
g	O	O
/	O	O
m2	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
5	O	O
days	O	O
;	O	O
total	O	O
,	O	O
20	O	O
g	O	O
/	O	O
m2	O	O
)	O	O
as	O	O
consolidation	O	O
therapy	O	O
.	O	O

The	O	O
first	O	O
course	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
resulted	O	O
in	O	O
no	O	O
unusual	O	O
symptoms	O	O
,	O	O
but	O	O
on	O	O
day	O	O
21	O	O
of	O	O
the	O	O
second	O	O
course	O	O
of	O	O
treatment	O	O
,	O	O
the	O	O
patient	O	O
complained	O	O
of	O	O
numbness	B-Disease	D006987
in	O	O
his	O	O
right	O	O
foot	O	O
.	O	O

Electromyogram	O	O
and	O	O
nerve	O	O
-	O	O
conduction	O	O
studies	O	O
showed	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
in	O	O
both	O	O
peroneal	O	O
nerves	O	O
.	O	O

This	O	O
neuropathy	B-Disease	D009422
was	O	O
gradually	O	O
resolving	O	O
;	O	O
however	O	O
,	O	O
after	O	O
the	O	O
patient	O	O
received	O	O
allogeneic	O	O
bone	O	O
marrow	O	O
transplantation	O	O
,	O	O
the	O	O
symptoms	O	O
worsened	O	O
,	O	O
with	O	O
the	O	O
development	O	O
of	O	O
graft	B-Disease	D006086
-	I-Disease	D006086
versus	I-Disease	D006086
-	I-Disease	D006086
host	I-Disease	D006086
disease	I-Disease	D006086
,	O	O
and	O	O
the	O	O
symptoms	O	O
subsequently	O	O
responded	O	O
to	O	O
methylprednisolone	B-Chemical	D008775
.	O	O

Although	O	O
the	O	O
mechanisms	O	O
of	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
are	O	O
still	O	O
unclear	O	O
,	O	O
high	O	O
-	O	O
dose	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
is	O	O
a	O	O
therapy	O	O
that	O	O
is	O	O
potentially	O	O
toxic	O	O
to	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
,	O	O
and	O	O
auto	O	O
/	O	O
alloimmunity	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
these	O	O
mechanisms	O	O
.	O	O

Atorvastatin	B-Chemical	C065179
prevented	O	O
and	O	O
reversed	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
the	O	O
rat	O	O
.	O	O

To	O	O
assess	O	O
the	O	O
antioxidant	O	O
effects	O	O
of	O	O
atorvastatin	B-Chemical	C065179
(	O	O
atorva	B-Chemical	C065179
)	O	O
on	O	O
dexamethasone	B-Chemical	D003907
(	O	O
dex	B-Chemical	D003907
)	O	O
-	O	O
induced	O	O
hypertension	B-Disease	D006973
,	O	O
60	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
atorva	B-Chemical	C065179
30	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
or	O	O
tap	O	O
water	O	O
for	O	O
15	O	O
days	O	O
.	O	O

Dex	B-Chemical	D003907
increased	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
from	O	O
109	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

8	O	O
to	O	O
135	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
mmHg	O	O
and	O	O
plasma	O	O
superoxide	B-Chemical	D013481
(	O	O
5711	O	O
+	O	O
/	O	O
-	O	O
284	O	O
.	O	O

9	O	O
saline	O	O
,	O	O
7931	O	O
+	O	O
/	O	O
-	O	O
392	O	O
.	O	O

8	O	O
U	O	O
/	O	O
ml	O	O
dex	B-Chemical	D003907
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

In	O	O
this	O	O
prevention	O	O
study	O	O
,	O	O
SBP	O	O
in	O	O
the	O	O
atorva	B-Chemical	C065179
+	O	O
dex	B-Chemical	D003907
group	O	O
was	O	O
increased	O	O
from	O	O
115	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
to	O	O
124	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5	O	O
mmHg	O	O
,	O	O
but	O	O
this	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
in	O	O
the	O	O
dex	B-Chemical	D003907
-	O	O
only	O	O
group	O	O
(	O	O
P'	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Atorva	B-Chemical	C065179
reversed	O	O
dex	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
(	O	O
129	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
mmHg	O	O
,	O	O
vs	O	O
.	O	O

135	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
mmHg	O	O
P'	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
decreased	O	O
plasma	O	O
superoxide	B-Chemical	D013481
(	O	O
7931	O	O
+	O	O
/	O	O
-	O	O
392	O	O
.	O	O

8	O	O
dex	B-Chemical	D003907
,	O	O
1187	O	O
+	O	O
/	O	O
-	O	O
441	O	O
.	O	O

2	O	O
atorva	B-Chemical	C065179
+	O	O
dex	B-Chemical	D003907
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Plasma	O	O
nitrate	B-Chemical	D009566
/	O	O
nitrite	B-Chemical	D009573
(	O	O
NOx	O	O
)	O	O
was	O	O
decreased	O	O
in	O	O
dex	B-Chemical	D003907
-	O	O
treated	O	O
rats	O	O
compared	O	O
to	O	O
saline	O	O
-	O	O
treated	O	O
rats	O	O
(	O	O
11	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

08	O	O
microm	O	O
,	O	O
15	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

17	O	O
microm	O	O
,	O	O
respectively	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Atorva	B-Chemical	C065179
affected	O	O
neither	O	O
plasma	O	O
NOx	O	O
nor	O	O
thymus	O	O
weight	O	O
.	O	O

Thus	O	O
,	O	O
atorvastatin	B-Chemical	C065179
prevented	O	O
and	O	O
reversed	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
the	O	O
rat	O	O
.	O	O

Two	O	O
prodrugs	O	O
of	O	O
potent	O	O
and	O	O
selective	O	O
GluR5	O	O
kainate	B-Chemical	D007608
receptor	O	O
antagonists	O	O
actives	O	O
in	O	O
three	O	O
animal	O	O
models	O	O
of	O	O
pain	B-Disease	D010146
.	O	O

Amino	O	O
acids	O	O
5	O	O
and	O	O
7	O	O
,	O	O
two	O	O
potent	O	O
and	O	O
selective	O	O
competitive	O	O
GluR5	O	O
KA	B-Chemical	D007608
receptor	O	O
antagonists	O	O
,	O	O
exhibited	O	O
high	O	O
GluR5	O	O
receptor	O	O
affinity	O	O
over	O	O
other	O	O
glutamate	B-Chemical	D018698
receptors	O	O
.	O	O

Their	O	O
ester	O	O
prodrugs	O	O
6	O	O
and	O	O
8	O	O
were	O	O
orally	O	O
active	O	O
in	O	O
three	O	O
models	O	O
of	O	O
pain	B-Disease	D010146
:	O	O
reversal	O	O
of	O	O
formalin	B-Chemical	D005557
-	O	O
induced	O	O
paw	O	O
licking	O	O
,	O	O
carrageenan	B-Chemical	D002351
-	O	O
induced	O	O
thermal	B-Disease	D006930
hyperalgesia	I-Disease	D006930
,	O	O
and	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
mechanical	B-Disease	D006930
hyperalgesia	I-Disease	D006930
.	O	O

Sirolimus	B-Chemical	D020123
and	O	O
mycophenolate	B-Chemical	C063008
mofetil	I-Chemical	C063008
for	O	O
calcineurin	O	O
-	O	O
free	O	O
immunosuppression	O	O
in	O	O
renal	O	O
transplant	O	O
recipients	O	O
.	O	O

Calcineurin	O	O
inhibitors	O	O
,	O	O
such	O	O
as	O	O
cyclosporine	B-Chemical	D016572
and	O	O
tacrolimus	B-Chemical	D016559
,	O	O
have	O	O
been	O	O
available	O	O
for	O	O
almost	O	O
20	O	O
years	O	O
.	O	O

Although	O	O
these	O	O
drugs	O	O
are	O	O
highly	O	O
effective	O	O
and	O	O
represent	O	O
the	O	O
mainstay	O	O
of	O	O
transplant	O	O
immunosuppression	O	O
,	O	O
they	O	O
are	O	O
associated	O	O
with	O	O
acute	O	O
and	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Acute	O	O
nephrotoxicity	B-Disease	D007674
,	O	O
which	O	O
occurs	O	O
in	O	O
the	O	O
early	O	O
period	O	O
after	O	O
transplantation	O	O
,	O	O
leads	O	O
to	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
dialysis	O	O
,	O	O
and	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
may	O	O
eventually	O	O
result	O	O
in	O	O
graft	O	O
loss	O	O
.	O	O

Acute	O	O
and	O	O
chronic	O	O
nephrotoxicity	B-Disease	D007674
is	O	O
becoming	O	O
more	O	O
common	O	O
as	O	O
the	O	O
use	O	O
of	O	O
marginal	O	O
kidneys	O	O
for	O	O
transplantation	O	O
increases	O	O
.	O	O

Two	O	O
recently	O	O
available	O	O
immunosuppressive	O	O
agents	O	O
,	O	O
mycophenolate	B-Chemical	C063008
mofetil	I-Chemical	C063008
and	O	O
sirolimus	B-Chemical	D020123
(	O	O
rapamycin	B-Chemical	D020123
)	O	O
,	O	O
have	O	O
no	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

The	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
agents	O	O
has	O	O
led	O	O
to	O	O
the	O	O
development	O	O
of	O	O
new	O	O
paradigms	O	O
of	O	O
immunosuppressive	O	O
therapy	O	O
.	O	O

This	O	O
paper	O	O
reviews	O	O
the	O	O
results	O	O
of	O	O
clinical	O	O
trials	O	O
that	O	O
have	O	O
investigated	O	O
these	O	O
new	O	O
approaches	O	O
to	O	O
immunosuppression	O	O
in	O	O
renal	O	O
transplant	O	O
recipients	O	O
.	O	O

Erythropoietin	O	O
restores	O	O
the	O	O
anemia	B-Disease	D000740
-	O	O
induced	O	O
reduction	O	O
in	O	O
cyclophosphamide	B-Chemical	D003520
cytotoxicity	B-Disease	D064420
in	O	O
rat	O	O
tumors	B-Disease	D009369
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
impact	O	O
of	O	O
anemia	B-Disease	D000740
prevention	O	O
by	O	O
recombinant	O	O
human	O	O
erythropoietin	O	O
(	O	O
rHuEPO	O	O
)	O	O
treatment	O	O
on	O	O
the	O	O
cytotoxicity	B-Disease	D064420
of	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
solid	O	O
experimental	O	O
tumors	B-Disease	D009369
.	O	O

Anemia	B-Disease	D000740
was	O	O
induced	O	O
using	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
carboplatin	B-Chemical	D016190
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
resulting	O	O
in	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
reduction	O	O
(	O	O
30%	O	O
)	O	O
of	O	O
the	O	O
hemoglobin	O	O
concentration	O	O
.	O	O

In	O	O
a	O	O
second	O	O
group	O	O
,	O	O
the	O	O
development	O	O
of	O	O
anemia	B-Disease	D000740
was	O	O
prevented	O	O
by	O	O
rHuEPO	O	O
(	O	O
1000	O	O
IU	O	O
/	O	O
kg	O	O
)	O	O
administered	O	O
s	O	O
.	O	O

c	O	O
.	O	O

three	O	O
times	O	O
/	O	O
week	O	O
starting	O	O
7	O	O
days	O	O
before	O	O
carboplatin	B-Chemical	D016190
application	O	O
.	O	O

Four	O	O
days	O	O
after	O	O
carboplatin	B-Chemical	D016190
treatment	O	O
,	O	O
tumors	B-Disease	D009369
(	O	O
DS	O	O
-	O	O
sarcoma	B-Disease	D012509
of	O	O
the	O	O
rat	O	O
)	O	O
were	O	O
implanted	O	O
s	O	O
.	O	O

c	O	O
.	O	O

onto	O	O
the	O	O
hind	O	O
food	O	O
dorsum	O	O
.	O	O

Neither	O	O
carboplatin	B-Chemical	D016190
nor	O	O
rHuEPO	O	O
treatment	O	O
influenced	O	O
tumor	B-Disease	D009369
growth	O	O
rate	O	O
per	O	O
se	O	O
.	O	O

When	O	O
tumors	B-Disease	D009369
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
5	O	O
days	O	O
after	O	O
implantation	O	O
,	O	O
a	O	O
growth	O	O
delay	O	O
with	O	O
a	O	O
subsequent	O	O
regrowth	O	O
of	O	O
the	O	O
tumors	B-Disease	D009369
was	O	O
observed	O	O
.	O	O

In	O	O
the	O	O
anemia	B-Disease	D000740
group	O	O
,	O	O
the	O	O
growth	O	O
delay	O	O
was	O	O
significantly	O	O
shorter	O	O
compared	O	O
with	O	O
nonanemic	O	O
controls	O	O
(	O	O
13	O	O
.	O	O

3	O	O
days	O	O
versus	O	O
8	O	O
.	O	O

6	O	O
days	O	O
)	O	O
.	O	O

In	O	O
the	O	O
group	O	O
where	O	O
anemia	B-Disease	D000740
was	O	O
prevented	O	O
by	O	O
rHuEPO	O	O
treatment	O	O
,	O	O
growth	O	O
delay	O	O
was	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
nonanemic	O	O
controls	O	O
(	O	O
13	O	O
.	O	O

3	O	O
days	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
chemotherapy	O	O
-	O	O
induced	O	O
anemia	B-Disease	D000740
reduces	O	O
cytotoxicity	B-Disease	D064420
of	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
tumors	B-Disease	D009369
,	O	O
whereas	O	O
correction	O	O
of	O	O
anemia	B-Disease	D000740
by	O	O
rHuEPO	O	O
treatment	O	O
(	O	O
epoetin	O	O
alpha	O	O
)	O	O
increases	O	O
the	O	O
sensitivity	O	O
,	O	O
probably	O	O
as	O	O
a	O	O
result	O	O
of	O	O
an	O	O
improved	O	O
oxygen	B-Chemical	D010100
supply	O	O
to	O	O
tumor	B-Disease	D009369
tissue	O	O
.	O	O

The	O	O
role	O	O
of	O	O
nitrergic	O	O
system	O	O
in	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsion	B-Disease	D012640
in	O	O
the	O	O
mouse	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
N	B-Chemical	D019331
-	I-Chemical	D019331
nitro	I-Chemical	D019331
-	I-Chemical	D019331
L	I-Chemical	D019331
-	I-Chemical	D019331
arginine	I-Chemical	D019331
-	I-Chemical	D019331
methyl	I-Chemical	D019331
ester	I-Chemical	D019331
(	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
)	O	O
a	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
synthase	O	O
inhibitor	O	O
and	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
,	O	O
a	O	O
NO	B-Chemical	D009569
precursor	O	O
,	O	O
were	O	O
investigated	O	O
on	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

In	O	O
the	O	O
first	O	O
experiment	O	O
,	O	O
four	O	O
groups	O	O
of	O	O
mice	O	O
received	O	O
physiological	O	O
saline	O	O
(	O	O
0	O	O
.	O	O

9%	O	O
)	O	O
,	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
(	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
diazepam	B-Chemical	D003975
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Thirty	O	O
minutes	O	O
after	O	O
these	O	O
injections	O	O
,	O	O
all	O	O
mice	O	O
received	O	O
lidocaine	B-Chemical	D008012
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

In	O	O
the	O	O
second	O	O
experiment	O	O
,	O	O
four	O	O
groups	O	O
of	O	O
mice	O	O
received	O	O
similar	O	O
treatment	O	O
in	O	O
the	O	O
first	O	O
experiment	O	O
,	O	O
and	O	O
30	O	O
min	O	O
after	O	O
these	O	O
injections	O	O
,	O	O
all	O	O
mice	O	O
received	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
lidocaine	B-Chemical	D008012
(	O	O
80	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
diazepam	B-Chemical	D003975
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
significantly	O	O
decreased	O	O
the	O	O
incidence	O	O
of	O	O
lidocaine	B-Chemical	D008012
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
treatment	O	O
increased	O	O
the	O	O
incidence	O	O
of	O	O
lidocaine	B-Chemical	D008012
(	O	O
80	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
-	O	O
induced	O	O
convulsions	B-Disease	D012640
significantly	O	O
.	O	O

These	O	O
results	O	O
may	O	O
suggest	O	O
that	O	O
NO	B-Chemical	D009569
is	O	O
a	O	O
proconvulsant	O	O
mediator	O	O
in	O	O
lidocaine	B-Chemical	D008012
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

Effect	O	O
of	O	O
intravenous	O	O
metoprolol	B-Chemical	D008790
or	O	O
intravenous	O	O
metoprolol	B-Chemical	D008790
plus	O	O
glucagon	O	O
on	O	O
dobutamine	B-Chemical	D004280
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
metoprolol	B-Chemical	D008790
on	O	O
dobutamine	B-Chemical	D004280
stress	O	O
testing	O	O
with	O	O
technetium	B-Chemical	D017256
-	I-Chemical	D017256
99m	I-Chemical	D017256
sestamibi	I-Chemical	D017256
single	O	O
-	O	O
photon	O	O
emission	O	O
computed	O	O
tomography	O	O
imaging	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
monitoring	O	O
,	O	O
and	O	O
to	O	O
assess	O	O
the	O	O
impact	O	O
of	O	O
intravenous	O	O
glucagon	O	O
on	O	O
metoprolol's	O	O
effects	O	O
.	O	O

DESIGN	O	O
:	O	O
Randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
.	O	O

SETTING	O	O
:	O	O
Community	O	O
hospital	O	O
.	O	O

PATIENTS	O	O
:	O	O
Twenty	O	O
-	O	O
two	O	O
patients	O	O
with	O	O
known	O	O
reversible	O	O
perfusion	O	O
defects	O	O
.	O	O

INTERVENTION	O	O
:	O	O
Patients	O	O
underwent	O	O
dobutamine	B-Chemical	D004280
stress	O	O
tests	O	O
per	O	O
standard	O	O
protocol	O	O
.	O	O

Before	O	O
dobutamine	B-Chemical	D004280
was	O	O
begun	O	O
,	O	O
no	O	O
therapy	O	O
was	O	O
given	O	O
during	O	O
the	O	O
first	O	O
visit	O	O
,	O	O
and	O	O
patients	O	O
were	O	O
randomized	O	O
on	O	O
subsequent	O	O
visits	O	O
to	O	O
receive	O	O
metoprolol	B-Chemical	D008790
or	O	O
metoprolol	B-Chemical	D008790
plus	O	O
glucagon	O	O
1	O	O
mg	O	O
.	O	O

Metoprolol	B-Chemical	D008790
was	O	O
dosed	O	O
to	O	O
achieve	O	O
a	O	O
resting	O	O
predobutamine	B-Chemical	-1
heart	O	O
rate	O	O
below	O	O
65	O	O
beats	O	O
/	O	O
minute	O	O
or	O	O
a	O	O
total	O	O
intravenous	O	O
dose	O	O
of	O	O
20	O	O
mg	O	O
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
Metoprolol	B-Chemical	D008790
reduced	O	O
maximum	O	O
heart	O	O
rate	O	O
31%	O	O
,	O	O
summed	O	O
stress	O	O
scores	O	O
29%	O	O
,	O	O
and	O	O
summed	O	O
difference	O	O
scores	O	O
43%	O	O
versus	O	O
control	O	O
.	O	O

Metoprolol	B-Chemical	D008790
plus	O	O
glucagon	O	O
also	O	O
reduced	O	O
the	O	O
maximum	O	O
heart	O	O
rate	O	O
29%	O	O
versus	O	O
control	O	O
.	O	O

Summed	O	O
stress	O	O
and	O	O
summed	O	O
difference	O	O
scores	O	O
were	O	O
not	O	O
significantly	O	O
reduced	O	O
,	O	O
although	O	O
they	O	O
were	O	O
18%	O	O
and	O	O
30%	O	O
lower	O	O
,	O	O
respectively	O	O
,	O	O
than	O	O
control	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
any	O	O
parameter	O	O
between	O	O
metoprolol	B-Chemical	D008790
and	O	O
metoprolol	B-Chemical	D008790
-	O	O
glucagon	O	O
.	O	O

CONCLUSION	O	O
:	O	O
During	O	O
dobutamine	B-Chemical	D004280
stress	O	O
testing	O	O
,	O	O
metoprolol	B-Chemical	D008790
attenuates	O	O
or	O	O
eliminates	O	O
evidence	O	O
of	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

Glucagon	O	O
1	O	O
mg	O	O
,	O	O
although	O	O
somewhat	O	O
effective	O	O
,	O	O
does	O	O
not	O	O
correct	O	O
this	O	O
effect	O	O
to	O	O
the	O	O
extent	O	O
that	O	O
it	O	O
can	O	O
be	O	O
administered	O	O
clinically	O	O
.	O	O

Prednisolone	B-Chemical	D011239
-	O	O
induced	O	O
muscle	B-Disease	D018908
dysfunction	I-Disease	D018908
is	O	O
caused	O	O
more	O	O
by	O	O
atrophy	B-Disease	D001284
than	O	O
by	O	O
altered	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
expression	O	O
.	O	O

Large	O	O
doses	O	O
of	O	O
glucocorticoids	O	O
can	O	O
alter	O	O
muscle	O	O
physiology	O	O
and	O	O
susceptibility	O	O
to	O	O
neuromuscular	O	O
blocking	O	O
drugs	O	O
by	O	O
mechanisms	O	O
not	O	O
clearly	O	O
understood	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
moderate	O	O
and	O	O
large	O	O
doses	O	O
of	O	O
prednisolone	B-Chemical	D011239
on	O	O
muscle	O	O
function	O	O
and	O	O
pharmacology	O	O
,	O	O
and	O	O
their	O	O
relationship	O	O
to	O	O
changes	O	O
in	O	O
muscle	O	O
size	O	O
and	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
(	O	O
AChR	O	O
)	O	O
expression	O	O
.	O	O

With	O	O
institutional	O	O
approval	O	O
,	O	O
35	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
randomly	O	O
allocated	O	O
to	O	O
receive	O	O
daily	O	O
subcutaneous	O	O
doses	O	O
of	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
prednisolone	B-Chemical	D011239
(	O	O
P10	O	O
group	O	O
)	O	O
,	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
prednisolone	B-Chemical	D011239
(	O	O
P100	O	O
group	O	O
)	O	O
,	O	O
or	O	O
an	O	O
equal	O	O
volume	O	O
of	O	O
saline	O	O
(	O	O
S	O	O
group	O	O
)	O	O
for	O	O
7	O	O
days	O	O
.	O	O

A	O	O
fourth	O	O
group	O	O
of	O	O
rats	O	O
was	O	O
pair	O	O
fed	O	O
(	O	O
food	O	O
restricted	O	O
)	O	O
with	O	O
the	O	O
P100	O	O
rats	O	O
for	O	O
7	O	O
days	O	O
(	O	O
FR	O	O
group	O	O
)	O	O
.	O	O

On	O	O
Day	O	O
8	O	O
,	O	O
the	O	O
nerve	O	O
-	O	O
evoked	O	O
peak	O	O
twitch	O	O
tensions	O	O
,	O	O
tetanic	B-Disease	D013746
tensions	O	O
,	O	O
and	O	O
fatigability	O	O
,	O	O
and	O	O
the	O	O
dose	O	O
-	O	O
response	O	O
curves	O	O
of	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
in	O	O
the	O	O
tibialis	O	O
cranialis	O	O
muscle	O	O
were	O	O
measured	O	O
in	O	O
vivo	O	O
and	O	O
related	O	O
to	O	O
muscle	O	O
mass	O	O
or	O	O
expression	O	O
of	O	O
AChRs	O	O
.	O	O

Rate	O	O
of	O	O
body	O	O
weight	O	O
gain	O	O
was	O	O
depressed	O	O
in	O	O
the	O	O
P100	O	O
,	O	O
FR	O	O
,	O	O
and	O	O
P10	O	O
groups	O	O
compared	O	O
with	O	O
the	O	O
S	O	O
group	O	O
.	O	O

Tibialis	O	O
muscle	O	O
mass	O	O
was	O	O
smaller	O	O
in	O	O
the	O	O
P100	O	O
group	O	O
than	O	O
in	O	O
the	O	O
P10	O	O
or	O	O
S	O	O
groups	O	O
.	O	O

The	O	O
evoked	O	O
peak	O	O
twitch	O	O
and	O	O
tetanic	B-Disease	D013746
tensions	O	O
were	O	O
less	O	O
in	O	O
the	O	O
P100	O	O
group	O	O
than	O	O
in	O	O
the	O	O
P10	O	O
or	O	O
S	O	O
groups	O	O
,	O	O
however	O	O
,	O	O
tension	O	O
per	O	O
milligram	O	O
of	O	O
muscle	O	O
mass	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
P100	O	O
group	O	O
than	O	O
in	O	O
the	O	O
S	O	O
group	O	O
.	O	O

The	O	O
50%	O	O
effective	O	O
dose	O	O
of	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
(	O	O
microg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
the	O	O
tibialis	O	O
muscle	O	O
was	O	O
smaller	O	O
in	O	O
the	O	O
P10	O	O
(	O	O
33	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

4	O	O
)	O	O
than	O	O
in	O	O
the	O	O
S	O	O
(	O	O
61	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

0	O	O
)	O	O
or	O	O
the	O	O
P100	O	O
(	O	O
71	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
9	O	O
.	O	O

6	O	O
)	O	O
groups	O	O
.	O	O

AChR	O	O
expression	O	O
was	O	O
less	O	O
in	O	O
the	O	O
P10	O	O
group	O	O
than	O	O
in	O	O
the	O	O
S	O	O
group	O	O
.	O	O

The	O	O
evoked	O	O
tensions	O	O
correlated	O	O
with	O	O
muscle	O	O
mass	O	O
(	O	O
r	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O

32	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
however	O	O
,	O	O
not	O	O
with	O	O
expression	O	O
of	O	O
AChR	O	O
.	O	O

The	O	O
50%	O	O
effective	O	O
dose	O	O
of	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
did	O	O
not	O	O
correlate	O	O
with	O	O
muscle	O	O
mass	O	O
or	O	O
AChR	O	O
expression	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
neuromuscular	B-Disease	D009468
dysfunction	I-Disease	D009468
after	O	O
prednisolone	B-Chemical	D011239
is	O	O
dose	O	O
-	O	O
dependent	O	O
,	O	O
and	O	O
derives	O	O
primarily	O	O
from	O	O
muscle	B-Disease	D009133
atrophy	I-Disease	D009133
and	O	O
derives	O	O
less	O	O
so	O	O
from	O	O
changes	O	O
in	O	O
AChR	O	O
expression	O	O
.	O	O

IMPLICATIONS	O	O
:	O	O
The	O	O
mechanisms	O	O
by	O	O
which	O	O
chronic	O	O
glucocorticoid	O	O
therapy	O	O
alters	O	O
neuromuscular	O	O
physiology	O	O
and	O	O
pharmacology	O	O
are	O	O
unclear	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
the	O	O
observed	O	O
effects	O	O
are	O	O
dose	O	O
-	O	O
dependent	O	O
and	O	O
derive	O	O
primarily	O	O
from	O	O
muscle	B-Disease	D009133
atrophy	I-Disease	D009133
and	O	O
derive	O	O
less	O	O
from	O	O
changes	O	O
in	O	O
acetylcholine	B-Chemical	D000109
receptor	O	O
expression	O	O
.	O	O

Rapid	O	O
reversal	O	O
of	O	O
life	O	O
-	O	O
threatening	O	O
diltiazem	B-Chemical	D004110
-	O	O
induced	O	O
tetany	B-Disease	D013746
with	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
tetany	B-Disease	D013746
with	O	O
sudden	O	O
respiratory	B-Disease	D012131
arrest	I-Disease	D012131
after	O	O
the	O	O
infusion	O	O
of	O	O
intravenous	O	O
diltiazem	B-Chemical	D004110
.	O	O

The	O	O
administration	O	O
of	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
rapidly	O	O
resolved	O	O
the	O	O
patient's	O	O
tetany	B-Disease	D013746
with	O	O
prompt	O	O
recovery	O	O
of	O	O
respiratory	O	O
function	O	O
,	O	O
averting	O	O
the	O	O
need	O	O
for	O	O
more	O	O
aggressive	O	O
airway	O	O
management	O	O
and	O	O
ventilatory	O	O
support	O	O
.	O	O

The	O	O
emergency	O	O
physician	O	O
should	O	O
be	O	O
aware	O	O
that	O	O
life	O	O
-	O	O
threatening	O	O
tetany	B-Disease	D013746
may	O	O
accompany	O	O
the	O	O
administration	O	O
of	O	O
intravenous	O	O
diltiazem	B-Chemical	D004110
and	O	O
that	O	O
calcium	B-Chemical	D002122
chloride	I-Chemical	D002122
may	O	O
be	O	O
a	O	O
rapid	O	O
and	O	O
effective	O	O
remedy	O	O
.	O	O

Effects	O	O
of	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
on	O	O
hemostasis	O	O
in	O	O
patients	O	O
with	O	O
aneurysmal	B-Disease	D013345
subarachnoid	I-Disease	D013345
hemorrhage	I-Disease	D013345
.	O	O

Platelet	O	O
function	O	O
is	O	O
impaired	O	O
by	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
with	O	O
prominent	O	O
anti	O	O
-	O	O
inflammatory	O	O
properties	O	O
.	O	O

Their	O	O
safety	O	O
in	O	O
patients	O	O
undergoing	O	O
intracranial	O	O
surgery	O	O
is	O	O
under	O	O
debate	O	O
.	O	O

Patients	O	O
with	O	O
aneurysmal	B-Disease	D013345
subarachnoid	I-Disease	D013345
hemorrhage	I-Disease	D013345
(	O	O
SAH	B-Disease	D013345
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
ketoprofen	B-Chemical	D007660
,	O	O
100	O	O
mg	O	O
,	O	O
three	O	O
times	O	O
a	O	O
day	O	O
(	O	O
ketoprofen	B-Chemical	D007660
group	O	O
,	O	O
n	O	O
=	O	O
9	O	O
)	O	O
or	O	O
a	O	O
weak	O	O
NSAID	O	O
,	O	O
acetaminophen	B-Chemical	D000082
,	O	O
1	O	O
g	O	O
,	O	O
three	O	O
times	O	O
a	O	O
day	O	O
(	O	O
acetaminophen	B-Chemical	D000082
group	O	O
,	O	O
n	O	O
=	O	O
9	O	O
)	O	O
starting	O	O
immediately	O	O
after	O	O
the	O	O
diagnosis	O	O
of	O	O
aneurysmal	B-Disease	D017542
SAH	B-Disease	D013345
.	O	O

Treatment	O	O
was	O	O
continued	O	O
for	O	O
3	O	O
days	O	O
postoperatively	O	O
.	O	O

Test	O	O
blood	O	O
samples	O	O
were	O	O
taken	O	O
before	O	O
treatment	O	O
and	O	O
surgery	O	O
as	O	O
well	O	O
as	O	O
on	O	O
the	O	O
first	O	O
,	O	O
third	O	O
,	O	O
and	O	O
fifth	O	O
postoperative	O	O
mornings	O	O
.	O	O

Maximal	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
induced	O	O
by	O	O
6	O	O
microM	O	O
of	O	O
adenosine	B-Chemical	D000244
diphosphate	I-Chemical	D000244
decreased	O	O
after	O	O
administration	O	O
of	O	O
ketoprofen	B-Chemical	D007660
.	O	O

Aggregation	O	O
was	O	O
lower	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
in	O	O
the	O	O
ketoprofen	B-Chemical	D007660
group	O	O
than	O	O
in	O	O
the	O	O
acetaminophen	B-Chemical	D000082
group	O	O
just	O	O
before	O	O
surgery	O	O
and	O	O
on	O	O
the	O	O
third	O	O
postoperative	O	O
day	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
maximal	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
increased	O	O
in	O	O
the	O	O
acetaminophen	B-Chemical	D000082
group	O	O
on	O	O
the	O	O
third	O	O
postoperative	O	O
day	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
pretreatment	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
results	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
.	O	O

One	O	O
patient	O	O
in	O	O
the	O	O
ketoprofen	B-Chemical	D007660
group	O	O
developed	O	O
a	O	O
postoperative	O	O
intracranial	O	O
hematoma	B-Disease	D006406
.	O	O

Coagulation	O	O
(	O	O
prothrombin	O	O
time	O	O
[	O	O
PT	O	O
]	O	O
,	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
time	O	O
[	O	O
APPT	O	O
]	O	O
,	O	O
fibrinogen	O	O
concentration	O	O
,	O	O
and	O	O
antithrombin	O	O
III	O	O
[	O	O
AT	O	O
III	O	O
]	O	O
)	O	O
was	O	O
comparable	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

Ketoprofen	B-Chemical	D007660
but	O	O
not	O	O
acetaminophen	B-Chemical	D000082
impaired	O	O
platelet	O	O
function	O	O
in	O	O
patients	O	O
with	O	O
SAH	B-Disease	D013345
.	O	O

If	O	O
ketoprofen	B-Chemical	D007660
is	O	O
used	O	O
before	O	O
surgery	O	O
on	O	O
cerebral	O	O
artery	B-Disease	D002532
aneurysms	I-Disease	D002532
,	O	O
it	O	O
may	O	O
pose	O	O
an	O	O
additional	O	O
risk	O	O
factor	O	O
for	O	O
hemorrhage	B-Disease	D006470
.	O	O

Value	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
in	O	O
prevention	O	O
of	O	O
the	O	O
arthralgia	B-Disease	D018771
-	O	O
myalgia	B-Disease	D063806
syndrome	O	O
associated	O	O
with	O	O
the	O	O
total	O	O
dose	O	O
infusion	O	O
of	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
:	O	O
a	O	O
double	O	O
blind	O	O
randomized	O	O
trial	O	O
.	O	O

The	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
total	O	O
dose	O	O
infusion	O	O
(	O	O
TDI	O	O
)	O	O
of	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
has	O	O
been	O	O
well	O	O
documented	O	O
.	O	O

In	O	O
40%	O	O
of	O	O
treated	O	O
patients	O	O
,	O	O
an	O	O
arthralgia	B-Disease	D018771
-	O	O
myalgia	B-Disease	D063806
syndrome	O	O
develops	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
prospective	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
intravenous	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
administration	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
(	O	O
MP	B-Chemical	D008775
)	O	O
prevents	O	O
this	O	O
complication	O	O
.	O	O

Sixty	O	O
-	O	O
five	O	O
patients	O	O
,	O	O
34	O	O
women	O	O
and	O	O
31	O	O
men	O	O
,	O	O
ages	O	O
36	O	O
to	O	O
80	O	O
years	O	O
,	O	O
received	O	O
either	O	O
normal	O	O
saline	O	O
before	O	O
and	O	O
after	O	O
TDI	O	O
(	O	O
group	O	O
1	O	O
)	O	O
,	O	O
125	O	O
mg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

MP	B-Chemical	D008775
before	O	O
and	O	O
saline	O	O
after	O	O
TDI	O	O
(	O	O
group	O	O
2	O	O
)	O	O
,	O	O
or	O	O
125	O	O
mg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

MP	B-Chemical	D008775
before	O	O
and	O	O
after	O	O
TDI	O	O
(	O	O
group	O	O
3	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
observed	O	O
for	O	O
72	O	O
hours	O	O
and	O	O
reactions	O	O
were	O	O
recorded	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
severity	O	O
.	O	O

Fifty	O	O
-	O	O
eight	O	O
percent	O	O
of	O	O
group	O	O
1	O	O
patients	O	O
,	O	O
33%	O	O
of	O	O
group	O	O
2	O	O
,	O	O
and	O	O
26%	O	O
of	O	O
group	O	O
3	O	O
had	O	O
reactions	O	O
to	O	O
TDI	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
reactions	O	O
(	O	O
minimal	O	O
,	O	O
mild	O	O
,	O	O
and	O	O
moderate	O	O
,	O	O
respectively	O	O
)	O	O
was	O	O
as	O	O
follows	O	O
:	O	O
group	O	O
1	O	O
-	O	O
-	O	O
6	O	O
,	O	O
6	O	O
,	O	O
and	O	O
2	O	O
;	O	O
group	O	O
2	O	O
-	O	O
-	O	O
1	O	O
,	O	O
5	O	O
,	O	O
and	O	O
0	O	O
;	O	O
group	O	O
3	O	O
-	O	O
-	O	O
5	O	O
,	O	O
1	O	O
,	O	O
and	O	O
0	O	O
.	O	O

Data	O	O
were	O	O
analyzed	O	O
by	O	O
the	O	O
two	O	O
-	O	O
sided	O	O
Fisher's	O	O
exact	O	O
test	O	O
using	O	O
95%	O	O
confidence	O	O
intervals	O	O
with	O	O
the	O	O
approximation	O	O
of	O	O
Woolf	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
administration	O	O
of	O	O
MP	B-Chemical	D008775
before	O	O
and	O	O
after	O	O
TDI	O	O
reduces	O	O
the	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
the	O	O
arthralgia	B-Disease	D018771
-	O	O
myalgia	B-Disease	D063806
syndrome	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
125	O	O
mg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

MP	B-Chemical	D008775
should	O	O
be	O	O
given	O	O
routinely	O	O
before	O	O
and	O	O
after	O	O
TDI	O	O
of	O	O
iron	B-Chemical	D007505
dextran	I-Chemical	D007505
.	O	O

Long	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
vincristine	B-Chemical	D014750
on	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
.	O	O

Forty	O	O
patients	O	O
with	O	O
Non	B-Disease	D008228
-	I-Disease	D008228
Hodgkin's	I-Disease	D008228
Lymphoma	I-Disease	D008228
treated	O	O
with	O	O
vincristine	B-Chemical	D014750
between	O	O
1984	O	O
and	O	O
1990	O	O
(	O	O
cumulative	O	O
dose	O	O
12	O	O
mg	O	O
in	O	O
18	O	O
-	O	O
24	O	O
weeks	O	O
)	O	O
were	O	O
investigated	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
long	O	O
term	O	O
effects	O	O
of	O	O
vincristine	B-Chemical	D014750
on	O	O
the	O	O
peripheral	O	O
nervous	O	O
system	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
interviewed	O	O
with	O	O
emphasis	O	O
on	O	O
neuropathic	B-Disease	D012678
symptoms	I-Disease	D012678
.	O	O

Physical	O	O
and	O	O
quantitative	O	O
sensory	O	O
examination	O	O
with	O	O
determination	O	O
of	O	O
vibratory	O	O
perception	O	O
and	O	O
thermal	O	O
discrimination	O	O
thresholds	O	O
were	O	O
performed	O	O
,	O	O
four	O	O
to	O	O
77	O	O
months	O	O
(	O	O
median	O	O
34	O	O
months	O	O
)	O	O
after	O	O
vincristine	B-Chemical	D014750
treatment	O	O
.	O	O

Twenty	O	O
-	O	O
seven	O	O
patients	O	O
reported	O	O
neuropathic	B-Disease	D012678
symptoms	I-Disease	D012678
.	O	O

In	O	O
13	O	O
of	O	O
these	O	O
27	O	O
patients	O	O
symptoms	O	O
were	O	O
still	O	O
present	O	O
at	O	O
the	O	O
time	O	O
of	O	O
examination	O	O
.	O	O

In	O	O
these	O	O
patients	O	O
sensory	O	O
signs	O	O
and	O	O
symptoms	O	O
predominated	O	O
.	O	O

In	O	O
the	O	O
other	O	O
14	O	O
patients	O	O
symptoms	O	O
had	O	O
been	O	O
present	O	O
in	O	O
the	O	O
past	O	O
.	O	O

Symptoms	O	O
persisted	O	O
maximally	O	O
40	O	O
months	O	O
since	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

There	O	O
was	O	O
no	O	O
age	O	O
difference	O	O
between	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
complaints	O	O
at	O	O
the	O	O
time	O	O
of	O	O
examination	O	O
.	O	O

Normal	O	O
reflexes	O	O
were	O	O
found	O	O
in	O	O
two	O	O
third	O	O
of	O	O
patients	O	O
.	O	O

Neuropathic	O	O
complaints	O	O
were	O	O
not	O	O
very	O	O
troublesome	O	O
on	O	O
the	O	O
long	O	O
term	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
with	O	O
the	O	O
above	O	O
mentioned	O	O
vincristine	B-Chemical	D014750
dose	O	O
schedule	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
vincristine	B-Chemical	D014750
neuropathy	B-Disease	D009422
are	O	O
reversible	O	O
for	O	O
a	O	O
great	O	O
deal	O	O
and	O	O
prognosis	O	O
is	O	O
fairly	O	O
good	O	O
.	O	O

A	O	O
case	O	O
of	O	O
polymyositis	B-Disease	D017285
in	O	O
a	O	O
patient	O	O
with	O	O
primary	B-Disease	D008105
biliary	I-Disease	D008105
cirrhosis	I-Disease	D008105
treated	O	O
with	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
.	O	O

Although	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
has	O	O
been	O	O
used	O	O
for	O	O
many	O	O
rheumatologic	B-Disease	D012216
diseases	I-Disease	D012216
,	O	O
toxicity	B-Disease	D064420
limits	O	O
its	O	O
usefulness	O	O
in	O	O
many	O	O
patients	O	O
.	O	O

Polymyositis	B-Disease	D017285
/	O	O
dermatomyositis	B-Disease	D003882
can	O	O
develop	O	O
as	O	O
one	O	O
of	O	O
the	O	O
autoimmune	O	O
complications	O	O
of	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
treatment	O	O
,	O	O
but	O	O
its	O	O
exact	O	O
pathogenesis	O	O
remains	O	O
unclear	O	O
.	O	O

We	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
primary	B-Disease	D008105
biliary	I-Disease	D008105
cirrhosis	I-Disease	D008105
,	O	O
who	O	O
developed	O	O
polymyositis	B-Disease	D017285
while	O	O
receiving	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
therapy	O	O
.	O	O

We	O	O
described	O	O
the	O	O
special	O	O
clinical	O	O
course	O	O
of	O	O
the	O	O
patient	O	O
.	O	O

Patients	O	O
receiving	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
penicillamine	I-Chemical	D010396
therapy	O	O
should	O	O
be	O	O
followed	O	O
carefully	O	O
for	O	O
the	O	O
development	O	O
of	O	O
autoimmune	O	O
complications	O	O
like	O	O
polymyositis	B-Disease	D017285
/	O	O
dermatomyositis	B-Disease	D003882
.	O	O

Photodistributed	O	O
nifedipine	B-Chemical	D009543
-	O	O
induced	O	O
facial	O	O
telangiectasia	B-Disease	D013684
.	O	O

Five	O	O
months	O	O
after	O	O
starting	O	O
nifedipine	B-Chemical	D009543
(	O	O
Adalat	B-Chemical	D009543
)	O	O
,	O	O
two	O	O
patients	O	O
developed	O	O
photodistributed	O	O
facial	O	O
telangiectasia	B-Disease	D013684
,	O	O
which	O	O
became	O	O
more	O	O
noticeable	O	O
with	O	O
time	O	O
.	O	O

Neither	O	O
patient	O	O
complained	O	O
of	O	O
photosensitivity	O	O
or	O	O
flushing	B-Disease	D005483
.	O	O

Both	O	O
patients	O	O
reported	O	O
a	O	O
significant	O	O
cosmetic	O	O
improvement	O	O
after	O	O
discontinuing	O	O
the	O	O
drug	O	O
.	O	O

One	O	O
commenced	O	O
the	O	O
closely	O	O
related	O	O
drug	O	O
amlodipine	B-Chemical	D017311
3	O	O
years	O	O
later	O	O
,	O	O
with	O	O
recurrence	O	O
of	O	O
telangiectasia	B-Disease	D013684
.	O	O

The	O	O
photodistribution	O	O
of	O	O
the	O	O
telangiectasia	B-Disease	D013684
suggests	O	O
a	O	O
significant	O	O
drug	O	O
/	O	O
light	O	O
interaction	O	O
.	O	O

Nephrotoxicity	B-Disease	D007674
of	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
:	O	O
inhibition	O	O
of	O	O
calcineurin	O	O
phosphatase	O	O
.	O	O

Cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
(	O	O
CsA	B-Chemical	D016572
;	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
Fujimycine	B-Chemical	D016559
(	O	O
FK506	B-Chemical	D016559
;	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
but	O	O
not	O	O
the	O	O
related	O	O
macrolide	B-Chemical	D018942
immunosuppressant	O	O
rapamycin	B-Chemical	D020123
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
caused	O	O
a	O	O
reduction	O	O
of	O	O
glomerular	O	O
filtration	O	O
rate	O	O
,	O	O
degenerative	O	O
changes	O	O
of	O	O
proximal	O	O
tubular	O	O
epithelium	O	O
,	O	O
and	O	O
hypertrophy	B-Disease	D006984
of	O	O
the	O	O
juxtaglomerular	O	O
apparatus	O	O
in	O	O
male	O	O
Wistar	O	O
rats	O	O
when	O	O
given	O	O
for	O	O
10	O	O
days	O	O
.	O	O

The	O	O
molecular	O	O
mechanisms	O	O
of	O	O
CsA	B-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
toxicity	B-Disease	D064420
were	O	O
investigated	O	O
.	O	O

Cyclophilin	O	O
A	O	O
and	O	O
FK506	B-Chemical	D016559
-	O	O
binding	O	O
protein	O	O
,	O	O
the	O	O
main	O	O
intracytoplasmic	O	O
receptors	O	O
for	O	O
CsA	B-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
,	O	O
respectively	O	O
,	O	O
were	O	O
each	O	O
detected	O	O
in	O	O
renal	O	O
tissue	O	O
extract	O	O
.	O	O

In	O	O
the	O	O
kidney	O	O
,	O	O
high	O	O
levels	O	O
of	O	O
immunoreactive	O	O
and	O	O
enzymatically	O	O
active	O	O
calcineurin	O	O
were	O	O
found	O	O
which	O	O
were	O	O
inhibited	O	O
by	O	O
the	O	O
immunosuppressants	O	O
CsA	B-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
,	O	O
but	O	O
not	O	O
by	O	O
rapamycin	B-Chemical	D020123
.	O	O

Finally	O	O
,	O	O
specific	O	O
immunophilin	O	O
-	O	O
drug	O	O
-	O	O
calcineurin	O	O
complexes	O	O
formed	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
CsA	B-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
,	O	O
but	O	O
not	O	O
rapamycin	B-Chemical	D020123
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
nephrotoxic	B-Disease	D007674
effects	O	O
of	O	O
CsA	B-Chemical	D016572
and	O	O
FK506	B-Chemical	D016559
is	O	O
likely	O	O
mediated	O	O
through	O	O
binding	O	O
to	O	O
renal	O	O
immunophilin	O	O
and	O	O
inhibiting	O	O
calcineurin	O	O
phosphatase	O	O
.	O	O

Massive	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
associated	O	O
with	O	O
fulminant	B-Disease	D017093
hepatic	I-Disease	D017093
failure	I-Disease	D017093
in	O	O
acetaminophen	B-Chemical	D000082
overdose	B-Disease	D062787
:	O	O
possible	O	O
role	O	O
of	O	O
cranial	O	O
decompression	O	O
.	O	O

Cerebral	B-Disease	D001929
edema	I-Disease	D001929
may	O	O
complicate	O	O
the	O	O
course	O	O
of	O	O
fulminant	B-Disease	D017093
hepatic	I-Disease	D017093
failure	I-Disease	D017093
.	O	O

Response	O	O
to	O	O
conventional	O	O
therapy	O	O
has	O	O
been	O	O
disappointing	O	O
.	O	O

We	O	O
present	O	O
a	O	O
patient	O	O
with	O	O
fatal	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
fulminant	B-Disease	D017093
hepatic	I-Disease	D017093
failure	I-Disease	D017093
,	O	O
with	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
,	O	O
unresponsive	O	O
to	O	O
conventional	O	O
medical	O	O
therapy	O	O
.	O	O

Cranial	O	O
decompression	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

A	O	O
justification	O	O
of	O	O
the	O	O
need	O	O
for	O	O
further	O	O
evaluation	O	O
of	O	O
cranial	O	O
decompression	O	O
in	O	O
such	O	O
patients	O	O
is	O	O
presented	O	O
.	O	O

Gentamicin	B-Chemical	D005839
nephropathy	B-Disease	D007674
in	O	O
a	O	O
neonate	O	O
.	O	O

The	O	O
clinical	O	O
and	O	O
autopsy	O	O
findings	O	O
in	O	O
a	O	O
premature	O	O
baby	O	O
who	O	O
died	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
after	O	O
therapy	O	O
with	O	O
gentamicin	B-Chemical	D005839
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
and	O	O
penicillin	B-Chemical	D010406
are	O	O
presented	O	O
.	O	O

The	O	O
serum	O	O
gentamicin	B-Chemical	D005839
concentration	O	O
had	O	O
reached	O	O
toxic	O	O
levels	O	O
when	O	O
anuria	B-Disease	D001002
developed	O	O
.	O	O

Numerous	O	O
periodic	B-Chemical	D010504
acid	I-Chemical	D010504
Schiff	O	O
(	O	O
PAS	O	O
)	O	O
positive	O	O
,	O	O
diastase	O	O
resistant	O	O
cytoplasmic	O	O
inclusion	O	O
bodies	O	O
which	O	O
appeared	O	O
as	O	O
myelin	O	O
figures	O	O
in	O	O
cytosegresomes	O	O
under	O	O
the	O	O
electron	O	O
microscope	O	O
were	O	O
identified	O	O
in	O	O
the	O	O
proximal	O	O
convoluted	O	O
tubules	O	O
.	O	O

The	O	O
pathological	O	O
changes	O	O
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
in	O	O
the	O	O
human	O	O
neonatal	O	O
kidneys	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Anti	O	O
-	O	O
carcinogenic	B-Disease	D063646
action	O	O
of	O	O
phenobarbital	B-Chemical	D010634
given	O	O
simultaneously	O	O
with	O	O
diethylnitrosamine	B-Chemical	D004052
in	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
present	O	O
work	O	O
has	O	O
been	O	O
planned	O	O
in	O	O
order	O	O
to	O	O
elucidate	O	O
the	O	O
effect	O	O
of	O	O
phenobarbital	B-Chemical	D010634
(	O	O
PB	B-Chemical	D010634
:	O	O
15	O	O
mg	O	O
per	O	O
rat	O	O
of	O	O
ingested	O	O
dose	O	O
)	O	O
on	O	O
carcinogenesis	B-Disease	D063646
when	O	O
it	O	O
is	O	O
administered	O	O
simultaneously	O	O
with	O	O
diethylnitrosamine	B-Chemical	D004052
(	O	O
DEN	B-Chemical	D004052
:	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

Wistar	O	O
rats	O	O
(	O	O
180	O	O
g	O	O
)	O	O
were	O	O
treated	O	O
by	O	O
DEN	B-Chemical	D004052
alone	O	O
or	O	O
by	O	O
DEN	B-Chemical	D004052
+	O	O
PB	B-Chemical	D010634
during	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
weeks	O	O
according	O	O
to	O	O
our	O	O
schedule	O	O
for	O	O
hepatocarcinogenesis	B-Disease	D063646
.	O	O

After	O	O
the	O	O
end	O	O
of	O	O
the	O	O
treatment	O	O
,	O	O
the	O	O
number	O	O
and	O	O
the	O	O
size	O	O
of	O	O
induced	O	O
PAS	O	O
positive	O	O
preneoplastic	B-Disease	D011230
foci	I-Disease	D011230
was	O	O
significantly	O	O
reduced	O	O
when	O	O
PB	B-Chemical	D010634
was	O	O
given	O	O
simultaneously	O	O
with	O	O
DEN	B-Chemical	D004052
for	O	O
4	O	O
and	O	O
6	O	O
weeks	O	O
.	O	O

The	O	O
mitotic	O	O
inhibition	O	O
and	O	O
the	O	O
production	O	O
of	O	O
micronuclei	O	O
normally	O	O
observed	O	O
after	O	O
partial	O	O
hepatectomy	O	O
in	O	O
DEN	B-Chemical	D004052
treated	O	O
rats	O	O
were	O	O
also	O	O
significantly	O	O
decreased	O	O
in	O	O
DEN	B-Chemical	D004052
+	O	O
PB	B-Chemical	D010634
treated	O	O
rats	O	O
.	O	O

When	O	O
the	O	O
treatment	O	O
last	O	O
only	O	O
2	O	O
weeks	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
PB	B-Chemical	D010634
did	O	O
not	O	O
change	O	O
significantly	O	O
the	O	O
last	O	O
parameters	O	O
.	O	O

In	O	O
DEN	B-Chemical	D004052
+	O	O
PB	B-Chemical	D010634
treated	O	O
rats	O	O
,	O	O
the	O	O
survival	O	O
was	O	O
prolonged	O	O
and	O	O
the	O	O
tumor	B-Disease	D009369
incidence	O	O
decreased	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
results	O	O
obtained	O	O
by	O	O
DEN	B-Chemical	D004052
alone	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
PB	B-Chemical	D010634
,	O	O
which	O	O
promotes	O	O
carcinogenesis	B-Disease	D063646
when	O	O
administered	O	O
after	O	O
the	O	O
DEN	B-Chemical	D004052
treatment	O	O
,	O	O
reduces	O	O
the	O	O
carcinogen	O	O
effect	O	O
when	O	O
given	O	O
simultaneously	O	O
with	O	O
DEN	B-Chemical	D004052
.	O	O

This	O	O
'anti	O	O
-	O	O
carcinogen'	O	O
effect	O	O
acts	O	O
on	O	O
the	O	O
initiation	O	O
as	O	O
well	O	O
as	O	O
on	O	O
the	O	O
promotion	O	O
of	O	O
the	O	O
precancerous	B-Disease	D011230
lesions	I-Disease	D011230
.	O	O

Biochemical	O	O
investigations	O	O
are	O	O
in	O	O
progress	O	O
to	O	O
obtain	O	O
more	O	O
information	O	O
about	O	O
this	O	O
'paradoxical'	O	O
PB	B-Chemical	D010634
effect	O	O
.	O	O

Post	O	O
-	O	O
operative	O	O
rigidity	B-Disease	D009127
after	O	O
fentanyl	B-Chemical	D005283
administration	O	O
.	O	O

A	O	O
case	O	O
of	O	O
thoraco	O	O
-	O	O
abdominal	O	O
rigidity	B-Disease	D009127
leading	O	O
to	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
is	O	O
described	O	O
in	O	O
the	O	O
post	O	O
-	O	O
operative	O	O
period	O	O
in	O	O
an	O	O
elderly	O	O
patient	O	O
who	O	O
received	O	O
a	O	O
moderate	O	O
dose	O	O
of	O	O
fentanyl	B-Chemical	D005283
.	O	O

This	O	O
was	O	O
successfully	O	O
reversed	O	O
by	O	O
naloxone	B-Chemical	D009270
.	O	O

The	O	O
mechanisms	O	O
possibly	O	O
implicated	O	O
in	O	O
this	O	O
accident	O	O
are	O	O
discussed	O	O
.	O	O

Postpartum	O	O
psychosis	B-Disease	D011605
induced	O	O
by	O	O
bromocriptine	B-Chemical	D001971
.	O	O

Two	O	O
multigravida	O	O
patients	O	O
with	O	O
no	O	O
prior	O	O
psychiatric	B-Disease	D001523
history	O	O
were	O	O
seen	O	O
with	O	O
postpartum	O	O
psychosis	B-Disease	D011605
,	O	O
having	O	O
received	O	O
bromocriptine	B-Chemical	D001971
for	O	O
inhibition	B-Disease	D007775
of	I-Disease	D007775
lactation	I-Disease	D007775
.	O	O

Bromocriptine	B-Chemical	D001971
given	O	O
in	O	O
high	O	O
doses	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
psychosis	B-Disease	D011605
in	O	O
patients	O	O
receiving	O	O
the	O	O
drug	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

These	O	O
cases	O	O
demonstrate	O	O
that	O	O
bromocriptine	B-Chemical	D001971
may	O	O
cause	O	O
psychosis	B-Disease	D011605
even	O	O
when	O	O
given	O	O
in	O	O
low	O	O
doses	O	O
.	O	O

A	O	O
prospective	O	O
study	O	O
on	O	O
the	O	O
dose	O	O
dependency	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
induced	O	O
by	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
.	O	O

Since	O	O
1975	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
(	O	O
MMC	B-Chemical	D016685
)	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
be	O	O
cardiotoxic	B-Disease	D066126
,	O	O
especially	O	O
when	O	O
combined	O	O
with	O	O
or	O	O
given	O	O
following	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Data	O	O
on	O	O
dose	O	O
dependency	O	O
or	O	O
incidence	O	O
concerning	O	O
this	O	O
side	O	O
effect	O	O
were	O	O
not	O	O
known	O	O
.	O	O

We	O	O
have	O	O
initiated	O	O
a	O	O
prospective	O	O
study	O	O
to	O	O
obtain	O	O
some	O	O
more	O	O
data	O	O
on	O	O
these	O	O
subjects	O	O
.	O	O

Forty	O	O
-	O	O
four	O	O
MMC	B-Chemical	D016685
-	O	O
treated	O	O
patients	O	O
were	O	O
studied	O	O
,	O	O
37	O	O
of	O	O
them	O	O
could	O	O
be	O	O
evaluated	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
studied	O	O
by	O	O
repeated	O	O
physical	O	O
examinations	O	O
,	O	O
chest	O	O
X	O	O
-	O	O
rays	O	O
,	O	O
electro	O	O
-	O	O
and	O	O
echocardiography	O	O
and	O	O
radionuclide	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
EF	O	O
)	O	O
determinations	O	O
.	O	O

The	O	O
results	O	O
were	O	O
evaluated	O	O
per	O	O
cumulative	O	O
dose	O	O
level	O	O
.	O	O

One	O	O
of	O	O
the	O	O
patients	O	O
developed	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
after	O	O
30	O	O
mg	O	O
m	O	O
-	O	O
2	O	O
MMC	B-Chemical	D016685
and	O	O
only	O	O
150	O	O
mg	O	O
m	O	O
-	O	O
2	O	O
doxorubicin	B-Chemical	D004317
.	O	O

The	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
was	O	O
predicted	O	O
by	O	O
a	O	O
drop	O	O
in	O	O
EF	O	O
determined	O	O
during	O	O
a	O	O
cold	O	O
pressor	O	O
test	O	O
.	O	O

None	O	O
of	O	O
the	O	O
other	O	O
patients	O	O
developed	O	O
clinical	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
nor	O	O
did	O	O
the	O	O
studied	O	O
parameters	O	O
change	O	O
.	O	O

The	O	O
literature	O	O
on	O	O
this	O	O
subject	O	O
was	O	O
also	O	O
reviewed	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
combined	O	O
data	O	O
from	O	O
the	O	O
present	O	O
study	O	O
and	O	O
the	O	O
literature	O	O
,	O	O
we	O	O
suggest	O	O
that	O	O
MMC	B-Chemical	D016685
-	O	O
related	O	O
cardiotoxicity	B-Disease	D066126
is	O	O
dose	O	O
dependent	O	O
,	O	O
occurring	O	O
at	O	O
cumulative	O	O
dose	O	O
levels	O	O
of	O	O
30	O	O
mg	O	O
m	O	O
-	O	O
2	O	O
or	O	O
more	O	O
,	O	O
mainly	O	O
in	O	O
patients	O	O
also	O	O
(	O	O
previously	O	O
or	O	O
simultaneously	O	O
)	O	O
treated	O	O
with	O	O
doxorubicin	B-Chemical	D004317
.	O	O

The	O	O
incidence	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
less	O	O
than	O	O
10%	O	O
even	O	O
for	O	O
this	O	O
risk	O	O
group	O	O
.	O	O

Phlorizin	B-Chemical	D010695
-	O	O
induced	O	O
glycosuria	B-Disease	D006029
does	O	O
not	O	O
prevent	O	O
gentamicin	B-Chemical	D005839
nephrotoxicity	B-Disease	D007674
in	O	O
rats	O	O
.	O	O

Because	O	O
rats	O	O
with	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
(	O	O
DM	B-Disease	D003920
)	O	O
have	O	O
a	O	O
high	O	O
solute	O	O
diuresis	O	O
(	O	O
glycosuria	B-Disease	D006029
of	O	O
10	O	O
to	O	O
12	O	O
g	O	O
/	O	O
day	O	O
)	O	O
,	O	O
we	O	O
have	O	O
suggested	O	O
that	O	O
this	O	O
may	O	O
in	O	O
part	O	O
be	O	O
responsible	O	O
for	O	O
their	O	O
resistance	O	O
to	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
(	O	O
ARF	B-Disease	D058186
)	O	O
.	O	O

The	O	O
protection	O	O
from	O	O
gentamicin	B-Chemical	D005839
nephrotoxicity	B-Disease	D007674
was	O	O
studied	O	O
in	O	O
non	O	O
-	O	O
diabetic	B-Disease	D003920
rats	O	O
with	O	O
chronic	O	O
solute	O	O
diuresis	O	O
induced	O	O
by	O	O
blockage	O	O
of	O	O
tubular	O	O
glucose	B-Chemical	D005947
reabsorption	O	O
with	O	O
phlorizin	B-Chemical	D010695
(	O	O
P	B-Chemical	D010695
)	O	O
.	O	O

DM	B-Disease	D003920
rats	O	O
with	O	O
mild	O	O
glycosuria	B-Disease	D006029
(	O	O
similar	O	O
in	O	O
degree	O	O
to	O	O
that	O	O
of	O	O
the	O	O
P	B-Chemical	D010695
treated	O	O
animals	O	O
)	O	O
were	O	O
also	O	O
studied	O	O
.	O	O

Unanesthetized	O	O
adult	O	O
female	O	O
,	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
divided	O	O
in	O	O
four	O	O
groups	O	O
and	O	O
studied	O	O
for	O	O
15	O	O
days	O	O
.	O	O

Group	O	O
1	O	O
(	O	O
P	B-Chemical	D010695
alone	O	O
)	O	O
received	O	O
P	B-Chemical	D010695
,	O	O
360	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
for	O	O
15	O	O
days	O	O
;	O	O
Group	O	O
II	O	O
(	O	O
P	B-Chemical	D010695
+	O	O
gentamicin	B-Chemical	D005839
)	O	O
;	O	O
Group	O	O
III	O	O
(	O	O
gentamicin	B-Chemical	D005839
alone	O	O
)	O	O
and	O	O
Group	O	O
IV	O	O
(	O	O
mild	O	O
DM	B-Disease	D003920
+	O	O
gentamicin	B-Chemical	D005839
)	O	O
.	O	O

Nephrotoxic	B-Disease	D007674
doses	O	O
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
/	O	O
day	O	O
)	O	O
of	O	O
gentamicin	B-Chemical	D005839
were	O	O
injected	O	O
during	O	O
the	O	O
last	O	O
nine	O	O
days	O	O
of	O	O
study	O	O
to	O	O
the	O	O
animals	O	O
of	O	O
groups	O	O
II	O	O
to	O	O
IV	O	O
.	O	O

In	O	O
Group	O	O
I	O	O
,	O	O
P	B-Chemical	D010695
induced	O	O
a	O	O
moderate	O	O
and	O	O
stable	O	O
glycosuria	B-Disease	D006029
(	O	O
3	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
g	O	O
/	O	O
day	O	O
,	O	O
SE	O	O
)	O	O
,	O	O
and	O	O
no	O	O
functional	O	O
or	O	O
morphologic	O	O
evidence	O	O
of	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
(	O	O
baseline	O	O
CCr	O	O
2	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
ml	O	O
/	O	O
min	O	O
,	O	O
undetectable	O	O
lysozymuria	O	O
)	O	O
or	O	O
damage	O	O
(	O	O
tubular	B-Disease	D009956
necrosis	I-Disease	D009956
score	O	O
[	O	O
maximum	O	O
4	O	O
]	O	O
,	O	O
zero	O	O
)	O	O
.	O	O

In	O	O
Group	O	O
II	O	O
,	O	O
P	B-Chemical	D010695
did	O	O
not	O	O
prevent	O	O
gentamicin	B-Chemical	D005839
-	O	O
ARF	B-Disease	D058186
(	O	O
maximal	O	O
decrease	O	O
in	O	O
CCr	O	O
at	O	O
day	O	O
9	O	O
.	O	O

89%	O	O
,	O	O
P	B-Chemical	D010695
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
;	O	O
peak	O	O
lysozymuria	O	O
,	O	O
1863	O	O
+	O	O
/	O	O
-	O	O
321	O	O
micrograms	O	O
/	O	O
day	O	O
;	O	O
and	O	O
tubular	B-Disease	D009956
necrosis	I-Disease	D009956
score	O	O
,	O	O
3	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
)	O	O
.	O	O

These	O	O
values	O	O
were	O	O
not	O	O
different	O	O
from	O	O
those	O	O
of	O	O
Group	O	O
III	O	O
:	O	O
maximal	O	O
decrease	O	O
in	O	O
CCr	O	O
73%	O	O
(	O	O
P	B-Chemical	D010695
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
lysozymuria	O	O
,	O	O
2147	O	O
+	O	O
/	O	O
-	O	O
701	O	O
micrograms	O	O
/	O	O
day	O	O
;	O	O
tubular	B-Disease	D009956
necrosis	I-Disease	D009956
score	O	O
,	O	O
3	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Tiapride	B-Chemical	D063325
in	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
involuntary	B-Disease	D004409
movements	I-Disease	D004409
.	O	O

Tiapride	B-Chemical	D063325
,	O	O
a	O	O
substituted	O	O
benzamide	B-Chemical	C037689
derivative	O	O
closely	O	O
related	O	O
to	O	O
metoclopramide	B-Chemical	D008787
,	O	O
reduced	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
peak	O	O
dose	O	O
involuntary	B-Disease	D004409
movements	I-Disease	D004409
in	O	O
16	O	O
patients	O	O
with	O	O
idiopathic	B-Disease	D010300
Parkinson's	I-Disease	D010300
disease	I-Disease	D010300
.	O	O

However	O	O
,	O	O
an	O	O
unacceptable	O	O
increase	O	O
in	O	O
disability	O	O
from	O	O
Parkinsonism	B-Disease	D010300
with	O	O
aggravation	O	O
of	O	O
end	O	O
-	O	O
of	O	O
-	O	O
dose	O	O
akinesia	B-Disease	D004409
led	O	O
to	O	O
its	O	O
cessation	O	O
in	O	O
14	O	O
patients	O	O
.	O	O

Tiapride	B-Chemical	D063325
had	O	O
no	O	O
effect	O	O
on	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
early	O	O
morning	O	O
of	O	O
"off	O	O
-	O	O
period"	O	O
segmental	O	O
dystonia	B-Disease	D004421
.	O	O

These	O	O
results	O	O
fail	O	O
to	O	O
support	O	O
the	O	O
notion	O	O
that	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
are	O	O
caused	O	O
by	O	O
overstimulation	O	O
of	O	O
a	O	O
separate	O	O
group	O	O
of	O	O
dopamine	B-Chemical	D004298
receptors	O	O
.	O	O

Effects	O	O
of	O	O
the	O	O
hippocampal	O	O
deep	O	O
brain	O	O
stimulation	O	O
on	O	O
cortical	O	O
epileptic	B-Disease	D004827
discharges	O	O
in	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
epilepsy	B-Disease	D004827
model	O	O
in	O	O
rats	O	O
.	O	O

AIM	O	O
:	O	O
Experimental	O	O
and	O	O
clinical	O	O
studies	O	O
have	O	O
revealed	O	O
that	O	O
hippocampal	O	O
DBS	O	O
can	O	O
control	O	O
epileptic	B-Disease	D004827
activity	O	O
,	O	O
but	O	O
the	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
obscure	O	O
and	O	O
optimal	O	O
stimulation	O	O
parameters	O	O
are	O	O
not	O	O
clearly	O	O
defined	O	O
.	O	O

The	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
high	O	O
frequency	O	O
hippocampal	O	O
stimulation	O	O
on	O	O
cortical	O	O
epileptic	B-Disease	D004827
activity	O	O
in	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
epilepsy	B-Disease	D004827
model	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
Twenty	O	O
-	O	O
five	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
were	O	O
implanted	O	O
DBS	O	O
electrodes	O	O
.	O	O

In	O	O
group	O	O
-	O	O
1	O	O
(	O	O
n=10	O	O
)	O	O
hippocampal	O	O
DBS	O	O
was	O	O
off	O	O
and	O	O
in	O	O
the	O	O
group	O	O
-	O	O
2	O	O
(	O	O
n=10	O	O
)	O	O
hippocampal	O	O
DBS	O	O
was	O	O
on	O	O
(	O	O
185	O	O
Hz	O	O
,	O	O
0	O	O
.	O	O

5V	O	O
,	O	O
1V	O	O
,	O	O
2V	O	O
,	O	O
and	O	O
5V	O	O
for	O	O
60	O	O
sec	O	O
)	O	O
following	O	O
penicillin	B-Chemical	D010406
G	O	O
injection	O	O
intracortically	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
hippocampal	O	O
DBS	O	O
was	O	O
on	O	O
following	O	O
8	O	O
l	O	O
saline	O	O
injection	O	O
intracortically	O	O
.	O	O

EEG	O	O
recordings	O	O
were	O	O
obtained	O	O
before	O	O
and	O	O
15	O	O
minutes	O	O
following	O	O
penicillin	B-Chemical	D010406
-	O	O
G	O	O
injection	O	O
,	O	O
and	O	O
at	O	O
10th	O	O
minutes	O	O
following	O	O
each	O	O
stimulus	O	O
for	O	O
analysis	O	O
in	O	O
terms	O	O
of	O	O
frequency	O	O
,	O	O
amplitude	O	O
,	O	O
and	O	O
power	O	O
spectrum	O	O
.	O	O

RESULTS	O	O
:	O	O
High	O	O
frequency	O	O
hippocampal	O	O
DBS	O	O
suppressed	O	O
the	O	O
acute	O	O
penicillin	B-Chemical	D010406
-	O	O
induced	O	O
cortical	O	O
epileptic	B-Disease	D004827
activity	O	O
independent	O	O
from	O	O
stimulus	O	O
intensity	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
,	O	O
hippocampal	O	O
stimulation	O	O
alone	O	O
lead	O	O
only	O	O
to	O	O
diffuse	O	O
slowing	O	O
of	O	O
cerebral	O	O
bioelectrical	O	O
activity	O	O
at	O	O
5V	O	O
stimulation	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
revealed	O	O
that	O	O
continuous	O	O
high	O	O
frequency	O	O
stimulation	O	O
of	O	O
the	O	O
hippocampus	O	O
suppressed	O	O
acute	O	O
cortical	O	O
epileptic	B-Disease	D004827
activity	O	O
effectively	O	O
without	O	O
causing	O	O
secondary	O	O
epileptic	B-Disease	D004827
discharges	O	O
.	O	O

These	O	O
results	O	O
are	O	O
important	O	O
in	O	O
terms	O	O
of	O	O
defining	O	O
the	O	O
optimal	O	O
parameters	O	O
of	O	O
hippocampal	O	O
DBS	O	O
in	O	O
patients	O	O
with	O	O
epilepsy	B-Disease	D004827
.	O	O

Neural	O	O
correlates	O	O
of	O	O
S	B-Chemical	-1
-	I-Chemical	-1
ketamine	I-Chemical	-1
induced	O	O
psychosis	B-Disease	D011605
during	O	O
overt	O	O
continuous	O	O
verbal	O	O
fluency	O	O
.	O	O

The	O	O
glutamatergic	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
has	O	O
been	O	O
implicated	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

Administered	O	O
to	O	O
healthy	O	O
volunteers	O	O
,	O	O
a	O	O
subanesthetic	O	O
dose	O	O
of	O	O
the	O	O
non	O	O
-	O	O
competitive	O	O
NMDA	B-Chemical	D016202
receptor	O	O
antagonist	O	O
ketamine	B-Chemical	D007649
leads	O	O
to	O	O
psychopathological	O	O
symptoms	O	O
similar	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
schizophrenia	B-Disease	D012559
.	O	O

In	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
,	O	O
ketamine	B-Chemical	D007649
exacerbates	O	O
the	O	O
core	O	O
symptoms	O	O
of	O	O
illness	O	O
,	O	O
supporting	O	O
the	O	O
hypothesis	O	O
of	O	O
a	O	O
glutamatergic	B-Disease	D018754
dysfunction	I-Disease	D018754
.	O	O

In	O	O
a	O	O
counterbalanced	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
design	O	O
,	O	O
healthy	O	O
subjects	O	O
were	O	O
administered	O	O
a	O	O
continuous	O	O
subanesthetic	O	O
S	B-Chemical	-1
-	I-Chemical	-1
ketamine	I-Chemical	-1
infusion	O	O
while	O	O
differences	O	O
in	O	O
BOLD	O	O
responses	O	O
measured	O	O
with	O	O
fMRI	O	O
were	O	O
detected	O	O
.	O	O

During	O	O
the	O	O
scanning	O	O
period	O	O
,	O	O
subjects	O	O
performed	O	O
continuous	O	O
overt	O	O
verbal	O	O
fluency	O	O
tasks	O	O
(	O	O
phonological	O	O
,	O	O
lexical	O	O
and	O	O
semantic	O	O
)	O	O
.	O	O

Ketamine	B-Chemical	D007649
-	O	O
induced	O	O
psychopathological	O	O
symptoms	O	O
were	O	O
assessed	O	O
with	O	O
the	O	O
Positive	O	O
and	O	O
Negative	O	O
Syndrome	O	O
Scale	O	O
(	O	O
PANSS	O	O
)	O	O
.	O	O

Ketamine	B-Chemical	D007649
elicited	O	O
psychosis	B-Disease	D011605
like	O	O
psychopathology	O	O
.	O	O

Post	O	O
-	O	O
hoc	O	O
t	O	O
-	O	O
tests	O	O
revealed	O	O
significant	O	O
differences	O	O
between	O	O
placebo	O	O
and	O	O
ketamine	B-Chemical	D007649
for	O	O
the	O	O
amounts	O	O
of	O	O
words	O	O
generated	O	O
during	O	O
lexical	O	O
and	O	O
semantic	O	O
verbal	O	O
fluency	O	O
,	O	O
while	O	O
the	O	O
phonological	O	O
domain	O	O
remained	O	O
unaffected	O	O
.	O	O

Ketamine	B-Chemical	D007649
led	O	O
to	O	O
enhanced	O	O
cortical	O	O
activations	O	O
in	O	O
supramarginal	O	O
and	O	O
frontal	O	O
brain	O	O
regions	O	O
for	O	O
phonological	O	O
and	O	O
lexical	O	O
verbal	O	O
fluency	O	O
,	O	O
but	O	O
not	O	O
for	O	O
semantic	O	O
verbal	O	O
fluency	O	O
.	O	O

Ketamine	B-Chemical	D007649
induces	O	O
activation	O	O
changes	O	O
in	O	O
healthy	O	O
subjects	O	O
similar	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
,	O	O
particularly	O	O
in	O	O
frontal	O	O
and	O	O
temporal	O	O
brain	O	O
regions	O	O
.	O	O

Our	O	O
results	O	O
provide	O	O
further	O	O
support	O	O
for	O	O
the	O	O
hypothesis	O	O
of	O	O
an	O	O
NMDA	B-Chemical	D016202
receptor	O	O
dysfunction	O	O
in	O	O
the	O	O
pathophysiology	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

Dopamine	B-Chemical	D004298
is	O	O
not	O	O
essential	O	O
for	O	O
the	O	O
development	O	O
of	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
neurotoxicity	B-Disease	D020258
.	O	O

It	O	O
is	O	O
widely	O	O
believed	O	O
that	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
mediates	O	O
methamphetamine	B-Chemical	D008694
(	O	O
METH	B-Chemical	D008694
)	O	O
-	O	O
induced	O	O
toxicity	B-Disease	D064420
to	O	O
brain	O	O
dopaminergic	O	O
neurons	O	O
,	O	O
because	O	O
drugs	O	O
that	O	O
interfere	O	O
with	O	O
DA	B-Chemical	D004298
neurotransmission	O	O
decrease	O	O
toxicity	B-Disease	D064420
,	O	O
whereas	O	O
drugs	O	O
that	O	O
increase	O	O
DA	B-Chemical	D004298
neurotransmission	O	O
enhance	O	O
toxicity	B-Disease	D064420
.	O	O

However	O	O
,	O	O
temperature	O	O
effects	O	O
of	O	O
drugs	O	O
that	O	O
have	O	O
been	O	O
used	O	O
to	O	O
manipulate	O	O
brain	O	O
DA	B-Chemical	D004298
neurotransmission	O	O
confound	O	O
interpretation	O	O
of	O	O
the	O	O
data	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
recently	O	O
reported	O	O
ability	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dihydroxyphenylalanine	I-Chemical	D007980
to	O	O
reverse	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
alpha	B-Chemical	D019805
-	I-Chemical	D019805
methyl	I-Chemical	D019805
-	I-Chemical	D019805
para	I-Chemical	D019805
-	I-Chemical	D019805
tyrosine	I-Chemical	D019805
on	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
DA	B-Chemical	D004298
neurotoxicity	B-Disease	D020258
is	O	O
also	O	O
confounded	O	O
by	O	O
drug	O	O
effects	O	O
on	O	O
body	O	O
temperature	O	O
.	O	O

Further	O	O
,	O	O
we	O	O
show	O	O
that	O	O
mice	O	O
genetically	O	O
engineered	O	O
to	O	O
be	O	O
deficient	O	O
in	O	O
brain	O	O
DA	B-Chemical	D004298
develop	O	O
METH	B-Chemical	D008694
neurotoxicity	B-Disease	D020258
,	O	O
as	O	O
long	O	O
as	O	O
the	O	O
thermic	O	O
effects	O	O
of	O	O
METH	B-Chemical	D008694
are	O	O
preserved	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
mice	O	O
genetically	O	O
engineered	O	O
to	O	O
have	O	O
unilateral	O	O
brain	O	O
DA	B-Chemical	D004298
deficits	O	O
develop	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
dopaminergic	B-Disease	D009461
deficits	I-Disease	D009461
that	O	O
are	O	O
of	O	O
comparable	O	O
magnitude	O	O
on	O	O
both	O	O
sides	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
findings	O	O
demonstrate	O	O
that	O	O
DA	B-Chemical	D004298
is	O	O
not	O	O
essential	O	O
for	O	O
the	O	O
development	O	O
of	O	O
METH	B-Chemical	D008694
-	O	O
induced	O	O
dopaminergic	O	O
neurotoxicity	B-Disease	D020258
and	O	O
suggest	O	O
that	O	O
mechanisms	O	O
independent	O	O
of	O	O
DA	B-Chemical	D004298
warrant	O	O
more	O	O
intense	O	O
investigation	O	O
.	O	O

Brainstem	B-Disease	-1
dysgenesis	I-Disease	-1
in	O	O
an	O	O
infant	O	O
prenatally	O	O
exposed	O	O
to	O	O
cocaine	B-Chemical	D003042
.	O	O

Many	O	O
authors	O	O
described	O	O
the	O	O
effects	O	O
on	O	O
the	O	O
fetus	O	O
of	O	O
maternal	O	O
cocaine	B-Chemical	D003042
abuse	O	O
during	O	O
pregnancy	O	O
.	O	O

Vasoconstriction	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
common	O	O
mechanism	O	O
of	O	O
action	O	O
leading	O	O
to	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
fetal	B-Disease	D005315
anomalies	I-Disease	D005315
.	O	O

We	O	O
report	O	O
on	O	O
an	O	O
infant	O	O
with	O	O
multiple	B-Disease	D003389
cranial	I-Disease	D003389
-	I-Disease	D003389
nerve	I-Disease	D003389
involvement	I-Disease	D003389
attributable	O	O
to	O	O
brainstem	B-Disease	-1
dysgenesis	I-Disease	-1
,	O	O
born	O	O
to	O	O
a	O	O
cocaine	B-Chemical	D003042
-	O	O
addicted	O	O
mother	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
Nrf2	O	O
in	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

OBJECTIVE	O	O
:	O	O
Diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
is	O	O
one	O	O
of	O	O
the	O	O
major	O	O
causes	O	O
of	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
,	O	O
which	O	O
is	O	O
accompanied	O	O
by	O	O
the	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
(	O	O
ROS	O	O
)	O	O
.	O	O

Nrf2	O	O
is	O	O
the	O	O
primary	O	O
transcription	O	O
factor	O	O
that	O	O
controls	O	O
the	O	O
antioxidant	O	O
response	O	O
essential	O	O
for	O	O
maintaining	O	O
cellular	O	O
redox	O	O
homeostasis	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
our	O	O
findings	O	O
demonstrating	O	O
a	O	O
protective	O	O
role	O	O
of	O	O
Nrf2	O	O
against	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
explore	O	O
the	O	O
protective	O	O
role	O	O
of	O	O
Nrf2	O	O
against	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
using	O	O
human	O	O
kidney	O	O
biopsy	O	O
tissues	O	O
from	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
patients	O	O
,	O	O
a	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
model	O	O
in	O	O
Nrf2	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
and	O	O
cultured	O	O
human	O	O
mesangial	O	O
cells	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
glomeruli	O	O
of	O	O
human	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
patients	O	O
were	O	O
under	O	O
oxidative	O	O
stress	O	O
and	O	O
had	O	O
elevated	O	O
Nrf2	O	O
levels	O	O
.	O	O

In	O	O
the	O	O
animal	O	O
study	O	O
,	O	O
Nrf2	O	O
was	O	O
demonstrated	O	O
to	O	O
be	O	O
crucial	O	O
in	O	O
ameliorating	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
renal	B-Disease	D058186
damage	I-Disease	D058186
.	O	O

This	O	O
is	O	O
evident	O	O
by	O	O
Nrf2	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
having	O	O
higher	O	O
ROS	O	O
production	O	O
and	O	O
suffering	O	O
from	O	O
greater	O	O
oxidative	O	O
DNA	O	O
damage	O	O
and	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
compared	O	O
with	O	O
Nrf2	O	O
(	O	O
+	O	O
/	O	O
+	O	O
)	O	O
mice	O	O
.	O	O

Mechanistic	O	O
studies	O	O
in	O	O
both	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
systems	O	O
showed	O	O
that	O	O
the	O	O
Nrf2	O	O
-	O	O
mediated	O	O
protection	O	O
against	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
is	O	O
,	O	O
at	O	O
least	O	O
,	O	O
partially	O	O
through	O	O
inhibition	O	O
of	O	O
transforming	O	O
growth	O	O
factor	O	O
-	O	O
beta1	O	O
(	O	O
TGF	O	O
-	O	O
beta1	O	O
)	O	O
and	O	O
reduction	O	O
of	O	O
extracellular	O	O
matrix	O	O
production	O	O
.	O	O

In	O	O
human	O	O
renal	O	O
mesangial	O	O
cells	O	O
,	O	O
high	O	O
glucose	B-Chemical	D005947
induced	O	O
ROS	O	O
production	O	O
and	O	O
activated	O	O
expression	O	O
of	O	O
Nrf2	O	O
and	O	O
its	O	O
downstream	O	O
genes	O	O
.	O	O

Furthermore	O	O
,	O	O
activation	O	O
or	O	O
overexpression	O	O
of	O	O
Nrf2	O	O
inhibited	O	O
the	O	O
promoter	O	O
activity	O	O
of	O	O
TGF	O	O
-	O	O
beta1	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
,	O	O
whereas	O	O
knockdown	O	O
of	O	O
Nrf2	O	O
by	O	O
siRNA	O	O
enhanced	O	O
TGF	O	O
-	O	O
beta1	O	O
transcription	O	O
and	O	O
fibronectin	O	O
production	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
work	O	O
clearly	O	O
indicates	O	O
a	O	O
protective	O	O
role	O	O
of	O	O
Nrf2	O	O
in	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
,	O	O
suggesting	O	O
that	O	O
dietary	O	O
or	O	O
therapeutic	O	O
activation	O	O
of	O	O
Nrf2	O	O
could	O	O
be	O	O
used	O	O
as	O	O
a	O	O
strategy	O	O
to	O	O
prevent	O	O
or	O	O
slow	O	O
down	O	O
the	O	O
progression	O	O
of	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

High	O	O
-	O	O
dose	O	O
tranexamic	B-Chemical	D014148
Acid	I-Chemical	D014148
is	O	O
associated	O	O
with	O	O
nonischemic	O	O
clinical	O	O
seizures	B-Disease	D012640
in	O	O
cardiac	O	O
surgical	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
2	O	O
separate	O	O
centers	O	O
,	O	O
we	O	O
observed	O	O
a	O	O
notable	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
postoperative	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
from	O	O
1	O	O
.	O	O

3%	O	O
to	O	O
3	O	O
.	O	O

8%	O	O
in	O	O
patients	O	O
having	O	O
undergone	O	O
major	O	O
cardiac	O	O
surgical	O	O
procedures	O	O
.	O	O

These	O	O
events	O	O
were	O	O
temporally	O	O
coincident	O	O
with	O	O
the	O	O
initial	O	O
use	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
(	O	O
TXA	B-Chemical	D014148
)	O	O
therapy	O	O
after	O	O
withdrawal	O	O
of	O	O
aprotinin	O	O
from	O	O
general	O	O
clinical	O	O
usage	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
review	O	O
was	O	O
to	O	O
perform	O	O
a	O	O
retrospective	O	O
analysis	O	O
to	O	O
examine	O	O
whether	O	O
there	O	O
was	O	O
a	O	O
relation	O	O
between	O	O
TXA	B-Chemical	D014148
usage	O	O
and	O	O
seizures	B-Disease	D012640
after	O	O
cardiac	O	O
surgery	O	O
.	O	O

METHODS	O	O
:	O	O
An	O	O
in	O	O
-	O	O
depth	O	O
chart	O	O
review	O	O
was	O	O
undertaken	O	O
in	O	O
all	O	O
24	O	O
patients	O	O
who	O	O
developed	O	O
perioperative	O	O
seizures	B-Disease	D012640
.	O	O

Electroencephalographic	O	O
activity	O	O
was	O	O
recorded	O	O
in	O	O
11	O	O
of	O	O
these	O	O
patients	O	O
,	O	O
and	O	O
all	O	O
patients	O	O
had	O	O
a	O	O
formal	O	O
neurological	O	O
evaluation	O	O
and	O	O
brain	O	O
imaging	O	O
studies	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty	O	O
-	O	O
one	O	O
of	O	O
the	O	O
24	O	O
patients	O	O
did	O	O
not	O	O
have	O	O
evidence	O	O
of	O	O
new	O	O
cerebral	B-Disease	D001930
ischemic	I-Disease	D001930
injury	I-Disease	D001930
,	O	O
but	O	O
seizures	B-Disease	D012640
were	O	O
likely	O	O
due	O	O
to	O	O
ischemic	B-Disease	D001930
brain	I-Disease	D001930
injury	I-Disease	D001930
in	O	O
3	O	O
patients	O	O
.	O	O

All	O	O
patients	O	O
with	O	O
seizures	B-Disease	D012640
did	O	O
not	O	O
have	O	O
permanent	O	O
neurological	B-Disease	D009422
abnormalities	I-Disease	D009422
.	O	O

All	O	O
24	O	O
patients	O	O
with	O	O
seizures	B-Disease	D012640
received	O	O
high	O	O
doses	O	O
of	O	O
TXA	B-Chemical	D014148
intraoperatively	O	O
ranging	O	O
from	O	O
61	O	O
to	O	O
259	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
had	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
69	O	O
.	O	O

9	O	O
years	O	O
,	O	O
and	O	O
21	O	O
of	O	O
24	O	O
had	O	O
undergone	O	O
open	O	O
chamber	O	O
rather	O	O
than	O	O
coronary	O	O
bypass	O	O
procedures	O	O
.	O	O

All	O	O
but	O	O
one	O	O
patient	O	O
were	O	O
managed	O	O
using	O	O
cardiopulmonary	O	O
bypass	O	O
.	O	O

No	O	O
evidence	O	O
of	O	O
brain	B-Disease	D002546
ischemic	I-Disease	D002546
,	O	O
metabolic	O	O
,	O	O
or	O	O
hyperthermia	B-Disease	D005334
-	O	O
induced	O	O
causes	O	O
for	O	O
their	O	O
seizures	B-Disease	D012640
was	O	O
apparent	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
use	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
TXA	B-Chemical	D014148
in	O	O
older	O	O
patients	O	O
in	O	O
conjunction	O	O
with	O	O
cardiopulmonary	O	O
bypass	O	O
and	O	O
open	O	O
-	O	O
chamber	O	O
cardiac	O	O
surgery	O	O
is	O	O
associated	O	O
with	O	O
clinical	O	O
seizures	B-Disease	D012640
in	O	O
susceptible	O	O
patients	O	O
.	O	O

Recurrent	O	O
dysosmia	B-Disease	D000857
induced	O	O
by	O	O
pyrazinamide	B-Chemical	D011718
.	O	O

Pyrazinamide	B-Chemical	D011718
can	O	O
have	O	O
adverse	O	O
effects	O	O
such	O	O
as	O	O
hepatic	B-Disease	D056486
toxicity	I-Disease	D056486
,	O	O
hyperuricemia	B-Disease	D033461
or	O	O
digestive	O	O
disorders	O	O
.	O	O

In	O	O
rare	O	O
cases	O	O
,	O	O
alterations	O	O
in	O	O
taste	O	O
and	O	O
smell	O	O
function	O	O
have	O	O
been	O	O
reported	O	O
for	O	O
pyrazinamide	B-Chemical	D011718
when	O	O
combined	O	O
with	O	O
other	O	O
drugs	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
reversible	O	O
olfactory	B-Disease	D000857
disorder	I-Disease	D000857
related	O	O
to	O	O
pyrazinamide	B-Chemical	D011718
in	O	O
a	O	O
woman	O	O
,	O	O
with	O	O
a	O	O
positive	O	O
rechallenge	O	O
.	O	O

The	O	O
patient	O	O
presented	O	O
every	O	O
day	O	O
a	O	O
sensation	O	O
of	O	O
smelling	O	O
something	O	O
burning	O	O
15	O	O
min	O	O
after	O	O
drug	O	O
intake	O	O
.	O	O

Dysosmia	B-Disease	D000857
disappeared	O	O
completely	O	O
after	O	O
pyrazinamide	B-Chemical	D011718
withdrawal	O	O
and	O	O
recurred	O	O
after	O	O
its	O	O
rechallenge	O	O
.	O	O

The	O	O
case	O	O
was	O	O
reported	O	O
to	O	O
the	O	O
Tunisian	O	O
Centre	O	O
of	O	O
Pharmacovigilance	O	O
.	O	O

Longitudinal	O	O
assessment	O	O
of	O	O
air	O	O
conduction	O	O
audiograms	O	O
in	O	O
a	O	O
phase	O	O
III	O	O
clinical	O	O
trial	O	O
of	O	O
difluoromethylornithine	B-Chemical	D000518
and	O	O
sulindac	B-Chemical	D013467
for	O	O
prevention	O	O
of	O	O
sporadic	O	O
colorectal	B-Disease	D015179
adenomas	I-Disease	D015179
.	O	O

A	O	O
phase	O	O
III	O	O
clinical	O	O
trial	O	O
assessed	O	O
the	O	O
recurrence	O	O
of	O	O
adenomatous	B-Disease	D018256
polyps	I-Disease	D018256
after	O	O
treatment	O	O
for	O	O
36	O	O
months	O	O
with	O	O
difluoromethylornithine	B-Chemical	D000518
(	O	O
DFMO	B-Chemical	D000518
)	O	O
plus	O	O
sulindac	B-Chemical	D013467
or	O	O
matched	O	O
placebos	O	O
.	O	O

Temporary	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
is	O	O
a	O	O
known	O	O
toxicity	B-Disease	D064420
of	O	O
treatment	O	O
with	O	O
DFMO	B-Chemical	D000518
,	O	O
thus	O	O
a	O	O
comprehensive	O	O
approach	O	O
was	O	O
developed	O	O
to	O	O
analyze	O	O
serial	O	O
air	O	O
conduction	O	O
audiograms	O	O
.	O	O

The	O	O
generalized	O	O
estimating	O	O
equation	O	O
method	O	O
estimated	O	O
the	O	O
mean	O	O
difference	O	O
between	O	O
treatment	O	O
arms	O	O
with	O	O
regard	O	O
to	O	O
change	O	O
in	O	O
air	O	O
conduction	O	O
pure	O	O
tone	O	O
thresholds	O	O
while	O	O
accounting	O	O
for	O	O
within	O	O
-	O	O
subject	O	O
correlation	O	O
due	O	O
to	O	O
repeated	O	O
measurements	O	O
at	O	O
frequencies	O	O
.	O	O

Based	O	O
on	O	O
290	O	O
subjects	O	O
,	O	O
there	O	O
was	O	O
an	O	O
average	O	O
difference	O	O
of	O	O
0	O	O
.	O	O

50	O	O
dB	O	O
between	O	O
subjects	O	O
treated	O	O
with	O	O
DFMO	B-Chemical	D000518
plus	O	O
sulindac	B-Chemical	D013467
compared	O	O
with	O	O
those	O	O
treated	O	O
with	O	O
placebo	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
-	O	O
0	O	O
.	O	O

64	O	O
to	O	O
1	O	O
.	O	O

63	O	O
dB	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

39	O	O
)	O	O
,	O	O
adjusted	O	O
for	O	O
baseline	O	O
values	O	O
,	O	O
age	O	O
,	O	O
and	O	O
frequencies	O	O
.	O	O

In	O	O
the	O	O
normal	O	O
speech	O	O
range	O	O
of	O	O
500	O	O
to	O	O
3	O	O
,	O	O
000	O	O
Hz	O	O
,	O	O
an	O	O
estimated	O	O
difference	O	O
of	O	O
0	O	O
.	O	O

99	O	O
dB	O	O
(	O	O
-	O	O
0	O	O
.	O	O

17	O	O
to	O	O
2	O	O
.	O	O

14	O	O
dB	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

09	O	O
)	O	O
was	O	O
detected	O	O
.	O	O

Dose	O	O
intensity	O	O
did	O	O
not	O	O
add	O	O
information	O	O
to	O	O
models	O	O
.	O	O

There	O	O
were	O	O
14	O	O
of	O	O
151	O	O
(	O	O
9	O	O
.	O	O

3%	O	O
)	O	O
in	O	O
the	O	O
DFMO	B-Chemical	D000518
plus	O	O
sulindac	B-Chemical	D013467
group	O	O
and	O	O
4	O	O
of	O	O
139	O	O
(	O	O
2	O	O
.	O	O

9%	O	O
)	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
who	O	O
experienced	O	O
at	O	O
least	O	O
15	O	O
dB	O	O
hearing	O	O
reduction	O	O
from	O	O
baseline	O	O
in	O	O
2	O	O
or	O	O
more	O	O
consecutive	O	O
frequencies	O	O
across	O	O
the	O	O
entire	O	O
range	O	O
tested	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Follow	O	O
-	O	O
up	O	O
air	O	O
conduction	O	O
done	O	O
at	O	O
least	O	O
6	O	O
months	O	O
after	O	O
end	O	O
of	O	O
treatment	O	O
showed	O	O
an	O	O
adjusted	O	O
mean	O	O
difference	O	O
in	O	O
hearing	O	O
thresholds	O	O
of	O	O
1	O	O
.	O	O

08	O	O
dB	O	O
(	O	O
-	O	O
0	O	O
.	O	O

81	O	O
to	O	O
2	O	O
.	O	O

96	O	O
dB	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

26	O	O
)	O	O
between	O	O
treatment	O	O
arms	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
proportion	O	O
of	O	O
subjects	O	O
in	O	O
the	O	O
DFMO	B-Chemical	D000518
plus	O	O
sulindac	B-Chemical	D013467
group	O	O
who	O	O
experienced	O	O
clinically	O	O
significant	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
compared	O	O
with	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

The	O	O
estimated	O	O
attributable	O	O
risk	O	O
of	O	O
ototoxicity	B-Disease	D006311
from	O	O
exposure	O	O
to	O	O
the	O	O
drug	O	O
is	O	O
8	O	O
.	O	O

4%	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
-	O	O
2	O	O
.	O	O

0%	O	O
to	O	O
18	O	O
.	O	O

8%	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

12	O	O
)	O	O
.	O	O

There	O	O
is	O	O
a	O	O
<2	O	O
dB	O	O
difference	O	O
in	O	O
mean	O	O
threshold	O	O
for	O	O
patients	O	O
treated	O	O
with	O	O
DFMO	B-Chemical	D000518
plus	O	O
sulindac	B-Chemical	D013467
compared	O	O
with	O	O
those	O	O
treated	O	O
with	O	O
placebo	O	O
.	O	O

Increased	O	O
mental	B-Disease	D003072
slowing	I-Disease	D003072
associated	O	O
with	O	O
the	O	O
APOE	O	O
epsilon4	O	O
allele	O	O
after	O	O
trihexyphenidyl	B-Chemical	D014282
oral	O	O
anticholinergic	O	O
challenge	O	O
in	O	O
healthy	O	O
elderly	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
objectives	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
examine	O	O
the	O	O
relationship	O	O
between	O	O
APOE	O	O
epsilon4	O	O
and	O	O
subjective	O	O
effects	O	O
of	O	O
trihexyphenidyl	B-Chemical	D014282
on	O	O
measures	O	O
reflecting	O	O
sedation	O	O
and	O	O
confusion	B-Disease	D003221
and	O	O
to	O	O
investigate	O	O
the	O	O
relationship	O	O
between	O	O
trihexyphenidyl	B-Chemical	D014282
-	O	O
induced	O	O
subjective	O	O
effects	O	O
and	O	O
objective	O	O
memory	O	O
performance	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
study	O	O
comprised	O	O
24	O	O
cognitively	O	O
intact	O	O
,	O	O
health	O	O
elderly	O	O
adults	O	O
(	O	O
12	O	O
APOE	O	O
epsilon4	O	O
carriers	O	O
)	O	O
at	O	O
an	O	O
outpatient	O	O
geriatric	O	O
psychiatry	O	O
research	O	O
clinic	O	O
.	O	O

This	O	O
was	O	O
a	O	O
randomized	O	O
,	O	O
double	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
three	O	O
-	O	O
way	O	O
,	O	O
crossover	O	O
experimental	O	O
design	O	O
.	O	O

All	O	O
participants	O	O
received	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
or	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
trihexyphenidyl	B-Chemical	D014282
or	O	O
placebo	O	O
administered	O	O
in	O	O
counterbalanced	O	O
sequences	O	O
over	O	O
a	O	O
period	O	O
of	O	O
three	O	O
consecutive	O	O
weeks	O	O
.	O	O

Bond	O	O
and	O	O
Lader's	O	O
visual	O	O
analog	O	O
scales	O	O
and	O	O
alternate	O	O
versions	O	O
of	O	O
the	O	O
Buschke	O	O
Selective	O	O
Reminding	O	O
Test	O	O
were	O	O
administered	O	O
in	O	O
a	O	O
repeated	O	O
measures	O	O
design	O	O
at	O	O
baseline	O	O
,	O	O
1	O	O
,	O	O
2	O	O
.	O	O

5	O	O
,	O	O
and	O	O
5	O	O
hours	O	O
postdrug	O	O
administration	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
2	O	O
.	O	O

0	O	O
-	O	O
mg	O	O
oral	O	O
dose	O	O
of	O	O
trihexyphenidyl	B-Chemical	D014282
resulted	O	O
in	O	O
increased	O	O
subjective	O	O
ratings	O	O
of	O	O
mental	B-Disease	D003072
slowness	I-Disease	D003072
in	O	O
carriers	O	O
of	O	O
the	O	O
APOE	O	O
epsilon4	O	O
allele	O	O
only	O	O
.	O	O

Drug	O	O
effects	O	O
as	O	O
determined	O	O
by	O	O
difference	O	O
scores	O	O
between	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
trihexyphenidyl	B-Chemical	D014282
and	O	O
placebo	O	O
on	O	O
ratings	O	O
of	O	O
mental	B-Disease	D003072
slowness	I-Disease	D003072
significantly	O	O
correlated	O	O
with	O	O
total	O	O
and	O	O
delayed	O	O
recall	O	O
on	O	O
the	O	O
Buschke	O	O
Selective	O	O
Reminding	O	O
Test	O	O
in	O	O
carriers	O	O
of	O	O
the	O	O
APOE	O	O
epsilon4	O	O
allele	O	O
only	O	O
.	O	O

However	O	O
,	O	O
no	O	O
significant	O	O
effects	O	O
were	O	O
found	O	O
with	O	O
other	O	O
visual	O	O
analog	O	O
scales	O	O
reflecting	O	O
subjective	O	O
sedation	O	O
and	O	O
clear	O	O
-	O	O
headedness	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
epsilon4	O	O
allele	O	O
in	O	O
healthy	O	O
elderly	O	O
was	O	O
associated	O	O
with	O	O
increased	O	O
subjective	O	O
mental	B-Disease	D003072
slowing	I-Disease	D003072
after	O	O
trihexyphenidyl	B-Chemical	D014282
anticholinergic	O	O
challenge	O	O
.	O	O

Behavioral	O	O
effects	O	O
of	O	O
pubertal	O	O
anabolic	O	O
androgenic	O	O
steroid	B-Chemical	D013256
exposure	O	O
in	O	O
male	O	O
rats	O	O
with	O	O
low	O	O
serotonin	B-Chemical	D012701
.	O	O

The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
interactive	O	O
effects	O	O
of	O	O
chronic	O	O
anabolic	O	O
androgenic	O	O
steroid	B-Chemical	D013256
(	O	O
AAS	O	O
)	O	O
exposure	O	O
and	O	O
brain	O	O
serotonin	B-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine	I-Chemical	D012701
,	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
depletion	O	O
on	O	O
behavior	O	O
of	O	O
pubertal	O	O
male	O	O
rats	O	O
.	O	O

Serotonin	B-Chemical	D012701
was	O	O
depleted	O	O
beginning	O	O
on	O	O
postnatal	O	O
day	O	O
26	O	O
with	O	O
parachlorophenylalanine	B-Chemical	-1
(	O	O
PCPA	B-Chemical	-1
100	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
every	O	O
other	O	O
day	O	O
)	O	O
;	O	O
controls	O	O
received	O	O
saline	O	O
.	O	O

At	O	O
puberty	O	O
(	O	O
P40	O	O
)	O	O
,	O	O
half	O	O
the	O	O
PCPA	B-Chemical	-1
-	O	O
treated	O	O
rats	O	O
and	O	O
half	O	O
the	O	O
saline	O	O
-	O	O
treated	O	O
rats	O	O
began	O	O
treatment	O	O
with	O	O
testosterone	B-Chemical	D013739
(	O	O
T	B-Chemical	D013739
,	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
5	O	O
days	O	O
/	O	O
week	O	O
)	O	O
.	O	O

Behavioral	O	O
measures	O	O
included	O	O
locomotion	O	O
,	O	O
irritability	B-Disease	D001523
,	O	O
copulation	O	O
,	O	O
partner	O	O
preference	O	O
,	O	O
and	O	O
aggression	B-Disease	D001523
.	O	O

Animals	O	O
were	O	O
tested	O	O
for	O	O
aggression	B-Disease	D001523
in	O	O
their	O	O
home	O	O
cage	O	O
,	O	O
both	O	O
with	O	O
and	O	O
without	O	O
physical	O	O
provocation	O	O
(	O	O
mild	O	O
tail	O	O
pinch	O	O
)	O	O
.	O	O

Brain	O	O
levels	O	O
of	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
and	O	O
its	O	O
metabolite	O	O
,	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
hydroxyindoleacetic	I-Chemical	D006897
acid	I-Chemical	D006897
(	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
HIAA	I-Chemical	D006897
)	O	O
,	O	O
were	O	O
determined	O	O
using	O	O
HPLC	O	O
.	O	O

PCPA	B-Chemical	-1
significantly	O	O
and	O	O
substantially	O	O
depleted	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
and	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
HIAA	I-Chemical	D006897
in	O	O
all	O	O
brain	O	O
regions	O	O
examined	O	O
.	O	O

Chronic	O	O
T	B-Chemical	D013739
treatment	O	O
significantly	O	O
decreased	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
and	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
HIAA	I-Chemical	D006897
in	O	O
certain	O	O
brain	O	O
areas	O	O
,	O	O
but	O	O
to	O	O
a	O	O
much	O	O
lesser	O	O
extent	O	O
than	O	O
PCPA	B-Chemical	-1
.	O	O

Chronic	O	O
exposure	O	O
to	O	O
PCPA	B-Chemical	-1
alone	O	O
significantly	O	O
decreased	O	O
locomotor	O	O
activity	O	O
and	O	O
increased	O	O
irritability	B-Disease	D001523
but	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
sexual	O	O
behavior	O	O
,	O	O
partner	O	O
preference	O	O
,	O	O
or	O	O
aggression	B-Disease	D001523
.	O	O

T	B-Chemical	D013739
alone	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
locomotion	O	O
,	O	O
irritability	B-Disease	D001523
,	O	O
or	O	O
sexual	O	O
behavior	O	O
but	O	O
increased	O	O
partner	O	O
preference	O	O
and	O	O
aggression	B-Disease	D001523
.	O	O

The	O	O
most	O	O
striking	O	O
effect	O	O
of	O	O
combining	O	O
T+PCPA	O	O
was	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
attack	O	O
frequency	O	O
as	O	O
well	O	O
as	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
latency	O	O
to	O	O
attack	O	O
,	O	O
particularly	O	O
following	O	O
physical	O	O
provocation	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
data	O	O
,	O	O
it	O	O
can	O	O
be	O	O
speculated	O	O
that	O	O
pubertal	O	O
AAS	O	O
users	O	O
with	O	O
low	O	O
central	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
may	O	O
be	O	O
especially	O	O
prone	O	O
to	O	O
exhibit	O	O
aggressive	B-Disease	D001523
behavior	I-Disease	D001523
.	O	O

Intracavitary	O	O
chemotherapy	O	O
(	O	O
paclitaxel	B-Chemical	D017239
/	O	O
carboplatin	B-Chemical	D016190
liquid	O	O
crystalline	O	O
cubic	O	O
phases	O	O
)	O	O
for	O	O
recurrent	O	O
glioblastoma	B-Disease	D005909
-	O	O
-	O	O
clinical	O	O
observations	O	O
.	O	O

Human	O	O
malignant	O	O
brain	B-Disease	D001932
tumors	I-Disease	D001932
have	O	O
a	O	O
poor	O	O
prognosis	O	O
in	O	O
spite	O	O
of	O	O
surgery	O	O
and	O	O
radiation	O	O
therapy	O	O
.	O	O

Cubic	O	O
phases	O	O
consist	O	O
of	O	O
curved	O	O
biocontinuous	O	O
lipid	O	O
bilayers	O	O
,	O	O
separating	O	O
two	O	O
congruent	O	O
networks	O	O
of	O	O
water	O	O
channels	O	O
.	O	O

Used	O	O
as	O	O
a	O	O
host	O	O
for	O	O
cytotoxic	O	O
drugs	O	O
,	O	O
the	O	O
gel	O	O
-	O	O
like	O	O
matrix	O	O
can	O	O
easily	O	O
be	O	O
applied	O	O
to	O	O
the	O	O
walls	O	O
of	O	O
a	O	O
surgical	O	O
resection	O	O
cavity	O	O
.	O	O

For	O	O
human	O	O
glioblastoma	B-Disease	D005909
recurrences	O	O
,	O	O
the	O	O
feasibility	O	O
,	O	O
safety	O	O
,	O	O
and	O	O
short	O	O
-	O	O
term	O	O
effects	O	O
of	O	O
a	O	O
surgical	O	O
intracavitary	O	O
application	O	O
of	O	O
paclitaxel	B-Chemical	D017239
and	O	O
carboplatin	B-Chemical	D016190
encapsulated	O	O
by	O	O
liquid	O	O
crystalline	O	O
cubic	O	O
phases	O	O
are	O	O
examined	O	O
in	O	O
a	O	O
pilot	O	O
study	O	O
.	O	O

A	O	O
total	O	O
of	O	O
12	O	O
patients	O	O
with	O	O
a	O	O
recurrence	O	O
of	O	O
a	O	O
glioblastoma	B-Disease	D005909
multiforme	O	O
underwent	O	O
re	O	O
-	O	O
resection	O	O
and	O	O
received	O	O
an	O	O
intracavitary	O	O
application	O	O
of	O	O
paclitaxel	B-Chemical	D017239
and	O	O
carboplatin	B-Chemical	D016190
cubic	O	O
phases	O	O
in	O	O
different	O	O
dosages	O	O
.	O	O

Six	O	O
of	O	O
the	O	O
patients	O	O
received	O	O
more	O	O
than	O	O
15	O	O
mg	O	O
paclitaxel	B-Chemical	D017239
and	O	O
suffered	O	O
from	O	O
moderate	O	O
to	O	O
severe	O	O
brain	B-Disease	D001929
edema	I-Disease	D001929
,	O	O
while	O	O
the	O	O
remaining	O	O
patients	O	O
received	O	O
only	O	O
a	O	O
total	O	O
of	O	O
15	O	O
mg	O	O
paclitaxel	B-Chemical	D017239
.	O	O

In	O	O
the	O	O
latter	O	O
group	O	O
,	O	O
brain	B-Disease	D001929
edema	I-Disease	D001929
was	O	O
markedly	O	O
reduced	O	O
and	O	O
dealt	O	O
medically	O	O
.	O	O

Intracavitary	O	O
chemotherapy	O	O
in	O	O
recurrent	O	O
glioblastoma	B-Disease	D005909
using	O	O
cubic	O	O
phases	O	O
is	O	O
feasible	O	O
and	O	O
safe	O	O
,	O	O
yet	O	O
the	O	O
clinical	O	O
benefit	O	O
remains	O	O
to	O	O
be	O	O
examined	O	O
in	O	O
a	O	O
clinical	O	O
phase	O	O
II	O	O
study	O	O
.	O	O

Methylphenidate	B-Chemical	D008774
-	O	O
induced	O	O
obsessive	B-Disease	D009771
-	I-Disease	D009771
compulsive	I-Disease	D009771
symptoms	I-Disease	D009771
in	O	O
an	O	O
elderly	O	O
man	O	O
.	O	O

An	O	O
82	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
treatment	B-Disease	D061218
-	I-Disease	D061218
resistant	I-Disease	D061218
depression	I-Disease	D061218
and	O	O
early	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
was	O	O
started	O	O
on	O	O
methylphenidate	B-Chemical	D008774
.	O	O

Significant	O	O
obsessive	B-Disease	D009771
-	I-Disease	D009771
compulsive	I-Disease	D009771
behavior	I-Disease	D009771
ensued	O	O
but	O	O
diminished	O	O
over	O	O
several	O	O
weeks	O	O
when	O	O
methylphenidate	B-Chemical	D008774
was	O	O
replaced	O	O
by	O	O
fluvoxamine	B-Chemical	D016666
.	O	O

The	O	O
patient	O	O
had	O	O
no	O	O
prior	O	O
psychiatric	B-Disease	D001523
history	O	O
,	O	O
but	O	O
he	O	O
had	O	O
a	O	O
sister	O	O
with	O	O
obsessive	B-Disease	D009771
-	I-Disease	D009771
compulsive	I-Disease	D009771
disorder	I-Disease	D009771
.	O	O

It	O	O
appears	O	O
that	O	O
methylphenidate	B-Chemical	D008774
precipitated	O	O
the	O	O
patient's	O	O
pathological	O	O
behavior	O	O
.	O	O

Cardiac	B-Disease	D006323
arrest	I-Disease	D006323
after	O	O
intravenous	O	O
metoclopramide	B-Chemical	D008787
-	O	O
a	O	O
case	O	O
of	O	O
five	O	O
repeated	O	O
injections	O	O
of	O	O
metoclopramide	B-Chemical	D008787
causing	O	O
five	O	O
episodes	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
.	O	O

We	O	O
describe	O	O
a	O	O
patient	O	O
where	O	O
intravenous	O	O
injection	O	O
of	O	O
metoclopramide	B-Chemical	D008787
was	O	O
immediately	O	O
followed	O	O
by	O	O
asystole	B-Disease	D006323
repeatedly	O	O
.	O	O

The	O	O
patient	O	O
received	O	O
metoclopramide	B-Chemical	D008787
10	O	O
mg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

five	O	O
times	O	O
during	O	O
48	O	O
h	O	O
.	O	O

After	O	O
interviewing	O	O
the	O	O
attending	O	O
nurses	O	O
and	O	O
reviewing	O	O
the	O	O
written	O	O
documentation	O	O
,	O	O
it	O	O
is	O	O
clear	O	O
that	O	O
every	O	O
administration	O	O
of	O	O
metoclopramide	B-Chemical	D008787
was	O	O
immediately	O	O
(	O	O
within	O	O
s	O	O
)	O	O
followed	O	O
by	O	O
asystole	B-Disease	D006323
.	O	O

The	O	O
asystole	B-Disease	D006323
lasted	O	O
15	O	O
-	O	O
30	O	O
s	O	O
on	O	O
four	O	O
occasions	O	O
,	O	O
on	O	O
one	O	O
occasion	O	O
it	O	O
lasted	O	O
2	O	O
min	O	O
.	O	O

The	O	O
patient	O	O
received	O	O
atropine	B-Chemical	D001285
0	O	O
.	O	O

5	O	O
-	O	O
1	O	O
mg	O	O
and	O	O
chest	O	O
compressions	O	O
,	O	O
before	O	O
sinus	O	O
rhythm	O	O
again	O	O
took	O	O
over	O	O
.	O	O

We	O	O
interpret	O	O
this	O	O
as	O	O
episodes	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
caused	O	O
by	O	O
metoclopramide	B-Chemical	D008787
.	O	O

The	O	O
rapid	O	O
injection	O	O
via	O	O
the	O	O
central	O	O
venous	O	O
route	O	O
and	O	O
the	O	O
concomitant	O	O
tapering	O	O
of	O	O
dopamine	B-Chemical	D004298
infusion	O	O
might	O	O
have	O	O
contributed	O	O
in	O	O
precipitating	O	O
the	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

Severe	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
associated	O	O
with	O	O
prophylactic	O	O
use	O	O
of	O	O
cefotetan	B-Chemical	D015313
in	O	O
obstetric	O	O
and	O	O
gynecologic	O	O
procedures	O	O
.	O	O

Second	O	O
-	O	O
and	O	O
third	O	O
-	O	O
generation	O	O
cephalosporins	B-Chemical	D002511
,	O	O
especially	O	O
cefotetan	B-Chemical	D015313
,	O	O
are	O	O
increasingly	O	O
associated	O	O
with	O	O
severe	O	O
,	O	O
sometimes	O	O
fatal	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

We	O	O
noticed	O	O
that	O	O
10	O	O
of	O	O
our	O	O
35	O	O
cases	O	O
of	O	O
cefotetan	B-Chemical	D015313
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemias	I-Disease	D000743
were	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
received	O	O
cefotetan	B-Chemical	D015313
prophylactically	O	O
for	O	O
obstetric	O	O
and	O	O
gynecologic	O	O
procedures	O	O
.	O	O

Eight	O	O
of	O	O
these	O	O
cases	O	O
of	O	O
severe	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
are	O	O
described	O	O
.	O	O

Cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
after	O	O
spinal	O	O
anaesthesia	O	O
with	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
:	O	O
a	O	O
review	O	O
of	O	O
six	O	O
cases	O	O
of	O	O
cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
reported	O	O
to	O	O
the	O	O
Swedish	O	O
Pharmaceutical	O	O
Insurance	O	O
1993	O	O
-	O	O
1997	O	O
.	O	O

Six	O	O
cases	O	O
of	O	O
cauda	B-Disease	D011128
equina	I-Disease	D011128
syndrome	I-Disease	D011128
with	O	O
varying	O	O
severity	O	O
were	O	O
reported	O	O
to	O	O
the	O	O
Swedish	O	O
Pharmaceutical	O	O
Insurance	O	O
during	O	O
the	O	O
period	O	O
1993	O	O
-	O	O
1997	O	O
.	O	O

All	O	O
were	O	O
associated	O	O
with	O	O
spinal	O	O
anaesthesia	O	O
using	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
.	O	O

Five	O	O
cases	O	O
had	O	O
single	O	O
-	O	O
shot	O	O
spinal	O	O
anaesthesia	O	O
and	O	O
one	O	O
had	O	O
a	O	O
repeat	O	O
spinal	O	O
anaesthetic	O	O
due	O	O
to	O	O
inadequate	O	O
block	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
administered	O	O
ranged	O	O
from	O	O
60	O	O
to	O	O
120	O	O
mg	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
most	O	O
likely	O	O
caused	O	O
by	O	O
direct	O	O
neurotoxicity	B-Disease	D020258
of	O	O
hyperbaric	O	O
5%	O	O
lignocaine	B-Chemical	D008012
.	O	O

In	O	O
the	O	O
other	O	O
3	O	O
cases	O	O
,	O	O
direct	O	O
neurotoxicity	B-Disease	D020258
was	O	O
also	O	O
probable	O	O
,	O	O
but	O	O
unfortunately	O	O
radiological	O	O
investigations	O	O
were	O	O
not	O	O
done	O	O
to	O	O
definitely	O	O
exclude	O	O
a	O	O
compressive	O	O
aetiology	O	O
.	O	O

All	O	O
cases	O	O
sustained	O	O
permanent	O	O
neurological	B-Disease	D009461
deficits	I-Disease	D009461
.	O	O

We	O	O
recommend	O	O
that	O	O
hyperbaric	O	O
lignocaine	B-Chemical	D008012
should	O	O
be	O	O
administered	O	O
in	O	O
concentrations	O	O
not	O	O
greater	O	O
than	O	O
2%	O	O
and	O	O
at	O	O
a	O	O
total	O	O
dose	O	O
preferably	O	O
not	O	O
exceeding	O	O
60	O	O
mg	O	O
.	O	O

Cortical	O	O
motor	O	O
overactivation	O	O
in	O	O
parkinsonian	B-Disease	D020734
patients	O	O
with	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
-	O	O
induced	O	O
peak	O	O
-	O	O
dose	O	O
dyskinesia	B-Disease	D004409
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
regional	O	O
cerebral	O	O
blood	O	O
flow	O	O
(	O	O
rCBF	O	O
)	O	O
changes	O	O
induced	O	O
by	O	O
the	O	O
execution	O	O
of	O	O
a	O	O
finger	O	O
-	O	O
to	O	O
-	O	O
thumb	O	O
opposition	O	O
motor	O	O
task	O	O
in	O	O
the	O	O
supplementary	O	O
and	O	O
primary	O	O
motor	O	O
cortex	O	O
of	O	O
two	O	O
groups	O	O
of	O	O
parkinsonian	B-Disease	D020734
patients	O	O
on	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
medication	O	O
,	O	O
the	O	O
first	O	O
one	O	O
without	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
induced	O	O
dyskinesia	B-Disease	D004409
(	O	O
n	O	O
=	O	O
23	O	O
)	O	O
and	O	O
the	O	O
other	O	O
with	O	O
moderate	O	O
peak	O	O
-	O	O
dose	O	O
dyskinesia	B-Disease	D004409
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
,	O	O
and	O	O
of	O	O
a	O	O
group	O	O
of	O	O
14	O	O
normal	O	O
subjects	O	O
.	O	O

Single	O	O
photon	O	O
emission	O	O
tomography	O	O
with	O	O
i	O	O
.	O	O

v	O	O
.	O	O

133Xe	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
the	O	O
rCBF	O	O
changes	O	O
.	O	O

The	O	O
dyskinetic	B-Disease	D004409
parkinsonian	B-Disease	D020734
patients	O	O
exhibited	O	O
a	O	O
pattern	O	O
of	O	O
response	O	O
which	O	O
was	O	O
markedly	O	O
different	O	O
from	O	O
those	O	O
of	O	O
the	O	O
normal	O	O
subjects	O	O
and	O	O
non	O	O
-	O	O
dyskinetic	B-Disease	D004409
parkinsonian	B-Disease	D020734
patients	O	O
,	O	O
with	O	O
a	O	O
significant	O	O
overactivation	O	O
in	O	O
the	O	O
supplementary	O	O
motor	O	O
area	O	O
and	O	O
the	O	O
ipsi	O	O
-	O	O
and	O	O
contralateral	O	O
primary	O	O
motor	O	O
areas	O	O
.	O	O

These	O	O
results	O	O
are	O	O
compatible	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
an	O	O
hyperkinetic	B-Disease	D006948
abnormal	B-Disease	D004409
involuntary	I-Disease	D004409
movement	I-Disease	D004409
,	O	O
like	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
-	O	O
induced	O	O
peak	O	O
dose	O	O
dyskinesia	B-Disease	D004409
,	O	O
is	O	O
due	O	O
to	O	O
a	O	O
disinhibition	O	O
of	O	O
the	O	O
primary	O	O
and	O	O
associated	O	O
motor	O	O
cortex	O	O
secondary	O	O
to	O	O
an	O	O
excessive	O	O
outflow	O	O
of	O	O
the	O	O
pallidothalamocortical	O	O
motor	O	O
loop	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
in	O	O
perfusion	O	O
-	O	O
cultured	O	O
human	O	O
eyes	O	O
.	O	O

PURPOSE	O	O
:	O	O
Glucocorticoid	O	O
administration	O	O
can	O	O
lead	O	O
to	O	O
the	O	O
development	O	O
of	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
and	O	O
corticosteroid	B-Disease	D005901
glaucoma	I-Disease	D005901
in	O	O
a	O	O
subset	O	O
of	O	O
the	O	O
population	O	O
through	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
aqueous	O	O
humor	O	O
outflow	O	O
facility	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
glucocorticoid	O	O
treatment	O	O
can	O	O
directly	O	O
affect	O	O
the	O	O
outflow	O	O
facility	O	O
of	O	O
isolated	O	O
,	O	O
perfusion	O	O
-	O	O
cultured	O	O
human	O	O
eyes	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
anterior	O	O
segments	O	O
of	O	O
human	O	O
donor	O	O
eyes	O	O
from	O	O
regional	O	O
eye	O	O
banks	O	O
were	O	O
placed	O	O
in	O	O
a	O	O
constant	O	O
flow	O	O
,	O	O
variable	O	O
pressure	O	O
perfusion	O	O
culture	O	O
system	O	O
.	O	O

Paired	O	O
eyes	O	O
were	O	O
perfused	O	O
in	O	O
serum	O	O
-	O	O
free	O	O
media	O	O
with	O	O
or	O	O
without	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
dexamethasone	B-Chemical	D003907
for	O	O
12	O	O
days	O	O
.	O	O

Intraocular	O	O
pressure	O	O
was	O	O
monitored	O	O
daily	O	O
.	O	O

After	O	O
incubation	O	O
,	O	O
the	O	O
eyes	O	O
were	O	O
morphologically	O	O
characterized	O	O
by	O	O
light	O	O
microscopy	O	O
,	O	O
transmission	O	O
and	O	O
scanning	O	O
electron	O	O
microscopy	O	O
,	O	O
and	O	O
scanning	O	O
laser	O	O
confocal	O	O
microscopy	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
significant	O	O
increase	O	O
in	O	O
intraocular	O	O
pressure	O	O
developed	O	O
in	O	O
13	O	O
of	O	O
the	O	O
44	O	O
pairs	O	O
of	O	O
eyes	O	O
perfused	O	O
with	O	O
dexamethasone	B-Chemical	D003907
with	O	O
an	O	O
average	O	O
pressure	O	O
rise	O	O
of	O	O
17	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

8	O	O
mm	O	O
Hg	O	O
after	O	O
12	O	O
days	O	O
of	O	O
dexamethasone	B-Chemical	D003907
exposure	O	O
.	O	O

The	O	O
contralateral	O	O
control	O	O
eyes	O	O
,	O	O
which	O	O
did	O	O
not	O	O
receive	O	O
dexamethasone	B-Chemical	D003907
,	O	O
maintained	O	O
a	O	O
stable	O	O
intraocular	O	O
pressure	O	O
during	O	O
the	O	O
same	O	O
period	O	O
.	O	O

The	O	O
outflow	O	O
pathway	O	O
of	O	O
the	O	O
untreated	O	O
eyes	O	O
appeared	O	O
morphologically	O	O
normal	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
dexamethasone	B-Chemical	D003907
-	O	O
treated	O	O
hypertensive	B-Disease	D009798
eyes	I-Disease	D009798
had	O	O
thickened	O	O
trabecular	O	O
beams	O	O
,	O	O
decreased	O	O
intertrabecular	O	O
spaces	O	O
,	O	O
thickened	O	O
juxtacanalicular	O	O
tissue	O	O
,	O	O
activated	O	O
trabecular	O	O
meshwork	O	O
cells	O	O
,	O	O
and	O	O
increased	O	O
amounts	O	O
of	O	O
amorphogranular	O	O
extracellular	O	O
material	O	O
,	O	O
especially	O	O
in	O	O
the	O	O
juxtacanalicular	O	O
tissue	O	O
and	O	O
beneath	O	O
the	O	O
endothelial	O	O
lining	O	O
of	O	O
the	O	O
canal	O	O
of	O	O
Schlemm	O	O
.	O	O

The	O	O
dexamethasone	B-Chemical	D003907
-	O	O
treated	O	O
nonresponder	O	O
eyes	O	O
appeared	O	O
to	O	O
be	O	O
morphologically	O	O
similar	O	O
to	O	O
the	O	O
untreated	O	O
eyes	O	O
,	O	O
although	O	O
several	O	O
subtle	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
morphologic	O	O
changes	O	O
were	O	O
evident	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Dexamethasone	B-Chemical	D003907
treatment	O	O
of	O	O
isolated	O	O
,	O	O
perfusion	O	O
-	O	O
cultured	O	O
human	O	O
eyes	O	O
led	O	O
to	O	O
the	O	O
generation	O	O
of	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
in	O	O
approximately	O	O
30%	O	O
of	O	O
the	O	O
dexamethasone	B-Chemical	D003907
-	O	O
treated	O	O
eyes	O	O
.	O	O

Steroid	B-Chemical	D013256
treatment	O	O
resulted	O	O
in	O	O
morphologic	O	O
changes	O	O
in	O	O
the	O	O
trabecular	O	O
meshwork	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
for	O	O
corticosteroid	B-Disease	D005901
glaucoma	I-Disease	D005901
and	O	O
open	B-Disease	D005902
angle	I-Disease	D005902
glaucoma	I-Disease	D005902
.	O	O

This	O	O
system	O	O
may	O	O
provide	O	O
an	O	O
acute	O	O
model	O	O
in	O	O
which	O	O
to	O	O
study	O	O
the	O	O
pathogenic	O	O
mechanisms	O	O
involved	O	O
in	O	O
steroid	B-Disease	D005901
glaucoma	I-Disease	D005901
and	O	O
primary	B-Disease	D005902
open	I-Disease	D005902
angle	I-Disease	D005902
glaucoma	I-Disease	D005902
.	O	O

Cognitive	B-Disease	D003072
deterioration	I-Disease	D003072
from	O	O
long	O	O
-	O	O
term	O	O
abuse	O	O
of	O	O
dextromethorphan	B-Chemical	D003915
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Dextromethorphan	B-Chemical	D003915
(	O	O
DM	B-Chemical	D003915
)	O	O
,	O	O
the	O	O
dextrorotatory	O	O
isomer	O	O
of	O	O
3	B-Chemical	D007981
-	I-Chemical	D007981
hydroxy	I-Chemical	D007981
-	I-Chemical	D007981
N	I-Chemical	D007981
-	I-Chemical	D007981
methylmorphinan	I-Chemical	D007981
,	O	O
is	O	O
the	O	O
main	O	O
ingredient	O	O
in	O	O
a	O	O
number	O	O
of	O	O
widely	O	O
available	O	O
,	O	O
over	O	O
-	O	O
the	O	O
-	O	O
counter	O	O
antitussives	O	O
.	O	O

Initial	O	O
studies	O	O
(	O	O
Bornstein	O	O
1968	O	O
)	O	O
showed	O	O
that	O	O
it	O	O
possessed	O	O
no	O	O
respiratory	O	O
suppressant	O	O
effects	O	O
and	O	O
no	O	O
addiction	O	O
liability	O	O
.	O	O

Subsequently	O	O
,	O	O
however	O	O
,	O	O
several	O	O
articles	O	O
reporting	O	O
abuse	O	O
of	O	O
this	O	O
drug	O	O
have	O	O
appeared	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

The	O	O
drug	O	O
is	O	O
known	O	O
to	O	O
cause	O	O
a	O	O
variety	O	O
of	O	O
acute	O	O
toxic	O	O
effects	O	O
,	O	O
ranging	O	O
from	O	O
nausea	B-Disease	D009325
,	O	O
restlessness	B-Disease	D011595
,	O	O
insomnia	B-Disease	D007319
,	O	O
ataxia	B-Disease	D001259
,	O	O
slurred	O	O
speech	O	O
and	O	O
nystagmus	B-Disease	C564088
to	O	O
mood	O	O
changes	O	O
,	O	O
perceptual	O	O
alterations	O	O
,	O	O
inattention	O	O
,	O	O
disorientation	O	O
and	O	O
aggressive	B-Disease	D001523
behavior	I-Disease	D001523
(	O	O
Rammer	O	O
et	O	O
al	O	O
1988	O	O
;	O	O
Katona	O	O
and	O	O
Watson	O	O
1986	O	O
;	O	O
Isbell	O	O
and	O	O
Fraser	O	O
1953	O	O
;	O	O
Devlin	O	O
et	O	O
al	O	O
1985	O	O
;	O	O
McCarthy	O	O
1971	O	O
;	O	O
Dodds	O	O
and	O	O
Revai	O	O
1967	O	O
;	O	O
Degkwitz	O	O
1964	O	O
;	O	O
Hildebrand	O	O
et	O	O
al	O	O
1989	O	O
)	O	O
.	O	O

There	O	O
have	O	O
also	O	O
been	O	O
two	O	O
reported	O	O
fatalities	O	O
from	O	O
DM	B-Chemical	D003915
overdoses	O	O
(	O	O
Fleming	O	O
1986	O	O
)	O	O
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O	O
describing	O	O
the	O	O
effects	O	O
of	O	O
chronic	O	O
abuse	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
cognitive	B-Disease	D003072
deterioration	I-Disease	D003072
resulting	O	O
from	O	O
prolonged	O	O
use	O	O
of	O	O
DM	B-Chemical	D003915
.	O	O

Long	O	O
-	O	O
term	O	O
lithium	B-Chemical	D008094
treatment	O	O
and	O	O
the	O	O
kidney	O	O
.	O	O

Interim	O	O
report	O	O
on	O	O
fifty	O	O
patients	O	O
.	O	O

This	O	O
is	O	O
a	O	O
report	O	O
on	O	O
the	O	O
first	O	O
part	O	O
of	O	O
our	O	O
study	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
long	O	O
-	O	O
term	O	O
lithium	B-Chemical	D008094
treatment	O	O
on	O	O
the	O	O
kidney	O	O
.	O	O

Creatinine	B-Chemical	D003404
clearance	O	O
,	O	O
maximum	O	O
urinary	O	O
osmolality	O	O
and	O	O
24	O	O
hour	O	O
urine	O	O
volume	O	O
have	O	O
been	O	O
tested	O	O
in	O	O
50	O	O
affectively	O	O
ill	O	O
patients	O	O
who	O	O
have	O	O
been	O	O
on	O	O
long	O	O
-	O	O
term	O	O
lithium	B-Chemical	D008094
for	O	O
more	O	O
than	O	O
one	O	O
year	O	O
.	O	O

These	O	O
findings	O	O
have	O	O
been	O	O
compared	O	O
with	O	O
norms	O	O
and	O	O
with	O	O
values	O	O
of	O	O
the	O	O
same	O	O
tests	O	O
from	O	O
screening	O	O
prior	O	O
to	O	O
lithium	B-Chemical	D008094
,	O	O
available	O	O
for	O	O
most	O	O
of	O	O
our	O	O
patients	O	O
.	O	O

No	O	O
evidence	O	O
was	O	O
found	O	O
for	O	O
any	O	O
reduction	O	O
of	O	O
glomerular	O	O
filtration	O	O
during	O	O
lithium	B-Chemical	D008094
treatment	O	O
.	O	O

Low	O	O
clearance	O	O
values	O	O
found	O	O
in	O	O
several	O	O
patients	O	O
could	O	O
be	O	O
accounted	O	O
for	O	O
by	O	O
their	O	O
age	O	O
and	O	O
their	O	O
pre	O	O
-	O	O
lithium	B-Chemical	D008094
values	O	O
.	O	O

Urinary	O	O
concentration	O	O
defect	O	O
appeared	O	O
frequent	O	O
but	O	O
the	O	O
extent	O	O
of	O	O
the	O	O
impairment	O	O
is	O	O
difficult	O	O
to	O	O
assess	O	O
because	O	O
of	O	O
the	O	O
uncertainty	O	O
about	O	O
the	O	O
norms	O	O
applicable	O	O
to	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
concentration	O	O
defect	O	O
appeared	O	O
reversible	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
.	O	O

Polyuria	B-Disease	D011141
above	O	O
3	O	O
litres	O	O
/	O	O
24	O	O
hours	O	O
was	O	O
found	O	O
in	O	O
10%	O	O
of	O	O
patients	O	O
.	O	O

An	O	O
attempt	O	O
is	O	O
made	O	O
to	O	O
draw	O	O
practical	O	O
conclusions	O	O
from	O	O
the	O	O
preliminary	O	O
findings	O	O
.	O	O

Complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
following	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
trazodone	B-Chemical	D014196
.	O	O

Forty	O	O
minutes	O	O
after	O	O
receiving	O	O
a	O	O
single	O	O
starting	O	O
dose	O	O
of	O	O
trazodone	B-Chemical	D014196
,	O	O
a	O	O
patient	O	O
developed	O	O
complete	O	O
heart	B-Disease	D006327
block	I-Disease	D006327
.	O	O

The	O	O
case	O	O
illustrates	O	O
that	O	O
,	O	O
despite	O	O
the	O	O
results	O	O
of	O	O
earlier	O	O
studies	O	O
,	O	O
trazodone's	O	O
effect	O	O
on	O	O
cardiac	O	O
conduction	O	O
may	O	O
be	O	O
severe	O	O
in	O	O
individuals	O	O
at	O	O
risk	O	O
for	O	O
conduction	O	O
delay	O	O
.	O	O

Quinidine	B-Chemical	C033457
phenylethylbarbiturate	I-Chemical	C033457
-	O	O
induced	O	O
fulminant	O	O
hepatitis	B-Disease	D056486
in	O	O
a	O	O
pregnant	O	O
woman	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
19	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Laotian	O	O
patient	O	O
affected	O	O
by	O	O
fulminant	O	O
hepatitis	B-Disease	D056486
during	O	O
the	O	O
third	O	O
trimester	O	O
of	O	O
her	O	O
pregnancy	O	O
after	O	O
a	O	O
1	O	O
-	O	O
month	O	O
administration	O	O
of	O	O
quinidine	B-Chemical	C033457
phenylethylbarbiturate	I-Chemical	C033457
.	O	O

After	O	O
delivery	O	O
,	O	O
the	O	O
patient	O	O
underwent	O	O
orthotopic	O	O
liver	O	O
transplantation	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
in	O	O
good	O	O
condition	O	O
16	O	O
months	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

Quinidine	B-Chemical	D011802
itself	O	O
or	O	O
phenylethylbarbiturate	B-Chemical	C033457
may	O	O
be	O	O
responsible	O	O
for	O	O
fulminant	O	O
hepatitis	B-Disease	D056486
in	O	O
this	O	O
patient	O	O
.	O	O

The	O	O
epidemiology	O	O
of	O	O
the	O	O
acute	O	O
flank	B-Disease	D021501
pain	I-Disease	D021501
syndrome	O	O
from	O	O
suprofen	B-Chemical	D013496
.	O	O

Suprofen	B-Chemical	D013496
,	O	O
a	O	O
new	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
,	O	O
was	O	O
marketed	O	O
in	O	O
early	O	O
1986	O	O
as	O	O
an	O	O
analgesic	O	O
agent	O	O
.	O	O

Until	O	O
physicians	O	O
began	O	O
reporting	O	O
an	O	O
unusual	O	O
acute	O	O
flank	B-Disease	D021501
pain	I-Disease	D021501
syndrome	O	O
to	O	O
the	O	O
spontaneous	O	O
reporting	O	O
system	O	O
,	O	O
700	O	O
,	O	O
000	O	O
persons	O	O
used	O	O
the	O	O
drug	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

Through	O	O
August	O	O
1986	O	O
,	O	O
a	O	O
total	O	O
of	O	O
163	O	O
cases	O	O
of	O	O
this	O	O
syndrome	O	O
were	O	O
reported	O	O
.	O	O

To	O	O
elucidate	O	O
the	O	O
epidemiology	O	O
of	O	O
the	O	O
syndrome	O	O
,	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
was	O	O
performed	O	O
,	O	O
comparing	O	O
62	O	O
of	O	O
the	O	O
case	O	O
patients	O	O
who	O	O
had	O	O
been	O	O
reported	O	O
to	O	O
the	O	O
spontaneous	O	O
reporting	O	O
system	O	O
to	O	O
185	O	O
suprofen	B-Chemical	D013496
-	O	O
exposed	O	O
control	O	O
subjects	O	O
who	O	O
did	O	O
not	O	O
have	O	O
the	O	O
syndrome	O	O
.	O	O

Case	O	O
patients	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
men	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
3	O	O
.	O	O

8	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

2	O	O
-	O	O
12	O	O
.	O	O

1	O	O
)	O	O
,	O	O
suffer	O	O
from	O	O
hay	B-Disease	D006255
fever	I-Disease	D006255
and	O	O
asthma	B-Disease	D001249
(	O	O
odds	O	O
ratio	O	O
,	O	O
3	O	O
.	O	O

4	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

0	O	O
-	O	O
11	O	O
.	O	O

9	O	O
)	O	O
;	O	O
to	O	O
participate	O	O
in	O	O
regular	O	O
exercise	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
5	O	O
.	O	O

9	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
30	O	O
.	O	O

7	O	O
)	O	O
,	O	O
especially	O	O
in	O	O
the	O	O
use	O	O
of	O	O
Nautilus	O	O
equipment	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
;	O	O
and	O	O
to	O	O
use	O	O
alcohol	B-Chemical	D000431
(	O	O
odds	O	O
ratio	O	O
,	O	O
4	O	O
.	O	O

4	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

1	O	O
-	O	O
17	O	O
.	O	O

5	O	O
)	O	O
.	O	O

Possible	O	O
risk	O	O
factors	O	O
included	O	O
young	O	O
age	O	O
,	O	O
concurrent	O	O
use	O	O
of	O	O
other	O	O
analgesic	O	O
agents	O	O
(	O	O
especially	O	O
ibuprofen	B-Chemical	D007052
)	O	O
,	O	O
preexisting	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
,	O	O
a	O	O
history	O	O
of	O	O
kidney	B-Disease	D007669
stones	I-Disease	D007669
,	O	O
a	O	O
history	O	O
of	O	O
gout	B-Disease	D006073
,	O	O
a	O	O
recent	O	O
increase	O	O
in	O	O
activity	O	O
,	O	O
a	O	O
recent	O	O
increase	O	O
in	O	O
sun	O	O
exposure	O	O
,	O	O
and	O	O
residence	O	O
in	O	O
the	O	O
Sunbelt	O	O
.	O	O

These	O	O
were	O	O
findings	O	O
that	O	O
were	O	O
suggestive	O	O
but	O	O
did	O	O
not	O	O
reach	O	O
conventional	O	O
statistical	O	O
significance	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
postulated	O	O
mechanism	O	O
for	O	O
this	O	O
unusual	O	O
syndrome	O	O
:	O	O
acute	O	O
diffuse	O	O
crystallization	O	O
of	O	O
uric	B-Chemical	D014527
acid	I-Chemical	D014527
in	O	O
renal	O	O
tubules	O	O
.	O	O

Hemolytic	B-Disease	D006463
-	I-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
associated	O	O
with	O	O
ingestion	O	O
of	O	O
quinine	B-Chemical	D011803
.	O	O

Hemolytic	B-Disease	D006463
-	I-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
following	O	O
quinine	B-Chemical	D011803
ingestion	O	O
is	O	O
a	O	O
newly	O	O
described	O	O
phenomenon	O	O
,	O	O
with	O	O
just	O	O
two	O	O
previous	O	O
descriptions	O	O
of	O	O
4	O	O
cases	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
5th	O	O
case	O	O
.	O	O

The	O	O
reaction	O	O
may	O	O
be	O	O
mediated	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
antibodies	O	O
reactive	O	O
against	O	O
platelets	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
quinine	B-Chemical	D011803
.	O	O

Treatment	O	O
has	O	O
included	O	O
use	O	O
of	O	O
plasma	O	O
exchange	O	O
,	O	O
prednisone	B-Chemical	D011241
,	O	O
aspirin	B-Chemical	D001241
,	O	O
and	O	O
dipyridamole	B-Chemical	D004176
.	O	O

The	O	O
patients	O	O
have	O	O
all	O	O
regained	O	O
some	O	O
degree	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
pharmacological	O	O
treatment	O	O
or	O	O
spontaneous	O	O
resolution	O	O
is	O	O
responsible	O	O
for	O	O
the	O	O
improvement	O	O
.	O	O

Quinine	B-Chemical	D011803
-	O	O
associated	O	O
hemolytic	B-Disease	D006463
-	I-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
probably	O	O
occurs	O	O
more	O	O
often	O	O
than	O	O
is	O	O
recognized	O	O
.	O	O

It	O	O
is	O	O
important	O	O
to	O	O
recognize	O	O
this	O	O
reaction	O	O
when	O	O
it	O	O
occurs	O	O
and	O	O
to	O	O
avoid	O	O
further	O	O
quinine	B-Chemical	D011803
exposure	O	O
,	O	O
since	O	O
the	O	O
reaction	O	O
seems	O	O
to	O	O
be	O	O
recurrent	O	O
.	O	O

Pyeloureteral	O	O
filling	O	O
defects	O	O
associated	O	O
with	O	O
systemic	O	O
anticoagulation	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

The	O	O
etiology	O	O
of	O	O
pyeloureteritis	B-Disease	D011702
cystica	I-Disease	D011702
has	O	O
long	O	O
been	O	O
attributed	O	O
to	O	O
chronic	O	O
infection	B-Disease	D007239
and	O	O
inflammation	B-Disease	D007249
.	O	O

A	O	O
case	O	O
is	O	O
presented	O	O
that	O	O
is	O	O
unique	O	O
in	O	O
that	O	O
the	O	O
acute	O	O
onset	O	O
and	O	O
the	O	O
rapid	O	O
resolution	O	O
of	O	O
pyeloureteral	O	O
filling	O	O
defects	O	O
in	O	O
this	O	O
patient	O	O
were	O	O
documented	O	O
by	O	O
radiography	O	O
.	O	O

There	O	O
is	O	O
no	O	O
evidence	O	O
of	O	O
antecedent	O	O
or	O	O
concurrent	O	O
infection	B-Disease	D007239
in	O	O
this	O	O
patient	O	O
.	O	O

The	O	O
disease	O	O
occurred	O	O
subsequent	O	O
to	O	O
the	O	O
initiation	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
for	O	O
suspected	O	O
pelvic	O	O
thrombophlebitis	B-Disease	D013924
and	O	O
cleared	O	O
rapidly	O	O
subsequent	O	O
to	O	O
its	O	O
discontinuation	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
resolution	O	O
of	O	O
the	O	O
radiographic	O	O
findings	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
distinguishing	O	O
between	O	O
true	O	O
pyeloureteritis	B-Disease	D011702
cystica	I-Disease	D011702
and	O	O
submucosal	B-Disease	D006470
hemorrhage	I-Disease	D006470
.	O	O

Changes	O	O
in	O	O
peroxisomes	O	O
in	O	O
preneoplastic	O	O
liver	O	O
and	O	O
hepatoma	B-Disease	D006528
of	O	O
mice	O	O
induced	O	O
by	O	O
alpha	B-Chemical	D001556
-	I-Chemical	D001556
benzene	I-Chemical	D001556
hexachloride	I-Chemical	D001556
.	O	O

Peroxisomes	O	O
in	O	O
hepatomas	B-Disease	D006528
and	O	O
hyperplastic	O	O
preneoplastic	O	O
liver	B-Disease	D017093
lesions	I-Disease	D017093
induced	O	O
in	O	O
mice	O	O
by	O	O
500	O	O
ppm	O	O
alpha	B-Chemical	D001556
-	I-Chemical	D001556
benzene	I-Chemical	D001556
hexachloride	I-Chemical	D001556
were	O	O
examined	O	O
histochemically	O	O
and	O	O
electron	O	O
microscopically	O	O
.	O	O

Although	O	O
most	O	O
of	O	O
the	O	O
hepatomas	B-Disease	D006528
were	O	O
well	O	O
-	O	O
differentiated	O	O
tumors	B-Disease	D009369
and	O	O
contained	O	O
a	O	O
considerable	O	O
number	O	O
of	O	O
peroxisomes	O	O
,	O	O
the	O	O
tumor	B-Disease	D009369
cells	O	O
did	O	O
not	O	O
respond	O	O
to	O	O
ethyl	B-Chemical	C012282
-	I-Chemical	C012282
alpha	I-Chemical	C012282
-	I-Chemical	C012282
p	I-Chemical	C012282
-	I-Chemical	C012282
chlorophenoxyisobutyrate	I-Chemical	C012282
with	O	O
proliferation	O	O
of	O	O
peroxisomes	O	O
.	O	O

At	O	O
the	O	O
16th	O	O
week	O	O
of	O	O
carcinogen	O	O
feeding	O	O
,	O	O
hyperplastic	O	O
nodules	O	O
appeared	O	O
and	O	O
advanced	O	O
to	O	O
further	O	O
stages	O	O
.	O	O

A	O	O
majority	O	O
of	O	O
the	O	O
nodules	O	O
showed	O	O
a	O	O
considerable	O	O
number	O	O
of	O	O
peroxisomes	O	O
and	O	O
the	O	O
inductive	O	O
proliferation	O	O
of	O	O
peroxisomes	O	O
.	O	O

Within	O	O
the	O	O
nodules	O	O
,	O	O
foci	O	O
of	O	O
proliferation	O	O
of	O	O
the	O	O
cells	O	O
that	O	O
showed	O	O
no	O	O
inducibility	O	O
of	O	O
proliferation	O	O
of	O	O
peroxisomes	O	O
appeared	O	O
.	O	O

These	O	O
cells	O	O
proliferated	O	O
further	O	O
,	O	O
replacing	O	O
the	O	O
most	O	O
part	O	O
of	O	O
the	O	O
nodules	O	O
,	O	O
and	O	O
with	O	O
this	O	O
process	O	O
hepatomas	B-Disease	D006528
appeared	O	O
to	O	O
have	O	O
been	O	O
formed	O	O
.	O	O

No	O	O
abnormal	O	O
matrical	O	O
inclusions	O	O
of	O	O
peroxisomes	O	O
were	O	O
formed	O	O
in	O	O
the	O	O
cells	O	O
of	O	O
hyperplastic	O	O
nodules	O	O
by	O	O
ethyl	B-Chemical	C012282
-	I-Chemical	C012282
alpha	I-Chemical	C012282
-	I-Chemical	C012282
p	I-Chemical	C012282
-	I-Chemical	C012282
chlorophenoxyisobutyrate	I-Chemical	C012282
unlike	O	O
in	O	O
the	O	O
case	O	O
of	O	O
rats	O	O
.	O	O

Quinidine	B-Chemical	D011802
hepatitis	B-Disease	D056486
.	O	O

Long	O	O
-	O	O
term	O	O
administration	O	O
of	O	O
quinidine	B-Chemical	D011802
was	O	O
associated	O	O
with	O	O
persistent	O	O
elevation	O	O
of	O	O
serum	O	O
concentrations	O	O
of	O	O
SGOT	O	O
,	O	O
lactic	B-Chemical	D019344
acid	I-Chemical	D019344
dehydrogenase	O	O
,	O	O
and	O	O
alkaline	O	O
phosphatase	O	O
.	O	O

Liver	O	O
biopsy	O	O
showed	O	O
active	O	O
hepatitis	B-Disease	D056486
.	O	O

Discontinuance	O	O
of	O	O
quinidine	B-Chemical	D011802
therapy	O	O
led	O	O
to	O	O
normalization	O	O
of	O	O
liver	O	O
function	O	O
tests	O	O
.	O	O

A	O	O
challenge	O	O
dose	O	O
of	O	O
quinidine	B-Chemical	D011802
caused	O	O
clinical	O	O
symptoms	O	O
and	O	O
abrupt	O	O
elevation	O	O
of	O	O
SGOT	O	O
,	O	O
alkaline	O	O
phosphatase	O	O
,	O	O
and	O	O
lactic	B-Chemical	D019344
acid	I-Chemical	D019344
dehydrogenase	O	O
values	O	O
.	O	O

We	O	O
concluded	O	O
that	O	O
this	O	O
patient	O	O
had	O	O
quinidine	B-Chemical	D011802
hepatotoxicity	B-Disease	D056486
and	O	O
believe	O	O
that	O	O
this	O	O
is	O	O
the	O	O
first	O	O
case	O	O
reported	O	O
with	O	O
liver	O	O
biopsy	O	O
documentation	O	O
.	O	O

This	O	O
report	O	O
also	O	O
suggests	O	O
that	O	O
,	O	O
even	O	O
after	O	O
long	O	O
-	O	O
term	O	O
administration	O	O
,	O	O
the	O	O
hepatic	B-Disease	D056486
toxicity	I-Disease	D056486
is	O	O
reversible	O	O
.	O	O

Cholesteryl	B-Chemical	C013440
hemisuccinate	I-Chemical	C013440
treatment	O	O
protects	O	O
rodents	O	O
from	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
acetaminophen	B-Chemical	D000082
,	O	O
adriamycin	B-Chemical	D004317
,	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
,	O	O
chloroform	B-Chemical	D002725
and	O	O
galactosamine	B-Chemical	D005688
.	O	O

In	O	O
addition	O	O
to	O	O
its	O	O
use	O	O
as	O	O
a	O	O
stabilizer	O	O
/	O	O
rigidifier	O	O
of	O	O
membranes	O	O
,	O	O
cholesteryl	B-Chemical	C013440
hemisuccinate	I-Chemical	C013440
,	O	O
tris	B-Chemical	-1
salt	I-Chemical	-1
(	O	O
CS	B-Chemical	-1
)	O	O
administration	O	O
has	O	O
also	O	O
been	O	O
shown	O	O
to	O	O
protect	O	O
rats	O	O
from	O	O
the	O	O
hepatotoxic	B-Disease	D056486
effects	O	O
of	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
(	O	O
CCl4	B-Chemical	D002251
)	O	O
.	O	O

To	O	O
further	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
mechanism	O	O
of	O	O
CS	B-Chemical	-1
cytoprotection	O	O
,	O	O
we	O	O
examined	O	O
in	O	O
rats	O	O
and	O	O
mice	O	O
the	O	O
protective	O	O
abilities	O	O
of	O	O
CS	B-Chemical	-1
and	O	O
the	O	O
non	O	O
-	O	O
hydrolyzable	O	O
ether	O	O
form	O	O
of	O	O
CS	B-Chemical	-1
,	O	O
gamma	B-Chemical	C103872
-	I-Chemical	C103872
cholesteryloxybutyric	I-Chemical	C103872
acid	I-Chemical	C103872
,	O	O
tris	B-Chemical	-1
salt	I-Chemical	-1
(	O	O
CSE	B-Chemical	-1
)	O	O
against	O	O
acetaminophen	B-Chemical	D000082
-	O	O
,	O	O
adriamycin	B-Chemical	D004317
-	O	O
,	O	O
carbon	B-Chemical	D002251
tetrachloride	I-Chemical	D002251
-	O	O
,	O	O
chloroform	B-Chemical	D002725
-	O	O
and	O	O
galactosamine	B-Chemical	D005688
-	O	O
induced	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
results	O	O
of	O	O
these	O	O
studies	O	O
demonstrated	O	O
that	O	O
CS	B-Chemical	-1
-	O	O
mediated	O	O
protection	O	O
is	O	O
not	O	O
selective	O	O
for	O	O
a	O	O
particular	O	O
species	O	O
,	O	O
organ	O	O
system	O	O
or	O	O
toxic	O	O
chemical	O	O
.	O	O

A	O	O
24	O	O
-	O	O
h	O	O
pretreatment	O	O
of	O	O
both	O	O
rats	O	O
and	O	O
mice	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
CS	B-Chemical	-1
(	O	O
100mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
resulted	O	O
in	O	O
significant	O	O
protection	O	O
against	O	O
the	O	O
hepatotoxic	B-Disease	D056486
effects	O	O
of	O	O
CCl4	B-Chemical	D002251
,	O	O
CHCl3	B-Chemical	D002725
,	O	O
acetaminophen	B-Chemical	D000082
and	O	O
galactosamine	B-Chemical	D005688
and	O	O
against	O	O
the	O	O
lethal	O	O
(	O	O
and	O	O
presumably	O	O
cardiotoxic	B-Disease	D066126
)	O	O
effect	O	O
of	O	O
adriamycin	B-Chemical	D004317
administration	O	O
.	O	O

Maximal	O	O
CS	B-Chemical	-1
-	O	O
mediated	O	O
protection	O	O
was	O	O
observed	O	O
in	O	O
experimental	O	O
animals	O	O
pretreated	O	O
24	O	O
h	O	O
prior	O	O
to	O	O
the	O	O
toxic	O	O
insult	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
CS	B-Chemical	-1
intervenes	O	O
in	O	O
a	O	O
critical	O	O
cellular	O	O
event	O	O
that	O	O
is	O	O
an	O	O
important	O	O
common	O	O
pathway	O	O
to	O	O
toxic	O	O
cell	O	O
death	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
CS	B-Chemical	-1
protection	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
dependent	O	O
on	O	O
the	O	O
inhibition	O	O
of	O	O
chemical	O	O
bioactivation	O	O
to	O	O
a	O	O
toxic	O	O
reactive	O	O
intermediate	O	O
(	O	O
in	O	O
light	O	O
of	O	O
the	O	O
protection	O	O
observed	O	O
against	O	O
galactosamine	B-Chemical	D005688
hepatotoxicity	B-Disease	D056486
)	O	O
.	O	O

However	O	O
,	O	O
based	O	O
on	O	O
the	O	O
data	O	O
presented	O	O
,	O	O
we	O	O
can	O	O
not	O	O
exclude	O	O
the	O	O
possibility	O	O
that	O	O
CS	B-Chemical	-1
administration	O	O
inhibits	O	O
chemical	O	O
bioactivation	O	O
.	O	O

Our	O	O
findings	O	O
do	O	O
suggest	O	O
that	O	O
CS	B-Chemical	-1
-	O	O
mediated	O	O
protection	O	O
is	O	O
dependent	O	O
on	O	O
the	O	O
action	O	O
of	O	O
the	O	O
intact	O	O
anionic	O	O
CS	B-Chemical	-1
molecule	O	O
(	O	O
non	O	O
-	O	O
hydrolyzable	O	O
CSE	B-Chemical	-1
was	O	O
as	O	O
protective	O	O
as	O	O
CS	B-Chemical	-1
)	O	O
,	O	O
whose	O	O
mechanism	O	O
has	O	O
yet	O	O
to	O	O
be	O	O
defined	O	O
.	O	O

DSMM	O	O
XI	O	O
study	O	O
:	O	O
dose	O	O
definition	O	O
for	O	O
intravenous	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
combination	O	O
with	O	O
bortezomib	B-Chemical	C400082
/	O	O
dexamethasone	B-Chemical	D003907
for	O	O
remission	O	O
induction	O	O
in	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
myeloma	B-Disease	D009101
.	O	O

A	O	O
clinical	O	O
trial	O	O
was	O	O
initiated	O	O
to	O	O
evaluate	O	O
the	O	O
recommended	O	O
dose	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
combination	O	O
with	O	O
bortezomib	B-Chemical	C400082
and	O	O
dexamethasone	B-Chemical	D003907
as	O	O
induction	O	O
treatment	O	O
before	O	O
stem	O	O
cell	O	O
transplantation	O	O
for	O	O
younger	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
(	O	O
MM	B-Disease	D009101
)	O	O
.	O	O

Thirty	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
three	O	O
21	O	O
-	O	O
day	O	O
cycles	O	O
of	O	O
bortezomib	B-Chemical	C400082
1	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
11	O	O
plus	O	O
dexamethasone	B-Chemical	D003907
40	O	O
mg	O	O
on	O	O
the	O	O
day	O	O
of	O	O
bortezomib	B-Chemical	C400082
injection	O	O
and	O	O
the	O	O
day	O	O
after	O	O
plus	O	O
cyclophosphamide	B-Chemical	D003520
at	O	O
900	O	O
,	O	O
1	O	O
,	O	O
200	O	O
,	O	O
or	O	O
1	O	O
,	O	O
500	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
day	O	O
1	O	O
.	O	O

The	O	O
maximum	O	O
tolerated	O	O
dose	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
was	O	O
defined	O	O
as	O	O
900	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
.	O	O

At	O	O
this	O	O
dose	O	O
level	O	O
,	O	O
92%	O	O
of	O	O
patients	O	O
achieved	O	O
at	O	O
least	O	O
a	O	O
partial	O	O
response	O	O
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
[	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
plus	O	O
partial	O	O
response	O	O
(	O	O
PR	O	O
)	O	O
]	O	O
across	O	O
all	O	O
dose	O	O
levels	O	O
was	O	O
77%	O	O
,	O	O
with	O	O
a	O	O
10%	O	O
CR	O	O
rate	O	O
.	O	O

No	O	O
patient	O	O
experienced	O	O
progressive	O	O
disease	O	O
.	O	O

The	O	O
most	O	O
frequent	O	O
adverse	O	O
events	O	O
were	O	O
hematological	O	O
and	O	O
gastrointestinal	O	O
toxicities	O	O
as	O	O
well	O	O
as	O	O
neuropathy	B-Disease	D009422
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
bortezomib	B-Chemical	C400082
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
at	O	O
900	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
dexamethasone	B-Chemical	D003907
is	O	O
an	O	O
effective	O	O
induction	O	O
treatment	O	O
for	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
MM	B-Disease	D009101
that	O	O
warrants	O	O
further	O	O
investigation	O	O
.	O	O

Results	O	O
of	O	O
a	O	O
comparative	O	O
,	O	O
phase	O	O
III	O	O
,	O	O
12	O	O
-	O	O
week	O	O
,	O	O
multicenter	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
assessment	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
a	O	O
fixed	O	O
-	O	O
dose	O	O
combination	O	O
of	O	O
telmisartan	B-Chemical	C084178
and	O	O
amlodipine	B-Chemical	D017311
versus	O	O
amlodipine	B-Chemical	D017311
monotherapy	O	O
in	O	O
Indian	O	O
adults	O	O
with	O	O
stage	O	O
II	O	O
hypertension	B-Disease	D006973
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
a	O	O
new	O	O
fixed	O	O
-	O	O
dose	O	O
combination	O	O
(	O	O
FDC	O	O
)	O	O
of	O	O
telmisartan	B-Chemical	C084178
40	O	O
mg	O	O
+	O	O
amlodipine	B-Chemical	D017311
5	O	O
mg	O	O
(	O	O
T+A	O	O
)	O	O
compared	O	O
with	O	O
amlodipine	B-Chemical	D017311
5	O	O
-	O	O
mg	O	O
monotherapy	O	O
(	O	O
A	O	O
)	O	O
in	O	O
adult	O	O
Indian	O	O
patients	O	O
with	O	O
stage	O	O
II	O	O
hypertension	B-Disease	D006973
.	O	O

METHODS	O	O
:	O	O
This	O	O
comparative	O	O
,	O	O
Phase	O	O
III	O	O
,	O	O
12	O	O
-	O	O
week	O	O
,	O	O
multicenter	O	O
,	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
Indian	O	O
patients	O	O
aged	O	O
18	O	O
to	O	O
65	O	O
years	O	O
with	O	O
established	O	O
stage	O	O
II	O	O
hypertension	B-Disease	D006973
.	O	O

Patients	O	O
were	O	O
treated	O	O
with	O	O
oral	O	O
FDC	O	O
of	O	O
T+A	O	O
or	O	O
A	O	O
QD	O	O
before	O	O
breakfast	O	O
for	O	O
12	O	O
weeks	O	O
;	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
measured	O	O
in	O	O
the	O	O
sitting	O	O
position	O	O
.	O	O

Primary	O	O
efficacy	O	O
end	O	O
points	O	O
were	O	O
reduction	O	O
in	O	O
clinical	O	O
systolic	O	O
BP	O	O
(	O	O
SBP	O	O
)	O	O
/	O	O
diastolic	O	O
BP	O	O
(	O	O
DBP	O	O
)	O	O
from	O	O
baseline	O	O
to	O	O
study	O	O
end	O	O
and	O	O
number	O	O
of	O	O
responders	O	O
(	O	O
ie	O	O
,	O	O
patients	O	O
who	O	O
achieved	O	O
target	O	O
SBP	O	O
/	O	O
DBP	O	O
<130	O	O
/	O	O
<80	O	O
mm	O	O
Hg	O	O
)	O	O
at	O	O
end	O	O
of	O	O
study	O	O
.	O	O

Tolerability	O	O
was	O	O
assessed	O	O
by	O	O
treatment	O	O
-	O	O
emergent	O	O
adverse	O	O
events	O	O
,	O	O
identified	O	O
using	O	O
physical	O	O
examination	O	O
,	O	O
laboratory	O	O
analysis	O	O
,	O	O
and	O	O
electrocardiography	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
210	O	O
patients	O	O
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
;	O	O
203	O	O
patients	O	O
(	O	O
143	O	O
men	O	O
,	O	O
60	O	O
women	O	O
)	O	O
completed	O	O
the	O	O
study	O	O
while	O	O
7	O	O
were	O	O
lost	O	O
to	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
4	O	O
patients	O	O
in	O	O
the	O	O
T+A	O	O
group	O	O
and	O	O
3	O	O
in	O	O
the	O	O
A	O	O
group	O	O
)	O	O
and	O	O
considered	O	O
with	O	O
-	O	O
drawn	O	O
.	O	O

At	O	O
study	O	O
end	O	O
,	O	O
statistically	O	O
significant	O	O
percentage	O	O
reductions	O	O
from	O	O
baseline	O	O
within	O	O
groups	O	O
and	O	O
between	O	O
groups	O	O
were	O	O
observed	O	O
in	O	O
SBP	O	O
(	O	O
T+A	O	O
[	O	O
-	O	O
27	O	O
.	O	O

4%	O	O
]	O	O
;	O	O
A	O	O
[	O	O
-	O	O
16	O	O
.	O	O

6%	O	O
]	O	O
)	O	O
and	O	O
DBP	O	O
(	O	O
T+A	O	O
[	O	O
-	O	O
20	O	O
.	O	O

1%	O	O
]	O	O
;	O	O
A	O	O
[	O	O
-	O	O
13	O	O
.	O	O

3%	O	O
]	O	O
)	O	O
(	O	O
all	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Response	O	O
rates	O	O
were	O	O
87	O	O
.	O	O

3%	O	O
(	O	O
89	O	O
/	O	O
102	O	O
)	O	O
in	O	O
the	O	O
T+A	O	O
group	O	O
and	O	O
69	O	O
.	O	O

3%	O	O
(	O	O
70	O	O
/	O	O
101	O	O
)	O	O
in	O	O
the	O	O
A	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
prevalences	O	O
of	O	O
adverse	O	O
events	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
2	O	O
treatment	O	O
groups	O	O
(	O	O
T+A	O	O
,	O	O
16	O	O
.	O	O

0%	O	O
[	O	O
17	O	O
/	O	O
106	O	O
]	O	O
;	O	O
A	O	O
,	O	O
15	O	O
.	O	O

4%	O	O
[	O	O
16	O	O
/	O	O
104	O	O
]	O	O
)	O	O
.	O	O

Peripheral	O	O
edema	B-Disease	D004487
was	O	O
reported	O	O
in	O	O
8	O	O
.	O	O

5%	O	O
patients	O	O
(	O	O
9	O	O
/	O	O
106	O	O
)	O	O
in	O	O
the	O	O
T+A	O	O
group	O	O
compared	O	O
with	O	O
13	O	O
.	O	O

5%	O	O
(	O	O
14	O	O
/	O	O
104	O	O
)	O	O
in	O	O
the	O	O
A	O	O
group	O	O
,	O	O
and	O	O
cough	B-Disease	D003371
was	O	O
reported	O	O
in	O	O
3	O	O
.	O	O

8%	O	O
patients	O	O
(	O	O
4	O	O
/	O	O
106	O	O
)	O	O
in	O	O
the	O	O
T+A	O	O
group	O	O
and	O	O
1	O	O
.	O	O

0%	O	O
(	O	O
1	O	O
/	O	O
104	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
A	O	O
group	O	O
;	O	O
these	O	O
differences	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
.	O	O

The	O	O
incidences	O	O
of	O	O
headache	B-Disease	D006261
,	O	O
dizziness	B-Disease	D004244
,	O	O
and	O	O
diarrhea	B-Disease	D003967
were	O	O
similar	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Among	O	O
these	O	O
Indian	O	O
patients	O	O
with	O	O
stage	O	O
II	O	O
hypertension	B-Disease	D006973
,	O	O
the	O	O
FDC	O	O
of	O	O
T+A	O	O
was	O	O
found	O	O
to	O	O
be	O	O
significantly	O	O
more	O	O
effective	O	O
,	O	O
with	O	O
regard	O	O
to	O	O
BP	O	O
reductions	O	O
,	O	O
than	O	O
A	O	O
,	O	O
and	O	O
both	O	O
treatments	O	O
were	O	O
well	O	O
tolerated	O	O
.	O	O

Cutaneous	B-Disease	D018366
leucocytoclastic	I-Disease	D018366
vasculitis	I-Disease	D018366
associated	O	O
with	O	O
oxacillin	B-Chemical	D010068
.	O	O

A	O	O
67	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
oxacillin	B-Chemical	D010068
for	O	O
one	O	O
week	O	O
because	O	O
of	O	O
Staphylococcus	O	O
aureus	O	O
bacteremia	O	O
,	O	O
developed	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
diffuse	O	O
,	O	O
symmetric	O	O
,	O	O
palpable	O	O
purpuric	B-Disease	D011693
lesions	I-Disease	D011693
on	O	O
his	O	O
feet	O	O
.	O	O

Necrotic	O	O
blisters	O	O
were	O	O
noted	O	O
on	O	O
his	O	O
fingers	O	O
.	O	O

Skin	O	O
biopsies	O	O
showed	O	O
findings	O	O
diagnostic	O	O
of	O	O
leucocytoclastic	B-Disease	D018366
vasculitis	I-Disease	D018366
.	O	O

Oxacillin	B-Chemical	D010068
was	O	O
discontinued	O	O
and	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
corticosteroids	B-Chemical	D000305
.	O	O

The	O	O
rash	B-Disease	D005076
disappeared	O	O
after	O	O
three	O	O
weeks	O	O
and	O	O
renal	O	O
function	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

Leucocytoclastic	B-Disease	D018366
vasculitis	I-Disease	D018366
presents	O	O
as	O	O
palpable	O	O
purpura	B-Disease	D011693
of	O	O
the	O	O
lower	O	O
extremities	O	O
often	O	O
accompanied	O	O
by	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
,	O	O
arthralgia	B-Disease	D018771
,	O	O
and	O	O
renal	B-Disease	D007674
involvement	I-Disease	D007674
.	O	O

Etiologic	O	O
factors	O	O
or	O	O
associated	O	O
disorders	O	O
include	O	O
infections	B-Disease	D007239
,	O	O
medications	O	O
,	O	O
collagen	B-Disease	D003095
vascular	I-Disease	D003095
disease	I-Disease	D003095
and	O	O
neoplasia	B-Disease	D009369
.	O	O

However	O	O
,	O	O
in	O	O
half	O	O
of	O	O
the	O	O
cases	O	O
no	O	O
etiologic	O	O
factor	O	O
is	O	O
identified	O	O
.	O	O

Usually	O	O
it	O	O
is	O	O
a	O	O
self	O	O
-	O	O
limited	O	O
disorder	O	O
,	O	O
but	O	O
corticosteroid	B-Chemical	D000305
therapy	O	O
may	O	O
be	O	O
needed	O	O
in	O	O
life	O	O
-	O	O
threatening	O	O
cases	O	O
since	O	O
early	O	O
treatment	O	O
with	O	O
corticosteroids	B-Chemical	D000305
in	O	O
severe	O	O
cases	O	O
can	O	O
prevent	O	O
complications	O	O
.	O	O

Oxacillin	B-Chemical	D010068
should	O	O
be	O	O
included	O	O
among	O	O
the	O	O
drugs	O	O
that	O	O
can	O	O
cause	O	O
leucocytoclastic	B-Disease	D018366
vasculitis	I-Disease	D018366
.	O	O

Naloxazone	B-Chemical	C024224
pretreatment	O	O
modifies	O	O
cardiorespiratory	O	O
,	O	O
temperature	O	O
,	O	O
and	O	O
behavioral	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

Behavioral	O	O
and	O	O
cardiorespiratory	O	O
responses	O	O
to	O	O
a	O	O
lethal	O	O
dose	O	O
of	O	O
morphine	B-Chemical	D009020
were	O	O
evaluated	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
saline	O	O
or	O	O
naloxazone	B-Chemical	C024224
,	O	O
an	O	O
antagonist	O	O
of	O	O
high	O	O
-	O	O
affinity	O	O
mu	O	O
1	O	O
opioid	O	O
receptors	O	O
.	O	O

Pretreatment	O	O
with	O	O
naloxazone	B-Chemical	C024224
significantly	O	O
blocked	O	O
morphine	B-Chemical	D009020
analgesia	B-Disease	D000699
,	O	O
catalepsy	B-Disease	D002375
and	O	O
hypothermia	B-Disease	D007035
at	O	O
a	O	O
dose	O	O
which	O	O
completely	O	O
eliminated	O	O
high	O	O
-	O	O
affinity	O	O
binding	O	O
in	O	O
brain	O	O
membranes	O	O
.	O	O

Moreover	O	O
,	O	O
naloxazone	B-Chemical	C024224
significantly	O	O
attenuated	O	O
the	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
respiratory	B-Disease	D012131
depression	I-Disease	D012131
,	O	O
whereas	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
bradycardia	B-Disease	D001919
was	O	O
less	O	O
affected	O	O
.	O	O

Results	O	O
indicate	O	O
that	O	O
subpopulations	O	O
of	O	O
mu	O	O
receptors	O	O
may	O	O
mediate	O	O
selective	O	O
behavioral	O	O
and	O	O
cardiorespiratory	O	O
responses	O	O
to	O	O
morphine	B-Chemical	D009020
.	O	O

Dexrazoxane	B-Chemical	D064730
protects	O	O
against	O	O
myelosuppression	B-Disease	D001855
from	O	O
the	O	O
DNA	O	O
cleavage	O	O
-	O	O
enhancing	O	O
drugs	O	O
etoposide	B-Chemical	D005047
and	O	O
daunorubicin	B-Chemical	D003630
but	O	O
not	O	O
doxorubicin	B-Chemical	D004317
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
anthracyclines	B-Chemical	D018943
daunorubicin	B-Chemical	D003630
and	O	O
doxorubicin	B-Chemical	D004317
and	O	O
the	O	O
epipodophyllotoxin	B-Chemical	D011034
etoposide	B-Chemical	D005047
are	O	O
potent	O	O
DNA	O	O
cleavage	O	O
-	O	O
enhancing	O	O
drugs	O	O
that	O	O
are	O	O
widely	O	O
used	O	O
in	O	O
clinical	O	O
oncology	O	O
;	O	O
however	O	O
,	O	O
myelosuppression	B-Disease	D001855
and	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
limit	O	O
their	O	O
use	O	O
.	O	O

Dexrazoxane	B-Chemical	D064730
(	O	O
ICRF	B-Chemical	D064730
-	I-Chemical	D064730
187	I-Chemical	D064730
)	O	O
is	O	O
recommended	O	O
for	O	O
protection	O	O
against	O	O
anthracycline	B-Chemical	D018943
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

EXPERIMENTAL	O	O
DESIGN	O	O
:	O	O
Because	O	O
of	O	O
their	O	O
widespread	O	O
use	O	O
,	O	O
the	O	O
hematologic	B-Disease	D006402
toxicity	I-Disease	D006402
following	O	O
coadministration	O	O
of	O	O
dexrazoxane	B-Chemical	D064730
and	O	O
these	O	O
three	O	O
structurally	O	O
different	O	O
DNA	O	O
cleavage	O	O
enhancers	O	O
was	O	O
investigated	O	O
:	O	O
Sensitivity	O	O
of	O	O
human	O	O
and	O	O
murine	O	O
blood	O	O
progenitor	O	O
cells	O	O
to	O	O
etoposide	B-Chemical	D005047
,	O	O
daunorubicin	B-Chemical	D003630
,	O	O
and	O	O
doxorubicin	B-Chemical	D004317
+	O	O
/	O	O
-	O	O
dexrazoxane	B-Chemical	D064730
was	O	O
determined	O	O
in	O	O
granulocyte	O	O
-	O	O
macrophage	O	O
colony	O	O
forming	O	O
assays	O	O
.	O	O

Likewise	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
B6D2F1	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
etoposide	B-Chemical	D005047
,	O	O
daunorubicin	B-Chemical	D003630
,	O	O
and	O	O
doxorubicin	B-Chemical	D004317
,	O	O
with	O	O
or	O	O
without	O	O
dexrazoxane	B-Chemical	D064730
over	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
doses	O	O
:	O	O
posttreatment	O	O
,	O	O
a	O	O
full	O	O
hematologic	O	O
evaluation	O	O
was	O	O
done	O	O
.	O	O

RESULTS	O	O
:	O	O
Nontoxic	O	O
doses	O	O
of	O	O
dexrazoxane	B-Chemical	D064730
reduced	O	O
myelosuppression	B-Disease	D001855
and	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
from	O	O
daunorubicin	B-Chemical	D003630
and	O	O
etoposide	B-Chemical	D005047
in	O	O
mice	O	O
and	O	O
antagonized	O	O
their	O	O
antiproliferative	O	O
effects	O	O
in	O	O
the	O	O
colony	O	O
assay	O	O
;	O	O
however	O	O
,	O	O
dexrazoxane	B-Chemical	D064730
neither	O	O
reduced	O	O
myelosuppression	B-Disease	D001855
,	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
,	O	O
nor	O	O
the	O	O
in	O	O
vitro	O	O
cytotoxicity	B-Disease	D064420
from	O	O
doxorubicin	B-Chemical	D004317
.	O	O

CONCLUSION	O	O
:	O	O
Although	O	O
our	O	O
findings	O	O
support	O	O
the	O	O
observation	O	O
that	O	O
dexrazoxane	B-Chemical	D064730
reduces	O	O
neither	O	O
hematologic	O	O
activity	O	O
nor	O	O
antitumor	O	O
activity	O	O
from	O	O
doxorubicin	B-Chemical	D004317
clinically	O	O
,	O	O
the	O	O
potent	O	O
antagonism	O	O
of	O	O
daunorubicin	B-Chemical	D003630
activity	O	O
raises	O	O
concern	O	O
;	O	O
a	O	O
possible	O	O
interference	O	O
with	O	O
anticancer	O	O
efficacy	O	O
certainly	O	O
would	O	O
call	O	O
for	O	O
renewed	O	O
attention	O	O
.	O	O

Our	O	O
data	O	O
also	O	O
suggest	O	O
that	O	O
significant	O	O
etoposide	B-Chemical	D005047
dose	O	O
escalation	O	O
is	O	O
perhaps	O	O
possible	O	O
by	O	O
the	O	O
use	O	O
of	O	O
dexrazoxane	B-Chemical	D064730
.	O	O

Clinical	O	O
trials	O	O
in	O	O
patients	O	O
with	O	O
brain	O	O
metastases	B-Disease	D009362
combining	O	O
dexrazoxane	B-Chemical	D064730
and	O	O
high	O	O
doses	O	O
of	O	O
etoposide	B-Chemical	D005047
is	O	O
ongoing	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
efficacy	O	O
without	O	O
aggravating	O	O
hematologic	B-Disease	D006402
toxicity	I-Disease	D006402
.	O	O

If	O	O
successful	O	O
,	O	O
this	O	O
represents	O	O
an	O	O
exciting	O	O
mechanism	O	O
for	O	O
pharmacologic	O	O
regulation	O	O
of	O	O
side	O	O
effects	O	O
from	O	O
cytotoxic	O	O
chemotherapy	O	O
.	O	O

Effects	O	O
of	O	O
the	O	O
novel	O	O
compound	O	O
aniracetam	B-Chemical	C036466
(	O	O
Ro	B-Chemical	C036466
13	I-Chemical	C036466
-	I-Chemical	C036466
5057	I-Chemical	C036466
)	O	O
upon	O	O
impaired	O	O
learning	O	O
and	O	O
memory	O	O
in	O	O
rodents	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
aniracetam	B-Chemical	C036466
(	O	O
Ro	B-Chemical	C036466
13	I-Chemical	C036466
-	I-Chemical	C036466
5057	I-Chemical	C036466
,	O	O
1	B-Chemical	C036466
-	I-Chemical	C036466
anisoyl	I-Chemical	C036466
-	I-Chemical	C036466
2	I-Chemical	C036466
-	I-Chemical	C036466
pyrrolidinone	I-Chemical	C036466
)	O	O
was	O	O
studied	O	O
on	O	O
various	O	O
forms	O	O
of	O	O
experimentally	O	O
impaired	B-Disease	D003072
cognitive	I-Disease	D003072
functions	I-Disease	D003072
(	O	O
learning	O	O
and	O	O
memory	O	O
)	O	O
in	O	O
rodents	O	O
and	O	O
produced	O	O
the	O	O
following	O	O
effects	O	O
:	O	O
(	O	O
1	O	O
)	O	O
almost	O	O
complete	O	O
prevention	O	O
of	O	O
the	O	O
incapacity	O	O
to	O	O
learn	O	O
a	O	O
discrete	O	O
escape	O	O
response	O	O
in	O	O
rats	O	O
exposed	O	O
to	O	O
sublethal	O	O
hypercapnia	B-Disease	D006935
immediately	O	O
before	O	O
the	O	O
acquisition	O	O
session	O	O
;	O	O
(	O	O
2	O	O
)	O	O
partial	O	O
(	O	O
rats	O	O
)	O	O
or	O	O
complete	O	O
(	O	O
mice	O	O
)	O	O
prevention	O	O
of	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
short	O	O
-	O	O
term	O	O
amnesia	B-Disease	D000647
for	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
;	O	O
(	O	O
3	O	O
)	O	O
complete	O	O
protection	O	O
against	O	O
amnesia	B-Disease	D000647
for	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
in	O	O
rats	O	O
submitted	O	O
to	O	O
electroconvulsive	O	O
shock	O	O
immediately	O	O
after	O	O
avoidance	O	O
acquisition	O	O
;	O	O
(	O	O
4	O	O
)	O	O
prevention	O	O
of	O	O
the	O	O
long	O	O
-	O	O
term	O	O
retention	O	O
-	O	O
or	O	O
retrieval	O	O
-	O	O
deficit	O	O
for	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
induced	O	O
in	O	O
rats	O	O
and	O	O
mice	O	O
by	O	O
chloramphenicol	B-Chemical	D002701
or	O	O
cycloheximide	B-Chemical	D003513
administered	O	O
immediately	O	O
after	O	O
acquisition	O	O
;	O	O
(	O	O
5	O	O
)	O	O
reversal	O	O
,	O	O
when	O	O
administered	O	O
as	O	O
late	O	O
as	O	O
1	O	O
h	O	O
before	O	O
the	O	O
retention	O	O
test	O	O
,	O	O
of	O	O
the	O	O
deficit	O	O
in	O	O
retention	O	O
or	O	O
retrieval	O	O
of	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
induced	O	O
by	O	O
cycloheximide	B-Chemical	D003513
injected	O	O
2	O	O
days	O	O
previously	O	O
;	O	O
(	O	O
6	O	O
)	O	O
prevention	O	O
of	O	O
the	O	O
deficit	O	O
in	O	O
the	O	O
retrieval	O	O
of	O	O
an	O	O
active	O	O
avoidance	O	O
task	O	O
induced	O	O
in	O	O
mice	O	O
by	O	O
subconvulsant	O	O
electroshock	O	O
or	O	O
hypercapnia	B-Disease	D006935
applied	O	O
immediately	O	O
before	O	O
retrieval	O	O
testing	O	O
(	O	O
24	O	O
h	O	O
after	O	O
acquisition	O	O
)	O	O
.	O	O

These	O	O
improvements	O	O
or	O	O
normalizations	O	O
of	O	O
impaired	B-Disease	D003072
cognitive	I-Disease	D003072
functions	I-Disease	D003072
were	O	O
seen	O	O
at	O	O
oral	O	O
aniracetam	B-Chemical	C036466
doses	O	O
of	O	O
10	O	O
-	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Generally	O	O
,	O	O
the	O	O
dose	O	O
-	O	O
response	O	O
curves	O	O
were	O	O
bell	O	O
-	O	O
shaped	O	O
.	O	O

The	O	O
mechanisms	O	O
underlying	O	O
the	O	O
activity	O	O
of	O	O
aniracetam	B-Chemical	C036466
and	O	O
its	O	O
'therapeutic	O	O
window'	O	O
are	O	O
unknown	O	O
.	O	O

Piracetam	B-Chemical	D010889
,	O	O
another	O	O
pyrrolidinone	B-Chemical	D011760
derivative	O	O
was	O	O
used	O	O
for	O	O
comparison	O	O
.	O	O

It	O	O
was	O	O
active	O	O
only	O	O
in	O	O
six	O	O
of	O	O
nine	O	O
tests	O	O
and	O	O
had	O	O
about	O	O
one	O	O
-	O	O
tenth	O	O
the	O	O
potency	O	O
of	O	O
aniracetam	B-Chemical	C036466
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
aniracetam	B-Chemical	C036466
improves	O	O
cognitive	O	O
functions	O	O
which	O	O
are	O	O
impaired	O	O
by	O	O
different	O	O
procedure	O	O
and	O	O
in	O	O
different	O	O
phases	O	O
of	O	O
the	O	O
learning	O	O
and	O	O
memory	O	O
process	O	O
.	O	O

Nicotine	B-Chemical	D009538
potentiation	O	O
of	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
in	O	O
mice	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
effects	O	O
of	O	O
nicotine	B-Chemical	D009538
on	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
morphine	B-Chemical	D009020
in	O	O
mice	O	O
have	O	O
been	O	O
investigated	O	O
.	O	O

Morphine	B-Chemical	D009020
but	O	O
not	O	O
nicotine	B-Chemical	D009538
induced	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
catalepsy	B-Disease	D002375
.	O	O

The	O	O
response	O	O
of	O	O
morphine	B-Chemical	D009020
was	O	O
potentiated	O	O
by	O	O
nicotine	B-Chemical	D009538
.	O	O

Intraperitoneal	O	O
administration	O	O
of	O	O
atropine	B-Chemical	D001285
,	O	O
naloxone	B-Chemical	D009270
,	O	O
mecamylamine	B-Chemical	D008464
,	O	O
and	O	O
hexamethonium	B-Chemical	D018738
to	O	O
mice	O	O
reduced	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
morphine	B-Chemical	D009020
with	O	O
nicotine	B-Chemical	D009538
.	O	O

Intracerebroventricular	O	O
injection	O	O
of	O	O
atropine	B-Chemical	D001285
,	O	O
hexamethonium	B-Chemical	D018738
,	O	O
and	O	O
naloxone	B-Chemical	D009270
also	O	O
decreased	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
morphine	B-Chemical	D009020
plus	O	O
nicotine	B-Chemical	D009538
.	O	O

Intraperitoneal	O	O
administration	O	O
of	O	O
atropine	B-Chemical	D001285
,	O	O
but	O	O
not	O	O
intraperitoneal	O	O
or	O	O
intracerebroventricular	O	O
injection	O	O
of	O	O
hexamethonium	B-Chemical	D018738
,	O	O
decreased	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
morphine	B-Chemical	D009020
catalepsy	B-Disease	D002375
can	O	O
be	O	O
elicited	O	O
by	O	O
opioid	O	O
and	O	O
cholinergic	O	O
receptors	O	O
,	O	O
and	O	O
the	O	O
potentiation	O	O
of	O	O
morphine	B-Chemical	D009020
induced	O	O
by	O	O
nicotine	B-Chemical	D009538
may	O	O
also	O	O
be	O	O
mediated	O	O
through	O	O
cholinergic	O	O
receptor	O	O
mechanisms	O	O
.	O	O

Reduced	O	O
cardiotoxicity	B-Disease	D066126
and	O	O
preserved	O	O
antitumor	O	O
efficacy	O	O
of	O	O
liposome	O	O
-	O	O
encapsulated	O	O
doxorubicin	B-Chemical	D004317
and	O	O
cyclophosphamide	B-Chemical	D003520
compared	O	O
with	O	O
conventional	O	O
doxorubicin	B-Chemical	D004317
and	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
a	O	O
randomized	O	O
,	O	O
multicenter	O	O
trial	O	O
of	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
determine	O	O
whether	O	O
Myocet	B-Chemical	D004317
(	O	O
liposome	O	O
-	O	O
encapsulated	O	O
doxorubicin	B-Chemical	D004317
;	O	O
The	O	O
Liposome	O	O
Company	O	O
,	O	O
Elan	O	O
Corporation	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
significantly	O	O
reduces	O	O
doxorubicin	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
while	O	O
providing	O	O
comparable	O	O
antitumor	O	O
efficacy	O	O
in	O	O
first	O	O
-	O	O
line	O	O
treatment	O	O
of	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
(	O	O
MBC	B-Disease	D001943
)	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Two	O	O
hundred	O	O
ninety	O	O
-	O	O
seven	O	O
patients	O	O
with	O	O
MBC	B-Disease	D001943
and	O	O
no	O	O
prior	O	O
chemotherapy	O	O
for	O	O
metastatic	O	O
disease	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
60	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
Myocet	B-Chemical	D004317
(	O	O
M	O	O
)	O	O
or	O	O
conventional	O	O
doxorubicin	B-Chemical	D004317
(	O	O
A	O	O
)	O	O
,	O	O
in	O	O
combination	O	O
with	O	O
600	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
C	O	O
)	O	O
,	O	O
every	O	O
3	O	O
weeks	O	O
until	O	O
disease	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxicity	B-Disease	D064420
.	O	O

Cardiotoxicity	B-Disease	D066126
was	O	O
defined	O	O
by	O	O
reductions	O	O
in	O	O
left	O	O
-	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
,	O	O
assessed	O	O
by	O	O
serial	O	O
multigated	O	O
radionuclide	O	O
angiography	O	O
scans	O	O
,	O	O
or	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
(	O	O
CHF	B-Disease	D006333
)	O	O
.	O	O

Antitumor	O	O
efficacy	O	O
was	O	O
assessed	O	O
by	O	O
objective	O	O
tumor	B-Disease	D009369
response	O	O
rates	O	O
(	O	O
World	O	O
Health	O	O
Organization	O	O
criteria	O	O
)	O	O
,	O	O
time	O	O
to	O	O
progression	O	O
,	O	O
and	O	O
survival	O	O
.	O	O

RESULTS	O	O
:	O	O
Six	O	O
percent	O	O
of	O	O
MC	O	O
patients	O	O
versus	O	O
21%	O	O
(	O	O
including	O	O
five	O	O
cases	O	O
of	O	O
CHF	B-Disease	D006333
)	O	O
of	O	O
AC	O	O
patients	O	O
developed	O	O
cardiotoxicity	B-Disease	D066126
(	O	O
P	O	O
=	O	O
.	O	O

0002	O	O
)	O	O
.	O	O

Median	O	O
cumulative	O	O
doxorubicin	B-Chemical	D004317
dose	O	O
at	O	O
onset	O	O
was	O	O
more	O	O
than	O	O
2	O	O
,	O	O
220	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
MC	O	O
versus	O	O
480	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
AC	O	O
(	O	O
P	O	O
=	O	O
.	O	O

0001	O	O
,	O	O
hazard	O	O
ratio	O	O
,	O	O
5	O	O
.	O	O

04	O	O
)	O	O
.	O	O

MC	O	O
patients	O	O
also	O	O
experienced	O	O
less	O	O
grade	O	O
4	O	O
neutropenia	B-Disease	D009503
.	O	O

Antitumor	O	O
efficacy	O	O
of	O	O
MC	O	O
versus	O	O
AC	O	O
was	O	O
comparable	O	O
:	O	O
objective	O	O
response	O	O
rates	O	O
,	O	O
43%	O	O
versus	O	O
43%	O	O
;	O	O
median	O	O
time	O	O
to	O	O
progression	O	O
,	O	O
5	O	O
.	O	O

1%	O	O
versus	O	O
5	O	O
.	O	O

5	O	O
months	O	O
;	O	O
median	O	O
time	O	O
to	O	O
treatment	O	O
failure	O	O
,	O	O
4	O	O
.	O	O

6	O	O
versus	O	O
4	O	O
.	O	O

4	O	O
months	O	O
;	O	O
and	O	O
median	O	O
survival	O	O
,	O	O
19	O	O
versus	O	O
16	O	O
months	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Myocet	B-Chemical	D004317
improves	O	O
the	O	O
therapeutic	O	O
index	O	O
of	O	O
doxorubicin	B-Chemical	D004317
by	O	O
significantly	O	O
reducing	O	O
cardiotoxicity	B-Disease	D066126
and	O	O
grade	O	O
4	O	O
neutropenia	B-Disease	D009503
and	O	O
provides	O	O
comparable	O	O
antitumor	O	O
efficacy	O	O
,	O	O
when	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
as	O	O
first	O	O
-	O	O
line	O	O
therapy	O	O
for	O	O
MBC	B-Disease	D001943
.	O	O

Protective	O	O
effect	O	O
of	O	O
a	O	O
specific	O	O
platelet	O	O
-	O	O
activating	O	O
factor	O	O
antagonist	O	O
,	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
,	O	O
on	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiovascular	B-Disease	D002318
impairments	I-Disease	D002318
in	O	O
rats	O	O
.	O	O

Administration	O	O
of	O	O
the	O	O
local	O	O
anaesthetic	O	O
bupivacaine	B-Chemical	D002045
(	O	O
1	O	O
.	O	O

5	O	O
or	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
to	O	O
rats	O	O
elicited	O	O
a	O	O
marked	O	O
decrease	O	O
of	O	O
mean	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
MBP	O	O
)	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
leading	O	O
to	O	O
death	O	O
(	O	O
in	O	O
67%	O	O
or	O	O
90%	O	O
of	O	O
animals	O	O
respectively	O	O
)	O	O
.	O	O

Intravenous	O	O
injection	O	O
of	O	O
the	O	O
specific	O	O
platelet	O	O
-	O	O
activating	O	O
factor	O	O
(	O	O
PAF	O	O
)	O	O
antagonist	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
30	O	O
min	O	O
before	O	O
bupivacaine	B-Chemical	D002045
administration	O	O
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
suppressed	O	O
both	O	O
the	O	O
decrease	O	O
of	O	O
MBP	O	O
and	O	O
HR	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
doses	O	O
of	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
given	O	O
30	O	O
min	O	O
before	O	O
or	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
administered	O	O
5	O	O
min	O	O
before	O	O
i	O	O
.	O	O

v	O	O
.	O	O

injection	O	O
of	O	O
bupivacaine	B-Chemical	D002045
were	O	O
ineffective	O	O
.	O	O

When	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
was	O	O
injected	O	O
immediately	O	O
after	O	O
bupivacaine	B-Chemical	D002045
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
a	O	O
partial	O	O
reversion	O	O
of	O	O
the	O	O
decrease	O	O
of	O	O
MBP	O	O
and	O	O
HR	O	O
was	O	O
observed	O	O
,	O	O
whereas	O	O
the	O	O
dose	O	O
of	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
was	O	O
ineffective	O	O
.	O	O

A	O	O
partial	O	O
recovery	O	O
of	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
ECG	O	O
alterations	O	O
was	O	O
observed	O	O
after	O	O
pretreatment	O	O
of	O	O
the	O	O
rats	O	O
with	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
.	O	O

Since	O	O
the	O	O
administration	O	O
of	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
,	O	O
at	O	O
all	O	O
doses	O	O
studied	O	O
,	O	O
did	O	O
not	O	O
alter	O	O
MBP	O	O
and	O	O
HR	O	O
at	O	O
the	O	O
doses	O	O
used	O	O
,	O	O
the	O	O
bulk	O	O
of	O	O
these	O	O
results	O	O
clearly	O	O
demonstrate	O	O
a	O	O
protective	O	O
action	O	O
of	O	O
BN	B-Chemical	C045856
52021	I-Chemical	C045856
,	O	O
a	O	O
specific	O	O
antagonist	O	O
of	O	O
PAF	O	O
,	O	O
against	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiovascular	B-Disease	D002318
toxicity	I-Disease	D002318
.	O	O

Thus	O	O
,	O	O
consistent	O	O
with	O	O
its	O	O
direct	O	O
effect	O	O
on	O	O
heart	O	O
,	O	O
PAF	O	O
appears	O	O
to	O	O
be	O	O
implicated	O	O
in	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiovascular	B-Disease	D018376
alterations	I-Disease	D018376
.	O	O

Benzylacyclouridine	B-Chemical	C034753
reverses	O	O
azidothymidine	B-Chemical	D015215
-	O	O
induced	O	O
marrow	B-Disease	D001855
suppression	I-Disease	D001855
without	O	O
impairment	O	O
of	O	O
anti	O	O
-	O	O
human	O	O
immunodeficiency	B-Disease	D007153
virus	O	O
activity	O	O
.	O	O

Increased	O	O
extracellular	O	O
concentrations	O	O
of	O	O
uridine	B-Chemical	D014529
(	O	O
Urd	B-Chemical	D014529
)	O	O
have	O	O
been	O	O
reported	O	O
to	O	O
reduce	O	O
,	O	O
in	O	O
vitro	O	O
,	O	O
azidothymidine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
-	O	O
induced	O	O
inhibition	O	O
of	O	O
human	O	O
granulocyte	O	O
-	O	O
macrophage	O	O
progenitor	O	O
cells	O	O
without	O	O
impairment	O	O
of	O	O
its	O	O
antihuman	O	O
immunodeficiency	B-Disease	D007153
virus	O	O
(	O	O
HIV	O	O
)	O	O
activity	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
clinical	O	O
toxicities	B-Disease	D064420
associated	O	O
with	O	O
chronic	O	O
Urd	B-Chemical	D014529
administration	O	O
,	O	O
the	O	O
ability	O	O
of	O	O
benzylacyclouridine	B-Chemical	C034753
(	O	O
BAU	B-Chemical	C034753
)	O	O
to	O	O
effect	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
AZT	B-Chemical	D015215
-	O	O
induced	O	O
anemia	B-Disease	D000740
and	O	O
leukopenia	B-Disease	D007970
was	O	O
assessed	O	O
.	O	O

This	O	O
agent	O	O
inhibits	O	O
Urd	B-Chemical	D014529
catabolism	O	O
and	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
increases	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
Urd	B-Chemical	D014529
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
,	O	O
without	O	O
Urd	B-Chemical	D014529
-	O	O
related	O	O
toxicity	B-Disease	D064420
.	O	O

In	O	O
mice	O	O
rendered	O	O
anemic	B-Disease	D000740
and	O	O
leukopenic	B-Disease	D007970
by	O	O
the	O	O
administration	O	O
of	O	O
AZT	B-Chemical	D015215
for	O	O
28	O	O
days	O	O
in	O	O
drinking	O	O
water	O	O
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
mL	O	O
)	O	O
,	O	O
the	O	O
continued	O	O
administration	O	O
of	O	O
AZT	B-Chemical	D015215
plus	O	O
daily	O	O
BAU	B-Chemical	C034753
(	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
orally	O	O
)	O	O
partially	O	O
reversed	O	O
AZT	B-Chemical	D015215
-	O	O
induced	O	O
anemia	B-Disease	D000740
and	O	O
leukopenia	B-Disease	D007970
(	O	O
P	O	O
less	O	O
than	O	O
.	O	O

05	O	O
)	O	O
,	O	O
increased	O	O
peripheral	O	O
reticulocytes	O	O
(	O	O
to	O	O
4	O	O
.	O	O

9%	O	O
,	O	O
P	O	O
less	O	O
than	O	O
.	O	O

01	O	O
)	O	O
,	O	O
increased	O	O
cellularity	O	O
in	O	O
the	O	O
marrow	O	O
,	O	O
and	O	O
improved	O	O
megaloblastosis	B-Disease	-1
.	O	O

When	O	O
coadministered	O	O
with	O	O
AZT	B-Chemical	D015215
from	O	O
the	O	O
onset	O	O
of	O	O
drug	O	O
administration	O	O
,	O	O
BAU	B-Chemical	C034753
reduced	O	O
AZT	B-Chemical	D015215
-	O	O
induced	O	O
marrow	B-Disease	D001855
toxicity	I-Disease	D001855
.	O	O

In	O	O
vitro	O	O
,	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
100	O	O
mumol	O	O
/	O	O
L	O	O
,	O	O
BAU	B-Chemical	C034753
possesses	O	O
minimal	O	O
anti	O	O
-	O	O
HIV	O	O
activity	O	O
and	O	O
has	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
ability	O	O
of	O	O
AZT	B-Chemical	D015215
to	O	O
reverse	O	O
the	O	O
HIV	O	O
-	O	O
induced	O	O
cytopathic	O	O
effect	O	O
in	O	O
MT4	O	O
cells	O	O
.	O	O

The	O	O
clinical	O	O
and	O	O
biochemical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

Cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
freely	O	O
-	O	O
moving	O	O
conscious	O	O
rats	O	O
:	O	O
behavioral	O	O
approach	O	O
to	O	O
a	O	O
new	O	O
model	O	O
of	O	O
visceral	B-Disease	D059265
pain	I-Disease	D059265
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
develop	O	O
a	O	O
model	O	O
of	O	O
visceral	B-Disease	D059265
pain	I-Disease	D059265
in	O	O
rats	O	O
using	O	O
a	O	O
behavioral	O	O
approach	O	O
.	O	O

Cyclophosphamide	B-Chemical	D003520
(	O	O
CP	B-Chemical	D003520
)	O	O
,	O	O
an	O	O
antitumoral	O	O
agent	O	O
known	O	O
to	O	O
produce	O	O
toxic	O	O
effects	O	O
on	O	O
the	O	O
bladder	O	O
wall	O	O
through	O	O
its	O	O
main	O	O
toxic	O	O
metabolite	O	O
acrolein	B-Chemical	D000171
,	O	O
was	O	O
used	O	O
to	O	O
induce	O	O
cystitis	B-Disease	D003556
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
CP	B-Chemical	D003520
was	O	O
administered	O	O
at	O	O
doses	O	O
of	O	O
50	O	O
,	O	O
100	O	O
and	O	O
200	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

p	O	O
.	O	O

to	O	O
male	O	O
rats	O	O
,	O	O
and	O	O
their	O	O
behavior	O	O
observed	O	O
and	O	O
scored	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
morphine	B-Chemical	D009020
(	O	O
0	O	O
.	O	O

5	O	O
to	O	O
4	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
on	O	O
CP	B-Chemical	D003520
-	O	O
induced	O	O
behavioral	O	O
modifications	O	O
were	O	O
tested	O	O
administered	O	O
alone	O	O
and	O	O
after	O	O
naloxone	B-Chemical	D009270
(	O	O
1	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
90	O	O
minutes	O	O
after	O	O
CP	B-Chemical	D003520
injection	O	O
,	O	O
that	O	O
is	O	O
,	O	O
at	O	O
the	O	O
time	O	O
of	O	O
administration	O	O
of	O	O
morphine	B-Chemical	D009020
,	O	O
the	O	O
bladder	O	O
was	O	O
removed	O	O
in	O	O
some	O	O
rats	O	O
for	O	O
histological	O	O
examination	O	O
.	O	O

Finally	O	O
,	O	O
to	O	O
show	O	O
that	O	O
the	O	O
bladder	O	O
is	O	O
essential	O	O
for	O	O
the	O	O
CP	B-Chemical	D003520
-	O	O
induced	O	O
behavioral	O	O
modifications	O	O
,	O	O
female	O	O
rats	O	O
also	O	O
received	O	O
CP	B-Chemical	D003520
at	O	O
doses	O	O
of	O	O
200	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

p	O	O
.	O	O

and	O	O
of	O	O
20	O	O
mg	O	O
.	O	O

by	O	O
the	O	O
intravesical	O	O
route	O	O
,	O	O
and	O	O
acrolein	B-Chemical	D000171
at	O	O
doses	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

by	O	O
the	O	O
intravesical	O	O
route	O	O
and	O	O
of	O	O
5	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

v	O	O
.	O	O

RESULTS	O	O
:	O	O
CP	B-Chemical	D003520
dose	O	O
-	O	O
relatedly	O	O
induced	O	O
marked	O	O
behavioral	O	O
modifications	O	O
in	O	O
male	O	O
rats	O	O
:	O	O
breathing	O	O
rate	O	O
decrease	O	O
,	O	O
closing	O	O
of	O	O
the	O	O
eyes	O	O
and	O	O
occurrence	O	O
of	O	O
specific	O	O
postures	O	O
.	O	O

Morphine	B-Chemical	D009020
dose	O	O
-	O	O
dependently	O	O
reversed	O	O
these	O	O
behavioral	B-Disease	D001523
disorders	I-Disease	D001523
.	O	O

A	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

produced	O	O
a	O	O
reduction	O	O
of	O	O
almost	O	O
50%	O	O
of	O	O
the	O	O
behavioral	O	O
score	O	O
induced	O	O
by	O	O
CP	B-Chemical	D003520
200	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

This	O	O
effect	O	O
was	O	O
completely	O	O
prevented	O	O
by	O	O
pretreatment	O	O
with	O	O
naloxone	B-Chemical	D009270
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
administration	O	O
of	O	O
morphine	B-Chemical	D009020
,	O	O
histological	O	O
modifications	O	O
of	O	O
the	O	O
bladder	O	O
wall	O	O
,	O	O
such	O	O
as	O	O
chorionic	O	O
and	O	O
muscle	O	O
layer	O	O
edema	B-Disease	D004487
,	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
female	O	O
rats	O	O
,	O	O
CP	B-Chemical	D003520
200	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

p	O	O
.	O	O

produced	O	O
the	O	O
same	O	O
marked	O	O
behavioral	O	O
modifications	O	O
as	O	O
those	O	O
observed	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

Administered	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
20	O	O
mg	O	O
.	O	O

intravesically	O	O
,	O	O
CP	B-Chemical	D003520
did	O	O
not	O	O
produce	O	O
any	O	O
behavioral	O	O
effects	O	O
,	O	O
whereas	O	O
acrolein	B-Chemical	D000171
at	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

intravesically	O	O
induced	O	O
behavioral	O	O
modifications	O	O
identical	O	O
to	O	O
those	O	O
under	O	O
CP	B-Chemical	D003520
200	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
with	O	O
the	O	O
same	O	O
maximal	O	O
levels	O	O
.	O	O

Conversely	O	O
,	O	O
acrolein	B-Chemical	D000171
5	O	O
mg	O	O
.	O	O

/	O	O
kg	O	O
.	O	O

i	O	O
.	O	O

v	O	O
.	O	O

did	O	O
not	O	O
produce	O	O
any	O	O
behavioral	O	O
effects	O	O
at	O	O
all	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Overall	O	O
,	O	O
these	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
experimental	O	O
model	O	O
of	O	O
CP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
may	O	O
be	O	O
an	O	O
interesting	O	O
new	O	O
behavioral	O	O
model	O	O
of	O	O
inflammatory	O	O
visceral	B-Disease	D059265
pain	I-Disease	D059265
,	O	O
allowing	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
these	O	O
painful	B-Disease	D010146
syndromes	I-Disease	D010146
and	O	O
thus	O	O
a	O	O
better	O	O
therapeutic	O	O
approach	O	O
to	O	O
them	O	O
.	O	O

Hyperalgesia	B-Disease	D006930
and	O	O
myoclonus	B-Disease	D009207
in	O	O
terminal	O	O
cancer	B-Disease	D009369
patients	O	O
treated	O	O
with	O	O
continuous	O	O
intravenous	O	O
morphine	B-Chemical	D009020
.	O	O

Eight	O	O
cancer	B-Disease	D009369
patients	O	O
in	O	O
the	O	O
terminal	O	O
stages	O	O
of	O	O
the	O	O
disease	O	O
treated	O	O
with	O	O
high	O	O
doses	O	O
of	O	O
intravenous	O	O
morphine	B-Chemical	D009020
developed	O	O
hyperalgesia	B-Disease	D006930
.	O	O

All	O	O
cases	O	O
were	O	O
retrospectively	O	O
sampled	O	O
from	O	O
three	O	O
different	O	O
hospitals	O	O
in	O	O
Copenhagen	O	O
.	O	O

Five	O	O
patients	O	O
developed	O	O
universal	O	O
hyperalgesia	B-Disease	D006930
and	O	O
hyperesthesia	B-Disease	D006941
which	O	O
in	O	O
2	O	O
cases	O	O
were	O	O
accompanied	O	O
by	O	O
myoclonus	B-Disease	D009207
.	O	O

In	O	O
3	O	O
patients	O	O
a	O	O
pre	O	O
-	O	O
existing	O	O
neuralgia	B-Disease	D009437
increased	O	O
to	O	O
excruciating	O	O
intensity	O	O
and	O	O
in	O	O
2	O	O
of	O	O
these	O	O
cases	O	O
myoclonus	B-Disease	D009207
occurred	O	O
simultaneously	O	O
.	O	O

Although	O	O
only	O	O
few	O	O
clinical	O	O
descriptions	O	O
of	O	O
the	O	O
relationship	O	O
between	O	O
hyperalgesia	B-Disease	D006930
/	O	O
myoclonus	B-Disease	D009207
and	O	O
high	O	O
doses	O	O
of	O	O
morphine	B-Chemical	D009020
are	O	O
available	O	O
,	O	O
experimental	O	O
support	O	O
from	O	O
animal	O	O
studies	O	O
indicates	O	O
that	O	O
morphine	B-Chemical	D009020
,	O	O
or	O	O
its	O	O
metabolites	O	O
,	O	O
plays	O	O
a	O	O
causative	O	O
role	O	O
for	O	O
the	O	O
observed	O	O
behavioural	O	O
syndrome	O	O
.	O	O

The	O	O
possible	O	O
mechanisms	O	O
are	O	O
discussed	O	O
and	O	O
treatment	O	O
proposals	O	O
given	O	O
suggesting	O	O
the	O	O
use	O	O
of	O	O
more	O	O
efficacious	O	O
opioids	O	O
with	O	O
less	O	O
excitatory	O	O
potency	O	O
in	O	O
these	O	O
situations	O	O
.	O	O

A	O	O
prospective	O	O
study	O	O
of	O	O
adverse	O	O
reactions	O	O
associated	O	O
with	O	O
vancomycin	B-Chemical	D014640
therapy	O	O
.	O	O

A	O	O
prospective	O	O
evaluation	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
vancomycin	B-Chemical	D014640
was	O	O
conducted	O	O
in	O	O
54	O	O
consecutive	O	O
patients	O	O
over	O	O
a	O	O
16	O	O
-	O	O
month	O	O
period	O	O
.	O	O

Vancomycin	B-Chemical	D014640
was	O	O
curative	O	O
in	O	O
95%	O	O
of	O	O
43	O	O
patients	O	O
with	O	O
proven	O	O
infection	B-Disease	D007239
.	O	O

Drugs	O	O
were	O	O
ceased	O	O
in	O	O
six	O	O
patients	O	O
because	O	O
of	O	O
adverse	O	O
reactions	O	O
;	O	O
in	O	O
three	O	O
of	O	O
these	O	O
vancomycin	B-Chemical	D014640
was	O	O
considered	O	O
the	O	O
likely	O	O
cause	O	O
.	O	O

Reactions	O	O
included	O	O
thrombophlebitis	B-Disease	D013924
(	O	O
20	O	O
of	O	O
54	O	O
patients	O	O
)	O	O
,	O	O
rash	B-Disease	D005076
(	O	O
4	O	O
of	O	O
54	O	O
)	O	O
,	O	O
nephrotoxicity	B-Disease	D007674
(	O	O
4	O	O
of	O	O
50	O	O
)	O	O
,	O	O
proteinuria	B-Disease	D011507
(	O	O
1	O	O
of	O	O
50	O	O
)	O	O
and	O	O
ototoxicity	B-Disease	D006311
(	O	O
1	O	O
of	O	O
11	O	O
patients	O	O
tested	O	O
by	O	O
audiometry	O	O
)	O	O
.	O	O

Thrombophlebitis	B-Disease	D013924
occurred	O	O
only	O	O
with	O	O
infusion	O	O
through	O	O
peripheral	O	O
cannulae	O	O
;	O	O
nephrotoxicity	B-Disease	D007674
and	O	O
ototoxicity	B-Disease	D006311
were	O	O
confined	O	O
to	O	O
patients	O	O
receiving	O	O
an	O	O
aminoglycoside	B-Chemical	D000617
plus	O	O
vancomycin	B-Chemical	D014640
.	O	O

We	O	O
conclude	O	O
that	O	O
vancomycin	B-Chemical	D014640
,	O	O
administered	O	O
appropriately	O	O
,	O	O
constitutes	O	O
safe	O	O
,	O	O
effective	O	O
therapy	O	O
for	O	O
infections	B-Disease	D007239
caused	O	O
by	O	O
susceptible	O	O
bacteria	O	O
.	O	O

Blockade	O	O
of	O	O
both	O	O
D	O	O
-	O	O
1	O	O
and	O	O
D	O	O
-	O	O
2	O	O
dopamine	B-Chemical	D004298
receptors	O	O
may	O	O
induce	O	O
catalepsy	B-Disease	D002375
in	O	O
mice	O	O
.	O	O

1	O	O
.	O	O

The	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
dopamine	B-Chemical	D004298
antagonists	O	O
has	O	O
been	O	O
tested	O	O
and	O	O
the	O	O
possible	O	O
dopamine	B-Chemical	D004298
subtypes	O	O
involved	O	O
in	O	O
catalepsy	B-Disease	D002375
was	O	O
determined	O	O
.	O	O

2	O	O
.	O	O

Dopamine	B-Chemical	D004298
antagonist	O	O
fluphenazine	B-Chemical	D005476
,	O	O
D	O	O
-	O	O
1	O	O
antagonist	O	O
SCH	B-Chemical	C534628
23390	I-Chemical	C534628
or	O	O
D	O	O
-	O	O
2	O	O
antagonist	O	O
sulpiride	B-Chemical	D013469
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

The	O	O
effect	O	O
of	O	O
fluphenazine	B-Chemical	D005476
and	O	O
sulpiride	B-Chemical	D013469
was	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

Combination	O	O
of	O	O
SCH	B-Chemical	C534628
23390	I-Chemical	C534628
with	O	O
sulpiride	B-Chemical	D013469
did	O	O
not	O	O
induce	O	O
catalepsy	B-Disease	D002375
potentiation	O	O
.	O	O

3	O	O
.	O	O

D	O	O
-	O	O
1	O	O
agonist	O	O
SKF	B-Chemical	D015647
38393	I-Chemical	D015647
or	O	O
D	O	O
-	O	O
2	O	O
agonist	O	O
quinpirole	B-Chemical	D019257
decreased	O	O
the	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
fluphenazine	B-Chemical	D005476
,	O	O
SCH	B-Chemical	C534628
23390	I-Chemical	C534628
or	O	O
sulpiride	B-Chemical	D013469
.	O	O

4	O	O
.	O	O

Combination	O	O
of	O	O
SKF	B-Chemical	D015647
38393	I-Chemical	D015647
with	O	O
quinpirole	B-Chemical	D019257
did	O	O
not	O	O
cause	O	O
potentiated	O	O
inhibitory	O	O
effect	O	O
on	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
dopamine	B-Chemical	D004298
antagonists	O	O
.	O	O

5	O	O
.	O	O

The	O	O
data	O	O
may	O	O
indicate	O	O
that	O	O
although	O	O
D	O	O
-	O	O
2	O	O
receptor	O	O
blockade	O	O
is	O	O
involved	O	O
in	O	O
catalepsy	B-Disease	D002375
,	O	O
the	O	O
D	O	O
-	O	O
1	O	O
receptor	O	O
may	O	O
plan	O	O
a	O	O
role	O	O
.	O	O

Dextran	B-Chemical	D003911
-	O	O
etodolac	B-Chemical	D017308
conjugates	O	O
:	O	O
synthesis	O	O
,	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
evaluation	O	O
.	O	O

Etodolac	B-Chemical	D017308
(	O	O
E	B-Chemical	D017308
)	O	O
,	O	O
is	O	O
a	O	O
non	O	O
-	O	O
narcotic	O	O
analgesic	O	O
and	O	O
antiinflammatory	O	O
drug	O	O
.	O	O

A	O	O
biodegradable	O	O
polymer	O	O
dextran	B-Chemical	D003911
has	O	O
been	O	O
utilized	O	O
as	O	O
a	O	O
carrier	O	O
for	O	O
synthesis	O	O
of	O	O
etodolac	B-Chemical	D017308
-	O	O
dextran	B-Chemical	D003911
conjugates	O	O
(	O	O
ED	O	O
)	O	O
to	O	O
improve	O	O
its	O	O
aqueous	O	O
solubility	O	O
and	O	O
reduce	O	O
gastrointestinal	O	O
side	O	O
effects	O	O
.	O	O

An	O	O
activated	O	O
moiety	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

N	B-Chemical	-1
-	I-Chemical	-1
acylimidazole	I-Chemical	-1
derivative	O	O
of	O	O
etodolac	B-Chemical	D017308
(	O	O
EAI	B-Chemical	-1
)	O	O
,	O	O
was	O	O
condensed	O	O
with	O	O
the	O	O
polysaccharide	O	O
polymer	O	O
dextran	B-Chemical	D003911
of	O	O
different	O	O
molecular	O	O
weights	O	O
(	O	O
40000	O	O
,	O	O
60000	O	O
,	O	O
110000	O	O
and	O	O
200000	O	O
)	O	O
.	O	O

IR	O	O
spectral	O	O
data	O	O
confirmed	O	O
formation	O	O
of	O	O
ester	O	O
bonding	O	O
in	O	O
the	O	O
conjugates	O	O
.	O	O

Etodolac	B-Chemical	D017308
contents	O	O
were	O	O
evaluated	O	O
by	O	O
UV	O	O
-	O	O
spectrophotometric	O	O
analysis	O	O
.	O	O

The	O	O
molecular	O	O
weights	O	O
were	O	O
determined	O	O
by	O	O
measuring	O	O
viscosity	O	O
using	O	O
the	O	O
Mark	O	O
-	O	O
Howink	O	O
-	O	O
Sakurada	O	O
equation	O	O
.	O	O

In	O	O
vitro	O	O
hydrolysis	O	O
of	O	O
ED	O	O
was	O	O
done	O	O
in	O	O
aqueous	O	O
buffers	O	O
(	O	O
pH	O	O
1	O	O
.	O	O

2	O	O
,	O	O
7	O	O
.	O	O

4	O	O
,	O	O
9	O	O
)	O	O
and	O	O
in	O	O
80%	O	O
(	O	O
v	O	O
/	O	O
v	O	O
)	O	O
human	O	O
plasma	O	O
(	O	O
pH	O	O
7	O	O
.	O	O

4	O	O
)	O	O
.	O	O

At	O	O
pH	O	O
9	O	O
,	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
etodolac	B-Chemical	D017308
release	O	O
from	O	O
ED	O	O
was	O	O
observed	O	O
as	O	O
compared	O	O
to	O	O
aqueous	O	O
buffer	O	O
of	O	O
pH	O	O
7	O	O
.	O	O

4	O	O
and	O	O
80%	O	O
human	O	O
plasma	O	O
(	O	O
pH	O	O
7	O	O
.	O	O

4	O	O
)	O	O
,	O	O
following	O	O
first	O	O
-	O	O
order	O	O
kinetics	O	O
.	O	O

In	O	O
vivo	O	O
investigations	O	O
were	O	O
performed	O	O
in	O	O
animals	O	O
.	O	O

Acute	O	O
analgesic	O	O
and	O	O
antiinflammatory	O	O
activities	O	O
were	O	O
ascertained	O	O
using	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
induced	O	O
writhing	B-Disease	D010146
model	O	O
(	O	O
mice	O	O
)	O	O
and	O	O
carrageenan	B-Chemical	D002351
-	O	O
induced	O	O
rat	O	O
paw	O	O
edema	B-Disease	D004487
model	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
comparison	O	O
to	O	O
control	O	O
,	O	O
E	B-Chemical	D017308
and	O	O
ED1	O	O
-	O	O
ED4	O	O
showed	O	O
highly	O	O
significant	O	O
analgesic	O	O
and	O	O
antiinflammatory	O	O
activities	O	O
(	O	O
p	O	O
<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Biological	O	O
evaluation	O	O
suggested	O	O
that	O	O
conjugates	O	O
(	O	O
ED1	O	O
-	O	O
ED4	O	O
)	O	O
retained	O	O
comparable	O	O
analgesic	O	O
and	O	O
antiinflammatory	O	O
activities	O	O
with	O	O
remarkably	O	O
reduced	O	O
ulcerogenicity	O	O
as	O	O
compared	O	O
to	O	O
their	O	O
parent	O	O
drug	O	O
-	O	O
-	O	O
etodolac	B-Chemical	D017308
.	O	O

Hypersensitivity	B-Disease	D004342
myocarditis	B-Disease	D009205
complicating	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
heart	O	O
.	O	O

The	O	O
present	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
eosinophilic	B-Disease	D004802
myocarditis	B-Disease	D009205
complicating	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
.	O	O

The	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
patient	O	O
,	O	O
known	O	O
to	O	O
have	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
,	O	O
was	O	O
admitted	O	O
with	O	O
biventricular	B-Disease	D018754
failure	I-Disease	D018754
and	O	O
managed	O	O
aggressively	O	O
with	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
and	O	O
other	O	O
drugs	O	O
while	O	O
being	O	O
assessed	O	O
for	O	O
heart	O	O
transplantation	O	O
.	O	O

On	O	O
transthoracic	O	O
echocardiogram	O	O
,	O	O
she	O	O
had	O	O
moderate	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
with	O	O
regional	O	O
variability	O	O
and	O	O
moderate	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
.	O	O

The	O	O
recipient's	O	O
heart	O	O
showed	O	O
the	O	O
features	O	O
of	O	O
apical	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
and	O	O
myocarditis	B-Disease	D009205
with	O	O
abundant	O	O
eosinophils	O	O
.	O	O

Myocarditis	B-Disease	D009205
is	O	O
rare	O	O
and	O	O
eosinophilic	B-Disease	D004802
myocarditis	B-Disease	D009205
is	O	O
rarer	O	O
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
the	O	O
hypersensitivity	B-Disease	D004342
(	O	O
eosinophilic	B-Disease	D004802
)	O	O
myocarditis	B-Disease	D009205
was	O	O
related	O	O
to	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
therapy	O	O
.	O	O

Eosinophilic	O	O
myocarditis	B-Disease	D009205
has	O	O
been	O	O
reported	O	O
with	O	O
an	O	O
incidence	O	O
of	O	O
2	O	O
.	O	O

4%	O	O
to	O	O
7	O	O
.	O	O

2%	O	O
in	O	O
explanted	O	O
hearts	O	O
and	O	O
may	O	O
be	O	O
related	O	O
to	O	O
multidrug	O	O
therapy	O	O
.	O	O

All	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
-	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
-	O	O
induced	O	O
erythema	B-Disease	D004893
nodosum	I-Disease	D004893
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
.	O	O

Erythema	B-Disease	D004893
nodosum	I-Disease	D004893
associated	O	O
with	O	O
all	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
-	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
(	O	O
ATRA	B-Chemical	D014212
)	O	O
for	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
(	O	O
APL	B-Disease	D015473
)	O	O
is	O	O
very	O	O
rare	O	O
.	O	O

We	O	O
describe	O	O
four	O	O
patients	O	O
with	O	O
classic	O	O
APL	B-Disease	D015473
who	O	O
developed	O	O
erythema	B-Disease	D004893
nodosum	I-Disease	D004893
during	O	O
ATRA	B-Chemical	D014212
therapy	O	O
.	O	O

Fever	B-Disease	D005334
and	O	O
subsequent	O	O
multiple	O	O
painful	B-Disease	D010146
erythematous	B-Disease	D004893
nodules	I-Disease	D004893
over	O	O
extremities	O	O
developed	O	O
on	O	O
D11	O	O
,	O	O
D16	O	O
,	O	O
D17	O	O
,	O	O
and	O	O
D19	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
ATRA	B-Chemical	D014212
therapy	O	O
.	O	O

The	O	O
skin	O	O
biopsy	O	O
taken	O	O
from	O	O
each	O	O
patient	O	O
was	O	O
consistent	O	O
with	O	O
erythema	B-Disease	D004893
nodosum	I-Disease	D004893
.	O	O

All	O	O
patients	O	O
received	O	O
short	O	O
course	O	O
of	O	O
steroids	B-Chemical	D013256
.	O	O

Fever	B-Disease	D005334
subsided	O	O
rapidly	O	O
and	O	O
the	O	O
skin	O	O
lesions	O	O
regressed	O	O
completely	O	O
.	O	O

All	O	O
patients	O	O
achieved	O	O
complete	O	O
remission	O	O
without	O	O
withdrawal	O	O
of	O	O
ATRA	B-Chemical	D014212
.	O	O

ATRA	B-Chemical	D014212
seemed	O	O
to	O	O
be	O	O
the	O	O
most	O	O
possible	O	O
etiology	O	O
of	O	O
erythema	B-Disease	D004893
nodosum	I-Disease	D004893
in	O	O
our	O	O
patients	O	O
.	O	O

Short	O	O
-	O	O
term	O	O
use	O	O
of	O	O
steroid	B-Chemical	D013256
is	O	O
very	O	O
effective	O	O
in	O	O
ATRA	B-Chemical	D014212
-	O	O
induced	O	O
erythema	B-Disease	D004893
nodosum	I-Disease	D004893
.	O	O

Delayed	O	O
-	O	O
onset	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

BACKGROUND	O	O
:	O	O
Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
presents	O	O
5	O	O
to	O	O
12	O	O
days	O	O
after	O	O
heparin	B-Chemical	D006493
exposure	O	O
,	O	O
with	O	O
or	O	O
without	O	O
arterial	O	O
or	O	O
venous	O	O
thromboemboli	O	O
.	O	O

Delayed	O	O
recognition	O	O
and	O	O
treatment	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
contribute	O	O
to	O	O
poor	O	O
patient	O	O
outcomes	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
and	O	O
increase	O	O
awareness	O	O
of	O	O
a	O	O
clinical	O	O
scenario	O	O
in	O	O
which	O	O
the	O	O
onset	O	O
or	O	O
manifestations	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
are	O	O
delayed	O	O
.	O	O

DESIGN	O	O
:	O	O
Retrospective	O	O
case	O	O
series	O	O
.	O	O

SETTING	O	O
:	O	O
Three	O	O
large	O	O
urban	O	O
hospitals	O	O
(	O	O
with	O	O
active	O	O
cardiovascular	O	O
surgery	O	O
programs	O	O
)	O	O
.	O	O

PATIENTS	O	O
:	O	O
14	O	O
patients	O	O
seen	O	O
over	O	O
a	O	O
3	O	O
-	O	O
year	O	O
period	O	O
in	O	O
whom	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
became	O	O
apparent	O	O
on	O	O
delayed	O	O
presentation	O	O
with	O	O
thromboembolic	B-Disease	D013923
complications	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Platelet	O	O
counts	O	O
,	O	O
onset	O	O
of	O	O
objectively	O	O
determined	O	O
thromboembolism	B-Disease	D013923
,	O	O
results	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
platelet	O	O
factor	O	O
4	O	O
antibody	O	O
tests	O	O
,	O	O
and	O	O
outcomes	O	O
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
went	O	O
home	O	O
after	O	O
hospitalizations	O	O
that	O	O
had	O	O
included	O	O
heparin	B-Chemical	D006493
exposure	O	O
-	O	O
-	O	O
in	O	O
most	O	O
cases	O	O
,	O	O
with	O	O
no	O	O
thrombocytopenia	B-Disease	D013921
recognized	O	O
-	O	O
-	O	O
only	O	O
to	O	O
return	O	O
to	O	O
the	O	O
hospital	O	O
(	O	O
median	O	O
,	O	O
day	O	O
14	O	O
)	O	O
with	O	O
thromboembolic	B-Disease	D013923
complications	O	O
.	O	O

Thromboemboli	B-Disease	D013923
were	O	O
venous	O	O
(	O	O
12	O	O
patients	O	O
,	O	O
7	O	O
with	O	O
pulmonary	B-Disease	D011655
emboli	I-Disease	D011655
)	O	O
or	O	O
arterial	O	O
(	O	O
4	O	O
patients	O	O
)	O	O
or	O	O
both	O	O
.	O	O

Platelet	O	O
counts	O	O
were	O	O
mildly	O	O
decreased	O	O
in	O	O
all	O	O
but	O	O
2	O	O
patients	O	O
on	O	O
second	O	O
presentation	O	O
.	O	O

On	O	O
readmission	O	O
,	O	O
11	O	O
patients	O	O
received	O	O
therapeutic	O	O
heparin	B-Chemical	D006493
,	O	O
which	O	O
worsened	O	O
the	O	O
patients'	O	O
clinical	O	O
condition	O	O
and	O	O
,	O	O
in	O	O
all	O	O
11	O	O
cases	O	O
,	O	O
decreased	O	O
the	O	O
platelet	O	O
count	O	O
(	O	O
mean	O	O
at	O	O
readmission	O	O
,	O	O
143	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
cells	O	O
/	O	O
L	O	O
;	O	O
mean	O	O
nadir	O	O
after	O	O
heparin	B-Chemical	D006493
re	O	O
-	O	O
exposure	O	O
,	O	O
39	O	O
x	O	O
10	O	O
(	O	O
9	O	O
)	O	O
cells	O	O
/	O	O
L	O	O
)	O	O
.	O	O

Results	O	O
of	O	O
serologic	O	O
tests	O	O
for	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
antibodies	O	O
were	O	O
positive	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

Subsequent	O	O
treatments	O	O
included	O	O
alternative	O	O
anticoagulants	O	O
(	O	O
11	O	O
patients	O	O
)	O	O
,	O	O
thrombolytic	O	O
drugs	O	O
(	O	O
3	O	O
patients	O	O
)	O	O
,	O	O
inferior	O	O
vena	O	O
cava	O	O
filters	O	O
(	O	O
3	O	O
patients	O	O
)	O	O
and	O	O
,	O	O
eventually	O	O
,	O	O
warfarin	B-Chemical	D014859
(	O	O
11	O	O
patients	O	O
)	O	O
.	O	O

Three	O	O
patients	O	O
died	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Delayed	O	O
-	O	O
onset	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
is	O	O
increasingly	O	O
being	O	O
recognized	O	O
.	O	O

To	O	O
avoid	O	O
disastrous	O	O
outcomes	O	O
,	O	O
physicians	O	O
must	O	O
consider	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
whenever	O	O
a	O	O
recently	O	O
hospitalized	O	O
patient	O	O
returns	O	O
with	O	O
thromboembolism	B-Disease	D013923
;	O	O
therapy	O	O
with	O	O
alternative	O	O
anticoagulants	O	O
,	O	O
not	O	O
heparin	B-Chemical	D006493
,	O	O
should	O	O
be	O	O
initiated	O	O
.	O	O

Valsartan	B-Chemical	C081489
,	O	O
a	O	O
new	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
antagonist	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
essential	O	O
hypertension	B-Disease	D006973
:	O	O
a	O	O
comparative	O	O
study	O	O
of	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
against	O	O
amlodipine	B-Chemical	D017311
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
compare	O	O
the	O	O
antihypertensive	O	O
efficacy	O	O
of	O	O
a	O	O
new	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
antagonist	O	O
,	O	O
valsartan	B-Chemical	C081489
,	O	O
with	O	O
a	O	O
reference	O	O
therapy	O	O
,	O	O
amlodipine	B-Chemical	D017311
.	O	O

METHODS	O	O
:	O	O
One	O	O
hundred	O	O
sixty	O	O
-	O	O
eight	O	O
adult	O	O
outpatients	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
hypertension	B-Disease	D006973
were	O	O
randomly	O	O
allocated	O	O
in	O	O
double	O	O
-	O	O
blind	O	O
fashion	O	O
and	O	O
equal	O	O
number	O	O
to	O	O
receive	O	O
80	O	O
mg	O	O
valsartan	B-Chemical	C081489
or	O	O
5	O	O
mg	O	O
amlodipine	B-Chemical	D017311
for	O	O
12	O	O
weeks	O	O
.	O	O

After	O	O
8	O	O
weeks	O	O
of	O	O
therapy	O	O
,	O	O
in	O	O
patients	O	O
whose	O	O
blood	O	O
pressure	O	O
remained	O	O
uncontrolled	O	O
,	O	O
5	O	O
mg	O	O
amlodipine	B-Chemical	D017311
was	O	O
added	O	O
to	O	O
the	O	O
initial	O	O
therapy	O	O
.	O	O

Patients	O	O
were	O	O
assessed	O	O
at	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
weeks	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
variable	O	O
was	O	O
change	O	O
from	O	O
baseline	O	O
in	O	O
mean	O	O
sitting	O	O
diastolic	O	O
blood	O	O
pressure	O	O
at	O	O
8	O	O
weeks	O	O
.	O	O

Secondary	O	O
variables	O	O
included	O	O
change	O	O
in	O	O
sitting	O	O
systolic	O	O
blood	O	O
pressure	O	O
and	O	O
responder	O	O
rates	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
valsartan	B-Chemical	C081489
and	O	O
amlodipine	B-Chemical	D017311
were	O	O
effective	O	O
at	O	O
lowering	O	O
blood	O	O
pressure	O	O
at	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
12	O	O
weeks	O	O
.	O	O

Similar	O	O
decreases	O	O
were	O	O
observed	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
with	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
groups	O	O
for	O	O
any	O	O
variable	O	O
analyzed	O	O
.	O	O

For	O	O
the	O	O
primary	O	O
variable	O	O
the	O	O
difference	O	O
was	O	O
0	O	O
.	O	O

5	O	O
mm	O	O
Hg	O	O
in	O	O
favor	O	O
of	O	O
valsartan	B-Chemical	C081489
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

68	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
-	O	O
2	O	O
.	O	O

7	O	O
to	O	O
1	O	O
.	O	O

7	O	O
)	O	O
.	O	O

Responder	O	O
rates	O	O
at	O	O
8	O	O
weeks	O	O
were	O	O
66	O	O
.	O	O

7%	O	O
for	O	O
valsartan	B-Chemical	C081489
and	O	O
60	O	O
.	O	O

2%	O	O
for	O	O
amlodipine	B-Chemical	D017311
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

39	O	O
)	O	O
.	O	O

Both	O	O
treatments	O	O
were	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
drug	O	O
-	O	O
related	O	O
dependent	O	O
edema	B-Disease	D004487
was	O	O
somewhat	O	O
higher	O	O
in	O	O
the	O	O
amlodipine	B-Chemical	D017311
group	O	O
,	O	O
particularly	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
10	O	O
mg	O	O
per	O	O
day	O	O
(	O	O
2	O	O
.	O	O

4%	O	O
for	O	O
80	O	O
mg	O	O
valsartan	B-Chemical	C081489
;	O	O
3	O	O
.	O	O

6%	O	O
for	O	O
5	O	O
mg	O	O
amlodipine	B-Chemical	D017311
;	O	O
0%	O	O
for	O	O
valsartan	B-Chemical	C081489
plus	O	O
5	O	O
mg	O	O
amlodipine	B-Chemical	D017311
;	O	O
14	O	O
.	O	O

3%	O	O
for	O	O
10	O	O
mg	O	O
amlodipine	B-Chemical	D017311
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
show	O	O
that	O	O
valsartan	B-Chemical	C081489
is	O	O
at	O	O
least	O	O
as	O	O
effective	O	O
as	O	O
amlodipine	B-Chemical	D017311
in	O	O
the	O	O
treatment	O	O
of	O	O
mild	O	O
to	O	O
moderate	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
results	O	O
also	O	O
show	O	O
valsartan	B-Chemical	C081489
to	O	O
be	O	O
well	O	O
tolerated	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
side	O	O
effects	O	O
characteristic	O	O
of	O	O
this	O	O
comparator	O	O
class	O	O
,	O	O
dihydropyridine	B-Chemical	C038806
calcium	B-Chemical	D002118
antagonists	O	O
.	O	O

KF17837	B-Chemical	C081198
:	O	O
a	O	O
novel	O	O
selective	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
antagonist	O	O
with	O	O
anticataleptic	O	O
activity	O	O
.	O	O

KF17837	B-Chemical	C081198
is	O	O
a	O	O
novel	O	O
selective	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
antagonist	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
KF17837	B-Chemical	C081198
(	O	O
2	O	O
.	O	O

5	O	O
,	O	O
10	O	O
.	O	O

0	O	O
and	O	O
30	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
significantly	O	O
ameliorated	O	O
the	O	O
cataleptic	B-Disease	D002375
responses	O	O
induced	O	O
by	O	O
intracerebroventricular	O	O
administration	O	O
of	O	O
an	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
agonist	O	O
,	O	O
CGS	B-Chemical	C061282
21680	I-Chemical	C061282
(	O	O
10	O	O
micrograms	O	O
)	O	O
,	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

KF17837	B-Chemical	C081198
also	O	O
reduced	O	O
the	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
and	O	O
by	O	O
reserpine	B-Chemical	D012110
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

These	O	O
anticataleptic	O	O
effects	O	O
were	O	O
exhibited	O	O
dose	O	O
dependently	O	O
at	O	O
doses	O	O
from	O	O
0	O	O
.	O	O

625	O	O
and	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
respectively	O	O
.	O	O

Moreover	O	O
,	O	O
KF17837	B-Chemical	C081198
(	O	O
0	O	O
.	O	O

625	O	O
mg	O	O
/	O	O
kg	O	O
p	O	O
.	O	O

o	O	O
.	O	O

)	O	O
potentiated	O	O
the	O	O
anticataleptic	O	O
effects	O	O
of	O	O
a	O	O
subthreshold	O	O
dose	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
3	I-Chemical	D007980
,	I-Chemical	D007980
4	I-Chemical	D007980
-	I-Chemical	D007980
dihydroxyphenylalanine	I-Chemical	D007980
(	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
;	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
plus	O	O
benserazide	B-Chemical	D001545
(	O	O
6	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

These	O	O
results	O	O
suggested	O	O
that	O	O
KF17837	B-Chemical	C081198
is	O	O
a	O	O
centrally	O	O
active	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
antagonist	O	O
and	O	O
that	O	O
the	O	O
dopaminergic	O	O
function	O	O
of	O	O
the	O	O
nigrostriatal	O	O
pathway	O	O
is	O	O
potentiated	O	O
by	O	O
adenosine	B-Chemical	D000241
A2A	O	O
receptor	O	O
antagonists	O	O
.	O	O

Furthermore	O	O
,	O	O
KF17837	B-Chemical	C081198
may	O	O
be	O	O
a	O	O
useful	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
parkinsonism	B-Disease	D010302
.	O	O

Some	O	O
central	O	O
effects	O	O
of	O	O
repeated	O	O
treatment	O	O
with	O	O
fluvoxamine	B-Chemical	D016666
.	O	O

We	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
repeated	O	O
treatment	O	O
with	O	O
fluvoxamine	B-Chemical	D016666
,	O	O
a	O	O
selective	O	O
serotonin	B-Chemical	D012701
uptake	O	O
inhibitor	O	O
,	O	O
on	O	O
behavioral	O	O
effects	O	O
of	O	O
dopaminomimetics	O	O
and	O	O
methoxamine	B-Chemical	D008729
and	O	O
on	O	O
the	O	O
animal	O	O
behavior	O	O
in	O	O
the	O	O
"behavioral	O	O
despair"	O	O
test	O	O
.	O	O

A	O	O
repeated	O	O
treatment	O	O
with	O	O
fluvoxamine	B-Chemical	D016666
(	O	O
twice	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
)	O	O
potentiated	O	O
in	O	O
mice	O	O
and	O	O
in	O	O
rats	O	O
(	O	O
weaker	O	O
)	O	O
the	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

The	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
nomifensine	B-Chemical	D009627
in	O	O
mice	O	O
remained	O	O
unaffected	O	O
by	O	O
fluvoxamine	B-Chemical	D016666
.	O	O

The	O	O
stimulation	O	O
of	O	O
locomotor	O	O
activity	O	O
by	O	O
intracerebroventricularly	O	O
administered	O	O
methoxamine	B-Chemical	D008729
was	O	O
not	O	O
affected	O	O
by	O	O
repeated	O	O
treatment	O	O
with	O	O
fluvoxamine	B-Chemical	D016666
.	O	O

Given	O	O
three	O	O
times	O	O
fluvoxamine	B-Chemical	D016666
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
immobilization	O	O
time	O	O
in	O	O
the	O	O
"behavioral	O	O
despair"	O	O
test	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
fluvoxamine	B-Chemical	D016666
given	O	O
repeatedly	O	O
acts	O	O
differently	O	O
than	O	O
citalopram	B-Chemical	D015283
,	O	O
another	O	O
selective	O	O
serotonin	B-Chemical	D012701
uptake	O	O
inhibitor	O	O
,	O	O
and	O	O
differs	O	O
also	O	O
from	O	O
other	O	O
antidepressant	O	O
drugs	O	O
.	O	O

Severe	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
patient	O	O
on	O	O
amiodarone	B-Chemical	D000638
presenting	O	O
with	O	O
myxedemic	O	O
coma	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

This	O	O
is	O	O
a	O	O
case	O	O
report	O	O
of	O	O
myxedema	O	O
coma	O	O
secondary	O	O
to	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
hypothyroidism	B-Disease	D007037
in	O	O
a	O	O
patient	O	O
with	O	O
severe	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
(	O	O
CHF	B-Disease	D006333
)	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
and	O	O
after	O	O
reviewing	O	O
the	O	O
literature	O	O
there	O	O
is	O	O
one	O	O
case	O	O
report	O	O
of	O	O
myxedema	O	O
coma	O	O
during	O	O
long	O	O
term	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
.	O	O

Myxedema	O	O
coma	O	O
is	O	O
a	O	O
life	O	O
threatening	O	O
condition	O	O
that	O	O
carries	O	O
a	O	O
mortality	O	O
reaching	O	O
as	O	O
high	O	O
as	O	O
20%	O	O
with	O	O
treatment	O	O
.	O	O

The	O	O
condition	O	O
is	O	O
treated	O	O
with	O	O
intravenous	O	O
thyroxine	B-Chemical	D013974
(	O	O
T4	B-Chemical	D013974
)	O	O
or	O	O
intravenous	O	O
tri	B-Chemical	D014284
-	I-Chemical	D014284
iodo	I-Chemical	D014284
-	I-Chemical	D014284
thyronine	I-Chemical	D014284
(	O	O
T3	B-Chemical	D014284
)	O	O
.	O	O

Patients	O	O
with	O	O
CHF	B-Disease	D006333
on	O	O
amiodarone	B-Chemical	D000638
may	O	O
suffer	O	O
serious	O	O
morbidity	O	O
and	O	O
mortality	O	O
from	O	O
hypothyroidism	B-Disease	D007037
,	O	O
and	O	O
thus	O	O
may	O	O
deserve	O	O
closer	O	O
follow	O	O
up	O	O
for	O	O
thyroid	O	O
stimulating	O	O
hormone	O	O
(	O	O
TSH	O	O
)	O	O
levels	O	O
.	O	O

This	O	O
case	O	O
report	O	O
carries	O	O
an	O	O
important	O	O
clinical	O	O
application	O	O
given	O	O
the	O	O
frequent	O	O
usage	O	O
of	O	O
amiodarone	B-Chemical	D000638
among	O	O
CHF	B-Disease	D006333
patients	O	O
.	O	O

The	O	O
myriad	O	O
clinical	O	O
presentation	O	O
of	O	O
myxedema	O	O
coma	O	O
and	O	O
its	O	O
serious	O	O
morbidity	O	O
and	O	O
mortality	O	O
stresses	O	O
the	O	O
need	O	O
to	O	O
suspect	O	O
this	O	O
clinical	O	O
syndrome	O	O
among	O	O
CHF	B-Disease	D006333
patients	O	O
presenting	O	O
with	O	O
hypotension	B-Disease	D007022
,	O	O
weakness	B-Disease	D018908
or	O	O
other	O	O
unexplained	O	O
symptoms	O	O
.	O	O

Fear	O	O
-	O	O
potentiated	O	O
startle	B-Disease	D012021
,	O	O
but	O	O
not	O	O
light	O	O
-	O	O
enhanced	O	O
startle	B-Disease	D012021
,	O	O
is	O	O
enhanced	O	O
by	O	O
anxiogenic	O	O
drugs	O	O
.	O	O

RATIONALE	O	O
AND	O	O
OBJECTIVES	O	O
:	O	O
The	O	O
light	O	O
-	O	O
enhanced	O	O
startle	B-Disease	D012021
paradigm	O	O
(	O	O
LES	O	O
)	O	O
is	O	O
suggested	O	O
to	O	O
model	O	O
anxiety	B-Disease	D001008
,	O	O
because	O	O
of	O	O
the	O	O
non	O	O
-	O	O
specific	O	O
cue	O	O
and	O	O
the	O	O
long	O	O
-	O	O
term	O	O
effect	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
fear	O	O
-	O	O
potentiated	O	O
startle	B-Disease	D012021
(	O	O
FPS	O	O
)	O	O
is	O	O
suggested	O	O
to	O	O
model	O	O
conditioned	O	O
fear	O	O
.	O	O

However	O	O
,	O	O
the	O	O
pharmacological	O	O
profiles	O	O
of	O	O
these	O	O
two	O	O
paradigms	O	O
are	O	O
very	O	O
similar	O	O
.	O	O

The	O	O
present	O	O
study	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
putative	O	O
anxiogenic	O	O
drugs	O	O
on	O	O
LES	O	O
and	O	O
FPS	O	O
and	O	O
aimed	O	O
at	O	O
determining	O	O
the	O	O
sensitivity	O	O
of	O	O
LES	O	O
for	O	O
anxiogenic	O	O
drugs	O	O
and	O	O
to	O	O
potentially	O	O
showing	O	O
a	O	O
pharmacological	O	O
differentiation	O	O
between	O	O
these	O	O
two	O	O
paradigms	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
Wistar	O	O
rats	O	O
received	O	O
each	O	O
dose	O	O
of	O	O
the	O	O
alpha	O	O
(	O	O
2	O	O
)	O	O
-	O	O
adrenoceptor	O	O
antagonist	O	O
yohimbine	B-Chemical	D015016
(	O	O
0	O	O
.	O	O

25	O	O
-	O	O
1	O	O
.	O	O

0mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
(	O	O
2C	O	O
)	O	O
receptor	O	O
agonist	O	O
m	B-Chemical	C015068
-	I-Chemical	C015068
chlorophenylpiperazine	I-Chemical	C015068
(	O	O
mCPP	B-Chemical	C015068
,	O	O
0	O	O
.	O	O

5	O	O
-	O	O
2	O	O
.	O	O

0mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
the	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
inverse	O	O
receptor	O	O
agonist	O	O
pentylenetetrazole	B-Chemical	D010433
(	O	O
PTZ	B-Chemical	D010433
,	O	O
3	O	O
-	O	O
30mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
were	O	O
subsequently	O	O
tested	O	O
in	O	O
either	O	O
LES	O	O
or	O	O
FPS	O	O
.	O	O

RESULTS	O	O
:	O	O
None	O	O
of	O	O
the	O	O
drugs	O	O
enhanced	O	O
LES	O	O
,	O	O
whereas	O	O
mCPP	B-Chemical	C015068
increased	O	O
percentage	O	O
FPS	O	O
and	O	O
yohimbine	B-Chemical	D015016
increased	O	O
absolute	O	O
FPS	O	O
values	O	O
.	O	O

Furthermore	O	O
,	O	O
yohimbine	B-Chemical	D015016
increased	O	O
baseline	O	O
startle	B-Disease	D012021
amplitude	O	O
in	O	O
the	O	O
LES	O	O
,	O	O
while	O	O
mCPP	B-Chemical	C015068
suppressed	O	O
baseline	O	O
startle	B-Disease	D012021
in	O	O
both	O	O
the	O	O
LES	O	O
and	O	O
FPS	O	O
and	O	O
PTZ	B-Chemical	D010433
suppressed	O	O
baseline	O	O
startle	B-Disease	D012021
in	O	O
the	O	O
FPS	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
contrast	O	O
to	O	O
findings	O	O
in	O	O
the	O	O
FPS	O	O
paradigm	O	O
,	O	O
none	O	O
of	O	O
the	O	O
drugs	O	O
were	O	O
able	O	O
to	O	O
exacerbate	O	O
the	O	O
LES	O	O
response	O	O
.	O	O

Thus	O	O
,	O	O
a	O	O
clear	O	O
pharmacological	O	O
differentiation	O	O
was	O	O
found	O	O
between	O	O
LES	O	O
and	O	O
FPS	O	O
.	O	O

Proteinase	O	O
3	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
-	O	O
(	O	O
PR3	O	O
-	O	O
ANCA	O	O
)	O	O
positive	O	O
necrotizing	O	O
glomerulonephritis	B-Disease	D005921
after	O	O
restarting	O	O
sulphasalazine	B-Chemical	D012460
treatment	O	O
.	O	O

A	O	O
59	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
ulcerative	B-Disease	D003093
colitis	I-Disease	D003093
developed	O	O
red	B-Disease	D005128
eyes	I-Disease	D005128
,	O	O
pleural	B-Disease	D010996
effusion	I-Disease	D010996
,	O	O
eosinophilia	B-Disease	D004802
and	O	O
urinary	B-Disease	D001745
abnormalities	I-Disease	D001745
after	O	O
restarting	O	O
of	O	O
sulphasalazine	B-Chemical	D012460
treatment	O	O
.	O	O

Light	O	O
microscopy	O	O
of	O	O
a	O	O
kidney	O	O
biopsy	O	O
revealed	O	O
segmental	B-Disease	D005923
necrotizing	I-Disease	D005923
glomerulonephritis	I-Disease	D005923
without	O	O
deposition	O	O
of	O	O
immunoglobulin	O	O
or	O	O
complement	O	O
.	O	O

Proteinase	O	O
3	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
PR3	O	O
-	O	O
ANCA	O	O
)	O	O
titer	O	O
was	O	O
elevated	O	O
at	O	O
183	O	O
ELISA	O	O
units	O	O
(	O	O
EU	O	O
)	O	O
in	O	O
sera	O	O
(	O	O
normal	O	O
range	O	O
less	O	O
than	O	O
10	O	O
EU	O	O
)	O	O
,	O	O
myeloperoxidase	O	O
-	O	O
ANCA	O	O
was	O	O
negative	O	O
.	O	O

PR3	O	O
-	O	O
ANCA	O	O
titer	O	O
was	O	O
250	O	O
and	O	O
1	O	O
,	O	O
070	O	O
EU	O	O
in	O	O
pleural	B-Disease	D010996
effusions	I-Disease	D010996
on	O	O
right	O	O
and	O	O
left	O	O
side	O	O
,	O	O
respectively	O	O
.	O	O

Although	O	O
cessation	O	O
of	O	O
sulphasalazine	B-Chemical	D012460
treatment	O	O
resulted	O	O
in	O	O
improvements	O	O
in	O	O
fever	B-Disease	D005334
,	O	O
red	B-Disease	D005128
eyes	I-Disease	D005128
,	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
titer	O	O
of	O	O
C	O	O
-	O	O
reactive	O	O
protein	O	O
and	O	O
volume	O	O
of	O	O
the	O	O
pleural	B-Disease	D010996
effusions	I-Disease	D010996
,	O	O
we	O	O
initiated	O	O
steroid	B-Chemical	D013256
therapy	O	O
,	O	O
because	O	O
PR3	O	O
-	O	O
ANCA	O	O
titer	O	O
rose	O	O
to	O	O
320	O	O
EU	O	O
,	O	O
eosinophil	O	O
count	O	O
increased	O	O
to	O	O
1	O	O
,	O	O
100	O	O
cells	O	O
/	O	O
microl	O	O
,	O	O
and	O	O
the	O	O
pleural	B-Disease	D010996
effusion	I-Disease	D010996
remained	O	O
.	O	O

One	O	O
month	O	O
after	O	O
steroid	B-Chemical	D013256
therapy	O	O
,	O	O
the	O	O
pleural	B-Disease	D010996
effusion	I-Disease	D010996
disappeared	O	O
,	O	O
and	O	O
PR3	O	O
-	O	O
ANCA	O	O
titer	O	O
normalized	O	O
3	O	O
months	O	O
later	O	O
.	O	O

This	O	O
case	O	O
suggests	O	O
that	O	O
sulphasalazine	B-Chemical	D012460
can	O	O
induce	O	O
PR3	O	O
-	O	O
ANCA	O	O
-	O	O
positive	O	O
necrotizing	O	O
glomerulonephritis	B-Disease	D005921
.	O	O

Is	O	O
phenytoin	B-Chemical	D010672
administration	O	O
safe	O	O
in	O	O
a	O	O
hypothermic	B-Disease	D007035
child?	O	O
A	O	O
male	O	O
neonate	O	O
with	O	O
a	O	O
Chiari	B-Disease	D001139
malformation	I-Disease	D001139
and	O	O
a	O	O
leaking	O	O
myelomeningocoele	O	O
underwent	O	O
ventriculoperitoneal	O	O
shunt	O	O
insertion	O	O
followed	O	O
by	O	O
repair	O	O
of	O	O
myelomeningocoele	O	O
.	O	O

During	O	O
anaesthesia	O	O
and	O	O
surgery	O	O
,	O	O
he	O	O
inadvertently	O	O
became	O	O
moderately	O	O
hypothermic	B-Disease	D007035
.	O	O

Intravenous	O	O
phenytoin	B-Chemical	D010672
was	O	O
administered	O	O
during	O	O
the	O	O
later	O	O
part	O	O
of	O	O
the	O	O
surgery	O	O
for	O	O
seizure	B-Disease	D012640
prophylaxis	O	O
.	O	O

Following	O	O
phenytoin	B-Chemical	D010672
administration	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
acute	O	O
severe	O	O
bradycardia	B-Disease	D001919
,	O	O
refractory	O	O
to	O	O
atropine	B-Chemical	D001285
and	O	O
adrenaline	B-Chemical	D004837
.	O	O

The	O	O
cardiac	O	O
depressant	O	O
actions	O	O
of	O	O
phenytoin	B-Chemical	D010672
and	O	O
hypothermia	B-Disease	D007035
can	O	O
be	O	O
additive	O	O
.	O	O

Administration	O	O
of	O	O
phenytoin	B-Chemical	D010672
in	O	O
the	O	O
presence	O	O
of	O	O
hypothermia	B-Disease	D007035
may	O	O
lead	O	O
to	O	O
an	O	O
adverse	O	O
cardiac	O	O
event	O	O
in	O	O
children	O	O
.	O	O

As	O	O
phenytoin	B-Chemical	D010672
is	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
,	O	O
clinicians	O	O
need	O	O
to	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
interaction	O	O
.	O	O

Amisulpride	B-Chemical	C012052
related	O	O
tic	B-Disease	D013981
-	I-Disease	D013981
like	I-Disease	D013981
symptoms	I-Disease	D013981
in	O	O
an	O	O
adolescent	O	O
schizophrenic	B-Disease	D012559
.	O	O

Tic	B-Disease	D013981
disorders	I-Disease	D013981
can	O	O
be	O	O
effectively	O	O
treated	O	O
by	O	O
atypical	O	O
antipsychotics	O	O
such	O	O
as	O	O
risperidone	B-Chemical	D018967
,	O	O
olanzapine	B-Chemical	C076029
and	O	O
ziprasidone	B-Chemical	C092292
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
two	O	O
case	O	O
reports	O	O
that	O	O
show	O	O
tic	B-Disease	D013981
-	I-Disease	D013981
like	I-Disease	D013981
symptoms	I-Disease	D013981
,	O	O
including	O	O
motor	O	O
and	O	O
phonic	O	O
variants	O	O
,	O	O
occurring	O	O
during	O	O
treatment	O	O
with	O	O
quetiapine	B-Chemical	C069541
or	O	O
clozapine	B-Chemical	D003024
.	O	O

We	O	O
present	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
schizophrenic	B-Disease	D012559
who	O	O
developed	O	O
frequent	O	O
involuntary	B-Disease	D020820
eye	I-Disease	D020820
-	I-Disease	D020820
blinking	I-Disease	D020820
movements	I-Disease	D020820
after	O	O
5	O	O
months	O	O
of	O	O
amisulpride	B-Chemical	C012052
treatment	O	O
(	O	O
1000	O	O
mg	O	O
per	O	O
day	O	O
)	O	O
.	O	O

The	O	O
tic	B-Disease	D013981
-	I-Disease	D013981
like	I-Disease	D013981
symptoms	I-Disease	D013981
resolved	O	O
completely	O	O
after	O	O
we	O	O
reduced	O	O
the	O	O
dose	O	O
of	O	O
amisulpride	B-Chemical	C012052
down	O	O
to	O	O
800	O	O
mg	O	O
per	O	O
day	O	O
.	O	O

However	O	O
,	O	O
her	O	O
psychosis	B-Disease	D011605
recurred	O	O
after	O	O
the	O	O
dose	O	O
reduction	O	O
.	O	O

We	O	O
then	O	O
placed	O	O
her	O	O
on	O	O
an	O	O
additional	O	O
100	O	O
mg	O	O
per	O	O
day	O	O
of	O	O
quetiapine	B-Chemical	C069541
.	O	O

She	O	O
has	O	O
been	O	O
in	O	O
complete	O	O
remission	O	O
under	O	O
the	O	O
combined	O	O
medications	O	O
for	O	O
more	O	O
than	O	O
one	O	O
year	O	O
and	O	O
maintains	O	O
a	O	O
fair	O	O
role	O	O
function	O	O
.	O	O

No	O	O
more	O	O
tic	B-Disease	D013981
-	I-Disease	D013981
like	I-Disease	D013981
symptoms	I-Disease	D013981
or	O	O
other	O	O
side	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

Together	O	O
with	O	O
previously	O	O
reported	O	O
cases	O	O
,	O	O
our	O	O
patient	O	O
suggests	O	O
that	O	O
tic	B-Disease	D013981
-	I-Disease	D013981
like	I-Disease	D013981
symptoms	I-Disease	D013981
might	O	O
occur	O	O
in	O	O
certain	O	O
vulnerable	O	O
individuals	O	O
during	O	O
treatment	O	O
with	O	O
atypical	O	O
antipsychotics	O	O
such	O	O
as	O	O
quetiapine	B-Chemical	C069541
,	O	O
clozapine	B-Chemical	D003024
,	O	O
or	O	O
amisulpride	B-Chemical	C012052
.	O	O

Comparison	O	O
of	O	O
developmental	O	O
toxicology	O	O
of	O	O
aspirin	B-Chemical	D001241
(	O	O
acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
)	O	O
in	O	O
rats	O	O
using	O	O
selected	O	O
dosing	O	O
paradigms	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Analysis	O	O
of	O	O
the	O	O
literature	O	O
for	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
suggests	O	O
that	O	O
a	O	O
low	O	O
incidence	O	O
of	O	O
developmental	B-Disease	D000014
anomalies	I-Disease	D000014
occurs	O	O
in	O	O
rats	O	O
given	O	O
NSAIDs	O	O
on	O	O
specific	O	O
days	O	O
during	O	O
organogenesis	O	O
.	O	O

Aspirin	B-Chemical	D001241
(	O	O
acetylsalicylic	B-Chemical	D001241
acid	I-Chemical	D001241
[	O	O
ASA	B-Chemical	D001241
]	O	O
)	O	O
,	O	O
an	O	O
irreversible	O	O
cyclooxygenase	O	O
1	O	O
and	O	O
2	O	O
inhibitor	O	O
,	O	O
induces	O	O
developmental	B-Disease	D000014
anomalies	I-Disease	D000014
when	O	O
administered	O	O
to	O	O
Wistar	O	O
rats	O	O
on	O	O
gestational	O	O
day	O	O
(	O	O
GD	O	O
)	O	O
9	O	O
,	O	O
10	O	O
,	O	O
or	O	O
11	O	O
(	O	O
Kimmel	O	O
CA	O	O
,	O	O
Wilson	O	O
JG	O	O
,	O	O
Schumacher	O	O
HJ	O	O
.	O	O

Teratology	O	O
4	O	O
:	O	O
15	O	O
-	O	O
24	O	O
,	O	O
1971	O	O
)	O	O
.	O	O

There	O	O
are	O	O
no	O	O
published	O	O
ASA	B-Chemical	D001241
studies	O	O
using	O	O
the	O	O
multiple	O	O
dosing	O	O
paradigm	O	O
of	O	O
GDs	O	O
6	O	O
to	O	O
17	O	O
.	O	O

Objectives	O	O
of	O	O
the	O	O
current	O	O
study	O	O
were	O	O
to	O	O
compare	O	O
results	O	O
between	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
and	O	O
Wistar	O	O
strains	O	O
when	O	O
ASA	B-Chemical	D001241
is	O	O
administered	O	O
on	O	O
GD	O	O
9	O	O
,	O	O
10	O	O
,	O	O
or	O	O
11	O	O
;	O	O
to	O	O
compare	O	O
the	O	O
malformation	O	O
patterns	O	O
following	O	O
single	O	O
and	O	O
multiple	O	O
dosings	O	O
during	O	O
organogenesis	O	O
in	O	O
SD	O	O
rats	O	O
;	O	O
and	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
maternal	O	O
gastrointestinal	B-Disease	D005767
toxicity	I-Disease	D005767
confounds	O	O
the	O	O
detection	O	O
of	O	O
low	O	O
incidence	O	O
malformations	B-Disease	D000014
with	O	O
ASA	B-Chemical	D001241
when	O	O
a	O	O
multiple	O	O
dosing	O	O
paradigm	O	O
is	O	O
used	O	O
.	O	O

METHODS	O	O
:	O	O
ASA	B-Chemical	D001241
was	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
dose	O	O
on	O	O
GD	O	O
9	O	O
(	O	O
0	O	O
,	O	O
250	O	O
,	O	O
500	O	O
,	O	O
or	O	O
625	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
10	O	O
(	O	O
0	O	O
,	O	O
500	O	O
,	O	O
625	O	O
,	O	O
or	O	O
750	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
or	O	O
11	O	O
(	O	O
0	O	O
,	O	O
500	O	O
,	O	O
750	O	O
,	O	O
or	O	O
1000	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
from	O	O
GD	O	O
6	O	O
to	O	O
GD	O	O
17	O	O
(	O	O
0	O	O
,	O	O
50	O	O
,	O	O
125	O	O
,	O	O
or	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
a	O	O
day	O	O
)	O	O
in	O	O
the	O	O
multiple	O	O
dose	O	O
study	O	O
to	O	O
SD	O	O
rats	O	O
.	O	O

Animals	O	O
were	O	O
killed	O	O
on	O	O
GD	O	O
21	O	O
,	O	O
and	O	O
fetuses	O	O
were	O	O
examined	O	O
viscerally	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
literature	O	O
evaluation	O	O
suggested	O	O
that	O	O
NSAIDs	O	O
induce	O	O
ventricular	B-Disease	D006345
septal	I-Disease	D006345
defects	I-Disease	D006345
(	O	O
VSDs	B-Disease	D006345
)	O	O
and	O	O
midline	B-Disease	D009436
defects	I-Disease	D009436
(	O	O
MDs	B-Disease	D009436
)	O	O
in	O	O
rats	O	O
and	O	O
diaphragmatic	B-Disease	D065630
hernia	I-Disease	D065630
(	O	O
DH	B-Disease	D065630
)	O	O
,	O	O
MDs	B-Disease	D009436
,	O	O
and	O	O
VSDs	B-Disease	D006345
in	O	O
rabbits	O	O
(	O	O
Cook	O	O
JC	O	O
et	O	O
al	O	O
.	O	O

,	O	O
2003	O	O
)	O	O
;	O	O
hence	O	O
,	O	O
the	O	O
present	O	O
study	O	O
focused	O	O
on	O	O
these	O	O
malformations	B-Disease	D000014
,	O	O
even	O	O
though	O	O
ASA	B-Chemical	D001241
induces	O	O
several	O	O
other	O	O
low	O	O
-	O	O
incidence	O	O
malformations	B-Disease	D000014
.	O	O

In	O	O
single	O	O
dose	O	O
studies	O	O
,	O	O
DH	B-Disease	D065630
,	O	O
MD	B-Disease	D009436
,	O	O
and	O	O
VSD	B-Disease	D006345
were	O	O
induced	O	O
on	O	O
GDs	O	O
9	O	O
and	O	O
10	O	O
.	O	O

VSD	B-Disease	D006345
also	O	O
was	O	O
noted	O	O
following	O	O
treatment	O	O
on	O	O
GD	O	O
11	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
DH	B-Disease	D065630
and	O	O
MD	B-Disease	D009436
were	O	O
noted	O	O
in	O	O
the	O	O
multiple	O	O
dose	O	O
study	O	O
design	O	O
only	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
,	O	O
and	O	O
VSD	B-Disease	D006345
was	O	O
noted	O	O
across	O	O
all	O	O
dose	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
High	O	O
concordance	O	O
in	O	O
major	O	O
developmental	B-Disease	D000014
anomalies	I-Disease	D000014
between	O	O
Wistar	O	O
and	O	O
SD	O	O
rats	O	O
were	O	O
noted	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
VSD	B-Disease	D006345
in	O	O
the	O	O
SD	O	O
rats	O	O
and	O	O
hydrocephalus	B-Disease	D006849
in	O	O
the	O	O
Wistar	O	O
rats	O	O
.	O	O

Variations	O	O
and	O	O
malformations	B-Disease	D000014
were	O	O
similar	O	O
when	O	O
ASA	B-Chemical	D001241
was	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
dose	O	O
or	O	O
during	O	O
the	O	O
period	O	O
of	O	O
organogenesis	O	O
(	O	O
GDs	O	O
6	O	O
to	O	O
17	O	O
)	O	O
.	O	O

It	O	O
was	O	O
also	O	O
evident	O	O
that	O	O
,	O	O
by	O	O
titrating	O	O
the	O	O
dose	O	O
to	O	O
achieve	O	O
a	O	O
maximum	O	O
tolerated	O	O
dose	O	O
,	O	O
malformations	B-Disease	D000014
that	O	O
normally	O	O
occur	O	O
at	O	O
low	O	O
incidence	O	O
,	O	O
as	O	O
reported	O	O
from	O	O
previous	O	O
single	O	O
dose	O	O
studies	O	O
,	O	O
could	O	O
also	O	O
be	O	O
induced	O	O
with	O	O
ASA	B-Chemical	D001241
given	O	O
at	O	O
multiple	O	O
doses	O	O
.	O	O

Torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
induced	O	O
by	O	O
metoclopramide	B-Chemical	D008787
in	O	O
an	O	O
elderly	O	O
woman	O	O
with	O	O
preexisting	O	O
complete	O	O
left	B-Disease	D002037
bundle	I-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
.	O	O

There	O	O
is	O	O
a	O	O
growing	O	O
list	O	O
of	O	O
drugs	O	O
implicated	O	O
in	O	O
acquired	O	O
long	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
and	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

However	O	O
,	O	O
the	O	O
torsadogenic	O	O
potential	O	O
of	O	O
metoclopramide	B-Chemical	D008787
,	O	O
a	O	O
commonly	O	O
used	O	O
antiemetic	O	O
and	O	O
prokinetic	O	O
drug	O	O
,	O	O
has	O	O
not	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
,	O	O
despite	O	O
its	O	O
chemical	O	O
similarity	O	O
to	O	O
procainamide	B-Chemical	D011342
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
92	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
preexisting	O	O
complete	O	O
left	B-Disease	D002037
bundle	I-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
who	O	O
developed	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
after	O	O
intravenous	O	O
and	O	O
oral	O	O
administration	O	O
of	O	O
metoclopramide	B-Chemical	D008787
.	O	O

This	O	O
patient	O	O
also	O	O
developed	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
when	O	O
cisapride	B-Chemical	D020117
and	O	O
erythromycin	B-Chemical	D004917
were	O	O
given	O	O
simultaneously	O	O
.	O	O

These	O	O
two	O	O
episodes	O	O
were	O	O
suppressed	O	O
successfully	O	O
after	O	O
discontinuing	O	O
the	O	O
offending	O	O
drugs	O	O
and	O	O
administering	O	O
class	O	O
IB	O	O
drugs	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
documentation	O	O
that	O	O
metoclopramide	B-Chemical	D008787
provokes	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
clinically	O	O
.	O	O

Metoclopramide	B-Chemical	D008787
should	O	O
be	O	O
used	O	O
cautiously	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
risk	O	O
of	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

Apomorphine	B-Chemical	D001058
:	O	O
an	O	O
underutilized	O	O
therapy	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Apomorphine	B-Chemical	D001058
was	O	O
the	O	O
first	O	O
dopaminergic	O	O
drug	O	O
ever	O	O
used	O	O
to	O	O
treat	O	O
symptoms	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

While	O	O
powerful	O	O
antiparkinsonian	O	O
effects	O	O
had	O	O
been	O	O
observed	O	O
as	O	O
early	O	O
as	O	O
1951	O	O
,	O	O
the	O	O
potential	O	O
of	O	O
treating	O	O
fluctuating	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
by	O	O
subcutaneous	O	O
administration	O	O
of	O	O
apomorphine	B-Chemical	D001058
has	O	O
only	O	O
recently	O	O
become	O	O
the	O	O
subject	O	O
of	O	O
systematic	O	O
study	O	O
.	O	O

A	O	O
number	O	O
of	O	O
small	O	O
scale	O	O
clinical	O	O
trials	O	O
have	O	O
unequivocally	O	O
shown	O	O
that	O	O
intermittent	O	O
subcutaneous	O	O
apomorphine	B-Chemical	D001058
injections	O	O
produce	O	O
antiparkinsonian	O	O
benefit	O	O
close	O	O
if	O	O
not	O	O
identical	O	O
to	O	O
that	O	O
seen	O	O
with	O	O
levodopa	B-Chemical	D007980
and	O	O
that	O	O
apomorphine	B-Chemical	D001058
rescue	O	O
injections	O	O
can	O	O
reliably	O	O
revert	O	O
off	O	O
-	O	O
periods	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
complex	O	O
on	O	O
-	O	O
off	O	O
motor	O	O
swings	O	O
.	O	O

Continuous	O	O
subcutaneous	O	O
apomorphine	B-Chemical	D001058
infusions	O	O
can	O	O
reduce	O	O
daily	O	O
off	O	O
-	O	O
time	O	O
by	O	O
more	O	O
than	O	O
50%	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
,	O	O
which	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
stronger	O	O
effect	O	O
than	O	O
that	O	O
generally	O	O
seen	O	O
with	O	O
add	O	O
-	O	O
on	O	O
therapy	O	O
with	O	O
oral	O	O
dopamine	B-Chemical	D004298
agonists	O	O
or	O	O
COMT	O	O
inhibitors	O	O
.	O	O

Extended	O	O
follow	O	O
-	O	O
up	O	O
studies	O	O
of	O	O
up	O	O
to	O	O
8	O	O
years	O	O
have	O	O
demonstrated	O	O
long	O	O
-	O	O
term	O	O
persistence	O	O
of	O	O
apomorphine	B-Chemical	D001058
efficacy	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
there	O	O
is	O	O
convincing	O	O
clinical	O	O
evidence	O	O
that	O	O
monotherapy	O	O
with	O	O
continuous	O	O
subcutaneous	O	O
apomorphine	B-Chemical	D001058
infusions	O	O
is	O	O
associated	O	O
with	O	O
marked	O	O
reductions	O	O
of	O	O
preexisting	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

The	O	O
main	O	O
side	O	O
effects	O	O
of	O	O
subcutaneous	O	O
apomorphine	B-Chemical	D001058
treatment	O	O
are	O	O
related	O	O
to	O	O
cutaneous	O	O
tolerability	O	O
problems	O	O
,	O	O
whereas	O	O
sedation	O	O
and	O	O
psychiatric	B-Disease	D001523
complications	O	O
play	O	O
a	O	O
lesser	O	O
role	O	O
.	O	O

Given	O	O
the	O	O
marked	O	O
degree	O	O
of	O	O
efficacy	O	O
of	O	O
subcutaneous	O	O
apomorphine	B-Chemical	D001058
treatment	O	O
in	O	O
fluctuating	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
this	O	O
approach	O	O
seems	O	O
to	O	O
deserve	O	O
more	O	O
widespread	O	O
clinical	O	O
use	O	O
.	O	O

Fatal	O	O
excited	O	O
delirium	B-Disease	D003693
following	O	O
cocaine	B-Chemical	D003042
use	O	O
:	O	O
epidemiologic	O	O
findings	O	O
provide	O	O
new	O	O
evidence	O	O
for	O	O
mechanisms	O	O
of	O	O
cocaine	B-Chemical	D003042
toxicity	B-Disease	D064420
.	O	O

We	O	O
describe	O	O
an	O	O
outbreak	O	O
of	O	O
deaths	O	O
from	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
excited	O	O
delirium	B-Disease	D003693
(	O	O
EDDs	B-Disease	D003693
)	O	O
in	O	O
Dade	O	O
County	O	O
,	O	O
Florida	O	O
between	O	O
1979	O	O
and	O	O
1990	O	O
.	O	O

From	O	O
a	O	O
registry	O	O
of	O	O
all	O	O
cocaine	B-Chemical	D003042
-	O	O
related	O	O
deaths	O	O
in	O	O
Dade	O	O
County	O	O
,	O	O
Florida	O	O
,	O	O
from	O	O
1969	O	O
-	O	O
1990	O	O
,	O	O
58	O	O
EDDs	B-Disease	D003693
were	O	O
compared	O	O
with	O	O
125	O	O
victims	O	O
of	O	O
accidental	O	O
cocaine	B-Chemical	D003042
overdose	B-Disease	D062787
without	O	O
excited	O	O
delirium	B-Disease	D003693
.	O	O

Compared	O	O
with	O	O
controls	O	O
,	O	O
EDDs	B-Disease	D003693
were	O	O
more	O	O
frequently	O	O
black	O	O
,	O	O
male	O	O
,	O	O
and	O	O
younger	O	O
.	O	O

They	O	O
were	O	O
less	O	O
likely	O	O
to	O	O
have	O	O
a	O	O
low	O	O
body	O	O
mass	O	O
index	O	O
,	O	O
and	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
died	O	O
in	O	O
police	O	O
custody	O	O
,	O	O
to	O	O
have	O	O
received	O	O
medical	O	O
treatment	O	O
immediately	O	O
before	O	O
death	O	O
,	O	O
to	O	O
have	O	O
survived	O	O
for	O	O
a	O	O
longer	O	O
period	O	O
,	O	O
to	O	O
have	O	O
developed	O	O
hyperthermia	B-Disease	D005334
,	O	O
and	O	O
to	O	O
have	O	O
died	O	O
in	O	O
summer	O	O
months	O	O
.	O	O

EDDs	B-Disease	D003693
had	O	O
concentrations	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
benzoylecgonine	B-Chemical	C005618
in	O	O
autopsy	O	O
blood	O	O
that	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
for	O	O
controls	O	O
.	O	O

The	O	O
epidemiologic	O	O
findings	O	O
are	O	O
most	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
chronic	O	O
cocaine	B-Chemical	D003042
use	O	O
disrupts	O	O
dopaminergic	O	O
function	O	O
and	O	O
,	O	O
when	O	O
coupled	O	O
with	O	O
recent	O	O
cocaine	B-Chemical	D003042
use	O	O
,	O	O
may	O	O
precipitate	O	O
agitation	B-Disease	D011595
,	O	O
delirium	B-Disease	D003693
,	O	O
aberrant	O	O
thermoregulation	O	O
,	O	O
rhabdomyolysis	B-Disease	D012206
,	O	O
and	O	O
sudden	B-Disease	D003645
death	I-Disease	D003645
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
thrombosis	B-Disease	D013927
,	O	O
and	O	O
hemorrhage	B-Disease	D006470
.	O	O

Sixty	O	O
-	O	O
two	O	O
patients	O	O
with	O	O
a	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
are	O	O
reported	O	O
.	O	O

Clinical	O	O
manifestations	O	O
of	O	O
this	O	O
disorder	O	O
include	O	O
hemorrhage	B-Disease	D006470
or	O	O
,	O	O
more	O	O
frequently	O	O
,	O	O
thromboembolic	B-Disease	D013923
events	O	O
in	O	O
patients	O	O
receiving	O	O
heparin	B-Chemical	D006493
.	O	O

Laboratory	O	O
testing	O	O
has	O	O
revealed	O	O
a	B-Disease	D001791
falling	I-Disease	D001791
platelet	I-Disease	D001791
count	I-Disease	D001791
,	O	O
increased	O	O
resistance	O	O
to	O	O
heparin	B-Chemical	D006493
,	O	O
and	O	O
aggregation	O	O
of	O	O
platelets	O	O
by	O	O
the	O	O
patient's	O	O
plasma	O	O
when	O	O
heparin	B-Chemical	D006493
is	O	O
added	O	O
.	O	O

Immunologic	O	O
testing	O	O
has	O	O
demonstrated	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
heparin	B-Chemical	D006493
-	O	O
dependent	O	O
platelet	O	O
membrane	O	O
antibody	O	O
.	O	O

The	O	O
20	O	O
deaths	O	O
,	O	O
52	O	O
hemorrhagic	O	O
and	O	O
thromboembolic	B-Disease	D013923
complications	O	O
,	O	O
and	O	O
21	O	O
surgical	O	O
procedures	O	O
to	O	O
manage	O	O
the	O	O
complications	O	O
confirm	O	O
the	O	O
seriousness	O	O
of	O	O
the	O	O
disorder	O	O
.	O	O

Specific	O	O
risk	O	O
factors	O	O
have	O	O
not	O	O
been	O	O
identified	O	O
;	O	O
therefore	O	O
,	O	O
all	O	O
patients	O	O
receiving	O	O
heparin	B-Chemical	D006493
should	O	O
be	O	O
monitored	O	O
.	O	O

If	O	O
the	O	O
platelet	O	O
count	O	O
falls	O	O
to	O	O
less	O	O
than	O	O
100	O	O
,	O	O
000	O	O
/	O	O
mm3	O	O
,	O	O
while	O	O
the	O	O
patient	O	O
is	O	O
receiving	O	O
heparin	B-Chemical	D006493
,	O	O
platelet	B-Disease	D001791
aggregation	I-Disease	D001791
testing	O	O
,	O	O
using	O	O
the	O	O
patient's	O	O
plasma	O	O
,	O	O
is	O	O
indicated	O	O
.	O	O

Management	O	O
consists	O	O
of	O	O
cessation	O	O
of	O	O
heparin	B-Chemical	D006493
,	O	O
platelet	O	O
anti	O	O
-	O	O
aggregating	O	O
agents	O	O
,	O	O
and	O	O
alternate	O	O
forms	O	O
of	O	O
anticoagulation	O	O
when	O	O
indicated	O	O
.	O	O

Cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
.	O	O

Report	O	O
of	O	O
a	O	O
case	O	O
of	O	O
spontaneous	O	O
angina	B-Disease	D000787
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
colon	B-Disease	D003110
carcinoma	I-Disease	D003110
and	O	O
liver	O	O
metastasis	B-Disease	D009362
who	O	O
presented	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
after	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
administration	O	O
.	O	O

Clinical	O	O
electrocardiographic	O	O
evolution	O	O
was	O	O
similar	O	O
to	O	O
that	O	O
observed	O	O
in	O	O
Prinzmetal's	B-Disease	D000788
angina	I-Disease	D000788
,	O	O
and	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
promptly	O	O
resolved	O	O
with	O	O
nifedipine	B-Chemical	D009543
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
may	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
due	O	O
to	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
,	O	O
and	O	O
that	O	O
calcium	B-Chemical	D002118
antagonists	O	O
may	O	O
probably	O	O
be	O	O
used	O	O
in	O	O
the	O	O
prevention	O	O
or	O	O
treatment	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
cardiotoxicity	B-Disease	D066126
.	O	O

Toxicity	B-Disease	D064420
due	O	O
to	O	O
remission	O	O
inducing	O	O
drugs	O	O
in	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
.	O	O

Association	O	O
with	O	O
HLA	O	O
-	O	O
B35	O	O
and	O	O
Cw4	O	O
antigens	O	O
.	O	O

Twenty	O	O
-	O	O
five	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
(	O	O
RA	B-Disease	D001172
)	O	O
who	O	O
developed	O	O
toxicity	B-Disease	D064420
while	O	O
taking	O	O
remission	O	O
inducing	O	O
drugs	O	O
and	O	O
30	O	O
without	O	O
toxicity	B-Disease	D064420
were	O	O
studied	O	O
for	O	O
possible	O	O
associations	O	O
with	O	O
class	O	O
I	O	O
and	O	O
II	O	O
HLA	O	O
antigens	O	O
.	O	O

A	O	O
strong	O	O
association	O	O
has	O	O
been	O	O
found	O	O
between	O	O
nephritis	B-Disease	D009393
and	O	O
dermatitis	B-Disease	D003872
due	O	O
to	O	O
Tiopronin	B-Chemical	D008625
(	O	O
a	O	O
D	B-Chemical	D010396
-	I-Chemical	D010396
Penicillamine	I-Chemical	D010396
like	O	O
compound	O	O
)	O	O
and	O	O
class	O	O
I	O	O
antigens	O	O
B35	O	O
-	O	O
Cw4	O	O
,	O	O
and	O	O
between	O	O
dermatitis	B-Disease	D003872
due	O	O
to	O	O
gold	B-Chemical	D006046
thiosulphate	B-Chemical	-1
and	O	O
B35	O	O
.	O	O

Compared	O	O
to	O	O
healthy	O	O
controls	O	O
a	O	O
lower	O	O
DR5	O	O
frequency	O	O
was	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
RA	B-Disease	D001172
except	O	O
for	O	O
the	O	O
Tiopronin	B-Chemical	D008625
related	O	O
nephritis	B-Disease	D009393
group	O	O
.	O	O

Transient	O	O
hemiparesis	B-Disease	D010291
:	O	O
a	O	O
rare	O	O
manifestation	O	O
of	O	O
diphenylhydantoin	B-Chemical	D010672
toxicity	B-Disease	D064420
.	O	O

Report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Among	O	O
the	O	O
common	O	O
side	O	O
effects	O	O
of	O	O
diphenylhydantoin	B-Chemical	D010672
(	O	O
DPH	B-Chemical	D010672
)	O	O
overdose	B-Disease	D062787
,	O	O
the	O	O
most	O	O
frequently	O	O
encountered	O	O
neurological	O	O
signs	O	O
are	O	O
those	O	O
of	O	O
cerebellar	B-Disease	D002526
dysfunction	I-Disease	D002526
.	O	O

Very	O	O
rarely	O	O
,	O	O
the	O	O
toxic	O	O
neurological	O	O
manifestations	O	O
of	O	O
this	O	O
drug	O	O
are	O	O
of	O	O
cerebral	O	O
origin	O	O
.	O	O

Two	O	O
patients	O	O
are	O	O
presented	O	O
who	O	O
suffered	O	O
progressive	O	O
hemiparesis	B-Disease	D010291
due	O	O
to	O	O
DPH	B-Chemical	D010672
overdose	B-Disease	D062787
.	O	O

Both	O	O
had	O	O
brain	O	O
surgery	O	O
before	O	O
DPH	B-Chemical	D010672
treatment	O	O
.	O	O

It	O	O
is	O	O
assumed	O	O
that	O	O
patients	O	O
with	O	O
some	O	O
cerebral	B-Disease	D001927
damage	I-Disease	D001927
are	O	O
liable	O	O
to	O	O
manifest	O	O
DPH	B-Chemical	D010672
toxicity	B-Disease	D064420
as	O	O
focal	O	O
neurological	O	O
signs	O	O
.	O	O

Nerve	O	O
growth	O	O
factor	O	O
and	O	O
prostaglandins	B-Chemical	D011453
in	O	O
the	O	O
urine	O	O
of	O	O
female	O	O
patients	O	O
with	O	O
overactive	B-Disease	D053201
bladder	I-Disease	D053201
.	O	O

PURPOSE	O	O
:	O	O
NGF	O	O
and	O	O
PGs	B-Chemical	D011453
in	O	O
the	O	O
bladder	O	O
can	O	O
be	O	O
affected	O	O
by	O	O
pathological	O	O
changes	O	O
in	O	O
the	O	O
bladder	O	O
and	O	O
these	O	O
changes	O	O
can	O	O
be	O	O
detected	O	O
in	O	O
urine	O	O
.	O	O

We	O	O
investigated	O	O
changes	O	O
in	O	O
urinary	O	O
NGF	O	O
and	O	O
PGs	B-Chemical	D011453
in	O	O
women	O	O
with	O	O
OAB	B-Disease	D053201
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
The	O	O
study	O	O
groups	O	O
included	O	O
65	O	O
women	O	O
with	O	O
OAB	B-Disease	D053201
and	O	O
20	O	O
without	O	O
bladder	O	O
symptoms	O	O
who	O	O
served	O	O
as	O	O
controls	O	O
.	O	O

Evaluation	O	O
included	O	O
patient	O	O
history	O	O
,	O	O
urinalysis	O	O
,	O	O
a	O	O
voiding	O	O
diary	O	O
and	O	O
urodynamic	O	O
studies	O	O
.	O	O

Urine	O	O
samples	O	O
were	O	O
collected	O	O
.	O	O

NGF	O	O
,	O	O
PGE2	B-Chemical	D015232
,	O	O
PGF2alpha	B-Chemical	D015237
and	O	O
PGI2	B-Chemical	D011464
were	O	O
measured	O	O
using	O	O
enzyme	O	O
-	O	O
linked	O	O
immunosorbent	O	O
assay	O	O
and	O	O
compared	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
correlations	O	O
between	O	O
urinary	O	O
NGF	O	O
and	O	O
PG	B-Chemical	D011453
,	O	O
and	O	O
urodynamic	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
OAB	B-Disease	D053201
were	O	O
examined	O	O
.	O	O

RESULTS	O	O
:	O	O
Urinary	O	O
NGF	O	O
,	O	O
PGE2	B-Chemical	D015232
and	O	O
PGF2alpha	B-Chemical	D015237
were	O	O
significantly	O	O
increased	O	O
in	O	O
patients	O	O
with	O	O
OAB	B-Disease	D053201
compared	O	O
with	O	O
controls	O	O
(	O	O
p	O	O
<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
urinary	O	O
PGI2	B-Chemical	D011464
was	O	O
not	O	O
different	O	O
between	O	O
controls	O	O
and	O	O
patients	O	O
with	O	O
OAB	B-Disease	D053201
.	O	O

In	O	O
patients	O	O
with	O	O
OAB	B-Disease	D053201
urinary	O	O
PGE2	B-Chemical	D015232
positively	O	O
correlated	O	O
with	O	O
volume	O	O
at	O	O
first	O	O
desire	O	O
to	O	O
void	O	O
and	O	O
maximum	O	O
cystometric	O	O
capacity	O	O
(	O	O
p	O	O
<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Urinary	O	O
NGF	O	O
,	O	O
PGF2alpha	B-Chemical	D015237
and	O	O
PGI2	B-Chemical	D011464
did	O	O
not	O	O
correlate	O	O
with	O	O
urodynamic	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
OAB	B-Disease	D053201
.	O	O

CONCLUSIONS	O	O
:	O	O
NGF	O	O
and	O	O
PGs	B-Chemical	D011453
have	O	O
important	O	O
roles	O	O
in	O	O
the	O	O
development	O	O
of	O	O
OAB	B-Disease	D053201
symptoms	O	O
in	O	O
female	O	O
patients	O	O
.	O	O

Urinary	O	O
levels	O	O
of	O	O
these	O	O
factors	O	O
may	O	O
be	O	O
used	O	O
as	O	O
markers	O	O
to	O	O
evaluate	O	O
OAB	B-Disease	D053201
symptoms	O	O
.	O	O

Acute	O	O
low	B-Disease	D017116
back	I-Disease	D017116
pain	I-Disease	D017116
during	O	O
intravenous	O	O
administration	O	O
of	O	O
amiodarone	B-Chemical	D000638
:	O	O
a	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Amiodarone	B-Chemical	D000638
represents	O	O
an	O	O
effective	O	O
antiarrhythmic	O	O
drug	O	O
for	O	O
cardioversion	O	O
of	O	O
recent	O	O
-	O	O
onset	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
(	O	O
AF	B-Disease	D001281
)	O	O
and	O	O
maintenance	O	O
of	O	O
sinus	O	O
rhythm	O	O
.	O	O

We	O	O
briefly	O	O
describe	O	O
two	O	O
patients	O	O
suffering	O	O
from	O	O
recent	O	O
-	O	O
onset	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
,	O	O
who	O	O
experienced	O	O
an	O	O
acute	O	O
devastating	O	O
low	B-Disease	D017116
back	I-Disease	D017116
pain	I-Disease	D017116
a	O	O
few	O	O
minutes	O	O
after	O	O
initiation	O	O
of	O	O
intravenous	O	O
amiodarone	B-Chemical	D000638
loading	O	O
.	O	O

Notably	O	O
,	O	O
this	O	O
side	O	O
effect	O	O
has	O	O
not	O	O
been	O	O
ever	O	O
reported	O	O
in	O	O
the	O	O
medical	O	O
literature	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
reaction	O	O
since	O	O
prompt	O	O
termination	O	O
of	O	O
parenteral	O	O
administration	O	O
leads	O	O
to	O	O
complete	O	O
resolution	O	O
.	O	O

Postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
after	O	O
succinylcholine	B-Chemical	D013390
:	O	O
no	O	O
evidence	O	O
for	O	O
an	O	O
inflammatory	O	O
origin	O	O
.	O	O

A	O	O
common	O	O
side	O	O
effect	O	O
associated	O	O
with	O	O
succinylcholine	B-Chemical	D013390
is	O	O
postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
.	O	O

The	O	O
pathogenesis	O	O
of	O	O
this	O	O
myalgia	B-Disease	D063806
is	O	O
still	O	O
unclear	O	O
;	O	O
inflammation	B-Disease	D007249
has	O	O
been	O	O
suggested	O	O
but	O	O
without	O	O
convincing	O	O
evidence	O	O
.	O	O

We	O	O
designed	O	O
the	O	O
present	O	O
study	O	O
to	O	O
investigate	O	O
whether	O	O
an	O	O
inflammatory	O	O
reaction	O	O
contributes	O	O
to	O	O
this	O	O
myalgia	B-Disease	D063806
.	O	O

The	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
succinylcholine	B-Chemical	D013390
-	O	O
associated	O	O
myalgia	B-Disease	D063806
was	O	O
determined	O	O
in	O	O
64	O	O
patients	O	O
pretreated	O	O
with	O	O
saline	O	O
or	O	O
dexamethasone	B-Chemical	D003907
before	O	O
succinylcholine	B-Chemical	D013390
(	O	O
n	O	O
=	O	O
32	O	O
for	O	O
each	O	O
)	O	O
.	O	O

Incidence	O	O
and	O	O
severity	O	O
of	O	O
myalgia	B-Disease	D063806
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
:	O	O
15	O	O
patients	O	O
in	O	O
the	O	O
dexamethasone	B-Chemical	D003907
group	O	O
complained	O	O
of	O	O
myalgia	B-Disease	D063806
compared	O	O
with	O	O
18	O	O
patients	O	O
in	O	O
the	O	O
saline	O	O
group	O	O
,	O	O
and	O	O
severe	O	O
myalgia	B-Disease	D063806
was	O	O
reported	O	O
by	O	O
five	O	O
patients	O	O
and	O	O
three	O	O
patients	O	O
,	O	O
respectively	O	O
(	O	O
not	O	O
significant	O	O
)	O	O
.	O	O

At	O	O
48	O	O
h	O	O
after	O	O
surgery	O	O
,	O	O
12	O	O
patients	O	O
in	O	O
both	O	O
groups	O	O
still	O	O
suffered	O	O
from	O	O
myalgia	B-Disease	D063806
(	O	O
not	O	O
significant	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
interleukin	O	O
-	O	O
6	O	O
(	O	O
IL	O	O
-	O	O
6	O	O
)	O	O
as	O	O
an	O	O
early	O	O
marker	O	O
of	O	O
inflammation	B-Disease	D007249
was	O	O
assessed	O	O
in	O	O
a	O	O
subgroup	O	O
of	O	O
10	O	O
patients	O	O
pretreated	O	O
with	O	O
saline	O	O
.	O	O

We	O	O
found	O	O
an	O	O
increase	O	O
of	O	O
IL	O	O
-	O	O
6	O	O
for	O	O
only	O	O
three	O	O
patients	O	O
,	O	O
but	O	O
only	O	O
one	O	O
patient	O	O
reported	O	O
myalgia	B-Disease	D063806
;	O	O
no	O	O
relationship	O	O
between	O	O
myalgia	B-Disease	D063806
and	O	O
the	O	O
increase	O	O
of	O	O
IL	O	O
-	O	O
6	O	O
was	O	O
found	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
there	O	O
is	O	O
no	O	O
evidence	O	O
for	O	O
an	O	O
inflammatory	O	O
origin	O	O
of	O	O
succinylcholine	B-Chemical	D013390
-	O	O
associated	O	O
myalgia	B-Disease	D063806
.	O	O

IMPLICATIONS	O	O
:	O	O
Administration	O	O
of	O	O
dexamethasone	B-Chemical	D003907
before	O	O
succinylcholine	B-Chemical	D013390
was	O	O
not	O	O
effective	O	O
in	O	O
decreasing	O	O
the	O	O
incidence	O	O
or	O	O
the	O	O
severity	O	O
of	O	O
succinylcholine	B-Chemical	D013390
-	O	O
induced	O	O
postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
.	O	O

Furthermore	O	O
,	O	O
there	O	O
was	O	O
no	O	O
significant	O	O
relationship	O	O
between	O	O
postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
and	O	O
time	O	O
course	O	O
of	O	O
interleukin	O	O
-	O	O
6	O	O
concentrations	O	O
,	O	O
a	O	O
marker	O	O
of	O	O
inflammation	B-Disease	D007249
.	O	O

Pretreatment	O	O
with	O	O
dexamethasone	B-Chemical	D003907
is	O	O
not	O	O
justified	O	O
to	O	O
prevent	O	O
postoperative	B-Disease	D010149
myalgia	I-Disease	D010149
after	O	O
succinylcholine	B-Chemical	D013390
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
oromandibular	O	O
dystonia	B-Disease	D004421
in	O	O
progressive	B-Disease	D013494
supranuclear	I-Disease	D013494
palsy	I-Disease	D013494
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
have	O	O
been	O	O
reported	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
and	O	O
multiple	B-Disease	D019578
system	I-Disease	D019578
atrophy	I-Disease	D019578
.	O	O

Cranial	O	O
dystonias	B-Disease	D004421
are	O	O
rare	O	O
in	O	O
patients	O	O
with	O	O
progressive	B-Disease	D013494
supranuclear	I-Disease	D013494
palsy	I-Disease	D013494
(	O	O
PSP	B-Disease	D013494
)	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
describe	O	O
an	O	O
unusual	O	O
case	O	O
of	O	O
reversible	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
Oromandibular	B-Disease	D008538
dystonia	I-Disease	D008538
(	O	O
OMD	B-Disease	D008538
)	O	O
in	O	O
a	O	O
PSP	B-Disease	D013494
patient	O	O
to	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
recognizing	O	O
this	O	O
drug	O	O
related	O	O
complication	O	O
in	O	O
the	O	O
management	O	O
of	O	O
PSP	B-Disease	D013494
,	O	O
and	O	O
discuss	O	O
the	O	O
possible	O	O
underlying	O	O
pathophysiology	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
edaravone	B-Chemical	C005435
against	O	O
streptomycin	B-Chemical	D013307
-	O	O
induced	O	O
vestibulotoxicity	B-Disease	D015837
in	O	O
the	O	O
guinea	O	O
pig	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
alleviation	O	O
of	O	O
streptomycin	B-Chemical	D013307
-	O	O
induced	O	O
vestibulotoxicity	B-Disease	D015837
by	O	O
edaravone	B-Chemical	C005435
in	O	O
guinea	O	O
pigs	O	O
.	O	O

Edaravone	B-Chemical	C005435
,	O	O
a	O	O
free	O	O
radical	O	O
scavenger	O	O
,	O	O
has	O	O
potent	O	O
free	O	O
radical	O	O
quenching	O	O
action	O	O
and	O	O
is	O	O
used	O	O
in	O	O
clinical	O	O
practice	O	O
to	O	O
treat	O	O
cerebral	B-Disease	D002544
infarction	I-Disease	D002544
.	O	O

Streptomycin	B-Chemical	D013307
was	O	O
administered	O	O
to	O	O
the	O	O
inner	O	O
ear	O	O
by	O	O
osmotic	O	O
pump	O	O
for	O	O
24	O	O
h	O	O
,	O	O
and	O	O
edaravone	B-Chemical	C005435
(	O	O
n=8	O	O
)	O	O
or	O	O
saline	O	O
(	O	O
n=6	O	O
)	O	O
was	O	O
intraperitoneally	O	O
injected	O	O
once	O	O
a	O	O
day	O	O
for	O	O
7	O	O
days	O	O
.	O	O

We	O	O
observed	O	O
horizontal	O	O
vestibulo	O	O
-	O	O
ocular	O	O
reflex	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
postoperative	O	O
vestibular	O	O
function	O	O
.	O	O

Animals	O	O
injected	O	O
with	O	O
saline	O	O
showed	O	O
statistically	O	O
smaller	O	O
gains	O	O
than	O	O
those	O	O
injected	O	O
with	O	O
edaravone	B-Chemical	C005435
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
edaravone	B-Chemical	C005435
suppresses	O	O
streptomycin	B-Chemical	D013307
-	O	O
induced	O	O
vestibulotoxicity	B-Disease	D015837
.	O	O

Ketamine	B-Chemical	D007649
in	O	O
war	O	O
/	O	O
tropical	O	O
surgery	O	O
(	O	O
a	O	O
final	O	O
tribute	O	O
to	O	O
the	O	O
racemic	O	O
mixture	O	O
)	O	O
.	O	O

A	O	O
technique	O	O
of	O	O
continuous	O	O
intravenous	O	O
anaesthesia	O	O
with	O	O
ketamine	B-Chemical	D007649
was	O	O
used	O	O
successfully	O	O
during	O	O
the	O	O
Somalia	O	O
civil	O	O
war	O	O
in	O	O
1994	O	O
and	O	O
in	O	O
north	O	O
Uganda	O	O
in	O	O
1999	O	O
for	O	O
64	O	O
operations	O	O
in	O	O
62	O	O
patients	O	O
,	O	O
aged	O	O
from	O	O
6	O	O
weeks	O	O
to	O	O
70	O	O
years	O	O
,	O	O
undergoing	O	O
limb	O	O
and	O	O
abdominal	O	O
surgery	O	O
including	O	O
caesarian	O	O
sections	O	O
and	O	O
interventions	O	O
in	O	O
neonates	O	O
.	O	O

Operations	O	O
lasting	O	O
up	O	O
to	O	O
2h	O	O
could	O	O
be	O	O
performed	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
sophisticated	O	O
equipment	O	O
such	O	O
as	O	O
pulse	O	O
oximeters	O	O
or	O	O
ventilators	O	O
in	O	O
patients	O	O
on	O	O
spontaneous	O	O
ventilation	O	O
breathing	O	O
air	O	O
/	O	O
oxygen	B-Chemical	D010100
only	O	O
.	O	O

After	O	O
premedication	O	O
with	O	O
diazepam	B-Chemical	D003975
,	O	O
glycopyrrolate	B-Chemical	D006024
and	O	O
local	O	O
anaesthesia	O	O
,	O	O
and	O	O
induction	O	O
with	O	O
standard	O	O
doses	O	O
of	O	O
ketamine	B-Chemical	D007649
,	O	O
a	O	O
maintenance	O	O
dose	O	O
of	O	O
10	O	O
-	O	O
20	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
of	O	O
ketamine	B-Chemical	D007649
proved	O	O
safe	O	O
and	O	O
effective	O	O
.	O	O

Emphasis	O	O
was	O	O
placed	O	O
on	O	O
bedside	O	O
clinical	O	O
monitoring	O	O
,	O	O
relying	O	O
heavily	O	O
on	O	O
the	O	O
heart	O	O
rate	O	O
.	O	O

Diazepam	B-Chemical	D003975
,	O	O
unless	O	O
contraindicated	O	O
or	O	O
risky	O	O
,	O	O
remains	O	O
the	O	O
only	O	O
necessary	O	O
complementary	O	O
drug	O	O
to	O	O
ketamine	B-Chemical	D007649
as	O	O
it	O	O
buffers	O	O
its	O	O
cardiovascular	O	O
response	O	O
and	O	O
decreases	O	O
the	O	O
duration	O	O
and	O	O
intensity	O	O
of	O	O
operative	O	O
and	O	O
postoperative	O	O
hallucinations	B-Disease	D006212
.	O	O

Local	O	O
anaesthetic	O	O
blocks	O	O
were	O	O
useful	O	O
in	O	O
decreasing	O	O
the	O	O
requirement	O	O
for	O	O
postoperative	O	O
analgesia	B-Disease	D000699
.	O	O

An	O	O
antisialogue	O	O
was	O	O
usually	O	O
unnecessary	O	O
in	O	O
operations	O	O
lasting	O	O
up	O	O
to	O	O
2	O	O
h	O	O
,	O	O
glycopyrrolate	B-Chemical	D006024
being	O	O
the	O	O
best	O	O
choice	O	O
for	O	O
its	O	O
lowest	O	O
psychotropic	O	O
and	O	O
chronotropic	O	O
effects	O	O
,	O	O
especially	O	O
in	O	O
a	O	O
hot	O	O
climate	O	O
.	O	O

Experience	O	O
in	O	O
war	O	O
/	O	O
tropical	O	O
settings	O	O
suggests	O	O
this	O	O
technique	O	O
could	O	O
be	O	O
useful	O	O
in	O	O
civilian	O	O
contexts	O	O
such	O	O
as	O	O
outdoor	O	O
life	O	O
-	O	O
saving	O	O
emergency	O	O
surgery	O	O
or	O	O
in	O	O
mass	O	O
casualties	O	O
where	O	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

amputation	O	O
and	O	O
rapid	O	O
extrication	O	O
were	O	O
required	O	O
.	O	O

Steroid	B-Chemical	D013256
structure	O	O
and	O	O
pharmacological	O	O
properties	O	O
determine	O	O
the	O	O
anti	O	O
-	O	O
amnesic	B-Disease	D000647
effects	O	O
of	O	O
pregnenolone	B-Chemical	C018370
sulphate	I-Chemical	C018370
in	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
in	O	O
rats	O	O
.	O	O

Pregnenolone	B-Chemical	C018370
sulphate	I-Chemical	C018370
(	O	O
PREGS	B-Chemical	C018370
)	O	O
has	O	O
generated	O	O
interest	O	O
as	O	O
one	O	O
of	O	O
the	O	O
most	O	O
potent	O	O
memory	O	O
-	O	O
enhancing	O	O
neurosteroids	O	O
to	O	O
be	O	O
examined	O	O
in	O	O
rodent	O	O
learning	O	O
studies	O	O
,	O	O
with	O	O
particular	O	O
importance	O	O
in	O	O
the	O	O
ageing	O	O
process	O	O
.	O	O

The	O	O
mechanism	O	O
by	O	O
which	O	O
this	O	O
endogenous	O	O
steroid	B-Chemical	D013256
enhances	O	O
memory	O	O
formation	O	O
is	O	O
hypothesized	O	O
to	O	O
involve	O	O
actions	O	O
on	O	O
glutamatergic	O	O
and	O	O
GABAergic	O	O
systems	O	O
.	O	O

This	O	O
hypothesis	O	O
stems	O	O
from	O	O
findings	O	O
that	O	O
PREGS	B-Chemical	C018370
is	O	O
a	O	O
potent	O	O
positive	O	O
modulator	O	O
of	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
d	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
receptors	O	O
(	O	O
NMDARs	O	O
)	O	O
and	O	O
a	O	O
negative	O	O
modulator	O	O
of	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptors	O	O
(	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
Rs	O	O
)	O	O
.	O	O

Moreover	O	O
,	O	O
PREGS	B-Chemical	C018370
is	O	O
able	O	O
to	O	O
reverse	O	O
the	O	O
amnesic	B-Disease	D000647
-	O	O
like	O	O
effects	O	O
of	O	O
NMDAR	O	O
and	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
R	O	O
ligands	O	O
.	O	O

To	O	O
investigate	O	O
this	O	O
hypothesis	O	O
,	O	O
the	O	O
present	O	O
study	O	O
in	O	O
rats	O	O
examined	O	O
the	O	O
memory	O	O
-	O	O
altering	O	O
abilities	O	O
of	O	O
structural	O	O
analogs	O	O
of	O	O
PREGS	B-Chemical	C018370
,	O	O
which	O	O
differ	O	O
in	O	O
their	O	O
modulation	O	O
of	O	O
NMDAR	O	O
and	O	O
/	O	O
or	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
R	O	O
function	O	O
.	O	O

The	O	O
analogs	O	O
tested	O	O
were	O	O
:	O	O
11	B-Chemical	-1
-	I-Chemical	-1
ketopregnenolone	I-Chemical	-1
sulphate	I-Chemical	-1
(	O	O
an	O	O
agent	O	O
that	O	O
is	O	O
inactive	O	O
at	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
Rs	O	O
and	O	O
NMDARs	O	O
)	O	O
,	O	O
epipregnanolone	B-Chemical	C018370
(	I-Chemical	C018370
[	I-Chemical	C018370
3beta	I-Chemical	C018370
-	I-Chemical	C018370
hydroxy	I-Chemical	C018370
-	I-Chemical	C018370
5beta	I-Chemical	C018370
-	I-Chemical	C018370
pregnan	I-Chemical	C018370
-	I-Chemical	C018370
20	I-Chemical	C018370
-	I-Chemical	C018370
one	I-Chemical	C018370
]	I-Chemical	C018370
sulphate	I-Chemical	C018370
,	O	O
an	O	O
inhibitor	O	O
of	O	O
both	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
Rs	O	O
and	O	O
NMDARs	O	O
)	O	O
,	O	O
and	O	O
a	O	O
newly	O	O
synthesized	O	O
(	O	O
-	O	O
)	O	O
PREGS	B-Chemical	C018370
enantiomer	O	O
(	O	O
which	O	O
is	O	O
identical	O	O
to	O	O
PREGS	B-Chemical	C018370
in	O	O
effects	O	O
on	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
Rs	O	O
and	O	O
NMDARs	O	O
)	O	O
.	O	O

The	O	O
memory	O	O
-	O	O
enhancing	O	O
effects	O	O
of	O	O
PREGS	B-Chemical	C018370
and	O	O
its	O	O
analogs	O	O
were	O	O
tested	O	O
in	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
using	O	O
the	O	O
model	O	O
of	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

Both	O	O
PREGS	B-Chemical	C018370
and	O	O
its	O	O
(	O	O
-	O	O
)	O	O
enantiomer	O	O
blocked	O	O
the	O	O
effects	O	O
of	O	O
scopolamine	B-Chemical	D012601
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
,	O	O
unlike	O	O
PREGS	B-Chemical	C018370
,	O	O
11	B-Chemical	-1
-	I-Chemical	-1
ketopregnenolone	I-Chemical	-1
sulphate	I-Chemical	-1
and	O	O
epipregnanolone	B-Chemical	C018370
sulphate	I-Chemical	C018370
failed	O	O
to	O	O
block	O	O
the	O	O
effect	O	O
of	O	O
scopolamine	B-Chemical	D012601
,	O	O
suggesting	O	O
that	O	O
altering	O	O
the	O	O
modulation	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
diminishes	O	O
the	O	O
memory	O	O
-	O	O
enhancing	O	O
effects	O	O
of	O	O
PREGS	B-Chemical	C018370
.	O	O

Moreover	O	O
,	O	O
enantioselectivity	O	O
was	O	O
demonstrated	O	O
by	O	O
the	O	O
ability	O	O
of	O	O
natural	O	O
PREGS	B-Chemical	C018370
to	O	O
be	O	O
an	O	O
order	O	O
of	O	O
magnitude	O	O
more	O	O
effective	O	O
than	O	O
its	O	O
synthetic	O	O
enantiomer	O	O
in	O	O
reversing	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

These	O	O
results	O	O
identify	O	O
a	O	O
novel	O	O
neuropharmacological	O	O
site	O	O
for	O	O
the	O	O
modulation	O	O
of	O	O
memory	O	O
processes	O	O
by	O	O
neuroactive	O	O
steroids	B-Chemical	D013256
.	O	O

Preliminary	O	O
efficacy	O	O
assessment	O	O
of	O	O
intrathecal	O	O
injection	O	O
of	O	O
an	O	O
American	O	O
formulation	O	O
of	O	O
adenosine	B-Chemical	D000241
in	O	O
humans	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Preclinical	O	O
studies	O	O
of	O	O
intrathecal	O	O
adenosine	B-Chemical	D000241
suggest	O	O
it	O	O
may	O	O
be	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
and	O	O
chronic	O	O
pain	B-Disease	D010146
in	O	O
humans	O	O
,	O	O
and	O	O
preliminary	O	O
studies	O	O
in	O	O
volunteers	O	O
and	O	O
patients	O	O
with	O	O
a	O	O
Swedish	O	O
formulation	O	O
of	O	O
adenosine	B-Chemical	D000241
suggests	O	O
it	O	O
may	O	O
be	O	O
effective	O	O
in	O	O
hypersensitivity	B-Disease	D004342
states	O	O
but	O	O
not	O	O
with	O	O
acute	O	O
noxious	O	O
stimulation	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
screen	O	O
for	O	O
efficacy	O	O
of	O	O
a	O	O
different	O	O
formulation	O	O
of	O	O
adenosine	B-Chemical	D000241
marketed	O	O
in	O	O
the	O	O
US	O	O
,	O	O
using	O	O
both	O	O
acute	O	O
noxious	O	O
stimulation	O	O
and	O	O
capsaicin	B-Chemical	D002211
-	O	O
evoked	O	O
mechanical	O	O
hypersensitivity	B-Disease	D004342
.	O	O

METHODS	O	O
:	O	O
Following	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
and	O	O
institutional	O	O
review	O	O
board	O	O
approval	O	O
and	O	O
written	O	O
informed	O	O
consent	O	O
,	O	O
65	O	O
volunteers	O	O
were	O	O
studied	O	O
in	O	O
two	O	O
trials	O	O
:	O	O
an	O	O
open	O	O
-	O	O
label	O	O
,	O	O
dose	O	O
-	O	O
escalating	O	O
trial	O	O
with	O	O
intrathecal	O	O
adenosine	B-Chemical	D000241
doses	O	O
of	O	O
0	O	O
.	O	O

25	O	O
-	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
and	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
of	O	O
adenosine	B-Chemical	D000241
,	O	O
2	O	O
mg	O	O
.	O	O

Cerebrospinal	O	O
fluid	O	O
was	O	O
obtained	O	O
for	O	O
pharmacokinetic	O	O
analysis	O	O
,	O	O
and	O	O
pain	B-Disease	D010146
ratings	O	O
in	O	O
response	O	O
to	O	O
acute	O	O
heat	O	O
stimuli	O	O
and	O	O
areas	O	O
of	O	O
mechanical	B-Disease	D006930
hyperalgesia	I-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
after	O	O
intradermal	O	O
capsaicin	B-Chemical	D002211
injection	O	O
were	O	O
determined	O	O
.	O	O

RESULTS	O	O
:	O	O
Adenosine	B-Chemical	D000241
produced	O	O
no	O	O
effect	O	O
on	O	O
pain	B-Disease	D010146
report	O	O
to	O	O
acute	O	O
noxious	O	O
thermal	O	O
or	O	O
chemical	O	O
stimulation	O	O
but	O	O
reduced	O	O
mechanical	B-Disease	D006930
hyperalgesia	I-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
from	O	O
intradermal	O	O
capsaicin	B-Chemical	D002211
injection	O	O
for	O	O
at	O	O
least	O	O
24	O	O
h	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
residence	O	O
time	O	O
of	O	O
adenosine	B-Chemical	D000241
in	O	O
cerebrospinal	O	O
fluid	O	O
was	O	O
short	O	O
(	O	O
<	O	O
4	O	O
h	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
show	O	O
selective	O	O
inhibition	O	O
by	O	O
intrathecal	O	O
adenosine	B-Chemical	D000241
of	O	O
hypersensitivity	B-Disease	D004342
,	O	O
presumed	O	O
to	O	O
reflect	O	O
central	O	O
sensitization	O	O
in	O	O
humans	O	O
after	O	O
peripheral	O	O
capsaicin	B-Chemical	D002211
injection	O	O
.	O	O

The	O	O
long	O	O
-	O	O
lasting	O	O
effect	O	O
is	O	O
consistent	O	O
with	O	O
that	O	O
observed	O	O
in	O	O
preliminary	O	O
reports	O	O
of	O	O
patients	O	O
with	O	O
chronic	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
and	O	O
is	O	O
not	O	O
due	O	O
to	O	O
prolonged	O	O
residence	O	O
of	O	O
adenosine	B-Chemical	D000241
in	O	O
cerebrospinal	O	O
fluid	O	O
.	O	O

Effect	O	O
of	O	O
lithium	B-Chemical	D008094
maintenance	O	O
therapy	O	O
on	O	O
thyroid	O	O
and	O	O
parathyroid	O	O
function	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
changes	O	O
induced	O	O
by	O	O
lithium	B-Chemical	D008094
maintenance	O	O
therapy	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
thyroid	O	O
,	O	O
parathyroid	O	O
and	O	O
ion	O	O
alterations	O	O
.	O	O

These	O	O
were	O	O
evaluated	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
duration	O	O
of	O	O
lithium	B-Chemical	D008094
therapy	O	O
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
and	O	O
family	O	O
history	O	O
(	O	O
whether	O	O
or	O	O
not	O	O
the	O	O
patient	O	O
had	O	O
a	O	O
first	O	O
-	O	O
degree	O	O
relative	O	O
with	O	O
thyroid	B-Disease	D013959
disease	I-Disease	D013959
)	O	O
.	O	O

DESIGN	O	O
:	O	O
Prospective	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Affective	O	O
Disorders	O	O
Clinic	O	O
at	O	O
St	O	O
.	O	O

Mary's	O	O
Hospital	O	O
,	O	O
Montreal	O	O
.	O	O

PATIENTS	O	O
:	O	O
One	O	O
hundred	O	O
and	O	O
one	O	O
patients	O	O
(	O	O
28	O	O
men	O	O
and	O	O
73	O	O
women	O	O
)	O	O
with	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
receiving	O	O
lithium	B-Chemical	D008094
maintenance	O	O
therapy	O	O
ranging	O	O
from	O	O
1	O	O
year's	O	O
to	O	O
32	O	O
years'	O	O
duration	O	O
.	O	O

The	O	O
control	O	O
group	O	O
consisted	O	O
of	O	O
82	O	O
patients	O	O
with	O	O
no	O	O
psychiatric	B-Disease	D001523
or	O	O
endocrinological	O	O
diagnoses	O	O
from	O	O
the	O	O
hospital's	O	O
out	O	O
-	O	O
patient	O	O
clinics	O	O
.	O	O

OUTCOME	O	O
MEASURES	O	O
:	O	O
Laboratory	O	O
analyses	O	O
of	O	O
calcium	B-Chemical	D002118
,	O	O
magnesium	B-Chemical	D008274
and	O	O
thyroid	O	O
-	O	O
stimulating	O	O
hormone	O	O
levels	O	O
performed	O	O
before	O	O
beginning	O	O
lithium	B-Chemical	D008094
therapy	O	O
and	O	O
at	O	O
biannual	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

RESULTS	O	O
:	O	O
Hypothyroidism	B-Disease	D007037
developed	O	O
in	O	O
40	O	O
patients	O	O
,	O	O
excluding	O	O
8	O	O
patients	O	O
who	O	O
were	O	O
hypothyroid	B-Disease	D007037
at	O	O
baseline	O	O
.	O	O

All	O	O
patients	O	O
having	O	O
first	O	O
-	O	O
degree	O	O
relatives	O	O
affected	O	O
by	O	O
thyroid	B-Disease	D013959
illness	I-Disease	D013959
had	O	O
accelerated	O	O
onset	O	O
of	O	O
hypothyroidism	B-Disease	D007037
(	O	O
3	O	O
.	O	O

7	O	O
years	O	O
after	O	O
onset	O	O
of	O	O
lithium	B-Chemical	D008094
therapy	O	O
)	O	O
compared	O	O
with	O	O
patients	O	O
without	O	O
a	O	O
family	O	O
history	O	O
(	O	O
8	O	O
.	O	O

6	O	O
years	O	O
after	O	O
onset	O	O
of	O	O
lithium	B-Chemical	D008094
therapy	O	O
)	O	O
.	O	O

Women	O	O
over	O	O
60	O	O
years	O	O
of	O	O
age	O	O
were	O	O
more	O	O
often	O	O
affected	O	O
by	O	O
hypothyroidism	B-Disease	D007037
than	O	O
women	O	O
under	O	O
60	O	O
years	O	O
of	O	O
age	O	O
(	O	O
34	O	O
.	O	O

6%	O	O
versus	O	O
31	O	O
.	O	O

9%	O	O
)	O	O
.	O	O

Magnesium	B-Chemical	D008274
levels	O	O
in	O	O
patients	O	O
on	O	O
lithium	B-Chemical	D008094
treatment	O	O
were	O	O
unchanged	O	O
from	O	O
baseline	O	O
levels	O	O
.	O	O

After	O	O
lithium	B-Chemical	D008094
treatment	O	O
,	O	O
calcium	B-Chemical	D002118
levels	O	O
were	O	O
higher	O	O
than	O	O
either	O	O
baseline	O	O
levels	O	O
or	O	O
control	O	O
levels	O	O
.	O	O

Thus	O	O
,	O	O
lithium	B-Chemical	D008094
treatment	O	O
counteracted	O	O
the	O	O
decrease	O	O
in	O	O
plasma	O	O
calcium	B-Chemical	D002118
levels	O	O
associated	O	O
with	O	O
aging	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Familial	O	O
thyroid	B-Disease	D013959
illness	I-Disease	D013959
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
hypothyroidism	B-Disease	D007037
and	O	O
hypercalcemia	B-Disease	D006934
during	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

Systemic	O	O
toxicity	B-Disease	D064420
following	O	O
administration	O	O
of	O	O
sirolimus	B-Chemical	D020123
(	O	O
formerly	O	O
rapamycin	B-Chemical	D020123
)	O	O
for	O	O
psoriasis	B-Disease	D011565
:	O	O
association	O	O
of	O	O
capillary	B-Disease	D019559
leak	I-Disease	D019559
syndrome	I-Disease	D019559
with	O	O
apoptosis	O	O
of	O	O
lesional	O	O
lymphocytes	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Sirolimus	B-Chemical	D020123
(	O	O
formerly	O	O
rapamycin	B-Chemical	D020123
)	O	O
is	O	O
an	O	O
immunosuppressive	O	O
agent	O	O
that	O	O
interferes	O	O
with	O	O
T	O	O
-	O	O
cell	O	O
activation	O	O
.	O	O

After	O	O
2	O	O
individuals	O	O
with	O	O
psoriasis	B-Disease	D011565
developed	O	O
a	O	O
capillary	B-Disease	D019559
leak	I-Disease	D019559
syndrome	I-Disease	D019559
following	O	O
treatment	O	O
with	O	O
oral	O	O
sirolimus	B-Chemical	D020123
lesional	O	O
skin	O	O
cells	O	O
and	O	O
activated	O	O
peripheral	O	O
blood	O	O
cells	O	O
were	O	O
analyzed	O	O
for	O	O
induction	O	O
of	O	O
apoptosis	O	O
.	O	O

OBSERVATIONS	O	O
:	O	O
A	O	O
keratome	O	O
skin	O	O
specimen	O	O
from	O	O
1	O	O
patient	O	O
with	O	O
sirolimus	B-Chemical	D020123
-	O	O
induced	O	O
capillary	B-Disease	D019559
leak	I-Disease	D019559
syndrome	I-Disease	D019559
had	O	O
a	O	O
2	O	O
.	O	O

3	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
percentage	O	O
of	O	O
apoptotic	O	O
cells	O	O
(	O	O
to	O	O
48%	O	O
)	O	O
compared	O	O
with	O	O
an	O	O
unaffected	O	O
sirolimus	B-Chemical	D020123
-	O	O
treated	O	O
patient	O	O
with	O	O
psoriasis	B-Disease	D011565
(	O	O
21%	O	O
)	O	O
.	O	O

Activated	O	O
peripheral	O	O
blood	O	O
T	O	O
cells	O	O
from	O	O
patients	O	O
with	O	O
psoriasis	B-Disease	D011565
tended	O	O
to	O	O
exhibit	O	O
greater	O	O
spontaneous	O	O
or	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
apoptosis	O	O
than	O	O
did	O	O
normal	O	O
T	O	O
cells	O	O
,	O	O
particularly	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
sirolimus	B-Chemical	D020123
.	O	O

CONCLUSIONS	O	O
:	O	O
Severe	O	O
adverse	O	O
effects	O	O
of	O	O
sirolimus	B-Chemical	D020123
include	O	O
fever	B-Disease	D005334
,	O	O
anemia	B-Disease	D000740
,	O	O
and	O	O
capillary	B-Disease	D019559
leak	I-Disease	D019559
syndrome	I-Disease	D019559
.	O	O

These	O	O
symptoms	O	O
may	O	O
be	O	O
the	O	O
result	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
apoptosis	O	O
of	O	O
lesional	O	O
leukocytes	O	O
,	O	O
especially	O	O
activated	O	O
T	O	O
lymphocytes	O	O
,	O	O
and	O	O
possibly	O	O
release	O	O
of	O	O
inflammatory	O	O
mediators	O	O
.	O	O

Because	O	O
patients	O	O
with	O	O
severe	O	O
psoriasis	B-Disease	D011565
may	O	O
develop	O	O
capillary	B-Disease	D019559
leak	I-Disease	D019559
from	O	O
various	O	O
systemic	O	O
therapies	O	O
,	O	O
clinical	O	O
monitoring	O	O
is	O	O
advisable	O	O
for	O	O
patients	O	O
with	O	O
inflammatory	B-Disease	D007249
diseases	I-Disease	D007249
who	O	O
are	O	O
treated	O	O
with	O	O
immune	O	O
modulators	O	O
.	O	O

Contribution	O	O
of	O	O
the	O	O
glycine	B-Chemical	D005998
site	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
in	O	O
rostral	O	O
and	O	O
intermediate	O	O
-	O	O
caudal	O	O
parts	O	O
of	O	O
the	O	O
striatum	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
muscle	O	O
tone	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
contribution	O	O
of	O	O
the	O	O
glycine	B-Chemical	D005998
site	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
in	O	O
the	O	O
striatum	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
muscle	O	O
tone	O	O
.	O	O

Muscle	O	O
tone	O	O
was	O	O
examined	O	O
using	O	O
a	O	O
combined	O	O
mechanoand	O	O
electromyographic	O	O
method	O	O
,	O	O
which	O	O
measured	O	O
simultaneously	O	O
the	O	O
muscle	O	O
resistance	O	O
(	O	O
MMG	O	O
)	O	O
of	O	O
the	O	O
rat's	O	O
hind	O	O
foot	O	O
to	O	O
passive	O	O
extension	O	O
and	O	O
flexion	O	O
in	O	O
the	O	O
ankle	O	O
joint	O	O
and	O	O
the	O	O
electromyographic	O	O
activity	O	O
(	O	O
EMG	O	O
)	O	O
of	O	O
the	O	O
antagonistic	O	O
muscles	O	O
of	O	O
that	O	O
joint	O	O
:	O	O
gastrocnemius	O	O
and	O	O
tibialis	O	O
anterior	O	O
.	O	O

Muscle	B-Disease	D009127
rigidity	I-Disease	D009127
was	O	O
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
(	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

5	B-Chemical	C066192
,	I-Chemical	C066192
7	I-Chemical	C066192
-	I-Chemical	C066192
dichlorokynurenic	I-Chemical	C066192
acid	I-Chemical	C066192
(	O	O
5	B-Chemical	C066192
,	I-Chemical	C066192
7	I-Chemical	C066192
-	I-Chemical	C066192
DCKA	I-Chemical	C066192
)	O	O
,	O	O
a	O	O
selective	O	O
glycine	B-Chemical	D005998
site	O	O
antagonist	O	O
,	O	O
injected	O	O
in	O	O
doses	O	O
of	O	O
2	O	O
.	O	O

5	O	O
and	O	O
4	O	O
.	O	O

5	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
bilaterally	O	O
,	O	O
into	O	O
the	O	O
rostral	O	O
region	O	O
of	O	O
the	O	O
striatum	O	O
,	O	O
decreased	O	O
both	O	O
the	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
(	O	O
MMG	O	O
)	O	O
and	O	O
the	O	O
enhanced	O	O
electromyographic	O	O
activity	O	O
(	O	O
EMG	O	O
)	O	O
.	O	O

5	B-Chemical	C066192
,	I-Chemical	C066192
7	I-Chemical	C066192
-	I-Chemical	C066192
DCKA	I-Chemical	C066192
injected	O	O
bilaterally	O	O
in	O	O
a	O	O
dose	O	O
of	O	O
4	O	O
.	O	O

5	O	O
microg	O	O
/	O	O
0	O	O
.	O	O

5	O	O
microl	O	O
into	O	O
the	O	O
intermediate	O	O
-	O	O
caudal	O	O
region	O	O
of	O	O
the	O	O
striatum	O	O
of	O	O
rats	O	O
not	O	O
pretreated	O	O
with	O	O
haloperidol	B-Chemical	D006220
had	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
muscle	O	O
tone	O	O
.	O	O

The	O	O
present	O	O
results	O	O
suggest	O	O
that	O	O
blockade	O	O
of	O	O
the	O	O
glycine	B-Chemical	D005998
site	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
in	O	O
the	O	O
rostral	O	O
part	O	O
of	O	O
the	O	O
striatum	O	O
may	O	O
be	O	O
mainly	O	O
responsible	O	O
for	O	O
the	O	O
antiparkinsonian	O	O
action	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

Efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
lovastatin	B-Chemical	D008148
in	O	O
3390	O	O
women	O	O
with	O	O
moderate	O	O
hypercholesterolemia	B-Disease	D006937
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
lovastatin	B-Chemical	D008148
in	O	O
women	O	O
with	O	O
moderate	O	O
hypercholesterolemia	B-Disease	D006937
.	O	O

DESIGN	O	O
:	O	O
The	O	O
Expanded	O	O
Clinical	O	O
Evaluation	O	O
of	O	O
Lovastatin	B-Chemical	D008148
(	O	O
EXCEL	O	O
)	O	O
Study	O	O
,	O	O
a	O	O
multicenter	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
diet	O	O
-	O	O
and	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
,	O	O
in	O	O
which	O	O
participants	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
placebo	O	O
or	O	O
lovastatin	B-Chemical	D008148
at	O	O
doses	O	O
of	O	O
20	O	O
or	O	O
40	O	O
mg	O	O
once	O	O
daily	O	O
,	O	O
or	O	O
20	O	O
or	O	O
40	O	O
mg	O	O
twice	O	O
daily	O	O
for	O	O
48	O	O
weeks	O	O
.	O	O

SETTING	O	O
:	O	O
Ambulatory	O	O
patients	O	O
recruited	O	O
by	O	O
362	O	O
participating	O	O
centers	O	O
throughout	O	O
the	O	O
United	O	O
States	O	O
.	O	O

PATIENTS	O	O
:	O	O
Women	O	O
(	O	O
n	O	O
=	O	O
3390	O	O
)	O	O
from	O	O
the	O	O
total	O	O
cohort	O	O
of	O	O
8245	O	O
volunteers	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Plasma	O	O
total	O	O
,	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
,	O	O
and	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
cholesterol	B-Chemical	D002784
,	O	O
and	O	O
triglycerides	B-Chemical	D014280
;	O	O
and	O	O
laboratory	O	O
and	O	O
clinical	O	O
evidence	O	O
of	O	O
adverse	O	O
events	O	O
monitored	O	O
periodically	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

RESULTS	O	O
:	O	O
Among	O	O
women	O	O
,	O	O
lovastatin	B-Chemical	D008148
(	O	O
20	O	O
to	O	O
80	O	O
mg	O	O
/	O	O
d	O	O
)	O	O
produced	O	O
sustained	O	O
(	O	O
12	O	O
-	O	O
to	O	O
48	O	O
-	O	O
week	O	O
)	O	O
,	O	O
dose	O	O
-	O	O
related	O	O
changes	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
:	O	O
decreases	O	O
in	O	O
LDL	O	O
cholesterol	B-Chemical	D002784
(	O	O
24%	O	O
to	O	O
40%	O	O
)	O	O
and	O	O
triglycerides	B-Chemical	D014280
(	O	O
9%	O	O
to	O	O
18%	O	O
)	O	O
,	O	O
and	O	O
increases	O	O
in	O	O
HDL	O	O
cholesterol	B-Chemical	D002784
(	O	O
6	O	O
.	O	O

7%	O	O
to	O	O
8	O	O
.	O	O

6%	O	O
)	O	O
.	O	O

Depending	O	O
on	O	O
the	O	O
dose	O	O
,	O	O
from	O	O
82%	O	O
to	O	O
95%	O	O
of	O	O
lovastatin	B-Chemical	D008148
-	O	O
treated	O	O
women	O	O
achieved	O	O
the	O	O
National	O	O
Cholesterol	B-Chemical	D002784
Education	O	O
Program	O	O
goal	O	O
of	O	O
LDL	O	O
cholesterol	B-Chemical	D002784
levels	O	O
less	O	O
than	O	O
4	O	O
.	O	O

14	O	O
mmol	O	O
/	O	O
L	O	O
(	O	O
160	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
,	O	O
and	O	O
40%	O	O
to	O	O
87%	O	O
achieved	O	O
the	O	O
goal	O	O
of	O	O
3	O	O
.	O	O

36	O	O
mmol	O	O
/	O	O
L	O	O
(	O	O
130	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
.	O	O

Successive	O	O
transaminase	O	O
elevations	O	O
greater	O	O
than	O	O
three	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
occurred	O	O
in	O	O
0	O	O
.	O	O

1%	O	O
of	O	O
women	O	O
and	O	O
were	O	O
dose	O	O
dependent	O	O
above	O	O
the	O	O
20	O	O
-	O	O
mg	O	O
dose	O	O
.	O	O

Myopathy	B-Disease	D009135
,	O	O
defined	O	O
as	O	O
muscle	O	O
symptoms	O	O
with	O	O
creatine	B-Chemical	D003401
kinase	O	O
elevations	O	O
greater	O	O
than	O	O
10	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
,	O	O
was	O	O
rare	O	O
and	O	O
associated	O	O
with	O	O
the	O	O
highest	O	O
recommended	O	O
daily	O	O
dose	O	O
of	O	O
lovastatin	B-Chemical	D008148
(	O	O
80	O	O
mg	O	O
)	O	O
.	O	O

Estrogen	O	O
-	O	O
replacement	O	O
therapy	O	O
appeared	O	O
to	O	O
have	O	O
no	O	O
effect	O	O
on	O	O
either	O	O
the	O	O
efficacy	O	O
or	O	O
safety	O	O
profile	O	O
of	O	O
lovastatin	B-Chemical	D008148
.	O	O

CONCLUSION	O	O
:	O	O
Lovastatin	B-Chemical	D008148
is	O	O
highly	O	O
effective	O	O
and	O	O
generally	O	O
well	O	O
tolerated	O	O
as	O	O
therapy	O	O
for	O	O
primary	O	O
hypercholesterolemia	B-Disease	D006937
in	O	O
women	O	O
.	O	O

REM	B-Disease	D012892
sleep	I-Disease	D012892
deprivation	I-Disease	D012892
changes	O	O
behavioral	O	O
response	O	O
to	O	O
catecholaminergic	O	O
and	O	O
serotonergic	O	O
receptor	O	O
activation	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
REM	B-Disease	D012892
sleep	I-Disease	D012892
deprivation	I-Disease	D012892
(	O	O
REMD	B-Disease	D012892
)	O	O
on	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
aggressiveness	B-Disease	D001523
and	O	O
quipazine	B-Chemical	D011814
-	O	O
induced	O	O
head	B-Disease	D009069
twitches	I-Disease	D009069
in	O	O
rats	O	O
were	O	O
determined	O	O
.	O	O

Forty	O	O
-	O	O
eight	O	O
hr	O	O
of	O	O
REMD	B-Disease	D012892
increased	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
aggressiveness	B-Disease	D001523
,	O	O
and	O	O
reduced	O	O
(	O	O
immediately	O	O
after	O	O
completing	O	O
of	O	O
REMD	B-Disease	D012892
)	O	O
or	O	O
increased	O	O
(	O	O
96	O	O
hr	O	O
after	O	O
completing	O	O
of	O	O
REMD	B-Disease	D012892
)	O	O
quipazine	B-Chemical	D011814
-	O	O
induced	O	O
head	B-Disease	D009069
twitches	I-Disease	D009069
.	O	O

Results	O	O
are	O	O
discussed	O	O
in	O	O
terms	O	O
of	O	O
similarity	O	O
to	O	O
pharmacological	O	O
effects	O	O
of	O	O
other	O	O
antidepressive	O	O
treatments	O	O
.	O	O

Extrapyramidal	O	O
side	O	O
effects	O	O
and	O	O
oral	O	O
haloperidol	B-Chemical	D006220
:	O	O
an	O	O
analysis	O	O
of	O	O
explanatory	O	O
patient	O	O
and	O	O
treatment	O	O
characteristics	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
(	O	O
EPS	O	O
)	O	O
was	O	O
evaluated	O	O
in	O	O
98	O	O
patients	O	O
treated	O	O
with	O	O
haloperidol	B-Chemical	D006220
.	O	O

The	O	O
incidence	O	O
of	O	O
parkinsonism	B-Disease	D010302
was	O	O
higher	O	O
at	O	O
higher	O	O
doses	O	O
of	O	O
haloperidol	B-Chemical	D006220
and	O	O
in	O	O
younger	O	O
patients	O	O
.	O	O

Prophylactic	O	O
antiparkinsonian	O	O
medication	O	O
was	O	O
effective	O	O
in	O	O
younger	O	O
but	O	O
not	O	O
in	O	O
older	O	O
patients	O	O
.	O	O

However	O	O
,	O	O
these	O	O
medications	O	O
were	O	O
more	O	O
effective	O	O
in	O	O
both	O	O
young	O	O
and	O	O
old	O	O
patients	O	O
when	O	O
given	O	O
after	O	O
parkinsonism	B-Disease	D010302
developed	O	O
.	O	O

Akathisia	B-Disease	D017109
was	O	O
controlled	O	O
by	O	O
the	O	O
benzodiazepine	B-Chemical	D001569
lorazepam	B-Chemical	D008140
in	O	O
14	O	O
out	O	O
of	O	O
16	O	O
patients	O	O
,	O	O
while	O	O
prophylactic	O	O
antiparkinsonians	O	O
were	O	O
ineffective	O	O
.	O	O

The	O	O
present	O	O
study	O	O
points	O	O
to	O	O
patient	O	O
characteristics	O	O
that	O	O
may	O	O
be	O	O
of	O	O
significance	O	O
in	O	O
the	O	O
development	O	O
of	O	O
EPS	O	O
due	O	O
to	O	O
haloperidol	B-Chemical	D006220
.	O	O

Hepatic	B-Disease	D006504
veno	I-Disease	D006504
-	I-Disease	D006504
occlusive	I-Disease	D006504
disease	I-Disease	D006504
caused	O	O
by	O	O
6	B-Chemical	D013866
-	I-Chemical	D013866
thioguanine	I-Chemical	D013866
.	O	O

Clinically	O	O
reversible	O	O
veno	B-Disease	D006504
-	I-Disease	D006504
occlusive	I-Disease	D006504
disease	I-Disease	D006504
of	I-Disease	D006504
the	I-Disease	D006504
liver	I-Disease	D006504
developed	O	O
in	O	O
a	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
acute	B-Disease	D054198
lymphocytic	I-Disease	D054198
leukemia	I-Disease	D054198
after	O	O
10	O	O
months	O	O
of	O	O
maintenance	O	O
therapy	O	O
with	O	O
6	B-Chemical	D013866
-	I-Chemical	D013866
thioguanine	I-Chemical	D013866
.	O	O

Serial	O	O
liver	O	O
biopsies	O	O
showed	O	O
the	O	O
development	O	O
and	O	O
resolution	O	O
of	O	O
intense	O	O
sinusoidal	O	O
engorgement	O	O
.	O	O

Although	O	O
this	O	O
disease	O	O
was	O	O
clinically	O	O
reversible	O	O
,	O	O
some	O	O
subintimal	O	O
fibrosis	B-Disease	D005355
about	O	O
the	O	O
terminal	O	O
hepatic	O	O
veins	O	O
persisted	O	O
.	O	O

This	O	O
case	O	O
presented	O	O
a	O	O
unique	O	O
opportunity	O	O
to	O	O
observe	O	O
the	O	O
histologic	O	O
features	O	O
of	O	O
clinically	O	O
reversible	O	O
hepatic	B-Disease	D006504
veno	I-Disease	D006504
-	I-Disease	D006504
occlusive	I-Disease	D006504
disease	I-Disease	D006504
over	O	O
time	O	O
,	O	O
and	O	O
may	O	O
be	O	O
the	O	O
first	O	O
case	O	O
of	O	O
veno	O	O
-	O	O
occlusive	O	O
related	O	O
solely	O	O
to	O	O
6	B-Chemical	D013866
-	I-Chemical	D013866
thioguanine	I-Chemical	D013866
.	O	O

Treatment	O	O
of	O	O
ifosfamide	B-Chemical	D007069
-	O	O
induced	O	O
urothelial	B-Disease	D001745
toxicity	I-Disease	D001745
by	O	O
oral	O	O
administration	O	O
of	O	O
sodium	B-Chemical	D015080
2	I-Chemical	D015080
-	I-Chemical	D015080
mercaptoethane	I-Chemical	D015080
sulphonate	I-Chemical	D015080
(	O	O
MESNA	B-Chemical	D015080
)	O	O
to	O	O
patients	O	O
with	O	O
inoperable	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
.	O	O

The	O	O
protective	O	O
effect	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
the	O	O
thiol	B-Chemical	D013438
compound	O	O
sodium	B-Chemical	D015080
2	I-Chemical	D015080
-	I-Chemical	D015080
mercaptoethane	I-Chemical	D015080
sulphonate	I-Chemical	D015080
(	O	O
MESNA	B-Chemical	D015080
)	O	O
against	O	O
urothelial	B-Disease	D001745
toxicity	I-Disease	D001745
induced	O	O
by	O	O
ifosfamide	B-Chemical	D007069
(	O	O
IF	B-Chemical	D007069
)	O	O
was	O	O
tested	O	O
in	O	O
a	O	O
group	O	O
of	O	O
45	O	O
patients	O	O
with	O	O
inoperable	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
under	O	O
treatment	O	O
with	O	O
IF	B-Chemical	D007069
(	O	O
2250	O	O
mg	O	O
/	O	O
m2	O	O
on	O	O
days	O	O
2	O	O
-	O	O
5	O	O
)	O	O
as	O	O
part	O	O
of	O	O
a	O	O
polychemotherapy	O	O
regimen	O	O
repeated	O	O
in	O	O
a	O	O
4	O	O
-	O	O
week	O	O
cycle	O	O
.	O	O

MESNA	B-Chemical	D015080
was	O	O
given	O	O
orally	O	O
on	O	O
the	O	O
days	O	O
of	O	O
treatment	O	O
with	O	O
IF	B-Chemical	D007069
in	O	O
3	O	O
doses	O	O
of	O	O
840	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
each	O	O
administered	O	O
at	O	O
0	O	O
hr	O	O
(	O	O
=	O	O
injection	O	O
of	O	O
IF	B-Chemical	D007069
)	O	O
,	O	O
4	O	O
hr	O	O
and	O	O
8	O	O
hr	O	O
p	O	O
.	O	O

i	O	O
.	O	O

Out	O	O
of	O	O
a	O	O
total	O	O
of	O	O
88	O	O
courses	O	O
of	O	O
this	O	O
treatment	O	O
we	O	O
observed	O	O
10	O	O
episodes	O	O
of	O	O
asymptomatic	O	O
microscopic	O	O
haematuria	B-Disease	D006417
and	O	O
no	O	O
episodes	O	O
of	O	O
gross	O	O
haematuria	B-Disease	D006417
.	O	O

In	O	O
this	O	O
group	O	O
of	O	O
45	O	O
patients	O	O
under	O	O
protection	O	O
with	O	O
MESNA	B-Chemical	D015080
there	O	O
were	O	O
5	O	O
complete	O	O
remissions	O	O
and	O	O
9	O	O
partial	O	O
remissions	O	O
(	O	O
total	O	O
31%	O	O
)	O	O
.	O	O

A	O	O
further	O	O
group	O	O
of	O	O
25	O	O
patients	O	O
under	O	O
polychemotherapy	O	O
with	O	O
IF	B-Chemical	D007069
were	O	O
treated	O	O
by	O	O
conventional	O	O
prophylactic	O	O
measures	O	O
(	O	O
raised	O	O
fluid	O	O
intake	O	O
and	O	O
forced	O	O
diuresis	O	O
)	O	O
.	O	O

In	O	O
this	O	O
group	O	O
there	O	O
were	O	O
1	O	O
complete	O	O
and	O	O
5	O	O
partial	O	O
remissions	O	O
(	O	O
total	O	O
24%	O	O
)	O	O
,	O	O
but	O	O
nearly	O	O
all	O	O
patients	O	O
developed	O	O
either	O	O
gross	O	O
haematuria	B-Disease	D006417
and	O	O
/	O	O
or	O	O
symptoms	O	O
of	O	O
bladder	B-Disease	D001745
irritation	I-Disease	D001745
(	O	O
cystitis	B-Disease	D003556
and	O	O
pollakisuria	B-Disease	D014555
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
appreciable	O	O
differences	O	O
between	O	O
the	O	O
MESNA	B-Chemical	D015080
series	O	O
and	O	O
the	O	O
conventional	O	O
prophylaxis	O	O
series	O	O
with	O	O
respect	O	O
to	O	O
either	O	O
haematological	O	O
or	O	O
systemic	O	O
toxicity	B-Disease	D064420
of	O	O
the	O	O
cytostatic	O	O
treatment	O	O
.	O	O

Our	O	O
results	O	O
support	O	O
the	O	O
view	O	O
that	O	O
MESNA	B-Chemical	D015080
,	O	O
given	O	O
orally	O	O
in	O	O
conjunction	O	O
with	O	O
combined	O	O
cytostatic	O	O
regimens	O	O
which	O	O
include	O	O
IF	B-Chemical	D007069
,	O	O
simplifies	O	O
the	O	O
treatment	O	O
and	O	O
provides	O	O
optimum	O	O
protection	O	O
for	O	O
the	O	O
urinary	O	O
epithelium	O	O
.	O	O

Protection	O	O
with	O	O
oral	O	O
MESNA	B-Chemical	D015080
is	O	O
particularly	O	O
suitable	O	O
for	O	O
outpatients	O	O
.	O	O

Time	O	O
course	O	O
alterations	O	O
of	O	O
QTC	O	O
interval	O	O
due	O	O
to	O	O
hypaque	B-Chemical	C027278
76	I-Chemical	C027278
.	O	O

Sequential	O	O
measurement	O	O
of	O	O
QT	O	O
interval	O	O
during	O	O
left	O	O
ventricular	O	O
angiography	O	O
was	O	O
made	O	O
30	O	O
seconds	O	O
and	O	O
one	O	O
,	O	O
three	O	O
,	O	O
five	O	O
and	O	O
ten	O	O
minutes	O	O
after	O	O
injection	O	O
of	O	O
hypaque	B-Chemical	C027278
76	I-Chemical	C027278
.	O	O

The	O	O
subjects	O	O
were	O	O
ten	O	O
patients	O	O
found	O	O
to	O	O
have	O	O
normal	O	O
left	O	O
ventricles	O	O
and	O	O
coronary	O	O
arteries	O	O
.	O	O

Significant	O	O
QTC	B-Disease	D008133
prolongation	I-Disease	D008133
occurred	O	O
in	O	O
30	O	O
seconds	O	O
to	O	O
one	O	O
minute	O	O
in	O	O
association	O	O
with	O	O
marked	O	O
hypotension	B-Disease	D007022
and	O	O
elevation	O	O
of	O	O
cardiac	O	O
output	O	O
.	O	O

Production	O	O
of	O	O
autochthonous	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
in	O	O
Lobund	O	O
-	O	O
Wistar	O	O
rats	O	O
by	O	O
treatments	O	O
with	O	O
N	B-Chemical	D008770
-	I-Chemical	D008770
nitroso	I-Chemical	D008770
-	I-Chemical	D008770
N	I-Chemical	D008770
-	I-Chemical	D008770
methylurea	I-Chemical	D008770
and	O	O
testosterone	B-Chemical	D013739
.	O	O

More	O	O
than	O	O
50%	O	O
of	O	O
Lobund	O	O
-	O	O
Wistar	O	O
(	O	O
L	O	O
-	O	O
W	O	O
)	O	O
strain	O	O
rats	O	O
developed	O	O
large	O	O
,	O	O
palpable	O	O
prostate	B-Disease	D011471
adenocarcinomas	I-Disease	D011471
(	O	O
PAs	B-Disease	D011471
)	O	O
following	O	O
treatments	O	O
with	O	O
N	B-Chemical	D008770
-	I-Chemical	D008770
nitroso	I-Chemical	D008770
-	I-Chemical	D008770
N	I-Chemical	D008770
-	I-Chemical	D008770
methylurea	I-Chemical	D008770
(	O	O
CAS	O	O
:	O	O
684	O	O
-	O	O
93	O	O
-	O	O
5	O	O
)	O	O
and	O	O
testosterone	B-Chemical	D013739
propionate	O	O
[	O	O
(	O	O
TP	B-Chemical	D043343
)	O	O
CAS	O	O
:	O	O
57	O	O
-	O	O
85	O	O
-	O	O
2	O	O
]	O	O
,	O	O
and	O	O
most	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
-	O	O
bearing	O	O
rats	O	O
manifested	O	O
metastatic	O	O
lesions	O	O
.	O	O

The	O	O
incubation	O	O
periods	O	O
averaged	O	O
10	O	O
.	O	O

6	O	O
months	O	O
.	O	O

Within	O	O
the	O	O
same	O	O
timeframe	O	O
,	O	O
no	O	O
L	O	O
-	O	O
W	O	O
rat	O	O
developed	O	O
a	O	O
similar	O	O
palpable	O	O
PA	B-Disease	D011471
when	O	O
treated	O	O
only	O	O
with	O	O
TP	B-Chemical	D043343
.	O	O

In	O	O
L	O	O
-	O	O
W	O	O
rats	O	O
,	O	O
TP	B-Chemical	D043343
acted	O	O
as	O	O
a	O	O
tumor	B-Disease	D009369
enhancement	O	O
agent	O	O
,	O	O
with	O	O
primary	O	O
emphasis	O	O
on	O	O
the	O	O
development	O	O
of	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

A	O	O
dystonia	B-Disease	D004421
-	O	O
like	O	O
syndrome	O	O
after	O	O
neuropeptide	O	O
(	O	O
MSH	B-Chemical	D009074
/	O	O
ACTH	B-Chemical	D000324
)	O	O
stimulation	O	O
of	O	O
the	O	O
rat	O	O
locus	O	O
ceruleus	O	O
.	O	O

The	O	O
movement	B-Disease	D009069
disorder	I-Disease	D009069
investigated	O	O
in	O	O
these	O	O
studies	O	O
has	O	O
some	O	O
features	O	O
in	O	O
common	O	O
with	O	O
human	O	O
idiopathic	O	O
dystonia	B-Disease	D004421
,	O	O
and	O	O
information	O	O
obtained	O	O
in	O	O
these	O	O
studies	O	O
may	O	O
be	O	O
of	O	O
potential	O	O
clinical	O	O
benefit	O	O
.	O	O

The	O	O
present	O	O
experimental	O	O
results	O	O
indicated	O	O
that	O	O
peptidergic	O	O
stimulation	O	O
of	O	O
the	O	O
LC	O	O
resulted	O	O
in	O	O
a	O	O
NE	O	O
-	O	O
mediated	O	O
inhibition	O	O
of	O	O
cerebellar	O	O
Purkinje	O	O
cells	O	O
located	O	O
at	O	O
terminals	O	O
of	O	O
the	O	O
ceruleo	O	O
-	O	O
cerebellar	O	O
pathway	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
certain	O	O
as	O	O
to	O	O
the	O	O
following	O	O
:	O	O
(	O	O
a	O	O
)	O	O
what	O	O
receptors	O	O
were	O	O
stimulated	O	O
by	O	O
the	O	O
ACTH	B-Chemical	D000324
N	O	O
-	O	O
terminal	O	O
fragments	O	O
at	O	O
the	O	O
LC	O	O
that	O	O
resulted	O	O
in	O	O
this	O	O
disorder	O	O
;	O	O
(	O	O
b	O	O
)	O	O
whether	O	O
NE	O	O
,	O	O
released	O	O
onto	O	O
Purkinje	O	O
cell	O	O
synapses	O	O
located	O	O
at	O	O
terminals	O	O
of	O	O
the	O	O
ceruleo	O	O
-	O	O
cerebellar	O	O
pathway	O	O
,	O	O
did	O	O
indeed	O	O
cause	O	O
the	O	O
long	O	O
-	O	O
term	O	O
depression	B-Disease	D003866
at	O	O
Purkinje	O	O
cell	O	O
synapses	O	O
(	O	O
previously	O	O
described	O	O
by	O	O
others	O	O
)	O	O
that	O	O
resulted	O	O
in	O	O
the	O	O
long	O	O
duration	O	O
of	O	O
the	O	O
movement	B-Disease	D009069
disorder	I-Disease	D009069
;	O	O
(	O	O
c	O	O
)	O	O
whether	O	O
the	O	O
inhibition	O	O
of	O	O
inhibitory	O	O
Purkinje	O	O
cells	O	O
resulted	O	O
in	O	O
disinhibition	O	O
or	O	O
increased	O	O
excitability	O	O
of	O	O
the	O	O
unilateral	O	O
cerebellar	O	O
fastigial	O	O
or	O	O
interpositus	O	O
nuclei	O	O
,	O	O
the	O	O
output	O	O
targets	O	O
of	O	O
the	O	O
Purkinje	O	O
cell	O	O
axons	O	O
,	O	O
that	O	O
may	O	O
have	O	O
been	O	O
an	O	O
important	O	O
contributing	O	O
factor	O	O
to	O	O
this	O	O
disorder	O	O
.	O	O

These	O	O
questions	O	O
are	O	O
currently	O	O
being	O	O
investigated	O	O
.	O	O

Dexmedetomidine	B-Chemical	D020927
,	O	O
acting	O	O
through	O	O
central	O	O
alpha	O	O
-	O	O
2	O	O
adrenoceptors	O	O
,	O	O
prevents	O	O
opiate	O	O
-	O	O
induced	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
in	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
highly	O	O
-	O	O
selective	O	O
alpha	O	O
-	O	O
2	O	O
adrenergic	O	O
agonist	O	O
dexmedetomidine	B-Chemical	D020927
(	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
)	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
muscle	B-Disease	D009123
flaccidity	I-Disease	D009123
and	O	O
anesthesia	O	O
in	O	O
rats	O	O
and	O	O
dogs	O	O
.	O	O

Intense	O	O
generalized	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
is	O	O
an	O	O
undesirable	O	O
side	O	O
effect	O	O
of	O	O
potent	O	O
opiate	O	O
agonists	O	O
.	O	O

Although	O	O
the	O	O
neurochemistry	O	O
of	O	O
opiate	O	O
-	O	O
induced	O	O
rigidity	B-Disease	D009127
has	O	O
yet	O	O
to	O	O
be	O	O
fully	O	O
elucidated	O	O
,	O	O
recent	O	O
work	O	O
suggests	O	O
a	O	O
role	O	O
for	O	O
a	O	O
central	O	O
adrenergic	O	O
mechanism	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
authors	O	O
determined	O	O
if	O	O
treatment	O	O
with	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
prevents	O	O
the	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
caused	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
alfentanil	B-Chemical	D015760
anesthesia	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Animals	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
were	O	O
treated	O	O
intraperitoneally	O	O
with	O	O
one	O	O
of	O	O
the	O	O
following	O	O
six	O	O
regimens	O	O
:	O	O
1	O	O
)	O	O
L	O	O
-	O	O
MED	O	O
(	O	O
the	O	O
inactive	O	O
L	O	O
-	O	O
isomer	O	O
of	O	O
medetomidine	B-Chemical	D020926
)	O	O
,	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
;	O	O
2	O	O
)	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
,	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
;	O	O
3	O	O
)	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
,	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
;	O	O
4	O	O
)	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
[	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
]	O	O
and	O	O
the	O	O
central	O	O
-	O	O
acting	O	O
alpha	O	O
-	O	O
2	O	O
antagonist	O	O
,	O	O
idazoxan	B-Chemical	D019329
[	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
]	O	O
;	O	O
5	O	O
)	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
[	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
]	O	O
and	O	O
the	O	O
peripheral	O	O
-	O	O
acting	O	O
alpha	O	O
-	O	O
2	O	O
antagonist	O	O
DG	B-Chemical	C032368
-	I-Chemical	C032368
5128	I-Chemical	C032368
[	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
]	O	O
,	O	O
or	O	O
;	O	O
6	O	O
)	O	O
saline	O	O
.	O	O

Baseline	O	O
electromyographic	O	O
activity	O	O
was	O	O
recorded	O	O
from	O	O
the	O	O
gastrocnemius	O	O
muscle	O	O
before	O	O
and	O	O
after	O	O
drug	O	O
treatment	O	O
.	O	O

Each	O	O
rat	O	O
was	O	O
then	O	O
injected	O	O
with	O	O
alfentanil	B-Chemical	D015760
(	O	O
ALF	B-Chemical	D015760
,	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
.	O	O

ALF	B-Chemical	D015760
injection	O	O
resulted	O	O
in	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
hindlimb	O	O
EMG	O	O
activity	O	O
in	O	O
the	O	O
L	O	O
-	O	O
MED	O	O
treatment	O	O
group	O	O
which	O	O
was	O	O
indistinguishable	O	O
from	O	O
that	O	O
seen	O	O
in	O	O
animals	O	O
treated	O	O
with	O	O
saline	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
prevented	O	O
alfentanil	B-Chemical	D015760
-	O	O
induced	O	O
muscle	B-Disease	D009127
rigidity	I-Disease	D009127
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
fashion	O	O
.	O	O

The	O	O
small	O	O
EMG	O	O
values	O	O
obtained	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
group	O	O
were	O	O
comparable	O	O
with	O	O
those	O	O
recorded	O	O
in	O	O
earlier	O	O
studies	O	O
from	O	O
control	O	O
animals	O	O
not	O	O
given	O	O
any	O	O
opiate	O	O
.	O	O

The	O	O
high	O	O
-	O	O
dose	O	O
D	B-Chemical	D020927
-	I-Chemical	D020927
MED	I-Chemical	D020927
animals	O	O
were	O	O
flaccid	O	O
,	O	O
akinetic	B-Disease	D018476
,	O	O
and	O	O
lacked	O	O
a	O	O
startle	B-Disease	D012021
response	O	O
during	O	O
the	O	O
entire	O	O
experimental	O	O
period	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Seizure	B-Disease	D012640
activity	O	O
with	O	O
imipenem	B-Chemical	D015378
therapy	O	O
:	O	O
incidence	O	O
and	O	O
risk	O	O
factors	O	O
.	O	O

Two	O	O
elderly	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
either	O	O
cerebral	B-Disease	D020521
vascular	I-Disease	D020521
accident	I-Disease	D020521
(	O	O
CVA	B-Disease	D020521
)	O	O
or	O	O
head	B-Disease	D006259
trauma	I-Disease	D006259
and	O	O
no	O	O
evidence	O	O
of	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
developed	O	O
seizures	B-Disease	D012640
while	O	O
receiving	O	O
maximum	O	O
doses	O	O
of	O	O
imipenem	B-Chemical	D015378
/	O	O
cilastatin	O	O
.	O	O

Neither	O	O
patient	O	O
had	O	O
reported	O	O
previous	O	O
seizures	B-Disease	D012640
or	O	O
seizure	B-Disease	D012640
-	O	O
like	O	O
activity	O	O
nor	O	O
was	O	O
receiving	O	O
anticonvulsant	O	O
agents	O	O
.	O	O

All	O	O
seizures	B-Disease	D012640
were	O	O
controlled	O	O
with	O	O
therapeutic	O	O
doses	O	O
of	O	O
phenytoin	B-Chemical	D010672
.	O	O

Both	O	O
patients	O	O
had	O	O
received	O	O
maximum	O	O
doses	O	O
of	O	O
other	O	O
beta	B-Chemical	D047090
-	I-Chemical	D047090
lactam	I-Chemical	D047090
antibiotics	O	O
without	O	O
evidence	O	O
of	O	O
seizure	B-Disease	D012640
activity	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
insulin	O	O
treatment	O	O
to	O	O
reverse	O	O
or	O	O
prevent	O	O
the	O	O
changes	O	O
in	O	O
urinary	O	O
bladder	O	O
function	O	O
caused	O	O
by	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
.	O	O

1	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
insulin	O	O
treatment	O	O
on	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
urinary	O	O
bladder	O	O
function	O	O
in	O	O
streptozotocin	B-Chemical	D013311
-	O	O
diabetic	B-Disease	D003920
rats	O	O
were	O	O
investigated	O	O
.	O	O

2	O	O
.	O	O

Diabetes	B-Disease	D003920
of	O	O
2	O	O
months	O	O
duration	O	O
resulted	O	O
in	O	O
decreases	O	O
in	O	O
body	O	O
weight	O	O
and	O	O
increases	O	O
in	O	O
fluid	O	O
consumption	O	O
,	O	O
urine	O	O
volume	O	O
,	O	O
frequency	O	O
of	O	O
micturition	O	O
,	O	O
and	O	O
average	O	O
volume	O	O
per	O	O
micturition	O	O
;	O	O
effects	O	O
which	O	O
were	O	O
prevented	O	O
by	O	O
insulin	O	O
treatment	O	O
.	O	O

3	O	O
.	O	O

Insulin	O	O
treatment	O	O
also	O	O
prevented	O	O
the	O	O
increases	O	O
in	O	O
contractile	O	O
responses	O	O
of	O	O
bladder	O	O
body	O	O
strips	O	O
from	O	O
diabetic	B-Disease	D003920
rats	O	O
to	O	O
nerve	O	O
stimulation	O	O
,	O	O
ATP	B-Chemical	D000255
,	O	O
and	O	O
bethanechol	B-Chemical	D018723
.	O	O

4	O	O
.	O	O

Diabetes	B-Disease	D003920
of	O	O
4	O	O
months	O	O
duration	O	O
also	O	O
resulted	O	O
in	O	O
decreases	O	O
in	O	O
body	O	O
weight	O	O
,	O	O
and	O	O
increases	O	O
in	O	O
fluid	O	O
consumption	O	O
,	O	O
urine	O	O
volume	O	O
,	O	O
frequency	O	O
of	O	O
micturition	O	O
,	O	O
and	O	O
average	O	O
volume	O	O
per	O	O
micturition	O	O
,	O	O
effects	O	O
which	O	O
were	O	O
reversed	O	O
by	O	O
insulin	O	O
treatment	O	O
for	O	O
the	O	O
final	O	O
2	O	O
months	O	O
of	O	O
the	O	O
study	O	O
.	O	O

5	O	O
.	O	O

Insulin	O	O
treatment	O	O
reversed	O	O
the	O	O
increases	O	O
in	O	O
contractile	O	O
responses	O	O
of	O	O
bladder	O	O
body	O	O
strips	O	O
from	O	O
diabetic	B-Disease	D003920
rats	O	O
to	O	O
nerve	O	O
stimulation	O	O
,	O	O
ATP	B-Chemical	D000255
,	O	O
and	O	O
bethanechol	B-Chemical	D018723
.	O	O

6	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetes	B-Disease	D003920
on	O	O
urinary	O	O
bladder	O	O
function	O	O
are	O	O
both	O	O
prevented	O	O
and	O	O
reversed	O	O
by	O	O
insulin	O	O
treatment	O	O
.	O	O

Delayed	O	O
institution	O	O
of	O	O
hypertension	B-Disease	D006973
during	O	O
focal	O	O
cerebral	B-Disease	D002545
ischemia	I-Disease	D002545
:	O	O
effect	O	O
on	O	O
brain	B-Disease	D001929
edema	I-Disease	D001929
.	O	O

The	O	O
effect	O	O
of	O	O
induced	O	O
hypertension	B-Disease	D006973
instituted	O	O
after	O	O
a	O	O
2	O	O
-	O	O
h	O	O
delay	O	O
following	O	O
middle	B-Disease	D020244
cerebral	I-Disease	D020244
artery	I-Disease	D020244
occlusion	I-Disease	D020244
(	O	O
MCAO	B-Disease	D020244
)	O	O
on	O	O
brain	B-Disease	D001929
edema	I-Disease	D001929
formation	O	O
and	O	O
histochemical	O	O
injury	O	O
was	O	O
studied	O	O
.	O	O

Under	O	O
isoflurane	B-Chemical	D007530
anesthesia	O	O
,	O	O
the	O	O
MCA	O	O
of	O	O
14	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
was	O	O
occluded	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
was	O	O
not	O	O
manipulated	O	O
.	O	O

In	O	O
the	O	O
hypertensive	B-Disease	D006973
group	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
the	O	O
MAP	O	O
was	O	O
elevated	O	O
by	O	O
25	O	O
-	O	O
30	O	O
mm	O	O
Hg	O	O
beginning	O	O
2	O	O
h	O	O
after	O	O
MCAO	B-Disease	D020244
.	O	O

Four	O	O
hours	O	O
after	O	O
MCAO	B-Disease	D020244
,	O	O
the	O	O
rats	O	O
were	O	O
killed	O	O
and	O	O
the	O	O
brains	O	O
harvested	O	O
.	O	O

The	O	O
brains	O	O
were	O	O
sectioned	O	O
along	O	O
coronal	O	O
planes	O	O
spanning	O	O
the	O	O
distribution	O	O
of	O	O
ischemia	B-Disease	D007511
produced	O	O
by	O	O
MCAO	B-Disease	D020244
.	O	O

Specific	O	O
gravity	O	O
(	O	O
SG	O	O
)	O	O
was	O	O
determined	O	O
in	O	O
the	O	O
subcortex	O	O
and	O	O
in	O	O
two	O	O
sites	O	O
in	O	O
the	O	O
cortex	O	O
(	O	O
core	O	O
and	O	O
periphery	O	O
of	O	O
the	O	O
ischemic	B-Disease	D007511
territory	O	O
)	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
neuronal	B-Disease	D009410
injury	I-Disease	D009410
was	O	O
determined	O	O
by	O	O
2	B-Chemical	C009591
,	I-Chemical	C009591
3	I-Chemical	C009591
,	I-Chemical	C009591
5	I-Chemical	C009591
-	I-Chemical	C009591
triphenyltetrazolium	I-Chemical	C009591
staining	O	O
.	O	O

In	O	O
the	O	O
ischemic	B-Disease	D007511
core	O	O
,	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
SG	O	O
in	O	O
the	O	O
subcortex	O	O
and	O	O
cortex	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

In	O	O
the	O	O
periphery	O	O
of	O	O
the	O	O
ischemic	B-Disease	D007511
territory	O	O
,	O	O
SG	O	O
in	O	O
the	O	O
cortex	O	O
was	O	O
greater	O	O
(	O	O
less	O	O
edema	B-Disease	D004487
accumulation	O	O
)	O	O
in	O	O
the	O	O
hypertensive	B-Disease	D006973
group	O	O
(	O	O
1	O	O
.	O	O

041	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

001	O	O
vs	O	O
1	O	O
.	O	O

039	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

001	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
area	O	O
of	O	O
histochemical	O	O
injury	O	O
(	O	O
as	O	O
a	O	O
percent	O	O
of	O	O
the	O	O
cross	O	O
-	O	O
sectional	O	O
area	O	O
of	O	O
the	O	O
hemisphere	O	O
)	O	O
was	O	O
less	O	O
in	O	O
the	O	O
hypertensive	B-Disease	D006973
group	O	O
(	O	O
33	O	O
+	O	O
/	O	O
-	O	O
3%	O	O
vs	O	O
21	O	O
+	O	O
/	O	O
-	O	O
2%	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
phenylephrine	B-Chemical	D010656
-	O	O
induced	O	O
hypertension	B-Disease	D006973
instituted	O	O
2	O	O
h	O	O
after	O	O
MCAO	B-Disease	D020244
does	O	O
not	O	O
aggravate	O	O
edema	B-Disease	D004487
in	O	O
the	O	O
ischemic	B-Disease	D007511
core	O	O
,	O	O
that	O	O
it	O	O
improves	O	O
edema	B-Disease	D004487
in	O	O
the	O	O
periphery	O	O
of	O	O
the	O	O
ischemic	B-Disease	D007511
territory	O	O
,	O	O
and	O	O
that	O	O
it	O	O
reduces	O	O
the	O	O
area	O	O
of	O	O
histochemical	O	O
neuronal	B-Disease	D009410
dysfunction	I-Disease	D009410
.	O	O

Amiodarone	B-Chemical	D000638
pulmonary	B-Disease	D008171
toxicity	I-Disease	D008171
.	O	O

Amiodarone	B-Chemical	D000638
is	O	O
an	O	O
effective	O	O
antiarrhythmic	O	O
agent	O	O
whose	O	O
utility	O	O
is	O	O
limited	O	O
by	O	O
many	O	O
side	O	O
-	O	O
effects	O	O
,	O	O
the	O	O
most	O	O
problematic	O	O
being	O	O
pneumonitis	B-Disease	D011014
.	O	O

The	O	O
pulmonary	B-Disease	D008171
toxicity	I-Disease	D008171
of	O	O
amiodarone	B-Chemical	D000638
is	O	O
thought	O	O
to	O	O
result	O	O
from	O	O
direct	O	O
injury	O	O
related	O	O
to	O	O
the	O	O
intracellular	O	O
accumulation	O	O
of	O	O
phospholipid	O	O
and	O	O
T	O	O
cell	O	O
-	O	O
mediated	O	O
hypersensitivity	O	O
pneumonitis	B-Disease	D011014
.	O	O

The	O	O
clinical	O	O
and	O	O
radiographic	O	O
features	O	O
of	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
pulmonary	B-Disease	D008171
toxicity	I-Disease	D008171
are	O	O
characteristic	O	O
but	O	O
nonspecific	O	O
.	O	O

The	O	O
diagnosis	O	O
depends	O	O
on	O	O
exclusion	O	O
of	O	O
other	O	O
entities	O	O
,	O	O
such	O	O
as	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
infection	B-Disease	D007239
,	O	O
and	O	O
malignancy	B-Disease	D009369
.	O	O

While	O	O
withdrawal	O	O
of	O	O
amiodarone	B-Chemical	D000638
leads	O	O
to	O	O
clinical	O	O
improvement	O	O
in	O	O
majority	O	O
of	O	O
cases	O	O
,	O	O
this	O	O
is	O	O
not	O	O
always	O	O
possible	O	O
or	O	O
advisable	O	O
.	O	O

Dose	O	O
reduction	O	O
or	O	O
concomitant	O	O
steroid	B-Chemical	D013256
therapy	O	O
may	O	O
have	O	O
a	O	O
role	O	O
in	O	O
selected	O	O
patients	O	O
.	O	O

Light	O	O
chain	O	O
proteinuria	B-Disease	D011507
and	O	O
cellular	O	O
mediated	O	O
immunity	O	O
in	O	O
rifampin	B-Chemical	D012293
treated	O	O
patients	O	O
with	O	O
tuberculosis	B-Disease	D014376
.	O	O

Light	O	O
chain	O	O
proteinuria	B-Disease	D011507
was	O	O
found	O	O
in	O	O
9	O	O
of	O	O
17	O	O
tuberculosis	B-Disease	D014376
patients	O	O
treated	O	O
with	O	O
rifampin	B-Chemical	D012293
.	O	O

Concomitant	O	O
assay	O	O
of	O	O
cellular	O	O
mediated	O	O
immunity	O	O
in	O	O
these	O	O
patients	O	O
using	O	O
skin	O	O
test	O	O
antigen	O	O
and	O	O
a	O	O
lymphokine	O	O
in	O	O
vitro	O	O
test	O	O
provided	O	O
results	O	O
that	O	O
were	O	O
different	O	O
.	O	O

Response	O	O
to	O	O
Varidase	O	O
skin	O	O
test	O	O
antigen	O	O
was	O	O
negative	O	O
for	O	O
all	O	O
eight	O	O
tuberculosis	B-Disease	D014376
patients	O	O
tested	O	O
,	O	O
but	O	O
there	O	O
occurred	O	O
a	O	O
hyper	O	O
-	O	O
responsiveness	O	O
of	O	O
the	O	O
lymphocytes	O	O
of	O	O
these	O	O
eight	O	O
patients	O	O
to	O	O
phytomitogen	O	O
(	O	O
PHA	O	O
-	O	O
P	O	O
)	O	O
.	O	O

as	O	O
well	O	O
as	O	O
of	O	O
those	O	O
of	O	O
seven	O	O
other	O	O
tuberculous	B-Disease	D014376
patients	O	O
.	O	O

This	O	O
last	O	O
finding	O	O
may	O	O
be	O	O
related	O	O
to	O	O
time	O	O
of	O	O
testing	O	O
and	O	O
/	O	O
or	O	O
endogenous	O	O
serum	O	O
binding	O	O
of	O	O
rifampin	B-Chemical	D012293
which	O	O
could	O	O
have	O	O
inhibited	O	O
mitogen	O	O
activity	O	O
for	O	O
the	O	O
lymphocyte	O	O
.	O	O

Initial	O	O
potassium	B-Chemical	D011188
loss	O	O
and	O	O
hypokalaemia	B-Disease	D007008
during	O	O
chlorthalidone	B-Chemical	D002752
administration	O	O
in	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	B-Disease	D006973
:	O	O
the	O	O
influence	O	O
of	O	O
dietary	O	O
sodium	B-Chemical	D012964
restriction	O	O
.	O	O

To	O	O
investigate	O	O
the	O	O
initial	O	O
potassium	B-Chemical	D011188
loss	O	O
and	O	O
development	O	O
of	O	O
hypokalaemia	B-Disease	D007008
during	O	O
the	O	O
administration	O	O
of	O	O
an	O	O
oral	O	O
diuretic	O	O
,	O	O
metabolic	O	O
balance	O	O
studies	O	O
were	O	O
performed	O	O
in	O	O
ten	O	O
patients	O	O
with	O	O
essential	O	O
hypertension	B-Disease	D006973
who	O	O
had	O	O
shown	O	O
hypokalaemia	B-Disease	D007008
under	O	O
prior	O	O
oral	O	O
diuretic	O	O
treatment	O	O
.	O	O

Chlorthalidone	B-Chemical	D002752
(	O	O
50	O	O
mg	O	O
daily	O	O
)	O	O
was	O	O
given	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Six	O	O
patients	O	O
received	O	O
a	O	O
normal	O	O
-	O	O
sodium	B-Chemical	D012964
diet	O	O
and	O	O
four	O	O
a	O	O
low	O	O
-	O	O
sodium	B-Chemical	D012964
(	O	O
17	O	O
mmol	O	O
/	O	O
day	O	O
)	O	O
diet	O	O
.	O	O

All	O	O
patients	O	O
had	O	O
a	O	O
normal	O	O
initial	O	O
total	O	O
body	O	O
potassium	B-Chemical	D011188
(	O	O
40K	O	O
)	O	O
.	O	O

The	O	O
electrolyte	O	O
balances	O	O
,	O	O
weight	O	O
,	O	O
bromide	O	O
space	O	O
,	O	O
plasma	O	O
renin	O	O
activity	O	O
,	O	O
and	O	O
aldosterone	B-Chemical	D000450
secretion	O	O
rate	O	O
were	O	O
measured	O	O
.	O	O

In	O	O
both	O	O
groups	O	O
a	O	O
potassium	B-Chemical	D011188
deficit	O	O
developed	O	O
,	O	O
with	O	O
proportionally	O	O
larger	O	O
losses	O	O
from	O	O
the	O	O
extracellular	O	O
than	O	O
from	O	O
the	O	O
intracellular	O	O
compartment	O	O
.	O	O

In	O	O
the	O	O
normal	O	O
-	O	O
sodium	B-Chemical	D012964
group	O	O
the	O	O
highest	O	O
mean	O	O
potassium	B-Chemical	D011188
deficit	O	O
was	O	O
176	O	O
mmol	O	O
on	O	O
day	O	O
9	O	O
,	O	O
after	O	O
which	O	O
some	O	O
potassium	B-Chemical	D011188
was	O	O
regained	O	O
;	O	O
in	O	O
the	O	O
low	O	O
-	O	O
sodium	B-Chemical	D012964
group	O	O
the	O	O
highest	O	O
deficit	O	O
was	O	O
276	O	O
mmol	O	O
on	O	O
day	O	O
13	O	O
.	O	O

The	O	O
normal	O	O
-	O	O
sodium	B-Chemical	D012964
group	O	O
showed	O	O
an	O	O
immediate	O	O
but	O	O
temporary	O	O
rise	O	O
of	O	O
the	O	O
renin	O	O
and	O	O
aldosterone	B-Chemical	D000450
levels	O	O
;	O	O
in	O	O
the	O	O
low	O	O
-	O	O
sodium	B-Chemical	D012964
group	O	O
renin	O	O
and	O	O
aldosterone	B-Chemical	D000450
increased	O	O
more	O	O
slowly	O	O
but	O	O
remained	O	O
elevated	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
dietary	O	O
sodium	B-Chemical	D012964
restriction	O	O
increases	O	O
diuretic	O	O
-	O	O
induced	O	O
potassium	B-Chemical	D011188
loss	O	O
,	O	O
presumably	O	O
by	O	O
an	O	O
increased	O	O
activity	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
-	O	O
aldosterone	B-Chemical	D000450
system	O	O
,	O	O
while	O	O
sodium	B-Chemical	D012964
delivery	O	O
to	O	O
the	O	O
distal	O	O
renal	O	O
tubules	O	O
remains	O	O
sufficiently	O	O
high	O	O
to	O	O
allow	O	O
increased	O	O
potassium	B-Chemical	D011188
secretion	O	O
.	O	O

Dynamic	O	O
response	O	O
of	O	O
blood	O	O
vessel	O	O
in	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
postulated	O	O
that	O	O
during	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
the	O	O
transient	O	O
or	O	O
dynamic	O	O
response	O	O
of	O	O
blood	O	O
vessels	O	O
could	O	O
be	O	O
affected	O	O
,	O	O
and	O	O
that	O	O
antioxidants	O	O
can	O	O
prevent	O	O
the	O	O
changes	O	O
in	O	O
dynamic	O	O
responses	O	O
of	O	O
blood	O	O
vessels	O	O
.	O	O

The	O	O
new	O	O
approach	O	O
to	O	O
ex	O	O
vivo	O	O
blood	O	O
vessel	O	O
experiments	O	O
in	O	O
which	O	O
not	O	O
only	O	O
the	O	O
end	O	O
points	O	O
of	O	O
vessels	O	O
response	O	O
within	O	O
the	O	O
time	O	O
interval	O	O
is	O	O
considered	O	O
,	O	O
but	O	O
also	O	O
dynamics	O	O
of	O	O
this	O	O
response	O	O
,	O	O
was	O	O
used	O	O
in	O	O
this	O	O
paper	O	O
.	O	O

Our	O	O
results	O	O
confirm	O	O
the	O	O
alteration	O	O
in	O	O
dynamic	O	O
response	O	O
of	O	O
blood	O	O
vessels	O	O
during	O	O
the	O	O
change	O	O
of	O	O
pressure	O	O
in	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
animals	O	O
.	O	O

The	O	O
beneficial	O	O
effects	O	O
of	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
administration	O	O
to	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
animals	O	O
are	O	O
also	O	O
confirmed	O	O
through	O	O
:	O	O
lower	O	O
level	O	O
of	O	O
blood	O	O
urea	B-Chemical	D014508
and	O	O
creatinine	B-Chemical	D003404
and	O	O
higher	O	O
level	O	O
of	O	O
potassium	B-Chemical	D011188
.	O	O

The	O	O
pressure	O	O
dynamic	O	O
responses	O	O
of	O	O
isolated	O	O
blood	O	O
vessels	O	O
show	O	O
a	O	O
faster	O	O
pressure	O	O
change	O	O
in	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
animals	O	O
(	O	O
8	O	O
.	O	O

07	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

7	O	O
s	O	O
vs	O	O
.	O	O

5	O	O
.	O	O

64	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

18	O	O
s	O	O
)	O	O
.	O	O

Vitamin	B-Chemical	D001205
C	I-Chemical	D001205
administration	O	O
induced	O	O
slowdown	O	O
of	O	O
pressure	O	O
change	O	O
back	O	O
to	O	O
the	O	O
control	O	O
values	O	O
.	O	O

The	O	O
pressure	O	O
dynamic	O	O
properties	O	O
,	O	O
quantitatively	O	O
defined	O	O
by	O	O
comparative	O	O
pressure	O	O
dynamic	O	O
and	O	O
total	O	O
pressure	O	O
dynamic	O	O
,	O	O
confirm	O	O
the	O	O
alteration	O	O
in	O	O
dynamic	O	O
response	O	O
of	O	O
blood	O	O
vessels	O	O
during	O	O
the	O	O
change	O	O
of	O	O
pressure	O	O
in	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
animals	O	O
and	O	O
beneficial	O	O
effects	O	O
of	O	O
vitamin	B-Chemical	D001205
C	I-Chemical	D001205
administration	O	O
.	O	O

The	O	O
hemodynamics	O	O
of	O	O
oxytocin	B-Chemical	D010121
and	O	O
other	O	O
vasoactive	O	O
agents	O	O
during	O	O
neuraxial	O	O
anesthesia	O	O
for	O	O
cesarean	O	O
delivery	O	O
:	O	O
findings	O	O
in	O	O
six	O	O
cases	O	O
.	O	O

Oxytocin	B-Chemical	D010121
is	O	O
a	O	O
commonly	O	O
used	O	O
uterotonic	O	O
that	O	O
can	O	O
cause	O	O
significant	O	O
and	O	O
even	O	O
fatal	O	O
hypotension	B-Disease	D007022
,	O	O
particularly	O	O
when	O	O
given	O	O
as	O	O
a	O	O
bolus	O	O
.	O	O

The	O	O
resulting	O	O
hypotension	B-Disease	D007022
can	O	O
be	O	O
produced	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
systemic	O	O
vascular	O	O
resistance	O	O
or	O	O
cardiac	O	O
output	O	O
through	O	O
a	O	O
decrease	O	O
in	O	O
venous	O	O
return	O	O
.	O	O

Parturients	O	O
with	O	O
normal	O	O
volume	O	O
status	O	O
,	O	O
heart	O	O
valves	O	O
and	O	O
pulmonary	O	O
vasculature	O	O
most	O	O
often	O	O
respond	O	O
to	O	O
this	O	O
hypotension	B-Disease	D007022
with	O	O
a	O	O
compensatory	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
and	O	O
stroke	B-Disease	D020521
volume	O	O
.	O	O

Oxytocin	B-Chemical	D010121
-	O	O
induced	O	O
hypotension	B-Disease	D007022
at	O	O
cesarean	O	O
delivery	O	O
may	O	O
be	O	O
incorrectly	O	O
attributed	O	O
to	O	O
blood	B-Disease	D006473
loss	I-Disease	D006473
.	O	O

Pulse	O	O
power	O	O
analysis	O	O
(	O	O
also	O	O
called	O	O
"pulse	O	O
contour	O	O
analysis"	O	O
)	O	O
of	O	O
an	O	O
arterial	O	O
pressure	O	O
wave	O	O
form	O	O
allows	O	O
continuous	O	O
evaluation	O	O
of	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
cardiac	O	O
output	O	O
in	O	O
real	O	O
time	O	O
,	O	O
thereby	O	O
elucidating	O	O
the	O	O
causative	O	O
factors	O	O
behind	O	O
changes	O	O
in	O	O
blood	O	O
pressure	O	O
.	O	O

Pulse	O	O
power	O	O
analysis	O	O
was	O	O
conducted	O	O
in	O	O
six	O	O
cases	O	O
of	O	O
cesarean	O	O
delivery	O	O
performed	O	O
under	O	O
neuraxial	O	O
anesthesia	O	O
.	O	O

Hypotension	B-Disease	D007022
in	O	O
response	O	O
to	O	O
oxytocin	B-Chemical	D010121
was	O	O
associated	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
a	O	O
compensatory	O	O
increase	O	O
in	O	O
stroke	B-Disease	D020521
volume	O	O
,	O	O
heart	O	O
rate	O	O
and	O	O
cardiac	O	O
output	O	O
.	O	O

Pulse	O	O
power	O	O
analysis	O	O
may	O	O
be	O	O
helpful	O	O
in	O	O
determining	O	O
the	O	O
etiology	O	O
of	O	O
and	O	O
treating	O	O
hypotension	B-Disease	D007022
during	O	O
cesarean	O	O
delivery	O	O
under	O	O
neuraxial	O	O
anesthesia	O	O
.	O	O

Exaggerated	O	O
expression	O	O
of	O	O
inflammatory	O	O
mediators	O	O
in	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
knockout	O	O
(	O	O
VIP	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYP	B-Chemical	D003520
)	O	O
-	O	O
induced	O	O
cystitis	B-Disease	D003556
.	O	O

Vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
is	O	O
an	O	O
immunomodulatory	O	O
neuropeptide	O	O
distributed	O	O
in	O	O
micturition	O	O
pathways	O	O
.	O	O

VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
exhibit	O	O
altered	O	O
bladder	O	O
function	O	O
and	O	O
neurochemical	O	O
properties	O	O
in	O	O
micturition	O	O
pathways	O	O
after	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYP	B-Chemical	D003520
)	O	O
-	O	O
induced	O	O
cystitis	B-Disease	D003556
.	O	O

Given	O	O
VIP's	O	O
role	O	O
as	O	O
an	O	O
anti	O	O
-	O	O
inflammatory	O	O
mediator	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
would	O	O
exhibit	O	O
enhanced	O	O
inflammatory	O	O
mediator	O	O
expression	O	O
after	O	O
cystitis	B-Disease	D003556
.	O	O

A	O	O
mouse	O	O
inflammatory	O	O
cytokine	O	O
and	O	O
receptor	O	O
RT2	O	O
profiler	O	O
array	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
regulated	O	O
transcripts	O	O
in	O	O
the	O	O
urinary	O	O
bladder	O	O
of	O	O
wild	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
and	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
with	O	O
or	O	O
without	O	O
CYP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
i	O	O
.	O	O

p	O	O
.	O	O

;	O	O
48	O	O
h	O	O
)	O	O
.	O	O

Four	O	O
binary	O	O
comparisons	O	O
were	O	O
made	O	O
:	O	O
WT	O	O
control	O	O
versus	O	O
CYP	B-Chemical	D003520
treatment	O	O
(	O	O
48	O	O
h	O	O
)	O	O
,	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
control	O	O
versus	O	O
CYP	B-Chemical	D003520
treatment	O	O
(	O	O
48	O	O
h	O	O
)	O	O
,	O	O
WT	O	O
control	O	O
versus	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
control	O	O
,	O	O
and	O	O
WT	O	O
with	O	O
CYP	B-Chemical	D003520
treatment	O	O
(	O	O
48	O	O
h	O	O
)	O	O
versus	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
with	O	O
CYP	B-Chemical	D003520
treatment	O	O
(	O	O
48	O	O
h	O	O
)	O	O
.	O	O

The	O	O
genes	O	O
presented	O	O
represent	O	O
(	O	O
1	O	O
)	O	O
greater	O	O
than	O	O
1	O	O
.	O	O

5	O	O
-	O	O
fold	O	O
change	O	O
in	O	O
either	O	O
direction	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
p	O	O
value	O	O
is	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
for	O	O
the	O	O
comparison	O	O
being	O	O
made	O	O
.	O	O

Several	O	O
regulated	O	O
genes	O	O
were	O	O
validated	O	O
using	O	O
enzyme	O	O
-	O	O
linked	O	O
immunoassays	O	O
including	O	O
IL	O	O
-	O	O
1beta	O	O
and	O	O
CXCL1	O	O
.	O	O

CYP	B-Chemical	D003520
treatment	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
increased	O	O
expression	O	O
of	O	O
CXCL1	O	O
and	O	O
IL	O	O
-	O	O
1beta	O	O
in	O	O
the	O	O
urinary	O	O
bladder	O	O
of	O	O
WT	O	O
and	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
,	O	O
but	O	O
expression	O	O
in	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
with	O	O
CYP	B-Chemical	D003520
treatment	O	O
was	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
greater	O	O
(	O	O
4	O	O
.	O	O

2	O	O
-	O	O
to	O	O
13	O	O
-	O	O
fold	O	O
increase	O	O
)	O	O
than	O	O
that	O	O
observed	O	O
in	O	O
WT	O	O
urinary	O	O
bladder	O	O
(	O	O
3	O	O
.	O	O

6	O	O
-	O	O
to	O	O
5	O	O
-	O	O
fold	O	O
increase	O	O
)	O	O
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
in	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
with	O	O
bladder	B-Disease	D001745
inflammation	I-Disease	D001745
,	O	O
inflammatory	O	O
mediators	O	O
are	O	O
increased	O	O
above	O	O
that	O	O
observed	O	O
in	O	O
WT	O	O
with	O	O
CYP	B-Chemical	D003520
.	O	O

This	O	O
shift	O	O
in	O	O
balance	O	O
may	O	O
contribute	O	O
to	O	O
increased	O	O
bladder	B-Disease	D001745
dysfunction	I-Disease	D001745
in	O	O
VIP	O	O
(	O	O
-	O	O
/	O	O
-	O	O
)	O	O
mice	O	O
with	O	O
bladder	B-Disease	D001745
inflammation	I-Disease	D001745
and	O	O
altered	O	O
neurochemical	O	O
expression	O	O
in	O	O
micturition	O	O
pathways	O	O
.	O	O

Intraocular	O	O
pressure	O	O
in	O	O
patients	O	O
with	O	O
uveitis	B-Disease	D014605
treated	O	O
with	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
implants	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
the	O	O
incidence	O	O
and	O	O
management	O	O
of	O	O
elevated	B-Disease	D009798
intraocular	I-Disease	D009798
pressure	I-Disease	D009798
(	O	O
IOP	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
uveitis	B-Disease	D014605
treated	O	O
with	O	O
the	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
(	O	O
FA	B-Chemical	D005446
)	O	O
intravitreal	O	O
implant	O	O
.	O	O

DESIGN	O	O
:	O	O
Pooled	O	O
data	O	O
from	O	O
3	O	O
multicenter	O	O
,	O	O
double	O	O
-	O	O
masked	O	O
,	O	O
randomized	O	O
,	O	O
controlled	O	O
,	O	O
phase	O	O
2b	O	O
/	O	O
3	O	O
clinical	O	O
trials	O	O
evaluating	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
the	O	O
0	O	O
.	O	O

59	O	O
-	O	O
mg	O	O
or	O	O
2	O	O
.	O	O

1	O	O
-	O	O
mg	O	O
FA	B-Chemical	D005446
intravitreal	O	O
implant	O	O
or	O	O
standard	O	O
therapy	O	O
were	O	O
analyzed	O	O
.	O	O

RESULTS	O	O
:	O	O
During	O	O
the	O	O
3	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
71	O	O
.	O	O

0%	O	O
of	O	O
implanted	O	O
eyes	O	O
had	O	O
an	O	O
IOP	O	O
increase	O	O
of	O	O
10	O	O
mm	O	O
Hg	O	O
or	O	O
more	O	O
than	O	O
baseline	O	O
and	O	O
55	O	O
.	O	O

1%	O	O
,	O	O
24	O	O
.	O	O

7%	O	O
,	O	O
and	O	O
6	O	O
.	O	O

2%	O	O
of	O	O
eyes	O	O
reached	O	O
an	O	O
IOP	O	O
of	O	O
30	O	O
mm	O	O
Hg	O	O
or	O	O
more	O	O
,	O	O
40	O	O
mm	O	O
Hg	O	O
or	O	O
more	O	O
,	O	O
and	O	O
50	O	O
mm	O	O
Hg	O	O
or	O	O
more	O	O
,	O	O
respectively	O	O
.	O	O

Topical	O	O
IOP	O	O
-	O	O
lowering	O	O
medication	O	O
was	O	O
administered	O	O
in	O	O
74	O	O
.	O	O

8%	O	O
of	O	O
implanted	O	O
eyes	O	O
,	O	O
and	O	O
IOP	O	O
-	O	O
lowering	O	O
surgeries	O	O
,	O	O
most	O	O
of	O	O
which	O	O
were	O	O
trabeculectomies	O	O
(	O	O
76	O	O
.	O	O

2%	O	O
)	O	O
,	O	O
were	O	O
performed	O	O
on	O	O
36	O	O
.	O	O

6%	O	O
of	O	O
implanted	O	O
eyes	O	O
.	O	O

Intraocular	O	O
pressure	O	O
-	O	O
lowering	O	O
surgeries	O	O
were	O	O
considered	O	O
a	O	O
success	O	O
(	O	O
postoperative	O	O
IOP	O	O
of	O	O
6	O	O
-	O	O
21	O	O
mm	O	O
Hg	O	O
with	O	O
or	O	O
without	O	O
additional	O	O
IOP	O	O
-	O	O
lowering	O	O
medication	O	O
)	O	O
in	O	O
85	O	O
.	O	O

1%	O	O
of	O	O
eyes	O	O
at	O	O
1	O	O
year	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
hypotony	B-Disease	D015814
(	O	O
IOP	O	O
<	O	O
/	O	O
=	O	O
5	O	O
mm	O	O
Hg	O	O
)	O	O
following	O	O
IOP	O	O
-	O	O
lowering	O	O
surgery	O	O
(	O	O
42	O	O
.	O	O

5%	O	O
)	O	O
was	O	O
not	O	O
different	O	O
from	O	O
that	O	O
of	O	O
implanted	O	O
eyes	O	O
not	O	O
subjected	O	O
to	O	O
surgery	O	O
(	O	O
35	O	O
.	O	O

4%	O	O
)	O	O
(	O	O
P	O	O
=	O	O
.	O	O

09	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Elevated	O	O
IOP	O	O
is	O	O
a	O	O
significant	O	O
complication	O	O
with	O	O
the	O	O
FA	B-Chemical	D005446
intravitreal	O	O
implant	O	O
but	O	O
may	O	O
be	O	O
controlled	O	O
with	O	O
medication	O	O
and	O	O
surgery	O	O
.	O	O

Pallidal	O	O
stimulation	O	O
:	O	O
an	O	O
alternative	O	O
to	O	O
pallidotomy?	O	O
A	O	O
resurgence	O	O
of	O	O
interest	O	O
in	O	O
the	O	O
surgical	O	O
treatment	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
came	O	O
with	O	O
the	O	O
rediscovery	O	O
of	O	O
posteroventral	O	O
pallidotomy	O	O
by	O	O
Laitinen	O	O
in	O	O
1985	O	O
.	O	O

Laitinen's	O	O
procedure	O	O
improved	O	O
most	O	O
symptoms	O	O
in	O	O
drug	O	O
-	O	O
resistant	O	O
PD	B-Disease	D010300
,	O	O
which	O	O
engendered	O	O
wide	O	O
interest	O	O
in	O	O
the	O	O
neurosurgical	O	O
community	O	O
.	O	O

Another	O	O
lesioning	O	O
procedure	O	O
,	O	O
ventrolateral	O	O
thalamotomy	O	O
,	O	O
has	O	O
become	O	O
a	O	O
powerful	O	O
alternative	O	O
to	O	O
stimulate	O	O
the	O	O
nucleus	O	O
ventralis	O	O
intermedius	O	O
,	O	O
producing	O	O
high	O	O
long	O	O
-	O	O
term	O	O
success	O	O
rates	O	O
and	O	O
low	O	O
morbidity	O	O
rates	O	O
.	O	O

Pallidal	O	O
stimulation	O	O
has	O	O
not	O	O
met	O	O
with	O	O
the	O	O
same	O	O
success	O	O
.	O	O

According	O	O
to	O	O
the	O	O
literature	O	O
pallidotomy	O	O
improves	O	O
the	O	O
"on"	O	O
symptoms	O	O
of	O	O
PD	B-Disease	D010300
,	O	O
such	O	O
as	O	O
dyskinesias	B-Disease	D004409
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
"off"	O	O
symptoms	O	O
,	O	O
such	O	O
as	O	O
rigidity	B-Disease	D009127
,	O	O
bradykinesia	B-Disease	D018476
,	O	O
and	O	O
on	O	O
-	O	O
off	O	O
fluctuations	O	O
.	O	O

Pallidal	O	O
stimulation	O	O
improves	O	O
bradykinesia	B-Disease	D018476
and	O	O
rigidity	B-Disease	D009127
to	O	O
a	O	O
minor	O	O
extent	O	O
;	O	O
however	O	O
,	O	O
its	O	O
strength	O	O
seems	O	O
to	O	O
be	O	O
in	O	O
improving	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

Stimulation	O	O
often	O	O
produces	O	O
an	O	O
improvement	O	O
in	O	O
the	O	O
hyper	B-Disease	D006948
-	I-Disease	D006948
or	I-Disease	D006948
dyskinetic	I-Disease	D006948
upper	O	O
limbs	O	O
,	O	O
but	O	O
increases	O	O
the	O	O
"freezing"	O	O
phenomenon	O	O
in	O	O
the	O	O
lower	O	O
limbs	O	O
at	O	O
the	O	O
same	O	O
time	O	O
.	O	O

Considering	O	O
the	O	O
small	O	O
increase	O	O
in	O	O
the	O	O
patient's	O	O
independence	O	O
,	O	O
the	O	O
high	O	O
costs	O	O
of	O	O
bilateral	O	O
implants	O	O
,	O	O
and	O	O
the	O	O
difficulty	O	O
most	O	O
patients	O	O
experience	O	O
in	O	O
handling	O	O
the	O	O
devices	O	O
,	O	O
the	O	O
question	O	O
arises	O	O
as	O	O
to	O	O
whether	O	O
bilateral	O	O
pallidal	O	O
stimulation	O	O
is	O	O
a	O	O
real	O	O
alternative	O	O
to	O	O
pallidotomy	O	O
.	O	O

Case	O	O
report	O	O
:	O	O
Dexatrim	B-Chemical	D010665
(	O	O
Phenylpropanolamine	B-Chemical	D010665
)	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Phenylpropanolamine	B-Chemical	D010665
(	O	O
PPA	B-Chemical	D010665
)	O	O
is	O	O
a	O	O
sympathetic	O	O
amine	B-Chemical	D000588
used	O	O
in	O	O
over	O	O
-	O	O
the	O	O
-	O	O
counter	O	O
cold	O	O
remedies	O	O
and	O	O
weight	O	O
-	O	O
control	O	O
preparations	O	O
worldwide	O	O
.	O	O

Its	O	O
use	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
hypertensive	B-Disease	D006973
episodes	O	O
and	O	O
hemorrhagic	O	O
strokes	O	O
in	O	O
younger	O	O
women	O	O
.	O	O

Several	O	O
reports	O	O
have	O	O
linked	O	O
the	O	O
abuse	O	O
of	O	O
PPA	B-Chemical	D010665
with	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
,	O	O
especially	O	O
when	O	O
overdose	B-Disease	D062787
is	O	O
involved	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
first	O	O
case	O	O
of	O	O
Dexatrim	B-Chemical	D010665
(	O	O
PPA	B-Chemical	D010665
)	O	O
-	O	O
induced	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
in	O	O
a	O	O
young	O	O
woman	O	O
who	O	O
was	O	O
using	O	O
it	O	O
at	O	O
recommended	O	O
doses	O	O
for	O	O
weight	O	O
control	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
review	O	O
the	O	O
7	O	O
other	O	O
cases	O	O
of	O	O
PPA	B-Chemical	D010665
related	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
that	O	O
have	O	O
been	O	O
reported	O	O
so	O	O
far	O	O
.	O	O

Physicians	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
alert	O	O
to	O	O
the	O	O
potential	O	O
cardiac	O	O
risk	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
PPA	B-Chemical	D010665
,	O	O
even	O	O
at	O	O
doses	O	O
generally	O	O
considered	O	O
to	O	O
be	O	O
safe	O	O
.	O	O

Risperidone	B-Chemical	D018967
-	O	O
associated	O	O
,	O	O
benign	O	O
transient	O	O
visual	B-Disease	D010468
disturbances	I-Disease	D010468
in	O	O
schizophrenic	B-Disease	D012559
patients	O	O
with	O	O
a	O	O
past	O	O
history	O	O
of	O	O
LSD	B-Chemical	D008238
abuse	O	O
.	O	O

Two	O	O
schizophrenic	B-Disease	D012559
patients	O	O
,	O	O
who	O	O
had	O	O
a	O	O
prior	O	O
history	O	O
of	O	O
LSD	B-Chemical	D008238
abuse	O	O
and	O	O
who	O	O
had	O	O
previously	O	O
developed	O	O
EPS	B-Disease	D001480
with	O	O
classic	O	O
antipsychotics	O	O
,	O	O
were	O	O
successfully	O	O
treated	O	O
with	O	O
risperidone	B-Chemical	D018967
.	O	O

They	O	O
both	O	O
reported	O	O
short	O	O
episodes	O	O
of	O	O
transient	O	O
visual	B-Disease	D010468
disturbances	I-Disease	D010468
,	O	O
which	O	O
appeared	O	O
immediately	O	O
after	O	O
starting	O	O
treatment	O	O
with	O	O
risperidone	B-Chemical	D018967
.	O	O

This	O	O
imagery	O	O
resembled	O	O
visual	B-Disease	D010468
disturbances	I-Disease	D010468
previously	O	O
experienced	O	O
as	O	O
"flashbacks"	O	O
related	O	O
to	O	O
prior	O	O
LSD	B-Chemical	D008238
consumption	O	O
.	O	O

Risperidone	B-Chemical	D018967
administration	O	O
was	O	O
continued	O	O
and	O	O
the	O	O
visual	B-Disease	D010468
disturbances	I-Disease	D010468
gradually	O	O
wore	O	O
off	O	O
.	O	O

During	O	O
a	O	O
six	O	O
-	O	O
month	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
there	O	O
was	O	O
no	O	O
recurrence	O	O
of	O	O
visual	B-Disease	D010468
disturbances	I-Disease	D010468
.	O	O

This	O	O
phenomenon	O	O
may	O	O
be	O	O
interpreted	O	O
as	O	O
a	O	O
benign	O	O
,	O	O
short	O	O
-	O	O
term	O	O
and	O	O
self	O	O
-	O	O
limiting	O	O
side	O	O
effect	O	O
which	O	O
does	O	O
not	O	O
contraindicate	O	O
the	O	O
use	O	O
of	O	O
risperidone	B-Chemical	D018967
or	O	O
interfere	O	O
with	O	O
treatment	O	O
.	O	O

Conclusions	O	O
based	O	O
on	O	O
two	O	O
case	O	O
reports	O	O
should	O	O
be	O	O
taken	O	O
with	O	O
appropriate	O	O
caution	O	O
.	O	O

Activation	O	O
of	O	O
poly	B-Chemical	D011064
(	I-Chemical	D011064
ADP	I-Chemical	D011064
-	I-Chemical	D011064
ribose	I-Chemical	D011064
)	I-Chemical	D011064
polymerase	O	O
contributes	O	O
to	O	O
development	O	O
of	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Activation	O	O
of	O	O
the	O	O
nuclear	O	O
enzyme	O	O
poly	B-Chemical	D011064
(	I-Chemical	D011064
ADP	I-Chemical	D011064
-	I-Chemical	D011064
ribose	I-Chemical	D011064
)	I-Chemical	D011064
polymerase	O	O
(	O	O
PARP	O	O
)	O	O
by	O	O
oxidant	O	O
-	O	O
mediated	O	O
DNA	O	O
damage	O	O
is	O	O
an	O	O
important	O	O
pathway	O	O
of	O	O
cell	O	O
dysfunction	O	O
and	O	O
tissue	O	O
injury	O	O
in	O	O
conditions	O	O
associated	O	O
with	O	O
oxidative	O	O
stress	O	O
.	O	O

Increased	O	O
oxidative	O	O
stress	O	O
is	O	O
a	O	O
major	O	O
factor	O	O
implicated	O	O
in	O	O
the	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
,	O	O
a	O	O
widely	O	O
used	O	O
antitumor	O	O
anthracycline	B-Chemical	D018943
antibiotic	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
the	O	O
activation	O	O
of	O	O
PARP	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Using	O	O
a	O	O
dual	O	O
approach	O	O
of	O	O
PARP	O	O
-	O	O
1	O	O
suppression	O	O
,	O	O
by	O	O
genetic	O	O
deletion	O	O
or	O	O
pharmacological	O	O
inhibition	O	O
with	O	O
the	O	O
phenanthridinone	O	O
PARP	O	O
inhibitor	O	O
PJ34	B-Chemical	C434926
,	O	O
we	O	O
now	O	O
demonstrate	O	O
the	O	O
role	O	O
of	O	O
PARP	O	O
in	O	O
the	O	O
development	O	O
of	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
induced	O	O
by	O	O
DOX	B-Chemical	D004317
.	O	O

PARP	O	O
-	O	O
1+	O	O
/	O	O
+	O	O
and	O	O
PARP	O	O
-	O	O
1	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
received	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
DOX	B-Chemical	D004317
(	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
)	O	O
.	O	O

Five	O	O
days	O	O
after	O	O
DOX	B-Chemical	D004317
administration	O	O
,	O	O
left	O	O
ventricular	O	O
performance	O	O
was	O	O
significantly	O	O
depressed	O	O
in	O	O
PARP	O	O
-	O	O
1+	O	O
/	O	O
+	O	O
mice	O	O
,	O	O
but	O	O
only	O	O
to	O	O
a	O	O
smaller	O	O
extent	O	O
in	O	O
PARP	O	O
-	O	O
1	O	O
-	O	O
/	O	O
-	O	O
ones	O	O
.	O	O

Similar	O	O
experiments	O	O
were	O	O
conducted	O	O
in	O	O
BALB	O	O
/	O	O
c	O	O
mice	O	O
treated	O	O
with	O	O
PJ34	B-Chemical	C434926
or	O	O
vehicle	O	O
.	O	O

Treatment	O	O
with	O	O
a	O	O
PJ34	B-Chemical	C434926
significantly	O	O
improved	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
and	O	O
increased	O	O
the	O	O
survival	O	O
of	O	O
the	O	O
animals	O	O
.	O	O

In	O	O
addition	O	O
PJ34	B-Chemical	C434926
significantly	O	O
reduced	O	O
the	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
increase	O	O
in	O	O
the	O	O
serum	O	O
lactate	B-Chemical	D019344
dehydrogenase	O	O
and	O	O
creatine	B-Chemical	D003401
kinase	O	O
activities	O	O
but	O	O
not	O	O
metalloproteinase	O	O
activation	O	O
in	O	O
the	O	O
heart	O	O
.	O	O

Thus	O	O
,	O	O
PARP	O	O
activation	O	O
contributes	O	O
to	O	O
the	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
DOX	B-Chemical	D004317
.	O	O

PARP	O	O
inhibitors	O	O
may	O	O
exert	O	O
protective	O	O
effects	O	O
against	O	O
the	O	O
development	O	O
of	O	O
severe	O	O
cardiac	B-Disease	D005117
complications	I-Disease	D005117
associated	O	O
with	O	O
the	O	O
DOX	B-Chemical	D004317
treatment	O	O
.	O	O

Fluconazole	B-Chemical	D015725
-	O	O
induced	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
present	O	O
a	O	O
case	O	O
of	O	O
fluconazole	B-Chemical	D015725
-	O	O
associated	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TDP	B-Disease	D016171
)	O	O
and	O	O
discuss	O	O
fluconazole's	O	O
role	O	O
in	O	O
causing	O	O
TDP	B-Disease	D016171
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
68	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
woman	O	O
with	O	O
Candida	O	O
glabrata	O	O
isolated	O	O
from	O	O
a	O	O
presacral	O	O
abscess	O	O
developed	O	O
TDP	B-Disease	D016171
eight	O	O
days	O	O
after	O	O
commencing	O	O
oral	O	O
fluconazole	B-Chemical	D015725
The	O	O
patient	O	O
had	O	O
no	O	O
other	O	O
risk	O	O
factors	O	O
for	O	O
TDP	B-Disease	D016171
,	O	O
including	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
,	O	O
and	O	O
electrolyte	O	O
abnormalities	O	O
There	O	O
was	O	O
a	O	O
temporal	O	O
association	O	O
between	O	O
the	O	O
initiation	O	O
of	O	O
fluconazole	B-Chemical	D015725
and	O	O
TDP	B-Disease	D016171
.	O	O

The	O	O
TDP	B-Disease	D016171
resolved	O	O
when	O	O
fluconazole	B-Chemical	D015725
was	O	O
discontinued	O	O
;	O	O
however	O	O
,	O	O
the	O	O
patient	O	O
continued	O	O
to	O	O
have	O	O
premature	B-Disease	D018879
ventricular	I-Disease	D018879
contractions	I-Disease	D018879
and	O	O
nonsustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
(	O	O
NSVT	B-Disease	D017180
)	O	O
until	O	O
six	O	O
days	O	O
after	O	O
drug	O	O
cessation	O	O
DISCUSSION	O	O
:	O	O
Use	O	O
of	O	O
the	O	O
Naranjo	O	O
probability	O	O
scale	O	O
indicates	O	O
a	O	O
probable	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
fluconazole	B-Chemical	D015725
and	O	O
the	O	O
development	O	O
of	O	O
TDP	B-Disease	D016171
.	O	O

The	O	O
possible	O	O
mechanism	O	O
is	O	O
depression	B-Disease	D003866
of	O	O
rapidly	O	O
activating	O	O
delayed	O	O
rectifier	O	O
potassium	B-Chemical	D011188
currents	O	O
.	O	O

In	O	O
our	O	O
patient	O	O
,	O	O
there	O	O
was	O	O
no	O	O
other	O	O
etiology	O	O
identified	O	O
that	O	O
could	O	O
explain	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
or	O	O
TDP	B-Disease	D016171
The	O	O
complete	O	O
disappearance	O	O
of	O	O
NSVT	B-Disease	D017180
and	O	O
premature	B-Disease	D018879
ventricular	I-Disease	D018879
contractions	I-Disease	D018879
followed	O	O
by	O	O
normalization	O	O
of	O	O
QT	O	O
interval	O	O
after	O	O
the	O	O
drug	O	O
was	O	O
stopped	O	O
strongly	O	O
suggests	O	O
fluconazole	B-Chemical	D015725
as	O	O
the	O	O
etiology	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinicians	O	O
should	O	O
be	O	O
aware	O	O
that	O	O
fluconazole	B-Chemical	D015725
,	O	O
even	O	O
at	O	O
low	O	O
doses	O	O
,	O	O
may	O	O
cause	O	O
prolongation	B-Disease	D008133
of	I-Disease	D008133
the	I-Disease	D008133
QT	I-Disease	D008133
interval	I-Disease	D008133
,	O	O
leading	O	O
to	O	O
TDP	B-Disease	D016171
.	O	O

Serial	O	O
electrocardiographic	O	O
monitoring	O	O
may	O	O
be	O	O
considered	O	O
when	O	O
fluconazole	B-Chemical	D015725
is	O	O
administered	O	O
in	O	O
patients	O	O
who	O	O
are	O	O
at	O	O
risk	O	O
for	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

High	O	O
-	O	O
dose	O	O
methylprednisolone	B-Chemical	D008775
may	O	O
do	O	O
more	O	O
harm	O	O
for	O	O
spinal	B-Disease	D013119
cord	I-Disease	D013119
injury	I-Disease	D013119
.	O	O

Because	O	O
of	O	O
the	O	O
National	O	O
Acute	O	O
Spinal	B-Disease	D013119
Cord	I-Disease	D013119
Injury	I-Disease	D013119
Studies	O	O
(	O	O
NASCIS	O	O
)	O	O
,	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-Chemical	D008775
became	O	O
the	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
the	O	O
acute	O	O
spinal	B-Disease	D013119
cord	I-Disease	D013119
injury	I-Disease	D013119
.	O	O

In	O	O
the	O	O
NASCIS	O	O
,	O	O
there	O	O
was	O	O
no	O	O
mention	O	O
regarding	O	O
the	O	O
possibility	O	O
of	O	O
acute	O	O
corticosteroid	B-Chemical	D000305
myopathy	B-Disease	D009135
that	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-Chemical	D008775
may	O	O
cause	O	O
.	O	O

The	O	O
dosage	O	O
of	O	O
methylprednisolone	B-Chemical	D008775
recommended	O	O
by	O	O
the	O	O
NASCIS	O	O
3	O	O
is	O	O
the	O	O
highest	O	O
dose	O	O
of	O	O
steroids	B-Chemical	D013256
ever	O	O
being	O	O
used	O	O
during	O	O
a	O	O
2	O	O
-	O	O
day	O	O
period	O	O
for	O	O
any	O	O
clinical	O	O
condition	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
it	O	O
may	O	O
cause	O	O
some	O	O
damage	B-Disease	D009135
to	I-Disease	D009135
the	I-Disease	D009135
muscle	I-Disease	D009135
of	O	O
spinal	B-Disease	D013119
cord	I-Disease	D013119
injury	I-Disease	D013119
patients	O	O
.	O	O

Further	O	O
,	O	O
steroid	B-Chemical	D013256
myopathy	B-Disease	D009135
recovers	O	O
naturally	O	O
and	O	O
the	O	O
neurological	O	O
improvement	O	O
shown	O	O
in	O	O
the	O	O
NASCIS	O	O
may	O	O
be	O	O
just	O	O
a	O	O
recording	O	O
of	O	O
this	O	O
natural	O	O
motor	O	O
recovery	O	O
from	O	O
the	O	O
steroid	B-Chemical	D013256
myopathy	B-Disease	D009135
,	O	O
instead	O	O
of	O	O
any	O	O
protection	O	O
that	O	O
methylprednisolone	B-Chemical	D008775
offers	O	O
to	O	O
the	O	O
spinal	B-Disease	D013119
cord	I-Disease	D013119
injury	I-Disease	D013119
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
discussion	O	O
considering	O	O
the	O	O
possibility	O	O
that	O	O
the	O	O
methylprednisolone	B-Chemical	D008775
recommended	O	O
by	O	O
NASCIS	O	O
may	O	O
cause	O	O
acute	O	O
corticosteroid	B-Chemical	D000305
myopathy	B-Disease	D009135
.	O	O

Probing	O	O
peripheral	O	O
and	O	O
central	O	O
cholinergic	O	O
system	O	O
responses	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
pharmacological	O	O
response	O	O
to	O	O
drugs	O	O
that	O	O
act	O	O
on	O	O
the	O	O
cholinergic	O	O
system	O	O
of	O	O
the	O	O
iris	O	O
has	O	O
been	O	O
used	O	O
to	O	O
predict	O	O
deficits	O	O
in	O	O
central	O	O
cholinergic	O	O
functioning	O	O
due	O	O
to	O	O
diseases	O	O
such	O	O
as	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
,	O	O
yet	O	O
correlations	O	O
between	O	O
central	O	O
and	O	O
peripheral	O	O
responses	O	O
have	O	O
not	O	O
been	O	O
properly	O	O
studied	O	O
.	O	O

This	O	O
study	O	O
assessed	O	O
the	O	O
effect	O	O
of	O	O
normal	O	O
aging	O	O
on	O	O
(	O	O
1	O	O
)	O	O
the	O	O
tropicamide	B-Chemical	D014331
-	O	O
induced	O	O
increase	O	O
in	O	O
pupil	O	O
diameter	O	O
,	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
reversal	O	O
of	O	O
this	O	O
effect	O	O
with	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Scopolamine	B-Chemical	D012601
was	O	O
used	O	O
as	O	O
a	O	O
positive	O	O
control	O	O
to	O	O
detect	O	O
age	O	O
-	O	O
dependent	O	O
changes	O	O
in	O	O
central	O	O
cholinergic	O	O
functioning	O	O
in	O	O
the	O	O
elderly	O	O
.	O	O

DESIGN	O	O
:	O	O
Randomized	O	O
double	O	O
-	O	O
blind	O	O
controlled	O	O
trial	O	O
.	O	O

PARTICIPANTS	O	O
:	O	O
Ten	O	O
healthy	O	O
elderly	O	O
(	O	O
mean	O	O
age	O	O
70	O	O
)	O	O
and	O	O
9	O	O
young	O	O
(	O	O
mean	O	O
age	O	O
33	O	O
)	O	O
volunteers	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Pupil	O	O
diameter	O	O
was	O	O
monitored	O	O
using	O	O
a	O	O
computerized	O	O
infrared	O	O
pupillometer	O	O
over	O	O
4	O	O
hours	O	O
.	O	O

The	O	O
study	O	O
involved	O	O
4	O	O
sessions	O	O
.	O	O

In	O	O
1	O	O
session	O	O
,	O	O
tropicamide	B-Chemical	D014331
(	O	O
20	O	O
microL	O	O
,	O	O
0	O	O
.	O	O

01%	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
one	O	O
eye	O	O
and	O	O
placebo	O	O
to	O	O
the	O	O
other	O	O
.	O	O

In	O	O
another	O	O
session	O	O
,	O	O
tropicamide	B-Chemical	D014331
(	O	O
20	O	O
microL	O	O
,	O	O
0	O	O
.	O	O

01%	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
both	O	O
eyes	O	O
,	O	O
followed	O	O
23	O	O
minutes	O	O
later	O	O
by	O	O
the	O	O
application	O	O
of	O	O
pilocarpine	B-Chemical	D010862
(	O	O
20	O	O
microL	O	O
,	O	O
0	O	O
.	O	O

1%	O	O
)	O	O
to	O	O
one	O	O
eye	O	O
and	O	O
placebo	O	O
to	O	O
the	O	O
other	O	O
.	O	O

All	O	O
eye	O	O
drops	O	O
were	O	O
given	O	O
in	O	O
a	O	O
randomized	O	O
order	O	O
.	O	O

In	O	O
2	O	O
separate	O	O
sessions	O	O
,	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
scopolamine	B-Chemical	D012601
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
,	O	O
intravenously	O	O
)	O	O
or	O	O
placebo	O	O
was	O	O
administered	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
on	O	O
word	O	O
recall	O	O
were	O	O
measured	O	O
using	O	O
the	O	O
Buschke	O	O
Selective	O	O
Reminding	O	O
Test	O	O
over	O	O
2	O	O
hours	O	O
.	O	O

OUTCOME	O	O
MEASURES	O	O
:	O	O
Pupil	O	O
size	O	O
at	O	O
time	O	O
points	O	O
after	O	O
administration	O	O
of	O	O
tropicamide	B-Chemical	D014331
and	O	O
pilocarpine	B-Chemical	D010862
;	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
impairment	B-Disease	D008569
in	I-Disease	D008569
word	I-Disease	D008569
recall	I-Disease	D008569
.	O	O

RESULTS	O	O
:	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
elderly	O	O
and	O	O
young	O	O
volunteers	O	O
in	O	O
pupillary	O	O
response	O	O
to	O	O
tropicamide	B-Chemical	D014331
at	O	O
any	O	O
time	O	O
point	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
elderly	O	O
group	O	O
had	O	O
a	O	O
significantly	O	O
greater	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
net	O	O
decrease	O	O
in	O	O
pupil	O	O
size	O	O
85	O	O
,	O	O
125	O	O
,	O	O
165	O	O
and	O	O
215	O	O
minutes	O	O
after	O	O
administration	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
young	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Compared	O	O
with	O	O
the	O	O
young	O	O
group	O	O
,	O	O
the	O	O
elderly	O	O
group	O	O
had	O	O
greater	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
impairment	B-Disease	D008569
in	I-Disease	D008569
word	I-Disease	D008569
recall	I-Disease	D008569
60	O	O
,	O	O
90	O	O
and	O	O
120	O	O
minutes	O	O
after	O	O
administration	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
There	O	O
is	O	O
an	O	O
age	O	O
-	O	O
related	O	O
pupillary	O	O
response	O	O
to	O	O
pilocarpine	B-Chemical	D010862
that	O	O
is	O	O
not	O	O
found	O	O
with	O	O
tropicamide	B-Chemical	D014331
.	O	O

Thus	O	O
,	O	O
pilocarpine	B-Chemical	D010862
may	O	O
be	O	O
useful	O	O
to	O	O
assess	O	O
variations	O	O
in	O	O
central	O	O
cholinergic	O	O
function	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

Acetazolamide	B-Chemical	D000086
-	O	O
induced	O	O
Gerstmann	B-Disease	D005862
syndrome	I-Disease	D005862
.	O	O

Acute	O	O
confusion	B-Disease	D003221
induced	O	O
by	O	O
acetazolamide	B-Chemical	D000086
is	O	O
a	O	O
well	O	O
known	O	O
adverse	O	O
drug	O	O
reaction	O	O
in	O	O
patients	O	O
with	O	O
renal	B-Disease	D007674
impairment	I-Disease	D007674
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acetazolamide	B-Chemical	D000086
-	O	O
induced	O	O
Gerstmann	B-Disease	D005862
syndrome	I-Disease	D005862
in	O	O
a	O	O
patient	O	O
with	O	O
normal	O	O
renal	O	O
function	O	O
,	O	O
to	O	O
highlight	O	O
predisposing	O	O
factors	O	O
that	O	O
are	O	O
frequently	O	O
overlooked	O	O
.	O	O

Hypomania	B-Disease	D001714
-	O	O
like	O	O
syndrome	O	O
induced	O	O
by	O	O
olanzapine	B-Chemical	C076029
.	O	O

We	O	O
report	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
a	O	O
not	O	O
otherwise	O	O
specified	O	O
psychotic	B-Disease	D011618
disorder	I-Disease	D011618
(	O	O
DSM	O	O
-	O	O
IV	O	O
)	O	O
who	O	O
developed	O	O
hypomania	B-Disease	D001714
shortly	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
olanzapine	B-Chemical	C076029
treatment	O	O
.	O	O

Neutrophil	O	O
superoxide	B-Chemical	D013481
and	O	O
hydrogen	B-Chemical	D006861
peroxide	I-Chemical	D006861
production	O	O
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

Defects	O	O
in	O	O
superoxide	B-Chemical	D013481
and	O	O
hydrogen	B-Chemical	D006861
peroxide	I-Chemical	D006861
production	O	O
may	O	O
be	O	O
implicated	O	O
in	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
ALF	B-Disease	D017114
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
oxygen	B-Chemical	D010100
radical	O	O
production	O	O
in	O	O
patients	O	O
with	O	O
ALF	B-Disease	D017114
due	O	O
to	O	O
paracetamol	B-Chemical	D000082
overdose	B-Disease	D062787
was	O	O
compared	O	O
with	O	O
that	O	O
of	O	O
healthy	O	O
volunteers	O	O
.	O	O

Neutrophils	O	O
from	O	O
14	O	O
ALF	B-Disease	D017114
patients	O	O
were	O	O
stimulated	O	O
via	O	O
the	O	O
complement	O	O
receptors	O	O
using	O	O
zymosan	O	O
opsonized	O	O
with	O	O
ALF	B-Disease	D017114
or	O	O
control	O	O
serum	O	O
.	O	O

Superoxide	B-Chemical	D013481
and	O	O
hydrogen	B-Chemical	D006861
peroxide	I-Chemical	D006861
production	O	O
by	O	O
ALF	B-Disease	D017114
neutrophils	O	O
stimulated	O	O
with	O	O
zymosan	O	O
opsonized	O	O
with	O	O
ALF	B-Disease	D017114
serum	O	O
was	O	O
significantly	O	O
reduced	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
subjects	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

This	O	O
defect	O	O
persisted	O	O
when	O	O
zymosan	O	O
opsonized	O	O
by	O	O
control	O	O
serum	O	O
was	O	O
used	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Superoxide	B-Chemical	D013481
and	O	O
hydrogen	B-Chemical	D006861
peroxide	I-Chemical	D006861
production	O	O
in	O	O
neutrophils	O	O
stimulated	O	O
with	O	O
formyl	B-Chemical	D009240
-	I-Chemical	D009240
methionyl	I-Chemical	D009240
-	I-Chemical	D009240
leucyl	I-Chemical	D009240
-	I-Chemical	D009240
phenylalanine	I-Chemical	D009240
(	O	O
fMLP	B-Chemical	D009240
)	O	O
from	O	O
a	O	O
further	O	O
18	O	O
ALF	B-Disease	D017114
patients	O	O
was	O	O
unaffected	O	O
compared	O	O
with	O	O
control	O	O
neutrophils	O	O
.	O	O

Serum	O	O
C3	O	O
complement	O	O
levels	O	O
were	O	O
significantly	O	O
reduced	O	O
in	O	O
ALF	B-Disease	D017114
patients	O	O
compared	O	O
with	O	O
control	O	O
subjects	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0005	O	O
)	O	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
a	O	O
neutrophil	O	O
defect	O	O
in	O	O
ALF	B-Disease	D017114
due	O	O
to	O	O
paracetamol	B-Chemical	D000082
overdose	B-Disease	D062787
,	O	O
that	O	O
is	O	O
complement	O	O
dependent	O	O
but	O	O
independent	O	O
of	O	O
serum	O	O
complement	O	O
,	O	O
possibly	O	O
connected	O	O
to	O	O
the	O	O
complement	O	O
receptor	O	O
.	O	O

Absence	O	O
of	O	O
effect	O	O
of	O	O
sertraline	B-Chemical	D020280
on	O	O
time	O	O
-	O	O
based	O	O
sensitization	O	O
of	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
with	O	O
haloperidol	B-Chemical	D006220
.	O	O

This	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
evaluated	O	O
the	O	O
effects	O	O
of	O	O
haloperidol	B-Chemical	D006220
alone	O	O
and	O	O
haloperidol	B-Chemical	D006220
plus	O	O
sertraline	B-Chemical	D020280
on	O	O
cognitive	O	O
and	O	O
psychomotor	O	O
function	O	O
in	O	O
24	O	O
healthy	O	O
male	O	O
subjects	O	O
.	O	O

METHOD	O	O
:	O	O
All	O	O
subjects	O	O
received	O	O
placebo	O	O
on	O	O
Day	O	O
1	O	O
and	O	O
haloperidol	B-Chemical	D006220
2	O	O
mg	O	O
on	O	O
Days	O	O
2	O	O
and	O	O
25	O	O
.	O	O

From	O	O
Days	O	O
9	O	O
to	O	O
25	O	O
,	O	O
subjects	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
either	O	O
sertraline	B-Chemical	D020280
(	O	O
12	O	O
subjects	O	O
)	O	O
or	O	O
placebo	O	O
(	O	O
12	O	O
subjects	O	O
)	O	O
;	O	O
the	O	O
sertraline	B-Chemical	D020280
dose	O	O
was	O	O
titrated	O	O
from	O	O
50	O	O
to	O	O
200	O	O
mg	O	O
/	O	O
day	O	O
from	O	O
Days	O	O
9	O	O
to	O	O
16	O	O
,	O	O
and	O	O
remained	O	O
at	O	O
200	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
the	O	O
final	O	O
10	O	O
days	O	O
of	O	O
the	O	O
drug	O	O
administration	O	O
period	O	O
.	O	O

Cognitive	O	O
function	O	O
testing	O	O
was	O	O
performed	O	O
before	O	O
dosing	O	O
and	O	O
over	O	O
a	O	O
24	O	O
-	O	O
hour	O	O
period	O	O
after	O	O
dosing	O	O
on	O	O
Days	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
25	O	O
.	O	O

RESULTS	O	O
:	O	O
Impairment	B-Disease	D003072
of	I-Disease	D003072
cognitive	I-Disease	D003072
function	I-Disease	D003072
was	O	O
observed	O	O
6	O	O
to	O	O
8	O	O
hours	O	O
after	O	O
administration	O	O
of	O	O
haloperidol	B-Chemical	D006220
on	O	O
Day	O	O
2	O	O
but	O	O
was	O	O
not	O	O
evident	O	O
23	O	O
hours	O	O
after	O	O
dosing	O	O
.	O	O

When	O	O
single	O	O
-	O	O
dose	O	O
haloperidol	B-Chemical	D006220
was	O	O
given	O	O
again	O	O
25	O	O
days	O	O
later	O	O
,	O	O
greater	O	O
impairment	O	O
with	O	O
earlier	O	O
onset	O	O
was	O	O
noted	O	O
in	O	O
several	O	O
tests	O	O
in	O	O
both	O	O
treatment	O	O
groups	O	O
,	O	O
suggesting	O	O
enhancement	O	O
of	O	O
this	O	O
effect	O	O
.	O	O

There	O	O
was	O	O
no	O	O
indication	O	O
that	O	O
sertraline	B-Chemical	D020280
exacerbated	O	O
the	O	O
impairment	O	O
produced	O	O
by	O	O
haloperidol	B-Chemical	D006220
since	O	O
an	O	O
equivalent	O	O
effect	O	O
also	O	O
occurred	O	O
in	O	O
the	O	O
placebo	O	O
group	O	O
.	O	O

Three	O	O
subjects	O	O
(	O	O
2	O	O
on	O	O
sertraline	B-Chemical	D020280
and	O	O
1	O	O
on	O	O
placebo	O	O
)	O	O
withdrew	O	O
from	O	O
the	O	O
study	O	O
because	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

Ten	O	O
subjects	O	O
in	O	O
each	O	O
group	O	O
reported	O	O
side	O	O
effects	O	O
related	O	O
to	O	O
treatment	O	O
.	O	O

The	O	O
side	O	O
effect	O	O
profiles	O	O
of	O	O
sertraline	B-Chemical	D020280
and	O	O
of	O	O
placebo	O	O
were	O	O
similar	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Haloperidol	B-Chemical	D006220
produced	O	O
a	O	O
clear	O	O
profile	O	O
of	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
that	O	O
was	O	O
not	O	O
worsened	O	O
by	O	O
concomitant	O	O
sertraline	B-Chemical	D020280
administration	O	O
.	O	O

Ciprofloxacin	B-Chemical	D002939
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
in	O	O
patients	O	O
with	O	O
cancer	B-Disease	D009369
.	O	O

Nephrotoxicity	B-Disease	D007674
associated	O	O
with	O	O
ciprofloxacin	B-Chemical	D002939
is	O	O
uncommon	O	O
.	O	O

Five	O	O
patients	O	O
with	O	O
cancer	B-Disease	D009369
who	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
that	O	O
followed	O	O
treatment	O	O
with	O	O
ciprofloxacin	B-Chemical	D002939
are	O	O
described	O	O
and	O	O
an	O	O
additional	O	O
15	O	O
cases	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
are	O	O
reviewed	O	O
.	O	O

Other	O	O
than	O	O
elevation	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
,	O	O
characteristic	O	O
clinical	O	O
manifestations	O	O
and	O	O
abnormal	O	O
laboratory	O	O
findings	O	O
are	O	O
not	O	O
frequently	O	O
present	O	O
.	O	O

Allergic	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
is	O	O
believed	O	O
to	O	O
be	O	O
the	O	O
underlying	O	O
pathological	O	O
-	O	O
process	O	O
.	O	O

Definitive	O	O
diagnosis	O	O
requires	O	O
performance	O	O
of	O	O
renal	O	O
biopsy	O	O
,	O	O
although	O	O
this	O	O
is	O	O
not	O	O
always	O	O
feasible	O	O
.	O	O

An	O	O
improvement	O	O
in	O	O
renal	O	O
function	O	O
that	O	O
followed	O	O
the	O	O
discontinuation	O	O
of	O	O
the	O	O
offending	O	O
antibiotic	O	O
supports	O	O
the	O	O
presumptive	O	O
diagnosis	O	O
of	O	O
ciprofloxacin	B-Chemical	D002939
-	O	O
induced	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

Case	O	O
report	O	O
:	O	O
pentamidine	B-Chemical	D010419
and	O	O
polymorphic	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
revisited	O	O
.	O	O

Pentamidine	B-Chemical	D010419
isethionate	I-Chemical	D010419
has	O	O
been	O	O
associated	O	O
with	O	O
ventricular	B-Disease	D017180
tachyarrhythmias	I-Disease	D017180
,	O	O
including	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

This	O	O
article	O	O
reports	O	O
two	O	O
cases	O	O
of	O	O
this	O	O
complication	O	O
and	O	O
reviews	O	O
all	O	O
reported	O	O
cases	O	O
to	O	O
date	O	O
.	O	O

Pentamidine	B-Chemical	D010419
-	O	O
induced	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
may	O	O
be	O	O
related	O	O
to	O	O
serum	O	O
magnesium	B-Chemical	D008274
levels	O	O
and	O	O
hypomagnesemia	B-Disease	C537153
may	O	O
synergistically	O	O
induce	O	O
torsade	O	O
.	O	O

Torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
occurred	O	O
after	O	O
an	O	O
average	O	O
of	O	O
10	O	O
days	O	O
of	O	O
treatment	O	O
with	O	O
pentamidine	B-Chemical	D010419
.	O	O

In	O	O
these	O	O
patients	O	O
,	O	O
no	O	O
other	O	O
acute	O	O
side	O	O
effects	O	O
of	O	O
pentamidine	B-Chemical	D010419
were	O	O
observed	O	O
.	O	O

Torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
can	O	O
be	O	O
treated	O	O
when	O	O
recognized	O	O
early	O	O
,	O	O
possibly	O	O
without	O	O
discontinuation	O	O
of	O	O
pentamidine	B-Chemical	D010419
.	O	O

When	O	O
QTc	B-Disease	D008133
interval	I-Disease	D008133
prolongation	I-Disease	D008133
is	O	O
observed	O	O
,	O	O
early	O	O
magnesium	B-Chemical	D008274
supplementation	O	O
is	O	O
advocated	O	O
.	O	O

Time	O	O
dependence	O	O
of	O	O
plasma	O	O
malondialdehyde	B-Chemical	D008315
,	O	O
oxypurines	B-Chemical	-1
,	O	O
and	O	O
nucleosides	B-Chemical	D009705
during	O	O
incomplete	O	O
cerebral	B-Disease	D002545
ischemia	I-Disease	D002545
in	O	O
the	O	O
rat	O	O
.	O	O

Incomplete	O	O
cerebral	B-Disease	D002545
ischemia	I-Disease	D002545
(	O	O
30	O	O
min	O	O
)	O	O
was	O	O
induced	O	O
in	O	O
the	O	O
rat	O	O
by	O	O
bilaterally	O	O
clamping	O	O
the	O	O
common	O	O
carotid	O	O
arteries	O	O
.	O	O

Peripheral	O	O
venous	O	O
blood	O	O
samples	O	O
were	O	O
withdrawn	O	O
from	O	O
the	O	O
femoral	O	O
vein	O	O
four	O	O
times	O	O
(	O	O
once	O	O
every	O	O
5	O	O
min	O	O
)	O	O
before	O	O
ischemia	B-Disease	D007511
(	O	O
0	O	O
time	O	O
)	O	O
and	O	O
5	O	O
,	O	O
15	O	O
,	O	O
and	O	O
30	O	O
min	O	O
after	O	O
ischemia	B-Disease	D007511
.	O	O

Plasma	O	O
extracts	O	O
were	O	O
analyzed	O	O
by	O	O
a	O	O
highly	O	O
sensitive	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatographic	O	O
method	O	O
for	O	O
the	O	O
direct	O	O
determination	O	O
of	O	O
malondialdehyde	B-Chemical	D008315
,	O	O
oxypurines	B-Chemical	-1
,	O	O
and	O	O
nucleosides	B-Chemical	D009705
.	O	O

During	O	O
ischemia	B-Disease	D007511
,	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
increase	O	O
of	O	O
plasma	O	O
oxypurines	B-Chemical	-1
and	O	O
nucleosides	B-Chemical	D009705
was	O	O
observed	O	O
.	O	O

Plasma	O	O
malondialdehyde	B-Chemical	D008315
,	O	O
which	O	O
was	O	O
present	O	O
in	O	O
minimal	O	O
amount	O	O
at	O	O
zero	O	O
time	O	O
(	O	O
0	O	O
.	O	O

058	O	O
mumol	O	O
/	O	O
liter	O	O
plasma	O	O
;	O	O
SD	O	O
0	O	O
.	O	O

015	O	O
)	O	O
,	O	O
increased	O	O
after	O	O
5	O	O
min	O	O
of	O	O
ischemia	B-Disease	D007511
,	O	O
resulting	O	O
in	O	O
a	O	O
fivefold	O	O
increase	O	O
after	O	O
30	O	O
min	O	O
of	O	O
carotid	O	O
occlusion	O	O
(	O	O
0	O	O
.	O	O

298	O	O
mumol	O	O
/	O	O
liter	O	O
plasma	O	O
;	O	O
SD	O	O
0	O	O
.	O	O

078	O	O
)	O	O
.	O	O

Increased	O	O
plasma	O	O
malondialdehyde	B-Chemical	D008315
was	O	O
also	O	O
recorded	O	O
in	O	O
two	O	O
other	O	O
groups	O	O
of	O	O
animals	O	O
subjected	O	O
to	O	O
the	O	O
same	O	O
experimental	O	O
model	O	O
,	O	O
one	O	O
receiving	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
b	O	O
.	O	O

w	O	O
.	O	O

of	O	O
the	O	O
cyclooxygenase	O	O
inhibitor	O	O
acetylsalicylate	B-Chemical	D001241
intravenously	O	O
immediately	O	O
before	O	O
ischemia	B-Disease	D007511
,	O	O
the	O	O
other	O	O
receiving	O	O
650	O	O
micrograms	O	O
/	O	O
kg	O	O
b	O	O
.	O	O

w	O	O
.	O	O

of	O	O
the	O	O
hypotensive	B-Disease	D007022
drug	O	O
nitroprusside	B-Chemical	D009599
at	O	O
a	O	O
flow	O	O
rate	O	O
of	O	O
103	O	O
microliters	O	O
/	O	O
min	O	O
intravenously	O	O
during	O	O
ischemia	B-Disease	D007511
,	O	O
although	O	O
in	O	O
this	O	O
latter	O	O
group	O	O
malondialdehyde	B-Chemical	D008315
was	O	O
significantly	O	O
higher	O	O
.	O	O

The	O	O
present	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
determination	O	O
of	O	O
malondialdehyde	B-Chemical	D008315
,	O	O
oxypurines	B-Chemical	-1
,	O	O
and	O	O
nucleosides	B-Chemical	D009705
in	O	O
peripheral	O	O
blood	O	O
,	O	O
may	O	O
be	O	O
used	O	O
to	O	O
monitor	O	O
the	O	O
metabolic	O	O
alterations	O	O
of	O	O
tissues	O	O
occurring	O	O
during	O	O
ischemic	B-Disease	D007511
phenomena	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Cholinergic	O	O
toxicity	B-Disease	D064420
resulting	O	O
from	O	O
ocular	O	O
instillation	O	O
of	O	O
echothiophate	B-Chemical	D004456
iodide	I-Chemical	D004456
eye	O	O
drops	O	O
.	O	O

A	O	O
patient	O	O
developed	O	O
a	O	O
severe	O	O
cholinergic	O	O
syndrome	O	O
from	O	O
the	O	O
use	O	O
of	O	O
echothiophate	B-Chemical	D004456
iodide	I-Chemical	D004456
ophthalmic	O	O
drops	O	O
,	O	O
presented	O	O
with	O	O
profound	O	O
muscle	B-Disease	D018908
weakness	I-Disease	D018908
and	O	O
was	O	O
initially	O	O
given	O	O
the	O	O
diagnosis	O	O
of	O	O
myasthenia	B-Disease	D009157
gravis	I-Disease	D009157
.	O	O

Red	O	O
blood	O	O
cell	O	O
and	O	O
serum	O	O
cholinesterase	O	O
levels	O	O
were	O	O
severely	O	O
depressed	O	O
and	O	O
symptoms	O	O
resolved	O	O
spontaneously	O	O
following	O	O
discontinuation	O	O
of	O	O
the	O	O
eye	O	O
drops	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
in	O	O
high	O	O
dose	O	O
carboplatin	B-Chemical	D016190
chemotherapy	O	O
.	O	O

Carboplatin	B-Chemical	D016190
has	O	O
been	O	O
reported	O	O
to	O	O
cause	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
when	O	O
administered	O	O
in	O	O
high	O	O
doses	O	O
to	O	O
adult	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
a	O	O
4	O	O
1	O	O
/	O	O
2	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
was	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
carboplatin	B-Chemical	D016190
for	O	O
metastatic	O	O
parameningeal	O	O
embryonal	B-Disease	D018233
rhabdomyosarcoma	I-Disease	D018233
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
developed	O	O
followed	O	O
by	O	O
a	O	O
slow	O	O
partial	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

Possible	O	O
contributing	O	O
factors	O	O
are	O	O
discussed	O	O
.	O	O

Endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
after	O	O
Hodgkin	B-Disease	D006689
disease	I-Disease	D006689
in	O	O
childhood	O	O
.	O	O

A	O	O
34	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
developed	O	O
metastic	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
after	O	O
Hodgkin	B-Disease	D006689
disease	I-Disease	D006689
in	O	O
childhood	O	O
.	O	O

She	O	O
had	O	O
ovarian	B-Disease	D010049
failure	I-Disease	D010049
after	O	O
abdominal	O	O
irradiation	O	O
and	O	O
chemotherapy	O	O
for	O	O
Hodgkin	B-Disease	D006689
disease	I-Disease	D006689
,	O	O
and	O	O
received	O	O
exogenous	O	O
estrogens	B-Chemical	D004967
,	O	O
a	O	O
treatment	O	O
implicated	O	O
in	O	O
the	O	O
development	O	O
of	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
in	O	O
menopausal	O	O
women	O	O
.	O	O

Young	O	O
women	O	O
on	O	O
replacement	O	O
estrogens	B-Chemical	D004967
for	O	O
ovarian	B-Disease	D010049
failure	I-Disease	D010049
after	O	O
cancer	B-Disease	D009369
therapy	O	O
may	O	O
also	O	O
have	O	O
increased	O	O
risk	O	O
of	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
and	O	O
should	O	O
be	O	O
examined	O	O
periodically	O	O
.	O	O

Induction	O	O
of	O	O
the	O	O
obstructive	B-Disease	D020181
sleep	I-Disease	D020181
apnea	I-Disease	D020181
syndrome	I-Disease	D020181
in	O	O
a	O	O
woman	O	O
by	O	O
exogenous	O	O
androgen	B-Chemical	D000728
administration	O	O
.	O	O

We	O	O
documented	O	O
airway	O	O
occlusion	O	O
during	O	O
sleep	O	O
and	O	O
an	O	O
abnormally	O	O
high	O	O
supraglottic	O	O
resistance	O	O
while	O	O
awake	O	O
in	O	O
a	O	O
54	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
had	O	O
developed	O	O
physical	O	O
changes	O	O
and	O	O
the	O	O
syndrome	B-Disease	D020181
of	I-Disease	D020181
obstructive	I-Disease	D020181
sleep	I-Disease	D020181
apnea	I-Disease	D020181
while	O	O
being	O	O
administered	O	O
exogenous	O	O
androgens	B-Chemical	D000728
.	O	O

When	O	O
the	O	O
androgens	B-Chemical	D000728
were	O	O
withdrawn	O	O
,	O	O
the	O	O
patient's	O	O
physical	O	O
changes	O	O
,	O	O
symptoms	O	O
,	O	O
sleep	O	O
study	O	O
,	O	O
and	O	O
supraglottic	O	O
resistance	O	O
all	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

A	O	O
rechallenge	O	O
with	O	O
androgen	B-Chemical	D000728
produced	O	O
symptoms	O	O
of	O	O
obstructive	B-Disease	D020181
sleep	I-Disease	D020181
apnea	I-Disease	D020181
that	O	O
abated	O	O
upon	O	O
withdrawal	O	O
of	O	O
the	O	O
hormone	O	O
.	O	O

Previous	O	O
reports	O	O
have	O	O
favored	O	O
a	O	O
role	O	O
of	O	O
androgens	B-Chemical	D000728
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
sleep	B-Disease	D012891
apnea	I-Disease	D012891
.	O	O

Our	O	O
report	O	O
provides	O	O
direct	O	O
evidence	O	O
for	O	O
this	O	O
role	O	O
.	O	O

Structural	O	O
and	O	O
functional	O	O
measurements	O	O
indicate	O	O
that	O	O
androgens	B-Chemical	D000728
exert	O	O
a	O	O
permissive	O	O
or	O	O
necessary	O	O
action	O	O
on	O	O
the	O	O
structural	O	O
configuration	O	O
of	O	O
the	O	O
oropharynx	O	O
that	O	O
predisposes	O	O
to	O	O
obstruction	O	O
during	O	O
sleep	O	O
.	O	O

Development	O	O
of	O	O
the	O	O
obstructive	B-Disease	D020181
sleep	I-Disease	D020181
apnea	I-Disease	D020181
syndrome	I-Disease	D020181
must	O	O
be	O	O
considered	O	O
a	O	O
possible	O	O
side	O	O
effect	O	O
of	O	O
androgen	B-Chemical	D000728
therapy	O	O
.	O	O

Effect	O	O
of	O	O
captopril	B-Chemical	D002216
on	O	O
pre	O	O
-	O	O
existing	O	O
and	O	O
aminonucleoside	B-Chemical	D011692
-	O	O
induced	O	O
proteinuria	B-Disease	D011507
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

Proteinuria	B-Disease	D011507
is	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
captopril	B-Chemical	D002216
treatment	O	O
in	O	O
hypertensive	B-Disease	D006973
patients	O	O
.	O	O

The	O	O
possibility	O	O
of	O	O
reproducing	O	O
the	O	O
same	O	O
renal	B-Disease	D007674
abnormality	I-Disease	D007674
with	O	O
captopril	B-Chemical	D002216
was	O	O
examined	O	O
in	O	O
SHR	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
captopril	B-Chemical	D002216
at	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
14	O	O
days	O	O
failed	O	O
to	O	O
aggravate	O	O
proteinuria	B-Disease	D011507
pre	O	O
-	O	O
existing	O	O
in	O	O
SHR	O	O
.	O	O

Also	O	O
,	O	O
captopril	B-Chemical	D002216
treatment	O	O
failed	O	O
to	O	O
potentiate	O	O
or	O	O
facilitate	O	O
development	O	O
of	O	O
massive	O	O
proteinuria	B-Disease	D011507
invoked	O	O
by	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
in	O	O
SHR	O	O
.	O	O

Captopril	B-Chemical	D002216
had	O	O
little	O	O
or	O	O
no	O	O
demonstrable	O	O
effects	O	O
on	O	O
serum	O	O
electrolyte	O	O
concentrations	O	O
,	O	O
excretion	O	O
of	O	O
urine	O	O
,	O	O
sodium	B-Chemical	D012964
and	O	O
potassium	B-Chemical	D011188
,	O	O
endogenous	O	O
creatinine	B-Chemical	D003404
clearance	O	O
,	O	O
body	O	O
weight	O	O
,	O	O
and	O	O
food	O	O
and	O	O
water	O	O
consumption	O	O
.	O	O

However	O	O
,	O	O
ketone	B-Chemical	D007659
bodies	O	O
were	O	O
consistently	O	O
present	O	O
in	O	O
urine	O	O
and	O	O
several	O	O
lethalities	O	O
occurred	O	O
during	O	O
multiple	O	O
dosing	O	O
of	O	O
captopril	B-Chemical	D002216
in	O	O
SHR	O	O
.	O	O

Epileptogenic	O	O
properties	O	O
of	O	O
enflurane	B-Chemical	D004737
and	O	O
their	O	O
clinical	O	O
interpretation	O	O
.	O	O

Three	O	O
cases	O	O
of	O	O
EEG	O	O
changes	O	O
induced	O	O
by	O	O
single	O	O
exposure	O	O
to	O	O
enflurane	B-Chemical	D004737
anesthesia	O	O
are	O	O
reported	O	O
.	O	O

In	O	O
one	O	O
patient	O	O
,	O	O
enflurane	B-Chemical	D004737
administered	O	O
during	O	O
a	O	O
donor	O	O
nephrectomy	O	O
resulted	O	O
in	O	O
unexpected	O	O
partial	O	O
motor	O	O
seizures	B-Disease	D012640
.	O	O

Until	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
seizures	B-Disease	D012640
was	O	O
correctly	O	O
identified	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
inappropriately	O	O
treated	O	O
with	O	O
anticonvulsants	O	O
.	O	O

Two	O	O
other	O	O
patients	O	O
suffered	O	O
from	O	O
partial	O	O
,	O	O
complex	O	O
and	O	O
generalized	O	O
seizures	B-Disease	D012640
uncontrolled	O	O
by	O	O
medication	O	O
.	O	O

Epileptic	B-Disease	D004827
foci	O	O
delineated	O	O
and	O	O
activated	O	O
by	O	O
enflurane	B-Chemical	D004737
were	O	O
surgically	O	O
ablated	O	O
and	O	O
the	O	O
patients	O	O
are	O	O
now	O	O
seizure	B-Disease	D012640
-	O	O
free	O	O
.	O	O

Previous	O	O
exposures	O	O
to	O	O
enflurane	B-Chemical	D004737
have	O	O
to	O	O
be	O	O
disclosed	O	O
to	O	O
avoid	O	O
mistakes	O	O
in	O	O
clinical	O	O
interpretation	O	O
of	O	O
the	O	O
EEG	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
enflurane	B-Chemical	D004737
may	O	O
prove	O	O
to	O	O
be	O	O
a	O	O
safe	O	O
fast	O	O
acting	O	O
activator	O	O
of	O	O
epileptic	B-Disease	D004827
foci	O	O
during	O	O
corticography	O	O
or	O	O
depth	O	O
electrode	O	O
intraoperative	O	O
recordings	O	O
.	O	O

Reversible	O	O
cerebral	B-Disease	D001927
lesions	I-Disease	D001927
associated	O	O
with	O	O
tiazofurin	B-Chemical	C033706
usage	O	O
:	O	O
MR	O	O
demonstration	O	O
.	O	O

Tiazofurin	B-Chemical	C033706
is	O	O
an	O	O
experimental	O	O
chemotherapeutic	O	O
agent	O	O
currently	O	O
undergoing	O	O
clinical	O	O
evaluation	O	O
.	O	O

We	O	O
report	O	O
our	O	O
results	O	O
with	O	O
magnetic	O	O
resonance	O	O
(	O	O
MR	O	O
)	O	O
in	O	O
demonstrating	O	O
reversible	O	O
cerebral	B-Disease	D001927
abnormalities	I-Disease	D001927
concurrent	O	O
with	O	O
the	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

The	O	O
abnormalities	O	O
on	O	O
MR	O	O
were	O	O
correlated	O	O
with	O	O
findings	O	O
on	O	O
CT	O	O
as	O	O
well	O	O
as	O	O
with	O	O
cerebral	O	O
angiography	O	O
.	O	O

The	O	O
utility	O	O
of	O	O
MR	O	O
in	O	O
the	O	O
evaluation	O	O
of	O	O
patients	O	O
receiving	O	O
this	O	O
new	O	O
agent	O	O
is	O	O
illustrated	O	O
.	O	O

Antagonism	O	O
of	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
sedative	O	O
effects	O	O
by	O	O
Ro15	B-Chemical	D005442
-	I-Chemical	D005442
1788	I-Chemical	D005442
in	O	O
patients	O	O
after	O	O
surgery	O	O
under	O	O
lumbar	O	O
epidural	O	O
block	O	O
.	O	O

A	O	O
double	O	O
-	O	O
blind	O	O
placebo	O	O
-	O	O
controlled	O	O
investigation	O	O
of	O	O
efficacy	O	O
and	O	O
safety	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
efficacy	O	O
of	O	O
Ro15	B-Chemical	D005442
-	I-Chemical	D005442
1788	I-Chemical	D005442
and	O	O
a	O	O
placebo	O	O
in	O	O
reversing	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
effects	O	O
after	O	O
surgery	O	O
under	O	O
epidural	O	O
block	O	O
,	O	O
and	O	O
to	O	O
evaluate	O	O
the	O	O
local	O	O
tolerance	O	O
and	O	O
general	O	O
safety	O	O
of	O	O
Ro15	B-Chemical	D005442
-	I-Chemical	D005442
1788	I-Chemical	D005442
.	O	O

Fifty	O	O
-	O	O
seven	O	O
patients	O	O
were	O	O
sedated	O	O
with	O	O
diazepam	B-Chemical	D003975
for	O	O
surgery	O	O
under	O	O
epidural	O	O
anaesthesia	O	O
.	O	O

Antagonism	O	O
of	O	O
diazepam	B-Chemical	D003975
-	O	O
induced	O	O
effects	O	O
by	O	O
Ro15	B-Chemical	D005442
-	I-Chemical	D005442
1788	I-Chemical	D005442
was	O	O
investigated	O	O
postoperatively	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
.	O	O

The	O	O
patient's	O	O
subjective	O	O
assessment	O	O
of	O	O
mood	O	O
rating	O	O
,	O	O
an	O	O
objective	O	O
test	O	O
of	O	O
performance	O	O
,	O	O
a	O	O
test	O	O
for	O	O
amnesia	B-Disease	D000647
,	O	O
and	O	O
vital	O	O
signs	O	O
were	O	O
recorded	O	O
for	O	O
up	O	O
to	O	O
300	O	O
min	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
trial	O	O
drug	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
observed	O	O
for	O	O
mood	O	O
rating	O	O
,	O	O
amnesia	B-Disease	D000647
,	O	O
or	O	O
vital	O	O
signs	O	O
.	O	O

The	O	O
Ro15	B-Chemical	D005442
-	I-Chemical	D005442
1788	I-Chemical	D005442
group	O	O
showed	O	O
a	O	O
significant	O	O
improvement	O	O
in	O	O
the	O	O
performance	O	O
test	O	O
up	O	O
to	O	O
120	O	O
min	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
reaction	O	O
at	O	O
the	O	O
injection	O	O
site	O	O
.	O	O

Enhanced	O	O
stimulus	O	O
-	O	O
induced	O	O
neurotransmitter	O	O
overflow	O	O
in	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
hypertensive	B-Disease	D006973
rats	O	O
is	O	O
not	O	O
mediated	O	O
by	O	O
prejunctional	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
activation	O	O
.	O	O

The	O	O
present	O	O
study	O	O
examines	O	O
the	O	O
effect	O	O
of	O	O
6	O	O
-	O	O
day	O	O
epinephrine	B-Chemical	D004837
treatment	O	O
(	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
per	O	O
h	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
on	O	O
stimulus	O	O
-	O	O
induced	O	O
(	O	O
1	O	O
Hz	O	O
)	O	O
endogenous	O	O
neurotransmitter	O	O
overflow	O	O
from	O	O
the	O	O
isolated	O	O
perfused	O	O
kidney	O	O
of	O	O
vehicle	O	O
-	O	O
and	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
rats	O	O
.	O	O

Renal	O	O
catecholamine	B-Chemical	D002395
stores	O	O
and	O	O
stimulus	O	O
-	O	O
induced	O	O
overflow	O	O
in	O	O
the	O	O
vehicle	O	O
-	O	O
treated	O	O
group	O	O
consisted	O	O
of	O	O
norepinephrine	B-Chemical	D009638
only	O	O
.	O	O

However	O	O
,	O	O
epinephrine	B-Chemical	D004837
treatment	O	O
resulted	O	O
in	O	O
the	O	O
incorporation	O	O
of	O	O
epinephrine	B-Chemical	D004837
into	O	O
renal	O	O
catecholamine	B-Chemical	D002395
stores	O	O
such	O	O
that	O	O
approximately	O	O
40%	O	O
of	O	O
the	O	O
catecholamine	B-Chemical	D002395
present	O	O
was	O	O
epinephrine	B-Chemical	D004837
while	O	O
the	O	O
norepinephrine	B-Chemical	D009638
content	O	O
was	O	O
reduced	O	O
by	O	O
a	O	O
similar	O	O
degree	O	O
.	O	O

Total	O	O
tissue	O	O
catecholamine	B-Chemical	D002395
content	O	O
of	O	O
the	O	O
kidney	O	O
on	O	O
a	O	O
molar	O	O
basis	O	O
was	O	O
unchanged	O	O
.	O	O

Stimulus	O	O
-	O	O
induced	O	O
fractional	O	O
overflow	O	O
of	O	O
neurotransmitter	O	O
from	O	O
the	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
kidneys	O	O
was	O	O
approximately	O	O
twice	O	O
normal	O	O
and	O	O
consisted	O	O
of	O	O
both	O	O
norepinephrine	B-Chemical	D009638
and	O	O
epinephrine	B-Chemical	D004837
in	O	O
proportions	O	O
similar	O	O
to	O	O
those	O	O
found	O	O
in	O	O
the	O	O
kidney	O	O
.	O	O

This	O	O
difference	O	O
in	O	O
fractional	O	O
overflow	O	O
between	O	O
groups	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
neuronal	O	O
and	O	O
extraneuronal	O	O
uptake	O	O
blockade	O	O
.	O	O

Propranolol	B-Chemical	D011433
had	O	O
no	O	O
effect	O	O
on	O	O
stimulus	O	O
-	O	O
induced	O	O
overflow	O	O
in	O	O
either	O	O
group	O	O
.	O	O

Phentolamine	B-Chemical	D010646
increased	O	O
stimulus	O	O
-	O	O
induced	O	O
overflow	O	O
in	O	O
both	O	O
groups	O	O
although	O	O
the	O	O
increment	O	O
in	O	O
overflow	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
group	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
chronic	O	O
epinephrine	B-Chemical	D004837
treatment	O	O
results	O	O
in	O	O
enhanced	O	O
fractional	O	O
neurotransmitter	O	O
overflow	O	O
.	O	O

However	O	O
,	O	O
neither	O	O
alterations	O	O
in	O	O
prejunctional	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
influences	O	O
nor	O	O
alterations	O	O
in	O	O
neuronal	O	O
and	O	O
extraneuronal	O	O
uptake	O	O
mechanisms	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
this	O	O
alteration	O	O
.	O	O

Furthermore	O	O
,	O	O
data	O	O
obtained	O	O
with	O	O
phentolamine	B-Chemical	D010646
alone	O	O
do	O	O
not	O	O
suggest	O	O
alpha	O	O
-	O	O
adrenoceptor	O	O
desensitization	O	O
as	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
enhanced	O	O
neurotransmitter	O	O
overflow	O	O
after	O	O
epinephrine	B-Chemical	D004837
treatment	O	O
.	O	O

Ocular	O	O
manifestations	O	O
of	O	O
juvenile	B-Disease	D001171
rheumatoid	I-Disease	D001171
arthritis	I-Disease	D001171
.	O	O

We	O	O
followed	O	O
210	O	O
cases	O	O
of	O	O
juvenile	B-Disease	D001171
rheumatoid	I-Disease	D001171
arthritis	I-Disease	D001171
closely	O	O
for	O	O
eleven	O	O
years	O	O
.	O	O

Thirty	O	O
-	O	O
six	O	O
of	O	O
the	O	O
210	O	O
patients	O	O
(	O	O
17	O	O
.	O	O

2%	O	O
)	O	O
developed	O	O
iridocyclitis	B-Disease	D015863
.	O	O

Iridocyclitis	B-Disease	D015863
was	O	O
seen	O	O
most	O	O
frequently	O	O
in	O	O
young	O	O
female	O	O
patients	O	O
(	O	O
0	O	O
to	O	O
4	O	O
years	O	O
)	O	O
with	O	O
the	O	O
monoarticular	O	O
or	O	O
pauciatricular	O	O
form	O	O
of	O	O
the	O	O
arthritis	B-Disease	D001168
.	O	O

However	O	O
,	O	O
30%	O	O
of	O	O
the	O	O
patients	O	O
developed	O	O
uveitis	B-Disease	D014605
after	O	O
16	O	O
years	O	O
of	O	O
age	O	O
.	O	O

Although	O	O
61%	O	O
of	O	O
patients	O	O
had	O	O
a	O	O
noncontributory	O	O
ocular	O	O
history	O	O
on	O	O
entry	O	O
,	O	O
42%	O	O
had	O	O
active	O	O
uveitis	B-Disease	D014605
on	O	O
entry	O	O
.	O	O

Our	O	O
approach	O	O
was	O	O
effective	O	O
in	O	O
detecting	O	O
uveitis	B-Disease	D014605
in	O	O
new	O	O
cases	O	O
and	O	O
exacerbations	O	O
of	O	O
uveitis	B-Disease	D014605
in	O	O
established	O	O
cases	O	O
.	O	O

Forty	O	O
-	O	O
four	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
uveitis	B-Disease	D014605
had	O	O
one	O	O
or	O	O
more	O	O
identifiable	O	O
signs	O	O
or	O	O
symptoms	O	O
,	O	O
such	O	O
as	O	O
red	O	O
eye	O	O
,	O	O
ocular	B-Disease	D058447
pain	I-Disease	D058447
,	O	O
decreased	B-Disease	D014786
visual	I-Disease	D014786
acuity	I-Disease	D014786
,	O	O
or	O	O
photophobia	B-Disease	D020795
,	O	O
in	O	O
order	O	O
of	O	O
decreasing	O	O
frequency	O	O
.	O	O

Even	O	O
after	O	O
early	O	O
detection	O	O
and	O	O
prompt	O	O
treatment	O	O
,	O	O
41%	O	O
of	O	O
cases	O	O
of	O	O
uveitis	B-Disease	D014605
did	O	O
not	O	O
respond	O	O
to	O	O
more	O	O
than	O	O
six	O	O
months	O	O
of	O	O
intensive	O	O
topical	O	O
treatment	O	O
with	O	O
corticosteroids	B-Chemical	D000305
and	O	O
mydriatics	O	O
.	O	O

Despite	O	O
this	O	O
,	O	O
there	O	O
was	O	O
a	O	O
dramatic	O	O
decrease	O	O
in	O	O
the	O	O
50%	O	O
incidence	O	O
of	O	O
blinding	O	O
complications	O	O
of	O	O
uveitis	B-Disease	D014605
cited	O	O
in	O	O
earlier	O	O
studies	O	O
.	O	O

Cataract	B-Disease	D002386
and	O	O
band	B-Disease	C562399
keratopathy	I-Disease	C562399
occurred	O	O
in	O	O
only	O	O
22	O	O
and	O	O
13%	O	O
of	O	O
our	O	O
group	O	O
,	O	O
respectively	O	O
.	O	O

We	O	O
used	O	O
chloroquine	B-Chemical	D002738
or	O	O
hydroxychloroquine	B-Chemical	D006886
in	O	O
173	O	O
of	O	O
210	O	O
cases	O	O
and	O	O
found	O	O
only	O	O
one	O	O
case	O	O
of	O	O
chorioretinopathy	B-Disease	D012164
attributable	O	O
to	O	O
these	O	O
drugs	O	O
.	O	O

Systemically	O	O
administered	O	O
corticosteroids	B-Chemical	D000305
were	O	O
used	O	O
in	O	O
75	O	O
of	O	O
210	O	O
cases	O	O
;	O	O
a	O	O
significant	O	O
number	O	O
of	O	O
posterior	O	O
subcapsular	O	O
cataracts	B-Disease	D002386
was	O	O
found	O	O
.	O	O

Typical	O	O
keratoconjunctivitis	B-Disease	D007637
sicca	O	O
developed	O	O
in	O	O
three	O	O
of	O	O
the	O	O
uveitis	B-Disease	D014605
cases	O	O
.	O	O

This	O	O
association	O	O
with	O	O
uveitis	B-Disease	D014605
and	O	O
JRA	O	O
was	O	O
not	O	O
noted	O	O
previously	O	O
.	O	O

Surgical	O	O
treatment	O	O
of	O	O
cataracts	B-Disease	D002386
,	O	O
band	B-Disease	C562399
keratopathy	I-Disease	C562399
,	O	O
and	O	O
glaucoma	B-Disease	D005901
achieved	O	O
uniformly	O	O
discouraging	O	O
results	O	O
.	O	O

Water	B-Disease	D014869
intoxication	I-Disease	D014869
associated	O	O
with	O	O
oxytocin	B-Chemical	D010121
administration	O	O
during	O	O
saline	O	O
-	O	O
induced	O	O
abortion	B-Disease	D000031
.	O	O

Four	O	O
cases	O	O
of	O	O
water	B-Disease	D014869
intoxication	I-Disease	D014869
in	O	O
connection	O	O
with	O	O
oxytocin	B-Chemical	D010121
administration	O	O
during	O	O
saline	O	O
-	O	O
induced	O	O
abortions	B-Disease	D000031
are	O	O
described	O	O
.	O	O

The	O	O
mechanism	O	O
of	O	O
water	B-Disease	D014869
intoxication	I-Disease	D014869
is	O	O
discussed	O	O
in	O	O
regard	O	O
to	O	O
these	O	O
cases	O	O
.	O	O

Oxytocin	B-Chemical	D010121
administration	O	O
during	O	O
midtrimester	O	O
-	O	O
induced	O	O
abortions	B-Disease	D000031
is	O	O
advocated	O	O
only	O	O
if	O	O
it	O	O
can	O	O
be	O	O
carried	O	O
out	O	O
under	O	O
careful	O	O
observations	O	O
of	O	O
an	O	O
alert	O	O
nursing	O	O
staff	O	O
,	O	O
aware	O	O
of	O	O
the	O	O
symptoms	O	O
of	O	O
water	B-Disease	D014869
intoxication	I-Disease	D014869
and	O	O
instructed	O	O
to	O	O
watch	O	O
the	O	O
diuresis	O	O
and	O	O
report	O	O
such	O	O
early	O	O
signs	O	O
of	O	O
the	O	O
syndrome	O	O
as	O	O
asthenia	B-Disease	D001247
,	O	O
muscular	O	O
irritability	B-Disease	D001523
,	O	O
or	O	O
headaches	B-Disease	D006261
.	O	O

The	O	O
oxytocin	B-Chemical	D010121
should	O	O
be	O	O
given	O	O
only	O	O
in	O	O
Ringers	O	O
lactate	B-Chemical	D019344
or	O	O
,	O	O
alternately	O	O
,	O	O
in	O	O
Ringers	O	O
lactate	B-Chemical	D019344
and	O	O
a	O	O
5	O	O
per	O	O
cent	O	O
dextrose	B-Chemical	D005947
and	O	O
water	O	O
solutions	O	O
.	O	O

The	O	O
urinary	O	O
output	O	O
should	O	O
be	O	O
monitored	O	O
and	O	O
the	O	O
oxytocin	B-Chemical	D010121
administration	O	O
discontinued	O	O
and	O	O
the	O	O
serum	O	O
electrolytes	O	O
checked	O	O
if	O	O
the	O	O
urinary	O	O
output	O	O
decreases	O	O
.	O	O

The	O	O
oxytocin	B-Chemical	D010121
should	O	O
not	O	O
be	O	O
administered	O	O
in	O	O
excess	O	O
of	O	O
36	O	O
hours	O	O
.	O	O

If	O	O
the	O	O
patient	O	O
has	O	O
not	O	O
aborted	O	O
by	O	O
then	O	O
the	O	O
oxytocin	B-Chemical	D010121
should	O	O
be	O	O
discontinued	O	O
for	O	O
10	O	O
to	O	O
12	O	O
hours	O	O
in	O	O
order	O	O
to	O	O
perform	O	O
electrolyte	O	O
determinations	O	O
and	O	O
correct	O	O
any	O	O
electrolyte	O	O
imbalance	O	O
.	O	O

